data_2lzj_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2lzj _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 217' ' ' LEU . . . . . 0.481 ' C ' ' HG ' ' A' ' 293' ' ' SER . 0.2 OUTLIER . . . . . 0 CA--C 1.505 -0.77 0 N-CA-C 106.439 -1.689 . . . . 0.0 106.439 . . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 50.3 m -113.84 146.78 39.48 Favored 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 -173.506 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -138.73 148.69 44.21 Favored 'General case' 0 C--O 1.243 0.742 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.099 -174.278 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 97.4 mmm -74.63 125.15 28.04 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.599 -0.728 . . . . 0.0 109.873 176.26 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 60.1 t -87.06 129.11 39.08 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.948 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 177.136 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -83.87 -69.96 0.6 Allowed 'General case' 0 N--CA 1.433 -1.309 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 176.93 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -138.12 156.29 47.9 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.274 174.868 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 224' ' ' VAL . . . . . 0.56 ' CG1' ' SD ' ' A' ' 256' ' ' MET . 62.0 t -122.48 133.58 68.26 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.946 0 N-CA-C 108.18 -1.045 . . . . 0.0 108.18 173.488 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -102.83 121.91 43.43 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-O 120.555 0.217 . . . . 0.0 110.603 -175.842 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 226' ' ' LYS . . . . . 0.402 ' HA ' ' OG1' ' A' ' 280' ' ' THR . 0.4 OUTLIER -70.52 89.67 0.71 Allowed 'General case' 0 C--O 1.242 0.704 0 CA-C-O 120.966 0.412 . . . . 0.0 109.967 178.979 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 227' ' ' ASP . . . . . 0.428 ' H ' ' HG1' ' A' ' 280' ' ' THR . 52.9 t0 -158.47 171.69 19.69 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.492 -0.776 . . . . 0.0 109.993 -176.789 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 228' ' ' ASN . . . . . 0.431 ' HB2' ' CG ' ' A' ' 279' ' ' ASP . 0.7 OUTLIER -136.16 123.32 14.46 Favored Pre-proline 0 C--N 1.325 -0.459 0 CA-C-N 116.576 -0.284 . . . . 0.0 110.544 175.192 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 229' ' ' PRO . . . . . 0.407 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 45.7 Cg_endo -65.89 146.5 71.49 Favored 'Cis proline' 0 N--CA 1.494 1.538 0 C-N-CA 122.783 -1.757 . . . . 0.0 109.22 -1.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . 0.498 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -68.43 144.06 41.8 Favored Glycine 0 C--O 1.219 -0.812 0 N-CA-C 109.787 -1.325 . . . . 0.0 109.787 -177.72 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.5 p -128.12 134.95 64.02 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 CA-C-N 116.989 0.394 . . . . 0.0 110.079 178.168 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 232' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -133.8 156.44 41.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 C-N-CA 120.428 -0.509 . . . . 0.0 110.836 -179.817 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 24.5 m -117.49 134.3 55.01 Favored 'General case' 0 C--O 1.242 0.693 0 CA-C-N 115.998 -0.546 . . . . 0.0 109.683 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.8 m -106.4 158.58 16.79 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.961 -175.372 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . 0.413 ' O ' ' HB3' ' A' ' 238' ' ' ALA . 22.8 tp -63.29 150.79 42.39 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.226 -0.897 . . . . 0.0 108.686 179.225 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -59.63 -39.7 85.16 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 121.089 0.471 . . . . 0.0 109.847 -177.697 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 237' ' ' GLU . . . . . 0.439 ' O ' ' N ' ' A' ' 239' ' ' ARG . 98.8 mt-10 -70.53 -21.09 62.76 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.16 174.062 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 238' ' ' ALA . . . . . 0.413 ' HB3' ' O ' ' A' ' 235' ' ' LEU . . . -65.83 61.25 0.03 OUTLIER 'General case' 0 C--O 1.241 0.653 0 CA-C-O 121.227 0.537 . . . . 0.0 111.027 -178.472 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 239' ' ' ARG . . . . . 0.439 ' N ' ' O ' ' A' ' 237' ' ' GLU . 61.5 mtp180 -67.78 85.09 0.21 Allowed 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 174.215 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 240' ' ' HIS . . . . . 0.607 ' HB2' ' CG ' ' A' ' 242' ' ' PHE . 3.5 p80 -57.92 -46.83 84.39 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-N 115.163 -0.926 . . . . 0.0 112.398 -170.903 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 80.32 14.47 80.23 Favored Glycine 0 C--N 1.313 -0.743 0 N-CA-C 109.867 -1.293 . . . . 0.0 109.867 -174.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 242' ' ' PHE . . . . . 0.647 ' CD1' ' HB3' ' A' ' 294' ' ' GLN . 4.6 m-30 -80.02 148.69 31.01 Favored 'General case' 0 CA--C 1.509 -0.617 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 -179.301 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 243' ' ' GLU . . . . . 0.434 ' HB2' ' HB2' ' A' ' 246' ' ' ASP . 37.7 mt-10 -115.46 150.66 36.12 Favored 'General case' 0 C--N 1.308 -1.238 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 179.634 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 32.6 m -62.43 127.62 32.16 Favored 'General case' 0 C--N 1.305 -1.34 0 C-N-CA 119.235 -0.986 . . . . 0.0 108.652 177.316 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 86.16 4.01 84.44 Favored Glycine 0 C--N 1.311 -0.847 0 N-CA-C 110.489 -1.044 . . . . 0.0 110.489 -176.326 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 246' ' ' ASP . . . . . 0.434 ' HB2' ' HB2' ' A' ' 243' ' ' GLU . 31.6 t0 -81.58 164.06 22.16 Favored 'General case' 0 CA--C 1.515 -0.402 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 177.737 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 247' ' ' PHE . . . . . 0.441 ' HA ' ' O ' ' A' ' 265' ' ' MET . 69.3 m-85 -110.05 134.68 51.89 Favored 'General case' 0 C--N 1.311 -1.085 0 O-C-N 123.413 0.446 . . . . 0.0 110.337 -179.644 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 248' ' ' VAL . . . . . 0.5 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 3.1 m -132.04 163.81 36.46 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.572 0 CA-C-O 120.745 0.307 . . . . 0.0 111.082 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 12.0 p -130.89 162.2 30.17 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 115.126 -0.943 . . . . 0.0 108.896 176.509 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 250' ' ' PHE . . . . . 0.557 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 73.7 m-85 -121.57 157.92 29.67 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-O 121.146 0.498 . . . . 0.0 111.6 -174.763 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 3.7 m -152.25 155.89 38.63 Favored 'General case' 0 C--N 1.313 -1.017 0 CA-C-N 115.473 -0.785 . . . . 0.0 109.473 175.359 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 54.21 25.77 6.09 Favored 'General case' 0 C--N 1.314 -0.947 0 N-CA-C 112.7 0.63 . . . . 0.0 112.7 174.846 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 95.6 t -82.53 129.76 36.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 174.487 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -99.92 138.59 36.78 Favored 'General case' 0 C--O 1.24 0.601 0 C-N-CA 120.548 -0.461 . . . . 0.0 110.361 -179.74 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 80.94 -61.56 4.54 Favored Glycine 0 C--N 1.319 -0.378 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 -175.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 256' ' ' MET . . . . . 0.56 ' SD ' ' CG1' ' A' ' 224' ' ' VAL . 31.3 mtt -80.71 62.43 4.75 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.608 0.718 . . . . 0.0 110.172 174.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 47.6 pt -72.54 -19.41 19.19 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.86 -177.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 258' ' ' GLN . . . . . 0.401 ' O ' ' N ' ' A' ' 262' ' ' CYS . 0.7 OUTLIER -56.02 -39.36 71.82 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 -179.624 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 259' ' ' LEU . . . . . 0.557 ' HB3' ' CG ' ' A' ' 250' ' ' PHE . 89.8 mt -62.21 -41.7 98.62 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 116.009 -0.542 . . . . 0.0 109.742 178.767 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 97.1 m-20 -60.76 -40.72 93.52 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 178.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -96.95 11.04 66.12 Favored Glycine 0 CA--C 1.526 0.78 0 CA-C-N 115.485 -0.78 . . . . 0.0 112.676 -177.664 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 262' ' ' CYS . . . . . 0.401 ' N ' ' O ' ' A' ' 258' ' ' GLN . 4.0 m -102.84 146.75 27.81 Favored 'General case' 0 CA--C 1.517 -0.315 0 CA-C-N 117.6 0.7 . . . . 0.0 111.475 -179.457 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 51.5 mt-30 -62.34 161.96 22.29 Favored Pre-proline 0 C--N 1.326 -0.421 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 172.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 264' ' ' PRO . . . . . 0.5 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 37.6 Cg_endo -62.56 146.02 95.4 Favored 'Trans proline' 0 C--N 1.305 -1.727 0 C-N-CA 121.33 1.353 . . . . 0.0 111.219 178.644 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 265' ' ' MET . . . . . 0.611 ' SD ' ' N ' ' A' ' 265' ' ' MET . 0.9 OUTLIER -128.35 162.27 27.48 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 116.782 -0.19 . . . . 0.0 111.502 -175.702 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 70.3 tt0 -71.0 139.4 50.5 Favored 'General case' 0 C--O 1.245 0.818 0 O-C-N 123.585 0.553 . . . . 0.0 109.621 176.641 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 267' ' ' ILE . . . . . 0.433 HG23 ' CE2' ' A' ' 275' ' ' PHE . 1.9 pp -127.41 152.43 35.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-O 121.049 0.452 . . . . 0.0 111.777 -179.766 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 63.8 mttp -129.3 114.23 15.97 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.852 178.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 34.7 m -74.98 106.75 4.94 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 CA-C-O 121.145 0.497 . . . . 0.0 112.242 -176.679 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 92.9 mt -66.11 -41.02 91.14 Favored 'General case' 0 N--CA 1.449 -0.503 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.517 175.546 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -149.04 -176.19 22.12 Favored Glycine 0 C--N 1.322 -0.224 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 178.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 272' ' ' PRO . . . . . 0.429 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 33.6 Cg_endo -60.98 -34.84 90.14 Favored 'Trans proline' 0 N--CA 1.496 1.672 0 C-N-CA 121.97 1.78 . . . . 0.0 111.992 -177.29 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 57.1 m-85 -118.76 7.75 11.69 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 112.245 0.461 . . . . 0.0 112.245 178.826 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 6.0 p -120.97 124.36 44.7 Favored 'General case' 0 C--N 1.319 -0.725 0 C-N-CA 120.888 -0.325 . . . . 0.0 110.323 178.586 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 275' ' ' PHE . . . . . 0.521 ' C ' ' CD1' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -132.66 157.55 44.55 Favored 'General case' 0 CA--C 1.501 -0.924 0 C-N-CA 120.133 -0.627 . . . . 0.0 112.599 179.43 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 276' ' ' SER . . . . . 0.498 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 7.4 p -125.79 142.36 51.55 Favored 'General case' 0 N--CA 1.431 -1.408 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.937 -173.803 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 277' ' ' ILE . . . . . 0.427 HG23 ' CE1' ' A' ' 275' ' ' PHE . 32.8 pt -139.77 163.56 24.73 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.917 0 CA-C-N 115.166 -0.924 . . . . 0.0 111.964 -172.783 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 278' ' ' CYS . . . . . 0.414 ' C ' ' O ' ' A' ' 277' ' ' ILE . 86.1 m -17.78 -96.25 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 124.413 1.085 . . . . 0.0 113.611 -178.86 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . 0.431 ' CG ' ' HB2' ' A' ' 228' ' ' ASN . 67.2 t0 -149.38 112.51 4.91 Favored 'General case' 0 CA--C 1.499 -1.017 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 178.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 280' ' ' THR . . . . . 0.749 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 11.3 p -67.21 -23.81 65.78 Favored 'General case' 0 N--CA 1.42 -1.949 0 CA-C-O 121.084 0.468 . . . . 0.0 110.4 179.08 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -66.28 -19.12 65.73 Favored 'General case' 0 C--N 1.315 -0.897 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.613 173.478 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 282' ' ' ASN . . . . . 0.48 ' ND2' ' C ' ' A' ' 282' ' ' ASN . 0.0 OUTLIER -91.46 2.72 56.22 Favored 'General case' 0 CA--C 1.513 -0.474 0 C-N-CA 120.409 -0.516 . . . . 0.0 109.809 176.324 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 283' ' ' PHE . . . . . 0.749 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 16.2 m-85 -100.98 -76.52 0.56 Allowed 'General case' 0 N--CA 1.445 -0.703 0 CA-C-O 121.404 0.621 . . . . 0.0 109.417 173.616 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 284' ' ' SER . . . . . 0.437 ' HG ' ' C ' ' A' ' 283' ' ' PHE . 0.0 OUTLIER 166.48 -175.06 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 114.41 -1.268 . . . . 0.0 109.132 -172.875 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 285' ' ' ASP . . . . . 0.403 ' C ' ' HG3' ' A' ' 256' ' ' MET . 19.8 m-20 -86.5 134.5 33.67 Favored 'General case' 0 N--CA 1.472 0.643 0 CA-C-N 117.406 0.094 . . . . 0.0 110.756 179.143 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 286' ' ' TYR . . . . . 0.458 ' HB2' ' SD ' ' A' ' 256' ' ' MET . 55.5 t80 -76.65 128.34 34.5 Favored 'General case' 0 N--CA 1.468 0.447 0 C-N-CA 123.102 0.561 . . . . 0.0 111.094 179.256 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 7.0 mm -100.75 -69.15 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 116.563 -0.29 . . . . 0.0 110.672 173.271 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 95.5 mtm-85 -160.8 -179.44 7.59 Favored 'General case' 0 C--O 1.241 0.63 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.452 -178.748 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 63.35 -143.74 48.58 Favored Glycine 0 CA--C 1.498 -1.027 0 CA-C-N 114.963 -1.017 . . . . 0.0 111.338 174.03 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 98.76 123.15 4.82 Favored Glycine 0 N--CA 1.436 -1.324 0 C-N-CA 120.968 -0.634 . . . . 0.0 111.774 178.625 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . 0.47 HG22 HD13 ' A' ' 291' ' ' ILE . 47.9 mm -119.05 130.18 74.2 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.488 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 175.28 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 11.3 p -122.04 135.87 60.77 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.985 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 -178.063 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 293' ' ' SER . . . . . 0.481 ' HG ' ' C ' ' A' ' 217' ' ' LEU . 0.3 OUTLIER -136.19 140.03 43.26 Favored 'General case' 0 C--N 1.316 -0.878 0 C-N-CA 120.478 -0.489 . . . . 0.0 110.237 -177.416 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 294' ' ' GLN . . . . . 0.647 ' HB3' ' CD1' ' A' ' 242' ' ' PHE . 2.3 pt20 . . . . . 0 CA--C 1.502 -0.902 0 C-N-CA 120.083 -0.647 . . . . 0.0 110.847 178.322 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 217' ' ' LEU . . . . . 0.497 ' HB3' ' O ' ' A' ' 240' ' ' HIS . 0.4 OUTLIER . . . . . 0 CA--C 1.514 -0.43 0 N-CA-C 110.448 -0.205 . . . . 0.0 110.448 . . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 218' ' ' SER . . . . . 0.451 ' HG ' ' CB ' ' A' ' 293' ' ' SER . 66.8 m -131.48 153.78 49.41 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-N 116.416 -0.357 . . . . 0.0 110.174 175.68 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -150.84 155.63 39.6 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.531 -0.304 . . . . 0.0 111.368 -178.404 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 92.1 mtp -76.83 135.37 38.89 Favored 'General case' 0 N--CA 1.447 -0.615 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.549 176.512 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 94.3 t -87.13 130.99 36.11 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.067 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 175.567 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 222' ' ' SER . . . . . 0.419 ' OG ' ' N ' ' A' ' 223' ' ' MET . 0.0 OUTLIER -82.44 -71.51 0.48 Allowed 'General case' 0 C--N 1.308 -1.216 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 176.836 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 223' ' ' MET . . . . . 0.419 ' N ' ' OG ' ' A' ' 222' ' ' SER . 5.5 ptm -137.66 149.09 46.29 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.711 174.843 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 224' ' ' VAL . . . . . 0.567 HG12 ' SD ' ' A' ' 256' ' ' MET . 2.3 t -113.37 124.3 69.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 174.822 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 74.6 p -79.66 133.08 36.38 Favored 'General case' 0 C--N 1.321 -0.647 0 C-N-CA 120.474 -0.491 . . . . 0.0 110.491 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -79.21 75.11 5.76 Favored 'General case' 0 C--O 1.243 0.727 0 CA-C-O 121.283 0.563 . . . . 0.0 109.595 179.22 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 227' ' ' ASP . . . . . 0.522 ' N ' ' OG1' ' A' ' 280' ' ' THR . 3.9 t0 -148.72 176.56 10.26 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-N 115.475 -0.784 . . . . 0.0 110.594 -179.742 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 228' ' ' ASN . . . . . 0.424 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.2 OUTLIER -142.87 123.52 8.16 Favored Pre-proline 0 C--N 1.313 -1.02 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.881 179.05 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 229' ' ' PRO . . . . . 0.424 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 47.8 Cg_endo -63.83 146.69 62.47 Favored 'Cis proline' 0 N--CA 1.496 1.62 0 C-N-CA 123.185 -1.589 . . . . 0.0 110.744 -2.12 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . 0.488 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -76.04 141.14 26.7 Favored Glycine 0 N--CA 1.443 -0.857 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 -178.173 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.3 p -124.1 133.0 70.5 Favored 'Isoleucine or valine' 0 C--O 1.241 0.624 0 N-CA-C 109.059 -0.719 . . . . 0.0 109.059 174.22 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 232' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -132.34 156.36 42.34 Favored 'Isoleucine or valine' 0 C--O 1.246 0.895 0 C-N-CA 120.438 -0.505 . . . . 0.0 110.353 -175.024 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 233' ' ' THR . . . . . 0.466 ' HA ' ' O ' ' A' ' 273' ' ' TYR . 1.6 p -106.41 159.07 16.43 Favored 'General case' 0 N--CA 1.441 -0.907 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.665 177.556 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 39.3 m -124.36 161.95 24.86 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 123.063 0.545 . . . . 0.0 109.861 -178.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 37.2 tp -62.87 135.7 57.46 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 107.88 -1.155 . . . . 0.0 107.88 176.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 236' ' ' ASP . . . . . 0.438 ' O ' ' CZ ' ' A' ' 273' ' ' TYR . 1.9 m-20 -59.54 -35.65 74.62 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-O 121.251 0.548 . . . . 0.0 111.117 -173.611 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 70.1 mt-10 -86.47 -5.02 59.26 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.605 -177.611 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -101.99 100.47 10.76 Favored 'General case' 0 CA--C 1.516 -0.344 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.554 179.393 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 66.4 mtp180 -86.82 107.53 18.34 Favored 'General case' 0 C--N 1.317 -0.847 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 -179.686 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 240' ' ' HIS . . . . . 0.497 ' O ' ' HB3' ' A' ' 217' ' ' LEU . 9.9 p80 -57.48 -47.38 82.05 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.655 -176.902 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 71.18 25.31 75.85 Favored Glycine 0 C--N 1.309 -0.92 0 N-CA-C 109.783 -1.327 . . . . 0.0 109.783 -179.173 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 242' ' ' PHE . . . . . 0.463 ' CD2' ' HB2' ' A' ' 240' ' ' HIS . 15.4 m-30 -79.51 141.28 36.84 Favored 'General case' 0 N--CA 1.435 -1.213 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 -179.82 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 243' ' ' GLU . . . . . 0.456 ' HB2' ' HB2' ' A' ' 246' ' ' ASP . 96.5 mt-10 -96.79 146.5 24.84 Favored 'General case' 0 C--N 1.31 -1.138 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.343 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.1 122.44 16.09 Favored 'General case' 0 C--N 1.307 -1.269 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 -178.408 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 85.0 7.33 83.92 Favored Glycine 0 N--CA 1.442 -0.912 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 -177.211 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 246' ' ' ASP . . . . . 0.456 ' HB2' ' HB2' ' A' ' 243' ' ' GLU . 13.5 t0 -83.79 168.3 16.29 Favored 'General case' 0 C--O 1.24 0.557 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 176.032 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 247' ' ' PHE . . . . . 0.45 ' HA ' ' O ' ' A' ' 265' ' ' MET . 66.3 m-85 -109.4 141.6 41.55 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 112.099 0.407 . . . . 0.0 112.099 -176.349 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 2.8 m -134.21 161.16 41.18 Favored 'Isoleucine or valine' 0 C--O 1.241 0.655 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.098 178.059 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 47.7 m -128.04 159.37 35.24 Favored 'General case' 0 C--N 1.321 -0.669 0 C-N-CA 124.338 1.055 . . . . 0.0 108.53 173.626 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 250' ' ' PHE . . . . . 0.481 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 69.9 m-85 -110.54 145.8 37.15 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 121.264 0.554 . . . . 0.0 112.171 -177.789 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 19.7 m -137.73 153.3 49.77 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.227 177.048 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 71.6 mm-40 56.08 21.37 5.05 Favored 'General case' 0 C--N 1.314 -0.954 0 N-CA-C 113.354 0.872 . . . . 0.0 113.354 173.023 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . 0.437 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 94.1 t -84.37 130.7 35.53 Favored 'Isoleucine or valine' 0 C--O 1.239 0.52 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 177.262 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 83.1 mt-30 -105.26 144.44 32.05 Favored 'General case' 0 C--O 1.243 0.728 0 CA-C-O 121.001 0.429 . . . . 0.0 109.897 176.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 84.91 -68.42 3.5 Favored Glycine 0 C--N 1.313 -0.747 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -174.049 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 256' ' ' MET . . . . . 0.567 ' SD ' HG12 ' A' ' 224' ' ' VAL . 47.8 mtt -78.25 65.04 3.51 Favored 'General case' 0 CA--C 1.515 -0.381 0 CA-C-O 121.397 0.617 . . . . 0.0 110.318 173.072 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 46.9 pt -70.82 -23.06 23.54 Favored 'Isoleucine or valine' 0 C--O 1.244 0.797 0 CA-C-N 115.475 -0.784 . . . . 0.0 110.135 -178.271 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 258' ' ' GLN . . . . . 0.53 ' HG3' ' SG ' ' A' ' 262' ' ' CYS . 70.7 tp60 -60.8 -36.62 79.49 Favored 'General case' 0 N--CA 1.445 -0.682 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 179.459 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 259' ' ' LEU . . . . . 0.499 HD21 ' CE2' ' A' ' 283' ' ' PHE . 92.3 mt -61.88 -40.52 95.68 Favored 'General case' 0 N--CA 1.448 -0.542 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.204 179.09 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 260' ' ' ASN . . . . . 0.437 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 98.8 m-20 -60.2 -41.14 92.35 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 179.218 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -96.48 10.94 67.06 Favored Glycine 0 CA--C 1.532 1.132 0 CA-C-N 116.042 -0.527 . . . . 0.0 112.269 179.572 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 262' ' ' CYS . . . . . 0.53 ' SG ' ' HG3' ' A' ' 258' ' ' GLN . 1.2 m -82.24 142.41 32.15 Favored 'General case' 0 CA--C 1.513 -0.444 0 CA-C-N 117.382 0.591 . . . . 0.0 110.827 -178.379 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 27.9 mm100 -62.57 152.51 80.76 Favored Pre-proline 0 C--N 1.321 -0.662 0 N-CA-C 107.572 -1.27 . . . . 0.0 107.572 171.582 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -61.22 142.96 98.11 Favored 'Trans proline' 0 C--N 1.307 -1.644 0 C-N-CA 121.059 1.172 . . . . 0.0 110.447 -178.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 265' ' ' MET . . . . . 0.45 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 24.0 ptp -129.12 154.34 46.81 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 112.162 0.43 . . . . 0.0 112.162 -172.429 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -71.02 136.1 48.17 Favored 'General case' 0 C--O 1.245 0.816 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 177.611 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 267' ' ' ILE . . . . . . . . . . . . . 2.0 pp -126.65 158.54 36.94 Favored 'Isoleucine or valine' 0 C--O 1.243 0.735 0 N-CA-C 112.546 0.573 . . . . 0.0 112.546 -175.864 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 75.1 tttt -127.83 115.81 19.2 Favored 'General case' 0 N--CA 1.448 -0.532 0 CA-C-N 115.213 -0.903 . . . . 0.0 109.86 -179.322 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 17.8 m -70.59 134.5 29.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.244 -179.629 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 81.6 mt -107.75 -24.16 11.81 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.023 0.44 . . . . 0.0 110.124 178.161 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . 0.448 ' N ' ' HG1' ' A' ' 274' ' ' THR . . . -176.4 -178.27 46.05 Favored Glycine 0 C--N 1.319 -0.396 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 -178.072 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 272' ' ' PRO . . . . . 0.428 ' O ' ' CD2' ' A' ' 240' ' ' HIS . 75.5 Cg_exo -52.89 -43.6 55.21 Favored 'Trans proline' 0 C--N 1.311 -1.424 0 C-N-CA 121.958 1.772 . . . . 0.0 111.582 -177.303 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 273' ' ' TYR . . . . . 0.466 ' O ' ' HA ' ' A' ' 233' ' ' THR . 7.3 m-85 -117.76 10.75 13.4 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 115.933 -0.576 . . . . 0.0 112.084 -176.407 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 274' ' ' THR . . . . . 0.448 ' HG1' ' N ' ' A' ' 271' ' ' GLY . 5.4 p -123.77 130.02 51.98 Favored 'General case' 0 C--N 1.321 -0.66 0 C-N-CA 120.927 -0.309 . . . . 0.0 110.992 -179.51 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 275' ' ' PHE . . . . . 0.547 ' C ' ' CD1' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -143.81 164.08 31.52 Favored 'General case' 0 C--O 1.238 0.48 0 C-N-CA 120.926 -0.309 . . . . 0.0 111.406 175.811 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 276' ' ' SER . . . . . 0.488 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 4.4 p -131.05 145.38 52.0 Favored 'General case' 0 C--O 1.244 0.805 0 C-N-CA 120.672 -0.411 . . . . 0.0 111.912 -175.723 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 35.0 pt -140.18 165.05 21.86 Favored 'Isoleucine or valine' 0 C--O 1.236 0.368 0 CA-C-N 114.766 -1.107 . . . . 0.0 112.582 -173.077 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 278' ' ' CYS . . . . . 0.421 ' SG ' ' SD ' ' A' ' 265' ' ' MET . 2.6 p -27.2 -94.76 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.416 0 N-CA-C 114.478 1.288 . . . . 0.0 114.478 -176.394 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 58.2 m-20 -144.48 110.0 5.24 Favored 'General case' 0 CA--C 1.513 -0.456 0 CA-C-N 116.622 -0.263 . . . . 0.0 111.423 -171.402 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 280' ' ' THR . . . . . 0.749 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 59.7 p -66.02 -27.7 68.31 Favored 'General case' 0 C--N 1.31 -1.137 0 CA-C-O 121.215 0.531 . . . . 0.0 109.712 172.066 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 1.5 p -63.68 -17.06 62.57 Favored 'General case' 0 N--CA 1.43 -1.435 0 CA-C-N 114.799 -1.092 . . . . 0.0 109.753 174.071 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 17.9 t-20 -98.27 -8.71 26.74 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.6 175.05 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 283' ' ' PHE . . . . . 0.749 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 15.6 m-30 -90.66 -83.08 0.27 Allowed 'General case' 0 C--O 1.237 0.404 0 CA-C-O 121.436 0.636 . . . . 0.0 110.952 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 284' ' ' SER . . . . . 0.489 ' HG ' ' C ' ' A' ' 283' ' ' PHE . 0.0 OUTLIER 169.25 -174.0 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 114.342 -1.299 . . . . 0.0 108.874 -173.71 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 31.1 t0 -92.99 112.36 24.3 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 120.906 -0.318 . . . . 0.0 111.678 -179.788 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 286' ' ' TYR . . . . . 0.521 ' N ' ' HG3' ' A' ' 256' ' ' MET . 12.4 t80 -63.66 128.49 36.07 Favored 'General case' 0 CA--C 1.512 -0.485 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 177.865 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 96.5 mt -106.64 -64.06 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 175.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 9.6 ptp180 -161.15 -178.67 6.9 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.088 178.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 70.02 -161.08 53.19 Favored Glycine 0 CA--C 1.504 -0.615 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 178.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 108.8 117.59 4.06 Favored Glycine 0 N--CA 1.442 -0.958 0 C-N-CA 120.934 -0.651 . . . . 0.0 113.291 174.686 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 97.2 mt -118.16 130.34 73.17 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.25 0 N-CA-C 107.321 -1.363 . . . . 0.0 107.321 170.562 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 4.8 p -109.19 128.89 64.77 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 -179.355 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 293' ' ' SER . . . . . 0.451 ' CB ' ' HG ' ' A' ' 218' ' ' SER . 36.7 m -116.63 137.42 52.2 Favored 'General case' 0 N--CA 1.438 -1.039 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.932 -176.543 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 . . . . . 0 N--CA 1.431 -1.399 0 CA-C-N 115.609 -0.723 . . . . 0.0 109.752 176.884 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 217' ' ' LEU . . . . . 0.459 ' HB3' ' O ' ' A' ' 240' ' ' HIS . 3.8 mm? . . . . . 0 CA--C 1.503 -0.829 0 N-CA-C 112.35 0.5 . . . . 0.0 112.35 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 5.9 m -142.79 133.45 25.21 Favored 'General case' 0 N--CA 1.441 -0.92 0 CA-C-N 115.126 -0.943 . . . . 0.0 109.533 175.803 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -147.78 164.41 33.71 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 121.336 0.589 . . . . 0.0 112.295 -177.129 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 220' ' ' MET . . . . . 0.69 ' N ' ' SD ' ' A' ' 220' ' ' MET . 0.0 OUTLIER -74.77 132.62 41.75 Favored 'General case' 0 C--O 1.243 0.747 0 CA-C-N 115.023 -0.99 . . . . 0.0 109.876 178.264 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 52.4 t -88.91 130.21 38.67 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 175.142 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 36.9 p -88.1 -57.72 2.83 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 120.351 -0.54 . . . . 0.0 110.189 -178.661 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 1.7 ptm -137.04 149.75 47.64 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.481 175.69 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 224' ' ' VAL . . . . . 0.729 HG12 ' SD ' ' A' ' 256' ' ' MET . 21.7 t -127.21 132.32 69.76 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.963 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 174.004 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 225' ' ' THR . . . . . 0.404 ' O ' ' OG1' ' A' ' 280' ' ' THR . 0.2 OUTLIER -106.42 121.55 44.48 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 -177.082 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 226' ' ' LYS . . . . . 0.495 ' HA ' ' HB ' ' A' ' 280' ' ' THR . 0.1 OUTLIER -77.38 73.39 3.95 Favored 'General case' 0 C--O 1.237 0.436 0 C-N-CA 119.721 -0.792 . . . . 0.0 111.642 -179.596 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 227' ' ' ASP . . . . . 0.502 ' CG ' ' H ' ' A' ' 228' ' ' ASN . 41.5 t0 -126.23 -178.85 4.47 Favored 'General case' 0 C--O 1.238 0.499 0 CA-C-N 114.827 -1.079 . . . . 0.0 109.989 -179.587 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 228' ' ' ASN . . . . . 0.502 ' H ' ' CG ' ' A' ' 227' ' ' ASP . 0.4 OUTLIER -136.89 123.19 13.54 Favored Pre-proline 0 CA--C 1.538 0.499 0 CA-C-O 120.571 0.224 . . . . 0.0 111.205 175.799 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 229' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -66.8 151.0 82.05 Favored 'Cis proline' 0 N--CA 1.495 1.61 0 C-N-CA 123.288 -1.547 . . . . 0.0 108.592 -2.397 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . 0.49 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -63.28 139.96 44.62 Favored Glycine 0 C--N 1.315 -0.586 0 C-N-CA 119.515 -1.326 . . . . 0.0 110.233 -175.249 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 3.1 p -125.07 131.3 72.68 Favored 'Isoleucine or valine' 0 C--O 1.241 0.641 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 178.408 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 232' ' ' VAL . . . . . 0.425 ' CG1' HG13 ' A' ' 224' ' ' VAL . 0.7 OUTLIER -135.26 157.14 39.95 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-N 116.546 -0.297 . . . . 0.0 110.334 -178.293 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 233' ' ' THR . . . . . 0.428 ' HA ' ' O ' ' A' ' 273' ' ' TYR . 11.9 m -114.78 147.03 40.33 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.012 177.365 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 55.7 m -106.47 153.09 22.79 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.021 -178.315 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 32.9 tp -56.81 130.03 43.93 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 236' ' ' ASP . . . . . 0.515 ' HA ' ' CE1' ' A' ' 273' ' ' TYR . 34.6 t70 -55.23 -42.97 74.08 Favored 'General case' 0 CA--C 1.509 -0.62 0 CA-C-O 121.459 0.647 . . . . 0.0 109.865 -176.26 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -64.79 -33.54 76.23 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-N 114.851 -1.068 . . . . 0.0 110.52 -179.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -114.94 92.8 4.06 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.532 -176.828 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 239' ' ' ARG . . . . . 0.41 ' HG2' ' CE1' ' A' ' 273' ' ' TYR . 58.9 mtm180 -67.29 138.14 56.62 Favored 'General case' 0 N--CA 1.448 -0.532 0 C-N-CA 119.927 -0.709 . . . . 0.0 109.821 174.334 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 240' ' ' HIS . . . . . 0.583 ' CD2' ' H ' ' A' ' 240' ' ' HIS . 6.2 p80 -58.9 -45.35 90.5 Favored 'General case' 0 C--N 1.313 -0.988 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.414 178.384 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 80.26 12.67 82.9 Favored Glycine 0 C--N 1.319 -0.39 0 N-CA-C 109.73 -1.348 . . . . 0.0 109.73 -177.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 242' ' ' PHE . . . . . 0.564 ' CD2' ' HB2' ' A' ' 240' ' ' HIS . 8.6 m-30 -81.61 149.58 28.53 Favored 'General case' 0 N--CA 1.442 -0.862 0 CA-C-N 115.327 -0.436 . . . . 0.0 110.329 -179.813 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -117.96 150.76 38.7 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-N 115.335 -0.848 . . . . 0.0 108.783 176.828 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 28.5 m -57.56 125.75 24.27 Favored 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 119.319 -0.952 . . . . 0.0 109.16 179.643 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 104.27 -10.93 51.17 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 -175.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 68.3 m-20 -67.73 147.56 52.46 Favored 'General case' 0 C--N 1.328 -0.358 0 O-C-N 122.82 -0.224 . . . . 0.0 111.0 178.18 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 247' ' ' PHE . . . . . 0.427 ' HA ' ' O ' ' A' ' 265' ' ' MET . 66.9 m-85 -109.52 125.75 52.82 Favored 'General case' 0 C--O 1.242 0.697 0 CA-C-N 116.1 -0.5 . . . . 0.0 109.909 178.037 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 3.4 m -132.48 164.52 34.78 Favored 'Isoleucine or valine' 0 C--O 1.246 0.908 0 N-CA-C 112.472 0.545 . . . . 0.0 112.472 -175.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 13.5 p -131.98 159.25 39.29 Favored 'General case' 0 C--O 1.241 0.634 0 CA-C-N 114.66 -1.155 . . . . 0.0 108.911 174.856 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 250' ' ' PHE . . . . . 0.464 ' CE2' ' HB ' ' A' ' 292' ' ' VAL . 65.9 m-85 -114.85 159.21 20.92 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 121.327 0.584 . . . . 0.0 112.529 -172.725 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 251' ' ' SER . . . . . 0.427 ' HG ' ' C ' ' A' ' 250' ' ' PHE . 7.0 m -157.5 161.73 38.85 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-N 115.208 -0.905 . . . . 0.0 109.323 174.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 61.9 mm-40 59.17 18.47 6.53 Favored 'General case' 0 CA--C 1.544 0.732 0 N-CA-C 112.024 0.379 . . . . 0.0 112.024 177.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . 0.47 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 57.3 t -86.98 132.41 32.5 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 178.734 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 90.2 mt-30 -105.83 146.05 30.4 Favored 'General case' 0 C--O 1.24 0.589 0 CA-C-O 121.244 0.545 . . . . 0.0 111.096 177.511 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 79.65 -65.94 3.61 Favored Glycine 0 CA--C 1.505 -0.585 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 -177.255 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 256' ' ' MET . . . . . 0.729 ' SD ' HG12 ' A' ' 224' ' ' VAL . 26.5 ttm -81.98 54.5 2.49 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-O 121.551 0.691 . . . . 0.0 109.324 175.106 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 48.2 pt -68.81 -20.06 24.58 Favored 'Isoleucine or valine' 0 C--O 1.239 0.546 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.607 -176.061 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 258' ' ' GLN . . . . . 0.687 ' HG3' ' SG ' ' A' ' 262' ' ' CYS . 47.4 tp60 -56.42 -31.66 64.13 Favored 'General case' 0 N--CA 1.439 -1.002 0 C-N-CA 120.009 -0.676 . . . . 0.0 110.353 178.851 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 259' ' ' LEU . . . . . 0.523 ' CD2' ' CE2' ' A' ' 283' ' ' PHE . 78.9 mt -62.18 -41.32 98.22 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 120.911 0.386 . . . . 0.0 110.323 174.17 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 260' ' ' ASN . . . . . 0.47 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 98.3 m-20 -59.77 -40.52 88.48 Favored 'General case' 0 CA--C 1.509 -0.612 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 -179.852 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -101.27 17.32 55.91 Favored Glycine 0 C--N 1.322 -0.2 0 CA-C-N 115.543 -0.753 . . . . 0.0 112.158 -178.425 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 262' ' ' CYS . . . . . 0.687 ' SG ' ' HG3' ' A' ' 258' ' ' GLN . 0.9 OUTLIER -91.77 155.32 18.33 Favored 'General case' 0 CA--C 1.51 -0.565 0 CA-C-N 117.157 0.478 . . . . 0.0 111.687 -178.009 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 28.1 mm-40 -74.18 153.72 88.39 Favored Pre-proline 0 C--N 1.325 -0.491 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 170.612 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -65.37 148.78 88.49 Favored 'Trans proline' 0 C--N 1.305 -1.716 0 C-N-CA 121.375 1.383 . . . . 0.0 111.253 -178.538 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 265' ' ' MET . . . . . 0.445 ' SD ' ' HB ' ' A' ' 277' ' ' ILE . 12.9 ptp -138.38 160.21 40.1 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.831 -174.853 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -71.48 144.82 49.54 Favored 'General case' 0 C--O 1.242 0.663 0 O-C-N 123.999 0.812 . . . . 0.0 109.325 177.097 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 267' ' ' ILE . . . . . 0.462 HG21 ' CE2' ' A' ' 275' ' ' PHE . 1.5 pp -126.71 155.16 37.21 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-O 120.753 0.311 . . . . 0.0 111.501 -179.704 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 65.9 mttm -127.99 123.31 34.45 Favored 'General case' 0 C--O 1.239 0.548 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 177.496 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 34.6 m -81.42 105.11 10.93 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.689 0 CA-C-O 121.284 0.564 . . . . 0.0 112.484 -176.398 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 92.4 mt -67.13 -41.42 86.15 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.639 -0.709 . . . . 0.0 110.089 175.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -150.51 -177.65 24.64 Favored Glycine 0 CA--C 1.52 0.356 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 -179.202 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 272' ' ' PRO . . . . . 0.566 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 33.7 Cg_endo -62.51 -32.23 80.17 Favored 'Trans proline' 0 C--N 1.309 -1.541 0 C-N-CA 121.883 1.722 . . . . 0.0 110.726 -177.203 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 273' ' ' TYR . . . . . 0.515 ' CE1' ' HA ' ' A' ' 236' ' ' ASP . 74.2 m-85 -116.87 0.07 12.39 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.608 -0.724 . . . . 0.0 112.89 -179.015 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -120.17 127.71 52.73 Favored 'General case' 0 C--O 1.242 0.696 0 C-N-CA 120.658 -0.417 . . . . 0.0 111.659 178.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 275' ' ' PHE . . . . . 0.536 ' C ' ' CD1' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -133.43 162.68 31.21 Favored 'General case' 0 CA--C 1.501 -0.936 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.535 177.12 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 276' ' ' SER . . . . . 0.49 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 4.4 p -134.4 146.92 50.32 Favored 'General case' 0 C--N 1.313 -0.984 0 C-N-CA 119.949 -0.701 . . . . 0.0 111.629 -178.579 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 277' ' ' ILE . . . . . 0.531 HG21 ' CE1' ' A' ' 275' ' ' PHE . 34.9 pt -137.26 167.8 22.52 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.961 0 CA-C-N 114.694 -1.139 . . . . 0.0 111.481 -173.243 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 278' ' ' CYS . . . . . 0.404 ' C ' ' O ' ' A' ' 277' ' ' ILE . 71.7 m -22.05 -85.02 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.764 0 N-CA-C 113.771 1.026 . . . . 0.0 113.771 -175.409 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 58.4 t0 -153.26 106.76 3.01 Favored 'General case' 0 CA--C 1.506 -0.743 0 CA-C-O 120.753 0.311 . . . . 0.0 110.372 179.552 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 280' ' ' THR . . . . . 0.776 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 5.9 p -65.99 -27.46 68.15 Favored 'General case' 0 C--N 1.297 -1.695 0 CA-C-O 121.214 0.531 . . . . 0.0 111.057 177.07 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -64.81 -19.98 66.14 Favored 'General case' 0 C--N 1.314 -0.978 0 CA-C-N 115.464 -0.789 . . . . 0.0 109.183 174.776 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 282' ' ' ASN . . . . . 0.414 ' O ' ' ND2' ' A' ' 282' ' ' ASN . 0.2 OUTLIER -87.76 -8.55 55.86 Favored 'General case' 0 CA--C 1.508 -0.667 0 N-CA-C 108.752 -0.832 . . . . 0.0 108.752 179.554 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 283' ' ' PHE . . . . . 0.776 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 13.3 m-85 -92.25 -77.01 0.44 Allowed 'General case' 0 N--CA 1.443 -0.798 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 174.159 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 169.23 -179.3 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 114.522 -1.217 . . . . 0.0 109.702 -174.401 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 35.8 t0 -85.62 132.96 34.07 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 116.496 -0.32 . . . . 0.0 111.179 178.804 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 286' ' ' TYR . . . . . 0.675 ' CZ ' ' HA ' ' A' ' 288' ' ' ARG . 91.1 t80 -68.56 130.56 43.21 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.096 -179.895 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 85.8 mt -100.17 -63.11 1.76 Allowed 'Isoleucine or valine' 0 CA--C 1.514 -0.433 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 170.072 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . 0.675 ' HA ' ' CZ ' ' A' ' 286' ' ' TYR . 9.5 ptm180 -172.41 -173.2 1.02 Allowed 'General case' 0 C--O 1.243 0.726 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.987 175.307 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 68.48 -163.08 49.51 Favored Glycine 0 CA--C 1.507 -0.464 0 N-CA-C 110.629 -0.988 . . . . 0.0 110.629 175.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 113.97 124.61 4.07 Favored Glycine 0 N--CA 1.443 -0.889 0 C-N-CA 121.462 -0.399 . . . . 0.0 112.486 175.768 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 92.2 mt -123.09 132.51 71.26 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 172.234 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . 0.464 ' HB ' ' CE2' ' A' ' 250' ' ' PHE . 4.9 p -118.1 133.45 64.86 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 C-N-CA 120.624 -0.431 . . . . 0.0 110.028 -176.866 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 3.9 m -128.13 146.56 50.67 Favored 'General case' 0 N--CA 1.446 -0.64 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.648 -175.142 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 294' ' ' GLN . . . . . 0.499 ' HG3' ' CE1' ' A' ' 242' ' ' PHE . 90.7 mt-30 . . . . . 0 CA--C 1.505 -0.778 0 CA-C-O 121.279 0.561 . . . . 0.0 110.224 176.481 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 217' ' ' LEU . . . . . 0.411 ' O ' ' HA ' ' A' ' 293' ' ' SER . 1.3 tm? . . . . . 0 CA--C 1.51 -0.592 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 218' ' ' SER . . . . . 0.545 ' HG ' ' CB ' ' A' ' 293' ' ' SER . 75.6 m -114.72 131.45 56.76 Favored 'General case' 0 N--CA 1.438 -1.066 0 CA-C-N 115.846 -0.615 . . . . 0.0 109.358 178.238 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -127.74 150.33 49.84 Favored 'General case' 0 CA--C 1.503 -0.845 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.899 -177.097 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 220' ' ' MET . . . . . 0.691 ' SD ' HG12 ' A' ' 291' ' ' ILE . 87.6 mmm -76.56 131.21 38.81 Favored 'General case' 0 N--CA 1.44 -0.926 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 176.587 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 91.5 t -75.51 128.21 37.14 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.311 0 N-CA-C 107.586 -1.265 . . . . 0.0 107.586 175.877 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 222' ' ' SER . . . . . 0.597 ' CB ' ' HG1' ' A' ' 233' ' ' THR . 0.1 OUTLIER -84.6 -67.33 0.8 Allowed 'General case' 0 N--CA 1.437 -1.087 0 C-N-CA 119.717 -0.793 . . . . 0.0 109.375 179.703 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 3.6 ptm -137.9 151.39 47.97 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 112.552 0.575 . . . . 0.0 112.552 173.056 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 224' ' ' VAL . . . . . 0.417 HG12 ' SD ' ' A' ' 256' ' ' MET . 68.8 t -123.78 132.59 71.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 174.95 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 28.2 p -92.76 131.32 37.92 Favored 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 121.031 -0.268 . . . . 0.0 110.38 179.588 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 6.0 ttmt -77.94 87.61 4.12 Favored 'General case' 0 N--CA 1.446 -0.646 0 C-N-CA 119.477 -0.889 . . . . 0.0 109.152 178.548 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 227' ' ' ASP . . . . . 0.526 ' N ' ' OG1' ' A' ' 280' ' ' THR . 47.5 t0 -158.63 175.0 14.19 Favored 'General case' 0 C--N 1.312 -1.056 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.532 -179.574 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 228' ' ' ASN . . . . . 0.434 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.9 OUTLIER -140.85 123.56 9.75 Favored Pre-proline 0 C--O 1.237 0.406 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.112 173.866 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 229' ' ' PRO . . . . . 0.434 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 44.8 Cg_endo -66.31 144.7 67.88 Favored 'Cis proline' 0 C--N 1.313 -1.294 0 C-N-CA 122.492 -1.878 . . . . 0.0 109.308 -2.029 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . 0.447 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -82.71 144.9 23.37 Favored Glycine 0 C--N 1.312 -0.8 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 -178.179 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.6 p -121.22 130.53 74.56 Favored 'Isoleucine or valine' 0 C--O 1.241 0.657 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 176.299 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 232' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -132.66 157.14 42.95 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 CA-C-N 116.264 -0.425 . . . . 0.0 109.874 -177.413 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 233' ' ' THR . . . . . 0.597 ' HG1' ' CB ' ' A' ' 222' ' ' SER . 61.6 p -110.35 158.47 18.41 Favored 'General case' 0 N--CA 1.429 -1.486 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.229 179.711 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.8 m -113.08 148.97 34.14 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 172.656 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 40.2 tp -56.69 133.73 54.17 Favored 'General case' 0 C--N 1.308 -1.22 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 -179.69 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 236' ' ' ASP . . . . . 0.409 ' O ' ' CE1' ' A' ' 273' ' ' TYR . 7.8 t70 -52.72 -37.96 60.02 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.683 -171.523 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 10.0 mm-40 -75.31 -6.67 51.1 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.076 -178.011 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -97.39 99.88 11.32 Favored 'General case' 0 C--O 1.239 0.505 0 N-CA-C 112.554 0.575 . . . . 0.0 112.554 -175.453 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 239' ' ' ARG . . . . . 0.412 ' O ' ' C ' ' A' ' 240' ' ' HIS . 0.0 OUTLIER -70.61 66.49 0.34 Allowed 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 116.519 -0.31 . . . . 0.0 110.678 175.396 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 240' ' ' HIS . . . . . 0.552 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 14.0 p80 -33.49 -49.04 0.28 Allowed 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.227 0.537 . . . . 0.0 111.291 -178.942 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 79.41 19.31 71.83 Favored Glycine 0 C--O 1.245 0.841 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 178.432 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 242' ' ' PHE . . . . . 0.654 ' CD1' ' HB3' ' A' ' 294' ' ' GLN . 4.3 m-30 -79.85 141.53 36.1 Favored 'General case' 0 N--CA 1.444 -0.745 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 -179.256 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 243' ' ' GLU . . . . . 0.432 ' HB2' ' HB2' ' A' ' 246' ' ' ASP . 96.5 mt-10 -109.35 158.37 17.97 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 178.925 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 7.9 m -65.14 123.98 20.93 Favored 'General case' 0 C--N 1.312 -1.022 0 C-N-CA 119.115 -1.034 . . . . 0.0 108.538 178.101 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 85.87 8.04 80.11 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.559 -1.016 . . . . 0.0 110.559 -176.374 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 246' ' ' ASP . . . . . 0.432 ' HB2' ' HB2' ' A' ' 243' ' ' GLU . 45.7 t0 -82.44 167.19 18.7 Favored 'General case' 0 CA--C 1.518 -0.287 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 179.616 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 247' ' ' PHE . . . . . 0.405 ' HA ' ' O ' ' A' ' 265' ' ' MET . 95.8 m-85 -111.95 137.77 49.48 Favored 'General case' 0 C--O 1.24 0.584 0 CA-C-O 120.64 0.257 . . . . 0.0 111.295 -177.932 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 248' ' ' VAL . . . . . 0.494 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.6 m -133.58 160.89 41.96 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.306 0 CA-C-N 116.557 -0.292 . . . . 0.0 111.159 177.5 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 2.9 p -117.84 152.01 36.21 Favored 'General case' 0 C--N 1.318 -0.786 0 C-N-CA 123.958 0.903 . . . . 0.0 109.404 175.082 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 250' ' ' PHE . . . . . 0.613 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 75.0 m-85 -110.92 146.56 36.35 Favored 'General case' 0 CA--C 1.506 -0.715 0 C-N-CA 122.695 0.398 . . . . 0.0 110.758 -178.007 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 2.0 m -154.59 154.65 33.37 Favored 'General case' 0 C--N 1.31 -1.149 0 C-N-CA 120.765 -0.374 . . . . 0.0 110.145 176.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 73.5 mm-40 55.13 30.18 13.94 Favored 'General case' 0 C--N 1.313 -0.979 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.787 176.17 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 2.8 t -97.93 115.24 37.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 177.269 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 2.0 mm100 -79.1 137.76 37.64 Favored 'General case' 0 C--O 1.238 0.473 0 CA-C-O 121.035 0.445 . . . . 0.0 111.481 -179.769 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 81.99 -55.59 4.92 Favored Glycine 0 CA--C 1.506 -0.479 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 -178.579 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 256' ' ' MET . . . . . 0.492 ' N ' ' O ' ' A' ' 285' ' ' ASP . 3.1 ttm -81.24 49.93 1.35 Allowed 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.814 0.816 . . . . 0.0 109.215 176.927 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 46.7 pt -72.13 -20.73 20.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-N 114.836 -1.074 . . . . 0.0 110.974 -176.61 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 258' ' ' GLN . . . . . 0.599 ' O ' ' SG ' ' A' ' 262' ' ' CYS . 2.8 tp-100 -54.48 -41.07 69.12 Favored 'General case' 0 N--CA 1.448 -0.555 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 179.147 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 259' ' ' LEU . . . . . 0.613 ' HB3' ' CG ' ' A' ' 250' ' ' PHE . 98.2 mt -63.09 -39.92 96.14 Favored 'General case' 0 N--CA 1.445 -0.695 0 CA-C-N 114.861 -1.063 . . . . 0.0 110.116 177.545 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -59.76 -40.74 89.19 Favored 'General case' 0 CA--C 1.51 -0.591 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 -178.161 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -88.59 -1.12 81.16 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 115.548 -0.751 . . . . 0.0 112.106 -179.594 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 262' ' ' CYS . . . . . 0.599 ' SG ' ' O ' ' A' ' 258' ' ' GLN . 61.5 m -83.1 153.34 24.91 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-N 117.157 0.479 . . . . 0.0 111.017 -179.259 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 5.9 mm100 -79.07 163.96 57.33 Favored Pre-proline 0 C--N 1.323 -0.567 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 169.116 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 264' ' ' PRO . . . . . 0.494 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 36.7 Cg_exo -59.54 143.32 99.71 Favored 'Trans proline' 0 C--N 1.307 -1.608 0 C-N-CA 121.013 1.142 . . . . 0.0 111.105 -176.823 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 265' ' ' MET . . . . . 0.642 ' SD ' ' N ' ' A' ' 265' ' ' MET . 0.9 OUTLIER -126.88 160.76 30.02 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 116.627 -0.26 . . . . 0.0 111.396 -175.966 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 3.2 tt0 -71.44 137.72 48.49 Favored 'General case' 0 C--O 1.241 0.632 0 O-C-N 123.653 0.596 . . . . 0.0 110.224 178.697 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 267' ' ' ILE . . . . . 0.488 HG22 ' CE2' ' A' ' 275' ' ' PHE . 1.7 pp -132.01 162.96 38.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.113 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 64.3 mttp -124.85 136.22 53.61 Favored 'General case' 0 C--O 1.216 -0.705 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 175.189 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 15.9 m -95.64 102.3 13.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 CA-C-O 121.355 0.597 . . . . 0.0 111.634 -179.403 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 95.9 mt -66.8 -39.77 87.87 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.672 178.278 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -144.73 -170.3 13.82 Favored Glycine 0 N--CA 1.465 0.585 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 -176.516 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 272' ' ' PRO . . . . . 0.552 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 28.6 Cg_endo -59.31 -37.82 88.55 Favored 'Trans proline' 0 N--CA 1.491 1.37 0 C-N-CA 121.95 1.767 . . . . 0.0 111.88 -177.103 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 273' ' ' TYR . . . . . 0.409 ' CE1' ' O ' ' A' ' 236' ' ' ASP . 23.1 m-85 -124.03 5.53 8.61 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 111.726 0.269 . . . . 0.0 111.726 176.834 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -105.99 128.43 53.82 Favored 'General case' 0 C--N 1.32 -0.715 0 C-N-CA 120.586 -0.445 . . . . 0.0 110.724 -175.757 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 275' ' ' PHE . . . . . 0.535 ' C ' ' CD1' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -136.11 161.57 35.35 Favored 'General case' 0 CA--C 1.505 -0.77 0 C-N-CA 120.828 -0.349 . . . . 0.0 111.871 179.154 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 276' ' ' SER . . . . . 0.447 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 3.7 p -131.83 139.86 48.98 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-O 121.272 0.558 . . . . 0.0 111.883 -175.413 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 277' ' ' ILE . . . . . 0.446 HG22 ' CE1' ' A' ' 275' ' ' PHE . 37.0 pt -136.95 164.56 30.02 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.723 0 CA-C-N 114.69 -1.141 . . . . 0.0 112.378 -172.099 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 278' ' ' CYS . . . . . 0.428 ' O ' ' HA ' ' A' ' 229' ' ' PRO . 71.2 m -29.73 -92.15 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.402 0 N-CA-C 114.113 1.153 . . . . 0.0 114.113 -176.794 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 19.8 t0 -145.78 114.38 6.79 Favored 'General case' 0 CA--C 1.503 -0.847 0 CA-C-O 120.719 0.295 . . . . 0.0 111.214 -175.673 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 280' ' ' THR . . . . . 0.713 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 21.7 p -65.53 -30.59 71.36 Favored 'General case' 0 C--N 1.3 -1.586 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.576 176.18 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -65.32 -20.16 66.28 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 115.271 -0.877 . . . . 0.0 109.321 177.339 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -87.37 -8.09 57.02 Favored 'General case' 0 CA--C 1.506 -0.717 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.848 179.663 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 283' ' ' PHE . . . . . 0.713 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 5.3 m-85 -94.96 -68.38 0.8 Allowed 'General case' 0 N--CA 1.443 -0.824 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 172.808 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 284' ' ' SER . . . . . 0.414 ' OG ' ' HA ' ' A' ' 256' ' ' MET . 1.7 p 164.39 -87.93 0.0 OUTLIER 'General case' 0 C--O 1.244 0.763 0 CA-C-N 115.246 -0.888 . . . . 0.0 110.909 176.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 285' ' ' ASP . . . . . 0.492 ' O ' ' N ' ' A' ' 256' ' ' MET . 3.7 t0 -157.59 165.32 35.86 Favored 'General case' 0 C--O 1.22 -0.496 0 CA-C-N 116.614 -0.266 . . . . 0.0 111.055 179.579 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 286' ' ' TYR . . . . . 0.461 ' CD2' ' O ' ' A' ' 286' ' ' TYR . 35.7 t80 -106.8 89.22 2.95 Favored 'General case' 0 C--N 1.319 -0.728 0 C-N-CA 123.317 0.647 . . . . 0.0 110.038 179.052 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 96.5 mt -70.44 -46.11 72.04 Favored 'Isoleucine or valine' 0 C--O 1.24 0.597 0 CA-C-O 121.197 0.522 . . . . 0.0 110.14 179.235 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 173.45 173.09 0.15 Allowed 'General case' 0 C--O 1.243 0.755 0 CA-C-N 115.588 -0.733 . . . . 0.0 111.219 -177.623 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 68.08 -140.9 36.79 Favored Glycine 0 CA--C 1.508 -0.363 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 175.39 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 97.31 115.58 3.34 Favored Glycine 0 N--CA 1.442 -0.913 0 C-N-CA 121.487 -0.387 . . . . 0.0 112.148 176.71 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . 0.691 HG12 ' SD ' ' A' ' 220' ' ' MET . 89.8 mt -116.08 130.46 70.77 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.93 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 174.111 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 2.8 p -118.08 127.34 75.29 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 -179.231 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 293' ' ' SER . . . . . 0.545 ' CB ' ' HG ' ' A' ' 218' ' ' SER . 4.7 m -121.43 122.76 40.5 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.258 -176.155 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 294' ' ' GLN . . . . . 0.654 ' HB3' ' CD1' ' A' ' 242' ' ' PHE . 12.8 pt20 . . . . . 0 CA--C 1.497 -1.093 0 CA-C-O 121.257 0.551 . . . . 0.0 111.872 -179.358 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.244 0.774 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 218' ' ' SER . . . . . 0.511 ' CB ' ' HG ' ' A' ' 293' ' ' SER . 22.4 m -131.9 152.35 51.11 Favored 'General case' 0 N--CA 1.442 -0.829 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.529 -175.787 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -145.79 156.06 43.34 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.56 179.855 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 97.7 mtp -76.46 140.39 41.23 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 174.62 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 97.9 t -80.89 129.21 37.91 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.014 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 178.263 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 222' ' ' SER . . . . . 0.41 ' HG ' ' C ' ' A' ' 234' ' ' CYS . 29.0 m -77.98 -70.58 0.47 Allowed 'General case' 0 N--CA 1.434 -1.273 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 177.36 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 5.9 ptm -138.25 160.29 39.85 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.275 174.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 224' ' ' VAL . . . . . 0.509 HG13 ' SD ' ' A' ' 256' ' ' MET . 61.3 t -124.53 132.13 71.77 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.037 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 173.867 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -100.35 120.33 39.78 Favored 'General case' 0 C--N 1.313 -1.013 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 -177.993 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.82 82.11 0.9 Allowed 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.003 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 227' ' ' ASP . . . . . 0.513 ' N ' ' OG1' ' A' ' 280' ' ' THR . 4.1 t70 -153.49 -175.45 5.36 Favored 'General case' 0 C--O 1.246 0.886 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.037 -179.319 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 228' ' ' ASN . . . . . 0.511 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.2 OUTLIER -142.12 124.08 8.98 Favored Pre-proline 0 C--N 1.331 -0.228 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.307 176.696 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 229' ' ' PRO . . . . . 0.511 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 33.7 Cg_exo -61.71 147.02 50.93 Favored 'Cis proline' 0 N--CA 1.489 1.213 0 C-N-CA 123.091 -1.629 . . . . 0.0 109.984 -1.73 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . 0.449 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -68.71 134.12 27.77 Favored Glycine 0 C--N 1.3 -1.461 0 N-CA-C 108.864 -1.694 . . . . 0.0 108.864 179.064 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 231' ' ' VAL . . . . . 0.403 ' HB ' ' OG ' ' A' ' 276' ' ' SER . 2.1 p -125.7 132.34 70.94 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 117.332 0.566 . . . . 0.0 110.11 179.549 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 232' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -135.07 156.98 40.33 Favored 'Isoleucine or valine' 0 C--O 1.248 0.979 0 C-N-CA 120.754 -0.378 . . . . 0.0 110.084 -178.697 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 14.9 p -105.56 154.8 19.89 Favored 'General case' 0 N--CA 1.435 -1.209 0 CA-C-N 116.134 -0.485 . . . . 0.0 109.822 176.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 234' ' ' CYS . . . . . 0.41 ' C ' ' HG ' ' A' ' 222' ' ' SER . 2.1 m -111.78 161.07 16.71 Favored 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 176.043 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 38.4 tp -60.07 121.91 13.06 Favored 'General case' 0 C--N 1.309 -1.157 0 N-CA-C 107.143 -1.428 . . . . 0.0 107.143 178.659 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 236' ' ' ASP . . . . . 0.478 ' O ' ' NH2' ' A' ' 239' ' ' ARG . 13.9 p-10 -51.67 -44.93 63.24 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.29 0.566 . . . . 0.0 111.021 -171.55 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -64.9 -35.17 80.29 Favored 'General case' 0 C--N 1.301 -1.538 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.128 -179.355 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -70.98 95.9 1.23 Allowed 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.777 -179.198 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 239' ' ' ARG . . . . . 0.578 ' NH2' ' OH ' ' A' ' 273' ' ' TYR . 0.0 OUTLIER -62.66 99.09 0.14 Allowed 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 172.124 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 240' ' ' HIS . . . . . 0.46 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 7.2 p80 -59.48 -46.47 88.71 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.891 -175.278 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 83.5 13.09 76.93 Favored Glycine 0 C--N 1.32 -0.351 0 N-CA-C 110.505 -1.038 . . . . 0.0 110.505 -178.897 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 242' ' ' PHE . . . . . 0.5 ' CE1' ' HB3' ' A' ' 294' ' ' GLN . 4.2 m-30 -82.01 138.3 34.91 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.422 -0.585 . . . . 0.0 109.422 179.511 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 243' ' ' GLU . . . . . 0.4 ' N ' ' OD2' ' A' ' 246' ' ' ASP . 0.0 OUTLIER -110.28 161.96 15.09 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-O 121.315 0.578 . . . . 0.0 109.656 175.642 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.71 111.41 2.4 Favored 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 178.589 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 104.86 0.15 42.07 Favored Glycine 0 CA--C 1.52 0.385 0 N-CA-C 111.661 -0.576 . . . . 0.0 111.661 -178.717 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 246' ' ' ASP . . . . . 0.4 ' OD2' ' N ' ' A' ' 243' ' ' GLU . 42.3 m-20 -72.95 161.65 30.44 Favored 'General case' 0 CA--C 1.514 -0.417 0 CA-C-N 116.918 0.359 . . . . 0.0 110.562 175.703 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 247' ' ' PHE . . . . . 0.443 ' HA ' ' O ' ' A' ' 265' ' ' MET . 70.3 m-85 -109.49 130.31 55.51 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.929 -0.578 . . . . 0.0 109.721 177.471 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 248' ' ' VAL . . . . . 0.403 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.3 m -132.4 161.29 41.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 C-N-CA 120.619 -0.432 . . . . 0.0 110.817 179.548 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 3.4 p -126.64 149.61 49.4 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.842 174.427 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 250' ' ' PHE . . . . . 0.501 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 71.6 m-85 -102.99 162.42 12.95 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.117 -176.104 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 69.1 m -157.31 155.21 30.29 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.323 174.451 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 19.3 mt-10 51.76 26.37 3.45 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 113.123 0.786 . . . . 0.0 113.123 178.733 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . 0.433 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 16.2 t -82.18 117.47 28.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 174.22 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 87.4 mt-30 -89.28 144.36 26.15 Favored 'General case' 0 C--O 1.245 0.859 0 CA-C-O 121.218 0.533 . . . . 0.0 111.486 -176.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 77.82 -60.42 3.77 Favored Glycine 0 N--CA 1.449 -0.475 0 N-CA-C 109.702 -1.359 . . . . 0.0 109.702 -177.184 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 256' ' ' MET . . . . . 0.509 ' SD ' HG13 ' A' ' 224' ' ' VAL . 57.3 ttm -86.57 65.43 9.03 Favored 'General case' 0 C--N 1.318 -0.775 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 174.831 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 47.4 pt -75.42 -17.22 15.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 115.176 -0.92 . . . . 0.0 111.322 -174.31 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 258' ' ' GLN . . . . . 0.4 ' O ' ' N ' ' A' ' 262' ' ' CYS . 6.6 mp0 -55.3 -35.98 65.69 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 -178.742 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 259' ' ' LEU . . . . . 0.501 ' HB3' ' CG ' ' A' ' 250' ' ' PHE . 91.6 mt -62.18 -41.83 98.7 Favored 'General case' 0 C--N 1.315 -0.897 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.785 176.87 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 260' ' ' ASN . . . . . 0.433 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 97.5 m-20 -60.84 -40.32 92.4 Favored 'General case' 0 CA--C 1.512 -0.495 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 179.753 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -91.28 -3.79 69.21 Favored Glycine 0 CA--C 1.522 0.489 0 CA-C-N 115.466 -0.788 . . . . 0.0 111.968 -177.104 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 262' ' ' CYS . . . . . 0.4 ' N ' ' O ' ' A' ' 258' ' ' GLN . 2.9 m -87.18 141.78 28.39 Favored 'General case' 0 CA--C 1.514 -0.424 0 CA-C-N 117.249 0.524 . . . . 0.0 110.812 -177.053 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 29.3 pt20 -63.36 165.58 10.92 Favored Pre-proline 0 C--N 1.323 -0.554 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 176.054 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 264' ' ' PRO . . . . . 0.403 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 36.8 Cg_exo -60.1 141.9 97.19 Favored 'Trans proline' 0 C--N 1.316 -1.148 0 N-CA-C 109.245 -1.098 . . . . 0.0 109.245 177.42 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 265' ' ' MET . . . . . 0.443 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 23.1 ptp -134.21 155.34 50.3 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 111.969 0.359 . . . . 0.0 111.969 -173.002 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 266' ' ' GLU . . . . . 0.403 ' HB2' ' CE2' ' A' ' 247' ' ' PHE . 78.5 tt0 -71.5 137.87 48.49 Favored 'General case' 0 C--O 1.239 0.519 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.865 179.306 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 267' ' ' ILE . . . . . 0.476 HG22 ' CE2' ' A' ' 275' ' ' PHE . 1.8 pp -129.03 164.19 32.07 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.995 -177.16 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 48.4 mmtm -129.05 125.09 36.53 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 109.114 -0.698 . . . . 0.0 109.114 176.158 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 14.9 m -79.24 125.12 38.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 C-N-CA 120.743 -0.383 . . . . 0.0 110.578 179.801 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 78.6 mt -101.64 -12.49 18.38 Favored 'General case' 0 C--O 1.237 0.427 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.284 -179.034 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -164.4 -179.57 38.62 Favored Glycine 0 C--N 1.317 -0.491 0 N-CA-C 109.892 -1.283 . . . . 0.0 109.892 -177.048 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 272' ' ' PRO . . . . . 0.46 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 26.2 Cg_endo -59.7 -39.71 71.14 Favored 'Trans proline' 0 C--N 1.306 -1.687 0 C-N-CA 122.159 1.906 . . . . 0.0 111.148 -177.577 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 273' ' ' TYR . . . . . 0.578 ' OH ' ' NH2' ' A' ' 239' ' ' ARG . 29.2 m-85 -123.95 13.4 9.14 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-N 115.328 -0.851 . . . . 0.0 110.686 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -119.1 127.49 53.41 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 -174.433 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 275' ' ' PHE . . . . . 0.549 ' C ' ' CD1' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -140.47 161.75 36.98 Favored 'General case' 0 CA--C 1.502 -0.89 0 C-N-CA 120.645 -0.422 . . . . 0.0 112.126 -179.588 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 276' ' ' SER . . . . . 0.449 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 1.8 m -130.07 156.07 45.12 Favored 'General case' 0 N--CA 1.433 -1.307 0 CA-C-O 121.568 0.699 . . . . 0.0 112.75 -177.172 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 277' ' ' ILE . . . . . 0.534 HD13 ' CE2' ' A' ' 283' ' ' PHE . 2.3 pp -137.16 -179.28 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.273 0 CA-C-N 113.682 -1.599 . . . . 0.0 109.113 -177.518 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 278' ' ' CYS . . . . . 0.443 ' SG ' HD11 ' A' ' 277' ' ' ILE . 0.8 OUTLIER -40.1 -88.88 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.406 0 O-C-N 123.516 0.51 . . . . 0.0 112.185 179.753 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . 0.493 ' O ' ' ND2' ' A' ' 282' ' ' ASN . 65.5 t0 -149.22 115.55 5.81 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-O 120.602 0.239 . . . . 0.0 111.26 -178.097 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 280' ' ' THR . . . . . 0.597 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 14.6 p -63.56 -29.65 70.88 Favored 'General case' 0 C--N 1.308 -1.233 0 CA-C-O 121.295 0.569 . . . . 0.0 110.166 175.25 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -63.82 -19.57 65.12 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-N 115.329 -0.851 . . . . 0.0 109.763 177.146 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 282' ' ' ASN . . . . . 0.493 ' ND2' ' O ' ' A' ' 279' ' ' ASP . 0.0 OUTLIER -95.05 -7.97 38.02 Favored 'General case' 0 C--N 1.344 0.334 0 C-N-CA 120.507 -0.477 . . . . 0.0 110.436 177.949 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 283' ' ' PHE . . . . . 0.597 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 21.4 m-30 -85.2 -80.74 0.21 Allowed 'General case' 0 CA--C 1.512 -0.498 0 CA-C-O 121.854 0.835 . . . . 0.0 109.035 175.609 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 284' ' ' SER . . . . . 0.413 ' OG ' ' HA ' ' A' ' 256' ' ' MET . 0.1 OUTLIER 175.45 -173.37 0.08 Allowed 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 114.121 -1.399 . . . . 0.0 108.196 -176.442 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 33.4 t0 -91.18 116.3 28.7 Favored 'General case' 0 C--N 1.316 -0.876 0 C-N-CA 121.045 -0.262 . . . . 0.0 111.668 -178.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 286' ' ' TYR . . . . . 0.405 ' OH ' ' NH2' ' A' ' 288' ' ' ARG . 1.1 t80 -64.94 135.32 55.54 Favored 'General case' 0 CA--C 1.511 -0.53 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.37 179.24 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 287' ' ' ILE . . . . . 0.461 ' C ' ' HG2' ' A' ' 288' ' ' ARG . 96.9 mt -118.71 -74.78 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.433 -1.306 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.737 174.731 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . 0.537 ' NE ' ' HA ' ' A' ' 288' ' ' ARG . 4.1 mmp_? -148.71 175.58 11.09 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.587 -177.511 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 75.35 -156.3 48.35 Favored Glycine 0 C--O 1.238 0.393 0 N-CA-C 110.689 -0.964 . . . . 0.0 110.689 178.145 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 103.82 111.56 3.59 Favored Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 121.712 -0.28 . . . . 0.0 112.524 176.416 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . 0.412 HG23 HD11 ' A' ' 291' ' ' ILE . 93.2 mt -121.16 131.7 72.37 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.928 0 N-CA-C 107.532 -1.284 . . . . 0.0 107.532 173.605 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 2.8 p -122.61 137.07 57.38 Favored 'Isoleucine or valine' 0 C--O 1.242 0.683 0 C-N-CA 120.702 -0.399 . . . . 0.0 111.17 -174.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 293' ' ' SER . . . . . 0.511 ' HG ' ' CB ' ' A' ' 218' ' ' SER . 41.7 m -126.21 140.31 52.64 Favored 'General case' 0 CA--C 1.51 -0.565 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.438 179.533 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 294' ' ' GLN . . . . . 0.5 ' HB3' ' CE1' ' A' ' 242' ' ' PHE . 0.9 OUTLIER . . . . . 0 CA--C 1.504 -0.823 0 C-N-CA 120.499 -0.48 . . . . 0.0 110.023 176.764 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.44 -0.964 0 N-CA-C 109.7 -0.481 . . . . 0.0 109.7 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 218' ' ' SER . . . . . 0.575 ' CB ' ' HG ' ' A' ' 293' ' ' SER . 4.0 m -128.71 145.04 51.28 Favored 'General case' 0 N--CA 1.435 -1.179 0 CA-C-N 115.489 -0.778 . . . . 0.0 110.433 -177.057 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -130.24 154.96 47.05 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.395 179.078 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 220' ' ' MET . . . . . 0.597 ' SD ' HG12 ' A' ' 291' ' ' ILE . 87.8 mmm -82.46 129.34 34.88 Favored 'General case' 0 N--CA 1.438 -1.041 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 177.831 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 65.5 t -76.23 132.6 32.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 -179.808 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 33.5 m -97.16 -68.52 0.8 Allowed 'General case' 0 N--CA 1.44 -0.964 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.044 179.083 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 223' ' ' MET . . . . . 0.595 ' C ' ' SD ' ' A' ' 223' ' ' MET . 1.8 ppp? -137.14 147.95 46.31 Favored 'General case' 0 C--N 1.323 -0.567 0 C-N-CA 120.686 -0.406 . . . . 0.0 112.0 173.533 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 224' ' ' VAL . . . . . 0.482 ' N ' ' SD ' ' A' ' 223' ' ' MET . 71.2 t -125.83 131.79 71.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 N-CA-C 109.546 -0.538 . . . . 0.0 109.546 177.233 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 23.0 p -88.09 129.82 35.19 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.78 -0.368 . . . . 0.0 110.15 177.534 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 226' ' ' LYS . . . . . 0.424 ' CE ' ' O ' ' A' ' 284' ' ' SER . 51.9 tttm -80.27 81.6 6.5 Favored 'General case' 0 N--CA 1.447 -0.601 0 CA-C-O 121.674 0.749 . . . . 0.0 109.984 179.235 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 227' ' ' ASP . . . . . 0.557 ' N ' ' OG1' ' A' ' 280' ' ' THR . 42.7 t0 -151.14 169.49 21.73 Favored 'General case' 0 C--O 1.245 0.826 0 CA-C-N 114.508 -1.224 . . . . 0.0 108.923 -177.085 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 228' ' ' ASN . . . . . 0.418 ' N ' ' OD1' ' A' ' 227' ' ' ASP . 15.8 p-10 -140.91 121.83 8.96 Favored Pre-proline 0 C--N 1.325 -0.494 0 C-N-CA 120.516 -0.473 . . . . 0.0 111.717 176.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 229' ' ' PRO . . . . . 0.466 ' HA ' ' O ' ' A' ' 278' ' ' CYS . 56.6 Cg_endo -65.12 142.96 55.04 Favored 'Cis proline' 0 C--N 1.311 -1.424 0 C-N-CA 122.632 -1.82 . . . . 0.0 109.437 -4.138 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . 0.456 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -93.14 154.69 22.0 Favored Glycine 0 C--N 1.311 -0.817 0 N-CA-C 110.192 -1.163 . . . . 0.0 110.192 -177.296 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.4 p -123.3 137.66 55.87 Favored 'Isoleucine or valine' 0 C--O 1.239 0.529 0 CA-C-N 116.724 0.262 . . . . 0.0 110.318 179.188 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 232' ' ' VAL . . . . . 0.409 HG11 HG12 ' A' ' 224' ' ' VAL . 0.8 OUTLIER -130.95 155.9 42.32 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.016 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.299 -177.998 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 27.6 m -110.73 140.45 45.11 Favored 'General case' 0 C--N 1.312 -1.028 0 CA-C-N 115.49 -0.777 . . . . 0.0 108.918 174.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 48.2 m -107.69 162.22 14.18 Favored 'General case' 0 C--N 1.314 -0.954 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 179.315 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 50.1 tp -61.41 130.32 45.5 Favored 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 179.198 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 55.6 m-20 -58.75 -40.41 83.79 Favored 'General case' 0 N--CA 1.476 0.857 0 CA-C-O 120.902 0.382 . . . . 0.0 111.244 -174.823 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 54.6 mp0 -64.85 -29.79 70.76 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.254 178.36 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -77.5 138.97 39.52 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.796 -176.164 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 49.9 mtp85 -104.36 108.92 20.56 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.795 174.413 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 240' ' ' HIS . . . . . 0.511 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 12.7 p80 -67.01 -46.65 73.84 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-O 121.248 0.546 . . . . 0.0 109.804 176.416 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 77.87 14.74 82.03 Favored Glycine 0 CA--C 1.502 -0.743 0 N-CA-C 109.837 -1.305 . . . . 0.0 109.837 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 242' ' ' PHE . . . . . 0.49 ' CD2' ' HB2' ' A' ' 240' ' ' HIS . 8.7 m-30 -80.26 143.21 33.89 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 -177.391 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -107.66 159.95 16.07 Favored 'General case' 0 C--N 1.308 -1.239 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.712 174.716 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -62.35 117.66 6.42 Favored 'General case' 0 C--N 1.297 -1.679 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 177.305 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 90.53 4.42 70.48 Favored Glycine 0 C--N 1.313 -0.748 0 N-CA-C 111.393 -0.683 . . . . 0.0 111.393 -177.679 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 23.7 t0 -79.23 163.28 25.1 Favored 'General case' 0 C--O 1.237 0.422 0 N-CA-C 109.319 -0.622 . . . . 0.0 109.319 176.531 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 247' ' ' PHE . . . . . 0.484 ' CE2' ' HB2' ' A' ' 266' ' ' GLU . 89.7 m-85 -111.3 134.09 53.14 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.507 0.194 . . . . 0.0 110.572 -176.112 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 248' ' ' VAL . . . . . 0.457 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.9 m -131.17 165.94 30.12 Favored 'Isoleucine or valine' 0 C--O 1.239 0.51 0 CA-C-O 121.345 0.593 . . . . 0.0 112.441 -176.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 10.8 p -135.24 163.24 30.41 Favored 'General case' 0 C--N 1.32 -0.713 0 C-N-CA 124.92 1.288 . . . . 0.0 109.264 176.065 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 250' ' ' PHE . . . . . 0.568 ' CB ' ' HB3' ' A' ' 259' ' ' LEU . 78.7 m-85 -125.67 158.88 33.65 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.574 0.226 . . . . 0.0 111.027 -172.096 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 251' ' ' SER . . . . . 0.416 ' N ' ' O ' ' A' ' 291' ' ' ILE . 2.0 m -155.9 164.65 38.23 Favored 'General case' 0 C--N 1.322 -0.623 0 C-N-CA 122.326 0.251 . . . . 0.0 110.466 177.584 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 50.5 mm-40 48.59 27.36 1.45 Allowed 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.44 -0.346 . . . . 0.0 111.929 176.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 44.0 t -84.12 130.76 35.37 Favored 'Isoleucine or valine' 0 C--O 1.235 0.323 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 179.152 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 97.7 mm-40 -95.65 135.35 37.44 Favored 'General case' 0 C--O 1.247 0.954 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 178.86 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 84.53 -68.64 3.47 Favored Glycine 0 C--N 1.312 -0.752 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 -178.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 256' ' ' MET . . . . . 0.481 ' SD ' ' C ' ' A' ' 284' ' ' SER . 1.7 tpp -81.68 67.69 7.75 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.48 0.657 . . . . 0.0 109.407 176.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 257' ' ' ILE . . . . . 0.41 ' O ' ' HB2' ' A' ' 260' ' ' ASN . 48.5 pt -73.94 -21.24 17.98 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.945 0 CA-C-N 115.231 -0.895 . . . . 0.0 110.69 -176.546 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 258' ' ' GLN . . . . . 0.662 ' HG3' ' SG ' ' A' ' 262' ' ' CYS . 52.5 tp60 -56.52 -33.49 66.09 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.167 179.633 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 259' ' ' LEU . . . . . 0.568 ' HB3' ' CB ' ' A' ' 250' ' ' PHE . 84.4 mt -62.16 -39.97 94.41 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.048 174.702 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 260' ' ' ASN . . . . . 0.41 ' HB2' ' O ' ' A' ' 257' ' ' ILE . 97.1 m-20 -59.9 -40.53 89.08 Favored 'General case' 0 C--O 1.238 0.45 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.713 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -102.24 16.38 55.46 Favored Glycine 0 CA--C 1.527 0.816 0 CA-C-N 115.901 -0.59 . . . . 0.0 112.386 -178.363 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 262' ' ' CYS . . . . . 0.662 ' SG ' ' HG3' ' A' ' 258' ' ' GLN . 1.1 m -88.14 156.3 19.33 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-N 117.184 0.492 . . . . 0.0 112.028 -178.086 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 38.2 mt-30 -73.0 160.11 83.7 Favored Pre-proline 0 C--O 1.241 0.61 0 N-CA-C 107.761 -1.199 . . . . 0.0 107.761 171.423 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 264' ' ' PRO . . . . . 0.457 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 59.4 Cg_endo -66.77 145.9 76.72 Favored 'Trans proline' 0 C--N 1.309 -1.537 0 C-N-CA 121.086 1.191 . . . . 0.0 110.353 178.281 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 265' ' ' MET . . . . . 0.405 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 20.8 ptp -136.47 152.53 50.66 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 112.007 0.373 . . . . 0.0 112.007 -172.473 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 266' ' ' GLU . . . . . 0.484 ' HB2' ' CE2' ' A' ' 247' ' ' PHE . 69.5 tt0 -71.48 140.71 50.09 Favored 'General case' 0 C--O 1.239 0.532 0 O-C-N 123.898 0.749 . . . . 0.0 109.487 177.388 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 267' ' ' ILE . . . . . 0.493 HG23 ' CE2' ' A' ' 275' ' ' PHE . 2.1 pp -128.37 165.98 26.64 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-O 121.205 0.526 . . . . 0.0 112.069 -176.608 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . 0.402 ' HB2' ' OG ' ' A' ' 276' ' ' SER . 62.3 mttm -124.99 123.06 39.06 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 178.628 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 9.3 m -86.08 94.86 4.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 C-N-CA 119.363 -0.935 . . . . 0.0 109.966 176.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 97.0 mt -65.49 -41.21 93.5 Favored 'General case' 0 CA--C 1.511 -0.535 0 CA-C-N 115.424 -0.807 . . . . 0.0 109.441 -178.752 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -138.07 -178.5 16.18 Favored Glycine 0 N--CA 1.448 -0.532 0 N-CA-C 108.401 -1.88 . . . . 0.0 108.401 178.591 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 272' ' ' PRO . . . . . 0.511 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 38.4 Cg_endo -64.12 -32.7 63.34 Favored 'Trans proline' 0 C--N 1.303 -1.85 0 C-N-CA 121.513 1.475 . . . . 0.0 111.307 -177.448 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -124.5 9.54 8.43 Favored 'General case' 0 C--O 1.24 0.555 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.861 -178.407 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 7.9 p -125.66 126.56 44.89 Favored 'General case' 0 C--O 1.247 0.962 0 CA-C-O 121.171 0.51 . . . . 0.0 110.844 179.582 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 275' ' ' PHE . . . . . 0.523 ' C ' ' CD1' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -139.56 163.98 31.12 Favored 'General case' 0 CA--C 1.502 -0.897 0 N-CA-C 112.532 0.567 . . . . 0.0 112.532 -175.871 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 276' ' ' SER . . . . . 0.456 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 4.1 p -130.59 152.67 49.71 Favored 'General case' 0 N--CA 1.436 -1.159 0 CA-C-O 121.241 0.543 . . . . 0.0 112.225 -174.946 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 277' ' ' ILE . . . . . 0.555 HD11 ' CE2' ' A' ' 283' ' ' PHE . 2.0 pp -134.92 173.19 14.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 114.684 -1.144 . . . . 0.0 111.461 -174.033 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 278' ' ' CYS . . . . . 0.466 ' O ' ' HA ' ' A' ' 229' ' ' PRO . 1.5 p -48.95 -78.77 0.02 OUTLIER 'General case' 0 C--N 1.323 -0.556 0 C-N-CA 123.815 0.846 . . . . 0.0 113.05 -177.173 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . 0.47 ' HB2' ' CB ' ' A' ' 282' ' ' ASN . 9.8 m-20 -140.1 103.87 4.71 Favored 'General case' 0 N--CA 1.452 -0.354 0 O-C-N 122.315 -0.241 . . . . 0.0 110.644 -176.256 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 280' ' ' THR . . . . . 0.715 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 20.7 p -65.46 -32.75 74.53 Favored 'General case' 0 C--N 1.315 -0.892 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 172.672 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -61.57 -23.1 65.75 Favored 'General case' 0 N--CA 1.43 -1.464 0 CA-C-N 114.019 -1.446 . . . . 0.0 109.522 175.307 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 282' ' ' ASN . . . . . 0.47 ' CB ' ' HB2' ' A' ' 279' ' ' ASP . 15.0 t30 -89.11 -10.16 48.38 Favored 'General case' 0 CA--C 1.51 -0.596 0 C-N-CA 120.372 -0.531 . . . . 0.0 109.825 178.866 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 283' ' ' PHE . . . . . 0.715 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 12.7 m-30 -83.76 -74.78 0.36 Allowed 'General case' 0 N--CA 1.441 -0.882 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 172.033 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 284' ' ' SER . . . . . 0.481 ' C ' ' SD ' ' A' ' 256' ' ' MET . 0.2 OUTLIER 171.68 -112.38 0.0 OUTLIER 'General case' 0 CA--C 1.541 0.631 0 CA-C-N 115.223 -0.899 . . . . 0.0 110.355 -178.552 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 285' ' ' ASP . . . . . 0.44 ' N ' ' SD ' ' A' ' 256' ' ' MET . 41.1 t0 -145.58 119.13 9.09 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 119.03 0.832 . . . . 0.0 110.687 177.495 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 1.7 t80 -68.19 123.96 22.14 Favored 'General case' 0 C--O 1.239 0.523 0 CA-C-O 120.739 0.305 . . . . 0.0 110.789 178.53 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 96.7 mt -106.03 -54.71 6.0 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.863 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.316 176.285 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 9.7 ptp180 -169.69 -179.05 3.2 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.079 177.842 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 63.6 -151.09 49.24 Favored Glycine 0 C--O 1.239 0.421 0 N-CA-C 110.605 -0.998 . . . . 0.0 110.605 177.281 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 99.24 129.42 6.55 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 121.59 -0.338 . . . . 0.0 112.525 175.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . 0.597 HG12 ' SD ' ' A' ' 220' ' ' MET . 98.1 mt -125.24 133.77 68.51 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 175.704 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . 0.422 ' O ' ' HA ' ' A' ' 218' ' ' SER . 4.5 p -122.63 134.6 65.35 Favored 'Isoleucine or valine' 0 C--O 1.241 0.615 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -177.955 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 293' ' ' SER . . . . . 0.575 ' HG ' ' CB ' ' A' ' 218' ' ' SER . 23.6 m -127.44 145.29 50.88 Favored 'General case' 0 CA--C 1.513 -0.478 0 CA-C-O 120.624 0.249 . . . . 0.0 111.016 -178.418 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 294' ' ' GLN . . . . . 0.417 ' O ' ' NE2' ' A' ' 294' ' ' GLN . 1.6 pp0? . . . . . 0 C--N 1.323 -0.557 0 CA-C-N 116.517 -0.31 . . . . 0.0 110.424 178.091 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 217' ' ' LEU . . . . . 0.443 ' HB3' ' O ' ' A' ' 240' ' ' HIS . 0.1 OUTLIER . . . . . 0 CA--C 1.511 -0.536 0 N-CA-C 108.365 -0.976 . . . . 0.0 108.365 . . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -127.0 147.73 50.12 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-O 120.745 0.307 . . . . 0.0 110.499 -174.734 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -146.41 154.41 41.58 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.509 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 56.3 mtm -79.98 138.95 37.18 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.842 176.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 99.2 t -85.13 130.01 36.85 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.94 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 -178.901 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 65.4 m -83.35 -70.68 0.54 Allowed 'General case' 0 N--CA 1.434 -1.254 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 179.414 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -138.57 152.94 48.62 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.834 174.007 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 224' ' ' VAL . . . . . 0.434 HG22 ' CE1' ' A' ' 286' ' ' TYR . 53.6 t -120.93 132.43 70.45 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 175.329 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 75.5 p -90.85 116.56 28.77 Favored 'General case' 0 C--O 1.236 0.393 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 175.435 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 226' ' ' LYS . . . . . 0.458 ' HA ' ' OG1' ' A' ' 280' ' ' THR . 3.7 tttm -75.86 64.37 1.81 Allowed 'General case' 0 C--O 1.249 1.06 0 C-N-CA 120.616 -0.434 . . . . 0.0 111.259 -175.147 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 227' ' ' ASP . . . . . 0.479 ' CG ' ' H ' ' A' ' 228' ' ' ASN . 36.0 t0 -133.04 -175.69 3.87 Favored 'General case' 0 C--O 1.243 0.752 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.621 178.358 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 228' ' ' ASN . . . . . 0.479 ' H ' ' CG ' ' A' ' 227' ' ' ASP . 0.6 OUTLIER -138.52 125.29 13.04 Favored Pre-proline 0 CA--C 1.533 0.307 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.031 175.631 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 229' ' ' PRO . . . . . 0.446 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 48.6 Cg_endo -66.35 141.24 52.34 Favored 'Cis proline' 0 C--N 1.313 -1.337 0 C-N-CA 122.715 -1.785 . . . . 0.0 110.01 -1.04 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . 0.436 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -75.13 139.3 24.79 Favored Glycine 0 C--N 1.308 -1.01 0 N-CA-C 110.662 -0.975 . . . . 0.0 110.662 -177.745 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.4 p -128.29 137.56 57.08 Favored 'Isoleucine or valine' 0 C--O 1.244 0.775 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 175.001 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 232' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -133.53 155.67 40.65 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.786 0 C-N-CA 120.475 -0.49 . . . . 0.0 110.985 -178.693 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 3.1 m -104.06 140.65 37.46 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 115.459 -0.791 . . . . 0.0 108.902 176.769 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.9 m -107.35 156.84 18.48 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -178.593 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 27.0 tp -58.47 130.21 45.7 Favored 'General case' 0 C--N 1.318 -0.801 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 -178.334 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -55.32 -44.03 75.45 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 120.992 0.425 . . . . 0.0 110.69 -175.025 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -67.6 -23.18 65.35 Favored 'General case' 0 C--N 1.312 -1.065 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.604 -179.72 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -94.54 90.75 6.29 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.964 0.412 . . . . 0.0 111.984 -175.002 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.74 110.12 2.69 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 108.633 -0.876 . . . . 0.0 108.633 174.799 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 240' ' ' HIS . . . . . 0.577 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 12.3 p80 -64.44 -49.81 70.0 Favored 'General case' 0 C--O 1.216 -0.674 0 CA-C-O 120.647 0.26 . . . . 0.0 111.212 -176.501 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 80.71 17.8 72.07 Favored Glycine 0 C--O 1.242 0.599 0 N-CA-C 110.961 -0.855 . . . . 0.0 110.961 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 242' ' ' PHE . . . . . . . . . . . . . 7.3 m-30 -81.38 139.94 35.01 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 179.391 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 76.6 mm-40 -98.79 157.13 16.49 Favored 'General case' 0 C--N 1.308 -1.201 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 172.601 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 25.0 m -65.57 123.4 19.58 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 172.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 94.72 0.09 64.64 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 110.994 -0.842 . . . . 0.0 110.994 -174.705 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 45.9 t0 -79.31 159.62 27.13 Favored 'General case' 0 C--O 1.239 0.542 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 176.736 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 247' ' ' PHE . . . . . . . . . . . . . 87.4 m-85 -110.29 129.96 55.64 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.311 -176.559 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 248' ' ' VAL . . . . . 0.476 ' HA ' ' HA ' ' A' ' 294' ' ' GLN . 2.4 m -128.33 161.54 36.65 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.332 0 C-N-CA 120.658 -0.417 . . . . 0.0 111.494 -179.09 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 50.1 m -129.63 153.15 48.38 Favored 'General case' 0 N--CA 1.444 -0.774 0 CA-C-N 115.108 -0.951 . . . . 0.0 108.676 172.817 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 250' ' ' PHE . . . . . 0.452 ' CB ' ' HB3' ' A' ' 259' ' ' LEU . 73.5 m-85 -105.26 145.25 30.92 Favored 'General case' 0 C--N 1.311 -1.066 0 C-N-CA 122.948 0.499 . . . . 0.0 109.882 -177.333 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 4.8 m -132.17 151.54 51.74 Favored 'General case' 0 C--N 1.304 -1.387 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 175.145 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 7.3 mm-40 47.34 38.22 7.03 Favored 'General case' 0 C--N 1.308 -1.233 0 N-CA-C 112.938 0.718 . . . . 0.0 112.938 174.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . 0.491 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 24.2 t -85.2 132.38 31.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 172.499 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 98.6 mm-40 -96.76 145.12 26.11 Favored 'General case' 0 C--N 1.32 -0.698 0 C-N-CA 120.68 -0.408 . . . . 0.0 110.214 176.671 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 81.19 -67.51 3.6 Favored Glycine 0 C--N 1.32 -0.352 0 N-CA-C 110.244 -1.143 . . . . 0.0 110.244 -177.207 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 256' ' ' MET . . . . . 0.455 ' HG3' ' C ' ' A' ' 285' ' ' ASP . 47.8 mtt -78.65 65.65 3.97 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.475 0.655 . . . . 0.0 110.586 176.219 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 48.9 pt -66.27 -23.78 32.37 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.897 0 CA-C-N 115.285 -0.871 . . . . 0.0 109.577 179.511 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 258' ' ' GLN . . . . . 0.421 ' NE2' ' O ' ' A' ' 283' ' ' PHE . 1.3 mp0 -54.37 -40.99 68.67 Favored 'General case' 0 N--CA 1.442 -0.862 0 CA-C-N 115.14 -0.936 . . . . 0.0 109.044 178.485 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 259' ' ' LEU . . . . . 0.471 HD23 ' CE1' ' A' ' 283' ' ' PHE . 87.3 mt -62.92 -41.83 99.59 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.783 178.067 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 260' ' ' ASN . . . . . 0.491 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 93.3 m-20 -59.37 -41.03 88.38 Favored 'General case' 0 CA--C 1.509 -0.623 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 -177.873 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -102.36 10.98 56.74 Favored Glycine 0 CA--C 1.525 0.706 0 CA-C-N 116.027 -0.533 . . . . 0.0 112.265 -179.359 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 11.8 t -88.48 139.98 29.93 Favored 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 117.512 0.656 . . . . 0.0 111.458 -177.471 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 9.6 mp0 -56.4 158.53 7.7 Favored Pre-proline 0 C--N 1.322 -0.621 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 173.219 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 264' ' ' PRO . . . . . 0.452 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 36.7 Cg_endo -61.71 146.87 96.4 Favored 'Trans proline' 0 N--CA 1.495 1.568 0 C-N-CA 121.488 1.459 . . . . 0.0 111.713 -178.719 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 265' ' ' MET . . . . . 0.63 ' SD ' ' N ' ' A' ' 265' ' ' MET . 0.0 OUTLIER -119.35 152.27 37.06 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.888 -176.461 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 73.0 tt0 -76.53 137.17 39.42 Favored 'General case' 0 C--O 1.238 0.46 0 N-CA-C 107.964 -1.124 . . . . 0.0 107.964 174.803 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 267' ' ' ILE . . . . . 0.499 HG22 ' CE2' ' A' ' 275' ' ' PHE . 1.9 pp -129.51 159.09 41.92 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 N-CA-C 113.069 0.766 . . . . 0.0 113.069 -174.928 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 65.6 mttm -123.54 115.04 20.88 Favored 'General case' 0 CA--C 1.534 0.331 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.367 178.694 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 17.7 m -78.35 100.18 3.26 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.497 0 CA-C-O 121.138 0.494 . . . . 0.0 111.613 -179.149 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 97.5 mt -66.25 -40.82 90.44 Favored 'General case' 0 CA--C 1.513 -0.462 0 CA-C-N 115.723 -0.672 . . . . 0.0 110.477 179.033 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -145.17 179.5 22.23 Favored Glycine 0 C--N 1.315 -0.638 0 N-CA-C 109.724 -1.35 . . . . 0.0 109.724 -177.238 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 272' ' ' PRO . . . . . 0.577 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 33.0 Cg_endo -61.39 -31.82 88.74 Favored 'Trans proline' 0 C--N 1.303 -1.845 0 C-N-CA 121.797 1.665 . . . . 0.0 110.976 -178.448 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 88.4 m-85 -121.36 8.67 10.25 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.18 -0.464 . . . . 0.0 112.067 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -123.77 126.34 46.31 Favored 'General case' 0 C--O 1.242 0.665 0 CA-C-O 120.855 0.359 . . . . 0.0 110.998 -179.48 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 275' ' ' PHE . . . . . 0.558 ' C ' ' CD1' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -132.71 161.03 35.05 Favored 'General case' 0 CA--C 1.499 -1.007 0 C-N-CA 120.733 -0.387 . . . . 0.0 111.766 178.038 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 276' ' ' SER . . . . . 0.436 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 7.7 p -133.36 154.39 50.78 Favored 'General case' 0 N--CA 1.432 -1.346 0 CA-C-O 121.25 0.547 . . . . 0.0 112.456 -173.636 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 35.7 pt -140.94 -165.93 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 CA-C-N 113.991 -1.458 . . . . 0.0 109.569 -171.049 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 278' ' ' CYS . . . . . 0.408 ' O ' ' HA ' ' A' ' 229' ' ' PRO . 14.7 p -69.81 -110.64 0.0 OUTLIER 'General case' 0 N--CA 1.45 -0.474 0 O-C-N 122.996 0.185 . . . . 0.0 111.056 178.793 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . 0.412 ' CG ' ' HB2' ' A' ' 228' ' ' ASN . 50.8 t0 -117.5 119.9 36.47 Favored 'General case' 0 CA--C 1.507 -0.682 0 CA-C-O 121.048 0.452 . . . . 0.0 110.855 -179.591 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 280' ' ' THR . . . . . 0.482 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 9.4 p -64.44 -29.29 70.35 Favored 'General case' 0 C--N 1.292 -1.919 0 CA-C-N 115.501 -0.772 . . . . 0.0 109.597 175.186 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -65.19 -11.66 42.99 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.008 -0.996 . . . . 0.0 109.642 174.483 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 -85.87 -8.65 57.92 Favored 'General case' 0 CA--C 1.507 -0.69 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 175.772 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 283' ' ' PHE . . . . . 0.482 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 3.3 m-85 -99.73 -78.41 0.51 Allowed 'General case' 0 N--CA 1.442 -0.84 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 171.117 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 284' ' ' SER . . . . . 0.474 ' OG ' ' N ' ' A' ' 285' ' ' ASP . 31.3 t 168.33 -144.33 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.291 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 -179.121 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 285' ' ' ASP . . . . . 0.474 ' N ' ' OG ' ' A' ' 284' ' ' SER . 64.8 m-20 -98.46 131.67 44.53 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 122.289 0.236 . . . . 0.0 110.567 176.734 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 286' ' ' TYR . . . . . 0.434 ' CE1' HG22 ' A' ' 224' ' ' VAL . 13.0 t80 -84.23 125.56 32.33 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 178.935 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 287' ' ' ILE . . . . . 0.401 ' O ' ' CG ' ' A' ' 288' ' ' ARG . 9.3 mm -94.01 -54.07 7.67 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 N-CA-C 110.471 -0.196 . . . . 0.0 110.471 179.539 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . 0.401 ' CG ' ' O ' ' A' ' 287' ' ' ILE . 0.7 OUTLIER 176.34 -178.0 0.14 Allowed 'General case' 0 C--O 1.244 0.766 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.019 -179.53 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 64.98 -140.64 42.3 Favored Glycine 0 CA--C 1.5 -0.856 0 N-CA-C 110.027 -1.229 . . . . 0.0 110.027 177.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 290' ' ' GLY . . . . . 0.402 ' HA3' ' OH ' ' A' ' 286' ' ' TYR . . . 87.93 126.34 2.41 Favored Glycine 0 N--CA 1.434 -1.478 0 C-N-CA 120.82 -0.705 . . . . 0.0 111.474 177.916 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . 0.407 HG22 HD12 ' A' ' 291' ' ' ILE . 82.1 mt -120.62 131.21 73.37 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 N-CA-C 106.474 -1.676 . . . . 0.0 106.474 175.06 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 3.9 p -117.85 133.1 65.72 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.051 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -176.038 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 1.4 m -129.35 141.16 51.15 Favored 'General case' 0 CA--C 1.505 -0.781 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.71 -177.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 294' ' ' GLN . . . . . 0.476 ' HA ' ' HA ' ' A' ' 248' ' ' VAL . 0.2 OUTLIER . . . . . 0 C--N 1.318 -0.797 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 172.398 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.234 0.28 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 24.1 m -133.63 152.46 51.9 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.277 -174.092 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -142.98 156.08 44.8 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 116.037 -0.528 . . . . 0.0 110.559 177.303 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 220' ' ' MET . . . . . 0.504 ' SD ' HD11 ' A' ' 291' ' ' ILE . 1.6 mpp? -75.22 134.57 41.13 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 176.659 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 99.3 t -82.06 128.29 38.85 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.886 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 178.836 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 20.2 m -86.3 -71.59 0.54 Allowed 'General case' 0 N--CA 1.439 -0.993 0 CA-C-N 116.017 -0.538 . . . . 0.0 109.876 178.037 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 8.7 ptm -137.71 149.68 46.69 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.168 174.504 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 224' ' ' VAL . . . . . 0.415 HG12 ' SD ' ' A' ' 256' ' ' MET . 72.4 t -121.74 127.27 75.46 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.993 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 174.748 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 225' ' ' THR . . . . . 0.446 ' O ' HG23 ' A' ' 280' ' ' THR . 11.6 p -77.44 130.72 37.41 Favored 'General case' 0 CA--C 1.512 -0.485 0 C-N-CA 120.399 -0.52 . . . . 0.0 110.382 -179.117 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 226' ' ' LYS . . . . . 0.441 ' NZ ' ' OG ' ' A' ' 281' ' ' SER . 26.7 tptp -81.97 74.5 8.95 Favored 'General case' 0 N--CA 1.441 -0.916 0 N-CA-C 108.728 -0.842 . . . . 0.0 108.728 176.232 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 227' ' ' ASP . . . . . 0.535 ' CG ' ' H ' ' A' ' 228' ' ' ASN . 8.6 t70 -153.65 -173.15 4.47 Favored 'General case' 0 C--O 1.244 0.797 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.599 -176.224 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 228' ' ' ASN . . . . . 0.535 ' H ' ' CG ' ' A' ' 227' ' ' ASP . 0.1 OUTLIER -140.51 125.08 10.85 Favored Pre-proline 0 N--CA 1.452 -0.353 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.2 176.094 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 229' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -69.68 148.31 86.29 Favored 'Cis proline' 0 C--N 1.311 -1.422 0 C-N-CA 123.029 -1.655 . . . . 0.0 109.722 -1.636 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . 0.429 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -71.32 130.38 18.57 Favored Glycine 0 C--N 1.311 -0.839 0 N-CA-C 109.231 -1.548 . . . . 0.0 109.231 -179.719 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.1 p -120.93 131.35 73.18 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.8 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 177.903 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 232' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -130.09 153.13 38.47 Favored 'Isoleucine or valine' 0 C--O 1.249 1.061 0 C-N-CA 119.474 -0.89 . . . . 0.0 111.361 -174.78 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 3.1 m -108.11 140.37 41.4 Favored 'General case' 0 N--CA 1.432 -1.358 0 CA-C-N 114.807 -1.088 . . . . 0.0 108.857 177.832 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 34.6 m -107.28 161.0 15.18 Favored 'General case' 0 C--N 1.308 -1.227 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 178.422 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 40.1 tp -60.53 127.65 32.76 Favored 'General case' 0 C--N 1.314 -0.978 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 -178.747 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -56.79 -39.89 74.93 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-O 121.242 0.544 . . . . 0.0 110.608 -174.481 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -65.89 -29.63 70.1 Favored 'General case' 0 C--N 1.308 -1.224 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.99 179.602 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -96.96 130.92 44.2 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 112.106 0.41 . . . . 0.0 112.106 -172.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 90.6 mtm-85 -86.3 137.45 32.6 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 174.351 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 240' ' ' HIS . . . . . 0.574 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 8.9 p80 -88.62 -45.18 10.07 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 121.073 0.463 . . . . 0.0 109.832 175.699 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 83.25 12.15 79.41 Favored Glycine 0 C--O 1.239 0.436 0 N-CA-C 110.719 -0.952 . . . . 0.0 110.719 178.539 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 242' ' ' PHE . . . . . 0.489 ' CD1' ' HB3' ' A' ' 294' ' ' GLN . 4.4 m-30 -80.87 145.35 31.4 Favored 'General case' 0 C--N 1.318 -0.781 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 -179.495 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -122.17 168.1 12.39 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.951 -179.158 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 17.7 m -58.84 122.12 12.8 Favored 'General case' 0 C--N 1.313 -1.003 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 179.356 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 78.48 7.02 88.14 Favored Glycine 0 C--N 1.319 -0.394 0 N-CA-C 111.25 -0.74 . . . . 0.0 111.25 179.646 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 40.0 t0 -76.93 162.2 27.78 Favored 'General case' 0 CA--C 1.514 -0.43 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 178.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 247' ' ' PHE . . . . . 0.45 ' HA ' ' O ' ' A' ' 265' ' ' MET . 72.3 m-85 -109.64 137.21 47.79 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.041 0.448 . . . . 0.0 111.511 -177.534 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 2.9 m -133.47 162.02 40.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.308 178.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 67.1 m -125.89 151.48 46.85 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 172.692 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 250' ' ' PHE . . . . . 0.562 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 88.3 m-85 -107.37 149.58 27.7 Favored 'General case' 0 C--N 1.308 -1.207 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.218 -175.552 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 7.3 p -146.92 156.8 43.36 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.231 179.424 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 87.0 mt-10 45.8 26.8 0.4 Allowed 'General case' 0 C--N 1.316 -0.849 0 N-CA-C 112.914 0.709 . . . . 0.0 112.914 177.767 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . 0.505 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 52.5 t -83.32 132.78 30.59 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.415 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 174.921 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 93.8 mm-40 -98.52 137.23 37.49 Favored 'General case' 0 C--N 1.317 -0.833 0 C-N-CA 120.043 -0.663 . . . . 0.0 110.036 -179.254 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 83.38 -57.28 5.07 Favored Glycine 0 C--N 1.317 -0.514 0 N-CA-C 110.899 -0.881 . . . . 0.0 110.899 -177.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 256' ' ' MET . . . . . 0.415 ' SD ' HG12 ' A' ' 224' ' ' VAL . 4.4 ttm -78.29 63.11 3.11 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.632 0.729 . . . . 0.0 109.388 178.747 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 48.6 pt -69.76 -25.59 28.72 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 114.853 -1.067 . . . . 0.0 111.39 -174.748 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 258' ' ' GLN . . . . . 0.475 ' HG3' ' SG ' ' A' ' 262' ' ' CYS . 60.9 tp60 -58.93 -40.6 85.07 Favored 'General case' 0 CA--C 1.509 -0.608 0 C-N-CA 120.343 -0.543 . . . . 0.0 110.085 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 259' ' ' LEU . . . . . 0.562 ' HB3' ' CG ' ' A' ' 250' ' ' PHE . 96.0 mt -62.51 -42.28 99.4 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.981 -0.554 . . . . 0.0 109.554 179.009 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 260' ' ' ASN . . . . . 0.505 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 99.0 m-20 -60.23 -40.44 90.22 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.079 -178.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -92.19 -5.12 65.98 Favored Glycine 0 CA--C 1.523 0.557 0 C-N-CA 121.268 -0.491 . . . . 0.0 111.904 -178.238 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 262' ' ' CYS . . . . . 0.475 ' SG ' ' HG3' ' A' ' 258' ' ' GLN . 1.1 m -78.19 154.6 30.98 Favored 'General case' 0 C--N 1.326 -0.456 0 C-N-CA 120.363 -0.535 . . . . 0.0 111.614 -176.207 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . 0.505 ' N ' ' CD ' ' A' ' 263' ' ' GLN . 0.0 OUTLIER -67.9 170.72 6.67 Favored Pre-proline 0 C--N 1.322 -0.623 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 172.93 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -63.92 142.99 84.22 Favored 'Trans proline' 0 C--N 1.311 -1.436 0 N-CA-C 109.452 -1.018 . . . . 0.0 109.452 177.555 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 265' ' ' MET . . . . . 0.45 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 17.1 ptp -130.97 153.97 48.64 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 112.254 0.464 . . . . 0.0 112.254 -173.982 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -71.83 137.54 47.63 Favored 'General case' 0 C--O 1.236 0.383 0 O-C-N 124.133 0.896 . . . . 0.0 109.919 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 267' ' ' ILE . . . . . 0.415 ' C ' ' CD1' ' A' ' 267' ' ' ILE . 1.8 pp -128.47 162.5 34.99 Favored 'Isoleucine or valine' 0 C--O 1.244 0.771 0 CA-C-O 121.085 0.469 . . . . 0.0 112.106 -179.035 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 61.4 mttm -122.6 126.5 47.82 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.522 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 13.0 m -84.92 123.69 39.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 C-N-CA 120.644 -0.422 . . . . 0.0 111.477 -179.567 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 90.0 mt -102.86 -12.01 17.86 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.588 178.334 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -171.81 -177.77 41.67 Favored Glycine 0 C--N 1.318 -0.463 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.109 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 272' ' ' PRO . . . . . 0.574 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 29.8 Cg_endo -60.37 -34.1 93.67 Favored 'Trans proline' 0 C--N 1.306 -1.677 0 C-N-CA 122.091 1.861 . . . . 0.0 111.7 -179.785 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 73.1 m-85 -125.59 10.04 7.8 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.172 -179.722 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -120.7 128.5 53.01 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 116.486 -0.324 . . . . 0.0 110.51 -173.167 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 275' ' ' PHE . . . . . 0.518 ' C ' ' CD1' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -141.54 166.25 25.28 Favored 'General case' 0 CA--C 1.508 -0.659 0 N-CA-C 112.597 0.592 . . . . 0.0 112.597 178.748 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 276' ' ' SER . . . . . 0.429 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 7.8 p -133.66 146.92 51.32 Favored 'General case' 0 N--CA 1.44 -0.952 0 CA-C-O 121.182 0.515 . . . . 0.0 111.276 -179.73 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 28.9 pt -139.79 164.1 23.98 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.005 0 CA-C-N 114.518 -1.219 . . . . 0.0 111.511 -173.174 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -23.99 -92.76 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.574 0 N-CA-C 113.603 0.964 . . . . 0.0 113.603 -176.71 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 66.8 t0 -151.34 121.75 7.35 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 -177.597 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 280' ' ' THR . . . . . 0.668 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 23.7 p -65.04 -30.12 71.07 Favored 'General case' 0 C--N 1.293 -1.882 0 CA-C-O 120.982 0.42 . . . . 0.0 111.095 177.01 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 281' ' ' SER . . . . . 0.441 ' OG ' ' NZ ' ' A' ' 226' ' ' LYS . 15.7 m -70.39 -14.59 62.62 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.017 174.132 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 60.4 t30 -89.22 -5.71 57.44 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.872 174.395 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 283' ' ' PHE . . . . . 0.668 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 12.4 m-85 -102.89 -73.86 0.65 Allowed 'General case' 0 CA--C 1.511 -0.521 0 CA-C-O 121.594 0.711 . . . . 0.0 109.79 175.057 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 284' ' ' SER . . . . . 0.5 ' HG ' ' C ' ' A' ' 283' ' ' PHE . 0.0 OUTLIER 172.48 -166.36 0.02 OUTLIER 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 114.02 -1.446 . . . . 0.0 107.827 -171.895 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -97.06 146.4 25.05 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 117.907 0.322 . . . . 0.0 111.115 178.068 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 10.8 t80 -86.54 123.17 31.44 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.006 -179.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 287' ' ' ILE . . . . . 0.496 ' O ' ' HG3' ' A' ' 288' ' ' ARG . 21.4 mm -100.51 -73.66 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -0.981 0 CA-C-N 116.501 -0.318 . . . . 0.0 110.265 176.906 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . 0.496 ' HG3' ' O ' ' A' ' 287' ' ' ILE . 92.1 mtt-85 -164.61 178.43 7.33 Favored 'General case' 0 C--O 1.242 0.663 0 C-N-CA 124.112 0.965 . . . . 0.0 110.409 179.265 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 68.63 -158.14 52.78 Favored Glycine 0 CA--C 1.505 -0.536 0 N-CA-C 110.319 -1.113 . . . . 0.0 110.319 177.078 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 108.31 113.57 3.69 Favored Glycine 0 N--CA 1.439 -1.158 0 C-N-CA 120.769 -0.729 . . . . 0.0 111.946 177.715 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . 0.504 HD11 ' SD ' ' A' ' 220' ' ' MET . 43.5 mm -112.96 128.71 69.55 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.477 0 N-CA-C 105.899 -1.889 . . . . 0.0 105.899 172.352 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 3.5 p -118.9 134.45 62.51 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.039 0 C-N-CA 120.253 -0.579 . . . . 0.0 109.657 -177.694 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 15.2 m -125.21 144.48 50.43 Favored 'General case' 0 CA--C 1.508 -0.65 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.91 -176.504 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 294' ' ' GLN . . . . . 0.489 ' HB3' ' CD1' ' A' ' 242' ' ' PHE . 3.4 pt20 . . . . . 0 CA--C 1.502 -0.873 0 C-N-CA 120.205 -0.598 . . . . 0.0 110.745 179.159 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.239 0.543 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 218' ' ' SER . . . . . 0.604 ' CB ' ' HG ' ' A' ' 293' ' ' SER . 45.9 m -132.46 148.6 52.4 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.692 -174.574 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -143.08 157.11 44.83 Favored 'General case' 0 CA--C 1.51 -0.573 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.884 178.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 66.2 mtt -75.18 144.2 42.83 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 115.736 -0.666 . . . . 0.0 109.61 176.503 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 95.7 t -85.38 129.32 38.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.35 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 25.3 p -94.44 -55.14 3.26 Favored 'General case' 0 N--CA 1.439 -0.979 0 CA-C-O 120.867 0.365 . . . . 0.0 110.218 -178.164 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -137.46 149.39 46.81 Favored 'General case' 0 C--O 1.219 -0.551 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.599 177.573 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 224' ' ' VAL . . . . . 0.447 ' HB ' ' CD1' ' A' ' 286' ' ' TYR . 43.2 t -124.96 133.2 70.09 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.828 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 172.667 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -103.88 116.88 33.08 Favored 'General case' 0 C--N 1.31 -1.141 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 -178.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 226' ' ' LYS . . . . . 0.433 ' HA ' ' OG1' ' A' ' 280' ' ' THR . 88.1 tttt -78.55 90.38 4.51 Favored 'General case' 0 CA--C 1.505 -0.776 0 C-N-CA 119.296 -0.962 . . . . 0.0 110.044 -177.924 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 227' ' ' ASP . . . . . 0.544 ' N ' ' OG1' ' A' ' 280' ' ' THR . 43.9 t0 -159.5 179.85 8.55 Favored 'General case' 0 C--N 1.307 -1.241 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.03 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 228' ' ' ASN . . . . . 0.464 ' H ' ' CG ' ' A' ' 227' ' ' ASP . 1.8 p30 -132.99 125.5 19.15 Favored Pre-proline 0 C--N 1.324 -0.523 0 CA-C-N 115.878 -0.601 . . . . 0.0 109.912 175.982 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 229' ' ' PRO . . . . . 0.44 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 46.4 Cg_endo -66.32 145.12 69.42 Favored 'Cis proline' 0 N--CA 1.491 1.349 0 C-N-CA 123.204 -1.582 . . . . 0.0 110.641 -0.68 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -68.01 132.86 28.77 Favored Glycine 0 N--CA 1.452 -0.234 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.169 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.9 p -128.26 136.12 60.91 Favored 'Isoleucine or valine' 0 C--O 1.241 0.629 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 178.35 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 232' ' ' VAL . . . . . 0.421 ' HB ' ' HA ' ' A' ' 224' ' ' VAL . 0.6 OUTLIER -134.85 156.01 39.21 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.047 0 C-N-CA 120.164 -0.614 . . . . 0.0 110.493 -179.422 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 21.7 m -104.65 144.78 31.25 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 115.413 -0.812 . . . . 0.0 109.106 176.11 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 2.4 m -106.1 159.51 16.02 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 177.484 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 43.1 tp -57.85 127.24 31.07 Favored 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 -178.469 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 236' ' ' ASP . . . . . 0.402 ' O ' ' CZ ' ' A' ' 273' ' ' TYR . 7.5 m-20 -62.46 -37.91 87.75 Favored 'General case' 0 CA--C 1.512 -0.497 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.19 -172.279 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 57.9 mp0 -69.67 -19.5 63.59 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.659 177.734 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -108.78 99.94 9.23 Favored 'General case' 0 C--O 1.238 0.479 0 N-CA-C 112.102 0.408 . . . . 0.0 112.102 -177.197 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -70.57 117.4 12.05 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 173.342 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 240' ' ' HIS . . . . . 0.606 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 6.6 p80 -66.54 -45.71 78.49 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.681 -179.504 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 82.31 21.43 60.55 Favored Glycine 0 C--N 1.315 -0.62 0 N-CA-C 110.775 -0.93 . . . . 0.0 110.775 -178.275 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 242' ' ' PHE . . . . . 0.421 ' CE1' ' HB2' ' A' ' 240' ' ' HIS . 7.5 m-30 -83.74 156.02 22.79 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 120.69 0.281 . . . . 0.0 110.339 179.629 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 -124.3 165.08 18.29 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.545 174.821 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -69.61 126.44 29.74 Favored 'General case' 0 C--N 1.319 -0.76 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 177.374 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 90.43 2.38 73.43 Favored Glycine 0 C--N 1.317 -0.513 0 N-CA-C 110.476 -1.05 . . . . 0.0 110.476 -176.422 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 246' ' ' ASP . . . . . 0.462 ' O ' HG12 ' A' ' 267' ' ' ILE . 46.3 t0 -77.8 163.86 25.72 Favored 'General case' 0 C--O 1.237 0.445 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 176.427 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 247' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -115.84 128.85 56.13 Favored 'General case' 0 C--O 1.241 0.637 0 O-C-N 123.287 0.367 . . . . 0.0 110.661 -178.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 248' ' ' VAL . . . . . 0.411 ' O ' ' SD ' ' A' ' 265' ' ' MET . 2.4 m -132.4 164.58 34.56 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.308 0 C-N-CA 120.223 -0.591 . . . . 0.0 111.905 178.287 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 31.4 m -130.66 153.0 49.41 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.179 172.56 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 250' ' ' PHE . . . . . 0.546 ' CB ' ' HB3' ' A' ' 259' ' ' LEU . 61.3 m-85 -103.14 146.58 28.18 Favored 'General case' 0 C--N 1.322 -0.616 0 C-N-CA 122.729 0.411 . . . . 0.0 110.327 -178.912 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 2.5 m -143.74 153.06 42.04 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.417 176.715 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 49.42 37.51 12.09 Favored 'General case' 0 C--O 1.245 0.865 0 N-CA-C 113.044 0.757 . . . . 0.0 113.044 175.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 78.7 t -90.37 132.38 35.13 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 175.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 86.8 mt-30 -88.08 140.56 29.36 Favored 'General case' 0 C--O 1.242 0.709 0 C-N-CA 120.411 -0.516 . . . . 0.0 110.068 177.487 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 80.06 -63.82 4.03 Favored Glycine 0 C--N 1.314 -0.691 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 179.174 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 256' ' ' MET . . . . . 0.464 ' N ' ' O ' ' A' ' 285' ' ' ASP . 20.9 ttm -84.69 71.76 10.78 Favored 'General case' 0 CA--C 1.504 -0.804 0 C-N-CA 119.853 -0.739 . . . . 0.0 109.377 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 45.0 pt -80.35 -15.3 12.91 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 CA-C-N 115.005 -0.998 . . . . 0.0 110.144 -177.756 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 258' ' ' GLN . . . . . 0.504 ' O ' ' SG ' ' A' ' 262' ' ' CYS . 63.3 tp60 -57.53 -39.13 75.92 Favored 'General case' 0 N--CA 1.437 -1.11 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 177.643 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 259' ' ' LEU . . . . . 0.546 ' HB3' ' CB ' ' A' ' 250' ' ' PHE . 88.1 mt -62.78 -40.67 98.01 Favored 'General case' 0 N--CA 1.449 -0.508 0 CA-C-N 115.113 -0.949 . . . . 0.0 110.222 175.001 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -60.04 -40.63 90.06 Favored 'General case' 0 C--O 1.241 0.607 0 N-CA-C 109.306 -0.628 . . . . 0.0 109.306 -179.577 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -101.18 23.2 36.25 Favored Glycine 0 CA--C 1.526 0.736 0 N-CA-C 111.246 -0.741 . . . . 0.0 111.246 -179.178 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 262' ' ' CYS . . . . . 0.504 ' SG ' ' O ' ' A' ' 258' ' ' GLN . 1.3 m -96.68 147.34 24.01 Favored 'General case' 0 C--O 1.239 0.51 0 CA-C-N 117.362 0.581 . . . . 0.0 112.382 -177.708 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 5.3 mt-30 -61.93 154.34 68.62 Favored Pre-proline 0 C--N 1.324 -0.518 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 170.699 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -64.4 145.06 87.4 Favored 'Trans proline' 0 C--N 1.304 -1.806 0 C-N-CA 121.08 1.187 . . . . 0.0 109.868 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 265' ' ' MET . . . . . 0.554 ' SD ' ' N ' ' A' ' 265' ' ' MET . 0.2 OUTLIER -122.8 148.8 44.96 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 112.405 0.52 . . . . 0.0 112.405 -174.237 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 75.8 tt0 -77.97 134.3 37.87 Favored 'General case' 0 C--O 1.242 0.662 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 174.355 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 267' ' ' ILE . . . . . 0.462 HG12 ' O ' ' A' ' 246' ' ' ASP . 49.5 pt -125.26 159.64 32.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 N-CA-C 114.023 1.12 . . . . 0.0 114.023 -166.342 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 66.5 mttm -120.55 106.59 11.93 Favored 'General case' 0 CA--C 1.537 0.459 0 CA-C-N 115.154 -0.93 . . . . 0.0 110.021 177.325 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 17.3 m -80.24 102.31 6.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 120.999 0.428 . . . . 0.0 110.516 178.452 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 96.1 mt -66.3 -41.27 89.99 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.964 -179.707 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -149.16 -172.09 18.49 Favored Glycine 0 C--N 1.318 -0.458 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -177.383 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 272' ' ' PRO . . . . . 0.606 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 37.9 Cg_endo -62.98 -33.93 72.68 Favored 'Trans proline' 0 C--N 1.308 -1.57 0 C-N-CA 121.827 1.685 . . . . 0.0 111.369 -178.024 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 273' ' ' TYR . . . . . 0.402 ' CZ ' ' O ' ' A' ' 236' ' ' ASP . 83.3 m-85 -122.54 8.44 9.55 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 112.818 0.673 . . . . 0.0 112.818 -177.968 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 2.8 p -120.88 128.05 52.44 Favored 'General case' 0 C--O 1.243 0.747 0 CA-C-O 120.605 0.24 . . . . 0.0 110.865 178.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 275' ' ' PHE . . . . . 0.561 ' C ' ' CD1' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -138.25 159.44 42.04 Favored 'General case' 0 CA--C 1.507 -0.697 0 C-N-CA 120.671 -0.411 . . . . 0.0 111.658 177.667 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 7.9 p -137.79 154.29 49.58 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.521 -173.388 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -141.72 -155.04 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.912 0 CA-C-N 115.428 -0.805 . . . . 0.0 110.106 -173.087 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 1.1 p -60.04 -89.03 0.0 OUTLIER 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 116.499 -0.318 . . . . 0.0 111.306 178.338 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . 0.503 ' HB3' HD21 ' A' ' 282' ' ' ASN . 66.0 t0 -151.7 118.98 5.94 Favored 'General case' 0 N--CA 1.447 -0.611 0 CA-C-O 120.825 0.345 . . . . 0.0 111.421 -176.736 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 280' ' ' THR . . . . . 0.633 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 11.1 p -64.34 -30.34 71.39 Favored 'General case' 0 C--N 1.299 -1.626 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.101 175.095 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -61.73 -21.05 64.17 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.449 175.852 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 282' ' ' ASN . . . . . 0.503 HD21 ' HB3' ' A' ' 279' ' ' ASP . 40.1 m-80 -93.94 -3.83 50.9 Favored 'General case' 0 N--CA 1.451 -0.419 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.023 176.847 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 283' ' ' PHE . . . . . 0.633 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 22.8 m-85 -91.84 -80.72 0.35 Allowed 'General case' 0 CA--C 1.512 -0.508 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 171.674 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 3.9 p 179.25 -109.85 0.0 OUTLIER 'General case' 0 N--CA 1.453 -0.305 0 CA-C-N 115.193 -0.912 . . . . 0.0 109.675 173.463 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 285' ' ' ASP . . . . . 0.464 ' O ' ' N ' ' A' ' 256' ' ' MET . 2.1 p-10 -145.49 163.37 34.9 Favored 'General case' 0 C--O 1.219 -0.514 0 N-CA-C 107.667 -1.234 . . . . 0.0 107.667 174.114 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 286' ' ' TYR . . . . . 0.447 ' CD1' ' HB ' ' A' ' 224' ' ' VAL . 1.1 p90 -123.95 145.51 49.11 Favored 'General case' 0 N--CA 1.468 0.442 0 C-N-CA 119.663 -0.815 . . . . 0.0 111.495 -178.046 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 96.9 mt -100.77 -57.68 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 176.781 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 32.2 ptt-85 -176.17 -169.3 0.31 Allowed 'General case' 0 C--O 1.242 0.688 0 CA-C-N 115.447 -0.797 . . . . 0.0 109.979 177.584 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 67.32 -153.47 52.9 Favored Glycine 0 CA--C 1.502 -0.779 0 N-CA-C 110.944 -0.863 . . . . 0.0 110.944 175.837 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 93.51 136.49 7.96 Favored Glycine 0 N--CA 1.442 -0.958 0 N-CA-C 111.778 -0.529 . . . . 0.0 111.778 176.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . 0.436 HD13 HG21 ' A' ' 291' ' ' ILE . 92.2 mt -122.87 129.38 75.17 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 173.756 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 3.8 p -112.21 129.72 67.19 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 178.855 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 293' ' ' SER . . . . . 0.604 ' HG ' ' CB ' ' A' ' 218' ' ' SER . 55.7 m -126.9 147.88 50.05 Favored 'General case' 0 CA--C 1.5 -0.972 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.371 -174.495 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 85.0 mt-30 . . . . . 0 C--N 1.318 -0.772 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 171.804 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 217' ' ' LEU . . . . . 0.468 ' O ' ' HA ' ' A' ' 293' ' ' SER . 0.3 OUTLIER . . . . . 0 CA--C 1.513 -0.445 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 . . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 218' ' ' SER . . . . . 0.583 ' CB ' ' HG ' ' A' ' 293' ' ' SER . 50.8 m -114.04 131.88 56.21 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.163 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -131.75 150.74 52.05 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.703 -175.362 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 97.8 mtp -81.02 129.69 34.66 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.163 178.42 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 97.3 t -79.85 133.98 28.54 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.011 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 177.356 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 13.8 p -93.28 -62.0 1.46 Allowed 'General case' 0 N--CA 1.436 -1.151 0 C-N-CA 120.129 -0.628 . . . . 0.0 109.777 -179.358 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -138.06 139.05 39.36 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.946 173.818 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 224' ' ' VAL . . . . . 0.537 HG13 ' SD ' ' A' ' 256' ' ' MET . 59.4 t -117.01 130.79 71.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 174.489 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 62.3 p -88.02 138.9 31.05 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-O 120.826 0.346 . . . . 0.0 110.944 -178.509 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 226' ' ' LYS . . . . . 0.409 ' HE3' ' O ' ' A' ' 284' ' ' SER . 2.6 tptm -78.34 77.66 4.83 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 178.807 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 227' ' ' ASP . . . . . 0.413 ' CG ' ' H ' ' A' ' 228' ' ' ASN . 45.8 t0 -157.0 174.04 16.12 Favored 'General case' 0 N--CA 1.468 0.454 0 N-CA-C 112.249 0.462 . . . . 0.0 112.249 -176.172 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 228' ' ' ASN . . . . . 0.461 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.4 OUTLIER -130.86 125.14 21.16 Favored Pre-proline 0 N--CA 1.451 -0.403 0 CA-C-N 115.382 -0.826 . . . . 0.0 110.244 173.083 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 229' ' ' PRO . . . . . 0.461 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 24.6 Cg_exo -64.86 147.37 70.15 Favored 'Cis proline' 0 C--N 1.31 -1.498 0 C-N-CA 123.611 -1.412 . . . . 0.0 110.059 -2.157 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . 0.451 ' N ' ' O ' ' A' ' 277' ' ' ILE . . . -72.75 100.86 1.03 Allowed Glycine 0 C--N 1.295 -1.704 0 N-CA-C 110.025 -1.23 . . . . 0.0 110.025 -179.732 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 7.1 p -88.51 127.32 41.51 Favored 'Isoleucine or valine' 0 C--O 1.244 0.784 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 177.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 232' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -131.46 156.43 42.64 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.897 0 CA-C-O 121.124 0.488 . . . . 0.0 109.827 -177.503 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -117.69 145.45 44.41 Favored 'General case' 0 N--CA 1.429 -1.489 0 CA-C-N 114.838 -1.074 . . . . 0.0 109.032 179.336 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.8 m -107.0 160.3 15.64 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.095 -177.553 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 24.1 tp -54.82 132.62 46.61 Favored 'General case' 0 C--N 1.314 -0.966 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 178.749 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 236' ' ' ASP . . . . . 0.41 ' O ' ' CE1' ' A' ' 273' ' ' TYR . 28.4 t70 -53.89 -42.82 69.07 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-O 121.341 0.591 . . . . 0.0 111.007 -176.174 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 74.0 mt-10 -65.49 -32.15 73.61 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.32 179.126 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -72.11 135.03 46.1 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.961 0.41 . . . . 0.0 111.896 -176.861 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 66.2 mtp180 -113.13 92.96 4.19 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 175.565 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 240' ' ' HIS . . . . . 0.567 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 7.3 p80 -54.7 -49.12 71.48 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 -173.337 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 79.86 17.57 74.67 Favored Glycine 0 C--N 1.309 -0.964 0 N-CA-C 110.491 -1.044 . . . . 0.0 110.491 -179.21 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 242' ' ' PHE . . . . . 0.457 ' CD1' ' N ' ' A' ' 242' ' ' PHE . 6.5 m-30 -80.4 144.12 32.93 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 -179.11 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 243' ' ' GLU . . . . . 0.406 ' CD ' ' H ' ' A' ' 244' ' ' THR . 0.2 OUTLIER -106.83 164.85 11.77 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.346 0.594 . . . . 0.0 111.364 179.145 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 244' ' ' THR . . . . . 0.406 ' H ' ' CD ' ' A' ' 243' ' ' GLU . 0.3 OUTLIER -65.56 120.8 13.55 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 177.866 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 79.76 7.69 88.3 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 -177.358 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 43.2 t0 -79.51 166.49 21.9 Favored 'General case' 0 C--O 1.233 0.188 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 -179.694 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 247' ' ' PHE . . . . . 0.476 ' HA ' ' O ' ' A' ' 265' ' ' MET . 26.9 m-85 -110.19 133.63 53.04 Favored 'General case' 0 C--O 1.239 0.525 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -176.868 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 248' ' ' VAL . . . . . 0.434 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 3.0 m -131.89 160.37 42.47 Favored 'Isoleucine or valine' 0 C--O 1.237 0.435 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.472 178.144 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 1.2 m -121.84 161.65 22.34 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 114.907 -1.042 . . . . 0.0 109.171 173.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 250' ' ' PHE . . . . . 0.483 ' CB ' ' HB3' ' A' ' 259' ' ' LEU . 61.0 m-85 -125.88 151.77 46.45 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 110.306 -0.257 . . . . 0.0 110.306 -175.066 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 16.4 m -156.36 163.08 39.91 Favored 'General case' 0 C--O 1.215 -0.719 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 177.032 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 67.3 mm-40 54.4 30.15 12.24 Favored 'General case' 0 C--N 1.316 -0.887 0 N-CA-C 111.746 0.276 . . . . 0.0 111.746 175.419 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 2.9 t -98.96 126.74 52.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 176.758 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 83.2 mt-30 -90.94 138.41 31.62 Favored 'General case' 0 C--O 1.246 0.906 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 178.224 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . 0.421 ' C ' ' H ' ' A' ' 257' ' ' ILE . . . 81.2 -59.0 4.82 Favored Glycine 0 C--O 1.244 0.76 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 -178.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 256' ' ' MET . . . . . 0.537 ' SD ' HG13 ' A' ' 224' ' ' VAL . 3.8 ttm -80.13 49.86 1.16 Allowed 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 121.988 0.899 . . . . 0.0 109.766 178.285 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 257' ' ' ILE . . . . . 0.421 ' H ' ' C ' ' A' ' 255' ' ' GLY . 47.6 pt -67.43 -22.29 28.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 114.262 -1.335 . . . . 0.0 111.116 -176.768 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 258' ' ' GLN . . . . . 0.451 ' O ' ' SG ' ' A' ' 262' ' ' CYS . 63.9 tp60 -57.1 -39.11 74.43 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 179.199 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 259' ' ' LEU . . . . . 0.483 ' HB3' ' CB ' ' A' ' 250' ' ' PHE . 99.2 mt -62.15 -40.8 97.17 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 115.47 -0.786 . . . . 0.0 109.721 178.037 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 -60.27 -40.98 92.28 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 -178.254 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -99.27 17.86 57.32 Favored Glycine 0 CA--C 1.521 0.464 0 N-CA-C 111.55 -0.62 . . . . 0.0 111.55 -179.633 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 262' ' ' CYS . . . . . 0.451 ' SG ' ' O ' ' A' ' 258' ' ' GLN . 1.4 m -94.45 160.39 14.68 Favored 'General case' 0 C--O 1.239 0.512 0 CA-C-N 117.052 0.426 . . . . 0.0 110.455 -179.71 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -82.1 159.72 64.67 Favored Pre-proline 0 C--N 1.318 -0.766 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 172.306 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 264' ' ' PRO . . . . . 0.434 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 24.3 Cg_exo -62.16 143.26 94.29 Favored 'Trans proline' 0 C--N 1.309 -1.538 0 CA-C-N 119.743 0.944 . . . . 0.0 109.949 -179.248 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 265' ' ' MET . . . . . 0.476 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 8.7 ptp -133.57 167.94 19.56 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 112.892 0.701 . . . . 0.0 112.892 -175.088 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 72.2 tt0 -70.1 139.88 52.6 Favored 'General case' 0 C--O 1.243 0.735 0 O-C-N 124.164 0.915 . . . . 0.0 110.177 -179.69 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 267' ' ' ILE . . . . . . . . . . . . . 1.7 pp -129.22 154.35 39.97 Favored 'Isoleucine or valine' 0 C--O 1.243 0.755 0 CA-C-O 121.263 0.554 . . . . 0.0 111.526 178.389 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 66.2 mttm -125.72 109.61 12.79 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.744 -178.052 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 18.8 m -70.39 131.39 34.32 Favored 'Isoleucine or valine' 0 C--O 1.237 0.407 0 CA-C-O 120.681 0.277 . . . . 0.0 111.235 -177.394 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 95.1 mt -109.48 -25.55 10.43 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.582 179.149 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -156.41 -174.79 26.61 Favored Glycine 0 CA--C 1.511 -0.188 0 N-CA-C 110.124 -1.19 . . . . 0.0 110.124 -179.218 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 272' ' ' PRO . . . . . 0.567 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 28.6 Cg_endo -60.24 -39.87 64.41 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 121.844 1.696 . . . . 0.0 111.439 -177.434 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 273' ' ' TYR . . . . . 0.41 ' CE1' ' O ' ' A' ' 236' ' ' ASP . 57.6 m-85 -118.98 9.81 12.0 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.207 178.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -116.01 129.14 56.23 Favored 'General case' 0 C--O 1.241 0.612 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.727 -172.465 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 275' ' ' PHE . . . . . 0.575 ' C ' ' CD1' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -144.24 167.87 21.41 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 111.84 0.311 . . . . 0.0 111.84 179.729 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 276' ' ' SER . . . . . 0.421 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 4.6 p -133.27 142.26 48.42 Favored 'General case' 0 C--N 1.319 -0.728 0 C-N-CA 120.764 -0.374 . . . . 0.0 111.65 -177.353 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 277' ' ' ILE . . . . . 0.451 ' O ' ' N ' ' A' ' 230' ' ' GLY . 38.0 pt -137.02 163.07 33.25 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-N 115.137 -0.938 . . . . 0.0 111.739 -176.779 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 278' ' ' CYS . . . . . 0.434 ' C ' ' O ' ' A' ' 277' ' ' ILE . 88.1 m -14.98 -92.73 0.0 OUTLIER 'General case' 0 CA--C 1.543 0.703 0 N-CA-C 113.979 1.103 . . . . 0.0 113.979 -177.893 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 67.1 t0 -154.99 114.82 3.75 Favored 'General case' 0 CA--C 1.509 -0.601 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 -179.209 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 280' ' ' THR . . . . . 0.771 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 20.8 p -65.43 -27.79 68.78 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-O 120.99 0.424 . . . . 0.0 110.755 178.488 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -63.08 -23.95 67.68 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-N 115.169 -0.923 . . . . 0.0 109.224 175.526 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 20.4 t-20 -89.14 -9.53 50.65 Favored 'General case' 0 CA--C 1.512 -0.518 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.932 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 283' ' ' PHE . . . . . 0.771 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 10.2 m-85 -87.05 -64.86 1.08 Allowed 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 172.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 284' ' ' SER . . . . . 0.486 ' OG ' ' HA ' ' A' ' 256' ' ' MET . 2.4 p 170.35 -101.27 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 114.306 -1.316 . . . . 0.0 109.415 176.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 285' ' ' ASP . . . . . 0.47 ' O ' ' N ' ' A' ' 256' ' ' MET . 5.9 t0 -148.92 164.25 35.08 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-O 120.611 0.243 . . . . 0.0 110.793 176.851 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 286' ' ' TYR . . . . . 0.409 ' N ' ' OD1' ' A' ' 285' ' ' ASP . 83.9 t80 -94.69 114.99 26.99 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 177.387 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 22.2 mm -100.12 -58.73 3.69 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.519 175.012 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 85.5 mtm180 -160.97 167.53 26.34 Favored 'General case' 0 CA--C 1.503 -0.84 0 O-C-N 123.604 0.565 . . . . 0.0 112.352 178.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 51.21 -138.97 26.34 Favored Glycine 0 CA--C 1.504 -0.649 0 CA-C-N 113.339 -1.755 . . . . 0.0 112.556 168.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 100.83 117.32 4.14 Favored Glycine 0 N--CA 1.433 -1.565 0 N-CA-C 110.602 -0.999 . . . . 0.0 110.602 -177.637 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 87.3 mt -108.75 128.06 64.8 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.285 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 175.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 3.3 p -118.85 135.38 59.46 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.035 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 -178.115 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 293' ' ' SER . . . . . 0.583 ' HG ' ' CB ' ' A' ' 218' ' ' SER . 4.7 m -128.9 147.65 50.85 Favored 'General case' 0 N--CA 1.442 -0.856 0 C-N-CA 120.323 -0.551 . . . . 0.0 112.466 -174.426 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 48.1 tt0 . . . . . 0 N--CA 1.443 -0.823 0 CA-C-N 114.998 -1.001 . . . . 0.0 111.295 177.932 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 217' ' ' LEU . . . . . 0.418 ' HB3' ' O ' ' A' ' 240' ' ' HIS . 0.5 OUTLIER . . . . . 0 CA--C 1.506 -0.746 0 N-CA-C 110.661 -0.126 . . . . 0.0 110.661 . . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 67.1 m -124.38 149.13 47.01 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.458 179.044 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -148.31 151.08 34.78 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.181 179.046 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 71.8 mtm -78.92 136.87 37.39 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 116.039 -0.528 . . . . 0.0 109.719 176.761 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 91.5 t -86.11 130.87 35.83 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.148 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -81.82 -71.01 0.5 Allowed 'General case' 0 N--CA 1.435 -1.179 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 178.656 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 223' ' ' MET . . . . . 0.661 ' C ' ' SD ' ' A' ' 223' ' ' MET . 2.1 ppp? -138.43 147.79 43.7 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 112.393 0.516 . . . . 0.0 112.393 173.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 224' ' ' VAL . . . . . 0.43 ' N ' ' SD ' ' A' ' 223' ' ' MET . 55.1 t -122.55 131.76 72.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 176.345 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 49.8 p -87.56 134.67 33.58 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 110.503 -0.184 . . . . 0.0 110.503 179.43 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 226' ' ' LYS . . . . . 0.464 ' HZ3' ' CG ' ' A' ' 285' ' ' ASP . 0.7 OUTLIER -80.42 76.88 7.23 Favored 'General case' 0 C--O 1.239 0.541 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 176.8 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 227' ' ' ASP . . . . . 0.411 ' H ' ' HG1' ' A' ' 280' ' ' THR . 5.8 t70 -147.87 177.33 9.42 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.302 -176.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 228' ' ' ASN . . . . . 0.43 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 4.3 t-20 -139.78 124.23 11.13 Favored Pre-proline 0 C--N 1.326 -0.414 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.415 176.072 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 229' ' ' PRO . . . . . 0.43 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 48.2 Cg_endo -66.17 144.59 66.84 Favored 'Cis proline' 0 C--N 1.313 -1.319 0 C-N-CA 122.802 -1.749 . . . . 0.0 109.873 -1.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . 0.462 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -70.69 138.29 28.41 Favored Glycine 0 C--O 1.222 -0.635 0 N-CA-C 109.821 -1.312 . . . . 0.0 109.821 -177.862 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.5 p -123.05 131.1 73.88 Favored 'Isoleucine or valine' 0 C--O 1.242 0.674 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 177.048 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 232' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -133.05 156.78 42.56 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 C-N-CA 120.347 -0.541 . . . . 0.0 110.819 -176.557 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -110.2 147.91 32.85 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 115.073 -0.967 . . . . 0.0 108.577 177.844 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 2.8 m -107.36 146.83 31.1 Favored 'General case' 0 C--N 1.313 -0.987 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 177.457 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 14.0 tp -49.41 125.26 10.78 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 -177.841 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 16.1 t70 -52.39 -40.84 62.58 Favored 'General case' 0 CA--C 1.507 -0.68 0 CA-C-N 116.463 -0.335 . . . . 0.0 111.07 -171.611 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 83.6 mt-10 -65.47 -35.41 80.81 Favored 'General case' 0 C--N 1.314 -0.977 0 C-N-CA 120.33 -0.548 . . . . 0.0 110.606 -177.794 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -72.34 138.32 47.23 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 112.442 0.534 . . . . 0.0 112.442 -175.226 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 84.9 mtp180 -105.14 104.42 14.15 Favored 'General case' 0 C--O 1.239 0.509 0 CA-C-N 115.734 -0.666 . . . . 0.0 109.26 172.829 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 240' ' ' HIS . . . . . 0.447 ' HB2' ' CG ' ' A' ' 242' ' ' PHE . 8.4 p80 -67.38 -46.96 71.76 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.923 -0.581 . . . . 0.0 111.599 -176.685 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 241' ' ' GLY . . . . . 0.441 ' N ' ' ND1' ' A' ' 240' ' ' HIS . . . 83.33 12.44 78.67 Favored Glycine 0 C--N 1.31 -0.902 0 N-CA-C 110.477 -1.049 . . . . 0.0 110.477 -176.909 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 242' ' ' PHE . . . . . 0.45 ' CD1' ' N ' ' A' ' 242' ' ' PHE . 4.3 m-30 -80.84 145.39 31.41 Favored 'General case' 0 CA--C 1.514 -0.41 0 CA-C-O 120.731 0.301 . . . . 0.0 110.261 -178.915 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 243' ' ' GLU . . . . . 0.465 ' N ' ' OD2' ' A' ' 246' ' ' ASP . 99.2 mt-10 -131.55 165.01 24.55 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 115.734 -0.666 . . . . 0.0 109.592 173.392 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 4.9 m -59.56 125.82 25.15 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 -178.739 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 99.6 -5.88 58.74 Favored Glycine 0 C--N 1.318 -0.441 0 N-CA-C 111.215 -0.754 . . . . 0.0 111.215 -177.425 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 246' ' ' ASP . . . . . 0.465 ' OD2' ' N ' ' A' ' 243' ' ' GLU . 0.9 OUTLIER -67.54 149.64 49.87 Favored 'General case' 0 CA--C 1.502 -0.884 0 C-N-CA 120.814 -0.355 . . . . 0.0 111.44 176.525 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 247' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -108.74 125.84 52.36 Favored 'General case' 0 C--N 1.317 -0.81 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 176.142 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 248' ' ' VAL . . . . . 0.418 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.9 m -128.09 160.86 37.41 Favored 'Isoleucine or valine' 0 C--O 1.24 0.566 0 C-N-CA 120.47 -0.492 . . . . 0.0 111.577 -175.38 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 44.1 m -124.17 160.21 28.36 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-N 114.778 -1.101 . . . . 0.0 108.679 173.495 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 250' ' ' PHE . . . . . 0.526 ' CB ' ' HB3' ' A' ' 259' ' ' LEU . 76.4 m-85 -123.99 153.89 40.62 Favored 'General case' 0 C--N 1.314 -0.935 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 -173.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 14.6 p -159.69 161.17 34.83 Favored 'General case' 0 C--N 1.309 -1.176 0 C-N-CA 120.969 -0.293 . . . . 0.0 111.266 177.162 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 27.1 mm-40 51.62 27.86 4.29 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.395 177.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 6.5 t -90.3 129.41 41.21 Favored 'Isoleucine or valine' 0 C--O 1.236 0.371 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 175.802 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 81.4 mt-30 -94.27 136.86 34.1 Favored 'General case' 0 C--O 1.244 0.785 0 C-N-CA 120.276 -0.57 . . . . 0.0 109.836 -178.16 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 82.59 -58.15 5.01 Favored Glycine 0 C--N 1.32 -0.323 0 N-CA-C 109.945 -1.262 . . . . 0.0 109.945 -176.853 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 256' ' ' MET . . . . . 0.485 ' N ' ' O ' ' A' ' 285' ' ' ASP . 4.3 ttm -81.73 53.76 2.23 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.665 0.745 . . . . 0.0 109.708 177.797 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 48.8 pt -69.37 -23.16 26.23 Favored 'Isoleucine or valine' 0 C--O 1.242 0.702 0 CA-C-N 115.042 -0.981 . . . . 0.0 110.899 -175.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 258' ' ' GLN . . . . . 0.432 ' O ' ' SG ' ' A' ' 262' ' ' CYS . 1.2 mp0 -56.5 -37.07 69.9 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 179.673 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 259' ' ' LEU . . . . . 0.526 ' HB3' ' CB ' ' A' ' 250' ' ' PHE . 93.0 mt -62.35 -40.2 95.61 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.755 175.375 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 98.1 m-20 -59.32 -39.79 84.2 Favored 'General case' 0 CA--C 1.516 -0.336 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 -178.322 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -98.21 8.78 62.92 Favored Glycine 0 CA--C 1.531 1.043 0 CA-C-N 116.165 -0.47 . . . . 0.0 112.224 -178.083 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 262' ' ' CYS . . . . . 0.432 ' SG ' ' O ' ' A' ' 258' ' ' GLN . 1.7 m -88.51 146.02 25.41 Favored 'General case' 0 C--O 1.236 0.39 0 O-C-N 122.262 -0.552 . . . . 0.0 112.204 -176.407 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 36.4 mt-30 -64.73 156.91 77.04 Favored Pre-proline 0 C--N 1.325 -0.476 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 171.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 264' ' ' PRO . . . . . 0.418 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 38.1 Cg_endo -63.5 144.24 89.9 Favored 'Trans proline' 0 C--N 1.318 -1.06 0 C-N-CA 121.098 1.199 . . . . 0.0 110.426 -178.794 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 265' ' ' MET . . . . . . . . . . . . . 11.3 ptp -133.6 154.45 50.87 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 112.174 0.435 . . . . 0.0 112.174 -175.597 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 34.8 tt0 -71.34 143.85 50.11 Favored 'General case' 0 C--O 1.236 0.378 0 O-C-N 123.837 0.711 . . . . 0.0 109.328 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 267' ' ' ILE . . . . . 0.419 HG23 ' CE2' ' A' ' 275' ' ' PHE . 1.9 pp -131.92 165.77 30.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 N-CA-C 112.639 0.607 . . . . 0.0 112.639 -175.957 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 49.9 tttp -124.83 125.46 44.03 Favored 'General case' 0 C--O 1.217 -0.612 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.343 177.79 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 35.5 m -93.12 102.61 13.83 Favored 'Isoleucine or valine' 0 C--O 1.238 0.472 0 C-N-CA 120.452 -0.499 . . . . 0.0 111.235 179.127 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 95.9 mt -66.57 -39.44 88.48 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.148 -179.424 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -143.34 -169.74 12.73 Favored Glycine 0 C--N 1.32 -0.311 0 N-CA-C 110.441 -1.064 . . . . 0.0 110.441 -177.775 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -64.11 -33.29 61.98 Favored 'Trans proline' 0 C--N 1.306 -1.707 0 C-N-CA 122.038 1.825 . . . . 0.0 111.714 -179.287 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 90.6 m-85 -126.51 10.11 7.23 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 112.1 0.407 . . . . 0.0 112.1 -177.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.1 p -121.61 131.11 53.93 Favored 'General case' 0 C--O 1.244 0.765 0 CA-C-N 116.701 -0.227 . . . . 0.0 111.072 -177.182 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 275' ' ' PHE . . . . . 0.543 ' C ' ' CD1' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -139.31 161.68 36.84 Favored 'General case' 0 CA--C 1.511 -0.541 0 N-CA-C 112.34 0.496 . . . . 0.0 112.34 179.147 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 276' ' ' SER . . . . . 0.462 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 4.2 p -130.38 144.1 51.18 Favored 'General case' 0 N--CA 1.437 -1.078 0 CA-C-O 121.246 0.546 . . . . 0.0 111.512 -175.827 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 31.8 pt -139.0 165.84 23.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 114.725 -1.125 . . . . 0.0 111.824 -173.304 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 278' ' ' CYS . . . . . 0.404 ' O ' ' HA ' ' A' ' 229' ' ' PRO . 4.8 m -28.36 -86.4 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.57 0 N-CA-C 113.498 0.925 . . . . 0.0 113.498 -175.51 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 55.3 t0 -153.02 112.2 3.81 Favored 'General case' 0 CA--C 1.508 -0.645 0 CA-C-O 120.5 0.19 . . . . 0.0 110.498 -177.374 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 280' ' ' THR . . . . . 0.739 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 21.6 p -67.68 -28.79 67.98 Favored 'General case' 0 C--N 1.303 -1.428 0 CA-C-O 121.323 0.582 . . . . 0.0 110.645 176.314 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -63.99 -21.56 66.55 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 115.067 -0.969 . . . . 0.0 108.521 175.604 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 44.3 t30 -88.42 -8.7 54.54 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.398 -179.501 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 283' ' ' PHE . . . . . 0.739 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 7.2 m-85 -92.45 -67.71 0.84 Allowed 'General case' 0 CA--C 1.512 -0.492 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.273 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 284' ' ' SER . . . . . 0.444 ' OG ' ' HA ' ' A' ' 256' ' ' MET . 3.8 p 173.41 -105.8 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 114.85 -1.068 . . . . 0.0 110.565 176.392 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 285' ' ' ASP . . . . . 0.485 ' O ' ' N ' ' A' ' 256' ' ' MET . 40.2 t0 -145.44 158.8 43.77 Favored 'General case' 0 C--O 1.217 -0.606 0 CA-C-O 120.408 0.147 . . . . 0.0 110.607 -179.637 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 66.7 t80 -101.1 118.89 37.89 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.744 -0.207 . . . . 0.0 110.634 179.628 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 97.1 mt -97.94 -63.86 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 175.79 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 67.5 mtm180 -166.96 175.86 7.35 Favored 'General case' 0 C--O 1.24 0.601 0 C-N-CA 123.973 0.909 . . . . 0.0 110.605 176.342 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 70.24 -158.8 53.53 Favored Glycine 0 C--N 1.318 -0.462 0 N-CA-C 111.053 -0.819 . . . . 0.0 111.053 175.103 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 104.93 124.77 5.46 Favored Glycine 0 N--CA 1.442 -0.955 0 N-CA-C 111.977 -0.449 . . . . 0.0 111.977 177.258 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 95.7 mt -116.93 131.64 69.02 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.037 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 174.629 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 4.8 p -120.11 135.04 61.67 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.026 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 -179.138 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 293' ' ' SER . . . . . 0.4 ' HA ' ' O ' ' A' ' 217' ' ' LEU . 15.6 m -132.03 144.81 51.03 Favored 'General case' 0 C--N 1.319 -0.759 0 C-N-CA 120.063 -0.655 . . . . 0.0 112.535 -174.939 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 48.5 tt0 . . . . . 0 CA--C 1.489 -1.381 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 168.31 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 217' ' ' LEU . . . . . 0.476 ' HB3' ' O ' ' A' ' 240' ' ' HIS . 0.2 OUTLIER . . . . . 0 C--O 1.237 0.409 0 N-CA-C 110.223 -0.288 . . . . 0.0 110.223 . . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 16.5 p -136.18 156.16 49.09 Favored 'General case' 0 CA--C 1.51 -0.595 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.509 -177.352 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 219' ' ' ALA . . . . . 0.438 ' HA ' ' HB3' ' A' ' 238' ' ' ALA . . . -150.72 151.2 32.06 Favored 'General case' 0 N--CA 1.448 -0.556 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.134 -178.751 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 220' ' ' MET . . . . . 0.499 ' SD ' HG12 ' A' ' 291' ' ' ILE . 1.5 mpp? -73.67 131.2 41.39 Favored 'General case' 0 C--O 1.244 0.772 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 177.891 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 69.1 t -74.77 131.76 34.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 178.659 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 58.0 m -92.2 -69.09 0.76 Allowed 'General case' 0 N--CA 1.435 -1.176 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.342 179.661 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 12.6 ptm -138.14 148.59 45.07 Favored 'General case' 0 N--CA 1.472 0.63 0 C-N-CA 120.999 -0.281 . . . . 0.0 111.141 172.762 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 224' ' ' VAL . . . . . 0.407 HG21 ' CE1' ' A' ' 286' ' ' TYR . 52.9 t -121.67 129.35 75.58 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 174.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 17.2 p -81.29 128.03 33.36 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 119.85 -0.74 . . . . 0.0 110.54 179.623 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 17.0 tptm -76.4 84.11 3.14 Favored 'General case' 0 N--CA 1.437 -1.097 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 177.463 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 227' ' ' ASP . . . . . 0.543 ' N ' ' OG1' ' A' ' 280' ' ' THR . 4.8 t0 -159.97 175.74 12.67 Favored 'General case' 0 C--O 1.245 0.861 0 CA-C-N 115.53 -0.759 . . . . 0.0 110.304 -176.162 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 228' ' ' ASN . . . . . 0.444 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.1 OUTLIER -143.01 122.75 7.75 Favored Pre-proline 0 C--N 1.321 -0.656 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.838 172.65 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 229' ' ' PRO . . . . . 0.444 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 42.0 Cg_endo -65.23 148.33 73.27 Favored 'Cis proline' 0 N--CA 1.496 1.652 0 C-N-CA 122.908 -1.705 . . . . 0.0 109.875 -1.507 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . 0.463 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -88.43 140.57 16.19 Favored Glycine 0 C--N 1.315 -0.612 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 -177.916 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.4 p -121.01 132.79 69.59 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.579 0 CA-C-N 117.182 0.491 . . . . 0.0 109.791 177.125 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 232' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -129.83 153.63 39.12 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.042 0 C-N-CA 120.038 -0.665 . . . . 0.0 111.214 -176.581 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 233' ' ' THR . . . . . 0.416 ' HA ' ' O ' ' A' ' 273' ' ' TYR . 0.6 OUTLIER -106.84 140.48 39.61 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-N 115.151 -0.931 . . . . 0.0 109.445 178.065 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.8 m -107.07 160.39 15.59 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-N 116.182 -0.463 . . . . 0.0 109.823 -178.339 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 41.5 tp -63.74 131.34 47.58 Favored 'General case' 0 C--N 1.32 -0.674 0 C-N-CA 120.686 -0.406 . . . . 0.0 109.975 -177.678 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 19.0 p-10 -51.61 -44.43 62.88 Favored 'General case' 0 N--CA 1.475 0.801 0 CA-C-N 115.881 -0.6 . . . . 0.0 111.073 -176.628 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 92.6 mt-10 -65.77 -35.24 80.16 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 179.556 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 238' ' ' ALA . . . . . 0.438 ' HB3' ' HA ' ' A' ' 219' ' ' ALA . . . -91.54 92.61 8.58 Favored 'General case' 0 N--CA 1.439 -1.017 0 CA-C-N 115.481 -0.781 . . . . 0.0 111.855 -175.261 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 84.7 mtp180 -75.66 118.13 18.15 Favored 'General case' 0 C--N 1.312 -1.022 0 N-CA-C 108.478 -0.934 . . . . 0.0 108.478 174.386 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 240' ' ' HIS . . . . . 0.615 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 7.1 p80 -60.09 -46.09 90.73 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.799 -176.939 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 78.87 19.12 73.66 Favored Glycine 0 C--O 1.238 0.381 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 -178.532 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 242' ' ' PHE . . . . . 0.495 ' CG ' ' HB2' ' A' ' 240' ' ' HIS . 10.4 m-30 -81.04 146.66 30.53 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 -179.545 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 73.9 mm-40 -101.64 158.88 15.77 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 116.011 -0.54 . . . . 0.0 109.672 172.544 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 16.3 m -66.66 126.72 29.83 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 174.762 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 88.14 2.78 80.06 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -176.491 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 15.2 t0 -79.42 167.51 20.74 Favored 'General case' 0 CA--C 1.516 -0.337 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 178.285 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 247' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -112.66 134.71 54.05 Favored 'General case' 0 C--O 1.244 0.811 0 O-C-N 123.127 0.267 . . . . 0.0 110.874 -176.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 248' ' ' VAL . . . . . 0.404 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.9 m -131.59 160.92 42.03 Favored 'Isoleucine or valine' 0 C--O 1.236 0.369 0 CA-C-O 121.078 0.466 . . . . 0.0 111.899 178.37 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 249' ' ' SER . . . . . 0.41 ' OG ' ' HG3' ' A' ' 264' ' ' PRO . 1.3 m -123.26 153.48 40.13 Favored 'General case' 0 C--O 1.244 0.798 0 CA-C-N 114.893 -1.048 . . . . 0.0 109.229 176.653 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 250' ' ' PHE . . . . . 0.423 ' C ' ' HG ' ' A' ' 251' ' ' SER . 79.3 m-85 -109.43 153.0 24.63 Favored 'General case' 0 CA--C 1.505 -0.773 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.787 -179.357 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 251' ' ' SER . . . . . 0.449 ' O ' ' HA2' ' A' ' 290' ' ' GLY . 39.0 m -152.71 154.69 35.76 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-N 115.694 -0.684 . . . . 0.0 109.196 176.688 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 12.6 mm-40 57.47 21.17 6.71 Favored 'General case' 0 CA--C 1.542 0.655 0 N-CA-C 112.664 0.616 . . . . 0.0 112.664 177.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 61.5 t -76.0 133.89 30.23 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 C-N-CA 120.949 -0.3 . . . . 0.0 111.0 178.759 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 85.2 mt-30 -96.78 136.01 37.93 Favored 'General case' 0 C--O 1.24 0.605 0 O-C-N 123.334 0.396 . . . . 0.0 110.045 179.251 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 76.35 -61.4 3.13 Favored Glycine 0 N--CA 1.463 0.453 0 N-CA-C 111.472 -0.651 . . . . 0.0 111.472 177.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 256' ' ' MET . . . . . 0.621 ' SD ' ' CD1' ' A' ' 259' ' ' LEU . 48.5 ttm -77.67 63.08 2.69 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 178.547 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 48.9 pt -70.22 -20.63 23.01 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 114.914 -1.039 . . . . 0.0 111.136 -173.786 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 258' ' ' GLN . . . . . 0.564 ' HG3' ' SG ' ' A' ' 262' ' ' CYS . 55.7 tp60 -54.76 -39.53 68.42 Favored 'General case' 0 N--CA 1.44 -0.955 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.035 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 259' ' ' LEU . . . . . 0.621 ' CD1' ' SD ' ' A' ' 256' ' ' MET . 97.8 mt -62.58 -41.71 99.11 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.17 -0.468 . . . . 0.0 109.909 178.542 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -61.52 -40.38 94.41 Favored 'General case' 0 CA--C 1.509 -0.598 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 178.377 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -94.64 13.12 67.81 Favored Glycine 0 CA--C 1.527 0.801 0 CA-C-N 115.395 -0.82 . . . . 0.0 111.775 -178.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 262' ' ' CYS . . . . . 0.564 ' SG ' ' HG3' ' A' ' 258' ' ' GLN . 1.0 OUTLIER -105.64 156.92 17.8 Favored 'General case' 0 CA--C 1.508 -0.637 0 CA-C-N 117.45 0.625 . . . . 0.0 112.322 -178.051 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 28.4 mt-30 -71.52 158.38 88.03 Favored Pre-proline 0 C--N 1.319 -0.733 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 171.431 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 264' ' ' PRO . . . . . 0.41 ' HG3' ' OG ' ' A' ' 249' ' ' SER . 26.0 Cg_exo -61.87 147.47 95.15 Favored 'Trans proline' 0 C--N 1.304 -1.809 0 C-N-CA 121.347 1.365 . . . . 0.0 110.551 177.514 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 265' ' ' MET . . . . . . . . . . . . . 4.4 ptp -125.64 164.78 19.84 Favored 'General case' 0 N--CA 1.473 0.706 0 N-CA-C 111.79 0.293 . . . . 0.0 111.79 -177.673 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 266' ' ' GLU . . . . . 0.4 ' C ' HG21 ' A' ' 267' ' ' ILE . 31.9 tt0 -71.04 142.62 50.88 Favored 'General case' 0 CA--C 1.513 -0.443 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 176.517 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 267' ' ' ILE . . . . . 0.498 HG22 ' CE2' ' A' ' 275' ' ' PHE . 1.7 pp -131.04 160.04 42.56 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 CA-C-O 121.054 0.454 . . . . 0.0 111.611 -179.82 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 55.5 mttm -130.6 110.63 11.55 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -177.187 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 27.7 m -77.17 102.1 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 CA-C-O 121.389 0.614 . . . . 0.0 112.255 -176.771 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 97.0 mt -69.6 -39.11 77.46 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.521 177.208 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -144.26 -175.34 17.3 Favored Glycine 0 N--CA 1.461 0.361 0 N-CA-C 109.977 -1.249 . . . . 0.0 109.977 -178.434 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 272' ' ' PRO . . . . . 0.615 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 36.9 Cg_endo -62.15 -34.27 79.61 Favored 'Trans proline' 0 C--N 1.313 -1.341 0 C-N-CA 121.888 1.725 . . . . 0.0 110.939 -177.914 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 273' ' ' TYR . . . . . 0.416 ' O ' ' HA ' ' A' ' 233' ' ' THR . 94.4 m-85 -123.12 6.57 9.19 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.575 -0.739 . . . . 0.0 112.253 -179.796 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 2.2 p -117.11 127.39 54.09 Favored 'General case' 0 C--O 1.244 0.795 0 CA-C-O 121.046 0.45 . . . . 0.0 110.901 179.455 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 275' ' ' PHE . . . . . 0.576 ' C ' ' CD1' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -137.28 161.94 34.87 Favored 'General case' 0 CA--C 1.502 -0.872 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.092 -179.085 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 276' ' ' SER . . . . . 0.463 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 4.4 p -132.22 145.84 51.6 Favored 'General case' 0 C--N 1.309 -1.163 0 C-N-CA 120.369 -0.532 . . . . 0.0 112.124 -173.864 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 28.0 pt -139.22 164.77 24.43 Favored 'Isoleucine or valine' 0 C--O 1.243 0.726 0 CA-C-N 114.744 -1.117 . . . . 0.0 112.899 -172.368 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 2.2 m -28.63 -88.27 0.0 OUTLIER 'General case' 0 C--O 1.237 0.405 0 N-CA-C 113.928 1.084 . . . . 0.0 113.928 -176.099 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 59.8 t0 -152.4 115.65 4.7 Favored 'General case' 0 CA--C 1.507 -0.696 0 CA-C-O 120.695 0.283 . . . . 0.0 110.793 -175.764 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 280' ' ' THR . . . . . 0.658 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 29.7 p -64.84 -29.53 70.49 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-O 121.023 0.44 . . . . 0.0 110.732 175.611 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -64.64 -23.74 67.36 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.324 175.751 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 18.0 t-20 -89.2 -9.31 51.3 Favored 'General case' 0 CA--C 1.509 -0.612 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.77 -179.557 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 283' ' ' PHE . . . . . 0.658 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 15.7 m-85 -92.46 -75.27 0.49 Allowed 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 121.641 0.734 . . . . 0.0 109.372 174.938 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 284' ' ' SER . . . . . 0.47 ' HG ' ' C ' ' A' ' 283' ' ' PHE . 0.1 OUTLIER 165.6 -174.23 0.02 OUTLIER 'General case' 0 C--N 1.313 -1.0 0 N-CA-C 106.835 -1.543 . . . . 0.0 106.835 -174.066 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -94.98 121.56 36.72 Favored 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 119.687 -0.805 . . . . 0.0 111.899 -179.782 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 286' ' ' TYR . . . . . 0.407 ' CE1' HG21 ' A' ' 224' ' ' VAL . 3.3 t80 -72.74 108.19 5.6 Favored 'General case' 0 C--O 1.236 0.386 0 C-N-CA 123.535 0.734 . . . . 0.0 109.744 -177.359 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 287' ' ' ILE . . . . . 0.519 ' O ' ' HB3' ' A' ' 288' ' ' ARG . 89.9 mt -67.39 -44.94 86.72 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.66 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 173.077 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . 0.519 ' HB3' ' O ' ' A' ' 287' ' ' ILE . 7.4 ptm180 157.95 -161.26 0.0 OUTLIER 'General case' 0 C--O 1.237 0.409 0 C-N-CA 124.89 1.276 . . . . 0.0 109.164 177.476 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . 0.48 ' N ' ' HG3' ' A' ' 288' ' ' ARG . . . 70.99 -157.16 53.51 Favored Glycine 0 CA--C 1.5 -0.903 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 176.498 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 290' ' ' GLY . . . . . 0.449 ' HA2' ' O ' ' A' ' 251' ' ' SER . . . 88.84 145.82 12.02 Favored Glycine 0 N--CA 1.436 -1.309 0 CA-C-O 121.533 0.518 . . . . 0.0 112.714 175.52 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . 0.499 HG12 ' SD ' ' A' ' 220' ' ' MET . 92.6 mt -123.41 128.52 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.344 0 N-CA-C 106.74 -1.578 . . . . 0.0 106.74 172.658 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 14.8 p -107.68 130.6 59.74 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.823 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 -179.801 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 3.8 m -132.27 146.9 52.32 Favored 'General case' 0 CA--C 1.506 -0.73 0 C-N-CA 120.52 -0.472 . . . . 0.0 112.187 -173.817 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 49.2 tt0 . . . . . 0 CA--C 1.497 -1.085 0 CA-C-N 115.342 -0.844 . . . . 0.0 109.601 174.368 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 217' ' ' LEU . . . . . 0.447 ' HB3' ' O ' ' A' ' 240' ' ' HIS . 3.7 mm? . . . . . 0 CA--C 1.509 -0.627 0 CA-C-O 120.524 0.202 . . . . 0.0 111.524 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 3.7 m -132.22 132.1 42.77 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 175.423 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -145.38 152.95 40.67 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-O 120.744 0.307 . . . . 0.0 110.762 179.551 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -73.71 134.8 43.59 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.055 178.745 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 98.7 t -80.17 131.12 34.82 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.102 0 N-CA-C 107.406 -1.331 . . . . 0.0 107.406 172.553 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 11.8 p -95.69 -60.48 1.64 Allowed 'General case' 0 N--CA 1.439 -1.016 0 C-N-CA 120.237 -0.585 . . . . 0.0 110.645 -177.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 223' ' ' MET . . . . . 0.568 ' C ' ' SD ' ' A' ' 223' ' ' MET . 0.5 OUTLIER -138.42 141.7 39.54 Favored 'General case' 0 C--O 1.221 -0.407 0 N-CA-C 112.219 0.452 . . . . 0.0 112.219 175.78 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 224' ' ' VAL . . . . . 0.455 ' N ' ' SD ' ' A' ' 223' ' ' MET . 48.4 t -125.19 132.25 71.41 Favored 'Isoleucine or valine' 0 C--O 1.24 0.587 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 177.441 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 225' ' ' THR . . . . . 0.474 HG23 ' SD ' ' A' ' 223' ' ' MET . 5.5 p -99.76 117.36 33.92 Favored 'General case' 0 C--O 1.237 0.424 0 C-N-CA 120.373 -0.531 . . . . 0.0 110.324 176.897 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 226' ' ' LYS . . . . . 0.402 ' HD3' ' HA ' ' A' ' 281' ' ' SER . 0.0 OUTLIER -67.55 85.51 0.19 Allowed 'General case' 0 C--O 1.242 0.687 0 N-CA-C 110.151 -0.315 . . . . 0.0 110.151 178.756 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 227' ' ' ASP . . . . . 0.594 ' N ' ' OG1' ' A' ' 280' ' ' THR . 4.2 t70 -150.73 -177.61 6.09 Favored 'General case' 0 C--O 1.242 0.686 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.518 -179.045 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 228' ' ' ASN . . . . . 0.473 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.0 OUTLIER -141.28 125.59 10.39 Favored Pre-proline 0 N--CA 1.467 0.396 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.967 174.96 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 229' ' ' PRO . . . . . 0.473 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 55.7 Cg_endo -66.17 147.77 75.18 Favored 'Cis proline' 0 N--CA 1.496 1.634 0 C-N-CA 123.347 -1.522 . . . . 0.0 110.116 -0.566 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -70.71 138.45 28.61 Favored Glycine 0 N--CA 1.449 -0.473 0 N-CA-C 110.004 -1.238 . . . . 0.0 110.004 -178.154 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 1.8 p -125.69 131.78 71.6 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.804 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 176.335 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 232' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -137.28 157.0 34.43 Favored 'Isoleucine or valine' 0 C--O 1.248 0.988 0 C-N-CA 120.103 -0.639 . . . . 0.0 111.548 -177.553 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 6.0 m -113.07 146.9 38.35 Favored 'General case' 0 C--N 1.309 -1.162 0 CA-C-N 114.987 -1.006 . . . . 0.0 109.532 178.613 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 24.7 m -107.36 160.97 15.22 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 178.244 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 45.2 tp -59.31 128.61 37.97 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 179.431 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -51.35 -44.78 62.15 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.846 -175.164 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 76.8 mt-10 -65.85 -33.08 75.01 Favored 'General case' 0 C--N 1.311 -1.066 0 C-N-CA 120.724 -0.39 . . . . 0.0 111.147 178.834 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -91.62 102.68 15.32 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.729 -175.1 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 78.5 mtm-85 -74.22 127.36 32.77 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 107.717 -1.216 . . . . 0.0 107.717 174.713 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 240' ' ' HIS . . . . . 0.52 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 6.8 p80 -66.28 -45.45 80.44 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 121.137 0.494 . . . . 0.0 110.855 -179.018 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 81.45 12.12 82.33 Favored Glycine 0 C--N 1.311 -0.823 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 -178.257 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 242' ' ' PHE . . . . . 0.483 ' CD2' ' HB2' ' A' ' 240' ' ' HIS . 4.0 m-30 -81.5 151.95 27.55 Favored 'General case' 0 CA--C 1.504 -0.804 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 178.373 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -130.57 158.07 40.98 Favored 'General case' 0 C--N 1.309 -1.178 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 177.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 22.8 m -57.85 127.97 34.71 Favored 'General case' 0 C--N 1.306 -1.284 0 C-N-CA 120.007 -0.677 . . . . 0.0 109.973 -177.26 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 92.06 -6.41 78.91 Favored Glycine 0 N--CA 1.449 -0.497 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.609 -179.019 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 246' ' ' ASP . . . . . 0.421 ' CG ' HE21 ' A' ' 294' ' ' GLN . 1.7 t70 -79.24 162.4 25.71 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 117.223 0.511 . . . . 0.0 111.004 -179.821 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 247' ' ' PHE . . . . . 0.46 ' HA ' ' O ' ' A' ' 265' ' ' MET . 73.0 m-85 -111.94 131.39 55.41 Favored 'General case' 0 C--O 1.24 0.574 0 N-CA-C 112.241 0.46 . . . . 0.0 112.241 -176.076 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 248' ' ' VAL . . . . . 0.433 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.6 m -132.71 158.88 43.39 Favored 'Isoleucine or valine' 0 C--O 1.235 0.319 0 CA-C-O 120.873 0.368 . . . . 0.0 111.809 177.397 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 49.6 m -123.92 160.55 27.28 Favored 'General case' 0 C--N 1.319 -0.734 0 C-N-CA 124.498 1.119 . . . . 0.0 108.565 173.029 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 250' ' ' PHE . . . . . 0.534 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 68.4 m-85 -110.63 146.72 35.68 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 120.461 0.172 . . . . 0.0 111.081 -177.364 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 1.5 m -133.54 153.39 51.68 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 176.24 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . 0.418 ' O ' ' NE2' ' A' ' 254' ' ' GLN . 79.1 mm-40 55.37 30.34 14.71 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 112.81 0.671 . . . . 0.0 112.81 173.213 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . 0.485 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 51.3 t -89.01 134.69 27.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 N-CA-C 110.231 -0.285 . . . . 0.0 110.231 177.319 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . 0.418 ' NE2' ' O ' ' A' ' 252' ' ' GLU . 3.9 mp0 -99.81 135.19 41.61 Favored 'General case' 0 C--O 1.239 0.518 0 CA-C-O 121.031 0.443 . . . . 0.0 110.658 178.909 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 83.37 -55.08 5.02 Favored Glycine 0 C--N 1.32 -0.321 0 N-CA-C 111.098 -0.801 . . . . 0.0 111.098 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 256' ' ' MET . . . . . 0.524 ' SD ' ' CD1' ' A' ' 259' ' ' LEU . 4.6 ttm -83.41 69.47 10.03 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 178.481 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 257' ' ' ILE . . . . . 0.42 HG23 HD13 ' A' ' 257' ' ' ILE . 45.5 pt -72.69 -22.23 20.08 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.916 0 CA-C-N 114.78 -1.1 . . . . 0.0 111.075 -174.78 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 258' ' ' GLN . . . . . 0.496 ' O ' ' SG ' ' A' ' 262' ' ' CYS . 23.4 mp0 -59.34 -41.49 89.29 Favored 'General case' 0 C--N 1.313 -0.994 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 179.359 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 259' ' ' LEU . . . . . 0.534 ' HB3' ' CG ' ' A' ' 250' ' ' PHE . 90.4 mt -62.8 -41.92 99.49 Favored 'General case' 0 N--CA 1.443 -0.802 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.589 178.198 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 260' ' ' ASN . . . . . 0.485 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 89.5 m-20 -60.44 -41.22 93.6 Favored 'General case' 0 CA--C 1.507 -0.678 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 -179.206 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -100.39 14.11 59.6 Favored Glycine 0 C--N 1.316 -0.583 0 N-CA-C 111.359 -0.696 . . . . 0.0 111.359 -178.495 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 262' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 258' ' ' GLN . 1.2 m -85.62 144.81 27.65 Favored 'General case' 0 C--O 1.242 0.707 0 C-N-CA 120.714 -0.394 . . . . 0.0 110.786 -179.607 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 95.7 mm-40 -68.96 162.96 60.87 Favored Pre-proline 0 C--N 1.315 -0.892 0 N-CA-C 107.4 -1.333 . . . . 0.0 107.4 170.224 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 264' ' ' PRO . . . . . 0.433 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 24.1 Cg_exo -61.46 143.89 97.71 Favored 'Trans proline' 0 C--N 1.307 -1.637 0 N-CA-C 109.562 -0.976 . . . . 0.0 109.562 -178.129 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 265' ' ' MET . . . . . 0.46 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 8.9 ptp -126.65 150.8 48.74 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 116.689 -0.232 . . . . 0.0 110.935 -175.296 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -70.92 137.49 49.29 Favored 'General case' 0 C--O 1.242 0.686 0 O-C-N 123.828 0.705 . . . . 0.0 109.14 178.846 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 267' ' ' ILE . . . . . 0.44 HG22 ' CE2' ' A' ' 275' ' ' PHE . 1.9 pp -127.24 161.24 34.89 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-O 120.867 0.365 . . . . 0.0 111.601 -175.727 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.38 120.87 29.47 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 176.621 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 28.3 m -69.92 133.71 31.39 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 C-N-CA 120.653 -0.419 . . . . 0.0 111.337 -177.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 74.5 mt -97.06 -46.08 6.32 Favored 'General case' 0 CA--C 1.508 -0.67 0 CA-C-O 121.422 0.63 . . . . 0.0 109.537 177.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -149.25 -171.46 17.92 Favored Glycine 0 C--N 1.311 -0.843 0 N-CA-C 108.428 -1.869 . . . . 0.0 108.428 179.84 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 272' ' ' PRO . . . . . 0.52 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 37.8 Cg_endo -62.71 -30.66 78.63 Favored 'Trans proline' 0 C--N 1.301 -1.957 0 C-N-CA 121.332 1.355 . . . . 0.0 111.054 -179.12 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 95.3 m-85 -122.86 11.45 9.66 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 113.32 0.859 . . . . 0.0 113.32 -178.07 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 20.4 p -130.09 146.38 51.74 Favored 'General case' 0 C--O 1.241 0.638 0 C-N-CA 120.66 -0.416 . . . . 0.0 111.259 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 275' ' ' PHE . . . . . 0.502 ' C ' ' CD1' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -150.0 166.1 30.7 Favored 'General case' 0 C--O 1.243 0.736 0 N-CA-C 112.1 0.408 . . . . 0.0 112.1 177.161 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -129.21 141.83 51.03 Favored 'General case' 0 N--CA 1.438 -1.046 0 C-N-CA 120.535 -0.466 . . . . 0.0 111.382 179.643 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 277' ' ' ILE . . . . . 0.432 ' O ' ' C ' ' A' ' 278' ' ' CYS . 39.4 pt -136.17 166.38 26.95 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.79 0 CA-C-N 114.649 -1.159 . . . . 0.0 111.227 -171.653 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 278' ' ' CYS . . . . . 0.432 ' C ' ' O ' ' A' ' 277' ' ' ILE . 0.9 OUTLIER -21.3 -93.53 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 123.845 0.858 . . . . 0.0 113.137 -176.831 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . 0.444 ' OD1' ' N ' ' A' ' 281' ' ' SER . 60.9 t0 -151.98 116.41 5.04 Favored 'General case' 0 CA--C 1.508 -0.645 0 CA-C-N 116.639 -0.255 . . . . 0.0 110.53 -177.937 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 280' ' ' THR . . . . . 0.708 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 11.8 p -66.38 -26.73 67.4 Favored 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 120.508 -0.477 . . . . 0.0 110.832 175.014 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 281' ' ' SER . . . . . 0.444 ' N ' ' OD1' ' A' ' 279' ' ' ASP . 0.8 OUTLIER -66.38 -20.73 66.15 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.497 -0.774 . . . . 0.0 109.511 174.582 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -87.51 -9.7 53.79 Favored 'General case' 0 CA--C 1.504 -0.797 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 178.316 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 283' ' ' PHE . . . . . 0.708 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 8.0 m-85 -92.18 -82.9 0.31 Allowed 'General case' 0 N--CA 1.44 -0.943 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 170.921 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 284' ' ' SER . . . . . 0.427 ' H ' ' HB2' ' A' ' 283' ' ' PHE . 9.5 t 169.1 -149.18 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 177.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -85.74 166.44 16.1 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-O 120.59 0.234 . . . . 0.0 110.414 174.655 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 286' ' ' TYR . . . . . 0.489 ' OH ' ' HA3' ' A' ' 290' ' ' GLY . 12.9 t80 -119.55 102.04 8.36 Favored 'General case' 0 N--CA 1.467 0.394 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 178.486 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 287' ' ' ILE . . . . . 0.505 ' O ' ' HB3' ' A' ' 288' ' ' ARG . 93.4 mt -66.79 -45.53 87.65 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.824 0 C-N-CA 120.211 -0.596 . . . . 0.0 110.287 -179.085 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . 0.505 ' HB3' ' O ' ' A' ' 287' ' ' ILE . 14.7 ptm180 168.4 -173.51 0.02 OUTLIER 'General case' 0 C--O 1.238 0.492 0 O-C-N 123.934 0.771 . . . . 0.0 111.165 -176.45 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 64.96 -147.38 50.99 Favored Glycine 0 C--N 1.338 0.691 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.55 174.313 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 290' ' ' GLY . . . . . 0.489 ' HA3' ' OH ' ' A' ' 286' ' ' TYR . . . 92.16 127.5 4.16 Favored Glycine 0 N--CA 1.443 -0.87 0 CA-C-O 121.252 0.362 . . . . 0.0 113.399 174.636 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . 0.428 HG23 HD11 ' A' ' 291' ' ' ILE . 95.0 mt -115.76 127.69 73.26 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.047 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 170.84 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 7.4 p -98.89 132.06 44.91 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 179.641 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -121.42 122.85 40.7 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-N 115.473 -0.785 . . . . 0.0 110.525 -172.331 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 294' ' ' GLN . . . . . 0.475 ' HB2' ' CE1' ' A' ' 242' ' ' PHE . 49.0 tt0 . . . . . 0 CA--C 1.497 -1.086 0 C-N-CA 119.973 -0.691 . . . . 0.0 109.218 172.647 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 217' ' ' LEU . . . . . 0.514 ' O ' ' HA ' ' A' ' 293' ' ' SER . 0.5 OUTLIER . . . . . 0 CA--C 1.493 -1.233 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 . . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 3.0 m -115.43 132.01 56.75 Favored 'General case' 0 C--N 1.313 -1.011 0 O-C-N 123.445 0.465 . . . . 0.0 110.097 -176.2 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 219' ' ' ALA . . . . . 0.404 ' HA ' ' HB2' ' A' ' 238' ' ' ALA . . . -134.4 142.66 47.23 Favored 'General case' 0 N--CA 1.449 -0.516 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.02 -178.804 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 220' ' ' MET . . . . . 0.618 ' SD ' HG12 ' A' ' 291' ' ' ILE . 99.6 mmm -72.18 131.93 43.44 Favored 'General case' 0 C--O 1.244 0.764 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.255 175.829 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 80.5 t -85.11 128.14 39.29 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.999 0 N-CA-C 108.971 -0.752 . . . . 0.0 108.971 178.798 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 222' ' ' SER . . . . . 0.491 ' OG ' ' N ' ' A' ' 223' ' ' MET . 0.1 OUTLIER -79.82 -72.66 0.39 Allowed 'General case' 0 N--CA 1.434 -1.247 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 177.924 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 223' ' ' MET . . . . . 0.491 ' N ' ' OG ' ' A' ' 222' ' ' SER . 8.6 ptm -137.69 147.15 44.59 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.703 -0.68 . . . . 0.0 111.646 175.612 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 224' ' ' VAL . . . . . . . . . . . . . 59.6 t -122.07 130.16 74.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 175.447 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 41.0 p -77.31 134.72 38.44 Favored 'General case' 0 C--N 1.321 -0.668 0 C-N-CA 120.604 -0.438 . . . . 0.0 110.775 179.451 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 21.8 tptm -77.63 65.66 3.18 Favored 'General case' 0 C--O 1.24 0.596 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 174.784 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 227' ' ' ASP . . . . . 0.472 ' N ' ' OG1' ' A' ' 280' ' ' THR . 2.3 t0 -147.33 177.41 9.24 Favored 'General case' 0 C--O 1.245 0.816 0 CA-C-N 115.41 -0.814 . . . . 0.0 111.251 -171.802 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 228' ' ' ASN . . . . . 0.568 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 16.0 p-10 -144.13 124.39 7.58 Favored Pre-proline 0 C--N 1.319 -0.754 0 CA-C-N 115.525 -0.762 . . . . 0.0 110.82 175.755 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 229' ' ' PRO . . . . . 0.568 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 34.1 Cg_exo -60.18 143.18 33.09 Favored 'Cis proline' 0 N--CA 1.489 1.256 0 C-N-CA 123.14 -1.608 . . . . 0.0 110.926 -1.192 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . 0.496 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -74.79 131.06 12.25 Favored Glycine 0 C--N 1.296 -1.681 0 N-CA-C 108.184 -1.966 . . . . 0.0 108.184 176.221 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.1 p -124.96 133.39 69.6 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.791 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 232' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -131.01 155.57 42.07 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.224 0 C-N-CA 120.27 -0.572 . . . . 0.0 110.863 -176.446 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 63.3 m -108.85 135.08 50.64 Favored 'General case' 0 C--N 1.307 -1.254 0 CA-C-N 115.247 -0.888 . . . . 0.0 108.636 176.553 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 44.6 m -105.64 151.11 24.8 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 -177.334 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 38.6 tp -56.24 132.11 49.77 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 -175.528 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 236' ' ' ASP . . . . . 0.541 ' O ' ' NH2' ' A' ' 239' ' ' ARG . 23.0 p-10 -52.42 -44.23 65.31 Favored 'General case' 0 N--CA 1.474 0.734 0 CA-C-O 121.072 0.463 . . . . 0.0 110.606 -174.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 99.6 mt-10 -64.59 -34.91 79.36 Favored 'General case' 0 C--N 1.302 -1.466 0 CA-C-N 115.641 -0.708 . . . . 0.0 110.421 178.62 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 238' ' ' ALA . . . . . 0.404 ' HB2' ' HA ' ' A' ' 219' ' ' ALA . . . -79.76 73.63 6.48 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 116.004 -0.544 . . . . 0.0 112.176 -174.759 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 239' ' ' ARG . . . . . 0.541 ' NH2' ' O ' ' A' ' 236' ' ' ASP . 0.0 OUTLIER -58.2 90.19 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.024 0.44 . . . . 0.0 110.607 176.477 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 240' ' ' HIS . . . . . 0.481 ' O ' ' HB3' ' A' ' 217' ' ' LEU . 9.1 p80 -55.19 -48.57 73.63 Favored 'General case' 0 C--O 1.217 -0.629 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.249 -175.411 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 78.3 24.56 63.18 Favored Glycine 0 C--N 1.311 -0.858 0 N-CA-C 110.874 -0.891 . . . . 0.0 110.874 179.25 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 242' ' ' PHE . . . . . . . . . . . . . 9.3 m-30 -80.19 144.16 33.2 Favored 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 177.869 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -116.03 158.42 23.15 Favored 'General case' 0 C--N 1.312 -1.052 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.737 -177.695 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -56.58 118.03 4.45 Favored 'General case' 0 C--N 1.311 -1.069 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 178.618 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . 0.463 ' HA2' ' CG ' ' A' ' 266' ' ' GLU . . . 86.85 5.95 80.4 Favored Glycine 0 C--O 1.243 0.672 0 C-N-CA 120.847 -0.692 . . . . 0.0 111.892 -179.531 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -83.14 163.99 20.5 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-N 117.199 0.499 . . . . 0.0 109.913 177.676 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 247' ' ' PHE . . . . . 0.416 ' HA ' ' O ' ' A' ' 265' ' ' MET . 74.9 m-85 -111.18 135.79 51.19 Favored 'General case' 0 C--O 1.238 0.483 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -173.521 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 248' ' ' VAL . . . . . 0.414 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 3.1 m -131.13 161.92 40.17 Favored 'Isoleucine or valine' 0 C--O 1.237 0.421 0 CA-C-O 121.063 0.458 . . . . 0.0 111.996 178.62 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 2.5 m -125.9 165.09 19.36 Favored 'General case' 0 C--N 1.321 -0.664 0 C-N-CA 124.773 1.229 . . . . 0.0 108.115 173.506 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 250' ' ' PHE . . . . . 0.528 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 96.5 m-85 -124.31 156.78 36.37 Favored 'General case' 0 C--N 1.317 -0.816 0 N-CA-C 110.505 -0.183 . . . . 0.0 110.505 -176.115 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 1.2 m -156.62 161.27 39.92 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.222 -0.444 . . . . 0.0 109.823 176.368 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 16.2 mt-10 51.85 28.63 5.19 Favored 'General case' 0 C--N 1.314 -0.939 0 N-CA-C 112.305 0.483 . . . . 0.0 112.305 177.865 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 3.2 t -92.78 127.4 44.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 176.363 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 77.3 mt-30 -91.27 138.16 31.81 Favored 'General case' 0 C--O 1.241 0.609 0 CA-C-O 120.827 0.346 . . . . 0.0 110.585 -177.508 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 76.23 -58.45 3.22 Favored Glycine 0 C--N 1.319 -0.376 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 -179.052 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 256' ' ' MET . . . . . 0.471 ' SD ' HD11 ' A' ' 259' ' ' LEU . 30.7 ttm -77.32 50.36 0.77 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.429 0.633 . . . . 0.0 109.603 176.619 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 46.2 pt -71.11 -18.05 20.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-N 115.233 -0.894 . . . . 0.0 111.218 -175.12 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 258' ' ' GLN . . . . . 0.557 ' HG3' ' SG ' ' A' ' 262' ' ' CYS . 68.5 tp60 -54.86 -38.37 67.39 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 177.897 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 259' ' ' LEU . . . . . 0.528 ' HB3' ' CG ' ' A' ' 250' ' ' PHE . 93.7 mt -62.22 -40.48 96.24 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.506 -0.77 . . . . 0.0 110.197 176.343 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -59.49 -40.24 86.37 Favored 'General case' 0 CA--C 1.51 -0.59 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 -179.186 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -101.97 21.99 39.85 Favored Glycine 0 CA--C 1.524 0.656 0 CA-C-N 115.927 -0.578 . . . . 0.0 112.049 -179.312 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 262' ' ' CYS . . . . . 0.557 ' SG ' ' HG3' ' A' ' 258' ' ' GLN . 1.3 m -95.95 149.35 21.66 Favored 'General case' 0 C--O 1.236 0.382 0 CA-C-N 117.33 0.565 . . . . 0.0 111.488 -179.429 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . 0.47 ' N ' ' CD ' ' A' ' 263' ' ' GLN . 16.6 mp0 -67.66 156.07 89.82 Favored Pre-proline 0 C--N 1.325 -0.475 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 172.572 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 264' ' ' PRO . . . . . 0.414 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 37.3 Cg_endo -62.67 143.09 91.77 Favored 'Trans proline' 0 C--N 1.308 -1.575 0 C-N-CA 120.722 0.948 . . . . 0.0 110.25 179.131 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 265' ' ' MET . . . . . 0.416 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 22.5 ptp -130.55 155.01 47.23 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.663 -173.513 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 266' ' ' GLU . . . . . 0.463 ' CG ' ' HA2' ' A' ' 245' ' ' GLY . 39.7 tt0 -71.8 144.56 49.11 Favored 'General case' 0 C--O 1.239 0.535 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 177.777 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 267' ' ' ILE . . . . . . . . . . . . . 2.1 pp -128.27 162.06 35.46 Favored 'Isoleucine or valine' 0 C--O 1.249 1.043 0 N-CA-C 113.608 0.966 . . . . 0.0 113.608 -175.221 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 25.7 mtpp -118.7 109.42 16.08 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 114.762 -1.108 . . . . 0.0 109.66 -178.406 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 8.2 m -80.65 96.04 2.71 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.457 0 C-N-CA 120.275 -0.57 . . . . 0.0 111.268 178.103 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 98.4 mt -67.25 -40.59 86.26 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.406 0.622 . . . . 0.0 110.131 178.128 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -139.64 177.54 20.38 Favored Glycine 0 C--N 1.315 -0.609 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.29 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_endo -60.1 -31.54 93.47 Favored 'Trans proline' 0 C--N 1.302 -1.881 0 C-N-CA 121.772 1.648 . . . . 0.0 111.233 -178.769 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 22.9 m-85 -123.94 11.08 8.93 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.422 179.383 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -122.52 125.67 46.23 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 116.025 -0.534 . . . . 0.0 109.654 -176.276 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 275' ' ' PHE . . . . . 0.545 ' C ' ' CD1' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -138.68 164.02 30.61 Favored 'General case' 0 CA--C 1.501 -0.931 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 -179.611 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 276' ' ' SER . . . . . 0.496 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 6.4 p -137.49 159.07 42.97 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.456 -178.082 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 277' ' ' ILE . . . . . 0.584 HD12 ' CE2' ' A' ' 283' ' ' PHE . 2.5 pp -138.05 -173.74 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 CA-C-N 114.977 -1.01 . . . . 0.0 109.948 -175.825 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 278' ' ' CYS . . . . . 0.451 ' O ' ' HA ' ' A' ' 229' ' ' PRO . 1.2 p -46.87 -93.83 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.304 0 O-C-N 123.324 0.39 . . . . 0.0 111.812 -179.694 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -137.55 126.75 24.55 Favored 'General case' 0 CA--C 1.514 -0.406 0 N-CA-C 109.541 -0.541 . . . . 0.0 109.541 -179.323 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 280' ' ' THR . . . . . 0.605 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 25.0 p -69.56 -23.76 63.61 Favored 'General case' 0 C--N 1.317 -0.808 0 C-N-CA 119.436 -0.906 . . . . 0.0 108.682 171.06 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -61.85 -21.05 64.34 Favored 'General case' 0 N--CA 1.435 -1.199 0 CA-C-N 114.635 -1.166 . . . . 0.0 108.812 173.802 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 29.3 t-20 -89.22 -9.13 51.92 Favored 'General case' 0 CA--C 1.509 -0.621 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.481 175.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 283' ' ' PHE . . . . . 0.605 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 19.5 m-30 -95.79 -87.91 0.28 Allowed 'General case' 0 N--CA 1.444 -0.74 0 CA-C-O 121.524 0.678 . . . . 0.0 110.456 178.396 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 284' ' ' SER . . . . . 0.464 ' HG ' ' C ' ' A' ' 283' ' ' PHE . 0.0 OUTLIER 170.3 -170.22 0.02 OUTLIER 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 107.689 -1.226 . . . . 0.0 107.689 -173.44 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -94.06 131.37 39.62 Favored 'General case' 0 N--CA 1.471 0.623 0 CA-C-N 118.646 0.657 . . . . 0.0 112.766 -176.052 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 286' ' ' TYR . . . . . 0.474 ' CD2' ' O ' ' A' ' 286' ' ' TYR . 60.8 t80 -68.87 87.04 0.35 Allowed 'General case' 0 N--CA 1.472 0.639 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.177 177.399 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 287' ' ' ILE . . . . . 0.478 ' O ' ' HG3' ' A' ' 288' ' ' ARG . 87.5 mt -69.94 -48.05 65.58 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.723 0 C-N-CA 120.298 -0.561 . . . . 0.0 110.806 175.405 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . 0.478 ' HG3' ' O ' ' A' ' 287' ' ' ILE . 43.8 mtp180 -170.52 170.67 6.78 Favored 'General case' 0 N--CA 1.47 0.574 0 N-CA-C 112.986 0.735 . . . . 0.0 112.986 -179.114 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 56.48 -143.55 38.51 Favored Glycine 0 N--CA 1.466 0.681 0 CA-C-N 113.77 -1.559 . . . . 0.0 113.199 167.483 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 100.71 130.31 6.99 Favored Glycine 0 N--CA 1.441 -1.009 0 CA-C-O 121.163 0.313 . . . . 0.0 112.506 178.93 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . 0.618 HG12 ' SD ' ' A' ' 220' ' ' MET . 95.2 mt -116.29 129.82 72.08 Favored 'Isoleucine or valine' 0 C--O 1.244 0.769 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 171.675 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 7.2 p -109.31 130.35 62.47 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.064 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 176.789 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 293' ' ' SER . . . . . 0.514 ' HA ' ' O ' ' A' ' 217' ' ' LEU . 3.2 m -131.08 138.73 49.69 Favored 'General case' 0 N--CA 1.441 -0.875 0 C-N-CA 120.43 -0.508 . . . . 0.0 111.558 -175.124 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 2.7 tm0? . . . . . 0 C--N 1.316 -0.88 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 173.29 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 217' ' ' LEU . . . . . 0.404 ' HB3' ' O ' ' A' ' 240' ' ' HIS . 0.2 OUTLIER . . . . . 0 C--O 1.239 0.549 0 CA-C-O 120.89 0.376 . . . . 0.0 110.327 . . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 218' ' ' SER . . . . . 0.559 ' CB ' ' HG ' ' A' ' 293' ' ' SER . 8.5 t -151.72 152.61 32.98 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.012 -175.683 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -143.57 160.38 40.73 Favored 'General case' 0 C--O 1.244 0.797 0 CA-C-O 120.918 0.389 . . . . 0.0 110.95 178.413 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 97.2 mtp -71.57 136.73 47.58 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.463 -0.79 . . . . 0.0 109.239 176.474 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 91.1 t -83.7 129.48 37.46 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.052 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 178.027 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 74.9 m -79.79 -73.05 0.37 Allowed 'General case' 0 N--CA 1.432 -1.34 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 177.704 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 223' ' ' MET . . . . . 0.463 ' SD ' ' HB ' ' A' ' 233' ' ' THR . 1.0 OUTLIER -139.71 161.95 36.31 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.111 172.771 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 224' ' ' VAL . . . . . 0.428 ' HA ' ' HB ' ' A' ' 232' ' ' VAL . 69.6 t -127.37 129.8 70.69 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 175.749 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 225' ' ' THR . . . . . 0.428 ' O ' HG23 ' A' ' 280' ' ' THR . 75.4 p -78.88 131.25 36.35 Favored 'General case' 0 C--O 1.225 -0.225 0 C-N-CA 120.08 -0.648 . . . . 0.0 110.163 177.615 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 226' ' ' LYS . . . . . 0.498 ' HE3' ' HA ' ' A' ' 281' ' ' SER . 0.0 OUTLIER -77.72 52.28 1.0 Allowed 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 120.723 0.297 . . . . 0.0 110.868 -179.012 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 227' ' ' ASP . . . . . 0.504 ' CG ' ' H ' ' A' ' 228' ' ' ASN . 42.3 t0 -131.29 -179.8 5.57 Favored 'General case' 0 C--O 1.242 0.674 0 CA-C-O 120.862 0.363 . . . . 0.0 111.952 -178.562 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 228' ' ' ASN . . . . . 0.504 ' H ' ' CG ' ' A' ' 227' ' ' ASP . 1.5 p30 -137.6 125.07 13.95 Favored Pre-proline 0 CA--C 1.539 0.536 0 CA-C-N 115.162 -0.926 . . . . 0.0 109.634 175.073 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 229' ' ' PRO . . . . . 0.44 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 44.9 Cg_endo -65.63 143.87 61.41 Favored 'Cis proline' 0 N--CA 1.49 1.314 0 C-N-CA 123.121 -1.616 . . . . 0.0 109.984 -0.46 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . 0.451 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -76.26 136.9 20.34 Favored Glycine 0 C--N 1.305 -1.157 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 -177.301 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 1.6 p -125.74 133.84 68.1 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 175.82 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 232' ' ' VAL . . . . . 0.428 ' HB ' ' HA ' ' A' ' 224' ' ' VAL . 0.7 OUTLIER -132.42 156.36 42.33 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.81 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.241 -176.713 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 233' ' ' THR . . . . . 0.463 ' HB ' ' SD ' ' A' ' 223' ' ' MET . 24.4 m -109.65 143.93 38.71 Favored 'General case' 0 N--CA 1.441 -0.914 0 CA-C-N 115.848 -0.614 . . . . 0.0 109.675 176.278 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 34.2 m -107.58 157.55 17.96 Favored 'General case' 0 C--N 1.31 -1.127 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 -179.552 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 33.2 tp -57.19 123.27 14.74 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 -178.062 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 8.4 p-10 -59.7 -32.71 70.77 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.211 0.529 . . . . 0.0 111.05 -175.717 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -66.89 -32.07 73.09 Favored 'General case' 0 C--N 1.303 -1.42 0 CA-C-N 115.751 -0.658 . . . . 0.0 112.047 177.444 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -109.08 132.99 53.58 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 120.777 0.322 . . . . 0.0 111.647 -176.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 90.2 mtm-85 -91.39 133.6 35.33 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 175.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 240' ' ' HIS . . . . . 0.623 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 3.0 p80 -66.57 -40.55 89.02 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.749 0.309 . . . . 0.0 111.208 -179.516 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 82.34 20.71 61.83 Favored Glycine 0 C--N 1.316 -0.544 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 -176.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 242' ' ' PHE . . . . . 0.467 ' CG ' ' HB2' ' A' ' 240' ' ' HIS . 7.6 m-30 -92.31 146.41 23.72 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.184 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 71.4 mm-40 -109.27 160.07 16.43 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.512 171.471 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 19.9 m -64.6 122.36 16.63 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 175.717 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 95.04 0.14 63.87 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 111.564 -0.614 . . . . 0.0 111.564 -178.668 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 48.6 t0 -76.76 163.93 26.34 Favored 'General case' 0 C--O 1.238 0.489 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 176.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 247' ' ' PHE . . . . . 0.438 ' HA ' ' O ' ' A' ' 265' ' ' MET . 83.1 m-85 -110.27 129.82 55.66 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.522 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 248' ' ' VAL . . . . . 0.415 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.3 m -129.98 159.45 41.99 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 C-N-CA 120.357 -0.537 . . . . 0.0 111.519 -178.162 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 40.7 m -122.65 159.6 27.55 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 114.308 -1.315 . . . . 0.0 108.81 172.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 250' ' ' PHE . . . . . 0.57 ' CB ' ' HB3' ' A' ' 259' ' ' LEU . 79.1 m-85 -118.79 157.82 26.82 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.271 -174.167 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 4.8 m -151.59 157.48 42.25 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.324 178.078 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER 50.62 27.44 2.94 Favored 'General case' 0 C--N 1.308 -1.196 0 N-CA-C 112.87 0.693 . . . . 0.0 112.87 174.995 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . 0.431 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 12.6 t -88.81 129.23 40.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 175.237 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . 0.477 ' NE2' ' N ' ' A' ' 254' ' ' GLN . 1.5 mp0 -97.27 138.91 34.03 Favored 'General case' 0 C--O 1.242 0.665 0 C-N-CA 120.737 -0.385 . . . . 0.0 110.84 -178.723 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 80.55 -55.66 4.69 Favored Glycine 0 C--O 1.238 0.358 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 -176.3 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 256' ' ' MET . . . . . 0.519 ' N ' ' O ' ' A' ' 285' ' ' ASP . 3.4 ttm -84.55 48.18 1.48 Allowed 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 175.973 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 48.8 pt -69.37 -20.6 24.28 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.758 0 CA-C-N 114.745 -1.116 . . . . 0.0 110.542 -174.544 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 258' ' ' GLN . . . . . 0.472 ' O ' ' SG ' ' A' ' 262' ' ' CYS . 2.5 mp0 -54.14 -35.1 61.87 Favored 'General case' 0 C--N 1.318 -0.801 0 N-CA-C 108.351 -0.981 . . . . 0.0 108.351 177.297 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 259' ' ' LEU . . . . . 0.57 ' HB3' ' CB ' ' A' ' 250' ' ' PHE . 92.5 mt -62.04 -41.24 97.9 Favored 'General case' 0 N--CA 1.445 -0.683 0 CA-C-N 115.399 -0.819 . . . . 0.0 109.915 176.154 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 260' ' ' ASN . . . . . 0.431 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 97.5 m-20 -60.71 -40.05 90.82 Favored 'General case' 0 CA--C 1.512 -0.49 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 -179.618 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -100.13 11.74 60.35 Favored Glycine 0 CA--C 1.524 0.62 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.872 -178.45 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 262' ' ' CYS . . . . . 0.472 ' SG ' ' O ' ' A' ' 258' ' ' GLN . 1.3 m -88.37 152.71 21.73 Favored 'General case' 0 CA--C 1.51 -0.579 0 CA-C-N 116.988 0.394 . . . . 0.0 110.787 -178.185 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 47.7 mt-30 -72.24 160.84 81.67 Favored Pre-proline 0 C--N 1.32 -0.678 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 173.331 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 264' ' ' PRO . . . . . 0.415 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 20.9 Cg_exo -61.47 143.75 97.56 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 N-CA-C 109.224 -1.106 . . . . 0.0 109.224 178.628 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 265' ' ' MET . . . . . 0.438 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 24.3 ptp -133.32 158.19 43.6 Favored 'General case' 0 C--N 1.317 -0.842 0 C-N-CA 120.98 -0.288 . . . . 0.0 111.695 -174.015 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 66.4 tt0 -71.25 139.18 49.94 Favored 'General case' 0 CA--C 1.507 -0.679 0 O-C-N 123.664 0.603 . . . . 0.0 109.718 176.372 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 267' ' ' ILE . . . . . 0.474 ' C ' ' CD1' ' A' ' 267' ' ' ILE . 1.9 pp -131.74 160.14 42.6 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.865 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.274 178.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 64.7 mttp -130.21 125.84 35.91 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.135 176.41 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 17.9 m -84.73 106.6 14.97 Favored 'Isoleucine or valine' 0 C--O 1.235 0.315 0 CA-C-O 121.18 0.514 . . . . 0.0 111.837 -177.436 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 91.0 mt -66.27 -40.3 90.04 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.458 -0.792 . . . . 0.0 109.45 177.451 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -147.16 -175.46 20.06 Favored Glycine 0 C--N 1.321 -0.299 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 179.069 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 272' ' ' PRO . . . . . 0.623 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 36.4 Cg_endo -61.99 -33.93 82.1 Favored 'Trans proline' 0 C--N 1.307 -1.625 0 C-N-CA 121.778 1.652 . . . . 0.0 111.153 -177.619 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -119.19 6.51 11.24 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.984 -0.553 . . . . 0.0 112.18 -179.751 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 2.9 p -119.95 126.22 50.33 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 120.712 0.291 . . . . 0.0 110.506 179.323 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 275' ' ' PHE . . . . . 0.566 ' C ' ' CD1' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -138.0 162.93 32.84 Favored 'General case' 0 CA--C 1.499 -0.992 0 C-N-CA 120.766 -0.374 . . . . 0.0 111.987 -179.744 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 276' ' ' SER . . . . . 0.451 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 4.7 p -132.47 151.2 51.98 Favored 'General case' 0 N--CA 1.433 -1.277 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.921 -173.204 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 277' ' ' ILE . . . . . 0.468 HD12 ' CE2' ' A' ' 283' ' ' PHE . 2.2 pp -138.19 175.57 8.48 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 CA-C-N 114.824 -1.08 . . . . 0.0 110.505 -175.684 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 278' ' ' CYS . . . . . 0.42 ' SG ' HD13 ' A' ' 277' ' ' ILE . 1.4 p -42.58 -88.44 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.435 0 N-CA-C 112.744 0.646 . . . . 0.0 112.744 -179.707 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . 0.431 ' O ' ' HB2' ' A' ' 282' ' ' ASN . 18.1 t0 -145.75 121.04 10.23 Favored 'General case' 0 CA--C 1.515 -0.371 0 CA-C-O 120.767 0.317 . . . . 0.0 111.109 -176.277 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 280' ' ' THR . . . . . 0.636 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 35.9 p -68.22 -25.75 65.36 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-O 121.26 0.553 . . . . 0.0 110.534 176.546 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 281' ' ' SER . . . . . 0.498 ' HA ' ' HE3' ' A' ' 226' ' ' LYS . 0.7 OUTLIER -69.76 -12.86 61.96 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.459 -0.791 . . . . 0.0 109.519 176.06 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 282' ' ' ASN . . . . . 0.431 ' HB2' ' O ' ' A' ' 279' ' ' ASP . 2.0 m-80 -88.06 -6.06 58.15 Favored 'General case' 0 CA--C 1.509 -0.627 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 173.604 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 283' ' ' PHE . . . . . 0.636 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 6.0 m-85 -100.41 -71.8 0.69 Allowed 'General case' 0 N--CA 1.444 -0.738 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 172.29 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 1.6 p 167.02 -99.04 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.466 0 CA-C-N 115.144 -0.935 . . . . 0.0 110.213 178.81 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 285' ' ' ASP . . . . . 0.519 ' O ' ' N ' ' A' ' 256' ' ' MET . 48.4 t0 -150.74 163.33 38.85 Favored 'General case' 0 C--O 1.214 -0.815 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 177.416 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 286' ' ' TYR . . . . . 0.429 ' N ' ' OD1' ' A' ' 285' ' ' ASP . 71.6 t80 -100.54 124.1 45.65 Favored 'General case' 0 C--N 1.318 -0.774 0 C-N-CA 121.1 -0.24 . . . . 0.0 110.841 -179.777 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 287' ' ' ILE . . . . . 0.435 ' O ' ' CG ' ' A' ' 288' ' ' ARG . 96.6 mt -100.06 -61.5 2.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 C-N-CA 120.77 -0.372 . . . . 0.0 110.455 173.696 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . 0.435 ' CG ' ' O ' ' A' ' 287' ' ' ILE . 54.6 mtp180 -166.67 176.79 6.96 Favored 'General case' 0 C--O 1.241 0.617 0 CA-C-O 121.135 0.493 . . . . 0.0 111.787 179.064 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 67.95 -156.27 52.8 Favored Glycine 0 CA--C 1.508 -0.399 0 CA-C-N 115.284 -0.871 . . . . 0.0 111.104 174.893 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 109.91 123.81 4.68 Favored Glycine 0 N--CA 1.443 -0.893 0 N-CA-C 112.281 -0.327 . . . . 0.0 112.281 176.255 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . 0.422 HD13 HG22 ' A' ' 291' ' ' ILE . 99.2 mt -127.52 133.72 67.19 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.09 0 N-CA-C 107.496 -1.298 . . . . 0.0 107.496 173.676 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 4.0 p -124.76 136.06 61.93 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.893 0 C-N-CA 120.466 -0.494 . . . . 0.0 109.824 -177.529 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 293' ' ' SER . . . . . 0.559 ' HG ' ' CB ' ' A' ' 218' ' ' SER . 4.4 m -127.42 146.75 50.37 Favored 'General case' 0 C--O 1.237 0.441 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.768 -178.414 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 CA--C 1.51 -0.588 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 173.449 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 217' ' ' LEU . . . . . 0.443 ' HB3' ' O ' ' A' ' 240' ' ' HIS . 0.1 OUTLIER . . . . . 0 N--CA 1.444 -0.76 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 . . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 218' ' ' SER . . . . . 0.579 ' CB ' ' HG ' ' A' ' 293' ' ' SER . 5.1 m -130.89 151.87 50.84 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.867 -174.719 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -144.84 160.59 41.04 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.051 0.453 . . . . 0.0 110.803 179.05 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 220' ' ' MET . . . . . 0.479 ' SD ' HD21 ' A' ' 235' ' ' LEU . 92.7 mtp -75.57 130.74 39.31 Favored 'General case' 0 N--CA 1.443 -0.814 0 CA-C-N 115.366 -0.834 . . . . 0.0 108.916 176.474 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 99.7 t -78.92 128.69 38.35 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.92 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 176.413 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 26.9 m -85.26 -72.73 0.47 Allowed 'General case' 0 C--N 1.307 -1.245 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 178.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 223' ' ' MET . . . . . 0.535 ' C ' ' SD ' ' A' ' 223' ' ' MET . 2.7 ppp? -138.2 151.26 47.52 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 112.235 0.457 . . . . 0.0 112.235 174.168 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 224' ' ' VAL . . . . . 0.427 HG11 ' SD ' ' A' ' 256' ' ' MET . 62.2 t -121.11 126.65 75.38 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 176.098 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 37.5 p -77.53 133.72 38.46 Favored 'General case' 0 C--N 1.327 -0.386 0 C-N-CA 120.259 -0.576 . . . . 0.0 110.407 178.49 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 20.6 tptm -78.32 77.23 4.81 Favored 'General case' 0 C--N 1.316 -0.87 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 179.813 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 227' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -161.31 178.09 9.53 Favored 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 112.615 0.598 . . . . 0.0 112.615 -176.208 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 228' ' ' ASN . . . . . 0.451 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 2.0 t-20 -140.29 124.46 10.75 Favored Pre-proline 0 CA--C 1.533 0.324 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.786 175.086 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 229' ' ' PRO . . . . . 0.451 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 46.8 Cg_endo -65.61 143.57 60.0 Favored 'Cis proline' 0 N--CA 1.492 1.402 0 C-N-CA 122.759 -1.767 . . . . 0.0 109.717 -1.244 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . 0.487 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -81.9 140.02 20.48 Favored Glycine 0 CA--C 1.501 -0.795 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 -178.496 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.4 p -122.79 133.85 67.71 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 176.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 232' ' ' VAL . . . . . 0.417 ' CG1' HG12 ' A' ' 224' ' ' VAL . 0.6 OUTLIER -131.39 155.41 41.79 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 C-N-CA 120.605 -0.438 . . . . 0.0 110.829 -176.182 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 26.1 m -110.17 142.67 41.37 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-N 115.425 -0.807 . . . . 0.0 109.629 177.474 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 48.7 m -107.92 158.22 17.54 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-N 115.804 -0.634 . . . . 0.0 109.484 178.39 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . 0.479 HD21 ' SD ' ' A' ' 220' ' ' MET . 33.9 tp -64.5 117.21 7.0 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 178.459 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 236' ' ' ASP . . . . . 0.523 ' HA ' ' CE1' ' A' ' 273' ' ' TYR . 37.4 p-10 -59.71 -28.56 67.43 Favored 'General case' 0 C--O 1.239 0.515 0 CA-C-O 120.885 0.374 . . . . 0.0 111.872 -173.144 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 72.4 mm-40 -66.22 -33.18 75.18 Favored 'General case' 0 C--N 1.311 -1.068 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.316 178.78 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -99.51 122.96 43.32 Favored 'General case' 0 CA--C 1.516 -0.337 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.408 179.795 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 90.2 mtm180 -75.57 138.73 41.67 Favored 'General case' 0 C--N 1.316 -0.861 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 174.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 240' ' ' HIS . . . . . 0.447 ' HB2' ' CD2' ' A' ' 242' ' ' PHE . 6.4 p80 -88.82 -37.73 15.17 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 121.026 0.441 . . . . 0.0 109.924 177.26 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 81.24 10.73 84.36 Favored Glycine 0 CA--C 1.505 -0.592 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 179.405 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 242' ' ' PHE . . . . . 0.493 ' CD1' ' N ' ' A' ' 242' ' ' PHE . 3.7 m-30 -81.22 147.14 30.11 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.305 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -131.17 167.42 19.18 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 109.095 -0.705 . . . . 0.0 109.095 172.359 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 2.9 m -59.48 129.38 41.7 Favored 'General case' 0 C--N 1.294 -1.835 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.556 -176.561 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 83.8 1.8 89.85 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 111.807 -0.517 . . . . 0.0 111.807 -179.165 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 44.4 t0 -77.69 159.62 29.01 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 117.315 0.557 . . . . 0.0 110.255 178.476 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 247' ' ' PHE . . . . . 0.416 ' HA ' ' O ' ' A' ' 265' ' ' MET . 66.0 m-85 -110.48 133.79 52.95 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 116.592 -0.276 . . . . 0.0 110.394 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 248' ' ' VAL . . . . . 0.426 ' O ' ' SD ' ' A' ' 265' ' ' MET . 3.1 m -129.98 162.22 38.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.54 -179.093 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 5.0 m -126.19 151.79 46.89 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.332 -0.849 . . . . 0.0 109.016 175.782 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 250' ' ' PHE . . . . . 0.537 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 74.4 m-85 -109.6 155.9 20.85 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.409 0.623 . . . . 0.0 111.693 -176.25 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 44.8 m -152.4 151.82 31.28 Favored 'General case' 0 C--N 1.308 -1.211 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.579 175.851 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 30.7 mm-40 51.89 28.47 5.13 Favored 'General case' 0 C--N 1.317 -0.808 0 N-CA-C 113.018 0.747 . . . . 0.0 113.018 176.427 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . 0.501 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 60.8 t -82.36 129.67 37.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 174.216 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 81.9 mt-30 -101.59 138.15 38.96 Favored 'General case' 0 C--O 1.243 0.745 0 C-N-CA 120.272 -0.571 . . . . 0.0 111.296 -175.275 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 81.73 -57.53 4.92 Favored Glycine 0 C--O 1.239 0.417 0 N-CA-C 109.969 -1.252 . . . . 0.0 109.969 -176.47 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 256' ' ' MET . . . . . 0.476 ' SD ' ' CD1' ' A' ' 259' ' ' LEU . 57.0 ttm -85.78 65.04 8.94 Favored 'General case' 0 CA--C 1.516 -0.364 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 175.383 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 49.1 pt -73.92 -19.55 17.58 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-N 114.659 -1.155 . . . . 0.0 111.875 -172.848 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 15.4 tt0 -58.16 -36.39 72.94 Favored 'General case' 0 C--N 1.321 -0.647 0 C-N-CA 119.547 -0.861 . . . . 0.0 110.055 -177.636 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 259' ' ' LEU . . . . . 0.537 ' HB3' ' CG ' ' A' ' 250' ' ' PHE . 90.4 mt -61.44 -40.39 94.27 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 177.814 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 260' ' ' ASN . . . . . 0.501 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 98.3 m-20 -60.24 -40.1 89.06 Favored 'General case' 0 CA--C 1.508 -0.635 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 178.376 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -102.27 22.72 36.8 Favored Glycine 0 C--N 1.315 -0.615 0 CA-C-N 115.468 -0.787 . . . . 0.0 111.919 -178.259 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 11.1 t -111.14 146.48 36.78 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 117.308 0.554 . . . . 0.0 111.734 -176.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 -59.31 158.99 17.35 Favored Pre-proline 0 C--N 1.327 -0.376 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 174.005 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -62.64 148.16 93.75 Favored 'Trans proline' 0 N--CA 1.493 1.491 0 C-N-CA 121.578 1.519 . . . . 0.0 111.395 179.159 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 265' ' ' MET . . . . . 0.623 ' SD ' ' N ' ' A' ' 265' ' ' MET . 0.3 OUTLIER -124.7 150.49 46.09 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.731 -174.412 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 266' ' ' GLU . . . . . 0.47 ' OE2' ' NZ ' ' A' ' 268' ' ' LYS . 0.7 OUTLIER -71.53 140.14 49.77 Favored 'General case' 0 C--O 1.24 0.596 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 172.958 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 267' ' ' ILE . . . . . 0.528 HG23 ' CE2' ' A' ' 275' ' ' PHE . 1.5 pp -130.63 159.92 42.25 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-O 121.245 0.545 . . . . 0.0 111.958 -177.065 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . 0.47 ' NZ ' ' OE2' ' A' ' 266' ' ' GLU . 35.4 mttp -128.79 120.51 26.48 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.617 178.182 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 26.8 m -82.58 100.14 6.07 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.256 0 CA-C-O 121.018 0.437 . . . . 0.0 111.85 -176.657 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 97.4 mt -65.81 -41.07 92.32 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.341 0.591 . . . . 0.0 109.636 177.264 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -139.41 179.49 18.67 Favored Glycine 0 C--N 1.317 -0.525 0 N-CA-C 109.253 -1.539 . . . . 0.0 109.253 178.166 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -61.99 -30.23 82.9 Favored 'Trans proline' 0 C--N 1.306 -1.694 0 C-N-CA 121.899 1.733 . . . . 0.0 111.067 -178.27 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 273' ' ' TYR . . . . . 0.523 ' CE1' ' HA ' ' A' ' 236' ' ' ASP . 72.9 m-85 -122.56 6.8 9.49 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 112.782 0.66 . . . . 0.0 112.782 179.027 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 7.0 p -119.41 126.89 52.43 Favored 'General case' 0 C--O 1.243 0.717 0 CA-C-O 120.67 0.272 . . . . 0.0 110.461 177.658 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 275' ' ' PHE . . . . . 0.533 ' C ' ' CD1' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -133.0 163.2 29.76 Favored 'General case' 0 CA--C 1.493 -1.243 0 C-N-CA 120.446 -0.501 . . . . 0.0 112.296 179.893 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 276' ' ' SER . . . . . 0.487 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 5.0 p -130.65 143.27 50.63 Favored 'General case' 0 N--CA 1.43 -1.432 0 C-N-CA 120.611 -0.436 . . . . 0.0 111.526 -174.781 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 32.6 pt -141.31 165.79 18.6 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.765 0 CA-C-N 114.614 -1.176 . . . . 0.0 111.488 -172.784 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -27.5 -90.99 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.687 0 N-CA-C 113.757 1.021 . . . . 0.0 113.757 -176.379 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 50.7 t0 -148.81 113.56 5.39 Favored 'General case' 0 CA--C 1.504 -0.825 0 CA-C-N 116.615 -0.266 . . . . 0.0 110.293 -175.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 280' ' ' THR . . . . . 0.689 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 26.7 p -73.65 -23.52 59.87 Favored 'General case' 0 N--CA 1.426 -1.627 0 CA-C-O 121.086 0.47 . . . . 0.0 110.04 177.411 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -67.75 -20.75 65.27 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.06 -0.973 . . . . 0.0 108.783 173.243 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 18.8 t30 -89.63 -9.08 51.0 Favored 'General case' 0 CA--C 1.51 -0.588 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.455 -179.547 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 283' ' ' PHE . . . . . 0.689 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 21.3 m-85 -92.14 -71.76 0.63 Allowed 'General case' 0 CA--C 1.505 -0.757 0 CA-C-O 121.66 0.743 . . . . 0.0 109.643 179.002 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 284' ' ' SER . . . . . 0.434 ' HG ' ' C ' ' A' ' 283' ' ' PHE . 0.1 OUTLIER 168.95 -175.78 0.03 OUTLIER 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 114.133 -1.394 . . . . 0.0 107.967 -173.908 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 7.9 t70 -92.41 121.43 33.88 Favored 'General case' 0 C--N 1.322 -0.617 0 C-N-CA 120.246 -0.582 . . . . 0.0 111.925 -178.861 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 12.1 t80 -69.58 126.73 30.63 Favored 'General case' 0 C--O 1.237 0.423 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 177.299 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 96.4 mt -106.08 -58.26 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 CA-C-O 121.021 0.438 . . . . 0.0 110.13 174.834 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 22.3 ptt180 -166.91 -179.31 4.64 Favored 'General case' 0 C--O 1.24 0.554 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.934 -176.285 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 65.64 -156.29 49.13 Favored Glycine 0 C--N 1.331 0.305 0 N-CA-C 110.6 -1.0 . . . . 0.0 110.6 178.051 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 105.42 122.81 5.1 Favored Glycine 0 CA--C 1.52 0.373 0 CA-C-O 121.266 0.37 . . . . 0.0 112.813 176.413 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 95.6 mt -123.0 130.76 74.25 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 N-CA-C 107.587 -1.264 . . . . 0.0 107.587 175.262 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . 0.414 HG21 ' CZ ' ' A' ' 242' ' ' PHE . 4.0 p -126.35 137.98 56.08 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 -177.455 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 293' ' ' SER . . . . . 0.579 ' HG ' ' CB ' ' A' ' 218' ' ' SER . 12.5 m -129.64 147.27 51.42 Favored 'General case' 0 CA--C 1.509 -0.598 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.498 -178.425 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 294' ' ' GLN . . . . . 0.44 ' HB3' ' CD1' ' A' ' 242' ' ' PHE . 0.7 OUTLIER . . . . . 0 CA--C 1.507 -0.678 0 C-N-CA 120.183 -0.607 . . . . 0.0 110.535 175.41 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 217' ' ' LEU . . . . . 0.454 ' HB3' ' O ' ' A' ' 240' ' ' HIS . 0.3 OUTLIER . . . . . 0 CA--C 1.505 -0.781 0 CA-C-O 121.089 0.471 . . . . 0.0 111.218 . . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 218' ' ' SER . . . . . 0.411 ' HA ' ' O ' ' A' ' 292' ' ' VAL . 15.6 m -127.96 150.67 49.8 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 -179.041 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -138.05 152.57 48.95 Favored 'General case' 0 C--N 1.311 -1.095 0 CA-C-O 120.848 0.356 . . . . 0.0 111.112 -177.468 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 220' ' ' MET . . . . . 0.556 ' SD ' HG12 ' A' ' 291' ' ' ILE . 3.5 tpp -76.11 126.82 31.71 Favored 'General case' 0 N--CA 1.443 -0.821 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 174.647 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 72.5 t -77.14 129.48 37.33 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.122 0 N-CA-C 109.646 -0.502 . . . . 0.0 109.646 -178.419 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 3.0 m -83.43 -73.07 0.43 Allowed 'General case' 0 N--CA 1.437 -1.108 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 176.374 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 223' ' ' MET . . . . . 0.458 ' SD ' HG23 ' A' ' 225' ' ' THR . 3.6 ppp? -138.38 152.79 48.73 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.42 -0.354 . . . . 0.0 111.658 174.566 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 224' ' ' VAL . . . . . 0.45 HG12 ' SD ' ' A' ' 256' ' ' MET . 61.6 t -119.84 126.55 75.42 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.991 0 N-CA-C 108.323 -0.991 . . . . 0.0 108.323 175.08 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 225' ' ' THR . . . . . 0.458 HG23 ' SD ' ' A' ' 223' ' ' MET . 71.0 p -84.82 126.77 33.73 Favored 'General case' 0 C--N 1.322 -0.594 0 C-N-CA 119.726 -0.79 . . . . 0.0 109.648 176.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 86.5 tttt -77.86 89.85 4.08 Favored 'General case' 0 C--N 1.316 -0.874 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 -178.435 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 227' ' ' ASP . . . . . . . . . . . . . 43.5 t0 -163.86 173.68 12.43 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.429 -177.363 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -133.14 123.54 17.94 Favored Pre-proline 0 C--N 1.323 -0.559 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.855 172.926 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 229' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -66.78 144.25 68.2 Favored 'Cis proline' 0 C--N 1.311 -1.4 0 C-N-CA 122.845 -1.731 . . . . 0.0 109.774 -2.266 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . 0.459 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -84.03 139.06 18.1 Favored Glycine 0 CA--C 1.502 -0.766 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 -178.985 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.4 p -124.78 137.57 57.01 Favored 'Isoleucine or valine' 0 C--O 1.243 0.745 0 N-CA-C 109.967 -0.382 . . . . 0.0 109.967 177.162 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 232' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -132.61 155.34 41.23 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.892 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.801 -178.493 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 21.7 m -109.06 144.19 37.4 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.811 178.861 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 2.1 m -107.6 150.44 26.87 Favored 'General case' 0 C--N 1.316 -0.882 0 C-N-CA 123.023 0.529 . . . . 0.0 109.718 -179.662 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 37.4 tp -65.27 134.51 53.79 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.431 -176.638 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 236' ' ' ASP . . . . . 0.428 ' O ' ' NH1' ' A' ' 239' ' ' ARG . 13.0 t70 -49.1 -44.51 42.29 Favored 'General case' 0 N--CA 1.474 0.748 0 N-CA-C 114.0 1.111 . . . . 0.0 114.0 -171.779 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 237' ' ' GLU . . . . . 0.456 ' O ' ' NH1' ' A' ' 239' ' ' ARG . 54.6 mp0 -63.83 -33.5 75.82 Favored 'General case' 0 C--N 1.316 -0.851 0 C-N-CA 119.044 -1.062 . . . . 0.0 109.615 -177.534 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -77.36 95.2 4.35 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 112.869 0.692 . . . . 0.0 112.869 -177.952 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 239' ' ' ARG . . . . . 0.456 ' NH1' ' O ' ' A' ' 237' ' ' GLU . 0.0 OUTLIER -73.39 92.28 1.83 Allowed 'General case' 0 C--O 1.237 0.395 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 169.755 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 240' ' ' HIS . . . . . 0.553 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 9.4 p80 -53.0 -47.02 68.58 Favored 'General case' 0 C--O 1.213 -0.853 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.297 -174.382 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 76.8 20.75 75.83 Favored Glycine 0 C--N 1.311 -0.811 0 N-CA-C 110.416 -1.074 . . . . 0.0 110.416 177.752 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 242' ' ' PHE . . . . . 0.565 ' CE1' ' HB3' ' A' ' 294' ' ' GLN . 5.2 m-30 -80.17 143.63 33.68 Favored 'General case' 0 C--N 1.318 -0.778 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 179.405 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -119.41 166.26 13.29 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-O 121.153 0.502 . . . . 0.0 110.663 175.604 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 9.1 m -59.44 127.56 32.66 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 115.774 -0.648 . . . . 0.0 109.55 -179.032 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 84.54 6.7 85.48 Favored Glycine 0 N--CA 1.438 -1.175 0 N-CA-C 111.698 -0.561 . . . . 0.0 111.698 -179.815 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 246' ' ' ASP . . . . . 0.453 ' CG ' HE22 ' A' ' 294' ' ' GLN . 3.6 t0 -84.36 165.42 18.25 Favored 'General case' 0 CA--C 1.512 -0.483 0 C-N-CA 119.377 -0.929 . . . . 0.0 109.494 176.814 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 247' ' ' PHE . . . . . 0.547 ' CZ ' ' HB2' ' A' ' 266' ' ' GLU . 47.3 m-85 -112.61 138.11 49.87 Favored 'General case' 0 C--N 1.315 -0.906 0 N-CA-C 111.935 0.346 . . . . 0.0 111.935 -175.476 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 248' ' ' VAL . . . . . 0.495 ' HA ' ' HA ' ' A' ' 294' ' ' GLN . 2.7 m -133.01 160.38 42.67 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.363 0 C-N-CA 120.297 -0.561 . . . . 0.0 112.189 177.213 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 2.2 m -125.13 153.89 42.3 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 114.483 -1.235 . . . . 0.0 107.694 174.329 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 250' ' ' PHE . . . . . 0.59 ' CB ' ' HB3' ' A' ' 259' ' ' LEU . 64.5 m-85 -112.83 144.64 42.03 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-O 120.865 0.364 . . . . 0.0 111.126 -179.373 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 4.0 m -140.92 161.16 38.48 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 115.503 -0.772 . . . . 0.0 109.426 176.398 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 51.3 mm-40 52.96 27.49 5.63 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 112.278 0.473 . . . . 0.0 112.278 173.507 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . 0.445 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 83.4 t -88.68 133.6 30.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 177.771 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 90.9 mm-40 -100.37 145.75 27.8 Favored 'General case' 0 C--O 1.237 0.436 0 CA-C-O 120.852 0.358 . . . . 0.0 110.104 176.692 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 78.36 -68.85 2.86 Favored Glycine 0 C--N 1.315 -0.612 0 N-CA-C 110.417 -1.073 . . . . 0.0 110.417 -179.505 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 256' ' ' MET . . . . . 0.482 ' SD ' ' HD2' ' A' ' 283' ' ' PHE . 29.9 ttm -79.55 68.11 5.5 Favored 'General case' 0 C--N 1.321 -0.638 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 178.087 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 44.9 pt -75.23 -19.21 16.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.857 -175.344 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 258' ' ' GLN . . . . . 0.447 ' O ' ' N ' ' A' ' 262' ' ' CYS . 0.2 OUTLIER -53.18 -39.66 63.81 Favored 'General case' 0 C--O 1.213 -0.849 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 177.576 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 259' ' ' LEU . . . . . 0.59 ' HB3' ' CB ' ' A' ' 250' ' ' PHE . 94.6 mt -61.6 -41.96 98.19 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.137 179.075 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 260' ' ' ASN . . . . . 0.445 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 91.5 m-20 -59.73 -41.25 90.5 Favored 'General case' 0 CA--C 1.51 -0.567 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 179.524 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -101.14 9.48 57.89 Favored Glycine 0 CA--C 1.523 0.537 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.942 -177.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 262' ' ' CYS . . . . . 0.447 ' N ' ' O ' ' A' ' 258' ' ' GLN . 15.6 t -87.99 144.24 26.65 Favored 'General case' 0 C--O 1.241 0.632 0 CA-C-N 117.174 0.487 . . . . 0.0 111.415 -176.122 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -61.21 156.06 52.51 Favored Pre-proline 0 C--N 1.319 -0.721 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 173.6 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -64.77 143.32 79.95 Favored 'Trans proline' 0 C--N 1.307 -1.618 0 C-N-CA 120.757 0.971 . . . . 0.0 109.842 179.938 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 265' ' ' MET . . . . . 0.46 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 19.5 ptp -126.1 153.61 44.26 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 112.07 0.396 . . . . 0.0 112.07 -174.45 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 266' ' ' GLU . . . . . 0.547 ' HB2' ' CZ ' ' A' ' 247' ' ' PHE . 75.8 tt0 -79.82 137.34 36.93 Favored 'General case' 0 C--O 1.238 0.478 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 179.789 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 267' ' ' ILE . . . . . 0.484 HG21 ' CE2' ' A' ' 275' ' ' PHE . 1.9 pp -128.33 163.02 33.63 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 N-CA-C 113.752 1.019 . . . . 0.0 113.752 -169.674 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 52.9 tttp -124.95 121.3 34.06 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.148 -0.933 . . . . 0.0 109.995 175.155 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 29.5 m -75.64 132.19 33.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 C-N-CA 121.096 -0.242 . . . . 0.0 110.723 178.432 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 84.5 mt -106.38 -13.82 15.26 Favored 'General case' 0 CA--C 1.515 -0.393 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.737 -179.335 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -170.6 -177.93 40.98 Favored Glycine 0 C--N 1.318 -0.436 0 N-CA-C 110.364 -1.094 . . . . 0.0 110.364 -177.801 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 272' ' ' PRO . . . . . 0.553 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 36.2 Cg_endo -61.52 -31.4 87.51 Favored 'Trans proline' 0 C--N 1.308 -1.588 0 C-N-CA 122.097 1.865 . . . . 0.0 111.118 -178.302 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 273' ' ' TYR . . . . . 0.405 ' CE1' ' HA ' ' A' ' 236' ' ' ASP . 88.7 m-85 -124.49 7.43 8.31 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.877 -0.602 . . . . 0.0 112.407 -179.569 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 11.0 p -123.07 141.14 52.29 Favored 'General case' 0 C--O 1.244 0.784 0 C-N-CA 120.146 -0.622 . . . . 0.0 111.957 -177.893 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 275' ' ' PHE . . . . . 0.564 ' C ' ' CD1' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -143.34 165.95 26.09 Favored 'General case' 0 CA--C 1.508 -0.654 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.17 178.113 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 276' ' ' SER . . . . . 0.459 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 4.6 p -133.08 146.02 51.28 Favored 'General case' 0 N--CA 1.439 -1.01 0 N-CA-C 112.502 0.556 . . . . 0.0 112.502 -175.918 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 277' ' ' ILE . . . . . 0.446 HG23 ' CE1' ' A' ' 275' ' ' PHE . 29.1 pt -141.46 167.99 16.0 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.896 0 CA-C-N 114.224 -1.353 . . . . 0.0 111.332 -172.102 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 1.6 p -28.75 -95.19 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.759 0 N-CA-C 113.354 0.872 . . . . 0.0 113.354 -177.436 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -143.8 108.7 4.94 Favored 'General case' 0 CA--C 1.501 -0.912 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -178.626 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 280' ' ' THR . . . . . 0.746 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 17.8 p -64.58 -30.63 71.66 Favored 'General case' 0 C--N 1.29 -2.016 0 CA-C-O 121.492 0.663 . . . . 0.0 110.459 177.55 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -61.26 -31.37 71.18 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-N 114.836 -1.075 . . . . 0.0 110.297 175.953 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -87.07 -9.44 55.42 Favored 'General case' 0 CA--C 1.507 -0.686 0 C-N-CA 119.362 -0.935 . . . . 0.0 110.24 -176.609 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 283' ' ' PHE . . . . . 0.746 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 19.1 m-85 -77.11 -71.61 0.4 Allowed 'General case' 0 N--CA 1.437 -1.106 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 169.455 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 175.92 -169.5 0.05 Allowed 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 113.975 -1.466 . . . . 0.0 109.129 -175.574 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -97.47 120.66 38.24 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-O 120.377 0.132 . . . . 0.0 110.772 -177.432 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 286' ' ' TYR . . . . . 0.453 ' CZ ' ' HA ' ' A' ' 288' ' ' ARG . 64.6 t80 -63.87 126.41 27.53 Favored 'General case' 0 N--CA 1.478 0.94 0 C-N-CA 122.754 0.422 . . . . 0.0 111.254 -177.543 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 4.1 mm -100.92 -65.39 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.666 173.399 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . 0.453 ' HA ' ' CZ ' ' A' ' 286' ' ' TYR . 0.1 OUTLIER -173.25 -178.8 1.8 Allowed 'General case' 0 C--O 1.243 0.751 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.305 178.58 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 68.33 -156.75 52.99 Favored Glycine 0 CA--C 1.504 -0.625 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 175.432 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 106.72 129.68 6.31 Favored Glycine 0 N--CA 1.437 -1.251 0 C-N-CA 120.884 -0.674 . . . . 0.0 112.014 177.498 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . 0.556 HG12 ' SD ' ' A' ' 220' ' ' MET . 96.5 mt -122.43 130.58 74.41 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.31 0 N-CA-C 107.215 -1.402 . . . . 0.0 107.215 173.172 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . 0.411 ' O ' ' HA ' ' A' ' 218' ' ' SER . 2.6 p -112.12 126.9 69.56 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.828 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 -178.182 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 3.3 m -115.93 121.22 41.67 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 110.041 -0.355 . . . . 0.0 110.041 -176.915 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 294' ' ' GLN . . . . . 0.565 ' HB3' ' CE1' ' A' ' 242' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.435 -1.197 0 C-N-CA 120.149 -0.621 . . . . 0.0 110.576 178.362 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 217' ' ' LEU . . . . . 0.468 ' O ' ' HA ' ' A' ' 293' ' ' SER . 0.5 OUTLIER . . . . . 0 CA--C 1.513 -0.478 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 . . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 218' ' ' SER . . . . . 0.422 ' HG ' ' CB ' ' A' ' 293' ' ' SER . 34.5 m -119.19 132.57 55.97 Favored 'General case' 0 C--N 1.324 -0.532 0 O-C-N 123.661 0.601 . . . . 0.0 110.616 -179.652 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -122.53 139.55 53.77 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.821 0.343 . . . . 0.0 110.259 -179.436 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 1.3 tpt -76.6 122.37 24.53 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 177.813 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 73.5 t -74.19 132.65 33.05 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 -177.642 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 222' ' ' SER . . . . . 0.402 ' OG ' ' C ' ' A' ' 233' ' ' THR . 5.8 p -90.68 -54.64 3.9 Favored 'General case' 0 N--CA 1.434 -1.252 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 177.829 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -138.53 151.87 47.73 Favored 'General case' 0 C--O 1.222 -0.389 0 N-CA-C 112.649 0.611 . . . . 0.0 112.649 174.856 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 224' ' ' VAL . . . . . 0.555 HG11 ' SD ' ' A' ' 256' ' ' MET . 39.5 t -126.64 132.33 70.3 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 172.143 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -104.1 122.98 46.42 Favored 'General case' 0 C--N 1.313 -1.002 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 -177.817 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.3 77.72 3.07 Favored 'General case' 0 C--O 1.234 0.265 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 179.379 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 227' ' ' ASP . . . . . 0.59 ' N ' ' OG1' ' A' ' 280' ' ' THR . 2.8 t0 -148.42 178.34 8.68 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.762 179.459 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 228' ' ' ASN . . . . . 0.455 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.1 OUTLIER -138.47 125.25 13.06 Favored Pre-proline 0 C--N 1.324 -0.507 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.21 176.43 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 229' ' ' PRO . . . . . 0.455 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 38.2 Cg_endo -65.0 144.76 62.38 Favored 'Cis proline' 0 N--CA 1.499 1.814 0 C-N-CA 123.286 -1.548 . . . . 0.0 110.564 -1.063 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . 0.452 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -68.66 136.96 29.95 Favored Glycine 0 N--CA 1.445 -0.732 0 N-CA-C 110.05 -1.22 . . . . 0.0 110.05 -177.915 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.1 p -127.05 133.93 67.23 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 177.772 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 232' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -134.76 156.7 40.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 C-N-CA 120.084 -0.646 . . . . 0.0 111.451 -179.695 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 233' ' ' THR . . . . . 0.402 ' C ' ' OG ' ' A' ' 222' ' ' SER . 6.7 m -111.37 140.68 45.75 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 115.148 -0.933 . . . . 0.0 109.044 178.755 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 44.5 m -107.92 155.97 19.71 Favored 'General case' 0 C--N 1.315 -0.903 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 176.621 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 40.3 tp -57.74 133.71 55.6 Favored 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 177.401 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -53.8 -46.57 71.1 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.145 0.498 . . . . 0.0 110.557 -170.599 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 59.1 mp0 -68.04 -20.33 64.98 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.93 -0.577 . . . . 0.0 112.375 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -73.93 94.84 2.38 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.629 -177.253 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 77.3 mtp85 -71.44 99.31 1.98 Allowed 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 176.149 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 240' ' ' HIS . . . . . 0.661 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 12.8 p80 -68.2 -42.97 79.1 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 120.791 0.329 . . . . 0.0 111.748 -176.182 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 80.32 14.42 80.31 Favored Glycine 0 C--N 1.315 -0.586 0 N-CA-C 110.791 -0.924 . . . . 0.0 110.791 -178.514 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 242' ' ' PHE . . . . . 0.501 ' CD1' ' HB3' ' A' ' 294' ' ' GLN . 5.2 m-30 -81.0 142.97 32.87 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -179.613 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -112.19 167.88 10.06 Favored 'General case' 0 CA--C 1.505 -0.76 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 172.882 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 21.1 m -62.58 126.24 26.65 Favored 'General case' 0 N--CA 1.436 -1.165 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 169.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . 0.47 ' HA2' ' CG ' ' A' ' 266' ' ' GLU . . . 82.04 7.21 88.14 Favored Glycine 0 C--N 1.309 -0.941 0 C-N-CA 120.902 -0.666 . . . . 0.0 111.717 -179.029 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 42.1 t0 -84.87 161.7 19.78 Favored 'General case' 0 C--O 1.235 0.305 0 C-N-CA 120.049 -0.66 . . . . 0.0 109.952 177.798 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 247' ' ' PHE . . . . . 0.452 ' HA ' ' O ' ' A' ' 265' ' ' MET . 30.1 m-85 -109.94 131.7 54.82 Favored 'General case' 0 C--O 1.242 0.702 0 N-CA-C 112.134 0.42 . . . . 0.0 112.134 -174.35 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 248' ' ' VAL . . . . . 0.441 ' HA ' ' HA ' ' A' ' 294' ' ' GLN . 2.7 m -129.92 160.99 40.42 Favored 'Isoleucine or valine' 0 C--O 1.236 0.381 0 CA-C-N 115.89 -0.596 . . . . 0.0 111.884 -179.334 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 3.0 m -126.49 156.0 41.42 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 173.661 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 250' ' ' PHE . . . . . 0.614 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 91.9 m-85 -112.72 146.84 38.01 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-O 120.518 0.199 . . . . 0.0 111.072 -174.059 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 43.4 m -134.4 151.65 51.32 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.105 178.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 4.0 mm-40 41.91 37.12 0.74 Allowed 'General case' 0 C--O 1.245 0.832 0 N-CA-C 113.266 0.839 . . . . 0.0 113.266 174.671 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . 0.464 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 79.2 t -89.56 129.98 39.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 174.641 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . 0.529 HE22 ' CZ ' ' A' ' 288' ' ' ARG . 75.3 mt-30 -99.3 141.32 32.23 Favored 'General case' 0 C--O 1.24 0.577 0 C-N-CA 120.523 -0.471 . . . . 0.0 111.222 -178.249 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 79.61 -57.22 4.49 Favored Glycine 0 CA--C 1.507 -0.438 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -177.081 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 256' ' ' MET . . . . . 0.555 ' SD ' HG11 ' A' ' 224' ' ' VAL . 4.2 ttm -86.74 49.59 1.84 Allowed 'General case' 0 C--N 1.314 -0.949 0 CA-C-O 121.911 0.862 . . . . 0.0 108.721 176.344 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 257' ' ' ILE . . . . . 0.41 ' O ' ' HB2' ' A' ' 260' ' ' ASN . 46.5 pt -68.22 -24.32 29.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 114.453 -1.249 . . . . 0.0 110.917 -174.969 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 258' ' ' GLN . . . . . 0.576 ' HG3' ' SG ' ' A' ' 262' ' ' CYS . 69.2 tp60 -57.68 -30.07 65.17 Favored 'General case' 0 C--N 1.318 -0.795 0 C-N-CA 119.458 -0.897 . . . . 0.0 109.608 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 259' ' ' LEU . . . . . 0.614 ' HB3' ' CG ' ' A' ' 250' ' ' PHE . 94.3 mt -62.07 -40.21 95.03 Favored 'General case' 0 N--CA 1.448 -0.55 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 174.038 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 260' ' ' ASN . . . . . 0.464 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 96.8 m-20 -60.31 -40.89 92.18 Favored 'General case' 0 CA--C 1.514 -0.431 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 179.58 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -98.33 17.65 58.22 Favored Glycine 0 CA--C 1.525 0.706 0 CA-C-N 115.447 -0.797 . . . . 0.0 112.005 -179.392 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 262' ' ' CYS . . . . . 0.576 ' SG ' ' HG3' ' A' ' 258' ' ' GLN . 1.5 m -93.97 146.59 23.82 Favored 'General case' 0 CA--C 1.508 -0.661 0 C-N-CA 120.579 -0.448 . . . . 0.0 111.032 -179.379 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 46.6 mt-30 -59.81 161.2 12.37 Favored Pre-proline 0 C--N 1.323 -0.548 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 172.277 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 264' ' ' PRO . . . . . 0.423 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 38.0 Cg_endo -63.37 143.39 88.67 Favored 'Trans proline' 0 C--N 1.307 -1.651 0 N-CA-C 108.437 -1.409 . . . . 0.0 108.437 174.974 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 265' ' ' MET . . . . . 0.452 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 22.7 ptp -135.35 152.36 51.37 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 112.071 0.397 . . . . 0.0 112.071 -171.222 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 266' ' ' GLU . . . . . 0.47 ' CG ' ' HA2' ' A' ' 245' ' ' GLY . 39.5 tt0 -71.79 136.94 47.27 Favored 'General case' 0 C--N 1.331 -0.228 0 O-C-N 124.034 0.834 . . . . 0.0 109.516 178.757 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 267' ' ' ILE . . . . . 0.458 HG23 ' CE2' ' A' ' 275' ' ' PHE . 1.9 pp -128.3 162.39 34.85 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-O 121.142 0.496 . . . . 0.0 112.1 -179.346 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 60.1 tttm -118.98 131.52 56.02 Favored 'General case' 0 C--O 1.219 -0.501 0 CA-C-N 115.66 -0.7 . . . . 0.0 109.541 174.081 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 23.2 m -82.4 128.21 38.93 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.974 0 C-N-CA 120.313 -0.555 . . . . 0.0 110.276 176.822 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 95.6 mt -98.99 -17.89 18.07 Favored 'General case' 0 CA--C 1.502 -0.871 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 178.298 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -171.27 177.0 44.4 Favored Glycine 0 N--CA 1.443 -0.872 0 N-CA-C 108.546 -1.821 . . . . 0.0 108.546 179.092 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 272' ' ' PRO . . . . . 0.661 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 60.2 Cg_exo -54.07 -38.32 87.09 Favored 'Trans proline' 0 C--N 1.298 -2.091 0 C-N-CA 121.443 1.429 . . . . 0.0 110.559 -179.219 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 8.9 m-85 -118.69 11.57 12.8 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 112.646 0.61 . . . . 0.0 112.646 -174.455 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 22.2 p -130.13 143.59 50.87 Favored 'General case' 0 C--O 1.242 0.675 0 C-N-CA 120.669 -0.413 . . . . 0.0 111.177 177.158 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 275' ' ' PHE . . . . . 0.521 ' C ' ' CD1' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -146.59 165.85 28.26 Favored 'General case' 0 C--O 1.246 0.869 0 N-CA-C 112.363 0.505 . . . . 0.0 112.363 178.75 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 276' ' ' SER . . . . . 0.452 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 4.4 p -130.88 143.01 50.42 Favored 'General case' 0 N--CA 1.431 -1.416 0 CA-C-O 121.773 0.797 . . . . 0.0 111.605 -178.695 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 277' ' ' ILE . . . . . 0.406 HG23 ' CE1' ' A' ' 275' ' ' PHE . 33.8 pt -135.91 165.32 29.95 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.058 0 CA-C-N 114.428 -1.26 . . . . 0.0 110.71 -173.136 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 15.2 t -30.54 -90.71 0.0 OUTLIER 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 112.859 0.689 . . . . 0.0 112.859 -174.874 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . 0.423 ' CG ' ' HB2' ' A' ' 228' ' ' ASN . 66.3 t0 -148.93 117.18 6.43 Favored 'General case' 0 N--CA 1.447 -0.593 0 CA-C-O 120.943 0.402 . . . . 0.0 110.827 -178.91 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 280' ' ' THR . . . . . 0.708 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 21.3 p -65.49 -27.33 68.41 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.54 176.56 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -64.35 -19.36 65.41 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.664 175.889 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -88.49 -9.88 50.91 Favored 'General case' 0 CA--C 1.508 -0.655 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.378 179.839 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 283' ' ' PHE . . . . . 0.708 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 4.4 m-85 -93.69 -64.96 1.03 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 174.303 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 284' ' ' SER . . . . . 0.437 ' OG ' ' HA ' ' A' ' 256' ' ' MET . 1.9 p 169.43 -94.18 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 115.205 -0.907 . . . . 0.0 111.625 177.242 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 285' ' ' ASP . . . . . 0.531 ' O ' ' N ' ' A' ' 256' ' ' MET . 45.0 t0 -156.19 166.09 34.46 Favored 'General case' 0 C--O 1.214 -0.786 0 N-CA-C 110.409 -0.219 . . . . 0.0 110.409 -177.308 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 286' ' ' TYR . . . . . 0.511 ' CZ ' ' HA ' ' A' ' 288' ' ' ARG . 68.2 t80 -99.61 119.4 38.02 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 110.226 -0.287 . . . . 0.0 110.226 177.359 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 287' ' ' ILE . . . . . 0.419 HG23 HD13 ' A' ' 287' ' ' ILE . 21.1 mm -99.91 -56.44 5.2 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.586 0 N-CA-C 109.114 -0.698 . . . . 0.0 109.114 173.575 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . 0.529 ' CZ ' HE22 ' A' ' 254' ' ' GLN . 45.9 ptt85 177.87 -173.92 0.14 Allowed 'General case' 0 C--O 1.241 0.639 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.145 175.532 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 66.16 -158.93 47.67 Favored Glycine 0 CA--C 1.51 -0.281 0 N-CA-C 111.018 -0.833 . . . . 0.0 111.018 176.619 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 110.6 127.15 5.16 Favored Glycine 0 N--CA 1.447 -0.592 0 CA-C-O 121.52 0.511 . . . . 0.0 112.988 175.224 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 94.2 mt -130.32 133.07 64.5 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.807 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 174.312 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 3.8 p -124.52 134.29 67.14 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 C-N-CA 120.442 -0.503 . . . . 0.0 109.669 -177.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 293' ' ' SER . . . . . 0.468 ' HA ' ' O ' ' A' ' 217' ' ' LEU . 2.6 m -127.23 145.43 50.77 Favored 'General case' 0 C--N 1.324 -0.532 0 C-N-CA 120.488 -0.485 . . . . 0.0 111.042 -178.364 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 294' ' ' GLN . . . . . 0.501 ' HB3' ' CD1' ' A' ' 242' ' ' PHE . 0.3 OUTLIER . . . . . 0 CA--C 1.508 -0.659 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.185 176.661 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 CA--C 1.513 -0.473 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 4.6 m -126.3 147.95 49.62 Favored 'General case' 0 C--N 1.313 -1.011 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.335 -176.374 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -152.5 153.8 34.22 Favored 'General case' 0 C--O 1.24 0.605 0 CA-C-O 121.112 0.482 . . . . 0.0 111.062 -178.709 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 71.3 mtm -80.15 129.67 34.66 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.652 -0.703 . . . . 0.0 109.662 175.9 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 57.5 t -76.29 131.24 35.25 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.694 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 177.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 46.8 p -88.72 -65.84 0.98 Allowed 'General case' 0 C--N 1.309 -1.169 0 C-N-CA 120.325 -0.55 . . . . 0.0 110.024 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 23.3 ptm -137.73 142.43 40.99 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.923 -0.58 . . . . 0.0 112.205 176.581 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 224' ' ' VAL . . . . . 0.451 ' CG2' ' HB ' ' A' ' 232' ' ' VAL . 75.0 t -119.89 133.57 66.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 177.294 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 62.7 p -98.5 128.6 44.91 Favored 'General case' 0 C--N 1.323 -0.569 0 C-N-CA 120.234 -0.587 . . . . 0.0 110.974 -179.517 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.86 85.76 3.44 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 177.908 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 227' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -152.04 175.82 12.15 Favored 'General case' 0 N--CA 1.469 0.521 0 CA-C-N 116.476 -0.329 . . . . 0.0 111.39 -175.495 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 228' ' ' ASN . . . . . 0.457 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 9.4 t30 -140.69 124.09 10.17 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.508 174.625 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 229' ' ' PRO . . . . . 0.457 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 40.4 Cg_endo -65.22 142.24 52.16 Favored 'Cis proline' 0 N--CA 1.493 1.488 0 C-N-CA 122.702 -1.791 . . . . 0.0 109.854 -1.12 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . 0.428 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -74.39 136.84 21.84 Favored Glycine 0 C--N 1.315 -0.629 0 N-CA-C 110.575 -1.01 . . . . 0.0 110.575 -176.957 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.1 p -127.69 137.74 56.75 Favored 'Isoleucine or valine' 0 C--O 1.248 0.997 0 CA-C-O 120.807 0.337 . . . . 0.0 110.697 177.574 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 232' ' ' VAL . . . . . 0.451 ' HB ' ' CG2' ' A' ' 224' ' ' VAL . 0.7 OUTLIER -132.28 157.17 43.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.951 179.292 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 233' ' ' THR . . . . . 0.442 ' HA ' ' O ' ' A' ' 273' ' ' TYR . 0.9 OUTLIER -114.36 146.96 39.88 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.388 -178.836 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 34.0 m -107.31 152.24 24.4 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.111 -0.495 . . . . 0.0 109.948 179.263 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 15.7 tp -51.72 135.09 29.78 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 -178.881 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 24.7 p-10 -48.63 -47.44 40.2 Favored 'General case' 0 N--CA 1.475 0.793 0 N-CA-C 111.936 0.347 . . . . 0.0 111.936 -171.838 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -70.51 -34.65 72.55 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-O 120.944 0.402 . . . . 0.0 111.62 178.218 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -83.96 89.42 7.23 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.262 -176.615 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 239' ' ' ARG . . . . . 0.52 ' NH1' ' O ' ' A' ' 239' ' ' ARG . 0.0 OUTLIER -78.83 123.16 26.94 Favored 'General case' 0 CA--C 1.513 -0.443 0 N-CA-C 108.771 -0.825 . . . . 0.0 108.771 173.698 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 240' ' ' HIS . . . . . 0.534 ' HB2' ' CD2' ' A' ' 242' ' ' PHE . 7.0 p80 -57.13 -48.71 77.98 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.397 -175.818 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 80.01 19.93 68.84 Favored Glycine 0 C--N 1.314 -0.666 0 N-CA-C 110.131 -1.188 . . . . 0.0 110.131 -177.674 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 242' ' ' PHE . . . . . 0.534 ' CD2' ' HB2' ' A' ' 240' ' ' HIS . 8.3 m-30 -81.53 151.87 27.54 Favored 'General case' 0 C--N 1.316 -0.877 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 177.946 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -116.19 160.78 19.92 Favored 'General case' 0 C--N 1.314 -0.935 0 CA-C-O 120.893 0.378 . . . . 0.0 110.887 177.491 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -58.84 125.88 25.37 Favored 'General case' 0 C--N 1.312 -1.029 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 -179.65 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 80.86 5.81 89.83 Favored Glycine 0 C--N 1.319 -0.365 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 -178.326 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 246' ' ' ASP . . . . . 0.477 ' CG ' HE21 ' A' ' 294' ' ' GLN . 5.3 t70 -79.86 162.34 25.09 Favored 'General case' 0 CA--C 1.514 -0.42 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 178.416 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 247' ' ' PHE . . . . . . . . . . . . . 78.0 m-85 -109.78 129.04 55.67 Favored 'General case' 0 C--O 1.242 0.708 0 CA-C-O 120.846 0.355 . . . . 0.0 111.191 -177.488 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 248' ' ' VAL . . . . . 0.475 HG12 ' CD2' ' A' ' 242' ' ' PHE . 2.4 m -129.95 162.26 38.01 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.399 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.364 178.369 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.48 145.82 46.87 Favored 'General case' 0 C--N 1.308 -1.226 0 CA-C-N 115.324 -0.853 . . . . 0.0 109.982 177.363 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 250' ' ' PHE . . . . . 0.558 ' CB ' ' HB3' ' A' ' 259' ' ' LEU . 67.5 m-85 -104.81 145.68 30.04 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.65 177.701 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 4.3 m -143.36 150.12 38.69 Favored 'General case' 0 C--N 1.309 -1.153 0 N-CA-C 110.084 -0.339 . . . . 0.0 110.084 176.07 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 23.7 mm-40 54.1 26.78 6.86 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 112.816 0.673 . . . . 0.0 112.816 173.07 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . 0.517 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 88.0 t -76.53 130.93 35.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 173.702 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 86.5 mm-40 -100.45 139.72 35.72 Favored 'General case' 0 C--O 1.244 0.765 0 C-N-CA 119.68 -0.808 . . . . 0.0 111.651 -176.152 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 78.71 -58.16 4.21 Favored Glycine 0 C--O 1.239 0.453 0 N-CA-C 108.983 -1.647 . . . . 0.0 108.983 -173.688 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 256' ' ' MET . . . . . 0.481 ' SD ' ' HB2' ' A' ' 286' ' ' TYR . 31.7 mtt -80.57 61.04 4.14 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-O 121.242 0.544 . . . . 0.0 109.788 172.682 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 41.8 pt -76.23 -15.78 15.14 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.731 -178.512 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 258' ' ' GLN . . . . . 0.414 ' O ' ' N ' ' A' ' 262' ' ' CYS . 70.5 tp60 -55.38 -39.31 69.99 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 179.423 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 259' ' ' LEU . . . . . 0.558 ' HB3' ' CB ' ' A' ' 250' ' ' PHE . 89.0 mt -61.86 -41.71 98.17 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.747 -0.661 . . . . 0.0 109.925 176.908 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 260' ' ' ASN . . . . . 0.517 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 97.9 m-20 -61.29 -40.58 94.67 Favored 'General case' 0 CA--C 1.509 -0.612 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 179.347 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -87.66 -5.67 78.0 Favored Glycine 0 CA--C 1.523 0.538 0 CA-C-N 115.529 -0.76 . . . . 0.0 111.496 -178.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 262' ' ' CYS . . . . . 0.414 ' N ' ' O ' ' A' ' 258' ' ' GLN . 49.0 t -87.98 150.58 23.36 Favored 'General case' 0 CA--C 1.512 -0.493 0 CA-C-O 120.765 0.317 . . . . 0.0 111.062 -178.285 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . 0.576 ' CD ' ' H ' ' A' ' 263' ' ' GLN . 0.0 OUTLIER -72.45 169.39 17.09 Favored Pre-proline 0 C--N 1.319 -0.758 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 172.631 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_exo -61.76 145.12 97.5 Favored 'Trans proline' 0 C--N 1.307 -1.608 0 C-N-CA 121.462 1.441 . . . . 0.0 109.983 179.099 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 265' ' ' MET . . . . . 0.655 ' SD ' ' N ' ' A' ' 265' ' ' MET . 0.8 OUTLIER -122.83 157.26 32.85 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 -176.466 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 64.1 tt0 -75.94 134.85 40.12 Favored 'General case' 0 C--O 1.238 0.493 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 175.513 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 267' ' ' ILE . . . . . 0.436 ' C ' ' CD1' ' A' ' 267' ' ' ILE . 1.9 pp -128.66 163.3 33.63 Favored 'Isoleucine or valine' 0 C--O 1.237 0.405 0 N-CA-C 114.095 1.146 . . . . 0.0 114.095 -170.495 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . 0.43 ' NZ ' ' OG ' ' A' ' 276' ' ' SER . 8.0 mtpm? -119.36 123.31 43.84 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-N 115.009 -0.996 . . . . 0.0 110.065 178.737 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . 0.415 HG13 ' O ' ' A' ' 242' ' ' PHE . 30.1 m -84.59 97.93 5.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-O 121.087 0.47 . . . . 0.0 111.236 177.056 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 91.9 mt -66.79 -40.4 88.14 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.528 0.68 . . . . 0.0 109.747 176.38 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -155.33 -177.85 28.99 Favored Glycine 0 N--CA 1.447 -0.624 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 -179.827 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 272' ' ' PRO . . . . . 0.5 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 35.6 Cg_endo -61.32 -30.88 88.49 Favored 'Trans proline' 0 C--N 1.306 -1.702 0 C-N-CA 122.066 1.844 . . . . 0.0 111.471 -178.519 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 273' ' ' TYR . . . . . 0.442 ' O ' ' HA ' ' A' ' 233' ' ' THR . 94.5 m-85 -122.85 7.0 9.33 Favored 'General case' 0 C--N 1.319 -0.733 0 N-CA-C 112.942 0.719 . . . . 0.0 112.942 -178.497 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 4.3 p -126.84 129.02 47.45 Favored 'General case' 0 C--O 1.244 0.816 0 CA-C-O 120.884 0.374 . . . . 0.0 110.835 178.031 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 275' ' ' PHE . . . . . 0.511 ' C ' ' CD1' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -139.41 160.47 39.76 Favored 'General case' 0 CA--C 1.499 -0.986 0 C-N-CA 120.446 -0.502 . . . . 0.0 112.206 177.281 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 276' ' ' SER . . . . . 0.43 ' OG ' ' NZ ' ' A' ' 268' ' ' LYS . 10.9 p -130.79 154.49 47.95 Favored 'General case' 0 N--CA 1.43 -1.427 0 CA-C-O 121.456 0.646 . . . . 0.0 111.953 -175.11 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 277' ' ' ILE . . . . . 0.532 HD13 ' CE2' ' A' ' 283' ' ' PHE . 2.5 pp -138.19 -172.48 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.154 0 CA-C-N 114.313 -1.312 . . . . 0.0 108.961 -176.926 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -48.14 -85.93 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.751 0.31 . . . . 0.0 111.708 -178.245 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 31.7 t0 -145.0 115.45 7.62 Favored 'General case' 0 CA--C 1.515 -0.397 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.534 -177.625 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 280' ' ' THR . . . . . 0.662 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 12.6 p -71.42 -22.66 61.83 Favored 'General case' 0 N--CA 1.432 -1.37 0 CA-C-O 121.108 0.48 . . . . 0.0 109.77 176.294 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -67.37 -19.85 65.48 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 174.765 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 26.8 t-20 -89.2 -9.16 51.83 Favored 'General case' 0 CA--C 1.505 -0.752 0 CA-C-N 115.662 -0.699 . . . . 0.0 109.637 178.408 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 283' ' ' PHE . . . . . 0.662 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 22.8 m-30 -84.28 -79.0 0.22 Allowed 'General case' 0 N--CA 1.441 -0.906 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 174.612 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 284' ' ' SER . . . . . 0.458 ' HG ' ' C ' ' A' ' 283' ' ' PHE . 0.0 OUTLIER 175.01 -165.21 0.03 OUTLIER 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 114.892 -1.049 . . . . 0.0 109.589 -175.674 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 27.7 t0 -92.81 118.64 31.32 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.643 0.259 . . . . 0.0 111.301 178.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 286' ' ' TYR . . . . . 0.481 ' HB2' ' SD ' ' A' ' 256' ' ' MET . 6.1 t80 -68.86 122.0 17.73 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.6 179.341 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 96.4 mt -103.0 -59.9 3.15 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 175.027 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 50.8 ptt85 179.7 -163.04 0.04 OUTLIER 'General case' 0 C--O 1.24 0.553 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.397 174.755 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 68.83 -147.93 47.3 Favored Glycine 0 C--O 1.237 0.336 0 N-CA-C 109.811 -1.316 . . . . 0.0 109.811 -179.05 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 87.13 122.11 1.53 Allowed Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.823 175.111 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 97.7 mt -118.19 128.9 75.18 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.137 0 N-CA-C 107.262 -1.385 . . . . 0.0 107.262 172.346 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 14.9 p -116.94 128.92 74.24 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 -179.658 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 3.4 m -134.52 143.52 47.49 Favored 'General case' 0 N--CA 1.439 -0.996 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.409 -176.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 294' ' ' GLN . . . . . 0.477 HE21 ' CG ' ' A' ' 246' ' ' ASP . 52.6 tt0 . . . . . 0 N--CA 1.432 -1.358 0 CA-C-N 115.378 -0.828 . . . . 0.0 108.924 173.88 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 CA--C 1.515 -0.395 0 CA-C-O 120.764 0.316 . . . . 0.0 111.242 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 96.4 p -155.06 164.3 39.07 Favored 'General case' 0 N--CA 1.446 -0.652 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.258 -177.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -154.5 163.22 40.52 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-N 115.548 -0.751 . . . . 0.0 109.682 177.246 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 8.4 ttt -78.78 127.0 31.47 Favored 'General case' 0 N--CA 1.436 -1.144 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 175.703 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 98.0 t -69.22 130.13 33.98 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.174 0 N-CA-C 107.726 -1.213 . . . . 0.0 107.726 178.017 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -84.6 -70.36 0.58 Allowed 'General case' 0 N--CA 1.432 -1.331 0 C-N-CA 120.211 -0.596 . . . . 0.0 109.922 179.649 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 8.5 ptm -138.08 146.25 42.71 Favored 'General case' 0 N--CA 1.47 0.536 0 N-CA-C 112.446 0.536 . . . . 0.0 112.446 174.827 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 224' ' ' VAL . . . . . . . . . . . . . 53.1 t -121.94 132.85 70.01 Favored 'Isoleucine or valine' 0 C--O 1.239 0.537 0 C-N-CA 122.814 0.446 . . . . 0.0 110.557 178.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 39.2 p -88.25 133.0 34.16 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.554 -0.293 . . . . 0.0 110.694 178.731 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 15.9 tttm -82.11 80.16 8.42 Favored 'General case' 0 C--O 1.241 0.623 0 C-N-CA 120.349 -0.54 . . . . 0.0 110.014 177.549 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 227' ' ' ASP . . . . . 0.605 ' N ' ' OG1' ' A' ' 280' ' ' THR . 2.2 t0 -154.3 -179.86 8.32 Favored 'General case' 0 C--O 1.247 0.93 0 CA-C-N 115.391 -0.822 . . . . 0.0 111.2 178.853 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 228' ' ' ASN . . . . . 0.486 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.4 OUTLIER -141.77 125.48 9.91 Favored Pre-proline 0 C--N 1.324 -0.502 0 CA-C-N 115.529 -0.759 . . . . 0.0 109.645 176.747 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 229' ' ' PRO . . . . . 0.486 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 42.6 Cg_endo -64.71 142.32 50.21 Favored 'Cis proline' 0 N--CA 1.491 1.379 0 C-N-CA 122.995 -1.669 . . . . 0.0 110.198 -0.651 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 230' ' ' GLY . . . . . 0.478 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -74.42 138.89 24.84 Favored Glycine 0 C--N 1.308 -0.981 0 N-CA-C 109.912 -1.275 . . . . 0.0 109.912 -178.531 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.2 p -125.08 130.98 73.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 176.271 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 232' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -133.64 156.54 41.55 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 C-N-CA 120.502 -0.479 . . . . 0.0 110.494 -177.255 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 233' ' ' THR . . . . . 0.404 ' HA ' ' O ' ' A' ' 273' ' ' TYR . 2.4 m -105.35 149.27 26.22 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 115.268 -0.878 . . . . 0.0 109.321 177.777 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 2.6 m -113.08 147.26 37.66 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 175.478 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 33.7 tp -53.7 113.92 1.36 Allowed 'General case' 0 C--N 1.312 -1.065 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 178.623 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 36.7 p-10 -63.1 -10.38 14.41 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.94 -170.87 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 76.5 mm-40 -65.47 -32.76 74.55 Favored 'General case' 0 C--N 1.312 -1.048 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.231 177.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -121.45 133.52 55.06 Favored 'General case' 0 C--O 1.233 0.223 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.839 -177.868 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 239' ' ' ARG . . . . . 0.552 HH11 ' CE1' ' A' ' 240' ' ' HIS . 0.1 OUTLIER -77.87 112.57 14.89 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 173.439 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 240' ' ' HIS . . . . . 0.605 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 2.8 p80 -43.19 -34.2 1.08 Allowed 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 121.133 0.492 . . . . 0.0 109.988 -179.011 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 87.19 8.36 75.25 Favored Glycine 0 CA--C 1.503 -0.669 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 179.724 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 242' ' ' PHE . . . . . 0.552 ' O ' ' NH1' ' A' ' 239' ' ' ARG . 5.7 m-30 -81.82 146.16 30.04 Favored 'General case' 0 N--CA 1.444 -0.772 0 CA-C-O 120.85 0.357 . . . . 0.0 110.19 -179.192 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 243' ' ' GLU . . . . . 0.421 ' OE2' ' NH2' ' A' ' 239' ' ' ARG . 64.9 mm-40 -121.67 167.99 12.3 Favored 'General case' 0 C--N 1.309 -1.19 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.431 176.446 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 17.7 m -61.1 124.15 19.72 Favored 'General case' 0 C--N 1.298 -1.633 0 C-N-CA 120.152 -0.619 . . . . 0.0 109.718 -178.682 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 82.64 7.39 87.49 Favored Glycine 0 CA--C 1.523 0.578 0 CA-C-N 116.192 -0.458 . . . . 0.0 112.066 179.312 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 40.3 t0 -74.41 162.15 29.13 Favored 'General case' 0 C--O 1.238 0.482 0 CA-C-N 117.44 0.62 . . . . 0.0 109.457 177.809 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 247' ' ' PHE . . . . . . . . . . . . . 78.3 m-85 -109.31 131.05 55.43 Favored 'General case' 0 C--N 1.316 -0.849 0 N-CA-C 109.705 -0.479 . . . . 0.0 109.705 -179.27 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 248' ' ' VAL . . . . . 0.404 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 3.1 m -129.04 163.29 34.48 Favored 'Isoleucine or valine' 0 C--O 1.24 0.602 0 CA-C-O 121.027 0.441 . . . . 0.0 112.058 -177.251 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 9.6 p -133.91 162.04 33.13 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 114.522 -1.217 . . . . 0.0 108.905 175.172 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 250' ' ' PHE . . . . . 0.582 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 82.1 m-85 -124.37 159.36 30.52 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.087 0.47 . . . . 0.0 111.831 -169.231 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 20.2 m -158.42 160.0 36.36 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.192 177.489 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 78.0 mm-40 52.17 20.39 1.31 Allowed 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 113.234 0.827 . . . . 0.0 113.234 175.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 12.4 t -85.94 131.06 35.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 175.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 87.5 mt-30 -96.93 144.06 27.21 Favored 'General case' 0 C--O 1.24 0.56 0 C-N-CA 120.666 -0.413 . . . . 0.0 110.649 -179.689 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 77.75 -57.43 3.86 Favored Glycine 0 CA--C 1.509 -0.321 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -177.158 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 256' ' ' MET . . . . . 0.428 ' HG2' ' HB3' ' A' ' 283' ' ' PHE . 15.3 ttm -85.81 55.84 3.7 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-O 121.493 0.663 . . . . 0.0 109.446 175.684 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 44.4 pt -73.93 -18.1 17.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.036 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 3.5 tp60 -54.1 -39.04 66.02 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 108.231 -1.026 . . . . 0.0 108.231 178.157 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 259' ' ' LEU . . . . . 0.582 ' HB3' ' CG ' ' A' ' 250' ' ' PHE . 85.5 mt -62.16 -41.67 98.52 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.121 177.07 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 97.2 m-20 -59.98 -40.53 89.45 Favored 'General case' 0 CA--C 1.506 -0.734 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 -176.436 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -102.27 14.75 56.77 Favored Glycine 0 CA--C 1.523 0.552 0 CA-C-N 115.787 -0.642 . . . . 0.0 112.235 -179.603 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 262' ' ' CYS . . . . . 0.401 ' HB2' ' HA ' ' A' ' 259' ' ' LEU . 1.1 m -91.16 158.83 16.4 Favored 'General case' 0 CA--C 1.513 -0.456 0 CA-C-N 117.469 0.634 . . . . 0.0 111.684 -178.005 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -76.59 151.25 82.69 Favored Pre-proline 0 C--N 1.323 -0.553 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 173.927 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 264' ' ' PRO . . . . . 0.404 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 49.5 Cg_endo -64.01 147.11 91.82 Favored 'Trans proline' 0 C--N 1.306 -1.668 0 C-N-CA 121.76 1.64 . . . . 0.0 112.052 -176.177 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 265' ' ' MET . . . . . 0.479 ' SD ' ' HZ ' ' A' ' 283' ' ' PHE . 7.8 ptp -134.07 157.4 46.22 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 112.484 0.55 . . . . 0.0 112.484 -173.661 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -73.57 141.55 46.64 Favored 'General case' 0 C--O 1.241 0.631 0 O-C-N 124.006 0.816 . . . . 0.0 109.846 177.015 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 267' ' ' ILE . . . . . 0.452 HG22 ' CE2' ' A' ' 275' ' ' PHE . 1.8 pp -130.66 163.58 36.05 Favored 'Isoleucine or valine' 0 C--O 1.237 0.445 0 N-CA-C 112.114 0.413 . . . . 0.0 112.114 -177.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 45.1 mmtm -124.88 127.35 46.97 Favored 'General case' 0 CA--C 1.541 0.628 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 174.555 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 27.2 m -83.64 98.27 5.3 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.612 0 CA-C-O 120.887 0.375 . . . . 0.0 111.507 -179.818 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 98.6 mt -65.73 -42.46 90.99 Favored 'General case' 0 CA--C 1.513 -0.46 0 CA-C-O 121.399 0.619 . . . . 0.0 109.577 178.137 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -145.04 176.44 24.08 Favored Glycine 0 C--N 1.314 -0.693 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 178.499 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 272' ' ' PRO . . . . . 0.605 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 67.9 Cg_exo -54.03 -40.05 82.86 Favored 'Trans proline' 0 C--N 1.305 -1.72 0 C-N-CA 122.159 1.906 . . . . 0.0 111.068 -178.805 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 273' ' ' TYR . . . . . 0.404 ' O ' ' HA ' ' A' ' 233' ' ' THR . 6.9 m-85 -115.71 8.96 15.08 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.623 -176.062 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.7 p -126.74 124.97 40.97 Favored 'General case' 0 C--O 1.247 0.937 0 CA-C-O 121.047 0.451 . . . . 0.0 111.431 179.284 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 275' ' ' PHE . . . . . 0.536 ' C ' ' CD1' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -133.09 164.72 26.39 Favored 'General case' 0 CA--C 1.494 -1.189 0 C-N-CA 120.492 -0.483 . . . . 0.0 112.224 177.95 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 276' ' ' SER . . . . . 0.478 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 13.7 p -132.12 152.4 51.26 Favored 'General case' 0 N--CA 1.432 -1.347 0 C-N-CA 120.436 -0.506 . . . . 0.0 110.944 -176.382 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.26 -169.19 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.195 0 CA-C-N 115.258 -0.883 . . . . 0.0 110.564 -175.185 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 12.9 m -58.32 -75.64 0.05 OUTLIER 'General case' 0 CA--C 1.536 0.438 0 N-CA-C 112.941 0.719 . . . . 0.0 112.941 -175.273 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 66.7 t0 -154.99 114.78 3.74 Favored 'General case' 0 N--CA 1.45 -0.441 0 O-C-N 122.266 -0.271 . . . . 0.0 111.122 -175.276 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 280' ' ' THR . . . . . 0.658 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 21.5 p -66.89 -29.52 69.43 Favored 'General case' 0 C--N 1.303 -1.417 0 CA-C-O 121.101 0.477 . . . . 0.0 110.262 174.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -62.28 -19.45 63.26 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 115.29 -0.868 . . . . 0.0 109.125 174.794 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -88.48 -8.48 54.82 Favored 'General case' 0 CA--C 1.507 -0.703 0 N-CA-C 109.454 -0.572 . . . . 0.0 109.454 175.163 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 283' ' ' PHE . . . . . 0.658 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 12.2 m-30 -98.82 -83.35 0.42 Allowed 'General case' 0 N--CA 1.442 -0.843 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 174.8 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 284' ' ' SER . . . . . 0.418 ' H ' ' HB2' ' A' ' 283' ' ' PHE . 0.2 OUTLIER 172.88 -162.02 0.02 OUTLIER 'General case' 0 N--CA 1.448 -0.535 0 C-N-CA 124.908 1.283 . . . . 0.0 107.929 -178.998 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 9.4 p-10 -91.64 169.99 10.28 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.666 0.27 . . . . 0.0 110.631 175.618 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 86.2 t80 -106.85 120.98 43.48 Favored 'General case' 0 C--O 1.239 0.531 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.199 179.731 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 287' ' ' ILE . . . . . 0.447 ' O ' ' HG3' ' A' ' 288' ' ' ARG . 96.9 mt -93.32 -57.67 4.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 109.993 -0.373 . . . . 0.0 109.993 175.413 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 288' ' ' ARG . . . . . 0.447 ' HG3' ' O ' ' A' ' 287' ' ' ILE . 15.9 mtm180 -178.9 179.05 0.72 Allowed 'General case' 0 C--O 1.243 0.722 0 C-N-CA 124.525 1.13 . . . . 0.0 110.122 177.773 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 69.52 -163.14 51.75 Favored Glycine 0 C--O 1.235 0.21 0 N-CA-C 111.275 -0.73 . . . . 0.0 111.275 175.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 113.68 128.23 4.72 Favored Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 121.251 -0.5 . . . . 0.0 113.076 175.686 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 291' ' ' ILE . . . . . 0.417 HG21 HD11 ' A' ' 291' ' ' ILE . 98.5 mt -124.42 132.11 71.81 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.858 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 172.751 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 5.5 p -125.33 137.69 56.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -178.189 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 4.4 m -132.18 147.0 52.4 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.299 -177.299 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 CA--C 1.507 -0.7 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 173.318 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . 0.544 ' C ' ' H ' ' A' ' 203' ' ' GLY . 1.7 mp0 . . . . . 0 N--CA 1.479 1.021 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 13.9 m-85 65.02 -33.1 0.15 Allowed 'General case' 0 N--CA 1.475 0.784 0 C-N-CA 122.824 0.45 . . . . 0.0 111.754 178.296 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . 0.544 ' H ' ' C ' ' A' ' 201' ' ' GLU . . . -60.81 -35.14 89.51 Favored Glycine 0 C--O 1.213 -1.205 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 177.3 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 204' ' ' GLU . . . . . 0.49 ' OE1' ' N ' ' A' ' 204' ' ' GLU . 1.8 mp0 -54.76 -45.21 74.19 Favored 'General case' 0 C--N 1.315 -0.897 0 N-CA-C 108.258 -1.016 . . . . 0.0 108.258 177.739 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -72.02 -44.28 63.66 Favored 'General case' 0 N--CA 1.444 -0.749 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.108 173.358 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 78.0 mtm -95.38 69.84 3.11 Favored 'General case' 0 C--O 1.24 0.574 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.583 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . 0.429 ' HB ' ' O ' ' A' ' 203' ' ' GLY . 9.9 p -149.21 149.95 14.37 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.054 0 CA-C-N 115.707 -0.679 . . . . 0.0 109.654 175.147 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 208' ' ' LEU . . . . . 0.53 ' C ' ' H ' ' A' ' 210' ' ' ASP . 89.4 mt -71.71 144.01 49.46 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-O 121.015 0.436 . . . . 0.0 110.557 178.534 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 7.9 p -74.58 34.39 0.1 Allowed 'General case' 0 C--N 1.306 -1.287 0 CA-C-N 115.425 -0.807 . . . . 0.0 110.021 175.397 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 210' ' ' ASP . . . . . 0.53 ' H ' ' C ' ' A' ' 208' ' ' LEU . 18.2 p-10 -50.28 -28.47 7.82 Favored 'General case' 0 CA--C 1.512 -0.504 0 CA-C-N 115.408 -0.815 . . . . 0.0 110.641 -174.805 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -60.6 94.17 0.03 OUTLIER 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 173.256 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 212' ' ' ASN . . . . . 0.542 ' C ' ' H ' ' A' ' 214' ' ' GLU . 17.7 t30 -85.33 105.09 15.73 Favored 'General case' 0 CA--C 1.507 -0.698 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.277 -173.679 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 66.82 -39.24 0.18 Allowed Glycine 0 CA--C 1.526 0.733 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -176.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 214' ' ' GLU . . . . . 0.542 ' H ' ' C ' ' A' ' 212' ' ' ASN . 74.8 mm-40 -71.18 110.1 5.63 Favored 'General case' 0 N--CA 1.446 -0.672 0 N-CA-C 110.197 -0.298 . . . . 0.0 110.197 178.911 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -95.23 150.85 38.22 Favored Pre-proline 0 C--N 1.317 -0.846 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 172.669 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -57.79 139.23 89.62 Favored 'Trans proline' 0 C--N 1.3 -1.982 0 N-CA-C 109.406 -1.036 . . . . 0.0 109.406 179.131 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 217' ' ' LEU . . . . . 0.481 ' C ' ' HG ' ' A' ' 293' ' ' SER . 0.2 OUTLIER -86.16 124.46 32.6 Favored 'General case' 0 CA--C 1.505 -0.77 0 N-CA-C 106.439 -1.689 . . . . 0.0 106.439 178.586 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 50.3 m -113.84 146.78 39.48 Favored 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 -173.506 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -138.73 148.69 44.21 Favored 'General case' 0 C--O 1.243 0.742 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.099 -174.278 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 97.4 mmm -74.63 125.15 28.04 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.599 -0.728 . . . . 0.0 109.873 176.26 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 60.1 t -87.06 129.11 39.08 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.948 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 177.136 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -83.87 -69.96 0.6 Allowed 'General case' 0 N--CA 1.433 -1.309 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 176.93 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -138.12 156.29 47.9 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.274 174.868 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 224' ' ' VAL . . . . . 0.56 ' CG1' ' SD ' ' A' ' 256' ' ' MET . 62.0 t -122.48 133.58 68.26 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.946 0 N-CA-C 108.18 -1.045 . . . . 0.0 108.18 173.488 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -102.83 121.91 43.43 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-O 120.555 0.217 . . . . 0.0 110.603 -175.842 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 226' ' ' LYS . . . . . 0.402 ' HA ' ' OG1' ' A' ' 280' ' ' THR . 0.4 OUTLIER -70.52 89.67 0.71 Allowed 'General case' 0 C--O 1.242 0.704 0 CA-C-O 120.966 0.412 . . . . 0.0 109.967 178.979 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 227' ' ' ASP . . . . . 0.428 ' H ' ' HG1' ' A' ' 280' ' ' THR . 52.9 t0 -158.47 171.69 19.69 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.492 -0.776 . . . . 0.0 109.993 -176.789 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 228' ' ' ASN . . . . . 0.431 ' HB2' ' CG ' ' A' ' 279' ' ' ASP . 0.7 OUTLIER -136.16 123.32 14.46 Favored Pre-proline 0 C--N 1.325 -0.459 0 CA-C-N 116.576 -0.284 . . . . 0.0 110.544 175.192 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 229' ' ' PRO . . . . . 0.407 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 45.7 Cg_endo -65.89 146.5 71.49 Favored 'Cis proline' 0 N--CA 1.494 1.538 0 C-N-CA 122.783 -1.757 . . . . 0.0 109.22 -1.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . 0.498 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -68.43 144.06 41.8 Favored Glycine 0 C--O 1.219 -0.812 0 N-CA-C 109.787 -1.325 . . . . 0.0 109.787 -177.72 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.5 p -128.12 134.95 64.02 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 CA-C-N 116.989 0.394 . . . . 0.0 110.079 178.168 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 232' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -133.8 156.44 41.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 C-N-CA 120.428 -0.509 . . . . 0.0 110.836 -179.817 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 24.5 m -117.49 134.3 55.01 Favored 'General case' 0 C--O 1.242 0.693 0 CA-C-N 115.998 -0.546 . . . . 0.0 109.683 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.8 m -106.4 158.58 16.79 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.961 -175.372 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . 0.413 ' O ' ' HB3' ' A' ' 238' ' ' ALA . 22.8 tp -63.29 150.79 42.39 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.226 -0.897 . . . . 0.0 108.686 179.225 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -59.63 -39.7 85.16 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 121.089 0.471 . . . . 0.0 109.847 -177.697 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 237' ' ' GLU . . . . . 0.439 ' O ' ' N ' ' A' ' 239' ' ' ARG . 98.8 mt-10 -70.53 -21.09 62.76 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.16 174.062 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . 0.413 ' HB3' ' O ' ' A' ' 235' ' ' LEU . . . -65.83 61.25 0.03 OUTLIER 'General case' 0 C--O 1.241 0.653 0 CA-C-O 121.227 0.537 . . . . 0.0 111.027 -178.472 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 239' ' ' ARG . . . . . 0.439 ' N ' ' O ' ' A' ' 237' ' ' GLU . 61.5 mtp180 -67.78 85.09 0.21 Allowed 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 174.215 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 240' ' ' HIS . . . . . 0.607 ' HB2' ' CG ' ' A' ' 242' ' ' PHE . 3.5 p80 -57.92 -46.83 84.39 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-N 115.163 -0.926 . . . . 0.0 112.398 -170.903 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 80.32 14.47 80.23 Favored Glycine 0 C--N 1.313 -0.743 0 N-CA-C 109.867 -1.293 . . . . 0.0 109.867 -174.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 242' ' ' PHE . . . . . 0.647 ' CD1' ' HB3' ' A' ' 294' ' ' GLN . 4.6 m-30 -80.02 148.69 31.01 Favored 'General case' 0 CA--C 1.509 -0.617 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 -179.301 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 243' ' ' GLU . . . . . 0.434 ' HB2' ' HB2' ' A' ' 246' ' ' ASP . 37.7 mt-10 -115.46 150.66 36.12 Favored 'General case' 0 C--N 1.308 -1.238 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 179.634 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 32.6 m -62.43 127.62 32.16 Favored 'General case' 0 C--N 1.305 -1.34 0 C-N-CA 119.235 -0.986 . . . . 0.0 108.652 177.316 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 86.16 4.01 84.44 Favored Glycine 0 C--N 1.311 -0.847 0 N-CA-C 110.489 -1.044 . . . . 0.0 110.489 -176.326 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 246' ' ' ASP . . . . . 0.434 ' HB2' ' HB2' ' A' ' 243' ' ' GLU . 31.6 t0 -81.58 164.06 22.16 Favored 'General case' 0 CA--C 1.515 -0.402 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 177.737 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 247' ' ' PHE . . . . . 0.441 ' HA ' ' O ' ' A' ' 265' ' ' MET . 69.3 m-85 -110.05 134.68 51.89 Favored 'General case' 0 C--N 1.311 -1.085 0 O-C-N 123.413 0.446 . . . . 0.0 110.337 -179.644 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . 0.5 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 3.1 m -132.04 163.81 36.46 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.572 0 CA-C-O 120.745 0.307 . . . . 0.0 111.082 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 12.0 p -130.89 162.2 30.17 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 115.126 -0.943 . . . . 0.0 108.896 176.509 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 250' ' ' PHE . . . . . 0.557 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 73.7 m-85 -121.57 157.92 29.67 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-O 121.146 0.498 . . . . 0.0 111.6 -174.763 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 3.7 m -152.25 155.89 38.63 Favored 'General case' 0 C--N 1.313 -1.017 0 CA-C-N 115.473 -0.785 . . . . 0.0 109.473 175.359 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 54.21 25.77 6.09 Favored 'General case' 0 C--N 1.314 -0.947 0 N-CA-C 112.7 0.63 . . . . 0.0 112.7 174.846 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 95.6 t -82.53 129.76 36.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 174.487 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -99.92 138.59 36.78 Favored 'General case' 0 C--O 1.24 0.601 0 C-N-CA 120.548 -0.461 . . . . 0.0 110.361 -179.74 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 80.94 -61.56 4.54 Favored Glycine 0 C--N 1.319 -0.378 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 -175.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 256' ' ' MET . . . . . 0.56 ' SD ' ' CG1' ' A' ' 224' ' ' VAL . 31.3 mtt -80.71 62.43 4.75 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.608 0.718 . . . . 0.0 110.172 174.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 47.6 pt -72.54 -19.41 19.19 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.86 -177.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 258' ' ' GLN . . . . . 0.401 ' O ' ' N ' ' A' ' 262' ' ' CYS . 0.7 OUTLIER -56.02 -39.36 71.82 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 -179.624 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 259' ' ' LEU . . . . . 0.557 ' HB3' ' CG ' ' A' ' 250' ' ' PHE . 89.8 mt -62.21 -41.7 98.62 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 116.009 -0.542 . . . . 0.0 109.742 178.767 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 97.1 m-20 -60.76 -40.72 93.52 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 178.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -96.95 11.04 66.12 Favored Glycine 0 CA--C 1.526 0.78 0 CA-C-N 115.485 -0.78 . . . . 0.0 112.676 -177.664 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 262' ' ' CYS . . . . . 0.401 ' N ' ' O ' ' A' ' 258' ' ' GLN . 4.0 m -102.84 146.75 27.81 Favored 'General case' 0 CA--C 1.517 -0.315 0 CA-C-N 117.6 0.7 . . . . 0.0 111.475 -179.457 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 51.5 mt-30 -62.34 161.96 22.29 Favored Pre-proline 0 C--N 1.326 -0.421 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 172.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 264' ' ' PRO . . . . . 0.5 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 37.6 Cg_endo -62.56 146.02 95.4 Favored 'Trans proline' 0 C--N 1.305 -1.727 0 C-N-CA 121.33 1.353 . . . . 0.0 111.219 178.644 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 265' ' ' MET . . . . . 0.611 ' SD ' ' N ' ' A' ' 265' ' ' MET . 0.9 OUTLIER -128.35 162.27 27.48 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 116.782 -0.19 . . . . 0.0 111.502 -175.702 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 70.3 tt0 -71.0 139.4 50.5 Favored 'General case' 0 C--O 1.245 0.818 0 O-C-N 123.585 0.553 . . . . 0.0 109.621 176.641 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 267' ' ' ILE . . . . . 0.433 HG23 ' CE2' ' A' ' 275' ' ' PHE . 1.9 pp -127.41 152.43 35.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-O 121.049 0.452 . . . . 0.0 111.777 -179.766 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 63.8 mttp -129.3 114.23 15.97 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.852 178.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 34.7 m -74.98 106.75 4.94 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 CA-C-O 121.145 0.497 . . . . 0.0 112.242 -176.679 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 92.9 mt -66.11 -41.02 91.14 Favored 'General case' 0 N--CA 1.449 -0.503 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.517 175.546 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -149.04 -176.19 22.12 Favored Glycine 0 C--N 1.322 -0.224 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 178.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 272' ' ' PRO . . . . . 0.429 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 33.6 Cg_endo -60.98 -34.84 90.14 Favored 'Trans proline' 0 N--CA 1.496 1.672 0 C-N-CA 121.97 1.78 . . . . 0.0 111.992 -177.29 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 57.1 m-85 -118.76 7.75 11.69 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 112.245 0.461 . . . . 0.0 112.245 178.826 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 6.0 p -120.97 124.36 44.7 Favored 'General case' 0 C--N 1.319 -0.725 0 C-N-CA 120.888 -0.325 . . . . 0.0 110.323 178.586 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 275' ' ' PHE . . . . . 0.521 ' C ' ' CD1' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -132.66 157.55 44.55 Favored 'General case' 0 CA--C 1.501 -0.924 0 C-N-CA 120.133 -0.627 . . . . 0.0 112.599 179.43 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 276' ' ' SER . . . . . 0.498 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 7.4 p -125.79 142.36 51.55 Favored 'General case' 0 N--CA 1.431 -1.408 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.937 -173.803 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . 0.427 HG23 ' CE1' ' A' ' 275' ' ' PHE . 32.8 pt -139.77 163.56 24.73 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.917 0 CA-C-N 115.166 -0.924 . . . . 0.0 111.964 -172.783 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 278' ' ' CYS . . . . . 0.414 ' C ' ' O ' ' A' ' 277' ' ' ILE . 86.1 m -17.78 -96.25 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 124.413 1.085 . . . . 0.0 113.611 -178.86 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . 0.431 ' CG ' ' HB2' ' A' ' 228' ' ' ASN . 67.2 t0 -149.38 112.51 4.91 Favored 'General case' 0 CA--C 1.499 -1.017 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 178.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 280' ' ' THR . . . . . 0.749 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 11.3 p -67.21 -23.81 65.78 Favored 'General case' 0 N--CA 1.42 -1.949 0 CA-C-O 121.084 0.468 . . . . 0.0 110.4 179.08 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -66.28 -19.12 65.73 Favored 'General case' 0 C--N 1.315 -0.897 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.613 173.478 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 282' ' ' ASN . . . . . 0.48 ' ND2' ' C ' ' A' ' 282' ' ' ASN . 0.0 OUTLIER -91.46 2.72 56.22 Favored 'General case' 0 CA--C 1.513 -0.474 0 C-N-CA 120.409 -0.516 . . . . 0.0 109.809 176.324 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . 0.749 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 16.2 m-85 -100.98 -76.52 0.56 Allowed 'General case' 0 N--CA 1.445 -0.703 0 CA-C-O 121.404 0.621 . . . . 0.0 109.417 173.616 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 284' ' ' SER . . . . . 0.437 ' HG ' ' C ' ' A' ' 283' ' ' PHE . 0.0 OUTLIER 166.48 -175.06 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 114.41 -1.268 . . . . 0.0 109.132 -172.875 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 285' ' ' ASP . . . . . 0.403 ' C ' ' HG3' ' A' ' 256' ' ' MET . 19.8 m-20 -86.5 134.5 33.67 Favored 'General case' 0 N--CA 1.472 0.643 0 CA-C-N 117.406 0.094 . . . . 0.0 110.756 179.143 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . 0.458 ' HB2' ' SD ' ' A' ' 256' ' ' MET . 55.5 t80 -76.65 128.34 34.5 Favored 'General case' 0 N--CA 1.468 0.447 0 C-N-CA 123.102 0.561 . . . . 0.0 111.094 179.256 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 7.0 mm -100.75 -69.15 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 116.563 -0.29 . . . . 0.0 110.672 173.271 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 95.5 mtm-85 -160.8 -179.44 7.59 Favored 'General case' 0 C--O 1.241 0.63 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.452 -178.748 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 63.35 -143.74 48.58 Favored Glycine 0 CA--C 1.498 -1.027 0 CA-C-N 114.963 -1.017 . . . . 0.0 111.338 174.03 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 98.76 123.15 4.82 Favored Glycine 0 N--CA 1.436 -1.324 0 C-N-CA 120.968 -0.634 . . . . 0.0 111.774 178.625 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . 0.47 HG22 HD13 ' A' ' 291' ' ' ILE . 47.9 mm -119.05 130.18 74.2 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.488 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 175.28 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 11.3 p -122.04 135.87 60.77 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.985 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 -178.063 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 293' ' ' SER . . . . . 0.481 ' HG ' ' C ' ' A' ' 217' ' ' LEU . 0.3 OUTLIER -136.19 140.03 43.26 Favored 'General case' 0 C--N 1.316 -0.878 0 C-N-CA 120.478 -0.489 . . . . 0.0 110.237 -177.416 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 294' ' ' GLN . . . . . 0.647 ' HB3' ' CD1' ' A' ' 242' ' ' PHE . 2.3 pt20 -74.42 142.22 44.99 Favored 'General case' 0 CA--C 1.502 -0.902 0 C-N-CA 120.083 -0.647 . . . . 0.0 110.847 178.322 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 11.4 t -131.84 96.79 2.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 176.046 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -77.85 105.65 9.17 Favored 'General case' 0 N--CA 1.433 -1.291 0 N-CA-C 106.918 -1.512 . . . . 0.0 106.918 175.32 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 3.5 m -42.84 145.47 0.88 Allowed Pre-proline 0 C--N 1.325 -0.488 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.722 -171.507 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_exo -52.71 140.28 56.74 Favored 'Trans proline' 0 C--N 1.309 -1.548 0 C-N-CA 121.897 1.731 . . . . 0.0 111.853 -176.688 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 20.9 mmtm -121.98 154.15 37.59 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.659 -0.701 . . . . 0.0 109.494 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 50.6 mttp -73.48 149.82 42.05 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 107.4 -1.333 . . . . 0.0 107.4 170.67 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 41.1 pt -49.68 108.56 0.09 OUTLIER 'Isoleucine or valine' 0 C--O 1.235 0.291 0 C-N-CA 119.025 -1.07 . . . . 0.0 109.237 -178.396 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 31.3 t -155.56 166.24 34.13 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.1 -170.191 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 80.6 t80 -102.96 111.61 24.04 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 116.171 -0.468 . . . . 0.0 109.771 177.598 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . 0.403 ' HA ' ' HD3' ' A' ' 304' ' ' LYS . 20.6 mmtm -110.5 149.67 30.0 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.67 177.515 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -53.06 92.62 0.01 OUTLIER 'General case' 0 C--O 1.24 0.578 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 178.322 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 306' ' ' LEU . . . . . 0.402 ' N ' ' O ' ' A' ' 304' ' ' LYS . 0.2 OUTLIER -61.46 153.22 70.55 Favored Pre-proline 0 C--N 1.321 -0.639 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.845 -176.886 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . 0.492 ' O ' ' C ' ' A' ' 308' ' ' ALA . 36.6 Cg_exo -61.67 155.65 52.5 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 C-N-CA 122.417 2.078 . . . . 0.0 109.822 174.39 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . 0.492 ' C ' ' O ' ' A' ' 307' ' ' PRO . . . -27.91 120.48 0.11 Allowed 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 120.839 0.352 . . . . 0.0 110.823 -175.365 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 4.2 m -60.76 147.74 41.4 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.461 -174.302 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 7.7 mp -78.15 140.12 39.0 Favored 'General case' 0 C--O 1.243 0.74 0 CA-C-N 115.847 -0.615 . . . . 0.0 109.834 -176.626 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 26.7 m -107.78 125.03 64.27 Favored 'Isoleucine or valine' 0 C--O 1.239 0.519 0 CA-C-O 120.903 0.383 . . . . 0.0 111.101 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 67.7 mt-10 . . . . . 0 C--O 1.202 -1.4 0 CA-C-O 118.463 -0.78 . . . . 0.0 110.542 -178.554 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . 0.58 ' C ' ' H ' ' A' ' 203' ' ' GLY . 96.8 mt-10 . . . . . 0 N--CA 1.476 0.853 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 22.6 m-85 63.31 -29.17 0.09 Allowed 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 123.45 0.7 . . . . 0.0 111.798 -178.22 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . 0.58 ' H ' ' C ' ' A' ' 201' ' ' GLU . . . -60.66 -34.93 88.33 Favored Glycine 0 C--N 1.319 -0.364 0 N-CA-C 109.941 -1.264 . . . . 0.0 109.941 178.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -62.49 -40.48 96.84 Favored 'General case' 0 CA--C 1.516 -0.351 0 CA-C-O 121.307 0.575 . . . . 0.0 109.509 177.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 99.9 mt-10 -67.04 -39.3 86.94 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.813 -179.498 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 48.4 ttm -91.17 93.97 9.36 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.932 -176.424 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 27.2 m -132.35 158.39 43.27 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.292 178.228 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 5.1 mp -127.29 149.41 50.04 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 122.573 0.349 . . . . 0.0 110.247 179.618 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -102.34 -47.36 4.52 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 112.132 0.419 . . . . 0.0 112.132 177.142 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 210' ' ' ASP . . . . . 0.435 ' OD1' ' N ' ' A' ' 211' ' ' SER . 34.9 p-10 -64.18 -48.66 75.07 Favored 'General case' 0 CA--C 1.51 -0.575 0 C-N-CA 120.443 -0.503 . . . . 0.0 109.831 177.522 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 211' ' ' SER . . . . . 0.435 ' N ' ' OD1' ' A' ' 210' ' ' ASP . 4.4 m -76.01 144.22 41.0 Favored 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 114.871 -1.059 . . . . 0.0 109.58 178.659 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 212' ' ' ASN . . . . . 0.42 ' O ' ' C ' ' A' ' 213' ' ' GLY . 57.4 t-20 -84.88 91.77 8.11 Favored 'General case' 0 CA--C 1.514 -0.429 0 C-N-CA 120.643 -0.423 . . . . 0.0 110.192 -178.838 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 213' ' ' GLY . . . . . 0.469 ' O ' ' NE2' ' A' ' 215' ' ' GLN . . . 29.94 50.85 0.16 Allowed Glycine 0 C--N 1.334 0.44 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.54 178.642 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -69.83 128.44 36.4 Favored 'General case' 0 N--CA 1.442 -0.842 0 C-N-CA 120.728 -0.389 . . . . 0.0 110.398 -175.582 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 215' ' ' GLN . . . . . 0.469 ' NE2' ' O ' ' A' ' 213' ' ' GLY . 67.3 mm-40 -88.2 113.88 56.99 Favored Pre-proline 0 N--CA 1.443 -0.796 0 N-CA-C 108.636 -0.875 . . . . 0.0 108.636 175.821 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_exo -57.6 146.27 85.27 Favored 'Trans proline' 0 N--CA 1.496 1.627 0 C-N-CA 122.437 2.092 . . . . 0.0 112.951 -172.099 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 217' ' ' LEU . . . . . 0.497 ' HB3' ' O ' ' A' ' 240' ' ' HIS . 0.4 OUTLIER -75.7 148.07 38.91 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.232 -0.895 . . . . 0.0 110.448 179.359 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 218' ' ' SER . . . . . 0.451 ' HG ' ' CB ' ' A' ' 293' ' ' SER . 66.8 m -131.48 153.78 49.41 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-N 116.416 -0.357 . . . . 0.0 110.174 175.68 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -150.84 155.63 39.6 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.531 -0.304 . . . . 0.0 111.368 -178.404 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 92.1 mtp -76.83 135.37 38.89 Favored 'General case' 0 N--CA 1.447 -0.615 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.549 176.512 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 94.3 t -87.13 130.99 36.11 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.067 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 175.567 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 222' ' ' SER . . . . . 0.419 ' OG ' ' N ' ' A' ' 223' ' ' MET . 0.0 OUTLIER -82.44 -71.51 0.48 Allowed 'General case' 0 C--N 1.308 -1.216 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 176.836 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 223' ' ' MET . . . . . 0.419 ' N ' ' OG ' ' A' ' 222' ' ' SER . 5.5 ptm -137.66 149.09 46.29 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.711 174.843 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 224' ' ' VAL . . . . . 0.567 HG12 ' SD ' ' A' ' 256' ' ' MET . 2.3 t -113.37 124.3 69.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 174.822 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 74.6 p -79.66 133.08 36.38 Favored 'General case' 0 C--N 1.321 -0.647 0 C-N-CA 120.474 -0.491 . . . . 0.0 110.491 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -79.21 75.11 5.76 Favored 'General case' 0 C--O 1.243 0.727 0 CA-C-O 121.283 0.563 . . . . 0.0 109.595 179.22 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 227' ' ' ASP . . . . . 0.522 ' N ' ' OG1' ' A' ' 280' ' ' THR . 3.9 t0 -148.72 176.56 10.26 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-N 115.475 -0.784 . . . . 0.0 110.594 -179.742 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 228' ' ' ASN . . . . . 0.424 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.2 OUTLIER -142.87 123.52 8.16 Favored Pre-proline 0 C--N 1.313 -1.02 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.881 179.05 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 229' ' ' PRO . . . . . 0.424 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 47.8 Cg_endo -63.83 146.69 62.47 Favored 'Cis proline' 0 N--CA 1.496 1.62 0 C-N-CA 123.185 -1.589 . . . . 0.0 110.744 -2.12 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . 0.488 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -76.04 141.14 26.7 Favored Glycine 0 N--CA 1.443 -0.857 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 -178.173 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.3 p -124.1 133.0 70.5 Favored 'Isoleucine or valine' 0 C--O 1.241 0.624 0 N-CA-C 109.059 -0.719 . . . . 0.0 109.059 174.22 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 232' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -132.34 156.36 42.34 Favored 'Isoleucine or valine' 0 C--O 1.246 0.895 0 C-N-CA 120.438 -0.505 . . . . 0.0 110.353 -175.024 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 233' ' ' THR . . . . . 0.466 ' HA ' ' O ' ' A' ' 273' ' ' TYR . 1.6 p -106.41 159.07 16.43 Favored 'General case' 0 N--CA 1.441 -0.907 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.665 177.556 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 39.3 m -124.36 161.95 24.86 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 123.063 0.545 . . . . 0.0 109.861 -178.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 37.2 tp -62.87 135.7 57.46 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 107.88 -1.155 . . . . 0.0 107.88 176.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 236' ' ' ASP . . . . . 0.438 ' O ' ' CZ ' ' A' ' 273' ' ' TYR . 1.9 m-20 -59.54 -35.65 74.62 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-O 121.251 0.548 . . . . 0.0 111.117 -173.611 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 70.1 mt-10 -86.47 -5.02 59.26 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.605 -177.611 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -101.99 100.47 10.76 Favored 'General case' 0 CA--C 1.516 -0.344 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.554 179.393 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 66.4 mtp180 -86.82 107.53 18.34 Favored 'General case' 0 C--N 1.317 -0.847 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 -179.686 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 240' ' ' HIS . . . . . 0.497 ' O ' ' HB3' ' A' ' 217' ' ' LEU . 9.9 p80 -57.48 -47.38 82.05 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.655 -176.902 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 71.18 25.31 75.85 Favored Glycine 0 C--N 1.309 -0.92 0 N-CA-C 109.783 -1.327 . . . . 0.0 109.783 -179.173 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 242' ' ' PHE . . . . . 0.463 ' CD2' ' HB2' ' A' ' 240' ' ' HIS . 15.4 m-30 -79.51 141.28 36.84 Favored 'General case' 0 N--CA 1.435 -1.213 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 -179.82 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 243' ' ' GLU . . . . . 0.462 ' CD ' ' HZ3' ' A' ' 296' ' ' LYS . 96.5 mt-10 -96.79 146.5 24.84 Favored 'General case' 0 C--N 1.31 -1.138 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.343 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.1 122.44 16.09 Favored 'General case' 0 C--N 1.307 -1.269 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 -178.408 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 85.0 7.33 83.92 Favored Glycine 0 N--CA 1.442 -0.912 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 -177.211 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 246' ' ' ASP . . . . . 0.456 ' HB2' ' HB2' ' A' ' 243' ' ' GLU . 13.5 t0 -83.79 168.3 16.29 Favored 'General case' 0 C--O 1.24 0.557 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 176.032 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 247' ' ' PHE . . . . . 0.493 ' O ' ' N ' ' A' ' 295' ' ' VAL . 66.3 m-85 -109.4 141.6 41.55 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 112.099 0.407 . . . . 0.0 112.099 -176.349 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 2.8 m -134.21 161.16 41.18 Favored 'Isoleucine or valine' 0 C--O 1.241 0.655 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.098 178.059 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 47.7 m -128.04 159.37 35.24 Favored 'General case' 0 C--N 1.321 -0.669 0 C-N-CA 124.338 1.055 . . . . 0.0 108.53 173.626 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 250' ' ' PHE . . . . . 0.481 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 69.9 m-85 -110.54 145.8 37.15 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 121.264 0.554 . . . . 0.0 112.171 -177.789 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 19.7 m -137.73 153.3 49.77 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.227 177.048 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 71.6 mm-40 56.08 21.37 5.05 Favored 'General case' 0 C--N 1.314 -0.954 0 N-CA-C 113.354 0.872 . . . . 0.0 113.354 173.023 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . 0.437 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 94.1 t -84.37 130.7 35.53 Favored 'Isoleucine or valine' 0 C--O 1.239 0.52 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 177.262 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 83.1 mt-30 -105.26 144.44 32.05 Favored 'General case' 0 C--O 1.243 0.728 0 CA-C-O 121.001 0.429 . . . . 0.0 109.897 176.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 84.91 -68.42 3.5 Favored Glycine 0 C--N 1.313 -0.747 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -174.049 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 256' ' ' MET . . . . . 0.567 ' SD ' HG12 ' A' ' 224' ' ' VAL . 47.8 mtt -78.25 65.04 3.51 Favored 'General case' 0 CA--C 1.515 -0.381 0 CA-C-O 121.397 0.617 . . . . 0.0 110.318 173.072 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 46.9 pt -70.82 -23.06 23.54 Favored 'Isoleucine or valine' 0 C--O 1.244 0.797 0 CA-C-N 115.475 -0.784 . . . . 0.0 110.135 -178.271 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 258' ' ' GLN . . . . . 0.53 ' HG3' ' SG ' ' A' ' 262' ' ' CYS . 70.7 tp60 -60.8 -36.62 79.49 Favored 'General case' 0 N--CA 1.445 -0.682 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 179.459 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 259' ' ' LEU . . . . . 0.499 HD21 ' CE2' ' A' ' 283' ' ' PHE . 92.3 mt -61.88 -40.52 95.68 Favored 'General case' 0 N--CA 1.448 -0.542 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.204 179.09 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 260' ' ' ASN . . . . . 0.437 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 98.8 m-20 -60.2 -41.14 92.35 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 179.218 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -96.48 10.94 67.06 Favored Glycine 0 CA--C 1.532 1.132 0 CA-C-N 116.042 -0.527 . . . . 0.0 112.269 179.572 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 262' ' ' CYS . . . . . 0.53 ' SG ' ' HG3' ' A' ' 258' ' ' GLN . 1.2 m -82.24 142.41 32.15 Favored 'General case' 0 CA--C 1.513 -0.444 0 CA-C-N 117.382 0.591 . . . . 0.0 110.827 -178.379 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 27.9 mm100 -62.57 152.51 80.76 Favored Pre-proline 0 C--N 1.321 -0.662 0 N-CA-C 107.572 -1.27 . . . . 0.0 107.572 171.582 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -61.22 142.96 98.11 Favored 'Trans proline' 0 C--N 1.307 -1.644 0 C-N-CA 121.059 1.172 . . . . 0.0 110.447 -178.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 265' ' ' MET . . . . . 0.45 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 24.0 ptp -129.12 154.34 46.81 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 112.162 0.43 . . . . 0.0 112.162 -172.429 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -71.02 136.1 48.17 Favored 'General case' 0 C--O 1.245 0.816 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 177.611 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 267' ' ' ILE . . . . . . . . . . . . . 2.0 pp -126.65 158.54 36.94 Favored 'Isoleucine or valine' 0 C--O 1.243 0.735 0 N-CA-C 112.546 0.573 . . . . 0.0 112.546 -175.864 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 75.1 tttt -127.83 115.81 19.2 Favored 'General case' 0 N--CA 1.448 -0.532 0 CA-C-N 115.213 -0.903 . . . . 0.0 109.86 -179.322 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 17.8 m -70.59 134.5 29.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.244 -179.629 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 81.6 mt -107.75 -24.16 11.81 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.023 0.44 . . . . 0.0 110.124 178.161 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . 0.448 ' N ' ' HG1' ' A' ' 274' ' ' THR . . . -176.4 -178.27 46.05 Favored Glycine 0 C--N 1.319 -0.396 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 -178.072 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 272' ' ' PRO . . . . . 0.428 ' O ' ' CD2' ' A' ' 240' ' ' HIS . 75.5 Cg_exo -52.89 -43.6 55.21 Favored 'Trans proline' 0 C--N 1.311 -1.424 0 C-N-CA 121.958 1.772 . . . . 0.0 111.582 -177.303 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 273' ' ' TYR . . . . . 0.466 ' O ' ' HA ' ' A' ' 233' ' ' THR . 7.3 m-85 -117.76 10.75 13.4 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 115.933 -0.576 . . . . 0.0 112.084 -176.407 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 274' ' ' THR . . . . . 0.448 ' HG1' ' N ' ' A' ' 271' ' ' GLY . 5.4 p -123.77 130.02 51.98 Favored 'General case' 0 C--N 1.321 -0.66 0 C-N-CA 120.927 -0.309 . . . . 0.0 110.992 -179.51 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 275' ' ' PHE . . . . . 0.547 ' C ' ' CD1' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -143.81 164.08 31.52 Favored 'General case' 0 C--O 1.238 0.48 0 C-N-CA 120.926 -0.309 . . . . 0.0 111.406 175.811 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 276' ' ' SER . . . . . 0.488 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 4.4 p -131.05 145.38 52.0 Favored 'General case' 0 C--O 1.244 0.805 0 C-N-CA 120.672 -0.411 . . . . 0.0 111.912 -175.723 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 35.0 pt -140.18 165.05 21.86 Favored 'Isoleucine or valine' 0 C--O 1.236 0.368 0 CA-C-N 114.766 -1.107 . . . . 0.0 112.582 -173.077 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 278' ' ' CYS . . . . . 0.421 ' SG ' ' SD ' ' A' ' 265' ' ' MET . 2.6 p -27.2 -94.76 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.416 0 N-CA-C 114.478 1.288 . . . . 0.0 114.478 -176.394 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 58.2 m-20 -144.48 110.0 5.24 Favored 'General case' 0 CA--C 1.513 -0.456 0 CA-C-N 116.622 -0.263 . . . . 0.0 111.423 -171.402 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 280' ' ' THR . . . . . 0.749 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 59.7 p -66.02 -27.7 68.31 Favored 'General case' 0 C--N 1.31 -1.137 0 CA-C-O 121.215 0.531 . . . . 0.0 109.712 172.066 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 1.5 p -63.68 -17.06 62.57 Favored 'General case' 0 N--CA 1.43 -1.435 0 CA-C-N 114.799 -1.092 . . . . 0.0 109.753 174.071 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 17.9 t-20 -98.27 -8.71 26.74 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.6 175.05 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . 0.749 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 15.6 m-30 -90.66 -83.08 0.27 Allowed 'General case' 0 C--O 1.237 0.404 0 CA-C-O 121.436 0.636 . . . . 0.0 110.952 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 284' ' ' SER . . . . . 0.489 ' HG ' ' C ' ' A' ' 283' ' ' PHE . 0.0 OUTLIER 169.25 -174.0 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 114.342 -1.299 . . . . 0.0 108.874 -173.71 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 31.1 t0 -92.99 112.36 24.3 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 120.906 -0.318 . . . . 0.0 111.678 -179.788 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . 0.521 ' N ' ' HG3' ' A' ' 256' ' ' MET . 12.4 t80 -63.66 128.49 36.07 Favored 'General case' 0 CA--C 1.512 -0.485 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 177.865 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 96.5 mt -106.64 -64.06 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 175.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 9.6 ptp180 -161.15 -178.67 6.9 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.088 178.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 70.02 -161.08 53.19 Favored Glycine 0 CA--C 1.504 -0.615 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 178.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 108.8 117.59 4.06 Favored Glycine 0 N--CA 1.442 -0.958 0 C-N-CA 120.934 -0.651 . . . . 0.0 113.291 174.686 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 97.2 mt -118.16 130.34 73.17 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.25 0 N-CA-C 107.321 -1.363 . . . . 0.0 107.321 170.562 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 4.8 p -109.19 128.89 64.77 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 -179.355 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 293' ' ' SER . . . . . 0.451 ' CB ' ' HG ' ' A' ' 218' ' ' SER . 36.7 m -116.63 137.42 52.2 Favored 'General case' 0 N--CA 1.438 -1.039 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.932 -176.543 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -68.04 147.27 52.61 Favored 'General case' 0 N--CA 1.431 -1.399 0 CA-C-N 115.609 -0.723 . . . . 0.0 109.752 176.884 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . 0.493 ' N ' ' O ' ' A' ' 247' ' ' PHE . 76.2 t -126.23 97.95 4.56 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.869 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 173.774 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 296' ' ' LYS . . . . . 0.462 ' HZ3' ' CD ' ' A' ' 243' ' ' GLU . 4.8 mttp -97.11 99.25 10.76 Favored 'General case' 0 N--CA 1.435 -1.206 0 N-CA-C 109.003 -0.739 . . . . 0.0 109.003 179.555 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 5.0 m -104.58 165.38 13.4 Favored Pre-proline 0 C--N 1.318 -0.786 0 CA-C-N 115.216 -0.902 . . . . 0.0 108.951 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_exo -60.41 104.91 0.27 Allowed 'Trans proline' 0 C--N 1.302 -1.913 0 C-N-CA 120.48 0.787 . . . . 0.0 110.192 177.815 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 49.4 mttp -79.4 147.34 32.38 Favored 'General case' 0 C--N 1.321 -0.666 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 174.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 300' ' ' LYS . . . . . 0.567 ' NZ ' ' OG ' ' A' ' 302' ' ' SER . 62.3 tttm -63.43 128.03 33.98 Favored 'General case' 0 C--N 1.319 -0.736 0 C-N-CA 118.684 -1.207 . . . . 0.0 108.29 179.938 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 301' ' ' ILE . . . . . 0.444 ' C ' ' HG ' ' A' ' 302' ' ' SER . 40.4 mm -78.3 91.19 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.048 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 302' ' ' SER . . . . . 0.567 ' OG ' ' NZ ' ' A' ' 300' ' ' LYS . 7.2 m -155.43 94.97 1.65 Allowed 'General case' 0 C--N 1.302 -1.485 0 CA-C-N 115.263 -0.881 . . . . 0.0 109.396 -177.014 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 92.0 m-85 -132.83 153.9 50.84 Favored 'General case' 0 C--N 1.308 -1.231 0 CA-C-N 115.501 -0.772 . . . . 0.0 108.959 -176.499 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 23.2 mmtm -65.69 158.12 28.27 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 176.33 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 4.1 m -56.71 138.8 52.25 Favored 'General case' 0 C--N 1.311 -1.095 0 C-N-CA 121.029 -0.268 . . . . 0.0 110.712 -172.565 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 38.1 mt -62.21 170.29 2.29 Favored Pre-proline 0 C--O 1.243 0.724 0 N-CA-C 108.092 -1.077 . . . . 0.0 108.092 176.113 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -56.81 138.67 86.55 Favored 'Trans proline' 0 C--N 1.304 -1.784 0 C-N-CA 120.9 1.067 . . . . 0.0 110.275 -178.327 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . 0.4 ' O ' ' HG ' ' A' ' 310' ' ' LEU . . . -101.3 163.33 12.33 Favored 'General case' 0 CA--C 1.503 -0.839 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.465 179.429 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -72.01 83.36 0.96 Allowed 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 175.797 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 310' ' ' LEU . . . . . 0.4 ' HG ' ' O ' ' A' ' 308' ' ' ALA . 67.2 mt -77.59 117.08 18.68 Favored 'General case' 0 CA--C 1.508 -0.643 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.432 -172.678 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 6.6 m -123.25 130.39 74.33 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 175.382 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 312' ' ' GLU . . . . . 0.409 ' H ' ' CD ' ' A' ' 312' ' ' GLU . 51.1 mp0 . . . . . 0 C--O 1.214 -0.794 0 CA-C-O 118.081 -0.961 . . . . 0.0 110.616 -176.409 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . 0.48 ' O ' ' N ' ' A' ' 203' ' ' GLY . 0.0 OUTLIER . . . . . 0 N--CA 1.483 1.211 0 N-CA-C 107.699 -1.222 . . . . 0.0 107.699 . . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 202' ' ' PHE . . . . . 0.464 ' CD1' ' C ' ' A' ' 202' ' ' PHE . 0.1 OUTLIER 56.46 -47.8 0.03 OUTLIER 'General case' 0 N--CA 1.473 0.678 0 C-N-CA 123.889 0.876 . . . . 0.0 113.036 -179.505 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . 0.48 ' N ' ' O ' ' A' ' 201' ' ' GLU . . . -101.33 17.99 54.64 Favored Glycine 0 C--O 1.235 0.211 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 177.462 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 204' ' ' GLU . . . . . 0.416 ' OE1' ' N ' ' A' ' 201' ' ' GLU . 66.4 mt-10 -120.98 26.08 9.27 Favored 'General case' 0 C--N 1.323 -0.549 0 C-N-CA 122.584 0.354 . . . . 0.0 110.959 -178.381 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -62.88 -16.82 60.32 Favored 'General case' 0 C--O 1.24 0.57 0 CA-C-O 121.177 0.513 . . . . 0.0 110.305 -177.052 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 77.5 mtm -62.59 150.86 39.48 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.756 -177.838 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 27.7 m -129.5 160.92 39.95 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.867 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 173.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 73.7 mt -100.15 107.72 19.66 Favored 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 120.808 -0.357 . . . . 0.0 111.367 -173.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 9.8 m -64.37 -43.05 95.72 Favored 'General case' 0 C--N 1.316 -0.865 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 173.416 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 22.4 m-20 -60.76 -41.69 95.96 Favored 'General case' 0 CA--C 1.517 -0.315 0 CA-C-N 115.463 -0.789 . . . . 0.0 110.625 -176.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 211' ' ' SER . . . . . 0.403 ' CB ' ' HB2' ' A' ' 214' ' ' GLU . 0.8 OUTLIER -116.93 90.94 3.44 Favored 'General case' 0 C--N 1.318 -0.774 0 N-CA-C 107.514 -1.291 . . . . 0.0 107.514 172.423 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 55.3 t30 -79.19 112.89 16.85 Favored 'General case' 0 CA--C 1.51 -0.585 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.648 -171.735 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 68.86 17.65 71.66 Favored Glycine 0 CA--C 1.509 -0.29 0 N-CA-C 109.292 -1.523 . . . . 0.0 109.292 -177.776 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 214' ' ' GLU . . . . . 0.403 ' HB2' ' CB ' ' A' ' 211' ' ' SER . 99.0 mt-10 -110.75 112.43 24.3 Favored 'General case' 0 N--CA 1.438 -1.075 0 CA-C-O 121.214 0.53 . . . . 0.0 111.413 -177.385 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 215' ' ' GLN . . . . . 0.466 ' CB ' ' CD ' ' A' ' 216' ' ' PRO . 2.6 mt-30 -110.9 -172.25 0.23 Allowed Pre-proline 0 C--N 1.306 -1.305 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 171.702 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 216' ' ' PRO . . . . . 0.466 ' CD ' ' CB ' ' A' ' 215' ' ' GLN . 50.4 Cg_exo -56.43 139.21 86.6 Favored 'Trans proline' 0 C--N 1.301 -1.953 0 C-N-CA 121.034 1.156 . . . . 0.0 110.779 178.157 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 217' ' ' LEU . . . . . 0.459 ' HB3' ' O ' ' A' ' 240' ' ' HIS . 3.8 mm? -81.52 149.5 28.67 Favored 'General case' 0 CA--C 1.503 -0.829 0 N-CA-C 112.35 0.5 . . . . 0.0 112.35 -178.897 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 5.9 m -142.79 133.45 25.21 Favored 'General case' 0 N--CA 1.441 -0.92 0 CA-C-N 115.126 -0.943 . . . . 0.0 109.533 175.803 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -147.78 164.41 33.71 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 121.336 0.589 . . . . 0.0 112.295 -177.129 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 220' ' ' MET . . . . . 0.69 ' N ' ' SD ' ' A' ' 220' ' ' MET . 0.0 OUTLIER -74.77 132.62 41.75 Favored 'General case' 0 C--O 1.243 0.747 0 CA-C-N 115.023 -0.99 . . . . 0.0 109.876 178.264 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 52.4 t -88.91 130.21 38.67 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 175.142 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 36.9 p -88.1 -57.72 2.83 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 120.351 -0.54 . . . . 0.0 110.189 -178.661 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 1.7 ptm -137.04 149.75 47.64 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.481 175.69 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 224' ' ' VAL . . . . . 0.729 HG12 ' SD ' ' A' ' 256' ' ' MET . 21.7 t -127.21 132.32 69.76 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.963 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 174.004 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 225' ' ' THR . . . . . 0.404 ' O ' ' OG1' ' A' ' 280' ' ' THR . 0.2 OUTLIER -106.42 121.55 44.48 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 -177.082 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 226' ' ' LYS . . . . . 0.495 ' HA ' ' HB ' ' A' ' 280' ' ' THR . 0.1 OUTLIER -77.38 73.39 3.95 Favored 'General case' 0 C--O 1.237 0.436 0 C-N-CA 119.721 -0.792 . . . . 0.0 111.642 -179.596 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 227' ' ' ASP . . . . . 0.502 ' CG ' ' H ' ' A' ' 228' ' ' ASN . 41.5 t0 -126.23 -178.85 4.47 Favored 'General case' 0 C--O 1.238 0.499 0 CA-C-N 114.827 -1.079 . . . . 0.0 109.989 -179.587 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 228' ' ' ASN . . . . . 0.502 ' H ' ' CG ' ' A' ' 227' ' ' ASP . 0.4 OUTLIER -136.89 123.19 13.54 Favored Pre-proline 0 CA--C 1.538 0.499 0 CA-C-O 120.571 0.224 . . . . 0.0 111.205 175.799 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 229' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -66.8 151.0 82.05 Favored 'Cis proline' 0 N--CA 1.495 1.61 0 C-N-CA 123.288 -1.547 . . . . 0.0 108.592 -2.397 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . 0.49 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -63.28 139.96 44.62 Favored Glycine 0 C--N 1.315 -0.586 0 C-N-CA 119.515 -1.326 . . . . 0.0 110.233 -175.249 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 3.1 p -125.07 131.3 72.68 Favored 'Isoleucine or valine' 0 C--O 1.241 0.641 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 178.408 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 232' ' ' VAL . . . . . 0.425 ' CG1' HG13 ' A' ' 224' ' ' VAL . 0.7 OUTLIER -135.26 157.14 39.95 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-N 116.546 -0.297 . . . . 0.0 110.334 -178.293 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 233' ' ' THR . . . . . 0.428 ' HA ' ' O ' ' A' ' 273' ' ' TYR . 11.9 m -114.78 147.03 40.33 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.012 177.365 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 55.7 m -106.47 153.09 22.79 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.021 -178.315 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 32.9 tp -56.81 130.03 43.93 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 236' ' ' ASP . . . . . 0.515 ' HA ' ' CE1' ' A' ' 273' ' ' TYR . 34.6 t70 -55.23 -42.97 74.08 Favored 'General case' 0 CA--C 1.509 -0.62 0 CA-C-O 121.459 0.647 . . . . 0.0 109.865 -176.26 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -64.79 -33.54 76.23 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-N 114.851 -1.068 . . . . 0.0 110.52 -179.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -114.94 92.8 4.06 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.532 -176.828 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 239' ' ' ARG . . . . . 0.41 ' HG2' ' CE1' ' A' ' 273' ' ' TYR . 58.9 mtm180 -67.29 138.14 56.62 Favored 'General case' 0 N--CA 1.448 -0.532 0 C-N-CA 119.927 -0.709 . . . . 0.0 109.821 174.334 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 240' ' ' HIS . . . . . 0.583 ' CD2' ' H ' ' A' ' 240' ' ' HIS . 6.2 p80 -58.9 -45.35 90.5 Favored 'General case' 0 C--N 1.313 -0.988 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.414 178.384 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 80.26 12.67 82.9 Favored Glycine 0 C--N 1.319 -0.39 0 N-CA-C 109.73 -1.348 . . . . 0.0 109.73 -177.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 242' ' ' PHE . . . . . 0.564 ' CD2' ' HB2' ' A' ' 240' ' ' HIS . 8.6 m-30 -81.61 149.58 28.53 Favored 'General case' 0 N--CA 1.442 -0.862 0 CA-C-N 115.327 -0.436 . . . . 0.0 110.329 -179.813 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -117.96 150.76 38.7 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-N 115.335 -0.848 . . . . 0.0 108.783 176.828 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 28.5 m -57.56 125.75 24.27 Favored 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 119.319 -0.952 . . . . 0.0 109.16 179.643 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 104.27 -10.93 51.17 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 -175.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 246' ' ' ASP . . . . . 0.414 ' CG ' ' HZ2' ' A' ' 300' ' ' LYS . 68.3 m-20 -67.73 147.56 52.46 Favored 'General case' 0 C--N 1.328 -0.358 0 O-C-N 122.82 -0.224 . . . . 0.0 111.0 178.18 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 247' ' ' PHE . . . . . 0.427 ' HA ' ' O ' ' A' ' 265' ' ' MET . 66.9 m-85 -109.52 125.75 52.82 Favored 'General case' 0 C--O 1.242 0.697 0 CA-C-N 116.1 -0.5 . . . . 0.0 109.909 178.037 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 3.4 m -132.48 164.52 34.78 Favored 'Isoleucine or valine' 0 C--O 1.246 0.908 0 N-CA-C 112.472 0.545 . . . . 0.0 112.472 -175.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 13.5 p -131.98 159.25 39.29 Favored 'General case' 0 C--O 1.241 0.634 0 CA-C-N 114.66 -1.155 . . . . 0.0 108.911 174.856 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 250' ' ' PHE . . . . . 0.464 ' CE2' ' HB ' ' A' ' 292' ' ' VAL . 65.9 m-85 -114.85 159.21 20.92 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 121.327 0.584 . . . . 0.0 112.529 -172.725 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 251' ' ' SER . . . . . 0.427 ' HG ' ' C ' ' A' ' 250' ' ' PHE . 7.0 m -157.5 161.73 38.85 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-N 115.208 -0.905 . . . . 0.0 109.323 174.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 61.9 mm-40 59.17 18.47 6.53 Favored 'General case' 0 CA--C 1.544 0.732 0 N-CA-C 112.024 0.379 . . . . 0.0 112.024 177.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . 0.47 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 57.3 t -86.98 132.41 32.5 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 178.734 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 90.2 mt-30 -105.83 146.05 30.4 Favored 'General case' 0 C--O 1.24 0.589 0 CA-C-O 121.244 0.545 . . . . 0.0 111.096 177.511 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 79.65 -65.94 3.61 Favored Glycine 0 CA--C 1.505 -0.585 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 -177.255 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 256' ' ' MET . . . . . 0.729 ' SD ' HG12 ' A' ' 224' ' ' VAL . 26.5 ttm -81.98 54.5 2.49 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-O 121.551 0.691 . . . . 0.0 109.324 175.106 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 48.2 pt -68.81 -20.06 24.58 Favored 'Isoleucine or valine' 0 C--O 1.239 0.546 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.607 -176.061 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 258' ' ' GLN . . . . . 0.687 ' HG3' ' SG ' ' A' ' 262' ' ' CYS . 47.4 tp60 -56.42 -31.66 64.13 Favored 'General case' 0 N--CA 1.439 -1.002 0 C-N-CA 120.009 -0.676 . . . . 0.0 110.353 178.851 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 259' ' ' LEU . . . . . 0.523 ' CD2' ' CE2' ' A' ' 283' ' ' PHE . 78.9 mt -62.18 -41.32 98.22 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 120.911 0.386 . . . . 0.0 110.323 174.17 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 260' ' ' ASN . . . . . 0.47 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 98.3 m-20 -59.77 -40.52 88.48 Favored 'General case' 0 CA--C 1.509 -0.612 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 -179.852 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -101.27 17.32 55.91 Favored Glycine 0 C--N 1.322 -0.2 0 CA-C-N 115.543 -0.753 . . . . 0.0 112.158 -178.425 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 262' ' ' CYS . . . . . 0.687 ' SG ' ' HG3' ' A' ' 258' ' ' GLN . 0.9 OUTLIER -91.77 155.32 18.33 Favored 'General case' 0 CA--C 1.51 -0.565 0 CA-C-N 117.157 0.478 . . . . 0.0 111.687 -178.009 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 28.1 mm-40 -74.18 153.72 88.39 Favored Pre-proline 0 C--N 1.325 -0.491 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 170.612 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -65.37 148.78 88.49 Favored 'Trans proline' 0 C--N 1.305 -1.716 0 C-N-CA 121.375 1.383 . . . . 0.0 111.253 -178.538 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 265' ' ' MET . . . . . 0.445 ' SD ' ' HB ' ' A' ' 277' ' ' ILE . 12.9 ptp -138.38 160.21 40.1 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.831 -174.853 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -71.48 144.82 49.54 Favored 'General case' 0 C--O 1.242 0.663 0 O-C-N 123.999 0.812 . . . . 0.0 109.325 177.097 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 267' ' ' ILE . . . . . 0.462 HG21 ' CE2' ' A' ' 275' ' ' PHE . 1.5 pp -126.71 155.16 37.21 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-O 120.753 0.311 . . . . 0.0 111.501 -179.704 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 65.9 mttm -127.99 123.31 34.45 Favored 'General case' 0 C--O 1.239 0.548 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 177.496 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 34.6 m -81.42 105.11 10.93 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.689 0 CA-C-O 121.284 0.564 . . . . 0.0 112.484 -176.398 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 92.4 mt -67.13 -41.42 86.15 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.639 -0.709 . . . . 0.0 110.089 175.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -150.51 -177.65 24.64 Favored Glycine 0 CA--C 1.52 0.356 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 -179.202 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 272' ' ' PRO . . . . . 0.566 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 33.7 Cg_endo -62.51 -32.23 80.17 Favored 'Trans proline' 0 C--N 1.309 -1.541 0 C-N-CA 121.883 1.722 . . . . 0.0 110.726 -177.203 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 273' ' ' TYR . . . . . 0.515 ' CE1' ' HA ' ' A' ' 236' ' ' ASP . 74.2 m-85 -116.87 0.07 12.39 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.608 -0.724 . . . . 0.0 112.89 -179.015 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -120.17 127.71 52.73 Favored 'General case' 0 C--O 1.242 0.696 0 C-N-CA 120.658 -0.417 . . . . 0.0 111.659 178.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 275' ' ' PHE . . . . . 0.536 ' C ' ' CD1' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -133.43 162.68 31.21 Favored 'General case' 0 CA--C 1.501 -0.936 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.535 177.12 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 276' ' ' SER . . . . . 0.49 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 4.4 p -134.4 146.92 50.32 Favored 'General case' 0 C--N 1.313 -0.984 0 C-N-CA 119.949 -0.701 . . . . 0.0 111.629 -178.579 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . 0.531 HG21 ' CE1' ' A' ' 275' ' ' PHE . 34.9 pt -137.26 167.8 22.52 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.961 0 CA-C-N 114.694 -1.139 . . . . 0.0 111.481 -173.243 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 278' ' ' CYS . . . . . 0.404 ' C ' ' O ' ' A' ' 277' ' ' ILE . 71.7 m -22.05 -85.02 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.764 0 N-CA-C 113.771 1.026 . . . . 0.0 113.771 -175.409 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 58.4 t0 -153.26 106.76 3.01 Favored 'General case' 0 CA--C 1.506 -0.743 0 CA-C-O 120.753 0.311 . . . . 0.0 110.372 179.552 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 280' ' ' THR . . . . . 0.776 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 5.9 p -65.99 -27.46 68.15 Favored 'General case' 0 C--N 1.297 -1.695 0 CA-C-O 121.214 0.531 . . . . 0.0 111.057 177.07 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -64.81 -19.98 66.14 Favored 'General case' 0 C--N 1.314 -0.978 0 CA-C-N 115.464 -0.789 . . . . 0.0 109.183 174.776 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 282' ' ' ASN . . . . . 0.414 ' O ' ' ND2' ' A' ' 282' ' ' ASN . 0.2 OUTLIER -87.76 -8.55 55.86 Favored 'General case' 0 CA--C 1.508 -0.667 0 N-CA-C 108.752 -0.832 . . . . 0.0 108.752 179.554 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . 0.776 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 13.3 m-85 -92.25 -77.01 0.44 Allowed 'General case' 0 N--CA 1.443 -0.798 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 174.159 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 169.23 -179.3 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 114.522 -1.217 . . . . 0.0 109.702 -174.401 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 35.8 t0 -85.62 132.96 34.07 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 116.496 -0.32 . . . . 0.0 111.179 178.804 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . 0.675 ' CZ ' ' HA ' ' A' ' 288' ' ' ARG . 91.1 t80 -68.56 130.56 43.21 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.096 -179.895 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 85.8 mt -100.17 -63.11 1.76 Allowed 'Isoleucine or valine' 0 CA--C 1.514 -0.433 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 170.072 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . 0.675 ' HA ' ' CZ ' ' A' ' 286' ' ' TYR . 9.5 ptm180 -172.41 -173.2 1.02 Allowed 'General case' 0 C--O 1.243 0.726 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.987 175.307 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 68.48 -163.08 49.51 Favored Glycine 0 CA--C 1.507 -0.464 0 N-CA-C 110.629 -0.988 . . . . 0.0 110.629 175.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 113.97 124.61 4.07 Favored Glycine 0 N--CA 1.443 -0.889 0 C-N-CA 121.462 -0.399 . . . . 0.0 112.486 175.768 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 92.2 mt -123.09 132.51 71.26 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 172.234 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . 0.464 ' HB ' ' CE2' ' A' ' 250' ' ' PHE . 4.9 p -118.1 133.45 64.86 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 C-N-CA 120.624 -0.431 . . . . 0.0 110.028 -176.866 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 3.9 m -128.13 146.56 50.67 Favored 'General case' 0 N--CA 1.446 -0.64 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.648 -175.142 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 294' ' ' GLN . . . . . 0.499 ' HG3' ' CE1' ' A' ' 242' ' ' PHE . 90.7 mt-30 -78.1 163.6 25.74 Favored 'General case' 0 CA--C 1.505 -0.778 0 CA-C-O 121.279 0.561 . . . . 0.0 110.224 176.481 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 14.5 t -111.67 159.96 11.32 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-N 115.122 -0.945 . . . . 0.0 109.552 179.377 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 30.6 mttp -69.22 97.02 0.88 Allowed 'General case' 0 N--CA 1.438 -1.057 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 22.5 m -103.04 170.73 5.91 Favored Pre-proline 0 C--N 1.31 -1.147 0 CA-C-N 115.769 -0.651 . . . . 0.0 109.675 -179.857 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_exo -61.02 149.52 88.66 Favored 'Trans proline' 0 C--N 1.307 -1.637 0 C-N-CA 121.84 1.693 . . . . 0.0 109.404 174.043 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . 0.484 ' NZ ' ' OG ' ' A' ' 302' ' ' SER . 50.4 tttm -42.67 140.54 1.27 Allowed 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.04 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 300' ' ' LYS . . . . . 0.443 ' O ' ' HG2' ' A' ' 299' ' ' LYS . 34.1 mttm -63.31 137.09 58.06 Favored 'General case' 0 C--O 1.244 0.777 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 175.672 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 301' ' ' ILE . . . . . 0.488 HG22 HD12 ' A' ' 301' ' ' ILE . 45.9 pt -66.44 118.95 10.71 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.77 0 CA-C-N 115.765 -0.652 . . . . 0.0 112.291 -170.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 302' ' ' SER . . . . . 0.484 ' OG ' ' NZ ' ' A' ' 299' ' ' LYS . 11.6 m -84.78 154.43 22.38 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.345 -0.843 . . . . 0.0 108.865 173.603 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 25.9 m-85 -100.48 141.42 33.36 Favored 'General case' 0 C--N 1.312 -1.031 0 N-CA-C 107.467 -1.309 . . . . 0.0 107.467 172.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 65.2 mttp -50.06 106.87 0.13 Allowed 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 119.684 -0.806 . . . . 0.0 110.098 -173.357 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -129.39 151.16 50.33 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 115.213 -0.903 . . . . 0.0 109.686 -176.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 306' ' ' LEU . . . . . 0.44 ' C ' ' H ' ' A' ' 308' ' ' ALA . 20.8 mt -59.29 146.05 79.75 Favored Pre-proline 0 C--N 1.316 -0.849 0 C-N-CA 120.248 -0.581 . . . . 0.0 109.689 178.485 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . 0.414 ' O ' ' C ' ' A' ' 308' ' ' ALA . 58.4 Cg_endo -71.12 47.7 0.81 Allowed 'Trans proline' 0 N--CA 1.489 1.248 0 C-N-CA 122.291 1.994 . . . . 0.0 110.508 -179.577 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . 0.44 ' H ' ' C ' ' A' ' 306' ' ' LEU . . . -28.65 96.72 0.01 OUTLIER 'General case' 0 C--O 1.239 0.504 0 CA-C-N 115.05 -0.977 . . . . 0.0 112.015 -175.368 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 4.2 m -89.76 90.72 8.33 Favored 'General case' 0 C--O 1.238 0.483 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 173.72 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -65.3 106.17 1.29 Allowed 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.953 -171.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 70.3 t -116.35 127.76 73.86 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.059 0 N-CA-C 106.704 -1.591 . . . . 0.0 106.704 174.602 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 46.3 tp10 . . . . . 0 C--O 1.213 -0.868 0 CA-C-O 118.175 -0.917 . . . . 0.0 109.956 -174.281 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 . . . . . 0 N--CA 1.474 0.744 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 202' ' ' PHE . . . . . 0.411 ' C ' ' N ' ' A' ' 204' ' ' GLU . 0.4 OUTLIER -126.67 37.2 4.34 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.727 179.903 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -48.46 -19.73 1.33 Allowed Glycine 0 CA--C 1.521 0.45 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 178.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 204' ' ' GLU . . . . . 0.411 ' N ' ' C ' ' A' ' 202' ' ' PHE . 65.1 mm-40 -54.09 -19.49 5.01 Favored 'General case' 0 C--O 1.236 0.393 0 C-N-CA 122.761 0.424 . . . . 0.0 110.209 178.429 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 99.4 mt-10 -62.42 -39.74 94.29 Favored 'General case' 0 CA--C 1.512 -0.485 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 176.851 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 77.6 mtm -107.25 104.1 13.64 Favored 'General case' 0 N--CA 1.447 -0.612 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.634 177.301 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 12.1 m -115.02 128.85 72.02 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 176.47 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 52.3 tp -85.89 98.97 11.08 Favored 'General case' 0 N--CA 1.442 -0.855 0 C-N-CA 120.385 -0.526 . . . . 0.0 110.262 -177.245 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -107.35 -72.04 0.73 Allowed 'General case' 0 C--N 1.309 -1.157 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 175.209 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 210' ' ' ASP . . . . . 0.423 ' OD1' ' N ' ' A' ' 211' ' ' SER . 1.8 p30 -101.16 -48.33 4.44 Favored 'General case' 0 C--O 1.244 0.782 0 CA-C-N 115.785 -0.643 . . . . 0.0 109.698 170.902 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 211' ' ' SER . . . . . 0.423 ' N ' ' OD1' ' A' ' 210' ' ' ASP . 2.2 m -122.44 157.08 32.7 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.66 -179.185 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 30.0 t-20 -91.59 110.51 21.83 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.78 0.324 . . . . 0.0 110.8 177.579 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 74.11 -39.9 1.02 Allowed Glycine 0 C--N 1.317 -0.509 0 CA-C-N 116.134 -0.485 . . . . 0.0 112.14 179.329 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 214' ' ' GLU . . . . . 0.439 ' CD ' HH12 ' A' ' 239' ' ' ARG . 76.2 mm-40 -67.41 123.36 20.17 Favored 'General case' 0 C--N 1.324 -0.506 0 C-N-CA 120.321 -0.552 . . . . 0.0 111.356 -179.611 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 215' ' ' GLN . . . . . 0.549 ' O ' ' N ' ' A' ' 217' ' ' LEU . 0.0 OUTLIER -111.82 178.36 1.0 Allowed Pre-proline 0 C--N 1.316 -0.857 0 N-CA-C 108.231 -1.025 . . . . 0.0 108.231 177.378 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 216' ' ' PRO . . . . . 0.439 ' CD ' ' HB2' ' A' ' 215' ' ' GLN . 34.2 Cg_exo -59.89 74.36 0.06 OUTLIER 'Trans proline' 0 N--CA 1.492 1.418 0 C-N-CA 121.242 1.295 . . . . 0.0 110.033 176.471 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 217' ' ' LEU . . . . . 0.549 ' N ' ' O ' ' A' ' 215' ' ' GLN . 1.3 tm? -76.3 129.07 36.11 Favored 'General case' 0 CA--C 1.51 -0.592 0 CA-C-N 115.281 -0.872 . . . . 0.0 109.418 -175.279 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 218' ' ' SER . . . . . 0.545 ' HG ' ' CB ' ' A' ' 293' ' ' SER . 75.6 m -114.72 131.45 56.76 Favored 'General case' 0 N--CA 1.438 -1.066 0 CA-C-N 115.846 -0.615 . . . . 0.0 109.358 178.238 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -127.74 150.33 49.84 Favored 'General case' 0 CA--C 1.503 -0.845 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.899 -177.097 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 220' ' ' MET . . . . . 0.691 ' SD ' HG12 ' A' ' 291' ' ' ILE . 87.6 mmm -76.56 131.21 38.81 Favored 'General case' 0 N--CA 1.44 -0.926 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 176.587 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 91.5 t -75.51 128.21 37.14 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.311 0 N-CA-C 107.586 -1.265 . . . . 0.0 107.586 175.877 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 222' ' ' SER . . . . . 0.597 ' CB ' ' HG1' ' A' ' 233' ' ' THR . 0.1 OUTLIER -84.6 -67.33 0.8 Allowed 'General case' 0 N--CA 1.437 -1.087 0 C-N-CA 119.717 -0.793 . . . . 0.0 109.375 179.703 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 3.6 ptm -137.9 151.39 47.97 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 112.552 0.575 . . . . 0.0 112.552 173.056 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 224' ' ' VAL . . . . . 0.417 HG12 ' SD ' ' A' ' 256' ' ' MET . 68.8 t -123.78 132.59 71.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 174.95 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 28.2 p -92.76 131.32 37.92 Favored 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 121.031 -0.268 . . . . 0.0 110.38 179.588 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 6.0 ttmt -77.94 87.61 4.12 Favored 'General case' 0 N--CA 1.446 -0.646 0 C-N-CA 119.477 -0.889 . . . . 0.0 109.152 178.548 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 227' ' ' ASP . . . . . 0.526 ' N ' ' OG1' ' A' ' 280' ' ' THR . 47.5 t0 -158.63 175.0 14.19 Favored 'General case' 0 C--N 1.312 -1.056 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.532 -179.574 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 228' ' ' ASN . . . . . 0.434 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.9 OUTLIER -140.85 123.56 9.75 Favored Pre-proline 0 C--O 1.237 0.406 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.112 173.866 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 229' ' ' PRO . . . . . 0.434 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 44.8 Cg_endo -66.31 144.7 67.88 Favored 'Cis proline' 0 C--N 1.313 -1.294 0 C-N-CA 122.492 -1.878 . . . . 0.0 109.308 -2.029 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . 0.447 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -82.71 144.9 23.37 Favored Glycine 0 C--N 1.312 -0.8 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 -178.179 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.6 p -121.22 130.53 74.56 Favored 'Isoleucine or valine' 0 C--O 1.241 0.657 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 176.299 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 232' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -132.66 157.14 42.95 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 CA-C-N 116.264 -0.425 . . . . 0.0 109.874 -177.413 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 233' ' ' THR . . . . . 0.597 ' HG1' ' CB ' ' A' ' 222' ' ' SER . 61.6 p -110.35 158.47 18.41 Favored 'General case' 0 N--CA 1.429 -1.486 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.229 179.711 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.8 m -113.08 148.97 34.14 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 172.656 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 40.2 tp -56.69 133.73 54.17 Favored 'General case' 0 C--N 1.308 -1.22 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 -179.69 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 236' ' ' ASP . . . . . 0.409 ' O ' ' CE1' ' A' ' 273' ' ' TYR . 7.8 t70 -52.72 -37.96 60.02 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.683 -171.523 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 10.0 mm-40 -75.31 -6.67 51.1 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.076 -178.011 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -97.39 99.88 11.32 Favored 'General case' 0 C--O 1.239 0.505 0 N-CA-C 112.554 0.575 . . . . 0.0 112.554 -175.453 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 239' ' ' ARG . . . . . 0.439 HH12 ' CD ' ' A' ' 214' ' ' GLU . 0.0 OUTLIER -70.61 66.49 0.34 Allowed 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 116.519 -0.31 . . . . 0.0 110.678 175.396 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 240' ' ' HIS . . . . . 0.552 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 14.0 p80 -33.49 -49.04 0.28 Allowed 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.227 0.537 . . . . 0.0 111.291 -178.942 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 79.41 19.31 71.83 Favored Glycine 0 C--O 1.245 0.841 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 178.432 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 242' ' ' PHE . . . . . 0.654 ' CD1' ' HB3' ' A' ' 294' ' ' GLN . 4.3 m-30 -79.85 141.53 36.1 Favored 'General case' 0 N--CA 1.444 -0.745 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 -179.256 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 243' ' ' GLU . . . . . 0.432 ' HB2' ' HB2' ' A' ' 246' ' ' ASP . 96.5 mt-10 -109.35 158.37 17.97 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 178.925 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 7.9 m -65.14 123.98 20.93 Favored 'General case' 0 C--N 1.312 -1.022 0 C-N-CA 119.115 -1.034 . . . . 0.0 108.538 178.101 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 85.87 8.04 80.11 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.559 -1.016 . . . . 0.0 110.559 -176.374 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 246' ' ' ASP . . . . . 0.432 ' HB2' ' HB2' ' A' ' 243' ' ' GLU . 45.7 t0 -82.44 167.19 18.7 Favored 'General case' 0 CA--C 1.518 -0.287 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 179.616 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 247' ' ' PHE . . . . . 0.45 ' O ' ' N ' ' A' ' 295' ' ' VAL . 95.8 m-85 -111.95 137.77 49.48 Favored 'General case' 0 C--O 1.24 0.584 0 CA-C-O 120.64 0.257 . . . . 0.0 111.295 -177.932 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . 0.494 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.6 m -133.58 160.89 41.96 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.306 0 CA-C-N 116.557 -0.292 . . . . 0.0 111.159 177.5 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 2.9 p -117.84 152.01 36.21 Favored 'General case' 0 C--N 1.318 -0.786 0 C-N-CA 123.958 0.903 . . . . 0.0 109.404 175.082 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 250' ' ' PHE . . . . . 0.613 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 75.0 m-85 -110.92 146.56 36.35 Favored 'General case' 0 CA--C 1.506 -0.715 0 C-N-CA 122.695 0.398 . . . . 0.0 110.758 -178.007 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 2.0 m -154.59 154.65 33.37 Favored 'General case' 0 C--N 1.31 -1.149 0 C-N-CA 120.765 -0.374 . . . . 0.0 110.145 176.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 73.5 mm-40 55.13 30.18 13.94 Favored 'General case' 0 C--N 1.313 -0.979 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.787 176.17 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 2.8 t -97.93 115.24 37.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 177.269 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 2.0 mm100 -79.1 137.76 37.64 Favored 'General case' 0 C--O 1.238 0.473 0 CA-C-O 121.035 0.445 . . . . 0.0 111.481 -179.769 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 81.99 -55.59 4.92 Favored Glycine 0 CA--C 1.506 -0.479 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 -178.579 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 256' ' ' MET . . . . . 0.492 ' N ' ' O ' ' A' ' 285' ' ' ASP . 3.1 ttm -81.24 49.93 1.35 Allowed 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.814 0.816 . . . . 0.0 109.215 176.927 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 46.7 pt -72.13 -20.73 20.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-N 114.836 -1.074 . . . . 0.0 110.974 -176.61 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 258' ' ' GLN . . . . . 0.599 ' O ' ' SG ' ' A' ' 262' ' ' CYS . 2.8 tp-100 -54.48 -41.07 69.12 Favored 'General case' 0 N--CA 1.448 -0.555 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 179.147 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 259' ' ' LEU . . . . . 0.613 ' HB3' ' CG ' ' A' ' 250' ' ' PHE . 98.2 mt -63.09 -39.92 96.14 Favored 'General case' 0 N--CA 1.445 -0.695 0 CA-C-N 114.861 -1.063 . . . . 0.0 110.116 177.545 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -59.76 -40.74 89.19 Favored 'General case' 0 CA--C 1.51 -0.591 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 -178.161 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -88.59 -1.12 81.16 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 115.548 -0.751 . . . . 0.0 112.106 -179.594 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 262' ' ' CYS . . . . . 0.599 ' SG ' ' O ' ' A' ' 258' ' ' GLN . 61.5 m -83.1 153.34 24.91 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-N 117.157 0.479 . . . . 0.0 111.017 -179.259 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 5.9 mm100 -79.07 163.96 57.33 Favored Pre-proline 0 C--N 1.323 -0.567 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 169.116 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 264' ' ' PRO . . . . . 0.494 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 36.7 Cg_exo -59.54 143.32 99.71 Favored 'Trans proline' 0 C--N 1.307 -1.608 0 C-N-CA 121.013 1.142 . . . . 0.0 111.105 -176.823 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 265' ' ' MET . . . . . 0.642 ' SD ' ' N ' ' A' ' 265' ' ' MET . 0.9 OUTLIER -126.88 160.76 30.02 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 116.627 -0.26 . . . . 0.0 111.396 -175.966 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 3.2 tt0 -71.44 137.72 48.49 Favored 'General case' 0 C--O 1.241 0.632 0 O-C-N 123.653 0.596 . . . . 0.0 110.224 178.697 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 267' ' ' ILE . . . . . 0.488 HG22 ' CE2' ' A' ' 275' ' ' PHE . 1.7 pp -132.01 162.96 38.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.113 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 64.3 mttp -124.85 136.22 53.61 Favored 'General case' 0 C--O 1.216 -0.705 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 175.189 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 15.9 m -95.64 102.3 13.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 CA-C-O 121.355 0.597 . . . . 0.0 111.634 -179.403 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 95.9 mt -66.8 -39.77 87.87 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.672 178.278 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -144.73 -170.3 13.82 Favored Glycine 0 N--CA 1.465 0.585 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 -176.516 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 272' ' ' PRO . . . . . 0.552 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 28.6 Cg_endo -59.31 -37.82 88.55 Favored 'Trans proline' 0 N--CA 1.491 1.37 0 C-N-CA 121.95 1.767 . . . . 0.0 111.88 -177.103 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 273' ' ' TYR . . . . . 0.409 ' CE1' ' O ' ' A' ' 236' ' ' ASP . 23.1 m-85 -124.03 5.53 8.61 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 111.726 0.269 . . . . 0.0 111.726 176.834 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -105.99 128.43 53.82 Favored 'General case' 0 C--N 1.32 -0.715 0 C-N-CA 120.586 -0.445 . . . . 0.0 110.724 -175.757 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 275' ' ' PHE . . . . . 0.535 ' C ' ' CD1' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -136.11 161.57 35.35 Favored 'General case' 0 CA--C 1.505 -0.77 0 C-N-CA 120.828 -0.349 . . . . 0.0 111.871 179.154 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 276' ' ' SER . . . . . 0.447 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 3.7 p -131.83 139.86 48.98 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-O 121.272 0.558 . . . . 0.0 111.883 -175.413 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . 0.446 HG22 ' CE1' ' A' ' 275' ' ' PHE . 37.0 pt -136.95 164.56 30.02 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.723 0 CA-C-N 114.69 -1.141 . . . . 0.0 112.378 -172.099 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 278' ' ' CYS . . . . . 0.428 ' O ' ' HA ' ' A' ' 229' ' ' PRO . 71.2 m -29.73 -92.15 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.402 0 N-CA-C 114.113 1.153 . . . . 0.0 114.113 -176.794 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 19.8 t0 -145.78 114.38 6.79 Favored 'General case' 0 CA--C 1.503 -0.847 0 CA-C-O 120.719 0.295 . . . . 0.0 111.214 -175.673 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 280' ' ' THR . . . . . 0.713 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 21.7 p -65.53 -30.59 71.36 Favored 'General case' 0 C--N 1.3 -1.586 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.576 176.18 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -65.32 -20.16 66.28 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 115.271 -0.877 . . . . 0.0 109.321 177.339 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -87.37 -8.09 57.02 Favored 'General case' 0 CA--C 1.506 -0.717 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.848 179.663 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . 0.713 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 5.3 m-85 -94.96 -68.38 0.8 Allowed 'General case' 0 N--CA 1.443 -0.824 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 172.808 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 284' ' ' SER . . . . . 0.414 ' OG ' ' HA ' ' A' ' 256' ' ' MET . 1.7 p 164.39 -87.93 0.0 OUTLIER 'General case' 0 C--O 1.244 0.763 0 CA-C-N 115.246 -0.888 . . . . 0.0 110.909 176.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 285' ' ' ASP . . . . . 0.492 ' O ' ' N ' ' A' ' 256' ' ' MET . 3.7 t0 -157.59 165.32 35.86 Favored 'General case' 0 C--O 1.22 -0.496 0 CA-C-N 116.614 -0.266 . . . . 0.0 111.055 179.579 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . 0.461 ' CD2' ' O ' ' A' ' 286' ' ' TYR . 35.7 t80 -106.8 89.22 2.95 Favored 'General case' 0 C--N 1.319 -0.728 0 C-N-CA 123.317 0.647 . . . . 0.0 110.038 179.052 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 96.5 mt -70.44 -46.11 72.04 Favored 'Isoleucine or valine' 0 C--O 1.24 0.597 0 CA-C-O 121.197 0.522 . . . . 0.0 110.14 179.235 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 173.45 173.09 0.15 Allowed 'General case' 0 C--O 1.243 0.755 0 CA-C-N 115.588 -0.733 . . . . 0.0 111.219 -177.623 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 68.08 -140.9 36.79 Favored Glycine 0 CA--C 1.508 -0.363 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 175.39 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 97.31 115.58 3.34 Favored Glycine 0 N--CA 1.442 -0.913 0 C-N-CA 121.487 -0.387 . . . . 0.0 112.148 176.71 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . 0.691 HG12 ' SD ' ' A' ' 220' ' ' MET . 89.8 mt -116.08 130.46 70.77 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.93 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 174.111 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 2.8 p -118.08 127.34 75.29 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 -179.231 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 293' ' ' SER . . . . . 0.545 ' CB ' ' HG ' ' A' ' 218' ' ' SER . 4.7 m -121.43 122.76 40.5 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.258 -176.155 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 294' ' ' GLN . . . . . 0.654 ' HB3' ' CD1' ' A' ' 242' ' ' PHE . 12.8 pt20 -66.57 159.66 26.94 Favored 'General case' 0 CA--C 1.497 -1.093 0 CA-C-O 121.257 0.551 . . . . 0.0 111.872 -179.358 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . 0.45 ' N ' ' O ' ' A' ' 247' ' ' PHE . 2.5 t -144.15 96.26 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.563 0 CA-C-N 114.184 -1.371 . . . . 0.0 108.153 172.2 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 51.4 mttp -83.77 101.72 11.79 Favored 'General case' 0 N--CA 1.438 -1.073 0 N-CA-C 109.009 -0.738 . . . . 0.0 109.009 176.34 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 18.6 m -63.05 135.97 96.47 Favored Pre-proline 0 N--CA 1.442 -0.841 0 CA-C-N 115.475 -0.784 . . . . 0.0 110.991 -173.794 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -64.38 -20.48 66.39 Favored 'Trans proline' 0 N--CA 1.492 1.432 0 C-N-CA 122.365 2.043 . . . . 0.0 110.174 177.011 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 21.2 mmtp -96.05 92.92 6.68 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 173.06 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 47.4 mttp -84.55 140.81 31.16 Favored 'General case' 0 C--N 1.31 -1.141 0 N-CA-C 109.67 -0.492 . . . . 0.0 109.67 -179.009 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 301' ' ' ILE . . . . . 0.454 ' CD1' ' H ' ' A' ' 301' ' ' ILE . 0.3 OUTLIER -80.44 164.06 3.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 116.64 -0.255 . . . . 0.0 110.618 178.302 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 4.3 m -78.88 79.16 5.3 Favored 'General case' 0 C--N 1.323 -0.562 0 C-N-CA 120.115 -0.634 . . . . 0.0 110.525 -177.674 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -133.45 140.56 47.36 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-N 115.251 -0.886 . . . . 0.0 108.67 173.282 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 19.4 mttt -80.49 148.55 30.4 Favored 'General case' 0 C--N 1.315 -0.91 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 176.703 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 2.6 m -57.76 141.39 48.91 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 107.726 -1.213 . . . . 0.0 107.726 177.166 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -66.5 176.85 0.93 Allowed Pre-proline 0 C--N 1.312 -1.033 0 C-N-CA 120.559 -0.456 . . . . 0.0 109.852 -178.104 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . 0.465 ' O ' ' N ' ' A' ' 309' ' ' SER . 38.1 Cg_exo -58.89 -18.46 42.31 Favored 'Trans proline' 0 N--CA 1.494 1.52 0 C-N-CA 122.336 2.024 . . . . 0.0 111.446 179.41 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -59.45 74.73 0.01 OUTLIER 'General case' 0 C--O 1.237 0.428 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.241 -179.338 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.465 ' N ' ' O ' ' A' ' 307' ' ' PRO . 4.8 m -130.52 158.87 38.78 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.539 -176.636 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 96.6 mt -66.96 144.86 55.97 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.087 178.477 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 29.0 m -134.09 162.37 39.31 Favored 'Isoleucine or valine' 0 C--O 1.24 0.598 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.549 -179.728 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 99.4 mt-10 . . . . . 0 C--O 1.205 -1.266 0 CA-C-O 118.085 -0.959 . . . . 0.0 110.128 179.14 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . 0.623 ' O ' ' N ' ' A' ' 203' ' ' GLY . 76.5 mm-40 . . . . . 0 N--CA 1.48 1.057 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 202' ' ' PHE . . . . . 0.499 ' CG ' ' N ' ' A' ' 203' ' ' GLY . 0.1 OUTLIER 47.91 -58.04 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.767 0 C-N-CA 124.901 1.28 . . . . 0.0 114.028 -176.682 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . 0.623 ' N ' ' O ' ' A' ' 201' ' ' GLU . . . -68.91 -41.92 80.35 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 110.942 -0.863 . . . . 0.0 110.942 177.861 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -63.1 -40.13 96.72 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.358 0.599 . . . . 0.0 110.545 -175.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 205' ' ' GLU . . . . . 0.479 ' OE2' ' N ' ' A' ' 201' ' ' GLU . 52.0 mp0 -62.68 -17.43 60.54 Favored 'General case' 0 C--N 1.306 -1.321 0 CA-C-N 115.256 -0.884 . . . . 0.0 111.351 -178.561 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 12.5 tpt -71.08 124.76 25.15 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.825 0.345 . . . . 0.0 110.767 -177.519 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . 0.619 ' O ' ' N ' ' A' ' 209' ' ' THR . 28.6 m -128.8 167.73 23.48 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.766 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 177.881 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 10.9 mp -59.64 70.32 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.546 0 CA-C-O 121.82 0.819 . . . . 0.0 109.926 -177.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 209' ' ' THR . . . . . 0.619 ' N ' ' O ' ' A' ' 207' ' ' VAL . 5.8 m -73.45 -42.98 61.28 Favored 'General case' 0 C--N 1.307 -1.254 0 CA-C-N 114.507 -1.224 . . . . 0.0 110.616 -177.269 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 10.6 p-10 -57.48 -46.93 83.15 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.016 -0.993 . . . . 0.0 112.805 -172.618 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 4.7 m -115.09 109.96 18.84 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 112.712 0.634 . . . . 0.0 112.712 -174.395 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 99.4 m-20 -102.25 130.5 48.95 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 170.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 60.1 66.21 2.87 Favored Glycine 0 C--O 1.239 0.418 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 -176.271 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 70.6 mt-10 -56.94 145.58 29.61 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.03 0.443 . . . . 0.0 112.006 -175.384 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -40.84 146.55 0.46 Allowed Pre-proline 0 C--N 1.324 -0.536 0 CA-C-N 115.072 -0.967 . . . . 0.0 112.55 -175.671 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_exo -62.81 154.88 63.13 Favored 'Trans proline' 0 N--CA 1.495 1.616 0 C-N-CA 123.05 2.5 . . . . 0.0 109.994 170.794 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -45.95 118.34 1.83 Allowed 'General case' 0 C--O 1.244 0.774 0 C-N-CA 120.343 -0.543 . . . . 0.0 109.868 -177.256 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 218' ' ' SER . . . . . 0.511 ' CB ' ' HG ' ' A' ' 293' ' ' SER . 22.4 m -131.9 152.35 51.11 Favored 'General case' 0 N--CA 1.442 -0.829 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.529 -175.787 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -145.79 156.06 43.34 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.56 179.855 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 97.7 mtp -76.46 140.39 41.23 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 174.62 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 97.9 t -80.89 129.21 37.91 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.014 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 178.263 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 222' ' ' SER . . . . . 0.41 ' HG ' ' C ' ' A' ' 234' ' ' CYS . 29.0 m -77.98 -70.58 0.47 Allowed 'General case' 0 N--CA 1.434 -1.273 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 177.36 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 5.9 ptm -138.25 160.29 39.85 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.275 174.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 224' ' ' VAL . . . . . 0.509 HG13 ' SD ' ' A' ' 256' ' ' MET . 61.3 t -124.53 132.13 71.77 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.037 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 173.867 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -100.35 120.33 39.78 Favored 'General case' 0 C--N 1.313 -1.013 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 -177.993 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.82 82.11 0.9 Allowed 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.003 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 227' ' ' ASP . . . . . 0.513 ' N ' ' OG1' ' A' ' 280' ' ' THR . 4.1 t70 -153.49 -175.45 5.36 Favored 'General case' 0 C--O 1.246 0.886 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.037 -179.319 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 228' ' ' ASN . . . . . 0.511 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.2 OUTLIER -142.12 124.08 8.98 Favored Pre-proline 0 C--N 1.331 -0.228 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.307 176.696 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 229' ' ' PRO . . . . . 0.511 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 33.7 Cg_exo -61.71 147.02 50.93 Favored 'Cis proline' 0 N--CA 1.489 1.213 0 C-N-CA 123.091 -1.629 . . . . 0.0 109.984 -1.73 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . 0.449 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -68.71 134.12 27.77 Favored Glycine 0 C--N 1.3 -1.461 0 N-CA-C 108.864 -1.694 . . . . 0.0 108.864 179.064 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 231' ' ' VAL . . . . . 0.403 ' HB ' ' OG ' ' A' ' 276' ' ' SER . 2.1 p -125.7 132.34 70.94 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 117.332 0.566 . . . . 0.0 110.11 179.549 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 232' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -135.07 156.98 40.33 Favored 'Isoleucine or valine' 0 C--O 1.248 0.979 0 C-N-CA 120.754 -0.378 . . . . 0.0 110.084 -178.697 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 14.9 p -105.56 154.8 19.89 Favored 'General case' 0 N--CA 1.435 -1.209 0 CA-C-N 116.134 -0.485 . . . . 0.0 109.822 176.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 234' ' ' CYS . . . . . 0.41 ' C ' ' HG ' ' A' ' 222' ' ' SER . 2.1 m -111.78 161.07 16.71 Favored 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 176.043 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 38.4 tp -60.07 121.91 13.06 Favored 'General case' 0 C--N 1.309 -1.157 0 N-CA-C 107.143 -1.428 . . . . 0.0 107.143 178.659 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 236' ' ' ASP . . . . . 0.478 ' O ' ' NH2' ' A' ' 239' ' ' ARG . 13.9 p-10 -51.67 -44.93 63.24 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.29 0.566 . . . . 0.0 111.021 -171.55 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -64.9 -35.17 80.29 Favored 'General case' 0 C--N 1.301 -1.538 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.128 -179.355 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -70.98 95.9 1.23 Allowed 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.777 -179.198 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 239' ' ' ARG . . . . . 0.578 ' NH2' ' OH ' ' A' ' 273' ' ' TYR . 0.0 OUTLIER -62.66 99.09 0.14 Allowed 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 172.124 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 240' ' ' HIS . . . . . 0.46 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 7.2 p80 -59.48 -46.47 88.71 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.891 -175.278 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 83.5 13.09 76.93 Favored Glycine 0 C--N 1.32 -0.351 0 N-CA-C 110.505 -1.038 . . . . 0.0 110.505 -178.897 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 242' ' ' PHE . . . . . 0.5 ' CE1' ' HB3' ' A' ' 294' ' ' GLN . 4.2 m-30 -82.01 138.3 34.91 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.422 -0.585 . . . . 0.0 109.422 179.511 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 243' ' ' GLU . . . . . 0.4 ' N ' ' OD2' ' A' ' 246' ' ' ASP . 0.0 OUTLIER -110.28 161.96 15.09 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-O 121.315 0.578 . . . . 0.0 109.656 175.642 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.71 111.41 2.4 Favored 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 178.589 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 104.86 0.15 42.07 Favored Glycine 0 CA--C 1.52 0.385 0 N-CA-C 111.661 -0.576 . . . . 0.0 111.661 -178.717 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 246' ' ' ASP . . . . . 0.4 ' OD2' ' N ' ' A' ' 243' ' ' GLU . 42.3 m-20 -72.95 161.65 30.44 Favored 'General case' 0 CA--C 1.514 -0.417 0 CA-C-N 116.918 0.359 . . . . 0.0 110.562 175.703 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 247' ' ' PHE . . . . . 0.443 ' HA ' ' O ' ' A' ' 265' ' ' MET . 70.3 m-85 -109.49 130.31 55.51 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.929 -0.578 . . . . 0.0 109.721 177.471 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . 0.403 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.3 m -132.4 161.29 41.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 C-N-CA 120.619 -0.432 . . . . 0.0 110.817 179.548 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 3.4 p -126.64 149.61 49.4 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.842 174.427 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 250' ' ' PHE . . . . . 0.501 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 71.6 m-85 -102.99 162.42 12.95 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.117 -176.104 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 69.1 m -157.31 155.21 30.29 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.323 174.451 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 19.3 mt-10 51.76 26.37 3.45 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 113.123 0.786 . . . . 0.0 113.123 178.733 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . 0.433 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 16.2 t -82.18 117.47 28.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 174.22 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 87.4 mt-30 -89.28 144.36 26.15 Favored 'General case' 0 C--O 1.245 0.859 0 CA-C-O 121.218 0.533 . . . . 0.0 111.486 -176.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 77.82 -60.42 3.77 Favored Glycine 0 N--CA 1.449 -0.475 0 N-CA-C 109.702 -1.359 . . . . 0.0 109.702 -177.184 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 256' ' ' MET . . . . . 0.509 ' SD ' HG13 ' A' ' 224' ' ' VAL . 57.3 ttm -86.57 65.43 9.03 Favored 'General case' 0 C--N 1.318 -0.775 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 174.831 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 47.4 pt -75.42 -17.22 15.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 115.176 -0.92 . . . . 0.0 111.322 -174.31 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 258' ' ' GLN . . . . . 0.4 ' O ' ' N ' ' A' ' 262' ' ' CYS . 6.6 mp0 -55.3 -35.98 65.69 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 -178.742 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 259' ' ' LEU . . . . . 0.501 ' HB3' ' CG ' ' A' ' 250' ' ' PHE . 91.6 mt -62.18 -41.83 98.7 Favored 'General case' 0 C--N 1.315 -0.897 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.785 176.87 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 260' ' ' ASN . . . . . 0.433 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 97.5 m-20 -60.84 -40.32 92.4 Favored 'General case' 0 CA--C 1.512 -0.495 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 179.753 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -91.28 -3.79 69.21 Favored Glycine 0 CA--C 1.522 0.489 0 CA-C-N 115.466 -0.788 . . . . 0.0 111.968 -177.104 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 262' ' ' CYS . . . . . 0.4 ' N ' ' O ' ' A' ' 258' ' ' GLN . 2.9 m -87.18 141.78 28.39 Favored 'General case' 0 CA--C 1.514 -0.424 0 CA-C-N 117.249 0.524 . . . . 0.0 110.812 -177.053 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 29.3 pt20 -63.36 165.58 10.92 Favored Pre-proline 0 C--N 1.323 -0.554 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 176.054 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 264' ' ' PRO . . . . . 0.403 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 36.8 Cg_exo -60.1 141.9 97.19 Favored 'Trans proline' 0 C--N 1.316 -1.148 0 N-CA-C 109.245 -1.098 . . . . 0.0 109.245 177.42 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 265' ' ' MET . . . . . 0.443 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 23.1 ptp -134.21 155.34 50.3 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 111.969 0.359 . . . . 0.0 111.969 -173.002 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 266' ' ' GLU . . . . . 0.403 ' HB2' ' CE2' ' A' ' 247' ' ' PHE . 78.5 tt0 -71.5 137.87 48.49 Favored 'General case' 0 C--O 1.239 0.519 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.865 179.306 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 267' ' ' ILE . . . . . 0.476 HG22 ' CE2' ' A' ' 275' ' ' PHE . 1.8 pp -129.03 164.19 32.07 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.995 -177.16 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 48.4 mmtm -129.05 125.09 36.53 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 109.114 -0.698 . . . . 0.0 109.114 176.158 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 14.9 m -79.24 125.12 38.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 C-N-CA 120.743 -0.383 . . . . 0.0 110.578 179.801 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 78.6 mt -101.64 -12.49 18.38 Favored 'General case' 0 C--O 1.237 0.427 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.284 -179.034 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -164.4 -179.57 38.62 Favored Glycine 0 C--N 1.317 -0.491 0 N-CA-C 109.892 -1.283 . . . . 0.0 109.892 -177.048 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 272' ' ' PRO . . . . . 0.46 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 26.2 Cg_endo -59.7 -39.71 71.14 Favored 'Trans proline' 0 C--N 1.306 -1.687 0 C-N-CA 122.159 1.906 . . . . 0.0 111.148 -177.577 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 273' ' ' TYR . . . . . 0.578 ' OH ' ' NH2' ' A' ' 239' ' ' ARG . 29.2 m-85 -123.95 13.4 9.14 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-N 115.328 -0.851 . . . . 0.0 110.686 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -119.1 127.49 53.41 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 -174.433 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 275' ' ' PHE . . . . . 0.549 ' C ' ' CD1' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -140.47 161.75 36.98 Favored 'General case' 0 CA--C 1.502 -0.89 0 C-N-CA 120.645 -0.422 . . . . 0.0 112.126 -179.588 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 276' ' ' SER . . . . . 0.449 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 1.8 m -130.07 156.07 45.12 Favored 'General case' 0 N--CA 1.433 -1.307 0 CA-C-O 121.568 0.699 . . . . 0.0 112.75 -177.172 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . 0.534 HD13 ' CE2' ' A' ' 283' ' ' PHE . 2.3 pp -137.16 -179.28 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.273 0 CA-C-N 113.682 -1.599 . . . . 0.0 109.113 -177.518 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 278' ' ' CYS . . . . . 0.443 ' SG ' HD11 ' A' ' 277' ' ' ILE . 0.8 OUTLIER -40.1 -88.88 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.406 0 O-C-N 123.516 0.51 . . . . 0.0 112.185 179.753 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . 0.493 ' O ' ' ND2' ' A' ' 282' ' ' ASN . 65.5 t0 -149.22 115.55 5.81 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-O 120.602 0.239 . . . . 0.0 111.26 -178.097 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 280' ' ' THR . . . . . 0.597 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 14.6 p -63.56 -29.65 70.88 Favored 'General case' 0 C--N 1.308 -1.233 0 CA-C-O 121.295 0.569 . . . . 0.0 110.166 175.25 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -63.82 -19.57 65.12 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-N 115.329 -0.851 . . . . 0.0 109.763 177.146 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 282' ' ' ASN . . . . . 0.493 ' ND2' ' O ' ' A' ' 279' ' ' ASP . 0.0 OUTLIER -95.05 -7.97 38.02 Favored 'General case' 0 C--N 1.344 0.334 0 C-N-CA 120.507 -0.477 . . . . 0.0 110.436 177.949 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . 0.597 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 21.4 m-30 -85.2 -80.74 0.21 Allowed 'General case' 0 CA--C 1.512 -0.498 0 CA-C-O 121.854 0.835 . . . . 0.0 109.035 175.609 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 284' ' ' SER . . . . . 0.413 ' OG ' ' HA ' ' A' ' 256' ' ' MET . 0.1 OUTLIER 175.45 -173.37 0.08 Allowed 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 114.121 -1.399 . . . . 0.0 108.196 -176.442 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 33.4 t0 -91.18 116.3 28.7 Favored 'General case' 0 C--N 1.316 -0.876 0 C-N-CA 121.045 -0.262 . . . . 0.0 111.668 -178.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . 0.405 ' OH ' ' NH2' ' A' ' 288' ' ' ARG . 1.1 t80 -64.94 135.32 55.54 Favored 'General case' 0 CA--C 1.511 -0.53 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.37 179.24 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 287' ' ' ILE . . . . . 0.461 ' C ' ' HG2' ' A' ' 288' ' ' ARG . 96.9 mt -118.71 -74.78 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.433 -1.306 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.737 174.731 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . 0.537 ' NE ' ' HA ' ' A' ' 288' ' ' ARG . 4.1 mmp_? -148.71 175.58 11.09 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.587 -177.511 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 75.35 -156.3 48.35 Favored Glycine 0 C--O 1.238 0.393 0 N-CA-C 110.689 -0.964 . . . . 0.0 110.689 178.145 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 103.82 111.56 3.59 Favored Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 121.712 -0.28 . . . . 0.0 112.524 176.416 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . 0.412 HG23 HD11 ' A' ' 291' ' ' ILE . 93.2 mt -121.16 131.7 72.37 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.928 0 N-CA-C 107.532 -1.284 . . . . 0.0 107.532 173.605 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 2.8 p -122.61 137.07 57.38 Favored 'Isoleucine or valine' 0 C--O 1.242 0.683 0 C-N-CA 120.702 -0.399 . . . . 0.0 111.17 -174.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 293' ' ' SER . . . . . 0.511 ' HG ' ' CB ' ' A' ' 218' ' ' SER . 41.7 m -126.21 140.31 52.64 Favored 'General case' 0 CA--C 1.51 -0.565 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.438 179.533 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 294' ' ' GLN . . . . . 0.5 ' HB3' ' CE1' ' A' ' 242' ' ' PHE . 0.9 OUTLIER -82.11 141.49 33.07 Favored 'General case' 0 CA--C 1.504 -0.823 0 C-N-CA 120.499 -0.48 . . . . 0.0 110.023 176.764 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 39.0 t -131.05 127.02 60.44 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.176 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 178.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 64.0 mttp -87.14 98.16 11.15 Favored 'General case' 0 N--CA 1.432 -1.328 0 N-CA-C 107.399 -1.334 . . . . 0.0 107.399 170.732 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 297' ' ' VAL . . . . . 0.54 ' HB ' ' CD ' ' A' ' 298' ' ' PRO . 12.4 m -82.31 -174.4 0.52 Allowed Pre-proline 0 C--N 1.313 -1.018 0 N-CA-C 108.96 -0.756 . . . . 0.0 108.96 -177.36 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 298' ' ' PRO . . . . . 0.54 ' CD ' ' HB ' ' A' ' 297' ' ' VAL . 71.8 Cg_exo -53.28 -32.78 62.49 Favored 'Trans proline' 0 N--CA 1.495 1.584 0 C-N-CA 121.39 1.394 . . . . 0.0 109.232 179.208 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 64.4 mttp -87.55 94.47 9.72 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 171.478 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -125.1 135.74 52.97 Favored 'General case' 0 C--N 1.311 -1.077 0 C-N-CA 120.994 -0.282 . . . . 0.0 110.463 -177.565 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 43.9 mm -104.31 115.27 45.92 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.937 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 174.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 4.3 m -100.99 126.05 47.63 Favored 'General case' 0 C--N 1.317 -0.847 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 178.799 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 55.8 p90 -138.27 152.44 48.55 Favored 'General case' 0 C--N 1.316 -0.873 0 C-N-CA 120.973 -0.291 . . . . 0.0 110.8 -175.042 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 63.2 mttp -74.36 107.0 6.25 Favored 'General case' 0 CA--C 1.508 -0.643 0 N-CA-C 109.187 -0.671 . . . . 0.0 109.187 179.373 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 3.4 m -82.31 126.39 32.08 Favored 'General case' 0 C--N 1.311 -1.079 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 175.728 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 9.6 mp -43.83 129.58 4.14 Favored Pre-proline 0 C--N 1.327 -0.378 0 CA-C-N 116.621 -0.263 . . . . 0.0 110.292 -175.409 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -59.09 -32.76 97.92 Favored 'Trans proline' 0 N--CA 1.492 1.397 0 C-N-CA 121.824 1.683 . . . . 0.0 110.753 -179.567 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -110.16 60.01 0.6 Allowed 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 108.085 -1.08 . . . . 0.0 108.085 170.263 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -77.0 140.7 40.47 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.648 -0.706 . . . . 0.0 111.683 -174.696 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 97.3 mt -109.65 127.43 54.55 Favored 'General case' 0 C--N 1.316 -0.878 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 174.628 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 2.1 p -93.89 113.2 28.13 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.003 0 N-CA-C 107.702 -1.221 . . . . 0.0 107.702 173.551 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 . . . . . 0 C--N 1.311 -1.086 0 CA-C-O 118.021 -0.99 . . . . 0.0 110.716 -171.557 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . 0.48 ' H1 ' ' CD ' ' A' ' 205' ' ' GLU . 1.8 mp0 . . . . . 0 N--CA 1.472 0.629 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 202' ' ' PHE . . . . . 0.48 ' CE1' ' HG3' ' A' ' 205' ' ' GLU . 28.2 p90 -144.99 161.48 39.28 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.03 -0.532 . . . . 0.0 112.198 -179.436 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -56.16 -41.72 86.59 Favored Glycine 0 C--O 1.225 -0.415 0 CA-C-N 115.635 -0.711 . . . . 0.0 112.529 -170.829 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -53.99 -26.48 26.27 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-O 121.12 0.486 . . . . 0.0 110.836 -176.718 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 205' ' ' GLU . . . . . 0.48 ' CD ' ' H1 ' ' A' ' 201' ' ' GLU . 61.6 mt-10 -67.04 -37.54 84.29 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.525 -0.761 . . . . 0.0 111.47 179.06 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 78.8 mtm -79.45 133.27 36.53 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 112.183 0.438 . . . . 0.0 112.183 -175.307 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 29.0 m -131.13 161.4 41.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 176.374 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 208' ' ' LEU . . . . . 0.413 ' CD1' ' HD3' ' A' ' 216' ' ' PRO . 7.6 mp -112.9 123.79 51.12 Favored 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 120.424 -0.51 . . . . 0.0 110.956 -179.837 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 20.6 p -66.73 -30.48 70.72 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.889 0.376 . . . . 0.0 110.232 174.863 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 3.0 t70 -58.46 -48.7 79.89 Favored 'General case' 0 N--CA 1.471 0.604 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.045 176.349 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 211' ' ' SER . . . . . 0.421 ' CB ' ' HB2' ' A' ' 214' ' ' GLU . 5.9 m -75.08 161.87 29.04 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-N 114.981 -1.008 . . . . 0.0 109.578 179.385 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 24.2 t30 -84.53 84.4 7.67 Favored 'General case' 0 C--O 1.239 0.517 0 C-N-CA 119.804 -0.758 . . . . 0.0 110.169 -177.117 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 59.55 39.93 95.65 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 110.662 -0.975 . . . . 0.0 110.662 -179.257 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 214' ' ' GLU . . . . . 0.421 ' HB2' ' CB ' ' A' ' 211' ' ' SER . 28.1 mt-10 -119.71 161.89 19.95 Favored 'General case' 0 C--O 1.24 0.587 0 CA-C-O 121.217 0.532 . . . . 0.0 111.28 -175.181 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 57.1 mt-30 -104.59 173.87 3.07 Favored Pre-proline 0 C--N 1.313 -1.005 0 N-CA-C 105.581 -2.007 . . . . 0.0 105.581 164.295 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 216' ' ' PRO . . . . . 0.413 ' HD3' ' CD1' ' A' ' 208' ' ' LEU . 49.5 Cg_exo -60.92 138.94 82.19 Favored 'Trans proline' 0 C--N 1.305 -1.731 0 N-CA-C 108.32 -1.454 . . . . 0.0 108.32 173.253 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -77.97 102.27 7.28 Favored 'General case' 0 N--CA 1.44 -0.964 0 C-N-CA 119.365 -0.934 . . . . 0.0 109.7 -179.747 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 218' ' ' SER . . . . . 0.575 ' CB ' ' HG ' ' A' ' 293' ' ' SER . 4.0 m -128.71 145.04 51.28 Favored 'General case' 0 N--CA 1.435 -1.179 0 CA-C-N 115.489 -0.778 . . . . 0.0 110.433 -177.057 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -130.24 154.96 47.05 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.395 179.078 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 220' ' ' MET . . . . . 0.597 ' SD ' HG12 ' A' ' 291' ' ' ILE . 87.8 mmm -82.46 129.34 34.88 Favored 'General case' 0 N--CA 1.438 -1.041 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 177.831 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 65.5 t -76.23 132.6 32.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 -179.808 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 33.5 m -97.16 -68.52 0.8 Allowed 'General case' 0 N--CA 1.44 -0.964 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.044 179.083 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 223' ' ' MET . . . . . 0.595 ' C ' ' SD ' ' A' ' 223' ' ' MET . 1.8 ppp? -137.14 147.95 46.31 Favored 'General case' 0 C--N 1.323 -0.567 0 C-N-CA 120.686 -0.406 . . . . 0.0 112.0 173.533 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 224' ' ' VAL . . . . . 0.482 ' N ' ' SD ' ' A' ' 223' ' ' MET . 71.2 t -125.83 131.79 71.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 N-CA-C 109.546 -0.538 . . . . 0.0 109.546 177.233 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 23.0 p -88.09 129.82 35.19 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.78 -0.368 . . . . 0.0 110.15 177.534 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 226' ' ' LYS . . . . . 0.424 ' CE ' ' O ' ' A' ' 284' ' ' SER . 51.9 tttm -80.27 81.6 6.5 Favored 'General case' 0 N--CA 1.447 -0.601 0 CA-C-O 121.674 0.749 . . . . 0.0 109.984 179.235 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 227' ' ' ASP . . . . . 0.557 ' N ' ' OG1' ' A' ' 280' ' ' THR . 42.7 t0 -151.14 169.49 21.73 Favored 'General case' 0 C--O 1.245 0.826 0 CA-C-N 114.508 -1.224 . . . . 0.0 108.923 -177.085 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 228' ' ' ASN . . . . . 0.418 ' N ' ' OD1' ' A' ' 227' ' ' ASP . 15.8 p-10 -140.91 121.83 8.96 Favored Pre-proline 0 C--N 1.325 -0.494 0 C-N-CA 120.516 -0.473 . . . . 0.0 111.717 176.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 229' ' ' PRO . . . . . 0.466 ' HA ' ' O ' ' A' ' 278' ' ' CYS . 56.6 Cg_endo -65.12 142.96 55.04 Favored 'Cis proline' 0 C--N 1.311 -1.424 0 C-N-CA 122.632 -1.82 . . . . 0.0 109.437 -4.138 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . 0.456 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -93.14 154.69 22.0 Favored Glycine 0 C--N 1.311 -0.817 0 N-CA-C 110.192 -1.163 . . . . 0.0 110.192 -177.296 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.4 p -123.3 137.66 55.87 Favored 'Isoleucine or valine' 0 C--O 1.239 0.529 0 CA-C-N 116.724 0.262 . . . . 0.0 110.318 179.188 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 232' ' ' VAL . . . . . 0.409 HG11 HG12 ' A' ' 224' ' ' VAL . 0.8 OUTLIER -130.95 155.9 42.32 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.016 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.299 -177.998 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 27.6 m -110.73 140.45 45.11 Favored 'General case' 0 C--N 1.312 -1.028 0 CA-C-N 115.49 -0.777 . . . . 0.0 108.918 174.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 48.2 m -107.69 162.22 14.18 Favored 'General case' 0 C--N 1.314 -0.954 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 179.315 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 50.1 tp -61.41 130.32 45.5 Favored 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 179.198 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 55.6 m-20 -58.75 -40.41 83.79 Favored 'General case' 0 N--CA 1.476 0.857 0 CA-C-O 120.902 0.382 . . . . 0.0 111.244 -174.823 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 54.6 mp0 -64.85 -29.79 70.76 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.254 178.36 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -77.5 138.97 39.52 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.796 -176.164 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 49.9 mtp85 -104.36 108.92 20.56 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.795 174.413 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 240' ' ' HIS . . . . . 0.511 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 12.7 p80 -67.01 -46.65 73.84 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-O 121.248 0.546 . . . . 0.0 109.804 176.416 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 77.87 14.74 82.03 Favored Glycine 0 CA--C 1.502 -0.743 0 N-CA-C 109.837 -1.305 . . . . 0.0 109.837 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 242' ' ' PHE . . . . . 0.49 ' CD2' ' HB2' ' A' ' 240' ' ' HIS . 8.7 m-30 -80.26 143.21 33.89 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 -177.391 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -107.66 159.95 16.07 Favored 'General case' 0 C--N 1.308 -1.239 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.712 174.716 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -62.35 117.66 6.42 Favored 'General case' 0 C--N 1.297 -1.679 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 177.305 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 90.53 4.42 70.48 Favored Glycine 0 C--N 1.313 -0.748 0 N-CA-C 111.393 -0.683 . . . . 0.0 111.393 -177.679 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 23.7 t0 -79.23 163.28 25.1 Favored 'General case' 0 C--O 1.237 0.422 0 N-CA-C 109.319 -0.622 . . . . 0.0 109.319 176.531 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 247' ' ' PHE . . . . . 0.484 ' CE2' ' HB2' ' A' ' 266' ' ' GLU . 89.7 m-85 -111.3 134.09 53.14 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.507 0.194 . . . . 0.0 110.572 -176.112 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . 0.457 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.9 m -131.17 165.94 30.12 Favored 'Isoleucine or valine' 0 C--O 1.239 0.51 0 CA-C-O 121.345 0.593 . . . . 0.0 112.441 -176.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 10.8 p -135.24 163.24 30.41 Favored 'General case' 0 C--N 1.32 -0.713 0 C-N-CA 124.92 1.288 . . . . 0.0 109.264 176.065 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 250' ' ' PHE . . . . . 0.568 ' CB ' ' HB3' ' A' ' 259' ' ' LEU . 78.7 m-85 -125.67 158.88 33.65 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.574 0.226 . . . . 0.0 111.027 -172.096 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 251' ' ' SER . . . . . 0.416 ' N ' ' O ' ' A' ' 291' ' ' ILE . 2.0 m -155.9 164.65 38.23 Favored 'General case' 0 C--N 1.322 -0.623 0 C-N-CA 122.326 0.251 . . . . 0.0 110.466 177.584 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 50.5 mm-40 48.59 27.36 1.45 Allowed 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.44 -0.346 . . . . 0.0 111.929 176.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 44.0 t -84.12 130.76 35.37 Favored 'Isoleucine or valine' 0 C--O 1.235 0.323 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 179.152 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 97.7 mm-40 -95.65 135.35 37.44 Favored 'General case' 0 C--O 1.247 0.954 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 178.86 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 84.53 -68.64 3.47 Favored Glycine 0 C--N 1.312 -0.752 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 -178.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 256' ' ' MET . . . . . 0.481 ' SD ' ' C ' ' A' ' 284' ' ' SER . 1.7 tpp -81.68 67.69 7.75 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.48 0.657 . . . . 0.0 109.407 176.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 257' ' ' ILE . . . . . 0.41 ' O ' ' HB2' ' A' ' 260' ' ' ASN . 48.5 pt -73.94 -21.24 17.98 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.945 0 CA-C-N 115.231 -0.895 . . . . 0.0 110.69 -176.546 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 258' ' ' GLN . . . . . 0.662 ' HG3' ' SG ' ' A' ' 262' ' ' CYS . 52.5 tp60 -56.52 -33.49 66.09 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.167 179.633 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 259' ' ' LEU . . . . . 0.568 ' HB3' ' CB ' ' A' ' 250' ' ' PHE . 84.4 mt -62.16 -39.97 94.41 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.048 174.702 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 260' ' ' ASN . . . . . 0.41 ' HB2' ' O ' ' A' ' 257' ' ' ILE . 97.1 m-20 -59.9 -40.53 89.08 Favored 'General case' 0 C--O 1.238 0.45 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.713 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -102.24 16.38 55.46 Favored Glycine 0 CA--C 1.527 0.816 0 CA-C-N 115.901 -0.59 . . . . 0.0 112.386 -178.363 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 262' ' ' CYS . . . . . 0.662 ' SG ' ' HG3' ' A' ' 258' ' ' GLN . 1.1 m -88.14 156.3 19.33 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-N 117.184 0.492 . . . . 0.0 112.028 -178.086 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 38.2 mt-30 -73.0 160.11 83.7 Favored Pre-proline 0 C--O 1.241 0.61 0 N-CA-C 107.761 -1.199 . . . . 0.0 107.761 171.423 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 264' ' ' PRO . . . . . 0.457 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 59.4 Cg_endo -66.77 145.9 76.72 Favored 'Trans proline' 0 C--N 1.309 -1.537 0 C-N-CA 121.086 1.191 . . . . 0.0 110.353 178.281 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 265' ' ' MET . . . . . 0.405 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 20.8 ptp -136.47 152.53 50.66 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 112.007 0.373 . . . . 0.0 112.007 -172.473 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 266' ' ' GLU . . . . . 0.484 ' HB2' ' CE2' ' A' ' 247' ' ' PHE . 69.5 tt0 -71.48 140.71 50.09 Favored 'General case' 0 C--O 1.239 0.532 0 O-C-N 123.898 0.749 . . . . 0.0 109.487 177.388 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 267' ' ' ILE . . . . . 0.493 HG23 ' CE2' ' A' ' 275' ' ' PHE . 2.1 pp -128.37 165.98 26.64 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-O 121.205 0.526 . . . . 0.0 112.069 -176.608 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . 0.402 ' HB2' ' OG ' ' A' ' 276' ' ' SER . 62.3 mttm -124.99 123.06 39.06 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 178.628 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 9.3 m -86.08 94.86 4.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 C-N-CA 119.363 -0.935 . . . . 0.0 109.966 176.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 97.0 mt -65.49 -41.21 93.5 Favored 'General case' 0 CA--C 1.511 -0.535 0 CA-C-N 115.424 -0.807 . . . . 0.0 109.441 -178.752 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -138.07 -178.5 16.18 Favored Glycine 0 N--CA 1.448 -0.532 0 N-CA-C 108.401 -1.88 . . . . 0.0 108.401 178.591 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 272' ' ' PRO . . . . . 0.511 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 38.4 Cg_endo -64.12 -32.7 63.34 Favored 'Trans proline' 0 C--N 1.303 -1.85 0 C-N-CA 121.513 1.475 . . . . 0.0 111.307 -177.448 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -124.5 9.54 8.43 Favored 'General case' 0 C--O 1.24 0.555 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.861 -178.407 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 7.9 p -125.66 126.56 44.89 Favored 'General case' 0 C--O 1.247 0.962 0 CA-C-O 121.171 0.51 . . . . 0.0 110.844 179.582 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 275' ' ' PHE . . . . . 0.523 ' C ' ' CD1' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -139.56 163.98 31.12 Favored 'General case' 0 CA--C 1.502 -0.897 0 N-CA-C 112.532 0.567 . . . . 0.0 112.532 -175.871 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 276' ' ' SER . . . . . 0.456 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 4.1 p -130.59 152.67 49.71 Favored 'General case' 0 N--CA 1.436 -1.159 0 CA-C-O 121.241 0.543 . . . . 0.0 112.225 -174.946 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . 0.555 HD11 ' CE2' ' A' ' 283' ' ' PHE . 2.0 pp -134.92 173.19 14.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 114.684 -1.144 . . . . 0.0 111.461 -174.033 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 278' ' ' CYS . . . . . 0.466 ' O ' ' HA ' ' A' ' 229' ' ' PRO . 1.5 p -48.95 -78.77 0.02 OUTLIER 'General case' 0 C--N 1.323 -0.556 0 C-N-CA 123.815 0.846 . . . . 0.0 113.05 -177.173 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . 0.47 ' HB2' ' CB ' ' A' ' 282' ' ' ASN . 9.8 m-20 -140.1 103.87 4.71 Favored 'General case' 0 N--CA 1.452 -0.354 0 O-C-N 122.315 -0.241 . . . . 0.0 110.644 -176.256 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 280' ' ' THR . . . . . 0.715 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 20.7 p -65.46 -32.75 74.53 Favored 'General case' 0 C--N 1.315 -0.892 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 172.672 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -61.57 -23.1 65.75 Favored 'General case' 0 N--CA 1.43 -1.464 0 CA-C-N 114.019 -1.446 . . . . 0.0 109.522 175.307 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 282' ' ' ASN . . . . . 0.47 ' CB ' ' HB2' ' A' ' 279' ' ' ASP . 15.0 t30 -89.11 -10.16 48.38 Favored 'General case' 0 CA--C 1.51 -0.596 0 C-N-CA 120.372 -0.531 . . . . 0.0 109.825 178.866 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . 0.715 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 12.7 m-30 -83.76 -74.78 0.36 Allowed 'General case' 0 N--CA 1.441 -0.882 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 172.033 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 284' ' ' SER . . . . . 0.481 ' C ' ' SD ' ' A' ' 256' ' ' MET . 0.2 OUTLIER 171.68 -112.38 0.0 OUTLIER 'General case' 0 CA--C 1.541 0.631 0 CA-C-N 115.223 -0.899 . . . . 0.0 110.355 -178.552 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 285' ' ' ASP . . . . . 0.44 ' N ' ' SD ' ' A' ' 256' ' ' MET . 41.1 t0 -145.58 119.13 9.09 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 119.03 0.832 . . . . 0.0 110.687 177.495 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 1.7 t80 -68.19 123.96 22.14 Favored 'General case' 0 C--O 1.239 0.523 0 CA-C-O 120.739 0.305 . . . . 0.0 110.789 178.53 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 96.7 mt -106.03 -54.71 6.0 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.863 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.316 176.285 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 9.7 ptp180 -169.69 -179.05 3.2 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.079 177.842 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 63.6 -151.09 49.24 Favored Glycine 0 C--O 1.239 0.421 0 N-CA-C 110.605 -0.998 . . . . 0.0 110.605 177.281 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 99.24 129.42 6.55 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 121.59 -0.338 . . . . 0.0 112.525 175.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . 0.597 HG12 ' SD ' ' A' ' 220' ' ' MET . 98.1 mt -125.24 133.77 68.51 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 175.704 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . 0.422 ' O ' ' HA ' ' A' ' 218' ' ' SER . 4.5 p -122.63 134.6 65.35 Favored 'Isoleucine or valine' 0 C--O 1.241 0.615 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -177.955 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 293' ' ' SER . . . . . 0.575 ' HG ' ' CB ' ' A' ' 218' ' ' SER . 23.6 m -127.44 145.29 50.88 Favored 'General case' 0 CA--C 1.513 -0.478 0 CA-C-O 120.624 0.249 . . . . 0.0 111.016 -178.418 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 294' ' ' GLN . . . . . 0.417 ' O ' ' NE2' ' A' ' 294' ' ' GLN . 1.6 pp0? -75.38 148.26 39.36 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.517 -0.31 . . . . 0.0 110.424 178.091 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 72.4 t -126.52 130.79 71.77 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 177.601 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 1.4 mmpp? -98.83 99.44 10.52 Favored 'General case' 0 C--O 1.244 0.8 0 CA-C-O 121.49 0.662 . . . . 0.0 111.243 -179.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 297' ' ' VAL . . . . . 0.501 ' HB ' ' CD ' ' A' ' 298' ' ' PRO . 24.1 m -74.3 -176.9 0.56 Allowed Pre-proline 0 CA--C 1.542 0.655 0 CA-C-N 114.745 -1.116 . . . . 0.0 108.856 178.819 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 298' ' ' PRO . . . . . 0.501 ' CD ' ' HB ' ' A' ' 297' ' ' VAL . 77.4 Cg_exo -54.85 -35.55 89.06 Favored 'Trans proline' 0 N--CA 1.491 1.38 0 C-N-CA 121.711 1.607 . . . . 0.0 111.32 177.725 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 62.3 tttm -69.46 137.5 52.68 Favored 'General case' 0 C--O 1.239 0.521 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.402 -179.372 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -97.6 157.22 16.15 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.594 170.737 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 47.2 pt -99.17 130.01 48.76 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.955 0 CA-C-O 120.77 0.319 . . . . 0.0 111.374 -179.554 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 8.0 m -131.53 157.18 44.25 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 115.931 -0.577 . . . . 0.0 109.779 -177.333 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 85.2 t80 -111.5 132.43 54.5 Favored 'General case' 0 C--N 1.315 -0.895 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 -178.843 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 64.4 mttp -66.38 136.49 55.83 Favored 'General case' 0 CA--C 1.515 -0.376 0 C-N-CA 120.734 -0.386 . . . . 0.0 110.245 -175.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 6.2 m -70.5 141.18 51.98 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.003 177.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 6.1 mp -76.49 156.18 83.36 Favored Pre-proline 0 C--N 1.327 -0.396 0 C-N-CA 120.729 -0.388 . . . . 0.0 110.588 -177.334 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -61.95 -28.28 80.66 Favored 'Trans proline' 0 N--CA 1.496 1.636 0 C-N-CA 122.189 1.926 . . . . 0.0 110.559 179.492 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -141.29 143.22 33.95 Favored 'General case' 0 N--CA 1.445 -0.697 0 CA-C-N 115.728 -0.669 . . . . 0.0 109.509 176.61 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 6.4 m -72.89 158.48 35.42 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.988 -0.551 . . . . 0.0 111.013 -178.816 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -70.49 79.31 0.57 Allowed 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 178.166 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 26.9 m -126.86 161.55 33.34 Favored 'Isoleucine or valine' 0 C--O 1.241 0.647 0 CA-C-N 115.35 -0.841 . . . . 0.0 109.949 -176.827 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 86.8 mt-10 . . . . . 0 C--O 1.202 -1.428 0 CA-C-O 118.899 -0.572 . . . . 0.0 110.232 -179.121 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . 0.567 ' O ' ' N ' ' A' ' 203' ' ' GLY . 0.7 OUTLIER . . . . . 0 N--CA 1.479 0.981 0 N-CA-C 110.021 -0.363 . . . . 0.0 110.021 . . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 33.4 m-85 21.45 -70.54 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.368 0 C-N-CA 125.539 1.536 . . . . 0.0 114.223 -178.09 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 201' ' ' GLU . . . -63.18 -34.0 88.78 Favored Glycine 0 N--CA 1.454 -0.143 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 -177.991 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 99.6 mt-10 -65.62 -44.25 87.06 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.838 0.351 . . . . 0.0 110.388 -179.63 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 205' ' ' GLU . . . . . 0.42 ' OE1' ' N ' ' A' ' 205' ' ' GLU . 2.2 mp0 -62.77 -37.18 85.63 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.568 -177.641 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 64.2 ttp -89.45 120.98 31.24 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.471 -179.381 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 61.6 t -122.04 130.53 74.49 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.803 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 173.476 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 208' ' ' LEU . . . . . 0.572 ' C ' ' H ' ' A' ' 210' ' ' ASP . 10.9 mp -76.29 74.42 3.09 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.036 0.446 . . . . 0.0 111.422 -175.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -71.21 34.55 0.05 OUTLIER 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.98 172.273 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 210' ' ' ASP . . . . . 0.572 ' H ' ' C ' ' A' ' 208' ' ' LEU . 32.9 t70 -58.1 -38.95 77.42 Favored 'General case' 0 CA--C 1.512 -0.507 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.776 -175.235 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 1.1 m -57.79 91.6 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 175.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 23.3 t-20 -61.35 122.16 14.43 Favored 'General case' 0 CA--C 1.507 -0.7 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.276 -173.008 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 104.5 -22.39 34.4 Favored Glycine 0 C--O 1.24 0.517 0 N-CA-C 111.286 -0.726 . . . . 0.0 111.286 178.628 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 80.6 mm-40 -84.82 97.34 9.67 Favored 'General case' 0 N--CA 1.447 -0.6 0 C-N-CA 119.791 -0.763 . . . . 0.0 109.568 176.846 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 45.9 mm-40 -112.69 102.44 54.46 Favored Pre-proline 0 C--N 1.32 -0.707 0 CA-C-N 115.751 -0.659 . . . . 0.0 109.379 177.711 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -74.1 102.71 1.56 Allowed 'Trans proline' 0 C--N 1.305 -1.744 0 C-N-CA 121.318 1.345 . . . . 0.0 109.454 177.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 217' ' ' LEU . . . . . 0.443 ' HB3' ' O ' ' A' ' 240' ' ' HIS . 0.1 OUTLIER -54.04 128.04 28.95 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 108.365 -0.976 . . . . 0.0 108.365 -177.428 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -127.0 147.73 50.12 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-O 120.745 0.307 . . . . 0.0 110.499 -174.734 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -146.41 154.41 41.58 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.509 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 56.3 mtm -79.98 138.95 37.18 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.842 176.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 99.2 t -85.13 130.01 36.85 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.94 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 -178.901 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 65.4 m -83.35 -70.68 0.54 Allowed 'General case' 0 N--CA 1.434 -1.254 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 179.414 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -138.57 152.94 48.62 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.834 174.007 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 224' ' ' VAL . . . . . 0.434 HG22 ' CE1' ' A' ' 286' ' ' TYR . 53.6 t -120.93 132.43 70.45 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 175.329 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 75.5 p -90.85 116.56 28.77 Favored 'General case' 0 C--O 1.236 0.393 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 175.435 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 226' ' ' LYS . . . . . 0.458 ' HA ' ' OG1' ' A' ' 280' ' ' THR . 3.7 tttm -75.86 64.37 1.81 Allowed 'General case' 0 C--O 1.249 1.06 0 C-N-CA 120.616 -0.434 . . . . 0.0 111.259 -175.147 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 227' ' ' ASP . . . . . 0.479 ' CG ' ' H ' ' A' ' 228' ' ' ASN . 36.0 t0 -133.04 -175.69 3.87 Favored 'General case' 0 C--O 1.243 0.752 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.621 178.358 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 228' ' ' ASN . . . . . 0.479 ' H ' ' CG ' ' A' ' 227' ' ' ASP . 0.6 OUTLIER -138.52 125.29 13.04 Favored Pre-proline 0 CA--C 1.533 0.307 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.031 175.631 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 229' ' ' PRO . . . . . 0.446 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 48.6 Cg_endo -66.35 141.24 52.34 Favored 'Cis proline' 0 C--N 1.313 -1.337 0 C-N-CA 122.715 -1.785 . . . . 0.0 110.01 -1.04 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . 0.436 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -75.13 139.3 24.79 Favored Glycine 0 C--N 1.308 -1.01 0 N-CA-C 110.662 -0.975 . . . . 0.0 110.662 -177.745 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.4 p -128.29 137.56 57.08 Favored 'Isoleucine or valine' 0 C--O 1.244 0.775 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 175.001 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 232' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -133.53 155.67 40.65 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.786 0 C-N-CA 120.475 -0.49 . . . . 0.0 110.985 -178.693 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 3.1 m -104.06 140.65 37.46 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 115.459 -0.791 . . . . 0.0 108.902 176.769 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.9 m -107.35 156.84 18.48 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -178.593 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 27.0 tp -58.47 130.21 45.7 Favored 'General case' 0 C--N 1.318 -0.801 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 -178.334 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -55.32 -44.03 75.45 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 120.992 0.425 . . . . 0.0 110.69 -175.025 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -67.6 -23.18 65.35 Favored 'General case' 0 C--N 1.312 -1.065 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.604 -179.72 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -94.54 90.75 6.29 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.964 0.412 . . . . 0.0 111.984 -175.002 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.74 110.12 2.69 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 108.633 -0.876 . . . . 0.0 108.633 174.799 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 240' ' ' HIS . . . . . 0.577 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 12.3 p80 -64.44 -49.81 70.0 Favored 'General case' 0 C--O 1.216 -0.674 0 CA-C-O 120.647 0.26 . . . . 0.0 111.212 -176.501 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 80.71 17.8 72.07 Favored Glycine 0 C--O 1.242 0.599 0 N-CA-C 110.961 -0.855 . . . . 0.0 110.961 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 242' ' ' PHE . . . . . . . . . . . . . 7.3 m-30 -81.38 139.94 35.01 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 179.391 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 76.6 mm-40 -98.79 157.13 16.49 Favored 'General case' 0 C--N 1.308 -1.201 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 172.601 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 25.0 m -65.57 123.4 19.58 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 172.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 94.72 0.09 64.64 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 110.994 -0.842 . . . . 0.0 110.994 -174.705 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 45.9 t0 -79.31 159.62 27.13 Favored 'General case' 0 C--O 1.239 0.542 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 176.736 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 247' ' ' PHE . . . . . 0.404 ' CE1' ' HG3' ' A' ' 299' ' ' LYS . 87.4 m-85 -110.29 129.96 55.64 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.311 -176.559 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . 0.476 ' HA ' ' HA ' ' A' ' 294' ' ' GLN . 2.4 m -128.33 161.54 36.65 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.332 0 C-N-CA 120.658 -0.417 . . . . 0.0 111.494 -179.09 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 50.1 m -129.63 153.15 48.38 Favored 'General case' 0 N--CA 1.444 -0.774 0 CA-C-N 115.108 -0.951 . . . . 0.0 108.676 172.817 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 250' ' ' PHE . . . . . 0.452 ' CB ' ' HB3' ' A' ' 259' ' ' LEU . 73.5 m-85 -105.26 145.25 30.92 Favored 'General case' 0 C--N 1.311 -1.066 0 C-N-CA 122.948 0.499 . . . . 0.0 109.882 -177.333 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 4.8 m -132.17 151.54 51.74 Favored 'General case' 0 C--N 1.304 -1.387 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 175.145 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 7.3 mm-40 47.34 38.22 7.03 Favored 'General case' 0 C--N 1.308 -1.233 0 N-CA-C 112.938 0.718 . . . . 0.0 112.938 174.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . 0.491 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 24.2 t -85.2 132.38 31.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 172.499 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 98.6 mm-40 -96.76 145.12 26.11 Favored 'General case' 0 C--N 1.32 -0.698 0 C-N-CA 120.68 -0.408 . . . . 0.0 110.214 176.671 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 81.19 -67.51 3.6 Favored Glycine 0 C--N 1.32 -0.352 0 N-CA-C 110.244 -1.143 . . . . 0.0 110.244 -177.207 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 256' ' ' MET . . . . . 0.455 ' HG3' ' C ' ' A' ' 285' ' ' ASP . 47.8 mtt -78.65 65.65 3.97 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.475 0.655 . . . . 0.0 110.586 176.219 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 48.9 pt -66.27 -23.78 32.37 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.897 0 CA-C-N 115.285 -0.871 . . . . 0.0 109.577 179.511 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 258' ' ' GLN . . . . . 0.421 ' NE2' ' O ' ' A' ' 283' ' ' PHE . 1.3 mp0 -54.37 -40.99 68.67 Favored 'General case' 0 N--CA 1.442 -0.862 0 CA-C-N 115.14 -0.936 . . . . 0.0 109.044 178.485 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 259' ' ' LEU . . . . . 0.471 HD23 ' CE1' ' A' ' 283' ' ' PHE . 87.3 mt -62.92 -41.83 99.59 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.783 178.067 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 260' ' ' ASN . . . . . 0.491 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 93.3 m-20 -59.37 -41.03 88.38 Favored 'General case' 0 CA--C 1.509 -0.623 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 -177.873 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -102.36 10.98 56.74 Favored Glycine 0 CA--C 1.525 0.706 0 CA-C-N 116.027 -0.533 . . . . 0.0 112.265 -179.359 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 11.8 t -88.48 139.98 29.93 Favored 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 117.512 0.656 . . . . 0.0 111.458 -177.471 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 9.6 mp0 -56.4 158.53 7.7 Favored Pre-proline 0 C--N 1.322 -0.621 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 173.219 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 264' ' ' PRO . . . . . 0.452 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 36.7 Cg_endo -61.71 146.87 96.4 Favored 'Trans proline' 0 N--CA 1.495 1.568 0 C-N-CA 121.488 1.459 . . . . 0.0 111.713 -178.719 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 265' ' ' MET . . . . . 0.63 ' SD ' ' N ' ' A' ' 265' ' ' MET . 0.0 OUTLIER -119.35 152.27 37.06 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.888 -176.461 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 73.0 tt0 -76.53 137.17 39.42 Favored 'General case' 0 C--O 1.238 0.46 0 N-CA-C 107.964 -1.124 . . . . 0.0 107.964 174.803 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 267' ' ' ILE . . . . . 0.499 HG22 ' CE2' ' A' ' 275' ' ' PHE . 1.9 pp -129.51 159.09 41.92 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 N-CA-C 113.069 0.766 . . . . 0.0 113.069 -174.928 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 65.6 mttm -123.54 115.04 20.88 Favored 'General case' 0 CA--C 1.534 0.331 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.367 178.694 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 17.7 m -78.35 100.18 3.26 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.497 0 CA-C-O 121.138 0.494 . . . . 0.0 111.613 -179.149 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 97.5 mt -66.25 -40.82 90.44 Favored 'General case' 0 CA--C 1.513 -0.462 0 CA-C-N 115.723 -0.672 . . . . 0.0 110.477 179.033 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -145.17 179.5 22.23 Favored Glycine 0 C--N 1.315 -0.638 0 N-CA-C 109.724 -1.35 . . . . 0.0 109.724 -177.238 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 272' ' ' PRO . . . . . 0.577 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 33.0 Cg_endo -61.39 -31.82 88.74 Favored 'Trans proline' 0 C--N 1.303 -1.845 0 C-N-CA 121.797 1.665 . . . . 0.0 110.976 -178.448 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 88.4 m-85 -121.36 8.67 10.25 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.18 -0.464 . . . . 0.0 112.067 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -123.77 126.34 46.31 Favored 'General case' 0 C--O 1.242 0.665 0 CA-C-O 120.855 0.359 . . . . 0.0 110.998 -179.48 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 275' ' ' PHE . . . . . 0.558 ' C ' ' CD1' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -132.71 161.03 35.05 Favored 'General case' 0 CA--C 1.499 -1.007 0 C-N-CA 120.733 -0.387 . . . . 0.0 111.766 178.038 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 276' ' ' SER . . . . . 0.436 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 7.7 p -133.36 154.39 50.78 Favored 'General case' 0 N--CA 1.432 -1.346 0 CA-C-O 121.25 0.547 . . . . 0.0 112.456 -173.636 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 35.7 pt -140.94 -165.93 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 CA-C-N 113.991 -1.458 . . . . 0.0 109.569 -171.049 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 278' ' ' CYS . . . . . 0.408 ' O ' ' HA ' ' A' ' 229' ' ' PRO . 14.7 p -69.81 -110.64 0.0 OUTLIER 'General case' 0 N--CA 1.45 -0.474 0 O-C-N 122.996 0.185 . . . . 0.0 111.056 178.793 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . 0.412 ' CG ' ' HB2' ' A' ' 228' ' ' ASN . 50.8 t0 -117.5 119.9 36.47 Favored 'General case' 0 CA--C 1.507 -0.682 0 CA-C-O 121.048 0.452 . . . . 0.0 110.855 -179.591 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 280' ' ' THR . . . . . 0.482 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 9.4 p -64.44 -29.29 70.35 Favored 'General case' 0 C--N 1.292 -1.919 0 CA-C-N 115.501 -0.772 . . . . 0.0 109.597 175.186 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -65.19 -11.66 42.99 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.008 -0.996 . . . . 0.0 109.642 174.483 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 -85.87 -8.65 57.92 Favored 'General case' 0 CA--C 1.507 -0.69 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 175.772 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . 0.482 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 3.3 m-85 -99.73 -78.41 0.51 Allowed 'General case' 0 N--CA 1.442 -0.84 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 171.117 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 284' ' ' SER . . . . . 0.474 ' OG ' ' N ' ' A' ' 285' ' ' ASP . 31.3 t 168.33 -144.33 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.291 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 -179.121 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 285' ' ' ASP . . . . . 0.474 ' N ' ' OG ' ' A' ' 284' ' ' SER . 64.8 m-20 -98.46 131.67 44.53 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 122.289 0.236 . . . . 0.0 110.567 176.734 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . 0.434 ' CE1' HG22 ' A' ' 224' ' ' VAL . 13.0 t80 -84.23 125.56 32.33 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 178.935 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 287' ' ' ILE . . . . . 0.401 ' O ' ' CG ' ' A' ' 288' ' ' ARG . 9.3 mm -94.01 -54.07 7.67 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 N-CA-C 110.471 -0.196 . . . . 0.0 110.471 179.539 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . 0.401 ' CG ' ' O ' ' A' ' 287' ' ' ILE . 0.7 OUTLIER 176.34 -178.0 0.14 Allowed 'General case' 0 C--O 1.244 0.766 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.019 -179.53 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 64.98 -140.64 42.3 Favored Glycine 0 CA--C 1.5 -0.856 0 N-CA-C 110.027 -1.229 . . . . 0.0 110.027 177.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . 0.402 ' HA3' ' OH ' ' A' ' 286' ' ' TYR . . . 87.93 126.34 2.41 Favored Glycine 0 N--CA 1.434 -1.478 0 C-N-CA 120.82 -0.705 . . . . 0.0 111.474 177.916 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . 0.407 HG22 HD12 ' A' ' 291' ' ' ILE . 82.1 mt -120.62 131.21 73.37 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 N-CA-C 106.474 -1.676 . . . . 0.0 106.474 175.06 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 3.9 p -117.85 133.1 65.72 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.051 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -176.038 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 1.4 m -129.35 141.16 51.15 Favored 'General case' 0 CA--C 1.505 -0.781 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.71 -177.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 294' ' ' GLN . . . . . 0.476 ' HA ' ' HA ' ' A' ' 248' ' ' VAL . 0.2 OUTLIER -74.03 146.43 43.74 Favored 'General case' 0 C--N 1.318 -0.797 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 172.398 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 59.2 t -110.71 128.0 67.37 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.171 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 -179.501 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 7.9 mmmm -80.81 98.49 7.83 Favored 'General case' 0 C--N 1.321 -0.644 0 C-N-CA 120.631 -0.427 . . . . 0.0 110.31 -179.19 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -103.98 165.29 13.7 Favored Pre-proline 0 C--N 1.316 -0.878 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.241 177.621 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 298' ' ' PRO . . . . . 0.43 ' O ' ' HG3' ' A' ' 300' ' ' LYS . 38.4 Cg_endo -64.81 -6.9 13.47 Favored 'Trans proline' 0 C--N 1.308 -1.587 0 C-N-CA 122.738 2.292 . . . . 0.0 112.48 178.041 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . 0.404 ' HG3' ' CE1' ' A' ' 247' ' ' PHE . 75.2 mmtt -45.43 109.12 0.15 Allowed 'General case' 0 C--O 1.239 0.505 0 CA-C-N 116.501 -0.318 . . . . 0.0 110.231 -179.242 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 300' ' ' LYS . . . . . 0.43 ' HG3' ' O ' ' A' ' 298' ' ' PRO . 49.6 mttp -124.26 155.71 38.14 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 116.473 -0.33 . . . . 0.0 110.391 177.73 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 301' ' ' ILE . . . . . 0.442 HG23 HD13 ' A' ' 301' ' ' ILE . 41.7 mm -67.12 131.32 32.82 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 176.499 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 73.2 m -155.37 162.17 40.87 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-O 120.778 0.323 . . . . 0.0 111.123 -175.345 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -132.29 152.14 51.51 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 -179.753 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -68.15 141.72 55.96 Favored 'General case' 0 C--N 1.321 -0.646 0 C-N-CA 120.995 -0.282 . . . . 0.0 110.294 -177.249 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -69.86 95.45 0.92 Allowed 'General case' 0 N--CA 1.445 -0.705 0 CA-C-O 120.978 0.418 . . . . 0.0 110.028 179.25 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 6.7 mp -96.87 166.35 14.11 Favored Pre-proline 0 C--N 1.323 -0.58 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 179.799 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_exo -52.39 -40.8 70.15 Favored 'Trans proline' 0 N--CA 1.495 1.596 0 C-N-CA 121.903 1.735 . . . . 0.0 110.328 178.702 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -94.55 65.05 3.12 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 171.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -63.36 167.77 5.05 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.37 -176.62 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 77.4 mt -66.44 135.32 54.11 Favored 'General case' 0 C--O 1.239 0.516 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 179.759 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 79.2 t -128.04 134.89 64.2 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.239 -178.766 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 90.4 mt-10 . . . . . 0 C--O 1.208 -1.129 0 CA-C-O 118.228 -0.891 . . . . 0.0 110.84 179.224 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . 0.462 ' H1 ' ' CD ' ' A' ' 201' ' ' GLU . 1.8 mp0 . . . . . 0 N--CA 1.473 0.705 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 80.3 m-85 -92.43 81.36 4.88 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 178.562 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -78.6 -1.34 82.64 Favored Glycine 0 C--N 1.319 -0.416 0 N-CA-C 110.821 -0.912 . . . . 0.0 110.821 -179.226 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -54.56 -24.19 19.93 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.365 0.603 . . . . 0.0 109.605 179.569 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -64.36 -36.69 84.97 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-N 115.272 -0.877 . . . . 0.0 110.523 179.444 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 99.4 mtp -81.26 89.61 6.06 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.035 0.445 . . . . 0.0 111.862 -175.418 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 2.8 t -123.16 90.33 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.875 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 171.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 3.6 mp -97.32 72.45 2.41 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.762 -173.409 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 1.2 m -97.72 8.64 44.33 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 174.269 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 210' ' ' ASP . . . . . 0.474 ' CG ' ' N ' ' A' ' 211' ' ' SER . 13.0 p-10 -58.66 -48.59 80.54 Favored 'General case' 0 CA--C 1.508 -0.653 0 CA-C-N 115.199 -0.909 . . . . 0.0 109.682 179.233 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 211' ' ' SER . . . . . 0.474 ' N ' ' CG ' ' A' ' 210' ' ' ASP . 0.9 OUTLIER -74.22 123.21 24.09 Favored 'General case' 0 N--CA 1.439 -1.023 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.212 -178.765 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 212' ' ' ASN . . . . . 0.402 ' C ' ' H ' ' A' ' 214' ' ' GLU . 65.6 t30 -95.97 107.63 19.92 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.714 -175.83 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 71.73 -39.26 0.63 Allowed Glycine 0 CA--C 1.525 0.661 0 CA-C-N 116.411 -0.358 . . . . 0.0 112.636 178.257 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 214' ' ' GLU . . . . . 0.402 ' H ' ' C ' ' A' ' 212' ' ' ASN . 68.0 mt-10 -132.04 162.37 30.94 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 117.168 0.484 . . . . 0.0 111.977 -179.455 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 2.9 mt-30 -54.15 153.78 8.85 Favored Pre-proline 0 C--N 1.327 -0.379 0 CA-C-N 115.332 -0.849 . . . . 0.0 111.707 -176.789 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 61.8 Cg_endo -75.73 53.6 3.7 Favored 'Trans proline' 0 C--N 1.309 -1.532 0 C-N-CA 122.57 2.18 . . . . 0.0 110.698 175.634 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -47.24 115.7 1.18 Allowed 'General case' 0 C--O 1.234 0.28 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 -178.052 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 24.1 m -133.63 152.46 51.9 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.277 -174.092 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -142.98 156.08 44.8 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 116.037 -0.528 . . . . 0.0 110.559 177.303 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 220' ' ' MET . . . . . 0.504 ' SD ' HD11 ' A' ' 291' ' ' ILE . 1.6 mpp? -75.22 134.57 41.13 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 176.659 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 99.3 t -82.06 128.29 38.85 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.886 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 178.836 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 20.2 m -86.3 -71.59 0.54 Allowed 'General case' 0 N--CA 1.439 -0.993 0 CA-C-N 116.017 -0.538 . . . . 0.0 109.876 178.037 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 8.7 ptm -137.71 149.68 46.69 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.168 174.504 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 224' ' ' VAL . . . . . 0.415 HG12 ' SD ' ' A' ' 256' ' ' MET . 72.4 t -121.74 127.27 75.46 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.993 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 174.748 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 225' ' ' THR . . . . . 0.446 ' O ' HG23 ' A' ' 280' ' ' THR . 11.6 p -77.44 130.72 37.41 Favored 'General case' 0 CA--C 1.512 -0.485 0 C-N-CA 120.399 -0.52 . . . . 0.0 110.382 -179.117 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 226' ' ' LYS . . . . . 0.441 ' NZ ' ' OG ' ' A' ' 281' ' ' SER . 26.7 tptp -81.97 74.5 8.95 Favored 'General case' 0 N--CA 1.441 -0.916 0 N-CA-C 108.728 -0.842 . . . . 0.0 108.728 176.232 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 227' ' ' ASP . . . . . 0.535 ' CG ' ' H ' ' A' ' 228' ' ' ASN . 8.6 t70 -153.65 -173.15 4.47 Favored 'General case' 0 C--O 1.244 0.797 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.599 -176.224 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 228' ' ' ASN . . . . . 0.535 ' H ' ' CG ' ' A' ' 227' ' ' ASP . 0.1 OUTLIER -140.51 125.08 10.85 Favored Pre-proline 0 N--CA 1.452 -0.353 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.2 176.094 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 229' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -69.68 148.31 86.29 Favored 'Cis proline' 0 C--N 1.311 -1.422 0 C-N-CA 123.029 -1.655 . . . . 0.0 109.722 -1.636 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . 0.429 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -71.32 130.38 18.57 Favored Glycine 0 C--N 1.311 -0.839 0 N-CA-C 109.231 -1.548 . . . . 0.0 109.231 -179.719 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.1 p -120.93 131.35 73.18 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.8 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 177.903 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 232' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -130.09 153.13 38.47 Favored 'Isoleucine or valine' 0 C--O 1.249 1.061 0 C-N-CA 119.474 -0.89 . . . . 0.0 111.361 -174.78 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 3.1 m -108.11 140.37 41.4 Favored 'General case' 0 N--CA 1.432 -1.358 0 CA-C-N 114.807 -1.088 . . . . 0.0 108.857 177.832 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 34.6 m -107.28 161.0 15.18 Favored 'General case' 0 C--N 1.308 -1.227 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 178.422 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 40.1 tp -60.53 127.65 32.76 Favored 'General case' 0 C--N 1.314 -0.978 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 -178.747 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -56.79 -39.89 74.93 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-O 121.242 0.544 . . . . 0.0 110.608 -174.481 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -65.89 -29.63 70.1 Favored 'General case' 0 C--N 1.308 -1.224 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.99 179.602 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -96.96 130.92 44.2 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 112.106 0.41 . . . . 0.0 112.106 -172.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 90.6 mtm-85 -86.3 137.45 32.6 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 174.351 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 240' ' ' HIS . . . . . 0.574 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 8.9 p80 -88.62 -45.18 10.07 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 121.073 0.463 . . . . 0.0 109.832 175.699 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 83.25 12.15 79.41 Favored Glycine 0 C--O 1.239 0.436 0 N-CA-C 110.719 -0.952 . . . . 0.0 110.719 178.539 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 242' ' ' PHE . . . . . 0.489 ' CD1' ' HB3' ' A' ' 294' ' ' GLN . 4.4 m-30 -80.87 145.35 31.4 Favored 'General case' 0 C--N 1.318 -0.781 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 -179.495 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -122.17 168.1 12.39 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.951 -179.158 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 17.7 m -58.84 122.12 12.8 Favored 'General case' 0 C--N 1.313 -1.003 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 179.356 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 78.48 7.02 88.14 Favored Glycine 0 C--N 1.319 -0.394 0 N-CA-C 111.25 -0.74 . . . . 0.0 111.25 179.646 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 40.0 t0 -76.93 162.2 27.78 Favored 'General case' 0 CA--C 1.514 -0.43 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 178.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 247' ' ' PHE . . . . . 0.45 ' HA ' ' O ' ' A' ' 265' ' ' MET . 72.3 m-85 -109.64 137.21 47.79 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.041 0.448 . . . . 0.0 111.511 -177.534 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 2.9 m -133.47 162.02 40.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.308 178.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 67.1 m -125.89 151.48 46.85 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 172.692 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 250' ' ' PHE . . . . . 0.562 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 88.3 m-85 -107.37 149.58 27.7 Favored 'General case' 0 C--N 1.308 -1.207 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.218 -175.552 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 7.3 p -146.92 156.8 43.36 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.231 179.424 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 87.0 mt-10 45.8 26.8 0.4 Allowed 'General case' 0 C--N 1.316 -0.849 0 N-CA-C 112.914 0.709 . . . . 0.0 112.914 177.767 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . 0.505 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 52.5 t -83.32 132.78 30.59 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.415 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 174.921 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 93.8 mm-40 -98.52 137.23 37.49 Favored 'General case' 0 C--N 1.317 -0.833 0 C-N-CA 120.043 -0.663 . . . . 0.0 110.036 -179.254 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 83.38 -57.28 5.07 Favored Glycine 0 C--N 1.317 -0.514 0 N-CA-C 110.899 -0.881 . . . . 0.0 110.899 -177.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 256' ' ' MET . . . . . 0.415 ' SD ' HG12 ' A' ' 224' ' ' VAL . 4.4 ttm -78.29 63.11 3.11 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.632 0.729 . . . . 0.0 109.388 178.747 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 48.6 pt -69.76 -25.59 28.72 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 114.853 -1.067 . . . . 0.0 111.39 -174.748 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 258' ' ' GLN . . . . . 0.475 ' HG3' ' SG ' ' A' ' 262' ' ' CYS . 60.9 tp60 -58.93 -40.6 85.07 Favored 'General case' 0 CA--C 1.509 -0.608 0 C-N-CA 120.343 -0.543 . . . . 0.0 110.085 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 259' ' ' LEU . . . . . 0.562 ' HB3' ' CG ' ' A' ' 250' ' ' PHE . 96.0 mt -62.51 -42.28 99.4 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.981 -0.554 . . . . 0.0 109.554 179.009 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 260' ' ' ASN . . . . . 0.505 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 99.0 m-20 -60.23 -40.44 90.22 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.079 -178.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -92.19 -5.12 65.98 Favored Glycine 0 CA--C 1.523 0.557 0 C-N-CA 121.268 -0.491 . . . . 0.0 111.904 -178.238 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 262' ' ' CYS . . . . . 0.475 ' SG ' ' HG3' ' A' ' 258' ' ' GLN . 1.1 m -78.19 154.6 30.98 Favored 'General case' 0 C--N 1.326 -0.456 0 C-N-CA 120.363 -0.535 . . . . 0.0 111.614 -176.207 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . 0.505 ' N ' ' CD ' ' A' ' 263' ' ' GLN . 0.0 OUTLIER -67.9 170.72 6.67 Favored Pre-proline 0 C--N 1.322 -0.623 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 172.93 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -63.92 142.99 84.22 Favored 'Trans proline' 0 C--N 1.311 -1.436 0 N-CA-C 109.452 -1.018 . . . . 0.0 109.452 177.555 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 265' ' ' MET . . . . . 0.45 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 17.1 ptp -130.97 153.97 48.64 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 112.254 0.464 . . . . 0.0 112.254 -173.982 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -71.83 137.54 47.63 Favored 'General case' 0 C--O 1.236 0.383 0 O-C-N 124.133 0.896 . . . . 0.0 109.919 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 267' ' ' ILE . . . . . 0.415 ' C ' ' CD1' ' A' ' 267' ' ' ILE . 1.8 pp -128.47 162.5 34.99 Favored 'Isoleucine or valine' 0 C--O 1.244 0.771 0 CA-C-O 121.085 0.469 . . . . 0.0 112.106 -179.035 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 61.4 mttm -122.6 126.5 47.82 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.522 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 13.0 m -84.92 123.69 39.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 C-N-CA 120.644 -0.422 . . . . 0.0 111.477 -179.567 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 90.0 mt -102.86 -12.01 17.86 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.588 178.334 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -171.81 -177.77 41.67 Favored Glycine 0 C--N 1.318 -0.463 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.109 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 272' ' ' PRO . . . . . 0.574 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 29.8 Cg_endo -60.37 -34.1 93.67 Favored 'Trans proline' 0 C--N 1.306 -1.677 0 C-N-CA 122.091 1.861 . . . . 0.0 111.7 -179.785 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 73.1 m-85 -125.59 10.04 7.8 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.172 -179.722 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -120.7 128.5 53.01 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 116.486 -0.324 . . . . 0.0 110.51 -173.167 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 275' ' ' PHE . . . . . 0.518 ' C ' ' CD1' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -141.54 166.25 25.28 Favored 'General case' 0 CA--C 1.508 -0.659 0 N-CA-C 112.597 0.592 . . . . 0.0 112.597 178.748 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 276' ' ' SER . . . . . 0.429 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 7.8 p -133.66 146.92 51.32 Favored 'General case' 0 N--CA 1.44 -0.952 0 CA-C-O 121.182 0.515 . . . . 0.0 111.276 -179.73 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 28.9 pt -139.79 164.1 23.98 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.005 0 CA-C-N 114.518 -1.219 . . . . 0.0 111.511 -173.174 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -23.99 -92.76 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.574 0 N-CA-C 113.603 0.964 . . . . 0.0 113.603 -176.71 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 66.8 t0 -151.34 121.75 7.35 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 -177.597 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 280' ' ' THR . . . . . 0.668 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 23.7 p -65.04 -30.12 71.07 Favored 'General case' 0 C--N 1.293 -1.882 0 CA-C-O 120.982 0.42 . . . . 0.0 111.095 177.01 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 281' ' ' SER . . . . . 0.441 ' OG ' ' NZ ' ' A' ' 226' ' ' LYS . 15.7 m -70.39 -14.59 62.62 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.017 174.132 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 60.4 t30 -89.22 -5.71 57.44 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.872 174.395 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . 0.668 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 12.4 m-85 -102.89 -73.86 0.65 Allowed 'General case' 0 CA--C 1.511 -0.521 0 CA-C-O 121.594 0.711 . . . . 0.0 109.79 175.057 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 284' ' ' SER . . . . . 0.5 ' HG ' ' C ' ' A' ' 283' ' ' PHE . 0.0 OUTLIER 172.48 -166.36 0.02 OUTLIER 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 114.02 -1.446 . . . . 0.0 107.827 -171.895 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -97.06 146.4 25.05 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 117.907 0.322 . . . . 0.0 111.115 178.068 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 10.8 t80 -86.54 123.17 31.44 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.006 -179.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 287' ' ' ILE . . . . . 0.496 ' O ' ' HG3' ' A' ' 288' ' ' ARG . 21.4 mm -100.51 -73.66 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -0.981 0 CA-C-N 116.501 -0.318 . . . . 0.0 110.265 176.906 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . 0.496 ' HG3' ' O ' ' A' ' 287' ' ' ILE . 92.1 mtt-85 -164.61 178.43 7.33 Favored 'General case' 0 C--O 1.242 0.663 0 C-N-CA 124.112 0.965 . . . . 0.0 110.409 179.265 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 68.63 -158.14 52.78 Favored Glycine 0 CA--C 1.505 -0.536 0 N-CA-C 110.319 -1.113 . . . . 0.0 110.319 177.078 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 108.31 113.57 3.69 Favored Glycine 0 N--CA 1.439 -1.158 0 C-N-CA 120.769 -0.729 . . . . 0.0 111.946 177.715 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . 0.504 HD11 ' SD ' ' A' ' 220' ' ' MET . 43.5 mm -112.96 128.71 69.55 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.477 0 N-CA-C 105.899 -1.889 . . . . 0.0 105.899 172.352 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 3.5 p -118.9 134.45 62.51 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.039 0 C-N-CA 120.253 -0.579 . . . . 0.0 109.657 -177.694 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 15.2 m -125.21 144.48 50.43 Favored 'General case' 0 CA--C 1.508 -0.65 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.91 -176.504 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 294' ' ' GLN . . . . . 0.489 ' HB3' ' CD1' ' A' ' 242' ' ' PHE . 3.4 pt20 -77.76 151.48 34.05 Favored 'General case' 0 CA--C 1.502 -0.873 0 C-N-CA 120.205 -0.598 . . . . 0.0 110.745 179.159 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . 0.422 ' O ' ' HB2' ' A' ' 247' ' ' PHE . 76.8 t -130.66 130.7 64.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.563 0 N-CA-C 108.315 -0.994 . . . . 0.0 108.315 175.841 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 296' ' ' LYS . . . . . 0.452 ' NZ ' ' OE1' ' A' ' 294' ' ' GLN . 27.0 mmtp -103.86 105.87 16.2 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 120.071 -0.652 . . . . 0.0 109.429 177.015 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 297' ' ' VAL . . . . . 0.573 ' O ' ' N ' ' A' ' 299' ' ' LYS . 34.5 m -55.21 -175.65 0.04 OUTLIER Pre-proline 0 CA--C 1.54 0.591 0 CA-C-N 115.082 -0.963 . . . . 0.0 108.68 177.963 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 298' ' ' PRO . . . . . 0.538 ' CD ' ' HB ' ' A' ' 297' ' ' VAL . 87.0 Cg_exo -48.2 84.83 0.02 OUTLIER 'Trans proline' 0 N--CA 1.493 1.444 0 C-N-CA 121.201 1.267 . . . . 0.0 111.095 -178.09 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . 0.573 ' N ' ' O ' ' A' ' 297' ' ' VAL . 43.9 tttp -109.94 137.76 47.26 Favored 'General case' 0 CA--C 1.502 -0.868 0 CA-C-N 115.474 -0.785 . . . . 0.0 111.786 -175.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 24.3 mmtp -83.74 135.23 34.63 Favored 'General case' 0 N--CA 1.433 -1.287 0 N-CA-C 106.94 -1.504 . . . . 0.0 106.94 171.34 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 47.6 pt -74.89 -177.13 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.908 0 C-N-CA 120.357 -0.537 . . . . 0.0 109.867 -177.264 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 17.6 m -74.62 151.75 39.31 Favored 'General case' 0 C--N 1.316 -0.863 0 C-N-CA 120.318 -0.553 . . . . 0.0 109.862 178.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -125.77 154.46 42.52 Favored 'General case' 0 C--N 1.315 -0.897 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 179.477 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -65.14 140.03 58.74 Favored 'General case' 0 C--N 1.313 -0.997 0 N-CA-C 108.752 -0.832 . . . . 0.0 108.752 179.715 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 2.6 m -62.0 142.88 57.24 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.927 -173.646 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 306' ' ' LEU . . . . . 0.52 ' O ' ' N ' ' A' ' 308' ' ' ALA . 0.9 OUTLIER -59.1 178.31 0.23 Allowed Pre-proline 0 C--O 1.239 0.546 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.499 177.793 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . 0.473 ' CD ' ' HB2' ' A' ' 306' ' ' LEU . 24.1 Cg_exo -61.27 41.94 0.07 OUTLIER 'Trans proline' 0 N--CA 1.499 1.831 0 C-N-CA 122.391 2.061 . . . . 0.0 112.509 177.931 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . 0.52 ' N ' ' O ' ' A' ' 306' ' ' LEU . . . -82.08 -174.5 5.12 Favored 'General case' 0 C--O 1.24 0.59 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 175.122 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 3.8 m -56.22 131.44 47.91 Favored 'General case' 0 C--N 1.319 -0.719 0 C-N-CA 120.228 -0.589 . . . . 0.0 109.605 179.155 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 94.2 mt -75.66 148.98 38.27 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 109.276 -0.639 . . . . 0.0 109.276 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 2.7 m -114.84 128.91 71.77 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 CA-C-O 120.624 0.249 . . . . 0.0 111.333 -178.458 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 67.0 mt-10 . . . . . 0 C--O 1.204 -1.303 0 CA-C-O 118.462 -0.78 . . . . 0.0 111.747 179.296 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . 0.443 ' O ' ' HG3' ' A' ' 205' ' ' GLU . 65.2 mm-40 . . . . . 0 N--CA 1.476 0.854 0 N-CA-C 108.525 -0.916 . . . . 0.0 108.525 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 202' ' ' PHE . . . . . 0.479 ' CG ' ' N ' ' A' ' 203' ' ' GLY . 28.1 p90 -53.87 -46.71 71.38 Favored 'General case' 0 CA--C 1.513 -0.459 0 CA-C-N 115.955 -0.566 . . . . 0.0 112.084 -172.215 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . 0.479 ' N ' ' CG ' ' A' ' 202' ' ' PHE . . . -57.1 -47.76 85.02 Favored Glycine 0 C--N 1.318 -0.439 0 C-N-CA 119.837 -1.173 . . . . 0.0 110.357 -177.733 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 204' ' ' GLU . . . . . 0.426 ' OE1' ' N ' ' A' ' 204' ' ' GLU . 55.2 mp0 -66.39 -43.22 86.45 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 121.126 0.488 . . . . 0.0 110.208 177.35 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 205' ' ' GLU . . . . . 0.443 ' HG3' ' O ' ' A' ' 201' ' ' GLU . 83.1 mt-10 -66.43 -38.07 86.6 Favored 'General case' 0 C--O 1.241 0.633 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.708 -178.644 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 206' ' ' MET . . . . . 0.431 ' N ' ' O ' ' A' ' 202' ' ' PHE . 21.5 mmt -65.37 72.56 0.05 OUTLIER 'General case' 0 C--O 1.238 0.449 0 CA-C-O 121.383 0.611 . . . . 0.0 111.518 -178.261 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . 0.439 ' N ' ' O ' ' A' ' 205' ' ' GLU . 16.4 m -137.78 161.33 33.28 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.009 0 CA-C-N 114.902 -1.045 . . . . 0.0 109.051 173.723 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 69.8 mt -92.4 125.17 36.93 Favored 'General case' 0 C--N 1.316 -0.881 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 178.301 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 209' ' ' THR . . . . . 0.445 HG22 ' N ' ' A' ' 210' ' ' ASP . 15.3 t -88.38 -57.44 2.92 Favored 'General case' 0 C--O 1.24 0.604 0 C-N-CA 120.332 -0.547 . . . . 0.0 111.379 -175.861 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 210' ' ' ASP . . . . . 0.445 ' N ' HG22 ' A' ' 209' ' ' THR . 3.7 p-10 -74.85 -41.85 59.07 Favored 'General case' 0 CA--C 1.515 -0.402 0 C-N-CA 120.229 -0.589 . . . . 0.0 110.38 178.908 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -68.71 92.4 0.48 Allowed 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.817 -178.598 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 40.3 t-20 -97.53 128.91 44.65 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.309 -0.86 . . . . 0.0 109.717 179.82 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 70.72 33.1 66.73 Favored Glycine 0 N--CA 1.452 -0.264 0 N-CA-C 110.658 -0.977 . . . . 0.0 110.658 -176.721 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 2.7 mm-40 -110.23 152.87 25.57 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 121.014 0.435 . . . . 0.0 110.779 179.376 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 2.7 mp0 -74.38 150.24 87.09 Favored Pre-proline 0 C--N 1.313 -1.005 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.265 -178.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -60.24 147.49 93.41 Favored 'Trans proline' 0 C--N 1.307 -1.655 0 C-N-CA 122.264 1.976 . . . . 0.0 109.912 173.62 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -47.01 123.38 5.22 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 -178.607 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 218' ' ' SER . . . . . 0.604 ' CB ' ' HG ' ' A' ' 293' ' ' SER . 45.9 m -132.46 148.6 52.4 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.692 -174.574 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -143.08 157.11 44.83 Favored 'General case' 0 CA--C 1.51 -0.573 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.884 178.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 66.2 mtt -75.18 144.2 42.83 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 115.736 -0.666 . . . . 0.0 109.61 176.503 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 95.7 t -85.38 129.32 38.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.35 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 25.3 p -94.44 -55.14 3.26 Favored 'General case' 0 N--CA 1.439 -0.979 0 CA-C-O 120.867 0.365 . . . . 0.0 110.218 -178.164 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -137.46 149.39 46.81 Favored 'General case' 0 C--O 1.219 -0.551 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.599 177.573 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 224' ' ' VAL . . . . . 0.447 ' HB ' ' CD1' ' A' ' 286' ' ' TYR . 43.2 t -124.96 133.2 70.09 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.828 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 172.667 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -103.88 116.88 33.08 Favored 'General case' 0 C--N 1.31 -1.141 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 -178.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 226' ' ' LYS . . . . . 0.433 ' HA ' ' OG1' ' A' ' 280' ' ' THR . 88.1 tttt -78.55 90.38 4.51 Favored 'General case' 0 CA--C 1.505 -0.776 0 C-N-CA 119.296 -0.962 . . . . 0.0 110.044 -177.924 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 227' ' ' ASP . . . . . 0.544 ' N ' ' OG1' ' A' ' 280' ' ' THR . 43.9 t0 -159.5 179.85 8.55 Favored 'General case' 0 C--N 1.307 -1.241 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.03 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 228' ' ' ASN . . . . . 0.464 ' H ' ' CG ' ' A' ' 227' ' ' ASP . 1.8 p30 -132.99 125.5 19.15 Favored Pre-proline 0 C--N 1.324 -0.523 0 CA-C-N 115.878 -0.601 . . . . 0.0 109.912 175.982 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 229' ' ' PRO . . . . . 0.44 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 46.4 Cg_endo -66.32 145.12 69.42 Favored 'Cis proline' 0 N--CA 1.491 1.349 0 C-N-CA 123.204 -1.582 . . . . 0.0 110.641 -0.68 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -68.01 132.86 28.77 Favored Glycine 0 N--CA 1.452 -0.234 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.169 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.9 p -128.26 136.12 60.91 Favored 'Isoleucine or valine' 0 C--O 1.241 0.629 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 178.35 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 232' ' ' VAL . . . . . 0.421 ' HB ' ' HA ' ' A' ' 224' ' ' VAL . 0.6 OUTLIER -134.85 156.01 39.21 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.047 0 C-N-CA 120.164 -0.614 . . . . 0.0 110.493 -179.422 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 21.7 m -104.65 144.78 31.25 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 115.413 -0.812 . . . . 0.0 109.106 176.11 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 2.4 m -106.1 159.51 16.02 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 177.484 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 43.1 tp -57.85 127.24 31.07 Favored 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 -178.469 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 236' ' ' ASP . . . . . 0.402 ' O ' ' CZ ' ' A' ' 273' ' ' TYR . 7.5 m-20 -62.46 -37.91 87.75 Favored 'General case' 0 CA--C 1.512 -0.497 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.19 -172.279 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 57.9 mp0 -69.67 -19.5 63.59 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.659 177.734 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -108.78 99.94 9.23 Favored 'General case' 0 C--O 1.238 0.479 0 N-CA-C 112.102 0.408 . . . . 0.0 112.102 -177.197 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -70.57 117.4 12.05 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 173.342 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 240' ' ' HIS . . . . . 0.606 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 6.6 p80 -66.54 -45.71 78.49 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.681 -179.504 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 82.31 21.43 60.55 Favored Glycine 0 C--N 1.315 -0.62 0 N-CA-C 110.775 -0.93 . . . . 0.0 110.775 -178.275 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 242' ' ' PHE . . . . . 0.421 ' CE1' ' HB2' ' A' ' 240' ' ' HIS . 7.5 m-30 -83.74 156.02 22.79 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 120.69 0.281 . . . . 0.0 110.339 179.629 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 -124.3 165.08 18.29 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.545 174.821 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -69.61 126.44 29.74 Favored 'General case' 0 C--N 1.319 -0.76 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 177.374 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 90.43 2.38 73.43 Favored Glycine 0 C--N 1.317 -0.513 0 N-CA-C 110.476 -1.05 . . . . 0.0 110.476 -176.422 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 246' ' ' ASP . . . . . 0.462 ' O ' HG12 ' A' ' 267' ' ' ILE . 46.3 t0 -77.8 163.86 25.72 Favored 'General case' 0 C--O 1.237 0.445 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 176.427 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 247' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -115.84 128.85 56.13 Favored 'General case' 0 C--O 1.241 0.637 0 O-C-N 123.287 0.367 . . . . 0.0 110.661 -178.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . 0.411 ' O ' ' SD ' ' A' ' 265' ' ' MET . 2.4 m -132.4 164.58 34.56 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.308 0 C-N-CA 120.223 -0.591 . . . . 0.0 111.905 178.287 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 31.4 m -130.66 153.0 49.41 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.179 172.56 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 250' ' ' PHE . . . . . 0.546 ' CB ' ' HB3' ' A' ' 259' ' ' LEU . 61.3 m-85 -103.14 146.58 28.18 Favored 'General case' 0 C--N 1.322 -0.616 0 C-N-CA 122.729 0.411 . . . . 0.0 110.327 -178.912 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 2.5 m -143.74 153.06 42.04 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.417 176.715 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 49.42 37.51 12.09 Favored 'General case' 0 C--O 1.245 0.865 0 N-CA-C 113.044 0.757 . . . . 0.0 113.044 175.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 78.7 t -90.37 132.38 35.13 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 175.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 86.8 mt-30 -88.08 140.56 29.36 Favored 'General case' 0 C--O 1.242 0.709 0 C-N-CA 120.411 -0.516 . . . . 0.0 110.068 177.487 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 80.06 -63.82 4.03 Favored Glycine 0 C--N 1.314 -0.691 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 179.174 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 256' ' ' MET . . . . . 0.464 ' N ' ' O ' ' A' ' 285' ' ' ASP . 20.9 ttm -84.69 71.76 10.78 Favored 'General case' 0 CA--C 1.504 -0.804 0 C-N-CA 119.853 -0.739 . . . . 0.0 109.377 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 45.0 pt -80.35 -15.3 12.91 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 CA-C-N 115.005 -0.998 . . . . 0.0 110.144 -177.756 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 258' ' ' GLN . . . . . 0.504 ' O ' ' SG ' ' A' ' 262' ' ' CYS . 63.3 tp60 -57.53 -39.13 75.92 Favored 'General case' 0 N--CA 1.437 -1.11 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 177.643 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 259' ' ' LEU . . . . . 0.546 ' HB3' ' CB ' ' A' ' 250' ' ' PHE . 88.1 mt -62.78 -40.67 98.01 Favored 'General case' 0 N--CA 1.449 -0.508 0 CA-C-N 115.113 -0.949 . . . . 0.0 110.222 175.001 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -60.04 -40.63 90.06 Favored 'General case' 0 C--O 1.241 0.607 0 N-CA-C 109.306 -0.628 . . . . 0.0 109.306 -179.577 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -101.18 23.2 36.25 Favored Glycine 0 CA--C 1.526 0.736 0 N-CA-C 111.246 -0.741 . . . . 0.0 111.246 -179.178 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 262' ' ' CYS . . . . . 0.504 ' SG ' ' O ' ' A' ' 258' ' ' GLN . 1.3 m -96.68 147.34 24.01 Favored 'General case' 0 C--O 1.239 0.51 0 CA-C-N 117.362 0.581 . . . . 0.0 112.382 -177.708 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 5.3 mt-30 -61.93 154.34 68.62 Favored Pre-proline 0 C--N 1.324 -0.518 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 170.699 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -64.4 145.06 87.4 Favored 'Trans proline' 0 C--N 1.304 -1.806 0 C-N-CA 121.08 1.187 . . . . 0.0 109.868 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 265' ' ' MET . . . . . 0.554 ' SD ' ' N ' ' A' ' 265' ' ' MET . 0.2 OUTLIER -122.8 148.8 44.96 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 112.405 0.52 . . . . 0.0 112.405 -174.237 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 75.8 tt0 -77.97 134.3 37.87 Favored 'General case' 0 C--O 1.242 0.662 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 174.355 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 267' ' ' ILE . . . . . 0.462 HG12 ' O ' ' A' ' 246' ' ' ASP . 49.5 pt -125.26 159.64 32.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 N-CA-C 114.023 1.12 . . . . 0.0 114.023 -166.342 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 66.5 mttm -120.55 106.59 11.93 Favored 'General case' 0 CA--C 1.537 0.459 0 CA-C-N 115.154 -0.93 . . . . 0.0 110.021 177.325 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 17.3 m -80.24 102.31 6.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 120.999 0.428 . . . . 0.0 110.516 178.452 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 96.1 mt -66.3 -41.27 89.99 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.964 -179.707 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -149.16 -172.09 18.49 Favored Glycine 0 C--N 1.318 -0.458 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -177.383 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 272' ' ' PRO . . . . . 0.606 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 37.9 Cg_endo -62.98 -33.93 72.68 Favored 'Trans proline' 0 C--N 1.308 -1.57 0 C-N-CA 121.827 1.685 . . . . 0.0 111.369 -178.024 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 273' ' ' TYR . . . . . 0.402 ' CZ ' ' O ' ' A' ' 236' ' ' ASP . 83.3 m-85 -122.54 8.44 9.55 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 112.818 0.673 . . . . 0.0 112.818 -177.968 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 2.8 p -120.88 128.05 52.44 Favored 'General case' 0 C--O 1.243 0.747 0 CA-C-O 120.605 0.24 . . . . 0.0 110.865 178.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 275' ' ' PHE . . . . . 0.561 ' C ' ' CD1' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -138.25 159.44 42.04 Favored 'General case' 0 CA--C 1.507 -0.697 0 C-N-CA 120.671 -0.411 . . . . 0.0 111.658 177.667 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 7.9 p -137.79 154.29 49.58 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.521 -173.388 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -141.72 -155.04 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.912 0 CA-C-N 115.428 -0.805 . . . . 0.0 110.106 -173.087 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 1.1 p -60.04 -89.03 0.0 OUTLIER 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 116.499 -0.318 . . . . 0.0 111.306 178.338 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . 0.503 ' HB3' HD21 ' A' ' 282' ' ' ASN . 66.0 t0 -151.7 118.98 5.94 Favored 'General case' 0 N--CA 1.447 -0.611 0 CA-C-O 120.825 0.345 . . . . 0.0 111.421 -176.736 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 280' ' ' THR . . . . . 0.633 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 11.1 p -64.34 -30.34 71.39 Favored 'General case' 0 C--N 1.299 -1.626 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.101 175.095 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -61.73 -21.05 64.17 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.449 175.852 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 282' ' ' ASN . . . . . 0.503 HD21 ' HB3' ' A' ' 279' ' ' ASP . 40.1 m-80 -93.94 -3.83 50.9 Favored 'General case' 0 N--CA 1.451 -0.419 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.023 176.847 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . 0.633 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 22.8 m-85 -91.84 -80.72 0.35 Allowed 'General case' 0 CA--C 1.512 -0.508 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 171.674 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 3.9 p 179.25 -109.85 0.0 OUTLIER 'General case' 0 N--CA 1.453 -0.305 0 CA-C-N 115.193 -0.912 . . . . 0.0 109.675 173.463 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 285' ' ' ASP . . . . . 0.464 ' O ' ' N ' ' A' ' 256' ' ' MET . 2.1 p-10 -145.49 163.37 34.9 Favored 'General case' 0 C--O 1.219 -0.514 0 N-CA-C 107.667 -1.234 . . . . 0.0 107.667 174.114 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . 0.447 ' CD1' ' HB ' ' A' ' 224' ' ' VAL . 1.1 p90 -123.95 145.51 49.11 Favored 'General case' 0 N--CA 1.468 0.442 0 C-N-CA 119.663 -0.815 . . . . 0.0 111.495 -178.046 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 96.9 mt -100.77 -57.68 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 176.781 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 32.2 ptt-85 -176.17 -169.3 0.31 Allowed 'General case' 0 C--O 1.242 0.688 0 CA-C-N 115.447 -0.797 . . . . 0.0 109.979 177.584 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 67.32 -153.47 52.9 Favored Glycine 0 CA--C 1.502 -0.779 0 N-CA-C 110.944 -0.863 . . . . 0.0 110.944 175.837 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 93.51 136.49 7.96 Favored Glycine 0 N--CA 1.442 -0.958 0 N-CA-C 111.778 -0.529 . . . . 0.0 111.778 176.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . 0.436 HD13 HG21 ' A' ' 291' ' ' ILE . 92.2 mt -122.87 129.38 75.17 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 173.756 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 3.8 p -112.21 129.72 67.19 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 178.855 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 293' ' ' SER . . . . . 0.604 ' HG ' ' CB ' ' A' ' 218' ' ' SER . 55.7 m -126.9 147.88 50.05 Favored 'General case' 0 CA--C 1.5 -0.972 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.371 -174.495 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 85.0 mt-30 -63.85 164.03 10.86 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 171.804 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 60.7 t -127.24 111.68 26.12 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 176.763 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 8.0 tmtm? -75.69 97.88 3.93 Favored 'General case' 0 N--CA 1.443 -0.811 0 C-N-CA 118.803 -1.159 . . . . 0.0 108.859 177.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 35.7 m -56.54 134.97 77.29 Favored Pre-proline 0 C--O 1.245 0.849 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 178.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_exo -54.4 -43.34 59.62 Favored 'Trans proline' 0 N--CA 1.489 1.225 0 C-N-CA 121.226 1.284 . . . . 0.0 108.969 177.665 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 19.5 tptm -137.86 133.61 34.1 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 114.714 -1.13 . . . . 0.0 109.15 171.807 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 300' ' ' LYS . . . . . 0.57 ' NZ ' ' OG ' ' A' ' 302' ' ' SER . 1.1 ttpm? -89.25 111.39 22.18 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 177.808 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 37.8 pt -70.43 137.55 23.72 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.961 0 C-N-CA 120.636 -0.425 . . . . 0.0 110.544 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 302' ' ' SER . . . . . 0.57 ' OG ' ' NZ ' ' A' ' 300' ' ' LYS . 1.5 m -122.85 149.94 43.52 Favored 'General case' 0 C--O 1.242 0.675 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.8 -178.179 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 21.2 t80 -149.08 149.41 31.04 Favored 'General case' 0 C--N 1.32 -0.685 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 177.429 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 67.5 mttm -107.44 152.85 23.64 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.345 178.838 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 305' ' ' SER . . . . . 0.459 ' O ' ' C ' ' A' ' 306' ' ' LEU . 8.9 m -63.94 143.27 57.99 Favored 'General case' 0 C--N 1.315 -0.894 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 176.798 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 306' ' ' LEU . . . . . 0.459 ' C ' ' O ' ' A' ' 305' ' ' SER . 1.3 mp -30.77 106.94 0.24 Allowed Pre-proline 0 C--O 1.234 0.27 0 O-C-N 123.373 0.421 . . . . 0.0 111.171 -175.883 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_exo -59.0 143.18 99.92 Favored 'Trans proline' 0 C--N 1.311 -1.422 0 C-N-CA 122.114 1.876 . . . . 0.0 110.416 -178.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -70.25 149.43 47.46 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.861 -178.743 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 1.3 m -68.61 95.39 0.64 Allowed 'General case' 0 C--O 1.24 0.585 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 176.046 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 3.1 pp -112.64 145.51 40.29 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 112.935 0.717 . . . . 0.0 112.935 -171.303 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 6.3 m -131.81 132.02 61.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 115.098 -0.955 . . . . 0.0 109.12 175.341 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 36.2 mt-10 . . . . . 0 C--O 1.204 -1.336 0 CA-C-O 118.52 -0.752 . . . . 0.0 110.196 -176.189 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 . . . . . 0 N--CA 1.487 1.423 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 93.8 m-85 -70.92 137.71 49.48 Favored 'General case' 0 C--O 1.239 0.549 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 -179.147 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -115.81 44.61 1.44 Allowed Glycine 0 C--N 1.32 -0.345 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 -179.53 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 75.1 mm-40 -71.82 -44.11 64.46 Favored 'General case' 0 C--N 1.319 -0.734 0 C-N-CA 120.232 -0.587 . . . . 0.0 111.538 -178.572 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -72.9 -42.82 63.16 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.496 -0.482 . . . . 0.0 110.871 175.683 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 95.3 mtp -115.79 125.72 53.1 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 108.998 -0.742 . . . . 0.0 108.998 178.835 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 22.8 m -110.61 132.26 59.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-O 121.093 0.473 . . . . 0.0 111.1 178.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 85.1 mt -88.36 85.02 6.81 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.887 -176.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 44.9 p -132.87 -73.03 0.51 Allowed 'General case' 0 C--N 1.316 -0.871 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 176.74 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -121.26 -24.18 5.54 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-N 114.644 -1.162 . . . . 0.0 109.209 174.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -56.72 127.85 33.58 Favored 'General case' 0 N--CA 1.442 -0.86 0 CA-C-N 115.128 -0.942 . . . . 0.0 111.801 -176.254 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 212' ' ' ASN . . . . . 0.49 ' H ' ' CD ' ' A' ' 214' ' ' GLU . 0.5 OUTLIER -114.35 84.46 2.05 Favored 'General case' 0 C--O 1.24 0.558 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.694 173.531 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 47.94 34.95 12.22 Favored Glycine 0 CA--C 1.525 0.659 0 CA-C-N 116.358 -0.383 . . . . 0.0 112.698 174.448 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 214' ' ' GLU . . . . . 0.49 ' CD ' ' H ' ' A' ' 212' ' ' ASN . 58.7 mp0 -59.17 132.94 55.53 Favored 'General case' 0 C--O 1.242 0.685 0 CA-C-N 117.37 0.585 . . . . 0.0 112.149 -178.186 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 5.2 mt-30 -112.47 156.7 41.87 Favored Pre-proline 0 C--N 1.32 -0.7 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 168.355 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -55.73 132.79 54.19 Favored 'Trans proline' 0 C--N 1.303 -1.842 0 C-N-CA 121.299 1.333 . . . . 0.0 111.163 -178.043 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 217' ' ' LEU . . . . . 0.468 ' O ' ' HA ' ' A' ' 293' ' ' SER . 0.3 OUTLIER -113.85 126.81 55.6 Favored 'General case' 0 C--N 1.317 -0.816 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 179.405 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 218' ' ' SER . . . . . 0.583 ' CB ' ' HG ' ' A' ' 293' ' ' SER . 50.8 m -114.04 131.88 56.21 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.163 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -131.75 150.74 52.05 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.703 -175.362 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 97.8 mtp -81.02 129.69 34.66 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.163 178.42 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 97.3 t -79.85 133.98 28.54 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.011 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 177.356 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 13.8 p -93.28 -62.0 1.46 Allowed 'General case' 0 N--CA 1.436 -1.151 0 C-N-CA 120.129 -0.628 . . . . 0.0 109.777 -179.358 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -138.06 139.05 39.36 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.946 173.818 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 224' ' ' VAL . . . . . 0.537 HG13 ' SD ' ' A' ' 256' ' ' MET . 59.4 t -117.01 130.79 71.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 174.489 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 62.3 p -88.02 138.9 31.05 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-O 120.826 0.346 . . . . 0.0 110.944 -178.509 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 226' ' ' LYS . . . . . 0.409 ' HE3' ' O ' ' A' ' 284' ' ' SER . 2.6 tptm -78.34 77.66 4.83 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 178.807 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 227' ' ' ASP . . . . . 0.413 ' CG ' ' H ' ' A' ' 228' ' ' ASN . 45.8 t0 -157.0 174.04 16.12 Favored 'General case' 0 N--CA 1.468 0.454 0 N-CA-C 112.249 0.462 . . . . 0.0 112.249 -176.172 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 228' ' ' ASN . . . . . 0.461 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.4 OUTLIER -130.86 125.14 21.16 Favored Pre-proline 0 N--CA 1.451 -0.403 0 CA-C-N 115.382 -0.826 . . . . 0.0 110.244 173.083 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 229' ' ' PRO . . . . . 0.461 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 24.6 Cg_exo -64.86 147.37 70.15 Favored 'Cis proline' 0 C--N 1.31 -1.498 0 C-N-CA 123.611 -1.412 . . . . 0.0 110.059 -2.157 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . 0.451 ' N ' ' O ' ' A' ' 277' ' ' ILE . . . -72.75 100.86 1.03 Allowed Glycine 0 C--N 1.295 -1.704 0 N-CA-C 110.025 -1.23 . . . . 0.0 110.025 -179.732 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 7.1 p -88.51 127.32 41.51 Favored 'Isoleucine or valine' 0 C--O 1.244 0.784 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 177.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 232' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -131.46 156.43 42.64 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.897 0 CA-C-O 121.124 0.488 . . . . 0.0 109.827 -177.503 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -117.69 145.45 44.41 Favored 'General case' 0 N--CA 1.429 -1.489 0 CA-C-N 114.838 -1.074 . . . . 0.0 109.032 179.336 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.8 m -107.0 160.3 15.64 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.095 -177.553 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 24.1 tp -54.82 132.62 46.61 Favored 'General case' 0 C--N 1.314 -0.966 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 178.749 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 236' ' ' ASP . . . . . 0.41 ' O ' ' CE1' ' A' ' 273' ' ' TYR . 28.4 t70 -53.89 -42.82 69.07 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-O 121.341 0.591 . . . . 0.0 111.007 -176.174 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 74.0 mt-10 -65.49 -32.15 73.61 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.32 179.126 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -72.11 135.03 46.1 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.961 0.41 . . . . 0.0 111.896 -176.861 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 66.2 mtp180 -113.13 92.96 4.19 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 175.565 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 240' ' ' HIS . . . . . 0.567 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 7.3 p80 -54.7 -49.12 71.48 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 -173.337 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 79.86 17.57 74.67 Favored Glycine 0 C--N 1.309 -0.964 0 N-CA-C 110.491 -1.044 . . . . 0.0 110.491 -179.21 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 242' ' ' PHE . . . . . 0.457 ' CD1' ' N ' ' A' ' 242' ' ' PHE . 6.5 m-30 -80.4 144.12 32.93 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 -179.11 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 243' ' ' GLU . . . . . 0.406 ' CD ' ' H ' ' A' ' 244' ' ' THR . 0.2 OUTLIER -106.83 164.85 11.77 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.346 0.594 . . . . 0.0 111.364 179.145 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 244' ' ' THR . . . . . 0.406 ' H ' ' CD ' ' A' ' 243' ' ' GLU . 0.3 OUTLIER -65.56 120.8 13.55 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 177.866 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 79.76 7.69 88.3 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 -177.358 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 43.2 t0 -79.51 166.49 21.9 Favored 'General case' 0 C--O 1.233 0.188 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 -179.694 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 247' ' ' PHE . . . . . 0.476 ' HA ' ' O ' ' A' ' 265' ' ' MET . 26.9 m-85 -110.19 133.63 53.04 Favored 'General case' 0 C--O 1.239 0.525 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -176.868 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . 0.434 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 3.0 m -131.89 160.37 42.47 Favored 'Isoleucine or valine' 0 C--O 1.237 0.435 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.472 178.144 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 1.2 m -121.84 161.65 22.34 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 114.907 -1.042 . . . . 0.0 109.171 173.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 250' ' ' PHE . . . . . 0.483 ' CB ' ' HB3' ' A' ' 259' ' ' LEU . 61.0 m-85 -125.88 151.77 46.45 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 110.306 -0.257 . . . . 0.0 110.306 -175.066 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 16.4 m -156.36 163.08 39.91 Favored 'General case' 0 C--O 1.215 -0.719 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 177.032 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 67.3 mm-40 54.4 30.15 12.24 Favored 'General case' 0 C--N 1.316 -0.887 0 N-CA-C 111.746 0.276 . . . . 0.0 111.746 175.419 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 2.9 t -98.96 126.74 52.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 176.758 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 83.2 mt-30 -90.94 138.41 31.62 Favored 'General case' 0 C--O 1.246 0.906 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 178.224 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . 0.421 ' C ' ' H ' ' A' ' 257' ' ' ILE . . . 81.2 -59.0 4.82 Favored Glycine 0 C--O 1.244 0.76 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 -178.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 256' ' ' MET . . . . . 0.537 ' SD ' HG13 ' A' ' 224' ' ' VAL . 3.8 ttm -80.13 49.86 1.16 Allowed 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 121.988 0.899 . . . . 0.0 109.766 178.285 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 257' ' ' ILE . . . . . 0.421 ' H ' ' C ' ' A' ' 255' ' ' GLY . 47.6 pt -67.43 -22.29 28.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 114.262 -1.335 . . . . 0.0 111.116 -176.768 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 258' ' ' GLN . . . . . 0.451 ' O ' ' SG ' ' A' ' 262' ' ' CYS . 63.9 tp60 -57.1 -39.11 74.43 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 179.199 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 259' ' ' LEU . . . . . 0.483 ' HB3' ' CB ' ' A' ' 250' ' ' PHE . 99.2 mt -62.15 -40.8 97.17 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 115.47 -0.786 . . . . 0.0 109.721 178.037 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 -60.27 -40.98 92.28 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 -178.254 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -99.27 17.86 57.32 Favored Glycine 0 CA--C 1.521 0.464 0 N-CA-C 111.55 -0.62 . . . . 0.0 111.55 -179.633 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 262' ' ' CYS . . . . . 0.451 ' SG ' ' O ' ' A' ' 258' ' ' GLN . 1.4 m -94.45 160.39 14.68 Favored 'General case' 0 C--O 1.239 0.512 0 CA-C-N 117.052 0.426 . . . . 0.0 110.455 -179.71 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -82.1 159.72 64.67 Favored Pre-proline 0 C--N 1.318 -0.766 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 172.306 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 264' ' ' PRO . . . . . 0.434 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 24.3 Cg_exo -62.16 143.26 94.29 Favored 'Trans proline' 0 C--N 1.309 -1.538 0 CA-C-N 119.743 0.944 . . . . 0.0 109.949 -179.248 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 265' ' ' MET . . . . . 0.476 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 8.7 ptp -133.57 167.94 19.56 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 112.892 0.701 . . . . 0.0 112.892 -175.088 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 72.2 tt0 -70.1 139.88 52.6 Favored 'General case' 0 C--O 1.243 0.735 0 O-C-N 124.164 0.915 . . . . 0.0 110.177 -179.69 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 267' ' ' ILE . . . . . . . . . . . . . 1.7 pp -129.22 154.35 39.97 Favored 'Isoleucine or valine' 0 C--O 1.243 0.755 0 CA-C-O 121.263 0.554 . . . . 0.0 111.526 178.389 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 66.2 mttm -125.72 109.61 12.79 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.744 -178.052 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 18.8 m -70.39 131.39 34.32 Favored 'Isoleucine or valine' 0 C--O 1.237 0.407 0 CA-C-O 120.681 0.277 . . . . 0.0 111.235 -177.394 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 95.1 mt -109.48 -25.55 10.43 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.582 179.149 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -156.41 -174.79 26.61 Favored Glycine 0 CA--C 1.511 -0.188 0 N-CA-C 110.124 -1.19 . . . . 0.0 110.124 -179.218 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 272' ' ' PRO . . . . . 0.567 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 28.6 Cg_endo -60.24 -39.87 64.41 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 121.844 1.696 . . . . 0.0 111.439 -177.434 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 273' ' ' TYR . . . . . 0.41 ' CE1' ' O ' ' A' ' 236' ' ' ASP . 57.6 m-85 -118.98 9.81 12.0 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.207 178.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -116.01 129.14 56.23 Favored 'General case' 0 C--O 1.241 0.612 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.727 -172.465 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 275' ' ' PHE . . . . . 0.575 ' C ' ' CD1' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -144.24 167.87 21.41 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 111.84 0.311 . . . . 0.0 111.84 179.729 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 276' ' ' SER . . . . . 0.421 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 4.6 p -133.27 142.26 48.42 Favored 'General case' 0 C--N 1.319 -0.728 0 C-N-CA 120.764 -0.374 . . . . 0.0 111.65 -177.353 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . 0.451 ' O ' ' N ' ' A' ' 230' ' ' GLY . 38.0 pt -137.02 163.07 33.25 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-N 115.137 -0.938 . . . . 0.0 111.739 -176.779 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 278' ' ' CYS . . . . . 0.434 ' C ' ' O ' ' A' ' 277' ' ' ILE . 88.1 m -14.98 -92.73 0.0 OUTLIER 'General case' 0 CA--C 1.543 0.703 0 N-CA-C 113.979 1.103 . . . . 0.0 113.979 -177.893 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 67.1 t0 -154.99 114.82 3.75 Favored 'General case' 0 CA--C 1.509 -0.601 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 -179.209 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 280' ' ' THR . . . . . 0.771 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 20.8 p -65.43 -27.79 68.78 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-O 120.99 0.424 . . . . 0.0 110.755 178.488 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -63.08 -23.95 67.68 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-N 115.169 -0.923 . . . . 0.0 109.224 175.526 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 20.4 t-20 -89.14 -9.53 50.65 Favored 'General case' 0 CA--C 1.512 -0.518 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.932 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . 0.771 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 10.2 m-85 -87.05 -64.86 1.08 Allowed 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 172.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 284' ' ' SER . . . . . 0.486 ' OG ' ' HA ' ' A' ' 256' ' ' MET . 2.4 p 170.35 -101.27 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 114.306 -1.316 . . . . 0.0 109.415 176.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 285' ' ' ASP . . . . . 0.47 ' O ' ' N ' ' A' ' 256' ' ' MET . 5.9 t0 -148.92 164.25 35.08 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-O 120.611 0.243 . . . . 0.0 110.793 176.851 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . 0.409 ' N ' ' OD1' ' A' ' 285' ' ' ASP . 83.9 t80 -94.69 114.99 26.99 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 177.387 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 22.2 mm -100.12 -58.73 3.69 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.519 175.012 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 85.5 mtm180 -160.97 167.53 26.34 Favored 'General case' 0 CA--C 1.503 -0.84 0 O-C-N 123.604 0.565 . . . . 0.0 112.352 178.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 51.21 -138.97 26.34 Favored Glycine 0 CA--C 1.504 -0.649 0 CA-C-N 113.339 -1.755 . . . . 0.0 112.556 168.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 100.83 117.32 4.14 Favored Glycine 0 N--CA 1.433 -1.565 0 N-CA-C 110.602 -0.999 . . . . 0.0 110.602 -177.637 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 87.3 mt -108.75 128.06 64.8 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.285 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 175.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 3.3 p -118.85 135.38 59.46 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.035 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 -178.115 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 293' ' ' SER . . . . . 0.583 ' HG ' ' CB ' ' A' ' 218' ' ' SER . 4.7 m -128.9 147.65 50.85 Favored 'General case' 0 N--CA 1.442 -0.856 0 C-N-CA 120.323 -0.551 . . . . 0.0 112.466 -174.426 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 48.1 tt0 -75.74 138.42 41.25 Favored 'General case' 0 N--CA 1.443 -0.823 0 CA-C-N 114.998 -1.001 . . . . 0.0 111.295 177.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 22.8 t -121.63 98.18 5.67 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 N-CA-C 106.99 -1.485 . . . . 0.0 106.99 170.624 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 296' ' ' LYS . . . . . 0.458 ' HD3' ' C ' ' A' ' 296' ' ' LYS . 0.6 OUTLIER -73.05 98.36 2.53 Favored 'General case' 0 N--CA 1.438 -1.057 0 C-N-CA 118.966 -1.094 . . . . 0.0 108.93 -175.932 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 33.1 m -72.8 118.35 67.42 Favored Pre-proline 0 N--CA 1.438 -1.074 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.515 -178.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -59.58 -28.93 88.64 Favored 'Trans proline' 0 N--CA 1.498 1.776 0 C-N-CA 122.125 1.883 . . . . 0.0 109.623 174.04 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 66.5 mttm -54.45 148.97 11.03 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 114.679 -1.146 . . . . 0.0 108.379 179.536 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 63.0 mttp -67.73 132.49 47.55 Favored 'General case' 0 CA--C 1.511 -0.554 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 174.548 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 301' ' ' ILE . . . . . 0.472 ' CD1' ' H ' ' A' ' 301' ' ' ILE . 0.0 OUTLIER -84.18 127.07 40.15 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 C-N-CA 120.354 -0.538 . . . . 0.0 110.965 -177.647 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -79.46 93.44 5.39 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.564 177.658 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 31.2 p90 -144.84 163.99 32.43 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 178.762 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 44.3 mttm -72.83 119.71 17.45 Favored 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 -176.856 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 6.9 m -65.46 141.86 58.36 Favored 'General case' 0 C--N 1.316 -0.87 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 179.182 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 1.9 mp -63.1 136.65 96.78 Favored Pre-proline 0 C--N 1.318 -0.766 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 -177.302 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_exo -56.85 -35.3 98.2 Favored 'Trans proline' 0 N--CA 1.497 1.677 0 C-N-CA 122.179 1.919 . . . . 0.0 110.004 178.533 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -68.18 174.36 3.97 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.08 -0.964 . . . . 0.0 110.195 179.079 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 4.5 m -67.04 138.99 57.59 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 177.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 88.8 mt -78.9 146.83 33.33 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 116.566 -0.288 . . . . 0.0 110.739 -178.019 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 22.6 m -77.96 134.44 28.31 Favored 'Isoleucine or valine' 0 C--O 1.238 0.477 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 172.031 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 91.5 mt-10 . . . . . 0 C--O 1.203 -1.387 0 CA-C-O 118.182 -0.913 . . . . 0.0 111.331 -173.338 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . 0.46 ' H2 ' ' CD ' ' A' ' 201' ' ' GLU . 0.0 OUTLIER . . . . . 0 N--CA 1.475 0.777 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 . . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 -63.38 -42.72 98.84 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.581 -178.463 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -61.07 -40.65 98.82 Favored Glycine 0 C--N 1.317 -0.518 0 N-CA-C 111.374 -0.691 . . . . 0.0 111.374 -176.643 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 204' ' ' GLU . . . . . 0.445 ' CD ' ' H3 ' ' A' ' 201' ' ' GLU . 2.4 mp0 -66.73 2.5 1.34 Allowed 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 112.154 0.427 . . . . 0.0 112.154 -178.268 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 2.8 pp20? -53.83 -18.51 3.35 Favored 'General case' 0 C--O 1.242 0.677 0 CA-C-O 121.215 0.531 . . . . 0.0 109.812 179.102 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 77.2 mtm -59.85 148.37 34.98 Favored 'General case' 0 N--CA 1.444 -0.735 0 CA-C-N 115.172 -0.922 . . . . 0.0 109.824 -179.736 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . 0.416 ' O ' ' N ' ' A' ' 209' ' ' THR . 27.1 m -86.5 175.55 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.147 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 169.809 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 96.7 mt -72.36 72.47 0.95 Allowed 'General case' 0 C--N 1.308 -1.196 0 C-N-CA 118.948 -1.101 . . . . 0.0 110.043 -179.797 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 209' ' ' THR . . . . . 0.416 ' N ' ' O ' ' A' ' 207' ' ' VAL . 0.8 OUTLIER -71.2 -3.1 18.38 Favored 'General case' 0 N--CA 1.447 -0.616 0 CA-C-N 114.928 -1.033 . . . . 0.0 109.293 173.864 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 16.1 t70 -57.73 -43.44 85.31 Favored 'General case' 0 N--CA 1.442 -0.83 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 172.625 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 211' ' ' SER . . . . . 0.446 ' O ' ' C ' ' A' ' 212' ' ' ASN . 0.1 OUTLIER -65.0 91.75 0.1 Allowed 'General case' 0 N--CA 1.441 -0.915 0 N-CA-C 106.249 -1.76 . . . . 0.0 106.249 166.212 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 212' ' ' ASN . . . . . 0.446 ' C ' ' O ' ' A' ' 211' ' ' SER . 24.0 t-20 -29.14 94.81 0.01 OUTLIER 'General case' 0 CA--C 1.516 -0.339 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.844 -168.501 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 213' ' ' GLY . . . . . 0.432 ' C ' ' O ' ' A' ' 212' ' ' ASN . . . 29.76 66.48 0.12 Allowed Glycine 0 C--N 1.337 0.626 0 N-CA-C 111.082 -0.807 . . . . 0.0 111.082 -179.7 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 1.7 pt-20 -41.34 96.42 0.01 OUTLIER 'General case' 0 C--O 1.246 0.883 0 N-CA-C 112.579 0.585 . . . . 0.0 112.579 -172.27 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 215' ' ' GLN . . . . . 0.57 ' HB3' ' CD ' ' A' ' 216' ' ' PRO . 34.2 mm-40 -89.96 179.64 1.47 Allowed Pre-proline 0 C--N 1.321 -0.659 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 171.519 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 216' ' ' PRO . . . . . 0.57 ' CD ' ' HB3' ' A' ' 215' ' ' GLN . 50.4 Cg_exo -56.27 141.42 88.54 Favored 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 121.34 1.36 . . . . 0.0 111.077 -176.085 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 217' ' ' LEU . . . . . 0.418 ' HB3' ' O ' ' A' ' 240' ' ' HIS . 0.5 OUTLIER -80.18 134.98 36.19 Favored 'General case' 0 CA--C 1.506 -0.746 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.661 -176.237 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 67.1 m -124.38 149.13 47.01 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.458 179.044 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -148.31 151.08 34.78 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.181 179.046 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 71.8 mtm -78.92 136.87 37.39 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 116.039 -0.528 . . . . 0.0 109.719 176.761 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 91.5 t -86.11 130.87 35.83 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.148 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -81.82 -71.01 0.5 Allowed 'General case' 0 N--CA 1.435 -1.179 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 178.656 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 223' ' ' MET . . . . . 0.661 ' C ' ' SD ' ' A' ' 223' ' ' MET . 2.1 ppp? -138.43 147.79 43.7 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 112.393 0.516 . . . . 0.0 112.393 173.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 224' ' ' VAL . . . . . 0.43 ' N ' ' SD ' ' A' ' 223' ' ' MET . 55.1 t -122.55 131.76 72.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 176.345 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 49.8 p -87.56 134.67 33.58 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 110.503 -0.184 . . . . 0.0 110.503 179.43 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 226' ' ' LYS . . . . . 0.464 ' HZ3' ' CG ' ' A' ' 285' ' ' ASP . 0.7 OUTLIER -80.42 76.88 7.23 Favored 'General case' 0 C--O 1.239 0.541 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 176.8 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 227' ' ' ASP . . . . . 0.411 ' H ' ' HG1' ' A' ' 280' ' ' THR . 5.8 t70 -147.87 177.33 9.42 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.302 -176.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 228' ' ' ASN . . . . . 0.43 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 4.3 t-20 -139.78 124.23 11.13 Favored Pre-proline 0 C--N 1.326 -0.414 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.415 176.072 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 229' ' ' PRO . . . . . 0.43 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 48.2 Cg_endo -66.17 144.59 66.84 Favored 'Cis proline' 0 C--N 1.313 -1.319 0 C-N-CA 122.802 -1.749 . . . . 0.0 109.873 -1.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . 0.462 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -70.69 138.29 28.41 Favored Glycine 0 C--O 1.222 -0.635 0 N-CA-C 109.821 -1.312 . . . . 0.0 109.821 -177.862 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.5 p -123.05 131.1 73.88 Favored 'Isoleucine or valine' 0 C--O 1.242 0.674 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 177.048 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 232' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -133.05 156.78 42.56 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 C-N-CA 120.347 -0.541 . . . . 0.0 110.819 -176.557 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -110.2 147.91 32.85 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 115.073 -0.967 . . . . 0.0 108.577 177.844 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 2.8 m -107.36 146.83 31.1 Favored 'General case' 0 C--N 1.313 -0.987 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 177.457 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 14.0 tp -49.41 125.26 10.78 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 -177.841 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 16.1 t70 -52.39 -40.84 62.58 Favored 'General case' 0 CA--C 1.507 -0.68 0 CA-C-N 116.463 -0.335 . . . . 0.0 111.07 -171.611 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 83.6 mt-10 -65.47 -35.41 80.81 Favored 'General case' 0 C--N 1.314 -0.977 0 C-N-CA 120.33 -0.548 . . . . 0.0 110.606 -177.794 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -72.34 138.32 47.23 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 112.442 0.534 . . . . 0.0 112.442 -175.226 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 84.9 mtp180 -105.14 104.42 14.15 Favored 'General case' 0 C--O 1.239 0.509 0 CA-C-N 115.734 -0.666 . . . . 0.0 109.26 172.829 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 240' ' ' HIS . . . . . 0.447 ' HB2' ' CG ' ' A' ' 242' ' ' PHE . 8.4 p80 -67.38 -46.96 71.76 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.923 -0.581 . . . . 0.0 111.599 -176.685 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 241' ' ' GLY . . . . . 0.441 ' N ' ' ND1' ' A' ' 240' ' ' HIS . . . 83.33 12.44 78.67 Favored Glycine 0 C--N 1.31 -0.902 0 N-CA-C 110.477 -1.049 . . . . 0.0 110.477 -176.909 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 242' ' ' PHE . . . . . 0.45 ' CD1' ' N ' ' A' ' 242' ' ' PHE . 4.3 m-30 -80.84 145.39 31.41 Favored 'General case' 0 CA--C 1.514 -0.41 0 CA-C-O 120.731 0.301 . . . . 0.0 110.261 -178.915 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 243' ' ' GLU . . . . . 0.465 ' N ' ' OD2' ' A' ' 246' ' ' ASP . 99.2 mt-10 -131.55 165.01 24.55 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 115.734 -0.666 . . . . 0.0 109.592 173.392 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 4.9 m -59.56 125.82 25.15 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 -178.739 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 99.6 -5.88 58.74 Favored Glycine 0 C--N 1.318 -0.441 0 N-CA-C 111.215 -0.754 . . . . 0.0 111.215 -177.425 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 246' ' ' ASP . . . . . 0.465 ' OD2' ' N ' ' A' ' 243' ' ' GLU . 0.9 OUTLIER -67.54 149.64 49.87 Favored 'General case' 0 CA--C 1.502 -0.884 0 C-N-CA 120.814 -0.355 . . . . 0.0 111.44 176.525 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 247' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -108.74 125.84 52.36 Favored 'General case' 0 C--N 1.317 -0.81 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 176.142 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . 0.418 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.9 m -128.09 160.86 37.41 Favored 'Isoleucine or valine' 0 C--O 1.24 0.566 0 C-N-CA 120.47 -0.492 . . . . 0.0 111.577 -175.38 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 44.1 m -124.17 160.21 28.36 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-N 114.778 -1.101 . . . . 0.0 108.679 173.495 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 250' ' ' PHE . . . . . 0.526 ' CB ' ' HB3' ' A' ' 259' ' ' LEU . 76.4 m-85 -123.99 153.89 40.62 Favored 'General case' 0 C--N 1.314 -0.935 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 -173.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 14.6 p -159.69 161.17 34.83 Favored 'General case' 0 C--N 1.309 -1.176 0 C-N-CA 120.969 -0.293 . . . . 0.0 111.266 177.162 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 27.1 mm-40 51.62 27.86 4.29 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.395 177.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 6.5 t -90.3 129.41 41.21 Favored 'Isoleucine or valine' 0 C--O 1.236 0.371 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 175.802 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 81.4 mt-30 -94.27 136.86 34.1 Favored 'General case' 0 C--O 1.244 0.785 0 C-N-CA 120.276 -0.57 . . . . 0.0 109.836 -178.16 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 82.59 -58.15 5.01 Favored Glycine 0 C--N 1.32 -0.323 0 N-CA-C 109.945 -1.262 . . . . 0.0 109.945 -176.853 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 256' ' ' MET . . . . . 0.485 ' N ' ' O ' ' A' ' 285' ' ' ASP . 4.3 ttm -81.73 53.76 2.23 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.665 0.745 . . . . 0.0 109.708 177.797 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 48.8 pt -69.37 -23.16 26.23 Favored 'Isoleucine or valine' 0 C--O 1.242 0.702 0 CA-C-N 115.042 -0.981 . . . . 0.0 110.899 -175.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 258' ' ' GLN . . . . . 0.432 ' O ' ' SG ' ' A' ' 262' ' ' CYS . 1.2 mp0 -56.5 -37.07 69.9 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 179.673 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 259' ' ' LEU . . . . . 0.526 ' HB3' ' CB ' ' A' ' 250' ' ' PHE . 93.0 mt -62.35 -40.2 95.61 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.755 175.375 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 98.1 m-20 -59.32 -39.79 84.2 Favored 'General case' 0 CA--C 1.516 -0.336 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 -178.322 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -98.21 8.78 62.92 Favored Glycine 0 CA--C 1.531 1.043 0 CA-C-N 116.165 -0.47 . . . . 0.0 112.224 -178.083 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 262' ' ' CYS . . . . . 0.432 ' SG ' ' O ' ' A' ' 258' ' ' GLN . 1.7 m -88.51 146.02 25.41 Favored 'General case' 0 C--O 1.236 0.39 0 O-C-N 122.262 -0.552 . . . . 0.0 112.204 -176.407 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 36.4 mt-30 -64.73 156.91 77.04 Favored Pre-proline 0 C--N 1.325 -0.476 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 171.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 264' ' ' PRO . . . . . 0.418 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 38.1 Cg_endo -63.5 144.24 89.9 Favored 'Trans proline' 0 C--N 1.318 -1.06 0 C-N-CA 121.098 1.199 . . . . 0.0 110.426 -178.794 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 265' ' ' MET . . . . . . . . . . . . . 11.3 ptp -133.6 154.45 50.87 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 112.174 0.435 . . . . 0.0 112.174 -175.597 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 34.8 tt0 -71.34 143.85 50.11 Favored 'General case' 0 C--O 1.236 0.378 0 O-C-N 123.837 0.711 . . . . 0.0 109.328 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 267' ' ' ILE . . . . . 0.419 HG23 ' CE2' ' A' ' 275' ' ' PHE . 1.9 pp -131.92 165.77 30.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 N-CA-C 112.639 0.607 . . . . 0.0 112.639 -175.957 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 49.9 tttp -124.83 125.46 44.03 Favored 'General case' 0 C--O 1.217 -0.612 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.343 177.79 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 35.5 m -93.12 102.61 13.83 Favored 'Isoleucine or valine' 0 C--O 1.238 0.472 0 C-N-CA 120.452 -0.499 . . . . 0.0 111.235 179.127 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 95.9 mt -66.57 -39.44 88.48 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.148 -179.424 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -143.34 -169.74 12.73 Favored Glycine 0 C--N 1.32 -0.311 0 N-CA-C 110.441 -1.064 . . . . 0.0 110.441 -177.775 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -64.11 -33.29 61.98 Favored 'Trans proline' 0 C--N 1.306 -1.707 0 C-N-CA 122.038 1.825 . . . . 0.0 111.714 -179.287 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 90.6 m-85 -126.51 10.11 7.23 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 112.1 0.407 . . . . 0.0 112.1 -177.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.1 p -121.61 131.11 53.93 Favored 'General case' 0 C--O 1.244 0.765 0 CA-C-N 116.701 -0.227 . . . . 0.0 111.072 -177.182 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 275' ' ' PHE . . . . . 0.543 ' C ' ' CD1' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -139.31 161.68 36.84 Favored 'General case' 0 CA--C 1.511 -0.541 0 N-CA-C 112.34 0.496 . . . . 0.0 112.34 179.147 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 276' ' ' SER . . . . . 0.462 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 4.2 p -130.38 144.1 51.18 Favored 'General case' 0 N--CA 1.437 -1.078 0 CA-C-O 121.246 0.546 . . . . 0.0 111.512 -175.827 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 31.8 pt -139.0 165.84 23.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 114.725 -1.125 . . . . 0.0 111.824 -173.304 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 278' ' ' CYS . . . . . 0.404 ' O ' ' HA ' ' A' ' 229' ' ' PRO . 4.8 m -28.36 -86.4 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.57 0 N-CA-C 113.498 0.925 . . . . 0.0 113.498 -175.51 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 55.3 t0 -153.02 112.2 3.81 Favored 'General case' 0 CA--C 1.508 -0.645 0 CA-C-O 120.5 0.19 . . . . 0.0 110.498 -177.374 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 280' ' ' THR . . . . . 0.739 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 21.6 p -67.68 -28.79 67.98 Favored 'General case' 0 C--N 1.303 -1.428 0 CA-C-O 121.323 0.582 . . . . 0.0 110.645 176.314 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -63.99 -21.56 66.55 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 115.067 -0.969 . . . . 0.0 108.521 175.604 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 44.3 t30 -88.42 -8.7 54.54 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.398 -179.501 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . 0.739 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 7.2 m-85 -92.45 -67.71 0.84 Allowed 'General case' 0 CA--C 1.512 -0.492 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.273 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 284' ' ' SER . . . . . 0.444 ' OG ' ' HA ' ' A' ' 256' ' ' MET . 3.8 p 173.41 -105.8 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 114.85 -1.068 . . . . 0.0 110.565 176.392 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 285' ' ' ASP . . . . . 0.485 ' O ' ' N ' ' A' ' 256' ' ' MET . 40.2 t0 -145.44 158.8 43.77 Favored 'General case' 0 C--O 1.217 -0.606 0 CA-C-O 120.408 0.147 . . . . 0.0 110.607 -179.637 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 66.7 t80 -101.1 118.89 37.89 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.744 -0.207 . . . . 0.0 110.634 179.628 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 97.1 mt -97.94 -63.86 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 175.79 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 67.5 mtm180 -166.96 175.86 7.35 Favored 'General case' 0 C--O 1.24 0.601 0 C-N-CA 123.973 0.909 . . . . 0.0 110.605 176.342 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 70.24 -158.8 53.53 Favored Glycine 0 C--N 1.318 -0.462 0 N-CA-C 111.053 -0.819 . . . . 0.0 111.053 175.103 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 104.93 124.77 5.46 Favored Glycine 0 N--CA 1.442 -0.955 0 N-CA-C 111.977 -0.449 . . . . 0.0 111.977 177.258 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 95.7 mt -116.93 131.64 69.02 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.037 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 174.629 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 4.8 p -120.11 135.04 61.67 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.026 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 -179.138 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 293' ' ' SER . . . . . 0.4 ' HA ' ' O ' ' A' ' 217' ' ' LEU . 15.6 m -132.03 144.81 51.03 Favored 'General case' 0 C--N 1.319 -0.759 0 C-N-CA 120.063 -0.655 . . . . 0.0 112.535 -174.939 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 294' ' ' GLN . . . . . 0.494 ' O ' ' HB3' ' A' ' 216' ' ' PRO . 48.5 tt0 -72.52 148.02 45.43 Favored 'General case' 0 CA--C 1.489 -1.381 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 168.31 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 73.8 t -121.91 131.39 73.24 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.765 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 -178.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 20.5 mttp -72.52 96.62 1.97 Allowed 'General case' 0 C--O 1.238 0.448 0 N-CA-C 106.469 -1.678 . . . . 0.0 106.469 173.725 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 4.9 m -105.65 118.52 55.25 Favored Pre-proline 0 C--N 1.314 -0.947 0 CA-C-N 116.178 -0.465 . . . . 0.0 112.225 -174.426 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_exo -60.84 139.78 87.0 Favored 'Trans proline' 0 C--N 1.309 -1.507 0 N-CA-C 106.064 -2.322 . . . . 0.0 106.064 165.717 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -67.71 134.2 50.66 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 118.468 -1.293 . . . . 0.0 111.239 -174.221 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 66.7 mttm -69.23 160.88 30.35 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.346 -0.843 . . . . 0.0 108.91 179.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 301' ' ' ILE . . . . . 0.436 HD13 HG21 ' A' ' 301' ' ' ILE . 94.9 mt -70.15 119.84 16.93 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.867 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 176.877 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 2.1 m -76.26 101.28 5.38 Favored 'General case' 0 C--N 1.305 -1.336 0 CA-C-N 115.527 -0.761 . . . . 0.0 111.875 -170.897 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 73.5 m-85 -109.88 115.06 29.13 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 174.016 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 63.1 mttm -70.52 133.86 47.17 Favored 'General case' 0 C--N 1.317 -0.835 0 C-N-CA 119.565 -0.854 . . . . 0.0 109.212 -178.203 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 5.2 m -71.82 152.51 42.61 Favored 'General case' 0 C--N 1.312 -1.055 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 179.01 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 52.5 mt -46.82 131.06 8.64 Favored Pre-proline 0 C--O 1.238 0.456 0 N-CA-C 109.268 -0.641 . . . . 0.0 109.268 -179.865 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_exo -53.9 -42.54 65.74 Favored 'Trans proline' 0 N--CA 1.493 1.488 0 C-N-CA 121.952 1.768 . . . . 0.0 111.041 -176.1 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -109.13 105.75 15.35 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.223 178.244 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 2.8 m -71.37 83.81 0.79 Allowed 'General case' 0 N--CA 1.445 -0.708 0 C-N-CA 120.225 -0.59 . . . . 0.0 109.578 177.13 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 92.1 mt -99.23 134.51 41.98 Favored 'General case' 0 CA--C 1.507 -0.708 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.424 -178.648 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 17.3 m -113.37 130.96 66.42 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.113 -178.565 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 45.1 tp10 . . . . . 0 C--O 1.204 -1.315 0 CA-C-O 118.389 -0.815 . . . . 0.0 109.777 -175.565 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 . . . . . 0 N--CA 1.481 1.098 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -69.79 -34.83 74.27 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 112.563 0.579 . . . . 0.0 112.563 179.519 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -53.62 -45.47 67.91 Favored Glycine 0 CA--C 1.526 0.745 0 C-N-CA 121.342 -0.456 . . . . 0.0 112.041 -171.672 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 204' ' ' GLU . . . . . 0.52 ' H ' ' CD ' ' A' ' 204' ' ' GLU . 2.4 pm0 -68.02 -37.06 80.94 Favored 'General case' 0 CA--C 1.513 -0.45 0 C-N-CA 120.507 -0.477 . . . . 0.0 110.145 177.13 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 -61.95 -38.49 88.7 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 179.701 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 66.0 mtt -66.82 147.82 52.74 Favored 'General case' 0 N--CA 1.446 -0.667 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 175.532 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 21.4 m -119.67 158.54 21.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 CA-C-O 120.939 0.399 . . . . 0.0 110.78 -175.441 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 87.5 mt -78.96 155.73 28.81 Favored 'General case' 0 C--N 1.313 -1.017 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.116 179.012 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 7.5 m -58.56 -42.14 87.24 Favored 'General case' 0 C--N 1.31 -1.132 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 179.293 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 6.9 p-10 -73.97 -5.62 42.42 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.856 -0.611 . . . . 0.0 112.295 -179.022 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 55.7 m -40.35 112.04 0.25 Allowed 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.85 0.357 . . . . 0.0 111.752 -177.099 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 53.7 t-20 -91.39 117.46 29.7 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 177.189 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 131.12 53.93 0.09 OUTLIER Glycine 0 C--N 1.317 -0.483 0 N-CA-C 109.783 -1.327 . . . . 0.0 109.783 -175.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 214' ' ' GLU . . . . . 0.443 ' H ' ' CD ' ' A' ' 214' ' ' GLU . 1.8 mp0 -56.31 152.09 11.75 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 115.088 -0.556 . . . . 0.0 110.692 -178.797 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 14.7 pt20 -48.62 138.01 12.16 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.134 -179.873 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -60.42 147.42 94.16 Favored 'Trans proline' 0 C--N 1.311 -1.446 0 C-N-CA 122.099 1.866 . . . . 0.0 110.263 -179.8 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 217' ' ' LEU . . . . . 0.476 ' HB3' ' O ' ' A' ' 240' ' ' HIS . 0.2 OUTLIER -51.75 131.08 30.07 Favored 'General case' 0 C--O 1.237 0.409 0 N-CA-C 110.223 -0.288 . . . . 0.0 110.223 -177.801 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 16.5 p -136.18 156.16 49.09 Favored 'General case' 0 CA--C 1.51 -0.595 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.509 -177.352 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 219' ' ' ALA . . . . . 0.438 ' HA ' ' HB3' ' A' ' 238' ' ' ALA . . . -150.72 151.2 32.06 Favored 'General case' 0 N--CA 1.448 -0.556 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.134 -178.751 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 220' ' ' MET . . . . . 0.499 ' SD ' HG12 ' A' ' 291' ' ' ILE . 1.5 mpp? -73.67 131.2 41.39 Favored 'General case' 0 C--O 1.244 0.772 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 177.891 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 69.1 t -74.77 131.76 34.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 178.659 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 58.0 m -92.2 -69.09 0.76 Allowed 'General case' 0 N--CA 1.435 -1.176 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.342 179.661 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 12.6 ptm -138.14 148.59 45.07 Favored 'General case' 0 N--CA 1.472 0.63 0 C-N-CA 120.999 -0.281 . . . . 0.0 111.141 172.762 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 224' ' ' VAL . . . . . 0.407 HG21 ' CE1' ' A' ' 286' ' ' TYR . 52.9 t -121.67 129.35 75.58 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 174.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 17.2 p -81.29 128.03 33.36 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 119.85 -0.74 . . . . 0.0 110.54 179.623 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 17.0 tptm -76.4 84.11 3.14 Favored 'General case' 0 N--CA 1.437 -1.097 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 177.463 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 227' ' ' ASP . . . . . 0.543 ' N ' ' OG1' ' A' ' 280' ' ' THR . 4.8 t0 -159.97 175.74 12.67 Favored 'General case' 0 C--O 1.245 0.861 0 CA-C-N 115.53 -0.759 . . . . 0.0 110.304 -176.162 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 228' ' ' ASN . . . . . 0.444 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.1 OUTLIER -143.01 122.75 7.75 Favored Pre-proline 0 C--N 1.321 -0.656 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.838 172.65 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 229' ' ' PRO . . . . . 0.444 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 42.0 Cg_endo -65.23 148.33 73.27 Favored 'Cis proline' 0 N--CA 1.496 1.652 0 C-N-CA 122.908 -1.705 . . . . 0.0 109.875 -1.507 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . 0.463 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -88.43 140.57 16.19 Favored Glycine 0 C--N 1.315 -0.612 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 -177.916 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.4 p -121.01 132.79 69.59 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.579 0 CA-C-N 117.182 0.491 . . . . 0.0 109.791 177.125 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 232' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -129.83 153.63 39.12 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.042 0 C-N-CA 120.038 -0.665 . . . . 0.0 111.214 -176.581 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 233' ' ' THR . . . . . 0.416 ' HA ' ' O ' ' A' ' 273' ' ' TYR . 0.6 OUTLIER -106.84 140.48 39.61 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-N 115.151 -0.931 . . . . 0.0 109.445 178.065 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.8 m -107.07 160.39 15.59 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-N 116.182 -0.463 . . . . 0.0 109.823 -178.339 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 41.5 tp -63.74 131.34 47.58 Favored 'General case' 0 C--N 1.32 -0.674 0 C-N-CA 120.686 -0.406 . . . . 0.0 109.975 -177.678 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 19.0 p-10 -51.61 -44.43 62.88 Favored 'General case' 0 N--CA 1.475 0.801 0 CA-C-N 115.881 -0.6 . . . . 0.0 111.073 -176.628 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 92.6 mt-10 -65.77 -35.24 80.16 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 179.556 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . 0.438 ' HB3' ' HA ' ' A' ' 219' ' ' ALA . . . -91.54 92.61 8.58 Favored 'General case' 0 N--CA 1.439 -1.017 0 CA-C-N 115.481 -0.781 . . . . 0.0 111.855 -175.261 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 84.7 mtp180 -75.66 118.13 18.15 Favored 'General case' 0 C--N 1.312 -1.022 0 N-CA-C 108.478 -0.934 . . . . 0.0 108.478 174.386 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 240' ' ' HIS . . . . . 0.615 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 7.1 p80 -60.09 -46.09 90.73 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.799 -176.939 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 78.87 19.12 73.66 Favored Glycine 0 C--O 1.238 0.381 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 -178.532 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 242' ' ' PHE . . . . . 0.495 ' CG ' ' HB2' ' A' ' 240' ' ' HIS . 10.4 m-30 -81.04 146.66 30.53 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 -179.545 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 73.9 mm-40 -101.64 158.88 15.77 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 116.011 -0.54 . . . . 0.0 109.672 172.544 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 16.3 m -66.66 126.72 29.83 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 174.762 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 88.14 2.78 80.06 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -176.491 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 15.2 t0 -79.42 167.51 20.74 Favored 'General case' 0 CA--C 1.516 -0.337 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 178.285 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 247' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -112.66 134.71 54.05 Favored 'General case' 0 C--O 1.244 0.811 0 O-C-N 123.127 0.267 . . . . 0.0 110.874 -176.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . 0.404 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.9 m -131.59 160.92 42.03 Favored 'Isoleucine or valine' 0 C--O 1.236 0.369 0 CA-C-O 121.078 0.466 . . . . 0.0 111.899 178.37 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 249' ' ' SER . . . . . 0.411 ' HG ' ' CG2' ' A' ' 295' ' ' VAL . 1.3 m -123.26 153.48 40.13 Favored 'General case' 0 C--O 1.244 0.798 0 CA-C-N 114.893 -1.048 . . . . 0.0 109.229 176.653 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 250' ' ' PHE . . . . . 0.423 ' C ' ' HG ' ' A' ' 251' ' ' SER . 79.3 m-85 -109.43 153.0 24.63 Favored 'General case' 0 CA--C 1.505 -0.773 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.787 -179.357 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 251' ' ' SER . . . . . 0.449 ' O ' ' HA2' ' A' ' 290' ' ' GLY . 39.0 m -152.71 154.69 35.76 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-N 115.694 -0.684 . . . . 0.0 109.196 176.688 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 12.6 mm-40 57.47 21.17 6.71 Favored 'General case' 0 CA--C 1.542 0.655 0 N-CA-C 112.664 0.616 . . . . 0.0 112.664 177.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 61.5 t -76.0 133.89 30.23 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 C-N-CA 120.949 -0.3 . . . . 0.0 111.0 178.759 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 85.2 mt-30 -96.78 136.01 37.93 Favored 'General case' 0 C--O 1.24 0.605 0 O-C-N 123.334 0.396 . . . . 0.0 110.045 179.251 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 76.35 -61.4 3.13 Favored Glycine 0 N--CA 1.463 0.453 0 N-CA-C 111.472 -0.651 . . . . 0.0 111.472 177.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 256' ' ' MET . . . . . 0.621 ' SD ' ' CD1' ' A' ' 259' ' ' LEU . 48.5 ttm -77.67 63.08 2.69 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 178.547 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 48.9 pt -70.22 -20.63 23.01 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 114.914 -1.039 . . . . 0.0 111.136 -173.786 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 258' ' ' GLN . . . . . 0.564 ' HG3' ' SG ' ' A' ' 262' ' ' CYS . 55.7 tp60 -54.76 -39.53 68.42 Favored 'General case' 0 N--CA 1.44 -0.955 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.035 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 259' ' ' LEU . . . . . 0.621 ' CD1' ' SD ' ' A' ' 256' ' ' MET . 97.8 mt -62.58 -41.71 99.11 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.17 -0.468 . . . . 0.0 109.909 178.542 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -61.52 -40.38 94.41 Favored 'General case' 0 CA--C 1.509 -0.598 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 178.377 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -94.64 13.12 67.81 Favored Glycine 0 CA--C 1.527 0.801 0 CA-C-N 115.395 -0.82 . . . . 0.0 111.775 -178.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 262' ' ' CYS . . . . . 0.564 ' SG ' ' HG3' ' A' ' 258' ' ' GLN . 1.0 OUTLIER -105.64 156.92 17.8 Favored 'General case' 0 CA--C 1.508 -0.637 0 CA-C-N 117.45 0.625 . . . . 0.0 112.322 -178.051 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 28.4 mt-30 -71.52 158.38 88.03 Favored Pre-proline 0 C--N 1.319 -0.733 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 171.431 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 264' ' ' PRO . . . . . 0.41 ' HG3' ' OG ' ' A' ' 249' ' ' SER . 26.0 Cg_exo -61.87 147.47 95.15 Favored 'Trans proline' 0 C--N 1.304 -1.809 0 C-N-CA 121.347 1.365 . . . . 0.0 110.551 177.514 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 265' ' ' MET . . . . . . . . . . . . . 4.4 ptp -125.64 164.78 19.84 Favored 'General case' 0 N--CA 1.473 0.706 0 N-CA-C 111.79 0.293 . . . . 0.0 111.79 -177.673 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 266' ' ' GLU . . . . . 0.4 ' C ' HG21 ' A' ' 267' ' ' ILE . 31.9 tt0 -71.04 142.62 50.88 Favored 'General case' 0 CA--C 1.513 -0.443 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 176.517 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 267' ' ' ILE . . . . . 0.498 HG22 ' CE2' ' A' ' 275' ' ' PHE . 1.7 pp -131.04 160.04 42.56 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 CA-C-O 121.054 0.454 . . . . 0.0 111.611 -179.82 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 55.5 mttm -130.6 110.63 11.55 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -177.187 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 27.7 m -77.17 102.1 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 CA-C-O 121.389 0.614 . . . . 0.0 112.255 -176.771 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 97.0 mt -69.6 -39.11 77.46 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.521 177.208 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -144.26 -175.34 17.3 Favored Glycine 0 N--CA 1.461 0.361 0 N-CA-C 109.977 -1.249 . . . . 0.0 109.977 -178.434 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 272' ' ' PRO . . . . . 0.615 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 36.9 Cg_endo -62.15 -34.27 79.61 Favored 'Trans proline' 0 C--N 1.313 -1.341 0 C-N-CA 121.888 1.725 . . . . 0.0 110.939 -177.914 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 273' ' ' TYR . . . . . 0.416 ' O ' ' HA ' ' A' ' 233' ' ' THR . 94.4 m-85 -123.12 6.57 9.19 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.575 -0.739 . . . . 0.0 112.253 -179.796 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 2.2 p -117.11 127.39 54.09 Favored 'General case' 0 C--O 1.244 0.795 0 CA-C-O 121.046 0.45 . . . . 0.0 110.901 179.455 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 275' ' ' PHE . . . . . 0.576 ' C ' ' CD1' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -137.28 161.94 34.87 Favored 'General case' 0 CA--C 1.502 -0.872 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.092 -179.085 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 276' ' ' SER . . . . . 0.463 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 4.4 p -132.22 145.84 51.6 Favored 'General case' 0 C--N 1.309 -1.163 0 C-N-CA 120.369 -0.532 . . . . 0.0 112.124 -173.864 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 28.0 pt -139.22 164.77 24.43 Favored 'Isoleucine or valine' 0 C--O 1.243 0.726 0 CA-C-N 114.744 -1.117 . . . . 0.0 112.899 -172.368 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 2.2 m -28.63 -88.27 0.0 OUTLIER 'General case' 0 C--O 1.237 0.405 0 N-CA-C 113.928 1.084 . . . . 0.0 113.928 -176.099 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 59.8 t0 -152.4 115.65 4.7 Favored 'General case' 0 CA--C 1.507 -0.696 0 CA-C-O 120.695 0.283 . . . . 0.0 110.793 -175.764 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 280' ' ' THR . . . . . 0.658 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 29.7 p -64.84 -29.53 70.49 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-O 121.023 0.44 . . . . 0.0 110.732 175.611 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -64.64 -23.74 67.36 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.324 175.751 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 18.0 t-20 -89.2 -9.31 51.3 Favored 'General case' 0 CA--C 1.509 -0.612 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.77 -179.557 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . 0.658 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 15.7 m-85 -92.46 -75.27 0.49 Allowed 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 121.641 0.734 . . . . 0.0 109.372 174.938 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 284' ' ' SER . . . . . 0.47 ' HG ' ' C ' ' A' ' 283' ' ' PHE . 0.1 OUTLIER 165.6 -174.23 0.02 OUTLIER 'General case' 0 C--N 1.313 -1.0 0 N-CA-C 106.835 -1.543 . . . . 0.0 106.835 -174.066 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -94.98 121.56 36.72 Favored 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 119.687 -0.805 . . . . 0.0 111.899 -179.782 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . 0.407 ' CE1' HG21 ' A' ' 224' ' ' VAL . 3.3 t80 -72.74 108.19 5.6 Favored 'General case' 0 C--O 1.236 0.386 0 C-N-CA 123.535 0.734 . . . . 0.0 109.744 -177.359 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 287' ' ' ILE . . . . . 0.519 ' O ' ' HB3' ' A' ' 288' ' ' ARG . 89.9 mt -67.39 -44.94 86.72 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.66 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 173.077 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . 0.519 ' HB3' ' O ' ' A' ' 287' ' ' ILE . 7.4 ptm180 157.95 -161.26 0.0 OUTLIER 'General case' 0 C--O 1.237 0.409 0 C-N-CA 124.89 1.276 . . . . 0.0 109.164 177.476 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . 0.48 ' N ' ' HG3' ' A' ' 288' ' ' ARG . . . 70.99 -157.16 53.51 Favored Glycine 0 CA--C 1.5 -0.903 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 176.498 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . 0.449 ' HA2' ' O ' ' A' ' 251' ' ' SER . . . 88.84 145.82 12.02 Favored Glycine 0 N--CA 1.436 -1.309 0 CA-C-O 121.533 0.518 . . . . 0.0 112.714 175.52 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . 0.499 HG12 ' SD ' ' A' ' 220' ' ' MET . 92.6 mt -123.41 128.52 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.344 0 N-CA-C 106.74 -1.578 . . . . 0.0 106.74 172.658 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 14.8 p -107.68 130.6 59.74 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.823 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 -179.801 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 3.8 m -132.27 146.9 52.32 Favored 'General case' 0 CA--C 1.506 -0.73 0 C-N-CA 120.52 -0.472 . . . . 0.0 112.187 -173.817 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 49.2 tt0 -70.51 154.19 42.14 Favored 'General case' 0 CA--C 1.497 -1.085 0 CA-C-N 115.342 -0.844 . . . . 0.0 109.601 174.368 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . 0.411 ' CG2' ' HG ' ' A' ' 249' ' ' SER . 2.5 t -114.73 127.19 72.35 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.599 0 N-CA-C 108.177 -1.045 . . . . 0.0 108.177 172.002 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 296' ' ' LYS . . . . . 0.441 ' O ' ' HG3' ' A' ' 296' ' ' LYS . 23.3 pttp -112.84 98.06 6.95 Favored 'General case' 0 N--CA 1.434 -1.234 0 C-N-CA 119.756 -0.778 . . . . 0.0 110.83 179.77 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 31.5 m -68.87 171.85 5.73 Favored Pre-proline 0 C--N 1.314 -0.955 0 N-CA-C 107.225 -1.398 . . . . 0.0 107.225 173.747 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -55.84 140.49 85.24 Favored 'Trans proline' 0 C--N 1.303 -1.839 0 N-CA-C 108.173 -1.51 . . . . 0.0 108.173 177.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 60.0 mttp -65.25 141.59 58.58 Favored 'General case' 0 C--N 1.313 -0.988 0 C-N-CA 119.687 -0.805 . . . . 0.0 110.32 -175.012 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 69.1 mttm -66.75 140.95 57.88 Favored 'General case' 0 N--CA 1.44 -0.935 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 -177.519 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 18.4 tt -46.27 114.1 0.18 Allowed 'Isoleucine or valine' 0 C--O 1.241 0.629 0 CA-C-O 121.428 0.632 . . . . 0.0 111.245 -173.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 3.3 m -74.38 144.66 44.29 Favored 'General case' 0 N--CA 1.441 -0.917 0 CA-C-N 115.256 -0.883 . . . . 0.0 109.964 -177.849 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 93.6 t80 -132.84 157.4 45.13 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 177.198 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 32.6 mmtp -60.07 107.7 0.67 Allowed 'General case' 0 C--N 1.32 -0.677 0 C-N-CA 119.987 -0.685 . . . . 0.0 110.819 -176.559 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -80.0 171.88 14.51 Favored 'General case' 0 C--N 1.311 -1.096 0 CA-C-N 115.344 -0.844 . . . . 0.0 109.898 176.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 94.8 mt -48.84 155.81 0.99 Allowed Pre-proline 0 C--N 1.328 -0.357 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 176.001 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_exo -52.48 -39.0 75.41 Favored 'Trans proline' 0 N--CA 1.501 1.953 0 C-N-CA 121.939 1.759 . . . . 0.0 110.42 -177.499 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . 0.463 ' O ' ' N ' ' A' ' 310' ' ' LEU . . . -149.94 171.11 17.33 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 175.52 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 1.3 m -62.47 83.47 0.02 OUTLIER 'General case' 0 C--N 1.317 -0.847 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 175.391 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 310' ' ' LEU . . . . . 0.463 ' N ' ' O ' ' A' ' 308' ' ' ALA . 96.5 mt -61.06 111.07 1.55 Allowed 'General case' 0 C--O 1.237 0.422 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.335 -171.74 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 29.0 m -137.06 161.62 35.26 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 CA-C-N 115.154 -0.93 . . . . 0.0 108.565 174.272 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 43.3 mt-10 . . . . . 0 C--O 1.204 -1.34 0 CA-C-O 118.625 -0.702 . . . . 0.0 109.989 179.488 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . 0.525 ' CD ' ' H ' ' A' ' 202' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.476 0.853 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 . . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 202' ' ' PHE . . . . . 0.525 ' H ' ' CD ' ' A' ' 201' ' ' GLU . 87.3 m-85 -125.75 -2.43 7.25 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.143 175.595 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -100.86 14.88 58.64 Favored Glycine 0 N--CA 1.459 0.199 0 N-CA-C 111.721 -0.551 . . . . 0.0 111.721 -175.165 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 55.3 mp0 -52.3 -14.48 0.46 Allowed 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 111.927 0.343 . . . . 0.0 111.927 -179.442 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 205' ' ' GLU . . . . . 0.475 ' N ' ' CD ' ' A' ' 205' ' ' GLU . 2.6 mm-40 -54.72 -37.64 66.11 Favored 'General case' 0 C--O 1.236 0.38 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 175.689 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 99.7 mmm -106.0 96.92 6.82 Favored 'General case' 0 N--CA 1.444 -0.744 0 CA-C-N 114.713 -1.131 . . . . 0.0 108.476 172.039 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 2.7 p -128.1 143.2 41.64 Favored 'Isoleucine or valine' 0 C--O 1.243 0.711 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 -178.714 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 208' ' ' LEU . . . . . 0.443 ' C ' ' H ' ' A' ' 210' ' ' ASP . 96.0 mt -65.75 136.09 55.78 Favored 'General case' 0 C--O 1.238 0.492 0 CA-C-N 116.186 -0.461 . . . . 0.0 109.997 -176.391 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 4.7 p -79.12 25.39 0.29 Allowed 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.892 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 210' ' ' ASP . . . . . 0.443 ' H ' ' C ' ' A' ' 208' ' ' LEU . 28.0 t70 -64.09 -34.73 78.71 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.138 -0.483 . . . . 0.0 112.084 -176.813 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 211' ' ' SER . . . . . 0.439 ' C ' ' O ' ' A' ' 210' ' ' ASP . 0.9 OUTLIER -29.85 108.61 0.04 OUTLIER 'General case' 0 CA--C 1.539 0.521 0 O-C-N 123.61 0.569 . . . . 0.0 111.421 -177.656 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 26.8 t-20 -72.1 148.97 45.22 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.497 -0.774 . . . . 0.0 111.435 -175.126 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 80.87 6.36 89.48 Favored Glycine 0 C--O 1.235 0.206 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.465 177.81 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -118.46 126.35 51.85 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.552 0.215 . . . . 0.0 110.621 179.179 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 6.7 mt-30 -109.49 140.21 21.88 Favored Pre-proline 0 C--N 1.318 -0.765 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 178.743 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -73.18 142.98 34.91 Favored 'Trans proline' 0 C--N 1.305 -1.72 0 C-N-CA 122.214 1.943 . . . . 0.0 110.047 176.196 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 217' ' ' LEU . . . . . 0.447 ' HB3' ' O ' ' A' ' 240' ' ' HIS . 3.7 mm? -114.01 136.74 52.57 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 116.644 -0.253 . . . . 0.0 111.524 178.326 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 3.7 m -132.22 132.1 42.77 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 175.423 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -145.38 152.95 40.67 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-O 120.744 0.307 . . . . 0.0 110.762 179.551 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -73.71 134.8 43.59 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.055 178.745 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 98.7 t -80.17 131.12 34.82 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.102 0 N-CA-C 107.406 -1.331 . . . . 0.0 107.406 172.553 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 11.8 p -95.69 -60.48 1.64 Allowed 'General case' 0 N--CA 1.439 -1.016 0 C-N-CA 120.237 -0.585 . . . . 0.0 110.645 -177.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 223' ' ' MET . . . . . 0.568 ' C ' ' SD ' ' A' ' 223' ' ' MET . 0.5 OUTLIER -138.42 141.7 39.54 Favored 'General case' 0 C--O 1.221 -0.407 0 N-CA-C 112.219 0.452 . . . . 0.0 112.219 175.78 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 224' ' ' VAL . . . . . 0.455 ' N ' ' SD ' ' A' ' 223' ' ' MET . 48.4 t -125.19 132.25 71.41 Favored 'Isoleucine or valine' 0 C--O 1.24 0.587 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 177.441 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 225' ' ' THR . . . . . 0.474 HG23 ' SD ' ' A' ' 223' ' ' MET . 5.5 p -99.76 117.36 33.92 Favored 'General case' 0 C--O 1.237 0.424 0 C-N-CA 120.373 -0.531 . . . . 0.0 110.324 176.897 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 226' ' ' LYS . . . . . 0.402 ' HD3' ' HA ' ' A' ' 281' ' ' SER . 0.0 OUTLIER -67.55 85.51 0.19 Allowed 'General case' 0 C--O 1.242 0.687 0 N-CA-C 110.151 -0.315 . . . . 0.0 110.151 178.756 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 227' ' ' ASP . . . . . 0.594 ' N ' ' OG1' ' A' ' 280' ' ' THR . 4.2 t70 -150.73 -177.61 6.09 Favored 'General case' 0 C--O 1.242 0.686 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.518 -179.045 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 228' ' ' ASN . . . . . 0.473 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.0 OUTLIER -141.28 125.59 10.39 Favored Pre-proline 0 N--CA 1.467 0.396 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.967 174.96 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 229' ' ' PRO . . . . . 0.473 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 55.7 Cg_endo -66.17 147.77 75.18 Favored 'Cis proline' 0 N--CA 1.496 1.634 0 C-N-CA 123.347 -1.522 . . . . 0.0 110.116 -0.566 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . . . . . . . . . . . -70.71 138.45 28.61 Favored Glycine 0 N--CA 1.449 -0.473 0 N-CA-C 110.004 -1.238 . . . . 0.0 110.004 -178.154 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 1.8 p -125.69 131.78 71.6 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.804 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 176.335 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 232' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -137.28 157.0 34.43 Favored 'Isoleucine or valine' 0 C--O 1.248 0.988 0 C-N-CA 120.103 -0.639 . . . . 0.0 111.548 -177.553 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 6.0 m -113.07 146.9 38.35 Favored 'General case' 0 C--N 1.309 -1.162 0 CA-C-N 114.987 -1.006 . . . . 0.0 109.532 178.613 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 24.7 m -107.36 160.97 15.22 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 178.244 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 45.2 tp -59.31 128.61 37.97 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 179.431 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -51.35 -44.78 62.15 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.846 -175.164 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 76.8 mt-10 -65.85 -33.08 75.01 Favored 'General case' 0 C--N 1.311 -1.066 0 C-N-CA 120.724 -0.39 . . . . 0.0 111.147 178.834 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -91.62 102.68 15.32 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.729 -175.1 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 78.5 mtm-85 -74.22 127.36 32.77 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 107.717 -1.216 . . . . 0.0 107.717 174.713 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 240' ' ' HIS . . . . . 0.52 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 6.8 p80 -66.28 -45.45 80.44 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 121.137 0.494 . . . . 0.0 110.855 -179.018 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 81.45 12.12 82.33 Favored Glycine 0 C--N 1.311 -0.823 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 -178.257 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 242' ' ' PHE . . . . . 0.483 ' CD2' ' HB2' ' A' ' 240' ' ' HIS . 4.0 m-30 -81.5 151.95 27.55 Favored 'General case' 0 CA--C 1.504 -0.804 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 178.373 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -130.57 158.07 40.98 Favored 'General case' 0 C--N 1.309 -1.178 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 177.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 22.8 m -57.85 127.97 34.71 Favored 'General case' 0 C--N 1.306 -1.284 0 C-N-CA 120.007 -0.677 . . . . 0.0 109.973 -177.26 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 92.06 -6.41 78.91 Favored Glycine 0 N--CA 1.449 -0.497 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.609 -179.019 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 246' ' ' ASP . . . . . 0.421 ' CG ' HE21 ' A' ' 294' ' ' GLN . 1.7 t70 -79.24 162.4 25.71 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 117.223 0.511 . . . . 0.0 111.004 -179.821 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 247' ' ' PHE . . . . . 0.46 ' HA ' ' O ' ' A' ' 265' ' ' MET . 73.0 m-85 -111.94 131.39 55.41 Favored 'General case' 0 C--O 1.24 0.574 0 N-CA-C 112.241 0.46 . . . . 0.0 112.241 -176.076 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . 0.433 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.6 m -132.71 158.88 43.39 Favored 'Isoleucine or valine' 0 C--O 1.235 0.319 0 CA-C-O 120.873 0.368 . . . . 0.0 111.809 177.397 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 49.6 m -123.92 160.55 27.28 Favored 'General case' 0 C--N 1.319 -0.734 0 C-N-CA 124.498 1.119 . . . . 0.0 108.565 173.029 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 250' ' ' PHE . . . . . 0.534 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 68.4 m-85 -110.63 146.72 35.68 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 120.461 0.172 . . . . 0.0 111.081 -177.364 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 1.5 m -133.54 153.39 51.68 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 176.24 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . 0.418 ' O ' ' NE2' ' A' ' 254' ' ' GLN . 79.1 mm-40 55.37 30.34 14.71 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 112.81 0.671 . . . . 0.0 112.81 173.213 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . 0.485 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 51.3 t -89.01 134.69 27.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 N-CA-C 110.231 -0.285 . . . . 0.0 110.231 177.319 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . 0.418 ' NE2' ' O ' ' A' ' 252' ' ' GLU . 3.9 mp0 -99.81 135.19 41.61 Favored 'General case' 0 C--O 1.239 0.518 0 CA-C-O 121.031 0.443 . . . . 0.0 110.658 178.909 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 83.37 -55.08 5.02 Favored Glycine 0 C--N 1.32 -0.321 0 N-CA-C 111.098 -0.801 . . . . 0.0 111.098 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 256' ' ' MET . . . . . 0.524 ' SD ' ' CD1' ' A' ' 259' ' ' LEU . 4.6 ttm -83.41 69.47 10.03 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 178.481 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 257' ' ' ILE . . . . . 0.42 HG23 HD13 ' A' ' 257' ' ' ILE . 45.5 pt -72.69 -22.23 20.08 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.916 0 CA-C-N 114.78 -1.1 . . . . 0.0 111.075 -174.78 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 258' ' ' GLN . . . . . 0.496 ' O ' ' SG ' ' A' ' 262' ' ' CYS . 23.4 mp0 -59.34 -41.49 89.29 Favored 'General case' 0 C--N 1.313 -0.994 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 179.359 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 259' ' ' LEU . . . . . 0.534 ' HB3' ' CG ' ' A' ' 250' ' ' PHE . 90.4 mt -62.8 -41.92 99.49 Favored 'General case' 0 N--CA 1.443 -0.802 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.589 178.198 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 260' ' ' ASN . . . . . 0.485 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 89.5 m-20 -60.44 -41.22 93.6 Favored 'General case' 0 CA--C 1.507 -0.678 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 -179.206 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -100.39 14.11 59.6 Favored Glycine 0 C--N 1.316 -0.583 0 N-CA-C 111.359 -0.696 . . . . 0.0 111.359 -178.495 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 262' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 258' ' ' GLN . 1.2 m -85.62 144.81 27.65 Favored 'General case' 0 C--O 1.242 0.707 0 C-N-CA 120.714 -0.394 . . . . 0.0 110.786 -179.607 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 95.7 mm-40 -68.96 162.96 60.87 Favored Pre-proline 0 C--N 1.315 -0.892 0 N-CA-C 107.4 -1.333 . . . . 0.0 107.4 170.224 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 264' ' ' PRO . . . . . 0.433 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 24.1 Cg_exo -61.46 143.89 97.71 Favored 'Trans proline' 0 C--N 1.307 -1.637 0 N-CA-C 109.562 -0.976 . . . . 0.0 109.562 -178.129 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 265' ' ' MET . . . . . 0.46 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 8.9 ptp -126.65 150.8 48.74 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 116.689 -0.232 . . . . 0.0 110.935 -175.296 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -70.92 137.49 49.29 Favored 'General case' 0 C--O 1.242 0.686 0 O-C-N 123.828 0.705 . . . . 0.0 109.14 178.846 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 267' ' ' ILE . . . . . 0.44 HG22 ' CE2' ' A' ' 275' ' ' PHE . 1.9 pp -127.24 161.24 34.89 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-O 120.867 0.365 . . . . 0.0 111.601 -175.727 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.38 120.87 29.47 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 176.621 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 28.3 m -69.92 133.71 31.39 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 C-N-CA 120.653 -0.419 . . . . 0.0 111.337 -177.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 74.5 mt -97.06 -46.08 6.32 Favored 'General case' 0 CA--C 1.508 -0.67 0 CA-C-O 121.422 0.63 . . . . 0.0 109.537 177.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -149.25 -171.46 17.92 Favored Glycine 0 C--N 1.311 -0.843 0 N-CA-C 108.428 -1.869 . . . . 0.0 108.428 179.84 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 272' ' ' PRO . . . . . 0.52 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 37.8 Cg_endo -62.71 -30.66 78.63 Favored 'Trans proline' 0 C--N 1.301 -1.957 0 C-N-CA 121.332 1.355 . . . . 0.0 111.054 -179.12 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 95.3 m-85 -122.86 11.45 9.66 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 113.32 0.859 . . . . 0.0 113.32 -178.07 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 20.4 p -130.09 146.38 51.74 Favored 'General case' 0 C--O 1.241 0.638 0 C-N-CA 120.66 -0.416 . . . . 0.0 111.259 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 275' ' ' PHE . . . . . 0.502 ' C ' ' CD1' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -150.0 166.1 30.7 Favored 'General case' 0 C--O 1.243 0.736 0 N-CA-C 112.1 0.408 . . . . 0.0 112.1 177.161 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -129.21 141.83 51.03 Favored 'General case' 0 N--CA 1.438 -1.046 0 C-N-CA 120.535 -0.466 . . . . 0.0 111.382 179.643 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . 0.432 ' O ' ' C ' ' A' ' 278' ' ' CYS . 39.4 pt -136.17 166.38 26.95 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.79 0 CA-C-N 114.649 -1.159 . . . . 0.0 111.227 -171.653 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 278' ' ' CYS . . . . . 0.432 ' C ' ' O ' ' A' ' 277' ' ' ILE . 0.9 OUTLIER -21.3 -93.53 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 123.845 0.858 . . . . 0.0 113.137 -176.831 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . 0.444 ' OD1' ' N ' ' A' ' 281' ' ' SER . 60.9 t0 -151.98 116.41 5.04 Favored 'General case' 0 CA--C 1.508 -0.645 0 CA-C-N 116.639 -0.255 . . . . 0.0 110.53 -177.937 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 280' ' ' THR . . . . . 0.708 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 11.8 p -66.38 -26.73 67.4 Favored 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 120.508 -0.477 . . . . 0.0 110.832 175.014 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 281' ' ' SER . . . . . 0.444 ' N ' ' OD1' ' A' ' 279' ' ' ASP . 0.8 OUTLIER -66.38 -20.73 66.15 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.497 -0.774 . . . . 0.0 109.511 174.582 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -87.51 -9.7 53.79 Favored 'General case' 0 CA--C 1.504 -0.797 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 178.316 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . 0.708 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 8.0 m-85 -92.18 -82.9 0.31 Allowed 'General case' 0 N--CA 1.44 -0.943 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 170.921 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 284' ' ' SER . . . . . 0.427 ' H ' ' HB2' ' A' ' 283' ' ' PHE . 9.5 t 169.1 -149.18 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 177.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -85.74 166.44 16.1 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-O 120.59 0.234 . . . . 0.0 110.414 174.655 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . 0.489 ' OH ' ' HA3' ' A' ' 290' ' ' GLY . 12.9 t80 -119.55 102.04 8.36 Favored 'General case' 0 N--CA 1.467 0.394 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 178.486 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 287' ' ' ILE . . . . . 0.505 ' O ' ' HB3' ' A' ' 288' ' ' ARG . 93.4 mt -66.79 -45.53 87.65 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.824 0 C-N-CA 120.211 -0.596 . . . . 0.0 110.287 -179.085 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . 0.505 ' HB3' ' O ' ' A' ' 287' ' ' ILE . 14.7 ptm180 168.4 -173.51 0.02 OUTLIER 'General case' 0 C--O 1.238 0.492 0 O-C-N 123.934 0.771 . . . . 0.0 111.165 -176.45 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 64.96 -147.38 50.99 Favored Glycine 0 C--N 1.338 0.691 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.55 174.313 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . 0.489 ' HA3' ' OH ' ' A' ' 286' ' ' TYR . . . 92.16 127.5 4.16 Favored Glycine 0 N--CA 1.443 -0.87 0 CA-C-O 121.252 0.362 . . . . 0.0 113.399 174.636 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . 0.428 HG23 HD11 ' A' ' 291' ' ' ILE . 95.0 mt -115.76 127.69 73.26 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.047 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 170.84 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 7.4 p -98.89 132.06 44.91 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 179.641 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -121.42 122.85 40.7 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-N 115.473 -0.785 . . . . 0.0 110.525 -172.331 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 294' ' ' GLN . . . . . 0.511 ' OE1' ' NZ ' ' A' ' 296' ' ' LYS . 49.0 tt0 -71.93 139.86 48.92 Favored 'General case' 0 CA--C 1.497 -1.086 0 C-N-CA 119.973 -0.691 . . . . 0.0 109.218 172.647 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 24.0 t -119.25 109.21 25.85 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 N-CA-C 107.726 -1.213 . . . . 0.0 107.726 172.841 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 296' ' ' LYS . . . . . 0.511 ' NZ ' ' OE1' ' A' ' 294' ' ' GLN . 6.7 mmtm -72.63 98.29 2.32 Favored 'General case' 0 N--CA 1.436 -1.166 0 C-N-CA 119.385 -0.926 . . . . 0.0 109.77 -176.822 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 84.2 t -88.37 149.39 44.57 Favored Pre-proline 0 C--N 1.316 -0.879 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 177.075 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_exo -53.03 132.63 48.52 Favored 'Trans proline' 0 C--N 1.318 -1.076 0 CA-C-N 119.989 1.032 . . . . 0.0 109.651 177.146 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 35.0 mmtp -89.46 -162.92 0.92 Allowed 'General case' 0 C--N 1.315 -0.924 0 CA-C-N 115.626 -0.715 . . . . 0.0 110.49 -174.268 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 21.0 mmtp -51.42 152.45 2.59 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 -177.739 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 301' ' ' ILE . . . . . 0.407 HG21 HD11 ' A' ' 301' ' ' ILE . 98.5 mt -77.21 127.17 38.19 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.84 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 179.764 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 1.1 m -77.58 88.64 3.89 Favored 'General case' 0 C--N 1.311 -1.074 0 CA-C-N 116.207 -0.451 . . . . 0.0 109.946 -178.86 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 87.9 t80 -102.19 130.29 48.81 Favored 'General case' 0 CA--C 1.505 -0.758 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 -179.894 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 64.7 mttm -83.09 106.12 14.63 Favored 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 179.657 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 6.4 m -75.94 156.55 34.1 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.388 -179.271 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 306' ' ' LEU . . . . . 0.567 ' H ' ' CD2' ' A' ' 306' ' ' LEU . 0.3 OUTLIER -39.46 143.55 0.53 Allowed Pre-proline 0 C--N 1.327 -0.406 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.465 -179.241 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . 0.496 ' O ' ' N ' ' A' ' 309' ' ' SER . 76.2 Cg_exo -53.98 -39.55 84.64 Favored 'Trans proline' 0 N--CA 1.497 1.689 0 C-N-CA 122.534 2.156 . . . . 0.0 110.622 -179.155 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -59.91 79.81 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.408 0 CA-C-N 115.302 -0.863 . . . . 0.0 109.915 177.907 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.496 ' N ' ' O ' ' A' ' 307' ' ' PRO . 4.6 m -70.08 145.02 51.94 Favored 'General case' 0 C--N 1.306 -1.301 0 CA-C-N 115.335 -0.848 . . . . 0.0 109.042 -179.125 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 89.3 mt -77.65 130.51 36.93 Favored 'General case' 0 C--N 1.322 -0.63 0 C-N-CA 119.803 -0.759 . . . . 0.0 109.281 179.816 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 59.7 t -121.89 128.42 75.66 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.848 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 177.817 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 78.7 mm-40 . . . . . 0 C--O 1.202 -1.414 0 CA-C-O 118.326 -0.845 . . . . 0.0 110.717 -179.175 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . 0.5 ' H2 ' ' CD ' ' A' ' 204' ' ' GLU . 0.0 OUTLIER . . . . . 0 N--CA 1.476 0.845 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 . . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 86.5 t80 -59.25 -47.12 86.53 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.188 -176.132 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -64.62 -41.14 97.93 Favored Glycine 0 C--N 1.314 -0.642 0 N-CA-C 111.243 -0.743 . . . . 0.0 111.243 178.86 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 204' ' ' GLU . . . . . 0.5 ' CD ' ' H2 ' ' A' ' 201' ' ' GLU . 2.8 mp0 -59.53 -31.75 69.69 Favored 'General case' 0 C--O 1.237 0.446 0 CA-C-N 116.728 0.264 . . . . 0.0 111.404 -176.998 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 58.3 mt-10 -62.02 -35.81 79.68 Favored 'General case' 0 C--N 1.317 -0.841 0 N-CA-C 109.675 -0.491 . . . . 0.0 109.675 178.103 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 206' ' ' MET . . . . . 0.436 ' HG3' ' N ' ' A' ' 207' ' ' VAL . 62.9 tpp -92.11 161.14 14.88 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.733 177.376 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . 0.436 ' N ' ' HG3' ' A' ' 206' ' ' MET . 17.8 t -88.82 128.23 41.11 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.947 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 176.407 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 90.4 mt -70.78 75.38 0.61 Allowed 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 -179.593 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 2.2 p -118.41 -54.73 2.27 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.505 -0.77 . . . . 0.0 111.077 -177.349 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 210' ' ' ASP . . . . . 0.402 ' CG ' ' N ' ' A' ' 211' ' ' SER . 19.8 p-10 -63.59 -39.65 94.92 Favored 'General case' 0 CA--C 1.507 -0.705 0 N-CA-C 107.356 -1.35 . . . . 0.0 107.356 171.772 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 211' ' ' SER . . . . . 0.555 ' OG ' ' NZ ' ' A' ' 300' ' ' LYS . 9.1 m -114.98 94.31 4.69 Favored 'General case' 0 N--CA 1.43 -1.463 0 CA-C-N 113.732 -1.577 . . . . 0.0 108.258 177.149 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 59.5 t-20 -83.0 107.76 15.82 Favored 'General case' 0 C--N 1.322 -0.605 0 C-N-CA 120.613 -0.435 . . . . 0.0 111.258 -173.702 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 47.57 45.78 23.47 Favored Glycine 0 C--O 1.236 0.26 0 N-CA-C 111.449 -0.661 . . . . 0.0 111.449 177.204 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -83.82 97.89 9.42 Favored 'General case' 0 N--CA 1.445 -0.715 0 C-N-CA 119.851 -0.739 . . . . 0.0 111.032 -177.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -113.07 144.04 30.35 Favored Pre-proline 0 C--N 1.316 -0.889 0 N-CA-C 107.28 -1.378 . . . . 0.0 107.28 170.22 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -55.69 131.12 44.2 Favored 'Trans proline' 0 C--N 1.3 -1.997 0 N-CA-C 109.672 -0.934 . . . . 0.0 109.672 -179.026 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 217' ' ' LEU . . . . . 0.514 ' O ' ' HA ' ' A' ' 293' ' ' SER . 0.5 OUTLIER -87.64 125.98 34.69 Favored 'General case' 0 CA--C 1.493 -1.233 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 177.572 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 3.0 m -115.43 132.01 56.75 Favored 'General case' 0 C--N 1.313 -1.011 0 O-C-N 123.445 0.465 . . . . 0.0 110.097 -176.2 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 219' ' ' ALA . . . . . 0.404 ' HA ' ' HB2' ' A' ' 238' ' ' ALA . . . -134.4 142.66 47.23 Favored 'General case' 0 N--CA 1.449 -0.516 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.02 -178.804 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 220' ' ' MET . . . . . 0.618 ' SD ' HG12 ' A' ' 291' ' ' ILE . 99.6 mmm -72.18 131.93 43.44 Favored 'General case' 0 C--O 1.244 0.764 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.255 175.829 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 80.5 t -85.11 128.14 39.29 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.999 0 N-CA-C 108.971 -0.752 . . . . 0.0 108.971 178.798 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 222' ' ' SER . . . . . 0.491 ' OG ' ' N ' ' A' ' 223' ' ' MET . 0.1 OUTLIER -79.82 -72.66 0.39 Allowed 'General case' 0 N--CA 1.434 -1.247 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 177.924 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 223' ' ' MET . . . . . 0.491 ' N ' ' OG ' ' A' ' 222' ' ' SER . 8.6 ptm -137.69 147.15 44.59 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.703 -0.68 . . . . 0.0 111.646 175.612 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 224' ' ' VAL . . . . . . . . . . . . . 59.6 t -122.07 130.16 74.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 175.447 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 41.0 p -77.31 134.72 38.44 Favored 'General case' 0 C--N 1.321 -0.668 0 C-N-CA 120.604 -0.438 . . . . 0.0 110.775 179.451 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 21.8 tptm -77.63 65.66 3.18 Favored 'General case' 0 C--O 1.24 0.596 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 174.784 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 227' ' ' ASP . . . . . 0.472 ' N ' ' OG1' ' A' ' 280' ' ' THR . 2.3 t0 -147.33 177.41 9.24 Favored 'General case' 0 C--O 1.245 0.816 0 CA-C-N 115.41 -0.814 . . . . 0.0 111.251 -171.802 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 228' ' ' ASN . . . . . 0.568 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 16.0 p-10 -144.13 124.39 7.58 Favored Pre-proline 0 C--N 1.319 -0.754 0 CA-C-N 115.525 -0.762 . . . . 0.0 110.82 175.755 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 229' ' ' PRO . . . . . 0.568 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 34.1 Cg_exo -60.18 143.18 33.09 Favored 'Cis proline' 0 N--CA 1.489 1.256 0 C-N-CA 123.14 -1.608 . . . . 0.0 110.926 -1.192 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . 0.496 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -74.79 131.06 12.25 Favored Glycine 0 C--N 1.296 -1.681 0 N-CA-C 108.184 -1.966 . . . . 0.0 108.184 176.221 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.1 p -124.96 133.39 69.6 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.791 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 232' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -131.01 155.57 42.07 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.224 0 C-N-CA 120.27 -0.572 . . . . 0.0 110.863 -176.446 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 63.3 m -108.85 135.08 50.64 Favored 'General case' 0 C--N 1.307 -1.254 0 CA-C-N 115.247 -0.888 . . . . 0.0 108.636 176.553 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 44.6 m -105.64 151.11 24.8 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 -177.334 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 38.6 tp -56.24 132.11 49.77 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 -175.528 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 236' ' ' ASP . . . . . 0.541 ' O ' ' NH2' ' A' ' 239' ' ' ARG . 23.0 p-10 -52.42 -44.23 65.31 Favored 'General case' 0 N--CA 1.474 0.734 0 CA-C-O 121.072 0.463 . . . . 0.0 110.606 -174.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 99.6 mt-10 -64.59 -34.91 79.36 Favored 'General case' 0 C--N 1.302 -1.466 0 CA-C-N 115.641 -0.708 . . . . 0.0 110.421 178.62 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . 0.404 ' HB2' ' HA ' ' A' ' 219' ' ' ALA . . . -79.76 73.63 6.48 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 116.004 -0.544 . . . . 0.0 112.176 -174.759 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 239' ' ' ARG . . . . . 0.541 ' NH2' ' O ' ' A' ' 236' ' ' ASP . 0.0 OUTLIER -58.2 90.19 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.024 0.44 . . . . 0.0 110.607 176.477 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 240' ' ' HIS . . . . . 0.481 ' O ' ' HB3' ' A' ' 217' ' ' LEU . 9.1 p80 -55.19 -48.57 73.63 Favored 'General case' 0 C--O 1.217 -0.629 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.249 -175.411 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 78.3 24.56 63.18 Favored Glycine 0 C--N 1.311 -0.858 0 N-CA-C 110.874 -0.891 . . . . 0.0 110.874 179.25 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 242' ' ' PHE . . . . . . . . . . . . . 9.3 m-30 -80.19 144.16 33.2 Favored 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 177.869 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -116.03 158.42 23.15 Favored 'General case' 0 C--N 1.312 -1.052 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.737 -177.695 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -56.58 118.03 4.45 Favored 'General case' 0 C--N 1.311 -1.069 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 178.618 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . 0.463 ' HA2' ' CG ' ' A' ' 266' ' ' GLU . . . 86.85 5.95 80.4 Favored Glycine 0 C--O 1.243 0.672 0 C-N-CA 120.847 -0.692 . . . . 0.0 111.892 -179.531 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -83.14 163.99 20.5 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-N 117.199 0.499 . . . . 0.0 109.913 177.676 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 247' ' ' PHE . . . . . 0.416 ' HA ' ' O ' ' A' ' 265' ' ' MET . 74.9 m-85 -111.18 135.79 51.19 Favored 'General case' 0 C--O 1.238 0.483 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -173.521 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . 0.414 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 3.1 m -131.13 161.92 40.17 Favored 'Isoleucine or valine' 0 C--O 1.237 0.421 0 CA-C-O 121.063 0.458 . . . . 0.0 111.996 178.62 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 2.5 m -125.9 165.09 19.36 Favored 'General case' 0 C--N 1.321 -0.664 0 C-N-CA 124.773 1.229 . . . . 0.0 108.115 173.506 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 250' ' ' PHE . . . . . 0.528 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 96.5 m-85 -124.31 156.78 36.37 Favored 'General case' 0 C--N 1.317 -0.816 0 N-CA-C 110.505 -0.183 . . . . 0.0 110.505 -176.115 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 1.2 m -156.62 161.27 39.92 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.222 -0.444 . . . . 0.0 109.823 176.368 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 16.2 mt-10 51.85 28.63 5.19 Favored 'General case' 0 C--N 1.314 -0.939 0 N-CA-C 112.305 0.483 . . . . 0.0 112.305 177.865 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 3.2 t -92.78 127.4 44.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 176.363 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 77.3 mt-30 -91.27 138.16 31.81 Favored 'General case' 0 C--O 1.241 0.609 0 CA-C-O 120.827 0.346 . . . . 0.0 110.585 -177.508 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 76.23 -58.45 3.22 Favored Glycine 0 C--N 1.319 -0.376 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 -179.052 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 256' ' ' MET . . . . . 0.471 ' SD ' HD11 ' A' ' 259' ' ' LEU . 30.7 ttm -77.32 50.36 0.77 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.429 0.633 . . . . 0.0 109.603 176.619 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 46.2 pt -71.11 -18.05 20.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-N 115.233 -0.894 . . . . 0.0 111.218 -175.12 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 258' ' ' GLN . . . . . 0.557 ' HG3' ' SG ' ' A' ' 262' ' ' CYS . 68.5 tp60 -54.86 -38.37 67.39 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 177.897 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 259' ' ' LEU . . . . . 0.528 ' HB3' ' CG ' ' A' ' 250' ' ' PHE . 93.7 mt -62.22 -40.48 96.24 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.506 -0.77 . . . . 0.0 110.197 176.343 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -59.49 -40.24 86.37 Favored 'General case' 0 CA--C 1.51 -0.59 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 -179.186 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -101.97 21.99 39.85 Favored Glycine 0 CA--C 1.524 0.656 0 CA-C-N 115.927 -0.578 . . . . 0.0 112.049 -179.312 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 262' ' ' CYS . . . . . 0.557 ' SG ' ' HG3' ' A' ' 258' ' ' GLN . 1.3 m -95.95 149.35 21.66 Favored 'General case' 0 C--O 1.236 0.382 0 CA-C-N 117.33 0.565 . . . . 0.0 111.488 -179.429 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . 0.47 ' N ' ' CD ' ' A' ' 263' ' ' GLN . 16.6 mp0 -67.66 156.07 89.82 Favored Pre-proline 0 C--N 1.325 -0.475 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 172.572 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 264' ' ' PRO . . . . . 0.414 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 37.3 Cg_endo -62.67 143.09 91.77 Favored 'Trans proline' 0 C--N 1.308 -1.575 0 C-N-CA 120.722 0.948 . . . . 0.0 110.25 179.131 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 265' ' ' MET . . . . . 0.416 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 22.5 ptp -130.55 155.01 47.23 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.663 -173.513 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 266' ' ' GLU . . . . . 0.463 ' CG ' ' HA2' ' A' ' 245' ' ' GLY . 39.7 tt0 -71.8 144.56 49.11 Favored 'General case' 0 C--O 1.239 0.535 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 177.777 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 267' ' ' ILE . . . . . . . . . . . . . 2.1 pp -128.27 162.06 35.46 Favored 'Isoleucine or valine' 0 C--O 1.249 1.043 0 N-CA-C 113.608 0.966 . . . . 0.0 113.608 -175.221 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 25.7 mtpp -118.7 109.42 16.08 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 114.762 -1.108 . . . . 0.0 109.66 -178.406 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 8.2 m -80.65 96.04 2.71 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.457 0 C-N-CA 120.275 -0.57 . . . . 0.0 111.268 178.103 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 98.4 mt -67.25 -40.59 86.26 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.406 0.622 . . . . 0.0 110.131 178.128 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -139.64 177.54 20.38 Favored Glycine 0 C--N 1.315 -0.609 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.29 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_endo -60.1 -31.54 93.47 Favored 'Trans proline' 0 C--N 1.302 -1.881 0 C-N-CA 121.772 1.648 . . . . 0.0 111.233 -178.769 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 22.9 m-85 -123.94 11.08 8.93 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.422 179.383 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -122.52 125.67 46.23 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 116.025 -0.534 . . . . 0.0 109.654 -176.276 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 275' ' ' PHE . . . . . 0.545 ' C ' ' CD1' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -138.68 164.02 30.61 Favored 'General case' 0 CA--C 1.501 -0.931 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 -179.611 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 276' ' ' SER . . . . . 0.496 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 6.4 p -137.49 159.07 42.97 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.456 -178.082 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . 0.584 HD12 ' CE2' ' A' ' 283' ' ' PHE . 2.5 pp -138.05 -173.74 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 CA-C-N 114.977 -1.01 . . . . 0.0 109.948 -175.825 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 278' ' ' CYS . . . . . 0.451 ' O ' ' HA ' ' A' ' 229' ' ' PRO . 1.2 p -46.87 -93.83 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.304 0 O-C-N 123.324 0.39 . . . . 0.0 111.812 -179.694 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -137.55 126.75 24.55 Favored 'General case' 0 CA--C 1.514 -0.406 0 N-CA-C 109.541 -0.541 . . . . 0.0 109.541 -179.323 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 280' ' ' THR . . . . . 0.605 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 25.0 p -69.56 -23.76 63.61 Favored 'General case' 0 C--N 1.317 -0.808 0 C-N-CA 119.436 -0.906 . . . . 0.0 108.682 171.06 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -61.85 -21.05 64.34 Favored 'General case' 0 N--CA 1.435 -1.199 0 CA-C-N 114.635 -1.166 . . . . 0.0 108.812 173.802 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 29.3 t-20 -89.22 -9.13 51.92 Favored 'General case' 0 CA--C 1.509 -0.621 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.481 175.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . 0.605 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 19.5 m-30 -95.79 -87.91 0.28 Allowed 'General case' 0 N--CA 1.444 -0.74 0 CA-C-O 121.524 0.678 . . . . 0.0 110.456 178.396 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 284' ' ' SER . . . . . 0.464 ' HG ' ' C ' ' A' ' 283' ' ' PHE . 0.0 OUTLIER 170.3 -170.22 0.02 OUTLIER 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 107.689 -1.226 . . . . 0.0 107.689 -173.44 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -94.06 131.37 39.62 Favored 'General case' 0 N--CA 1.471 0.623 0 CA-C-N 118.646 0.657 . . . . 0.0 112.766 -176.052 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . 0.474 ' CD2' ' O ' ' A' ' 286' ' ' TYR . 60.8 t80 -68.87 87.04 0.35 Allowed 'General case' 0 N--CA 1.472 0.639 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.177 177.399 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 287' ' ' ILE . . . . . 0.478 ' O ' ' HG3' ' A' ' 288' ' ' ARG . 87.5 mt -69.94 -48.05 65.58 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.723 0 C-N-CA 120.298 -0.561 . . . . 0.0 110.806 175.405 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . 0.478 ' HG3' ' O ' ' A' ' 287' ' ' ILE . 43.8 mtp180 -170.52 170.67 6.78 Favored 'General case' 0 N--CA 1.47 0.574 0 N-CA-C 112.986 0.735 . . . . 0.0 112.986 -179.114 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 56.48 -143.55 38.51 Favored Glycine 0 N--CA 1.466 0.681 0 CA-C-N 113.77 -1.559 . . . . 0.0 113.199 167.483 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 100.71 130.31 6.99 Favored Glycine 0 N--CA 1.441 -1.009 0 CA-C-O 121.163 0.313 . . . . 0.0 112.506 178.93 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . 0.618 HG12 ' SD ' ' A' ' 220' ' ' MET . 95.2 mt -116.29 129.82 72.08 Favored 'Isoleucine or valine' 0 C--O 1.244 0.769 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 171.675 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 7.2 p -109.31 130.35 62.47 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.064 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 176.789 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 293' ' ' SER . . . . . 0.514 ' HA ' ' O ' ' A' ' 217' ' ' LEU . 3.2 m -131.08 138.73 49.69 Favored 'General case' 0 N--CA 1.441 -0.875 0 C-N-CA 120.43 -0.508 . . . . 0.0 111.558 -175.124 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 2.7 tm0? -76.89 148.99 36.12 Favored 'General case' 0 C--N 1.316 -0.88 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 173.29 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 54.2 t -109.62 130.0 63.47 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.031 0 C-N-CA 120.506 -0.477 . . . . 0.0 109.99 -178.302 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 296' ' ' LYS . . . . . 0.434 ' HG2' ' O ' ' A' ' 296' ' ' LYS . 0.0 OUTLIER -62.53 103.54 0.42 Allowed 'General case' 0 N--CA 1.44 -0.941 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 177.797 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 297' ' ' VAL . . . . . 0.424 HG23 ' H ' ' A' ' 299' ' ' LYS . 2.7 p -59.6 127.92 85.53 Favored Pre-proline 0 C--N 1.315 -0.909 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.299 -174.46 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -66.02 -22.79 54.68 Favored 'Trans proline' 0 N--CA 1.497 1.735 0 C-N-CA 122.3 2.0 . . . . 0.0 111.067 179.879 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . 0.424 ' H ' HG23 ' A' ' 297' ' ' VAL . 46.9 mmtm -97.25 143.26 28.21 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.74 -178.799 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 300' ' ' LYS . . . . . 0.555 ' NZ ' ' OG ' ' A' ' 211' ' ' SER . 11.7 mmtp -119.74 150.09 40.95 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.071 177.161 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 43.8 pt -64.83 130.65 30.22 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.898 -178.048 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 29.3 m -125.92 153.18 44.61 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.209 -176.85 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 89.3 m-85 -125.8 149.21 48.78 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 116.136 -0.484 . . . . 0.0 109.847 -177.738 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 49.2 mmtm -78.01 141.15 39.09 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 116.579 -0.282 . . . . 0.0 110.686 -178.293 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -128.64 162.81 26.47 Favored 'General case' 0 C--O 1.244 0.806 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.321 179.541 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 306' ' ' LEU . . . . . 0.488 ' H ' ' CD1' ' A' ' 306' ' ' LEU . 0.0 OUTLIER -88.21 160.48 45.66 Favored Pre-proline 0 C--N 1.323 -0.561 0 N-CA-C 109.295 -0.632 . . . . 0.0 109.295 176.126 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 78.4 Cg_exo -54.65 -39.89 86.8 Favored 'Trans proline' 0 N--CA 1.497 1.711 0 C-N-CA 122.161 1.908 . . . . 0.0 111.112 -179.824 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -150.62 152.56 34.22 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.272 176.518 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 13.2 p -78.93 168.37 19.8 Favored 'General case' 0 C--N 1.314 -0.946 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 175.517 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 85.1 mt -101.19 131.18 47.29 Favored 'General case' 0 C--N 1.324 -0.536 0 C-N-CA 120.541 -0.464 . . . . 0.0 110.239 177.888 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 2.3 t -123.35 132.68 70.97 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.004 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 -178.568 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.205 -1.268 0 CA-C-O 118.26 -0.876 . . . . 0.0 110.586 -179.633 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . 0.556 ' O ' ' N ' ' A' ' 203' ' ' GLY . 2.2 pm0 . . . . . 0 N--CA 1.483 1.178 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 202' ' ' PHE . . . . . 0.407 ' C ' ' H ' ' A' ' 204' ' ' GLU . 91.5 m-85 59.57 -62.31 0.05 OUTLIER 'General case' 0 N--CA 1.467 0.407 0 C-N-CA 122.697 0.399 . . . . 0.0 110.748 -178.022 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . 0.556 ' N ' ' O ' ' A' ' 201' ' ' GLU . . . -67.75 47.5 0.32 Allowed Glycine 0 N--CA 1.466 0.666 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 176.603 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 204' ' ' GLU . . . . . 0.407 ' H ' ' C ' ' A' ' 202' ' ' PHE . 48.8 mt-10 -70.89 -49.95 40.38 Favored 'General case' 0 C--N 1.319 -0.746 0 O-C-N 122.177 -0.602 . . . . 0.0 111.26 -177.186 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -71.71 -52.29 18.55 Favored 'General case' 0 C--O 1.235 0.314 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 178.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 99.6 mmm -103.3 129.6 50.35 Favored 'General case' 0 CA--C 1.503 -0.833 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 173.683 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 5.2 t -86.65 111.18 21.12 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.905 0 C-N-CA 120.304 -0.558 . . . . 0.0 110.354 -175.869 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 84.7 mt -81.73 81.27 7.83 Favored 'General case' 0 N--CA 1.442 -0.84 0 CA-C-N 115.564 -0.744 . . . . 0.0 109.304 -179.831 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 5.8 m -102.2 32.82 3.34 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 115.556 -0.747 . . . . 0.0 109.973 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -61.11 -36.66 80.29 Favored 'General case' 0 CA--C 1.507 -0.68 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.383 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 211' ' ' SER . . . . . 0.409 ' HB3' ' CD ' ' A' ' 214' ' ' GLU . 10.9 m -91.5 90.06 7.48 Favored 'General case' 0 N--CA 1.435 -1.206 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 175.824 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 59.7 t30 -113.49 98.94 7.39 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.712 -0.677 . . . . 0.0 109.74 -179.45 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 48.03 60.94 5.22 Favored Glycine 0 C--O 1.237 0.287 0 N-CA-C 109.365 -1.494 . . . . 0.0 109.365 -176.108 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 214' ' ' GLU . . . . . 0.409 ' CD ' ' HB3' ' A' ' 211' ' ' SER . 65.4 mt-10 -60.65 137.5 58.17 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-O 120.758 0.314 . . . . 0.0 111.194 -173.656 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 90.1 mt-30 -59.99 159.57 19.97 Favored Pre-proline 0 C--O 1.24 0.583 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 174.547 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -56.8 144.84 86.2 Favored 'Trans proline' 0 C--N 1.304 -1.804 0 C-N-CA 121.743 1.629 . . . . 0.0 110.669 -178.824 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 217' ' ' LEU . . . . . 0.404 ' HB3' ' O ' ' A' ' 240' ' ' HIS . 0.2 OUTLIER -58.64 138.25 57.05 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.327 -177.056 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 218' ' ' SER . . . . . 0.559 ' CB ' ' HG ' ' A' ' 293' ' ' SER . 8.5 t -151.72 152.61 32.98 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.012 -175.683 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -143.57 160.38 40.73 Favored 'General case' 0 C--O 1.244 0.797 0 CA-C-O 120.918 0.389 . . . . 0.0 110.95 178.413 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 97.2 mtp -71.57 136.73 47.58 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.463 -0.79 . . . . 0.0 109.239 176.474 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 91.1 t -83.7 129.48 37.46 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.052 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 178.027 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 74.9 m -79.79 -73.05 0.37 Allowed 'General case' 0 N--CA 1.432 -1.34 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 177.704 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 223' ' ' MET . . . . . 0.463 ' SD ' ' HB ' ' A' ' 233' ' ' THR . 1.0 OUTLIER -139.71 161.95 36.31 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.111 172.771 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 224' ' ' VAL . . . . . 0.428 ' HA ' ' HB ' ' A' ' 232' ' ' VAL . 69.6 t -127.37 129.8 70.69 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 175.749 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 225' ' ' THR . . . . . 0.428 ' O ' HG23 ' A' ' 280' ' ' THR . 75.4 p -78.88 131.25 36.35 Favored 'General case' 0 C--O 1.225 -0.225 0 C-N-CA 120.08 -0.648 . . . . 0.0 110.163 177.615 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 226' ' ' LYS . . . . . 0.498 ' HE3' ' HA ' ' A' ' 281' ' ' SER . 0.0 OUTLIER -77.72 52.28 1.0 Allowed 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 120.723 0.297 . . . . 0.0 110.868 -179.012 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 227' ' ' ASP . . . . . 0.504 ' CG ' ' H ' ' A' ' 228' ' ' ASN . 42.3 t0 -131.29 -179.8 5.57 Favored 'General case' 0 C--O 1.242 0.674 0 CA-C-O 120.862 0.363 . . . . 0.0 111.952 -178.562 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 228' ' ' ASN . . . . . 0.504 ' H ' ' CG ' ' A' ' 227' ' ' ASP . 1.5 p30 -137.6 125.07 13.95 Favored Pre-proline 0 CA--C 1.539 0.536 0 CA-C-N 115.162 -0.926 . . . . 0.0 109.634 175.073 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 229' ' ' PRO . . . . . 0.44 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 44.9 Cg_endo -65.63 143.87 61.41 Favored 'Cis proline' 0 N--CA 1.49 1.314 0 C-N-CA 123.121 -1.616 . . . . 0.0 109.984 -0.46 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . 0.451 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -76.26 136.9 20.34 Favored Glycine 0 C--N 1.305 -1.157 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 -177.301 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 1.6 p -125.74 133.84 68.1 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 175.82 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 232' ' ' VAL . . . . . 0.428 ' HB ' ' HA ' ' A' ' 224' ' ' VAL . 0.7 OUTLIER -132.42 156.36 42.33 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.81 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.241 -176.713 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 233' ' ' THR . . . . . 0.463 ' HB ' ' SD ' ' A' ' 223' ' ' MET . 24.4 m -109.65 143.93 38.71 Favored 'General case' 0 N--CA 1.441 -0.914 0 CA-C-N 115.848 -0.614 . . . . 0.0 109.675 176.278 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 34.2 m -107.58 157.55 17.96 Favored 'General case' 0 C--N 1.31 -1.127 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 -179.552 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 33.2 tp -57.19 123.27 14.74 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 -178.062 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 8.4 p-10 -59.7 -32.71 70.77 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.211 0.529 . . . . 0.0 111.05 -175.717 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -66.89 -32.07 73.09 Favored 'General case' 0 C--N 1.303 -1.42 0 CA-C-N 115.751 -0.658 . . . . 0.0 112.047 177.444 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -109.08 132.99 53.58 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 120.777 0.322 . . . . 0.0 111.647 -176.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 90.2 mtm-85 -91.39 133.6 35.33 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 175.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 240' ' ' HIS . . . . . 0.623 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 3.0 p80 -66.57 -40.55 89.02 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.749 0.309 . . . . 0.0 111.208 -179.516 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 82.34 20.71 61.83 Favored Glycine 0 C--N 1.316 -0.544 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 -176.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 242' ' ' PHE . . . . . 0.467 ' CG ' ' HB2' ' A' ' 240' ' ' HIS . 7.6 m-30 -92.31 146.41 23.72 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.184 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 71.4 mm-40 -109.27 160.07 16.43 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.512 171.471 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 19.9 m -64.6 122.36 16.63 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 175.717 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 95.04 0.14 63.87 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 111.564 -0.614 . . . . 0.0 111.564 -178.668 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 48.6 t0 -76.76 163.93 26.34 Favored 'General case' 0 C--O 1.238 0.489 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 176.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 247' ' ' PHE . . . . . 0.438 ' HA ' ' O ' ' A' ' 265' ' ' MET . 83.1 m-85 -110.27 129.82 55.66 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.522 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . 0.415 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.3 m -129.98 159.45 41.99 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 C-N-CA 120.357 -0.537 . . . . 0.0 111.519 -178.162 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 40.7 m -122.65 159.6 27.55 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 114.308 -1.315 . . . . 0.0 108.81 172.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 250' ' ' PHE . . . . . 0.57 ' CB ' ' HB3' ' A' ' 259' ' ' LEU . 79.1 m-85 -118.79 157.82 26.82 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.271 -174.167 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 4.8 m -151.59 157.48 42.25 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.324 178.078 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER 50.62 27.44 2.94 Favored 'General case' 0 C--N 1.308 -1.196 0 N-CA-C 112.87 0.693 . . . . 0.0 112.87 174.995 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . 0.431 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 12.6 t -88.81 129.23 40.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 175.237 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . 0.477 ' NE2' ' N ' ' A' ' 254' ' ' GLN . 1.5 mp0 -97.27 138.91 34.03 Favored 'General case' 0 C--O 1.242 0.665 0 C-N-CA 120.737 -0.385 . . . . 0.0 110.84 -178.723 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 80.55 -55.66 4.69 Favored Glycine 0 C--O 1.238 0.358 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 -176.3 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 256' ' ' MET . . . . . 0.519 ' N ' ' O ' ' A' ' 285' ' ' ASP . 3.4 ttm -84.55 48.18 1.48 Allowed 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 175.973 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 48.8 pt -69.37 -20.6 24.28 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.758 0 CA-C-N 114.745 -1.116 . . . . 0.0 110.542 -174.544 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 258' ' ' GLN . . . . . 0.472 ' O ' ' SG ' ' A' ' 262' ' ' CYS . 2.5 mp0 -54.14 -35.1 61.87 Favored 'General case' 0 C--N 1.318 -0.801 0 N-CA-C 108.351 -0.981 . . . . 0.0 108.351 177.297 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 259' ' ' LEU . . . . . 0.57 ' HB3' ' CB ' ' A' ' 250' ' ' PHE . 92.5 mt -62.04 -41.24 97.9 Favored 'General case' 0 N--CA 1.445 -0.683 0 CA-C-N 115.399 -0.819 . . . . 0.0 109.915 176.154 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 260' ' ' ASN . . . . . 0.431 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 97.5 m-20 -60.71 -40.05 90.82 Favored 'General case' 0 CA--C 1.512 -0.49 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 -179.618 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -100.13 11.74 60.35 Favored Glycine 0 CA--C 1.524 0.62 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.872 -178.45 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 262' ' ' CYS . . . . . 0.472 ' SG ' ' O ' ' A' ' 258' ' ' GLN . 1.3 m -88.37 152.71 21.73 Favored 'General case' 0 CA--C 1.51 -0.579 0 CA-C-N 116.988 0.394 . . . . 0.0 110.787 -178.185 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 47.7 mt-30 -72.24 160.84 81.67 Favored Pre-proline 0 C--N 1.32 -0.678 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 173.331 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 264' ' ' PRO . . . . . 0.415 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 20.9 Cg_exo -61.47 143.75 97.56 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 N-CA-C 109.224 -1.106 . . . . 0.0 109.224 178.628 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 265' ' ' MET . . . . . 0.438 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 24.3 ptp -133.32 158.19 43.6 Favored 'General case' 0 C--N 1.317 -0.842 0 C-N-CA 120.98 -0.288 . . . . 0.0 111.695 -174.015 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 66.4 tt0 -71.25 139.18 49.94 Favored 'General case' 0 CA--C 1.507 -0.679 0 O-C-N 123.664 0.603 . . . . 0.0 109.718 176.372 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 267' ' ' ILE . . . . . 0.474 ' C ' ' CD1' ' A' ' 267' ' ' ILE . 1.9 pp -131.74 160.14 42.6 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.865 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.274 178.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 64.7 mttp -130.21 125.84 35.91 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.135 176.41 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 17.9 m -84.73 106.6 14.97 Favored 'Isoleucine or valine' 0 C--O 1.235 0.315 0 CA-C-O 121.18 0.514 . . . . 0.0 111.837 -177.436 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 91.0 mt -66.27 -40.3 90.04 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.458 -0.792 . . . . 0.0 109.45 177.451 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -147.16 -175.46 20.06 Favored Glycine 0 C--N 1.321 -0.299 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 179.069 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 272' ' ' PRO . . . . . 0.623 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 36.4 Cg_endo -61.99 -33.93 82.1 Favored 'Trans proline' 0 C--N 1.307 -1.625 0 C-N-CA 121.778 1.652 . . . . 0.0 111.153 -177.619 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -119.19 6.51 11.24 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.984 -0.553 . . . . 0.0 112.18 -179.751 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 2.9 p -119.95 126.22 50.33 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 120.712 0.291 . . . . 0.0 110.506 179.323 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 275' ' ' PHE . . . . . 0.566 ' C ' ' CD1' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -138.0 162.93 32.84 Favored 'General case' 0 CA--C 1.499 -0.992 0 C-N-CA 120.766 -0.374 . . . . 0.0 111.987 -179.744 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 276' ' ' SER . . . . . 0.451 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 4.7 p -132.47 151.2 51.98 Favored 'General case' 0 N--CA 1.433 -1.277 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.921 -173.204 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . 0.468 HD12 ' CE2' ' A' ' 283' ' ' PHE . 2.2 pp -138.19 175.57 8.48 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 CA-C-N 114.824 -1.08 . . . . 0.0 110.505 -175.684 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 278' ' ' CYS . . . . . 0.42 ' SG ' HD13 ' A' ' 277' ' ' ILE . 1.4 p -42.58 -88.44 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.435 0 N-CA-C 112.744 0.646 . . . . 0.0 112.744 -179.707 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . 0.431 ' O ' ' HB2' ' A' ' 282' ' ' ASN . 18.1 t0 -145.75 121.04 10.23 Favored 'General case' 0 CA--C 1.515 -0.371 0 CA-C-O 120.767 0.317 . . . . 0.0 111.109 -176.277 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 280' ' ' THR . . . . . 0.636 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 35.9 p -68.22 -25.75 65.36 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-O 121.26 0.553 . . . . 0.0 110.534 176.546 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 281' ' ' SER . . . . . 0.498 ' HA ' ' HE3' ' A' ' 226' ' ' LYS . 0.7 OUTLIER -69.76 -12.86 61.96 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.459 -0.791 . . . . 0.0 109.519 176.06 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 282' ' ' ASN . . . . . 0.431 ' HB2' ' O ' ' A' ' 279' ' ' ASP . 2.0 m-80 -88.06 -6.06 58.15 Favored 'General case' 0 CA--C 1.509 -0.627 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 173.604 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . 0.636 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 6.0 m-85 -100.41 -71.8 0.69 Allowed 'General case' 0 N--CA 1.444 -0.738 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 172.29 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 1.6 p 167.02 -99.04 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.466 0 CA-C-N 115.144 -0.935 . . . . 0.0 110.213 178.81 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 285' ' ' ASP . . . . . 0.519 ' O ' ' N ' ' A' ' 256' ' ' MET . 48.4 t0 -150.74 163.33 38.85 Favored 'General case' 0 C--O 1.214 -0.815 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 177.416 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . 0.429 ' N ' ' OD1' ' A' ' 285' ' ' ASP . 71.6 t80 -100.54 124.1 45.65 Favored 'General case' 0 C--N 1.318 -0.774 0 C-N-CA 121.1 -0.24 . . . . 0.0 110.841 -179.777 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 287' ' ' ILE . . . . . 0.435 ' O ' ' CG ' ' A' ' 288' ' ' ARG . 96.6 mt -100.06 -61.5 2.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 C-N-CA 120.77 -0.372 . . . . 0.0 110.455 173.696 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . 0.435 ' CG ' ' O ' ' A' ' 287' ' ' ILE . 54.6 mtp180 -166.67 176.79 6.96 Favored 'General case' 0 C--O 1.241 0.617 0 CA-C-O 121.135 0.493 . . . . 0.0 111.787 179.064 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 67.95 -156.27 52.8 Favored Glycine 0 CA--C 1.508 -0.399 0 CA-C-N 115.284 -0.871 . . . . 0.0 111.104 174.893 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 109.91 123.81 4.68 Favored Glycine 0 N--CA 1.443 -0.893 0 N-CA-C 112.281 -0.327 . . . . 0.0 112.281 176.255 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . 0.422 HD13 HG22 ' A' ' 291' ' ' ILE . 99.2 mt -127.52 133.72 67.19 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.09 0 N-CA-C 107.496 -1.298 . . . . 0.0 107.496 173.676 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 4.0 p -124.76 136.06 61.93 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.893 0 C-N-CA 120.466 -0.494 . . . . 0.0 109.824 -177.529 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 293' ' ' SER . . . . . 0.559 ' HG ' ' CB ' ' A' ' 218' ' ' SER . 4.4 m -127.42 146.75 50.37 Favored 'General case' 0 C--O 1.237 0.441 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.768 -178.414 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -73.21 141.06 47.33 Favored 'General case' 0 CA--C 1.51 -0.588 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 173.449 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 69.9 t -125.51 135.71 63.12 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.067 0 C-N-CA 120.667 -0.413 . . . . 0.0 110.73 -176.25 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 51.5 mttp -86.11 99.23 11.36 Favored 'General case' 0 N--CA 1.442 -0.845 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 175.365 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 297' ' ' VAL . . . . . 0.54 ' O ' ' N ' ' A' ' 299' ' ' LYS . 14.5 m -56.47 171.98 0.37 Allowed Pre-proline 0 C--N 1.321 -0.655 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.236 -178.12 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_exo -59.79 75.86 0.06 OUTLIER 'Trans proline' 0 N--CA 1.491 1.34 0 C-N-CA 121.652 1.568 . . . . 0.0 109.519 176.663 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . 0.54 ' N ' ' O ' ' A' ' 297' ' ' VAL . 27.0 tttm -137.96 157.97 45.3 Favored 'General case' 0 C--N 1.308 -1.229 0 CA-C-N 114.945 -1.025 . . . . 0.0 110.77 -170.199 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 300' ' ' LYS . . . . . 0.458 ' O ' ' NZ ' ' A' ' 299' ' ' LYS . 48.0 mmtm -64.76 150.3 47.65 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 172.926 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 44.2 pt -68.28 132.81 32.52 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.803 0 C-N-CA 120.906 -0.318 . . . . 0.0 110.383 -176.006 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 302' ' ' SER . . . . . 0.477 ' CB ' ' HZ3' ' A' ' 299' ' ' LYS . 4.4 m -139.38 134.35 32.33 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.399 178.936 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 93.3 m-85 -129.2 147.45 51.04 Favored 'General case' 0 C--N 1.317 -0.812 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 176.679 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 62.2 mttm -99.8 110.19 22.57 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.263 177.16 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 305' ' ' SER . . . . . 0.456 ' O ' ' C ' ' A' ' 306' ' ' LEU . 1.4 m -72.91 93.44 1.72 Allowed 'General case' 0 C--N 1.311 -1.103 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 175.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 306' ' ' LEU . . . . . 0.456 ' C ' ' O ' ' A' ' 305' ' ' SER . 54.9 mt -33.29 125.49 0.43 Allowed Pre-proline 0 C--O 1.236 0.38 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 -173.836 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -64.09 146.82 91.36 Favored 'Trans proline' 0 C--N 1.304 -1.805 0 C-N-CA 121.781 1.654 . . . . 0.0 111.118 -174.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . 0.466 ' O ' ' C ' ' A' ' 309' ' ' SER . . . -56.23 148.5 18.22 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 179.372 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.466 ' C ' ' O ' ' A' ' 308' ' ' ALA . 1.2 m -28.52 106.32 0.03 OUTLIER 'General case' 0 C--N 1.319 -0.75 0 O-C-N 123.455 0.472 . . . . 0.0 111.634 -174.404 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 67.1 mt -71.67 101.76 2.62 Favored 'General case' 0 CA--C 1.51 -0.585 0 CA-C-N 116.383 -0.372 . . . . 0.0 110.34 -178.731 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 17.8 m -128.93 132.41 67.43 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.124 176.584 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 90.0 mt-10 . . . . . 0 C--O 1.205 -1.289 0 CA-C-O 118.558 -0.734 . . . . 0.0 111.19 179.66 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 45.2 mp0 . . . . . 0 N--CA 1.478 0.967 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 71.1 m-85 -139.26 145.79 39.63 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -179.609 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -113.44 29.23 8.05 Favored Glycine 0 C--O 1.225 -0.463 0 C-N-CA 121.055 -0.593 . . . . 0.0 112.137 -178.601 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 99.8 mt-10 -64.27 -42.35 96.5 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 117.073 0.437 . . . . 0.0 110.255 179.696 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 51.4 tp10 -67.29 -40.25 86.08 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.181 -176.329 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 99.7 mtp -79.5 99.3 7.19 Favored 'General case' 0 C--O 1.238 0.471 0 N-CA-C 110.11 -0.33 . . . . 0.0 110.11 179.501 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 27.0 m -100.13 72.58 0.47 Allowed 'Isoleucine or valine' 0 C--O 1.245 0.861 0 CA-C-O 121.361 0.601 . . . . 0.0 112.238 -177.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 208' ' ' LEU . . . . . 0.432 ' N ' ' CD2' ' A' ' 208' ' ' LEU . 1.5 mm? -123.09 112.68 18.04 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 174.182 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -65.63 -44.22 87.12 Favored 'General case' 0 C--O 1.236 0.353 0 C-N-CA 119.753 -0.779 . . . . 0.0 109.805 176.118 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -127.78 -70.29 0.7 Allowed 'General case' 0 CA--C 1.507 -0.689 0 CA-C-N 115.099 -0.955 . . . . 0.0 108.852 173.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -121.01 -162.49 0.96 Allowed 'General case' 0 C--N 1.314 -0.965 0 CA-C-N 114.166 -1.379 . . . . 0.0 108.861 177.863 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 212' ' ' ASN . . . . . 0.5 ' ND2' ' N ' ' A' ' 213' ' ' GLY . 0.0 OUTLIER -67.45 174.88 3.08 Favored 'General case' 0 C--N 1.322 -0.629 0 C-N-CA 120.844 -0.342 . . . . 0.0 110.158 176.126 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 213' ' ' GLY . . . . . 0.5 ' N ' ' ND2' ' A' ' 212' ' ' ASN . . . 131.99 37.94 0.27 Allowed Glycine 0 C--N 1.318 -0.452 0 N-CA-C 109.315 -1.514 . . . . 0.0 109.315 -176.611 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 53.8 mp0 -63.62 159.78 18.2 Favored 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 123.665 0.786 . . . . 0.0 109.26 -179.564 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 27.9 mt-30 -45.74 154.38 0.56 Allowed Pre-proline 0 C--N 1.326 -0.448 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 178.417 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -65.16 143.92 79.59 Favored 'Trans proline' 0 C--N 1.305 -1.731 0 C-N-CA 121.492 1.461 . . . . 0.0 109.479 176.549 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 217' ' ' LEU . . . . . 0.443 ' HB3' ' O ' ' A' ' 240' ' ' HIS . 0.1 OUTLIER -67.46 125.14 25.2 Favored 'General case' 0 C--N 1.313 -0.98 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 -178.889 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 218' ' ' SER . . . . . 0.579 ' CB ' ' HG ' ' A' ' 293' ' ' SER . 5.1 m -130.89 151.87 50.84 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.867 -174.719 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -144.84 160.59 41.04 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.051 0.453 . . . . 0.0 110.803 179.05 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 220' ' ' MET . . . . . 0.479 ' SD ' HD21 ' A' ' 235' ' ' LEU . 92.7 mtp -75.57 130.74 39.31 Favored 'General case' 0 N--CA 1.443 -0.814 0 CA-C-N 115.366 -0.834 . . . . 0.0 108.916 176.474 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 99.7 t -78.92 128.69 38.35 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.92 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 176.413 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 26.9 m -85.26 -72.73 0.47 Allowed 'General case' 0 C--N 1.307 -1.245 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 178.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 223' ' ' MET . . . . . 0.535 ' C ' ' SD ' ' A' ' 223' ' ' MET . 2.7 ppp? -138.2 151.26 47.52 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 112.235 0.457 . . . . 0.0 112.235 174.168 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 224' ' ' VAL . . . . . 0.427 HG11 ' SD ' ' A' ' 256' ' ' MET . 62.2 t -121.11 126.65 75.38 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 176.098 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 37.5 p -77.53 133.72 38.46 Favored 'General case' 0 C--N 1.327 -0.386 0 C-N-CA 120.259 -0.576 . . . . 0.0 110.407 178.49 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 20.6 tptm -78.32 77.23 4.81 Favored 'General case' 0 C--N 1.316 -0.87 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 179.813 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 227' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -161.31 178.09 9.53 Favored 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 112.615 0.598 . . . . 0.0 112.615 -176.208 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 228' ' ' ASN . . . . . 0.451 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 2.0 t-20 -140.29 124.46 10.75 Favored Pre-proline 0 CA--C 1.533 0.324 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.786 175.086 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 229' ' ' PRO . . . . . 0.451 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 46.8 Cg_endo -65.61 143.57 60.0 Favored 'Cis proline' 0 N--CA 1.492 1.402 0 C-N-CA 122.759 -1.767 . . . . 0.0 109.717 -1.244 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . 0.487 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -81.9 140.02 20.48 Favored Glycine 0 CA--C 1.501 -0.795 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 -178.496 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.4 p -122.79 133.85 67.71 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 176.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 232' ' ' VAL . . . . . 0.417 ' CG1' HG12 ' A' ' 224' ' ' VAL . 0.6 OUTLIER -131.39 155.41 41.79 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 C-N-CA 120.605 -0.438 . . . . 0.0 110.829 -176.182 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 26.1 m -110.17 142.67 41.37 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-N 115.425 -0.807 . . . . 0.0 109.629 177.474 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 48.7 m -107.92 158.22 17.54 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-N 115.804 -0.634 . . . . 0.0 109.484 178.39 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . 0.479 HD21 ' SD ' ' A' ' 220' ' ' MET . 33.9 tp -64.5 117.21 7.0 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 178.459 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 236' ' ' ASP . . . . . 0.523 ' HA ' ' CE1' ' A' ' 273' ' ' TYR . 37.4 p-10 -59.71 -28.56 67.43 Favored 'General case' 0 C--O 1.239 0.515 0 CA-C-O 120.885 0.374 . . . . 0.0 111.872 -173.144 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 72.4 mm-40 -66.22 -33.18 75.18 Favored 'General case' 0 C--N 1.311 -1.068 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.316 178.78 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -99.51 122.96 43.32 Favored 'General case' 0 CA--C 1.516 -0.337 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.408 179.795 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 90.2 mtm180 -75.57 138.73 41.67 Favored 'General case' 0 C--N 1.316 -0.861 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 174.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 240' ' ' HIS . . . . . 0.447 ' HB2' ' CD2' ' A' ' 242' ' ' PHE . 6.4 p80 -88.82 -37.73 15.17 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 121.026 0.441 . . . . 0.0 109.924 177.26 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 81.24 10.73 84.36 Favored Glycine 0 CA--C 1.505 -0.592 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 179.405 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 242' ' ' PHE . . . . . 0.493 ' CD1' ' N ' ' A' ' 242' ' ' PHE . 3.7 m-30 -81.22 147.14 30.11 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.305 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -131.17 167.42 19.18 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 109.095 -0.705 . . . . 0.0 109.095 172.359 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 2.9 m -59.48 129.38 41.7 Favored 'General case' 0 C--N 1.294 -1.835 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.556 -176.561 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 83.8 1.8 89.85 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 111.807 -0.517 . . . . 0.0 111.807 -179.165 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 44.4 t0 -77.69 159.62 29.01 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 117.315 0.557 . . . . 0.0 110.255 178.476 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 247' ' ' PHE . . . . . 0.416 ' HA ' ' O ' ' A' ' 265' ' ' MET . 66.0 m-85 -110.48 133.79 52.95 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 116.592 -0.276 . . . . 0.0 110.394 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . 0.426 ' O ' ' SD ' ' A' ' 265' ' ' MET . 3.1 m -129.98 162.22 38.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.54 -179.093 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 5.0 m -126.19 151.79 46.89 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.332 -0.849 . . . . 0.0 109.016 175.782 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 250' ' ' PHE . . . . . 0.537 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 74.4 m-85 -109.6 155.9 20.85 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.409 0.623 . . . . 0.0 111.693 -176.25 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 44.8 m -152.4 151.82 31.28 Favored 'General case' 0 C--N 1.308 -1.211 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.579 175.851 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 30.7 mm-40 51.89 28.47 5.13 Favored 'General case' 0 C--N 1.317 -0.808 0 N-CA-C 113.018 0.747 . . . . 0.0 113.018 176.427 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . 0.501 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 60.8 t -82.36 129.67 37.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 174.216 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 81.9 mt-30 -101.59 138.15 38.96 Favored 'General case' 0 C--O 1.243 0.745 0 C-N-CA 120.272 -0.571 . . . . 0.0 111.296 -175.275 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 81.73 -57.53 4.92 Favored Glycine 0 C--O 1.239 0.417 0 N-CA-C 109.969 -1.252 . . . . 0.0 109.969 -176.47 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 256' ' ' MET . . . . . 0.476 ' SD ' ' CD1' ' A' ' 259' ' ' LEU . 57.0 ttm -85.78 65.04 8.94 Favored 'General case' 0 CA--C 1.516 -0.364 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 175.383 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 49.1 pt -73.92 -19.55 17.58 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-N 114.659 -1.155 . . . . 0.0 111.875 -172.848 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 15.4 tt0 -58.16 -36.39 72.94 Favored 'General case' 0 C--N 1.321 -0.647 0 C-N-CA 119.547 -0.861 . . . . 0.0 110.055 -177.636 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 259' ' ' LEU . . . . . 0.537 ' HB3' ' CG ' ' A' ' 250' ' ' PHE . 90.4 mt -61.44 -40.39 94.27 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 177.814 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 260' ' ' ASN . . . . . 0.501 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 98.3 m-20 -60.24 -40.1 89.06 Favored 'General case' 0 CA--C 1.508 -0.635 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 178.376 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -102.27 22.72 36.8 Favored Glycine 0 C--N 1.315 -0.615 0 CA-C-N 115.468 -0.787 . . . . 0.0 111.919 -178.259 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 262' ' ' CYS . . . . . . . . . . . . . 11.1 t -111.14 146.48 36.78 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 117.308 0.554 . . . . 0.0 111.734 -176.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 -59.31 158.99 17.35 Favored Pre-proline 0 C--N 1.327 -0.376 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 174.005 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -62.64 148.16 93.75 Favored 'Trans proline' 0 N--CA 1.493 1.491 0 C-N-CA 121.578 1.519 . . . . 0.0 111.395 179.159 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 265' ' ' MET . . . . . 0.623 ' SD ' ' N ' ' A' ' 265' ' ' MET . 0.3 OUTLIER -124.7 150.49 46.09 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.731 -174.412 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 266' ' ' GLU . . . . . 0.47 ' OE2' ' NZ ' ' A' ' 268' ' ' LYS . 0.7 OUTLIER -71.53 140.14 49.77 Favored 'General case' 0 C--O 1.24 0.596 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 172.958 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 267' ' ' ILE . . . . . 0.528 HG23 ' CE2' ' A' ' 275' ' ' PHE . 1.5 pp -130.63 159.92 42.25 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-O 121.245 0.545 . . . . 0.0 111.958 -177.065 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . 0.47 ' NZ ' ' OE2' ' A' ' 266' ' ' GLU . 35.4 mttp -128.79 120.51 26.48 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.617 178.182 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 26.8 m -82.58 100.14 6.07 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.256 0 CA-C-O 121.018 0.437 . . . . 0.0 111.85 -176.657 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 97.4 mt -65.81 -41.07 92.32 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.341 0.591 . . . . 0.0 109.636 177.264 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -139.41 179.49 18.67 Favored Glycine 0 C--N 1.317 -0.525 0 N-CA-C 109.253 -1.539 . . . . 0.0 109.253 178.166 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -61.99 -30.23 82.9 Favored 'Trans proline' 0 C--N 1.306 -1.694 0 C-N-CA 121.899 1.733 . . . . 0.0 111.067 -178.27 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 273' ' ' TYR . . . . . 0.523 ' CE1' ' HA ' ' A' ' 236' ' ' ASP . 72.9 m-85 -122.56 6.8 9.49 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 112.782 0.66 . . . . 0.0 112.782 179.027 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 7.0 p -119.41 126.89 52.43 Favored 'General case' 0 C--O 1.243 0.717 0 CA-C-O 120.67 0.272 . . . . 0.0 110.461 177.658 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 275' ' ' PHE . . . . . 0.533 ' C ' ' CD1' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -133.0 163.2 29.76 Favored 'General case' 0 CA--C 1.493 -1.243 0 C-N-CA 120.446 -0.501 . . . . 0.0 112.296 179.893 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 276' ' ' SER . . . . . 0.487 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 5.0 p -130.65 143.27 50.63 Favored 'General case' 0 N--CA 1.43 -1.432 0 C-N-CA 120.611 -0.436 . . . . 0.0 111.526 -174.781 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 32.6 pt -141.31 165.79 18.6 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.765 0 CA-C-N 114.614 -1.176 . . . . 0.0 111.488 -172.784 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -27.5 -90.99 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.687 0 N-CA-C 113.757 1.021 . . . . 0.0 113.757 -176.379 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 50.7 t0 -148.81 113.56 5.39 Favored 'General case' 0 CA--C 1.504 -0.825 0 CA-C-N 116.615 -0.266 . . . . 0.0 110.293 -175.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 280' ' ' THR . . . . . 0.689 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 26.7 p -73.65 -23.52 59.87 Favored 'General case' 0 N--CA 1.426 -1.627 0 CA-C-O 121.086 0.47 . . . . 0.0 110.04 177.411 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -67.75 -20.75 65.27 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.06 -0.973 . . . . 0.0 108.783 173.243 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 18.8 t30 -89.63 -9.08 51.0 Favored 'General case' 0 CA--C 1.51 -0.588 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.455 -179.547 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . 0.689 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 21.3 m-85 -92.14 -71.76 0.63 Allowed 'General case' 0 CA--C 1.505 -0.757 0 CA-C-O 121.66 0.743 . . . . 0.0 109.643 179.002 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 284' ' ' SER . . . . . 0.434 ' HG ' ' C ' ' A' ' 283' ' ' PHE . 0.1 OUTLIER 168.95 -175.78 0.03 OUTLIER 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 114.133 -1.394 . . . . 0.0 107.967 -173.908 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 7.9 t70 -92.41 121.43 33.88 Favored 'General case' 0 C--N 1.322 -0.617 0 C-N-CA 120.246 -0.582 . . . . 0.0 111.925 -178.861 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 12.1 t80 -69.58 126.73 30.63 Favored 'General case' 0 C--O 1.237 0.423 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 177.299 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 96.4 mt -106.08 -58.26 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 CA-C-O 121.021 0.438 . . . . 0.0 110.13 174.834 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 22.3 ptt180 -166.91 -179.31 4.64 Favored 'General case' 0 C--O 1.24 0.554 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.934 -176.285 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 65.64 -156.29 49.13 Favored Glycine 0 C--N 1.331 0.305 0 N-CA-C 110.6 -1.0 . . . . 0.0 110.6 178.051 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 105.42 122.81 5.1 Favored Glycine 0 CA--C 1.52 0.373 0 CA-C-O 121.266 0.37 . . . . 0.0 112.813 176.413 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 95.6 mt -123.0 130.76 74.25 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 N-CA-C 107.587 -1.264 . . . . 0.0 107.587 175.262 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . 0.414 HG21 ' CZ ' ' A' ' 242' ' ' PHE . 4.0 p -126.35 137.98 56.08 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 -177.455 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 293' ' ' SER . . . . . 0.579 ' HG ' ' CB ' ' A' ' 218' ' ' SER . 12.5 m -129.64 147.27 51.42 Favored 'General case' 0 CA--C 1.509 -0.598 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.498 -178.425 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 294' ' ' GLN . . . . . 0.44 ' HB3' ' CD1' ' A' ' 242' ' ' PHE . 0.7 OUTLIER -82.61 139.83 33.55 Favored 'General case' 0 CA--C 1.507 -0.678 0 C-N-CA 120.183 -0.607 . . . . 0.0 110.535 175.41 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 79.1 t -121.49 129.06 75.91 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.154 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 177.811 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 16.9 mmtp -85.9 97.53 10.28 Favored 'General case' 0 C--N 1.315 -0.915 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 179.466 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 6.0 m -90.55 119.94 69.01 Favored Pre-proline 0 N--CA 1.442 -0.872 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.541 -179.029 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -57.81 139.83 91.64 Favored 'Trans proline' 0 N--CA 1.488 1.163 0 C-N-CA 121.69 1.593 . . . . 0.0 110.156 177.625 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 2.9 mptp? -107.14 153.21 22.99 Favored 'General case' 0 C--N 1.309 -1.176 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.212 -179.101 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -57.13 132.85 54.19 Favored 'General case' 0 C--N 1.317 -0.811 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 -179.45 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 301' ' ' ILE . . . . . 0.402 HG22 HD11 ' A' ' 301' ' ' ILE . 95.7 mt -71.0 115.18 10.38 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.019 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 -175.406 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -82.97 159.29 22.27 Favored 'General case' 0 C--N 1.312 -1.048 0 CA-C-N 115.496 -0.775 . . . . 0.0 111.867 -176.349 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 51.8 p90 -150.8 160.17 44.05 Favored 'General case' 0 C--N 1.307 -1.277 0 CA-C-N 115.097 -0.956 . . . . 0.0 108.762 179.029 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.06 128.11 35.18 Favored 'General case' 0 C--N 1.313 -0.983 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.454 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 12.8 p -63.61 156.26 27.23 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 179.193 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -43.76 103.34 0.32 Allowed Pre-proline 0 C--N 1.327 -0.389 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.797 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . 0.561 ' O ' ' N ' ' A' ' 309' ' ' SER . 57.9 Cg_endo -73.96 82.38 1.77 Allowed 'Trans proline' 0 C--N 1.305 -1.712 0 C-N-CA 121.617 1.545 . . . . 0.0 111.17 -174.941 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -66.14 60.43 0.04 OUTLIER 'General case' 0 CA--C 1.515 -0.369 0 CA-C-O 121.486 0.66 . . . . 0.0 109.272 178.262 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.561 ' N ' ' O ' ' A' ' 307' ' ' PRO . 10.3 p -81.93 162.33 22.76 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 114.853 -1.067 . . . . 0.0 111.424 -176.784 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 1.8 mm? -78.31 141.55 38.4 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 176.235 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 11.8 t -126.07 110.77 24.64 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 179.02 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 312' ' ' GLU . . . . . 0.44 ' OE1' ' N ' ' A' ' 312' ' ' GLU . 57.8 mp0 . . . . . 0 C--O 1.205 -1.239 0 CA-C-O 118.472 -0.775 . . . . 0.0 110.43 -178.654 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 110.232 -0.284 . . . . 0.0 110.232 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 32.6 p90 -149.11 155.13 40.25 Favored 'General case' 0 C--O 1.238 0.496 0 CA-C-O 120.994 0.426 . . . . 0.0 111.959 -177.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -118.4 -5.26 12.96 Favored Glycine 0 N--CA 1.461 0.365 0 N-CA-C 110.319 -1.112 . . . . 0.0 110.319 176.737 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -53.18 -15.82 1.02 Allowed 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 112.213 0.449 . . . . 0.0 112.213 -175.189 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 69.0 mt-10 -61.54 -37.76 84.94 Favored 'General case' 0 CA--C 1.514 -0.418 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 176.599 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 97.1 mtp -107.85 73.08 0.88 Allowed 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 114.832 -1.076 . . . . 0.0 109.228 177.767 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 4.8 p -100.39 114.16 38.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.14 0.495 . . . . 0.0 110.816 -177.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 86.7 mt -85.46 89.01 7.58 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.476 -179.105 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 1.6 p -100.21 -1.72 35.76 Favored 'General case' 0 C--N 1.314 -0.973 0 CA-C-O 121.061 0.457 . . . . 0.0 110.553 179.071 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 210' ' ' ASP . . . . . 0.412 ' O ' ' C ' ' A' ' 211' ' ' SER . 5.4 t70 -100.83 30.93 3.77 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.672 -0.694 . . . . 0.0 110.29 178.913 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 211' ' ' SER . . . . . 0.412 ' C ' ' O ' ' A' ' 210' ' ' ASP . 0.0 OUTLIER -29.58 123.47 0.15 Allowed 'General case' 0 C--O 1.236 0.353 0 CA-C-N 115.769 -0.651 . . . . 0.0 112.189 -174.984 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 212' ' ' ASN . . . . . 0.423 ' OD1' ' N ' ' A' ' 213' ' ' GLY . 50.4 t-20 -87.53 141.29 28.73 Favored 'General case' 0 C--O 1.243 0.713 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.674 -179.413 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 213' ' ' GLY . . . . . 0.423 ' N ' ' OD1' ' A' ' 212' ' ' ASN . . . 71.31 35.16 63.71 Favored Glycine 0 C--O 1.241 0.57 0 N-CA-C 111.783 -0.527 . . . . 0.0 111.783 176.806 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 73.9 mt-10 -65.06 130.85 44.88 Favored 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 120.56 -0.456 . . . . 0.0 110.465 179.007 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 215' ' ' GLN . . . . . 0.428 ' CD ' ' HD2' ' A' ' 216' ' ' PRO . 8.0 tp60 -64.33 150.45 92.94 Favored Pre-proline 0 C--N 1.321 -0.665 0 N-CA-C 106.155 -1.795 . . . . 0.0 106.155 171.452 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 216' ' ' PRO . . . . . 0.428 ' HD2' ' CD ' ' A' ' 215' ' ' GLN . 74.7 Cg_exo -53.13 135.51 59.55 Favored 'Trans proline' 0 C--O 1.247 0.934 0 N-CA-C 108.7 -1.308 . . . . 0.0 108.7 -178.987 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 217' ' ' LEU . . . . . 0.454 ' HB3' ' O ' ' A' ' 240' ' ' HIS . 0.3 OUTLIER -46.62 112.12 0.46 Allowed 'General case' 0 CA--C 1.505 -0.781 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.218 -168.436 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 218' ' ' SER . . . . . 0.411 ' HA ' ' O ' ' A' ' 292' ' ' VAL . 15.6 m -127.96 150.67 49.8 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 -179.041 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -138.05 152.57 48.95 Favored 'General case' 0 C--N 1.311 -1.095 0 CA-C-O 120.848 0.356 . . . . 0.0 111.112 -177.468 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 220' ' ' MET . . . . . 0.556 ' SD ' HG12 ' A' ' 291' ' ' ILE . 3.5 tpp -76.11 126.82 31.71 Favored 'General case' 0 N--CA 1.443 -0.821 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 174.647 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 72.5 t -77.14 129.48 37.33 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.122 0 N-CA-C 109.646 -0.502 . . . . 0.0 109.646 -178.419 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 3.0 m -83.43 -73.07 0.43 Allowed 'General case' 0 N--CA 1.437 -1.108 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 176.374 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 223' ' ' MET . . . . . 0.458 ' SD ' HG23 ' A' ' 225' ' ' THR . 3.6 ppp? -138.38 152.79 48.73 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.42 -0.354 . . . . 0.0 111.658 174.566 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 224' ' ' VAL . . . . . 0.45 HG12 ' SD ' ' A' ' 256' ' ' MET . 61.6 t -119.84 126.55 75.42 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.991 0 N-CA-C 108.323 -0.991 . . . . 0.0 108.323 175.08 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 225' ' ' THR . . . . . 0.458 HG23 ' SD ' ' A' ' 223' ' ' MET . 71.0 p -84.82 126.77 33.73 Favored 'General case' 0 C--N 1.322 -0.594 0 C-N-CA 119.726 -0.79 . . . . 0.0 109.648 176.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 86.5 tttt -77.86 89.85 4.08 Favored 'General case' 0 C--N 1.316 -0.874 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 -178.435 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 227' ' ' ASP . . . . . . . . . . . . . 43.5 t0 -163.86 173.68 12.43 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.429 -177.363 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 228' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -133.14 123.54 17.94 Favored Pre-proline 0 C--N 1.323 -0.559 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.855 172.926 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 229' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -66.78 144.25 68.2 Favored 'Cis proline' 0 C--N 1.311 -1.4 0 C-N-CA 122.845 -1.731 . . . . 0.0 109.774 -2.266 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . 0.459 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -84.03 139.06 18.1 Favored Glycine 0 CA--C 1.502 -0.766 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 -178.985 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.4 p -124.78 137.57 57.01 Favored 'Isoleucine or valine' 0 C--O 1.243 0.745 0 N-CA-C 109.967 -0.382 . . . . 0.0 109.967 177.162 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 232' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -132.61 155.34 41.23 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.892 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.801 -178.493 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 21.7 m -109.06 144.19 37.4 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.811 178.861 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 2.1 m -107.6 150.44 26.87 Favored 'General case' 0 C--N 1.316 -0.882 0 C-N-CA 123.023 0.529 . . . . 0.0 109.718 -179.662 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 37.4 tp -65.27 134.51 53.79 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.431 -176.638 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 236' ' ' ASP . . . . . 0.428 ' O ' ' NH1' ' A' ' 239' ' ' ARG . 13.0 t70 -49.1 -44.51 42.29 Favored 'General case' 0 N--CA 1.474 0.748 0 N-CA-C 114.0 1.111 . . . . 0.0 114.0 -171.779 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 237' ' ' GLU . . . . . 0.456 ' O ' ' NH1' ' A' ' 239' ' ' ARG . 54.6 mp0 -63.83 -33.5 75.82 Favored 'General case' 0 C--N 1.316 -0.851 0 C-N-CA 119.044 -1.062 . . . . 0.0 109.615 -177.534 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -77.36 95.2 4.35 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 112.869 0.692 . . . . 0.0 112.869 -177.952 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 239' ' ' ARG . . . . . 0.456 ' NH1' ' O ' ' A' ' 237' ' ' GLU . 0.0 OUTLIER -73.39 92.28 1.83 Allowed 'General case' 0 C--O 1.237 0.395 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 169.755 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 240' ' ' HIS . . . . . 0.553 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 9.4 p80 -53.0 -47.02 68.58 Favored 'General case' 0 C--O 1.213 -0.853 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.297 -174.382 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 76.8 20.75 75.83 Favored Glycine 0 C--N 1.311 -0.811 0 N-CA-C 110.416 -1.074 . . . . 0.0 110.416 177.752 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 242' ' ' PHE . . . . . 0.565 ' CE1' ' HB3' ' A' ' 294' ' ' GLN . 5.2 m-30 -80.17 143.63 33.68 Favored 'General case' 0 C--N 1.318 -0.778 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 179.405 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -119.41 166.26 13.29 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-O 121.153 0.502 . . . . 0.0 110.663 175.604 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 9.1 m -59.44 127.56 32.66 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 115.774 -0.648 . . . . 0.0 109.55 -179.032 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 84.54 6.7 85.48 Favored Glycine 0 N--CA 1.438 -1.175 0 N-CA-C 111.698 -0.561 . . . . 0.0 111.698 -179.815 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 246' ' ' ASP . . . . . 0.453 ' CG ' HE22 ' A' ' 294' ' ' GLN . 3.6 t0 -84.36 165.42 18.25 Favored 'General case' 0 CA--C 1.512 -0.483 0 C-N-CA 119.377 -0.929 . . . . 0.0 109.494 176.814 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 247' ' ' PHE . . . . . 0.547 ' CZ ' ' HB2' ' A' ' 266' ' ' GLU . 47.3 m-85 -112.61 138.11 49.87 Favored 'General case' 0 C--N 1.315 -0.906 0 N-CA-C 111.935 0.346 . . . . 0.0 111.935 -175.476 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . 0.495 ' HA ' ' HA ' ' A' ' 294' ' ' GLN . 2.7 m -133.01 160.38 42.67 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.363 0 C-N-CA 120.297 -0.561 . . . . 0.0 112.189 177.213 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 2.2 m -125.13 153.89 42.3 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 114.483 -1.235 . . . . 0.0 107.694 174.329 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 250' ' ' PHE . . . . . 0.59 ' CB ' ' HB3' ' A' ' 259' ' ' LEU . 64.5 m-85 -112.83 144.64 42.03 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-O 120.865 0.364 . . . . 0.0 111.126 -179.373 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 4.0 m -140.92 161.16 38.48 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 115.503 -0.772 . . . . 0.0 109.426 176.398 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 51.3 mm-40 52.96 27.49 5.63 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 112.278 0.473 . . . . 0.0 112.278 173.507 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . 0.445 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 83.4 t -88.68 133.6 30.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 177.771 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 90.9 mm-40 -100.37 145.75 27.8 Favored 'General case' 0 C--O 1.237 0.436 0 CA-C-O 120.852 0.358 . . . . 0.0 110.104 176.692 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 78.36 -68.85 2.86 Favored Glycine 0 C--N 1.315 -0.612 0 N-CA-C 110.417 -1.073 . . . . 0.0 110.417 -179.505 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 256' ' ' MET . . . . . 0.482 ' SD ' ' HD2' ' A' ' 283' ' ' PHE . 29.9 ttm -79.55 68.11 5.5 Favored 'General case' 0 C--N 1.321 -0.638 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 178.087 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 44.9 pt -75.23 -19.21 16.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.857 -175.344 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 258' ' ' GLN . . . . . 0.447 ' O ' ' N ' ' A' ' 262' ' ' CYS . 0.2 OUTLIER -53.18 -39.66 63.81 Favored 'General case' 0 C--O 1.213 -0.849 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 177.576 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 259' ' ' LEU . . . . . 0.59 ' HB3' ' CB ' ' A' ' 250' ' ' PHE . 94.6 mt -61.6 -41.96 98.19 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.137 179.075 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 260' ' ' ASN . . . . . 0.445 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 91.5 m-20 -59.73 -41.25 90.5 Favored 'General case' 0 CA--C 1.51 -0.567 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 179.524 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -101.14 9.48 57.89 Favored Glycine 0 CA--C 1.523 0.537 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.942 -177.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 262' ' ' CYS . . . . . 0.447 ' N ' ' O ' ' A' ' 258' ' ' GLN . 15.6 t -87.99 144.24 26.65 Favored 'General case' 0 C--O 1.241 0.632 0 CA-C-N 117.174 0.487 . . . . 0.0 111.415 -176.122 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -61.21 156.06 52.51 Favored Pre-proline 0 C--N 1.319 -0.721 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 173.6 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -64.77 143.32 79.95 Favored 'Trans proline' 0 C--N 1.307 -1.618 0 C-N-CA 120.757 0.971 . . . . 0.0 109.842 179.938 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 265' ' ' MET . . . . . 0.46 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 19.5 ptp -126.1 153.61 44.26 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 112.07 0.396 . . . . 0.0 112.07 -174.45 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 266' ' ' GLU . . . . . 0.547 ' HB2' ' CZ ' ' A' ' 247' ' ' PHE . 75.8 tt0 -79.82 137.34 36.93 Favored 'General case' 0 C--O 1.238 0.478 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 179.789 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 267' ' ' ILE . . . . . 0.484 HG21 ' CE2' ' A' ' 275' ' ' PHE . 1.9 pp -128.33 163.02 33.63 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 N-CA-C 113.752 1.019 . . . . 0.0 113.752 -169.674 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 52.9 tttp -124.95 121.3 34.06 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.148 -0.933 . . . . 0.0 109.995 175.155 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 29.5 m -75.64 132.19 33.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 C-N-CA 121.096 -0.242 . . . . 0.0 110.723 178.432 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 84.5 mt -106.38 -13.82 15.26 Favored 'General case' 0 CA--C 1.515 -0.393 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.737 -179.335 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -170.6 -177.93 40.98 Favored Glycine 0 C--N 1.318 -0.436 0 N-CA-C 110.364 -1.094 . . . . 0.0 110.364 -177.801 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 272' ' ' PRO . . . . . 0.553 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 36.2 Cg_endo -61.52 -31.4 87.51 Favored 'Trans proline' 0 C--N 1.308 -1.588 0 C-N-CA 122.097 1.865 . . . . 0.0 111.118 -178.302 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 273' ' ' TYR . . . . . 0.405 ' CE1' ' HA ' ' A' ' 236' ' ' ASP . 88.7 m-85 -124.49 7.43 8.31 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.877 -0.602 . . . . 0.0 112.407 -179.569 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 11.0 p -123.07 141.14 52.29 Favored 'General case' 0 C--O 1.244 0.784 0 C-N-CA 120.146 -0.622 . . . . 0.0 111.957 -177.893 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 275' ' ' PHE . . . . . 0.564 ' C ' ' CD1' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -143.34 165.95 26.09 Favored 'General case' 0 CA--C 1.508 -0.654 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.17 178.113 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 276' ' ' SER . . . . . 0.459 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 4.6 p -133.08 146.02 51.28 Favored 'General case' 0 N--CA 1.439 -1.01 0 N-CA-C 112.502 0.556 . . . . 0.0 112.502 -175.918 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . 0.446 HG23 ' CE1' ' A' ' 275' ' ' PHE . 29.1 pt -141.46 167.99 16.0 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.896 0 CA-C-N 114.224 -1.353 . . . . 0.0 111.332 -172.102 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 1.6 p -28.75 -95.19 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.759 0 N-CA-C 113.354 0.872 . . . . 0.0 113.354 -177.436 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -143.8 108.7 4.94 Favored 'General case' 0 CA--C 1.501 -0.912 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -178.626 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 280' ' ' THR . . . . . 0.746 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 17.8 p -64.58 -30.63 71.66 Favored 'General case' 0 C--N 1.29 -2.016 0 CA-C-O 121.492 0.663 . . . . 0.0 110.459 177.55 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -61.26 -31.37 71.18 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-N 114.836 -1.075 . . . . 0.0 110.297 175.953 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -87.07 -9.44 55.42 Favored 'General case' 0 CA--C 1.507 -0.686 0 C-N-CA 119.362 -0.935 . . . . 0.0 110.24 -176.609 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . 0.746 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 19.1 m-85 -77.11 -71.61 0.4 Allowed 'General case' 0 N--CA 1.437 -1.106 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 169.455 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 175.92 -169.5 0.05 Allowed 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 113.975 -1.466 . . . . 0.0 109.129 -175.574 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -97.47 120.66 38.24 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-O 120.377 0.132 . . . . 0.0 110.772 -177.432 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . 0.453 ' CZ ' ' HA ' ' A' ' 288' ' ' ARG . 64.6 t80 -63.87 126.41 27.53 Favored 'General case' 0 N--CA 1.478 0.94 0 C-N-CA 122.754 0.422 . . . . 0.0 111.254 -177.543 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 4.1 mm -100.92 -65.39 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.666 173.399 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . 0.453 ' HA ' ' CZ ' ' A' ' 286' ' ' TYR . 0.1 OUTLIER -173.25 -178.8 1.8 Allowed 'General case' 0 C--O 1.243 0.751 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.305 178.58 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 68.33 -156.75 52.99 Favored Glycine 0 CA--C 1.504 -0.625 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 175.432 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 106.72 129.68 6.31 Favored Glycine 0 N--CA 1.437 -1.251 0 C-N-CA 120.884 -0.674 . . . . 0.0 112.014 177.498 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . 0.556 HG12 ' SD ' ' A' ' 220' ' ' MET . 96.5 mt -122.43 130.58 74.41 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.31 0 N-CA-C 107.215 -1.402 . . . . 0.0 107.215 173.172 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . 0.411 ' O ' ' HA ' ' A' ' 218' ' ' SER . 2.6 p -112.12 126.9 69.56 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.828 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 -178.182 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 3.3 m -115.93 121.22 41.67 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 110.041 -0.355 . . . . 0.0 110.041 -176.915 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 294' ' ' GLN . . . . . 0.565 ' HB3' ' CE1' ' A' ' 242' ' ' PHE . 0.0 OUTLIER -75.76 138.85 41.5 Favored 'General case' 0 N--CA 1.435 -1.197 0 C-N-CA 120.149 -0.621 . . . . 0.0 110.576 178.362 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 3.2 t -106.52 106.11 20.0 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.196 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 179.6 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 296' ' ' LYS . . . . . 0.421 ' HD2' ' NE2' ' A' ' 294' ' ' GLN . 13.6 tptt -75.11 111.5 10.4 Favored 'General case' 0 N--CA 1.435 -1.214 0 N-CA-C 106.854 -1.536 . . . . 0.0 106.854 174.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 5.2 m -42.41 153.12 0.31 Allowed Pre-proline 0 C--N 1.321 -0.67 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.26 -169.691 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -61.94 -16.08 47.33 Favored 'Trans proline' 0 C--N 1.31 -1.494 0 C-N-CA 122.757 2.304 . . . . 0.0 110.884 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 27.0 mmtp -54.61 131.87 44.06 Favored 'General case' 0 C--O 1.24 0.584 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 179.035 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -96.39 118.84 33.75 Favored 'General case' 0 CA--C 1.507 -0.69 0 C-N-CA 120.44 -0.504 . . . . 0.0 110.166 175.274 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 44.3 pt -134.78 160.27 41.32 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.157 0 CA-C-N 115.453 -0.794 . . . . 0.0 109.856 -177.275 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -74.03 123.48 24.44 Favored 'General case' 0 C--N 1.311 -1.07 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 176.041 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 303' ' ' PHE . . . . . 0.402 ' CG ' ' N ' ' A' ' 304' ' ' LYS . 88.2 t80 -101.22 157.27 16.9 Favored 'General case' 0 C--N 1.312 -1.041 0 CA-C-N 116.145 -0.479 . . . . 0.0 109.855 -176.28 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . 0.402 ' N ' ' CG ' ' A' ' 303' ' ' PHE . 32.3 mmtp -47.74 107.33 0.12 Allowed 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.194 -0.457 . . . . 0.0 109.847 -177.554 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 70.1 m -71.68 143.08 49.82 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-N 116.333 -0.394 . . . . 0.0 109.991 178.327 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 48.1 mt -54.78 115.02 7.86 Favored Pre-proline 0 C--N 1.324 -0.52 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 177.222 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . 0.492 ' O ' ' N ' ' A' ' 309' ' ' SER . 53.1 Cg_exo -58.29 141.75 97.03 Favored 'Trans proline' 0 N--CA 1.495 1.596 0 C-N-CA 121.957 1.772 . . . . 0.0 111.262 -175.971 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -66.71 65.29 0.05 Allowed 'General case' 0 CA--C 1.516 -0.352 0 CA-C-O 121.309 0.576 . . . . 0.0 109.88 177.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.492 ' N ' ' O ' ' A' ' 307' ' ' PRO . 4.8 m -62.41 150.42 39.83 Favored 'General case' 0 C--N 1.31 -1.114 0 CA-C-N 115.496 -0.774 . . . . 0.0 109.534 -179.102 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 75.3 mt -68.68 76.66 0.29 Allowed 'General case' 0 C--N 1.323 -0.586 0 C-N-CA 120.393 -0.523 . . . . 0.0 110.206 -175.3 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 12.6 p -76.41 99.26 1.96 Allowed 'Isoleucine or valine' 0 C--O 1.243 0.73 0 CA-C-N 115.954 -0.567 . . . . 0.0 109.766 179.781 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 99.6 mt-10 . . . . . 0 C--O 1.21 -1.016 0 CA-C-O 118.491 -0.766 . . . . 0.0 110.11 -176.956 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . 0.543 ' O ' ' N ' ' A' ' 203' ' ' GLY . 14.1 mm-40 . . . . . 0 N--CA 1.48 1.041 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 202' ' ' PHE . . . . . 0.472 ' C ' ' H ' ' A' ' 204' ' ' GLU . 81.1 m-85 60.74 -57.83 0.09 Allowed 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 122.744 0.417 . . . . 0.0 110.584 -175.93 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . 0.543 ' N ' ' O ' ' A' ' 201' ' ' GLU . . . -73.49 42.27 1.02 Allowed Glycine 0 C--N 1.311 -0.825 0 N-CA-C 110.143 -1.183 . . . . 0.0 110.143 176.193 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 204' ' ' GLU . . . . . 0.472 ' H ' ' C ' ' A' ' 202' ' ' PHE . 73.4 mm-40 -59.94 -33.22 71.61 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 -179.679 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 205' ' ' GLU . . . . . 0.44 ' O ' ' N ' ' A' ' 207' ' ' VAL . 99.8 mt-10 -62.01 -21.72 65.11 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 114.605 -1.18 . . . . 0.0 110.906 177.837 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 99.5 mtp -64.92 72.01 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.923 0.392 . . . . 0.0 111.397 -175.695 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . 0.44 ' N ' ' O ' ' A' ' 205' ' ' GLU . 8.3 m -121.3 127.96 75.86 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.095 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 170.728 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 67.8 mt -89.47 69.78 7.98 Favored 'General case' 0 C--N 1.319 -0.718 0 C-N-CA 119.637 -0.825 . . . . 0.0 109.914 -173.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 19.0 m -71.55 -41.56 68.96 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.103 -0.953 . . . . 0.0 110.278 176.275 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 9.8 p-10 -51.48 -27.25 9.97 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.351 -177.49 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 1.4 m -56.22 134.32 53.06 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 179.754 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 28.8 t-20 -92.05 135.54 33.88 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 112.433 0.531 . . . . 0.0 112.433 -174.418 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 73.44 20.39 79.85 Favored Glycine 0 N--CA 1.452 -0.275 0 CA-C-N 115.349 -0.841 . . . . 0.0 112.944 172.446 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -93.9 114.95 27.28 Favored 'General case' 0 C--O 1.239 0.538 0 CA-C-N 117.678 0.739 . . . . 0.0 110.172 176.287 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 11.9 mt-30 -113.2 109.06 52.14 Favored Pre-proline 0 C--N 1.319 -0.747 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.36 179.716 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -71.55 102.3 1.27 Allowed 'Trans proline' 0 C--N 1.312 -1.379 0 C-N-CA 121.139 1.226 . . . . 0.0 110.319 178.302 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 217' ' ' LEU . . . . . 0.468 ' O ' ' HA ' ' A' ' 293' ' ' SER . 0.5 OUTLIER -90.29 125.7 35.6 Favored 'General case' 0 C--N 1.316 -0.88 0 CA-C-N 115.716 -0.675 . . . . 0.0 109.882 -179.487 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 218' ' ' SER . . . . . 0.422 ' HG ' ' CB ' ' A' ' 293' ' ' SER . 34.5 m -119.19 132.57 55.97 Favored 'General case' 0 C--N 1.324 -0.532 0 O-C-N 123.661 0.601 . . . . 0.0 110.616 -179.652 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -122.53 139.55 53.77 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.821 0.343 . . . . 0.0 110.259 -179.436 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 1.3 tpt -76.6 122.37 24.53 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 177.813 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 73.5 t -74.19 132.65 33.05 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 -177.642 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 222' ' ' SER . . . . . 0.402 ' OG ' ' C ' ' A' ' 233' ' ' THR . 5.8 p -90.68 -54.64 3.9 Favored 'General case' 0 N--CA 1.434 -1.252 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 177.829 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -138.53 151.87 47.73 Favored 'General case' 0 C--O 1.222 -0.389 0 N-CA-C 112.649 0.611 . . . . 0.0 112.649 174.856 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 224' ' ' VAL . . . . . 0.555 HG11 ' SD ' ' A' ' 256' ' ' MET . 39.5 t -126.64 132.33 70.3 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 172.143 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -104.1 122.98 46.42 Favored 'General case' 0 C--N 1.313 -1.002 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 -177.817 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.3 77.72 3.07 Favored 'General case' 0 C--O 1.234 0.265 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 179.379 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 227' ' ' ASP . . . . . 0.59 ' N ' ' OG1' ' A' ' 280' ' ' THR . 2.8 t0 -148.42 178.34 8.68 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.762 179.459 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 228' ' ' ASN . . . . . 0.455 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.1 OUTLIER -138.47 125.25 13.06 Favored Pre-proline 0 C--N 1.324 -0.507 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.21 176.43 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 229' ' ' PRO . . . . . 0.455 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 38.2 Cg_endo -65.0 144.76 62.38 Favored 'Cis proline' 0 N--CA 1.499 1.814 0 C-N-CA 123.286 -1.548 . . . . 0.0 110.564 -1.063 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . 0.452 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -68.66 136.96 29.95 Favored Glycine 0 N--CA 1.445 -0.732 0 N-CA-C 110.05 -1.22 . . . . 0.0 110.05 -177.915 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.1 p -127.05 133.93 67.23 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 177.772 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 232' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -134.76 156.7 40.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 C-N-CA 120.084 -0.646 . . . . 0.0 111.451 -179.695 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 233' ' ' THR . . . . . 0.402 ' C ' ' OG ' ' A' ' 222' ' ' SER . 6.7 m -111.37 140.68 45.75 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 115.148 -0.933 . . . . 0.0 109.044 178.755 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 44.5 m -107.92 155.97 19.71 Favored 'General case' 0 C--N 1.315 -0.903 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 176.621 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 40.3 tp -57.74 133.71 55.6 Favored 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 177.401 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -53.8 -46.57 71.1 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.145 0.498 . . . . 0.0 110.557 -170.599 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 59.1 mp0 -68.04 -20.33 64.98 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.93 -0.577 . . . . 0.0 112.375 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -73.93 94.84 2.38 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.629 -177.253 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 77.3 mtp85 -71.44 99.31 1.98 Allowed 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 176.149 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 240' ' ' HIS . . . . . 0.661 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 12.8 p80 -68.2 -42.97 79.1 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 120.791 0.329 . . . . 0.0 111.748 -176.182 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 80.32 14.42 80.31 Favored Glycine 0 C--N 1.315 -0.586 0 N-CA-C 110.791 -0.924 . . . . 0.0 110.791 -178.514 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 242' ' ' PHE . . . . . 0.501 ' CD1' ' HB3' ' A' ' 294' ' ' GLN . 5.2 m-30 -81.0 142.97 32.87 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -179.613 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -112.19 167.88 10.06 Favored 'General case' 0 CA--C 1.505 -0.76 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 172.882 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 21.1 m -62.58 126.24 26.65 Favored 'General case' 0 N--CA 1.436 -1.165 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 169.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . 0.47 ' HA2' ' CG ' ' A' ' 266' ' ' GLU . . . 82.04 7.21 88.14 Favored Glycine 0 C--N 1.309 -0.941 0 C-N-CA 120.902 -0.666 . . . . 0.0 111.717 -179.029 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 42.1 t0 -84.87 161.7 19.78 Favored 'General case' 0 C--O 1.235 0.305 0 C-N-CA 120.049 -0.66 . . . . 0.0 109.952 177.798 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 247' ' ' PHE . . . . . 0.452 ' HA ' ' O ' ' A' ' 265' ' ' MET . 30.1 m-85 -109.94 131.7 54.82 Favored 'General case' 0 C--O 1.242 0.702 0 N-CA-C 112.134 0.42 . . . . 0.0 112.134 -174.35 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . 0.441 ' HA ' ' HA ' ' A' ' 294' ' ' GLN . 2.7 m -129.92 160.99 40.42 Favored 'Isoleucine or valine' 0 C--O 1.236 0.381 0 CA-C-N 115.89 -0.596 . . . . 0.0 111.884 -179.334 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 3.0 m -126.49 156.0 41.42 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 173.661 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 250' ' ' PHE . . . . . 0.614 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 91.9 m-85 -112.72 146.84 38.01 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-O 120.518 0.199 . . . . 0.0 111.072 -174.059 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 43.4 m -134.4 151.65 51.32 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.105 178.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 4.0 mm-40 41.91 37.12 0.74 Allowed 'General case' 0 C--O 1.245 0.832 0 N-CA-C 113.266 0.839 . . . . 0.0 113.266 174.671 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . 0.464 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 79.2 t -89.56 129.98 39.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 174.641 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . 0.529 HE22 ' CZ ' ' A' ' 288' ' ' ARG . 75.3 mt-30 -99.3 141.32 32.23 Favored 'General case' 0 C--O 1.24 0.577 0 C-N-CA 120.523 -0.471 . . . . 0.0 111.222 -178.249 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 79.61 -57.22 4.49 Favored Glycine 0 CA--C 1.507 -0.438 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -177.081 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 256' ' ' MET . . . . . 0.555 ' SD ' HG11 ' A' ' 224' ' ' VAL . 4.2 ttm -86.74 49.59 1.84 Allowed 'General case' 0 C--N 1.314 -0.949 0 CA-C-O 121.911 0.862 . . . . 0.0 108.721 176.344 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 257' ' ' ILE . . . . . 0.41 ' O ' ' HB2' ' A' ' 260' ' ' ASN . 46.5 pt -68.22 -24.32 29.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 114.453 -1.249 . . . . 0.0 110.917 -174.969 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 258' ' ' GLN . . . . . 0.576 ' HG3' ' SG ' ' A' ' 262' ' ' CYS . 69.2 tp60 -57.68 -30.07 65.17 Favored 'General case' 0 C--N 1.318 -0.795 0 C-N-CA 119.458 -0.897 . . . . 0.0 109.608 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 259' ' ' LEU . . . . . 0.614 ' HB3' ' CG ' ' A' ' 250' ' ' PHE . 94.3 mt -62.07 -40.21 95.03 Favored 'General case' 0 N--CA 1.448 -0.55 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 174.038 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 260' ' ' ASN . . . . . 0.464 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 96.8 m-20 -60.31 -40.89 92.18 Favored 'General case' 0 CA--C 1.514 -0.431 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 179.58 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -98.33 17.65 58.22 Favored Glycine 0 CA--C 1.525 0.706 0 CA-C-N 115.447 -0.797 . . . . 0.0 112.005 -179.392 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 262' ' ' CYS . . . . . 0.576 ' SG ' ' HG3' ' A' ' 258' ' ' GLN . 1.5 m -93.97 146.59 23.82 Favored 'General case' 0 CA--C 1.508 -0.661 0 C-N-CA 120.579 -0.448 . . . . 0.0 111.032 -179.379 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 46.6 mt-30 -59.81 161.2 12.37 Favored Pre-proline 0 C--N 1.323 -0.548 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 172.277 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 264' ' ' PRO . . . . . 0.423 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 38.0 Cg_endo -63.37 143.39 88.67 Favored 'Trans proline' 0 C--N 1.307 -1.651 0 N-CA-C 108.437 -1.409 . . . . 0.0 108.437 174.974 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 265' ' ' MET . . . . . 0.452 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 22.7 ptp -135.35 152.36 51.37 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 112.071 0.397 . . . . 0.0 112.071 -171.222 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 266' ' ' GLU . . . . . 0.47 ' CG ' ' HA2' ' A' ' 245' ' ' GLY . 39.5 tt0 -71.79 136.94 47.27 Favored 'General case' 0 C--N 1.331 -0.228 0 O-C-N 124.034 0.834 . . . . 0.0 109.516 178.757 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 267' ' ' ILE . . . . . 0.458 HG23 ' CE2' ' A' ' 275' ' ' PHE . 1.9 pp -128.3 162.39 34.85 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-O 121.142 0.496 . . . . 0.0 112.1 -179.346 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 60.1 tttm -118.98 131.52 56.02 Favored 'General case' 0 C--O 1.219 -0.501 0 CA-C-N 115.66 -0.7 . . . . 0.0 109.541 174.081 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 23.2 m -82.4 128.21 38.93 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.974 0 C-N-CA 120.313 -0.555 . . . . 0.0 110.276 176.822 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 95.6 mt -98.99 -17.89 18.07 Favored 'General case' 0 CA--C 1.502 -0.871 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 178.298 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -171.27 177.0 44.4 Favored Glycine 0 N--CA 1.443 -0.872 0 N-CA-C 108.546 -1.821 . . . . 0.0 108.546 179.092 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 272' ' ' PRO . . . . . 0.661 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 60.2 Cg_exo -54.07 -38.32 87.09 Favored 'Trans proline' 0 C--N 1.298 -2.091 0 C-N-CA 121.443 1.429 . . . . 0.0 110.559 -179.219 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 8.9 m-85 -118.69 11.57 12.8 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 112.646 0.61 . . . . 0.0 112.646 -174.455 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 22.2 p -130.13 143.59 50.87 Favored 'General case' 0 C--O 1.242 0.675 0 C-N-CA 120.669 -0.413 . . . . 0.0 111.177 177.158 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 275' ' ' PHE . . . . . 0.521 ' C ' ' CD1' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -146.59 165.85 28.26 Favored 'General case' 0 C--O 1.246 0.869 0 N-CA-C 112.363 0.505 . . . . 0.0 112.363 178.75 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 276' ' ' SER . . . . . 0.452 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 4.4 p -130.88 143.01 50.42 Favored 'General case' 0 N--CA 1.431 -1.416 0 CA-C-O 121.773 0.797 . . . . 0.0 111.605 -178.695 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . 0.406 HG23 ' CE1' ' A' ' 275' ' ' PHE . 33.8 pt -135.91 165.32 29.95 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.058 0 CA-C-N 114.428 -1.26 . . . . 0.0 110.71 -173.136 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 15.2 t -30.54 -90.71 0.0 OUTLIER 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 112.859 0.689 . . . . 0.0 112.859 -174.874 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . 0.423 ' CG ' ' HB2' ' A' ' 228' ' ' ASN . 66.3 t0 -148.93 117.18 6.43 Favored 'General case' 0 N--CA 1.447 -0.593 0 CA-C-O 120.943 0.402 . . . . 0.0 110.827 -178.91 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 280' ' ' THR . . . . . 0.708 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 21.3 p -65.49 -27.33 68.41 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.54 176.56 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -64.35 -19.36 65.41 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.664 175.889 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -88.49 -9.88 50.91 Favored 'General case' 0 CA--C 1.508 -0.655 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.378 179.839 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . 0.708 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 4.4 m-85 -93.69 -64.96 1.03 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 174.303 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 284' ' ' SER . . . . . 0.437 ' OG ' ' HA ' ' A' ' 256' ' ' MET . 1.9 p 169.43 -94.18 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 115.205 -0.907 . . . . 0.0 111.625 177.242 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 285' ' ' ASP . . . . . 0.531 ' O ' ' N ' ' A' ' 256' ' ' MET . 45.0 t0 -156.19 166.09 34.46 Favored 'General case' 0 C--O 1.214 -0.786 0 N-CA-C 110.409 -0.219 . . . . 0.0 110.409 -177.308 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . 0.511 ' CZ ' ' HA ' ' A' ' 288' ' ' ARG . 68.2 t80 -99.61 119.4 38.02 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 110.226 -0.287 . . . . 0.0 110.226 177.359 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 287' ' ' ILE . . . . . 0.419 HG23 HD13 ' A' ' 287' ' ' ILE . 21.1 mm -99.91 -56.44 5.2 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.586 0 N-CA-C 109.114 -0.698 . . . . 0.0 109.114 173.575 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . 0.529 ' CZ ' HE22 ' A' ' 254' ' ' GLN . 45.9 ptt85 177.87 -173.92 0.14 Allowed 'General case' 0 C--O 1.241 0.639 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.145 175.532 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 66.16 -158.93 47.67 Favored Glycine 0 CA--C 1.51 -0.281 0 N-CA-C 111.018 -0.833 . . . . 0.0 111.018 176.619 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 110.6 127.15 5.16 Favored Glycine 0 N--CA 1.447 -0.592 0 CA-C-O 121.52 0.511 . . . . 0.0 112.988 175.224 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 94.2 mt -130.32 133.07 64.5 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.807 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 174.312 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 3.8 p -124.52 134.29 67.14 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 C-N-CA 120.442 -0.503 . . . . 0.0 109.669 -177.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 293' ' ' SER . . . . . 0.468 ' HA ' ' O ' ' A' ' 217' ' ' LEU . 2.6 m -127.23 145.43 50.77 Favored 'General case' 0 C--N 1.324 -0.532 0 C-N-CA 120.488 -0.485 . . . . 0.0 111.042 -178.364 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 294' ' ' GLN . . . . . 0.501 ' HB3' ' CD1' ' A' ' 242' ' ' PHE . 0.3 OUTLIER -84.27 148.74 26.53 Favored 'General case' 0 CA--C 1.508 -0.659 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.185 176.661 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 59.0 t -122.3 128.29 75.43 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.926 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 177.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 24.6 tptp -83.95 98.07 9.6 Favored 'General case' 0 N--CA 1.441 -0.905 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 174.56 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 297' ' ' VAL . . . . . 0.473 ' CG2' ' HZ3' ' A' ' 299' ' ' LYS . 26.5 m -80.89 162.12 61.01 Favored Pre-proline 0 C--N 1.312 -1.036 0 CA-C-N 115.798 -0.637 . . . . 0.0 109.928 -176.628 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -56.84 138.11 84.33 Favored 'Trans proline' 0 C--N 1.304 -1.768 0 C-N-CA 121.516 1.477 . . . . 0.0 112.1 -177.205 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . 0.473 ' HZ3' ' CG2' ' A' ' 297' ' ' VAL . 33.2 mmtm -139.25 -174.42 3.86 Favored 'General case' 0 C--N 1.314 -0.973 0 CA-C-N 114.611 -1.177 . . . . 0.0 108.371 177.115 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 300' ' ' LYS . . . . . 0.421 ' O ' ' N ' ' A' ' 302' ' ' SER . 8.1 tttm -69.74 122.73 19.76 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 168.057 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 99.1 mt -61.65 89.07 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-O 121.565 0.697 . . . . 0.0 110.032 -175.805 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 302' ' ' SER . . . . . 0.421 ' N ' ' O ' ' A' ' 300' ' ' LYS . 0.7 OUTLIER -134.03 85.14 2.17 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-N 114.894 -1.048 . . . . 0.0 109.716 -177.081 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 27.2 p90 -104.68 130.09 52.76 Favored 'General case' 0 C--O 1.242 0.667 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.71 -177.693 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 32.6 tttp -48.74 107.59 0.14 Allowed 'General case' 0 CA--C 1.51 -0.562 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.516 -174.733 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 8.5 m -130.32 148.48 52.15 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.286 179.72 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -90.05 127.36 53.9 Favored Pre-proline 0 C--N 1.322 -0.589 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 176.821 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -65.21 -25.2 57.83 Favored 'Trans proline' 0 C--N 1.306 -1.659 0 C-N-CA 121.961 1.774 . . . . 0.0 111.412 178.769 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -97.99 -178.14 3.98 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.899 -0.591 . . . . 0.0 111.621 -178.15 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 5.4 p -77.0 -161.56 0.22 Allowed 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.476 -0.784 . . . . 0.0 110.313 177.904 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 51.2 tp -62.89 133.09 54.14 Favored 'General case' 0 CA--C 1.508 -0.66 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 175.667 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 16.5 m -114.8 129.01 71.67 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-O 120.882 0.373 . . . . 0.0 111.055 -177.598 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 33.0 mp0 . . . . . 0 C--O 1.209 -1.069 0 CA-C-O 117.735 -1.126 . . . . 0.0 108.939 -179.803 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 . . . . . 0 N--CA 1.477 0.893 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 9.4 m-30 66.55 13.43 9.29 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.4 -179.404 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -57.44 -21.28 40.74 Favored Glycine 0 C--O 1.237 0.303 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 177.105 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 204' ' ' GLU . . . . . 0.401 ' H ' ' CD ' ' A' ' 204' ' ' GLU . 0.5 OUTLIER -40.37 -29.86 0.09 Allowed 'General case' 0 C--O 1.237 0.405 0 C-N-CA 123.514 0.726 . . . . 0.0 111.343 -179.316 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 205' ' ' GLU . . . . . 0.46 ' O ' ' N ' ' A' ' 207' ' ' VAL . 98.8 mt-10 -60.79 -30.67 70.19 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.581 -177.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 7.0 tpt -67.04 71.0 0.09 Allowed 'General case' 0 C--N 1.327 -0.383 0 C-N-CA 119.846 -0.742 . . . . 0.0 109.845 -178.543 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . 0.46 ' N ' ' O ' ' A' ' 205' ' ' GLU . 15.3 m -139.11 155.3 26.48 Favored 'Isoleucine or valine' 0 C--O 1.239 0.539 0 CA-C-N 115.607 -0.724 . . . . 0.0 109.86 177.179 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 90.3 mt -123.58 70.28 1.05 Allowed 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.061 0.458 . . . . 0.0 110.218 176.363 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -118.96 33.26 5.73 Favored 'General case' 0 C--N 1.311 -1.098 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.433 176.796 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -61.31 -43.92 98.06 Favored 'General case' 0 CA--C 1.513 -0.449 0 CA-C-N 115.13 -0.941 . . . . 0.0 110.385 -174.86 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 2.8 m -89.59 149.29 22.91 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.001 -179.129 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 58.9 t-20 -98.55 111.94 24.14 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 174.411 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 118.91 -8.59 12.66 Favored Glycine 0 C--O 1.24 0.512 0 N-CA-C 111.905 -0.478 . . . . 0.0 111.905 179.655 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 92.7 mt-10 -84.01 112.92 20.62 Favored 'General case' 0 C--O 1.238 0.472 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 175.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 27.5 mt-30 -110.95 142.12 25.58 Favored Pre-proline 0 C--N 1.323 -0.58 0 N-CA-C 109.581 -0.525 . . . . 0.0 109.581 177.724 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_exo -60.25 142.58 98.53 Favored 'Trans proline' 0 C--N 1.309 -1.539 0 C-N-CA 121.407 1.405 . . . . 0.0 108.797 173.678 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -61.55 118.7 7.38 Favored 'General case' 0 C--N 1.324 -0.501 0 C-N-CA 119.413 -0.915 . . . . 0.0 109.51 -177.686 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 4.6 m -126.3 147.95 49.62 Favored 'General case' 0 C--N 1.313 -1.011 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.335 -176.374 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -152.5 153.8 34.22 Favored 'General case' 0 C--O 1.24 0.605 0 CA-C-O 121.112 0.482 . . . . 0.0 111.062 -178.709 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 71.3 mtm -80.15 129.67 34.66 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.652 -0.703 . . . . 0.0 109.662 175.9 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 57.5 t -76.29 131.24 35.25 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.694 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 177.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 46.8 p -88.72 -65.84 0.98 Allowed 'General case' 0 C--N 1.309 -1.169 0 C-N-CA 120.325 -0.55 . . . . 0.0 110.024 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 23.3 ptm -137.73 142.43 40.99 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.923 -0.58 . . . . 0.0 112.205 176.581 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 224' ' ' VAL . . . . . 0.451 ' CG2' ' HB ' ' A' ' 232' ' ' VAL . 75.0 t -119.89 133.57 66.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 177.294 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 62.7 p -98.5 128.6 44.91 Favored 'General case' 0 C--N 1.323 -0.569 0 C-N-CA 120.234 -0.587 . . . . 0.0 110.974 -179.517 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.86 85.76 3.44 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 177.908 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 227' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -152.04 175.82 12.15 Favored 'General case' 0 N--CA 1.469 0.521 0 CA-C-N 116.476 -0.329 . . . . 0.0 111.39 -175.495 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 228' ' ' ASN . . . . . 0.457 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 9.4 t30 -140.69 124.09 10.17 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.508 174.625 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 229' ' ' PRO . . . . . 0.457 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 40.4 Cg_endo -65.22 142.24 52.16 Favored 'Cis proline' 0 N--CA 1.493 1.488 0 C-N-CA 122.702 -1.791 . . . . 0.0 109.854 -1.12 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . 0.428 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -74.39 136.84 21.84 Favored Glycine 0 C--N 1.315 -0.629 0 N-CA-C 110.575 -1.01 . . . . 0.0 110.575 -176.957 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.1 p -127.69 137.74 56.75 Favored 'Isoleucine or valine' 0 C--O 1.248 0.997 0 CA-C-O 120.807 0.337 . . . . 0.0 110.697 177.574 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 232' ' ' VAL . . . . . 0.451 ' HB ' ' CG2' ' A' ' 224' ' ' VAL . 0.7 OUTLIER -132.28 157.17 43.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.951 179.292 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 233' ' ' THR . . . . . 0.442 ' HA ' ' O ' ' A' ' 273' ' ' TYR . 0.9 OUTLIER -114.36 146.96 39.88 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.388 -178.836 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 34.0 m -107.31 152.24 24.4 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.111 -0.495 . . . . 0.0 109.948 179.263 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 15.7 tp -51.72 135.09 29.78 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 -178.881 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 24.7 p-10 -48.63 -47.44 40.2 Favored 'General case' 0 N--CA 1.475 0.793 0 N-CA-C 111.936 0.347 . . . . 0.0 111.936 -171.838 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -70.51 -34.65 72.55 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-O 120.944 0.402 . . . . 0.0 111.62 178.218 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -83.96 89.42 7.23 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.262 -176.615 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 239' ' ' ARG . . . . . 0.52 ' NH1' ' O ' ' A' ' 239' ' ' ARG . 0.0 OUTLIER -78.83 123.16 26.94 Favored 'General case' 0 CA--C 1.513 -0.443 0 N-CA-C 108.771 -0.825 . . . . 0.0 108.771 173.698 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 240' ' ' HIS . . . . . 0.534 ' HB2' ' CD2' ' A' ' 242' ' ' PHE . 7.0 p80 -57.13 -48.71 77.98 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.397 -175.818 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 80.01 19.93 68.84 Favored Glycine 0 C--N 1.314 -0.666 0 N-CA-C 110.131 -1.188 . . . . 0.0 110.131 -177.674 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 242' ' ' PHE . . . . . 0.534 ' CD2' ' HB2' ' A' ' 240' ' ' HIS . 8.3 m-30 -81.53 151.87 27.54 Favored 'General case' 0 C--N 1.316 -0.877 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 177.946 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -116.19 160.78 19.92 Favored 'General case' 0 C--N 1.314 -0.935 0 CA-C-O 120.893 0.378 . . . . 0.0 110.887 177.491 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -58.84 125.88 25.37 Favored 'General case' 0 C--N 1.312 -1.029 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 -179.65 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 80.86 5.81 89.83 Favored Glycine 0 C--N 1.319 -0.365 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 -178.326 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 246' ' ' ASP . . . . . 0.477 ' CG ' HE21 ' A' ' 294' ' ' GLN . 5.3 t70 -79.86 162.34 25.09 Favored 'General case' 0 CA--C 1.514 -0.42 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 178.416 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 247' ' ' PHE . . . . . . . . . . . . . 78.0 m-85 -109.78 129.04 55.67 Favored 'General case' 0 C--O 1.242 0.708 0 CA-C-O 120.846 0.355 . . . . 0.0 111.191 -177.488 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . 0.475 HG12 ' CD2' ' A' ' 242' ' ' PHE . 2.4 m -129.95 162.26 38.01 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.399 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.364 178.369 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.48 145.82 46.87 Favored 'General case' 0 C--N 1.308 -1.226 0 CA-C-N 115.324 -0.853 . . . . 0.0 109.982 177.363 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 250' ' ' PHE . . . . . 0.558 ' CB ' ' HB3' ' A' ' 259' ' ' LEU . 67.5 m-85 -104.81 145.68 30.04 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.65 177.701 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 4.3 m -143.36 150.12 38.69 Favored 'General case' 0 C--N 1.309 -1.153 0 N-CA-C 110.084 -0.339 . . . . 0.0 110.084 176.07 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 23.7 mm-40 54.1 26.78 6.86 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 112.816 0.673 . . . . 0.0 112.816 173.07 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . 0.517 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 88.0 t -76.53 130.93 35.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 173.702 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 86.5 mm-40 -100.45 139.72 35.72 Favored 'General case' 0 C--O 1.244 0.765 0 C-N-CA 119.68 -0.808 . . . . 0.0 111.651 -176.152 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 78.71 -58.16 4.21 Favored Glycine 0 C--O 1.239 0.453 0 N-CA-C 108.983 -1.647 . . . . 0.0 108.983 -173.688 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 256' ' ' MET . . . . . 0.481 ' SD ' ' HB2' ' A' ' 286' ' ' TYR . 31.7 mtt -80.57 61.04 4.14 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-O 121.242 0.544 . . . . 0.0 109.788 172.682 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 41.8 pt -76.23 -15.78 15.14 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.731 -178.512 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 258' ' ' GLN . . . . . 0.414 ' O ' ' N ' ' A' ' 262' ' ' CYS . 70.5 tp60 -55.38 -39.31 69.99 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 179.423 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 259' ' ' LEU . . . . . 0.558 ' HB3' ' CB ' ' A' ' 250' ' ' PHE . 89.0 mt -61.86 -41.71 98.17 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.747 -0.661 . . . . 0.0 109.925 176.908 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 260' ' ' ASN . . . . . 0.517 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 97.9 m-20 -61.29 -40.58 94.67 Favored 'General case' 0 CA--C 1.509 -0.612 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 179.347 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -87.66 -5.67 78.0 Favored Glycine 0 CA--C 1.523 0.538 0 CA-C-N 115.529 -0.76 . . . . 0.0 111.496 -178.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 262' ' ' CYS . . . . . 0.414 ' N ' ' O ' ' A' ' 258' ' ' GLN . 49.0 t -87.98 150.58 23.36 Favored 'General case' 0 CA--C 1.512 -0.493 0 CA-C-O 120.765 0.317 . . . . 0.0 111.062 -178.285 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . 0.576 ' CD ' ' H ' ' A' ' 263' ' ' GLN . 0.0 OUTLIER -72.45 169.39 17.09 Favored Pre-proline 0 C--N 1.319 -0.758 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 172.631 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_exo -61.76 145.12 97.5 Favored 'Trans proline' 0 C--N 1.307 -1.608 0 C-N-CA 121.462 1.441 . . . . 0.0 109.983 179.099 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 265' ' ' MET . . . . . 0.655 ' SD ' ' N ' ' A' ' 265' ' ' MET . 0.8 OUTLIER -122.83 157.26 32.85 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 -176.466 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 64.1 tt0 -75.94 134.85 40.12 Favored 'General case' 0 C--O 1.238 0.493 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 175.513 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 267' ' ' ILE . . . . . 0.436 ' C ' ' CD1' ' A' ' 267' ' ' ILE . 1.9 pp -128.66 163.3 33.63 Favored 'Isoleucine or valine' 0 C--O 1.237 0.405 0 N-CA-C 114.095 1.146 . . . . 0.0 114.095 -170.495 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . 0.43 ' NZ ' ' OG ' ' A' ' 276' ' ' SER . 8.0 mtpm? -119.36 123.31 43.84 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-N 115.009 -0.996 . . . . 0.0 110.065 178.737 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . 0.415 HG13 ' O ' ' A' ' 242' ' ' PHE . 30.1 m -84.59 97.93 5.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-O 121.087 0.47 . . . . 0.0 111.236 177.056 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 91.9 mt -66.79 -40.4 88.14 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.528 0.68 . . . . 0.0 109.747 176.38 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -155.33 -177.85 28.99 Favored Glycine 0 N--CA 1.447 -0.624 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 -179.827 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 272' ' ' PRO . . . . . 0.5 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 35.6 Cg_endo -61.32 -30.88 88.49 Favored 'Trans proline' 0 C--N 1.306 -1.702 0 C-N-CA 122.066 1.844 . . . . 0.0 111.471 -178.519 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 273' ' ' TYR . . . . . 0.442 ' O ' ' HA ' ' A' ' 233' ' ' THR . 94.5 m-85 -122.85 7.0 9.33 Favored 'General case' 0 C--N 1.319 -0.733 0 N-CA-C 112.942 0.719 . . . . 0.0 112.942 -178.497 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 4.3 p -126.84 129.02 47.45 Favored 'General case' 0 C--O 1.244 0.816 0 CA-C-O 120.884 0.374 . . . . 0.0 110.835 178.031 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 275' ' ' PHE . . . . . 0.511 ' C ' ' CD1' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -139.41 160.47 39.76 Favored 'General case' 0 CA--C 1.499 -0.986 0 C-N-CA 120.446 -0.502 . . . . 0.0 112.206 177.281 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 276' ' ' SER . . . . . 0.43 ' OG ' ' NZ ' ' A' ' 268' ' ' LYS . 10.9 p -130.79 154.49 47.95 Favored 'General case' 0 N--CA 1.43 -1.427 0 CA-C-O 121.456 0.646 . . . . 0.0 111.953 -175.11 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . 0.532 HD13 ' CE2' ' A' ' 283' ' ' PHE . 2.5 pp -138.19 -172.48 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.154 0 CA-C-N 114.313 -1.312 . . . . 0.0 108.961 -176.926 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -48.14 -85.93 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.751 0.31 . . . . 0.0 111.708 -178.245 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 31.7 t0 -145.0 115.45 7.62 Favored 'General case' 0 CA--C 1.515 -0.397 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.534 -177.625 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 280' ' ' THR . . . . . 0.662 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 12.6 p -71.42 -22.66 61.83 Favored 'General case' 0 N--CA 1.432 -1.37 0 CA-C-O 121.108 0.48 . . . . 0.0 109.77 176.294 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -67.37 -19.85 65.48 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 174.765 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 26.8 t-20 -89.2 -9.16 51.83 Favored 'General case' 0 CA--C 1.505 -0.752 0 CA-C-N 115.662 -0.699 . . . . 0.0 109.637 178.408 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . 0.662 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 22.8 m-30 -84.28 -79.0 0.22 Allowed 'General case' 0 N--CA 1.441 -0.906 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 174.612 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 284' ' ' SER . . . . . 0.458 ' HG ' ' C ' ' A' ' 283' ' ' PHE . 0.0 OUTLIER 175.01 -165.21 0.03 OUTLIER 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 114.892 -1.049 . . . . 0.0 109.589 -175.674 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 27.7 t0 -92.81 118.64 31.32 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.643 0.259 . . . . 0.0 111.301 178.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . 0.481 ' HB2' ' SD ' ' A' ' 256' ' ' MET . 6.1 t80 -68.86 122.0 17.73 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.6 179.341 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 96.4 mt -103.0 -59.9 3.15 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 175.027 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 50.8 ptt85 179.7 -163.04 0.04 OUTLIER 'General case' 0 C--O 1.24 0.553 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.397 174.755 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 68.83 -147.93 47.3 Favored Glycine 0 C--O 1.237 0.336 0 N-CA-C 109.811 -1.316 . . . . 0.0 109.811 -179.05 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 87.13 122.11 1.53 Allowed Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.823 175.111 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 97.7 mt -118.19 128.9 75.18 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.137 0 N-CA-C 107.262 -1.385 . . . . 0.0 107.262 172.346 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 14.9 p -116.94 128.92 74.24 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 -179.658 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 3.4 m -134.52 143.52 47.49 Favored 'General case' 0 N--CA 1.439 -0.996 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.409 -176.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 294' ' ' GLN . . . . . 0.477 HE21 ' CG ' ' A' ' 246' ' ' ASP . 52.6 tt0 -67.07 151.88 46.79 Favored 'General case' 0 N--CA 1.432 -1.358 0 CA-C-N 115.378 -0.828 . . . . 0.0 108.924 173.88 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 61.6 t -106.59 126.17 62.41 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 N-CA-C 107.975 -1.121 . . . . 0.0 107.975 176.398 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 2.6 tmtm? -66.01 98.99 0.46 Allowed 'General case' 0 N--CA 1.438 -1.046 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 -178.508 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 52.9 t -103.53 129.24 25.77 Favored Pre-proline 0 C--N 1.306 -1.303 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 179.211 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -68.8 86.13 0.47 Allowed 'Trans proline' 0 C--N 1.302 -1.872 0 N-CA-C 108.232 -1.488 . . . . 0.0 108.232 176.229 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -68.23 125.51 26.62 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.477 -171.734 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 19.0 pttm -129.99 130.4 44.96 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.409 176.573 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 47.0 pt -136.05 147.13 28.32 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.231 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 176.141 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -85.65 77.44 9.81 Favored 'General case' 0 C--N 1.313 -0.999 0 N-CA-C 107.65 -1.241 . . . . 0.0 107.65 175.111 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 16.9 t80 -165.08 145.78 7.33 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 114.754 -1.112 . . . . 0.0 108.92 -177.401 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 42.6 tttm -78.77 143.84 35.73 Favored 'General case' 0 C--N 1.313 -1.012 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 174.627 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 2.0 m -48.11 138.37 9.44 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.915 0.388 . . . . 0.0 111.755 -171.649 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 306' ' ' LEU . . . . . 0.409 ' H ' ' CD1' ' A' ' 306' ' ' LEU . 0.4 OUTLIER -92.45 162.39 29.87 Favored Pre-proline 0 C--N 1.327 -0.406 0 CA-C-N 115.703 -0.68 . . . . 0.0 109.912 179.602 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -73.88 42.5 0.72 Allowed 'Trans proline' 0 N--CA 1.493 1.452 0 C-N-CA 122.272 1.981 . . . . 0.0 111.678 178.763 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -78.6 86.3 4.6 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 177.043 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 4.8 m -68.4 137.89 54.9 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.698 -173.786 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 75.6 mt -117.1 126.71 53.25 Favored 'General case' 0 C--O 1.235 0.303 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 174.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -162.9 146.74 3.42 Favored 'Isoleucine or valine' 0 C--O 1.236 0.352 0 O-C-N 123.409 0.443 . . . . 0.0 111.225 177.796 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 312' ' ' GLU . . . . . 0.4 ' CD ' HH21 ' A' ' 239' ' ' ARG . 68.0 mt-10 . . . . . 0 C--O 1.211 -0.973 0 CA-C-O 118.496 -0.764 . . . . 0.0 109.86 175.096 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.483 1.184 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 202' ' ' PHE . . . . . 0.562 ' CE2' ' HG3' ' A' ' 206' ' ' MET . 34.8 t80 -57.32 -42.01 81.02 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.594 -0.73 . . . . 0.0 109.731 -179.853 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -53.02 -24.56 20.95 Favored Glycine 0 C--N 1.314 -0.69 0 CA-C-N 115.352 -0.84 . . . . 0.0 111.356 176.844 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 64.9 mt-10 -64.59 -46.84 80.96 Favored 'General case' 0 CA--C 1.508 -0.64 0 C-N-CA 119.373 -0.931 . . . . 0.0 109.174 177.04 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 3.9 mp0 -70.84 -38.37 73.19 Favored 'General case' 0 N--CA 1.444 -0.761 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 174.885 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 206' ' ' MET . . . . . 0.562 ' HG3' ' CE2' ' A' ' 202' ' ' PHE . 26.4 mmt -89.64 79.82 6.74 Favored 'General case' 0 C--O 1.24 0.6 0 CA-C-N 115.517 -0.765 . . . . 0.0 112.252 -178.515 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . 0.504 ' O ' ' N ' ' A' ' 209' ' ' THR . 3.7 m -114.45 131.45 66.46 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.098 0 N-CA-C 107.542 -1.281 . . . . 0.0 107.542 169.685 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 86.6 mt -62.61 75.86 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.478 0.656 . . . . 0.0 110.366 -172.151 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 209' ' ' THR . . . . . 0.504 ' N ' ' O ' ' A' ' 207' ' ' VAL . 1.2 p -123.36 3.95 9.11 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 114.774 -1.103 . . . . 0.0 111.573 -177.251 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -51.77 -42.49 62.44 Favored 'General case' 0 CA--C 1.509 -0.615 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 -179.824 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 211' ' ' SER . . . . . 0.41 ' CB ' ' HG3' ' A' ' 214' ' ' GLU . 1.5 m -115.04 118.35 33.16 Favored 'General case' 0 C--N 1.309 -1.176 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 174.432 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 16.0 t-20 -95.66 121.56 37.49 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 112.767 0.654 . . . . 0.0 112.767 -173.885 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 71.85 40.79 57.21 Favored Glycine 0 C--O 1.236 0.264 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.996 174.059 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 214' ' ' GLU . . . . . 0.41 ' HG3' ' CB ' ' A' ' 211' ' ' SER . 16.9 mm-40 -87.48 99.19 11.84 Favored 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 120.415 -0.514 . . . . 0.0 110.893 179.411 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -76.77 129.69 78.36 Favored Pre-proline 0 C--N 1.317 -0.842 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 173.303 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -56.15 133.93 61.04 Favored 'Trans proline' 0 C--N 1.31 -1.452 0 C-N-CA 121.053 1.169 . . . . 0.0 110.524 -177.029 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -79.04 141.93 36.99 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.242 -178.881 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 96.4 p -155.06 164.3 39.07 Favored 'General case' 0 N--CA 1.446 -0.652 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.258 -177.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -154.5 163.22 40.52 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-N 115.548 -0.751 . . . . 0.0 109.682 177.246 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 8.4 ttt -78.78 127.0 31.47 Favored 'General case' 0 N--CA 1.436 -1.144 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 175.703 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 98.0 t -69.22 130.13 33.98 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.174 0 N-CA-C 107.726 -1.213 . . . . 0.0 107.726 178.017 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -84.6 -70.36 0.58 Allowed 'General case' 0 N--CA 1.432 -1.331 0 C-N-CA 120.211 -0.596 . . . . 0.0 109.922 179.649 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 8.5 ptm -138.08 146.25 42.71 Favored 'General case' 0 N--CA 1.47 0.536 0 N-CA-C 112.446 0.536 . . . . 0.0 112.446 174.827 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 224' ' ' VAL . . . . . . . . . . . . . 53.1 t -121.94 132.85 70.01 Favored 'Isoleucine or valine' 0 C--O 1.239 0.537 0 C-N-CA 122.814 0.446 . . . . 0.0 110.557 178.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 39.2 p -88.25 133.0 34.16 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.554 -0.293 . . . . 0.0 110.694 178.731 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 15.9 tttm -82.11 80.16 8.42 Favored 'General case' 0 C--O 1.241 0.623 0 C-N-CA 120.349 -0.54 . . . . 0.0 110.014 177.549 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 227' ' ' ASP . . . . . 0.605 ' N ' ' OG1' ' A' ' 280' ' ' THR . 2.2 t0 -154.3 -179.86 8.32 Favored 'General case' 0 C--O 1.247 0.93 0 CA-C-N 115.391 -0.822 . . . . 0.0 111.2 178.853 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 228' ' ' ASN . . . . . 0.486 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.4 OUTLIER -141.77 125.48 9.91 Favored Pre-proline 0 C--N 1.324 -0.502 0 CA-C-N 115.529 -0.759 . . . . 0.0 109.645 176.747 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 229' ' ' PRO . . . . . 0.486 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 42.6 Cg_endo -64.71 142.32 50.21 Favored 'Cis proline' 0 N--CA 1.491 1.379 0 C-N-CA 122.995 -1.669 . . . . 0.0 110.198 -0.651 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 230' ' ' GLY . . . . . 0.478 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -74.42 138.89 24.84 Favored Glycine 0 C--N 1.308 -0.981 0 N-CA-C 109.912 -1.275 . . . . 0.0 109.912 -178.531 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.2 p -125.08 130.98 73.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 176.271 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 232' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -133.64 156.54 41.55 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 C-N-CA 120.502 -0.479 . . . . 0.0 110.494 -177.255 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 233' ' ' THR . . . . . 0.404 ' HA ' ' O ' ' A' ' 273' ' ' TYR . 2.4 m -105.35 149.27 26.22 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 115.268 -0.878 . . . . 0.0 109.321 177.777 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 2.6 m -113.08 147.26 37.66 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 175.478 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 33.7 tp -53.7 113.92 1.36 Allowed 'General case' 0 C--N 1.312 -1.065 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 178.623 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 36.7 p-10 -63.1 -10.38 14.41 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.94 -170.87 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 76.5 mm-40 -65.47 -32.76 74.55 Favored 'General case' 0 C--N 1.312 -1.048 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.231 177.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -121.45 133.52 55.06 Favored 'General case' 0 C--O 1.233 0.223 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.839 -177.868 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 239' ' ' ARG . . . . . 0.552 HH11 ' CE1' ' A' ' 240' ' ' HIS . 0.1 OUTLIER -77.87 112.57 14.89 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 173.439 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 240' ' ' HIS . . . . . 0.605 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 2.8 p80 -43.19 -34.2 1.08 Allowed 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 121.133 0.492 . . . . 0.0 109.988 -179.011 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 87.19 8.36 75.25 Favored Glycine 0 CA--C 1.503 -0.669 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 179.724 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 242' ' ' PHE . . . . . 0.552 ' O ' ' NH1' ' A' ' 239' ' ' ARG . 5.7 m-30 -81.82 146.16 30.04 Favored 'General case' 0 N--CA 1.444 -0.772 0 CA-C-O 120.85 0.357 . . . . 0.0 110.19 -179.192 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 243' ' ' GLU . . . . . 0.513 ' HG3' ' CE1' ' A' ' 303' ' ' PHE . 64.9 mm-40 -121.67 167.99 12.3 Favored 'General case' 0 C--N 1.309 -1.19 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.431 176.446 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 17.7 m -61.1 124.15 19.72 Favored 'General case' 0 C--N 1.298 -1.633 0 C-N-CA 120.152 -0.619 . . . . 0.0 109.718 -178.682 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 82.64 7.39 87.49 Favored Glycine 0 CA--C 1.523 0.578 0 CA-C-N 116.192 -0.458 . . . . 0.0 112.066 179.312 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 40.3 t0 -74.41 162.15 29.13 Favored 'General case' 0 C--O 1.238 0.482 0 CA-C-N 117.44 0.62 . . . . 0.0 109.457 177.809 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 247' ' ' PHE . . . . . . . . . . . . . 78.3 m-85 -109.31 131.05 55.43 Favored 'General case' 0 C--N 1.316 -0.849 0 N-CA-C 109.705 -0.479 . . . . 0.0 109.705 -179.27 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . 0.404 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 3.1 m -129.04 163.29 34.48 Favored 'Isoleucine or valine' 0 C--O 1.24 0.602 0 CA-C-O 121.027 0.441 . . . . 0.0 112.058 -177.251 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 9.6 p -133.91 162.04 33.13 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 114.522 -1.217 . . . . 0.0 108.905 175.172 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 250' ' ' PHE . . . . . 0.582 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 82.1 m-85 -124.37 159.36 30.52 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.087 0.47 . . . . 0.0 111.831 -169.231 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 20.2 m -158.42 160.0 36.36 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.192 177.489 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 78.0 mm-40 52.17 20.39 1.31 Allowed 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 113.234 0.827 . . . . 0.0 113.234 175.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 12.4 t -85.94 131.06 35.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 175.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 87.5 mt-30 -96.93 144.06 27.21 Favored 'General case' 0 C--O 1.24 0.56 0 C-N-CA 120.666 -0.413 . . . . 0.0 110.649 -179.689 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 77.75 -57.43 3.86 Favored Glycine 0 CA--C 1.509 -0.321 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -177.158 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 256' ' ' MET . . . . . 0.428 ' HG2' ' HB3' ' A' ' 283' ' ' PHE . 15.3 ttm -85.81 55.84 3.7 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-O 121.493 0.663 . . . . 0.0 109.446 175.684 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 44.4 pt -73.93 -18.1 17.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.036 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 3.5 tp60 -54.1 -39.04 66.02 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 108.231 -1.026 . . . . 0.0 108.231 178.157 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 259' ' ' LEU . . . . . 0.582 ' HB3' ' CG ' ' A' ' 250' ' ' PHE . 85.5 mt -62.16 -41.67 98.52 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.121 177.07 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 97.2 m-20 -59.98 -40.53 89.45 Favored 'General case' 0 CA--C 1.506 -0.734 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 -176.436 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -102.27 14.75 56.77 Favored Glycine 0 CA--C 1.523 0.552 0 CA-C-N 115.787 -0.642 . . . . 0.0 112.235 -179.603 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 262' ' ' CYS . . . . . 0.401 ' HB2' ' HA ' ' A' ' 259' ' ' LEU . 1.1 m -91.16 158.83 16.4 Favored 'General case' 0 CA--C 1.513 -0.456 0 CA-C-N 117.469 0.634 . . . . 0.0 111.684 -178.005 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -76.59 151.25 82.69 Favored Pre-proline 0 C--N 1.323 -0.553 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 173.927 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 264' ' ' PRO . . . . . 0.404 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 49.5 Cg_endo -64.01 147.11 91.82 Favored 'Trans proline' 0 C--N 1.306 -1.668 0 C-N-CA 121.76 1.64 . . . . 0.0 112.052 -176.177 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 265' ' ' MET . . . . . 0.479 ' SD ' ' HZ ' ' A' ' 283' ' ' PHE . 7.8 ptp -134.07 157.4 46.22 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 112.484 0.55 . . . . 0.0 112.484 -173.661 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -73.57 141.55 46.64 Favored 'General case' 0 C--O 1.241 0.631 0 O-C-N 124.006 0.816 . . . . 0.0 109.846 177.015 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 267' ' ' ILE . . . . . 0.452 HG22 ' CE2' ' A' ' 275' ' ' PHE . 1.8 pp -130.66 163.58 36.05 Favored 'Isoleucine or valine' 0 C--O 1.237 0.445 0 N-CA-C 112.114 0.413 . . . . 0.0 112.114 -177.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 45.1 mmtm -124.88 127.35 46.97 Favored 'General case' 0 CA--C 1.541 0.628 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 174.555 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 27.2 m -83.64 98.27 5.3 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.612 0 CA-C-O 120.887 0.375 . . . . 0.0 111.507 -179.818 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 98.6 mt -65.73 -42.46 90.99 Favored 'General case' 0 CA--C 1.513 -0.46 0 CA-C-O 121.399 0.619 . . . . 0.0 109.577 178.137 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -145.04 176.44 24.08 Favored Glycine 0 C--N 1.314 -0.693 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 178.499 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 272' ' ' PRO . . . . . 0.605 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 67.9 Cg_exo -54.03 -40.05 82.86 Favored 'Trans proline' 0 C--N 1.305 -1.72 0 C-N-CA 122.159 1.906 . . . . 0.0 111.068 -178.805 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 273' ' ' TYR . . . . . 0.404 ' O ' ' HA ' ' A' ' 233' ' ' THR . 6.9 m-85 -115.71 8.96 15.08 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.623 -176.062 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.7 p -126.74 124.97 40.97 Favored 'General case' 0 C--O 1.247 0.937 0 CA-C-O 121.047 0.451 . . . . 0.0 111.431 179.284 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 275' ' ' PHE . . . . . 0.536 ' C ' ' CD1' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -133.09 164.72 26.39 Favored 'General case' 0 CA--C 1.494 -1.189 0 C-N-CA 120.492 -0.483 . . . . 0.0 112.224 177.95 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 276' ' ' SER . . . . . 0.478 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 13.7 p -132.12 152.4 51.26 Favored 'General case' 0 N--CA 1.432 -1.347 0 C-N-CA 120.436 -0.506 . . . . 0.0 110.944 -176.382 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.26 -169.19 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.195 0 CA-C-N 115.258 -0.883 . . . . 0.0 110.564 -175.185 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 12.9 m -58.32 -75.64 0.05 OUTLIER 'General case' 0 CA--C 1.536 0.438 0 N-CA-C 112.941 0.719 . . . . 0.0 112.941 -175.273 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 66.7 t0 -154.99 114.78 3.74 Favored 'General case' 0 N--CA 1.45 -0.441 0 O-C-N 122.266 -0.271 . . . . 0.0 111.122 -175.276 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 280' ' ' THR . . . . . 0.658 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 21.5 p -66.89 -29.52 69.43 Favored 'General case' 0 C--N 1.303 -1.417 0 CA-C-O 121.101 0.477 . . . . 0.0 110.262 174.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -62.28 -19.45 63.26 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 115.29 -0.868 . . . . 0.0 109.125 174.794 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -88.48 -8.48 54.82 Favored 'General case' 0 CA--C 1.507 -0.703 0 N-CA-C 109.454 -0.572 . . . . 0.0 109.454 175.163 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 283' ' ' PHE . . . . . 0.658 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 12.2 m-30 -98.82 -83.35 0.42 Allowed 'General case' 0 N--CA 1.442 -0.843 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 174.8 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 284' ' ' SER . . . . . 0.418 ' H ' ' HB2' ' A' ' 283' ' ' PHE . 0.2 OUTLIER 172.88 -162.02 0.02 OUTLIER 'General case' 0 N--CA 1.448 -0.535 0 C-N-CA 124.908 1.283 . . . . 0.0 107.929 -178.998 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 9.4 p-10 -91.64 169.99 10.28 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.666 0.27 . . . . 0.0 110.631 175.618 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 86.2 t80 -106.85 120.98 43.48 Favored 'General case' 0 C--O 1.239 0.531 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.199 179.731 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 287' ' ' ILE . . . . . 0.447 ' O ' ' HG3' ' A' ' 288' ' ' ARG . 96.9 mt -93.32 -57.67 4.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 109.993 -0.373 . . . . 0.0 109.993 175.413 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 288' ' ' ARG . . . . . 0.447 ' HG3' ' O ' ' A' ' 287' ' ' ILE . 15.9 mtm180 -178.9 179.05 0.72 Allowed 'General case' 0 C--O 1.243 0.722 0 C-N-CA 124.525 1.13 . . . . 0.0 110.122 177.773 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 69.52 -163.14 51.75 Favored Glycine 0 C--O 1.235 0.21 0 N-CA-C 111.275 -0.73 . . . . 0.0 111.275 175.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 113.68 128.23 4.72 Favored Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 121.251 -0.5 . . . . 0.0 113.076 175.686 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 291' ' ' ILE . . . . . 0.417 HG21 HD11 ' A' ' 291' ' ' ILE . 98.5 mt -124.42 132.11 71.81 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.858 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 172.751 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 5.5 p -125.33 137.69 56.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -178.189 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 4.4 m -132.18 147.0 52.4 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.299 -177.299 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -75.08 152.11 38.61 Favored 'General case' 0 CA--C 1.507 -0.7 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 173.318 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 21.0 t -99.0 126.6 52.19 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.095 0 C-N-CA 120.449 -0.501 . . . . 0.0 111.635 -175.07 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 296' ' ' LYS . . . . . 0.402 ' HG3' ' HZ1' ' A' ' 296' ' ' LYS . 55.9 tttp -82.47 98.69 9.04 Favored 'General case' 0 N--CA 1.44 -0.959 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 175.739 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 297' ' ' VAL . . . . . 0.461 ' HB ' ' CD ' ' A' ' 298' ' ' PRO . 17.6 m -98.04 -178.78 0.76 Allowed Pre-proline 0 C--N 1.31 -1.139 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 178.846 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 298' ' ' PRO . . . . . 0.461 ' CD ' ' HB ' ' A' ' 297' ' ' VAL . 76.2 Cg_exo -54.36 -38.31 89.07 Favored 'Trans proline' 0 C--N 1.308 -1.589 0 C-N-CA 121.301 1.334 . . . . 0.0 110.314 177.346 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -137.9 114.38 10.36 Favored 'General case' 0 C--O 1.247 0.951 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.9 177.03 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 300' ' ' LYS . . . . . 0.471 ' HG3' ' N ' ' A' ' 301' ' ' ILE . 22.8 pttm -71.81 -156.35 0.03 OUTLIER 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 174.619 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 301' ' ' ILE . . . . . 0.471 ' N ' ' HG3' ' A' ' 300' ' ' LYS . 0.1 OUTLIER -99.85 128.38 51.76 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.887 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 173.194 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 49.2 m -74.1 144.97 44.73 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 178.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 303' ' ' PHE . . . . . 0.513 ' CE1' ' HG3' ' A' ' 243' ' ' GLU . 20.0 m-85 -101.58 147.28 26.59 Favored 'General case' 0 C--N 1.312 -1.042 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -175.166 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -71.45 129.45 38.82 Favored 'General case' 0 C--N 1.313 -1.01 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 176.337 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 6.8 m -73.43 149.15 42.63 Favored 'General case' 0 C--N 1.309 -1.163 0 C-N-CA 120.981 -0.288 . . . . 0.0 110.834 -176.083 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 90.4 mt -55.0 153.13 12.28 Favored Pre-proline 0 C--O 1.242 0.669 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 177.58 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -63.18 142.74 87.96 Favored 'Trans proline' 0 C--N 1.302 -1.914 0 C-N-CA 121.301 1.334 . . . . 0.0 110.856 -177.504 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -132.32 133.36 43.94 Favored 'General case' 0 C--N 1.315 -0.925 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 179.554 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 2.3 m -71.49 137.92 48.55 Favored 'General case' 0 C--N 1.308 -1.225 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 -178.826 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 92.1 mt -102.08 60.23 0.85 Allowed 'General case' 0 CA--C 1.509 -0.623 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 174.754 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 15.1 m -148.54 162.64 5.58 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.237 0 CA-C-N 114.025 -1.443 . . . . 0.0 107.978 176.683 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 . . . . . 0 C--O 1.204 -1.316 0 CA-C-O 118.492 -0.766 . . . . 0.0 110.917 177.394 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 217' ' ' LEU . . . . . 0.545 HD13 ' N ' ' A' ' 218' ' ' SER . 0.2 OUTLIER . . . . . 0 CA--C 1.505 -0.77 0 N-CA-C 106.439 -1.689 . . . . 0.0 106.439 . . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 218' ' ' SER . . . . . 0.545 ' N ' HD13 ' A' ' 217' ' ' LEU . 50.3 m -113.84 146.78 39.48 Favored 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 -173.506 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 219' ' ' ALA . . . . . 0.895 ' HB1' ' HB1' ' A' ' 238' ' ' ALA . . . -138.73 148.69 44.21 Favored 'General case' 0 C--O 1.243 0.742 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.099 -174.278 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 97.4 mmm -74.63 125.15 28.04 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.599 -0.728 . . . . 0.0 109.873 176.26 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 60.1 t -87.06 129.11 39.08 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.948 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 177.136 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -83.87 -69.96 0.6 Allowed 'General case' 0 N--CA 1.433 -1.309 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 176.93 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -138.12 156.29 47.9 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.274 174.868 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 224' ' ' VAL . . . . . 0.56 ' CG1' ' SD ' ' A' ' 256' ' ' MET . 62.0 t -122.48 133.58 68.26 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.946 0 N-CA-C 108.18 -1.045 . . . . 0.0 108.18 173.488 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -102.83 121.91 43.43 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-O 120.555 0.217 . . . . 0.0 110.603 -175.842 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 226' ' ' LYS . . . . . 0.416 ' HA ' ' OG1' ' A' ' 280' ' ' THR . 0.4 OUTLIER -70.52 89.67 0.71 Allowed 'General case' 0 C--O 1.242 0.704 0 CA-C-O 120.966 0.412 . . . . 0.0 109.967 178.979 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 227' ' ' ASP . . . . . 0.431 ' OD1' ' N ' ' A' ' 228' ' ' ASN . 52.9 t0 -158.47 171.69 19.69 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.492 -0.776 . . . . 0.0 109.993 -176.789 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 228' ' ' ASN . . . . . 0.454 ' HB2' ' CG ' ' A' ' 279' ' ' ASP . 0.7 OUTLIER -136.16 123.32 14.46 Favored Pre-proline 0 C--N 1.325 -0.459 0 CA-C-N 116.576 -0.284 . . . . 0.0 110.544 175.192 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 229' ' ' PRO . . . . . 0.452 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 45.7 Cg_endo -65.89 146.5 71.49 Favored 'Cis proline' 0 N--CA 1.494 1.538 0 C-N-CA 122.783 -1.757 . . . . 0.0 109.22 -1.942 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 230' ' ' GLY . . . . . 0.536 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -68.43 144.06 41.8 Favored Glycine 0 C--O 1.219 -0.812 0 N-CA-C 109.787 -1.325 . . . . 0.0 109.787 -177.72 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 231' ' ' VAL . . . . . 0.45 HG23 HD12 ' A' ' 270' ' ' LEU . 2.5 p -128.12 134.95 64.02 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 CA-C-N 116.989 0.394 . . . . 0.0 110.079 178.168 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 232' ' ' VAL . . . . . 0.5 HG12 HG13 ' A' ' 224' ' ' VAL . 0.6 OUTLIER -133.8 156.44 41.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 C-N-CA 120.428 -0.509 . . . . 0.0 110.836 -179.817 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 24.5 m -117.49 134.3 55.01 Favored 'General case' 0 C--O 1.242 0.693 0 CA-C-N 115.998 -0.546 . . . . 0.0 109.683 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.8 m -106.4 158.58 16.79 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.961 -175.372 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.485 ' O ' ' HB3' ' A' ' 238' ' ' ALA . 22.8 tp -63.29 150.79 42.39 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.226 -0.897 . . . . 0.0 108.686 179.225 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -59.63 -39.7 85.16 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 121.089 0.471 . . . . 0.0 109.847 -177.697 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 237' ' ' GLU . . . . . 0.447 ' O ' ' N ' ' A' ' 239' ' ' ARG . 98.8 mt-10 -70.53 -21.09 62.76 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.16 174.062 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 238' ' ' ALA . . . . . 0.895 ' HB1' ' HB1' ' A' ' 219' ' ' ALA . . . -65.83 61.25 0.03 OUTLIER 'General case' 0 C--O 1.241 0.653 0 CA-C-O 121.227 0.537 . . . . 0.0 111.027 -178.472 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 239' ' ' ARG . . . . . 0.447 ' N ' ' O ' ' A' ' 237' ' ' GLU . 61.5 mtp180 -67.78 85.09 0.21 Allowed 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 174.215 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 240' ' ' HIS . . . . . 0.627 ' HB2' ' CG ' ' A' ' 242' ' ' PHE . 3.5 p80 -57.92 -46.83 84.39 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-N 115.163 -0.926 . . . . 0.0 112.398 -170.903 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 80.32 14.47 80.23 Favored Glycine 0 C--N 1.313 -0.743 0 N-CA-C 109.867 -1.293 . . . . 0.0 109.867 -174.902 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 242' ' ' PHE . . . . . 0.681 ' CD1' ' HB3' ' A' ' 294' ' ' GLN . 4.6 m-30 -80.02 148.69 31.01 Favored 'General case' 0 CA--C 1.509 -0.617 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 -179.301 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 243' ' ' GLU . . . . . 0.474 ' HB2' ' HB2' ' A' ' 246' ' ' ASP . 37.7 mt-10 -115.46 150.66 36.12 Favored 'General case' 0 C--N 1.308 -1.238 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 179.634 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 244' ' ' THR . . . . . 0.56 ' OG1' HG22 ' A' ' 269' ' ' VAL . 32.6 m -62.43 127.62 32.16 Favored 'General case' 0 C--N 1.305 -1.34 0 C-N-CA 119.235 -0.986 . . . . 0.0 108.652 177.316 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 86.16 4.01 84.44 Favored Glycine 0 C--N 1.311 -0.847 0 N-CA-C 110.489 -1.044 . . . . 0.0 110.489 -176.326 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 246' ' ' ASP . . . . . 0.474 ' HB2' ' HB2' ' A' ' 243' ' ' GLU . 31.6 t0 -81.58 164.06 22.16 Favored 'General case' 0 CA--C 1.515 -0.402 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 177.737 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 247' ' ' PHE . . . . . 0.46 ' HA ' ' O ' ' A' ' 265' ' ' MET . 69.3 m-85 -110.05 134.68 51.89 Favored 'General case' 0 C--N 1.311 -1.085 0 O-C-N 123.413 0.446 . . . . 0.0 110.337 -179.644 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 248' ' ' VAL . . . . . 0.545 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 3.1 m -132.04 163.81 36.46 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.572 0 CA-C-O 120.745 0.307 . . . . 0.0 111.082 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 12.0 p -130.89 162.2 30.17 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 115.126 -0.943 . . . . 0.0 108.896 176.509 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 250' ' ' PHE . . . . . 0.583 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 73.7 m-85 -121.57 157.92 29.67 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-O 121.146 0.498 . . . . 0.0 111.6 -174.763 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 3.7 m -152.25 155.89 38.63 Favored 'General case' 0 C--N 1.313 -1.017 0 CA-C-N 115.473 -0.785 . . . . 0.0 109.473 175.359 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 54.21 25.77 6.09 Favored 'General case' 0 C--N 1.314 -0.947 0 N-CA-C 112.7 0.63 . . . . 0.0 112.7 174.846 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 0.401 HG22 ' CA ' ' A' ' 290' ' ' GLY . 95.6 t -82.53 129.76 36.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 174.487 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -99.92 138.59 36.78 Favored 'General case' 0 C--O 1.24 0.601 0 C-N-CA 120.548 -0.461 . . . . 0.0 110.361 -179.74 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 80.94 -61.56 4.54 Favored Glycine 0 C--N 1.319 -0.378 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 -175.815 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 256' ' ' MET . . . . . 0.56 ' SD ' ' CG1' ' A' ' 224' ' ' VAL . 31.3 mtt -80.71 62.43 4.75 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.608 0.718 . . . . 0.0 110.172 174.935 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 257' ' ' ILE . . . . . 0.4 ' O ' ' HB2' ' A' ' 260' ' ' ASN . 47.6 pt -72.54 -19.41 19.19 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.86 -177.868 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 258' ' ' GLN . . . . . 0.473 ' HB2' ' HG ' ' A' ' 284' ' ' SER . 0.7 OUTLIER -56.02 -39.36 71.82 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 -179.624 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 259' ' ' LEU . . . . . 0.939 HD21 ' CE2' ' A' ' 283' ' ' PHE . 89.8 mt -62.21 -41.7 98.62 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 116.009 -0.542 . . . . 0.0 109.742 178.767 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 260' ' ' ASN . . . . . 0.4 ' HB2' ' O ' ' A' ' 257' ' ' ILE . 97.1 m-20 -60.76 -40.72 93.52 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 178.798 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -96.95 11.04 66.12 Favored Glycine 0 CA--C 1.526 0.78 0 CA-C-N 115.485 -0.78 . . . . 0.0 112.676 -177.664 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 262' ' ' CYS . . . . . 0.401 ' N ' ' O ' ' A' ' 258' ' ' GLN . 4.0 m -102.84 146.75 27.81 Favored 'General case' 0 CA--C 1.517 -0.315 0 CA-C-N 117.6 0.7 . . . . 0.0 111.475 -179.457 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 51.5 mt-30 -62.34 161.96 22.29 Favored Pre-proline 0 C--N 1.326 -0.421 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 172.865 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 264' ' ' PRO . . . . . 0.545 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 37.6 Cg_endo -62.56 146.02 95.4 Favored 'Trans proline' 0 C--N 1.305 -1.727 0 C-N-CA 121.33 1.353 . . . . 0.0 111.219 178.644 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 265' ' ' MET . . . . . 0.611 ' N ' ' SD ' ' A' ' 265' ' ' MET . 0.9 OUTLIER -128.35 162.27 27.48 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 116.782 -0.19 . . . . 0.0 111.502 -175.702 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 70.3 tt0 -71.0 139.4 50.5 Favored 'General case' 0 C--O 1.245 0.818 0 O-C-N 123.585 0.553 . . . . 0.0 109.621 176.641 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 267' ' ' ILE . . . . . 0.65 HG22 HG22 ' A' ' 277' ' ' ILE . 1.9 pp -127.41 152.43 35.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-O 121.049 0.452 . . . . 0.0 111.777 -179.766 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 268' ' ' LYS . . . . . 0.458 ' HA ' HG23 ' A' ' 244' ' ' THR . 63.8 mttp -129.3 114.23 15.97 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.852 178.816 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.56 HG22 ' OG1' ' A' ' 244' ' ' THR . 34.7 m -74.98 106.75 4.94 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 CA-C-O 121.145 0.497 . . . . 0.0 112.242 -176.679 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 270' ' ' LEU . . . . . 0.45 HD12 HG23 ' A' ' 231' ' ' VAL . 92.9 mt -66.11 -41.02 91.14 Favored 'General case' 0 N--CA 1.449 -0.503 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.517 175.546 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -149.04 -176.19 22.12 Favored Glycine 0 C--N 1.322 -0.224 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 178.945 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 272' ' ' PRO . . . . . 0.429 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 33.6 Cg_endo -60.98 -34.84 90.14 Favored 'Trans proline' 0 N--CA 1.496 1.672 0 C-N-CA 121.97 1.78 . . . . 0.0 111.992 -177.29 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 57.1 m-85 -118.76 7.75 11.69 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 112.245 0.461 . . . . 0.0 112.245 178.826 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 6.0 p -120.97 124.36 44.7 Favored 'General case' 0 C--N 1.319 -0.725 0 C-N-CA 120.888 -0.325 . . . . 0.0 110.323 178.586 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 275' ' ' PHE . . . . . 0.521 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -132.66 157.55 44.55 Favored 'General case' 0 CA--C 1.501 -0.924 0 C-N-CA 120.133 -0.627 . . . . 0.0 112.599 179.43 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 276' ' ' SER . . . . . 0.536 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 7.4 p -125.79 142.36 51.55 Favored 'General case' 0 N--CA 1.431 -1.408 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.937 -173.803 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 277' ' ' ILE . . . . . 0.65 HG22 HG22 ' A' ' 267' ' ' ILE . 32.8 pt -139.77 163.56 24.73 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.917 0 CA-C-N 115.166 -0.924 . . . . 0.0 111.964 -172.783 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 278' ' ' CYS . . . . . 0.414 ' C ' ' O ' ' A' ' 277' ' ' ILE . 86.1 m -17.78 -96.25 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 124.413 1.085 . . . . 0.0 113.611 -178.86 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 279' ' ' ASP . . . . . 0.454 ' CG ' ' HB2' ' A' ' 228' ' ' ASN . 67.2 t0 -149.38 112.51 4.91 Favored 'General case' 0 CA--C 1.499 -1.017 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 178.985 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 280' ' ' THR . . . . . 0.791 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 11.3 p -67.21 -23.81 65.78 Favored 'General case' 0 N--CA 1.42 -1.949 0 CA-C-O 121.084 0.468 . . . . 0.0 110.4 179.08 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -66.28 -19.12 65.73 Favored 'General case' 0 C--N 1.315 -0.897 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.613 173.478 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 282' ' ' ASN . . . . . 0.48 ' ND2' ' C ' ' A' ' 282' ' ' ASN . 0.0 OUTLIER -91.46 2.72 56.22 Favored 'General case' 0 CA--C 1.513 -0.474 0 C-N-CA 120.409 -0.516 . . . . 0.0 109.809 176.324 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 283' ' ' PHE . . . . . 0.939 ' CE2' HD21 ' A' ' 259' ' ' LEU . 16.2 m-85 -100.98 -76.52 0.56 Allowed 'General case' 0 N--CA 1.445 -0.703 0 CA-C-O 121.404 0.621 . . . . 0.0 109.417 173.616 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 284' ' ' SER . . . . . 0.473 ' HG ' ' HB2' ' A' ' 258' ' ' GLN . 0.0 OUTLIER 166.48 -175.06 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 114.41 -1.268 . . . . 0.0 109.132 -172.875 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 285' ' ' ASP . . . . . 0.415 ' C ' ' HG3' ' A' ' 256' ' ' MET . 19.8 m-20 -86.5 134.5 33.67 Favored 'General case' 0 N--CA 1.472 0.643 0 CA-C-N 117.406 0.094 . . . . 0.0 110.756 179.143 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 286' ' ' TYR . . . . . 0.455 ' HB2' ' SD ' ' A' ' 256' ' ' MET . 55.5 t80 -76.65 128.34 34.5 Favored 'General case' 0 N--CA 1.468 0.447 0 C-N-CA 123.102 0.561 . . . . 0.0 111.094 179.256 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 7.0 mm -100.75 -69.15 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 116.563 -0.29 . . . . 0.0 110.672 173.271 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 95.5 mtm-85 -160.8 -179.44 7.59 Favored 'General case' 0 C--O 1.241 0.63 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.452 -178.748 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 63.35 -143.74 48.58 Favored Glycine 0 CA--C 1.498 -1.027 0 CA-C-N 114.963 -1.017 . . . . 0.0 111.338 174.03 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 290' ' ' GLY . . . . . 0.401 ' CA ' HG22 ' A' ' 253' ' ' VAL . . . 98.76 123.15 4.82 Favored Glycine 0 N--CA 1.436 -1.324 0 C-N-CA 120.968 -0.634 . . . . 0.0 111.774 178.625 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 47.9 mm -119.05 130.18 74.2 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.488 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 175.28 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 11.3 p -122.04 135.87 60.77 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.985 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 -178.063 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 293' ' ' SER . . . . . 0.497 ' HA ' ' O ' ' A' ' 217' ' ' LEU . 0.3 OUTLIER -136.19 140.03 43.26 Favored 'General case' 0 C--N 1.316 -0.878 0 C-N-CA 120.478 -0.489 . . . . 0.0 110.237 -177.416 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 294' ' ' GLN . . . . . 0.681 ' HB3' ' CD1' ' A' ' 242' ' ' PHE . 2.3 pt20 . . . . . 0 CA--C 1.502 -0.902 0 C-N-CA 120.083 -0.647 . . . . 0.0 110.847 178.322 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 217' ' ' LEU . . . . . 0.521 ' HB3' ' O ' ' A' ' 240' ' ' HIS . 0.4 OUTLIER . . . . . 0 CA--C 1.514 -0.43 0 N-CA-C 110.448 -0.205 . . . . 0.0 110.448 . . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 66.8 m -131.48 153.78 49.41 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-N 116.416 -0.357 . . . . 0.0 110.174 175.68 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -150.84 155.63 39.6 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.531 -0.304 . . . . 0.0 111.368 -178.404 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 220' ' ' MET . . . . . 0.435 ' SD ' HD22 ' A' ' 235' ' ' LEU . 92.1 mtp -76.83 135.37 38.89 Favored 'General case' 0 N--CA 1.447 -0.615 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.549 176.512 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 94.3 t -87.13 130.99 36.11 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.067 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 175.567 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 222' ' ' SER . . . . . 0.419 ' OG ' ' N ' ' A' ' 223' ' ' MET . 0.0 OUTLIER -82.44 -71.51 0.48 Allowed 'General case' 0 C--N 1.308 -1.216 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 176.836 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 223' ' ' MET . . . . . 0.419 ' N ' ' OG ' ' A' ' 222' ' ' SER . 5.5 ptm -137.66 149.09 46.29 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.711 174.843 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 224' ' ' VAL . . . . . 0.708 HG13 ' CG1' ' A' ' 232' ' ' VAL . 2.3 t -113.37 124.3 69.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 174.822 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 225' ' ' THR . . . . . 0.509 ' O ' HG21 ' A' ' 280' ' ' THR . 74.6 p -79.66 133.08 36.38 Favored 'General case' 0 C--N 1.321 -0.647 0 C-N-CA 120.474 -0.491 . . . . 0.0 110.491 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 226' ' ' LYS . . . . . 0.445 ' NZ ' ' OD1' ' A' ' 285' ' ' ASP . 0.1 OUTLIER -79.21 75.11 5.76 Favored 'General case' 0 C--O 1.243 0.727 0 CA-C-O 121.283 0.563 . . . . 0.0 109.595 179.22 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 227' ' ' ASP . . . . . 0.522 ' N ' ' OG1' ' A' ' 280' ' ' THR . 3.9 t0 -148.72 176.56 10.26 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-N 115.475 -0.784 . . . . 0.0 110.594 -179.742 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 228' ' ' ASN . . . . . 0.485 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.2 OUTLIER -142.87 123.52 8.16 Favored Pre-proline 0 C--N 1.313 -1.02 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.881 179.05 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 229' ' ' PRO . . . . . 0.485 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 47.8 Cg_endo -63.83 146.69 62.47 Favored 'Cis proline' 0 N--CA 1.496 1.62 0 C-N-CA 123.185 -1.589 . . . . 0.0 110.744 -2.12 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 230' ' ' GLY . . . . . 0.516 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -76.04 141.14 26.7 Favored Glycine 0 N--CA 1.443 -0.857 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 -178.173 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 231' ' ' VAL . . . . . 0.575 HG23 HD12 ' A' ' 270' ' ' LEU . 2.3 p -124.1 133.0 70.5 Favored 'Isoleucine or valine' 0 C--O 1.241 0.624 0 N-CA-C 109.059 -0.719 . . . . 0.0 109.059 174.22 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 232' ' ' VAL . . . . . 0.708 ' CG1' HG13 ' A' ' 224' ' ' VAL . 0.7 OUTLIER -132.34 156.36 42.34 Favored 'Isoleucine or valine' 0 C--O 1.246 0.895 0 C-N-CA 120.438 -0.505 . . . . 0.0 110.353 -175.024 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 233' ' ' THR . . . . . 0.5 ' HA ' ' O ' ' A' ' 273' ' ' TYR . 1.6 p -106.41 159.07 16.43 Favored 'General case' 0 N--CA 1.441 -0.907 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.665 177.556 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 39.3 m -124.36 161.95 24.86 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 123.063 0.545 . . . . 0.0 109.861 -178.893 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.435 HD22 ' SD ' ' A' ' 220' ' ' MET . 37.2 tp -62.87 135.7 57.46 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 107.88 -1.155 . . . . 0.0 107.88 176.928 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 236' ' ' ASP . . . . . 0.438 ' O ' ' CZ ' ' A' ' 273' ' ' TYR . 1.9 m-20 -59.54 -35.65 74.62 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-O 121.251 0.548 . . . . 0.0 111.117 -173.611 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 70.1 mt-10 -86.47 -5.02 59.26 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.605 -177.611 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -101.99 100.47 10.76 Favored 'General case' 0 CA--C 1.516 -0.344 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.554 179.393 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 66.4 mtp180 -86.82 107.53 18.34 Favored 'General case' 0 C--N 1.317 -0.847 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 -179.686 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 240' ' ' HIS . . . . . 0.521 ' O ' ' HB3' ' A' ' 217' ' ' LEU . 9.9 p80 -57.48 -47.38 82.05 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.655 -176.902 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 71.18 25.31 75.85 Favored Glycine 0 C--N 1.309 -0.92 0 N-CA-C 109.783 -1.327 . . . . 0.0 109.783 -179.173 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 242' ' ' PHE . . . . . 0.496 ' CD2' ' HB2' ' A' ' 240' ' ' HIS . 15.4 m-30 -79.51 141.28 36.84 Favored 'General case' 0 N--CA 1.435 -1.213 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 -179.82 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 243' ' ' GLU . . . . . 0.505 ' HB2' ' HB2' ' A' ' 246' ' ' ASP . 96.5 mt-10 -96.79 146.5 24.84 Favored 'General case' 0 C--N 1.31 -1.138 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.343 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.1 122.44 16.09 Favored 'General case' 0 C--N 1.307 -1.269 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 -178.408 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 85.0 7.33 83.92 Favored Glycine 0 N--CA 1.442 -0.912 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 -177.211 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 246' ' ' ASP . . . . . 0.505 ' HB2' ' HB2' ' A' ' 243' ' ' GLU . 13.5 t0 -83.79 168.3 16.29 Favored 'General case' 0 C--O 1.24 0.557 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 176.032 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 247' ' ' PHE . . . . . 0.46 ' HA ' ' O ' ' A' ' 265' ' ' MET . 66.3 m-85 -109.4 141.6 41.55 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 112.099 0.407 . . . . 0.0 112.099 -176.349 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 248' ' ' VAL . . . . . 0.445 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.8 m -134.21 161.16 41.18 Favored 'Isoleucine or valine' 0 C--O 1.241 0.655 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.098 178.059 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 47.7 m -128.04 159.37 35.24 Favored 'General case' 0 C--N 1.321 -0.669 0 C-N-CA 124.338 1.055 . . . . 0.0 108.53 173.626 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 250' ' ' PHE . . . . . 0.508 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 69.9 m-85 -110.54 145.8 37.15 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 121.264 0.554 . . . . 0.0 112.171 -177.789 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 19.7 m -137.73 153.3 49.77 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.227 177.048 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 71.6 mm-40 56.08 21.37 5.05 Favored 'General case' 0 C--N 1.314 -0.954 0 N-CA-C 113.354 0.872 . . . . 0.0 113.354 173.023 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 0.437 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 94.1 t -84.37 130.7 35.53 Favored 'Isoleucine or valine' 0 C--O 1.239 0.52 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 177.262 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 254' ' ' GLN . . . . . 0.414 ' HB2' ' O ' ' A' ' 288' ' ' ARG . 83.1 mt-30 -105.26 144.44 32.05 Favored 'General case' 0 C--O 1.243 0.728 0 CA-C-O 121.001 0.429 . . . . 0.0 109.897 176.984 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 84.91 -68.42 3.5 Favored Glycine 0 C--N 1.313 -0.747 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -174.049 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 256' ' ' MET . . . . . 0.536 ' HG3' ' N ' ' A' ' 286' ' ' TYR . 47.8 mtt -78.25 65.04 3.51 Favored 'General case' 0 CA--C 1.515 -0.381 0 CA-C-O 121.397 0.617 . . . . 0.0 110.318 173.072 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 46.9 pt -70.82 -23.06 23.54 Favored 'Isoleucine or valine' 0 C--O 1.244 0.797 0 CA-C-N 115.475 -0.784 . . . . 0.0 110.135 -178.271 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 258' ' ' GLN . . . . . 0.542 ' HG3' ' SG ' ' A' ' 262' ' ' CYS . 70.7 tp60 -60.8 -36.62 79.49 Favored 'General case' 0 N--CA 1.445 -0.682 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 179.459 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 259' ' ' LEU . . . . . 0.677 HD21 ' CD2' ' A' ' 283' ' ' PHE . 92.3 mt -61.88 -40.52 95.68 Favored 'General case' 0 N--CA 1.448 -0.542 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.204 179.09 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 260' ' ' ASN . . . . . 0.437 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 98.8 m-20 -60.2 -41.14 92.35 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 179.218 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -96.48 10.94 67.06 Favored Glycine 0 CA--C 1.532 1.132 0 CA-C-N 116.042 -0.527 . . . . 0.0 112.269 179.572 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 262' ' ' CYS . . . . . 0.542 ' SG ' ' HG3' ' A' ' 258' ' ' GLN . 1.2 m -82.24 142.41 32.15 Favored 'General case' 0 CA--C 1.513 -0.444 0 CA-C-N 117.382 0.591 . . . . 0.0 110.827 -178.379 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 27.9 mm100 -62.57 152.51 80.76 Favored Pre-proline 0 C--N 1.321 -0.662 0 N-CA-C 107.572 -1.27 . . . . 0.0 107.572 171.582 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 264' ' ' PRO . . . . . 0.445 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 36.8 Cg_endo -61.22 142.96 98.11 Favored 'Trans proline' 0 C--N 1.307 -1.644 0 C-N-CA 121.059 1.172 . . . . 0.0 110.447 -178.999 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 265' ' ' MET . . . . . 0.46 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 24.0 ptp -129.12 154.34 46.81 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 112.162 0.43 . . . . 0.0 112.162 -172.429 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -71.02 136.1 48.17 Favored 'General case' 0 C--O 1.245 0.816 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 177.611 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 267' ' ' ILE . . . . . 0.635 HG22 HG22 ' A' ' 277' ' ' ILE . 2.0 pp -126.65 158.54 36.94 Favored 'Isoleucine or valine' 0 C--O 1.243 0.735 0 N-CA-C 112.546 0.573 . . . . 0.0 112.546 -175.864 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 75.1 tttt -127.83 115.81 19.2 Favored 'General case' 0 N--CA 1.448 -0.532 0 CA-C-N 115.213 -0.903 . . . . 0.0 109.86 -179.322 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 17.8 m -70.59 134.5 29.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.244 -179.629 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 270' ' ' LEU . . . . . 0.575 HD12 HG23 ' A' ' 231' ' ' VAL . 81.6 mt -107.75 -24.16 11.81 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.023 0.44 . . . . 0.0 110.124 178.161 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -176.4 -178.27 46.05 Favored Glycine 0 C--N 1.319 -0.396 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 -178.072 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 272' ' ' PRO . . . . . 0.428 ' O ' ' CD2' ' A' ' 240' ' ' HIS . 75.5 Cg_exo -52.89 -43.6 55.21 Favored 'Trans proline' 0 C--N 1.311 -1.424 0 C-N-CA 121.958 1.772 . . . . 0.0 111.582 -177.303 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 273' ' ' TYR . . . . . 0.5 ' O ' ' HA ' ' A' ' 233' ' ' THR . 7.3 m-85 -117.76 10.75 13.4 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 115.933 -0.576 . . . . 0.0 112.084 -176.407 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 5.4 p -123.77 130.02 51.98 Favored 'General case' 0 C--N 1.321 -0.66 0 C-N-CA 120.927 -0.309 . . . . 0.0 110.992 -179.51 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 275' ' ' PHE . . . . . 0.547 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -143.81 164.08 31.52 Favored 'General case' 0 C--O 1.238 0.48 0 C-N-CA 120.926 -0.309 . . . . 0.0 111.406 175.811 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 276' ' ' SER . . . . . 0.522 ' HB3' HD11 ' A' ' 270' ' ' LEU . 4.4 p -131.05 145.38 52.0 Favored 'General case' 0 C--O 1.244 0.805 0 C-N-CA 120.672 -0.411 . . . . 0.0 111.912 -175.723 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 277' ' ' ILE . . . . . 0.635 HG22 HG22 ' A' ' 267' ' ' ILE . 35.0 pt -140.18 165.05 21.86 Favored 'Isoleucine or valine' 0 C--O 1.236 0.368 0 CA-C-N 114.766 -1.107 . . . . 0.0 112.582 -173.077 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 278' ' ' CYS . . . . . 0.413 ' SG ' ' SD ' ' A' ' 265' ' ' MET . 2.6 p -27.2 -94.76 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.416 0 N-CA-C 114.478 1.288 . . . . 0.0 114.478 -176.394 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 58.2 m-20 -144.48 110.0 5.24 Favored 'General case' 0 CA--C 1.513 -0.456 0 CA-C-N 116.622 -0.263 . . . . 0.0 111.423 -171.402 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 280' ' ' THR . . . . . 0.785 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 59.7 p -66.02 -27.7 68.31 Favored 'General case' 0 C--N 1.31 -1.137 0 CA-C-O 121.215 0.531 . . . . 0.0 109.712 172.066 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 1.5 p -63.68 -17.06 62.57 Favored 'General case' 0 N--CA 1.43 -1.435 0 CA-C-N 114.799 -1.092 . . . . 0.0 109.753 174.071 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 17.9 t-20 -98.27 -8.71 26.74 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.6 175.05 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 283' ' ' PHE . . . . . 0.785 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 15.6 m-30 -90.66 -83.08 0.27 Allowed 'General case' 0 C--O 1.237 0.404 0 CA-C-O 121.436 0.636 . . . . 0.0 110.952 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 169.25 -174.0 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 114.342 -1.299 . . . . 0.0 108.874 -173.71 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 285' ' ' ASP . . . . . 0.445 ' OD1' ' NZ ' ' A' ' 226' ' ' LYS . 31.1 t0 -92.99 112.36 24.3 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 120.906 -0.318 . . . . 0.0 111.678 -179.788 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 286' ' ' TYR . . . . . 0.536 ' N ' ' HG3' ' A' ' 256' ' ' MET . 12.4 t80 -63.66 128.49 36.07 Favored 'General case' 0 CA--C 1.512 -0.485 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 177.865 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 287' ' ' ILE . . . . . 0.448 HG22 ' HG2' ' A' ' 288' ' ' ARG . 96.5 mt -106.64 -64.06 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 175.894 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 288' ' ' ARG . . . . . 0.448 ' HG2' HG22 ' A' ' 287' ' ' ILE . 9.6 ptp180 -161.15 -178.67 6.9 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.088 178.921 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 70.02 -161.08 53.19 Favored Glycine 0 CA--C 1.504 -0.615 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 178.893 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 108.8 117.59 4.06 Favored Glycine 0 N--CA 1.442 -0.958 0 C-N-CA 120.934 -0.651 . . . . 0.0 113.291 174.686 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 97.2 mt -118.16 130.34 73.17 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.25 0 N-CA-C 107.321 -1.363 . . . . 0.0 107.321 170.562 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 4.8 p -109.19 128.89 64.77 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 -179.355 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 36.7 m -116.63 137.42 52.2 Favored 'General case' 0 N--CA 1.438 -1.039 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.932 -176.543 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 . . . . . 0 N--CA 1.431 -1.399 0 CA-C-N 115.609 -0.723 . . . . 0.0 109.752 176.884 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 217' ' ' LEU . . . . . 1.009 ' N ' HE21 ' A' ' 294' ' ' GLN . 3.8 mm? . . . . . 0 CA--C 1.503 -0.829 0 N-CA-C 112.35 0.5 . . . . 0.0 112.35 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 5.9 m -142.79 133.45 25.21 Favored 'General case' 0 N--CA 1.441 -0.92 0 CA-C-N 115.126 -0.943 . . . . 0.0 109.533 175.803 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -147.78 164.41 33.71 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 121.336 0.589 . . . . 0.0 112.295 -177.129 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 220' ' ' MET . . . . . 0.69 ' SD ' ' N ' ' A' ' 220' ' ' MET . 0.0 OUTLIER -74.77 132.62 41.75 Favored 'General case' 0 C--O 1.243 0.747 0 CA-C-N 115.023 -0.99 . . . . 0.0 109.876 178.264 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 52.4 t -88.91 130.21 38.67 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 175.142 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 36.9 p -88.1 -57.72 2.83 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 120.351 -0.54 . . . . 0.0 110.189 -178.661 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 1.7 ptm -137.04 149.75 47.64 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.481 175.69 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 224' ' ' VAL . . . . . 0.63 HG11 ' SD ' ' A' ' 256' ' ' MET . 21.7 t -127.21 132.32 69.76 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.963 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 174.004 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -106.42 121.55 44.48 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 -177.082 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 226' ' ' LYS . . . . . 0.548 ' HA ' ' HB ' ' A' ' 280' ' ' THR . 0.1 OUTLIER -77.38 73.39 3.95 Favored 'General case' 0 C--O 1.237 0.436 0 C-N-CA 119.721 -0.792 . . . . 0.0 111.642 -179.596 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 227' ' ' ASP . . . . . 0.419 ' N ' ' OG1' ' A' ' 280' ' ' THR . 41.5 t0 -126.23 -178.85 4.47 Favored 'General case' 0 C--O 1.238 0.499 0 CA-C-N 114.827 -1.079 . . . . 0.0 109.989 -179.587 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 228' ' ' ASN . . . . . 0.436 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.4 OUTLIER -136.89 123.19 13.54 Favored Pre-proline 0 CA--C 1.538 0.499 0 CA-C-O 120.571 0.224 . . . . 0.0 111.205 175.799 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 229' ' ' PRO . . . . . 0.436 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 50.0 Cg_endo -66.8 151.0 82.05 Favored 'Cis proline' 0 N--CA 1.495 1.61 0 C-N-CA 123.288 -1.547 . . . . 0.0 108.592 -2.397 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 230' ' ' GLY . . . . . 0.687 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -63.28 139.96 44.62 Favored Glycine 0 C--N 1.315 -0.586 0 C-N-CA 119.515 -1.326 . . . . 0.0 110.233 -175.249 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 3.1 p -125.07 131.3 72.68 Favored 'Isoleucine or valine' 0 C--O 1.241 0.641 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 178.408 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 232' ' ' VAL . . . . . 0.5 HG22 ' CD1' ' A' ' 275' ' ' PHE . 0.7 OUTLIER -135.26 157.14 39.95 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-N 116.546 -0.297 . . . . 0.0 110.334 -178.293 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 233' ' ' THR . . . . . 0.458 ' HA ' ' O ' ' A' ' 273' ' ' TYR . 11.9 m -114.78 147.03 40.33 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.012 177.365 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 55.7 m -106.47 153.09 22.79 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.021 -178.315 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.415 ' HB3' ' HB3' ' A' ' 238' ' ' ALA . 32.9 tp -56.81 130.03 43.93 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 -179.926 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 236' ' ' ASP . . . . . 0.538 ' HA ' ' CE1' ' A' ' 273' ' ' TYR . 34.6 t70 -55.23 -42.97 74.08 Favored 'General case' 0 CA--C 1.509 -0.62 0 CA-C-O 121.459 0.647 . . . . 0.0 109.865 -176.26 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -64.79 -33.54 76.23 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-N 114.851 -1.068 . . . . 0.0 110.52 -179.917 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 238' ' ' ALA . . . . . 0.415 ' HB3' ' HB3' ' A' ' 235' ' ' LEU . . . -114.94 92.8 4.06 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.532 -176.828 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 239' ' ' ARG . . . . . 0.454 ' HG2' ' CE1' ' A' ' 273' ' ' TYR . 58.9 mtm180 -67.29 138.14 56.62 Favored 'General case' 0 N--CA 1.448 -0.532 0 C-N-CA 119.927 -0.709 . . . . 0.0 109.821 174.334 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 240' ' ' HIS . . . . . 0.656 ' H ' ' CD2' ' A' ' 240' ' ' HIS . 6.2 p80 -58.9 -45.35 90.5 Favored 'General case' 0 C--N 1.313 -0.988 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.414 178.384 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 80.26 12.67 82.9 Favored Glycine 0 C--N 1.319 -0.39 0 N-CA-C 109.73 -1.348 . . . . 0.0 109.73 -177.871 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 242' ' ' PHE . . . . . 0.594 ' CD2' ' HB2' ' A' ' 240' ' ' HIS . 8.6 m-30 -81.61 149.58 28.53 Favored 'General case' 0 N--CA 1.442 -0.862 0 CA-C-N 115.327 -0.436 . . . . 0.0 110.329 -179.813 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -117.96 150.76 38.7 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-N 115.335 -0.848 . . . . 0.0 108.783 176.828 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 244' ' ' THR . . . . . 0.71 ' OG1' HG22 ' A' ' 269' ' ' VAL . 28.5 m -57.56 125.75 24.27 Favored 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 119.319 -0.952 . . . . 0.0 109.16 179.643 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 104.27 -10.93 51.17 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 -175.945 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 68.3 m-20 -67.73 147.56 52.46 Favored 'General case' 0 C--N 1.328 -0.358 0 O-C-N 122.82 -0.224 . . . . 0.0 111.0 178.18 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 247' ' ' PHE . . . . . 0.445 ' HA ' ' O ' ' A' ' 265' ' ' MET . 66.9 m-85 -109.52 125.75 52.82 Favored 'General case' 0 C--O 1.242 0.697 0 CA-C-N 116.1 -0.5 . . . . 0.0 109.909 178.037 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 248' ' ' VAL . . . . . 0.49 HG12 ' HG2' ' A' ' 294' ' ' GLN . 3.4 m -132.48 164.52 34.78 Favored 'Isoleucine or valine' 0 C--O 1.246 0.908 0 N-CA-C 112.472 0.545 . . . . 0.0 112.472 -175.794 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 13.5 p -131.98 159.25 39.29 Favored 'General case' 0 C--O 1.241 0.634 0 CA-C-N 114.66 -1.155 . . . . 0.0 108.911 174.856 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 250' ' ' PHE . . . . . 0.574 ' CD1' HD22 ' A' ' 259' ' ' LEU . 65.9 m-85 -114.85 159.21 20.92 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 121.327 0.584 . . . . 0.0 112.529 -172.725 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 7.0 m -157.5 161.73 38.85 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-N 115.208 -0.905 . . . . 0.0 109.323 174.974 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 252' ' ' GLU . . . . . 0.445 ' HG3' HD12 ' A' ' 291' ' ' ILE . 61.9 mm-40 59.17 18.47 6.53 Favored 'General case' 0 CA--C 1.544 0.732 0 N-CA-C 112.024 0.379 . . . . 0.0 112.024 177.933 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 0.47 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 57.3 t -86.98 132.41 32.5 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 178.734 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 90.2 mt-30 -105.83 146.05 30.4 Favored 'General case' 0 C--O 1.24 0.589 0 CA-C-O 121.244 0.545 . . . . 0.0 111.096 177.511 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 255' ' ' GLY . . . . . 0.424 ' HA3' HG13 ' A' ' 287' ' ' ILE . . . 79.65 -65.94 3.61 Favored Glycine 0 CA--C 1.505 -0.585 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 -177.255 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 256' ' ' MET . . . . . 0.63 ' SD ' HG11 ' A' ' 224' ' ' VAL . 26.5 ttm -81.98 54.5 2.49 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-O 121.551 0.691 . . . . 0.0 109.324 175.106 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 257' ' ' ILE . . . . . 0.404 ' O ' ' HB2' ' A' ' 260' ' ' ASN . 48.2 pt -68.81 -20.06 24.58 Favored 'Isoleucine or valine' 0 C--O 1.239 0.546 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.607 -176.061 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 258' ' ' GLN . . . . . 0.694 ' HG3' ' SG ' ' A' ' 262' ' ' CYS . 47.4 tp60 -56.42 -31.66 64.13 Favored 'General case' 0 N--CA 1.439 -1.002 0 C-N-CA 120.009 -0.676 . . . . 0.0 110.353 178.851 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 259' ' ' LEU . . . . . 1.057 HD21 ' CE2' ' A' ' 283' ' ' PHE . 78.9 mt -62.18 -41.32 98.22 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 120.911 0.386 . . . . 0.0 110.323 174.17 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 260' ' ' ASN . . . . . 0.47 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 98.3 m-20 -59.77 -40.52 88.48 Favored 'General case' 0 CA--C 1.509 -0.612 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 -179.852 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -101.27 17.32 55.91 Favored Glycine 0 C--N 1.322 -0.2 0 CA-C-N 115.543 -0.753 . . . . 0.0 112.158 -178.425 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 262' ' ' CYS . . . . . 0.694 ' SG ' ' HG3' ' A' ' 258' ' ' GLN . 0.9 OUTLIER -91.77 155.32 18.33 Favored 'General case' 0 CA--C 1.51 -0.565 0 CA-C-N 117.157 0.478 . . . . 0.0 111.687 -178.009 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 28.1 mm-40 -74.18 153.72 88.39 Favored Pre-proline 0 C--N 1.325 -0.491 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 170.612 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -65.37 148.78 88.49 Favored 'Trans proline' 0 C--N 1.305 -1.716 0 C-N-CA 121.375 1.383 . . . . 0.0 111.253 -178.538 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 265' ' ' MET . . . . . 0.483 ' SD ' HD12 ' A' ' 277' ' ' ILE . 12.9 ptp -138.38 160.21 40.1 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.831 -174.853 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 266' ' ' GLU . . . . . 0.427 ' OE2' ' NZ ' ' A' ' 268' ' ' LYS . 36.1 tt0 -71.48 144.82 49.54 Favored 'General case' 0 C--O 1.242 0.663 0 O-C-N 123.999 0.812 . . . . 0.0 109.325 177.097 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 267' ' ' ILE . . . . . 0.687 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.5 pp -126.71 155.16 37.21 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-O 120.753 0.311 . . . . 0.0 111.501 -179.704 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 268' ' ' LYS . . . . . 0.638 ' HA ' HG23 ' A' ' 244' ' ' THR . 65.9 mttm -127.99 123.31 34.45 Favored 'General case' 0 C--O 1.239 0.548 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 177.496 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.71 HG22 ' OG1' ' A' ' 244' ' ' THR . 34.6 m -81.42 105.11 10.93 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.689 0 CA-C-O 121.284 0.564 . . . . 0.0 112.484 -176.398 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 92.4 mt -67.13 -41.42 86.15 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.639 -0.709 . . . . 0.0 110.089 175.927 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -150.51 -177.65 24.64 Favored Glycine 0 CA--C 1.52 0.356 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 -179.202 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 272' ' ' PRO . . . . . 0.605 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 33.7 Cg_endo -62.51 -32.23 80.17 Favored 'Trans proline' 0 C--N 1.309 -1.541 0 C-N-CA 121.883 1.722 . . . . 0.0 110.726 -177.203 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 273' ' ' TYR . . . . . 0.538 ' CE1' ' HA ' ' A' ' 236' ' ' ASP . 74.2 m-85 -116.87 0.07 12.39 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.608 -0.724 . . . . 0.0 112.89 -179.015 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -120.17 127.71 52.73 Favored 'General case' 0 C--O 1.242 0.696 0 C-N-CA 120.658 -0.417 . . . . 0.0 111.659 178.936 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 275' ' ' PHE . . . . . 0.536 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -133.43 162.68 31.21 Favored 'General case' 0 CA--C 1.501 -0.936 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.535 177.12 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 276' ' ' SER . . . . . 0.521 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 4.4 p -134.4 146.92 50.32 Favored 'General case' 0 C--N 1.313 -0.984 0 C-N-CA 119.949 -0.701 . . . . 0.0 111.629 -178.579 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 277' ' ' ILE . . . . . 0.565 HG22 HG22 ' A' ' 267' ' ' ILE . 34.9 pt -137.26 167.8 22.52 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.961 0 CA-C-N 114.694 -1.139 . . . . 0.0 111.481 -173.243 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 278' ' ' CYS . . . . . 0.404 ' C ' ' O ' ' A' ' 277' ' ' ILE . 71.7 m -22.05 -85.02 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.764 0 N-CA-C 113.771 1.026 . . . . 0.0 113.771 -175.409 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 279' ' ' ASP . . . . . 0.429 ' HB3' ' HB2' ' A' ' 282' ' ' ASN . 58.4 t0 -153.26 106.76 3.01 Favored 'General case' 0 CA--C 1.506 -0.743 0 CA-C-O 120.753 0.311 . . . . 0.0 110.372 179.552 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 280' ' ' THR . . . . . 0.817 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 5.9 p -65.99 -27.46 68.15 Favored 'General case' 0 C--N 1.297 -1.695 0 CA-C-O 121.214 0.531 . . . . 0.0 111.057 177.07 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -64.81 -19.98 66.14 Favored 'General case' 0 C--N 1.314 -0.978 0 CA-C-N 115.464 -0.789 . . . . 0.0 109.183 174.776 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 282' ' ' ASN . . . . . 0.429 ' HB2' ' HB3' ' A' ' 279' ' ' ASP . 0.2 OUTLIER -87.76 -8.55 55.86 Favored 'General case' 0 CA--C 1.508 -0.667 0 N-CA-C 108.752 -0.832 . . . . 0.0 108.752 179.554 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 283' ' ' PHE . . . . . 1.057 ' CE2' HD21 ' A' ' 259' ' ' LEU . 13.3 m-85 -92.25 -77.01 0.44 Allowed 'General case' 0 N--CA 1.443 -0.798 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 174.159 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 169.23 -179.3 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 114.522 -1.217 . . . . 0.0 109.702 -174.401 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 35.8 t0 -85.62 132.96 34.07 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 116.496 -0.32 . . . . 0.0 111.179 178.804 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 286' ' ' TYR . . . . . 0.687 ' CZ ' ' HA ' ' A' ' 288' ' ' ARG . 91.1 t80 -68.56 130.56 43.21 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.096 -179.895 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 287' ' ' ILE . . . . . 0.424 HG13 ' HA3' ' A' ' 255' ' ' GLY . 85.8 mt -100.17 -63.11 1.76 Allowed 'Isoleucine or valine' 0 CA--C 1.514 -0.433 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 170.072 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 288' ' ' ARG . . . . . 0.687 ' HA ' ' CZ ' ' A' ' 286' ' ' TYR . 9.5 ptm180 -172.41 -173.2 1.02 Allowed 'General case' 0 C--O 1.243 0.726 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.987 175.307 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 68.48 -163.08 49.51 Favored Glycine 0 CA--C 1.507 -0.464 0 N-CA-C 110.629 -0.988 . . . . 0.0 110.629 175.929 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 113.97 124.61 4.07 Favored Glycine 0 N--CA 1.443 -0.889 0 C-N-CA 121.462 -0.399 . . . . 0.0 112.486 175.768 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 291' ' ' ILE . . . . . 0.445 HD12 ' HG3' ' A' ' 252' ' ' GLU . 92.2 mt -123.09 132.51 71.26 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 172.234 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 292' ' ' VAL . . . . . 0.469 ' HB ' ' CE2' ' A' ' 250' ' ' PHE . 4.9 p -118.1 133.45 64.86 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 C-N-CA 120.624 -0.431 . . . . 0.0 110.028 -176.866 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 3.9 m -128.13 146.56 50.67 Favored 'General case' 0 N--CA 1.446 -0.64 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.648 -175.142 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 294' ' ' GLN . . . . . 1.009 HE21 ' N ' ' A' ' 217' ' ' LEU . 32.2 mt-30 . . . . . 0 CA--C 1.505 -0.778 0 CA-C-O 121.279 0.561 . . . . 0.0 110.224 176.481 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 217' ' ' LEU . . . . . 0.792 HD13 ' N ' ' A' ' 218' ' ' SER . 1.3 tm? . . . . . 0 CA--C 1.51 -0.592 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 218' ' ' SER . . . . . 0.792 ' N ' HD13 ' A' ' 217' ' ' LEU . 75.6 m -114.72 131.45 56.76 Favored 'General case' 0 N--CA 1.438 -1.066 0 CA-C-N 115.846 -0.615 . . . . 0.0 109.358 178.238 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 219' ' ' ALA . . . . . 0.566 ' HB1' ' HB1' ' A' ' 238' ' ' ALA . . . -127.74 150.33 49.84 Favored 'General case' 0 CA--C 1.503 -0.845 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.899 -177.097 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 220' ' ' MET . . . . . 0.71 ' SD ' HG12 ' A' ' 291' ' ' ILE . 87.6 mmm -76.56 131.21 38.81 Favored 'General case' 0 N--CA 1.44 -0.926 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 176.587 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 91.5 t -75.51 128.21 37.14 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.311 0 N-CA-C 107.586 -1.265 . . . . 0.0 107.586 175.877 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 222' ' ' SER . . . . . 0.628 ' CB ' ' HG1' ' A' ' 233' ' ' THR . 0.1 OUTLIER -84.6 -67.33 0.8 Allowed 'General case' 0 N--CA 1.437 -1.087 0 C-N-CA 119.717 -0.793 . . . . 0.0 109.375 179.703 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 3.6 ptm -137.9 151.39 47.97 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 112.552 0.575 . . . . 0.0 112.552 173.056 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 224' ' ' VAL . . . . . 0.717 HG22 ' HB ' ' A' ' 232' ' ' VAL . 68.8 t -123.78 132.59 71.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 174.95 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 28.2 p -92.76 131.32 37.92 Favored 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 121.031 -0.268 . . . . 0.0 110.38 179.588 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 6.0 ttmt -77.94 87.61 4.12 Favored 'General case' 0 N--CA 1.446 -0.646 0 C-N-CA 119.477 -0.889 . . . . 0.0 109.152 178.548 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 227' ' ' ASP . . . . . 0.526 ' N ' ' OG1' ' A' ' 280' ' ' THR . 47.5 t0 -158.63 175.0 14.19 Favored 'General case' 0 C--N 1.312 -1.056 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.532 -179.574 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 228' ' ' ASN . . . . . 0.475 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 1.4 t-20 -140.85 123.56 9.75 Favored Pre-proline 0 C--O 1.237 0.406 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.112 173.866 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 229' ' ' PRO . . . . . 0.475 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 44.8 Cg_endo -66.31 144.7 67.88 Favored 'Cis proline' 0 C--N 1.313 -1.294 0 C-N-CA 122.492 -1.878 . . . . 0.0 109.308 -2.029 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 230' ' ' GLY . . . . . 0.48 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -82.71 144.9 23.37 Favored Glycine 0 C--N 1.312 -0.8 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 -178.179 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 231' ' ' VAL . . . . . 0.416 HG23 HD12 ' A' ' 270' ' ' LEU . 2.6 p -121.22 130.53 74.56 Favored 'Isoleucine or valine' 0 C--O 1.241 0.657 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 176.299 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 232' ' ' VAL . . . . . 0.717 ' HB ' HG22 ' A' ' 224' ' ' VAL . 0.7 OUTLIER -132.66 157.14 42.95 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 CA-C-N 116.264 -0.425 . . . . 0.0 109.874 -177.413 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 233' ' ' THR . . . . . 0.652 HG22 HG22 ' A' ' 274' ' ' THR . 61.6 p -110.35 158.47 18.41 Favored 'General case' 0 N--CA 1.429 -1.486 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.229 179.711 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.8 m -113.08 148.97 34.14 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 172.656 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 40.2 tp -56.69 133.73 54.17 Favored 'General case' 0 C--N 1.308 -1.22 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 -179.69 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 236' ' ' ASP . . . . . 0.409 ' O ' ' CE1' ' A' ' 273' ' ' TYR . 7.8 t70 -52.72 -37.96 60.02 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.683 -171.523 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 10.0 mm-40 -75.31 -6.67 51.1 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.076 -178.011 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 238' ' ' ALA . . . . . 0.566 ' HB1' ' HB1' ' A' ' 219' ' ' ALA . . . -97.39 99.88 11.32 Favored 'General case' 0 C--O 1.239 0.505 0 N-CA-C 112.554 0.575 . . . . 0.0 112.554 -175.453 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 239' ' ' ARG . . . . . 0.412 ' O ' ' C ' ' A' ' 240' ' ' HIS . 0.0 OUTLIER -70.61 66.49 0.34 Allowed 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 116.519 -0.31 . . . . 0.0 110.678 175.396 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 240' ' ' HIS . . . . . 0.6 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 14.0 p80 -33.49 -49.04 0.28 Allowed 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.227 0.537 . . . . 0.0 111.291 -178.942 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 79.41 19.31 71.83 Favored Glycine 0 C--O 1.245 0.841 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 178.432 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 242' ' ' PHE . . . . . 0.673 ' CD1' ' HB3' ' A' ' 294' ' ' GLN . 4.3 m-30 -79.85 141.53 36.1 Favored 'General case' 0 N--CA 1.444 -0.745 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 -179.256 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 243' ' ' GLU . . . . . 0.473 ' HB2' ' HB2' ' A' ' 246' ' ' ASP . 96.5 mt-10 -109.35 158.37 17.97 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 178.925 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 7.9 m -65.14 123.98 20.93 Favored 'General case' 0 C--N 1.312 -1.022 0 C-N-CA 119.115 -1.034 . . . . 0.0 108.538 178.101 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 85.87 8.04 80.11 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.559 -1.016 . . . . 0.0 110.559 -176.374 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 246' ' ' ASP . . . . . 0.473 ' HB2' ' HB2' ' A' ' 243' ' ' GLU . 45.7 t0 -82.44 167.19 18.7 Favored 'General case' 0 CA--C 1.518 -0.287 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 179.616 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 247' ' ' PHE . . . . . 0.419 ' HA ' ' O ' ' A' ' 265' ' ' MET . 95.8 m-85 -111.95 137.77 49.48 Favored 'General case' 0 C--O 1.24 0.584 0 CA-C-O 120.64 0.257 . . . . 0.0 111.295 -177.932 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 248' ' ' VAL . . . . . 0.562 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.6 m -133.58 160.89 41.96 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.306 0 CA-C-N 116.557 -0.292 . . . . 0.0 111.159 177.5 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 2.9 p -117.84 152.01 36.21 Favored 'General case' 0 C--N 1.318 -0.786 0 C-N-CA 123.958 0.903 . . . . 0.0 109.404 175.082 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 250' ' ' PHE . . . . . 0.644 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 75.0 m-85 -110.92 146.56 36.35 Favored 'General case' 0 CA--C 1.506 -0.715 0 C-N-CA 122.695 0.398 . . . . 0.0 110.758 -178.007 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 2.0 m -154.59 154.65 33.37 Favored 'General case' 0 C--N 1.31 -1.149 0 C-N-CA 120.765 -0.374 . . . . 0.0 110.145 176.778 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 73.5 mm-40 55.13 30.18 13.94 Favored 'General case' 0 C--N 1.313 -0.979 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.787 176.17 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 0.703 HG22 ' HA2' ' A' ' 290' ' ' GLY . 2.8 t -97.93 115.24 37.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 177.269 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 254' ' ' GLN . . . . . 0.416 ' HG3' ' HD2' ' A' ' 288' ' ' ARG . 2.0 mm100 -79.1 137.76 37.64 Favored 'General case' 0 C--O 1.238 0.473 0 CA-C-O 121.035 0.445 . . . . 0.0 111.481 -179.769 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 255' ' ' GLY . . . . . 0.405 ' N ' HD12 ' A' ' 287' ' ' ILE . . . 81.99 -55.59 4.92 Favored Glycine 0 CA--C 1.506 -0.479 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 -178.579 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 256' ' ' MET . . . . . 0.552 ' SD ' HG11 ' A' ' 224' ' ' VAL . 3.1 ttm -81.24 49.93 1.35 Allowed 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.814 0.816 . . . . 0.0 109.215 176.927 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 46.7 pt -72.13 -20.73 20.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-N 114.836 -1.074 . . . . 0.0 110.974 -176.61 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 258' ' ' GLN . . . . . 0.599 ' O ' ' SG ' ' A' ' 262' ' ' CYS . 19.1 tp60 -54.48 -41.07 69.12 Favored 'General case' 0 N--CA 1.448 -0.555 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 179.147 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 259' ' ' LEU . . . . . 0.689 HD21 ' CZ ' ' A' ' 283' ' ' PHE . 98.2 mt -63.09 -39.92 96.14 Favored 'General case' 0 N--CA 1.445 -0.695 0 CA-C-N 114.861 -1.063 . . . . 0.0 110.116 177.545 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -59.76 -40.74 89.19 Favored 'General case' 0 CA--C 1.51 -0.591 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 -178.161 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -88.59 -1.12 81.16 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 115.548 -0.751 . . . . 0.0 112.106 -179.594 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 262' ' ' CYS . . . . . 0.599 ' SG ' ' O ' ' A' ' 258' ' ' GLN . 61.5 m -83.1 153.34 24.91 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-N 117.157 0.479 . . . . 0.0 111.017 -179.259 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 5.9 mm100 -79.07 163.96 57.33 Favored Pre-proline 0 C--N 1.323 -0.567 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 169.116 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 264' ' ' PRO . . . . . 0.562 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 36.7 Cg_exo -59.54 143.32 99.71 Favored 'Trans proline' 0 C--N 1.307 -1.608 0 C-N-CA 121.013 1.142 . . . . 0.0 111.105 -176.823 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 265' ' ' MET . . . . . 0.642 ' N ' ' SD ' ' A' ' 265' ' ' MET . 0.9 OUTLIER -126.88 160.76 30.02 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 116.627 -0.26 . . . . 0.0 111.396 -175.966 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 3.2 tt0 -71.44 137.72 48.49 Favored 'General case' 0 C--O 1.241 0.632 0 O-C-N 123.653 0.596 . . . . 0.0 110.224 178.697 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 267' ' ' ILE . . . . . 0.732 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.7 pp -132.01 162.96 38.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.113 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 64.3 mttp -124.85 136.22 53.61 Favored 'General case' 0 C--O 1.216 -0.705 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 175.189 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 15.9 m -95.64 102.3 13.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 CA-C-O 121.355 0.597 . . . . 0.0 111.634 -179.403 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 270' ' ' LEU . . . . . 0.416 HD12 HG23 ' A' ' 231' ' ' VAL . 95.9 mt -66.8 -39.77 87.87 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.672 178.278 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -144.73 -170.3 13.82 Favored Glycine 0 N--CA 1.465 0.585 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 -176.516 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 272' ' ' PRO . . . . . 0.6 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 28.6 Cg_endo -59.31 -37.82 88.55 Favored 'Trans proline' 0 N--CA 1.491 1.37 0 C-N-CA 121.95 1.767 . . . . 0.0 111.88 -177.103 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 273' ' ' TYR . . . . . 0.409 ' CE1' ' O ' ' A' ' 236' ' ' ASP . 23.1 m-85 -124.03 5.53 8.61 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 111.726 0.269 . . . . 0.0 111.726 176.834 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 274' ' ' THR . . . . . 0.652 HG22 HG22 ' A' ' 233' ' ' THR . 0.7 OUTLIER -105.99 128.43 53.82 Favored 'General case' 0 C--N 1.32 -0.715 0 C-N-CA 120.586 -0.445 . . . . 0.0 110.724 -175.757 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 275' ' ' PHE . . . . . 0.562 ' CD1' HG22 ' A' ' 232' ' ' VAL . 0.0 OUTLIER -136.11 161.57 35.35 Favored 'General case' 0 CA--C 1.505 -0.77 0 C-N-CA 120.828 -0.349 . . . . 0.0 111.871 179.154 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 276' ' ' SER . . . . . 0.48 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 3.7 p -131.83 139.86 48.98 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-O 121.272 0.558 . . . . 0.0 111.883 -175.413 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 277' ' ' ILE . . . . . 0.497 HG22 HG22 ' A' ' 267' ' ' ILE . 37.0 pt -136.95 164.56 30.02 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.723 0 CA-C-N 114.69 -1.141 . . . . 0.0 112.378 -172.099 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 278' ' ' CYS . . . . . 0.449 ' O ' ' HA ' ' A' ' 229' ' ' PRO . 71.2 m -29.73 -92.15 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.402 0 N-CA-C 114.113 1.153 . . . . 0.0 114.113 -176.794 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 19.8 t0 -145.78 114.38 6.79 Favored 'General case' 0 CA--C 1.503 -0.847 0 CA-C-O 120.719 0.295 . . . . 0.0 111.214 -175.673 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 280' ' ' THR . . . . . 0.733 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 21.7 p -65.53 -30.59 71.36 Favored 'General case' 0 C--N 1.3 -1.586 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.576 176.18 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -65.32 -20.16 66.28 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 115.271 -0.877 . . . . 0.0 109.321 177.339 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -87.37 -8.09 57.02 Favored 'General case' 0 CA--C 1.506 -0.717 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.848 179.663 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 283' ' ' PHE . . . . . 0.733 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 5.3 m-85 -94.96 -68.38 0.8 Allowed 'General case' 0 N--CA 1.443 -0.824 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 172.808 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 284' ' ' SER . . . . . 0.406 ' OG ' ' HA ' ' A' ' 256' ' ' MET . 1.7 p 164.39 -87.93 0.0 OUTLIER 'General case' 0 C--O 1.244 0.763 0 CA-C-N 115.246 -0.888 . . . . 0.0 110.909 176.934 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 285' ' ' ASP . . . . . 0.492 ' O ' ' N ' ' A' ' 256' ' ' MET . 3.7 t0 -157.59 165.32 35.86 Favored 'General case' 0 C--O 1.22 -0.496 0 CA-C-N 116.614 -0.266 . . . . 0.0 111.055 179.579 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 286' ' ' TYR . . . . . 0.461 ' O ' ' CD2' ' A' ' 286' ' ' TYR . 35.7 t80 -106.8 89.22 2.95 Favored 'General case' 0 C--N 1.319 -0.728 0 C-N-CA 123.317 0.647 . . . . 0.0 110.038 179.052 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 287' ' ' ILE . . . . . 0.414 HG22 ' HG3' ' A' ' 288' ' ' ARG . 96.5 mt -70.44 -46.11 72.04 Favored 'Isoleucine or valine' 0 C--O 1.24 0.597 0 CA-C-O 121.197 0.522 . . . . 0.0 110.14 179.235 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 288' ' ' ARG . . . . . 0.416 ' HD2' ' HG3' ' A' ' 254' ' ' GLN . 0.0 OUTLIER 173.45 173.09 0.15 Allowed 'General case' 0 C--O 1.243 0.755 0 CA-C-N 115.588 -0.733 . . . . 0.0 111.219 -177.623 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 68.08 -140.9 36.79 Favored Glycine 0 CA--C 1.508 -0.363 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 175.39 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 290' ' ' GLY . . . . . 0.703 ' HA2' HG22 ' A' ' 253' ' ' VAL . . . 97.31 115.58 3.34 Favored Glycine 0 N--CA 1.442 -0.913 0 C-N-CA 121.487 -0.387 . . . . 0.0 112.148 176.71 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 291' ' ' ILE . . . . . 0.71 HG12 ' SD ' ' A' ' 220' ' ' MET . 89.8 mt -116.08 130.46 70.77 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.93 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 174.111 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 2.8 p -118.08 127.34 75.29 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 -179.231 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 293' ' ' SER . . . . . 0.42 ' HA ' ' O ' ' A' ' 217' ' ' LEU . 4.7 m -121.43 122.76 40.5 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.258 -176.155 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 294' ' ' GLN . . . . . 0.673 ' HB3' ' CD1' ' A' ' 242' ' ' PHE . 12.8 pt20 . . . . . 0 CA--C 1.497 -1.093 0 CA-C-O 121.257 0.551 . . . . 0.0 111.872 -179.358 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.244 0.774 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 218' ' ' SER . . . . . 0.423 ' OG ' ' OG ' ' A' ' 293' ' ' SER . 22.4 m -131.9 152.35 51.11 Favored 'General case' 0 N--CA 1.442 -0.829 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.529 -175.787 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -145.79 156.06 43.34 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.56 179.855 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 97.7 mtp -76.46 140.39 41.23 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 174.62 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 97.9 t -80.89 129.21 37.91 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.014 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 178.263 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 29.0 m -77.98 -70.58 0.47 Allowed 'General case' 0 N--CA 1.434 -1.273 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 177.36 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 5.9 ptm -138.25 160.29 39.85 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.275 174.99 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 224' ' ' VAL . . . . . 0.522 HG11 ' SD ' ' A' ' 256' ' ' MET . 61.3 t -124.53 132.13 71.77 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.037 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 173.867 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -100.35 120.33 39.78 Favored 'General case' 0 C--N 1.313 -1.013 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 -177.993 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 226' ' ' LYS . . . . . 0.519 ' NZ ' ' OD1' ' A' ' 285' ' ' ASP . 0.0 OUTLIER -71.82 82.11 0.9 Allowed 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.003 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 227' ' ' ASP . . . . . 0.513 ' N ' ' OG1' ' A' ' 280' ' ' THR . 4.1 t70 -153.49 -175.45 5.36 Favored 'General case' 0 C--O 1.246 0.886 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.037 -179.319 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 228' ' ' ASN . . . . . 0.557 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.1 OUTLIER -142.12 124.08 8.98 Favored Pre-proline 0 C--N 1.331 -0.228 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.307 176.696 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 229' ' ' PRO . . . . . 0.557 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 33.7 Cg_exo -61.71 147.02 50.93 Favored 'Cis proline' 0 N--CA 1.489 1.213 0 C-N-CA 123.091 -1.629 . . . . 0.0 109.984 -1.73 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 230' ' ' GLY . . . . . 0.635 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -68.71 134.12 27.77 Favored Glycine 0 C--N 1.3 -1.461 0 N-CA-C 108.864 -1.694 . . . . 0.0 108.864 179.064 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 231' ' ' VAL . . . . . 0.457 ' HB ' ' OG ' ' A' ' 276' ' ' SER . 2.1 p -125.7 132.34 70.94 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 117.332 0.566 . . . . 0.0 110.11 179.549 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 232' ' ' VAL . . . . . 0.458 HG22 ' CD1' ' A' ' 275' ' ' PHE . 0.7 OUTLIER -135.07 156.98 40.33 Favored 'Isoleucine or valine' 0 C--O 1.248 0.979 0 C-N-CA 120.754 -0.378 . . . . 0.0 110.084 -178.697 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 233' ' ' THR . . . . . 0.514 HG22 HG23 ' A' ' 274' ' ' THR . 14.9 p -105.56 154.8 19.89 Favored 'General case' 0 N--CA 1.435 -1.209 0 CA-C-N 116.134 -0.485 . . . . 0.0 109.822 176.844 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 2.1 m -111.78 161.07 16.71 Favored 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 176.043 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 38.4 tp -60.07 121.91 13.06 Favored 'General case' 0 C--N 1.309 -1.157 0 N-CA-C 107.143 -1.428 . . . . 0.0 107.143 178.659 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 236' ' ' ASP . . . . . 0.478 ' O ' ' NH2' ' A' ' 239' ' ' ARG . 13.9 p-10 -51.67 -44.93 63.24 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.29 0.566 . . . . 0.0 111.021 -171.55 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -64.9 -35.17 80.29 Favored 'General case' 0 C--N 1.301 -1.538 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.128 -179.355 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -70.98 95.9 1.23 Allowed 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.777 -179.198 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 239' ' ' ARG . . . . . 0.578 ' NH2' ' OH ' ' A' ' 273' ' ' TYR . 0.0 OUTLIER -62.66 99.09 0.14 Allowed 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 172.124 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 240' ' ' HIS . . . . . 0.474 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 7.2 p80 -59.48 -46.47 88.71 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.891 -175.278 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 83.5 13.09 76.93 Favored Glycine 0 C--N 1.32 -0.351 0 N-CA-C 110.505 -1.038 . . . . 0.0 110.505 -178.897 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 242' ' ' PHE . . . . . 0.518 ' CD1' ' HB3' ' A' ' 294' ' ' GLN . 4.2 m-30 -82.01 138.3 34.91 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.422 -0.585 . . . . 0.0 109.422 179.511 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -110.28 161.96 15.09 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-O 121.315 0.578 . . . . 0.0 109.656 175.642 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 244' ' ' THR . . . . . 0.436 HG22 ' HD2' ' A' ' 268' ' ' LYS . 0.2 OUTLIER -63.71 111.41 2.4 Favored 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 178.589 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 104.86 0.15 42.07 Favored Glycine 0 CA--C 1.52 0.385 0 N-CA-C 111.661 -0.576 . . . . 0.0 111.661 -178.717 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 42.3 m-20 -72.95 161.65 30.44 Favored 'General case' 0 CA--C 1.514 -0.417 0 CA-C-N 116.918 0.359 . . . . 0.0 110.562 175.703 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 247' ' ' PHE . . . . . 0.458 ' HA ' ' O ' ' A' ' 265' ' ' MET . 70.3 m-85 -109.49 130.31 55.51 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.929 -0.578 . . . . 0.0 109.721 177.471 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 248' ' ' VAL . . . . . 0.477 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.3 m -132.4 161.29 41.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 C-N-CA 120.619 -0.432 . . . . 0.0 110.817 179.548 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 3.4 p -126.64 149.61 49.4 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.842 174.427 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 250' ' ' PHE . . . . . 0.607 ' CD1' HD22 ' A' ' 259' ' ' LEU . 71.6 m-85 -102.99 162.42 12.95 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.117 -176.104 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 69.1 m -157.31 155.21 30.29 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.323 174.451 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 19.3 mt-10 51.76 26.37 3.45 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 113.123 0.786 . . . . 0.0 113.123 178.733 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 0.484 HG22 ' HA2' ' A' ' 290' ' ' GLY . 16.2 t -82.18 117.47 28.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 174.22 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 87.4 mt-30 -89.28 144.36 26.15 Favored 'General case' 0 C--O 1.245 0.859 0 CA-C-O 121.218 0.533 . . . . 0.0 111.486 -176.927 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 77.82 -60.42 3.77 Favored Glycine 0 N--CA 1.449 -0.475 0 N-CA-C 109.702 -1.359 . . . . 0.0 109.702 -177.184 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 256' ' ' MET . . . . . 0.522 ' SD ' HG11 ' A' ' 224' ' ' VAL . 57.3 ttm -86.57 65.43 9.03 Favored 'General case' 0 C--N 1.318 -0.775 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 174.831 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 257' ' ' ILE . . . . . 0.404 ' O ' ' HB2' ' A' ' 260' ' ' ASN . 47.4 pt -75.42 -17.22 15.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 115.176 -0.92 . . . . 0.0 111.322 -174.31 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 258' ' ' GLN . . . . . 0.4 ' O ' ' N ' ' A' ' 262' ' ' CYS . 6.6 mp0 -55.3 -35.98 65.69 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 -178.742 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 259' ' ' LEU . . . . . 1.01 HD21 ' CE2' ' A' ' 283' ' ' PHE . 91.6 mt -62.18 -41.83 98.7 Favored 'General case' 0 C--N 1.315 -0.897 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.785 176.87 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 260' ' ' ASN . . . . . 0.433 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 97.5 m-20 -60.84 -40.32 92.4 Favored 'General case' 0 CA--C 1.512 -0.495 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 179.753 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -91.28 -3.79 69.21 Favored Glycine 0 CA--C 1.522 0.489 0 CA-C-N 115.466 -0.788 . . . . 0.0 111.968 -177.104 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 262' ' ' CYS . . . . . 0.4 ' N ' ' O ' ' A' ' 258' ' ' GLN . 2.9 m -87.18 141.78 28.39 Favored 'General case' 0 CA--C 1.514 -0.424 0 CA-C-N 117.249 0.524 . . . . 0.0 110.812 -177.053 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 29.3 pt20 -63.36 165.58 10.92 Favored Pre-proline 0 C--N 1.323 -0.554 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 176.054 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 264' ' ' PRO . . . . . 0.477 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 36.8 Cg_exo -60.1 141.9 97.19 Favored 'Trans proline' 0 C--N 1.316 -1.148 0 N-CA-C 109.245 -1.098 . . . . 0.0 109.245 177.42 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 265' ' ' MET . . . . . 0.458 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 23.1 ptp -134.21 155.34 50.3 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 111.969 0.359 . . . . 0.0 111.969 -173.002 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 266' ' ' GLU . . . . . 0.414 ' HB2' ' CE2' ' A' ' 247' ' ' PHE . 78.5 tt0 -71.5 137.87 48.49 Favored 'General case' 0 C--O 1.239 0.519 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.865 179.306 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 267' ' ' ILE . . . . . 0.701 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.8 pp -129.03 164.19 32.07 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.995 -177.16 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 268' ' ' LYS . . . . . 0.436 ' HD2' HG22 ' A' ' 244' ' ' THR . 48.4 mmtm -129.05 125.09 36.53 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 109.114 -0.698 . . . . 0.0 109.114 176.158 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 14.9 m -79.24 125.12 38.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 C-N-CA 120.743 -0.383 . . . . 0.0 110.578 179.801 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 270' ' ' LEU . . . . . 0.539 HD11 ' OG ' ' A' ' 276' ' ' SER . 78.6 mt -101.64 -12.49 18.38 Favored 'General case' 0 C--O 1.237 0.427 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.284 -179.034 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -164.4 -179.57 38.62 Favored Glycine 0 C--N 1.317 -0.491 0 N-CA-C 109.892 -1.283 . . . . 0.0 109.892 -177.048 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 272' ' ' PRO . . . . . 0.474 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 26.2 Cg_endo -59.7 -39.71 71.14 Favored 'Trans proline' 0 C--N 1.306 -1.687 0 C-N-CA 122.159 1.906 . . . . 0.0 111.148 -177.577 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 273' ' ' TYR . . . . . 0.578 ' OH ' ' NH2' ' A' ' 239' ' ' ARG . 29.2 m-85 -123.95 13.4 9.14 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-N 115.328 -0.851 . . . . 0.0 110.686 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 274' ' ' THR . . . . . 0.514 HG23 HG22 ' A' ' 233' ' ' THR . 0.2 OUTLIER -119.1 127.49 53.41 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 -174.433 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 275' ' ' PHE . . . . . 0.559 ' CE2' HG21 ' A' ' 267' ' ' ILE . 0.0 OUTLIER -140.47 161.75 36.98 Favored 'General case' 0 CA--C 1.502 -0.89 0 C-N-CA 120.645 -0.422 . . . . 0.0 112.126 -179.588 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 276' ' ' SER . . . . . 0.539 ' OG ' HD11 ' A' ' 270' ' ' LEU . 1.8 m -130.07 156.07 45.12 Favored 'General case' 0 N--CA 1.433 -1.307 0 CA-C-O 121.568 0.699 . . . . 0.0 112.75 -177.172 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 277' ' ' ILE . . . . . 0.746 ' C ' HD12 ' A' ' 277' ' ' ILE . 2.3 pp -137.16 -179.28 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.273 0 CA-C-N 113.682 -1.599 . . . . 0.0 109.113 -177.518 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -40.1 -88.88 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.406 0 O-C-N 123.516 0.51 . . . . 0.0 112.185 179.753 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 279' ' ' ASP . . . . . 0.493 ' O ' ' ND2' ' A' ' 282' ' ' ASN . 65.5 t0 -149.22 115.55 5.81 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-O 120.602 0.239 . . . . 0.0 111.26 -178.097 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 280' ' ' THR . . . . . 0.635 HG23 ' HA3' ' A' ' 230' ' ' GLY . 14.6 p -63.56 -29.65 70.88 Favored 'General case' 0 C--N 1.308 -1.233 0 CA-C-O 121.295 0.569 . . . . 0.0 110.166 175.25 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -63.82 -19.57 65.12 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-N 115.329 -0.851 . . . . 0.0 109.763 177.146 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 282' ' ' ASN . . . . . 0.493 ' ND2' ' O ' ' A' ' 279' ' ' ASP . 0.0 OUTLIER -95.05 -7.97 38.02 Favored 'General case' 0 C--N 1.344 0.334 0 C-N-CA 120.507 -0.477 . . . . 0.0 110.436 177.949 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 283' ' ' PHE . . . . . 1.01 ' CE2' HD21 ' A' ' 259' ' ' LEU . 21.4 m-30 -85.2 -80.74 0.21 Allowed 'General case' 0 CA--C 1.512 -0.498 0 CA-C-O 121.854 0.835 . . . . 0.0 109.035 175.609 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 284' ' ' SER . . . . . 0.435 ' OG ' ' HA ' ' A' ' 256' ' ' MET . 0.1 OUTLIER 175.45 -173.37 0.08 Allowed 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 114.121 -1.399 . . . . 0.0 108.196 -176.442 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 285' ' ' ASP . . . . . 0.519 ' OD1' ' NZ ' ' A' ' 226' ' ' LYS . 33.4 t0 -91.18 116.3 28.7 Favored 'General case' 0 C--N 1.316 -0.876 0 C-N-CA 121.045 -0.262 . . . . 0.0 111.668 -178.985 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 286' ' ' TYR . . . . . 0.405 ' OH ' ' NH2' ' A' ' 288' ' ' ARG . 1.1 t80 -64.94 135.32 55.54 Favored 'General case' 0 CA--C 1.511 -0.53 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.37 179.24 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 287' ' ' ILE . . . . . 0.518 ' C ' ' HG2' ' A' ' 288' ' ' ARG . 96.9 mt -118.71 -74.78 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.433 -1.306 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.737 174.731 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 288' ' ' ARG . . . . . 0.533 ' HA ' ' NE ' ' A' ' 288' ' ' ARG . 4.1 mmp_? -148.71 175.58 11.09 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.587 -177.511 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 75.35 -156.3 48.35 Favored Glycine 0 C--O 1.238 0.393 0 N-CA-C 110.689 -0.964 . . . . 0.0 110.689 178.145 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 290' ' ' GLY . . . . . 0.484 ' HA2' HG22 ' A' ' 253' ' ' VAL . . . 103.82 111.56 3.59 Favored Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 121.712 -0.28 . . . . 0.0 112.524 176.416 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 93.2 mt -121.16 131.7 72.37 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.928 0 N-CA-C 107.532 -1.284 . . . . 0.0 107.532 173.605 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 2.8 p -122.61 137.07 57.38 Favored 'Isoleucine or valine' 0 C--O 1.242 0.683 0 C-N-CA 120.702 -0.399 . . . . 0.0 111.17 -174.893 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 293' ' ' SER . . . . . 0.423 ' OG ' ' OG ' ' A' ' 218' ' ' SER . 41.7 m -126.21 140.31 52.64 Favored 'General case' 0 CA--C 1.51 -0.565 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.438 179.533 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 294' ' ' GLN . . . . . 0.518 ' HB3' ' CD1' ' A' ' 242' ' ' PHE . 0.9 OUTLIER . . . . . 0 CA--C 1.504 -0.823 0 C-N-CA 120.499 -0.48 . . . . 0.0 110.023 176.764 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 217' ' ' LEU . . . . . 0.474 HD12 ' O ' ' A' ' 240' ' ' HIS . 0.5 OUTLIER . . . . . 0 N--CA 1.44 -0.964 0 N-CA-C 109.7 -0.481 . . . . 0.0 109.7 . . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 218' ' ' SER . . . . . 0.428 ' HA ' ' O ' ' A' ' 292' ' ' VAL . 4.0 m -128.71 145.04 51.28 Favored 'General case' 0 N--CA 1.435 -1.179 0 CA-C-N 115.489 -0.778 . . . . 0.0 110.433 -177.057 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 219' ' ' ALA . . . . . 0.474 ' HB2' ' HA ' ' A' ' 240' ' ' HIS . . . -130.24 154.96 47.05 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.395 179.078 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 220' ' ' MET . . . . . 0.601 ' SD ' HG12 ' A' ' 291' ' ' ILE . 87.8 mmm -82.46 129.34 34.88 Favored 'General case' 0 N--CA 1.438 -1.041 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 177.831 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 65.5 t -76.23 132.6 32.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 -179.808 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 222' ' ' SER . . . . . 0.435 ' O ' ' OH ' ' A' ' 286' ' ' TYR . 33.5 m -97.16 -68.52 0.8 Allowed 'General case' 0 N--CA 1.44 -0.964 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.044 179.083 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 223' ' ' MET . . . . . 0.595 ' C ' ' SD ' ' A' ' 223' ' ' MET . 1.8 ppp? -137.14 147.95 46.31 Favored 'General case' 0 C--N 1.323 -0.567 0 C-N-CA 120.686 -0.406 . . . . 0.0 112.0 173.533 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 224' ' ' VAL . . . . . 0.7 HG22 ' HB ' ' A' ' 232' ' ' VAL . 71.2 t -125.83 131.79 71.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 N-CA-C 109.546 -0.538 . . . . 0.0 109.546 177.233 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 23.0 p -88.09 129.82 35.19 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.78 -0.368 . . . . 0.0 110.15 177.534 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 226' ' ' LYS . . . . . 0.424 ' CE ' ' O ' ' A' ' 284' ' ' SER . 51.9 tttm -80.27 81.6 6.5 Favored 'General case' 0 N--CA 1.447 -0.601 0 CA-C-O 121.674 0.749 . . . . 0.0 109.984 179.235 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 227' ' ' ASP . . . . . 0.557 ' N ' ' OG1' ' A' ' 280' ' ' THR . 42.7 t0 -151.14 169.49 21.73 Favored 'General case' 0 C--O 1.245 0.826 0 CA-C-N 114.508 -1.224 . . . . 0.0 108.923 -177.085 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 228' ' ' ASN . . . . . 0.467 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 15.8 p-10 -140.91 121.83 8.96 Favored Pre-proline 0 C--N 1.325 -0.494 0 C-N-CA 120.516 -0.473 . . . . 0.0 111.717 176.993 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 229' ' ' PRO . . . . . 0.467 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 56.6 Cg_endo -65.12 142.96 55.04 Favored 'Cis proline' 0 C--N 1.311 -1.424 0 C-N-CA 122.632 -1.82 . . . . 0.0 109.437 -4.138 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 230' ' ' GLY . . . . . 0.474 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -93.14 154.69 22.0 Favored Glycine 0 C--N 1.311 -0.817 0 N-CA-C 110.192 -1.163 . . . . 0.0 110.192 -177.296 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 231' ' ' VAL . . . . . 0.447 HG23 HD12 ' A' ' 270' ' ' LEU . 2.4 p -123.3 137.66 55.87 Favored 'Isoleucine or valine' 0 C--O 1.239 0.529 0 CA-C-N 116.724 0.262 . . . . 0.0 110.318 179.188 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 232' ' ' VAL . . . . . 0.7 ' HB ' HG22 ' A' ' 224' ' ' VAL . 0.8 OUTLIER -130.95 155.9 42.32 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.016 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.299 -177.998 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 233' ' ' THR . . . . . 0.403 ' O ' ' HB2' ' A' ' 222' ' ' SER . 27.6 m -110.73 140.45 45.11 Favored 'General case' 0 C--N 1.312 -1.028 0 CA-C-N 115.49 -0.777 . . . . 0.0 108.918 174.981 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 48.2 m -107.69 162.22 14.18 Favored 'General case' 0 C--N 1.314 -0.954 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 179.315 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 50.1 tp -61.41 130.32 45.5 Favored 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 179.198 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 55.6 m-20 -58.75 -40.41 83.79 Favored 'General case' 0 N--CA 1.476 0.857 0 CA-C-O 120.902 0.382 . . . . 0.0 111.244 -174.823 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 54.6 mp0 -64.85 -29.79 70.76 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.254 178.36 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -77.5 138.97 39.52 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.796 -176.164 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 239' ' ' ARG . . . . . 0.403 HH11 ' HD2' ' A' ' 239' ' ' ARG . 49.9 mtp85 -104.36 108.92 20.56 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.795 174.413 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 240' ' ' HIS . . . . . 0.567 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 12.7 p80 -67.01 -46.65 73.84 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-O 121.248 0.546 . . . . 0.0 109.804 176.416 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 77.87 14.74 82.03 Favored Glycine 0 CA--C 1.502 -0.743 0 N-CA-C 109.837 -1.305 . . . . 0.0 109.837 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 242' ' ' PHE . . . . . 0.525 ' CD2' ' HB2' ' A' ' 240' ' ' HIS . 8.7 m-30 -80.26 143.21 33.89 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 -177.391 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 243' ' ' GLU . . . . . 0.404 ' OE1' ' N ' ' A' ' 244' ' ' THR . 1.3 mm-40 -107.66 159.95 16.07 Favored 'General case' 0 C--N 1.308 -1.239 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.712 174.716 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 244' ' ' THR . . . . . 0.404 ' N ' ' OE1' ' A' ' 243' ' ' GLU . 0.2 OUTLIER -62.35 117.66 6.42 Favored 'General case' 0 C--N 1.297 -1.679 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 177.305 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 90.53 4.42 70.48 Favored Glycine 0 C--N 1.313 -0.748 0 N-CA-C 111.393 -0.683 . . . . 0.0 111.393 -177.679 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 23.7 t0 -79.23 163.28 25.1 Favored 'General case' 0 C--O 1.237 0.422 0 N-CA-C 109.319 -0.622 . . . . 0.0 109.319 176.531 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 247' ' ' PHE . . . . . 0.484 ' CE2' ' HB2' ' A' ' 266' ' ' GLU . 89.7 m-85 -111.3 134.09 53.14 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.507 0.194 . . . . 0.0 110.572 -176.112 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 248' ' ' VAL . . . . . 0.53 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.9 m -131.17 165.94 30.12 Favored 'Isoleucine or valine' 0 C--O 1.239 0.51 0 CA-C-O 121.345 0.593 . . . . 0.0 112.441 -176.97 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 10.8 p -135.24 163.24 30.41 Favored 'General case' 0 C--N 1.32 -0.713 0 C-N-CA 124.92 1.288 . . . . 0.0 109.264 176.065 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 250' ' ' PHE . . . . . 0.603 ' CB ' ' HB3' ' A' ' 259' ' ' LEU . 78.7 m-85 -125.67 158.88 33.65 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.574 0.226 . . . . 0.0 111.027 -172.096 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 251' ' ' SER . . . . . 0.416 ' N ' ' O ' ' A' ' 291' ' ' ILE . 2.0 m -155.9 164.65 38.23 Favored 'General case' 0 C--N 1.322 -0.623 0 C-N-CA 122.326 0.251 . . . . 0.0 110.466 177.584 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 50.5 mm-40 48.59 27.36 1.45 Allowed 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.44 -0.346 . . . . 0.0 111.929 176.976 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 44.0 t -84.12 130.76 35.37 Favored 'Isoleucine or valine' 0 C--O 1.235 0.323 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 179.152 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 97.7 mm-40 -95.65 135.35 37.44 Favored 'General case' 0 C--O 1.247 0.954 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 178.86 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 255' ' ' GLY . . . . . 0.52 ' CA ' HD12 ' A' ' 287' ' ' ILE . . . 84.53 -68.64 3.47 Favored Glycine 0 C--N 1.312 -0.752 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 -178.921 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 256' ' ' MET . . . . . 0.481 ' SD ' ' C ' ' A' ' 284' ' ' SER . 1.7 tpp -81.68 67.69 7.75 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.48 0.657 . . . . 0.0 109.407 176.972 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 257' ' ' ILE . . . . . 0.469 ' O ' ' HB2' ' A' ' 260' ' ' ASN . 48.5 pt -73.94 -21.24 17.98 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.945 0 CA-C-N 115.231 -0.895 . . . . 0.0 110.69 -176.546 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 258' ' ' GLN . . . . . 0.669 ' HG3' ' SG ' ' A' ' 262' ' ' CYS . 52.5 tp60 -56.52 -33.49 66.09 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.167 179.633 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 259' ' ' LEU . . . . . 1.018 HD21 ' CE2' ' A' ' 283' ' ' PHE . 84.4 mt -62.16 -39.97 94.41 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.048 174.702 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 260' ' ' ASN . . . . . 0.469 ' HB2' ' O ' ' A' ' 257' ' ' ILE . 97.1 m-20 -59.9 -40.53 89.08 Favored 'General case' 0 C--O 1.238 0.45 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.713 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -102.24 16.38 55.46 Favored Glycine 0 CA--C 1.527 0.816 0 CA-C-N 115.901 -0.59 . . . . 0.0 112.386 -178.363 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 262' ' ' CYS . . . . . 0.669 ' SG ' ' HG3' ' A' ' 258' ' ' GLN . 1.1 m -88.14 156.3 19.33 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-N 117.184 0.492 . . . . 0.0 112.028 -178.086 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 38.2 mt-30 -73.0 160.11 83.7 Favored Pre-proline 0 C--O 1.241 0.61 0 N-CA-C 107.761 -1.199 . . . . 0.0 107.761 171.423 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 264' ' ' PRO . . . . . 0.53 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 59.4 Cg_endo -66.77 145.9 76.72 Favored 'Trans proline' 0 C--N 1.309 -1.537 0 C-N-CA 121.086 1.191 . . . . 0.0 110.353 178.281 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 265' ' ' MET . . . . . 0.422 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 20.8 ptp -136.47 152.53 50.66 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 112.007 0.373 . . . . 0.0 112.007 -172.473 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 266' ' ' GLU . . . . . 0.484 ' HB2' ' CE2' ' A' ' 247' ' ' PHE . 69.5 tt0 -71.48 140.71 50.09 Favored 'General case' 0 C--O 1.239 0.532 0 O-C-N 123.898 0.749 . . . . 0.0 109.487 177.388 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 267' ' ' ILE . . . . . 0.746 HD12 ' C ' ' A' ' 267' ' ' ILE . 2.1 pp -128.37 165.98 26.64 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-O 121.205 0.526 . . . . 0.0 112.069 -176.608 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 268' ' ' LYS . . . . . 0.426 ' HB2' ' OG ' ' A' ' 276' ' ' SER . 62.3 mttm -124.99 123.06 39.06 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 178.628 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 9.3 m -86.08 94.86 4.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 C-N-CA 119.363 -0.935 . . . . 0.0 109.966 176.954 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 270' ' ' LEU . . . . . 0.447 HD12 HG23 ' A' ' 231' ' ' VAL . 97.0 mt -65.49 -41.21 93.5 Favored 'General case' 0 CA--C 1.511 -0.535 0 CA-C-N 115.424 -0.807 . . . . 0.0 109.441 -178.752 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -138.07 -178.5 16.18 Favored Glycine 0 N--CA 1.448 -0.532 0 N-CA-C 108.401 -1.88 . . . . 0.0 108.401 178.591 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 272' ' ' PRO . . . . . 0.567 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 38.4 Cg_endo -64.12 -32.7 63.34 Favored 'Trans proline' 0 C--N 1.303 -1.85 0 C-N-CA 121.513 1.475 . . . . 0.0 111.307 -177.448 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -124.5 9.54 8.43 Favored 'General case' 0 C--O 1.24 0.555 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.861 -178.407 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 7.9 p -125.66 126.56 44.89 Favored 'General case' 0 C--O 1.247 0.962 0 CA-C-O 121.171 0.51 . . . . 0.0 110.844 179.582 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 275' ' ' PHE . . . . . 0.523 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -139.56 163.98 31.12 Favored 'General case' 0 CA--C 1.502 -0.897 0 N-CA-C 112.532 0.567 . . . . 0.0 112.532 -175.871 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 276' ' ' SER . . . . . 0.474 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 4.1 p -130.59 152.67 49.71 Favored 'General case' 0 N--CA 1.436 -1.159 0 CA-C-O 121.241 0.543 . . . . 0.0 112.225 -174.946 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 277' ' ' ILE . . . . . 0.731 ' C ' HD12 ' A' ' 277' ' ' ILE . 2.0 pp -134.92 173.19 14.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 114.684 -1.144 . . . . 0.0 111.461 -174.033 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 278' ' ' CYS . . . . . 0.457 ' O ' ' HA ' ' A' ' 229' ' ' PRO . 1.5 p -48.95 -78.77 0.02 OUTLIER 'General case' 0 C--N 1.323 -0.556 0 C-N-CA 123.815 0.846 . . . . 0.0 113.05 -177.173 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 279' ' ' ASP . . . . . 0.528 ' HB2' ' CB ' ' A' ' 282' ' ' ASN . 9.8 m-20 -140.1 103.87 4.71 Favored 'General case' 0 N--CA 1.452 -0.354 0 O-C-N 122.315 -0.241 . . . . 0.0 110.644 -176.256 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 280' ' ' THR . . . . . 0.74 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 20.7 p -65.46 -32.75 74.53 Favored 'General case' 0 C--N 1.315 -0.892 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 172.672 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -61.57 -23.1 65.75 Favored 'General case' 0 N--CA 1.43 -1.464 0 CA-C-N 114.019 -1.446 . . . . 0.0 109.522 175.307 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 282' ' ' ASN . . . . . 0.528 ' CB ' ' HB2' ' A' ' 279' ' ' ASP . 15.0 t30 -89.11 -10.16 48.38 Favored 'General case' 0 CA--C 1.51 -0.596 0 C-N-CA 120.372 -0.531 . . . . 0.0 109.825 178.866 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 283' ' ' PHE . . . . . 1.018 ' CE2' HD21 ' A' ' 259' ' ' LEU . 12.7 m-30 -83.76 -74.78 0.36 Allowed 'General case' 0 N--CA 1.441 -0.882 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 172.033 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 284' ' ' SER . . . . . 0.481 ' C ' ' SD ' ' A' ' 256' ' ' MET . 0.2 OUTLIER 171.68 -112.38 0.0 OUTLIER 'General case' 0 CA--C 1.541 0.631 0 CA-C-N 115.223 -0.899 . . . . 0.0 110.355 -178.552 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 285' ' ' ASP . . . . . 0.44 ' N ' ' SD ' ' A' ' 256' ' ' MET . 41.1 t0 -145.58 119.13 9.09 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 119.03 0.832 . . . . 0.0 110.687 177.495 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 286' ' ' TYR . . . . . 0.435 ' OH ' ' O ' ' A' ' 222' ' ' SER . 1.7 t80 -68.19 123.96 22.14 Favored 'General case' 0 C--O 1.239 0.523 0 CA-C-O 120.739 0.305 . . . . 0.0 110.789 178.53 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 287' ' ' ILE . . . . . 0.52 HD12 ' CA ' ' A' ' 255' ' ' GLY . 96.7 mt -106.03 -54.71 6.0 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.863 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.316 176.285 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 9.7 ptp180 -169.69 -179.05 3.2 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.079 177.842 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 63.6 -151.09 49.24 Favored Glycine 0 C--O 1.239 0.421 0 N-CA-C 110.605 -0.998 . . . . 0.0 110.605 177.281 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 99.24 129.42 6.55 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 121.59 -0.338 . . . . 0.0 112.525 175.894 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 291' ' ' ILE . . . . . 0.601 HG12 ' SD ' ' A' ' 220' ' ' MET . 98.1 mt -125.24 133.77 68.51 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 175.704 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 292' ' ' VAL . . . . . 0.428 ' O ' ' HA ' ' A' ' 218' ' ' SER . 4.5 p -122.63 134.6 65.35 Favored 'Isoleucine or valine' 0 C--O 1.241 0.615 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -177.955 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 23.6 m -127.44 145.29 50.88 Favored 'General case' 0 CA--C 1.513 -0.478 0 CA-C-O 120.624 0.249 . . . . 0.0 111.016 -178.418 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 294' ' ' GLN . . . . . 0.417 ' O ' ' NE2' ' A' ' 294' ' ' GLN . 1.6 pp0? . . . . . 0 C--N 1.323 -0.557 0 CA-C-N 116.517 -0.31 . . . . 0.0 110.424 178.091 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 217' ' ' LEU . . . . . 0.433 ' HB3' ' O ' ' A' ' 240' ' ' HIS . 0.1 OUTLIER . . . . . 0 CA--C 1.511 -0.536 0 N-CA-C 108.365 -0.976 . . . . 0.0 108.365 . . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 218' ' ' SER . . . . . 0.411 ' HA ' ' HA ' ' A' ' 293' ' ' SER . 0.7 OUTLIER -127.0 147.73 50.12 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-O 120.745 0.307 . . . . 0.0 110.499 -174.734 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -146.41 154.41 41.58 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.509 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 56.3 mtm -79.98 138.95 37.18 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.842 176.985 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 99.2 t -85.13 130.01 36.85 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.94 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 -178.901 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 65.4 m -83.35 -70.68 0.54 Allowed 'General case' 0 N--CA 1.434 -1.254 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 179.414 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -138.57 152.94 48.62 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.834 174.007 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 224' ' ' VAL . . . . . 0.58 HG22 ' HB ' ' A' ' 232' ' ' VAL . 53.6 t -120.93 132.43 70.45 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 175.329 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 75.5 p -90.85 116.56 28.77 Favored 'General case' 0 C--O 1.236 0.393 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 175.435 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 226' ' ' LYS . . . . . 0.494 ' HA ' ' OG1' ' A' ' 280' ' ' THR . 3.7 tttm -75.86 64.37 1.81 Allowed 'General case' 0 C--O 1.249 1.06 0 C-N-CA 120.616 -0.434 . . . . 0.0 111.259 -175.147 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 227' ' ' ASP . . . . . 0.416 ' N ' ' OG1' ' A' ' 280' ' ' THR . 36.0 t0 -133.04 -175.69 3.87 Favored 'General case' 0 C--O 1.243 0.752 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.621 178.358 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 228' ' ' ASN . . . . . 0.485 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.6 OUTLIER -138.52 125.29 13.04 Favored Pre-proline 0 CA--C 1.533 0.307 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.031 175.631 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 229' ' ' PRO . . . . . 0.485 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 48.6 Cg_endo -66.35 141.24 52.34 Favored 'Cis proline' 0 C--N 1.313 -1.337 0 C-N-CA 122.715 -1.785 . . . . 0.0 110.01 -1.04 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 230' ' ' GLY . . . . . 0.453 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -75.13 139.3 24.79 Favored Glycine 0 C--N 1.308 -1.01 0 N-CA-C 110.662 -0.975 . . . . 0.0 110.662 -177.745 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 231' ' ' VAL . . . . . 0.412 ' CG2' HD12 ' A' ' 270' ' ' LEU . 2.4 p -128.29 137.56 57.08 Favored 'Isoleucine or valine' 0 C--O 1.244 0.775 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 175.001 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 232' ' ' VAL . . . . . 0.58 ' HB ' HG22 ' A' ' 224' ' ' VAL . 0.6 OUTLIER -133.53 155.67 40.65 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.786 0 C-N-CA 120.475 -0.49 . . . . 0.0 110.985 -178.693 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 3.1 m -104.06 140.65 37.46 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 115.459 -0.791 . . . . 0.0 108.902 176.769 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.9 m -107.35 156.84 18.48 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -178.593 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.467 ' HB3' ' HB3' ' A' ' 238' ' ' ALA . 27.0 tp -58.47 130.21 45.7 Favored 'General case' 0 C--N 1.318 -0.801 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 -178.334 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -55.32 -44.03 75.45 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 120.992 0.425 . . . . 0.0 110.69 -175.025 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 237' ' ' GLU . . . . . 0.403 ' H ' ' CD ' ' A' ' 237' ' ' GLU . 1.7 mp0 -67.6 -23.18 65.35 Favored 'General case' 0 C--N 1.312 -1.065 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.604 -179.72 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 238' ' ' ALA . . . . . 0.467 ' HB3' ' HB3' ' A' ' 235' ' ' LEU . . . -94.54 90.75 6.29 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.964 0.412 . . . . 0.0 111.984 -175.002 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.74 110.12 2.69 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 108.633 -0.876 . . . . 0.0 108.633 174.799 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 240' ' ' HIS . . . . . 0.577 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 12.3 p80 -64.44 -49.81 70.0 Favored 'General case' 0 C--O 1.216 -0.674 0 CA-C-O 120.647 0.26 . . . . 0.0 111.212 -176.501 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 80.71 17.8 72.07 Favored Glycine 0 C--O 1.242 0.599 0 N-CA-C 110.961 -0.855 . . . . 0.0 110.961 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 242' ' ' PHE . . . . . 0.414 ' CD2' ' HB2' ' A' ' 240' ' ' HIS . 7.3 m-30 -81.38 139.94 35.01 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 179.391 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 76.6 mm-40 -98.79 157.13 16.49 Favored 'General case' 0 C--N 1.308 -1.201 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 172.601 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 244' ' ' THR . . . . . 0.666 HG23 ' HA ' ' A' ' 268' ' ' LYS . 25.0 m -65.57 123.4 19.58 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 172.86 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 94.72 0.09 64.64 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 110.994 -0.842 . . . . 0.0 110.994 -174.705 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 45.9 t0 -79.31 159.62 27.13 Favored 'General case' 0 C--O 1.239 0.542 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 176.736 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 247' ' ' PHE . . . . . . . . . . . . . 87.4 m-85 -110.29 129.96 55.64 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.311 -176.559 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 248' ' ' VAL . . . . . 0.496 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.4 m -128.33 161.54 36.65 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.332 0 C-N-CA 120.658 -0.417 . . . . 0.0 111.494 -179.09 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 50.1 m -129.63 153.15 48.38 Favored 'General case' 0 N--CA 1.444 -0.774 0 CA-C-N 115.108 -0.951 . . . . 0.0 108.676 172.817 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 250' ' ' PHE . . . . . 0.639 ' CD1' HD22 ' A' ' 259' ' ' LEU . 73.5 m-85 -105.26 145.25 30.92 Favored 'General case' 0 C--N 1.311 -1.066 0 C-N-CA 122.948 0.499 . . . . 0.0 109.882 -177.333 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 4.8 m -132.17 151.54 51.74 Favored 'General case' 0 C--N 1.304 -1.387 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 175.145 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 7.3 mm-40 47.34 38.22 7.03 Favored 'General case' 0 C--N 1.308 -1.233 0 N-CA-C 112.938 0.718 . . . . 0.0 112.938 174.962 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 0.54 HG13 ' CE1' ' A' ' 286' ' ' TYR . 24.2 t -85.2 132.38 31.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 172.499 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 98.6 mm-40 -96.76 145.12 26.11 Favored 'General case' 0 C--N 1.32 -0.698 0 C-N-CA 120.68 -0.408 . . . . 0.0 110.214 176.671 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 81.19 -67.51 3.6 Favored Glycine 0 C--N 1.32 -0.352 0 N-CA-C 110.244 -1.143 . . . . 0.0 110.244 -177.207 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 256' ' ' MET . . . . . 0.484 ' HG3' ' C ' ' A' ' 285' ' ' ASP . 47.8 mtt -78.65 65.65 3.97 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.475 0.655 . . . . 0.0 110.586 176.219 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 48.9 pt -66.27 -23.78 32.37 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.897 0 CA-C-N 115.285 -0.871 . . . . 0.0 109.577 179.511 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 258' ' ' GLN . . . . . 0.421 ' NE2' ' O ' ' A' ' 283' ' ' PHE . 1.3 mp0 -54.37 -40.99 68.67 Favored 'General case' 0 N--CA 1.442 -0.862 0 CA-C-N 115.14 -0.936 . . . . 0.0 109.044 178.485 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 259' ' ' LEU . . . . . 0.906 HD21 ' CE2' ' A' ' 283' ' ' PHE . 87.3 mt -62.92 -41.83 99.59 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.783 178.067 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 260' ' ' ASN . . . . . 0.491 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 93.3 m-20 -59.37 -41.03 88.38 Favored 'General case' 0 CA--C 1.509 -0.623 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 -177.873 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -102.36 10.98 56.74 Favored Glycine 0 CA--C 1.525 0.706 0 CA-C-N 116.027 -0.533 . . . . 0.0 112.265 -179.359 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 262' ' ' CYS . . . . . 0.415 ' HB2' ' O ' ' A' ' 258' ' ' GLN . 11.8 t -88.48 139.98 29.93 Favored 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 117.512 0.656 . . . . 0.0 111.458 -177.471 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 9.6 mp0 -56.4 158.53 7.7 Favored Pre-proline 0 C--N 1.322 -0.621 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 173.219 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 264' ' ' PRO . . . . . 0.496 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 36.7 Cg_endo -61.71 146.87 96.4 Favored 'Trans proline' 0 N--CA 1.495 1.568 0 C-N-CA 121.488 1.459 . . . . 0.0 111.713 -178.719 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 265' ' ' MET . . . . . 0.63 ' N ' ' SD ' ' A' ' 265' ' ' MET . 0.0 OUTLIER -119.35 152.27 37.06 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.888 -176.461 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 73.0 tt0 -76.53 137.17 39.42 Favored 'General case' 0 C--O 1.238 0.46 0 N-CA-C 107.964 -1.124 . . . . 0.0 107.964 174.803 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 267' ' ' ILE . . . . . 0.708 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.9 pp -129.51 159.09 41.92 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 N-CA-C 113.069 0.766 . . . . 0.0 113.069 -174.928 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 268' ' ' LYS . . . . . 0.666 ' HA ' HG23 ' A' ' 244' ' ' THR . 65.6 mttm -123.54 115.04 20.88 Favored 'General case' 0 CA--C 1.534 0.331 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.367 178.694 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.436 HG22 ' OG1' ' A' ' 244' ' ' THR . 17.7 m -78.35 100.18 3.26 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.497 0 CA-C-O 121.138 0.494 . . . . 0.0 111.613 -179.149 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 270' ' ' LEU . . . . . 0.412 HD12 ' CG2' ' A' ' 231' ' ' VAL . 97.5 mt -66.25 -40.82 90.44 Favored 'General case' 0 CA--C 1.513 -0.462 0 CA-C-N 115.723 -0.672 . . . . 0.0 110.477 179.033 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -145.17 179.5 22.23 Favored Glycine 0 C--N 1.315 -0.638 0 N-CA-C 109.724 -1.35 . . . . 0.0 109.724 -177.238 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 272' ' ' PRO . . . . . 0.577 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 33.0 Cg_endo -61.39 -31.82 88.74 Favored 'Trans proline' 0 C--N 1.303 -1.845 0 C-N-CA 121.797 1.665 . . . . 0.0 110.976 -178.448 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 88.4 m-85 -121.36 8.67 10.25 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.18 -0.464 . . . . 0.0 112.067 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -123.77 126.34 46.31 Favored 'General case' 0 C--O 1.242 0.665 0 CA-C-O 120.855 0.359 . . . . 0.0 110.998 -179.48 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 275' ' ' PHE . . . . . 0.561 ' CE2' HG21 ' A' ' 267' ' ' ILE . 0.0 OUTLIER -132.71 161.03 35.05 Favored 'General case' 0 CA--C 1.499 -1.007 0 C-N-CA 120.733 -0.387 . . . . 0.0 111.766 178.038 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 276' ' ' SER . . . . . 0.453 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 7.7 p -133.36 154.39 50.78 Favored 'General case' 0 N--CA 1.432 -1.346 0 CA-C-O 121.25 0.547 . . . . 0.0 112.456 -173.636 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 277' ' ' ILE . . . . . 0.699 HG22 HG22 ' A' ' 267' ' ' ILE . 35.7 pt -140.94 -165.93 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 CA-C-N 113.991 -1.458 . . . . 0.0 109.569 -171.049 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 278' ' ' CYS . . . . . 0.484 ' O ' ' HA ' ' A' ' 229' ' ' PRO . 14.7 p -69.81 -110.64 0.0 OUTLIER 'General case' 0 N--CA 1.45 -0.474 0 O-C-N 122.996 0.185 . . . . 0.0 111.056 178.793 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 279' ' ' ASP . . . . . 0.442 ' CG ' ' HB2' ' A' ' 228' ' ' ASN . 50.8 t0 -117.5 119.9 36.47 Favored 'General case' 0 CA--C 1.507 -0.682 0 CA-C-O 121.048 0.452 . . . . 0.0 110.855 -179.591 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 280' ' ' THR . . . . . 0.51 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 9.4 p -64.44 -29.29 70.35 Favored 'General case' 0 C--N 1.292 -1.919 0 CA-C-N 115.501 -0.772 . . . . 0.0 109.597 175.186 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -65.19 -11.66 42.99 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.008 -0.996 . . . . 0.0 109.642 174.483 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 -85.87 -8.65 57.92 Favored 'General case' 0 CA--C 1.507 -0.69 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 175.772 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 283' ' ' PHE . . . . . 0.906 ' CE2' HD21 ' A' ' 259' ' ' LEU . 3.3 m-85 -99.73 -78.41 0.51 Allowed 'General case' 0 N--CA 1.442 -0.84 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 171.117 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 284' ' ' SER . . . . . 0.474 ' OG ' ' N ' ' A' ' 285' ' ' ASP . 31.3 t 168.33 -144.33 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.291 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 -179.121 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 285' ' ' ASP . . . . . 0.484 ' C ' ' HG3' ' A' ' 256' ' ' MET . 64.8 m-20 -98.46 131.67 44.53 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 122.289 0.236 . . . . 0.0 110.567 176.734 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 286' ' ' TYR . . . . . 0.54 ' CE1' HG13 ' A' ' 253' ' ' VAL . 13.0 t80 -84.23 125.56 32.33 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 178.935 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 287' ' ' ILE . . . . . 0.401 ' O ' ' CG ' ' A' ' 288' ' ' ARG . 9.3 mm -94.01 -54.07 7.67 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 N-CA-C 110.471 -0.196 . . . . 0.0 110.471 179.539 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 288' ' ' ARG . . . . . 0.401 ' CG ' ' O ' ' A' ' 287' ' ' ILE . 0.7 OUTLIER 176.34 -178.0 0.14 Allowed 'General case' 0 C--O 1.244 0.766 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.019 -179.53 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 64.98 -140.64 42.3 Favored Glycine 0 CA--C 1.5 -0.856 0 N-CA-C 110.027 -1.229 . . . . 0.0 110.027 177.942 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 290' ' ' GLY . . . . . 0.45 ' HA3' HG22 ' A' ' 253' ' ' VAL . . . 87.93 126.34 2.41 Favored Glycine 0 N--CA 1.434 -1.478 0 C-N-CA 120.82 -0.705 . . . . 0.0 111.474 177.916 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 82.1 mt -120.62 131.21 73.37 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 N-CA-C 106.474 -1.676 . . . . 0.0 106.474 175.06 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 3.9 p -117.85 133.1 65.72 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.051 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -176.038 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 293' ' ' SER . . . . . 0.411 ' HA ' ' HA ' ' A' ' 218' ' ' SER . 1.4 m -129.35 141.16 51.15 Favored 'General case' 0 CA--C 1.505 -0.781 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.71 -177.98 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 294' ' ' GLN . . . . . 0.492 ' HA ' ' HA ' ' A' ' 248' ' ' VAL . 0.2 OUTLIER . . . . . 0 C--N 1.318 -0.797 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 172.398 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 217' ' ' LEU . . . . . 0.424 HD13 ' HA ' ' A' ' 217' ' ' LEU . 0.1 OUTLIER . . . . . 0 C--O 1.234 0.28 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 . . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 24.1 m -133.63 152.46 51.9 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.277 -174.092 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -142.98 156.08 44.8 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 116.037 -0.528 . . . . 0.0 110.559 177.303 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 220' ' ' MET . . . . . 0.545 ' SD ' HD12 ' A' ' 291' ' ' ILE . 1.6 mpp? -75.22 134.57 41.13 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 176.659 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 99.3 t -82.06 128.29 38.85 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.886 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 178.836 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 20.2 m -86.3 -71.59 0.54 Allowed 'General case' 0 N--CA 1.439 -0.993 0 CA-C-N 116.017 -0.538 . . . . 0.0 109.876 178.037 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 8.7 ptm -137.71 149.68 46.69 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.168 174.504 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 224' ' ' VAL . . . . . 0.532 HG22 ' HB ' ' A' ' 232' ' ' VAL . 72.4 t -121.74 127.27 75.46 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.993 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 174.748 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 225' ' ' THR . . . . . 0.413 ' O ' HG21 ' A' ' 280' ' ' THR . 11.6 p -77.44 130.72 37.41 Favored 'General case' 0 CA--C 1.512 -0.485 0 C-N-CA 120.399 -0.52 . . . . 0.0 110.382 -179.117 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 226' ' ' LYS . . . . . 0.555 ' NZ ' ' OG ' ' A' ' 281' ' ' SER . 26.7 tptp -81.97 74.5 8.95 Favored 'General case' 0 N--CA 1.441 -0.916 0 N-CA-C 108.728 -0.842 . . . . 0.0 108.728 176.232 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 227' ' ' ASP . . . . . 0.465 ' CG ' ' H ' ' A' ' 228' ' ' ASN . 8.6 t70 -153.65 -173.15 4.47 Favored 'General case' 0 C--O 1.244 0.797 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.599 -176.224 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 228' ' ' ASN . . . . . 0.465 ' H ' ' CG ' ' A' ' 227' ' ' ASP . 12.4 p30 -140.51 125.08 10.85 Favored Pre-proline 0 N--CA 1.452 -0.353 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.2 176.094 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 229' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -69.68 148.31 86.29 Favored 'Cis proline' 0 C--N 1.311 -1.422 0 C-N-CA 123.029 -1.655 . . . . 0.0 109.722 -1.636 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 230' ' ' GLY . . . . . 0.614 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -71.32 130.38 18.57 Favored Glycine 0 C--N 1.311 -0.839 0 N-CA-C 109.231 -1.548 . . . . 0.0 109.231 -179.719 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.1 p -120.93 131.35 73.18 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.8 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 177.903 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 232' ' ' VAL . . . . . 0.532 ' HB ' HG22 ' A' ' 224' ' ' VAL . 0.6 OUTLIER -130.09 153.13 38.47 Favored 'Isoleucine or valine' 0 C--O 1.249 1.061 0 C-N-CA 119.474 -0.89 . . . . 0.0 111.361 -174.78 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 3.1 m -108.11 140.37 41.4 Favored 'General case' 0 N--CA 1.432 -1.358 0 CA-C-N 114.807 -1.088 . . . . 0.0 108.857 177.832 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 34.6 m -107.28 161.0 15.18 Favored 'General case' 0 C--N 1.308 -1.227 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 178.422 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 40.1 tp -60.53 127.65 32.76 Favored 'General case' 0 C--N 1.314 -0.978 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 -178.747 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -56.79 -39.89 74.93 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-O 121.242 0.544 . . . . 0.0 110.608 -174.481 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -65.89 -29.63 70.1 Favored 'General case' 0 C--N 1.308 -1.224 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.99 179.602 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -96.96 130.92 44.2 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 112.106 0.41 . . . . 0.0 112.106 -172.924 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 90.6 mtm-85 -86.3 137.45 32.6 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 174.351 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 240' ' ' HIS . . . . . 0.574 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 8.9 p80 -88.62 -45.18 10.07 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 121.073 0.463 . . . . 0.0 109.832 175.699 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 83.25 12.15 79.41 Favored Glycine 0 C--O 1.239 0.436 0 N-CA-C 110.719 -0.952 . . . . 0.0 110.719 178.539 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 242' ' ' PHE . . . . . 0.506 ' CD1' ' HB3' ' A' ' 294' ' ' GLN . 4.4 m-30 -80.87 145.35 31.4 Favored 'General case' 0 C--N 1.318 -0.781 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 -179.495 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 243' ' ' GLU . . . . . 0.463 ' H ' ' CB ' ' A' ' 246' ' ' ASP . 98.2 mt-10 -122.17 168.1 12.39 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.951 -179.158 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 17.7 m -58.84 122.12 12.8 Favored 'General case' 0 C--N 1.313 -1.003 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 179.356 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 78.48 7.02 88.14 Favored Glycine 0 C--N 1.319 -0.394 0 N-CA-C 111.25 -0.74 . . . . 0.0 111.25 179.646 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 246' ' ' ASP . . . . . 0.463 ' CB ' ' H ' ' A' ' 243' ' ' GLU . 40.0 t0 -76.93 162.2 27.78 Favored 'General case' 0 CA--C 1.514 -0.43 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 178.928 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 247' ' ' PHE . . . . . 0.466 ' HA ' ' O ' ' A' ' 265' ' ' MET . 72.3 m-85 -109.64 137.21 47.79 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.041 0.448 . . . . 0.0 111.511 -177.534 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 248' ' ' VAL . . . . . 0.452 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.9 m -133.47 162.02 40.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.308 178.792 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 67.1 m -125.89 151.48 46.85 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 172.692 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 250' ' ' PHE . . . . . 0.586 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 88.3 m-85 -107.37 149.58 27.7 Favored 'General case' 0 C--N 1.308 -1.207 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.218 -175.552 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 7.3 p -146.92 156.8 43.36 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.231 179.424 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 87.0 mt-10 45.8 26.8 0.4 Allowed 'General case' 0 C--N 1.316 -0.849 0 N-CA-C 112.914 0.709 . . . . 0.0 112.914 177.767 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 0.505 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 52.5 t -83.32 132.78 30.59 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.415 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 174.921 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 93.8 mm-40 -98.52 137.23 37.49 Favored 'General case' 0 C--N 1.317 -0.833 0 C-N-CA 120.043 -0.663 . . . . 0.0 110.036 -179.254 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 83.38 -57.28 5.07 Favored Glycine 0 C--N 1.317 -0.514 0 N-CA-C 110.899 -0.881 . . . . 0.0 110.899 -177.934 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 256' ' ' MET . . . . . 0.411 ' SD ' HG11 ' A' ' 224' ' ' VAL . 4.4 ttm -78.29 63.11 3.11 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.632 0.729 . . . . 0.0 109.388 178.747 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 48.6 pt -69.76 -25.59 28.72 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 114.853 -1.067 . . . . 0.0 111.39 -174.748 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 258' ' ' GLN . . . . . 0.474 ' HG3' ' SG ' ' A' ' 262' ' ' CYS . 60.9 tp60 -58.93 -40.6 85.07 Favored 'General case' 0 CA--C 1.509 -0.608 0 C-N-CA 120.343 -0.543 . . . . 0.0 110.085 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 259' ' ' LEU . . . . . 0.628 HD21 ' CE2' ' A' ' 283' ' ' PHE . 96.0 mt -62.51 -42.28 99.4 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.981 -0.554 . . . . 0.0 109.554 179.009 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 260' ' ' ASN . . . . . 0.505 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 99.0 m-20 -60.23 -40.44 90.22 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.079 -178.898 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -92.19 -5.12 65.98 Favored Glycine 0 CA--C 1.523 0.557 0 C-N-CA 121.268 -0.491 . . . . 0.0 111.904 -178.238 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 262' ' ' CYS . . . . . 0.474 ' SG ' ' HG3' ' A' ' 258' ' ' GLN . 1.1 m -78.19 154.6 30.98 Favored 'General case' 0 C--N 1.326 -0.456 0 C-N-CA 120.363 -0.535 . . . . 0.0 111.614 -176.207 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 263' ' ' GLN . . . . . 0.561 ' CD ' ' H ' ' A' ' 263' ' ' GLN . 0.0 OUTLIER -67.9 170.72 6.67 Favored Pre-proline 0 C--N 1.322 -0.623 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 172.93 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 264' ' ' PRO . . . . . 0.452 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 45.1 Cg_endo -63.92 142.99 84.22 Favored 'Trans proline' 0 C--N 1.311 -1.436 0 N-CA-C 109.452 -1.018 . . . . 0.0 109.452 177.555 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 265' ' ' MET . . . . . 0.466 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 17.1 ptp -130.97 153.97 48.64 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 112.254 0.464 . . . . 0.0 112.254 -173.982 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -71.83 137.54 47.63 Favored 'General case' 0 C--O 1.236 0.383 0 O-C-N 124.133 0.896 . . . . 0.0 109.919 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 267' ' ' ILE . . . . . 0.673 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.8 pp -128.47 162.5 34.99 Favored 'Isoleucine or valine' 0 C--O 1.244 0.771 0 CA-C-O 121.085 0.469 . . . . 0.0 112.106 -179.035 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 61.4 mttm -122.6 126.5 47.82 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.522 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 13.0 m -84.92 123.69 39.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 C-N-CA 120.644 -0.422 . . . . 0.0 111.477 -179.567 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 90.0 mt -102.86 -12.01 17.86 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.588 178.334 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -171.81 -177.77 41.67 Favored Glycine 0 C--N 1.318 -0.463 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.109 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 272' ' ' PRO . . . . . 0.574 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 29.8 Cg_endo -60.37 -34.1 93.67 Favored 'Trans proline' 0 C--N 1.306 -1.677 0 C-N-CA 122.091 1.861 . . . . 0.0 111.7 -179.785 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 73.1 m-85 -125.59 10.04 7.8 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.172 -179.722 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -120.7 128.5 53.01 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 116.486 -0.324 . . . . 0.0 110.51 -173.167 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 275' ' ' PHE . . . . . 0.518 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -141.54 166.25 25.28 Favored 'General case' 0 CA--C 1.508 -0.659 0 N-CA-C 112.597 0.592 . . . . 0.0 112.597 178.748 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 276' ' ' SER . . . . . 0.452 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 7.8 p -133.66 146.92 51.32 Favored 'General case' 0 N--CA 1.44 -0.952 0 CA-C-O 121.182 0.515 . . . . 0.0 111.276 -179.73 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 277' ' ' ILE . . . . . 0.412 HG22 HG22 ' A' ' 267' ' ' ILE . 28.9 pt -139.79 164.1 23.98 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.005 0 CA-C-N 114.518 -1.219 . . . . 0.0 111.511 -173.174 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -23.99 -92.76 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.574 0 N-CA-C 113.603 0.964 . . . . 0.0 113.603 -176.71 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 279' ' ' ASP . . . . . 0.439 ' HB3' ' HB2' ' A' ' 282' ' ' ASN . 66.8 t0 -151.34 121.75 7.35 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 -177.597 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 280' ' ' THR . . . . . 0.679 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 23.7 p -65.04 -30.12 71.07 Favored 'General case' 0 C--N 1.293 -1.882 0 CA-C-O 120.982 0.42 . . . . 0.0 111.095 177.01 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 281' ' ' SER . . . . . 0.555 ' OG ' ' NZ ' ' A' ' 226' ' ' LYS . 15.7 m -70.39 -14.59 62.62 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.017 174.132 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 282' ' ' ASN . . . . . 0.439 ' HB2' ' HB3' ' A' ' 279' ' ' ASP . 60.4 t30 -89.22 -5.71 57.44 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.872 174.395 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 283' ' ' PHE . . . . . 0.679 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 12.4 m-85 -102.89 -73.86 0.65 Allowed 'General case' 0 CA--C 1.511 -0.521 0 CA-C-O 121.594 0.711 . . . . 0.0 109.79 175.057 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 172.48 -166.36 0.02 OUTLIER 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 114.02 -1.446 . . . . 0.0 107.827 -171.895 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -97.06 146.4 25.05 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 117.907 0.322 . . . . 0.0 111.115 178.068 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 10.8 t80 -86.54 123.17 31.44 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.006 -179.816 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 287' ' ' ILE . . . . . 0.567 ' O ' ' HG3' ' A' ' 288' ' ' ARG . 21.4 mm -100.51 -73.66 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -0.981 0 CA-C-N 116.501 -0.318 . . . . 0.0 110.265 176.906 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 288' ' ' ARG . . . . . 0.567 ' HG3' ' O ' ' A' ' 287' ' ' ILE . 92.1 mtt-85 -164.61 178.43 7.33 Favored 'General case' 0 C--O 1.242 0.663 0 C-N-CA 124.112 0.965 . . . . 0.0 110.409 179.265 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 68.63 -158.14 52.78 Favored Glycine 0 CA--C 1.505 -0.536 0 N-CA-C 110.319 -1.113 . . . . 0.0 110.319 177.078 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 108.31 113.57 3.69 Favored Glycine 0 N--CA 1.439 -1.158 0 C-N-CA 120.769 -0.729 . . . . 0.0 111.946 177.715 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 291' ' ' ILE . . . . . 0.545 HD12 ' SD ' ' A' ' 220' ' ' MET . 43.5 mm -112.96 128.71 69.55 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.477 0 N-CA-C 105.899 -1.889 . . . . 0.0 105.899 172.352 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 3.5 p -118.9 134.45 62.51 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.039 0 C-N-CA 120.253 -0.579 . . . . 0.0 109.657 -177.694 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 15.2 m -125.21 144.48 50.43 Favored 'General case' 0 CA--C 1.508 -0.65 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.91 -176.504 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 294' ' ' GLN . . . . . 0.506 ' HB3' ' CD1' ' A' ' 242' ' ' PHE . 3.4 pt20 . . . . . 0 CA--C 1.502 -0.873 0 C-N-CA 120.205 -0.598 . . . . 0.0 110.745 179.159 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 217' ' ' LEU . . . . . 0.629 HD11 ' NH2' ' A' ' 239' ' ' ARG . 0.1 OUTLIER . . . . . 0 C--O 1.239 0.543 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 . . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 218' ' ' SER . . . . . 0.431 ' OG ' ' OG ' ' A' ' 293' ' ' SER . 45.9 m -132.46 148.6 52.4 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.692 -174.574 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -143.08 157.11 44.83 Favored 'General case' 0 CA--C 1.51 -0.573 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.884 178.862 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 66.2 mtt -75.18 144.2 42.83 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 115.736 -0.666 . . . . 0.0 109.61 176.503 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 95.7 t -85.38 129.32 38.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.35 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 222' ' ' SER . . . . . 0.546 ' HG ' ' C ' ' A' ' 233' ' ' THR . 25.3 p -94.44 -55.14 3.26 Favored 'General case' 0 N--CA 1.439 -0.979 0 CA-C-O 120.867 0.365 . . . . 0.0 110.218 -178.164 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -137.46 149.39 46.81 Favored 'General case' 0 C--O 1.219 -0.551 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.599 177.573 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 224' ' ' VAL . . . . . 0.461 ' HB ' ' CD1' ' A' ' 286' ' ' TYR . 43.2 t -124.96 133.2 70.09 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.828 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 172.667 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -103.88 116.88 33.08 Favored 'General case' 0 C--N 1.31 -1.141 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 -178.975 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 226' ' ' LYS . . . . . 0.435 ' HA ' ' OG1' ' A' ' 280' ' ' THR . 88.1 tttt -78.55 90.38 4.51 Favored 'General case' 0 CA--C 1.505 -0.776 0 C-N-CA 119.296 -0.962 . . . . 0.0 110.044 -177.924 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 227' ' ' ASP . . . . . 0.617 ' H ' ' HG1' ' A' ' 280' ' ' THR . 43.9 t0 -159.5 179.85 8.55 Favored 'General case' 0 C--N 1.307 -1.241 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.03 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 228' ' ' ASN . . . . . 0.472 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 1.8 p30 -132.99 125.5 19.15 Favored Pre-proline 0 C--N 1.324 -0.523 0 CA-C-N 115.878 -0.601 . . . . 0.0 109.912 175.982 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 229' ' ' PRO . . . . . 0.472 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 46.4 Cg_endo -66.32 145.12 69.42 Favored 'Cis proline' 0 N--CA 1.491 1.349 0 C-N-CA 123.204 -1.582 . . . . 0.0 110.641 -0.68 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 230' ' ' GLY . . . . . 0.511 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -68.01 132.86 28.77 Favored Glycine 0 N--CA 1.452 -0.234 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.169 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.9 p -128.26 136.12 60.91 Favored 'Isoleucine or valine' 0 C--O 1.241 0.629 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 178.35 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 232' ' ' VAL . . . . . 0.56 HG22 ' CD1' ' A' ' 275' ' ' PHE . 0.6 OUTLIER -134.85 156.01 39.21 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.047 0 C-N-CA 120.164 -0.614 . . . . 0.0 110.493 -179.422 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 233' ' ' THR . . . . . 0.546 ' C ' ' HG ' ' A' ' 222' ' ' SER . 21.7 m -104.65 144.78 31.25 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 115.413 -0.812 . . . . 0.0 109.106 176.11 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 2.4 m -106.1 159.51 16.02 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 177.484 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.567 ' HB3' ' HB3' ' A' ' 238' ' ' ALA . 43.1 tp -57.85 127.24 31.07 Favored 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 -178.469 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 236' ' ' ASP . . . . . 0.402 ' O ' ' CZ ' ' A' ' 273' ' ' TYR . 7.5 m-20 -62.46 -37.91 87.75 Favored 'General case' 0 CA--C 1.512 -0.497 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.19 -172.279 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 57.9 mp0 -69.67 -19.5 63.59 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.659 177.734 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 238' ' ' ALA . . . . . 0.567 ' HB3' ' HB3' ' A' ' 235' ' ' LEU . . . -108.78 99.94 9.23 Favored 'General case' 0 C--O 1.238 0.479 0 N-CA-C 112.102 0.408 . . . . 0.0 112.102 -177.197 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 239' ' ' ARG . . . . . 0.629 ' NH2' HD11 ' A' ' 217' ' ' LEU . 0.0 OUTLIER -70.57 117.4 12.05 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 173.342 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 240' ' ' HIS . . . . . 0.606 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 6.6 p80 -66.54 -45.71 78.49 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.681 -179.504 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 82.31 21.43 60.55 Favored Glycine 0 C--N 1.315 -0.62 0 N-CA-C 110.775 -0.93 . . . . 0.0 110.775 -178.275 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 242' ' ' PHE . . . . . 0.772 ' HB3' HD11 ' A' ' 267' ' ' ILE . 7.5 m-30 -83.74 156.02 22.79 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 120.69 0.281 . . . . 0.0 110.339 179.629 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 -124.3 165.08 18.29 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.545 174.821 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 244' ' ' THR . . . . . 0.62 HG23 ' HA ' ' A' ' 268' ' ' LYS . 0.2 OUTLIER -69.61 126.44 29.74 Favored 'General case' 0 C--N 1.319 -0.76 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 177.374 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 90.43 2.38 73.43 Favored Glycine 0 C--N 1.317 -0.513 0 N-CA-C 110.476 -1.05 . . . . 0.0 110.476 -176.422 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 246' ' ' ASP . . . . . 0.511 ' O ' HG12 ' A' ' 267' ' ' ILE . 46.3 t0 -77.8 163.86 25.72 Favored 'General case' 0 C--O 1.237 0.445 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 176.427 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 247' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -115.84 128.85 56.13 Favored 'General case' 0 C--O 1.241 0.637 0 O-C-N 123.287 0.367 . . . . 0.0 110.661 -178.939 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 248' ' ' VAL . . . . . 0.541 ' CG1' HD13 ' A' ' 267' ' ' ILE . 2.4 m -132.4 164.58 34.56 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.308 0 C-N-CA 120.223 -0.591 . . . . 0.0 111.905 178.287 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 31.4 m -130.66 153.0 49.41 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.179 172.56 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 250' ' ' PHE . . . . . 0.604 ' CD1' HD22 ' A' ' 259' ' ' LEU . 61.3 m-85 -103.14 146.58 28.18 Favored 'General case' 0 C--N 1.322 -0.616 0 C-N-CA 122.729 0.411 . . . . 0.0 110.327 -178.912 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 2.5 m -143.74 153.06 42.04 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.417 176.715 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 49.42 37.51 12.09 Favored 'General case' 0 C--O 1.245 0.865 0 N-CA-C 113.044 0.757 . . . . 0.0 113.044 175.978 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 0.65 HG22 ' HA3' ' A' ' 290' ' ' GLY . 78.7 t -90.37 132.38 35.13 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 175.853 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 86.8 mt-30 -88.08 140.56 29.36 Favored 'General case' 0 C--O 1.242 0.709 0 C-N-CA 120.411 -0.516 . . . . 0.0 110.068 177.487 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 80.06 -63.82 4.03 Favored Glycine 0 C--N 1.314 -0.691 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 179.174 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 256' ' ' MET . . . . . 0.464 ' N ' ' O ' ' A' ' 285' ' ' ASP . 20.9 ttm -84.69 71.76 10.78 Favored 'General case' 0 CA--C 1.504 -0.804 0 C-N-CA 119.853 -0.739 . . . . 0.0 109.377 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 45.0 pt -80.35 -15.3 12.91 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 CA-C-N 115.005 -0.998 . . . . 0.0 110.144 -177.756 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 258' ' ' GLN . . . . . 0.504 ' O ' ' SG ' ' A' ' 262' ' ' CYS . 63.3 tp60 -57.53 -39.13 75.92 Favored 'General case' 0 N--CA 1.437 -1.11 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 177.643 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 259' ' ' LEU . . . . . 0.854 HD21 ' CE2' ' A' ' 283' ' ' PHE . 88.1 mt -62.78 -40.67 98.01 Favored 'General case' 0 N--CA 1.449 -0.508 0 CA-C-N 115.113 -0.949 . . . . 0.0 110.222 175.001 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -60.04 -40.63 90.06 Favored 'General case' 0 C--O 1.241 0.607 0 N-CA-C 109.306 -0.628 . . . . 0.0 109.306 -179.577 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -101.18 23.2 36.25 Favored Glycine 0 CA--C 1.526 0.736 0 N-CA-C 111.246 -0.741 . . . . 0.0 111.246 -179.178 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 262' ' ' CYS . . . . . 0.504 ' SG ' ' O ' ' A' ' 258' ' ' GLN . 1.3 m -96.68 147.34 24.01 Favored 'General case' 0 C--O 1.239 0.51 0 CA-C-N 117.362 0.581 . . . . 0.0 112.382 -177.708 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 5.3 mt-30 -61.93 154.34 68.62 Favored Pre-proline 0 C--N 1.324 -0.518 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 170.699 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -64.4 145.06 87.4 Favored 'Trans proline' 0 C--N 1.304 -1.806 0 C-N-CA 121.08 1.187 . . . . 0.0 109.868 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 265' ' ' MET . . . . . 0.554 ' N ' ' SD ' ' A' ' 265' ' ' MET . 0.2 OUTLIER -122.8 148.8 44.96 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 112.405 0.52 . . . . 0.0 112.405 -174.237 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 266' ' ' GLU . . . . . 0.419 ' HA ' ' O ' ' A' ' 246' ' ' ASP . 75.8 tt0 -77.97 134.3 37.87 Favored 'General case' 0 C--O 1.242 0.662 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 174.355 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 267' ' ' ILE . . . . . 0.772 HD11 ' HB3' ' A' ' 242' ' ' PHE . 49.5 pt -125.26 159.64 32.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 N-CA-C 114.023 1.12 . . . . 0.0 114.023 -166.342 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 268' ' ' LYS . . . . . 0.62 ' HA ' HG23 ' A' ' 244' ' ' THR . 66.5 mttm -120.55 106.59 11.93 Favored 'General case' 0 CA--C 1.537 0.459 0 CA-C-N 115.154 -0.93 . . . . 0.0 110.021 177.325 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.4 HG22 ' H ' ' A' ' 269' ' ' VAL . 17.3 m -80.24 102.31 6.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 120.999 0.428 . . . . 0.0 110.516 178.452 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 96.1 mt -66.3 -41.27 89.99 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.964 -179.707 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -149.16 -172.09 18.49 Favored Glycine 0 C--N 1.318 -0.458 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -177.383 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 272' ' ' PRO . . . . . 0.606 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 37.9 Cg_endo -62.98 -33.93 72.68 Favored 'Trans proline' 0 C--N 1.308 -1.57 0 C-N-CA 121.827 1.685 . . . . 0.0 111.369 -178.024 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 273' ' ' TYR . . . . . 0.409 ' O ' ' HA ' ' A' ' 233' ' ' THR . 83.3 m-85 -122.54 8.44 9.55 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 112.818 0.673 . . . . 0.0 112.818 -177.968 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 2.8 p -120.88 128.05 52.44 Favored 'General case' 0 C--O 1.243 0.747 0 CA-C-O 120.605 0.24 . . . . 0.0 110.865 178.923 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 275' ' ' PHE . . . . . 0.561 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -138.25 159.44 42.04 Favored 'General case' 0 CA--C 1.507 -0.697 0 C-N-CA 120.671 -0.411 . . . . 0.0 111.658 177.667 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 7.9 p -137.79 154.29 49.58 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.521 -173.388 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 277' ' ' ILE . . . . . 0.487 HG22 HG22 ' A' ' 267' ' ' ILE . 0.1 OUTLIER -141.72 -155.04 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.912 0 CA-C-N 115.428 -0.805 . . . . 0.0 110.106 -173.087 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 1.1 p -60.04 -89.03 0.0 OUTLIER 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 116.499 -0.318 . . . . 0.0 111.306 178.338 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 66.0 t0 -151.7 118.98 5.94 Favored 'General case' 0 N--CA 1.447 -0.611 0 CA-C-O 120.825 0.345 . . . . 0.0 111.421 -176.736 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 280' ' ' THR . . . . . 0.646 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 11.1 p -64.34 -30.34 71.39 Favored 'General case' 0 C--N 1.299 -1.626 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.101 175.095 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -61.73 -21.05 64.17 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.449 175.852 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 12.3 m120 -93.94 -3.83 50.9 Favored 'General case' 0 N--CA 1.451 -0.419 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.023 176.847 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 283' ' ' PHE . . . . . 0.854 ' CE2' HD21 ' A' ' 259' ' ' LEU . 22.8 m-85 -91.84 -80.72 0.35 Allowed 'General case' 0 CA--C 1.512 -0.508 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 171.674 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 3.9 p 179.25 -109.85 0.0 OUTLIER 'General case' 0 N--CA 1.453 -0.305 0 CA-C-N 115.193 -0.912 . . . . 0.0 109.675 173.463 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 285' ' ' ASP . . . . . 0.464 ' O ' ' N ' ' A' ' 256' ' ' MET . 2.1 p-10 -145.49 163.37 34.9 Favored 'General case' 0 C--O 1.219 -0.514 0 N-CA-C 107.667 -1.234 . . . . 0.0 107.667 174.114 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 286' ' ' TYR . . . . . 0.461 ' CD1' ' HB ' ' A' ' 224' ' ' VAL . 1.1 p90 -123.95 145.51 49.11 Favored 'General case' 0 N--CA 1.468 0.442 0 C-N-CA 119.663 -0.815 . . . . 0.0 111.495 -178.046 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 96.9 mt -100.77 -57.68 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 176.781 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 32.2 ptt-85 -176.17 -169.3 0.31 Allowed 'General case' 0 C--O 1.242 0.688 0 CA-C-N 115.447 -0.797 . . . . 0.0 109.979 177.584 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 67.32 -153.47 52.9 Favored Glycine 0 CA--C 1.502 -0.779 0 N-CA-C 110.944 -0.863 . . . . 0.0 110.944 175.837 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 290' ' ' GLY . . . . . 0.65 ' HA3' HG22 ' A' ' 253' ' ' VAL . . . 93.51 136.49 7.96 Favored Glycine 0 N--CA 1.442 -0.958 0 N-CA-C 111.778 -0.529 . . . . 0.0 111.778 176.841 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 92.2 mt -122.87 129.38 75.17 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 173.756 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 3.8 p -112.21 129.72 67.19 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 178.855 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 293' ' ' SER . . . . . 0.431 ' OG ' ' OG ' ' A' ' 218' ' ' SER . 55.7 m -126.9 147.88 50.05 Favored 'General case' 0 CA--C 1.5 -0.972 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.371 -174.495 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 294' ' ' GLN . . . . . 0.431 ' HG3' ' CE1' ' A' ' 242' ' ' PHE . 85.0 mt-30 . . . . . 0 C--N 1.318 -0.772 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 171.804 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 217' ' ' LEU . . . . . 0.707 HD13 ' N ' ' A' ' 218' ' ' SER . 0.3 OUTLIER . . . . . 0 CA--C 1.513 -0.445 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 . . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 218' ' ' SER . . . . . 0.707 ' N ' HD13 ' A' ' 217' ' ' LEU . 50.8 m -114.04 131.88 56.21 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.163 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 219' ' ' ALA . . . . . 0.622 ' HB1' ' HB1' ' A' ' 238' ' ' ALA . . . -131.75 150.74 52.05 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.703 -175.362 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 97.8 mtp -81.02 129.69 34.66 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.163 178.42 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 221' ' ' VAL . . . . . 0.455 HG11 ' CG2' ' A' ' 224' ' ' VAL . 97.3 t -79.85 133.98 28.54 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.011 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 177.356 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 13.8 p -93.28 -62.0 1.46 Allowed 'General case' 0 N--CA 1.436 -1.151 0 C-N-CA 120.129 -0.628 . . . . 0.0 109.777 -179.358 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -138.06 139.05 39.36 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.946 173.818 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 224' ' ' VAL . . . . . 0.742 HG13 HG12 ' A' ' 232' ' ' VAL . 59.4 t -117.01 130.79 71.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 174.489 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 62.3 p -88.02 138.9 31.05 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-O 120.826 0.346 . . . . 0.0 110.944 -178.509 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 226' ' ' LYS . . . . . 0.451 ' NZ ' ' OD2' ' A' ' 285' ' ' ASP . 2.6 tptm -78.34 77.66 4.83 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 178.807 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 227' ' ' ASP . . . . . 0.41 ' H ' ' HG1' ' A' ' 280' ' ' THR . 45.8 t0 -157.0 174.04 16.12 Favored 'General case' 0 N--CA 1.468 0.454 0 N-CA-C 112.249 0.462 . . . . 0.0 112.249 -176.172 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 228' ' ' ASN . . . . . 0.482 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 2.7 p30 -130.86 125.14 21.16 Favored Pre-proline 0 N--CA 1.451 -0.403 0 CA-C-N 115.382 -0.826 . . . . 0.0 110.244 173.083 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 229' ' ' PRO . . . . . 0.482 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 24.6 Cg_exo -64.86 147.37 70.15 Favored 'Cis proline' 0 C--N 1.31 -1.498 0 C-N-CA 123.611 -1.412 . . . . 0.0 110.059 -2.157 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 230' ' ' GLY . . . . . 0.664 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -72.75 100.86 1.03 Allowed Glycine 0 C--N 1.295 -1.704 0 N-CA-C 110.025 -1.23 . . . . 0.0 110.025 -179.732 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 231' ' ' VAL . . . . . 0.621 HG23 HD12 ' A' ' 270' ' ' LEU . 7.1 p -88.51 127.32 41.51 Favored 'Isoleucine or valine' 0 C--O 1.244 0.784 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 177.986 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 232' ' ' VAL . . . . . 0.742 HG12 HG13 ' A' ' 224' ' ' VAL . 0.6 OUTLIER -131.46 156.43 42.64 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.897 0 CA-C-O 121.124 0.488 . . . . 0.0 109.827 -177.503 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -117.69 145.45 44.41 Favored 'General case' 0 N--CA 1.429 -1.489 0 CA-C-N 114.838 -1.074 . . . . 0.0 109.032 179.336 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.8 m -107.0 160.3 15.64 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.095 -177.553 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 24.1 tp -54.82 132.62 46.61 Favored 'General case' 0 C--N 1.314 -0.966 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 178.749 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 236' ' ' ASP . . . . . 0.41 ' O ' ' CE1' ' A' ' 273' ' ' TYR . 28.4 t70 -53.89 -42.82 69.07 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-O 121.341 0.591 . . . . 0.0 111.007 -176.174 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 74.0 mt-10 -65.49 -32.15 73.61 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.32 179.126 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 238' ' ' ALA . . . . . 0.622 ' HB1' ' HB1' ' A' ' 219' ' ' ALA . . . -72.11 135.03 46.1 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.961 0.41 . . . . 0.0 111.896 -176.861 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 66.2 mtp180 -113.13 92.96 4.19 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 175.565 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 240' ' ' HIS . . . . . 0.567 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 7.3 p80 -54.7 -49.12 71.48 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 -173.337 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 79.86 17.57 74.67 Favored Glycine 0 C--N 1.309 -0.964 0 N-CA-C 110.491 -1.044 . . . . 0.0 110.491 -179.21 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 242' ' ' PHE . . . . . 0.49 ' CD2' ' HB2' ' A' ' 240' ' ' HIS . 6.5 m-30 -80.4 144.12 32.93 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 -179.11 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -106.83 164.85 11.77 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.346 0.594 . . . . 0.0 111.364 179.145 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -65.56 120.8 13.55 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 177.866 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 79.76 7.69 88.3 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 -177.358 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 43.2 t0 -79.51 166.49 21.9 Favored 'General case' 0 C--O 1.233 0.188 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 -179.694 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 247' ' ' PHE . . . . . 0.496 ' HA ' ' O ' ' A' ' 265' ' ' MET . 26.9 m-85 -110.19 133.63 53.04 Favored 'General case' 0 C--O 1.239 0.525 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -176.868 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 248' ' ' VAL . . . . . 0.499 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 3.0 m -131.89 160.37 42.47 Favored 'Isoleucine or valine' 0 C--O 1.237 0.435 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.472 178.144 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 1.2 m -121.84 161.65 22.34 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 114.907 -1.042 . . . . 0.0 109.171 173.953 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 250' ' ' PHE . . . . . 0.527 ' CB ' ' HB3' ' A' ' 259' ' ' LEU . 61.0 m-85 -125.88 151.77 46.45 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 110.306 -0.257 . . . . 0.0 110.306 -175.066 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 16.4 m -156.36 163.08 39.91 Favored 'General case' 0 C--O 1.215 -0.719 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 177.032 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 67.3 mm-40 54.4 30.15 12.24 Favored 'General case' 0 C--N 1.316 -0.887 0 N-CA-C 111.746 0.276 . . . . 0.0 111.746 175.419 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 0.657 HG22 ' CA ' ' A' ' 290' ' ' GLY . 2.9 t -98.96 126.74 52.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 176.758 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 83.2 mt-30 -90.94 138.41 31.62 Favored 'General case' 0 C--O 1.246 0.906 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 178.224 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 81.2 -59.0 4.82 Favored Glycine 0 C--O 1.244 0.76 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 -178.997 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 256' ' ' MET . . . . . 0.509 ' SD ' HG11 ' A' ' 224' ' ' VAL . 3.8 ttm -80.13 49.86 1.16 Allowed 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 121.988 0.899 . . . . 0.0 109.766 178.285 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 47.6 pt -67.43 -22.29 28.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 114.262 -1.335 . . . . 0.0 111.116 -176.768 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 258' ' ' GLN . . . . . 0.516 ' HG3' ' HG ' ' A' ' 262' ' ' CYS . 63.9 tp60 -57.1 -39.11 74.43 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 179.199 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 259' ' ' LEU . . . . . 0.682 HD21 ' CE2' ' A' ' 283' ' ' PHE . 99.2 mt -62.15 -40.8 97.17 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 115.47 -0.786 . . . . 0.0 109.721 178.037 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 -60.27 -40.98 92.28 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 -178.254 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -99.27 17.86 57.32 Favored Glycine 0 CA--C 1.521 0.464 0 N-CA-C 111.55 -0.62 . . . . 0.0 111.55 -179.633 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 262' ' ' CYS . . . . . 0.516 ' HG ' ' HG3' ' A' ' 258' ' ' GLN . 1.4 m -94.45 160.39 14.68 Favored 'General case' 0 C--O 1.239 0.512 0 CA-C-N 117.052 0.426 . . . . 0.0 110.455 -179.71 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 7.1 mt-30 -82.1 159.72 64.67 Favored Pre-proline 0 C--N 1.318 -0.766 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 172.306 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 264' ' ' PRO . . . . . 0.499 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 24.3 Cg_exo -62.16 143.26 94.29 Favored 'Trans proline' 0 C--N 1.309 -1.538 0 CA-C-N 119.743 0.944 . . . . 0.0 109.949 -179.248 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 265' ' ' MET . . . . . 0.496 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 8.7 ptp -133.57 167.94 19.56 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 112.892 0.701 . . . . 0.0 112.892 -175.088 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 72.2 tt0 -70.1 139.88 52.6 Favored 'General case' 0 C--O 1.243 0.735 0 O-C-N 124.164 0.915 . . . . 0.0 110.177 -179.69 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 267' ' ' ILE . . . . . 0.616 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.7 pp -129.22 154.35 39.97 Favored 'Isoleucine or valine' 0 C--O 1.243 0.755 0 CA-C-O 121.263 0.554 . . . . 0.0 111.526 178.389 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 66.2 mttm -125.72 109.61 12.79 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.744 -178.052 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 18.8 m -70.39 131.39 34.32 Favored 'Isoleucine or valine' 0 C--O 1.237 0.407 0 CA-C-O 120.681 0.277 . . . . 0.0 111.235 -177.394 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 270' ' ' LEU . . . . . 0.621 HD12 HG23 ' A' ' 231' ' ' VAL . 95.1 mt -109.48 -25.55 10.43 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.582 179.149 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -156.41 -174.79 26.61 Favored Glycine 0 CA--C 1.511 -0.188 0 N-CA-C 110.124 -1.19 . . . . 0.0 110.124 -179.218 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 272' ' ' PRO . . . . . 0.567 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 28.6 Cg_endo -60.24 -39.87 64.41 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 121.844 1.696 . . . . 0.0 111.439 -177.434 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 273' ' ' TYR . . . . . 0.41 ' CE1' ' O ' ' A' ' 236' ' ' ASP . 57.6 m-85 -118.98 9.81 12.0 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.207 178.975 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -116.01 129.14 56.23 Favored 'General case' 0 C--O 1.241 0.612 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.727 -172.465 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 275' ' ' PHE . . . . . 0.575 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -144.24 167.87 21.41 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 111.84 0.311 . . . . 0.0 111.84 179.729 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 276' ' ' SER . . . . . 0.432 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 4.6 p -133.27 142.26 48.42 Favored 'General case' 0 C--N 1.319 -0.728 0 C-N-CA 120.764 -0.374 . . . . 0.0 111.65 -177.353 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 277' ' ' ILE . . . . . 0.502 HG22 HG22 ' A' ' 267' ' ' ILE . 38.0 pt -137.02 163.07 33.25 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-N 115.137 -0.938 . . . . 0.0 111.739 -176.779 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 278' ' ' CYS . . . . . 0.434 ' C ' ' O ' ' A' ' 277' ' ' ILE . 88.1 m -14.98 -92.73 0.0 OUTLIER 'General case' 0 CA--C 1.543 0.703 0 N-CA-C 113.979 1.103 . . . . 0.0 113.979 -177.893 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 279' ' ' ASP . . . . . 0.416 ' CG ' ' HB3' ' A' ' 228' ' ' ASN . 67.1 t0 -154.99 114.82 3.75 Favored 'General case' 0 CA--C 1.509 -0.601 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 -179.209 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 280' ' ' THR . . . . . 0.796 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 20.8 p -65.43 -27.79 68.78 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-O 120.99 0.424 . . . . 0.0 110.755 178.488 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -63.08 -23.95 67.68 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-N 115.169 -0.923 . . . . 0.0 109.224 175.526 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 20.4 t-20 -89.14 -9.53 50.65 Favored 'General case' 0 CA--C 1.512 -0.518 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.932 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 283' ' ' PHE . . . . . 0.796 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 10.2 m-85 -87.05 -64.86 1.08 Allowed 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 172.969 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 284' ' ' SER . . . . . 0.475 ' OG ' ' HA ' ' A' ' 256' ' ' MET . 2.4 p 170.35 -101.27 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 114.306 -1.316 . . . . 0.0 109.415 176.989 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 285' ' ' ASP . . . . . 0.47 ' O ' ' N ' ' A' ' 256' ' ' MET . 5.9 t0 -148.92 164.25 35.08 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-O 120.611 0.243 . . . . 0.0 110.793 176.851 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 286' ' ' TYR . . . . . 0.441 ' N ' ' OD1' ' A' ' 285' ' ' ASP . 83.9 t80 -94.69 114.99 26.99 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 177.387 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 22.2 mm -100.12 -58.73 3.69 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.519 175.012 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 85.5 mtm180 -160.97 167.53 26.34 Favored 'General case' 0 CA--C 1.503 -0.84 0 O-C-N 123.604 0.565 . . . . 0.0 112.352 178.883 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 51.21 -138.97 26.34 Favored Glycine 0 CA--C 1.504 -0.649 0 CA-C-N 113.339 -1.755 . . . . 0.0 112.556 168.891 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 290' ' ' GLY . . . . . 0.657 ' CA ' HG22 ' A' ' 253' ' ' VAL . . . 100.83 117.32 4.14 Favored Glycine 0 N--CA 1.433 -1.565 0 N-CA-C 110.602 -0.999 . . . . 0.0 110.602 -177.637 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 87.3 mt -108.75 128.06 64.8 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.285 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 175.873 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 3.3 p -118.85 135.38 59.46 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.035 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 -178.115 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 293' ' ' SER . . . . . 0.475 ' HA ' ' O ' ' A' ' 217' ' ' LEU . 4.7 m -128.9 147.65 50.85 Favored 'General case' 0 N--CA 1.442 -0.856 0 C-N-CA 120.323 -0.551 . . . . 0.0 112.466 -174.426 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 48.1 tt0 . . . . . 0 N--CA 1.443 -0.823 0 CA-C-N 114.998 -1.001 . . . . 0.0 111.295 177.932 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 217' ' ' LEU . . . . . 0.448 HD22 ' HA ' ' A' ' 217' ' ' LEU . 0.5 OUTLIER . . . . . 0 CA--C 1.506 -0.746 0 N-CA-C 110.661 -0.126 . . . . 0.0 110.661 . . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 67.1 m -124.38 149.13 47.01 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.458 179.044 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -148.31 151.08 34.78 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.181 179.046 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 71.8 mtm -78.92 136.87 37.39 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 116.039 -0.528 . . . . 0.0 109.719 176.761 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 91.5 t -86.11 130.87 35.83 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.148 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -81.82 -71.01 0.5 Allowed 'General case' 0 N--CA 1.435 -1.179 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 178.656 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 223' ' ' MET . . . . . 0.661 ' C ' ' SD ' ' A' ' 223' ' ' MET . 2.1 ppp? -138.43 147.79 43.7 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 112.393 0.516 . . . . 0.0 112.393 173.973 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 224' ' ' VAL . . . . . 0.785 HG13 HG12 ' A' ' 232' ' ' VAL . 55.1 t -122.55 131.76 72.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 176.345 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 225' ' ' THR . . . . . 0.441 ' O ' ' OG1' ' A' ' 280' ' ' THR . 49.8 p -87.56 134.67 33.58 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 110.503 -0.184 . . . . 0.0 110.503 179.43 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 226' ' ' LYS . . . . . 0.492 ' NZ ' ' OD1' ' A' ' 285' ' ' ASP . 0.7 OUTLIER -80.42 76.88 7.23 Favored 'General case' 0 C--O 1.239 0.541 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 176.8 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 227' ' ' ASP . . . . . 0.433 ' H ' ' HG1' ' A' ' 280' ' ' THR . 5.8 t70 -147.87 177.33 9.42 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.302 -176.973 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 228' ' ' ASN . . . . . 0.474 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 4.3 t-20 -139.78 124.23 11.13 Favored Pre-proline 0 C--N 1.326 -0.414 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.415 176.072 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 229' ' ' PRO . . . . . 0.474 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 48.2 Cg_endo -66.17 144.59 66.84 Favored 'Cis proline' 0 C--N 1.313 -1.319 0 C-N-CA 122.802 -1.749 . . . . 0.0 109.873 -1.987 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 230' ' ' GLY . . . . . 0.503 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -70.69 138.29 28.41 Favored Glycine 0 C--O 1.222 -0.635 0 N-CA-C 109.821 -1.312 . . . . 0.0 109.821 -177.862 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.5 p -123.05 131.1 73.88 Favored 'Isoleucine or valine' 0 C--O 1.242 0.674 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 177.048 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 232' ' ' VAL . . . . . 0.785 HG12 HG13 ' A' ' 224' ' ' VAL . 0.7 OUTLIER -133.05 156.78 42.56 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 C-N-CA 120.347 -0.541 . . . . 0.0 110.819 -176.557 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 233' ' ' THR . . . . . 0.466 HG23 ' CG2' ' A' ' 274' ' ' THR . 0.2 OUTLIER -110.2 147.91 32.85 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 115.073 -0.967 . . . . 0.0 108.577 177.844 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 2.8 m -107.36 146.83 31.1 Favored 'General case' 0 C--N 1.313 -0.987 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 177.457 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 14.0 tp -49.41 125.26 10.78 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 -177.841 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 16.1 t70 -52.39 -40.84 62.58 Favored 'General case' 0 CA--C 1.507 -0.68 0 CA-C-N 116.463 -0.335 . . . . 0.0 111.07 -171.611 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 83.6 mt-10 -65.47 -35.41 80.81 Favored 'General case' 0 C--N 1.314 -0.977 0 C-N-CA 120.33 -0.548 . . . . 0.0 110.606 -177.794 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -72.34 138.32 47.23 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 112.442 0.534 . . . . 0.0 112.442 -175.226 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 84.9 mtp180 -105.14 104.42 14.15 Favored 'General case' 0 C--O 1.239 0.509 0 CA-C-N 115.734 -0.666 . . . . 0.0 109.26 172.829 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 240' ' ' HIS . . . . . 0.457 ' HB2' ' CG ' ' A' ' 242' ' ' PHE . 8.4 p80 -67.38 -46.96 71.76 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.923 -0.581 . . . . 0.0 111.599 -176.685 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 241' ' ' GLY . . . . . 0.441 ' N ' ' ND1' ' A' ' 240' ' ' HIS . . . 83.33 12.44 78.67 Favored Glycine 0 C--N 1.31 -0.902 0 N-CA-C 110.477 -1.049 . . . . 0.0 110.477 -176.909 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 242' ' ' PHE . . . . . 0.457 ' CG ' ' HB2' ' A' ' 240' ' ' HIS . 4.3 m-30 -80.84 145.39 31.41 Favored 'General case' 0 CA--C 1.514 -0.41 0 CA-C-O 120.731 0.301 . . . . 0.0 110.261 -178.915 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 243' ' ' GLU . . . . . 0.465 ' N ' ' OD2' ' A' ' 246' ' ' ASP . 99.2 mt-10 -131.55 165.01 24.55 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 115.734 -0.666 . . . . 0.0 109.592 173.392 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 244' ' ' THR . . . . . 0.439 HG23 ' HA ' ' A' ' 268' ' ' LYS . 4.9 m -59.56 125.82 25.15 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 -178.739 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 99.6 -5.88 58.74 Favored Glycine 0 C--N 1.318 -0.441 0 N-CA-C 111.215 -0.754 . . . . 0.0 111.215 -177.425 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 246' ' ' ASP . . . . . 0.465 ' OD2' ' N ' ' A' ' 243' ' ' GLU . 0.9 OUTLIER -67.54 149.64 49.87 Favored 'General case' 0 CA--C 1.502 -0.884 0 C-N-CA 120.814 -0.355 . . . . 0.0 111.44 176.525 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 247' ' ' PHE . . . . . 0.403 ' HA ' ' O ' ' A' ' 265' ' ' MET . 61.7 m-85 -108.74 125.84 52.36 Favored 'General case' 0 C--N 1.317 -0.81 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 176.142 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 248' ' ' VAL . . . . . 0.457 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.9 m -128.09 160.86 37.41 Favored 'Isoleucine or valine' 0 C--O 1.24 0.566 0 C-N-CA 120.47 -0.492 . . . . 0.0 111.577 -175.38 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 44.1 m -124.17 160.21 28.36 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-N 114.778 -1.101 . . . . 0.0 108.679 173.495 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 250' ' ' PHE . . . . . 0.558 ' CB ' ' HB3' ' A' ' 259' ' ' LEU . 76.4 m-85 -123.99 153.89 40.62 Favored 'General case' 0 C--N 1.314 -0.935 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 -173.987 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 14.6 p -159.69 161.17 34.83 Favored 'General case' 0 C--N 1.309 -1.176 0 C-N-CA 120.969 -0.293 . . . . 0.0 111.266 177.162 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 27.1 mm-40 51.62 27.86 4.29 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.395 177.942 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 0.542 HG22 ' CA ' ' A' ' 290' ' ' GLY . 6.5 t -90.3 129.41 41.21 Favored 'Isoleucine or valine' 0 C--O 1.236 0.371 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 175.802 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 81.4 mt-30 -94.27 136.86 34.1 Favored 'General case' 0 C--O 1.244 0.785 0 C-N-CA 120.276 -0.57 . . . . 0.0 109.836 -178.16 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 82.59 -58.15 5.01 Favored Glycine 0 C--N 1.32 -0.323 0 N-CA-C 109.945 -1.262 . . . . 0.0 109.945 -176.853 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 256' ' ' MET . . . . . 0.485 ' N ' ' O ' ' A' ' 285' ' ' ASP . 4.3 ttm -81.73 53.76 2.23 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.665 0.745 . . . . 0.0 109.708 177.797 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 257' ' ' ILE . . . . . 0.427 ' O ' ' HB2' ' A' ' 260' ' ' ASN . 48.8 pt -69.37 -23.16 26.23 Favored 'Isoleucine or valine' 0 C--O 1.242 0.702 0 CA-C-N 115.042 -0.981 . . . . 0.0 110.899 -175.959 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 258' ' ' GLN . . . . . 0.425 ' O ' ' SG ' ' A' ' 262' ' ' CYS . 1.2 mp0 -56.5 -37.07 69.9 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 179.673 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 259' ' ' LEU . . . . . 0.873 HD21 ' CE2' ' A' ' 283' ' ' PHE . 93.0 mt -62.35 -40.2 95.61 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.755 175.375 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 260' ' ' ASN . . . . . 0.427 ' HB2' ' O ' ' A' ' 257' ' ' ILE . 98.1 m-20 -59.32 -39.79 84.2 Favored 'General case' 0 CA--C 1.516 -0.336 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 -178.322 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -98.21 8.78 62.92 Favored Glycine 0 CA--C 1.531 1.043 0 CA-C-N 116.165 -0.47 . . . . 0.0 112.224 -178.083 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 262' ' ' CYS . . . . . 0.425 ' SG ' ' O ' ' A' ' 258' ' ' GLN . 1.7 m -88.51 146.02 25.41 Favored 'General case' 0 C--O 1.236 0.39 0 O-C-N 122.262 -0.552 . . . . 0.0 112.204 -176.407 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 36.4 mt-30 -64.73 156.91 77.04 Favored Pre-proline 0 C--N 1.325 -0.476 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 171.973 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 264' ' ' PRO . . . . . 0.457 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 38.1 Cg_endo -63.5 144.24 89.9 Favored 'Trans proline' 0 C--N 1.318 -1.06 0 C-N-CA 121.098 1.199 . . . . 0.0 110.426 -178.794 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 265' ' ' MET . . . . . 0.403 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 11.3 ptp -133.6 154.45 50.87 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 112.174 0.435 . . . . 0.0 112.174 -175.597 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 34.8 tt0 -71.34 143.85 50.11 Favored 'General case' 0 C--O 1.236 0.378 0 O-C-N 123.837 0.711 . . . . 0.0 109.328 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 267' ' ' ILE . . . . . 0.671 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.9 pp -131.92 165.77 30.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 N-CA-C 112.639 0.607 . . . . 0.0 112.639 -175.957 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 268' ' ' LYS . . . . . 0.439 ' HA ' HG23 ' A' ' 244' ' ' THR . 49.9 tttp -124.83 125.46 44.03 Favored 'General case' 0 C--O 1.217 -0.612 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.343 177.79 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.414 HG23 ' O ' ' A' ' 269' ' ' VAL . 35.5 m -93.12 102.61 13.83 Favored 'Isoleucine or valine' 0 C--O 1.238 0.472 0 C-N-CA 120.452 -0.499 . . . . 0.0 111.235 179.127 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 95.9 mt -66.57 -39.44 88.48 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.148 -179.424 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -143.34 -169.74 12.73 Favored Glycine 0 C--N 1.32 -0.311 0 N-CA-C 110.441 -1.064 . . . . 0.0 110.441 -177.775 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 272' ' ' PRO . . . . . 0.401 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 39.7 Cg_endo -64.11 -33.29 61.98 Favored 'Trans proline' 0 C--N 1.306 -1.707 0 C-N-CA 122.038 1.825 . . . . 0.0 111.714 -179.287 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 90.6 m-85 -126.51 10.11 7.23 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 112.1 0.407 . . . . 0.0 112.1 -177.981 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 274' ' ' THR . . . . . 0.466 ' CG2' HG23 ' A' ' 233' ' ' THR . 1.1 p -121.61 131.11 53.93 Favored 'General case' 0 C--O 1.244 0.765 0 CA-C-N 116.701 -0.227 . . . . 0.0 111.072 -177.182 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 275' ' ' PHE . . . . . 0.543 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -139.31 161.68 36.84 Favored 'General case' 0 CA--C 1.511 -0.541 0 N-CA-C 112.34 0.496 . . . . 0.0 112.34 179.147 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 276' ' ' SER . . . . . 0.495 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 4.2 p -130.38 144.1 51.18 Favored 'General case' 0 N--CA 1.437 -1.078 0 CA-C-O 121.246 0.546 . . . . 0.0 111.512 -175.827 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 277' ' ' ILE . . . . . 0.56 HG22 HG22 ' A' ' 267' ' ' ILE . 31.8 pt -139.0 165.84 23.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 114.725 -1.125 . . . . 0.0 111.824 -173.304 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 278' ' ' CYS . . . . . 0.435 ' O ' ' HA ' ' A' ' 229' ' ' PRO . 4.8 m -28.36 -86.4 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.57 0 N-CA-C 113.498 0.925 . . . . 0.0 113.498 -175.51 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 55.3 t0 -153.02 112.2 3.81 Favored 'General case' 0 CA--C 1.508 -0.645 0 CA-C-O 120.5 0.19 . . . . 0.0 110.498 -177.374 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 280' ' ' THR . . . . . 0.774 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 21.6 p -67.68 -28.79 67.98 Favored 'General case' 0 C--N 1.303 -1.428 0 CA-C-O 121.323 0.582 . . . . 0.0 110.645 176.314 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -63.99 -21.56 66.55 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 115.067 -0.969 . . . . 0.0 108.521 175.604 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 44.3 t30 -88.42 -8.7 54.54 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.398 -179.501 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 283' ' ' PHE . . . . . 0.873 ' CE2' HD21 ' A' ' 259' ' ' LEU . 7.2 m-85 -92.45 -67.71 0.84 Allowed 'General case' 0 CA--C 1.512 -0.492 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.273 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 284' ' ' SER . . . . . 0.436 ' OG ' ' HA ' ' A' ' 256' ' ' MET . 3.8 p 173.41 -105.8 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 114.85 -1.068 . . . . 0.0 110.565 176.392 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 285' ' ' ASP . . . . . 0.492 ' OD1' ' NZ ' ' A' ' 226' ' ' LYS . 40.2 t0 -145.44 158.8 43.77 Favored 'General case' 0 C--O 1.217 -0.606 0 CA-C-O 120.408 0.147 . . . . 0.0 110.607 -179.637 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 66.7 t80 -101.1 118.89 37.89 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.744 -0.207 . . . . 0.0 110.634 179.628 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 287' ' ' ILE . . . . . 0.439 ' O ' ' HG3' ' A' ' 288' ' ' ARG . 97.1 mt -97.94 -63.86 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 175.79 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 288' ' ' ARG . . . . . 0.439 ' HG3' ' O ' ' A' ' 287' ' ' ILE . 67.5 mtm180 -166.96 175.86 7.35 Favored 'General case' 0 C--O 1.24 0.601 0 C-N-CA 123.973 0.909 . . . . 0.0 110.605 176.342 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 70.24 -158.8 53.53 Favored Glycine 0 C--N 1.318 -0.462 0 N-CA-C 111.053 -0.819 . . . . 0.0 111.053 175.103 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 290' ' ' GLY . . . . . 0.542 ' CA ' HG22 ' A' ' 253' ' ' VAL . . . 104.93 124.77 5.46 Favored Glycine 0 N--CA 1.442 -0.955 0 N-CA-C 111.977 -0.449 . . . . 0.0 111.977 177.258 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 95.7 mt -116.93 131.64 69.02 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.037 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 174.629 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 4.8 p -120.11 135.04 61.67 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.026 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 -179.138 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 15.6 m -132.03 144.81 51.03 Favored 'General case' 0 C--N 1.319 -0.759 0 C-N-CA 120.063 -0.655 . . . . 0.0 112.535 -174.939 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 48.5 tt0 . . . . . 0 CA--C 1.489 -1.381 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 168.31 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 217' ' ' LEU . . . . . 0.469 ' HB3' ' O ' ' A' ' 240' ' ' HIS . 0.2 OUTLIER . . . . . 0 C--O 1.237 0.409 0 N-CA-C 110.223 -0.288 . . . . 0.0 110.223 . . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 16.5 p -136.18 156.16 49.09 Favored 'General case' 0 CA--C 1.51 -0.595 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.509 -177.352 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 219' ' ' ALA . . . . . 0.53 ' HA ' ' HB1' ' A' ' 238' ' ' ALA . . . -150.72 151.2 32.06 Favored 'General case' 0 N--CA 1.448 -0.556 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.134 -178.751 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 220' ' ' MET . . . . . 0.505 ' SD ' HG12 ' A' ' 291' ' ' ILE . 1.5 mpp? -73.67 131.2 41.39 Favored 'General case' 0 C--O 1.244 0.772 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 177.891 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 69.1 t -74.77 131.76 34.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 178.659 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 58.0 m -92.2 -69.09 0.76 Allowed 'General case' 0 N--CA 1.435 -1.176 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.342 179.661 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 12.6 ptm -138.14 148.59 45.07 Favored 'General case' 0 N--CA 1.472 0.63 0 C-N-CA 120.999 -0.281 . . . . 0.0 111.141 172.762 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 224' ' ' VAL . . . . . 0.55 HG22 ' HB ' ' A' ' 232' ' ' VAL . 52.9 t -121.67 129.35 75.58 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 174.94 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 17.2 p -81.29 128.03 33.36 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 119.85 -0.74 . . . . 0.0 110.54 179.623 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 17.0 tptm -76.4 84.11 3.14 Favored 'General case' 0 N--CA 1.437 -1.097 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 177.463 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 227' ' ' ASP . . . . . 0.543 ' N ' ' OG1' ' A' ' 280' ' ' THR . 4.8 t0 -159.97 175.74 12.67 Favored 'General case' 0 C--O 1.245 0.861 0 CA-C-N 115.53 -0.759 . . . . 0.0 110.304 -176.162 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 228' ' ' ASN . . . . . 0.48 ' N ' ' OD1' ' A' ' 227' ' ' ASP . 0.1 OUTLIER -143.01 122.75 7.75 Favored Pre-proline 0 C--N 1.321 -0.656 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.838 172.65 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 229' ' ' PRO . . . . . 0.48 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 42.0 Cg_endo -65.23 148.33 73.27 Favored 'Cis proline' 0 N--CA 1.496 1.652 0 C-N-CA 122.908 -1.705 . . . . 0.0 109.875 -1.507 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 230' ' ' GLY . . . . . 0.484 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -88.43 140.57 16.19 Favored Glycine 0 C--N 1.315 -0.612 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 -177.916 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.4 p -121.01 132.79 69.59 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.579 0 CA-C-N 117.182 0.491 . . . . 0.0 109.791 177.125 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 232' ' ' VAL . . . . . 0.556 HG22 ' CD1' ' A' ' 275' ' ' PHE . 0.6 OUTLIER -129.83 153.63 39.12 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.042 0 C-N-CA 120.038 -0.665 . . . . 0.0 111.214 -176.581 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 233' ' ' THR . . . . . 0.444 ' HA ' ' O ' ' A' ' 273' ' ' TYR . 0.6 OUTLIER -106.84 140.48 39.61 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-N 115.151 -0.931 . . . . 0.0 109.445 178.065 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.8 m -107.07 160.39 15.59 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-N 116.182 -0.463 . . . . 0.0 109.823 -178.339 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.464 ' HB3' ' HB3' ' A' ' 238' ' ' ALA . 41.5 tp -63.74 131.34 47.58 Favored 'General case' 0 C--N 1.32 -0.674 0 C-N-CA 120.686 -0.406 . . . . 0.0 109.975 -177.678 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 19.0 p-10 -51.61 -44.43 62.88 Favored 'General case' 0 N--CA 1.475 0.801 0 CA-C-N 115.881 -0.6 . . . . 0.0 111.073 -176.628 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 92.6 mt-10 -65.77 -35.24 80.16 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 179.556 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 238' ' ' ALA . . . . . 0.53 ' HB1' ' HA ' ' A' ' 219' ' ' ALA . . . -91.54 92.61 8.58 Favored 'General case' 0 N--CA 1.439 -1.017 0 CA-C-N 115.481 -0.781 . . . . 0.0 111.855 -175.261 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 84.7 mtp180 -75.66 118.13 18.15 Favored 'General case' 0 C--N 1.312 -1.022 0 N-CA-C 108.478 -0.934 . . . . 0.0 108.478 174.386 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 240' ' ' HIS . . . . . 0.615 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 7.1 p80 -60.09 -46.09 90.73 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.799 -176.939 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 78.87 19.12 73.66 Favored Glycine 0 C--O 1.238 0.381 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 -178.532 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 242' ' ' PHE . . . . . 0.544 ' CD2' ' HB2' ' A' ' 240' ' ' HIS . 10.4 m-30 -81.04 146.66 30.53 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 -179.545 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 73.9 mm-40 -101.64 158.88 15.77 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 116.011 -0.54 . . . . 0.0 109.672 172.544 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 16.3 m -66.66 126.72 29.83 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 174.762 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 88.14 2.78 80.06 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -176.491 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 15.2 t0 -79.42 167.51 20.74 Favored 'General case' 0 CA--C 1.516 -0.337 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 178.285 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 247' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -112.66 134.71 54.05 Favored 'General case' 0 C--O 1.244 0.811 0 O-C-N 123.127 0.267 . . . . 0.0 110.874 -176.922 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 248' ' ' VAL . . . . . 0.47 HG11 ' CD2' ' A' ' 242' ' ' PHE . 2.9 m -131.59 160.92 42.03 Favored 'Isoleucine or valine' 0 C--O 1.236 0.369 0 CA-C-O 121.078 0.466 . . . . 0.0 111.899 178.37 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 249' ' ' SER . . . . . 0.444 ' OG ' ' HG3' ' A' ' 264' ' ' PRO . 1.3 m -123.26 153.48 40.13 Favored 'General case' 0 C--O 1.244 0.798 0 CA-C-N 114.893 -1.048 . . . . 0.0 109.229 176.653 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 250' ' ' PHE . . . . . 0.446 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 79.3 m-85 -109.43 153.0 24.63 Favored 'General case' 0 CA--C 1.505 -0.773 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.787 -179.357 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 251' ' ' SER . . . . . 0.475 ' O ' ' HA2' ' A' ' 290' ' ' GLY . 39.0 m -152.71 154.69 35.76 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-N 115.694 -0.684 . . . . 0.0 109.196 176.688 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 12.6 mm-40 57.47 21.17 6.71 Favored 'General case' 0 CA--C 1.542 0.655 0 N-CA-C 112.664 0.616 . . . . 0.0 112.664 177.917 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 0.59 HG13 ' CE1' ' A' ' 286' ' ' TYR . 61.5 t -76.0 133.89 30.23 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 C-N-CA 120.949 -0.3 . . . . 0.0 111.0 178.759 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 254' ' ' GLN . . . . . 0.411 ' OE1' ' HG2' ' A' ' 288' ' ' ARG . 85.2 mt-30 -96.78 136.01 37.93 Favored 'General case' 0 C--O 1.24 0.605 0 O-C-N 123.334 0.396 . . . . 0.0 110.045 179.251 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 76.35 -61.4 3.13 Favored Glycine 0 N--CA 1.463 0.453 0 N-CA-C 111.472 -0.651 . . . . 0.0 111.472 177.974 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 256' ' ' MET . . . . . 0.664 ' SD ' HD11 ' A' ' 259' ' ' LEU . 48.5 ttm -77.67 63.08 2.69 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 178.547 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 48.9 pt -70.22 -20.63 23.01 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 114.914 -1.039 . . . . 0.0 111.136 -173.786 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 258' ' ' GLN . . . . . 0.566 ' HG3' ' SG ' ' A' ' 262' ' ' CYS . 9.4 tp-100 -54.76 -39.53 68.42 Favored 'General case' 0 N--CA 1.44 -0.955 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.035 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 259' ' ' LEU . . . . . 0.664 HD11 ' SD ' ' A' ' 256' ' ' MET . 97.8 mt -62.58 -41.71 99.11 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.17 -0.468 . . . . 0.0 109.909 178.542 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -61.52 -40.38 94.41 Favored 'General case' 0 CA--C 1.509 -0.598 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 178.377 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -94.64 13.12 67.81 Favored Glycine 0 CA--C 1.527 0.801 0 CA-C-N 115.395 -0.82 . . . . 0.0 111.775 -178.907 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 262' ' ' CYS . . . . . 0.566 ' SG ' ' HG3' ' A' ' 258' ' ' GLN . 1.0 OUTLIER -105.64 156.92 17.8 Favored 'General case' 0 CA--C 1.508 -0.637 0 CA-C-N 117.45 0.625 . . . . 0.0 112.322 -178.051 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 28.4 mt-30 -71.52 158.38 88.03 Favored Pre-proline 0 C--N 1.319 -0.733 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 171.431 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 264' ' ' PRO . . . . . 0.444 ' HG3' ' OG ' ' A' ' 249' ' ' SER . 26.0 Cg_exo -61.87 147.47 95.15 Favored 'Trans proline' 0 C--N 1.304 -1.809 0 C-N-CA 121.347 1.365 . . . . 0.0 110.551 177.514 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 265' ' ' MET . . . . . . . . . . . . . 4.4 ptp -125.64 164.78 19.84 Favored 'General case' 0 N--CA 1.473 0.706 0 N-CA-C 111.79 0.293 . . . . 0.0 111.79 -177.673 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -71.04 142.62 50.88 Favored 'General case' 0 CA--C 1.513 -0.443 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 176.517 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 267' ' ' ILE . . . . . 0.75 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.7 pp -131.04 160.04 42.56 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 CA-C-O 121.054 0.454 . . . . 0.0 111.611 -179.82 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 55.5 mttm -130.6 110.63 11.55 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -177.187 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.418 HG23 ' O ' ' A' ' 269' ' ' VAL . 27.7 m -77.17 102.1 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 CA-C-O 121.389 0.614 . . . . 0.0 112.255 -176.771 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 97.0 mt -69.6 -39.11 77.46 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.521 177.208 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -144.26 -175.34 17.3 Favored Glycine 0 N--CA 1.461 0.361 0 N-CA-C 109.977 -1.249 . . . . 0.0 109.977 -178.434 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 272' ' ' PRO . . . . . 0.615 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 36.9 Cg_endo -62.15 -34.27 79.61 Favored 'Trans proline' 0 C--N 1.313 -1.341 0 C-N-CA 121.888 1.725 . . . . 0.0 110.939 -177.914 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 273' ' ' TYR . . . . . 0.444 ' O ' ' HA ' ' A' ' 233' ' ' THR . 94.4 m-85 -123.12 6.57 9.19 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.575 -0.739 . . . . 0.0 112.253 -179.796 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 2.2 p -117.11 127.39 54.09 Favored 'General case' 0 C--O 1.244 0.795 0 CA-C-O 121.046 0.45 . . . . 0.0 110.901 179.455 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 275' ' ' PHE . . . . . 0.576 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -137.28 161.94 34.87 Favored 'General case' 0 CA--C 1.502 -0.872 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.092 -179.085 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 276' ' ' SER . . . . . 0.484 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 4.4 p -132.22 145.84 51.6 Favored 'General case' 0 C--N 1.309 -1.163 0 C-N-CA 120.369 -0.532 . . . . 0.0 112.124 -173.864 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 277' ' ' ILE . . . . . 0.591 HG22 HG22 ' A' ' 267' ' ' ILE . 28.0 pt -139.22 164.77 24.43 Favored 'Isoleucine or valine' 0 C--O 1.243 0.726 0 CA-C-N 114.744 -1.117 . . . . 0.0 112.899 -172.368 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 2.2 m -28.63 -88.27 0.0 OUTLIER 'General case' 0 C--O 1.237 0.405 0 N-CA-C 113.928 1.084 . . . . 0.0 113.928 -176.099 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 59.8 t0 -152.4 115.65 4.7 Favored 'General case' 0 CA--C 1.507 -0.696 0 CA-C-O 120.695 0.283 . . . . 0.0 110.793 -175.764 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 280' ' ' THR . . . . . 0.673 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 29.7 p -64.84 -29.53 70.49 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-O 121.023 0.44 . . . . 0.0 110.732 175.611 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -64.64 -23.74 67.36 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.324 175.751 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 18.0 t-20 -89.2 -9.31 51.3 Favored 'General case' 0 CA--C 1.509 -0.612 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.77 -179.557 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 283' ' ' PHE . . . . . 0.673 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 15.7 m-85 -92.46 -75.27 0.49 Allowed 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 121.641 0.734 . . . . 0.0 109.372 174.938 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 284' ' ' SER . . . . . 0.405 ' O ' ' CE ' ' A' ' 256' ' ' MET . 0.1 OUTLIER 165.6 -174.23 0.02 OUTLIER 'General case' 0 C--N 1.313 -1.0 0 N-CA-C 106.835 -1.543 . . . . 0.0 106.835 -174.066 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -94.98 121.56 36.72 Favored 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 119.687 -0.805 . . . . 0.0 111.899 -179.782 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 286' ' ' TYR . . . . . 0.59 ' CE1' HG13 ' A' ' 253' ' ' VAL . 3.3 t80 -72.74 108.19 5.6 Favored 'General case' 0 C--O 1.236 0.386 0 C-N-CA 123.535 0.734 . . . . 0.0 109.744 -177.359 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 287' ' ' ILE . . . . . 0.606 ' O ' ' HB3' ' A' ' 288' ' ' ARG . 89.9 mt -67.39 -44.94 86.72 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.66 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 173.077 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 288' ' ' ARG . . . . . 0.606 ' HB3' ' O ' ' A' ' 287' ' ' ILE . 7.4 ptm180 157.95 -161.26 0.0 OUTLIER 'General case' 0 C--O 1.237 0.409 0 C-N-CA 124.89 1.276 . . . . 0.0 109.164 177.476 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 289' ' ' GLY . . . . . 0.537 ' N ' ' HG3' ' A' ' 288' ' ' ARG . . . 70.99 -157.16 53.51 Favored Glycine 0 CA--C 1.5 -0.903 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 176.498 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 290' ' ' GLY . . . . . 0.475 ' HA2' ' O ' ' A' ' 251' ' ' SER . . . 88.84 145.82 12.02 Favored Glycine 0 N--CA 1.436 -1.309 0 CA-C-O 121.533 0.518 . . . . 0.0 112.714 175.52 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 291' ' ' ILE . . . . . 0.505 HG12 ' SD ' ' A' ' 220' ' ' MET . 92.6 mt -123.41 128.52 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.344 0 N-CA-C 106.74 -1.578 . . . . 0.0 106.74 172.658 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 14.8 p -107.68 130.6 59.74 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.823 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 -179.801 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 3.8 m -132.27 146.9 52.32 Favored 'General case' 0 CA--C 1.506 -0.73 0 C-N-CA 120.52 -0.472 . . . . 0.0 112.187 -173.817 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 49.2 tt0 . . . . . 0 CA--C 1.497 -1.085 0 CA-C-N 115.342 -0.844 . . . . 0.0 109.601 174.368 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 217' ' ' LEU . . . . . 0.429 ' HB3' ' O ' ' A' ' 240' ' ' HIS . 3.7 mm? . . . . . 0 CA--C 1.509 -0.627 0 CA-C-O 120.524 0.202 . . . . 0.0 111.524 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 3.7 m -132.22 132.1 42.77 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 175.423 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -145.38 152.95 40.67 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-O 120.744 0.307 . . . . 0.0 110.762 179.551 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -73.71 134.8 43.59 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.055 178.745 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 98.7 t -80.17 131.12 34.82 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.102 0 N-CA-C 107.406 -1.331 . . . . 0.0 107.406 172.553 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 11.8 p -95.69 -60.48 1.64 Allowed 'General case' 0 N--CA 1.439 -1.016 0 C-N-CA 120.237 -0.585 . . . . 0.0 110.645 -177.978 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 223' ' ' MET . . . . . 0.568 ' C ' ' SD ' ' A' ' 223' ' ' MET . 0.5 OUTLIER -138.42 141.7 39.54 Favored 'General case' 0 C--O 1.221 -0.407 0 N-CA-C 112.219 0.452 . . . . 0.0 112.219 175.78 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 224' ' ' VAL . . . . . 0.639 HG22 ' HB ' ' A' ' 232' ' ' VAL . 48.4 t -125.19 132.25 71.41 Favored 'Isoleucine or valine' 0 C--O 1.24 0.587 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 177.441 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 5.5 p -99.76 117.36 33.92 Favored 'General case' 0 C--O 1.237 0.424 0 C-N-CA 120.373 -0.531 . . . . 0.0 110.324 176.897 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 226' ' ' LYS . . . . . 0.512 ' HD3' ' HA ' ' A' ' 281' ' ' SER . 0.0 OUTLIER -67.55 85.51 0.19 Allowed 'General case' 0 C--O 1.242 0.687 0 N-CA-C 110.151 -0.315 . . . . 0.0 110.151 178.756 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 227' ' ' ASP . . . . . 0.594 ' N ' ' OG1' ' A' ' 280' ' ' THR . 4.2 t70 -150.73 -177.61 6.09 Favored 'General case' 0 C--O 1.242 0.686 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.518 -179.045 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 228' ' ' ASN . . . . . 0.494 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.0 OUTLIER -141.28 125.59 10.39 Favored Pre-proline 0 N--CA 1.467 0.396 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.967 174.96 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 229' ' ' PRO . . . . . 0.494 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 55.7 Cg_endo -66.17 147.77 75.18 Favored 'Cis proline' 0 N--CA 1.496 1.634 0 C-N-CA 123.347 -1.522 . . . . 0.0 110.116 -0.566 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 230' ' ' GLY . . . . . 0.494 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -70.71 138.45 28.61 Favored Glycine 0 N--CA 1.449 -0.473 0 N-CA-C 110.004 -1.238 . . . . 0.0 110.004 -178.154 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 231' ' ' VAL . . . . . 0.683 HG23 ' CD1' ' A' ' 270' ' ' LEU . 1.8 p -125.69 131.78 71.6 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.804 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 176.335 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 232' ' ' VAL . . . . . 0.639 ' HB ' HG22 ' A' ' 224' ' ' VAL . 0.8 OUTLIER -137.28 157.0 34.43 Favored 'Isoleucine or valine' 0 C--O 1.248 0.988 0 C-N-CA 120.103 -0.639 . . . . 0.0 111.548 -177.553 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 233' ' ' THR . . . . . 0.444 HG23 ' CG2' ' A' ' 274' ' ' THR . 6.0 m -113.07 146.9 38.35 Favored 'General case' 0 C--N 1.309 -1.162 0 CA-C-N 114.987 -1.006 . . . . 0.0 109.532 178.613 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 24.7 m -107.36 160.97 15.22 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 178.244 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.43 ' HB3' ' HB3' ' A' ' 238' ' ' ALA . 45.2 tp -59.31 128.61 37.97 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 179.431 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -51.35 -44.78 62.15 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.846 -175.164 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 76.8 mt-10 -65.85 -33.08 75.01 Favored 'General case' 0 C--N 1.311 -1.066 0 C-N-CA 120.724 -0.39 . . . . 0.0 111.147 178.834 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 238' ' ' ALA . . . . . 0.43 ' HB3' ' HB3' ' A' ' 235' ' ' LEU . . . -91.62 102.68 15.32 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.729 -175.1 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 78.5 mtm-85 -74.22 127.36 32.77 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 107.717 -1.216 . . . . 0.0 107.717 174.713 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 240' ' ' HIS . . . . . 0.536 ' H ' ' CD2' ' A' ' 240' ' ' HIS . 6.8 p80 -66.28 -45.45 80.44 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 121.137 0.494 . . . . 0.0 110.855 -179.018 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 81.45 12.12 82.33 Favored Glycine 0 C--N 1.311 -0.823 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 -178.257 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 242' ' ' PHE . . . . . 0.519 ' CE1' ' HB2' ' A' ' 294' ' ' GLN . 4.0 m-30 -81.5 151.95 27.55 Favored 'General case' 0 CA--C 1.504 -0.804 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 178.373 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -130.57 158.07 40.98 Favored 'General case' 0 C--N 1.309 -1.178 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 177.982 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 244' ' ' THR . . . . . 0.743 HG23 ' HG2' ' A' ' 268' ' ' LYS . 22.8 m -57.85 127.97 34.71 Favored 'General case' 0 C--N 1.306 -1.284 0 C-N-CA 120.007 -0.677 . . . . 0.0 109.973 -177.26 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 92.06 -6.41 78.91 Favored Glycine 0 N--CA 1.449 -0.497 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.609 -179.019 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -79.24 162.4 25.71 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 117.223 0.511 . . . . 0.0 111.004 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 247' ' ' PHE . . . . . 0.48 ' HA ' ' O ' ' A' ' 265' ' ' MET . 73.0 m-85 -111.94 131.39 55.41 Favored 'General case' 0 C--O 1.24 0.574 0 N-CA-C 112.241 0.46 . . . . 0.0 112.241 -176.076 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 248' ' ' VAL . . . . . 0.498 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.6 m -132.71 158.88 43.39 Favored 'Isoleucine or valine' 0 C--O 1.235 0.319 0 CA-C-O 120.873 0.368 . . . . 0.0 111.809 177.397 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 49.6 m -123.92 160.55 27.28 Favored 'General case' 0 C--N 1.319 -0.734 0 C-N-CA 124.498 1.119 . . . . 0.0 108.565 173.029 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 250' ' ' PHE . . . . . 0.641 ' CE1' HD22 ' A' ' 259' ' ' LEU . 68.4 m-85 -110.63 146.72 35.68 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 120.461 0.172 . . . . 0.0 111.081 -177.364 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 1.5 m -133.54 153.39 51.68 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 176.24 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 252' ' ' GLU . . . . . 0.462 ' O ' ' NE2' ' A' ' 254' ' ' GLN . 79.1 mm-40 55.37 30.34 14.71 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 112.81 0.671 . . . . 0.0 112.81 173.213 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 0.538 HG11 ' HB3' ' A' ' 256' ' ' MET . 51.3 t -89.01 134.69 27.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 N-CA-C 110.231 -0.285 . . . . 0.0 110.231 177.319 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 254' ' ' GLN . . . . . 0.462 ' NE2' ' O ' ' A' ' 252' ' ' GLU . 3.9 mp0 -99.81 135.19 41.61 Favored 'General case' 0 C--O 1.239 0.518 0 CA-C-O 121.031 0.443 . . . . 0.0 110.658 178.909 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 83.37 -55.08 5.02 Favored Glycine 0 C--N 1.32 -0.321 0 N-CA-C 111.098 -0.801 . . . . 0.0 111.098 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 256' ' ' MET . . . . . 0.538 ' HB3' HG11 ' A' ' 253' ' ' VAL . 4.6 ttm -83.41 69.47 10.03 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 178.481 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 45.5 pt -72.69 -22.23 20.08 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.916 0 CA-C-N 114.78 -1.1 . . . . 0.0 111.075 -174.78 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 258' ' ' GLN . . . . . 0.496 ' O ' ' SG ' ' A' ' 262' ' ' CYS . 23.4 mp0 -59.34 -41.49 89.29 Favored 'General case' 0 C--N 1.313 -0.994 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 179.359 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 259' ' ' LEU . . . . . 0.948 HD21 ' CE2' ' A' ' 283' ' ' PHE . 90.4 mt -62.8 -41.92 99.49 Favored 'General case' 0 N--CA 1.443 -0.802 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.589 178.198 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 260' ' ' ASN . . . . . 0.519 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 89.5 m-20 -60.44 -41.22 93.6 Favored 'General case' 0 CA--C 1.507 -0.678 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 -179.206 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -100.39 14.11 59.6 Favored Glycine 0 C--N 1.316 -0.583 0 N-CA-C 111.359 -0.696 . . . . 0.0 111.359 -178.495 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 262' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 258' ' ' GLN . 1.2 m -85.62 144.81 27.65 Favored 'General case' 0 C--O 1.242 0.707 0 C-N-CA 120.714 -0.394 . . . . 0.0 110.786 -179.607 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 95.7 mm-40 -68.96 162.96 60.87 Favored Pre-proline 0 C--N 1.315 -0.892 0 N-CA-C 107.4 -1.333 . . . . 0.0 107.4 170.224 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 264' ' ' PRO . . . . . 0.498 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 24.1 Cg_exo -61.46 143.89 97.71 Favored 'Trans proline' 0 C--N 1.307 -1.637 0 N-CA-C 109.562 -0.976 . . . . 0.0 109.562 -178.129 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 265' ' ' MET . . . . . 0.48 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 8.9 ptp -126.65 150.8 48.74 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 116.689 -0.232 . . . . 0.0 110.935 -175.296 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -70.92 137.49 49.29 Favored 'General case' 0 C--O 1.242 0.686 0 O-C-N 123.828 0.705 . . . . 0.0 109.14 178.846 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 267' ' ' ILE . . . . . 0.57 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.9 pp -127.24 161.24 34.89 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-O 120.867 0.365 . . . . 0.0 111.601 -175.727 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 268' ' ' LYS . . . . . 0.743 ' HG2' HG23 ' A' ' 244' ' ' THR . 0.0 OUTLIER -127.38 120.87 29.47 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 176.621 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.626 HG22 ' OG1' ' A' ' 244' ' ' THR . 28.3 m -69.92 133.71 31.39 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 C-N-CA 120.653 -0.419 . . . . 0.0 111.337 -177.972 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 270' ' ' LEU . . . . . 0.683 ' CD1' HG23 ' A' ' 231' ' ' VAL . 74.5 mt -97.06 -46.08 6.32 Favored 'General case' 0 CA--C 1.508 -0.67 0 CA-C-O 121.422 0.63 . . . . 0.0 109.537 177.951 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -149.25 -171.46 17.92 Favored Glycine 0 C--N 1.311 -0.843 0 N-CA-C 108.428 -1.869 . . . . 0.0 108.428 179.84 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 272' ' ' PRO . . . . . 0.52 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 37.8 Cg_endo -62.71 -30.66 78.63 Favored 'Trans proline' 0 C--N 1.301 -1.957 0 C-N-CA 121.332 1.355 . . . . 0.0 111.054 -179.12 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 95.3 m-85 -122.86 11.45 9.66 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 113.32 0.859 . . . . 0.0 113.32 -178.07 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 274' ' ' THR . . . . . 0.444 ' CG2' HG23 ' A' ' 233' ' ' THR . 20.4 p -130.09 146.38 51.74 Favored 'General case' 0 C--O 1.241 0.638 0 C-N-CA 120.66 -0.416 . . . . 0.0 111.259 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 275' ' ' PHE . . . . . 0.502 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -150.0 166.1 30.7 Favored 'General case' 0 C--O 1.243 0.736 0 N-CA-C 112.1 0.408 . . . . 0.0 112.1 177.161 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -129.21 141.83 51.03 Favored 'General case' 0 N--CA 1.438 -1.046 0 C-N-CA 120.535 -0.466 . . . . 0.0 111.382 179.643 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 277' ' ' ILE . . . . . 0.55 HG22 HG22 ' A' ' 267' ' ' ILE . 39.4 pt -136.17 166.38 26.95 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.79 0 CA-C-N 114.649 -1.159 . . . . 0.0 111.227 -171.653 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 278' ' ' CYS . . . . . 0.432 ' C ' ' O ' ' A' ' 277' ' ' ILE . 0.9 OUTLIER -21.3 -93.53 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 123.845 0.858 . . . . 0.0 113.137 -176.831 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 279' ' ' ASP . . . . . 0.444 ' OD1' ' N ' ' A' ' 281' ' ' SER . 60.9 t0 -151.98 116.41 5.04 Favored 'General case' 0 CA--C 1.508 -0.645 0 CA-C-N 116.639 -0.255 . . . . 0.0 110.53 -177.937 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 280' ' ' THR . . . . . 0.732 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 11.8 p -66.38 -26.73 67.4 Favored 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 120.508 -0.477 . . . . 0.0 110.832 175.014 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 281' ' ' SER . . . . . 0.512 ' HA ' ' HD3' ' A' ' 226' ' ' LYS . 0.8 OUTLIER -66.38 -20.73 66.15 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.497 -0.774 . . . . 0.0 109.511 174.582 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -87.51 -9.7 53.79 Favored 'General case' 0 CA--C 1.504 -0.797 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 178.316 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 283' ' ' PHE . . . . . 0.948 ' CE2' HD21 ' A' ' 259' ' ' LEU . 8.0 m-85 -92.18 -82.9 0.31 Allowed 'General case' 0 N--CA 1.44 -0.943 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 170.921 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 284' ' ' SER . . . . . 0.438 ' HB2' ' O ' ' A' ' 283' ' ' PHE . 9.5 t 169.1 -149.18 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 177.973 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -85.74 166.44 16.1 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-O 120.59 0.234 . . . . 0.0 110.414 174.655 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 286' ' ' TYR . . . . . 0.58 ' CE2' HG21 ' A' ' 224' ' ' VAL . 12.9 t80 -119.55 102.04 8.36 Favored 'General case' 0 N--CA 1.467 0.394 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 178.486 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 287' ' ' ILE . . . . . 0.561 ' O ' ' HB3' ' A' ' 288' ' ' ARG . 93.4 mt -66.79 -45.53 87.65 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.824 0 C-N-CA 120.211 -0.596 . . . . 0.0 110.287 -179.085 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 288' ' ' ARG . . . . . 0.561 ' HB3' ' O ' ' A' ' 287' ' ' ILE . 14.7 ptm180 168.4 -173.51 0.02 OUTLIER 'General case' 0 C--O 1.238 0.492 0 O-C-N 123.934 0.771 . . . . 0.0 111.165 -176.45 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 64.96 -147.38 50.99 Favored Glycine 0 C--N 1.338 0.691 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.55 174.313 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 290' ' ' GLY . . . . . 0.513 ' HA3' HG22 ' A' ' 253' ' ' VAL . . . 92.16 127.5 4.16 Favored Glycine 0 N--CA 1.443 -0.87 0 CA-C-O 121.252 0.362 . . . . 0.0 113.399 174.636 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 95.0 mt -115.76 127.69 73.26 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.047 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 170.84 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 7.4 p -98.89 132.06 44.91 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 179.641 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -121.42 122.85 40.7 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-N 115.473 -0.785 . . . . 0.0 110.525 -172.331 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 294' ' ' GLN . . . . . 0.519 ' HB2' ' CE1' ' A' ' 242' ' ' PHE . 17.7 tt0 . . . . . 0 CA--C 1.497 -1.086 0 C-N-CA 119.973 -0.691 . . . . 0.0 109.218 172.647 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 217' ' ' LEU . . . . . 0.532 ' O ' ' HA ' ' A' ' 293' ' ' SER . 0.5 OUTLIER . . . . . 0 CA--C 1.493 -1.233 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 . . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 3.0 m -115.43 132.01 56.75 Favored 'General case' 0 C--N 1.313 -1.011 0 O-C-N 123.445 0.465 . . . . 0.0 110.097 -176.2 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 219' ' ' ALA . . . . . 0.436 ' HA ' ' HB1' ' A' ' 238' ' ' ALA . . . -134.4 142.66 47.23 Favored 'General case' 0 N--CA 1.449 -0.516 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.02 -178.804 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 220' ' ' MET . . . . . 0.649 ' SD ' HG12 ' A' ' 291' ' ' ILE . 99.6 mmm -72.18 131.93 43.44 Favored 'General case' 0 C--O 1.244 0.764 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.255 175.829 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 80.5 t -85.11 128.14 39.29 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.999 0 N-CA-C 108.971 -0.752 . . . . 0.0 108.971 178.798 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 222' ' ' SER . . . . . 0.491 ' OG ' ' N ' ' A' ' 223' ' ' MET . 0.1 OUTLIER -79.82 -72.66 0.39 Allowed 'General case' 0 N--CA 1.434 -1.247 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 177.924 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 223' ' ' MET . . . . . 0.491 ' N ' ' OG ' ' A' ' 222' ' ' SER . 8.6 ptm -137.69 147.15 44.59 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.703 -0.68 . . . . 0.0 111.646 175.612 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 224' ' ' VAL . . . . . 0.845 HG13 HG12 ' A' ' 232' ' ' VAL . 59.6 t -122.07 130.16 74.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 175.447 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 41.0 p -77.31 134.72 38.44 Favored 'General case' 0 C--N 1.321 -0.668 0 C-N-CA 120.604 -0.438 . . . . 0.0 110.775 179.451 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 21.8 tptm -77.63 65.66 3.18 Favored 'General case' 0 C--O 1.24 0.596 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 174.784 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 227' ' ' ASP . . . . . 0.472 ' N ' ' OG1' ' A' ' 280' ' ' THR . 2.3 t0 -147.33 177.41 9.24 Favored 'General case' 0 C--O 1.245 0.816 0 CA-C-N 115.41 -0.814 . . . . 0.0 111.251 -171.802 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 228' ' ' ASN . . . . . 0.61 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 16.0 p-10 -144.13 124.39 7.58 Favored Pre-proline 0 C--N 1.319 -0.754 0 CA-C-N 115.525 -0.762 . . . . 0.0 110.82 175.755 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 229' ' ' PRO . . . . . 0.61 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 34.1 Cg_exo -60.18 143.18 33.09 Favored 'Cis proline' 0 N--CA 1.489 1.256 0 C-N-CA 123.14 -1.608 . . . . 0.0 110.926 -1.192 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 230' ' ' GLY . . . . . 0.756 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -74.79 131.06 12.25 Favored Glycine 0 C--N 1.296 -1.681 0 N-CA-C 108.184 -1.966 . . . . 0.0 108.184 176.221 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.1 p -124.96 133.39 69.6 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.791 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 232' ' ' VAL . . . . . 0.845 HG12 HG13 ' A' ' 224' ' ' VAL . 0.7 OUTLIER -131.01 155.57 42.07 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.224 0 C-N-CA 120.27 -0.572 . . . . 0.0 110.863 -176.446 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 63.3 m -108.85 135.08 50.64 Favored 'General case' 0 C--N 1.307 -1.254 0 CA-C-N 115.247 -0.888 . . . . 0.0 108.636 176.553 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 44.6 m -105.64 151.11 24.8 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 -177.334 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 38.6 tp -56.24 132.11 49.77 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 -175.528 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 236' ' ' ASP . . . . . 0.541 ' O ' ' NH2' ' A' ' 239' ' ' ARG . 23.0 p-10 -52.42 -44.23 65.31 Favored 'General case' 0 N--CA 1.474 0.734 0 CA-C-O 121.072 0.463 . . . . 0.0 110.606 -174.994 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 237' ' ' GLU . . . . . 0.413 ' HA ' ' NH2' ' A' ' 239' ' ' ARG . 99.6 mt-10 -64.59 -34.91 79.36 Favored 'General case' 0 C--N 1.302 -1.466 0 CA-C-N 115.641 -0.708 . . . . 0.0 110.421 178.62 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 238' ' ' ALA . . . . . 0.436 ' HB1' ' HA ' ' A' ' 219' ' ' ALA . . . -79.76 73.63 6.48 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 116.004 -0.544 . . . . 0.0 112.176 -174.759 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 239' ' ' ARG . . . . . 0.541 ' NH2' ' O ' ' A' ' 236' ' ' ASP . 0.0 OUTLIER -58.2 90.19 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.024 0.44 . . . . 0.0 110.607 176.477 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 240' ' ' HIS . . . . . 0.473 ' O ' ' HB3' ' A' ' 217' ' ' LEU . 9.1 p80 -55.19 -48.57 73.63 Favored 'General case' 0 C--O 1.217 -0.629 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.249 -175.411 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 78.3 24.56 63.18 Favored Glycine 0 C--N 1.311 -0.858 0 N-CA-C 110.874 -0.891 . . . . 0.0 110.874 179.25 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 242' ' ' PHE . . . . . 0.429 ' CD1' ' HB2' ' A' ' 294' ' ' GLN . 9.3 m-30 -80.19 144.16 33.2 Favored 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 177.869 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -116.03 158.42 23.15 Favored 'General case' 0 C--N 1.312 -1.052 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.737 -177.695 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -56.58 118.03 4.45 Favored 'General case' 0 C--N 1.311 -1.069 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 178.618 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 245' ' ' GLY . . . . . 0.476 ' HA2' ' CG ' ' A' ' 266' ' ' GLU . . . 86.85 5.95 80.4 Favored Glycine 0 C--O 1.243 0.672 0 C-N-CA 120.847 -0.692 . . . . 0.0 111.892 -179.531 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -83.14 163.99 20.5 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-N 117.199 0.499 . . . . 0.0 109.913 177.676 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 247' ' ' PHE . . . . . 0.432 ' HA ' ' O ' ' A' ' 265' ' ' MET . 74.9 m-85 -111.18 135.79 51.19 Favored 'General case' 0 C--O 1.238 0.483 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -173.521 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 248' ' ' VAL . . . . . 0.471 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 3.1 m -131.13 161.92 40.17 Favored 'Isoleucine or valine' 0 C--O 1.237 0.421 0 CA-C-O 121.063 0.458 . . . . 0.0 111.996 178.62 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 2.5 m -125.9 165.09 19.36 Favored 'General case' 0 C--N 1.321 -0.664 0 C-N-CA 124.773 1.229 . . . . 0.0 108.115 173.506 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 250' ' ' PHE . . . . . 0.628 ' CE1' HD22 ' A' ' 259' ' ' LEU . 96.5 m-85 -124.31 156.78 36.37 Favored 'General case' 0 C--N 1.317 -0.816 0 N-CA-C 110.505 -0.183 . . . . 0.0 110.505 -176.115 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 1.2 m -156.62 161.27 39.92 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.222 -0.444 . . . . 0.0 109.823 176.368 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 16.2 mt-10 51.85 28.63 5.19 Favored 'General case' 0 C--N 1.314 -0.939 0 N-CA-C 112.305 0.483 . . . . 0.0 112.305 177.865 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 0.543 HG22 ' CA ' ' A' ' 290' ' ' GLY . 3.2 t -92.78 127.4 44.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 176.363 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 77.3 mt-30 -91.27 138.16 31.81 Favored 'General case' 0 C--O 1.241 0.609 0 CA-C-O 120.827 0.346 . . . . 0.0 110.585 -177.508 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 255' ' ' GLY . . . . . 0.54 ' CA ' HD12 ' A' ' 287' ' ' ILE . . . 76.23 -58.45 3.22 Favored Glycine 0 C--N 1.319 -0.376 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 -179.052 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 256' ' ' MET . . . . . 0.423 ' SD ' HD11 ' A' ' 259' ' ' LEU . 30.7 ttm -77.32 50.36 0.77 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.429 0.633 . . . . 0.0 109.603 176.619 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 46.2 pt -71.11 -18.05 20.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-N 115.233 -0.894 . . . . 0.0 111.218 -175.12 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 258' ' ' GLN . . . . . 0.571 ' HG3' ' HG ' ' A' ' 262' ' ' CYS . 68.5 tp60 -54.86 -38.37 67.39 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 177.897 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 259' ' ' LEU . . . . . 0.822 HD21 ' CE2' ' A' ' 283' ' ' PHE . 93.7 mt -62.22 -40.48 96.24 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.506 -0.77 . . . . 0.0 110.197 176.343 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -59.49 -40.24 86.37 Favored 'General case' 0 CA--C 1.51 -0.59 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 -179.186 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -101.97 21.99 39.85 Favored Glycine 0 CA--C 1.524 0.656 0 CA-C-N 115.927 -0.578 . . . . 0.0 112.049 -179.312 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 262' ' ' CYS . . . . . 0.571 ' HG ' ' HG3' ' A' ' 258' ' ' GLN . 1.3 m -95.95 149.35 21.66 Favored 'General case' 0 C--O 1.236 0.382 0 CA-C-N 117.33 0.565 . . . . 0.0 111.488 -179.429 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 263' ' ' GLN . . . . . 0.525 ' CD ' ' H ' ' A' ' 263' ' ' GLN . 16.6 mp0 -67.66 156.07 89.82 Favored Pre-proline 0 C--N 1.325 -0.475 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 172.572 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 264' ' ' PRO . . . . . 0.471 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 37.3 Cg_endo -62.67 143.09 91.77 Favored 'Trans proline' 0 C--N 1.308 -1.575 0 C-N-CA 120.722 0.948 . . . . 0.0 110.25 179.131 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 265' ' ' MET . . . . . 0.432 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 22.5 ptp -130.55 155.01 47.23 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.663 -173.513 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 266' ' ' GLU . . . . . 0.476 ' CG ' ' HA2' ' A' ' 245' ' ' GLY . 39.7 tt0 -71.8 144.56 49.11 Favored 'General case' 0 C--O 1.239 0.535 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 177.777 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 267' ' ' ILE . . . . . 0.646 HD12 ' C ' ' A' ' 267' ' ' ILE . 2.1 pp -128.27 162.06 35.46 Favored 'Isoleucine or valine' 0 C--O 1.249 1.043 0 N-CA-C 113.608 0.966 . . . . 0.0 113.608 -175.221 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 25.7 mtpp -118.7 109.42 16.08 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 114.762 -1.108 . . . . 0.0 109.66 -178.406 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 8.2 m -80.65 96.04 2.71 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.457 0 C-N-CA 120.275 -0.57 . . . . 0.0 111.268 178.103 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 98.4 mt -67.25 -40.59 86.26 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.406 0.622 . . . . 0.0 110.131 178.128 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -139.64 177.54 20.38 Favored Glycine 0 C--N 1.315 -0.609 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.29 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_endo -60.1 -31.54 93.47 Favored 'Trans proline' 0 C--N 1.302 -1.881 0 C-N-CA 121.772 1.648 . . . . 0.0 111.233 -178.769 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 22.9 m-85 -123.94 11.08 8.93 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.422 179.383 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -122.52 125.67 46.23 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 116.025 -0.534 . . . . 0.0 109.654 -176.276 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 275' ' ' PHE . . . . . 0.545 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -138.68 164.02 30.61 Favored 'General case' 0 CA--C 1.501 -0.931 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 -179.611 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 276' ' ' SER . . . . . 0.524 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 6.4 p -137.49 159.07 42.97 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.456 -178.082 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 277' ' ' ILE . . . . . 0.694 ' C ' HD12 ' A' ' 277' ' ' ILE . 2.5 pp -138.05 -173.74 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 CA-C-N 114.977 -1.01 . . . . 0.0 109.948 -175.825 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 278' ' ' CYS . . . . . 0.46 ' O ' ' HA ' ' A' ' 229' ' ' PRO . 1.2 p -46.87 -93.83 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.304 0 O-C-N 123.324 0.39 . . . . 0.0 111.812 -179.694 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -137.55 126.75 24.55 Favored 'General case' 0 CA--C 1.514 -0.406 0 N-CA-C 109.541 -0.541 . . . . 0.0 109.541 -179.323 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 280' ' ' THR . . . . . 0.756 HG23 ' HA3' ' A' ' 230' ' ' GLY . 25.0 p -69.56 -23.76 63.61 Favored 'General case' 0 C--N 1.317 -0.808 0 C-N-CA 119.436 -0.906 . . . . 0.0 108.682 171.06 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -61.85 -21.05 64.34 Favored 'General case' 0 N--CA 1.435 -1.199 0 CA-C-N 114.635 -1.166 . . . . 0.0 108.812 173.802 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 29.3 t-20 -89.22 -9.13 51.92 Favored 'General case' 0 CA--C 1.509 -0.621 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.481 175.971 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 283' ' ' PHE . . . . . 0.822 ' CE2' HD21 ' A' ' 259' ' ' LEU . 19.5 m-30 -95.79 -87.91 0.28 Allowed 'General case' 0 N--CA 1.444 -0.74 0 CA-C-O 121.524 0.678 . . . . 0.0 110.456 178.396 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 284' ' ' SER . . . . . 0.418 ' CB ' ' HA ' ' A' ' 256' ' ' MET . 0.0 OUTLIER 170.3 -170.22 0.02 OUTLIER 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 107.689 -1.226 . . . . 0.0 107.689 -173.44 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -94.06 131.37 39.62 Favored 'General case' 0 N--CA 1.471 0.623 0 CA-C-N 118.646 0.657 . . . . 0.0 112.766 -176.052 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 286' ' ' TYR . . . . . 0.474 ' O ' ' CD2' ' A' ' 286' ' ' TYR . 60.8 t80 -68.87 87.04 0.35 Allowed 'General case' 0 N--CA 1.472 0.639 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.177 177.399 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 287' ' ' ILE . . . . . 0.577 ' O ' ' HG3' ' A' ' 288' ' ' ARG . 87.5 mt -69.94 -48.05 65.58 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.723 0 C-N-CA 120.298 -0.561 . . . . 0.0 110.806 175.405 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 288' ' ' ARG . . . . . 0.577 ' HG3' ' O ' ' A' ' 287' ' ' ILE . 43.8 mtp180 -170.52 170.67 6.78 Favored 'General case' 0 N--CA 1.47 0.574 0 N-CA-C 112.986 0.735 . . . . 0.0 112.986 -179.114 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 56.48 -143.55 38.51 Favored Glycine 0 N--CA 1.466 0.681 0 CA-C-N 113.77 -1.559 . . . . 0.0 113.199 167.483 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 290' ' ' GLY . . . . . 0.543 ' CA ' HG22 ' A' ' 253' ' ' VAL . . . 100.71 130.31 6.99 Favored Glycine 0 N--CA 1.441 -1.009 0 CA-C-O 121.163 0.313 . . . . 0.0 112.506 178.93 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 291' ' ' ILE . . . . . 0.649 HG12 ' SD ' ' A' ' 220' ' ' MET . 95.2 mt -116.29 129.82 72.08 Favored 'Isoleucine or valine' 0 C--O 1.244 0.769 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 171.675 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 7.2 p -109.31 130.35 62.47 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.064 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 176.789 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 293' ' ' SER . . . . . 0.532 ' HA ' ' O ' ' A' ' 217' ' ' LEU . 3.2 m -131.08 138.73 49.69 Favored 'General case' 0 N--CA 1.441 -0.875 0 C-N-CA 120.43 -0.508 . . . . 0.0 111.558 -175.124 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 294' ' ' GLN . . . . . 0.453 ' OE1' ' N ' ' A' ' 217' ' ' LEU . 2.7 tm0? . . . . . 0 C--N 1.316 -0.88 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 173.29 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 217' ' ' LEU . . . . . 0.882 ' N ' HE21 ' A' ' 294' ' ' GLN . 0.2 OUTLIER . . . . . 0 C--O 1.239 0.549 0 CA-C-O 120.89 0.376 . . . . 0.0 110.327 . . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 8.5 t -151.72 152.61 32.98 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.012 -175.683 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -143.57 160.38 40.73 Favored 'General case' 0 C--O 1.244 0.797 0 CA-C-O 120.918 0.389 . . . . 0.0 110.95 178.413 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 97.2 mtp -71.57 136.73 47.58 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.463 -0.79 . . . . 0.0 109.239 176.474 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 91.1 t -83.7 129.48 37.46 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.052 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 178.027 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 74.9 m -79.79 -73.05 0.37 Allowed 'General case' 0 N--CA 1.432 -1.34 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 177.704 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 223' ' ' MET . . . . . 0.477 ' SD ' ' HB ' ' A' ' 233' ' ' THR . 1.0 OUTLIER -139.71 161.95 36.31 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.111 172.771 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 224' ' ' VAL . . . . . 0.725 HG11 ' SD ' ' A' ' 256' ' ' MET . 69.6 t -127.37 129.8 70.69 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 175.749 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 225' ' ' THR . . . . . 0.509 ' O ' HG21 ' A' ' 280' ' ' THR . 75.4 p -78.88 131.25 36.35 Favored 'General case' 0 C--O 1.225 -0.225 0 C-N-CA 120.08 -0.648 . . . . 0.0 110.163 177.615 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 226' ' ' LYS . . . . . 0.605 ' HE3' ' HA ' ' A' ' 281' ' ' SER . 0.0 OUTLIER -77.72 52.28 1.0 Allowed 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 120.723 0.297 . . . . 0.0 110.868 -179.012 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 227' ' ' ASP . . . . . 0.419 ' CG ' ' H ' ' A' ' 228' ' ' ASN . 42.3 t0 -131.29 -179.8 5.57 Favored 'General case' 0 C--O 1.242 0.674 0 CA-C-O 120.862 0.363 . . . . 0.0 111.952 -178.562 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 228' ' ' ASN . . . . . 0.474 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 1.5 p30 -137.6 125.07 13.95 Favored Pre-proline 0 CA--C 1.539 0.536 0 CA-C-N 115.162 -0.926 . . . . 0.0 109.634 175.073 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 229' ' ' PRO . . . . . 0.474 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 44.9 Cg_endo -65.63 143.87 61.41 Favored 'Cis proline' 0 N--CA 1.49 1.314 0 C-N-CA 123.121 -1.616 . . . . 0.0 109.984 -0.46 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 230' ' ' GLY . . . . . 0.559 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -76.26 136.9 20.34 Favored Glycine 0 C--N 1.305 -1.157 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 -177.301 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 231' ' ' VAL . . . . . 0.482 HG23 HD12 ' A' ' 270' ' ' LEU . 1.6 p -125.74 133.84 68.1 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 175.82 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 232' ' ' VAL . . . . . 0.618 ' HB ' HG22 ' A' ' 224' ' ' VAL . 0.7 OUTLIER -132.42 156.36 42.33 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.81 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.241 -176.713 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 233' ' ' THR . . . . . 0.477 ' HB ' ' SD ' ' A' ' 223' ' ' MET . 24.4 m -109.65 143.93 38.71 Favored 'General case' 0 N--CA 1.441 -0.914 0 CA-C-N 115.848 -0.614 . . . . 0.0 109.675 176.278 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 34.2 m -107.58 157.55 17.96 Favored 'General case' 0 C--N 1.31 -1.127 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 -179.552 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 33.2 tp -57.19 123.27 14.74 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 -178.062 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 236' ' ' ASP . . . . . 0.405 ' HA ' ' CD1' ' A' ' 273' ' ' TYR . 8.4 p-10 -59.7 -32.71 70.77 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.211 0.529 . . . . 0.0 111.05 -175.717 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -66.89 -32.07 73.09 Favored 'General case' 0 C--N 1.303 -1.42 0 CA-C-N 115.751 -0.658 . . . . 0.0 112.047 177.444 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -109.08 132.99 53.58 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 120.777 0.322 . . . . 0.0 111.647 -176.902 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 90.2 mtm-85 -91.39 133.6 35.33 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 175.989 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 240' ' ' HIS . . . . . 0.623 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 3.0 p80 -66.57 -40.55 89.02 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.749 0.309 . . . . 0.0 111.208 -179.516 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 82.34 20.71 61.83 Favored Glycine 0 C--N 1.316 -0.544 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 -176.976 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 242' ' ' PHE . . . . . 0.502 ' CD2' ' HB2' ' A' ' 240' ' ' HIS . 7.6 m-30 -92.31 146.41 23.72 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.184 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 71.4 mm-40 -109.27 160.07 16.43 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.512 171.471 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 19.9 m -64.6 122.36 16.63 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 175.717 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 95.04 0.14 63.87 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 111.564 -0.614 . . . . 0.0 111.564 -178.668 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 48.6 t0 -76.76 163.93 26.34 Favored 'General case' 0 C--O 1.238 0.489 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 176.947 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 247' ' ' PHE . . . . . 0.459 ' HA ' ' O ' ' A' ' 265' ' ' MET . 83.1 m-85 -110.27 129.82 55.66 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.522 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 248' ' ' VAL . . . . . 0.494 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.3 m -129.98 159.45 41.99 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 C-N-CA 120.357 -0.537 . . . . 0.0 111.519 -178.162 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 40.7 m -122.65 159.6 27.55 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 114.308 -1.315 . . . . 0.0 108.81 172.926 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 250' ' ' PHE . . . . . 0.605 ' CB ' ' HB3' ' A' ' 259' ' ' LEU . 79.1 m-85 -118.79 157.82 26.82 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.271 -174.167 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 4.8 m -151.59 157.48 42.25 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.324 178.078 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER 50.62 27.44 2.94 Favored 'General case' 0 C--N 1.308 -1.196 0 N-CA-C 112.87 0.693 . . . . 0.0 112.87 174.995 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 0.478 HG22 ' CA ' ' A' ' 290' ' ' GLY . 12.6 t -88.81 129.23 40.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 175.237 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 254' ' ' GLN . . . . . 0.477 ' NE2' ' N ' ' A' ' 254' ' ' GLN . 1.5 mp0 -97.27 138.91 34.03 Favored 'General case' 0 C--O 1.242 0.665 0 C-N-CA 120.737 -0.385 . . . . 0.0 110.84 -178.723 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 80.55 -55.66 4.69 Favored Glycine 0 C--O 1.238 0.358 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 -176.3 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 256' ' ' MET . . . . . 0.725 ' SD ' HG11 ' A' ' 224' ' ' VAL . 3.4 ttm -84.55 48.18 1.48 Allowed 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 175.973 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 257' ' ' ILE . . . . . 0.416 ' O ' ' HB2' ' A' ' 260' ' ' ASN . 48.8 pt -69.37 -20.6 24.28 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.758 0 CA-C-N 114.745 -1.116 . . . . 0.0 110.542 -174.544 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 258' ' ' GLN . . . . . 0.472 ' O ' ' SG ' ' A' ' 262' ' ' CYS . 2.5 mp0 -54.14 -35.1 61.87 Favored 'General case' 0 C--N 1.318 -0.801 0 N-CA-C 108.351 -0.981 . . . . 0.0 108.351 177.297 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 259' ' ' LEU . . . . . 0.94 HD21 ' CE2' ' A' ' 283' ' ' PHE . 92.5 mt -62.04 -41.24 97.9 Favored 'General case' 0 N--CA 1.445 -0.683 0 CA-C-N 115.399 -0.819 . . . . 0.0 109.915 176.154 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 260' ' ' ASN . . . . . 0.431 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 97.5 m-20 -60.71 -40.05 90.82 Favored 'General case' 0 CA--C 1.512 -0.49 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 -179.618 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -100.13 11.74 60.35 Favored Glycine 0 CA--C 1.524 0.62 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.872 -178.45 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 262' ' ' CYS . . . . . 0.472 ' SG ' ' O ' ' A' ' 258' ' ' GLN . 1.3 m -88.37 152.71 21.73 Favored 'General case' 0 CA--C 1.51 -0.579 0 CA-C-N 116.988 0.394 . . . . 0.0 110.787 -178.185 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 47.7 mt-30 -72.24 160.84 81.67 Favored Pre-proline 0 C--N 1.32 -0.678 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 173.331 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 264' ' ' PRO . . . . . 0.494 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 20.9 Cg_exo -61.47 143.75 97.56 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 N-CA-C 109.224 -1.106 . . . . 0.0 109.224 178.628 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 265' ' ' MET . . . . . 0.459 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 24.3 ptp -133.32 158.19 43.6 Favored 'General case' 0 C--N 1.317 -0.842 0 C-N-CA 120.98 -0.288 . . . . 0.0 111.695 -174.015 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 66.4 tt0 -71.25 139.18 49.94 Favored 'General case' 0 CA--C 1.507 -0.679 0 O-C-N 123.664 0.603 . . . . 0.0 109.718 176.372 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 267' ' ' ILE . . . . . 0.746 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.9 pp -131.74 160.14 42.6 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.865 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.274 178.979 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 64.7 mttp -130.21 125.84 35.91 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.135 176.41 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 17.9 m -84.73 106.6 14.97 Favored 'Isoleucine or valine' 0 C--O 1.235 0.315 0 CA-C-O 121.18 0.514 . . . . 0.0 111.837 -177.436 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 270' ' ' LEU . . . . . 0.482 HD12 HG23 ' A' ' 231' ' ' VAL . 91.0 mt -66.27 -40.3 90.04 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.458 -0.792 . . . . 0.0 109.45 177.451 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -147.16 -175.46 20.06 Favored Glycine 0 C--N 1.321 -0.299 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 179.069 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 272' ' ' PRO . . . . . 0.623 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 36.4 Cg_endo -61.99 -33.93 82.1 Favored 'Trans proline' 0 C--N 1.307 -1.625 0 C-N-CA 121.778 1.652 . . . . 0.0 111.153 -177.619 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 273' ' ' TYR . . . . . 0.405 ' CD1' ' HA ' ' A' ' 236' ' ' ASP . 93.9 m-85 -119.19 6.51 11.24 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.984 -0.553 . . . . 0.0 112.18 -179.751 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 2.9 p -119.95 126.22 50.33 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 120.712 0.291 . . . . 0.0 110.506 179.323 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 275' ' ' PHE . . . . . 0.566 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -138.0 162.93 32.84 Favored 'General case' 0 CA--C 1.499 -0.992 0 C-N-CA 120.766 -0.374 . . . . 0.0 111.987 -179.744 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 276' ' ' SER . . . . . 0.467 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 4.7 p -132.47 151.2 51.98 Favored 'General case' 0 N--CA 1.433 -1.277 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.921 -173.204 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 277' ' ' ILE . . . . . 0.746 HG22 HG22 ' A' ' 267' ' ' ILE . 2.2 pp -138.19 175.57 8.48 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 CA-C-N 114.824 -1.08 . . . . 0.0 110.505 -175.684 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 278' ' ' CYS . . . . . 0.444 ' N ' HD12 ' A' ' 277' ' ' ILE . 1.4 p -42.58 -88.44 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.435 0 N-CA-C 112.744 0.646 . . . . 0.0 112.744 -179.707 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 279' ' ' ASP . . . . . 0.455 ' O ' ' HB2' ' A' ' 282' ' ' ASN . 18.1 t0 -145.75 121.04 10.23 Favored 'General case' 0 CA--C 1.515 -0.371 0 CA-C-O 120.767 0.317 . . . . 0.0 111.109 -176.277 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 280' ' ' THR . . . . . 0.657 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 35.9 p -68.22 -25.75 65.36 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-O 121.26 0.553 . . . . 0.0 110.534 176.546 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 281' ' ' SER . . . . . 0.605 ' HA ' ' HE3' ' A' ' 226' ' ' LYS . 0.7 OUTLIER -69.76 -12.86 61.96 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.459 -0.791 . . . . 0.0 109.519 176.06 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 282' ' ' ASN . . . . . 0.455 ' HB2' ' O ' ' A' ' 279' ' ' ASP . 2.0 m-80 -88.06 -6.06 58.15 Favored 'General case' 0 CA--C 1.509 -0.627 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 173.604 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 283' ' ' PHE . . . . . 0.94 ' CE2' HD21 ' A' ' 259' ' ' LEU . 6.0 m-85 -100.41 -71.8 0.69 Allowed 'General case' 0 N--CA 1.444 -0.738 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 172.29 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 1.6 p 167.02 -99.04 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.466 0 CA-C-N 115.144 -0.935 . . . . 0.0 110.213 178.81 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 285' ' ' ASP . . . . . 0.519 ' O ' ' N ' ' A' ' 256' ' ' MET . 48.4 t0 -150.74 163.33 38.85 Favored 'General case' 0 C--O 1.214 -0.815 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 177.416 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 286' ' ' TYR . . . . . 0.434 ' CE2' ' HA ' ' A' ' 288' ' ' ARG . 71.6 t80 -100.54 124.1 45.65 Favored 'General case' 0 C--N 1.318 -0.774 0 C-N-CA 121.1 -0.24 . . . . 0.0 110.841 -179.777 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 287' ' ' ILE . . . . . 0.435 ' O ' ' CG ' ' A' ' 288' ' ' ARG . 96.6 mt -100.06 -61.5 2.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 C-N-CA 120.77 -0.372 . . . . 0.0 110.455 173.696 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 288' ' ' ARG . . . . . 0.435 ' CG ' ' O ' ' A' ' 287' ' ' ILE . 54.6 mtp180 -166.67 176.79 6.96 Favored 'General case' 0 C--O 1.241 0.617 0 CA-C-O 121.135 0.493 . . . . 0.0 111.787 179.064 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 67.95 -156.27 52.8 Favored Glycine 0 CA--C 1.508 -0.399 0 CA-C-N 115.284 -0.871 . . . . 0.0 111.104 174.893 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 290' ' ' GLY . . . . . 0.478 ' CA ' HG22 ' A' ' 253' ' ' VAL . . . 109.91 123.81 4.68 Favored Glycine 0 N--CA 1.443 -0.893 0 N-CA-C 112.281 -0.327 . . . . 0.0 112.281 176.255 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 99.2 mt -127.52 133.72 67.19 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.09 0 N-CA-C 107.496 -1.298 . . . . 0.0 107.496 173.676 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 292' ' ' VAL . . . . . 0.414 HG22 ' CZ ' ' A' ' 242' ' ' PHE . 4.0 p -124.76 136.06 61.93 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.893 0 C-N-CA 120.466 -0.494 . . . . 0.0 109.824 -177.529 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 4.4 m -127.42 146.75 50.37 Favored 'General case' 0 C--O 1.237 0.441 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.768 -178.414 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 294' ' ' GLN . . . . . 0.882 HE21 ' N ' ' A' ' 217' ' ' LEU . 0.7 OUTLIER . . . . . 0 CA--C 1.51 -0.588 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 173.449 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 217' ' ' LEU . . . . . 0.455 ' HB3' ' O ' ' A' ' 240' ' ' HIS . 0.1 OUTLIER . . . . . 0 N--CA 1.444 -0.76 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 . . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 218' ' ' SER . . . . . 0.405 ' HA ' ' HA ' ' A' ' 293' ' ' SER . 5.1 m -130.89 151.87 50.84 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.867 -174.719 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -144.84 160.59 41.04 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.051 0.453 . . . . 0.0 110.803 179.05 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 220' ' ' MET . . . . . 0.662 ' SD ' HD22 ' A' ' 235' ' ' LEU . 92.7 mtp -75.57 130.74 39.31 Favored 'General case' 0 N--CA 1.443 -0.814 0 CA-C-N 115.366 -0.834 . . . . 0.0 108.916 176.474 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 99.7 t -78.92 128.69 38.35 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.92 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 176.413 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 26.9 m -85.26 -72.73 0.47 Allowed 'General case' 0 C--N 1.307 -1.245 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 178.988 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 223' ' ' MET . . . . . 0.535 ' C ' ' SD ' ' A' ' 223' ' ' MET . 2.7 ppp? -138.2 151.26 47.52 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 112.235 0.457 . . . . 0.0 112.235 174.168 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 224' ' ' VAL . . . . . 0.578 HG13 HG12 ' A' ' 232' ' ' VAL . 62.2 t -121.11 126.65 75.38 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 176.098 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 225' ' ' THR . . . . . 0.497 ' O ' ' OG1' ' A' ' 280' ' ' THR . 37.5 p -77.53 133.72 38.46 Favored 'General case' 0 C--N 1.327 -0.386 0 C-N-CA 120.259 -0.576 . . . . 0.0 110.407 178.49 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 20.6 tptm -78.32 77.23 4.81 Favored 'General case' 0 C--N 1.316 -0.87 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 179.813 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 227' ' ' ASP . . . . . 0.418 ' H ' ' HG1' ' A' ' 280' ' ' THR . 1.5 t0 -161.31 178.09 9.53 Favored 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 112.615 0.598 . . . . 0.0 112.615 -176.208 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 228' ' ' ASN . . . . . 0.502 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 2.0 t-20 -140.29 124.46 10.75 Favored Pre-proline 0 CA--C 1.533 0.324 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.786 175.086 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 229' ' ' PRO . . . . . 0.502 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 46.8 Cg_endo -65.61 143.57 60.0 Favored 'Cis proline' 0 N--CA 1.492 1.402 0 C-N-CA 122.759 -1.767 . . . . 0.0 109.717 -1.244 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 230' ' ' GLY . . . . . 0.517 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -81.9 140.02 20.48 Favored Glycine 0 CA--C 1.501 -0.795 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 -178.496 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 231' ' ' VAL . . . . . 0.446 ' CG2' HD12 ' A' ' 270' ' ' LEU . 2.4 p -122.79 133.85 67.71 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 176.922 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 232' ' ' VAL . . . . . 0.578 HG12 HG13 ' A' ' 224' ' ' VAL . 0.6 OUTLIER -131.39 155.41 41.79 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 C-N-CA 120.605 -0.438 . . . . 0.0 110.829 -176.182 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 26.1 m -110.17 142.67 41.37 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-N 115.425 -0.807 . . . . 0.0 109.629 177.474 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 48.7 m -107.92 158.22 17.54 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-N 115.804 -0.634 . . . . 0.0 109.484 178.39 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.662 HD22 ' SD ' ' A' ' 220' ' ' MET . 33.9 tp -64.5 117.21 7.0 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 178.459 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 236' ' ' ASP . . . . . 0.539 ' HA ' ' CE1' ' A' ' 273' ' ' TYR . 37.4 p-10 -59.71 -28.56 67.43 Favored 'General case' 0 C--O 1.239 0.515 0 CA-C-O 120.885 0.374 . . . . 0.0 111.872 -173.144 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 72.4 mm-40 -66.22 -33.18 75.18 Favored 'General case' 0 C--N 1.311 -1.068 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.316 178.78 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -99.51 122.96 43.32 Favored 'General case' 0 CA--C 1.516 -0.337 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.408 179.795 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 90.2 mtm180 -75.57 138.73 41.67 Favored 'General case' 0 C--N 1.316 -0.861 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 174.915 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 240' ' ' HIS . . . . . 0.474 ' HB2' ' CD2' ' A' ' 242' ' ' PHE . 6.4 p80 -88.82 -37.73 15.17 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 121.026 0.441 . . . . 0.0 109.924 177.26 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 81.24 10.73 84.36 Favored Glycine 0 CA--C 1.505 -0.592 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 179.405 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 242' ' ' PHE . . . . . 0.493 ' CD1' ' N ' ' A' ' 242' ' ' PHE . 3.7 m-30 -81.22 147.14 30.11 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.305 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -131.17 167.42 19.18 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 109.095 -0.705 . . . . 0.0 109.095 172.359 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 2.9 m -59.48 129.38 41.7 Favored 'General case' 0 C--N 1.294 -1.835 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.556 -176.561 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 83.8 1.8 89.85 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 111.807 -0.517 . . . . 0.0 111.807 -179.165 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 44.4 t0 -77.69 159.62 29.01 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 117.315 0.557 . . . . 0.0 110.255 178.476 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 247' ' ' PHE . . . . . 0.429 ' HA ' ' O ' ' A' ' 265' ' ' MET . 66.0 m-85 -110.48 133.79 52.95 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 116.592 -0.276 . . . . 0.0 110.394 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 248' ' ' VAL . . . . . 0.426 ' O ' ' SD ' ' A' ' 265' ' ' MET . 3.1 m -129.98 162.22 38.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.54 -179.093 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 5.0 m -126.19 151.79 46.89 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.332 -0.849 . . . . 0.0 109.016 175.782 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 250' ' ' PHE . . . . . 0.563 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 74.4 m-85 -109.6 155.9 20.85 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.409 0.623 . . . . 0.0 111.693 -176.25 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 44.8 m -152.4 151.82 31.28 Favored 'General case' 0 C--N 1.308 -1.211 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.579 175.851 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 30.7 mm-40 51.89 28.47 5.13 Favored 'General case' 0 C--N 1.317 -0.808 0 N-CA-C 113.018 0.747 . . . . 0.0 113.018 176.427 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 0.541 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 60.8 t -82.36 129.67 37.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 174.216 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 81.9 mt-30 -101.59 138.15 38.96 Favored 'General case' 0 C--O 1.243 0.745 0 C-N-CA 120.272 -0.571 . . . . 0.0 111.296 -175.275 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 81.73 -57.53 4.92 Favored Glycine 0 C--O 1.239 0.417 0 N-CA-C 109.969 -1.252 . . . . 0.0 109.969 -176.47 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 256' ' ' MET . . . . . 0.505 ' SD ' HD11 ' A' ' 259' ' ' LEU . 57.0 ttm -85.78 65.04 8.94 Favored 'General case' 0 CA--C 1.516 -0.364 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 175.383 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 257' ' ' ILE . . . . . 0.436 ' O ' ' HB2' ' A' ' 260' ' ' ASN . 49.1 pt -73.92 -19.55 17.58 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-N 114.659 -1.155 . . . . 0.0 111.875 -172.848 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 15.4 tt0 -58.16 -36.39 72.94 Favored 'General case' 0 C--N 1.321 -0.647 0 C-N-CA 119.547 -0.861 . . . . 0.0 110.055 -177.636 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 259' ' ' LEU . . . . . 0.875 HD21 ' CE2' ' A' ' 283' ' ' PHE . 90.4 mt -61.44 -40.39 94.27 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 177.814 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 260' ' ' ASN . . . . . 0.541 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 98.3 m-20 -60.24 -40.1 89.06 Favored 'General case' 0 CA--C 1.508 -0.635 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 178.376 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -102.27 22.72 36.8 Favored Glycine 0 C--N 1.315 -0.615 0 CA-C-N 115.468 -0.787 . . . . 0.0 111.919 -178.259 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 262' ' ' CYS . . . . . 0.4 ' HB3' ' HA ' ' A' ' 259' ' ' LEU . 11.1 t -111.14 146.48 36.78 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 117.308 0.554 . . . . 0.0 111.734 -176.994 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 -59.31 158.99 17.35 Favored Pre-proline 0 C--N 1.327 -0.376 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 174.005 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 264' ' ' PRO . . . . . 0.421 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 37.6 Cg_endo -62.64 148.16 93.75 Favored 'Trans proline' 0 N--CA 1.493 1.491 0 C-N-CA 121.578 1.519 . . . . 0.0 111.395 179.159 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 265' ' ' MET . . . . . 0.623 ' N ' ' SD ' ' A' ' 265' ' ' MET . 0.3 OUTLIER -124.7 150.49 46.09 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.731 -174.412 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 266' ' ' GLU . . . . . 0.522 ' OE2' ' NZ ' ' A' ' 268' ' ' LYS . 0.7 OUTLIER -71.53 140.14 49.77 Favored 'General case' 0 C--O 1.24 0.596 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 172.958 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 267' ' ' ILE . . . . . 0.687 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.5 pp -130.63 159.92 42.25 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-O 121.245 0.545 . . . . 0.0 111.958 -177.065 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 268' ' ' LYS . . . . . 0.522 ' NZ ' ' OE2' ' A' ' 266' ' ' GLU . 35.4 mttp -128.79 120.51 26.48 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.617 178.182 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.421 HG23 ' O ' ' A' ' 269' ' ' VAL . 26.8 m -82.58 100.14 6.07 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.256 0 CA-C-O 121.018 0.437 . . . . 0.0 111.85 -176.657 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 270' ' ' LEU . . . . . 0.446 HD12 ' CG2' ' A' ' 231' ' ' VAL . 97.4 mt -65.81 -41.07 92.32 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.341 0.591 . . . . 0.0 109.636 177.264 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -139.41 179.49 18.67 Favored Glycine 0 C--N 1.317 -0.525 0 N-CA-C 109.253 -1.539 . . . . 0.0 109.253 178.166 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -61.99 -30.23 82.9 Favored 'Trans proline' 0 C--N 1.306 -1.694 0 C-N-CA 121.899 1.733 . . . . 0.0 111.067 -178.27 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 273' ' ' TYR . . . . . 0.539 ' CE1' ' HA ' ' A' ' 236' ' ' ASP . 72.9 m-85 -122.56 6.8 9.49 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 112.782 0.66 . . . . 0.0 112.782 179.027 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 7.0 p -119.41 126.89 52.43 Favored 'General case' 0 C--O 1.243 0.717 0 CA-C-O 120.67 0.272 . . . . 0.0 110.461 177.658 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 275' ' ' PHE . . . . . 0.533 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -133.0 163.2 29.76 Favored 'General case' 0 CA--C 1.493 -1.243 0 C-N-CA 120.446 -0.501 . . . . 0.0 112.296 179.893 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 276' ' ' SER . . . . . 0.517 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 5.0 p -130.65 143.27 50.63 Favored 'General case' 0 N--CA 1.43 -1.432 0 C-N-CA 120.611 -0.436 . . . . 0.0 111.526 -174.781 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 277' ' ' ILE . . . . . 0.628 HG22 HG22 ' A' ' 267' ' ' ILE . 32.6 pt -141.31 165.79 18.6 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.765 0 CA-C-N 114.614 -1.176 . . . . 0.0 111.488 -172.784 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 278' ' ' CYS . . . . . 0.406 ' O ' ' HA ' ' A' ' 229' ' ' PRO . 0.9 OUTLIER -27.5 -90.99 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.687 0 N-CA-C 113.757 1.021 . . . . 0.0 113.757 -176.379 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 279' ' ' ASP . . . . . 0.424 ' HB3' ' HB2' ' A' ' 282' ' ' ASN . 50.7 t0 -148.81 113.56 5.39 Favored 'General case' 0 CA--C 1.504 -0.825 0 CA-C-N 116.615 -0.266 . . . . 0.0 110.293 -175.911 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 280' ' ' THR . . . . . 0.705 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 26.7 p -73.65 -23.52 59.87 Favored 'General case' 0 N--CA 1.426 -1.627 0 CA-C-O 121.086 0.47 . . . . 0.0 110.04 177.411 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -67.75 -20.75 65.27 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.06 -0.973 . . . . 0.0 108.783 173.243 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 282' ' ' ASN . . . . . 0.424 ' HB2' ' HB3' ' A' ' 279' ' ' ASP . 18.8 t30 -89.63 -9.08 51.0 Favored 'General case' 0 CA--C 1.51 -0.588 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.455 -179.547 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 283' ' ' PHE . . . . . 0.875 ' CE2' HD21 ' A' ' 259' ' ' LEU . 21.3 m-85 -92.14 -71.76 0.63 Allowed 'General case' 0 CA--C 1.505 -0.757 0 CA-C-O 121.66 0.743 . . . . 0.0 109.643 179.002 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER 168.95 -175.78 0.03 OUTLIER 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 114.133 -1.394 . . . . 0.0 107.967 -173.908 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 7.9 t70 -92.41 121.43 33.88 Favored 'General case' 0 C--N 1.322 -0.617 0 C-N-CA 120.246 -0.582 . . . . 0.0 111.925 -178.861 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 12.1 t80 -69.58 126.73 30.63 Favored 'General case' 0 C--O 1.237 0.423 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 177.299 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 96.4 mt -106.08 -58.26 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 CA-C-O 121.021 0.438 . . . . 0.0 110.13 174.834 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 22.3 ptt180 -166.91 -179.31 4.64 Favored 'General case' 0 C--O 1.24 0.554 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.934 -176.285 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 65.64 -156.29 49.13 Favored Glycine 0 C--N 1.331 0.305 0 N-CA-C 110.6 -1.0 . . . . 0.0 110.6 178.051 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 290' ' ' GLY . . . . . 0.403 ' CA ' HG22 ' A' ' 253' ' ' VAL . . . 105.42 122.81 5.1 Favored Glycine 0 CA--C 1.52 0.373 0 CA-C-O 121.266 0.37 . . . . 0.0 112.813 176.413 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 95.6 mt -123.0 130.76 74.25 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 N-CA-C 107.587 -1.264 . . . . 0.0 107.587 175.262 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 292' ' ' VAL . . . . . 0.474 HG22 ' CZ ' ' A' ' 242' ' ' PHE . 4.0 p -126.35 137.98 56.08 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 -177.455 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 293' ' ' SER . . . . . 0.405 ' HA ' ' HA ' ' A' ' 218' ' ' SER . 12.5 m -129.64 147.27 51.42 Favored 'General case' 0 CA--C 1.509 -0.598 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.498 -178.425 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 294' ' ' GLN . . . . . 0.459 ' HB3' ' CD1' ' A' ' 242' ' ' PHE . 0.7 OUTLIER . . . . . 0 CA--C 1.507 -0.678 0 C-N-CA 120.183 -0.607 . . . . 0.0 110.535 175.41 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 217' ' ' LEU . . . . . 0.458 ' CB ' ' HG2' ' A' ' 294' ' ' GLN . 0.3 OUTLIER . . . . . 0 CA--C 1.505 -0.781 0 CA-C-O 121.089 0.471 . . . . 0.0 111.218 . . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 218' ' ' SER . . . . . 0.43 ' HA ' ' O ' ' A' ' 292' ' ' VAL . 15.6 m -127.96 150.67 49.8 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 -179.041 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -138.05 152.57 48.95 Favored 'General case' 0 C--N 1.311 -1.095 0 CA-C-O 120.848 0.356 . . . . 0.0 111.112 -177.468 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 220' ' ' MET . . . . . 0.567 ' SD ' HG12 ' A' ' 291' ' ' ILE . 3.5 tpp -76.11 126.82 31.71 Favored 'General case' 0 N--CA 1.443 -0.821 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 174.647 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 72.5 t -77.14 129.48 37.33 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.122 0 N-CA-C 109.646 -0.502 . . . . 0.0 109.646 -178.419 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 3.0 m -83.43 -73.07 0.43 Allowed 'General case' 0 N--CA 1.437 -1.108 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 176.374 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 223' ' ' MET . . . . . 0.449 ' C ' ' SD ' ' A' ' 223' ' ' MET . 3.6 ppp? -138.38 152.79 48.73 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.42 -0.354 . . . . 0.0 111.658 174.566 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 224' ' ' VAL . . . . . 0.647 HG13 HG12 ' A' ' 232' ' ' VAL . 61.6 t -119.84 126.55 75.42 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.991 0 N-CA-C 108.323 -0.991 . . . . 0.0 108.323 175.08 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 225' ' ' THR . . . . . 0.489 ' O ' ' OG1' ' A' ' 280' ' ' THR . 71.0 p -84.82 126.77 33.73 Favored 'General case' 0 C--N 1.322 -0.594 0 C-N-CA 119.726 -0.79 . . . . 0.0 109.648 176.974 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 86.5 tttt -77.86 89.85 4.08 Favored 'General case' 0 C--N 1.316 -0.874 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 -178.435 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 227' ' ' ASP . . . . . . . . . . . . . 43.5 t0 -163.86 173.68 12.43 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.429 -177.363 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 228' ' ' ASN . . . . . 0.419 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 1.7 t-20 -133.14 123.54 17.94 Favored Pre-proline 0 C--N 1.323 -0.559 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.855 172.926 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 229' ' ' PRO . . . . . 0.419 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 55.3 Cg_endo -66.78 144.25 68.2 Favored 'Cis proline' 0 C--N 1.311 -1.4 0 C-N-CA 122.845 -1.731 . . . . 0.0 109.774 -2.266 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 230' ' ' GLY . . . . . 0.479 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -84.03 139.06 18.1 Favored Glycine 0 CA--C 1.502 -0.766 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 -178.985 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 231' ' ' VAL . . . . . 0.496 ' CG2' HD12 ' A' ' 270' ' ' LEU . 2.4 p -124.78 137.57 57.01 Favored 'Isoleucine or valine' 0 C--O 1.243 0.745 0 N-CA-C 109.967 -0.382 . . . . 0.0 109.967 177.162 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 232' ' ' VAL . . . . . 0.647 HG12 HG13 ' A' ' 224' ' ' VAL . 0.6 OUTLIER -132.61 155.34 41.23 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.892 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.801 -178.493 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 21.7 m -109.06 144.19 37.4 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.811 178.861 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 2.1 m -107.6 150.44 26.87 Favored 'General case' 0 C--N 1.316 -0.882 0 C-N-CA 123.023 0.529 . . . . 0.0 109.718 -179.662 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 37.4 tp -65.27 134.51 53.79 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.431 -176.638 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 236' ' ' ASP . . . . . 0.428 ' O ' ' NH1' ' A' ' 239' ' ' ARG . 13.0 t70 -49.1 -44.51 42.29 Favored 'General case' 0 N--CA 1.474 0.748 0 N-CA-C 114.0 1.111 . . . . 0.0 114.0 -171.779 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 237' ' ' GLU . . . . . 0.518 ' O ' ' NH1' ' A' ' 239' ' ' ARG . 54.6 mp0 -63.83 -33.5 75.82 Favored 'General case' 0 C--N 1.316 -0.851 0 C-N-CA 119.044 -1.062 . . . . 0.0 109.615 -177.534 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -77.36 95.2 4.35 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 112.869 0.692 . . . . 0.0 112.869 -177.952 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 239' ' ' ARG . . . . . 0.518 ' NH1' ' O ' ' A' ' 237' ' ' GLU . 0.0 OUTLIER -73.39 92.28 1.83 Allowed 'General case' 0 C--O 1.237 0.395 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 169.755 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 240' ' ' HIS . . . . . 0.604 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 9.4 p80 -53.0 -47.02 68.58 Favored 'General case' 0 C--O 1.213 -0.853 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.297 -174.382 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 76.8 20.75 75.83 Favored Glycine 0 C--N 1.311 -0.811 0 N-CA-C 110.416 -1.074 . . . . 0.0 110.416 177.752 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 242' ' ' PHE . . . . . 0.578 ' CE1' ' HB3' ' A' ' 294' ' ' GLN . 5.2 m-30 -80.17 143.63 33.68 Favored 'General case' 0 C--N 1.318 -0.778 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 179.405 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -119.41 166.26 13.29 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-O 121.153 0.502 . . . . 0.0 110.663 175.604 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 9.1 m -59.44 127.56 32.66 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 115.774 -0.648 . . . . 0.0 109.55 -179.032 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 84.54 6.7 85.48 Favored Glycine 0 N--CA 1.438 -1.175 0 N-CA-C 111.698 -0.561 . . . . 0.0 111.698 -179.815 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 3.6 t0 -84.36 165.42 18.25 Favored 'General case' 0 CA--C 1.512 -0.483 0 C-N-CA 119.377 -0.929 . . . . 0.0 109.494 176.814 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 247' ' ' PHE . . . . . 0.552 ' CZ ' ' HB2' ' A' ' 266' ' ' GLU . 47.3 m-85 -112.61 138.11 49.87 Favored 'General case' 0 C--N 1.315 -0.906 0 N-CA-C 111.935 0.346 . . . . 0.0 111.935 -175.476 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 248' ' ' VAL . . . . . 0.514 ' HA ' ' HA ' ' A' ' 294' ' ' GLN . 2.7 m -133.01 160.38 42.67 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.363 0 C-N-CA 120.297 -0.561 . . . . 0.0 112.189 177.213 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 2.2 m -125.13 153.89 42.3 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 114.483 -1.235 . . . . 0.0 107.694 174.329 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 250' ' ' PHE . . . . . 0.623 ' CB ' ' HB3' ' A' ' 259' ' ' LEU . 64.5 m-85 -112.83 144.64 42.03 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-O 120.865 0.364 . . . . 0.0 111.126 -179.373 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 4.0 m -140.92 161.16 38.48 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 115.503 -0.772 . . . . 0.0 109.426 176.398 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 51.3 mm-40 52.96 27.49 5.63 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 112.278 0.473 . . . . 0.0 112.278 173.507 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 0.445 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 83.4 t -88.68 133.6 30.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 177.771 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 90.9 mm-40 -100.37 145.75 27.8 Favored 'General case' 0 C--O 1.237 0.436 0 CA-C-O 120.852 0.358 . . . . 0.0 110.104 176.692 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 78.36 -68.85 2.86 Favored Glycine 0 C--N 1.315 -0.612 0 N-CA-C 110.417 -1.073 . . . . 0.0 110.417 -179.505 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 256' ' ' MET . . . . . 0.482 ' SD ' ' HD2' ' A' ' 283' ' ' PHE . 29.9 ttm -79.55 68.11 5.5 Favored 'General case' 0 C--N 1.321 -0.638 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 178.087 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 44.9 pt -75.23 -19.21 16.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.857 -175.344 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 258' ' ' GLN . . . . . 0.447 ' O ' ' N ' ' A' ' 262' ' ' CYS . 0.2 OUTLIER -53.18 -39.66 63.81 Favored 'General case' 0 C--O 1.213 -0.849 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 177.576 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 259' ' ' LEU . . . . . 0.978 HD21 ' CE2' ' A' ' 283' ' ' PHE . 94.6 mt -61.6 -41.96 98.19 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.137 179.075 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 260' ' ' ASN . . . . . 0.445 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 91.5 m-20 -59.73 -41.25 90.5 Favored 'General case' 0 CA--C 1.51 -0.567 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 179.524 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -101.14 9.48 57.89 Favored Glycine 0 CA--C 1.523 0.537 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.942 -177.884 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 262' ' ' CYS . . . . . 0.447 ' N ' ' O ' ' A' ' 258' ' ' GLN . 15.6 t -87.99 144.24 26.65 Favored 'General case' 0 C--O 1.241 0.632 0 CA-C-N 117.174 0.487 . . . . 0.0 111.415 -176.122 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -61.21 156.06 52.51 Favored Pre-proline 0 C--N 1.319 -0.721 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 173.6 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 264' ' ' PRO . . . . . 0.413 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 39.3 Cg_endo -64.77 143.32 79.95 Favored 'Trans proline' 0 C--N 1.307 -1.618 0 C-N-CA 120.757 0.971 . . . . 0.0 109.842 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 265' ' ' MET . . . . . 0.469 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 19.5 ptp -126.1 153.61 44.26 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 112.07 0.396 . . . . 0.0 112.07 -174.45 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 266' ' ' GLU . . . . . 0.552 ' HB2' ' CZ ' ' A' ' 247' ' ' PHE . 75.8 tt0 -79.82 137.34 36.93 Favored 'General case' 0 C--O 1.238 0.478 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 179.789 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 267' ' ' ILE . . . . . 0.641 HG22 HG22 ' A' ' 277' ' ' ILE . 1.9 pp -128.33 163.02 33.63 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 N-CA-C 113.752 1.019 . . . . 0.0 113.752 -169.674 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 52.9 tttp -124.95 121.3 34.06 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.148 -0.933 . . . . 0.0 109.995 175.155 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.429 HG11 ' O ' ' A' ' 242' ' ' PHE . 29.5 m -75.64 132.19 33.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 C-N-CA 121.096 -0.242 . . . . 0.0 110.723 178.432 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 270' ' ' LEU . . . . . 0.613 HD11 ' HB3' ' A' ' 276' ' ' SER . 84.5 mt -106.38 -13.82 15.26 Favored 'General case' 0 CA--C 1.515 -0.393 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.737 -179.335 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -170.6 -177.93 40.98 Favored Glycine 0 C--N 1.318 -0.436 0 N-CA-C 110.364 -1.094 . . . . 0.0 110.364 -177.801 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 272' ' ' PRO . . . . . 0.604 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 36.2 Cg_endo -61.52 -31.4 87.51 Favored 'Trans proline' 0 C--N 1.308 -1.588 0 C-N-CA 122.097 1.865 . . . . 0.0 111.118 -178.302 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 273' ' ' TYR . . . . . 0.413 ' CE1' ' HA ' ' A' ' 236' ' ' ASP . 88.7 m-85 -124.49 7.43 8.31 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.877 -0.602 . . . . 0.0 112.407 -179.569 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 11.0 p -123.07 141.14 52.29 Favored 'General case' 0 C--O 1.244 0.784 0 C-N-CA 120.146 -0.622 . . . . 0.0 111.957 -177.893 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 275' ' ' PHE . . . . . 0.564 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -143.34 165.95 26.09 Favored 'General case' 0 CA--C 1.508 -0.654 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.17 178.113 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 276' ' ' SER . . . . . 0.613 ' HB3' HD11 ' A' ' 270' ' ' LEU . 4.6 p -133.08 146.02 51.28 Favored 'General case' 0 N--CA 1.439 -1.01 0 N-CA-C 112.502 0.556 . . . . 0.0 112.502 -175.918 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 277' ' ' ILE . . . . . 0.641 HG22 HG22 ' A' ' 267' ' ' ILE . 29.1 pt -141.46 167.99 16.0 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.896 0 CA-C-N 114.224 -1.353 . . . . 0.0 111.332 -172.102 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 1.6 p -28.75 -95.19 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.759 0 N-CA-C 113.354 0.872 . . . . 0.0 113.354 -177.436 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -143.8 108.7 4.94 Favored 'General case' 0 CA--C 1.501 -0.912 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -178.626 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 280' ' ' THR . . . . . 0.773 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 17.8 p -64.58 -30.63 71.66 Favored 'General case' 0 C--N 1.29 -2.016 0 CA-C-O 121.492 0.663 . . . . 0.0 110.459 177.55 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -61.26 -31.37 71.18 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-N 114.836 -1.075 . . . . 0.0 110.297 175.953 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -87.07 -9.44 55.42 Favored 'General case' 0 CA--C 1.507 -0.686 0 C-N-CA 119.362 -0.935 . . . . 0.0 110.24 -176.609 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 283' ' ' PHE . . . . . 0.978 ' CE2' HD21 ' A' ' 259' ' ' LEU . 19.1 m-85 -77.11 -71.61 0.4 Allowed 'General case' 0 N--CA 1.437 -1.106 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 169.455 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 284' ' ' SER . . . . . 0.406 ' CB ' ' HA ' ' A' ' 256' ' ' MET . 0.0 OUTLIER 175.92 -169.5 0.05 Allowed 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 113.975 -1.466 . . . . 0.0 109.129 -175.574 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -97.47 120.66 38.24 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-O 120.377 0.132 . . . . 0.0 110.772 -177.432 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 286' ' ' TYR . . . . . 0.46 ' CZ ' ' HA ' ' A' ' 288' ' ' ARG . 64.6 t80 -63.87 126.41 27.53 Favored 'General case' 0 N--CA 1.478 0.94 0 C-N-CA 122.754 0.422 . . . . 0.0 111.254 -177.543 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 4.1 mm -100.92 -65.39 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.666 173.399 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 288' ' ' ARG . . . . . 0.46 ' HA ' ' CZ ' ' A' ' 286' ' ' TYR . 0.1 OUTLIER -173.25 -178.8 1.8 Allowed 'General case' 0 C--O 1.243 0.751 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.305 178.58 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 68.33 -156.75 52.99 Favored Glycine 0 CA--C 1.504 -0.625 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 175.432 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 290' ' ' GLY . . . . . 0.42 ' HA3' HG22 ' A' ' 253' ' ' VAL . . . 106.72 129.68 6.31 Favored Glycine 0 N--CA 1.437 -1.251 0 C-N-CA 120.884 -0.674 . . . . 0.0 112.014 177.498 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 291' ' ' ILE . . . . . 0.567 HG12 ' SD ' ' A' ' 220' ' ' MET . 96.5 mt -122.43 130.58 74.41 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.31 0 N-CA-C 107.215 -1.402 . . . . 0.0 107.215 173.172 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 292' ' ' VAL . . . . . 0.43 ' O ' ' HA ' ' A' ' 218' ' ' SER . 2.6 p -112.12 126.9 69.56 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.828 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 -178.182 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 3.3 m -115.93 121.22 41.67 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 110.041 -0.355 . . . . 0.0 110.041 -176.915 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 294' ' ' GLN . . . . . 0.578 ' HB3' ' CE1' ' A' ' 242' ' ' PHE . 0.7 OUTLIER . . . . . 0 N--CA 1.435 -1.197 0 C-N-CA 120.149 -0.621 . . . . 0.0 110.576 178.362 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 217' ' ' LEU . . . . . 0.494 HD12 ' O ' ' A' ' 239' ' ' ARG . 0.5 OUTLIER . . . . . 0 CA--C 1.513 -0.478 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 . . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 34.5 m -119.19 132.57 55.97 Favored 'General case' 0 C--N 1.324 -0.532 0 O-C-N 123.661 0.601 . . . . 0.0 110.616 -179.652 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 219' ' ' ALA . . . . . 0.421 ' HB2' ' HA ' ' A' ' 240' ' ' HIS . . . -122.53 139.55 53.77 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.821 0.343 . . . . 0.0 110.259 -179.436 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 1.3 tpt -76.6 122.37 24.53 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 177.813 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 73.5 t -74.19 132.65 33.05 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 -177.642 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 222' ' ' SER . . . . . 0.408 ' HG ' HG22 ' A' ' 233' ' ' THR . 5.8 p -90.68 -54.64 3.9 Favored 'General case' 0 N--CA 1.434 -1.252 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 177.829 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -138.53 151.87 47.73 Favored 'General case' 0 C--O 1.222 -0.389 0 N-CA-C 112.649 0.611 . . . . 0.0 112.649 174.856 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 224' ' ' VAL . . . . . 0.726 HG11 ' SD ' ' A' ' 256' ' ' MET . 39.5 t -126.64 132.33 70.3 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 172.143 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -104.1 122.98 46.42 Favored 'General case' 0 C--N 1.313 -1.002 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 -177.817 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 226' ' ' LYS . . . . . 0.464 ' NZ ' ' OD1' ' A' ' 285' ' ' ASP . 0.0 OUTLIER -76.3 77.72 3.07 Favored 'General case' 0 C--O 1.234 0.265 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 179.379 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 227' ' ' ASP . . . . . 0.59 ' N ' ' OG1' ' A' ' 280' ' ' THR . 2.8 t0 -148.42 178.34 8.68 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.762 179.459 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 228' ' ' ASN . . . . . 0.489 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.1 OUTLIER -138.47 125.25 13.06 Favored Pre-proline 0 C--N 1.324 -0.507 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.21 176.43 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 229' ' ' PRO . . . . . 0.489 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 38.2 Cg_endo -65.0 144.76 62.38 Favored 'Cis proline' 0 N--CA 1.499 1.814 0 C-N-CA 123.286 -1.548 . . . . 0.0 110.564 -1.063 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 230' ' ' GLY . . . . . 0.548 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -68.66 136.96 29.95 Favored Glycine 0 N--CA 1.445 -0.732 0 N-CA-C 110.05 -1.22 . . . . 0.0 110.05 -177.915 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 231' ' ' VAL . . . . . 0.409 HG23 HD12 ' A' ' 270' ' ' LEU . 2.1 p -127.05 133.93 67.23 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 177.772 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 232' ' ' VAL . . . . . 0.436 HG22 ' CD1' ' A' ' 275' ' ' PHE . 0.6 OUTLIER -134.76 156.7 40.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 C-N-CA 120.084 -0.646 . . . . 0.0 111.451 -179.695 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 233' ' ' THR . . . . . 0.408 HG22 ' HG ' ' A' ' 222' ' ' SER . 6.7 m -111.37 140.68 45.75 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 115.148 -0.933 . . . . 0.0 109.044 178.755 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 44.5 m -107.92 155.97 19.71 Favored 'General case' 0 C--N 1.315 -0.903 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 176.621 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 40.3 tp -57.74 133.71 55.6 Favored 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 177.401 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -53.8 -46.57 71.1 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.145 0.498 . . . . 0.0 110.557 -170.599 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 59.1 mp0 -68.04 -20.33 64.98 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.93 -0.577 . . . . 0.0 112.375 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -73.93 94.84 2.38 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.629 -177.253 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 239' ' ' ARG . . . . . 0.494 ' O ' HD12 ' A' ' 217' ' ' LEU . 77.3 mtp85 -71.44 99.31 1.98 Allowed 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 176.149 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 240' ' ' HIS . . . . . 0.661 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 12.8 p80 -68.2 -42.97 79.1 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 120.791 0.329 . . . . 0.0 111.748 -176.182 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 80.32 14.42 80.31 Favored Glycine 0 C--N 1.315 -0.586 0 N-CA-C 110.791 -0.924 . . . . 0.0 110.791 -178.514 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 242' ' ' PHE . . . . . 0.513 ' CD1' ' HB3' ' A' ' 294' ' ' GLN . 5.2 m-30 -81.0 142.97 32.87 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -179.613 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 243' ' ' GLU . . . . . 0.402 ' H ' ' CB ' ' A' ' 246' ' ' ASP . 95.0 mt-10 -112.19 167.88 10.06 Favored 'General case' 0 CA--C 1.505 -0.76 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 172.882 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 244' ' ' THR . . . . . 0.523 HG23 ' HG3' ' A' ' 268' ' ' LYS . 21.1 m -62.58 126.24 26.65 Favored 'General case' 0 N--CA 1.436 -1.165 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 169.919 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 245' ' ' GLY . . . . . 0.5 ' HA2' ' CG ' ' A' ' 266' ' ' GLU . . . 82.04 7.21 88.14 Favored Glycine 0 C--N 1.309 -0.941 0 C-N-CA 120.902 -0.666 . . . . 0.0 111.717 -179.029 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 246' ' ' ASP . . . . . 0.41 ' O ' ' HA ' ' A' ' 266' ' ' GLU . 42.1 t0 -84.87 161.7 19.78 Favored 'General case' 0 C--O 1.235 0.305 0 C-N-CA 120.049 -0.66 . . . . 0.0 109.952 177.798 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 247' ' ' PHE . . . . . 0.472 ' HA ' ' O ' ' A' ' 265' ' ' MET . 30.1 m-85 -109.94 131.7 54.82 Favored 'General case' 0 C--O 1.242 0.702 0 N-CA-C 112.134 0.42 . . . . 0.0 112.134 -174.35 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 248' ' ' VAL . . . . . 0.511 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.7 m -129.92 160.99 40.42 Favored 'Isoleucine or valine' 0 C--O 1.236 0.381 0 CA-C-N 115.89 -0.596 . . . . 0.0 111.884 -179.334 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 3.0 m -126.49 156.0 41.42 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 173.661 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 250' ' ' PHE . . . . . 0.627 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 91.9 m-85 -112.72 146.84 38.01 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-O 120.518 0.199 . . . . 0.0 111.072 -174.059 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 43.4 m -134.4 151.65 51.32 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.105 178.989 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 4.0 mm-40 41.91 37.12 0.74 Allowed 'General case' 0 C--O 1.245 0.832 0 N-CA-C 113.266 0.839 . . . . 0.0 113.266 174.671 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 0.464 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 79.2 t -89.56 129.98 39.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 174.641 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 34.1 mt-30 -99.3 141.32 32.23 Favored 'General case' 0 C--O 1.24 0.577 0 C-N-CA 120.523 -0.471 . . . . 0.0 111.222 -178.249 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 79.61 -57.22 4.49 Favored Glycine 0 CA--C 1.507 -0.438 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -177.081 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 256' ' ' MET . . . . . 0.726 ' SD ' HG11 ' A' ' 224' ' ' VAL . 4.2 ttm -86.74 49.59 1.84 Allowed 'General case' 0 C--N 1.314 -0.949 0 CA-C-O 121.911 0.862 . . . . 0.0 108.721 176.344 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 257' ' ' ILE . . . . . 0.481 ' O ' ' HB2' ' A' ' 260' ' ' ASN . 46.5 pt -68.22 -24.32 29.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 114.453 -1.249 . . . . 0.0 110.917 -174.969 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 258' ' ' GLN . . . . . 0.585 ' HG3' ' SG ' ' A' ' 262' ' ' CYS . 69.2 tp60 -57.68 -30.07 65.17 Favored 'General case' 0 C--N 1.318 -0.795 0 C-N-CA 119.458 -0.897 . . . . 0.0 109.608 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 259' ' ' LEU . . . . . 0.902 HD21 ' CE2' ' A' ' 283' ' ' PHE . 94.3 mt -62.07 -40.21 95.03 Favored 'General case' 0 N--CA 1.448 -0.55 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 174.038 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 260' ' ' ASN . . . . . 0.481 ' HB2' ' O ' ' A' ' 257' ' ' ILE . 96.8 m-20 -60.31 -40.89 92.18 Favored 'General case' 0 CA--C 1.514 -0.431 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 179.58 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -98.33 17.65 58.22 Favored Glycine 0 CA--C 1.525 0.706 0 CA-C-N 115.447 -0.797 . . . . 0.0 112.005 -179.392 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 262' ' ' CYS . . . . . 0.585 ' SG ' ' HG3' ' A' ' 258' ' ' GLN . 1.5 m -93.97 146.59 23.82 Favored 'General case' 0 CA--C 1.508 -0.661 0 C-N-CA 120.579 -0.448 . . . . 0.0 111.032 -179.379 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 46.6 mt-30 -59.81 161.2 12.37 Favored Pre-proline 0 C--N 1.323 -0.548 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 172.277 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 264' ' ' PRO . . . . . 0.511 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 38.0 Cg_endo -63.37 143.39 88.67 Favored 'Trans proline' 0 C--N 1.307 -1.651 0 N-CA-C 108.437 -1.409 . . . . 0.0 108.437 174.974 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 265' ' ' MET . . . . . 0.472 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 22.7 ptp -135.35 152.36 51.37 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 112.071 0.397 . . . . 0.0 112.071 -171.222 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 266' ' ' GLU . . . . . 0.5 ' CG ' ' HA2' ' A' ' 245' ' ' GLY . 39.5 tt0 -71.79 136.94 47.27 Favored 'General case' 0 C--N 1.331 -0.228 0 O-C-N 124.034 0.834 . . . . 0.0 109.516 178.757 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 267' ' ' ILE . . . . . 0.68 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.9 pp -128.3 162.39 34.85 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-O 121.142 0.496 . . . . 0.0 112.1 -179.346 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 268' ' ' LYS . . . . . 0.523 ' HG3' HG23 ' A' ' 244' ' ' THR . 60.1 tttm -118.98 131.52 56.02 Favored 'General case' 0 C--O 1.219 -0.501 0 CA-C-N 115.66 -0.7 . . . . 0.0 109.541 174.081 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 23.2 m -82.4 128.21 38.93 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.974 0 C-N-CA 120.313 -0.555 . . . . 0.0 110.276 176.822 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 270' ' ' LEU . . . . . 0.547 HD11 ' HB3' ' A' ' 276' ' ' SER . 95.6 mt -98.99 -17.89 18.07 Favored 'General case' 0 CA--C 1.502 -0.871 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 178.298 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -171.27 177.0 44.4 Favored Glycine 0 N--CA 1.443 -0.872 0 N-CA-C 108.546 -1.821 . . . . 0.0 108.546 179.092 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 272' ' ' PRO . . . . . 0.661 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 60.2 Cg_exo -54.07 -38.32 87.09 Favored 'Trans proline' 0 C--N 1.298 -2.091 0 C-N-CA 121.443 1.429 . . . . 0.0 110.559 -179.219 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 8.9 m-85 -118.69 11.57 12.8 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 112.646 0.61 . . . . 0.0 112.646 -174.455 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 22.2 p -130.13 143.59 50.87 Favored 'General case' 0 C--O 1.242 0.675 0 C-N-CA 120.669 -0.413 . . . . 0.0 111.177 177.158 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 275' ' ' PHE . . . . . 0.521 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -146.59 165.85 28.26 Favored 'General case' 0 C--O 1.246 0.869 0 N-CA-C 112.363 0.505 . . . . 0.0 112.363 178.75 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 276' ' ' SER . . . . . 0.547 ' HB3' HD11 ' A' ' 270' ' ' LEU . 4.4 p -130.88 143.01 50.42 Favored 'General case' 0 N--CA 1.431 -1.416 0 CA-C-O 121.773 0.797 . . . . 0.0 111.605 -178.695 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 277' ' ' ILE . . . . . 0.624 HG22 HG22 ' A' ' 267' ' ' ILE . 33.8 pt -135.91 165.32 29.95 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.058 0 CA-C-N 114.428 -1.26 . . . . 0.0 110.71 -173.136 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 15.2 t -30.54 -90.71 0.0 OUTLIER 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 112.859 0.689 . . . . 0.0 112.859 -174.874 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 279' ' ' ASP . . . . . 0.481 ' CG ' ' HB2' ' A' ' 228' ' ' ASN . 66.3 t0 -148.93 117.18 6.43 Favored 'General case' 0 N--CA 1.447 -0.593 0 CA-C-O 120.943 0.402 . . . . 0.0 110.827 -178.91 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 280' ' ' THR . . . . . 0.734 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 21.3 p -65.49 -27.33 68.41 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.54 176.56 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -64.35 -19.36 65.41 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.664 175.889 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -88.49 -9.88 50.91 Favored 'General case' 0 CA--C 1.508 -0.655 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.378 179.839 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 283' ' ' PHE . . . . . 0.902 ' CE2' HD21 ' A' ' 259' ' ' LEU . 4.4 m-85 -93.69 -64.96 1.03 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 174.303 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 284' ' ' SER . . . . . 0.422 ' OG ' ' HA ' ' A' ' 256' ' ' MET . 1.9 p 169.43 -94.18 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 115.205 -0.907 . . . . 0.0 111.625 177.242 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 285' ' ' ASP . . . . . 0.531 ' O ' ' N ' ' A' ' 256' ' ' MET . 45.0 t0 -156.19 166.09 34.46 Favored 'General case' 0 C--O 1.214 -0.786 0 N-CA-C 110.409 -0.219 . . . . 0.0 110.409 -177.308 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 286' ' ' TYR . . . . . 0.515 ' CZ ' ' HA ' ' A' ' 288' ' ' ARG . 68.2 t80 -99.61 119.4 38.02 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 110.226 -0.287 . . . . 0.0 110.226 177.359 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 21.1 mm -99.91 -56.44 5.2 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.586 0 N-CA-C 109.114 -0.698 . . . . 0.0 109.114 173.575 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 288' ' ' ARG . . . . . 0.515 ' HA ' ' CZ ' ' A' ' 286' ' ' TYR . 45.9 ptt85 177.87 -173.92 0.14 Allowed 'General case' 0 C--O 1.241 0.639 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.145 175.532 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 66.16 -158.93 47.67 Favored Glycine 0 CA--C 1.51 -0.281 0 N-CA-C 111.018 -0.833 . . . . 0.0 111.018 176.619 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 110.6 127.15 5.16 Favored Glycine 0 N--CA 1.447 -0.592 0 CA-C-O 121.52 0.511 . . . . 0.0 112.988 175.224 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 94.2 mt -130.32 133.07 64.5 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.807 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 174.312 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 3.8 p -124.52 134.29 67.14 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 C-N-CA 120.442 -0.503 . . . . 0.0 109.669 -177.969 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 293' ' ' SER . . . . . 0.477 ' HA ' ' O ' ' A' ' 217' ' ' LEU . 2.6 m -127.23 145.43 50.77 Favored 'General case' 0 C--N 1.324 -0.532 0 C-N-CA 120.488 -0.485 . . . . 0.0 111.042 -178.364 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 294' ' ' GLN . . . . . 0.513 ' HB3' ' CD1' ' A' ' 242' ' ' PHE . 0.3 OUTLIER . . . . . 0 CA--C 1.508 -0.659 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.185 176.661 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 217' ' ' LEU . . . . . 0.476 HD12 ' O ' ' A' ' 240' ' ' HIS . 0.1 OUTLIER . . . . . 0 CA--C 1.513 -0.473 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 . . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 4.6 m -126.3 147.95 49.62 Favored 'General case' 0 C--N 1.313 -1.011 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.335 -176.374 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 219' ' ' ALA . . . . . 0.487 ' HB1' ' HB1' ' A' ' 238' ' ' ALA . . . -152.5 153.8 34.22 Favored 'General case' 0 C--O 1.24 0.605 0 CA-C-O 121.112 0.482 . . . . 0.0 111.062 -178.709 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 71.3 mtm -80.15 129.67 34.66 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.652 -0.703 . . . . 0.0 109.662 175.9 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 57.5 t -76.29 131.24 35.25 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.694 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 177.991 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 46.8 p -88.72 -65.84 0.98 Allowed 'General case' 0 C--N 1.309 -1.169 0 C-N-CA 120.325 -0.55 . . . . 0.0 110.024 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 23.3 ptm -137.73 142.43 40.99 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.923 -0.58 . . . . 0.0 112.205 176.581 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 224' ' ' VAL . . . . . 0.885 HG22 ' HB ' ' A' ' 232' ' ' VAL . 75.0 t -119.89 133.57 66.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 177.294 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 225' ' ' THR . . . . . 0.478 ' O ' ' OG1' ' A' ' 280' ' ' THR . 62.7 p -98.5 128.6 44.91 Favored 'General case' 0 C--N 1.323 -0.569 0 C-N-CA 120.234 -0.587 . . . . 0.0 110.974 -179.517 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.86 85.76 3.44 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 177.908 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 227' ' ' ASP . . . . . 0.403 ' OD1' ' N ' ' A' ' 228' ' ' ASN . 2.6 t0 -152.04 175.82 12.15 Favored 'General case' 0 N--CA 1.469 0.521 0 CA-C-N 116.476 -0.329 . . . . 0.0 111.39 -175.495 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 228' ' ' ASN . . . . . 0.502 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 9.4 t30 -140.69 124.09 10.17 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.508 174.625 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 229' ' ' PRO . . . . . 0.502 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 40.4 Cg_endo -65.22 142.24 52.16 Favored 'Cis proline' 0 N--CA 1.493 1.488 0 C-N-CA 122.702 -1.791 . . . . 0.0 109.854 -1.12 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 230' ' ' GLY . . . . . 0.493 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -74.39 136.84 21.84 Favored Glycine 0 C--N 1.315 -0.629 0 N-CA-C 110.575 -1.01 . . . . 0.0 110.575 -176.957 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.1 p -127.69 137.74 56.75 Favored 'Isoleucine or valine' 0 C--O 1.248 0.997 0 CA-C-O 120.807 0.337 . . . . 0.0 110.697 177.574 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 232' ' ' VAL . . . . . 0.885 ' HB ' HG22 ' A' ' 224' ' ' VAL . 0.7 OUTLIER -132.28 157.17 43.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.951 179.292 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 233' ' ' THR . . . . . 0.47 ' HA ' ' O ' ' A' ' 273' ' ' TYR . 0.9 OUTLIER -114.36 146.96 39.88 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.388 -178.836 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 34.0 m -107.31 152.24 24.4 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.111 -0.495 . . . . 0.0 109.948 179.263 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 235' ' ' LEU . . . . . 0.482 ' HB3' ' HB3' ' A' ' 238' ' ' ALA . 15.7 tp -51.72 135.09 29.78 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 -178.881 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 24.7 p-10 -48.63 -47.44 40.2 Favored 'General case' 0 N--CA 1.475 0.793 0 N-CA-C 111.936 0.347 . . . . 0.0 111.936 -171.838 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -70.51 -34.65 72.55 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-O 120.944 0.402 . . . . 0.0 111.62 178.218 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 238' ' ' ALA . . . . . 0.487 ' HB1' ' HB1' ' A' ' 219' ' ' ALA . . . -83.96 89.42 7.23 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.262 -176.615 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 239' ' ' ARG . . . . . 0.52 ' NH1' ' O ' ' A' ' 239' ' ' ARG . 0.0 OUTLIER -78.83 123.16 26.94 Favored 'General case' 0 CA--C 1.513 -0.443 0 N-CA-C 108.771 -0.825 . . . . 0.0 108.771 173.698 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 240' ' ' HIS . . . . . 0.602 ' H ' ' CD2' ' A' ' 240' ' ' HIS . 7.0 p80 -57.13 -48.71 77.98 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.397 -175.818 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 80.01 19.93 68.84 Favored Glycine 0 C--N 1.314 -0.666 0 N-CA-C 110.131 -1.188 . . . . 0.0 110.131 -177.674 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 242' ' ' PHE . . . . . 0.681 ' CD2' HG11 ' A' ' 248' ' ' VAL . 8.3 m-30 -81.53 151.87 27.54 Favored 'General case' 0 C--N 1.316 -0.877 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 177.946 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -116.19 160.78 19.92 Favored 'General case' 0 C--N 1.314 -0.935 0 CA-C-O 120.893 0.378 . . . . 0.0 110.887 177.491 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 244' ' ' THR . . . . . 0.527 HG23 HG22 ' A' ' 269' ' ' VAL . 0.0 OUTLIER -58.84 125.88 25.37 Favored 'General case' 0 C--N 1.312 -1.029 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 -179.65 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 80.86 5.81 89.83 Favored Glycine 0 C--N 1.319 -0.365 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 -178.326 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 246' ' ' ASP . . . . . 0.403 ' O ' ' HA ' ' A' ' 266' ' ' GLU . 5.3 t70 -79.86 162.34 25.09 Favored 'General case' 0 CA--C 1.514 -0.42 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 178.416 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 247' ' ' PHE . . . . . . . . . . . . . 78.0 m-85 -109.78 129.04 55.67 Favored 'General case' 0 C--O 1.242 0.708 0 CA-C-O 120.846 0.355 . . . . 0.0 111.191 -177.488 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 248' ' ' VAL . . . . . 0.681 HG11 ' CD2' ' A' ' 242' ' ' PHE . 2.4 m -129.95 162.26 38.01 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.399 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.364 178.369 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.48 145.82 46.87 Favored 'General case' 0 C--N 1.308 -1.226 0 CA-C-N 115.324 -0.853 . . . . 0.0 109.982 177.363 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 250' ' ' PHE . . . . . 0.649 ' CD2' HD22 ' A' ' 259' ' ' LEU . 67.5 m-85 -104.81 145.68 30.04 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.65 177.701 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 4.3 m -143.36 150.12 38.69 Favored 'General case' 0 C--N 1.309 -1.153 0 N-CA-C 110.084 -0.339 . . . . 0.0 110.084 176.07 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 23.7 mm-40 54.1 26.78 6.86 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 112.816 0.673 . . . . 0.0 112.816 173.07 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 0.517 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 88.0 t -76.53 130.93 35.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 173.702 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 86.5 mm-40 -100.45 139.72 35.72 Favored 'General case' 0 C--O 1.244 0.765 0 C-N-CA 119.68 -0.808 . . . . 0.0 111.651 -176.152 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 78.71 -58.16 4.21 Favored Glycine 0 C--O 1.239 0.453 0 N-CA-C 108.983 -1.647 . . . . 0.0 108.983 -173.688 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 256' ' ' MET . . . . . 0.566 ' SD ' HG11 ' A' ' 224' ' ' VAL . 31.7 mtt -80.57 61.04 4.14 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-O 121.242 0.544 . . . . 0.0 109.788 172.682 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 257' ' ' ILE . . . . . 0.401 ' O ' ' HB2' ' A' ' 260' ' ' ASN . 41.8 pt -76.23 -15.78 15.14 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.731 -178.512 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 258' ' ' GLN . . . . . 0.414 ' O ' ' N ' ' A' ' 262' ' ' CYS . 70.5 tp60 -55.38 -39.31 69.99 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 179.423 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 259' ' ' LEU . . . . . 0.91 HD21 ' CE2' ' A' ' 283' ' ' PHE . 89.0 mt -61.86 -41.71 98.17 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.747 -0.661 . . . . 0.0 109.925 176.908 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 260' ' ' ASN . . . . . 0.517 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 97.9 m-20 -61.29 -40.58 94.67 Favored 'General case' 0 CA--C 1.509 -0.612 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 179.347 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -87.66 -5.67 78.0 Favored Glycine 0 CA--C 1.523 0.538 0 CA-C-N 115.529 -0.76 . . . . 0.0 111.496 -178.936 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 262' ' ' CYS . . . . . 0.414 ' N ' ' O ' ' A' ' 258' ' ' GLN . 49.0 t -87.98 150.58 23.36 Favored 'General case' 0 CA--C 1.512 -0.493 0 CA-C-O 120.765 0.317 . . . . 0.0 111.062 -178.285 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 263' ' ' GLN . . . . . 0.642 ' CD ' ' H ' ' A' ' 263' ' ' GLN . 0.0 OUTLIER -72.45 169.39 17.09 Favored Pre-proline 0 C--N 1.319 -0.758 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 172.631 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 264' ' ' PRO . . . . . 0.454 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 27.7 Cg_exo -61.76 145.12 97.5 Favored 'Trans proline' 0 C--N 1.307 -1.608 0 C-N-CA 121.462 1.441 . . . . 0.0 109.983 179.099 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 265' ' ' MET . . . . . 0.655 ' N ' ' SD ' ' A' ' 265' ' ' MET . 0.8 OUTLIER -122.83 157.26 32.85 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 -176.466 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 266' ' ' GLU . . . . . 0.403 ' HA ' ' O ' ' A' ' 246' ' ' ASP . 64.1 tt0 -75.94 134.85 40.12 Favored 'General case' 0 C--O 1.238 0.493 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 175.513 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 267' ' ' ILE . . . . . 0.703 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.9 pp -128.66 163.3 33.63 Favored 'Isoleucine or valine' 0 C--O 1.237 0.405 0 N-CA-C 114.095 1.146 . . . . 0.0 114.095 -170.495 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 268' ' ' LYS . . . . . 0.493 ' NZ ' ' OG ' ' A' ' 276' ' ' SER . 8.0 mtpm? -119.36 123.31 43.84 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-N 115.009 -0.996 . . . . 0.0 110.065 178.737 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.527 HG22 HG23 ' A' ' 244' ' ' THR . 30.1 m -84.59 97.93 5.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-O 121.087 0.47 . . . . 0.0 111.236 177.056 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 91.9 mt -66.79 -40.4 88.14 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.528 0.68 . . . . 0.0 109.747 176.38 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -155.33 -177.85 28.99 Favored Glycine 0 N--CA 1.447 -0.624 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 -179.827 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 272' ' ' PRO . . . . . 0.5 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 35.6 Cg_endo -61.32 -30.88 88.49 Favored 'Trans proline' 0 C--N 1.306 -1.702 0 C-N-CA 122.066 1.844 . . . . 0.0 111.471 -178.519 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 273' ' ' TYR . . . . . 0.47 ' O ' ' HA ' ' A' ' 233' ' ' THR . 94.5 m-85 -122.85 7.0 9.33 Favored 'General case' 0 C--N 1.319 -0.733 0 N-CA-C 112.942 0.719 . . . . 0.0 112.942 -178.497 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 4.3 p -126.84 129.02 47.45 Favored 'General case' 0 C--O 1.244 0.816 0 CA-C-O 120.884 0.374 . . . . 0.0 110.835 178.031 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 275' ' ' PHE . . . . . 0.518 ' HD2' HD13 ' A' ' 267' ' ' ILE . 0.0 OUTLIER -139.41 160.47 39.76 Favored 'General case' 0 CA--C 1.499 -0.986 0 C-N-CA 120.446 -0.502 . . . . 0.0 112.206 177.281 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 276' ' ' SER . . . . . 0.493 ' OG ' ' NZ ' ' A' ' 268' ' ' LYS . 10.9 p -130.79 154.49 47.95 Favored 'General case' 0 N--CA 1.43 -1.427 0 CA-C-O 121.456 0.646 . . . . 0.0 111.953 -175.11 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 277' ' ' ILE . . . . . 0.672 ' C ' HD12 ' A' ' 277' ' ' ILE . 2.5 pp -138.19 -172.48 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.154 0 CA-C-N 114.313 -1.312 . . . . 0.0 108.961 -176.926 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 278' ' ' CYS . . . . . 0.524 ' N ' HD12 ' A' ' 277' ' ' ILE . 0.5 OUTLIER -48.14 -85.93 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.751 0.31 . . . . 0.0 111.708 -178.245 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 31.7 t0 -145.0 115.45 7.62 Favored 'General case' 0 CA--C 1.515 -0.397 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.534 -177.625 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 280' ' ' THR . . . . . 0.69 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 12.6 p -71.42 -22.66 61.83 Favored 'General case' 0 N--CA 1.432 -1.37 0 CA-C-O 121.108 0.48 . . . . 0.0 109.77 176.294 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -67.37 -19.85 65.48 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 174.765 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 26.8 t-20 -89.2 -9.16 51.83 Favored 'General case' 0 CA--C 1.505 -0.752 0 CA-C-N 115.662 -0.699 . . . . 0.0 109.637 178.408 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 283' ' ' PHE . . . . . 0.91 ' CE2' HD21 ' A' ' 259' ' ' LEU . 22.8 m-30 -84.28 -79.0 0.22 Allowed 'General case' 0 N--CA 1.441 -0.906 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 174.612 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 284' ' ' SER . . . . . 0.436 ' CB ' ' HA ' ' A' ' 256' ' ' MET . 0.0 OUTLIER 175.01 -165.21 0.03 OUTLIER 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 114.892 -1.049 . . . . 0.0 109.589 -175.674 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 27.7 t0 -92.81 118.64 31.32 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.643 0.259 . . . . 0.0 111.301 178.997 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 286' ' ' TYR . . . . . 0.493 ' HB2' ' SD ' ' A' ' 256' ' ' MET . 6.1 t80 -68.86 122.0 17.73 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.6 179.341 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 96.4 mt -103.0 -59.9 3.15 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 175.027 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 50.8 ptt85 179.7 -163.04 0.04 OUTLIER 'General case' 0 C--O 1.24 0.553 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.397 174.755 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 68.83 -147.93 47.3 Favored Glycine 0 C--O 1.237 0.336 0 N-CA-C 109.811 -1.316 . . . . 0.0 109.811 -179.05 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 87.13 122.11 1.53 Allowed Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.823 175.111 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 97.7 mt -118.19 128.9 75.18 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.137 0 N-CA-C 107.262 -1.385 . . . . 0.0 107.262 172.346 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 14.9 p -116.94 128.92 74.24 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 -179.658 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 3.4 m -134.52 143.52 47.49 Favored 'General case' 0 N--CA 1.439 -0.996 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.409 -176.903 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 294' ' ' GLN . . . . . 0.423 ' HB2' ' CD1' ' A' ' 242' ' ' PHE . 11.2 tt0 . . . . . 0 N--CA 1.432 -1.358 0 CA-C-N 115.378 -0.828 . . . . 0.0 108.924 173.88 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 217' ' ' LEU . . . . . 0.459 HD22 ' HA ' ' A' ' 217' ' ' LEU . 0.3 OUTLIER . . . . . 0 CA--C 1.515 -0.395 0 CA-C-O 120.764 0.316 . . . . 0.0 111.242 . . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 96.4 p -155.06 164.3 39.07 Favored 'General case' 0 N--CA 1.446 -0.652 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.258 -177.967 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -154.5 163.22 40.52 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-N 115.548 -0.751 . . . . 0.0 109.682 177.246 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 8.4 ttt -78.78 127.0 31.47 Favored 'General case' 0 N--CA 1.436 -1.144 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 175.703 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 98.0 t -69.22 130.13 33.98 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.174 0 N-CA-C 107.726 -1.213 . . . . 0.0 107.726 178.017 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -84.6 -70.36 0.58 Allowed 'General case' 0 N--CA 1.432 -1.331 0 C-N-CA 120.211 -0.596 . . . . 0.0 109.922 179.649 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 8.5 ptm -138.08 146.25 42.71 Favored 'General case' 0 N--CA 1.47 0.536 0 N-CA-C 112.446 0.536 . . . . 0.0 112.446 174.827 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 224' ' ' VAL . . . . . 0.8 HG22 ' HB ' ' A' ' 232' ' ' VAL . 53.1 t -121.94 132.85 70.01 Favored 'Isoleucine or valine' 0 C--O 1.239 0.537 0 C-N-CA 122.814 0.446 . . . . 0.0 110.557 178.97 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 39.2 p -88.25 133.0 34.16 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.554 -0.293 . . . . 0.0 110.694 178.731 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 15.9 tttm -82.11 80.16 8.42 Favored 'General case' 0 C--O 1.241 0.623 0 C-N-CA 120.349 -0.54 . . . . 0.0 110.014 177.549 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 227' ' ' ASP . . . . . 0.605 ' N ' ' OG1' ' A' ' 280' ' ' THR . 2.2 t0 -154.3 -179.86 8.32 Favored 'General case' 0 C--O 1.247 0.93 0 CA-C-N 115.391 -0.822 . . . . 0.0 111.2 178.853 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 228' ' ' ASN . . . . . 0.523 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.4 OUTLIER -141.77 125.48 9.91 Favored Pre-proline 0 C--N 1.324 -0.502 0 CA-C-N 115.529 -0.759 . . . . 0.0 109.645 176.747 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 229' ' ' PRO . . . . . 0.523 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 42.6 Cg_endo -64.71 142.32 50.21 Favored 'Cis proline' 0 N--CA 1.491 1.379 0 C-N-CA 122.995 -1.669 . . . . 0.0 110.198 -0.651 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 230' ' ' GLY . . . . . 0.562 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -74.42 138.89 24.84 Favored Glycine 0 C--N 1.308 -0.981 0 N-CA-C 109.912 -1.275 . . . . 0.0 109.912 -178.531 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.2 p -125.08 130.98 73.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 176.271 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 232' ' ' VAL . . . . . 0.8 ' HB ' HG22 ' A' ' 224' ' ' VAL . 0.7 OUTLIER -133.64 156.54 41.55 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 C-N-CA 120.502 -0.479 . . . . 0.0 110.494 -177.255 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 233' ' ' THR . . . . . 0.427 ' HA ' ' O ' ' A' ' 273' ' ' TYR . 2.4 m -105.35 149.27 26.22 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 115.268 -0.878 . . . . 0.0 109.321 177.777 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 2.6 m -113.08 147.26 37.66 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 175.478 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 33.7 tp -53.7 113.92 1.36 Allowed 'General case' 0 C--N 1.312 -1.065 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 178.623 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 36.7 p-10 -63.1 -10.38 14.41 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.94 -170.87 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 76.5 mm-40 -65.47 -32.76 74.55 Favored 'General case' 0 C--N 1.312 -1.048 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.231 177.982 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -121.45 133.52 55.06 Favored 'General case' 0 C--O 1.233 0.223 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.839 -177.868 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 239' ' ' ARG . . . . . 0.552 ' NH1' ' O ' ' A' ' 242' ' ' PHE . 0.1 OUTLIER -77.87 112.57 14.89 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 173.439 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 240' ' ' HIS . . . . . 0.605 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 2.8 p80 -43.19 -34.2 1.08 Allowed 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 121.133 0.492 . . . . 0.0 109.988 -179.011 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 87.19 8.36 75.25 Favored Glycine 0 CA--C 1.503 -0.669 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 179.724 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 242' ' ' PHE . . . . . 0.552 ' O ' ' NH1' ' A' ' 239' ' ' ARG . 5.7 m-30 -81.82 146.16 30.04 Favored 'General case' 0 N--CA 1.444 -0.772 0 CA-C-O 120.85 0.357 . . . . 0.0 110.19 -179.192 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 243' ' ' GLU . . . . . 0.421 ' OE2' ' NH2' ' A' ' 239' ' ' ARG . 64.9 mm-40 -121.67 167.99 12.3 Favored 'General case' 0 C--N 1.309 -1.19 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.431 176.446 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 17.7 m -61.1 124.15 19.72 Favored 'General case' 0 C--N 1.298 -1.633 0 C-N-CA 120.152 -0.619 . . . . 0.0 109.718 -178.682 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 245' ' ' GLY . . . . . 0.41 ' HA2' ' CG ' ' A' ' 266' ' ' GLU . . . 82.64 7.39 87.49 Favored Glycine 0 CA--C 1.523 0.578 0 CA-C-N 116.192 -0.458 . . . . 0.0 112.066 179.312 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 246' ' ' ASP . . . . . 0.44 ' OD1' ' N ' ' A' ' 247' ' ' PHE . 40.3 t0 -74.41 162.15 29.13 Favored 'General case' 0 C--O 1.238 0.482 0 CA-C-N 117.44 0.62 . . . . 0.0 109.457 177.809 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 247' ' ' PHE . . . . . 0.44 ' N ' ' OD1' ' A' ' 246' ' ' ASP . 78.3 m-85 -109.31 131.05 55.43 Favored 'General case' 0 C--N 1.316 -0.849 0 N-CA-C 109.705 -0.479 . . . . 0.0 109.705 -179.27 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 248' ' ' VAL . . . . . 0.433 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 3.1 m -129.04 163.29 34.48 Favored 'Isoleucine or valine' 0 C--O 1.24 0.602 0 CA-C-O 121.027 0.441 . . . . 0.0 112.058 -177.251 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 9.6 p -133.91 162.04 33.13 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 114.522 -1.217 . . . . 0.0 108.905 175.172 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 250' ' ' PHE . . . . . 0.595 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 82.1 m-85 -124.37 159.36 30.52 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.087 0.47 . . . . 0.0 111.831 -169.231 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 20.2 m -158.42 160.0 36.36 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.192 177.489 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 78.0 mm-40 52.17 20.39 1.31 Allowed 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 113.234 0.827 . . . . 0.0 113.234 175.971 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 253' ' ' VAL . . . . . 0.43 HG22 ' CA ' ' A' ' 290' ' ' GLY . 12.4 t -85.94 131.06 35.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 175.969 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 87.5 mt-30 -96.93 144.06 27.21 Favored 'General case' 0 C--O 1.24 0.56 0 C-N-CA 120.666 -0.413 . . . . 0.0 110.649 -179.689 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 77.75 -57.43 3.86 Favored Glycine 0 CA--C 1.509 -0.321 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -177.158 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 256' ' ' MET . . . . . 0.522 ' HG2' ' HB3' ' A' ' 283' ' ' PHE . 15.3 ttm -85.81 55.84 3.7 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-O 121.493 0.663 . . . . 0.0 109.446 175.684 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 44.4 pt -73.93 -18.1 17.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.036 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 3.5 tp60 -54.1 -39.04 66.02 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 108.231 -1.026 . . . . 0.0 108.231 178.157 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 259' ' ' LEU . . . . . 0.846 HD21 ' CE2' ' A' ' 283' ' ' PHE . 85.5 mt -62.16 -41.67 98.52 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.121 177.07 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 97.2 m-20 -59.98 -40.53 89.45 Favored 'General case' 0 CA--C 1.506 -0.734 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 -176.436 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -102.27 14.75 56.77 Favored Glycine 0 CA--C 1.523 0.552 0 CA-C-N 115.787 -0.642 . . . . 0.0 112.235 -179.603 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 262' ' ' CYS . . . . . 0.439 ' HB2' ' HA ' ' A' ' 259' ' ' LEU . 1.1 m -91.16 158.83 16.4 Favored 'General case' 0 CA--C 1.513 -0.456 0 CA-C-N 117.469 0.634 . . . . 0.0 111.684 -178.005 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -76.59 151.25 82.69 Favored Pre-proline 0 C--N 1.323 -0.553 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 173.927 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 264' ' ' PRO . . . . . 0.433 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 49.5 Cg_endo -64.01 147.11 91.82 Favored 'Trans proline' 0 C--N 1.306 -1.668 0 C-N-CA 121.76 1.64 . . . . 0.0 112.052 -176.177 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 265' ' ' MET . . . . . 0.502 ' SD ' ' HZ ' ' A' ' 283' ' ' PHE . 7.8 ptp -134.07 157.4 46.22 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 112.484 0.55 . . . . 0.0 112.484 -173.661 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 266' ' ' GLU . . . . . 0.481 ' OE2' ' NZ ' ' A' ' 268' ' ' LYS . 39.6 tt0 -73.57 141.55 46.64 Favored 'General case' 0 C--O 1.241 0.631 0 O-C-N 124.006 0.816 . . . . 0.0 109.846 177.015 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 267' ' ' ILE . . . . . 0.681 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.8 pp -130.66 163.58 36.05 Favored 'Isoleucine or valine' 0 C--O 1.237 0.445 0 N-CA-C 112.114 0.413 . . . . 0.0 112.114 -177.99 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 268' ' ' LYS . . . . . 0.481 ' NZ ' ' OE2' ' A' ' 266' ' ' GLU . 45.1 mmtm -124.88 127.35 46.97 Favored 'General case' 0 CA--C 1.541 0.628 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 174.555 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.482 HG23 ' O ' ' A' ' 269' ' ' VAL . 27.2 m -83.64 98.27 5.3 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.612 0 CA-C-O 120.887 0.375 . . . . 0.0 111.507 -179.818 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 98.6 mt -65.73 -42.46 90.99 Favored 'General case' 0 CA--C 1.513 -0.46 0 CA-C-O 121.399 0.619 . . . . 0.0 109.577 178.137 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -145.04 176.44 24.08 Favored Glycine 0 C--N 1.314 -0.693 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 178.499 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 272' ' ' PRO . . . . . 0.605 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 67.9 Cg_exo -54.03 -40.05 82.86 Favored 'Trans proline' 0 C--N 1.305 -1.72 0 C-N-CA 122.159 1.906 . . . . 0.0 111.068 -178.805 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 273' ' ' TYR . . . . . 0.427 ' O ' ' HA ' ' A' ' 233' ' ' THR . 6.9 m-85 -115.71 8.96 15.08 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.623 -176.062 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.7 p -126.74 124.97 40.97 Favored 'General case' 0 C--O 1.247 0.937 0 CA-C-O 121.047 0.451 . . . . 0.0 111.431 179.284 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 275' ' ' PHE . . . . . 0.536 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -133.09 164.72 26.39 Favored 'General case' 0 CA--C 1.494 -1.189 0 C-N-CA 120.492 -0.483 . . . . 0.0 112.224 177.95 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 276' ' ' SER . . . . . 0.5 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 13.7 p -132.12 152.4 51.26 Favored 'General case' 0 N--CA 1.432 -1.347 0 C-N-CA 120.436 -0.506 . . . . 0.0 110.944 -176.382 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 277' ' ' ILE . . . . . 0.628 HG22 HG22 ' A' ' 267' ' ' ILE . 0.2 OUTLIER -138.26 -169.19 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.195 0 CA-C-N 115.258 -0.883 . . . . 0.0 110.564 -175.185 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 12.9 m -58.32 -75.64 0.05 OUTLIER 'General case' 0 CA--C 1.536 0.438 0 N-CA-C 112.941 0.719 . . . . 0.0 112.941 -175.273 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 279' ' ' ASP . . . . . 0.425 ' HB3' ' HB2' ' A' ' 282' ' ' ASN . 66.7 t0 -154.99 114.78 3.74 Favored 'General case' 0 N--CA 1.45 -0.441 0 O-C-N 122.266 -0.271 . . . . 0.0 111.122 -175.276 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 280' ' ' THR . . . . . 0.678 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 21.5 p -66.89 -29.52 69.43 Favored 'General case' 0 C--N 1.303 -1.417 0 CA-C-O 121.101 0.477 . . . . 0.0 110.262 174.962 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 281' ' ' SER . . . . . 0.416 ' N ' ' OD1' ' A' ' 279' ' ' ASP . 0.3 OUTLIER -62.28 -19.45 63.26 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 115.29 -0.868 . . . . 0.0 109.125 174.794 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 282' ' ' ASN . . . . . 0.425 ' HB2' ' HB3' ' A' ' 279' ' ' ASP . 2.1 m-80 -88.48 -8.48 54.82 Favored 'General case' 0 CA--C 1.507 -0.703 0 N-CA-C 109.454 -0.572 . . . . 0.0 109.454 175.163 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 283' ' ' PHE . . . . . 0.846 ' CE2' HD21 ' A' ' 259' ' ' LEU . 12.2 m-30 -98.82 -83.35 0.42 Allowed 'General case' 0 N--CA 1.442 -0.843 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 174.8 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 284' ' ' SER . . . . . 0.416 ' H ' ' HB2' ' A' ' 283' ' ' PHE . 0.2 OUTLIER 172.88 -162.02 0.02 OUTLIER 'General case' 0 N--CA 1.448 -0.535 0 C-N-CA 124.908 1.283 . . . . 0.0 107.929 -178.998 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 9.4 p-10 -91.64 169.99 10.28 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.666 0.27 . . . . 0.0 110.631 175.618 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 86.2 t80 -106.85 120.98 43.48 Favored 'General case' 0 C--O 1.239 0.531 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.199 179.731 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 287' ' ' ILE . . . . . 0.485 ' O ' ' HG3' ' A' ' 288' ' ' ARG . 96.9 mt -93.32 -57.67 4.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 109.993 -0.373 . . . . 0.0 109.993 175.413 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 288' ' ' ARG . . . . . 0.485 ' HG3' ' O ' ' A' ' 287' ' ' ILE . 15.9 mtm180 -178.9 179.05 0.72 Allowed 'General case' 0 C--O 1.243 0.722 0 C-N-CA 124.525 1.13 . . . . 0.0 110.122 177.773 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 69.52 -163.14 51.75 Favored Glycine 0 C--O 1.235 0.21 0 N-CA-C 111.275 -0.73 . . . . 0.0 111.275 175.903 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 290' ' ' GLY . . . . . 0.43 ' CA ' HG22 ' A' ' 253' ' ' VAL . . . 113.68 128.23 4.72 Favored Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 121.251 -0.5 . . . . 0.0 113.076 175.686 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 98.5 mt -124.42 132.11 71.81 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.858 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 172.751 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 292' ' ' VAL . . . . . 0.415 HG22 ' CZ ' ' A' ' 242' ' ' PHE . 5.5 p -125.33 137.69 56.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -178.189 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 4.4 m -132.18 147.0 52.4 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.299 -177.299 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 CA--C 1.507 -0.7 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 173.318 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 201' ' ' GLU . . . . . 0.517 ' C ' ' H ' ' A' ' 203' ' ' GLY . 1.7 mp0 . . . . . 0 N--CA 1.479 1.021 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 13.9 m-85 65.02 -33.1 0.15 Allowed 'General case' 0 N--CA 1.475 0.784 0 C-N-CA 122.824 0.45 . . . . 0.0 111.754 178.296 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 203' ' ' GLY . . . . . 0.517 ' H ' ' C ' ' A' ' 201' ' ' GLU . . . -60.81 -35.14 89.51 Favored Glycine 0 C--O 1.213 -1.205 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 177.3 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 204' ' ' GLU . . . . . 0.494 ' OE1' ' N ' ' A' ' 201' ' ' GLU . 1.8 mp0 -54.76 -45.21 74.19 Favored 'General case' 0 C--N 1.315 -0.897 0 N-CA-C 108.258 -1.016 . . . . 0.0 108.258 177.739 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -72.02 -44.28 63.66 Favored 'General case' 0 N--CA 1.444 -0.749 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.108 173.358 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 78.0 mtm -95.38 69.84 3.11 Favored 'General case' 0 C--O 1.24 0.574 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.583 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 207' ' ' VAL . . . . . 0.475 HG12 ' O ' ' A' ' 204' ' ' GLU . 9.9 p -149.21 149.95 14.37 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.054 0 CA-C-N 115.707 -0.679 . . . . 0.0 109.654 175.147 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 208' ' ' LEU . . . . . 0.499 ' C ' ' H ' ' A' ' 210' ' ' ASP . 89.4 mt -71.71 144.01 49.46 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-O 121.015 0.436 . . . . 0.0 110.557 178.534 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 7.9 p -74.58 34.39 0.1 Allowed 'General case' 0 C--N 1.306 -1.287 0 CA-C-N 115.425 -0.807 . . . . 0.0 110.021 175.397 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 210' ' ' ASP . . . . . 0.499 ' H ' ' C ' ' A' ' 208' ' ' LEU . 18.2 p-10 -50.28 -28.47 7.82 Favored 'General case' 0 CA--C 1.512 -0.504 0 CA-C-N 115.408 -0.815 . . . . 0.0 110.641 -174.805 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -60.6 94.17 0.03 OUTLIER 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 173.256 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 212' ' ' ASN . . . . . 0.518 ' C ' ' H ' ' A' ' 214' ' ' GLU . 17.7 t30 -85.33 105.09 15.73 Favored 'General case' 0 CA--C 1.507 -0.698 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.277 -173.679 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 66.82 -39.24 0.18 Allowed Glycine 0 CA--C 1.526 0.733 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -176.867 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 214' ' ' GLU . . . . . 0.518 ' H ' ' C ' ' A' ' 212' ' ' ASN . 74.8 mm-40 -71.18 110.1 5.63 Favored 'General case' 0 N--CA 1.446 -0.672 0 N-CA-C 110.197 -0.298 . . . . 0.0 110.197 178.911 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -95.23 150.85 38.22 Favored Pre-proline 0 C--N 1.317 -0.846 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 172.669 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -57.79 139.23 89.62 Favored 'Trans proline' 0 C--N 1.3 -1.982 0 N-CA-C 109.406 -1.036 . . . . 0.0 109.406 179.131 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 217' ' ' LEU . . . . . 0.545 HD13 ' N ' ' A' ' 218' ' ' SER . 0.2 OUTLIER -86.16 124.46 32.6 Favored 'General case' 0 CA--C 1.505 -0.77 0 N-CA-C 106.439 -1.689 . . . . 0.0 106.439 178.586 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 218' ' ' SER . . . . . 0.545 ' N ' HD13 ' A' ' 217' ' ' LEU . 50.3 m -113.84 146.78 39.48 Favored 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 -173.506 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 219' ' ' ALA . . . . . 0.895 ' HB1' ' HB1' ' A' ' 238' ' ' ALA . . . -138.73 148.69 44.21 Favored 'General case' 0 C--O 1.243 0.742 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.099 -174.278 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 97.4 mmm -74.63 125.15 28.04 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.599 -0.728 . . . . 0.0 109.873 176.26 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 60.1 t -87.06 129.11 39.08 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.948 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 177.136 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -83.87 -69.96 0.6 Allowed 'General case' 0 N--CA 1.433 -1.309 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 176.93 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -138.12 156.29 47.9 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.274 174.868 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 224' ' ' VAL . . . . . 0.56 ' CG1' ' SD ' ' A' ' 256' ' ' MET . 62.0 t -122.48 133.58 68.26 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.946 0 N-CA-C 108.18 -1.045 . . . . 0.0 108.18 173.488 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -102.83 121.91 43.43 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-O 120.555 0.217 . . . . 0.0 110.603 -175.842 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 226' ' ' LYS . . . . . 0.416 ' HA ' ' OG1' ' A' ' 280' ' ' THR . 0.4 OUTLIER -70.52 89.67 0.71 Allowed 'General case' 0 C--O 1.242 0.704 0 CA-C-O 120.966 0.412 . . . . 0.0 109.967 178.979 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 227' ' ' ASP . . . . . 0.431 ' OD1' ' N ' ' A' ' 228' ' ' ASN . 52.9 t0 -158.47 171.69 19.69 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.492 -0.776 . . . . 0.0 109.993 -176.789 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 228' ' ' ASN . . . . . 0.454 ' HB2' ' CG ' ' A' ' 279' ' ' ASP . 0.7 OUTLIER -136.16 123.32 14.46 Favored Pre-proline 0 C--N 1.325 -0.459 0 CA-C-N 116.576 -0.284 . . . . 0.0 110.544 175.192 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 229' ' ' PRO . . . . . 0.452 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 45.7 Cg_endo -65.89 146.5 71.49 Favored 'Cis proline' 0 N--CA 1.494 1.538 0 C-N-CA 122.783 -1.757 . . . . 0.0 109.22 -1.942 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 230' ' ' GLY . . . . . 0.536 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -68.43 144.06 41.8 Favored Glycine 0 C--O 1.219 -0.812 0 N-CA-C 109.787 -1.325 . . . . 0.0 109.787 -177.72 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 231' ' ' VAL . . . . . 0.45 HG23 HD12 ' A' ' 270' ' ' LEU . 2.5 p -128.12 134.95 64.02 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 CA-C-N 116.989 0.394 . . . . 0.0 110.079 178.168 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 232' ' ' VAL . . . . . 0.5 HG12 HG13 ' A' ' 224' ' ' VAL . 0.6 OUTLIER -133.8 156.44 41.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 C-N-CA 120.428 -0.509 . . . . 0.0 110.836 -179.817 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 24.5 m -117.49 134.3 55.01 Favored 'General case' 0 C--O 1.242 0.693 0 CA-C-N 115.998 -0.546 . . . . 0.0 109.683 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.8 m -106.4 158.58 16.79 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.961 -175.372 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.485 ' O ' ' HB3' ' A' ' 238' ' ' ALA . 22.8 tp -63.29 150.79 42.39 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.226 -0.897 . . . . 0.0 108.686 179.225 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -59.63 -39.7 85.16 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 121.089 0.471 . . . . 0.0 109.847 -177.697 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 237' ' ' GLU . . . . . 0.447 ' O ' ' N ' ' A' ' 239' ' ' ARG . 98.8 mt-10 -70.53 -21.09 62.76 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.16 174.062 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 238' ' ' ALA . . . . . 0.895 ' HB1' ' HB1' ' A' ' 219' ' ' ALA . . . -65.83 61.25 0.03 OUTLIER 'General case' 0 C--O 1.241 0.653 0 CA-C-O 121.227 0.537 . . . . 0.0 111.027 -178.472 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 239' ' ' ARG . . . . . 0.447 ' N ' ' O ' ' A' ' 237' ' ' GLU . 61.5 mtp180 -67.78 85.09 0.21 Allowed 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 174.215 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 240' ' ' HIS . . . . . 0.627 ' HB2' ' CG ' ' A' ' 242' ' ' PHE . 3.5 p80 -57.92 -46.83 84.39 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-N 115.163 -0.926 . . . . 0.0 112.398 -170.903 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 80.32 14.47 80.23 Favored Glycine 0 C--N 1.313 -0.743 0 N-CA-C 109.867 -1.293 . . . . 0.0 109.867 -174.902 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 242' ' ' PHE . . . . . 0.681 ' CD1' ' HB3' ' A' ' 294' ' ' GLN . 4.6 m-30 -80.02 148.69 31.01 Favored 'General case' 0 CA--C 1.509 -0.617 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 -179.301 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 243' ' ' GLU . . . . . 0.474 ' HB2' ' HB2' ' A' ' 246' ' ' ASP . 37.7 mt-10 -115.46 150.66 36.12 Favored 'General case' 0 C--N 1.308 -1.238 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 179.634 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 244' ' ' THR . . . . . 0.56 ' OG1' HG22 ' A' ' 269' ' ' VAL . 32.6 m -62.43 127.62 32.16 Favored 'General case' 0 C--N 1.305 -1.34 0 C-N-CA 119.235 -0.986 . . . . 0.0 108.652 177.316 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 86.16 4.01 84.44 Favored Glycine 0 C--N 1.311 -0.847 0 N-CA-C 110.489 -1.044 . . . . 0.0 110.489 -176.326 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 246' ' ' ASP . . . . . 0.474 ' HB2' ' HB2' ' A' ' 243' ' ' GLU . 31.6 t0 -81.58 164.06 22.16 Favored 'General case' 0 CA--C 1.515 -0.402 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 177.737 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 247' ' ' PHE . . . . . 0.46 ' HA ' ' O ' ' A' ' 265' ' ' MET . 69.3 m-85 -110.05 134.68 51.89 Favored 'General case' 0 C--N 1.311 -1.085 0 O-C-N 123.413 0.446 . . . . 0.0 110.337 -179.644 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.545 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 3.1 m -132.04 163.81 36.46 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.572 0 CA-C-O 120.745 0.307 . . . . 0.0 111.082 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 12.0 p -130.89 162.2 30.17 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 115.126 -0.943 . . . . 0.0 108.896 176.509 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 250' ' ' PHE . . . . . 0.583 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 73.7 m-85 -121.57 157.92 29.67 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-O 121.146 0.498 . . . . 0.0 111.6 -174.763 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 3.7 m -152.25 155.89 38.63 Favored 'General case' 0 C--N 1.313 -1.017 0 CA-C-N 115.473 -0.785 . . . . 0.0 109.473 175.359 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 54.21 25.77 6.09 Favored 'General case' 0 C--N 1.314 -0.947 0 N-CA-C 112.7 0.63 . . . . 0.0 112.7 174.846 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 0.401 HG22 ' CA ' ' A' ' 290' ' ' GLY . 95.6 t -82.53 129.76 36.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 174.487 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -99.92 138.59 36.78 Favored 'General case' 0 C--O 1.24 0.601 0 C-N-CA 120.548 -0.461 . . . . 0.0 110.361 -179.74 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 80.94 -61.56 4.54 Favored Glycine 0 C--N 1.319 -0.378 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 -175.815 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 256' ' ' MET . . . . . 0.56 ' SD ' ' CG1' ' A' ' 224' ' ' VAL . 31.3 mtt -80.71 62.43 4.75 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.608 0.718 . . . . 0.0 110.172 174.935 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 257' ' ' ILE . . . . . 0.4 ' O ' ' HB2' ' A' ' 260' ' ' ASN . 47.6 pt -72.54 -19.41 19.19 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.86 -177.868 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 258' ' ' GLN . . . . . 0.473 ' HB2' ' HG ' ' A' ' 284' ' ' SER . 0.7 OUTLIER -56.02 -39.36 71.82 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 -179.624 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 259' ' ' LEU . . . . . 0.939 HD21 ' CE2' ' A' ' 283' ' ' PHE . 89.8 mt -62.21 -41.7 98.62 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 116.009 -0.542 . . . . 0.0 109.742 178.767 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 260' ' ' ASN . . . . . 0.4 ' HB2' ' O ' ' A' ' 257' ' ' ILE . 97.1 m-20 -60.76 -40.72 93.52 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 178.798 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -96.95 11.04 66.12 Favored Glycine 0 CA--C 1.526 0.78 0 CA-C-N 115.485 -0.78 . . . . 0.0 112.676 -177.664 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 262' ' ' CYS . . . . . 0.401 ' N ' ' O ' ' A' ' 258' ' ' GLN . 4.0 m -102.84 146.75 27.81 Favored 'General case' 0 CA--C 1.517 -0.315 0 CA-C-N 117.6 0.7 . . . . 0.0 111.475 -179.457 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 51.5 mt-30 -62.34 161.96 22.29 Favored Pre-proline 0 C--N 1.326 -0.421 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 172.865 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 264' ' ' PRO . . . . . 0.545 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 37.6 Cg_endo -62.56 146.02 95.4 Favored 'Trans proline' 0 C--N 1.305 -1.727 0 C-N-CA 121.33 1.353 . . . . 0.0 111.219 178.644 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 265' ' ' MET . . . . . 0.611 ' N ' ' SD ' ' A' ' 265' ' ' MET . 0.9 OUTLIER -128.35 162.27 27.48 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 116.782 -0.19 . . . . 0.0 111.502 -175.702 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 70.3 tt0 -71.0 139.4 50.5 Favored 'General case' 0 C--O 1.245 0.818 0 O-C-N 123.585 0.553 . . . . 0.0 109.621 176.641 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 267' ' ' ILE . . . . . 0.65 HG22 HG22 ' A' ' 277' ' ' ILE . 1.9 pp -127.41 152.43 35.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-O 121.049 0.452 . . . . 0.0 111.777 -179.766 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 268' ' ' LYS . . . . . 0.458 ' HA ' HG23 ' A' ' 244' ' ' THR . 63.8 mttp -129.3 114.23 15.97 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.852 178.816 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.56 HG22 ' OG1' ' A' ' 244' ' ' THR . 34.7 m -74.98 106.75 4.94 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 CA-C-O 121.145 0.497 . . . . 0.0 112.242 -176.679 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 270' ' ' LEU . . . . . 0.45 HD12 HG23 ' A' ' 231' ' ' VAL . 92.9 mt -66.11 -41.02 91.14 Favored 'General case' 0 N--CA 1.449 -0.503 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.517 175.546 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -149.04 -176.19 22.12 Favored Glycine 0 C--N 1.322 -0.224 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 178.945 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 272' ' ' PRO . . . . . 0.429 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 33.6 Cg_endo -60.98 -34.84 90.14 Favored 'Trans proline' 0 N--CA 1.496 1.672 0 C-N-CA 121.97 1.78 . . . . 0.0 111.992 -177.29 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 57.1 m-85 -118.76 7.75 11.69 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 112.245 0.461 . . . . 0.0 112.245 178.826 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 6.0 p -120.97 124.36 44.7 Favored 'General case' 0 C--N 1.319 -0.725 0 C-N-CA 120.888 -0.325 . . . . 0.0 110.323 178.586 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 275' ' ' PHE . . . . . 0.521 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -132.66 157.55 44.55 Favored 'General case' 0 CA--C 1.501 -0.924 0 C-N-CA 120.133 -0.627 . . . . 0.0 112.599 179.43 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 276' ' ' SER . . . . . 0.536 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 7.4 p -125.79 142.36 51.55 Favored 'General case' 0 N--CA 1.431 -1.408 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.937 -173.803 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 277' ' ' ILE . . . . . 0.65 HG22 HG22 ' A' ' 267' ' ' ILE . 32.8 pt -139.77 163.56 24.73 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.917 0 CA-C-N 115.166 -0.924 . . . . 0.0 111.964 -172.783 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 278' ' ' CYS . . . . . 0.414 ' C ' ' O ' ' A' ' 277' ' ' ILE . 86.1 m -17.78 -96.25 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 124.413 1.085 . . . . 0.0 113.611 -178.86 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 279' ' ' ASP . . . . . 0.454 ' CG ' ' HB2' ' A' ' 228' ' ' ASN . 67.2 t0 -149.38 112.51 4.91 Favored 'General case' 0 CA--C 1.499 -1.017 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 178.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 280' ' ' THR . . . . . 0.791 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 11.3 p -67.21 -23.81 65.78 Favored 'General case' 0 N--CA 1.42 -1.949 0 CA-C-O 121.084 0.468 . . . . 0.0 110.4 179.08 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -66.28 -19.12 65.73 Favored 'General case' 0 C--N 1.315 -0.897 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.613 173.478 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 282' ' ' ASN . . . . . 0.48 ' ND2' ' C ' ' A' ' 282' ' ' ASN . 0.0 OUTLIER -91.46 2.72 56.22 Favored 'General case' 0 CA--C 1.513 -0.474 0 C-N-CA 120.409 -0.516 . . . . 0.0 109.809 176.324 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 283' ' ' PHE . . . . . 0.939 ' CE2' HD21 ' A' ' 259' ' ' LEU . 16.2 m-85 -100.98 -76.52 0.56 Allowed 'General case' 0 N--CA 1.445 -0.703 0 CA-C-O 121.404 0.621 . . . . 0.0 109.417 173.616 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 284' ' ' SER . . . . . 0.473 ' HG ' ' HB2' ' A' ' 258' ' ' GLN . 0.0 OUTLIER 166.48 -175.06 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 114.41 -1.268 . . . . 0.0 109.132 -172.875 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 285' ' ' ASP . . . . . 0.415 ' C ' ' HG3' ' A' ' 256' ' ' MET . 19.8 m-20 -86.5 134.5 33.67 Favored 'General case' 0 N--CA 1.472 0.643 0 CA-C-N 117.406 0.094 . . . . 0.0 110.756 179.143 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 286' ' ' TYR . . . . . 0.455 ' HB2' ' SD ' ' A' ' 256' ' ' MET . 55.5 t80 -76.65 128.34 34.5 Favored 'General case' 0 N--CA 1.468 0.447 0 C-N-CA 123.102 0.561 . . . . 0.0 111.094 179.256 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 7.0 mm -100.75 -69.15 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 116.563 -0.29 . . . . 0.0 110.672 173.271 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 95.5 mtm-85 -160.8 -179.44 7.59 Favored 'General case' 0 C--O 1.241 0.63 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.452 -178.748 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 63.35 -143.74 48.58 Favored Glycine 0 CA--C 1.498 -1.027 0 CA-C-N 114.963 -1.017 . . . . 0.0 111.338 174.03 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 290' ' ' GLY . . . . . 0.401 ' CA ' HG22 ' A' ' 253' ' ' VAL . . . 98.76 123.15 4.82 Favored Glycine 0 N--CA 1.436 -1.324 0 C-N-CA 120.968 -0.634 . . . . 0.0 111.774 178.625 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 47.9 mm -119.05 130.18 74.2 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.488 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 175.28 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 11.3 p -122.04 135.87 60.77 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.985 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 -178.063 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 293' ' ' SER . . . . . 0.497 ' HA ' ' O ' ' A' ' 217' ' ' LEU . 0.3 OUTLIER -136.19 140.03 43.26 Favored 'General case' 0 C--N 1.316 -0.878 0 C-N-CA 120.478 -0.489 . . . . 0.0 110.237 -177.416 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 294' ' ' GLN . . . . . 0.681 ' HB3' ' CD1' ' A' ' 242' ' ' PHE . 2.3 pt20 -74.42 142.22 44.99 Favored 'General case' 0 CA--C 1.502 -0.902 0 C-N-CA 120.083 -0.647 . . . . 0.0 110.847 178.322 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 11.4 t -131.84 96.79 2.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 176.046 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 296' ' ' LYS . . . . . 0.439 ' HZ1' ' CD ' ' A' ' 243' ' ' GLU . 68.4 mttm -77.85 105.65 9.17 Favored 'General case' 0 N--CA 1.433 -1.291 0 N-CA-C 106.918 -1.512 . . . . 0.0 106.918 175.32 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 3.5 m -42.84 145.47 0.88 Allowed Pre-proline 0 C--N 1.325 -0.488 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.722 -171.507 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_exo -52.71 140.28 56.74 Favored 'Trans proline' 0 C--N 1.309 -1.548 0 C-N-CA 121.897 1.731 . . . . 0.0 111.853 -176.688 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 20.9 mmtm -121.98 154.15 37.59 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.659 -0.701 . . . . 0.0 109.494 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 50.6 mttp -73.48 149.82 42.05 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 107.4 -1.333 . . . . 0.0 107.4 170.67 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 41.1 pt -49.68 108.56 0.09 OUTLIER 'Isoleucine or valine' 0 C--O 1.235 0.291 0 C-N-CA 119.025 -1.07 . . . . 0.0 109.237 -178.396 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 31.3 t -155.56 166.24 34.13 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.1 -170.191 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 80.6 t80 -102.96 111.61 24.04 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 116.171 -0.468 . . . . 0.0 109.771 177.598 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 304' ' ' LYS . . . . . 0.5 ' HD3' ' HA ' ' A' ' 304' ' ' LYS . 20.6 mmtm -110.5 149.67 30.0 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.67 177.515 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -53.06 92.62 0.01 OUTLIER 'General case' 0 C--O 1.24 0.578 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 178.322 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 306' ' ' LEU . . . . . 0.669 ' H ' HD23 ' A' ' 306' ' ' LEU . 0.2 OUTLIER -61.46 153.22 70.55 Favored Pre-proline 0 C--N 1.321 -0.639 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.845 -176.886 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 307' ' ' PRO . . . . . 0.492 ' O ' ' C ' ' A' ' 308' ' ' ALA . 36.6 Cg_exo -61.67 155.65 52.5 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 C-N-CA 122.417 2.078 . . . . 0.0 109.822 174.39 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 308' ' ' ALA . . . . . 0.492 ' C ' ' O ' ' A' ' 307' ' ' PRO . . . -27.91 120.48 0.11 Allowed 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 120.839 0.352 . . . . 0.0 110.823 -175.365 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 4.2 m -60.76 147.74 41.4 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.461 -174.302 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 310' ' ' LEU . . . . . 0.513 HD12 ' N ' ' A' ' 310' ' ' LEU . 7.7 mp -78.15 140.12 39.0 Favored 'General case' 0 C--O 1.243 0.74 0 CA-C-N 115.847 -0.615 . . . . 0.0 109.834 -176.626 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 26.7 m -107.78 125.03 64.27 Favored 'Isoleucine or valine' 0 C--O 1.239 0.519 0 CA-C-O 120.903 0.383 . . . . 0.0 111.101 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 67.7 mt-10 . . . . . 0 C--O 1.202 -1.4 0 CA-C-O 118.463 -0.78 . . . . 0.0 110.542 -178.554 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 201' ' ' GLU . . . . . 0.569 ' C ' ' H ' ' A' ' 203' ' ' GLY . 96.8 mt-10 . . . . . 0 N--CA 1.476 0.853 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 22.6 m-85 63.31 -29.17 0.09 Allowed 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 123.45 0.7 . . . . 0.0 111.798 -178.22 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 203' ' ' GLY . . . . . 0.569 ' H ' ' C ' ' A' ' 201' ' ' GLU . . . -60.66 -34.93 88.33 Favored Glycine 0 C--N 1.319 -0.364 0 N-CA-C 109.941 -1.264 . . . . 0.0 109.941 178.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 204' ' ' GLU . . . . . 0.483 ' OE1' ' N ' ' A' ' 201' ' ' GLU . 1.6 mp0 -62.49 -40.48 96.84 Favored 'General case' 0 CA--C 1.516 -0.351 0 CA-C-O 121.307 0.575 . . . . 0.0 109.509 177.948 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 99.9 mt-10 -67.04 -39.3 86.94 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.813 -179.498 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 206' ' ' MET . . . . . 0.43 ' CE ' HG13 ' A' ' 295' ' ' VAL . 48.4 ttm -91.17 93.97 9.36 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.932 -176.424 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 27.2 m -132.35 158.39 43.27 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.292 178.228 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 208' ' ' LEU . . . . . 0.66 HD11 ' O ' ' A' ' 296' ' ' LYS . 5.1 mp -127.29 149.41 50.04 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 122.573 0.349 . . . . 0.0 110.247 179.618 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -102.34 -47.36 4.52 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 112.132 0.419 . . . . 0.0 112.132 177.142 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 210' ' ' ASP . . . . . 0.496 ' OD1' ' N ' ' A' ' 211' ' ' SER . 34.9 p-10 -64.18 -48.66 75.07 Favored 'General case' 0 CA--C 1.51 -0.575 0 C-N-CA 120.443 -0.503 . . . . 0.0 109.831 177.522 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 211' ' ' SER . . . . . 0.496 ' N ' ' OD1' ' A' ' 210' ' ' ASP . 4.4 m -76.01 144.22 41.0 Favored 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 114.871 -1.059 . . . . 0.0 109.58 178.659 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 212' ' ' ASN . . . . . 0.42 ' O ' ' C ' ' A' ' 213' ' ' GLY . 57.4 t-20 -84.88 91.77 8.11 Favored 'General case' 0 CA--C 1.514 -0.429 0 C-N-CA 120.643 -0.423 . . . . 0.0 110.192 -178.838 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 213' ' ' GLY . . . . . 0.469 ' O ' ' NE2' ' A' ' 215' ' ' GLN . . . 29.94 50.85 0.16 Allowed Glycine 0 C--N 1.334 0.44 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.54 178.642 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -69.83 128.44 36.4 Favored 'General case' 0 N--CA 1.442 -0.842 0 C-N-CA 120.728 -0.389 . . . . 0.0 110.398 -175.582 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 215' ' ' GLN . . . . . 0.469 ' NE2' ' O ' ' A' ' 213' ' ' GLY . 67.3 mm-40 -88.2 113.88 56.99 Favored Pre-proline 0 N--CA 1.443 -0.796 0 N-CA-C 108.636 -0.875 . . . . 0.0 108.636 175.821 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 216' ' ' PRO . . . . . 0.416 ' HD3' ' HA ' ' A' ' 215' ' ' GLN . 47.2 Cg_exo -57.6 146.27 85.27 Favored 'Trans proline' 0 N--CA 1.496 1.627 0 C-N-CA 122.437 2.092 . . . . 0.0 112.951 -172.099 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 217' ' ' LEU . . . . . 0.521 ' HB3' ' O ' ' A' ' 240' ' ' HIS . 0.4 OUTLIER -75.7 148.07 38.91 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.232 -0.895 . . . . 0.0 110.448 179.359 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 66.8 m -131.48 153.78 49.41 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-N 116.416 -0.357 . . . . 0.0 110.174 175.68 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -150.84 155.63 39.6 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.531 -0.304 . . . . 0.0 111.368 -178.404 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 220' ' ' MET . . . . . 0.435 ' SD ' HD22 ' A' ' 235' ' ' LEU . 92.1 mtp -76.83 135.37 38.89 Favored 'General case' 0 N--CA 1.447 -0.615 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.549 176.512 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 94.3 t -87.13 130.99 36.11 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.067 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 175.567 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 222' ' ' SER . . . . . 0.419 ' OG ' ' N ' ' A' ' 223' ' ' MET . 0.0 OUTLIER -82.44 -71.51 0.48 Allowed 'General case' 0 C--N 1.308 -1.216 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 176.836 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 223' ' ' MET . . . . . 0.419 ' N ' ' OG ' ' A' ' 222' ' ' SER . 5.5 ptm -137.66 149.09 46.29 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.711 174.843 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 224' ' ' VAL . . . . . 0.708 HG13 ' CG1' ' A' ' 232' ' ' VAL . 2.3 t -113.37 124.3 69.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 174.822 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 225' ' ' THR . . . . . 0.509 ' O ' HG21 ' A' ' 280' ' ' THR . 74.6 p -79.66 133.08 36.38 Favored 'General case' 0 C--N 1.321 -0.647 0 C-N-CA 120.474 -0.491 . . . . 0.0 110.491 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 226' ' ' LYS . . . . . 0.445 ' NZ ' ' OD1' ' A' ' 285' ' ' ASP . 0.1 OUTLIER -79.21 75.11 5.76 Favored 'General case' 0 C--O 1.243 0.727 0 CA-C-O 121.283 0.563 . . . . 0.0 109.595 179.22 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 227' ' ' ASP . . . . . 0.522 ' N ' ' OG1' ' A' ' 280' ' ' THR . 3.9 t0 -148.72 176.56 10.26 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-N 115.475 -0.784 . . . . 0.0 110.594 -179.742 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 228' ' ' ASN . . . . . 0.485 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.2 OUTLIER -142.87 123.52 8.16 Favored Pre-proline 0 C--N 1.313 -1.02 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.881 179.05 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 229' ' ' PRO . . . . . 0.485 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 47.8 Cg_endo -63.83 146.69 62.47 Favored 'Cis proline' 0 N--CA 1.496 1.62 0 C-N-CA 123.185 -1.589 . . . . 0.0 110.744 -2.12 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 230' ' ' GLY . . . . . 0.516 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -76.04 141.14 26.7 Favored Glycine 0 N--CA 1.443 -0.857 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 -178.173 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 231' ' ' VAL . . . . . 0.575 HG23 HD12 ' A' ' 270' ' ' LEU . 2.3 p -124.1 133.0 70.5 Favored 'Isoleucine or valine' 0 C--O 1.241 0.624 0 N-CA-C 109.059 -0.719 . . . . 0.0 109.059 174.22 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 232' ' ' VAL . . . . . 0.708 ' CG1' HG13 ' A' ' 224' ' ' VAL . 0.7 OUTLIER -132.34 156.36 42.34 Favored 'Isoleucine or valine' 0 C--O 1.246 0.895 0 C-N-CA 120.438 -0.505 . . . . 0.0 110.353 -175.024 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 233' ' ' THR . . . . . 0.5 ' HA ' ' O ' ' A' ' 273' ' ' TYR . 1.6 p -106.41 159.07 16.43 Favored 'General case' 0 N--CA 1.441 -0.907 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.665 177.556 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 39.3 m -124.36 161.95 24.86 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 123.063 0.545 . . . . 0.0 109.861 -178.893 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.435 HD22 ' SD ' ' A' ' 220' ' ' MET . 37.2 tp -62.87 135.7 57.46 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 107.88 -1.155 . . . . 0.0 107.88 176.928 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 236' ' ' ASP . . . . . 0.438 ' O ' ' CZ ' ' A' ' 273' ' ' TYR . 1.9 m-20 -59.54 -35.65 74.62 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-O 121.251 0.548 . . . . 0.0 111.117 -173.611 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 70.1 mt-10 -86.47 -5.02 59.26 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.605 -177.611 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -101.99 100.47 10.76 Favored 'General case' 0 CA--C 1.516 -0.344 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.554 179.393 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 66.4 mtp180 -86.82 107.53 18.34 Favored 'General case' 0 C--N 1.317 -0.847 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 -179.686 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 240' ' ' HIS . . . . . 0.521 ' O ' ' HB3' ' A' ' 217' ' ' LEU . 9.9 p80 -57.48 -47.38 82.05 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.655 -176.902 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 71.18 25.31 75.85 Favored Glycine 0 C--N 1.309 -0.92 0 N-CA-C 109.783 -1.327 . . . . 0.0 109.783 -179.173 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 242' ' ' PHE . . . . . 0.496 ' CD2' ' HB2' ' A' ' 240' ' ' HIS . 15.4 m-30 -79.51 141.28 36.84 Favored 'General case' 0 N--CA 1.435 -1.213 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 -179.82 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 243' ' ' GLU . . . . . 0.505 ' HB2' ' HB2' ' A' ' 246' ' ' ASP . 96.5 mt-10 -96.79 146.5 24.84 Favored 'General case' 0 C--N 1.31 -1.138 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.343 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.1 122.44 16.09 Favored 'General case' 0 C--N 1.307 -1.269 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 -178.408 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 85.0 7.33 83.92 Favored Glycine 0 N--CA 1.442 -0.912 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 -177.211 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 246' ' ' ASP . . . . . 0.505 ' HB2' ' HB2' ' A' ' 243' ' ' GLU . 13.5 t0 -83.79 168.3 16.29 Favored 'General case' 0 C--O 1.24 0.557 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 176.032 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 247' ' ' PHE . . . . . 0.46 ' HA ' ' O ' ' A' ' 265' ' ' MET . 66.3 m-85 -109.4 141.6 41.55 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 112.099 0.407 . . . . 0.0 112.099 -176.349 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.445 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.8 m -134.21 161.16 41.18 Favored 'Isoleucine or valine' 0 C--O 1.241 0.655 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.098 178.059 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 249' ' ' SER . . . . . 0.425 ' OG ' HG21 ' A' ' 295' ' ' VAL . 47.7 m -128.04 159.37 35.24 Favored 'General case' 0 C--N 1.321 -0.669 0 C-N-CA 124.338 1.055 . . . . 0.0 108.53 173.626 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 250' ' ' PHE . . . . . 0.508 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 69.9 m-85 -110.54 145.8 37.15 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 121.264 0.554 . . . . 0.0 112.171 -177.789 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 19.7 m -137.73 153.3 49.77 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.227 177.048 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 71.6 mm-40 56.08 21.37 5.05 Favored 'General case' 0 C--N 1.314 -0.954 0 N-CA-C 113.354 0.872 . . . . 0.0 113.354 173.023 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 0.437 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 94.1 t -84.37 130.7 35.53 Favored 'Isoleucine or valine' 0 C--O 1.239 0.52 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 177.262 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 254' ' ' GLN . . . . . 0.414 ' HB2' ' O ' ' A' ' 288' ' ' ARG . 83.1 mt-30 -105.26 144.44 32.05 Favored 'General case' 0 C--O 1.243 0.728 0 CA-C-O 121.001 0.429 . . . . 0.0 109.897 176.984 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 84.91 -68.42 3.5 Favored Glycine 0 C--N 1.313 -0.747 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -174.049 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 256' ' ' MET . . . . . 0.536 ' HG3' ' N ' ' A' ' 286' ' ' TYR . 47.8 mtt -78.25 65.04 3.51 Favored 'General case' 0 CA--C 1.515 -0.381 0 CA-C-O 121.397 0.617 . . . . 0.0 110.318 173.072 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 46.9 pt -70.82 -23.06 23.54 Favored 'Isoleucine or valine' 0 C--O 1.244 0.797 0 CA-C-N 115.475 -0.784 . . . . 0.0 110.135 -178.271 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 258' ' ' GLN . . . . . 0.542 ' HG3' ' SG ' ' A' ' 262' ' ' CYS . 70.7 tp60 -60.8 -36.62 79.49 Favored 'General case' 0 N--CA 1.445 -0.682 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 179.459 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 259' ' ' LEU . . . . . 0.677 HD21 ' CD2' ' A' ' 283' ' ' PHE . 92.3 mt -61.88 -40.52 95.68 Favored 'General case' 0 N--CA 1.448 -0.542 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.204 179.09 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 260' ' ' ASN . . . . . 0.437 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 98.8 m-20 -60.2 -41.14 92.35 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 179.218 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -96.48 10.94 67.06 Favored Glycine 0 CA--C 1.532 1.132 0 CA-C-N 116.042 -0.527 . . . . 0.0 112.269 179.572 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 262' ' ' CYS . . . . . 0.542 ' SG ' ' HG3' ' A' ' 258' ' ' GLN . 1.2 m -82.24 142.41 32.15 Favored 'General case' 0 CA--C 1.513 -0.444 0 CA-C-N 117.382 0.591 . . . . 0.0 110.827 -178.379 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 27.9 mm100 -62.57 152.51 80.76 Favored Pre-proline 0 C--N 1.321 -0.662 0 N-CA-C 107.572 -1.27 . . . . 0.0 107.572 171.582 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 264' ' ' PRO . . . . . 0.579 ' HB3' HG21 ' A' ' 295' ' ' VAL . 36.8 Cg_endo -61.22 142.96 98.11 Favored 'Trans proline' 0 C--N 1.307 -1.644 0 C-N-CA 121.059 1.172 . . . . 0.0 110.447 -178.999 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 265' ' ' MET . . . . . 0.46 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 24.0 ptp -129.12 154.34 46.81 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 112.162 0.43 . . . . 0.0 112.162 -172.429 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -71.02 136.1 48.17 Favored 'General case' 0 C--O 1.245 0.816 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 177.611 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 267' ' ' ILE . . . . . 0.635 HG22 HG22 ' A' ' 277' ' ' ILE . 2.0 pp -126.65 158.54 36.94 Favored 'Isoleucine or valine' 0 C--O 1.243 0.735 0 N-CA-C 112.546 0.573 . . . . 0.0 112.546 -175.864 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 75.1 tttt -127.83 115.81 19.2 Favored 'General case' 0 N--CA 1.448 -0.532 0 CA-C-N 115.213 -0.903 . . . . 0.0 109.86 -179.322 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 17.8 m -70.59 134.5 29.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.244 -179.629 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 270' ' ' LEU . . . . . 0.575 HD12 HG23 ' A' ' 231' ' ' VAL . 81.6 mt -107.75 -24.16 11.81 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.023 0.44 . . . . 0.0 110.124 178.161 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -176.4 -178.27 46.05 Favored Glycine 0 C--N 1.319 -0.396 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 -178.072 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 272' ' ' PRO . . . . . 0.428 ' O ' ' CD2' ' A' ' 240' ' ' HIS . 75.5 Cg_exo -52.89 -43.6 55.21 Favored 'Trans proline' 0 C--N 1.311 -1.424 0 C-N-CA 121.958 1.772 . . . . 0.0 111.582 -177.303 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 273' ' ' TYR . . . . . 0.5 ' O ' ' HA ' ' A' ' 233' ' ' THR . 7.3 m-85 -117.76 10.75 13.4 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 115.933 -0.576 . . . . 0.0 112.084 -176.407 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 5.4 p -123.77 130.02 51.98 Favored 'General case' 0 C--N 1.321 -0.66 0 C-N-CA 120.927 -0.309 . . . . 0.0 110.992 -179.51 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 275' ' ' PHE . . . . . 0.547 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -143.81 164.08 31.52 Favored 'General case' 0 C--O 1.238 0.48 0 C-N-CA 120.926 -0.309 . . . . 0.0 111.406 175.811 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 276' ' ' SER . . . . . 0.522 ' HB3' HD11 ' A' ' 270' ' ' LEU . 4.4 p -131.05 145.38 52.0 Favored 'General case' 0 C--O 1.244 0.805 0 C-N-CA 120.672 -0.411 . . . . 0.0 111.912 -175.723 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 277' ' ' ILE . . . . . 0.635 HG22 HG22 ' A' ' 267' ' ' ILE . 35.0 pt -140.18 165.05 21.86 Favored 'Isoleucine or valine' 0 C--O 1.236 0.368 0 CA-C-N 114.766 -1.107 . . . . 0.0 112.582 -173.077 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 278' ' ' CYS . . . . . 0.413 ' SG ' ' SD ' ' A' ' 265' ' ' MET . 2.6 p -27.2 -94.76 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.416 0 N-CA-C 114.478 1.288 . . . . 0.0 114.478 -176.394 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 58.2 m-20 -144.48 110.0 5.24 Favored 'General case' 0 CA--C 1.513 -0.456 0 CA-C-N 116.622 -0.263 . . . . 0.0 111.423 -171.402 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 280' ' ' THR . . . . . 0.785 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 59.7 p -66.02 -27.7 68.31 Favored 'General case' 0 C--N 1.31 -1.137 0 CA-C-O 121.215 0.531 . . . . 0.0 109.712 172.066 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 1.5 p -63.68 -17.06 62.57 Favored 'General case' 0 N--CA 1.43 -1.435 0 CA-C-N 114.799 -1.092 . . . . 0.0 109.753 174.071 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 17.9 t-20 -98.27 -8.71 26.74 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.6 175.05 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 283' ' ' PHE . . . . . 0.785 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 15.6 m-30 -90.66 -83.08 0.27 Allowed 'General case' 0 C--O 1.237 0.404 0 CA-C-O 121.436 0.636 . . . . 0.0 110.952 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 169.25 -174.0 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 114.342 -1.299 . . . . 0.0 108.874 -173.71 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 285' ' ' ASP . . . . . 0.445 ' OD1' ' NZ ' ' A' ' 226' ' ' LYS . 31.1 t0 -92.99 112.36 24.3 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 120.906 -0.318 . . . . 0.0 111.678 -179.788 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 286' ' ' TYR . . . . . 0.536 ' N ' ' HG3' ' A' ' 256' ' ' MET . 12.4 t80 -63.66 128.49 36.07 Favored 'General case' 0 CA--C 1.512 -0.485 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 177.865 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 287' ' ' ILE . . . . . 0.448 HG22 ' HG2' ' A' ' 288' ' ' ARG . 96.5 mt -106.64 -64.06 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 175.894 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 288' ' ' ARG . . . . . 0.448 ' HG2' HG22 ' A' ' 287' ' ' ILE . 9.6 ptp180 -161.15 -178.67 6.9 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.088 178.921 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 70.02 -161.08 53.19 Favored Glycine 0 CA--C 1.504 -0.615 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 178.893 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 108.8 117.59 4.06 Favored Glycine 0 N--CA 1.442 -0.958 0 C-N-CA 120.934 -0.651 . . . . 0.0 113.291 174.686 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 97.2 mt -118.16 130.34 73.17 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.25 0 N-CA-C 107.321 -1.363 . . . . 0.0 107.321 170.562 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 4.8 p -109.19 128.89 64.77 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 -179.355 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 36.7 m -116.63 137.42 52.2 Favored 'General case' 0 N--CA 1.438 -1.039 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.932 -176.543 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -68.04 147.27 52.61 Favored 'General case' 0 N--CA 1.431 -1.399 0 CA-C-N 115.609 -0.723 . . . . 0.0 109.752 176.884 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 295' ' ' VAL . . . . . 0.579 HG21 ' HB3' ' A' ' 264' ' ' PRO . 76.2 t -126.23 97.95 4.56 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.869 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 173.774 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 296' ' ' LYS . . . . . 0.66 ' O ' HD11 ' A' ' 208' ' ' LEU . 4.8 mttp -97.11 99.25 10.76 Favored 'General case' 0 N--CA 1.435 -1.206 0 N-CA-C 109.003 -0.739 . . . . 0.0 109.003 179.555 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 5.0 m -104.58 165.38 13.4 Favored Pre-proline 0 C--N 1.318 -0.786 0 CA-C-N 115.216 -0.902 . . . . 0.0 108.951 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_exo -60.41 104.91 0.27 Allowed 'Trans proline' 0 C--N 1.302 -1.913 0 C-N-CA 120.48 0.787 . . . . 0.0 110.192 177.815 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 49.4 mttp -79.4 147.34 32.38 Favored 'General case' 0 C--N 1.321 -0.666 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 174.831 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 300' ' ' LYS . . . . . 0.567 ' NZ ' ' OG ' ' A' ' 302' ' ' SER . 62.3 tttm -63.43 128.03 33.98 Favored 'General case' 0 C--N 1.319 -0.736 0 C-N-CA 118.684 -1.207 . . . . 0.0 108.29 179.938 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 40.4 mm -78.3 91.19 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.048 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 302' ' ' SER . . . . . 0.567 ' OG ' ' NZ ' ' A' ' 300' ' ' LYS . 7.2 m -155.43 94.97 1.65 Allowed 'General case' 0 C--N 1.302 -1.485 0 CA-C-N 115.263 -0.881 . . . . 0.0 109.396 -177.014 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 92.0 m-85 -132.83 153.9 50.84 Favored 'General case' 0 C--N 1.308 -1.231 0 CA-C-N 115.501 -0.772 . . . . 0.0 108.959 -176.499 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 23.2 mmtm -65.69 158.12 28.27 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 176.33 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 4.1 m -56.71 138.8 52.25 Favored 'General case' 0 C--N 1.311 -1.095 0 C-N-CA 121.029 -0.268 . . . . 0.0 110.712 -172.565 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 306' ' ' LEU . . . . . 0.41 ' HB3' ' HD2' ' A' ' 307' ' ' PRO . 38.1 mt -62.21 170.29 2.29 Favored Pre-proline 0 C--O 1.243 0.724 0 N-CA-C 108.092 -1.077 . . . . 0.0 108.092 176.113 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 307' ' ' PRO . . . . . 0.41 ' HD2' ' HB3' ' A' ' 306' ' ' LEU . 50.1 Cg_exo -56.81 138.67 86.55 Favored 'Trans proline' 0 C--N 1.304 -1.784 0 C-N-CA 120.9 1.067 . . . . 0.0 110.275 -178.327 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 308' ' ' ALA . . . . . 0.424 ' O ' ' HG ' ' A' ' 310' ' ' LEU . . . -101.3 163.33 12.33 Favored 'General case' 0 CA--C 1.503 -0.839 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.465 179.429 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -72.01 83.36 0.96 Allowed 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 175.797 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 310' ' ' LEU . . . . . 0.424 ' HG ' ' O ' ' A' ' 308' ' ' ALA . 67.2 mt -77.59 117.08 18.68 Favored 'General case' 0 CA--C 1.508 -0.643 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.432 -172.678 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 6.6 m -123.25 130.39 74.33 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 175.382 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 312' ' ' GLU . . . . . 0.455 ' H ' ' CD ' ' A' ' 312' ' ' GLU . 51.1 mp0 . . . . . 0 C--O 1.214 -0.794 0 CA-C-O 118.081 -0.961 . . . . 0.0 110.616 -176.409 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 201' ' ' GLU . . . . . 0.562 ' O ' ' N ' ' A' ' 203' ' ' GLY . 0.0 OUTLIER . . . . . 0 N--CA 1.483 1.211 0 N-CA-C 107.699 -1.222 . . . . 0.0 107.699 . . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 202' ' ' PHE . . . . . 0.464 ' CD1' ' C ' ' A' ' 202' ' ' PHE . 0.1 OUTLIER 56.46 -47.8 0.03 OUTLIER 'General case' 0 N--CA 1.473 0.678 0 C-N-CA 123.889 0.876 . . . . 0.0 113.036 -179.505 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 203' ' ' GLY . . . . . 0.562 ' N ' ' O ' ' A' ' 201' ' ' GLU . . . -101.33 17.99 54.64 Favored Glycine 0 C--O 1.235 0.211 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 177.462 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 204' ' ' GLU . . . . . 0.491 ' OE1' ' N ' ' A' ' 201' ' ' GLU . 66.4 mt-10 -120.98 26.08 9.27 Favored 'General case' 0 C--N 1.323 -0.549 0 C-N-CA 122.584 0.354 . . . . 0.0 110.959 -178.381 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -62.88 -16.82 60.32 Favored 'General case' 0 C--O 1.24 0.57 0 CA-C-O 121.177 0.513 . . . . 0.0 110.305 -177.052 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 77.5 mtm -62.59 150.86 39.48 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.756 -177.838 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 27.7 m -129.5 160.92 39.95 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.867 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 173.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 73.7 mt -100.15 107.72 19.66 Favored 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 120.808 -0.357 . . . . 0.0 111.367 -173.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 9.8 m -64.37 -43.05 95.72 Favored 'General case' 0 C--N 1.316 -0.865 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 173.416 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 22.4 m-20 -60.76 -41.69 95.96 Favored 'General case' 0 CA--C 1.517 -0.315 0 CA-C-N 115.463 -0.789 . . . . 0.0 110.625 -176.912 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 211' ' ' SER . . . . . 0.43 ' CB ' ' HB2' ' A' ' 214' ' ' GLU . 0.8 OUTLIER -116.93 90.94 3.44 Favored 'General case' 0 C--N 1.318 -0.774 0 N-CA-C 107.514 -1.291 . . . . 0.0 107.514 172.423 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 55.3 t30 -79.19 112.89 16.85 Favored 'General case' 0 CA--C 1.51 -0.585 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.648 -171.735 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 68.86 17.65 71.66 Favored Glycine 0 CA--C 1.509 -0.29 0 N-CA-C 109.292 -1.523 . . . . 0.0 109.292 -177.776 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 214' ' ' GLU . . . . . 0.43 ' HB2' ' CB ' ' A' ' 211' ' ' SER . 99.0 mt-10 -110.75 112.43 24.3 Favored 'General case' 0 N--CA 1.438 -1.075 0 CA-C-O 121.214 0.53 . . . . 0.0 111.413 -177.385 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 215' ' ' GLN . . . . . 0.466 ' CB ' ' CD ' ' A' ' 216' ' ' PRO . 10.4 mt-30 -110.9 -172.25 0.23 Allowed Pre-proline 0 C--N 1.306 -1.305 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 171.702 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 216' ' ' PRO . . . . . 0.466 ' CD ' ' CB ' ' A' ' 215' ' ' GLN . 50.4 Cg_exo -56.43 139.21 86.6 Favored 'Trans proline' 0 C--N 1.301 -1.953 0 C-N-CA 121.034 1.156 . . . . 0.0 110.779 178.157 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 217' ' ' LEU . . . . . 0.47 ' HB3' ' O ' ' A' ' 240' ' ' HIS . 3.8 mm? -81.52 149.5 28.67 Favored 'General case' 0 CA--C 1.503 -0.829 0 N-CA-C 112.35 0.5 . . . . 0.0 112.35 -178.897 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 5.9 m -142.79 133.45 25.21 Favored 'General case' 0 N--CA 1.441 -0.92 0 CA-C-N 115.126 -0.943 . . . . 0.0 109.533 175.803 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -147.78 164.41 33.71 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 121.336 0.589 . . . . 0.0 112.295 -177.129 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 220' ' ' MET . . . . . 0.69 ' SD ' ' N ' ' A' ' 220' ' ' MET . 0.0 OUTLIER -74.77 132.62 41.75 Favored 'General case' 0 C--O 1.243 0.747 0 CA-C-N 115.023 -0.99 . . . . 0.0 109.876 178.264 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 52.4 t -88.91 130.21 38.67 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 175.142 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 36.9 p -88.1 -57.72 2.83 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 120.351 -0.54 . . . . 0.0 110.189 -178.661 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 1.7 ptm -137.04 149.75 47.64 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.481 175.69 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 224' ' ' VAL . . . . . 0.63 HG11 ' SD ' ' A' ' 256' ' ' MET . 21.7 t -127.21 132.32 69.76 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.963 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 174.004 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -106.42 121.55 44.48 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 -177.082 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 226' ' ' LYS . . . . . 0.548 ' HA ' ' HB ' ' A' ' 280' ' ' THR . 0.1 OUTLIER -77.38 73.39 3.95 Favored 'General case' 0 C--O 1.237 0.436 0 C-N-CA 119.721 -0.792 . . . . 0.0 111.642 -179.596 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 227' ' ' ASP . . . . . 0.419 ' N ' ' OG1' ' A' ' 280' ' ' THR . 41.5 t0 -126.23 -178.85 4.47 Favored 'General case' 0 C--O 1.238 0.499 0 CA-C-N 114.827 -1.079 . . . . 0.0 109.989 -179.587 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 228' ' ' ASN . . . . . 0.436 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.4 OUTLIER -136.89 123.19 13.54 Favored Pre-proline 0 CA--C 1.538 0.499 0 CA-C-O 120.571 0.224 . . . . 0.0 111.205 175.799 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 229' ' ' PRO . . . . . 0.436 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 50.0 Cg_endo -66.8 151.0 82.05 Favored 'Cis proline' 0 N--CA 1.495 1.61 0 C-N-CA 123.288 -1.547 . . . . 0.0 108.592 -2.397 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 230' ' ' GLY . . . . . 0.687 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -63.28 139.96 44.62 Favored Glycine 0 C--N 1.315 -0.586 0 C-N-CA 119.515 -1.326 . . . . 0.0 110.233 -175.249 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 3.1 p -125.07 131.3 72.68 Favored 'Isoleucine or valine' 0 C--O 1.241 0.641 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 178.408 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 232' ' ' VAL . . . . . 0.5 HG22 ' CD1' ' A' ' 275' ' ' PHE . 0.7 OUTLIER -135.26 157.14 39.95 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-N 116.546 -0.297 . . . . 0.0 110.334 -178.293 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 233' ' ' THR . . . . . 0.458 ' HA ' ' O ' ' A' ' 273' ' ' TYR . 11.9 m -114.78 147.03 40.33 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.012 177.365 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 55.7 m -106.47 153.09 22.79 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.021 -178.315 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.415 ' HB3' ' HB3' ' A' ' 238' ' ' ALA . 32.9 tp -56.81 130.03 43.93 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 -179.926 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 236' ' ' ASP . . . . . 0.538 ' HA ' ' CE1' ' A' ' 273' ' ' TYR . 34.6 t70 -55.23 -42.97 74.08 Favored 'General case' 0 CA--C 1.509 -0.62 0 CA-C-O 121.459 0.647 . . . . 0.0 109.865 -176.26 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -64.79 -33.54 76.23 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-N 114.851 -1.068 . . . . 0.0 110.52 -179.917 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 238' ' ' ALA . . . . . 0.415 ' HB3' ' HB3' ' A' ' 235' ' ' LEU . . . -114.94 92.8 4.06 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.532 -176.828 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 239' ' ' ARG . . . . . 0.454 ' HG2' ' CE1' ' A' ' 273' ' ' TYR . 58.9 mtm180 -67.29 138.14 56.62 Favored 'General case' 0 N--CA 1.448 -0.532 0 C-N-CA 119.927 -0.709 . . . . 0.0 109.821 174.334 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 240' ' ' HIS . . . . . 0.656 ' H ' ' CD2' ' A' ' 240' ' ' HIS . 6.2 p80 -58.9 -45.35 90.5 Favored 'General case' 0 C--N 1.313 -0.988 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.414 178.384 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 80.26 12.67 82.9 Favored Glycine 0 C--N 1.319 -0.39 0 N-CA-C 109.73 -1.348 . . . . 0.0 109.73 -177.871 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 242' ' ' PHE . . . . . 0.594 ' CD2' ' HB2' ' A' ' 240' ' ' HIS . 8.6 m-30 -81.61 149.58 28.53 Favored 'General case' 0 N--CA 1.442 -0.862 0 CA-C-N 115.327 -0.436 . . . . 0.0 110.329 -179.813 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 243' ' ' GLU . . . . . 0.532 ' CD ' ' HZ2' ' A' ' 300' ' ' LYS . 97.2 mt-10 -117.96 150.76 38.7 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-N 115.335 -0.848 . . . . 0.0 108.783 176.828 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 244' ' ' THR . . . . . 0.71 ' OG1' HG22 ' A' ' 269' ' ' VAL . 28.5 m -57.56 125.75 24.27 Favored 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 119.319 -0.952 . . . . 0.0 109.16 179.643 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 104.27 -10.93 51.17 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 -175.945 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 246' ' ' ASP . . . . . 0.45 ' OD1' ' NZ ' ' A' ' 300' ' ' LYS . 68.3 m-20 -67.73 147.56 52.46 Favored 'General case' 0 C--N 1.328 -0.358 0 O-C-N 122.82 -0.224 . . . . 0.0 111.0 178.18 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 247' ' ' PHE . . . . . 0.445 ' HA ' ' O ' ' A' ' 265' ' ' MET . 66.9 m-85 -109.52 125.75 52.82 Favored 'General case' 0 C--O 1.242 0.697 0 CA-C-N 116.1 -0.5 . . . . 0.0 109.909 178.037 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.49 HG12 ' HG2' ' A' ' 294' ' ' GLN . 3.4 m -132.48 164.52 34.78 Favored 'Isoleucine or valine' 0 C--O 1.246 0.908 0 N-CA-C 112.472 0.545 . . . . 0.0 112.472 -175.794 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 13.5 p -131.98 159.25 39.29 Favored 'General case' 0 C--O 1.241 0.634 0 CA-C-N 114.66 -1.155 . . . . 0.0 108.911 174.856 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 250' ' ' PHE . . . . . 0.574 ' CD1' HD22 ' A' ' 259' ' ' LEU . 65.9 m-85 -114.85 159.21 20.92 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 121.327 0.584 . . . . 0.0 112.529 -172.725 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 7.0 m -157.5 161.73 38.85 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-N 115.208 -0.905 . . . . 0.0 109.323 174.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 252' ' ' GLU . . . . . 0.445 ' HG3' HD12 ' A' ' 291' ' ' ILE . 61.9 mm-40 59.17 18.47 6.53 Favored 'General case' 0 CA--C 1.544 0.732 0 N-CA-C 112.024 0.379 . . . . 0.0 112.024 177.933 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 0.47 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 57.3 t -86.98 132.41 32.5 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 178.734 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 90.2 mt-30 -105.83 146.05 30.4 Favored 'General case' 0 C--O 1.24 0.589 0 CA-C-O 121.244 0.545 . . . . 0.0 111.096 177.511 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 255' ' ' GLY . . . . . 0.424 ' HA3' HG13 ' A' ' 287' ' ' ILE . . . 79.65 -65.94 3.61 Favored Glycine 0 CA--C 1.505 -0.585 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 -177.255 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 256' ' ' MET . . . . . 0.63 ' SD ' HG11 ' A' ' 224' ' ' VAL . 26.5 ttm -81.98 54.5 2.49 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-O 121.551 0.691 . . . . 0.0 109.324 175.106 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 257' ' ' ILE . . . . . 0.404 ' O ' ' HB2' ' A' ' 260' ' ' ASN . 48.2 pt -68.81 -20.06 24.58 Favored 'Isoleucine or valine' 0 C--O 1.239 0.546 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.607 -176.061 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 258' ' ' GLN . . . . . 0.694 ' HG3' ' SG ' ' A' ' 262' ' ' CYS . 47.4 tp60 -56.42 -31.66 64.13 Favored 'General case' 0 N--CA 1.439 -1.002 0 C-N-CA 120.009 -0.676 . . . . 0.0 110.353 178.851 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 259' ' ' LEU . . . . . 1.057 HD21 ' CE2' ' A' ' 283' ' ' PHE . 78.9 mt -62.18 -41.32 98.22 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 120.911 0.386 . . . . 0.0 110.323 174.17 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 260' ' ' ASN . . . . . 0.47 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 98.3 m-20 -59.77 -40.52 88.48 Favored 'General case' 0 CA--C 1.509 -0.612 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 -179.852 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -101.27 17.32 55.91 Favored Glycine 0 C--N 1.322 -0.2 0 CA-C-N 115.543 -0.753 . . . . 0.0 112.158 -178.425 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 262' ' ' CYS . . . . . 0.694 ' SG ' ' HG3' ' A' ' 258' ' ' GLN . 0.9 OUTLIER -91.77 155.32 18.33 Favored 'General case' 0 CA--C 1.51 -0.565 0 CA-C-N 117.157 0.478 . . . . 0.0 111.687 -178.009 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 28.1 mm-40 -74.18 153.72 88.39 Favored Pre-proline 0 C--N 1.325 -0.491 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 170.612 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 264' ' ' PRO . . . . . 0.674 ' CB ' HG21 ' A' ' 295' ' ' VAL . 56.2 Cg_endo -65.37 148.78 88.49 Favored 'Trans proline' 0 C--N 1.305 -1.716 0 C-N-CA 121.375 1.383 . . . . 0.0 111.253 -178.538 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 265' ' ' MET . . . . . 0.483 ' SD ' HD12 ' A' ' 277' ' ' ILE . 12.9 ptp -138.38 160.21 40.1 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.831 -174.853 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 266' ' ' GLU . . . . . 0.427 ' OE2' ' NZ ' ' A' ' 268' ' ' LYS . 36.1 tt0 -71.48 144.82 49.54 Favored 'General case' 0 C--O 1.242 0.663 0 O-C-N 123.999 0.812 . . . . 0.0 109.325 177.097 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 267' ' ' ILE . . . . . 0.687 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.5 pp -126.71 155.16 37.21 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-O 120.753 0.311 . . . . 0.0 111.501 -179.704 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 268' ' ' LYS . . . . . 0.638 ' HA ' HG23 ' A' ' 244' ' ' THR . 65.9 mttm -127.99 123.31 34.45 Favored 'General case' 0 C--O 1.239 0.548 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 177.496 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.71 HG22 ' OG1' ' A' ' 244' ' ' THR . 34.6 m -81.42 105.11 10.93 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.689 0 CA-C-O 121.284 0.564 . . . . 0.0 112.484 -176.398 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 92.4 mt -67.13 -41.42 86.15 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.639 -0.709 . . . . 0.0 110.089 175.927 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -150.51 -177.65 24.64 Favored Glycine 0 CA--C 1.52 0.356 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 -179.202 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 272' ' ' PRO . . . . . 0.605 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 33.7 Cg_endo -62.51 -32.23 80.17 Favored 'Trans proline' 0 C--N 1.309 -1.541 0 C-N-CA 121.883 1.722 . . . . 0.0 110.726 -177.203 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 273' ' ' TYR . . . . . 0.538 ' CE1' ' HA ' ' A' ' 236' ' ' ASP . 74.2 m-85 -116.87 0.07 12.39 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.608 -0.724 . . . . 0.0 112.89 -179.015 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -120.17 127.71 52.73 Favored 'General case' 0 C--O 1.242 0.696 0 C-N-CA 120.658 -0.417 . . . . 0.0 111.659 178.936 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 275' ' ' PHE . . . . . 0.536 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -133.43 162.68 31.21 Favored 'General case' 0 CA--C 1.501 -0.936 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.535 177.12 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 276' ' ' SER . . . . . 0.521 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 4.4 p -134.4 146.92 50.32 Favored 'General case' 0 C--N 1.313 -0.984 0 C-N-CA 119.949 -0.701 . . . . 0.0 111.629 -178.579 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 277' ' ' ILE . . . . . 0.565 HG22 HG22 ' A' ' 267' ' ' ILE . 34.9 pt -137.26 167.8 22.52 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.961 0 CA-C-N 114.694 -1.139 . . . . 0.0 111.481 -173.243 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 278' ' ' CYS . . . . . 0.404 ' C ' ' O ' ' A' ' 277' ' ' ILE . 71.7 m -22.05 -85.02 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.764 0 N-CA-C 113.771 1.026 . . . . 0.0 113.771 -175.409 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 279' ' ' ASP . . . . . 0.429 ' HB3' ' HB2' ' A' ' 282' ' ' ASN . 58.4 t0 -153.26 106.76 3.01 Favored 'General case' 0 CA--C 1.506 -0.743 0 CA-C-O 120.753 0.311 . . . . 0.0 110.372 179.552 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 280' ' ' THR . . . . . 0.817 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 5.9 p -65.99 -27.46 68.15 Favored 'General case' 0 C--N 1.297 -1.695 0 CA-C-O 121.214 0.531 . . . . 0.0 111.057 177.07 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -64.81 -19.98 66.14 Favored 'General case' 0 C--N 1.314 -0.978 0 CA-C-N 115.464 -0.789 . . . . 0.0 109.183 174.776 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 282' ' ' ASN . . . . . 0.429 ' HB2' ' HB3' ' A' ' 279' ' ' ASP . 0.2 OUTLIER -87.76 -8.55 55.86 Favored 'General case' 0 CA--C 1.508 -0.667 0 N-CA-C 108.752 -0.832 . . . . 0.0 108.752 179.554 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 283' ' ' PHE . . . . . 1.057 ' CE2' HD21 ' A' ' 259' ' ' LEU . 13.3 m-85 -92.25 -77.01 0.44 Allowed 'General case' 0 N--CA 1.443 -0.798 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 174.159 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 169.23 -179.3 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 114.522 -1.217 . . . . 0.0 109.702 -174.401 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 35.8 t0 -85.62 132.96 34.07 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 116.496 -0.32 . . . . 0.0 111.179 178.804 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 286' ' ' TYR . . . . . 0.687 ' CZ ' ' HA ' ' A' ' 288' ' ' ARG . 91.1 t80 -68.56 130.56 43.21 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.096 -179.895 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 287' ' ' ILE . . . . . 0.424 HG13 ' HA3' ' A' ' 255' ' ' GLY . 85.8 mt -100.17 -63.11 1.76 Allowed 'Isoleucine or valine' 0 CA--C 1.514 -0.433 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 170.072 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 288' ' ' ARG . . . . . 0.687 ' HA ' ' CZ ' ' A' ' 286' ' ' TYR . 9.5 ptm180 -172.41 -173.2 1.02 Allowed 'General case' 0 C--O 1.243 0.726 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.987 175.307 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 68.48 -163.08 49.51 Favored Glycine 0 CA--C 1.507 -0.464 0 N-CA-C 110.629 -0.988 . . . . 0.0 110.629 175.929 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 113.97 124.61 4.07 Favored Glycine 0 N--CA 1.443 -0.889 0 C-N-CA 121.462 -0.399 . . . . 0.0 112.486 175.768 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 291' ' ' ILE . . . . . 0.445 HD12 ' HG3' ' A' ' 252' ' ' GLU . 92.2 mt -123.09 132.51 71.26 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 172.234 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 292' ' ' VAL . . . . . 0.469 ' HB ' ' CE2' ' A' ' 250' ' ' PHE . 4.9 p -118.1 133.45 64.86 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 C-N-CA 120.624 -0.431 . . . . 0.0 110.028 -176.866 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 3.9 m -128.13 146.56 50.67 Favored 'General case' 0 N--CA 1.446 -0.64 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.648 -175.142 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 294' ' ' GLN . . . . . 0.539 ' HG3' ' CE1' ' A' ' 242' ' ' PHE . 90.7 mt-30 -78.1 163.6 25.74 Favored 'General case' 0 CA--C 1.505 -0.778 0 CA-C-O 121.279 0.561 . . . . 0.0 110.224 176.481 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 295' ' ' VAL . . . . . 0.674 HG21 ' CB ' ' A' ' 264' ' ' PRO . 14.5 t -111.67 159.96 11.32 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-N 115.122 -0.945 . . . . 0.0 109.552 179.377 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 30.6 mttp -69.22 97.02 0.88 Allowed 'General case' 0 N--CA 1.438 -1.057 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 297' ' ' VAL . . . . . 0.459 ' HB ' ' HD2' ' A' ' 298' ' ' PRO . 22.5 m -103.04 170.73 5.91 Favored Pre-proline 0 C--N 1.31 -1.147 0 CA-C-N 115.769 -0.651 . . . . 0.0 109.675 -179.857 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 298' ' ' PRO . . . . . 0.459 ' HD2' ' HB ' ' A' ' 297' ' ' VAL . 33.9 Cg_exo -61.02 149.52 88.66 Favored 'Trans proline' 0 C--N 1.307 -1.637 0 C-N-CA 121.84 1.693 . . . . 0.0 109.404 174.043 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 299' ' ' LYS . . . . . 0.453 ' HG2' ' O ' ' A' ' 300' ' ' LYS . 50.4 tttm -42.67 140.54 1.27 Allowed 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.04 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 300' ' ' LYS . . . . . 0.532 ' HZ2' ' CD ' ' A' ' 243' ' ' GLU . 34.1 mttm -63.31 137.09 58.06 Favored 'General case' 0 C--O 1.244 0.777 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 175.672 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 301' ' ' ILE . . . . . 0.461 ' O ' HG13 ' A' ' 301' ' ' ILE . 45.9 pt -66.44 118.95 10.71 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.77 0 CA-C-N 115.765 -0.652 . . . . 0.0 112.291 -170.986 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 11.6 m -84.78 154.43 22.38 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.345 -0.843 . . . . 0.0 108.865 173.603 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 25.9 m-85 -100.48 141.42 33.36 Favored 'General case' 0 C--N 1.312 -1.031 0 N-CA-C 107.467 -1.309 . . . . 0.0 107.467 172.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 65.2 mttp -50.06 106.87 0.13 Allowed 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 119.684 -0.806 . . . . 0.0 110.098 -173.357 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -129.39 151.16 50.33 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 115.213 -0.903 . . . . 0.0 109.686 -176.969 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 20.8 mt -59.29 146.05 79.75 Favored Pre-proline 0 C--N 1.316 -0.849 0 C-N-CA 120.248 -0.581 . . . . 0.0 109.689 178.485 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 307' ' ' PRO . . . . . 0.414 ' O ' ' C ' ' A' ' 308' ' ' ALA . 58.4 Cg_endo -71.12 47.7 0.81 Allowed 'Trans proline' 0 N--CA 1.489 1.248 0 C-N-CA 122.291 1.994 . . . . 0.0 110.508 -179.577 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 308' ' ' ALA . . . . . 0.414 ' C ' ' O ' ' A' ' 307' ' ' PRO . . . -28.65 96.72 0.01 OUTLIER 'General case' 0 C--O 1.239 0.504 0 CA-C-N 115.05 -0.977 . . . . 0.0 112.015 -175.368 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 4.2 m -89.76 90.72 8.33 Favored 'General case' 0 C--O 1.238 0.483 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 173.72 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -65.3 106.17 1.29 Allowed 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.953 -171.956 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 70.3 t -116.35 127.76 73.86 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.059 0 N-CA-C 106.704 -1.591 . . . . 0.0 106.704 174.602 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 46.3 tp10 . . . . . 0 C--O 1.213 -0.868 0 CA-C-O 118.175 -0.917 . . . . 0.0 109.956 -174.281 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 . . . . . 0 N--CA 1.474 0.744 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 202' ' ' PHE . . . . . 0.411 ' C ' ' N ' ' A' ' 204' ' ' GLU . 0.4 OUTLIER -126.67 37.2 4.34 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.727 179.903 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -48.46 -19.73 1.33 Allowed Glycine 0 CA--C 1.521 0.45 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 178.903 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 204' ' ' GLU . . . . . 0.411 ' N ' ' C ' ' A' ' 202' ' ' PHE . 65.1 mm-40 -54.09 -19.49 5.01 Favored 'General case' 0 C--O 1.236 0.393 0 C-N-CA 122.761 0.424 . . . . 0.0 110.209 178.429 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 99.4 mt-10 -62.42 -39.74 94.29 Favored 'General case' 0 CA--C 1.512 -0.485 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 176.851 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 77.6 mtm -107.25 104.1 13.64 Favored 'General case' 0 N--CA 1.447 -0.612 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.634 177.301 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 12.1 m -115.02 128.85 72.02 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 176.47 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 52.3 tp -85.89 98.97 11.08 Favored 'General case' 0 N--CA 1.442 -0.855 0 C-N-CA 120.385 -0.526 . . . . 0.0 110.262 -177.245 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -107.35 -72.04 0.73 Allowed 'General case' 0 C--N 1.309 -1.157 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 175.209 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 210' ' ' ASP . . . . . 0.423 ' OD1' ' N ' ' A' ' 211' ' ' SER . 1.8 p30 -101.16 -48.33 4.44 Favored 'General case' 0 C--O 1.244 0.782 0 CA-C-N 115.785 -0.643 . . . . 0.0 109.698 170.902 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 211' ' ' SER . . . . . 0.433 ' OG ' ' HB2' ' A' ' 296' ' ' LYS . 2.2 m -122.44 157.08 32.7 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.66 -179.185 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 30.0 t-20 -91.59 110.51 21.83 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.78 0.324 . . . . 0.0 110.8 177.579 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 74.11 -39.9 1.02 Allowed Glycine 0 C--N 1.317 -0.509 0 CA-C-N 116.134 -0.485 . . . . 0.0 112.14 179.329 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 214' ' ' GLU . . . . . 0.458 ' CD ' HH12 ' A' ' 239' ' ' ARG . 76.2 mm-40 -67.41 123.36 20.17 Favored 'General case' 0 C--N 1.324 -0.506 0 C-N-CA 120.321 -0.552 . . . . 0.0 111.356 -179.611 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 215' ' ' GLN . . . . . 0.552 ' O ' ' N ' ' A' ' 217' ' ' LEU . 0.0 OUTLIER -111.82 178.36 1.0 Allowed Pre-proline 0 C--N 1.316 -0.857 0 N-CA-C 108.231 -1.025 . . . . 0.0 108.231 177.378 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 216' ' ' PRO . . . . . 0.517 ' HD2' ' HB2' ' A' ' 215' ' ' GLN . 34.2 Cg_exo -59.89 74.36 0.06 OUTLIER 'Trans proline' 0 N--CA 1.492 1.418 0 C-N-CA 121.242 1.295 . . . . 0.0 110.033 176.471 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 217' ' ' LEU . . . . . 0.792 HD13 ' N ' ' A' ' 218' ' ' SER . 1.3 tm? -76.3 129.07 36.11 Favored 'General case' 0 CA--C 1.51 -0.592 0 CA-C-N 115.281 -0.872 . . . . 0.0 109.418 -175.279 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 218' ' ' SER . . . . . 0.792 ' N ' HD13 ' A' ' 217' ' ' LEU . 75.6 m -114.72 131.45 56.76 Favored 'General case' 0 N--CA 1.438 -1.066 0 CA-C-N 115.846 -0.615 . . . . 0.0 109.358 178.238 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 219' ' ' ALA . . . . . 0.566 ' HB1' ' HB1' ' A' ' 238' ' ' ALA . . . -127.74 150.33 49.84 Favored 'General case' 0 CA--C 1.503 -0.845 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.899 -177.097 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 220' ' ' MET . . . . . 0.71 ' SD ' HG12 ' A' ' 291' ' ' ILE . 87.6 mmm -76.56 131.21 38.81 Favored 'General case' 0 N--CA 1.44 -0.926 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 176.587 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 91.5 t -75.51 128.21 37.14 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.311 0 N-CA-C 107.586 -1.265 . . . . 0.0 107.586 175.877 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 222' ' ' SER . . . . . 0.628 ' CB ' ' HG1' ' A' ' 233' ' ' THR . 0.1 OUTLIER -84.6 -67.33 0.8 Allowed 'General case' 0 N--CA 1.437 -1.087 0 C-N-CA 119.717 -0.793 . . . . 0.0 109.375 179.703 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 3.6 ptm -137.9 151.39 47.97 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 112.552 0.575 . . . . 0.0 112.552 173.056 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 224' ' ' VAL . . . . . 0.717 HG22 ' HB ' ' A' ' 232' ' ' VAL . 68.8 t -123.78 132.59 71.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 174.95 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 28.2 p -92.76 131.32 37.92 Favored 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 121.031 -0.268 . . . . 0.0 110.38 179.588 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 6.0 ttmt -77.94 87.61 4.12 Favored 'General case' 0 N--CA 1.446 -0.646 0 C-N-CA 119.477 -0.889 . . . . 0.0 109.152 178.548 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 227' ' ' ASP . . . . . 0.526 ' N ' ' OG1' ' A' ' 280' ' ' THR . 47.5 t0 -158.63 175.0 14.19 Favored 'General case' 0 C--N 1.312 -1.056 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.532 -179.574 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 228' ' ' ASN . . . . . 0.475 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 1.4 t-20 -140.85 123.56 9.75 Favored Pre-proline 0 C--O 1.237 0.406 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.112 173.866 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 229' ' ' PRO . . . . . 0.475 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 44.8 Cg_endo -66.31 144.7 67.88 Favored 'Cis proline' 0 C--N 1.313 -1.294 0 C-N-CA 122.492 -1.878 . . . . 0.0 109.308 -2.029 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 230' ' ' GLY . . . . . 0.48 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -82.71 144.9 23.37 Favored Glycine 0 C--N 1.312 -0.8 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 -178.179 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 231' ' ' VAL . . . . . 0.416 HG23 HD12 ' A' ' 270' ' ' LEU . 2.6 p -121.22 130.53 74.56 Favored 'Isoleucine or valine' 0 C--O 1.241 0.657 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 176.299 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 232' ' ' VAL . . . . . 0.717 ' HB ' HG22 ' A' ' 224' ' ' VAL . 0.7 OUTLIER -132.66 157.14 42.95 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 CA-C-N 116.264 -0.425 . . . . 0.0 109.874 -177.413 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 233' ' ' THR . . . . . 0.652 HG22 HG22 ' A' ' 274' ' ' THR . 61.6 p -110.35 158.47 18.41 Favored 'General case' 0 N--CA 1.429 -1.486 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.229 179.711 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.8 m -113.08 148.97 34.14 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 172.656 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 40.2 tp -56.69 133.73 54.17 Favored 'General case' 0 C--N 1.308 -1.22 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 -179.69 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 236' ' ' ASP . . . . . 0.409 ' O ' ' CE1' ' A' ' 273' ' ' TYR . 7.8 t70 -52.72 -37.96 60.02 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.683 -171.523 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 10.0 mm-40 -75.31 -6.67 51.1 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.076 -178.011 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 238' ' ' ALA . . . . . 0.566 ' HB1' ' HB1' ' A' ' 219' ' ' ALA . . . -97.39 99.88 11.32 Favored 'General case' 0 C--O 1.239 0.505 0 N-CA-C 112.554 0.575 . . . . 0.0 112.554 -175.453 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 239' ' ' ARG . . . . . 0.458 HH12 ' CD ' ' A' ' 214' ' ' GLU . 0.0 OUTLIER -70.61 66.49 0.34 Allowed 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 116.519 -0.31 . . . . 0.0 110.678 175.396 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 240' ' ' HIS . . . . . 0.6 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 14.0 p80 -33.49 -49.04 0.28 Allowed 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.227 0.537 . . . . 0.0 111.291 -178.942 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 79.41 19.31 71.83 Favored Glycine 0 C--O 1.245 0.841 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 178.432 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 242' ' ' PHE . . . . . 0.673 ' CD1' ' HB3' ' A' ' 294' ' ' GLN . 4.3 m-30 -79.85 141.53 36.1 Favored 'General case' 0 N--CA 1.444 -0.745 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 -179.256 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 243' ' ' GLU . . . . . 0.473 ' HB2' ' HB2' ' A' ' 246' ' ' ASP . 96.5 mt-10 -109.35 158.37 17.97 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 178.925 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 244' ' ' THR . . . . . 0.603 HG21 HD22 ' A' ' 306' ' ' LEU . 7.9 m -65.14 123.98 20.93 Favored 'General case' 0 C--N 1.312 -1.022 0 C-N-CA 119.115 -1.034 . . . . 0.0 108.538 178.101 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 85.87 8.04 80.11 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.559 -1.016 . . . . 0.0 110.559 -176.374 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 246' ' ' ASP . . . . . 0.473 ' HB2' ' HB2' ' A' ' 243' ' ' GLU . 45.7 t0 -82.44 167.19 18.7 Favored 'General case' 0 CA--C 1.518 -0.287 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 179.616 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 247' ' ' PHE . . . . . 0.419 ' HA ' ' O ' ' A' ' 265' ' ' MET . 95.8 m-85 -111.95 137.77 49.48 Favored 'General case' 0 C--O 1.24 0.584 0 CA-C-O 120.64 0.257 . . . . 0.0 111.295 -177.932 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.562 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.6 m -133.58 160.89 41.96 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.306 0 CA-C-N 116.557 -0.292 . . . . 0.0 111.159 177.5 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 2.9 p -117.84 152.01 36.21 Favored 'General case' 0 C--N 1.318 -0.786 0 C-N-CA 123.958 0.903 . . . . 0.0 109.404 175.082 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 250' ' ' PHE . . . . . 0.644 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 75.0 m-85 -110.92 146.56 36.35 Favored 'General case' 0 CA--C 1.506 -0.715 0 C-N-CA 122.695 0.398 . . . . 0.0 110.758 -178.007 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 2.0 m -154.59 154.65 33.37 Favored 'General case' 0 C--N 1.31 -1.149 0 C-N-CA 120.765 -0.374 . . . . 0.0 110.145 176.778 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 73.5 mm-40 55.13 30.18 13.94 Favored 'General case' 0 C--N 1.313 -0.979 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.787 176.17 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 0.703 HG22 ' HA2' ' A' ' 290' ' ' GLY . 2.8 t -97.93 115.24 37.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 177.269 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 254' ' ' GLN . . . . . 0.416 ' HG3' ' HD2' ' A' ' 288' ' ' ARG . 2.0 mm100 -79.1 137.76 37.64 Favored 'General case' 0 C--O 1.238 0.473 0 CA-C-O 121.035 0.445 . . . . 0.0 111.481 -179.769 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 255' ' ' GLY . . . . . 0.405 ' N ' HD12 ' A' ' 287' ' ' ILE . . . 81.99 -55.59 4.92 Favored Glycine 0 CA--C 1.506 -0.479 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 -178.579 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 256' ' ' MET . . . . . 0.552 ' SD ' HG11 ' A' ' 224' ' ' VAL . 3.1 ttm -81.24 49.93 1.35 Allowed 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.814 0.816 . . . . 0.0 109.215 176.927 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 46.7 pt -72.13 -20.73 20.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-N 114.836 -1.074 . . . . 0.0 110.974 -176.61 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 258' ' ' GLN . . . . . 0.599 ' O ' ' SG ' ' A' ' 262' ' ' CYS . 19.1 tp60 -54.48 -41.07 69.12 Favored 'General case' 0 N--CA 1.448 -0.555 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 179.147 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 259' ' ' LEU . . . . . 0.689 HD21 ' CZ ' ' A' ' 283' ' ' PHE . 98.2 mt -63.09 -39.92 96.14 Favored 'General case' 0 N--CA 1.445 -0.695 0 CA-C-N 114.861 -1.063 . . . . 0.0 110.116 177.545 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -59.76 -40.74 89.19 Favored 'General case' 0 CA--C 1.51 -0.591 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 -178.161 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -88.59 -1.12 81.16 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 115.548 -0.751 . . . . 0.0 112.106 -179.594 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 262' ' ' CYS . . . . . 0.599 ' SG ' ' O ' ' A' ' 258' ' ' GLN . 61.5 m -83.1 153.34 24.91 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-N 117.157 0.479 . . . . 0.0 111.017 -179.259 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 5.9 mm100 -79.07 163.96 57.33 Favored Pre-proline 0 C--N 1.323 -0.567 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 169.116 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 264' ' ' PRO . . . . . 0.562 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 36.7 Cg_exo -59.54 143.32 99.71 Favored 'Trans proline' 0 C--N 1.307 -1.608 0 C-N-CA 121.013 1.142 . . . . 0.0 111.105 -176.823 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 265' ' ' MET . . . . . 0.642 ' N ' ' SD ' ' A' ' 265' ' ' MET . 0.9 OUTLIER -126.88 160.76 30.02 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 116.627 -0.26 . . . . 0.0 111.396 -175.966 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 3.2 tt0 -71.44 137.72 48.49 Favored 'General case' 0 C--O 1.241 0.632 0 O-C-N 123.653 0.596 . . . . 0.0 110.224 178.697 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 267' ' ' ILE . . . . . 0.732 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.7 pp -132.01 162.96 38.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.113 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 64.3 mttp -124.85 136.22 53.61 Favored 'General case' 0 C--O 1.216 -0.705 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 175.189 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 15.9 m -95.64 102.3 13.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 CA-C-O 121.355 0.597 . . . . 0.0 111.634 -179.403 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 270' ' ' LEU . . . . . 0.416 HD12 HG23 ' A' ' 231' ' ' VAL . 95.9 mt -66.8 -39.77 87.87 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.672 178.278 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -144.73 -170.3 13.82 Favored Glycine 0 N--CA 1.465 0.585 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 -176.516 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 272' ' ' PRO . . . . . 0.6 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 28.6 Cg_endo -59.31 -37.82 88.55 Favored 'Trans proline' 0 N--CA 1.491 1.37 0 C-N-CA 121.95 1.767 . . . . 0.0 111.88 -177.103 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 273' ' ' TYR . . . . . 0.409 ' CE1' ' O ' ' A' ' 236' ' ' ASP . 23.1 m-85 -124.03 5.53 8.61 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 111.726 0.269 . . . . 0.0 111.726 176.834 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 274' ' ' THR . . . . . 0.652 HG22 HG22 ' A' ' 233' ' ' THR . 0.7 OUTLIER -105.99 128.43 53.82 Favored 'General case' 0 C--N 1.32 -0.715 0 C-N-CA 120.586 -0.445 . . . . 0.0 110.724 -175.757 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 275' ' ' PHE . . . . . 0.562 ' CD1' HG22 ' A' ' 232' ' ' VAL . 0.0 OUTLIER -136.11 161.57 35.35 Favored 'General case' 0 CA--C 1.505 -0.77 0 C-N-CA 120.828 -0.349 . . . . 0.0 111.871 179.154 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 276' ' ' SER . . . . . 0.48 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 3.7 p -131.83 139.86 48.98 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-O 121.272 0.558 . . . . 0.0 111.883 -175.413 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 277' ' ' ILE . . . . . 0.497 HG22 HG22 ' A' ' 267' ' ' ILE . 37.0 pt -136.95 164.56 30.02 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.723 0 CA-C-N 114.69 -1.141 . . . . 0.0 112.378 -172.099 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 278' ' ' CYS . . . . . 0.449 ' O ' ' HA ' ' A' ' 229' ' ' PRO . 71.2 m -29.73 -92.15 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.402 0 N-CA-C 114.113 1.153 . . . . 0.0 114.113 -176.794 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 19.8 t0 -145.78 114.38 6.79 Favored 'General case' 0 CA--C 1.503 -0.847 0 CA-C-O 120.719 0.295 . . . . 0.0 111.214 -175.673 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 280' ' ' THR . . . . . 0.733 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 21.7 p -65.53 -30.59 71.36 Favored 'General case' 0 C--N 1.3 -1.586 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.576 176.18 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -65.32 -20.16 66.28 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 115.271 -0.877 . . . . 0.0 109.321 177.339 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -87.37 -8.09 57.02 Favored 'General case' 0 CA--C 1.506 -0.717 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.848 179.663 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 283' ' ' PHE . . . . . 0.733 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 5.3 m-85 -94.96 -68.38 0.8 Allowed 'General case' 0 N--CA 1.443 -0.824 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 172.808 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 284' ' ' SER . . . . . 0.406 ' OG ' ' HA ' ' A' ' 256' ' ' MET . 1.7 p 164.39 -87.93 0.0 OUTLIER 'General case' 0 C--O 1.244 0.763 0 CA-C-N 115.246 -0.888 . . . . 0.0 110.909 176.934 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 285' ' ' ASP . . . . . 0.492 ' O ' ' N ' ' A' ' 256' ' ' MET . 3.7 t0 -157.59 165.32 35.86 Favored 'General case' 0 C--O 1.22 -0.496 0 CA-C-N 116.614 -0.266 . . . . 0.0 111.055 179.579 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 286' ' ' TYR . . . . . 0.461 ' O ' ' CD2' ' A' ' 286' ' ' TYR . 35.7 t80 -106.8 89.22 2.95 Favored 'General case' 0 C--N 1.319 -0.728 0 C-N-CA 123.317 0.647 . . . . 0.0 110.038 179.052 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 287' ' ' ILE . . . . . 0.414 HG22 ' HG3' ' A' ' 288' ' ' ARG . 96.5 mt -70.44 -46.11 72.04 Favored 'Isoleucine or valine' 0 C--O 1.24 0.597 0 CA-C-O 121.197 0.522 . . . . 0.0 110.14 179.235 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 288' ' ' ARG . . . . . 0.416 ' HD2' ' HG3' ' A' ' 254' ' ' GLN . 0.0 OUTLIER 173.45 173.09 0.15 Allowed 'General case' 0 C--O 1.243 0.755 0 CA-C-N 115.588 -0.733 . . . . 0.0 111.219 -177.623 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 68.08 -140.9 36.79 Favored Glycine 0 CA--C 1.508 -0.363 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 175.39 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 290' ' ' GLY . . . . . 0.703 ' HA2' HG22 ' A' ' 253' ' ' VAL . . . 97.31 115.58 3.34 Favored Glycine 0 N--CA 1.442 -0.913 0 C-N-CA 121.487 -0.387 . . . . 0.0 112.148 176.71 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 291' ' ' ILE . . . . . 0.71 HG12 ' SD ' ' A' ' 220' ' ' MET . 89.8 mt -116.08 130.46 70.77 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.93 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 174.111 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 2.8 p -118.08 127.34 75.29 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 -179.231 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 293' ' ' SER . . . . . 0.42 ' HA ' ' O ' ' A' ' 217' ' ' LEU . 4.7 m -121.43 122.76 40.5 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.258 -176.155 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 294' ' ' GLN . . . . . 0.673 ' HB3' ' CD1' ' A' ' 242' ' ' PHE . 12.8 pt20 -66.57 159.66 26.94 Favored 'General case' 0 CA--C 1.497 -1.093 0 CA-C-O 121.257 0.551 . . . . 0.0 111.872 -179.358 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 2.5 t -144.15 96.26 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.563 0 CA-C-N 114.184 -1.371 . . . . 0.0 108.153 172.2 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 296' ' ' LYS . . . . . 0.433 ' HB2' ' OG ' ' A' ' 211' ' ' SER . 51.4 mttp -83.77 101.72 11.79 Favored 'General case' 0 N--CA 1.438 -1.073 0 N-CA-C 109.009 -0.738 . . . . 0.0 109.009 176.34 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 18.6 m -63.05 135.97 96.47 Favored Pre-proline 0 N--CA 1.442 -0.841 0 CA-C-N 115.475 -0.784 . . . . 0.0 110.991 -173.794 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -64.38 -20.48 66.39 Favored 'Trans proline' 0 N--CA 1.492 1.432 0 C-N-CA 122.365 2.043 . . . . 0.0 110.174 177.011 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 21.2 mmtp -96.05 92.92 6.68 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 173.06 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 47.4 mttp -84.55 140.81 31.16 Favored 'General case' 0 C--N 1.31 -1.141 0 N-CA-C 109.67 -0.492 . . . . 0.0 109.67 -179.009 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 301' ' ' ILE . . . . . 0.644 HD12 ' H ' ' A' ' 301' ' ' ILE . 0.3 OUTLIER -80.44 164.06 3.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 116.64 -0.255 . . . . 0.0 110.618 178.302 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 4.3 m -78.88 79.16 5.3 Favored 'General case' 0 C--N 1.323 -0.562 0 C-N-CA 120.115 -0.634 . . . . 0.0 110.525 -177.674 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 303' ' ' PHE . . . . . 0.561 ' HD1' HD13 ' A' ' 301' ' ' ILE . 81.1 m-85 -133.45 140.56 47.36 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-N 115.251 -0.886 . . . . 0.0 108.67 173.282 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 19.4 mttt -80.49 148.55 30.4 Favored 'General case' 0 C--N 1.315 -0.91 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 176.703 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 2.6 m -57.76 141.39 48.91 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 107.726 -1.213 . . . . 0.0 107.726 177.166 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 306' ' ' LEU . . . . . 0.603 HD22 HG21 ' A' ' 244' ' ' THR . 0.9 OUTLIER -66.5 176.85 0.93 Allowed Pre-proline 0 C--N 1.312 -1.033 0 C-N-CA 120.559 -0.456 . . . . 0.0 109.852 -178.104 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 307' ' ' PRO . . . . . 0.477 ' O ' ' N ' ' A' ' 309' ' ' SER . 38.1 Cg_exo -58.89 -18.46 42.31 Favored 'Trans proline' 0 N--CA 1.494 1.52 0 C-N-CA 122.336 2.024 . . . . 0.0 111.446 179.41 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -59.45 74.73 0.01 OUTLIER 'General case' 0 C--O 1.237 0.428 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.241 -179.338 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.477 ' N ' ' O ' ' A' ' 307' ' ' PRO . 4.8 m -130.52 158.87 38.78 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.539 -176.636 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 96.6 mt -66.96 144.86 55.97 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.087 178.477 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 29.0 m -134.09 162.37 39.31 Favored 'Isoleucine or valine' 0 C--O 1.24 0.598 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.549 -179.728 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 99.4 mt-10 . . . . . 0 C--O 1.205 -1.266 0 CA-C-O 118.085 -0.959 . . . . 0.0 110.128 179.14 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 201' ' ' GLU . . . . . 0.623 ' O ' ' N ' ' A' ' 203' ' ' GLY . 76.5 mm-40 . . . . . 0 N--CA 1.48 1.057 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 202' ' ' PHE . . . . . 0.499 ' CG ' ' N ' ' A' ' 203' ' ' GLY . 0.1 OUTLIER 47.91 -58.04 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.767 0 C-N-CA 124.901 1.28 . . . . 0.0 114.028 -176.682 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 203' ' ' GLY . . . . . 0.623 ' N ' ' O ' ' A' ' 201' ' ' GLU . . . -68.91 -41.92 80.35 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 110.942 -0.863 . . . . 0.0 110.942 177.861 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -63.1 -40.13 96.72 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.358 0.599 . . . . 0.0 110.545 -175.911 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 205' ' ' GLU . . . . . 0.48 ' OE2' ' N ' ' A' ' 201' ' ' GLU . 52.0 mp0 -62.68 -17.43 60.54 Favored 'General case' 0 C--N 1.306 -1.321 0 CA-C-N 115.256 -0.884 . . . . 0.0 111.351 -178.561 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 12.5 tpt -71.08 124.76 25.15 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.825 0.345 . . . . 0.0 110.767 -177.519 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 207' ' ' VAL . . . . . 0.619 ' O ' ' N ' ' A' ' 209' ' ' THR . 28.6 m -128.8 167.73 23.48 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.766 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 177.881 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 10.9 mp -59.64 70.32 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.546 0 CA-C-O 121.82 0.819 . . . . 0.0 109.926 -177.937 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 209' ' ' THR . . . . . 0.619 ' N ' ' O ' ' A' ' 207' ' ' VAL . 5.8 m -73.45 -42.98 61.28 Favored 'General case' 0 C--N 1.307 -1.254 0 CA-C-N 114.507 -1.224 . . . . 0.0 110.616 -177.269 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 10.6 p-10 -57.48 -46.93 83.15 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.016 -0.993 . . . . 0.0 112.805 -172.618 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 4.7 m -115.09 109.96 18.84 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 112.712 0.634 . . . . 0.0 112.712 -174.395 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 99.4 m-20 -102.25 130.5 48.95 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 170.892 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 60.1 66.21 2.87 Favored Glycine 0 C--O 1.239 0.418 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 -176.271 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 70.6 mt-10 -56.94 145.58 29.61 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.03 0.443 . . . . 0.0 112.006 -175.384 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -40.84 146.55 0.46 Allowed Pre-proline 0 C--N 1.324 -0.536 0 CA-C-N 115.072 -0.967 . . . . 0.0 112.55 -175.671 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_exo -62.81 154.88 63.13 Favored 'Trans proline' 0 N--CA 1.495 1.616 0 C-N-CA 123.05 2.5 . . . . 0.0 109.994 170.794 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -45.95 118.34 1.83 Allowed 'General case' 0 C--O 1.244 0.774 0 C-N-CA 120.343 -0.543 . . . . 0.0 109.868 -177.256 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 218' ' ' SER . . . . . 0.423 ' OG ' ' OG ' ' A' ' 293' ' ' SER . 22.4 m -131.9 152.35 51.11 Favored 'General case' 0 N--CA 1.442 -0.829 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.529 -175.787 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -145.79 156.06 43.34 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.56 179.855 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 97.7 mtp -76.46 140.39 41.23 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 174.62 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 97.9 t -80.89 129.21 37.91 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.014 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 178.263 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 29.0 m -77.98 -70.58 0.47 Allowed 'General case' 0 N--CA 1.434 -1.273 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 177.36 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 5.9 ptm -138.25 160.29 39.85 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.275 174.99 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 224' ' ' VAL . . . . . 0.522 HG11 ' SD ' ' A' ' 256' ' ' MET . 61.3 t -124.53 132.13 71.77 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.037 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 173.867 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -100.35 120.33 39.78 Favored 'General case' 0 C--N 1.313 -1.013 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 -177.993 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 226' ' ' LYS . . . . . 0.519 ' NZ ' ' OD1' ' A' ' 285' ' ' ASP . 0.0 OUTLIER -71.82 82.11 0.9 Allowed 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.003 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 227' ' ' ASP . . . . . 0.513 ' N ' ' OG1' ' A' ' 280' ' ' THR . 4.1 t70 -153.49 -175.45 5.36 Favored 'General case' 0 C--O 1.246 0.886 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.037 -179.319 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 228' ' ' ASN . . . . . 0.557 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.1 OUTLIER -142.12 124.08 8.98 Favored Pre-proline 0 C--N 1.331 -0.228 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.307 176.696 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 229' ' ' PRO . . . . . 0.557 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 33.7 Cg_exo -61.71 147.02 50.93 Favored 'Cis proline' 0 N--CA 1.489 1.213 0 C-N-CA 123.091 -1.629 . . . . 0.0 109.984 -1.73 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 230' ' ' GLY . . . . . 0.635 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -68.71 134.12 27.77 Favored Glycine 0 C--N 1.3 -1.461 0 N-CA-C 108.864 -1.694 . . . . 0.0 108.864 179.064 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 231' ' ' VAL . . . . . 0.457 ' HB ' ' OG ' ' A' ' 276' ' ' SER . 2.1 p -125.7 132.34 70.94 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 117.332 0.566 . . . . 0.0 110.11 179.549 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 232' ' ' VAL . . . . . 0.458 HG22 ' CD1' ' A' ' 275' ' ' PHE . 0.7 OUTLIER -135.07 156.98 40.33 Favored 'Isoleucine or valine' 0 C--O 1.248 0.979 0 C-N-CA 120.754 -0.378 . . . . 0.0 110.084 -178.697 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 233' ' ' THR . . . . . 0.514 HG22 HG23 ' A' ' 274' ' ' THR . 14.9 p -105.56 154.8 19.89 Favored 'General case' 0 N--CA 1.435 -1.209 0 CA-C-N 116.134 -0.485 . . . . 0.0 109.822 176.844 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 2.1 m -111.78 161.07 16.71 Favored 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 176.043 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 38.4 tp -60.07 121.91 13.06 Favored 'General case' 0 C--N 1.309 -1.157 0 N-CA-C 107.143 -1.428 . . . . 0.0 107.143 178.659 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 236' ' ' ASP . . . . . 0.478 ' O ' ' NH2' ' A' ' 239' ' ' ARG . 13.9 p-10 -51.67 -44.93 63.24 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.29 0.566 . . . . 0.0 111.021 -171.55 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -64.9 -35.17 80.29 Favored 'General case' 0 C--N 1.301 -1.538 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.128 -179.355 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -70.98 95.9 1.23 Allowed 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.777 -179.198 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 239' ' ' ARG . . . . . 0.578 ' NH2' ' OH ' ' A' ' 273' ' ' TYR . 0.0 OUTLIER -62.66 99.09 0.14 Allowed 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 172.124 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 240' ' ' HIS . . . . . 0.474 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 7.2 p80 -59.48 -46.47 88.71 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.891 -175.278 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 83.5 13.09 76.93 Favored Glycine 0 C--N 1.32 -0.351 0 N-CA-C 110.505 -1.038 . . . . 0.0 110.505 -178.897 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 242' ' ' PHE . . . . . 0.518 ' CD1' ' HB3' ' A' ' 294' ' ' GLN . 4.2 m-30 -82.01 138.3 34.91 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.422 -0.585 . . . . 0.0 109.422 179.511 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -110.28 161.96 15.09 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-O 121.315 0.578 . . . . 0.0 109.656 175.642 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 244' ' ' THR . . . . . 0.436 HG22 ' HD2' ' A' ' 268' ' ' LYS . 0.2 OUTLIER -63.71 111.41 2.4 Favored 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 178.589 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 104.86 0.15 42.07 Favored Glycine 0 CA--C 1.52 0.385 0 N-CA-C 111.661 -0.576 . . . . 0.0 111.661 -178.717 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 42.3 m-20 -72.95 161.65 30.44 Favored 'General case' 0 CA--C 1.514 -0.417 0 CA-C-N 116.918 0.359 . . . . 0.0 110.562 175.703 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 247' ' ' PHE . . . . . 0.458 ' HA ' ' O ' ' A' ' 265' ' ' MET . 70.3 m-85 -109.49 130.31 55.51 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.929 -0.578 . . . . 0.0 109.721 177.471 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.477 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.3 m -132.4 161.29 41.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 C-N-CA 120.619 -0.432 . . . . 0.0 110.817 179.548 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 3.4 p -126.64 149.61 49.4 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.842 174.427 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 250' ' ' PHE . . . . . 0.607 ' CD1' HD22 ' A' ' 259' ' ' LEU . 71.6 m-85 -102.99 162.42 12.95 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.117 -176.104 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 69.1 m -157.31 155.21 30.29 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.323 174.451 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 19.3 mt-10 51.76 26.37 3.45 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 113.123 0.786 . . . . 0.0 113.123 178.733 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 0.484 HG22 ' HA2' ' A' ' 290' ' ' GLY . 16.2 t -82.18 117.47 28.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 174.22 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 87.4 mt-30 -89.28 144.36 26.15 Favored 'General case' 0 C--O 1.245 0.859 0 CA-C-O 121.218 0.533 . . . . 0.0 111.486 -176.927 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 77.82 -60.42 3.77 Favored Glycine 0 N--CA 1.449 -0.475 0 N-CA-C 109.702 -1.359 . . . . 0.0 109.702 -177.184 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 256' ' ' MET . . . . . 0.522 ' SD ' HG11 ' A' ' 224' ' ' VAL . 57.3 ttm -86.57 65.43 9.03 Favored 'General case' 0 C--N 1.318 -0.775 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 174.831 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 257' ' ' ILE . . . . . 0.404 ' O ' ' HB2' ' A' ' 260' ' ' ASN . 47.4 pt -75.42 -17.22 15.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 115.176 -0.92 . . . . 0.0 111.322 -174.31 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 258' ' ' GLN . . . . . 0.4 ' O ' ' N ' ' A' ' 262' ' ' CYS . 6.6 mp0 -55.3 -35.98 65.69 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 -178.742 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 259' ' ' LEU . . . . . 1.01 HD21 ' CE2' ' A' ' 283' ' ' PHE . 91.6 mt -62.18 -41.83 98.7 Favored 'General case' 0 C--N 1.315 -0.897 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.785 176.87 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 260' ' ' ASN . . . . . 0.433 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 97.5 m-20 -60.84 -40.32 92.4 Favored 'General case' 0 CA--C 1.512 -0.495 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 179.753 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -91.28 -3.79 69.21 Favored Glycine 0 CA--C 1.522 0.489 0 CA-C-N 115.466 -0.788 . . . . 0.0 111.968 -177.104 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 262' ' ' CYS . . . . . 0.4 ' N ' ' O ' ' A' ' 258' ' ' GLN . 2.9 m -87.18 141.78 28.39 Favored 'General case' 0 CA--C 1.514 -0.424 0 CA-C-N 117.249 0.524 . . . . 0.0 110.812 -177.053 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 29.3 pt20 -63.36 165.58 10.92 Favored Pre-proline 0 C--N 1.323 -0.554 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 176.054 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 264' ' ' PRO . . . . . 0.477 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 36.8 Cg_exo -60.1 141.9 97.19 Favored 'Trans proline' 0 C--N 1.316 -1.148 0 N-CA-C 109.245 -1.098 . . . . 0.0 109.245 177.42 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 265' ' ' MET . . . . . 0.458 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 23.1 ptp -134.21 155.34 50.3 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 111.969 0.359 . . . . 0.0 111.969 -173.002 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 266' ' ' GLU . . . . . 0.414 ' HB2' ' CE2' ' A' ' 247' ' ' PHE . 78.5 tt0 -71.5 137.87 48.49 Favored 'General case' 0 C--O 1.239 0.519 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.865 179.306 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 267' ' ' ILE . . . . . 0.701 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.8 pp -129.03 164.19 32.07 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.995 -177.16 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 268' ' ' LYS . . . . . 0.436 ' HD2' HG22 ' A' ' 244' ' ' THR . 48.4 mmtm -129.05 125.09 36.53 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 109.114 -0.698 . . . . 0.0 109.114 176.158 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 14.9 m -79.24 125.12 38.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 C-N-CA 120.743 -0.383 . . . . 0.0 110.578 179.801 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 270' ' ' LEU . . . . . 0.539 HD11 ' OG ' ' A' ' 276' ' ' SER . 78.6 mt -101.64 -12.49 18.38 Favored 'General case' 0 C--O 1.237 0.427 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.284 -179.034 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -164.4 -179.57 38.62 Favored Glycine 0 C--N 1.317 -0.491 0 N-CA-C 109.892 -1.283 . . . . 0.0 109.892 -177.048 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 272' ' ' PRO . . . . . 0.474 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 26.2 Cg_endo -59.7 -39.71 71.14 Favored 'Trans proline' 0 C--N 1.306 -1.687 0 C-N-CA 122.159 1.906 . . . . 0.0 111.148 -177.577 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 273' ' ' TYR . . . . . 0.578 ' OH ' ' NH2' ' A' ' 239' ' ' ARG . 29.2 m-85 -123.95 13.4 9.14 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-N 115.328 -0.851 . . . . 0.0 110.686 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 274' ' ' THR . . . . . 0.514 HG23 HG22 ' A' ' 233' ' ' THR . 0.2 OUTLIER -119.1 127.49 53.41 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 -174.433 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 275' ' ' PHE . . . . . 0.559 ' CE2' HG21 ' A' ' 267' ' ' ILE . 0.0 OUTLIER -140.47 161.75 36.98 Favored 'General case' 0 CA--C 1.502 -0.89 0 C-N-CA 120.645 -0.422 . . . . 0.0 112.126 -179.588 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 276' ' ' SER . . . . . 0.539 ' OG ' HD11 ' A' ' 270' ' ' LEU . 1.8 m -130.07 156.07 45.12 Favored 'General case' 0 N--CA 1.433 -1.307 0 CA-C-O 121.568 0.699 . . . . 0.0 112.75 -177.172 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 277' ' ' ILE . . . . . 0.746 ' C ' HD12 ' A' ' 277' ' ' ILE . 2.3 pp -137.16 -179.28 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.273 0 CA-C-N 113.682 -1.599 . . . . 0.0 109.113 -177.518 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -40.1 -88.88 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.406 0 O-C-N 123.516 0.51 . . . . 0.0 112.185 179.753 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 279' ' ' ASP . . . . . 0.493 ' O ' ' ND2' ' A' ' 282' ' ' ASN . 65.5 t0 -149.22 115.55 5.81 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-O 120.602 0.239 . . . . 0.0 111.26 -178.097 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 280' ' ' THR . . . . . 0.635 HG23 ' HA3' ' A' ' 230' ' ' GLY . 14.6 p -63.56 -29.65 70.88 Favored 'General case' 0 C--N 1.308 -1.233 0 CA-C-O 121.295 0.569 . . . . 0.0 110.166 175.25 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -63.82 -19.57 65.12 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-N 115.329 -0.851 . . . . 0.0 109.763 177.146 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 282' ' ' ASN . . . . . 0.493 ' ND2' ' O ' ' A' ' 279' ' ' ASP . 0.0 OUTLIER -95.05 -7.97 38.02 Favored 'General case' 0 C--N 1.344 0.334 0 C-N-CA 120.507 -0.477 . . . . 0.0 110.436 177.949 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 283' ' ' PHE . . . . . 1.01 ' CE2' HD21 ' A' ' 259' ' ' LEU . 21.4 m-30 -85.2 -80.74 0.21 Allowed 'General case' 0 CA--C 1.512 -0.498 0 CA-C-O 121.854 0.835 . . . . 0.0 109.035 175.609 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 284' ' ' SER . . . . . 0.435 ' OG ' ' HA ' ' A' ' 256' ' ' MET . 0.1 OUTLIER 175.45 -173.37 0.08 Allowed 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 114.121 -1.399 . . . . 0.0 108.196 -176.442 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 285' ' ' ASP . . . . . 0.519 ' OD1' ' NZ ' ' A' ' 226' ' ' LYS . 33.4 t0 -91.18 116.3 28.7 Favored 'General case' 0 C--N 1.316 -0.876 0 C-N-CA 121.045 -0.262 . . . . 0.0 111.668 -178.985 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 286' ' ' TYR . . . . . 0.405 ' OH ' ' NH2' ' A' ' 288' ' ' ARG . 1.1 t80 -64.94 135.32 55.54 Favored 'General case' 0 CA--C 1.511 -0.53 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.37 179.24 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 287' ' ' ILE . . . . . 0.518 ' C ' ' HG2' ' A' ' 288' ' ' ARG . 96.9 mt -118.71 -74.78 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.433 -1.306 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.737 174.731 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 288' ' ' ARG . . . . . 0.533 ' HA ' ' NE ' ' A' ' 288' ' ' ARG . 4.1 mmp_? -148.71 175.58 11.09 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.587 -177.511 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 75.35 -156.3 48.35 Favored Glycine 0 C--O 1.238 0.393 0 N-CA-C 110.689 -0.964 . . . . 0.0 110.689 178.145 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 290' ' ' GLY . . . . . 0.484 ' HA2' HG22 ' A' ' 253' ' ' VAL . . . 103.82 111.56 3.59 Favored Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 121.712 -0.28 . . . . 0.0 112.524 176.416 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 93.2 mt -121.16 131.7 72.37 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.928 0 N-CA-C 107.532 -1.284 . . . . 0.0 107.532 173.605 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 2.8 p -122.61 137.07 57.38 Favored 'Isoleucine or valine' 0 C--O 1.242 0.683 0 C-N-CA 120.702 -0.399 . . . . 0.0 111.17 -174.893 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 293' ' ' SER . . . . . 0.423 ' OG ' ' OG ' ' A' ' 218' ' ' SER . 41.7 m -126.21 140.31 52.64 Favored 'General case' 0 CA--C 1.51 -0.565 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.438 179.533 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 294' ' ' GLN . . . . . 0.518 ' HB3' ' CD1' ' A' ' 242' ' ' PHE . 0.9 OUTLIER -82.11 141.49 33.07 Favored 'General case' 0 CA--C 1.504 -0.823 0 C-N-CA 120.499 -0.48 . . . . 0.0 110.023 176.764 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 39.0 t -131.05 127.02 60.44 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.176 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 178.798 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 64.0 mttp -87.14 98.16 11.15 Favored 'General case' 0 N--CA 1.432 -1.328 0 N-CA-C 107.399 -1.334 . . . . 0.0 107.399 170.732 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 297' ' ' VAL . . . . . 0.615 ' HB ' ' CD ' ' A' ' 298' ' ' PRO . 12.4 m -82.31 -174.4 0.52 Allowed Pre-proline 0 C--N 1.313 -1.018 0 N-CA-C 108.96 -0.756 . . . . 0.0 108.96 -177.36 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 298' ' ' PRO . . . . . 0.615 ' CD ' ' HB ' ' A' ' 297' ' ' VAL . 71.8 Cg_exo -53.28 -32.78 62.49 Favored 'Trans proline' 0 N--CA 1.495 1.584 0 C-N-CA 121.39 1.394 . . . . 0.0 109.232 179.208 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 299' ' ' LYS . . . . . 0.577 ' H ' HG23 ' A' ' 297' ' ' VAL . 64.4 mttp -87.55 94.47 9.72 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 171.478 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 300' ' ' LYS . . . . . 0.401 ' H ' ' HG3' ' A' ' 300' ' ' LYS . 0.0 OUTLIER -125.1 135.74 52.97 Favored 'General case' 0 C--N 1.311 -1.077 0 C-N-CA 120.994 -0.282 . . . . 0.0 110.463 -177.565 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 43.9 mm -104.31 115.27 45.92 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.937 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 174.929 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 4.3 m -100.99 126.05 47.63 Favored 'General case' 0 C--N 1.317 -0.847 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 178.799 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 55.8 p90 -138.27 152.44 48.55 Favored 'General case' 0 C--N 1.316 -0.873 0 C-N-CA 120.973 -0.291 . . . . 0.0 110.8 -175.042 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 63.2 mttp -74.36 107.0 6.25 Favored 'General case' 0 CA--C 1.508 -0.643 0 N-CA-C 109.187 -0.671 . . . . 0.0 109.187 179.373 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 3.4 m -82.31 126.39 32.08 Favored 'General case' 0 C--N 1.311 -1.079 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 175.728 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 9.6 mp -43.83 129.58 4.14 Favored Pre-proline 0 C--N 1.327 -0.378 0 CA-C-N 116.621 -0.263 . . . . 0.0 110.292 -175.409 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -59.09 -32.76 97.92 Favored 'Trans proline' 0 N--CA 1.492 1.397 0 C-N-CA 121.824 1.683 . . . . 0.0 110.753 -179.567 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -110.16 60.01 0.6 Allowed 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 108.085 -1.08 . . . . 0.0 108.085 170.263 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -77.0 140.7 40.47 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.648 -0.706 . . . . 0.0 111.683 -174.696 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 97.3 mt -109.65 127.43 54.55 Favored 'General case' 0 C--N 1.316 -0.878 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 174.628 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 2.1 p -93.89 113.2 28.13 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.003 0 N-CA-C 107.702 -1.221 . . . . 0.0 107.702 173.551 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 . . . . . 0 C--N 1.311 -1.086 0 CA-C-O 118.021 -0.99 . . . . 0.0 110.716 -171.557 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 201' ' ' GLU . . . . . 0.496 ' OE1' ' N ' ' A' ' 201' ' ' GLU . 1.8 mp0 . . . . . 0 N--CA 1.472 0.629 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 202' ' ' PHE . . . . . 0.494 ' CE1' ' HG3' ' A' ' 205' ' ' GLU . 28.2 p90 -144.99 161.48 39.28 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.03 -0.532 . . . . 0.0 112.198 -179.436 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -56.16 -41.72 86.59 Favored Glycine 0 C--O 1.225 -0.415 0 CA-C-N 115.635 -0.711 . . . . 0.0 112.529 -170.829 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 204' ' ' GLU . . . . . 0.428 ' H ' ' CD ' ' A' ' 204' ' ' GLU . 1.9 mp0 -53.99 -26.48 26.27 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-O 121.12 0.486 . . . . 0.0 110.836 -176.718 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 205' ' ' GLU . . . . . 0.494 ' HG3' ' CE1' ' A' ' 202' ' ' PHE . 61.6 mt-10 -67.04 -37.54 84.29 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.525 -0.761 . . . . 0.0 111.47 179.06 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 78.8 mtm -79.45 133.27 36.53 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 112.183 0.438 . . . . 0.0 112.183 -175.307 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 207' ' ' VAL . . . . . 0.533 HG12 ' HG2' ' A' ' 215' ' ' GLN . 29.0 m -131.13 161.4 41.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 176.374 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 208' ' ' LEU . . . . . 0.434 HD12 ' N ' ' A' ' 208' ' ' LEU . 7.6 mp -112.9 123.79 51.12 Favored 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 120.424 -0.51 . . . . 0.0 110.956 -179.837 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 20.6 p -66.73 -30.48 70.72 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.889 0.376 . . . . 0.0 110.232 174.863 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 3.0 t70 -58.46 -48.7 79.89 Favored 'General case' 0 N--CA 1.471 0.604 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.045 176.349 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 211' ' ' SER . . . . . 0.446 ' CB ' ' HB2' ' A' ' 214' ' ' GLU . 5.9 m -75.08 161.87 29.04 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-N 114.981 -1.008 . . . . 0.0 109.578 179.385 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 212' ' ' ASN . . . . . 0.405 ' O ' ' HG3' ' A' ' 214' ' ' GLU . 24.2 t30 -84.53 84.4 7.67 Favored 'General case' 0 C--O 1.239 0.517 0 C-N-CA 119.804 -0.758 . . . . 0.0 110.169 -177.117 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 59.55 39.93 95.65 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 110.662 -0.975 . . . . 0.0 110.662 -179.257 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 214' ' ' GLU . . . . . 0.446 ' HB2' ' CB ' ' A' ' 211' ' ' SER . 28.1 mt-10 -119.71 161.89 19.95 Favored 'General case' 0 C--O 1.24 0.587 0 CA-C-O 121.217 0.532 . . . . 0.0 111.28 -175.181 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 215' ' ' GLN . . . . . 0.533 ' HG2' HG12 ' A' ' 207' ' ' VAL . 57.1 mt-30 -104.59 173.87 3.07 Favored Pre-proline 0 C--N 1.313 -1.005 0 N-CA-C 105.581 -2.007 . . . . 0.0 105.581 164.295 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 216' ' ' PRO . . . . . 0.429 ' HD3' ' CD1' ' A' ' 208' ' ' LEU . 49.5 Cg_exo -60.92 138.94 82.19 Favored 'Trans proline' 0 C--N 1.305 -1.731 0 N-CA-C 108.32 -1.454 . . . . 0.0 108.32 173.253 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 217' ' ' LEU . . . . . 0.474 HD12 ' O ' ' A' ' 240' ' ' HIS . 0.5 OUTLIER -77.97 102.27 7.28 Favored 'General case' 0 N--CA 1.44 -0.964 0 C-N-CA 119.365 -0.934 . . . . 0.0 109.7 -179.747 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 218' ' ' SER . . . . . 0.428 ' HA ' ' O ' ' A' ' 292' ' ' VAL . 4.0 m -128.71 145.04 51.28 Favored 'General case' 0 N--CA 1.435 -1.179 0 CA-C-N 115.489 -0.778 . . . . 0.0 110.433 -177.057 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 219' ' ' ALA . . . . . 0.474 ' HB2' ' HA ' ' A' ' 240' ' ' HIS . . . -130.24 154.96 47.05 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.395 179.078 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 220' ' ' MET . . . . . 0.601 ' SD ' HG12 ' A' ' 291' ' ' ILE . 87.8 mmm -82.46 129.34 34.88 Favored 'General case' 0 N--CA 1.438 -1.041 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 177.831 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 65.5 t -76.23 132.6 32.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 -179.808 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 222' ' ' SER . . . . . 0.435 ' O ' ' OH ' ' A' ' 286' ' ' TYR . 33.5 m -97.16 -68.52 0.8 Allowed 'General case' 0 N--CA 1.44 -0.964 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.044 179.083 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 223' ' ' MET . . . . . 0.595 ' C ' ' SD ' ' A' ' 223' ' ' MET . 1.8 ppp? -137.14 147.95 46.31 Favored 'General case' 0 C--N 1.323 -0.567 0 C-N-CA 120.686 -0.406 . . . . 0.0 112.0 173.533 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 224' ' ' VAL . . . . . 0.7 HG22 ' HB ' ' A' ' 232' ' ' VAL . 71.2 t -125.83 131.79 71.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 N-CA-C 109.546 -0.538 . . . . 0.0 109.546 177.233 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 23.0 p -88.09 129.82 35.19 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.78 -0.368 . . . . 0.0 110.15 177.534 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 226' ' ' LYS . . . . . 0.424 ' CE ' ' O ' ' A' ' 284' ' ' SER . 51.9 tttm -80.27 81.6 6.5 Favored 'General case' 0 N--CA 1.447 -0.601 0 CA-C-O 121.674 0.749 . . . . 0.0 109.984 179.235 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 227' ' ' ASP . . . . . 0.557 ' N ' ' OG1' ' A' ' 280' ' ' THR . 42.7 t0 -151.14 169.49 21.73 Favored 'General case' 0 C--O 1.245 0.826 0 CA-C-N 114.508 -1.224 . . . . 0.0 108.923 -177.085 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 228' ' ' ASN . . . . . 0.467 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 15.8 p-10 -140.91 121.83 8.96 Favored Pre-proline 0 C--N 1.325 -0.494 0 C-N-CA 120.516 -0.473 . . . . 0.0 111.717 176.993 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 229' ' ' PRO . . . . . 0.467 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 56.6 Cg_endo -65.12 142.96 55.04 Favored 'Cis proline' 0 C--N 1.311 -1.424 0 C-N-CA 122.632 -1.82 . . . . 0.0 109.437 -4.138 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 230' ' ' GLY . . . . . 0.474 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -93.14 154.69 22.0 Favored Glycine 0 C--N 1.311 -0.817 0 N-CA-C 110.192 -1.163 . . . . 0.0 110.192 -177.296 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 231' ' ' VAL . . . . . 0.447 HG23 HD12 ' A' ' 270' ' ' LEU . 2.4 p -123.3 137.66 55.87 Favored 'Isoleucine or valine' 0 C--O 1.239 0.529 0 CA-C-N 116.724 0.262 . . . . 0.0 110.318 179.188 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 232' ' ' VAL . . . . . 0.7 ' HB ' HG22 ' A' ' 224' ' ' VAL . 0.8 OUTLIER -130.95 155.9 42.32 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.016 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.299 -177.998 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 233' ' ' THR . . . . . 0.403 ' O ' ' HB2' ' A' ' 222' ' ' SER . 27.6 m -110.73 140.45 45.11 Favored 'General case' 0 C--N 1.312 -1.028 0 CA-C-N 115.49 -0.777 . . . . 0.0 108.918 174.981 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 48.2 m -107.69 162.22 14.18 Favored 'General case' 0 C--N 1.314 -0.954 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 179.315 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 50.1 tp -61.41 130.32 45.5 Favored 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 179.198 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 55.6 m-20 -58.75 -40.41 83.79 Favored 'General case' 0 N--CA 1.476 0.857 0 CA-C-O 120.902 0.382 . . . . 0.0 111.244 -174.823 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 54.6 mp0 -64.85 -29.79 70.76 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.254 178.36 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -77.5 138.97 39.52 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.796 -176.164 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 239' ' ' ARG . . . . . 0.403 HH11 ' HD2' ' A' ' 239' ' ' ARG . 49.9 mtp85 -104.36 108.92 20.56 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.795 174.413 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 240' ' ' HIS . . . . . 0.567 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 12.7 p80 -67.01 -46.65 73.84 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-O 121.248 0.546 . . . . 0.0 109.804 176.416 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 77.87 14.74 82.03 Favored Glycine 0 CA--C 1.502 -0.743 0 N-CA-C 109.837 -1.305 . . . . 0.0 109.837 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 242' ' ' PHE . . . . . 0.525 ' CD2' ' HB2' ' A' ' 240' ' ' HIS . 8.7 m-30 -80.26 143.21 33.89 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 -177.391 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 243' ' ' GLU . . . . . 0.404 ' OE1' ' N ' ' A' ' 244' ' ' THR . 1.3 mm-40 -107.66 159.95 16.07 Favored 'General case' 0 C--N 1.308 -1.239 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.712 174.716 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 244' ' ' THR . . . . . 0.404 ' N ' ' OE1' ' A' ' 243' ' ' GLU . 0.2 OUTLIER -62.35 117.66 6.42 Favored 'General case' 0 C--N 1.297 -1.679 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 177.305 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 90.53 4.42 70.48 Favored Glycine 0 C--N 1.313 -0.748 0 N-CA-C 111.393 -0.683 . . . . 0.0 111.393 -177.679 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 23.7 t0 -79.23 163.28 25.1 Favored 'General case' 0 C--O 1.237 0.422 0 N-CA-C 109.319 -0.622 . . . . 0.0 109.319 176.531 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 247' ' ' PHE . . . . . 0.484 ' CE2' ' HB2' ' A' ' 266' ' ' GLU . 89.7 m-85 -111.3 134.09 53.14 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.507 0.194 . . . . 0.0 110.572 -176.112 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.53 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.9 m -131.17 165.94 30.12 Favored 'Isoleucine or valine' 0 C--O 1.239 0.51 0 CA-C-O 121.345 0.593 . . . . 0.0 112.441 -176.97 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 10.8 p -135.24 163.24 30.41 Favored 'General case' 0 C--N 1.32 -0.713 0 C-N-CA 124.92 1.288 . . . . 0.0 109.264 176.065 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 250' ' ' PHE . . . . . 0.603 ' CB ' ' HB3' ' A' ' 259' ' ' LEU . 78.7 m-85 -125.67 158.88 33.65 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.574 0.226 . . . . 0.0 111.027 -172.096 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 251' ' ' SER . . . . . 0.416 ' N ' ' O ' ' A' ' 291' ' ' ILE . 2.0 m -155.9 164.65 38.23 Favored 'General case' 0 C--N 1.322 -0.623 0 C-N-CA 122.326 0.251 . . . . 0.0 110.466 177.584 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 50.5 mm-40 48.59 27.36 1.45 Allowed 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.44 -0.346 . . . . 0.0 111.929 176.976 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 44.0 t -84.12 130.76 35.37 Favored 'Isoleucine or valine' 0 C--O 1.235 0.323 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 179.152 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 97.7 mm-40 -95.65 135.35 37.44 Favored 'General case' 0 C--O 1.247 0.954 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 178.86 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 255' ' ' GLY . . . . . 0.52 ' CA ' HD12 ' A' ' 287' ' ' ILE . . . 84.53 -68.64 3.47 Favored Glycine 0 C--N 1.312 -0.752 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 -178.921 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 256' ' ' MET . . . . . 0.481 ' SD ' ' C ' ' A' ' 284' ' ' SER . 1.7 tpp -81.68 67.69 7.75 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.48 0.657 . . . . 0.0 109.407 176.972 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 257' ' ' ILE . . . . . 0.469 ' O ' ' HB2' ' A' ' 260' ' ' ASN . 48.5 pt -73.94 -21.24 17.98 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.945 0 CA-C-N 115.231 -0.895 . . . . 0.0 110.69 -176.546 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 258' ' ' GLN . . . . . 0.669 ' HG3' ' SG ' ' A' ' 262' ' ' CYS . 52.5 tp60 -56.52 -33.49 66.09 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.167 179.633 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 259' ' ' LEU . . . . . 1.018 HD21 ' CE2' ' A' ' 283' ' ' PHE . 84.4 mt -62.16 -39.97 94.41 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.048 174.702 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 260' ' ' ASN . . . . . 0.469 ' HB2' ' O ' ' A' ' 257' ' ' ILE . 97.1 m-20 -59.9 -40.53 89.08 Favored 'General case' 0 C--O 1.238 0.45 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.713 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -102.24 16.38 55.46 Favored Glycine 0 CA--C 1.527 0.816 0 CA-C-N 115.901 -0.59 . . . . 0.0 112.386 -178.363 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 262' ' ' CYS . . . . . 0.669 ' SG ' ' HG3' ' A' ' 258' ' ' GLN . 1.1 m -88.14 156.3 19.33 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-N 117.184 0.492 . . . . 0.0 112.028 -178.086 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 38.2 mt-30 -73.0 160.11 83.7 Favored Pre-proline 0 C--O 1.241 0.61 0 N-CA-C 107.761 -1.199 . . . . 0.0 107.761 171.423 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 264' ' ' PRO . . . . . 0.53 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 59.4 Cg_endo -66.77 145.9 76.72 Favored 'Trans proline' 0 C--N 1.309 -1.537 0 C-N-CA 121.086 1.191 . . . . 0.0 110.353 178.281 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 265' ' ' MET . . . . . 0.422 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 20.8 ptp -136.47 152.53 50.66 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 112.007 0.373 . . . . 0.0 112.007 -172.473 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 266' ' ' GLU . . . . . 0.484 ' HB2' ' CE2' ' A' ' 247' ' ' PHE . 69.5 tt0 -71.48 140.71 50.09 Favored 'General case' 0 C--O 1.239 0.532 0 O-C-N 123.898 0.749 . . . . 0.0 109.487 177.388 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 267' ' ' ILE . . . . . 0.746 HD12 ' C ' ' A' ' 267' ' ' ILE . 2.1 pp -128.37 165.98 26.64 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-O 121.205 0.526 . . . . 0.0 112.069 -176.608 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 268' ' ' LYS . . . . . 0.426 ' HB2' ' OG ' ' A' ' 276' ' ' SER . 62.3 mttm -124.99 123.06 39.06 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 178.628 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 9.3 m -86.08 94.86 4.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 C-N-CA 119.363 -0.935 . . . . 0.0 109.966 176.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 270' ' ' LEU . . . . . 0.447 HD12 HG23 ' A' ' 231' ' ' VAL . 97.0 mt -65.49 -41.21 93.5 Favored 'General case' 0 CA--C 1.511 -0.535 0 CA-C-N 115.424 -0.807 . . . . 0.0 109.441 -178.752 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -138.07 -178.5 16.18 Favored Glycine 0 N--CA 1.448 -0.532 0 N-CA-C 108.401 -1.88 . . . . 0.0 108.401 178.591 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 272' ' ' PRO . . . . . 0.567 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 38.4 Cg_endo -64.12 -32.7 63.34 Favored 'Trans proline' 0 C--N 1.303 -1.85 0 C-N-CA 121.513 1.475 . . . . 0.0 111.307 -177.448 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -124.5 9.54 8.43 Favored 'General case' 0 C--O 1.24 0.555 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.861 -178.407 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 7.9 p -125.66 126.56 44.89 Favored 'General case' 0 C--O 1.247 0.962 0 CA-C-O 121.171 0.51 . . . . 0.0 110.844 179.582 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 275' ' ' PHE . . . . . 0.523 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -139.56 163.98 31.12 Favored 'General case' 0 CA--C 1.502 -0.897 0 N-CA-C 112.532 0.567 . . . . 0.0 112.532 -175.871 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 276' ' ' SER . . . . . 0.474 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 4.1 p -130.59 152.67 49.71 Favored 'General case' 0 N--CA 1.436 -1.159 0 CA-C-O 121.241 0.543 . . . . 0.0 112.225 -174.946 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 277' ' ' ILE . . . . . 0.731 ' C ' HD12 ' A' ' 277' ' ' ILE . 2.0 pp -134.92 173.19 14.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 114.684 -1.144 . . . . 0.0 111.461 -174.033 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 278' ' ' CYS . . . . . 0.457 ' O ' ' HA ' ' A' ' 229' ' ' PRO . 1.5 p -48.95 -78.77 0.02 OUTLIER 'General case' 0 C--N 1.323 -0.556 0 C-N-CA 123.815 0.846 . . . . 0.0 113.05 -177.173 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 279' ' ' ASP . . . . . 0.528 ' HB2' ' CB ' ' A' ' 282' ' ' ASN . 9.8 m-20 -140.1 103.87 4.71 Favored 'General case' 0 N--CA 1.452 -0.354 0 O-C-N 122.315 -0.241 . . . . 0.0 110.644 -176.256 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 280' ' ' THR . . . . . 0.74 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 20.7 p -65.46 -32.75 74.53 Favored 'General case' 0 C--N 1.315 -0.892 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 172.672 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -61.57 -23.1 65.75 Favored 'General case' 0 N--CA 1.43 -1.464 0 CA-C-N 114.019 -1.446 . . . . 0.0 109.522 175.307 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 282' ' ' ASN . . . . . 0.528 ' CB ' ' HB2' ' A' ' 279' ' ' ASP . 15.0 t30 -89.11 -10.16 48.38 Favored 'General case' 0 CA--C 1.51 -0.596 0 C-N-CA 120.372 -0.531 . . . . 0.0 109.825 178.866 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 283' ' ' PHE . . . . . 1.018 ' CE2' HD21 ' A' ' 259' ' ' LEU . 12.7 m-30 -83.76 -74.78 0.36 Allowed 'General case' 0 N--CA 1.441 -0.882 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 172.033 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 284' ' ' SER . . . . . 0.481 ' C ' ' SD ' ' A' ' 256' ' ' MET . 0.2 OUTLIER 171.68 -112.38 0.0 OUTLIER 'General case' 0 CA--C 1.541 0.631 0 CA-C-N 115.223 -0.899 . . . . 0.0 110.355 -178.552 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 285' ' ' ASP . . . . . 0.44 ' N ' ' SD ' ' A' ' 256' ' ' MET . 41.1 t0 -145.58 119.13 9.09 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 119.03 0.832 . . . . 0.0 110.687 177.495 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 286' ' ' TYR . . . . . 0.435 ' OH ' ' O ' ' A' ' 222' ' ' SER . 1.7 t80 -68.19 123.96 22.14 Favored 'General case' 0 C--O 1.239 0.523 0 CA-C-O 120.739 0.305 . . . . 0.0 110.789 178.53 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 287' ' ' ILE . . . . . 0.52 HD12 ' CA ' ' A' ' 255' ' ' GLY . 96.7 mt -106.03 -54.71 6.0 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.863 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.316 176.285 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 9.7 ptp180 -169.69 -179.05 3.2 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.079 177.842 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 63.6 -151.09 49.24 Favored Glycine 0 C--O 1.239 0.421 0 N-CA-C 110.605 -0.998 . . . . 0.0 110.605 177.281 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 99.24 129.42 6.55 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 121.59 -0.338 . . . . 0.0 112.525 175.894 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 291' ' ' ILE . . . . . 0.601 HG12 ' SD ' ' A' ' 220' ' ' MET . 98.1 mt -125.24 133.77 68.51 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 175.704 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 292' ' ' VAL . . . . . 0.428 ' O ' ' HA ' ' A' ' 218' ' ' SER . 4.5 p -122.63 134.6 65.35 Favored 'Isoleucine or valine' 0 C--O 1.241 0.615 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -177.955 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 23.6 m -127.44 145.29 50.88 Favored 'General case' 0 CA--C 1.513 -0.478 0 CA-C-O 120.624 0.249 . . . . 0.0 111.016 -178.418 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 294' ' ' GLN . . . . . 0.417 ' O ' ' NE2' ' A' ' 294' ' ' GLN . 1.6 pp0? -75.38 148.26 39.36 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.517 -0.31 . . . . 0.0 110.424 178.091 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 72.4 t -126.52 130.79 71.77 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 177.601 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 1.4 mmpp? -98.83 99.44 10.52 Favored 'General case' 0 C--O 1.244 0.8 0 CA-C-O 121.49 0.662 . . . . 0.0 111.243 -179.897 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 297' ' ' VAL . . . . . 0.594 ' HB ' ' HD2' ' A' ' 298' ' ' PRO . 24.1 m -74.3 -176.9 0.56 Allowed Pre-proline 0 CA--C 1.542 0.655 0 CA-C-N 114.745 -1.116 . . . . 0.0 108.856 178.819 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 298' ' ' PRO . . . . . 0.594 ' HD2' ' HB ' ' A' ' 297' ' ' VAL . 77.4 Cg_exo -54.85 -35.55 89.06 Favored 'Trans proline' 0 N--CA 1.491 1.38 0 C-N-CA 121.711 1.607 . . . . 0.0 111.32 177.725 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 299' ' ' LYS . . . . . 0.441 ' NZ ' ' O ' ' A' ' 300' ' ' LYS . 62.3 tttm -69.46 137.5 52.68 Favored 'General case' 0 C--O 1.239 0.521 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.402 -179.372 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 300' ' ' LYS . . . . . 0.441 ' O ' ' NZ ' ' A' ' 299' ' ' LYS . 67.4 mttm -97.6 157.22 16.15 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.594 170.737 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 47.2 pt -99.17 130.01 48.76 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.955 0 CA-C-O 120.77 0.319 . . . . 0.0 111.374 -179.554 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 8.0 m -131.53 157.18 44.25 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 115.931 -0.577 . . . . 0.0 109.779 -177.333 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 85.2 t80 -111.5 132.43 54.5 Favored 'General case' 0 C--N 1.315 -0.895 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 -178.843 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 64.4 mttp -66.38 136.49 55.83 Favored 'General case' 0 CA--C 1.515 -0.376 0 C-N-CA 120.734 -0.386 . . . . 0.0 110.245 -175.994 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 6.2 m -70.5 141.18 51.98 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.003 177.96 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 6.1 mp -76.49 156.18 83.36 Favored Pre-proline 0 C--N 1.327 -0.396 0 C-N-CA 120.729 -0.388 . . . . 0.0 110.588 -177.334 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -61.95 -28.28 80.66 Favored 'Trans proline' 0 N--CA 1.496 1.636 0 C-N-CA 122.189 1.926 . . . . 0.0 110.559 179.492 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -141.29 143.22 33.95 Favored 'General case' 0 N--CA 1.445 -0.697 0 CA-C-N 115.728 -0.669 . . . . 0.0 109.509 176.61 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.49 ' O ' HG22 ' A' ' 311' ' ' VAL . 6.4 m -72.89 158.48 35.42 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.988 -0.551 . . . . 0.0 111.013 -178.816 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 310' ' ' LEU . . . . . 0.469 HD13 ' HA ' ' A' ' 310' ' ' LEU . 4.3 mm? -70.49 79.31 0.57 Allowed 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 178.166 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 311' ' ' VAL . . . . . 0.49 HG22 ' O ' ' A' ' 309' ' ' SER . 26.9 m -126.86 161.55 33.34 Favored 'Isoleucine or valine' 0 C--O 1.241 0.647 0 CA-C-N 115.35 -0.841 . . . . 0.0 109.949 -176.827 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 86.8 mt-10 . . . . . 0 C--O 1.202 -1.428 0 CA-C-O 118.899 -0.572 . . . . 0.0 110.232 -179.121 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 201' ' ' GLU . . . . . 0.567 ' O ' ' N ' ' A' ' 203' ' ' GLY . 0.7 OUTLIER . . . . . 0 N--CA 1.479 0.981 0 N-CA-C 110.021 -0.363 . . . . 0.0 110.021 . . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 33.4 m-85 21.45 -70.54 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.368 0 C-N-CA 125.539 1.536 . . . . 0.0 114.223 -178.09 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 203' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 201' ' ' GLU . . . -63.18 -34.0 88.78 Favored Glycine 0 N--CA 1.454 -0.143 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 -177.991 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 204' ' ' GLU . . . . . 0.45 ' OE1' ' N ' ' A' ' 201' ' ' GLU . 99.6 mt-10 -65.62 -44.25 87.06 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.838 0.351 . . . . 0.0 110.388 -179.63 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 205' ' ' GLU . . . . . 0.497 ' OE1' ' N ' ' A' ' 201' ' ' GLU . 2.2 mp0 -62.77 -37.18 85.63 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.568 -177.641 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 64.2 ttp -89.45 120.98 31.24 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.471 -179.381 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 61.6 t -122.04 130.53 74.49 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.803 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 173.476 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 208' ' ' LEU . . . . . 0.525 ' C ' ' H ' ' A' ' 210' ' ' ASP . 10.9 mp -76.29 74.42 3.09 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.036 0.446 . . . . 0.0 111.422 -175.943 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -71.21 34.55 0.05 OUTLIER 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.98 172.273 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 210' ' ' ASP . . . . . 0.525 ' H ' ' C ' ' A' ' 208' ' ' LEU . 32.9 t70 -58.1 -38.95 77.42 Favored 'General case' 0 CA--C 1.512 -0.507 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.776 -175.235 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 1.1 m -57.79 91.6 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 175.838 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 23.3 t-20 -61.35 122.16 14.43 Favored 'General case' 0 CA--C 1.507 -0.7 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.276 -173.008 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 104.5 -22.39 34.4 Favored Glycine 0 C--O 1.24 0.517 0 N-CA-C 111.286 -0.726 . . . . 0.0 111.286 178.628 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 80.6 mm-40 -84.82 97.34 9.67 Favored 'General case' 0 N--CA 1.447 -0.6 0 C-N-CA 119.791 -0.763 . . . . 0.0 109.568 176.846 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 11.6 mm100 -112.69 102.44 54.46 Favored Pre-proline 0 C--N 1.32 -0.707 0 CA-C-N 115.751 -0.659 . . . . 0.0 109.379 177.711 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -74.1 102.71 1.56 Allowed 'Trans proline' 0 C--N 1.305 -1.744 0 C-N-CA 121.318 1.345 . . . . 0.0 109.454 177.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 217' ' ' LEU . . . . . 0.433 ' HB3' ' O ' ' A' ' 240' ' ' HIS . 0.1 OUTLIER -54.04 128.04 28.95 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 108.365 -0.976 . . . . 0.0 108.365 -177.428 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 218' ' ' SER . . . . . 0.411 ' HA ' ' HA ' ' A' ' 293' ' ' SER . 0.7 OUTLIER -127.0 147.73 50.12 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-O 120.745 0.307 . . . . 0.0 110.499 -174.734 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -146.41 154.41 41.58 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.509 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 56.3 mtm -79.98 138.95 37.18 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.842 176.985 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 99.2 t -85.13 130.01 36.85 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.94 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 -178.901 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 65.4 m -83.35 -70.68 0.54 Allowed 'General case' 0 N--CA 1.434 -1.254 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 179.414 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -138.57 152.94 48.62 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.834 174.007 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 224' ' ' VAL . . . . . 0.58 HG22 ' HB ' ' A' ' 232' ' ' VAL . 53.6 t -120.93 132.43 70.45 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 175.329 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 75.5 p -90.85 116.56 28.77 Favored 'General case' 0 C--O 1.236 0.393 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 175.435 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 226' ' ' LYS . . . . . 0.494 ' HA ' ' OG1' ' A' ' 280' ' ' THR . 3.7 tttm -75.86 64.37 1.81 Allowed 'General case' 0 C--O 1.249 1.06 0 C-N-CA 120.616 -0.434 . . . . 0.0 111.259 -175.147 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 227' ' ' ASP . . . . . 0.416 ' N ' ' OG1' ' A' ' 280' ' ' THR . 36.0 t0 -133.04 -175.69 3.87 Favored 'General case' 0 C--O 1.243 0.752 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.621 178.358 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 228' ' ' ASN . . . . . 0.485 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.6 OUTLIER -138.52 125.29 13.04 Favored Pre-proline 0 CA--C 1.533 0.307 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.031 175.631 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 229' ' ' PRO . . . . . 0.485 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 48.6 Cg_endo -66.35 141.24 52.34 Favored 'Cis proline' 0 C--N 1.313 -1.337 0 C-N-CA 122.715 -1.785 . . . . 0.0 110.01 -1.04 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 230' ' ' GLY . . . . . 0.453 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -75.13 139.3 24.79 Favored Glycine 0 C--N 1.308 -1.01 0 N-CA-C 110.662 -0.975 . . . . 0.0 110.662 -177.745 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 231' ' ' VAL . . . . . 0.412 ' CG2' HD12 ' A' ' 270' ' ' LEU . 2.4 p -128.29 137.56 57.08 Favored 'Isoleucine or valine' 0 C--O 1.244 0.775 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 175.001 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 232' ' ' VAL . . . . . 0.58 ' HB ' HG22 ' A' ' 224' ' ' VAL . 0.6 OUTLIER -133.53 155.67 40.65 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.786 0 C-N-CA 120.475 -0.49 . . . . 0.0 110.985 -178.693 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 3.1 m -104.06 140.65 37.46 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 115.459 -0.791 . . . . 0.0 108.902 176.769 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.9 m -107.35 156.84 18.48 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -178.593 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.467 ' HB3' ' HB3' ' A' ' 238' ' ' ALA . 27.0 tp -58.47 130.21 45.7 Favored 'General case' 0 C--N 1.318 -0.801 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 -178.334 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -55.32 -44.03 75.45 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 120.992 0.425 . . . . 0.0 110.69 -175.025 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 237' ' ' GLU . . . . . 0.403 ' H ' ' CD ' ' A' ' 237' ' ' GLU . 1.7 mp0 -67.6 -23.18 65.35 Favored 'General case' 0 C--N 1.312 -1.065 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.604 -179.72 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 238' ' ' ALA . . . . . 0.467 ' HB3' ' HB3' ' A' ' 235' ' ' LEU . . . -94.54 90.75 6.29 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.964 0.412 . . . . 0.0 111.984 -175.002 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.74 110.12 2.69 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 108.633 -0.876 . . . . 0.0 108.633 174.799 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 240' ' ' HIS . . . . . 0.577 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 12.3 p80 -64.44 -49.81 70.0 Favored 'General case' 0 C--O 1.216 -0.674 0 CA-C-O 120.647 0.26 . . . . 0.0 111.212 -176.501 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 80.71 17.8 72.07 Favored Glycine 0 C--O 1.242 0.599 0 N-CA-C 110.961 -0.855 . . . . 0.0 110.961 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 242' ' ' PHE . . . . . 0.414 ' CD2' ' HB2' ' A' ' 240' ' ' HIS . 7.3 m-30 -81.38 139.94 35.01 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 179.391 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 76.6 mm-40 -98.79 157.13 16.49 Favored 'General case' 0 C--N 1.308 -1.201 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 172.601 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 244' ' ' THR . . . . . 0.666 HG23 ' HA ' ' A' ' 268' ' ' LYS . 25.0 m -65.57 123.4 19.58 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 172.86 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 94.72 0.09 64.64 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 110.994 -0.842 . . . . 0.0 110.994 -174.705 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 45.9 t0 -79.31 159.62 27.13 Favored 'General case' 0 C--O 1.239 0.542 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 176.736 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 247' ' ' PHE . . . . . 0.406 ' CE1' ' HG3' ' A' ' 299' ' ' LYS . 87.4 m-85 -110.29 129.96 55.64 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.311 -176.559 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.496 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.4 m -128.33 161.54 36.65 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.332 0 C-N-CA 120.658 -0.417 . . . . 0.0 111.494 -179.09 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 50.1 m -129.63 153.15 48.38 Favored 'General case' 0 N--CA 1.444 -0.774 0 CA-C-N 115.108 -0.951 . . . . 0.0 108.676 172.817 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 250' ' ' PHE . . . . . 0.639 ' CD1' HD22 ' A' ' 259' ' ' LEU . 73.5 m-85 -105.26 145.25 30.92 Favored 'General case' 0 C--N 1.311 -1.066 0 C-N-CA 122.948 0.499 . . . . 0.0 109.882 -177.333 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 4.8 m -132.17 151.54 51.74 Favored 'General case' 0 C--N 1.304 -1.387 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 175.145 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 7.3 mm-40 47.34 38.22 7.03 Favored 'General case' 0 C--N 1.308 -1.233 0 N-CA-C 112.938 0.718 . . . . 0.0 112.938 174.962 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 0.54 HG13 ' CE1' ' A' ' 286' ' ' TYR . 24.2 t -85.2 132.38 31.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 172.499 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 98.6 mm-40 -96.76 145.12 26.11 Favored 'General case' 0 C--N 1.32 -0.698 0 C-N-CA 120.68 -0.408 . . . . 0.0 110.214 176.671 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 81.19 -67.51 3.6 Favored Glycine 0 C--N 1.32 -0.352 0 N-CA-C 110.244 -1.143 . . . . 0.0 110.244 -177.207 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 256' ' ' MET . . . . . 0.484 ' HG3' ' C ' ' A' ' 285' ' ' ASP . 47.8 mtt -78.65 65.65 3.97 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.475 0.655 . . . . 0.0 110.586 176.219 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 48.9 pt -66.27 -23.78 32.37 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.897 0 CA-C-N 115.285 -0.871 . . . . 0.0 109.577 179.511 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 258' ' ' GLN . . . . . 0.421 ' NE2' ' O ' ' A' ' 283' ' ' PHE . 1.3 mp0 -54.37 -40.99 68.67 Favored 'General case' 0 N--CA 1.442 -0.862 0 CA-C-N 115.14 -0.936 . . . . 0.0 109.044 178.485 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 259' ' ' LEU . . . . . 0.906 HD21 ' CE2' ' A' ' 283' ' ' PHE . 87.3 mt -62.92 -41.83 99.59 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.783 178.067 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 260' ' ' ASN . . . . . 0.491 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 93.3 m-20 -59.37 -41.03 88.38 Favored 'General case' 0 CA--C 1.509 -0.623 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 -177.873 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -102.36 10.98 56.74 Favored Glycine 0 CA--C 1.525 0.706 0 CA-C-N 116.027 -0.533 . . . . 0.0 112.265 -179.359 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 262' ' ' CYS . . . . . 0.415 ' HB2' ' O ' ' A' ' 258' ' ' GLN . 11.8 t -88.48 139.98 29.93 Favored 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 117.512 0.656 . . . . 0.0 111.458 -177.471 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 9.6 mp0 -56.4 158.53 7.7 Favored Pre-proline 0 C--N 1.322 -0.621 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 173.219 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 264' ' ' PRO . . . . . 0.496 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 36.7 Cg_endo -61.71 146.87 96.4 Favored 'Trans proline' 0 N--CA 1.495 1.568 0 C-N-CA 121.488 1.459 . . . . 0.0 111.713 -178.719 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 265' ' ' MET . . . . . 0.63 ' N ' ' SD ' ' A' ' 265' ' ' MET . 0.0 OUTLIER -119.35 152.27 37.06 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.888 -176.461 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 73.0 tt0 -76.53 137.17 39.42 Favored 'General case' 0 C--O 1.238 0.46 0 N-CA-C 107.964 -1.124 . . . . 0.0 107.964 174.803 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 267' ' ' ILE . . . . . 0.708 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.9 pp -129.51 159.09 41.92 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 N-CA-C 113.069 0.766 . . . . 0.0 113.069 -174.928 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 268' ' ' LYS . . . . . 0.666 ' HA ' HG23 ' A' ' 244' ' ' THR . 65.6 mttm -123.54 115.04 20.88 Favored 'General case' 0 CA--C 1.534 0.331 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.367 178.694 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.436 HG22 ' OG1' ' A' ' 244' ' ' THR . 17.7 m -78.35 100.18 3.26 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.497 0 CA-C-O 121.138 0.494 . . . . 0.0 111.613 -179.149 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 270' ' ' LEU . . . . . 0.412 HD12 ' CG2' ' A' ' 231' ' ' VAL . 97.5 mt -66.25 -40.82 90.44 Favored 'General case' 0 CA--C 1.513 -0.462 0 CA-C-N 115.723 -0.672 . . . . 0.0 110.477 179.033 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -145.17 179.5 22.23 Favored Glycine 0 C--N 1.315 -0.638 0 N-CA-C 109.724 -1.35 . . . . 0.0 109.724 -177.238 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 272' ' ' PRO . . . . . 0.577 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 33.0 Cg_endo -61.39 -31.82 88.74 Favored 'Trans proline' 0 C--N 1.303 -1.845 0 C-N-CA 121.797 1.665 . . . . 0.0 110.976 -178.448 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 88.4 m-85 -121.36 8.67 10.25 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.18 -0.464 . . . . 0.0 112.067 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -123.77 126.34 46.31 Favored 'General case' 0 C--O 1.242 0.665 0 CA-C-O 120.855 0.359 . . . . 0.0 110.998 -179.48 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 275' ' ' PHE . . . . . 0.561 ' CE2' HG21 ' A' ' 267' ' ' ILE . 0.0 OUTLIER -132.71 161.03 35.05 Favored 'General case' 0 CA--C 1.499 -1.007 0 C-N-CA 120.733 -0.387 . . . . 0.0 111.766 178.038 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 276' ' ' SER . . . . . 0.453 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 7.7 p -133.36 154.39 50.78 Favored 'General case' 0 N--CA 1.432 -1.346 0 CA-C-O 121.25 0.547 . . . . 0.0 112.456 -173.636 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 277' ' ' ILE . . . . . 0.699 HG22 HG22 ' A' ' 267' ' ' ILE . 35.7 pt -140.94 -165.93 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 CA-C-N 113.991 -1.458 . . . . 0.0 109.569 -171.049 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 278' ' ' CYS . . . . . 0.484 ' O ' ' HA ' ' A' ' 229' ' ' PRO . 14.7 p -69.81 -110.64 0.0 OUTLIER 'General case' 0 N--CA 1.45 -0.474 0 O-C-N 122.996 0.185 . . . . 0.0 111.056 178.793 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 279' ' ' ASP . . . . . 0.442 ' CG ' ' HB2' ' A' ' 228' ' ' ASN . 50.8 t0 -117.5 119.9 36.47 Favored 'General case' 0 CA--C 1.507 -0.682 0 CA-C-O 121.048 0.452 . . . . 0.0 110.855 -179.591 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 280' ' ' THR . . . . . 0.51 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 9.4 p -64.44 -29.29 70.35 Favored 'General case' 0 C--N 1.292 -1.919 0 CA-C-N 115.501 -0.772 . . . . 0.0 109.597 175.186 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -65.19 -11.66 42.99 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.008 -0.996 . . . . 0.0 109.642 174.483 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 -85.87 -8.65 57.92 Favored 'General case' 0 CA--C 1.507 -0.69 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 175.772 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 283' ' ' PHE . . . . . 0.906 ' CE2' HD21 ' A' ' 259' ' ' LEU . 3.3 m-85 -99.73 -78.41 0.51 Allowed 'General case' 0 N--CA 1.442 -0.84 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 171.117 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 284' ' ' SER . . . . . 0.474 ' OG ' ' N ' ' A' ' 285' ' ' ASP . 31.3 t 168.33 -144.33 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.291 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 -179.121 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 285' ' ' ASP . . . . . 0.484 ' C ' ' HG3' ' A' ' 256' ' ' MET . 64.8 m-20 -98.46 131.67 44.53 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 122.289 0.236 . . . . 0.0 110.567 176.734 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 286' ' ' TYR . . . . . 0.54 ' CE1' HG13 ' A' ' 253' ' ' VAL . 13.0 t80 -84.23 125.56 32.33 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 178.935 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 287' ' ' ILE . . . . . 0.401 ' O ' ' CG ' ' A' ' 288' ' ' ARG . 9.3 mm -94.01 -54.07 7.67 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 N-CA-C 110.471 -0.196 . . . . 0.0 110.471 179.539 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 288' ' ' ARG . . . . . 0.401 ' CG ' ' O ' ' A' ' 287' ' ' ILE . 0.7 OUTLIER 176.34 -178.0 0.14 Allowed 'General case' 0 C--O 1.244 0.766 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.019 -179.53 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 64.98 -140.64 42.3 Favored Glycine 0 CA--C 1.5 -0.856 0 N-CA-C 110.027 -1.229 . . . . 0.0 110.027 177.942 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 290' ' ' GLY . . . . . 0.45 ' HA3' HG22 ' A' ' 253' ' ' VAL . . . 87.93 126.34 2.41 Favored Glycine 0 N--CA 1.434 -1.478 0 C-N-CA 120.82 -0.705 . . . . 0.0 111.474 177.916 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 82.1 mt -120.62 131.21 73.37 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 N-CA-C 106.474 -1.676 . . . . 0.0 106.474 175.06 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 3.9 p -117.85 133.1 65.72 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.051 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -176.038 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 293' ' ' SER . . . . . 0.411 ' HA ' ' HA ' ' A' ' 218' ' ' SER . 1.4 m -129.35 141.16 51.15 Favored 'General case' 0 CA--C 1.505 -0.781 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.71 -177.98 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 294' ' ' GLN . . . . . 0.492 ' HA ' ' HA ' ' A' ' 248' ' ' VAL . 0.2 OUTLIER -74.03 146.43 43.74 Favored 'General case' 0 C--N 1.318 -0.797 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 172.398 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 59.2 t -110.71 128.0 67.37 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.171 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 -179.501 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 7.9 mmmm -80.81 98.49 7.83 Favored 'General case' 0 C--N 1.321 -0.644 0 C-N-CA 120.631 -0.427 . . . . 0.0 110.31 -179.19 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 297' ' ' VAL . . . . . 0.428 ' HB ' ' HD2' ' A' ' 298' ' ' PRO . 0.2 OUTLIER -103.98 165.29 13.7 Favored Pre-proline 0 C--N 1.316 -0.878 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.241 177.621 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 298' ' ' PRO . . . . . 0.447 ' O ' ' HG3' ' A' ' 300' ' ' LYS . 38.4 Cg_endo -64.81 -6.9 13.47 Favored 'Trans proline' 0 C--N 1.308 -1.587 0 C-N-CA 122.738 2.292 . . . . 0.0 112.48 178.041 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 299' ' ' LYS . . . . . 0.406 ' HG3' ' CE1' ' A' ' 247' ' ' PHE . 75.2 mmtt -45.43 109.12 0.15 Allowed 'General case' 0 C--O 1.239 0.505 0 CA-C-N 116.501 -0.318 . . . . 0.0 110.231 -179.242 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 300' ' ' LYS . . . . . 0.447 ' HG3' ' O ' ' A' ' 298' ' ' PRO . 49.6 mttp -124.26 155.71 38.14 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 116.473 -0.33 . . . . 0.0 110.391 177.73 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 41.7 mm -67.12 131.32 32.82 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 176.499 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 73.2 m -155.37 162.17 40.87 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-O 120.778 0.323 . . . . 0.0 111.123 -175.345 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 303' ' ' PHE . . . . . 0.407 ' HB2' HD11 ' A' ' 310' ' ' LEU . 94.6 m-85 -132.29 152.14 51.51 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 -179.753 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -68.15 141.72 55.96 Favored 'General case' 0 C--N 1.321 -0.646 0 C-N-CA 120.995 -0.282 . . . . 0.0 110.294 -177.249 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -69.86 95.45 0.92 Allowed 'General case' 0 N--CA 1.445 -0.705 0 CA-C-O 120.978 0.418 . . . . 0.0 110.028 179.25 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 306' ' ' LEU . . . . . 0.404 ' O ' ' OG ' ' A' ' 309' ' ' SER . 6.7 mp -96.87 166.35 14.11 Favored Pre-proline 0 C--N 1.323 -0.58 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 179.799 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_exo -52.39 -40.8 70.15 Favored 'Trans proline' 0 N--CA 1.495 1.596 0 C-N-CA 121.903 1.735 . . . . 0.0 110.328 178.702 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -94.55 65.05 3.12 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 171.868 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.404 ' OG ' ' O ' ' A' ' 306' ' ' LEU . 0.8 OUTLIER -63.36 167.77 5.05 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.37 -176.62 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 310' ' ' LEU . . . . . 0.407 HD11 ' HB2' ' A' ' 303' ' ' PHE . 77.4 mt -66.44 135.32 54.11 Favored 'General case' 0 C--O 1.239 0.516 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 179.759 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 79.2 t -128.04 134.89 64.2 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.239 -178.766 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 90.4 mt-10 . . . . . 0 C--O 1.208 -1.129 0 CA-C-O 118.228 -0.891 . . . . 0.0 110.84 179.224 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 201' ' ' GLU . . . . . 0.513 ' OE1' ' N ' ' A' ' 201' ' ' GLU . 1.8 mp0 . . . . . 0 N--CA 1.473 0.705 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 80.3 m-85 -92.43 81.36 4.88 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 178.562 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -78.6 -1.34 82.64 Favored Glycine 0 C--N 1.319 -0.416 0 N-CA-C 110.821 -0.912 . . . . 0.0 110.821 -179.226 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -54.56 -24.19 19.93 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.365 0.603 . . . . 0.0 109.605 179.569 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -64.36 -36.69 84.97 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-N 115.272 -0.877 . . . . 0.0 110.523 179.444 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 99.4 mtp -81.26 89.61 6.06 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.035 0.445 . . . . 0.0 111.862 -175.418 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 2.8 t -123.16 90.33 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.875 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 171.772 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 3.6 mp -97.32 72.45 2.41 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.762 -173.409 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 1.2 m -97.72 8.64 44.33 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 174.269 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 210' ' ' ASP . . . . . 0.474 ' CG ' ' N ' ' A' ' 211' ' ' SER . 13.0 p-10 -58.66 -48.59 80.54 Favored 'General case' 0 CA--C 1.508 -0.653 0 CA-C-N 115.199 -0.909 . . . . 0.0 109.682 179.233 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 211' ' ' SER . . . . . 0.474 ' N ' ' CG ' ' A' ' 210' ' ' ASP . 0.9 OUTLIER -74.22 123.21 24.09 Favored 'General case' 0 N--CA 1.439 -1.023 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.212 -178.765 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 212' ' ' ASN . . . . . 0.412 ' O ' ' HB2' ' A' ' 296' ' ' LYS . 65.6 t30 -95.97 107.63 19.92 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.714 -175.83 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 71.73 -39.26 0.63 Allowed Glycine 0 CA--C 1.525 0.661 0 CA-C-N 116.411 -0.358 . . . . 0.0 112.636 178.257 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 214' ' ' GLU . . . . . 0.424 ' OE1' ' NZ ' ' A' ' 296' ' ' LYS . 68.0 mt-10 -132.04 162.37 30.94 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 117.168 0.484 . . . . 0.0 111.977 -179.455 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 2.9 mt-30 -54.15 153.78 8.85 Favored Pre-proline 0 C--N 1.327 -0.379 0 CA-C-N 115.332 -0.849 . . . . 0.0 111.707 -176.789 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 61.8 Cg_endo -75.73 53.6 3.7 Favored 'Trans proline' 0 C--N 1.309 -1.532 0 C-N-CA 122.57 2.18 . . . . 0.0 110.698 175.634 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 217' ' ' LEU . . . . . 0.424 HD13 ' HA ' ' A' ' 217' ' ' LEU . 0.1 OUTLIER -47.24 115.7 1.18 Allowed 'General case' 0 C--O 1.234 0.28 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 -178.052 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 24.1 m -133.63 152.46 51.9 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.277 -174.092 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -142.98 156.08 44.8 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 116.037 -0.528 . . . . 0.0 110.559 177.303 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 220' ' ' MET . . . . . 0.545 ' SD ' HD12 ' A' ' 291' ' ' ILE . 1.6 mpp? -75.22 134.57 41.13 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 176.659 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 99.3 t -82.06 128.29 38.85 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.886 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 178.836 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 20.2 m -86.3 -71.59 0.54 Allowed 'General case' 0 N--CA 1.439 -0.993 0 CA-C-N 116.017 -0.538 . . . . 0.0 109.876 178.037 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 8.7 ptm -137.71 149.68 46.69 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.168 174.504 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 224' ' ' VAL . . . . . 0.532 HG22 ' HB ' ' A' ' 232' ' ' VAL . 72.4 t -121.74 127.27 75.46 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.993 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 174.748 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 225' ' ' THR . . . . . 0.413 ' O ' HG21 ' A' ' 280' ' ' THR . 11.6 p -77.44 130.72 37.41 Favored 'General case' 0 CA--C 1.512 -0.485 0 C-N-CA 120.399 -0.52 . . . . 0.0 110.382 -179.117 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 226' ' ' LYS . . . . . 0.555 ' NZ ' ' OG ' ' A' ' 281' ' ' SER . 26.7 tptp -81.97 74.5 8.95 Favored 'General case' 0 N--CA 1.441 -0.916 0 N-CA-C 108.728 -0.842 . . . . 0.0 108.728 176.232 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 227' ' ' ASP . . . . . 0.465 ' CG ' ' H ' ' A' ' 228' ' ' ASN . 8.6 t70 -153.65 -173.15 4.47 Favored 'General case' 0 C--O 1.244 0.797 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.599 -176.224 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 228' ' ' ASN . . . . . 0.465 ' H ' ' CG ' ' A' ' 227' ' ' ASP . 12.4 p30 -140.51 125.08 10.85 Favored Pre-proline 0 N--CA 1.452 -0.353 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.2 176.094 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 229' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -69.68 148.31 86.29 Favored 'Cis proline' 0 C--N 1.311 -1.422 0 C-N-CA 123.029 -1.655 . . . . 0.0 109.722 -1.636 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 230' ' ' GLY . . . . . 0.614 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -71.32 130.38 18.57 Favored Glycine 0 C--N 1.311 -0.839 0 N-CA-C 109.231 -1.548 . . . . 0.0 109.231 -179.719 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.1 p -120.93 131.35 73.18 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.8 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 177.903 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 232' ' ' VAL . . . . . 0.532 ' HB ' HG22 ' A' ' 224' ' ' VAL . 0.6 OUTLIER -130.09 153.13 38.47 Favored 'Isoleucine or valine' 0 C--O 1.249 1.061 0 C-N-CA 119.474 -0.89 . . . . 0.0 111.361 -174.78 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 3.1 m -108.11 140.37 41.4 Favored 'General case' 0 N--CA 1.432 -1.358 0 CA-C-N 114.807 -1.088 . . . . 0.0 108.857 177.832 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 34.6 m -107.28 161.0 15.18 Favored 'General case' 0 C--N 1.308 -1.227 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 178.422 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 40.1 tp -60.53 127.65 32.76 Favored 'General case' 0 C--N 1.314 -0.978 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 -178.747 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -56.79 -39.89 74.93 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-O 121.242 0.544 . . . . 0.0 110.608 -174.481 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -65.89 -29.63 70.1 Favored 'General case' 0 C--N 1.308 -1.224 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.99 179.602 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -96.96 130.92 44.2 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 112.106 0.41 . . . . 0.0 112.106 -172.924 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 90.6 mtm-85 -86.3 137.45 32.6 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 174.351 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 240' ' ' HIS . . . . . 0.574 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 8.9 p80 -88.62 -45.18 10.07 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 121.073 0.463 . . . . 0.0 109.832 175.699 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 83.25 12.15 79.41 Favored Glycine 0 C--O 1.239 0.436 0 N-CA-C 110.719 -0.952 . . . . 0.0 110.719 178.539 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 242' ' ' PHE . . . . . 0.506 ' CD1' ' HB3' ' A' ' 294' ' ' GLN . 4.4 m-30 -80.87 145.35 31.4 Favored 'General case' 0 C--N 1.318 -0.781 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 -179.495 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 243' ' ' GLU . . . . . 0.463 ' H ' ' CB ' ' A' ' 246' ' ' ASP . 98.2 mt-10 -122.17 168.1 12.39 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.951 -179.158 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 17.7 m -58.84 122.12 12.8 Favored 'General case' 0 C--N 1.313 -1.003 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 179.356 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 78.48 7.02 88.14 Favored Glycine 0 C--N 1.319 -0.394 0 N-CA-C 111.25 -0.74 . . . . 0.0 111.25 179.646 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 246' ' ' ASP . . . . . 0.463 ' CB ' ' H ' ' A' ' 243' ' ' GLU . 40.0 t0 -76.93 162.2 27.78 Favored 'General case' 0 CA--C 1.514 -0.43 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 178.928 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 247' ' ' PHE . . . . . 0.466 ' HA ' ' O ' ' A' ' 265' ' ' MET . 72.3 m-85 -109.64 137.21 47.79 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.041 0.448 . . . . 0.0 111.511 -177.534 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.452 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.9 m -133.47 162.02 40.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.308 178.792 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 249' ' ' SER . . . . . 0.44 ' OG ' HG21 ' A' ' 295' ' ' VAL . 67.1 m -125.89 151.48 46.85 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 172.692 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 250' ' ' PHE . . . . . 0.586 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 88.3 m-85 -107.37 149.58 27.7 Favored 'General case' 0 C--N 1.308 -1.207 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.218 -175.552 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 7.3 p -146.92 156.8 43.36 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.231 179.424 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 87.0 mt-10 45.8 26.8 0.4 Allowed 'General case' 0 C--N 1.316 -0.849 0 N-CA-C 112.914 0.709 . . . . 0.0 112.914 177.767 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 0.505 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 52.5 t -83.32 132.78 30.59 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.415 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 174.921 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 93.8 mm-40 -98.52 137.23 37.49 Favored 'General case' 0 C--N 1.317 -0.833 0 C-N-CA 120.043 -0.663 . . . . 0.0 110.036 -179.254 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 83.38 -57.28 5.07 Favored Glycine 0 C--N 1.317 -0.514 0 N-CA-C 110.899 -0.881 . . . . 0.0 110.899 -177.934 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 256' ' ' MET . . . . . 0.411 ' SD ' HG11 ' A' ' 224' ' ' VAL . 4.4 ttm -78.29 63.11 3.11 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.632 0.729 . . . . 0.0 109.388 178.747 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 48.6 pt -69.76 -25.59 28.72 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 114.853 -1.067 . . . . 0.0 111.39 -174.748 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 258' ' ' GLN . . . . . 0.474 ' HG3' ' SG ' ' A' ' 262' ' ' CYS . 60.9 tp60 -58.93 -40.6 85.07 Favored 'General case' 0 CA--C 1.509 -0.608 0 C-N-CA 120.343 -0.543 . . . . 0.0 110.085 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 259' ' ' LEU . . . . . 0.628 HD21 ' CE2' ' A' ' 283' ' ' PHE . 96.0 mt -62.51 -42.28 99.4 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.981 -0.554 . . . . 0.0 109.554 179.009 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 260' ' ' ASN . . . . . 0.505 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 99.0 m-20 -60.23 -40.44 90.22 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.079 -178.898 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -92.19 -5.12 65.98 Favored Glycine 0 CA--C 1.523 0.557 0 C-N-CA 121.268 -0.491 . . . . 0.0 111.904 -178.238 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 262' ' ' CYS . . . . . 0.474 ' SG ' ' HG3' ' A' ' 258' ' ' GLN . 1.1 m -78.19 154.6 30.98 Favored 'General case' 0 C--N 1.326 -0.456 0 C-N-CA 120.363 -0.535 . . . . 0.0 111.614 -176.207 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 263' ' ' GLN . . . . . 0.561 ' CD ' ' H ' ' A' ' 263' ' ' GLN . 0.0 OUTLIER -67.9 170.72 6.67 Favored Pre-proline 0 C--N 1.322 -0.623 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 172.93 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 264' ' ' PRO . . . . . 0.452 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 45.1 Cg_endo -63.92 142.99 84.22 Favored 'Trans proline' 0 C--N 1.311 -1.436 0 N-CA-C 109.452 -1.018 . . . . 0.0 109.452 177.555 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 265' ' ' MET . . . . . 0.466 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 17.1 ptp -130.97 153.97 48.64 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 112.254 0.464 . . . . 0.0 112.254 -173.982 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -71.83 137.54 47.63 Favored 'General case' 0 C--O 1.236 0.383 0 O-C-N 124.133 0.896 . . . . 0.0 109.919 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 267' ' ' ILE . . . . . 0.673 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.8 pp -128.47 162.5 34.99 Favored 'Isoleucine or valine' 0 C--O 1.244 0.771 0 CA-C-O 121.085 0.469 . . . . 0.0 112.106 -179.035 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 61.4 mttm -122.6 126.5 47.82 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.522 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 13.0 m -84.92 123.69 39.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 C-N-CA 120.644 -0.422 . . . . 0.0 111.477 -179.567 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 90.0 mt -102.86 -12.01 17.86 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.588 178.334 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -171.81 -177.77 41.67 Favored Glycine 0 C--N 1.318 -0.463 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.109 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 272' ' ' PRO . . . . . 0.574 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 29.8 Cg_endo -60.37 -34.1 93.67 Favored 'Trans proline' 0 C--N 1.306 -1.677 0 C-N-CA 122.091 1.861 . . . . 0.0 111.7 -179.785 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 73.1 m-85 -125.59 10.04 7.8 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.172 -179.722 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -120.7 128.5 53.01 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 116.486 -0.324 . . . . 0.0 110.51 -173.167 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 275' ' ' PHE . . . . . 0.518 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -141.54 166.25 25.28 Favored 'General case' 0 CA--C 1.508 -0.659 0 N-CA-C 112.597 0.592 . . . . 0.0 112.597 178.748 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 276' ' ' SER . . . . . 0.452 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 7.8 p -133.66 146.92 51.32 Favored 'General case' 0 N--CA 1.44 -0.952 0 CA-C-O 121.182 0.515 . . . . 0.0 111.276 -179.73 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 277' ' ' ILE . . . . . 0.412 HG22 HG22 ' A' ' 267' ' ' ILE . 28.9 pt -139.79 164.1 23.98 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.005 0 CA-C-N 114.518 -1.219 . . . . 0.0 111.511 -173.174 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -23.99 -92.76 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.574 0 N-CA-C 113.603 0.964 . . . . 0.0 113.603 -176.71 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 279' ' ' ASP . . . . . 0.439 ' HB3' ' HB2' ' A' ' 282' ' ' ASN . 66.8 t0 -151.34 121.75 7.35 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 -177.597 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 280' ' ' THR . . . . . 0.679 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 23.7 p -65.04 -30.12 71.07 Favored 'General case' 0 C--N 1.293 -1.882 0 CA-C-O 120.982 0.42 . . . . 0.0 111.095 177.01 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 281' ' ' SER . . . . . 0.555 ' OG ' ' NZ ' ' A' ' 226' ' ' LYS . 15.7 m -70.39 -14.59 62.62 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.017 174.132 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 282' ' ' ASN . . . . . 0.439 ' HB2' ' HB3' ' A' ' 279' ' ' ASP . 60.4 t30 -89.22 -5.71 57.44 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.872 174.395 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 283' ' ' PHE . . . . . 0.679 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 12.4 m-85 -102.89 -73.86 0.65 Allowed 'General case' 0 CA--C 1.511 -0.521 0 CA-C-O 121.594 0.711 . . . . 0.0 109.79 175.057 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 172.48 -166.36 0.02 OUTLIER 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 114.02 -1.446 . . . . 0.0 107.827 -171.895 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -97.06 146.4 25.05 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 117.907 0.322 . . . . 0.0 111.115 178.068 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 10.8 t80 -86.54 123.17 31.44 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.006 -179.816 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 287' ' ' ILE . . . . . 0.567 ' O ' ' HG3' ' A' ' 288' ' ' ARG . 21.4 mm -100.51 -73.66 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -0.981 0 CA-C-N 116.501 -0.318 . . . . 0.0 110.265 176.906 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 288' ' ' ARG . . . . . 0.567 ' HG3' ' O ' ' A' ' 287' ' ' ILE . 92.1 mtt-85 -164.61 178.43 7.33 Favored 'General case' 0 C--O 1.242 0.663 0 C-N-CA 124.112 0.965 . . . . 0.0 110.409 179.265 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 68.63 -158.14 52.78 Favored Glycine 0 CA--C 1.505 -0.536 0 N-CA-C 110.319 -1.113 . . . . 0.0 110.319 177.078 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 108.31 113.57 3.69 Favored Glycine 0 N--CA 1.439 -1.158 0 C-N-CA 120.769 -0.729 . . . . 0.0 111.946 177.715 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 291' ' ' ILE . . . . . 0.545 HD12 ' SD ' ' A' ' 220' ' ' MET . 43.5 mm -112.96 128.71 69.55 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.477 0 N-CA-C 105.899 -1.889 . . . . 0.0 105.899 172.352 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 3.5 p -118.9 134.45 62.51 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.039 0 C-N-CA 120.253 -0.579 . . . . 0.0 109.657 -177.694 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 15.2 m -125.21 144.48 50.43 Favored 'General case' 0 CA--C 1.508 -0.65 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.91 -176.504 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 294' ' ' GLN . . . . . 0.506 ' HB3' ' CD1' ' A' ' 242' ' ' PHE . 3.4 pt20 -77.76 151.48 34.05 Favored 'General case' 0 CA--C 1.502 -0.873 0 C-N-CA 120.205 -0.598 . . . . 0.0 110.745 179.159 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 295' ' ' VAL . . . . . 0.444 HG11 ' HG3' ' A' ' 264' ' ' PRO . 76.8 t -130.66 130.7 64.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.563 0 N-CA-C 108.315 -0.994 . . . . 0.0 108.315 175.841 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 296' ' ' LYS . . . . . 0.452 ' NZ ' ' OE1' ' A' ' 294' ' ' GLN . 27.0 mmtp -103.86 105.87 16.2 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 120.071 -0.652 . . . . 0.0 109.429 177.015 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 297' ' ' VAL . . . . . 0.702 ' HB ' ' HD2' ' A' ' 298' ' ' PRO . 34.5 m -55.21 -175.65 0.04 OUTLIER Pre-proline 0 CA--C 1.54 0.591 0 CA-C-N 115.082 -0.963 . . . . 0.0 108.68 177.963 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 298' ' ' PRO . . . . . 0.702 ' HD2' ' HB ' ' A' ' 297' ' ' VAL . 87.0 Cg_exo -48.2 84.83 0.02 OUTLIER 'Trans proline' 0 N--CA 1.493 1.444 0 C-N-CA 121.201 1.267 . . . . 0.0 111.095 -178.09 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 299' ' ' LYS . . . . . 0.573 ' N ' ' O ' ' A' ' 297' ' ' VAL . 43.9 tttp -109.94 137.76 47.26 Favored 'General case' 0 CA--C 1.502 -0.868 0 CA-C-N 115.474 -0.785 . . . . 0.0 111.786 -175.922 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 300' ' ' LYS . . . . . 0.403 ' O ' ' HG2' ' A' ' 299' ' ' LYS . 24.3 mmtp -83.74 135.23 34.63 Favored 'General case' 0 N--CA 1.433 -1.287 0 N-CA-C 106.94 -1.504 . . . . 0.0 106.94 171.34 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 47.6 pt -74.89 -177.13 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.908 0 C-N-CA 120.357 -0.537 . . . . 0.0 109.867 -177.264 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 17.6 m -74.62 151.75 39.31 Favored 'General case' 0 C--N 1.316 -0.863 0 C-N-CA 120.318 -0.553 . . . . 0.0 109.862 178.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -125.77 154.46 42.52 Favored 'General case' 0 C--N 1.315 -0.897 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 179.477 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -65.14 140.03 58.74 Favored 'General case' 0 C--N 1.313 -0.997 0 N-CA-C 108.752 -0.832 . . . . 0.0 108.752 179.715 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 2.6 m -62.0 142.88 57.24 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.927 -173.646 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 306' ' ' LEU . . . . . 0.55 ' HB2' ' HD2' ' A' ' 307' ' ' PRO . 0.9 OUTLIER -59.1 178.31 0.23 Allowed Pre-proline 0 C--O 1.239 0.546 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.499 177.793 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 307' ' ' PRO . . . . . 0.55 ' HD2' ' HB2' ' A' ' 306' ' ' LEU . 24.1 Cg_exo -61.27 41.94 0.07 OUTLIER 'Trans proline' 0 N--CA 1.499 1.831 0 C-N-CA 122.391 2.061 . . . . 0.0 112.509 177.931 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 308' ' ' ALA . . . . . 0.52 ' N ' ' O ' ' A' ' 306' ' ' LEU . . . -82.08 -174.5 5.12 Favored 'General case' 0 C--O 1.24 0.59 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 175.122 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 3.8 m -56.22 131.44 47.91 Favored 'General case' 0 C--N 1.319 -0.719 0 C-N-CA 120.228 -0.589 . . . . 0.0 109.605 179.155 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 94.2 mt -75.66 148.98 38.27 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 109.276 -0.639 . . . . 0.0 109.276 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 2.7 m -114.84 128.91 71.77 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 CA-C-O 120.624 0.249 . . . . 0.0 111.333 -178.458 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 67.0 mt-10 . . . . . 0 C--O 1.204 -1.303 0 CA-C-O 118.462 -0.78 . . . . 0.0 111.747 179.296 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 201' ' ' GLU . . . . . 0.485 ' O ' ' HG3' ' A' ' 205' ' ' GLU . 65.2 mm-40 . . . . . 0 N--CA 1.476 0.854 0 N-CA-C 108.525 -0.916 . . . . 0.0 108.525 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 202' ' ' PHE . . . . . 0.479 ' CG ' ' N ' ' A' ' 203' ' ' GLY . 28.1 p90 -53.87 -46.71 71.38 Favored 'General case' 0 CA--C 1.513 -0.459 0 CA-C-N 115.955 -0.566 . . . . 0.0 112.084 -172.215 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 203' ' ' GLY . . . . . 0.479 ' N ' ' CG ' ' A' ' 202' ' ' PHE . . . -57.1 -47.76 85.02 Favored Glycine 0 C--N 1.318 -0.439 0 C-N-CA 119.837 -1.173 . . . . 0.0 110.357 -177.733 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 204' ' ' GLU . . . . . 0.426 ' OE1' ' N ' ' A' ' 204' ' ' GLU . 55.2 mp0 -66.39 -43.22 86.45 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 121.126 0.488 . . . . 0.0 110.208 177.35 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 205' ' ' GLU . . . . . 0.485 ' HG3' ' O ' ' A' ' 201' ' ' GLU . 83.1 mt-10 -66.43 -38.07 86.6 Favored 'General case' 0 C--O 1.241 0.633 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.708 -178.644 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 206' ' ' MET . . . . . 0.431 ' N ' ' O ' ' A' ' 202' ' ' PHE . 21.5 mmt -65.37 72.56 0.05 OUTLIER 'General case' 0 C--O 1.238 0.449 0 CA-C-O 121.383 0.611 . . . . 0.0 111.518 -178.261 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 207' ' ' VAL . . . . . 0.439 ' N ' ' O ' ' A' ' 205' ' ' GLU . 16.4 m -137.78 161.33 33.28 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.009 0 CA-C-N 114.902 -1.045 . . . . 0.0 109.051 173.723 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 69.8 mt -92.4 125.17 36.93 Favored 'General case' 0 C--N 1.316 -0.881 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 178.301 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 209' ' ' THR . . . . . 0.468 HG23 ' N ' ' A' ' 210' ' ' ASP . 15.3 t -88.38 -57.44 2.92 Favored 'General case' 0 C--O 1.24 0.604 0 C-N-CA 120.332 -0.547 . . . . 0.0 111.379 -175.861 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 210' ' ' ASP . . . . . 0.468 ' N ' HG23 ' A' ' 209' ' ' THR . 3.7 p-10 -74.85 -41.85 59.07 Favored 'General case' 0 CA--C 1.515 -0.402 0 C-N-CA 120.229 -0.589 . . . . 0.0 110.38 178.908 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -68.71 92.4 0.48 Allowed 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.817 -178.598 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 40.3 t-20 -97.53 128.91 44.65 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.309 -0.86 . . . . 0.0 109.717 179.82 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 70.72 33.1 66.73 Favored Glycine 0 N--CA 1.452 -0.264 0 N-CA-C 110.658 -0.977 . . . . 0.0 110.658 -176.721 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 2.7 mm-40 -110.23 152.87 25.57 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 121.014 0.435 . . . . 0.0 110.779 179.376 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 215' ' ' GLN . . . . . 0.422 ' CD ' ' H ' ' A' ' 215' ' ' GLN . 2.7 mp0 -74.38 150.24 87.09 Favored Pre-proline 0 C--N 1.313 -1.005 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.265 -178.946 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -60.24 147.49 93.41 Favored 'Trans proline' 0 C--N 1.307 -1.655 0 C-N-CA 122.264 1.976 . . . . 0.0 109.912 173.62 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 217' ' ' LEU . . . . . 0.629 HD11 ' NH2' ' A' ' 239' ' ' ARG . 0.1 OUTLIER -47.01 123.38 5.22 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 -178.607 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 218' ' ' SER . . . . . 0.431 ' OG ' ' OG ' ' A' ' 293' ' ' SER . 45.9 m -132.46 148.6 52.4 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.692 -174.574 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -143.08 157.11 44.83 Favored 'General case' 0 CA--C 1.51 -0.573 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.884 178.862 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 66.2 mtt -75.18 144.2 42.83 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 115.736 -0.666 . . . . 0.0 109.61 176.503 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 95.7 t -85.38 129.32 38.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.35 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 222' ' ' SER . . . . . 0.546 ' HG ' ' C ' ' A' ' 233' ' ' THR . 25.3 p -94.44 -55.14 3.26 Favored 'General case' 0 N--CA 1.439 -0.979 0 CA-C-O 120.867 0.365 . . . . 0.0 110.218 -178.164 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -137.46 149.39 46.81 Favored 'General case' 0 C--O 1.219 -0.551 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.599 177.573 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 224' ' ' VAL . . . . . 0.461 ' HB ' ' CD1' ' A' ' 286' ' ' TYR . 43.2 t -124.96 133.2 70.09 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.828 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 172.667 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -103.88 116.88 33.08 Favored 'General case' 0 C--N 1.31 -1.141 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 -178.975 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 226' ' ' LYS . . . . . 0.435 ' HA ' ' OG1' ' A' ' 280' ' ' THR . 88.1 tttt -78.55 90.38 4.51 Favored 'General case' 0 CA--C 1.505 -0.776 0 C-N-CA 119.296 -0.962 . . . . 0.0 110.044 -177.924 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 227' ' ' ASP . . . . . 0.617 ' H ' ' HG1' ' A' ' 280' ' ' THR . 43.9 t0 -159.5 179.85 8.55 Favored 'General case' 0 C--N 1.307 -1.241 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.03 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 228' ' ' ASN . . . . . 0.472 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 1.8 p30 -132.99 125.5 19.15 Favored Pre-proline 0 C--N 1.324 -0.523 0 CA-C-N 115.878 -0.601 . . . . 0.0 109.912 175.982 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 229' ' ' PRO . . . . . 0.472 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 46.4 Cg_endo -66.32 145.12 69.42 Favored 'Cis proline' 0 N--CA 1.491 1.349 0 C-N-CA 123.204 -1.582 . . . . 0.0 110.641 -0.68 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 230' ' ' GLY . . . . . 0.511 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -68.01 132.86 28.77 Favored Glycine 0 N--CA 1.452 -0.234 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.169 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.9 p -128.26 136.12 60.91 Favored 'Isoleucine or valine' 0 C--O 1.241 0.629 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 178.35 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 232' ' ' VAL . . . . . 0.56 HG22 ' CD1' ' A' ' 275' ' ' PHE . 0.6 OUTLIER -134.85 156.01 39.21 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.047 0 C-N-CA 120.164 -0.614 . . . . 0.0 110.493 -179.422 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 233' ' ' THR . . . . . 0.546 ' C ' ' HG ' ' A' ' 222' ' ' SER . 21.7 m -104.65 144.78 31.25 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 115.413 -0.812 . . . . 0.0 109.106 176.11 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 2.4 m -106.1 159.51 16.02 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 177.484 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.567 ' HB3' ' HB3' ' A' ' 238' ' ' ALA . 43.1 tp -57.85 127.24 31.07 Favored 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 -178.469 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 236' ' ' ASP . . . . . 0.402 ' O ' ' CZ ' ' A' ' 273' ' ' TYR . 7.5 m-20 -62.46 -37.91 87.75 Favored 'General case' 0 CA--C 1.512 -0.497 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.19 -172.279 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 57.9 mp0 -69.67 -19.5 63.59 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.659 177.734 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 238' ' ' ALA . . . . . 0.567 ' HB3' ' HB3' ' A' ' 235' ' ' LEU . . . -108.78 99.94 9.23 Favored 'General case' 0 C--O 1.238 0.479 0 N-CA-C 112.102 0.408 . . . . 0.0 112.102 -177.197 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 239' ' ' ARG . . . . . 0.629 ' NH2' HD11 ' A' ' 217' ' ' LEU . 0.0 OUTLIER -70.57 117.4 12.05 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 173.342 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 240' ' ' HIS . . . . . 0.606 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 6.6 p80 -66.54 -45.71 78.49 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.681 -179.504 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 82.31 21.43 60.55 Favored Glycine 0 C--N 1.315 -0.62 0 N-CA-C 110.775 -0.93 . . . . 0.0 110.775 -178.275 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 242' ' ' PHE . . . . . 0.772 ' HB3' HD11 ' A' ' 267' ' ' ILE . 7.5 m-30 -83.74 156.02 22.79 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 120.69 0.281 . . . . 0.0 110.339 179.629 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 -124.3 165.08 18.29 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.545 174.821 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 244' ' ' THR . . . . . 0.62 HG23 ' HA ' ' A' ' 268' ' ' LYS . 0.2 OUTLIER -69.61 126.44 29.74 Favored 'General case' 0 C--N 1.319 -0.76 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 177.374 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 90.43 2.38 73.43 Favored Glycine 0 C--N 1.317 -0.513 0 N-CA-C 110.476 -1.05 . . . . 0.0 110.476 -176.422 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 246' ' ' ASP . . . . . 0.511 ' O ' HG12 ' A' ' 267' ' ' ILE . 46.3 t0 -77.8 163.86 25.72 Favored 'General case' 0 C--O 1.237 0.445 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 176.427 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 247' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -115.84 128.85 56.13 Favored 'General case' 0 C--O 1.241 0.637 0 O-C-N 123.287 0.367 . . . . 0.0 110.661 -178.939 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.541 ' CG1' HD13 ' A' ' 267' ' ' ILE . 2.4 m -132.4 164.58 34.56 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.308 0 C-N-CA 120.223 -0.591 . . . . 0.0 111.905 178.287 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 31.4 m -130.66 153.0 49.41 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.179 172.56 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 250' ' ' PHE . . . . . 0.604 ' CD1' HD22 ' A' ' 259' ' ' LEU . 61.3 m-85 -103.14 146.58 28.18 Favored 'General case' 0 C--N 1.322 -0.616 0 C-N-CA 122.729 0.411 . . . . 0.0 110.327 -178.912 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 2.5 m -143.74 153.06 42.04 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.417 176.715 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 49.42 37.51 12.09 Favored 'General case' 0 C--O 1.245 0.865 0 N-CA-C 113.044 0.757 . . . . 0.0 113.044 175.978 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 0.65 HG22 ' HA3' ' A' ' 290' ' ' GLY . 78.7 t -90.37 132.38 35.13 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 175.853 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 86.8 mt-30 -88.08 140.56 29.36 Favored 'General case' 0 C--O 1.242 0.709 0 C-N-CA 120.411 -0.516 . . . . 0.0 110.068 177.487 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 80.06 -63.82 4.03 Favored Glycine 0 C--N 1.314 -0.691 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 179.174 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 256' ' ' MET . . . . . 0.464 ' N ' ' O ' ' A' ' 285' ' ' ASP . 20.9 ttm -84.69 71.76 10.78 Favored 'General case' 0 CA--C 1.504 -0.804 0 C-N-CA 119.853 -0.739 . . . . 0.0 109.377 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 45.0 pt -80.35 -15.3 12.91 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 CA-C-N 115.005 -0.998 . . . . 0.0 110.144 -177.756 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 258' ' ' GLN . . . . . 0.504 ' O ' ' SG ' ' A' ' 262' ' ' CYS . 63.3 tp60 -57.53 -39.13 75.92 Favored 'General case' 0 N--CA 1.437 -1.11 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 177.643 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 259' ' ' LEU . . . . . 0.854 HD21 ' CE2' ' A' ' 283' ' ' PHE . 88.1 mt -62.78 -40.67 98.01 Favored 'General case' 0 N--CA 1.449 -0.508 0 CA-C-N 115.113 -0.949 . . . . 0.0 110.222 175.001 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -60.04 -40.63 90.06 Favored 'General case' 0 C--O 1.241 0.607 0 N-CA-C 109.306 -0.628 . . . . 0.0 109.306 -179.577 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -101.18 23.2 36.25 Favored Glycine 0 CA--C 1.526 0.736 0 N-CA-C 111.246 -0.741 . . . . 0.0 111.246 -179.178 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 262' ' ' CYS . . . . . 0.504 ' SG ' ' O ' ' A' ' 258' ' ' GLN . 1.3 m -96.68 147.34 24.01 Favored 'General case' 0 C--O 1.239 0.51 0 CA-C-N 117.362 0.581 . . . . 0.0 112.382 -177.708 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 5.3 mt-30 -61.93 154.34 68.62 Favored Pre-proline 0 C--N 1.324 -0.518 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 170.699 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 264' ' ' PRO . . . . . 0.798 ' HB3' HG21 ' A' ' 295' ' ' VAL . 50.9 Cg_endo -64.4 145.06 87.4 Favored 'Trans proline' 0 C--N 1.304 -1.806 0 C-N-CA 121.08 1.187 . . . . 0.0 109.868 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 265' ' ' MET . . . . . 0.554 ' N ' ' SD ' ' A' ' 265' ' ' MET . 0.2 OUTLIER -122.8 148.8 44.96 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 112.405 0.52 . . . . 0.0 112.405 -174.237 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 266' ' ' GLU . . . . . 0.419 ' HA ' ' O ' ' A' ' 246' ' ' ASP . 75.8 tt0 -77.97 134.3 37.87 Favored 'General case' 0 C--O 1.242 0.662 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 174.355 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 267' ' ' ILE . . . . . 0.772 HD11 ' HB3' ' A' ' 242' ' ' PHE . 49.5 pt -125.26 159.64 32.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 N-CA-C 114.023 1.12 . . . . 0.0 114.023 -166.342 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 268' ' ' LYS . . . . . 0.62 ' HA ' HG23 ' A' ' 244' ' ' THR . 66.5 mttm -120.55 106.59 11.93 Favored 'General case' 0 CA--C 1.537 0.459 0 CA-C-N 115.154 -0.93 . . . . 0.0 110.021 177.325 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.4 HG22 ' H ' ' A' ' 269' ' ' VAL . 17.3 m -80.24 102.31 6.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 120.999 0.428 . . . . 0.0 110.516 178.452 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 96.1 mt -66.3 -41.27 89.99 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.964 -179.707 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -149.16 -172.09 18.49 Favored Glycine 0 C--N 1.318 -0.458 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -177.383 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 272' ' ' PRO . . . . . 0.606 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 37.9 Cg_endo -62.98 -33.93 72.68 Favored 'Trans proline' 0 C--N 1.308 -1.57 0 C-N-CA 121.827 1.685 . . . . 0.0 111.369 -178.024 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 273' ' ' TYR . . . . . 0.409 ' O ' ' HA ' ' A' ' 233' ' ' THR . 83.3 m-85 -122.54 8.44 9.55 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 112.818 0.673 . . . . 0.0 112.818 -177.968 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 2.8 p -120.88 128.05 52.44 Favored 'General case' 0 C--O 1.243 0.747 0 CA-C-O 120.605 0.24 . . . . 0.0 110.865 178.923 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 275' ' ' PHE . . . . . 0.561 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -138.25 159.44 42.04 Favored 'General case' 0 CA--C 1.507 -0.697 0 C-N-CA 120.671 -0.411 . . . . 0.0 111.658 177.667 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 7.9 p -137.79 154.29 49.58 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.521 -173.388 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 277' ' ' ILE . . . . . 0.487 HG22 HG22 ' A' ' 267' ' ' ILE . 0.1 OUTLIER -141.72 -155.04 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.912 0 CA-C-N 115.428 -0.805 . . . . 0.0 110.106 -173.087 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 1.1 p -60.04 -89.03 0.0 OUTLIER 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 116.499 -0.318 . . . . 0.0 111.306 178.338 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 66.0 t0 -151.7 118.98 5.94 Favored 'General case' 0 N--CA 1.447 -0.611 0 CA-C-O 120.825 0.345 . . . . 0.0 111.421 -176.736 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 280' ' ' THR . . . . . 0.646 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 11.1 p -64.34 -30.34 71.39 Favored 'General case' 0 C--N 1.299 -1.626 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.101 175.095 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -61.73 -21.05 64.17 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.449 175.852 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 12.3 m120 -93.94 -3.83 50.9 Favored 'General case' 0 N--CA 1.451 -0.419 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.023 176.847 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 283' ' ' PHE . . . . . 0.854 ' CE2' HD21 ' A' ' 259' ' ' LEU . 22.8 m-85 -91.84 -80.72 0.35 Allowed 'General case' 0 CA--C 1.512 -0.508 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 171.674 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 3.9 p 179.25 -109.85 0.0 OUTLIER 'General case' 0 N--CA 1.453 -0.305 0 CA-C-N 115.193 -0.912 . . . . 0.0 109.675 173.463 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 285' ' ' ASP . . . . . 0.464 ' O ' ' N ' ' A' ' 256' ' ' MET . 2.1 p-10 -145.49 163.37 34.9 Favored 'General case' 0 C--O 1.219 -0.514 0 N-CA-C 107.667 -1.234 . . . . 0.0 107.667 174.114 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 286' ' ' TYR . . . . . 0.461 ' CD1' ' HB ' ' A' ' 224' ' ' VAL . 1.1 p90 -123.95 145.51 49.11 Favored 'General case' 0 N--CA 1.468 0.442 0 C-N-CA 119.663 -0.815 . . . . 0.0 111.495 -178.046 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 96.9 mt -100.77 -57.68 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 176.781 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 32.2 ptt-85 -176.17 -169.3 0.31 Allowed 'General case' 0 C--O 1.242 0.688 0 CA-C-N 115.447 -0.797 . . . . 0.0 109.979 177.584 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 67.32 -153.47 52.9 Favored Glycine 0 CA--C 1.502 -0.779 0 N-CA-C 110.944 -0.863 . . . . 0.0 110.944 175.837 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 290' ' ' GLY . . . . . 0.65 ' HA3' HG22 ' A' ' 253' ' ' VAL . . . 93.51 136.49 7.96 Favored Glycine 0 N--CA 1.442 -0.958 0 N-CA-C 111.778 -0.529 . . . . 0.0 111.778 176.841 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 92.2 mt -122.87 129.38 75.17 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 173.756 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 3.8 p -112.21 129.72 67.19 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 178.855 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 293' ' ' SER . . . . . 0.431 ' OG ' ' OG ' ' A' ' 218' ' ' SER . 55.7 m -126.9 147.88 50.05 Favored 'General case' 0 CA--C 1.5 -0.972 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.371 -174.495 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 294' ' ' GLN . . . . . 0.431 ' HG3' ' CE1' ' A' ' 242' ' ' PHE . 85.0 mt-30 -63.85 164.03 10.86 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 171.804 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 295' ' ' VAL . . . . . 0.798 HG21 ' HB3' ' A' ' 264' ' ' PRO . 60.7 t -127.24 111.68 26.12 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 176.763 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 8.0 tmtm? -75.69 97.88 3.93 Favored 'General case' 0 N--CA 1.443 -0.811 0 C-N-CA 118.803 -1.159 . . . . 0.0 108.859 177.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 35.7 m -56.54 134.97 77.29 Favored Pre-proline 0 C--O 1.245 0.849 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 178.918 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_exo -54.4 -43.34 59.62 Favored 'Trans proline' 0 N--CA 1.489 1.225 0 C-N-CA 121.226 1.284 . . . . 0.0 108.969 177.665 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 19.5 tptm -137.86 133.61 34.1 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 114.714 -1.13 . . . . 0.0 109.15 171.807 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 300' ' ' LYS . . . . . 0.595 ' NZ ' ' OG ' ' A' ' 302' ' ' SER . 1.1 ttpm? -89.25 111.39 22.18 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 177.808 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 301' ' ' ILE . . . . . 0.401 HD13 HG21 ' A' ' 301' ' ' ILE . 37.8 pt -70.43 137.55 23.72 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.961 0 C-N-CA 120.636 -0.425 . . . . 0.0 110.544 179.879 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 302' ' ' SER . . . . . 0.595 ' OG ' ' NZ ' ' A' ' 300' ' ' LYS . 1.5 m -122.85 149.94 43.52 Favored 'General case' 0 C--O 1.242 0.675 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.8 -178.179 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 21.2 t80 -149.08 149.41 31.04 Favored 'General case' 0 C--N 1.32 -0.685 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 177.429 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 67.5 mttm -107.44 152.85 23.64 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.345 178.838 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 305' ' ' SER . . . . . 0.459 ' O ' ' C ' ' A' ' 306' ' ' LEU . 8.9 m -63.94 143.27 57.99 Favored 'General case' 0 C--N 1.315 -0.894 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 176.798 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 306' ' ' LEU . . . . . 0.459 ' C ' ' O ' ' A' ' 305' ' ' SER . 1.3 mp -30.77 106.94 0.24 Allowed Pre-proline 0 C--O 1.234 0.27 0 O-C-N 123.373 0.421 . . . . 0.0 111.171 -175.883 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_exo -59.0 143.18 99.92 Favored 'Trans proline' 0 C--N 1.311 -1.422 0 C-N-CA 122.114 1.876 . . . . 0.0 110.416 -178.964 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -70.25 149.43 47.46 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.861 -178.743 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 1.3 m -68.61 95.39 0.64 Allowed 'General case' 0 C--O 1.24 0.585 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 176.046 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 3.1 pp -112.64 145.51 40.29 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 112.935 0.717 . . . . 0.0 112.935 -171.303 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 6.3 m -131.81 132.02 61.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 115.098 -0.955 . . . . 0.0 109.12 175.341 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 36.2 mt-10 . . . . . 0 C--O 1.204 -1.336 0 CA-C-O 118.52 -0.752 . . . . 0.0 110.196 -176.189 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 201' ' ' GLU . . . . . 0.413 ' N ' ' OE1' ' A' ' 201' ' ' GLU . 1.9 mp0 . . . . . 0 N--CA 1.487 1.423 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 93.8 m-85 -70.92 137.71 49.48 Favored 'General case' 0 C--O 1.239 0.549 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 -179.147 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -115.81 44.61 1.44 Allowed Glycine 0 C--N 1.32 -0.345 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 -179.53 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 75.1 mm-40 -71.82 -44.11 64.46 Favored 'General case' 0 C--N 1.319 -0.734 0 C-N-CA 120.232 -0.587 . . . . 0.0 111.538 -178.572 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -72.9 -42.82 63.16 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.496 -0.482 . . . . 0.0 110.871 175.683 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 95.3 mtp -115.79 125.72 53.1 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 108.998 -0.742 . . . . 0.0 108.998 178.835 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 22.8 m -110.61 132.26 59.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-O 121.093 0.473 . . . . 0.0 111.1 178.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 85.1 mt -88.36 85.02 6.81 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.887 -176.96 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 44.9 p -132.87 -73.03 0.51 Allowed 'General case' 0 C--N 1.316 -0.871 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 176.74 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -121.26 -24.18 5.54 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-N 114.644 -1.162 . . . . 0.0 109.209 174.95 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -56.72 127.85 33.58 Favored 'General case' 0 N--CA 1.442 -0.86 0 CA-C-N 115.128 -0.942 . . . . 0.0 111.801 -176.254 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 212' ' ' ASN . . . . . 0.434 ' H ' ' CD ' ' A' ' 214' ' ' GLU . 0.5 OUTLIER -114.35 84.46 2.05 Favored 'General case' 0 C--O 1.24 0.558 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.694 173.531 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 47.94 34.95 12.22 Favored Glycine 0 CA--C 1.525 0.659 0 CA-C-N 116.358 -0.383 . . . . 0.0 112.698 174.448 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 214' ' ' GLU . . . . . 0.434 ' CD ' ' H ' ' A' ' 212' ' ' ASN . 58.7 mp0 -59.17 132.94 55.53 Favored 'General case' 0 C--O 1.242 0.685 0 CA-C-N 117.37 0.585 . . . . 0.0 112.149 -178.186 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 5.2 mt-30 -112.47 156.7 41.87 Favored Pre-proline 0 C--N 1.32 -0.7 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 168.355 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -55.73 132.79 54.19 Favored 'Trans proline' 0 C--N 1.303 -1.842 0 C-N-CA 121.299 1.333 . . . . 0.0 111.163 -178.043 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 217' ' ' LEU . . . . . 0.707 HD13 ' N ' ' A' ' 218' ' ' SER . 0.3 OUTLIER -113.85 126.81 55.6 Favored 'General case' 0 C--N 1.317 -0.816 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 179.405 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 218' ' ' SER . . . . . 0.707 ' N ' HD13 ' A' ' 217' ' ' LEU . 50.8 m -114.04 131.88 56.21 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.163 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 219' ' ' ALA . . . . . 0.622 ' HB1' ' HB1' ' A' ' 238' ' ' ALA . . . -131.75 150.74 52.05 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.703 -175.362 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 97.8 mtp -81.02 129.69 34.66 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.163 178.42 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 221' ' ' VAL . . . . . 0.455 HG11 ' CG2' ' A' ' 224' ' ' VAL . 97.3 t -79.85 133.98 28.54 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.011 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 177.356 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 13.8 p -93.28 -62.0 1.46 Allowed 'General case' 0 N--CA 1.436 -1.151 0 C-N-CA 120.129 -0.628 . . . . 0.0 109.777 -179.358 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -138.06 139.05 39.36 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.946 173.818 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 224' ' ' VAL . . . . . 0.742 HG13 HG12 ' A' ' 232' ' ' VAL . 59.4 t -117.01 130.79 71.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 174.489 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 62.3 p -88.02 138.9 31.05 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-O 120.826 0.346 . . . . 0.0 110.944 -178.509 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 226' ' ' LYS . . . . . 0.451 ' NZ ' ' OD2' ' A' ' 285' ' ' ASP . 2.6 tptm -78.34 77.66 4.83 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 178.807 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 227' ' ' ASP . . . . . 0.41 ' H ' ' HG1' ' A' ' 280' ' ' THR . 45.8 t0 -157.0 174.04 16.12 Favored 'General case' 0 N--CA 1.468 0.454 0 N-CA-C 112.249 0.462 . . . . 0.0 112.249 -176.172 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 228' ' ' ASN . . . . . 0.482 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 2.7 p30 -130.86 125.14 21.16 Favored Pre-proline 0 N--CA 1.451 -0.403 0 CA-C-N 115.382 -0.826 . . . . 0.0 110.244 173.083 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 229' ' ' PRO . . . . . 0.482 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 24.6 Cg_exo -64.86 147.37 70.15 Favored 'Cis proline' 0 C--N 1.31 -1.498 0 C-N-CA 123.611 -1.412 . . . . 0.0 110.059 -2.157 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 230' ' ' GLY . . . . . 0.664 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -72.75 100.86 1.03 Allowed Glycine 0 C--N 1.295 -1.704 0 N-CA-C 110.025 -1.23 . . . . 0.0 110.025 -179.732 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 231' ' ' VAL . . . . . 0.621 HG23 HD12 ' A' ' 270' ' ' LEU . 7.1 p -88.51 127.32 41.51 Favored 'Isoleucine or valine' 0 C--O 1.244 0.784 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 177.986 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 232' ' ' VAL . . . . . 0.742 HG12 HG13 ' A' ' 224' ' ' VAL . 0.6 OUTLIER -131.46 156.43 42.64 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.897 0 CA-C-O 121.124 0.488 . . . . 0.0 109.827 -177.503 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -117.69 145.45 44.41 Favored 'General case' 0 N--CA 1.429 -1.489 0 CA-C-N 114.838 -1.074 . . . . 0.0 109.032 179.336 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.8 m -107.0 160.3 15.64 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.095 -177.553 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 24.1 tp -54.82 132.62 46.61 Favored 'General case' 0 C--N 1.314 -0.966 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 178.749 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 236' ' ' ASP . . . . . 0.41 ' O ' ' CE1' ' A' ' 273' ' ' TYR . 28.4 t70 -53.89 -42.82 69.07 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-O 121.341 0.591 . . . . 0.0 111.007 -176.174 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 74.0 mt-10 -65.49 -32.15 73.61 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.32 179.126 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 238' ' ' ALA . . . . . 0.622 ' HB1' ' HB1' ' A' ' 219' ' ' ALA . . . -72.11 135.03 46.1 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.961 0.41 . . . . 0.0 111.896 -176.861 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 66.2 mtp180 -113.13 92.96 4.19 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 175.565 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 240' ' ' HIS . . . . . 0.567 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 7.3 p80 -54.7 -49.12 71.48 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 -173.337 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 79.86 17.57 74.67 Favored Glycine 0 C--N 1.309 -0.964 0 N-CA-C 110.491 -1.044 . . . . 0.0 110.491 -179.21 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 242' ' ' PHE . . . . . 0.49 ' CD2' ' HB2' ' A' ' 240' ' ' HIS . 6.5 m-30 -80.4 144.12 32.93 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 -179.11 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -106.83 164.85 11.77 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.346 0.594 . . . . 0.0 111.364 179.145 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -65.56 120.8 13.55 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 177.866 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 79.76 7.69 88.3 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 -177.358 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 43.2 t0 -79.51 166.49 21.9 Favored 'General case' 0 C--O 1.233 0.188 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 -179.694 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 247' ' ' PHE . . . . . 0.496 ' HA ' ' O ' ' A' ' 265' ' ' MET . 26.9 m-85 -110.19 133.63 53.04 Favored 'General case' 0 C--O 1.239 0.525 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -176.868 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.499 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 3.0 m -131.89 160.37 42.47 Favored 'Isoleucine or valine' 0 C--O 1.237 0.435 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.472 178.144 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 1.2 m -121.84 161.65 22.34 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 114.907 -1.042 . . . . 0.0 109.171 173.953 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 250' ' ' PHE . . . . . 0.527 ' CB ' ' HB3' ' A' ' 259' ' ' LEU . 61.0 m-85 -125.88 151.77 46.45 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 110.306 -0.257 . . . . 0.0 110.306 -175.066 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 16.4 m -156.36 163.08 39.91 Favored 'General case' 0 C--O 1.215 -0.719 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 177.032 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 67.3 mm-40 54.4 30.15 12.24 Favored 'General case' 0 C--N 1.316 -0.887 0 N-CA-C 111.746 0.276 . . . . 0.0 111.746 175.419 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 0.657 HG22 ' CA ' ' A' ' 290' ' ' GLY . 2.9 t -98.96 126.74 52.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 176.758 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 83.2 mt-30 -90.94 138.41 31.62 Favored 'General case' 0 C--O 1.246 0.906 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 178.224 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 81.2 -59.0 4.82 Favored Glycine 0 C--O 1.244 0.76 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 -178.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 256' ' ' MET . . . . . 0.509 ' SD ' HG11 ' A' ' 224' ' ' VAL . 3.8 ttm -80.13 49.86 1.16 Allowed 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 121.988 0.899 . . . . 0.0 109.766 178.285 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 47.6 pt -67.43 -22.29 28.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 114.262 -1.335 . . . . 0.0 111.116 -176.768 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 258' ' ' GLN . . . . . 0.516 ' HG3' ' HG ' ' A' ' 262' ' ' CYS . 63.9 tp60 -57.1 -39.11 74.43 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 179.199 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 259' ' ' LEU . . . . . 0.682 HD21 ' CE2' ' A' ' 283' ' ' PHE . 99.2 mt -62.15 -40.8 97.17 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 115.47 -0.786 . . . . 0.0 109.721 178.037 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 -60.27 -40.98 92.28 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 -178.254 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -99.27 17.86 57.32 Favored Glycine 0 CA--C 1.521 0.464 0 N-CA-C 111.55 -0.62 . . . . 0.0 111.55 -179.633 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 262' ' ' CYS . . . . . 0.516 ' HG ' ' HG3' ' A' ' 258' ' ' GLN . 1.4 m -94.45 160.39 14.68 Favored 'General case' 0 C--O 1.239 0.512 0 CA-C-N 117.052 0.426 . . . . 0.0 110.455 -179.71 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 7.1 mt-30 -82.1 159.72 64.67 Favored Pre-proline 0 C--N 1.318 -0.766 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 172.306 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 264' ' ' PRO . . . . . 0.499 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 24.3 Cg_exo -62.16 143.26 94.29 Favored 'Trans proline' 0 C--N 1.309 -1.538 0 CA-C-N 119.743 0.944 . . . . 0.0 109.949 -179.248 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 265' ' ' MET . . . . . 0.496 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 8.7 ptp -133.57 167.94 19.56 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 112.892 0.701 . . . . 0.0 112.892 -175.088 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 72.2 tt0 -70.1 139.88 52.6 Favored 'General case' 0 C--O 1.243 0.735 0 O-C-N 124.164 0.915 . . . . 0.0 110.177 -179.69 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 267' ' ' ILE . . . . . 0.616 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.7 pp -129.22 154.35 39.97 Favored 'Isoleucine or valine' 0 C--O 1.243 0.755 0 CA-C-O 121.263 0.554 . . . . 0.0 111.526 178.389 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 66.2 mttm -125.72 109.61 12.79 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.744 -178.052 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 18.8 m -70.39 131.39 34.32 Favored 'Isoleucine or valine' 0 C--O 1.237 0.407 0 CA-C-O 120.681 0.277 . . . . 0.0 111.235 -177.394 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 270' ' ' LEU . . . . . 0.621 HD12 HG23 ' A' ' 231' ' ' VAL . 95.1 mt -109.48 -25.55 10.43 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.582 179.149 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -156.41 -174.79 26.61 Favored Glycine 0 CA--C 1.511 -0.188 0 N-CA-C 110.124 -1.19 . . . . 0.0 110.124 -179.218 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 272' ' ' PRO . . . . . 0.567 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 28.6 Cg_endo -60.24 -39.87 64.41 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 121.844 1.696 . . . . 0.0 111.439 -177.434 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 273' ' ' TYR . . . . . 0.41 ' CE1' ' O ' ' A' ' 236' ' ' ASP . 57.6 m-85 -118.98 9.81 12.0 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.207 178.975 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -116.01 129.14 56.23 Favored 'General case' 0 C--O 1.241 0.612 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.727 -172.465 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 275' ' ' PHE . . . . . 0.575 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -144.24 167.87 21.41 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 111.84 0.311 . . . . 0.0 111.84 179.729 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 276' ' ' SER . . . . . 0.432 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 4.6 p -133.27 142.26 48.42 Favored 'General case' 0 C--N 1.319 -0.728 0 C-N-CA 120.764 -0.374 . . . . 0.0 111.65 -177.353 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 277' ' ' ILE . . . . . 0.502 HG22 HG22 ' A' ' 267' ' ' ILE . 38.0 pt -137.02 163.07 33.25 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-N 115.137 -0.938 . . . . 0.0 111.739 -176.779 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 278' ' ' CYS . . . . . 0.434 ' C ' ' O ' ' A' ' 277' ' ' ILE . 88.1 m -14.98 -92.73 0.0 OUTLIER 'General case' 0 CA--C 1.543 0.703 0 N-CA-C 113.979 1.103 . . . . 0.0 113.979 -177.893 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 279' ' ' ASP . . . . . 0.416 ' CG ' ' HB3' ' A' ' 228' ' ' ASN . 67.1 t0 -154.99 114.82 3.75 Favored 'General case' 0 CA--C 1.509 -0.601 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 -179.209 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 280' ' ' THR . . . . . 0.796 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 20.8 p -65.43 -27.79 68.78 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-O 120.99 0.424 . . . . 0.0 110.755 178.488 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -63.08 -23.95 67.68 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-N 115.169 -0.923 . . . . 0.0 109.224 175.526 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 20.4 t-20 -89.14 -9.53 50.65 Favored 'General case' 0 CA--C 1.512 -0.518 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.932 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 283' ' ' PHE . . . . . 0.796 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 10.2 m-85 -87.05 -64.86 1.08 Allowed 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 172.969 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 284' ' ' SER . . . . . 0.475 ' OG ' ' HA ' ' A' ' 256' ' ' MET . 2.4 p 170.35 -101.27 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 114.306 -1.316 . . . . 0.0 109.415 176.989 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 285' ' ' ASP . . . . . 0.47 ' O ' ' N ' ' A' ' 256' ' ' MET . 5.9 t0 -148.92 164.25 35.08 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-O 120.611 0.243 . . . . 0.0 110.793 176.851 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 286' ' ' TYR . . . . . 0.441 ' N ' ' OD1' ' A' ' 285' ' ' ASP . 83.9 t80 -94.69 114.99 26.99 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 177.387 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 22.2 mm -100.12 -58.73 3.69 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.519 175.012 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 85.5 mtm180 -160.97 167.53 26.34 Favored 'General case' 0 CA--C 1.503 -0.84 0 O-C-N 123.604 0.565 . . . . 0.0 112.352 178.883 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 51.21 -138.97 26.34 Favored Glycine 0 CA--C 1.504 -0.649 0 CA-C-N 113.339 -1.755 . . . . 0.0 112.556 168.891 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 290' ' ' GLY . . . . . 0.657 ' CA ' HG22 ' A' ' 253' ' ' VAL . . . 100.83 117.32 4.14 Favored Glycine 0 N--CA 1.433 -1.565 0 N-CA-C 110.602 -0.999 . . . . 0.0 110.602 -177.637 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 87.3 mt -108.75 128.06 64.8 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.285 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 175.873 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 3.3 p -118.85 135.38 59.46 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.035 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 -178.115 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 293' ' ' SER . . . . . 0.475 ' HA ' ' O ' ' A' ' 217' ' ' LEU . 4.7 m -128.9 147.65 50.85 Favored 'General case' 0 N--CA 1.442 -0.856 0 C-N-CA 120.323 -0.551 . . . . 0.0 112.466 -174.426 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 48.1 tt0 -75.74 138.42 41.25 Favored 'General case' 0 N--CA 1.443 -0.823 0 CA-C-N 114.998 -1.001 . . . . 0.0 111.295 177.932 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 22.8 t -121.63 98.18 5.67 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 N-CA-C 106.99 -1.485 . . . . 0.0 106.99 170.624 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 296' ' ' LYS . . . . . 0.501 ' C ' ' HD3' ' A' ' 296' ' ' LYS . 0.6 OUTLIER -73.05 98.36 2.53 Favored 'General case' 0 N--CA 1.438 -1.057 0 C-N-CA 118.966 -1.094 . . . . 0.0 108.93 -175.932 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 297' ' ' VAL . . . . . 0.494 ' O ' ' NZ ' ' A' ' 296' ' ' LYS . 33.1 m -72.8 118.35 67.42 Favored Pre-proline 0 N--CA 1.438 -1.074 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.515 -178.983 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -59.58 -28.93 88.64 Favored 'Trans proline' 0 N--CA 1.498 1.776 0 C-N-CA 122.125 1.883 . . . . 0.0 109.623 174.04 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 66.5 mttm -54.45 148.97 11.03 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 114.679 -1.146 . . . . 0.0 108.379 179.536 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 63.0 mttp -67.73 132.49 47.55 Favored 'General case' 0 CA--C 1.511 -0.554 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 174.548 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 301' ' ' ILE . . . . . 0.701 HD13 ' H ' ' A' ' 301' ' ' ILE . 0.0 OUTLIER -84.18 127.07 40.15 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 C-N-CA 120.354 -0.538 . . . . 0.0 110.965 -177.647 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -79.46 93.44 5.39 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.564 177.658 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 31.2 p90 -144.84 163.99 32.43 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 178.762 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 44.3 mttm -72.83 119.71 17.45 Favored 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 -176.856 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 6.9 m -65.46 141.86 58.36 Favored 'General case' 0 C--N 1.316 -0.87 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 179.182 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 1.9 mp -63.1 136.65 96.78 Favored Pre-proline 0 C--N 1.318 -0.766 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 -177.302 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_exo -56.85 -35.3 98.2 Favored 'Trans proline' 0 N--CA 1.497 1.677 0 C-N-CA 122.179 1.919 . . . . 0.0 110.004 178.533 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -68.18 174.36 3.97 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.08 -0.964 . . . . 0.0 110.195 179.079 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 4.5 m -67.04 138.99 57.59 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 177.948 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 88.8 mt -78.9 146.83 33.33 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 116.566 -0.288 . . . . 0.0 110.739 -178.019 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 22.6 m -77.96 134.44 28.31 Favored 'Isoleucine or valine' 0 C--O 1.238 0.477 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 172.031 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 91.5 mt-10 . . . . . 0 C--O 1.203 -1.387 0 CA-C-O 118.182 -0.913 . . . . 0.0 111.331 -173.338 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 201' ' ' GLU . . . . . 0.468 ' N ' ' OE1' ' A' ' 204' ' ' GLU . 0.0 OUTLIER . . . . . 0 N--CA 1.475 0.777 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 . . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 -63.38 -42.72 98.84 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.581 -178.463 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -61.07 -40.65 98.82 Favored Glycine 0 C--N 1.317 -0.518 0 N-CA-C 111.374 -0.691 . . . . 0.0 111.374 -176.643 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 204' ' ' GLU . . . . . 0.468 ' OE1' ' N ' ' A' ' 201' ' ' GLU . 2.4 mp0 -66.73 2.5 1.34 Allowed 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 112.154 0.427 . . . . 0.0 112.154 -178.268 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 2.8 pp20? -53.83 -18.51 3.35 Favored 'General case' 0 C--O 1.242 0.677 0 CA-C-O 121.215 0.531 . . . . 0.0 109.812 179.102 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 77.2 mtm -59.85 148.37 34.98 Favored 'General case' 0 N--CA 1.444 -0.735 0 CA-C-N 115.172 -0.922 . . . . 0.0 109.824 -179.736 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 207' ' ' VAL . . . . . 0.416 ' O ' ' N ' ' A' ' 209' ' ' THR . 27.1 m -86.5 175.55 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.147 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 169.809 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 208' ' ' LEU . . . . . 0.422 HD23 ' HA ' ' A' ' 208' ' ' LEU . 96.7 mt -72.36 72.47 0.95 Allowed 'General case' 0 C--N 1.308 -1.196 0 C-N-CA 118.948 -1.101 . . . . 0.0 110.043 -179.797 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 209' ' ' THR . . . . . 0.416 ' N ' ' O ' ' A' ' 207' ' ' VAL . 0.8 OUTLIER -71.2 -3.1 18.38 Favored 'General case' 0 N--CA 1.447 -0.616 0 CA-C-N 114.928 -1.033 . . . . 0.0 109.293 173.864 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 16.1 t70 -57.73 -43.44 85.31 Favored 'General case' 0 N--CA 1.442 -0.83 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 172.625 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 211' ' ' SER . . . . . 0.446 ' O ' ' C ' ' A' ' 212' ' ' ASN . 0.1 OUTLIER -65.0 91.75 0.1 Allowed 'General case' 0 N--CA 1.441 -0.915 0 N-CA-C 106.249 -1.76 . . . . 0.0 106.249 166.212 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 212' ' ' ASN . . . . . 0.446 ' C ' ' O ' ' A' ' 211' ' ' SER . 24.0 t-20 -29.14 94.81 0.01 OUTLIER 'General case' 0 CA--C 1.516 -0.339 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.844 -168.501 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 213' ' ' GLY . . . . . 0.432 ' C ' ' O ' ' A' ' 212' ' ' ASN . . . 29.76 66.48 0.12 Allowed Glycine 0 C--N 1.337 0.626 0 N-CA-C 111.082 -0.807 . . . . 0.0 111.082 -179.7 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 214' ' ' GLU . . . . . 0.446 ' OE2' ' NZ ' ' A' ' 296' ' ' LYS . 1.7 pt-20 -41.34 96.42 0.01 OUTLIER 'General case' 0 C--O 1.246 0.883 0 N-CA-C 112.579 0.585 . . . . 0.0 112.579 -172.27 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 215' ' ' GLN . . . . . 0.617 ' HB3' ' CD ' ' A' ' 216' ' ' PRO . 34.2 mm-40 -89.96 179.64 1.47 Allowed Pre-proline 0 C--N 1.321 -0.659 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 171.519 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 216' ' ' PRO . . . . . 0.617 ' CD ' ' HB3' ' A' ' 215' ' ' GLN . 50.4 Cg_exo -56.27 141.42 88.54 Favored 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 121.34 1.36 . . . . 0.0 111.077 -176.085 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 217' ' ' LEU . . . . . 0.448 HD22 ' HA ' ' A' ' 217' ' ' LEU . 0.5 OUTLIER -80.18 134.98 36.19 Favored 'General case' 0 CA--C 1.506 -0.746 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.661 -176.237 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 67.1 m -124.38 149.13 47.01 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.458 179.044 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -148.31 151.08 34.78 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.181 179.046 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 71.8 mtm -78.92 136.87 37.39 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 116.039 -0.528 . . . . 0.0 109.719 176.761 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 91.5 t -86.11 130.87 35.83 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.148 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -81.82 -71.01 0.5 Allowed 'General case' 0 N--CA 1.435 -1.179 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 178.656 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 223' ' ' MET . . . . . 0.661 ' C ' ' SD ' ' A' ' 223' ' ' MET . 2.1 ppp? -138.43 147.79 43.7 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 112.393 0.516 . . . . 0.0 112.393 173.973 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 224' ' ' VAL . . . . . 0.785 HG13 HG12 ' A' ' 232' ' ' VAL . 55.1 t -122.55 131.76 72.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 176.345 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 225' ' ' THR . . . . . 0.441 ' O ' ' OG1' ' A' ' 280' ' ' THR . 49.8 p -87.56 134.67 33.58 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 110.503 -0.184 . . . . 0.0 110.503 179.43 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 226' ' ' LYS . . . . . 0.492 ' NZ ' ' OD1' ' A' ' 285' ' ' ASP . 0.7 OUTLIER -80.42 76.88 7.23 Favored 'General case' 0 C--O 1.239 0.541 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 176.8 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 227' ' ' ASP . . . . . 0.433 ' H ' ' HG1' ' A' ' 280' ' ' THR . 5.8 t70 -147.87 177.33 9.42 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.302 -176.973 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 228' ' ' ASN . . . . . 0.474 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 4.3 t-20 -139.78 124.23 11.13 Favored Pre-proline 0 C--N 1.326 -0.414 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.415 176.072 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 229' ' ' PRO . . . . . 0.474 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 48.2 Cg_endo -66.17 144.59 66.84 Favored 'Cis proline' 0 C--N 1.313 -1.319 0 C-N-CA 122.802 -1.749 . . . . 0.0 109.873 -1.987 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 230' ' ' GLY . . . . . 0.503 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -70.69 138.29 28.41 Favored Glycine 0 C--O 1.222 -0.635 0 N-CA-C 109.821 -1.312 . . . . 0.0 109.821 -177.862 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.5 p -123.05 131.1 73.88 Favored 'Isoleucine or valine' 0 C--O 1.242 0.674 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 177.048 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 232' ' ' VAL . . . . . 0.785 HG12 HG13 ' A' ' 224' ' ' VAL . 0.7 OUTLIER -133.05 156.78 42.56 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 C-N-CA 120.347 -0.541 . . . . 0.0 110.819 -176.557 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 233' ' ' THR . . . . . 0.466 HG23 ' CG2' ' A' ' 274' ' ' THR . 0.2 OUTLIER -110.2 147.91 32.85 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 115.073 -0.967 . . . . 0.0 108.577 177.844 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 2.8 m -107.36 146.83 31.1 Favored 'General case' 0 C--N 1.313 -0.987 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 177.457 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 14.0 tp -49.41 125.26 10.78 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 -177.841 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 16.1 t70 -52.39 -40.84 62.58 Favored 'General case' 0 CA--C 1.507 -0.68 0 CA-C-N 116.463 -0.335 . . . . 0.0 111.07 -171.611 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 83.6 mt-10 -65.47 -35.41 80.81 Favored 'General case' 0 C--N 1.314 -0.977 0 C-N-CA 120.33 -0.548 . . . . 0.0 110.606 -177.794 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -72.34 138.32 47.23 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 112.442 0.534 . . . . 0.0 112.442 -175.226 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 84.9 mtp180 -105.14 104.42 14.15 Favored 'General case' 0 C--O 1.239 0.509 0 CA-C-N 115.734 -0.666 . . . . 0.0 109.26 172.829 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 240' ' ' HIS . . . . . 0.457 ' HB2' ' CG ' ' A' ' 242' ' ' PHE . 8.4 p80 -67.38 -46.96 71.76 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.923 -0.581 . . . . 0.0 111.599 -176.685 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 241' ' ' GLY . . . . . 0.441 ' N ' ' ND1' ' A' ' 240' ' ' HIS . . . 83.33 12.44 78.67 Favored Glycine 0 C--N 1.31 -0.902 0 N-CA-C 110.477 -1.049 . . . . 0.0 110.477 -176.909 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 242' ' ' PHE . . . . . 0.457 ' CG ' ' HB2' ' A' ' 240' ' ' HIS . 4.3 m-30 -80.84 145.39 31.41 Favored 'General case' 0 CA--C 1.514 -0.41 0 CA-C-O 120.731 0.301 . . . . 0.0 110.261 -178.915 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 243' ' ' GLU . . . . . 0.465 ' N ' ' OD2' ' A' ' 246' ' ' ASP . 99.2 mt-10 -131.55 165.01 24.55 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 115.734 -0.666 . . . . 0.0 109.592 173.392 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 244' ' ' THR . . . . . 0.439 HG23 ' HA ' ' A' ' 268' ' ' LYS . 4.9 m -59.56 125.82 25.15 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 -178.739 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 99.6 -5.88 58.74 Favored Glycine 0 C--N 1.318 -0.441 0 N-CA-C 111.215 -0.754 . . . . 0.0 111.215 -177.425 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 246' ' ' ASP . . . . . 0.465 ' OD2' ' N ' ' A' ' 243' ' ' GLU . 0.9 OUTLIER -67.54 149.64 49.87 Favored 'General case' 0 CA--C 1.502 -0.884 0 C-N-CA 120.814 -0.355 . . . . 0.0 111.44 176.525 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 247' ' ' PHE . . . . . 0.403 ' HA ' ' O ' ' A' ' 265' ' ' MET . 61.7 m-85 -108.74 125.84 52.36 Favored 'General case' 0 C--N 1.317 -0.81 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 176.142 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.457 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.9 m -128.09 160.86 37.41 Favored 'Isoleucine or valine' 0 C--O 1.24 0.566 0 C-N-CA 120.47 -0.492 . . . . 0.0 111.577 -175.38 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 44.1 m -124.17 160.21 28.36 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-N 114.778 -1.101 . . . . 0.0 108.679 173.495 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 250' ' ' PHE . . . . . 0.558 ' CB ' ' HB3' ' A' ' 259' ' ' LEU . 76.4 m-85 -123.99 153.89 40.62 Favored 'General case' 0 C--N 1.314 -0.935 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 -173.987 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 14.6 p -159.69 161.17 34.83 Favored 'General case' 0 C--N 1.309 -1.176 0 C-N-CA 120.969 -0.293 . . . . 0.0 111.266 177.162 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 27.1 mm-40 51.62 27.86 4.29 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.395 177.942 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 0.542 HG22 ' CA ' ' A' ' 290' ' ' GLY . 6.5 t -90.3 129.41 41.21 Favored 'Isoleucine or valine' 0 C--O 1.236 0.371 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 175.802 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 81.4 mt-30 -94.27 136.86 34.1 Favored 'General case' 0 C--O 1.244 0.785 0 C-N-CA 120.276 -0.57 . . . . 0.0 109.836 -178.16 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 82.59 -58.15 5.01 Favored Glycine 0 C--N 1.32 -0.323 0 N-CA-C 109.945 -1.262 . . . . 0.0 109.945 -176.853 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 256' ' ' MET . . . . . 0.485 ' N ' ' O ' ' A' ' 285' ' ' ASP . 4.3 ttm -81.73 53.76 2.23 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.665 0.745 . . . . 0.0 109.708 177.797 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 257' ' ' ILE . . . . . 0.427 ' O ' ' HB2' ' A' ' 260' ' ' ASN . 48.8 pt -69.37 -23.16 26.23 Favored 'Isoleucine or valine' 0 C--O 1.242 0.702 0 CA-C-N 115.042 -0.981 . . . . 0.0 110.899 -175.959 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 258' ' ' GLN . . . . . 0.425 ' O ' ' SG ' ' A' ' 262' ' ' CYS . 1.2 mp0 -56.5 -37.07 69.9 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 179.673 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 259' ' ' LEU . . . . . 0.873 HD21 ' CE2' ' A' ' 283' ' ' PHE . 93.0 mt -62.35 -40.2 95.61 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.755 175.375 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 260' ' ' ASN . . . . . 0.427 ' HB2' ' O ' ' A' ' 257' ' ' ILE . 98.1 m-20 -59.32 -39.79 84.2 Favored 'General case' 0 CA--C 1.516 -0.336 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 -178.322 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -98.21 8.78 62.92 Favored Glycine 0 CA--C 1.531 1.043 0 CA-C-N 116.165 -0.47 . . . . 0.0 112.224 -178.083 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 262' ' ' CYS . . . . . 0.425 ' SG ' ' O ' ' A' ' 258' ' ' GLN . 1.7 m -88.51 146.02 25.41 Favored 'General case' 0 C--O 1.236 0.39 0 O-C-N 122.262 -0.552 . . . . 0.0 112.204 -176.407 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 36.4 mt-30 -64.73 156.91 77.04 Favored Pre-proline 0 C--N 1.325 -0.476 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 171.973 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 264' ' ' PRO . . . . . 0.457 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 38.1 Cg_endo -63.5 144.24 89.9 Favored 'Trans proline' 0 C--N 1.318 -1.06 0 C-N-CA 121.098 1.199 . . . . 0.0 110.426 -178.794 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 265' ' ' MET . . . . . 0.403 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 11.3 ptp -133.6 154.45 50.87 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 112.174 0.435 . . . . 0.0 112.174 -175.597 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 34.8 tt0 -71.34 143.85 50.11 Favored 'General case' 0 C--O 1.236 0.378 0 O-C-N 123.837 0.711 . . . . 0.0 109.328 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 267' ' ' ILE . . . . . 0.671 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.9 pp -131.92 165.77 30.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 N-CA-C 112.639 0.607 . . . . 0.0 112.639 -175.957 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 268' ' ' LYS . . . . . 0.439 ' HA ' HG23 ' A' ' 244' ' ' THR . 49.9 tttp -124.83 125.46 44.03 Favored 'General case' 0 C--O 1.217 -0.612 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.343 177.79 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.414 HG23 ' O ' ' A' ' 269' ' ' VAL . 35.5 m -93.12 102.61 13.83 Favored 'Isoleucine or valine' 0 C--O 1.238 0.472 0 C-N-CA 120.452 -0.499 . . . . 0.0 111.235 179.127 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 95.9 mt -66.57 -39.44 88.48 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.148 -179.424 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -143.34 -169.74 12.73 Favored Glycine 0 C--N 1.32 -0.311 0 N-CA-C 110.441 -1.064 . . . . 0.0 110.441 -177.775 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 272' ' ' PRO . . . . . 0.401 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 39.7 Cg_endo -64.11 -33.29 61.98 Favored 'Trans proline' 0 C--N 1.306 -1.707 0 C-N-CA 122.038 1.825 . . . . 0.0 111.714 -179.287 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 90.6 m-85 -126.51 10.11 7.23 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 112.1 0.407 . . . . 0.0 112.1 -177.981 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 274' ' ' THR . . . . . 0.466 ' CG2' HG23 ' A' ' 233' ' ' THR . 1.1 p -121.61 131.11 53.93 Favored 'General case' 0 C--O 1.244 0.765 0 CA-C-N 116.701 -0.227 . . . . 0.0 111.072 -177.182 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 275' ' ' PHE . . . . . 0.543 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -139.31 161.68 36.84 Favored 'General case' 0 CA--C 1.511 -0.541 0 N-CA-C 112.34 0.496 . . . . 0.0 112.34 179.147 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 276' ' ' SER . . . . . 0.495 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 4.2 p -130.38 144.1 51.18 Favored 'General case' 0 N--CA 1.437 -1.078 0 CA-C-O 121.246 0.546 . . . . 0.0 111.512 -175.827 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 277' ' ' ILE . . . . . 0.56 HG22 HG22 ' A' ' 267' ' ' ILE . 31.8 pt -139.0 165.84 23.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 114.725 -1.125 . . . . 0.0 111.824 -173.304 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 278' ' ' CYS . . . . . 0.435 ' O ' ' HA ' ' A' ' 229' ' ' PRO . 4.8 m -28.36 -86.4 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.57 0 N-CA-C 113.498 0.925 . . . . 0.0 113.498 -175.51 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 55.3 t0 -153.02 112.2 3.81 Favored 'General case' 0 CA--C 1.508 -0.645 0 CA-C-O 120.5 0.19 . . . . 0.0 110.498 -177.374 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 280' ' ' THR . . . . . 0.774 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 21.6 p -67.68 -28.79 67.98 Favored 'General case' 0 C--N 1.303 -1.428 0 CA-C-O 121.323 0.582 . . . . 0.0 110.645 176.314 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -63.99 -21.56 66.55 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 115.067 -0.969 . . . . 0.0 108.521 175.604 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 44.3 t30 -88.42 -8.7 54.54 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.398 -179.501 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 283' ' ' PHE . . . . . 0.873 ' CE2' HD21 ' A' ' 259' ' ' LEU . 7.2 m-85 -92.45 -67.71 0.84 Allowed 'General case' 0 CA--C 1.512 -0.492 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.273 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 284' ' ' SER . . . . . 0.436 ' OG ' ' HA ' ' A' ' 256' ' ' MET . 3.8 p 173.41 -105.8 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 114.85 -1.068 . . . . 0.0 110.565 176.392 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 285' ' ' ASP . . . . . 0.492 ' OD1' ' NZ ' ' A' ' 226' ' ' LYS . 40.2 t0 -145.44 158.8 43.77 Favored 'General case' 0 C--O 1.217 -0.606 0 CA-C-O 120.408 0.147 . . . . 0.0 110.607 -179.637 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 66.7 t80 -101.1 118.89 37.89 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.744 -0.207 . . . . 0.0 110.634 179.628 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 287' ' ' ILE . . . . . 0.439 ' O ' ' HG3' ' A' ' 288' ' ' ARG . 97.1 mt -97.94 -63.86 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 175.79 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 288' ' ' ARG . . . . . 0.439 ' HG3' ' O ' ' A' ' 287' ' ' ILE . 67.5 mtm180 -166.96 175.86 7.35 Favored 'General case' 0 C--O 1.24 0.601 0 C-N-CA 123.973 0.909 . . . . 0.0 110.605 176.342 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 70.24 -158.8 53.53 Favored Glycine 0 C--N 1.318 -0.462 0 N-CA-C 111.053 -0.819 . . . . 0.0 111.053 175.103 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 290' ' ' GLY . . . . . 0.542 ' CA ' HG22 ' A' ' 253' ' ' VAL . . . 104.93 124.77 5.46 Favored Glycine 0 N--CA 1.442 -0.955 0 N-CA-C 111.977 -0.449 . . . . 0.0 111.977 177.258 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 95.7 mt -116.93 131.64 69.02 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.037 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 174.629 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 4.8 p -120.11 135.04 61.67 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.026 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 -179.138 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 15.6 m -132.03 144.81 51.03 Favored 'General case' 0 C--N 1.319 -0.759 0 C-N-CA 120.063 -0.655 . . . . 0.0 112.535 -174.939 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 294' ' ' GLN . . . . . 0.554 ' O ' ' HB3' ' A' ' 216' ' ' PRO . 48.5 tt0 -72.52 148.02 45.43 Favored 'General case' 0 CA--C 1.489 -1.381 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 168.31 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 295' ' ' VAL . . . . . 0.553 HG12 HG13 ' A' ' 297' ' ' VAL . 73.8 t -121.91 131.39 73.24 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.765 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 -178.955 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 296' ' ' LYS . . . . . 0.446 ' NZ ' ' OE2' ' A' ' 214' ' ' GLU . 20.5 mttp -72.52 96.62 1.97 Allowed 'General case' 0 C--O 1.238 0.448 0 N-CA-C 106.469 -1.678 . . . . 0.0 106.469 173.725 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 297' ' ' VAL . . . . . 0.553 HG13 HG12 ' A' ' 295' ' ' VAL . 4.9 m -105.65 118.52 55.25 Favored Pre-proline 0 C--N 1.314 -0.947 0 CA-C-N 116.178 -0.465 . . . . 0.0 112.225 -174.426 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_exo -60.84 139.78 87.0 Favored 'Trans proline' 0 C--N 1.309 -1.507 0 N-CA-C 106.064 -2.322 . . . . 0.0 106.064 165.717 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -67.71 134.2 50.66 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 118.468 -1.293 . . . . 0.0 111.239 -174.221 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 66.7 mttm -69.23 160.88 30.35 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.346 -0.843 . . . . 0.0 108.91 179.907 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 94.9 mt -70.15 119.84 16.93 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.867 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 176.877 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 2.1 m -76.26 101.28 5.38 Favored 'General case' 0 C--N 1.305 -1.336 0 CA-C-N 115.527 -0.761 . . . . 0.0 111.875 -170.897 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 73.5 m-85 -109.88 115.06 29.13 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 174.016 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 63.1 mttm -70.52 133.86 47.17 Favored 'General case' 0 C--N 1.317 -0.835 0 C-N-CA 119.565 -0.854 . . . . 0.0 109.212 -178.203 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 5.2 m -71.82 152.51 42.61 Favored 'General case' 0 C--N 1.312 -1.055 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 179.01 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 306' ' ' LEU . . . . . 0.404 ' HA ' HD23 ' A' ' 306' ' ' LEU . 52.5 mt -46.82 131.06 8.64 Favored Pre-proline 0 C--O 1.238 0.456 0 N-CA-C 109.268 -0.641 . . . . 0.0 109.268 -179.865 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_exo -53.9 -42.54 65.74 Favored 'Trans proline' 0 N--CA 1.493 1.488 0 C-N-CA 121.952 1.768 . . . . 0.0 111.041 -176.1 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -109.13 105.75 15.35 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.223 178.244 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 2.8 m -71.37 83.81 0.79 Allowed 'General case' 0 N--CA 1.445 -0.708 0 C-N-CA 120.225 -0.59 . . . . 0.0 109.578 177.13 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 92.1 mt -99.23 134.51 41.98 Favored 'General case' 0 CA--C 1.507 -0.708 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.424 -178.648 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 17.3 m -113.37 130.96 66.42 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.113 -178.565 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 45.1 tp10 . . . . . 0 C--O 1.204 -1.315 0 CA-C-O 118.389 -0.815 . . . . 0.0 109.777 -175.565 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 201' ' ' GLU . . . . . 0.476 ' N ' ' OE2' ' A' ' 204' ' ' GLU . 97.2 mt-10 . . . . . 0 N--CA 1.481 1.098 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -69.79 -34.83 74.27 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 112.563 0.579 . . . . 0.0 112.563 179.519 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -53.62 -45.47 67.91 Favored Glycine 0 CA--C 1.526 0.745 0 C-N-CA 121.342 -0.456 . . . . 0.0 112.041 -171.672 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 204' ' ' GLU . . . . . 0.607 ' CD ' ' H ' ' A' ' 204' ' ' GLU . 2.4 pm0 -68.02 -37.06 80.94 Favored 'General case' 0 CA--C 1.513 -0.45 0 C-N-CA 120.507 -0.477 . . . . 0.0 110.145 177.13 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 -61.95 -38.49 88.7 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 179.701 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 66.0 mtt -66.82 147.82 52.74 Favored 'General case' 0 N--CA 1.446 -0.667 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 175.532 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 21.4 m -119.67 158.54 21.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 CA-C-O 120.939 0.399 . . . . 0.0 110.78 -175.441 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 87.5 mt -78.96 155.73 28.81 Favored 'General case' 0 C--N 1.313 -1.017 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.116 179.012 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 7.5 m -58.56 -42.14 87.24 Favored 'General case' 0 C--N 1.31 -1.132 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 179.293 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 6.9 p-10 -73.97 -5.62 42.42 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.856 -0.611 . . . . 0.0 112.295 -179.022 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 55.7 m -40.35 112.04 0.25 Allowed 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.85 0.357 . . . . 0.0 111.752 -177.099 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 53.7 t-20 -91.39 117.46 29.7 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 177.189 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 131.12 53.93 0.09 OUTLIER Glycine 0 C--N 1.317 -0.483 0 N-CA-C 109.783 -1.327 . . . . 0.0 109.783 -175.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 214' ' ' GLU . . . . . 0.505 ' H ' ' CD ' ' A' ' 214' ' ' GLU . 1.8 mp0 -56.31 152.09 11.75 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 115.088 -0.556 . . . . 0.0 110.692 -178.797 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 14.7 pt20 -48.62 138.01 12.16 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.134 -179.873 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 216' ' ' PRO . . . . . 0.453 ' HB2' ' O ' ' A' ' 294' ' ' GLN . 31.5 Cg_exo -60.42 147.42 94.16 Favored 'Trans proline' 0 C--N 1.311 -1.446 0 C-N-CA 122.099 1.866 . . . . 0.0 110.263 -179.8 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 217' ' ' LEU . . . . . 0.469 ' HB3' ' O ' ' A' ' 240' ' ' HIS . 0.2 OUTLIER -51.75 131.08 30.07 Favored 'General case' 0 C--O 1.237 0.409 0 N-CA-C 110.223 -0.288 . . . . 0.0 110.223 -177.801 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 16.5 p -136.18 156.16 49.09 Favored 'General case' 0 CA--C 1.51 -0.595 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.509 -177.352 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 219' ' ' ALA . . . . . 0.53 ' HA ' ' HB1' ' A' ' 238' ' ' ALA . . . -150.72 151.2 32.06 Favored 'General case' 0 N--CA 1.448 -0.556 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.134 -178.751 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 220' ' ' MET . . . . . 0.505 ' SD ' HG12 ' A' ' 291' ' ' ILE . 1.5 mpp? -73.67 131.2 41.39 Favored 'General case' 0 C--O 1.244 0.772 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 177.891 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 69.1 t -74.77 131.76 34.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 178.659 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 58.0 m -92.2 -69.09 0.76 Allowed 'General case' 0 N--CA 1.435 -1.176 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.342 179.661 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 12.6 ptm -138.14 148.59 45.07 Favored 'General case' 0 N--CA 1.472 0.63 0 C-N-CA 120.999 -0.281 . . . . 0.0 111.141 172.762 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 224' ' ' VAL . . . . . 0.55 HG22 ' HB ' ' A' ' 232' ' ' VAL . 52.9 t -121.67 129.35 75.58 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 174.94 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 17.2 p -81.29 128.03 33.36 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 119.85 -0.74 . . . . 0.0 110.54 179.623 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 17.0 tptm -76.4 84.11 3.14 Favored 'General case' 0 N--CA 1.437 -1.097 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 177.463 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 227' ' ' ASP . . . . . 0.543 ' N ' ' OG1' ' A' ' 280' ' ' THR . 4.8 t0 -159.97 175.74 12.67 Favored 'General case' 0 C--O 1.245 0.861 0 CA-C-N 115.53 -0.759 . . . . 0.0 110.304 -176.162 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 228' ' ' ASN . . . . . 0.48 ' N ' ' OD1' ' A' ' 227' ' ' ASP . 0.1 OUTLIER -143.01 122.75 7.75 Favored Pre-proline 0 C--N 1.321 -0.656 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.838 172.65 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 229' ' ' PRO . . . . . 0.48 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 42.0 Cg_endo -65.23 148.33 73.27 Favored 'Cis proline' 0 N--CA 1.496 1.652 0 C-N-CA 122.908 -1.705 . . . . 0.0 109.875 -1.507 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 230' ' ' GLY . . . . . 0.484 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -88.43 140.57 16.19 Favored Glycine 0 C--N 1.315 -0.612 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 -177.916 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.4 p -121.01 132.79 69.59 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.579 0 CA-C-N 117.182 0.491 . . . . 0.0 109.791 177.125 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 232' ' ' VAL . . . . . 0.556 HG22 ' CD1' ' A' ' 275' ' ' PHE . 0.6 OUTLIER -129.83 153.63 39.12 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.042 0 C-N-CA 120.038 -0.665 . . . . 0.0 111.214 -176.581 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 233' ' ' THR . . . . . 0.444 ' HA ' ' O ' ' A' ' 273' ' ' TYR . 0.6 OUTLIER -106.84 140.48 39.61 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-N 115.151 -0.931 . . . . 0.0 109.445 178.065 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.8 m -107.07 160.39 15.59 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-N 116.182 -0.463 . . . . 0.0 109.823 -178.339 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.464 ' HB3' ' HB3' ' A' ' 238' ' ' ALA . 41.5 tp -63.74 131.34 47.58 Favored 'General case' 0 C--N 1.32 -0.674 0 C-N-CA 120.686 -0.406 . . . . 0.0 109.975 -177.678 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 19.0 p-10 -51.61 -44.43 62.88 Favored 'General case' 0 N--CA 1.475 0.801 0 CA-C-N 115.881 -0.6 . . . . 0.0 111.073 -176.628 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 92.6 mt-10 -65.77 -35.24 80.16 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 179.556 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 238' ' ' ALA . . . . . 0.53 ' HB1' ' HA ' ' A' ' 219' ' ' ALA . . . -91.54 92.61 8.58 Favored 'General case' 0 N--CA 1.439 -1.017 0 CA-C-N 115.481 -0.781 . . . . 0.0 111.855 -175.261 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 84.7 mtp180 -75.66 118.13 18.15 Favored 'General case' 0 C--N 1.312 -1.022 0 N-CA-C 108.478 -0.934 . . . . 0.0 108.478 174.386 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 240' ' ' HIS . . . . . 0.615 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 7.1 p80 -60.09 -46.09 90.73 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.799 -176.939 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 78.87 19.12 73.66 Favored Glycine 0 C--O 1.238 0.381 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 -178.532 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 242' ' ' PHE . . . . . 0.544 ' CD2' ' HB2' ' A' ' 240' ' ' HIS . 10.4 m-30 -81.04 146.66 30.53 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 -179.545 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 73.9 mm-40 -101.64 158.88 15.77 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 116.011 -0.54 . . . . 0.0 109.672 172.544 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 16.3 m -66.66 126.72 29.83 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 174.762 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 88.14 2.78 80.06 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -176.491 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 15.2 t0 -79.42 167.51 20.74 Favored 'General case' 0 CA--C 1.516 -0.337 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 178.285 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 247' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -112.66 134.71 54.05 Favored 'General case' 0 C--O 1.244 0.811 0 O-C-N 123.127 0.267 . . . . 0.0 110.874 -176.922 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.47 HG11 ' CD2' ' A' ' 242' ' ' PHE . 2.9 m -131.59 160.92 42.03 Favored 'Isoleucine or valine' 0 C--O 1.236 0.369 0 CA-C-O 121.078 0.466 . . . . 0.0 111.899 178.37 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 249' ' ' SER . . . . . 0.444 ' OG ' ' HG3' ' A' ' 264' ' ' PRO . 1.3 m -123.26 153.48 40.13 Favored 'General case' 0 C--O 1.244 0.798 0 CA-C-N 114.893 -1.048 . . . . 0.0 109.229 176.653 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 250' ' ' PHE . . . . . 0.446 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 79.3 m-85 -109.43 153.0 24.63 Favored 'General case' 0 CA--C 1.505 -0.773 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.787 -179.357 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 251' ' ' SER . . . . . 0.475 ' O ' ' HA2' ' A' ' 290' ' ' GLY . 39.0 m -152.71 154.69 35.76 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-N 115.694 -0.684 . . . . 0.0 109.196 176.688 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 12.6 mm-40 57.47 21.17 6.71 Favored 'General case' 0 CA--C 1.542 0.655 0 N-CA-C 112.664 0.616 . . . . 0.0 112.664 177.917 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 0.59 HG13 ' CE1' ' A' ' 286' ' ' TYR . 61.5 t -76.0 133.89 30.23 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 C-N-CA 120.949 -0.3 . . . . 0.0 111.0 178.759 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 254' ' ' GLN . . . . . 0.411 ' OE1' ' HG2' ' A' ' 288' ' ' ARG . 85.2 mt-30 -96.78 136.01 37.93 Favored 'General case' 0 C--O 1.24 0.605 0 O-C-N 123.334 0.396 . . . . 0.0 110.045 179.251 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 76.35 -61.4 3.13 Favored Glycine 0 N--CA 1.463 0.453 0 N-CA-C 111.472 -0.651 . . . . 0.0 111.472 177.974 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 256' ' ' MET . . . . . 0.664 ' SD ' HD11 ' A' ' 259' ' ' LEU . 48.5 ttm -77.67 63.08 2.69 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 178.547 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 48.9 pt -70.22 -20.63 23.01 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 114.914 -1.039 . . . . 0.0 111.136 -173.786 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 258' ' ' GLN . . . . . 0.566 ' HG3' ' SG ' ' A' ' 262' ' ' CYS . 9.4 tp-100 -54.76 -39.53 68.42 Favored 'General case' 0 N--CA 1.44 -0.955 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.035 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 259' ' ' LEU . . . . . 0.664 HD11 ' SD ' ' A' ' 256' ' ' MET . 97.8 mt -62.58 -41.71 99.11 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.17 -0.468 . . . . 0.0 109.909 178.542 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -61.52 -40.38 94.41 Favored 'General case' 0 CA--C 1.509 -0.598 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 178.377 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -94.64 13.12 67.81 Favored Glycine 0 CA--C 1.527 0.801 0 CA-C-N 115.395 -0.82 . . . . 0.0 111.775 -178.907 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 262' ' ' CYS . . . . . 0.566 ' SG ' ' HG3' ' A' ' 258' ' ' GLN . 1.0 OUTLIER -105.64 156.92 17.8 Favored 'General case' 0 CA--C 1.508 -0.637 0 CA-C-N 117.45 0.625 . . . . 0.0 112.322 -178.051 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 28.4 mt-30 -71.52 158.38 88.03 Favored Pre-proline 0 C--N 1.319 -0.733 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 171.431 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 264' ' ' PRO . . . . . 0.62 ' CB ' HG21 ' A' ' 295' ' ' VAL . 26.0 Cg_exo -61.87 147.47 95.15 Favored 'Trans proline' 0 C--N 1.304 -1.809 0 C-N-CA 121.347 1.365 . . . . 0.0 110.551 177.514 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 265' ' ' MET . . . . . . . . . . . . . 4.4 ptp -125.64 164.78 19.84 Favored 'General case' 0 N--CA 1.473 0.706 0 N-CA-C 111.79 0.293 . . . . 0.0 111.79 -177.673 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -71.04 142.62 50.88 Favored 'General case' 0 CA--C 1.513 -0.443 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 176.517 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 267' ' ' ILE . . . . . 0.75 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.7 pp -131.04 160.04 42.56 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 CA-C-O 121.054 0.454 . . . . 0.0 111.611 -179.82 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 55.5 mttm -130.6 110.63 11.55 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -177.187 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.418 HG23 ' O ' ' A' ' 269' ' ' VAL . 27.7 m -77.17 102.1 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 CA-C-O 121.389 0.614 . . . . 0.0 112.255 -176.771 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 97.0 mt -69.6 -39.11 77.46 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.521 177.208 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -144.26 -175.34 17.3 Favored Glycine 0 N--CA 1.461 0.361 0 N-CA-C 109.977 -1.249 . . . . 0.0 109.977 -178.434 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 272' ' ' PRO . . . . . 0.615 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 36.9 Cg_endo -62.15 -34.27 79.61 Favored 'Trans proline' 0 C--N 1.313 -1.341 0 C-N-CA 121.888 1.725 . . . . 0.0 110.939 -177.914 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 273' ' ' TYR . . . . . 0.444 ' O ' ' HA ' ' A' ' 233' ' ' THR . 94.4 m-85 -123.12 6.57 9.19 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.575 -0.739 . . . . 0.0 112.253 -179.796 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 2.2 p -117.11 127.39 54.09 Favored 'General case' 0 C--O 1.244 0.795 0 CA-C-O 121.046 0.45 . . . . 0.0 110.901 179.455 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 275' ' ' PHE . . . . . 0.576 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -137.28 161.94 34.87 Favored 'General case' 0 CA--C 1.502 -0.872 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.092 -179.085 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 276' ' ' SER . . . . . 0.484 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 4.4 p -132.22 145.84 51.6 Favored 'General case' 0 C--N 1.309 -1.163 0 C-N-CA 120.369 -0.532 . . . . 0.0 112.124 -173.864 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 277' ' ' ILE . . . . . 0.591 HG22 HG22 ' A' ' 267' ' ' ILE . 28.0 pt -139.22 164.77 24.43 Favored 'Isoleucine or valine' 0 C--O 1.243 0.726 0 CA-C-N 114.744 -1.117 . . . . 0.0 112.899 -172.368 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 2.2 m -28.63 -88.27 0.0 OUTLIER 'General case' 0 C--O 1.237 0.405 0 N-CA-C 113.928 1.084 . . . . 0.0 113.928 -176.099 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 59.8 t0 -152.4 115.65 4.7 Favored 'General case' 0 CA--C 1.507 -0.696 0 CA-C-O 120.695 0.283 . . . . 0.0 110.793 -175.764 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 280' ' ' THR . . . . . 0.673 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 29.7 p -64.84 -29.53 70.49 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-O 121.023 0.44 . . . . 0.0 110.732 175.611 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -64.64 -23.74 67.36 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.324 175.751 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 18.0 t-20 -89.2 -9.31 51.3 Favored 'General case' 0 CA--C 1.509 -0.612 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.77 -179.557 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 283' ' ' PHE . . . . . 0.673 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 15.7 m-85 -92.46 -75.27 0.49 Allowed 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 121.641 0.734 . . . . 0.0 109.372 174.938 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 284' ' ' SER . . . . . 0.405 ' O ' ' CE ' ' A' ' 256' ' ' MET . 0.1 OUTLIER 165.6 -174.23 0.02 OUTLIER 'General case' 0 C--N 1.313 -1.0 0 N-CA-C 106.835 -1.543 . . . . 0.0 106.835 -174.066 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -94.98 121.56 36.72 Favored 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 119.687 -0.805 . . . . 0.0 111.899 -179.782 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 286' ' ' TYR . . . . . 0.59 ' CE1' HG13 ' A' ' 253' ' ' VAL . 3.3 t80 -72.74 108.19 5.6 Favored 'General case' 0 C--O 1.236 0.386 0 C-N-CA 123.535 0.734 . . . . 0.0 109.744 -177.359 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 287' ' ' ILE . . . . . 0.606 ' O ' ' HB3' ' A' ' 288' ' ' ARG . 89.9 mt -67.39 -44.94 86.72 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.66 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 173.077 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 288' ' ' ARG . . . . . 0.606 ' HB3' ' O ' ' A' ' 287' ' ' ILE . 7.4 ptm180 157.95 -161.26 0.0 OUTLIER 'General case' 0 C--O 1.237 0.409 0 C-N-CA 124.89 1.276 . . . . 0.0 109.164 177.476 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 289' ' ' GLY . . . . . 0.537 ' N ' ' HG3' ' A' ' 288' ' ' ARG . . . 70.99 -157.16 53.51 Favored Glycine 0 CA--C 1.5 -0.903 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 176.498 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 290' ' ' GLY . . . . . 0.475 ' HA2' ' O ' ' A' ' 251' ' ' SER . . . 88.84 145.82 12.02 Favored Glycine 0 N--CA 1.436 -1.309 0 CA-C-O 121.533 0.518 . . . . 0.0 112.714 175.52 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 291' ' ' ILE . . . . . 0.505 HG12 ' SD ' ' A' ' 220' ' ' MET . 92.6 mt -123.41 128.52 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.344 0 N-CA-C 106.74 -1.578 . . . . 0.0 106.74 172.658 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 14.8 p -107.68 130.6 59.74 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.823 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 -179.801 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 3.8 m -132.27 146.9 52.32 Favored 'General case' 0 CA--C 1.506 -0.73 0 C-N-CA 120.52 -0.472 . . . . 0.0 112.187 -173.817 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 294' ' ' GLN . . . . . 0.453 ' O ' ' HB2' ' A' ' 216' ' ' PRO . 49.2 tt0 -70.51 154.19 42.14 Favored 'General case' 0 CA--C 1.497 -1.085 0 CA-C-N 115.342 -0.844 . . . . 0.0 109.601 174.368 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 295' ' ' VAL . . . . . 0.62 HG21 ' CB ' ' A' ' 264' ' ' PRO . 2.5 t -114.73 127.19 72.35 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.599 0 N-CA-C 108.177 -1.045 . . . . 0.0 108.177 172.002 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 296' ' ' LYS . . . . . 0.47 ' O ' ' HG3' ' A' ' 296' ' ' LYS . 23.3 pttp -112.84 98.06 6.95 Favored 'General case' 0 N--CA 1.434 -1.234 0 C-N-CA 119.756 -0.778 . . . . 0.0 110.83 179.77 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 297' ' ' VAL . . . . . 0.454 ' HB ' ' HD2' ' A' ' 298' ' ' PRO . 31.5 m -68.87 171.85 5.73 Favored Pre-proline 0 C--N 1.314 -0.955 0 N-CA-C 107.225 -1.398 . . . . 0.0 107.225 173.747 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 298' ' ' PRO . . . . . 0.454 ' HD2' ' HB ' ' A' ' 297' ' ' VAL . 50.2 Cg_exo -55.84 140.49 85.24 Favored 'Trans proline' 0 C--N 1.303 -1.839 0 N-CA-C 108.173 -1.51 . . . . 0.0 108.173 177.975 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 60.0 mttp -65.25 141.59 58.58 Favored 'General case' 0 C--N 1.313 -0.988 0 C-N-CA 119.687 -0.805 . . . . 0.0 110.32 -175.012 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 69.1 mttm -66.75 140.95 57.88 Favored 'General case' 0 N--CA 1.44 -0.935 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 -177.519 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 18.4 tt -46.27 114.1 0.18 Allowed 'Isoleucine or valine' 0 C--O 1.241 0.629 0 CA-C-O 121.428 0.632 . . . . 0.0 111.245 -173.948 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 3.3 m -74.38 144.66 44.29 Favored 'General case' 0 N--CA 1.441 -0.917 0 CA-C-N 115.256 -0.883 . . . . 0.0 109.964 -177.849 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 93.6 t80 -132.84 157.4 45.13 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 177.198 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 32.6 mmtp -60.07 107.7 0.67 Allowed 'General case' 0 C--N 1.32 -0.677 0 C-N-CA 119.987 -0.685 . . . . 0.0 110.819 -176.559 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -80.0 171.88 14.51 Favored 'General case' 0 C--N 1.311 -1.096 0 CA-C-N 115.344 -0.844 . . . . 0.0 109.898 176.954 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 306' ' ' LEU . . . . . 0.535 HD13 HD12 ' A' ' 310' ' ' LEU . 94.8 mt -48.84 155.81 0.99 Allowed Pre-proline 0 C--N 1.328 -0.357 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 176.001 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_exo -52.48 -39.0 75.41 Favored 'Trans proline' 0 N--CA 1.501 1.953 0 C-N-CA 121.939 1.759 . . . . 0.0 110.42 -177.499 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 308' ' ' ALA . . . . . 0.463 ' O ' ' N ' ' A' ' 310' ' ' LEU . . . -149.94 171.11 17.33 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 175.52 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 1.3 m -62.47 83.47 0.02 OUTLIER 'General case' 0 C--N 1.317 -0.847 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 175.391 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 310' ' ' LEU . . . . . 0.535 HD12 HD13 ' A' ' 306' ' ' LEU . 96.5 mt -61.06 111.07 1.55 Allowed 'General case' 0 C--O 1.237 0.422 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.335 -171.74 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 29.0 m -137.06 161.62 35.26 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 CA-C-N 115.154 -0.93 . . . . 0.0 108.565 174.272 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 43.3 mt-10 . . . . . 0 C--O 1.204 -1.34 0 CA-C-O 118.625 -0.702 . . . . 0.0 109.989 179.488 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 201' ' ' GLU . . . . . 0.514 ' CD ' ' H ' ' A' ' 202' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.476 0.853 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 . . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 202' ' ' PHE . . . . . 0.514 ' H ' ' CD ' ' A' ' 201' ' ' GLU . 87.3 m-85 -125.75 -2.43 7.25 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.143 175.595 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -100.86 14.88 58.64 Favored Glycine 0 N--CA 1.459 0.199 0 N-CA-C 111.721 -0.551 . . . . 0.0 111.721 -175.165 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 204' ' ' GLU . . . . . 0.456 ' OE2' ' N ' ' A' ' 201' ' ' GLU . 55.3 mp0 -52.3 -14.48 0.46 Allowed 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 111.927 0.343 . . . . 0.0 111.927 -179.442 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 205' ' ' GLU . . . . . 0.475 ' N ' ' CD ' ' A' ' 205' ' ' GLU . 2.6 mm-40 -54.72 -37.64 66.11 Favored 'General case' 0 C--O 1.236 0.38 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 175.689 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 99.7 mmm -106.0 96.92 6.82 Favored 'General case' 0 N--CA 1.444 -0.744 0 CA-C-N 114.713 -1.131 . . . . 0.0 108.476 172.039 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 2.7 p -128.1 143.2 41.64 Favored 'Isoleucine or valine' 0 C--O 1.243 0.711 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 -178.714 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 96.0 mt -65.75 136.09 55.78 Favored 'General case' 0 C--O 1.238 0.492 0 CA-C-N 116.186 -0.461 . . . . 0.0 109.997 -176.391 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 4.7 p -79.12 25.39 0.29 Allowed 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.892 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 210' ' ' ASP . . . . . 0.439 ' O ' ' C ' ' A' ' 211' ' ' SER . 28.0 t70 -64.09 -34.73 78.71 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.138 -0.483 . . . . 0.0 112.084 -176.813 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 211' ' ' SER . . . . . 0.439 ' C ' ' O ' ' A' ' 210' ' ' ASP . 0.9 OUTLIER -29.85 108.61 0.04 OUTLIER 'General case' 0 CA--C 1.539 0.521 0 O-C-N 123.61 0.569 . . . . 0.0 111.421 -177.656 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 26.8 t-20 -72.1 148.97 45.22 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.497 -0.774 . . . . 0.0 111.435 -175.126 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 80.87 6.36 89.48 Favored Glycine 0 C--O 1.235 0.206 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.465 177.81 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -118.46 126.35 51.85 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.552 0.215 . . . . 0.0 110.621 179.179 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 6.7 mt-30 -109.49 140.21 21.88 Favored Pre-proline 0 C--N 1.318 -0.765 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 178.743 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 216' ' ' PRO . . . . . 0.44 ' O ' HD22 ' A' ' 217' ' ' LEU . 72.1 Cg_endo -73.18 142.98 34.91 Favored 'Trans proline' 0 C--N 1.305 -1.72 0 C-N-CA 122.214 1.943 . . . . 0.0 110.047 176.196 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 217' ' ' LEU . . . . . 0.44 HD22 ' O ' ' A' ' 216' ' ' PRO . 3.7 mm? -114.01 136.74 52.57 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 116.644 -0.253 . . . . 0.0 111.524 178.326 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 3.7 m -132.22 132.1 42.77 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 175.423 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -145.38 152.95 40.67 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-O 120.744 0.307 . . . . 0.0 110.762 179.551 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -73.71 134.8 43.59 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.055 178.745 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 98.7 t -80.17 131.12 34.82 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.102 0 N-CA-C 107.406 -1.331 . . . . 0.0 107.406 172.553 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 11.8 p -95.69 -60.48 1.64 Allowed 'General case' 0 N--CA 1.439 -1.016 0 C-N-CA 120.237 -0.585 . . . . 0.0 110.645 -177.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 223' ' ' MET . . . . . 0.568 ' C ' ' SD ' ' A' ' 223' ' ' MET . 0.5 OUTLIER -138.42 141.7 39.54 Favored 'General case' 0 C--O 1.221 -0.407 0 N-CA-C 112.219 0.452 . . . . 0.0 112.219 175.78 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 224' ' ' VAL . . . . . 0.639 HG22 ' HB ' ' A' ' 232' ' ' VAL . 48.4 t -125.19 132.25 71.41 Favored 'Isoleucine or valine' 0 C--O 1.24 0.587 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 177.441 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 5.5 p -99.76 117.36 33.92 Favored 'General case' 0 C--O 1.237 0.424 0 C-N-CA 120.373 -0.531 . . . . 0.0 110.324 176.897 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 226' ' ' LYS . . . . . 0.512 ' HD3' ' HA ' ' A' ' 281' ' ' SER . 0.0 OUTLIER -67.55 85.51 0.19 Allowed 'General case' 0 C--O 1.242 0.687 0 N-CA-C 110.151 -0.315 . . . . 0.0 110.151 178.756 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 227' ' ' ASP . . . . . 0.594 ' N ' ' OG1' ' A' ' 280' ' ' THR . 4.2 t70 -150.73 -177.61 6.09 Favored 'General case' 0 C--O 1.242 0.686 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.518 -179.045 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 228' ' ' ASN . . . . . 0.494 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.0 OUTLIER -141.28 125.59 10.39 Favored Pre-proline 0 N--CA 1.467 0.396 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.967 174.96 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 229' ' ' PRO . . . . . 0.494 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 55.7 Cg_endo -66.17 147.77 75.18 Favored 'Cis proline' 0 N--CA 1.496 1.634 0 C-N-CA 123.347 -1.522 . . . . 0.0 110.116 -0.566 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 230' ' ' GLY . . . . . 0.494 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -70.71 138.45 28.61 Favored Glycine 0 N--CA 1.449 -0.473 0 N-CA-C 110.004 -1.238 . . . . 0.0 110.004 -178.154 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 231' ' ' VAL . . . . . 0.683 HG23 ' CD1' ' A' ' 270' ' ' LEU . 1.8 p -125.69 131.78 71.6 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.804 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 176.335 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 232' ' ' VAL . . . . . 0.639 ' HB ' HG22 ' A' ' 224' ' ' VAL . 0.8 OUTLIER -137.28 157.0 34.43 Favored 'Isoleucine or valine' 0 C--O 1.248 0.988 0 C-N-CA 120.103 -0.639 . . . . 0.0 111.548 -177.553 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 233' ' ' THR . . . . . 0.444 HG23 ' CG2' ' A' ' 274' ' ' THR . 6.0 m -113.07 146.9 38.35 Favored 'General case' 0 C--N 1.309 -1.162 0 CA-C-N 114.987 -1.006 . . . . 0.0 109.532 178.613 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 24.7 m -107.36 160.97 15.22 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 178.244 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.43 ' HB3' ' HB3' ' A' ' 238' ' ' ALA . 45.2 tp -59.31 128.61 37.97 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 179.431 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -51.35 -44.78 62.15 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.846 -175.164 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 76.8 mt-10 -65.85 -33.08 75.01 Favored 'General case' 0 C--N 1.311 -1.066 0 C-N-CA 120.724 -0.39 . . . . 0.0 111.147 178.834 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 238' ' ' ALA . . . . . 0.43 ' HB3' ' HB3' ' A' ' 235' ' ' LEU . . . -91.62 102.68 15.32 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.729 -175.1 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 78.5 mtm-85 -74.22 127.36 32.77 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 107.717 -1.216 . . . . 0.0 107.717 174.713 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 240' ' ' HIS . . . . . 0.536 ' H ' ' CD2' ' A' ' 240' ' ' HIS . 6.8 p80 -66.28 -45.45 80.44 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 121.137 0.494 . . . . 0.0 110.855 -179.018 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 81.45 12.12 82.33 Favored Glycine 0 C--N 1.311 -0.823 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 -178.257 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 242' ' ' PHE . . . . . 0.519 ' CE1' ' HB2' ' A' ' 294' ' ' GLN . 4.0 m-30 -81.5 151.95 27.55 Favored 'General case' 0 CA--C 1.504 -0.804 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 178.373 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -130.57 158.07 40.98 Favored 'General case' 0 C--N 1.309 -1.178 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 177.982 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 244' ' ' THR . . . . . 0.743 HG23 ' HG2' ' A' ' 268' ' ' LYS . 22.8 m -57.85 127.97 34.71 Favored 'General case' 0 C--N 1.306 -1.284 0 C-N-CA 120.007 -0.677 . . . . 0.0 109.973 -177.26 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 92.06 -6.41 78.91 Favored Glycine 0 N--CA 1.449 -0.497 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.609 -179.019 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 246' ' ' ASP . . . . . 0.442 ' CG ' HE21 ' A' ' 294' ' ' GLN . 1.7 t70 -79.24 162.4 25.71 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 117.223 0.511 . . . . 0.0 111.004 -179.821 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 247' ' ' PHE . . . . . 0.48 ' HA ' ' O ' ' A' ' 265' ' ' MET . 73.0 m-85 -111.94 131.39 55.41 Favored 'General case' 0 C--O 1.24 0.574 0 N-CA-C 112.241 0.46 . . . . 0.0 112.241 -176.076 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.498 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.6 m -132.71 158.88 43.39 Favored 'Isoleucine or valine' 0 C--O 1.235 0.319 0 CA-C-O 120.873 0.368 . . . . 0.0 111.809 177.397 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 49.6 m -123.92 160.55 27.28 Favored 'General case' 0 C--N 1.319 -0.734 0 C-N-CA 124.498 1.119 . . . . 0.0 108.565 173.029 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 250' ' ' PHE . . . . . 0.641 ' CE1' HD22 ' A' ' 259' ' ' LEU . 68.4 m-85 -110.63 146.72 35.68 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 120.461 0.172 . . . . 0.0 111.081 -177.364 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 1.5 m -133.54 153.39 51.68 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 176.24 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 252' ' ' GLU . . . . . 0.462 ' O ' ' NE2' ' A' ' 254' ' ' GLN . 79.1 mm-40 55.37 30.34 14.71 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 112.81 0.671 . . . . 0.0 112.81 173.213 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 0.538 HG11 ' HB3' ' A' ' 256' ' ' MET . 51.3 t -89.01 134.69 27.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 N-CA-C 110.231 -0.285 . . . . 0.0 110.231 177.319 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 254' ' ' GLN . . . . . 0.462 ' NE2' ' O ' ' A' ' 252' ' ' GLU . 3.9 mp0 -99.81 135.19 41.61 Favored 'General case' 0 C--O 1.239 0.518 0 CA-C-O 121.031 0.443 . . . . 0.0 110.658 178.909 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 83.37 -55.08 5.02 Favored Glycine 0 C--N 1.32 -0.321 0 N-CA-C 111.098 -0.801 . . . . 0.0 111.098 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 256' ' ' MET . . . . . 0.538 ' HB3' HG11 ' A' ' 253' ' ' VAL . 4.6 ttm -83.41 69.47 10.03 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 178.481 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 45.5 pt -72.69 -22.23 20.08 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.916 0 CA-C-N 114.78 -1.1 . . . . 0.0 111.075 -174.78 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 258' ' ' GLN . . . . . 0.496 ' O ' ' SG ' ' A' ' 262' ' ' CYS . 23.4 mp0 -59.34 -41.49 89.29 Favored 'General case' 0 C--N 1.313 -0.994 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 179.359 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 259' ' ' LEU . . . . . 0.948 HD21 ' CE2' ' A' ' 283' ' ' PHE . 90.4 mt -62.8 -41.92 99.49 Favored 'General case' 0 N--CA 1.443 -0.802 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.589 178.198 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 260' ' ' ASN . . . . . 0.519 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 89.5 m-20 -60.44 -41.22 93.6 Favored 'General case' 0 CA--C 1.507 -0.678 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 -179.206 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -100.39 14.11 59.6 Favored Glycine 0 C--N 1.316 -0.583 0 N-CA-C 111.359 -0.696 . . . . 0.0 111.359 -178.495 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 262' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 258' ' ' GLN . 1.2 m -85.62 144.81 27.65 Favored 'General case' 0 C--O 1.242 0.707 0 C-N-CA 120.714 -0.394 . . . . 0.0 110.786 -179.607 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 95.7 mm-40 -68.96 162.96 60.87 Favored Pre-proline 0 C--N 1.315 -0.892 0 N-CA-C 107.4 -1.333 . . . . 0.0 107.4 170.224 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 264' ' ' PRO . . . . . 0.498 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 24.1 Cg_exo -61.46 143.89 97.71 Favored 'Trans proline' 0 C--N 1.307 -1.637 0 N-CA-C 109.562 -0.976 . . . . 0.0 109.562 -178.129 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 265' ' ' MET . . . . . 0.48 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 8.9 ptp -126.65 150.8 48.74 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 116.689 -0.232 . . . . 0.0 110.935 -175.296 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -70.92 137.49 49.29 Favored 'General case' 0 C--O 1.242 0.686 0 O-C-N 123.828 0.705 . . . . 0.0 109.14 178.846 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 267' ' ' ILE . . . . . 0.57 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.9 pp -127.24 161.24 34.89 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-O 120.867 0.365 . . . . 0.0 111.601 -175.727 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 268' ' ' LYS . . . . . 0.743 ' HG2' HG23 ' A' ' 244' ' ' THR . 0.0 OUTLIER -127.38 120.87 29.47 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 176.621 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.626 HG22 ' OG1' ' A' ' 244' ' ' THR . 28.3 m -69.92 133.71 31.39 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 C-N-CA 120.653 -0.419 . . . . 0.0 111.337 -177.972 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 270' ' ' LEU . . . . . 0.683 ' CD1' HG23 ' A' ' 231' ' ' VAL . 74.5 mt -97.06 -46.08 6.32 Favored 'General case' 0 CA--C 1.508 -0.67 0 CA-C-O 121.422 0.63 . . . . 0.0 109.537 177.951 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -149.25 -171.46 17.92 Favored Glycine 0 C--N 1.311 -0.843 0 N-CA-C 108.428 -1.869 . . . . 0.0 108.428 179.84 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 272' ' ' PRO . . . . . 0.52 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 37.8 Cg_endo -62.71 -30.66 78.63 Favored 'Trans proline' 0 C--N 1.301 -1.957 0 C-N-CA 121.332 1.355 . . . . 0.0 111.054 -179.12 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 95.3 m-85 -122.86 11.45 9.66 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 113.32 0.859 . . . . 0.0 113.32 -178.07 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 274' ' ' THR . . . . . 0.444 ' CG2' HG23 ' A' ' 233' ' ' THR . 20.4 p -130.09 146.38 51.74 Favored 'General case' 0 C--O 1.241 0.638 0 C-N-CA 120.66 -0.416 . . . . 0.0 111.259 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 275' ' ' PHE . . . . . 0.502 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -150.0 166.1 30.7 Favored 'General case' 0 C--O 1.243 0.736 0 N-CA-C 112.1 0.408 . . . . 0.0 112.1 177.161 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -129.21 141.83 51.03 Favored 'General case' 0 N--CA 1.438 -1.046 0 C-N-CA 120.535 -0.466 . . . . 0.0 111.382 179.643 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 277' ' ' ILE . . . . . 0.55 HG22 HG22 ' A' ' 267' ' ' ILE . 39.4 pt -136.17 166.38 26.95 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.79 0 CA-C-N 114.649 -1.159 . . . . 0.0 111.227 -171.653 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 278' ' ' CYS . . . . . 0.432 ' C ' ' O ' ' A' ' 277' ' ' ILE . 0.9 OUTLIER -21.3 -93.53 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 123.845 0.858 . . . . 0.0 113.137 -176.831 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 279' ' ' ASP . . . . . 0.444 ' OD1' ' N ' ' A' ' 281' ' ' SER . 60.9 t0 -151.98 116.41 5.04 Favored 'General case' 0 CA--C 1.508 -0.645 0 CA-C-N 116.639 -0.255 . . . . 0.0 110.53 -177.937 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 280' ' ' THR . . . . . 0.732 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 11.8 p -66.38 -26.73 67.4 Favored 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 120.508 -0.477 . . . . 0.0 110.832 175.014 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 281' ' ' SER . . . . . 0.512 ' HA ' ' HD3' ' A' ' 226' ' ' LYS . 0.8 OUTLIER -66.38 -20.73 66.15 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.497 -0.774 . . . . 0.0 109.511 174.582 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -87.51 -9.7 53.79 Favored 'General case' 0 CA--C 1.504 -0.797 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 178.316 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 283' ' ' PHE . . . . . 0.948 ' CE2' HD21 ' A' ' 259' ' ' LEU . 8.0 m-85 -92.18 -82.9 0.31 Allowed 'General case' 0 N--CA 1.44 -0.943 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 170.921 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 284' ' ' SER . . . . . 0.438 ' HB2' ' O ' ' A' ' 283' ' ' PHE . 9.5 t 169.1 -149.18 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 177.973 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -85.74 166.44 16.1 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-O 120.59 0.234 . . . . 0.0 110.414 174.655 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 286' ' ' TYR . . . . . 0.58 ' CE2' HG21 ' A' ' 224' ' ' VAL . 12.9 t80 -119.55 102.04 8.36 Favored 'General case' 0 N--CA 1.467 0.394 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 178.486 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 287' ' ' ILE . . . . . 0.561 ' O ' ' HB3' ' A' ' 288' ' ' ARG . 93.4 mt -66.79 -45.53 87.65 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.824 0 C-N-CA 120.211 -0.596 . . . . 0.0 110.287 -179.085 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 288' ' ' ARG . . . . . 0.561 ' HB3' ' O ' ' A' ' 287' ' ' ILE . 14.7 ptm180 168.4 -173.51 0.02 OUTLIER 'General case' 0 C--O 1.238 0.492 0 O-C-N 123.934 0.771 . . . . 0.0 111.165 -176.45 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 64.96 -147.38 50.99 Favored Glycine 0 C--N 1.338 0.691 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.55 174.313 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 290' ' ' GLY . . . . . 0.513 ' HA3' HG22 ' A' ' 253' ' ' VAL . . . 92.16 127.5 4.16 Favored Glycine 0 N--CA 1.443 -0.87 0 CA-C-O 121.252 0.362 . . . . 0.0 113.399 174.636 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 95.0 mt -115.76 127.69 73.26 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.047 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 170.84 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 7.4 p -98.89 132.06 44.91 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 179.641 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -121.42 122.85 40.7 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-N 115.473 -0.785 . . . . 0.0 110.525 -172.331 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 294' ' ' GLN . . . . . 0.595 ' OE1' ' NZ ' ' A' ' 296' ' ' LYS . 49.0 tt0 -71.93 139.86 48.92 Favored 'General case' 0 CA--C 1.497 -1.086 0 C-N-CA 119.973 -0.691 . . . . 0.0 109.218 172.647 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 295' ' ' VAL . . . . . 0.419 HG21 ' HG3' ' A' ' 264' ' ' PRO . 24.0 t -119.25 109.21 25.85 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 N-CA-C 107.726 -1.213 . . . . 0.0 107.726 172.841 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 296' ' ' LYS . . . . . 0.595 ' NZ ' ' OE1' ' A' ' 294' ' ' GLN . 6.7 mmtm -72.63 98.29 2.32 Favored 'General case' 0 N--CA 1.436 -1.166 0 C-N-CA 119.385 -0.926 . . . . 0.0 109.77 -176.822 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 84.2 t -88.37 149.39 44.57 Favored Pre-proline 0 C--N 1.316 -0.879 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 177.075 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_exo -53.03 132.63 48.52 Favored 'Trans proline' 0 C--N 1.318 -1.076 0 CA-C-N 119.989 1.032 . . . . 0.0 109.651 177.146 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 35.0 mmtp -89.46 -162.92 0.92 Allowed 'General case' 0 C--N 1.315 -0.924 0 CA-C-N 115.626 -0.715 . . . . 0.0 110.49 -174.268 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 21.0 mmtp -51.42 152.45 2.59 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 -177.739 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 98.5 mt -77.21 127.17 38.19 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.84 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 179.764 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 1.1 m -77.58 88.64 3.89 Favored 'General case' 0 C--N 1.311 -1.074 0 CA-C-N 116.207 -0.451 . . . . 0.0 109.946 -178.86 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 87.9 t80 -102.19 130.29 48.81 Favored 'General case' 0 CA--C 1.505 -0.758 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 -179.894 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 64.7 mttm -83.09 106.12 14.63 Favored 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 179.657 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 6.4 m -75.94 156.55 34.1 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.388 -179.271 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 306' ' ' LEU . . . . . 0.964 HD22 ' H ' ' A' ' 306' ' ' LEU . 0.3 OUTLIER -39.46 143.55 0.53 Allowed Pre-proline 0 C--N 1.327 -0.406 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.465 -179.241 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 307' ' ' PRO . . . . . 0.496 ' O ' ' N ' ' A' ' 309' ' ' SER . 76.2 Cg_exo -53.98 -39.55 84.64 Favored 'Trans proline' 0 N--CA 1.497 1.689 0 C-N-CA 122.534 2.156 . . . . 0.0 110.622 -179.155 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -59.91 79.81 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.408 0 CA-C-N 115.302 -0.863 . . . . 0.0 109.915 177.907 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.496 ' N ' ' O ' ' A' ' 307' ' ' PRO . 4.6 m -70.08 145.02 51.94 Favored 'General case' 0 C--N 1.306 -1.301 0 CA-C-N 115.335 -0.848 . . . . 0.0 109.042 -179.125 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 89.3 mt -77.65 130.51 36.93 Favored 'General case' 0 C--N 1.322 -0.63 0 C-N-CA 119.803 -0.759 . . . . 0.0 109.281 179.816 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 59.7 t -121.89 128.42 75.66 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.848 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 177.817 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 78.7 mm-40 . . . . . 0 C--O 1.202 -1.414 0 CA-C-O 118.326 -0.845 . . . . 0.0 110.717 -179.175 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 201' ' ' GLU . . . . . 0.455 ' N ' ' OE1' ' A' ' 204' ' ' GLU . 0.0 OUTLIER . . . . . 0 N--CA 1.476 0.845 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 . . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 86.5 t80 -59.25 -47.12 86.53 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.188 -176.132 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -64.62 -41.14 97.93 Favored Glycine 0 C--N 1.314 -0.642 0 N-CA-C 111.243 -0.743 . . . . 0.0 111.243 178.86 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 204' ' ' GLU . . . . . 0.455 ' OE1' ' N ' ' A' ' 201' ' ' GLU . 2.8 mp0 -59.53 -31.75 69.69 Favored 'General case' 0 C--O 1.237 0.446 0 CA-C-N 116.728 0.264 . . . . 0.0 111.404 -176.998 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 58.3 mt-10 -62.02 -35.81 79.68 Favored 'General case' 0 C--N 1.317 -0.841 0 N-CA-C 109.675 -0.491 . . . . 0.0 109.675 178.103 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 206' ' ' MET . . . . . 0.478 ' HG3' ' N ' ' A' ' 207' ' ' VAL . 62.9 tpp -92.11 161.14 14.88 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.733 177.376 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 207' ' ' VAL . . . . . 0.607 HG12 HG23 ' A' ' 209' ' ' THR . 17.8 t -88.82 128.23 41.11 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.947 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 176.407 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 208' ' ' LEU . . . . . 0.449 ' HB3' ' H ' ' A' ' 213' ' ' GLY . 90.4 mt -70.78 75.38 0.61 Allowed 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 -179.593 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 209' ' ' THR . . . . . 0.607 HG23 HG12 ' A' ' 207' ' ' VAL . 2.2 p -118.41 -54.73 2.27 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.505 -0.77 . . . . 0.0 111.077 -177.349 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 210' ' ' ASP . . . . . 0.402 ' CG ' ' N ' ' A' ' 211' ' ' SER . 19.8 p-10 -63.59 -39.65 94.92 Favored 'General case' 0 CA--C 1.507 -0.705 0 N-CA-C 107.356 -1.35 . . . . 0.0 107.356 171.772 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 211' ' ' SER . . . . . 0.614 ' OG ' ' NZ ' ' A' ' 300' ' ' LYS . 9.1 m -114.98 94.31 4.69 Favored 'General case' 0 N--CA 1.43 -1.463 0 CA-C-N 113.732 -1.577 . . . . 0.0 108.258 177.149 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 59.5 t-20 -83.0 107.76 15.82 Favored 'General case' 0 C--N 1.322 -0.605 0 C-N-CA 120.613 -0.435 . . . . 0.0 111.258 -173.702 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 213' ' ' GLY . . . . . 0.449 ' H ' ' HB3' ' A' ' 208' ' ' LEU . . . 47.57 45.78 23.47 Favored Glycine 0 C--O 1.236 0.26 0 N-CA-C 111.449 -0.661 . . . . 0.0 111.449 177.204 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -83.82 97.89 9.42 Favored 'General case' 0 N--CA 1.445 -0.715 0 C-N-CA 119.851 -0.739 . . . . 0.0 111.032 -177.844 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -113.07 144.04 30.35 Favored Pre-proline 0 C--N 1.316 -0.889 0 N-CA-C 107.28 -1.378 . . . . 0.0 107.28 170.22 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -55.69 131.12 44.2 Favored 'Trans proline' 0 C--N 1.3 -1.997 0 N-CA-C 109.672 -0.934 . . . . 0.0 109.672 -179.026 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 217' ' ' LEU . . . . . 0.532 ' O ' ' HA ' ' A' ' 293' ' ' SER . 0.5 OUTLIER -87.64 125.98 34.69 Favored 'General case' 0 CA--C 1.493 -1.233 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 177.572 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 3.0 m -115.43 132.01 56.75 Favored 'General case' 0 C--N 1.313 -1.011 0 O-C-N 123.445 0.465 . . . . 0.0 110.097 -176.2 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 219' ' ' ALA . . . . . 0.436 ' HA ' ' HB1' ' A' ' 238' ' ' ALA . . . -134.4 142.66 47.23 Favored 'General case' 0 N--CA 1.449 -0.516 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.02 -178.804 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 220' ' ' MET . . . . . 0.649 ' SD ' HG12 ' A' ' 291' ' ' ILE . 99.6 mmm -72.18 131.93 43.44 Favored 'General case' 0 C--O 1.244 0.764 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.255 175.829 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 80.5 t -85.11 128.14 39.29 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.999 0 N-CA-C 108.971 -0.752 . . . . 0.0 108.971 178.798 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 222' ' ' SER . . . . . 0.491 ' OG ' ' N ' ' A' ' 223' ' ' MET . 0.1 OUTLIER -79.82 -72.66 0.39 Allowed 'General case' 0 N--CA 1.434 -1.247 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 177.924 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 223' ' ' MET . . . . . 0.491 ' N ' ' OG ' ' A' ' 222' ' ' SER . 8.6 ptm -137.69 147.15 44.59 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.703 -0.68 . . . . 0.0 111.646 175.612 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 224' ' ' VAL . . . . . 0.845 HG13 HG12 ' A' ' 232' ' ' VAL . 59.6 t -122.07 130.16 74.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 175.447 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 41.0 p -77.31 134.72 38.44 Favored 'General case' 0 C--N 1.321 -0.668 0 C-N-CA 120.604 -0.438 . . . . 0.0 110.775 179.451 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 21.8 tptm -77.63 65.66 3.18 Favored 'General case' 0 C--O 1.24 0.596 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 174.784 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 227' ' ' ASP . . . . . 0.472 ' N ' ' OG1' ' A' ' 280' ' ' THR . 2.3 t0 -147.33 177.41 9.24 Favored 'General case' 0 C--O 1.245 0.816 0 CA-C-N 115.41 -0.814 . . . . 0.0 111.251 -171.802 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 228' ' ' ASN . . . . . 0.61 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 16.0 p-10 -144.13 124.39 7.58 Favored Pre-proline 0 C--N 1.319 -0.754 0 CA-C-N 115.525 -0.762 . . . . 0.0 110.82 175.755 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 229' ' ' PRO . . . . . 0.61 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 34.1 Cg_exo -60.18 143.18 33.09 Favored 'Cis proline' 0 N--CA 1.489 1.256 0 C-N-CA 123.14 -1.608 . . . . 0.0 110.926 -1.192 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 230' ' ' GLY . . . . . 0.756 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -74.79 131.06 12.25 Favored Glycine 0 C--N 1.296 -1.681 0 N-CA-C 108.184 -1.966 . . . . 0.0 108.184 176.221 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.1 p -124.96 133.39 69.6 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.791 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 232' ' ' VAL . . . . . 0.845 HG12 HG13 ' A' ' 224' ' ' VAL . 0.7 OUTLIER -131.01 155.57 42.07 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.224 0 C-N-CA 120.27 -0.572 . . . . 0.0 110.863 -176.446 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 63.3 m -108.85 135.08 50.64 Favored 'General case' 0 C--N 1.307 -1.254 0 CA-C-N 115.247 -0.888 . . . . 0.0 108.636 176.553 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 44.6 m -105.64 151.11 24.8 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 -177.334 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 38.6 tp -56.24 132.11 49.77 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 -175.528 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 236' ' ' ASP . . . . . 0.541 ' O ' ' NH2' ' A' ' 239' ' ' ARG . 23.0 p-10 -52.42 -44.23 65.31 Favored 'General case' 0 N--CA 1.474 0.734 0 CA-C-O 121.072 0.463 . . . . 0.0 110.606 -174.994 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 237' ' ' GLU . . . . . 0.413 ' HA ' ' NH2' ' A' ' 239' ' ' ARG . 99.6 mt-10 -64.59 -34.91 79.36 Favored 'General case' 0 C--N 1.302 -1.466 0 CA-C-N 115.641 -0.708 . . . . 0.0 110.421 178.62 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 238' ' ' ALA . . . . . 0.436 ' HB1' ' HA ' ' A' ' 219' ' ' ALA . . . -79.76 73.63 6.48 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 116.004 -0.544 . . . . 0.0 112.176 -174.759 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 239' ' ' ARG . . . . . 0.541 ' NH2' ' O ' ' A' ' 236' ' ' ASP . 0.0 OUTLIER -58.2 90.19 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.024 0.44 . . . . 0.0 110.607 176.477 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 240' ' ' HIS . . . . . 0.473 ' O ' ' HB3' ' A' ' 217' ' ' LEU . 9.1 p80 -55.19 -48.57 73.63 Favored 'General case' 0 C--O 1.217 -0.629 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.249 -175.411 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 78.3 24.56 63.18 Favored Glycine 0 C--N 1.311 -0.858 0 N-CA-C 110.874 -0.891 . . . . 0.0 110.874 179.25 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 242' ' ' PHE . . . . . 0.429 ' CD1' ' HB2' ' A' ' 294' ' ' GLN . 9.3 m-30 -80.19 144.16 33.2 Favored 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 177.869 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -116.03 158.42 23.15 Favored 'General case' 0 C--N 1.312 -1.052 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.737 -177.695 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -56.58 118.03 4.45 Favored 'General case' 0 C--N 1.311 -1.069 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 178.618 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 245' ' ' GLY . . . . . 0.476 ' HA2' ' CG ' ' A' ' 266' ' ' GLU . . . 86.85 5.95 80.4 Favored Glycine 0 C--O 1.243 0.672 0 C-N-CA 120.847 -0.692 . . . . 0.0 111.892 -179.531 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -83.14 163.99 20.5 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-N 117.199 0.499 . . . . 0.0 109.913 177.676 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 247' ' ' PHE . . . . . 0.432 ' HA ' ' O ' ' A' ' 265' ' ' MET . 74.9 m-85 -111.18 135.79 51.19 Favored 'General case' 0 C--O 1.238 0.483 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -173.521 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.471 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 3.1 m -131.13 161.92 40.17 Favored 'Isoleucine or valine' 0 C--O 1.237 0.421 0 CA-C-O 121.063 0.458 . . . . 0.0 111.996 178.62 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 2.5 m -125.9 165.09 19.36 Favored 'General case' 0 C--N 1.321 -0.664 0 C-N-CA 124.773 1.229 . . . . 0.0 108.115 173.506 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 250' ' ' PHE . . . . . 0.628 ' CE1' HD22 ' A' ' 259' ' ' LEU . 96.5 m-85 -124.31 156.78 36.37 Favored 'General case' 0 C--N 1.317 -0.816 0 N-CA-C 110.505 -0.183 . . . . 0.0 110.505 -176.115 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 1.2 m -156.62 161.27 39.92 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.222 -0.444 . . . . 0.0 109.823 176.368 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 16.2 mt-10 51.85 28.63 5.19 Favored 'General case' 0 C--N 1.314 -0.939 0 N-CA-C 112.305 0.483 . . . . 0.0 112.305 177.865 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 0.543 HG22 ' CA ' ' A' ' 290' ' ' GLY . 3.2 t -92.78 127.4 44.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 176.363 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 77.3 mt-30 -91.27 138.16 31.81 Favored 'General case' 0 C--O 1.241 0.609 0 CA-C-O 120.827 0.346 . . . . 0.0 110.585 -177.508 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 255' ' ' GLY . . . . . 0.54 ' CA ' HD12 ' A' ' 287' ' ' ILE . . . 76.23 -58.45 3.22 Favored Glycine 0 C--N 1.319 -0.376 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 -179.052 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 256' ' ' MET . . . . . 0.423 ' SD ' HD11 ' A' ' 259' ' ' LEU . 30.7 ttm -77.32 50.36 0.77 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.429 0.633 . . . . 0.0 109.603 176.619 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 46.2 pt -71.11 -18.05 20.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-N 115.233 -0.894 . . . . 0.0 111.218 -175.12 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 258' ' ' GLN . . . . . 0.571 ' HG3' ' HG ' ' A' ' 262' ' ' CYS . 68.5 tp60 -54.86 -38.37 67.39 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 177.897 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 259' ' ' LEU . . . . . 0.822 HD21 ' CE2' ' A' ' 283' ' ' PHE . 93.7 mt -62.22 -40.48 96.24 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.506 -0.77 . . . . 0.0 110.197 176.343 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -59.49 -40.24 86.37 Favored 'General case' 0 CA--C 1.51 -0.59 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 -179.186 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -101.97 21.99 39.85 Favored Glycine 0 CA--C 1.524 0.656 0 CA-C-N 115.927 -0.578 . . . . 0.0 112.049 -179.312 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 262' ' ' CYS . . . . . 0.571 ' HG ' ' HG3' ' A' ' 258' ' ' GLN . 1.3 m -95.95 149.35 21.66 Favored 'General case' 0 C--O 1.236 0.382 0 CA-C-N 117.33 0.565 . . . . 0.0 111.488 -179.429 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 263' ' ' GLN . . . . . 0.525 ' CD ' ' H ' ' A' ' 263' ' ' GLN . 16.6 mp0 -67.66 156.07 89.82 Favored Pre-proline 0 C--N 1.325 -0.475 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 172.572 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 264' ' ' PRO . . . . . 0.471 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 37.3 Cg_endo -62.67 143.09 91.77 Favored 'Trans proline' 0 C--N 1.308 -1.575 0 C-N-CA 120.722 0.948 . . . . 0.0 110.25 179.131 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 265' ' ' MET . . . . . 0.432 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 22.5 ptp -130.55 155.01 47.23 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.663 -173.513 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 266' ' ' GLU . . . . . 0.476 ' CG ' ' HA2' ' A' ' 245' ' ' GLY . 39.7 tt0 -71.8 144.56 49.11 Favored 'General case' 0 C--O 1.239 0.535 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 177.777 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 267' ' ' ILE . . . . . 0.646 HD12 ' C ' ' A' ' 267' ' ' ILE . 2.1 pp -128.27 162.06 35.46 Favored 'Isoleucine or valine' 0 C--O 1.249 1.043 0 N-CA-C 113.608 0.966 . . . . 0.0 113.608 -175.221 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 25.7 mtpp -118.7 109.42 16.08 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 114.762 -1.108 . . . . 0.0 109.66 -178.406 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 8.2 m -80.65 96.04 2.71 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.457 0 C-N-CA 120.275 -0.57 . . . . 0.0 111.268 178.103 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 98.4 mt -67.25 -40.59 86.26 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.406 0.622 . . . . 0.0 110.131 178.128 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -139.64 177.54 20.38 Favored Glycine 0 C--N 1.315 -0.609 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.29 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_endo -60.1 -31.54 93.47 Favored 'Trans proline' 0 C--N 1.302 -1.881 0 C-N-CA 121.772 1.648 . . . . 0.0 111.233 -178.769 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 22.9 m-85 -123.94 11.08 8.93 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.422 179.383 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -122.52 125.67 46.23 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 116.025 -0.534 . . . . 0.0 109.654 -176.276 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 275' ' ' PHE . . . . . 0.545 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -138.68 164.02 30.61 Favored 'General case' 0 CA--C 1.501 -0.931 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 -179.611 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 276' ' ' SER . . . . . 0.524 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 6.4 p -137.49 159.07 42.97 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.456 -178.082 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 277' ' ' ILE . . . . . 0.694 ' C ' HD12 ' A' ' 277' ' ' ILE . 2.5 pp -138.05 -173.74 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 CA-C-N 114.977 -1.01 . . . . 0.0 109.948 -175.825 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 278' ' ' CYS . . . . . 0.46 ' O ' ' HA ' ' A' ' 229' ' ' PRO . 1.2 p -46.87 -93.83 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.304 0 O-C-N 123.324 0.39 . . . . 0.0 111.812 -179.694 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -137.55 126.75 24.55 Favored 'General case' 0 CA--C 1.514 -0.406 0 N-CA-C 109.541 -0.541 . . . . 0.0 109.541 -179.323 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 280' ' ' THR . . . . . 0.756 HG23 ' HA3' ' A' ' 230' ' ' GLY . 25.0 p -69.56 -23.76 63.61 Favored 'General case' 0 C--N 1.317 -0.808 0 C-N-CA 119.436 -0.906 . . . . 0.0 108.682 171.06 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -61.85 -21.05 64.34 Favored 'General case' 0 N--CA 1.435 -1.199 0 CA-C-N 114.635 -1.166 . . . . 0.0 108.812 173.802 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 29.3 t-20 -89.22 -9.13 51.92 Favored 'General case' 0 CA--C 1.509 -0.621 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.481 175.971 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 283' ' ' PHE . . . . . 0.822 ' CE2' HD21 ' A' ' 259' ' ' LEU . 19.5 m-30 -95.79 -87.91 0.28 Allowed 'General case' 0 N--CA 1.444 -0.74 0 CA-C-O 121.524 0.678 . . . . 0.0 110.456 178.396 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 284' ' ' SER . . . . . 0.418 ' CB ' ' HA ' ' A' ' 256' ' ' MET . 0.0 OUTLIER 170.3 -170.22 0.02 OUTLIER 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 107.689 -1.226 . . . . 0.0 107.689 -173.44 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -94.06 131.37 39.62 Favored 'General case' 0 N--CA 1.471 0.623 0 CA-C-N 118.646 0.657 . . . . 0.0 112.766 -176.052 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 286' ' ' TYR . . . . . 0.474 ' O ' ' CD2' ' A' ' 286' ' ' TYR . 60.8 t80 -68.87 87.04 0.35 Allowed 'General case' 0 N--CA 1.472 0.639 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.177 177.399 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 287' ' ' ILE . . . . . 0.577 ' O ' ' HG3' ' A' ' 288' ' ' ARG . 87.5 mt -69.94 -48.05 65.58 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.723 0 C-N-CA 120.298 -0.561 . . . . 0.0 110.806 175.405 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 288' ' ' ARG . . . . . 0.577 ' HG3' ' O ' ' A' ' 287' ' ' ILE . 43.8 mtp180 -170.52 170.67 6.78 Favored 'General case' 0 N--CA 1.47 0.574 0 N-CA-C 112.986 0.735 . . . . 0.0 112.986 -179.114 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 56.48 -143.55 38.51 Favored Glycine 0 N--CA 1.466 0.681 0 CA-C-N 113.77 -1.559 . . . . 0.0 113.199 167.483 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 290' ' ' GLY . . . . . 0.543 ' CA ' HG22 ' A' ' 253' ' ' VAL . . . 100.71 130.31 6.99 Favored Glycine 0 N--CA 1.441 -1.009 0 CA-C-O 121.163 0.313 . . . . 0.0 112.506 178.93 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 291' ' ' ILE . . . . . 0.649 HG12 ' SD ' ' A' ' 220' ' ' MET . 95.2 mt -116.29 129.82 72.08 Favored 'Isoleucine or valine' 0 C--O 1.244 0.769 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 171.675 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 7.2 p -109.31 130.35 62.47 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.064 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 176.789 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 293' ' ' SER . . . . . 0.532 ' HA ' ' O ' ' A' ' 217' ' ' LEU . 3.2 m -131.08 138.73 49.69 Favored 'General case' 0 N--CA 1.441 -0.875 0 C-N-CA 120.43 -0.508 . . . . 0.0 111.558 -175.124 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 294' ' ' GLN . . . . . 0.429 ' HB2' ' CD1' ' A' ' 242' ' ' PHE . 2.7 tm0? -76.89 148.99 36.12 Favored 'General case' 0 C--N 1.316 -0.88 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 173.29 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 54.2 t -109.62 130.0 63.47 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.031 0 C-N-CA 120.506 -0.477 . . . . 0.0 109.99 -178.302 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 296' ' ' LYS . . . . . 0.515 ' O ' ' HG2' ' A' ' 296' ' ' LYS . 0.0 OUTLIER -62.53 103.54 0.42 Allowed 'General case' 0 N--CA 1.44 -0.941 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 177.797 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 297' ' ' VAL . . . . . 0.556 HG22 ' H ' ' A' ' 299' ' ' LYS . 2.7 p -59.6 127.92 85.53 Favored Pre-proline 0 C--N 1.315 -0.909 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.299 -174.46 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -66.02 -22.79 54.68 Favored 'Trans proline' 0 N--CA 1.497 1.735 0 C-N-CA 122.3 2.0 . . . . 0.0 111.067 179.879 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 299' ' ' LYS . . . . . 0.556 ' H ' HG22 ' A' ' 297' ' ' VAL . 46.9 mmtm -97.25 143.26 28.21 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.74 -178.799 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 300' ' ' LYS . . . . . 0.614 ' NZ ' ' OG ' ' A' ' 211' ' ' SER . 11.7 mmtp -119.74 150.09 40.95 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.071 177.161 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 43.8 pt -64.83 130.65 30.22 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.898 -178.048 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 29.3 m -125.92 153.18 44.61 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.209 -176.85 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 89.3 m-85 -125.8 149.21 48.78 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 116.136 -0.484 . . . . 0.0 109.847 -177.738 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 49.2 mmtm -78.01 141.15 39.09 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 116.579 -0.282 . . . . 0.0 110.686 -178.293 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -128.64 162.81 26.47 Favored 'General case' 0 C--O 1.244 0.806 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.321 179.541 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 306' ' ' LEU . . . . . 0.717 ' H ' HD12 ' A' ' 306' ' ' LEU . 0.0 OUTLIER -88.21 160.48 45.66 Favored Pre-proline 0 C--N 1.323 -0.561 0 N-CA-C 109.295 -0.632 . . . . 0.0 109.295 176.126 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 78.4 Cg_exo -54.65 -39.89 86.8 Favored 'Trans proline' 0 N--CA 1.497 1.711 0 C-N-CA 122.161 1.908 . . . . 0.0 111.112 -179.824 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -150.62 152.56 34.22 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.272 176.518 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 13.2 p -78.93 168.37 19.8 Favored 'General case' 0 C--N 1.314 -0.946 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 175.517 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 85.1 mt -101.19 131.18 47.29 Favored 'General case' 0 C--N 1.324 -0.536 0 C-N-CA 120.541 -0.464 . . . . 0.0 110.239 177.888 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 2.3 t -123.35 132.68 70.97 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.004 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 -178.568 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.205 -1.268 0 CA-C-O 118.26 -0.876 . . . . 0.0 110.586 -179.633 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 201' ' ' GLU . . . . . 0.556 ' O ' ' N ' ' A' ' 203' ' ' GLY . 2.2 pm0 . . . . . 0 N--CA 1.483 1.178 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 202' ' ' PHE . . . . . 0.415 ' O ' ' N ' ' A' ' 204' ' ' GLU . 91.5 m-85 59.57 -62.31 0.05 OUTLIER 'General case' 0 N--CA 1.467 0.407 0 C-N-CA 122.697 0.399 . . . . 0.0 110.748 -178.022 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 203' ' ' GLY . . . . . 0.556 ' N ' ' O ' ' A' ' 201' ' ' GLU . . . -67.75 47.5 0.32 Allowed Glycine 0 N--CA 1.466 0.666 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 176.603 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 204' ' ' GLU . . . . . 0.415 ' N ' ' O ' ' A' ' 202' ' ' PHE . 48.8 mt-10 -70.89 -49.95 40.38 Favored 'General case' 0 C--N 1.319 -0.746 0 O-C-N 122.177 -0.602 . . . . 0.0 111.26 -177.186 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -71.71 -52.29 18.55 Favored 'General case' 0 C--O 1.235 0.314 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 178.894 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 99.6 mmm -103.3 129.6 50.35 Favored 'General case' 0 CA--C 1.503 -0.833 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 173.683 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 5.2 t -86.65 111.18 21.12 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.905 0 C-N-CA 120.304 -0.558 . . . . 0.0 110.354 -175.869 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 84.7 mt -81.73 81.27 7.83 Favored 'General case' 0 N--CA 1.442 -0.84 0 CA-C-N 115.564 -0.744 . . . . 0.0 109.304 -179.831 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 5.8 m -102.2 32.82 3.34 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 115.556 -0.747 . . . . 0.0 109.973 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -61.11 -36.66 80.29 Favored 'General case' 0 CA--C 1.507 -0.68 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.383 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 211' ' ' SER . . . . . 0.435 ' HB3' ' CD ' ' A' ' 214' ' ' GLU . 10.9 m -91.5 90.06 7.48 Favored 'General case' 0 N--CA 1.435 -1.206 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 175.824 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 59.7 t30 -113.49 98.94 7.39 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.712 -0.677 . . . . 0.0 109.74 -179.45 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 48.03 60.94 5.22 Favored Glycine 0 C--O 1.237 0.287 0 N-CA-C 109.365 -1.494 . . . . 0.0 109.365 -176.108 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 214' ' ' GLU . . . . . 0.435 ' CD ' ' HB3' ' A' ' 211' ' ' SER . 65.4 mt-10 -60.65 137.5 58.17 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-O 120.758 0.314 . . . . 0.0 111.194 -173.656 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 90.1 mt-30 -59.99 159.57 19.97 Favored Pre-proline 0 C--O 1.24 0.583 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 174.547 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -56.8 144.84 86.2 Favored 'Trans proline' 0 C--N 1.304 -1.804 0 C-N-CA 121.743 1.629 . . . . 0.0 110.669 -178.824 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 217' ' ' LEU . . . . . 0.406 ' HB3' ' O ' ' A' ' 240' ' ' HIS . 0.2 OUTLIER -58.64 138.25 57.05 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.327 -177.056 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 8.5 t -151.72 152.61 32.98 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.012 -175.683 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -143.57 160.38 40.73 Favored 'General case' 0 C--O 1.244 0.797 0 CA-C-O 120.918 0.389 . . . . 0.0 110.95 178.413 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 97.2 mtp -71.57 136.73 47.58 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.463 -0.79 . . . . 0.0 109.239 176.474 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 91.1 t -83.7 129.48 37.46 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.052 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 178.027 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 74.9 m -79.79 -73.05 0.37 Allowed 'General case' 0 N--CA 1.432 -1.34 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 177.704 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 223' ' ' MET . . . . . 0.477 ' SD ' ' HB ' ' A' ' 233' ' ' THR . 1.0 OUTLIER -139.71 161.95 36.31 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.111 172.771 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 224' ' ' VAL . . . . . 0.725 HG11 ' SD ' ' A' ' 256' ' ' MET . 69.6 t -127.37 129.8 70.69 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 175.749 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 225' ' ' THR . . . . . 0.509 ' O ' HG21 ' A' ' 280' ' ' THR . 75.4 p -78.88 131.25 36.35 Favored 'General case' 0 C--O 1.225 -0.225 0 C-N-CA 120.08 -0.648 . . . . 0.0 110.163 177.615 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 226' ' ' LYS . . . . . 0.605 ' HE3' ' HA ' ' A' ' 281' ' ' SER . 0.0 OUTLIER -77.72 52.28 1.0 Allowed 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 120.723 0.297 . . . . 0.0 110.868 -179.012 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 227' ' ' ASP . . . . . 0.419 ' CG ' ' H ' ' A' ' 228' ' ' ASN . 42.3 t0 -131.29 -179.8 5.57 Favored 'General case' 0 C--O 1.242 0.674 0 CA-C-O 120.862 0.363 . . . . 0.0 111.952 -178.562 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 228' ' ' ASN . . . . . 0.474 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 1.5 p30 -137.6 125.07 13.95 Favored Pre-proline 0 CA--C 1.539 0.536 0 CA-C-N 115.162 -0.926 . . . . 0.0 109.634 175.073 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 229' ' ' PRO . . . . . 0.474 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 44.9 Cg_endo -65.63 143.87 61.41 Favored 'Cis proline' 0 N--CA 1.49 1.314 0 C-N-CA 123.121 -1.616 . . . . 0.0 109.984 -0.46 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 230' ' ' GLY . . . . . 0.559 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -76.26 136.9 20.34 Favored Glycine 0 C--N 1.305 -1.157 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 -177.301 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 231' ' ' VAL . . . . . 0.482 HG23 HD12 ' A' ' 270' ' ' LEU . 1.6 p -125.74 133.84 68.1 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 175.82 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 232' ' ' VAL . . . . . 0.618 ' HB ' HG22 ' A' ' 224' ' ' VAL . 0.7 OUTLIER -132.42 156.36 42.33 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.81 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.241 -176.713 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 233' ' ' THR . . . . . 0.477 ' HB ' ' SD ' ' A' ' 223' ' ' MET . 24.4 m -109.65 143.93 38.71 Favored 'General case' 0 N--CA 1.441 -0.914 0 CA-C-N 115.848 -0.614 . . . . 0.0 109.675 176.278 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 34.2 m -107.58 157.55 17.96 Favored 'General case' 0 C--N 1.31 -1.127 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 -179.552 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 33.2 tp -57.19 123.27 14.74 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 -178.062 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 236' ' ' ASP . . . . . 0.405 ' HA ' ' CD1' ' A' ' 273' ' ' TYR . 8.4 p-10 -59.7 -32.71 70.77 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.211 0.529 . . . . 0.0 111.05 -175.717 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -66.89 -32.07 73.09 Favored 'General case' 0 C--N 1.303 -1.42 0 CA-C-N 115.751 -0.658 . . . . 0.0 112.047 177.444 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -109.08 132.99 53.58 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 120.777 0.322 . . . . 0.0 111.647 -176.902 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 90.2 mtm-85 -91.39 133.6 35.33 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 175.989 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 240' ' ' HIS . . . . . 0.623 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 3.0 p80 -66.57 -40.55 89.02 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.749 0.309 . . . . 0.0 111.208 -179.516 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 82.34 20.71 61.83 Favored Glycine 0 C--N 1.316 -0.544 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 -176.976 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 242' ' ' PHE . . . . . 0.502 ' CD2' ' HB2' ' A' ' 240' ' ' HIS . 7.6 m-30 -92.31 146.41 23.72 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.184 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 71.4 mm-40 -109.27 160.07 16.43 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.512 171.471 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 19.9 m -64.6 122.36 16.63 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 175.717 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 95.04 0.14 63.87 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 111.564 -0.614 . . . . 0.0 111.564 -178.668 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 48.6 t0 -76.76 163.93 26.34 Favored 'General case' 0 C--O 1.238 0.489 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 176.947 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 247' ' ' PHE . . . . . 0.459 ' HA ' ' O ' ' A' ' 265' ' ' MET . 83.1 m-85 -110.27 129.82 55.66 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.522 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.494 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.3 m -129.98 159.45 41.99 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 C-N-CA 120.357 -0.537 . . . . 0.0 111.519 -178.162 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 249' ' ' SER . . . . . 0.651 ' OG ' HG21 ' A' ' 295' ' ' VAL . 40.7 m -122.65 159.6 27.55 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 114.308 -1.315 . . . . 0.0 108.81 172.926 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 250' ' ' PHE . . . . . 0.605 ' CB ' ' HB3' ' A' ' 259' ' ' LEU . 79.1 m-85 -118.79 157.82 26.82 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.271 -174.167 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 4.8 m -151.59 157.48 42.25 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.324 178.078 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER 50.62 27.44 2.94 Favored 'General case' 0 C--N 1.308 -1.196 0 N-CA-C 112.87 0.693 . . . . 0.0 112.87 174.995 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 0.478 HG22 ' CA ' ' A' ' 290' ' ' GLY . 12.6 t -88.81 129.23 40.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 175.237 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 254' ' ' GLN . . . . . 0.477 ' NE2' ' N ' ' A' ' 254' ' ' GLN . 1.5 mp0 -97.27 138.91 34.03 Favored 'General case' 0 C--O 1.242 0.665 0 C-N-CA 120.737 -0.385 . . . . 0.0 110.84 -178.723 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 80.55 -55.66 4.69 Favored Glycine 0 C--O 1.238 0.358 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 -176.3 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 256' ' ' MET . . . . . 0.725 ' SD ' HG11 ' A' ' 224' ' ' VAL . 3.4 ttm -84.55 48.18 1.48 Allowed 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 175.973 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 257' ' ' ILE . . . . . 0.416 ' O ' ' HB2' ' A' ' 260' ' ' ASN . 48.8 pt -69.37 -20.6 24.28 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.758 0 CA-C-N 114.745 -1.116 . . . . 0.0 110.542 -174.544 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 258' ' ' GLN . . . . . 0.472 ' O ' ' SG ' ' A' ' 262' ' ' CYS . 2.5 mp0 -54.14 -35.1 61.87 Favored 'General case' 0 C--N 1.318 -0.801 0 N-CA-C 108.351 -0.981 . . . . 0.0 108.351 177.297 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 259' ' ' LEU . . . . . 0.94 HD21 ' CE2' ' A' ' 283' ' ' PHE . 92.5 mt -62.04 -41.24 97.9 Favored 'General case' 0 N--CA 1.445 -0.683 0 CA-C-N 115.399 -0.819 . . . . 0.0 109.915 176.154 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 260' ' ' ASN . . . . . 0.431 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 97.5 m-20 -60.71 -40.05 90.82 Favored 'General case' 0 CA--C 1.512 -0.49 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 -179.618 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -100.13 11.74 60.35 Favored Glycine 0 CA--C 1.524 0.62 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.872 -178.45 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 262' ' ' CYS . . . . . 0.472 ' SG ' ' O ' ' A' ' 258' ' ' GLN . 1.3 m -88.37 152.71 21.73 Favored 'General case' 0 CA--C 1.51 -0.579 0 CA-C-N 116.988 0.394 . . . . 0.0 110.787 -178.185 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 47.7 mt-30 -72.24 160.84 81.67 Favored Pre-proline 0 C--N 1.32 -0.678 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 173.331 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 264' ' ' PRO . . . . . 0.494 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 20.9 Cg_exo -61.47 143.75 97.56 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 N-CA-C 109.224 -1.106 . . . . 0.0 109.224 178.628 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 265' ' ' MET . . . . . 0.459 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 24.3 ptp -133.32 158.19 43.6 Favored 'General case' 0 C--N 1.317 -0.842 0 C-N-CA 120.98 -0.288 . . . . 0.0 111.695 -174.015 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 66.4 tt0 -71.25 139.18 49.94 Favored 'General case' 0 CA--C 1.507 -0.679 0 O-C-N 123.664 0.603 . . . . 0.0 109.718 176.372 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 267' ' ' ILE . . . . . 0.746 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.9 pp -131.74 160.14 42.6 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.865 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.274 178.979 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 64.7 mttp -130.21 125.84 35.91 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.135 176.41 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 17.9 m -84.73 106.6 14.97 Favored 'Isoleucine or valine' 0 C--O 1.235 0.315 0 CA-C-O 121.18 0.514 . . . . 0.0 111.837 -177.436 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 270' ' ' LEU . . . . . 0.482 HD12 HG23 ' A' ' 231' ' ' VAL . 91.0 mt -66.27 -40.3 90.04 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.458 -0.792 . . . . 0.0 109.45 177.451 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -147.16 -175.46 20.06 Favored Glycine 0 C--N 1.321 -0.299 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 179.069 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 272' ' ' PRO . . . . . 0.623 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 36.4 Cg_endo -61.99 -33.93 82.1 Favored 'Trans proline' 0 C--N 1.307 -1.625 0 C-N-CA 121.778 1.652 . . . . 0.0 111.153 -177.619 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 273' ' ' TYR . . . . . 0.405 ' CD1' ' HA ' ' A' ' 236' ' ' ASP . 93.9 m-85 -119.19 6.51 11.24 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.984 -0.553 . . . . 0.0 112.18 -179.751 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 2.9 p -119.95 126.22 50.33 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 120.712 0.291 . . . . 0.0 110.506 179.323 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 275' ' ' PHE . . . . . 0.566 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -138.0 162.93 32.84 Favored 'General case' 0 CA--C 1.499 -0.992 0 C-N-CA 120.766 -0.374 . . . . 0.0 111.987 -179.744 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 276' ' ' SER . . . . . 0.467 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 4.7 p -132.47 151.2 51.98 Favored 'General case' 0 N--CA 1.433 -1.277 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.921 -173.204 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 277' ' ' ILE . . . . . 0.746 HG22 HG22 ' A' ' 267' ' ' ILE . 2.2 pp -138.19 175.57 8.48 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 CA-C-N 114.824 -1.08 . . . . 0.0 110.505 -175.684 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 278' ' ' CYS . . . . . 0.444 ' N ' HD12 ' A' ' 277' ' ' ILE . 1.4 p -42.58 -88.44 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.435 0 N-CA-C 112.744 0.646 . . . . 0.0 112.744 -179.707 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 279' ' ' ASP . . . . . 0.455 ' O ' ' HB2' ' A' ' 282' ' ' ASN . 18.1 t0 -145.75 121.04 10.23 Favored 'General case' 0 CA--C 1.515 -0.371 0 CA-C-O 120.767 0.317 . . . . 0.0 111.109 -176.277 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 280' ' ' THR . . . . . 0.657 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 35.9 p -68.22 -25.75 65.36 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-O 121.26 0.553 . . . . 0.0 110.534 176.546 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 281' ' ' SER . . . . . 0.605 ' HA ' ' HE3' ' A' ' 226' ' ' LYS . 0.7 OUTLIER -69.76 -12.86 61.96 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.459 -0.791 . . . . 0.0 109.519 176.06 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 282' ' ' ASN . . . . . 0.455 ' HB2' ' O ' ' A' ' 279' ' ' ASP . 2.0 m-80 -88.06 -6.06 58.15 Favored 'General case' 0 CA--C 1.509 -0.627 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 173.604 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 283' ' ' PHE . . . . . 0.94 ' CE2' HD21 ' A' ' 259' ' ' LEU . 6.0 m-85 -100.41 -71.8 0.69 Allowed 'General case' 0 N--CA 1.444 -0.738 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 172.29 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 1.6 p 167.02 -99.04 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.466 0 CA-C-N 115.144 -0.935 . . . . 0.0 110.213 178.81 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 285' ' ' ASP . . . . . 0.519 ' O ' ' N ' ' A' ' 256' ' ' MET . 48.4 t0 -150.74 163.33 38.85 Favored 'General case' 0 C--O 1.214 -0.815 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 177.416 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 286' ' ' TYR . . . . . 0.434 ' CE2' ' HA ' ' A' ' 288' ' ' ARG . 71.6 t80 -100.54 124.1 45.65 Favored 'General case' 0 C--N 1.318 -0.774 0 C-N-CA 121.1 -0.24 . . . . 0.0 110.841 -179.777 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 287' ' ' ILE . . . . . 0.435 ' O ' ' CG ' ' A' ' 288' ' ' ARG . 96.6 mt -100.06 -61.5 2.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 C-N-CA 120.77 -0.372 . . . . 0.0 110.455 173.696 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 288' ' ' ARG . . . . . 0.435 ' CG ' ' O ' ' A' ' 287' ' ' ILE . 54.6 mtp180 -166.67 176.79 6.96 Favored 'General case' 0 C--O 1.241 0.617 0 CA-C-O 121.135 0.493 . . . . 0.0 111.787 179.064 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 67.95 -156.27 52.8 Favored Glycine 0 CA--C 1.508 -0.399 0 CA-C-N 115.284 -0.871 . . . . 0.0 111.104 174.893 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 290' ' ' GLY . . . . . 0.478 ' CA ' HG22 ' A' ' 253' ' ' VAL . . . 109.91 123.81 4.68 Favored Glycine 0 N--CA 1.443 -0.893 0 N-CA-C 112.281 -0.327 . . . . 0.0 112.281 176.255 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 99.2 mt -127.52 133.72 67.19 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.09 0 N-CA-C 107.496 -1.298 . . . . 0.0 107.496 173.676 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 292' ' ' VAL . . . . . 0.414 HG22 ' CZ ' ' A' ' 242' ' ' PHE . 4.0 p -124.76 136.06 61.93 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.893 0 C-N-CA 120.466 -0.494 . . . . 0.0 109.824 -177.529 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 4.4 m -127.42 146.75 50.37 Favored 'General case' 0 C--O 1.237 0.441 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.768 -178.414 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -73.21 141.06 47.33 Favored 'General case' 0 CA--C 1.51 -0.588 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 173.449 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 295' ' ' VAL . . . . . 0.651 HG21 ' OG ' ' A' ' 249' ' ' SER . 69.9 t -125.51 135.71 63.12 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.067 0 C-N-CA 120.667 -0.413 . . . . 0.0 110.73 -176.25 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 51.5 mttp -86.11 99.23 11.36 Favored 'General case' 0 N--CA 1.442 -0.845 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 175.365 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 297' ' ' VAL . . . . . 0.54 ' O ' ' N ' ' A' ' 299' ' ' LYS . 14.5 m -56.47 171.98 0.37 Allowed Pre-proline 0 C--N 1.321 -0.655 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.236 -178.12 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 298' ' ' PRO . . . . . 0.445 ' HD2' ' HB ' ' A' ' 297' ' ' VAL . 34.1 Cg_exo -59.79 75.86 0.06 OUTLIER 'Trans proline' 0 N--CA 1.491 1.34 0 C-N-CA 121.652 1.568 . . . . 0.0 109.519 176.663 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 299' ' ' LYS . . . . . 0.54 ' N ' ' O ' ' A' ' 297' ' ' VAL . 27.0 tttm -137.96 157.97 45.3 Favored 'General case' 0 C--N 1.308 -1.229 0 CA-C-N 114.945 -1.025 . . . . 0.0 110.77 -170.199 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 300' ' ' LYS . . . . . 0.52 ' O ' ' NZ ' ' A' ' 299' ' ' LYS . 48.0 mmtm -64.76 150.3 47.65 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 172.926 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 44.2 pt -68.28 132.81 32.52 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.803 0 C-N-CA 120.906 -0.318 . . . . 0.0 110.383 -176.006 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 4.4 m -139.38 134.35 32.33 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.399 178.936 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 93.3 m-85 -129.2 147.45 51.04 Favored 'General case' 0 C--N 1.317 -0.812 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 176.679 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 62.2 mttm -99.8 110.19 22.57 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.263 177.16 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 305' ' ' SER . . . . . 0.456 ' O ' ' C ' ' A' ' 306' ' ' LEU . 1.4 m -72.91 93.44 1.72 Allowed 'General case' 0 C--N 1.311 -1.103 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 175.965 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 306' ' ' LEU . . . . . 0.456 ' C ' ' O ' ' A' ' 305' ' ' SER . 54.9 mt -33.29 125.49 0.43 Allowed Pre-proline 0 C--O 1.236 0.38 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 -173.836 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -64.09 146.82 91.36 Favored 'Trans proline' 0 C--N 1.304 -1.805 0 C-N-CA 121.781 1.654 . . . . 0.0 111.118 -174.898 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 308' ' ' ALA . . . . . 0.466 ' O ' ' C ' ' A' ' 309' ' ' SER . . . -56.23 148.5 18.22 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 179.372 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.466 ' C ' ' O ' ' A' ' 308' ' ' ALA . 1.2 m -28.52 106.32 0.03 OUTLIER 'General case' 0 C--N 1.319 -0.75 0 O-C-N 123.455 0.472 . . . . 0.0 111.634 -174.404 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 67.1 mt -71.67 101.76 2.62 Favored 'General case' 0 CA--C 1.51 -0.585 0 CA-C-N 116.383 -0.372 . . . . 0.0 110.34 -178.731 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 17.8 m -128.93 132.41 67.43 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.124 176.584 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 90.0 mt-10 . . . . . 0 C--O 1.205 -1.289 0 CA-C-O 118.558 -0.734 . . . . 0.0 111.19 179.66 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 201' ' ' GLU . . . . . 0.502 ' OE1' ' N ' ' A' ' 201' ' ' GLU . 45.2 mp0 . . . . . 0 N--CA 1.478 0.967 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 71.1 m-85 -139.26 145.79 39.63 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -179.609 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -113.44 29.23 8.05 Favored Glycine 0 C--O 1.225 -0.463 0 C-N-CA 121.055 -0.593 . . . . 0.0 112.137 -178.601 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 99.8 mt-10 -64.27 -42.35 96.5 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 117.073 0.437 . . . . 0.0 110.255 179.696 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 51.4 tp10 -67.29 -40.25 86.08 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.181 -176.329 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 99.7 mtp -79.5 99.3 7.19 Favored 'General case' 0 C--O 1.238 0.471 0 N-CA-C 110.11 -0.33 . . . . 0.0 110.11 179.501 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 207' ' ' VAL . . . . . 0.463 ' C ' HD22 ' A' ' 208' ' ' LEU . 27.0 m -100.13 72.58 0.47 Allowed 'Isoleucine or valine' 0 C--O 1.245 0.861 0 CA-C-O 121.361 0.601 . . . . 0.0 112.238 -177.927 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 208' ' ' LEU . . . . . 0.671 HD22 ' N ' ' A' ' 208' ' ' LEU . 1.5 mm? -123.09 112.68 18.04 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 174.182 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -65.63 -44.22 87.12 Favored 'General case' 0 C--O 1.236 0.353 0 C-N-CA 119.753 -0.779 . . . . 0.0 109.805 176.118 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -127.78 -70.29 0.7 Allowed 'General case' 0 CA--C 1.507 -0.689 0 CA-C-N 115.099 -0.955 . . . . 0.0 108.852 173.0 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -121.01 -162.49 0.96 Allowed 'General case' 0 C--N 1.314 -0.965 0 CA-C-N 114.166 -1.379 . . . . 0.0 108.861 177.863 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 212' ' ' ASN . . . . . 0.61 ' HA ' HD12 ' A' ' 208' ' ' LEU . 0.0 OUTLIER -67.45 174.88 3.08 Favored 'General case' 0 C--N 1.322 -0.629 0 C-N-CA 120.844 -0.342 . . . . 0.0 110.158 176.126 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 213' ' ' GLY . . . . . 0.5 ' N ' ' ND2' ' A' ' 212' ' ' ASN . . . 131.99 37.94 0.27 Allowed Glycine 0 C--N 1.318 -0.452 0 N-CA-C 109.315 -1.514 . . . . 0.0 109.315 -176.611 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 214' ' ' GLU . . . . . 0.416 ' H ' ' CD ' ' A' ' 214' ' ' GLU . 53.8 mp0 -63.62 159.78 18.2 Favored 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 123.665 0.786 . . . . 0.0 109.26 -179.564 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 27.9 mt-30 -45.74 154.38 0.56 Allowed Pre-proline 0 C--N 1.326 -0.448 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 178.417 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -65.16 143.92 79.59 Favored 'Trans proline' 0 C--N 1.305 -1.731 0 C-N-CA 121.492 1.461 . . . . 0.0 109.479 176.549 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 217' ' ' LEU . . . . . 0.455 ' HB3' ' O ' ' A' ' 240' ' ' HIS . 0.1 OUTLIER -67.46 125.14 25.2 Favored 'General case' 0 C--N 1.313 -0.98 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 -178.889 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 218' ' ' SER . . . . . 0.405 ' HA ' ' HA ' ' A' ' 293' ' ' SER . 5.1 m -130.89 151.87 50.84 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.867 -174.719 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -144.84 160.59 41.04 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.051 0.453 . . . . 0.0 110.803 179.05 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 220' ' ' MET . . . . . 0.662 ' SD ' HD22 ' A' ' 235' ' ' LEU . 92.7 mtp -75.57 130.74 39.31 Favored 'General case' 0 N--CA 1.443 -0.814 0 CA-C-N 115.366 -0.834 . . . . 0.0 108.916 176.474 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 99.7 t -78.92 128.69 38.35 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.92 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 176.413 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 26.9 m -85.26 -72.73 0.47 Allowed 'General case' 0 C--N 1.307 -1.245 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 178.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 223' ' ' MET . . . . . 0.535 ' C ' ' SD ' ' A' ' 223' ' ' MET . 2.7 ppp? -138.2 151.26 47.52 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 112.235 0.457 . . . . 0.0 112.235 174.168 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 224' ' ' VAL . . . . . 0.578 HG13 HG12 ' A' ' 232' ' ' VAL . 62.2 t -121.11 126.65 75.38 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 176.098 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 225' ' ' THR . . . . . 0.497 ' O ' ' OG1' ' A' ' 280' ' ' THR . 37.5 p -77.53 133.72 38.46 Favored 'General case' 0 C--N 1.327 -0.386 0 C-N-CA 120.259 -0.576 . . . . 0.0 110.407 178.49 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 20.6 tptm -78.32 77.23 4.81 Favored 'General case' 0 C--N 1.316 -0.87 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 179.813 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 227' ' ' ASP . . . . . 0.418 ' H ' ' HG1' ' A' ' 280' ' ' THR . 1.5 t0 -161.31 178.09 9.53 Favored 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 112.615 0.598 . . . . 0.0 112.615 -176.208 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 228' ' ' ASN . . . . . 0.502 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 2.0 t-20 -140.29 124.46 10.75 Favored Pre-proline 0 CA--C 1.533 0.324 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.786 175.086 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 229' ' ' PRO . . . . . 0.502 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 46.8 Cg_endo -65.61 143.57 60.0 Favored 'Cis proline' 0 N--CA 1.492 1.402 0 C-N-CA 122.759 -1.767 . . . . 0.0 109.717 -1.244 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 230' ' ' GLY . . . . . 0.517 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -81.9 140.02 20.48 Favored Glycine 0 CA--C 1.501 -0.795 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 -178.496 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 231' ' ' VAL . . . . . 0.446 ' CG2' HD12 ' A' ' 270' ' ' LEU . 2.4 p -122.79 133.85 67.71 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 176.922 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 232' ' ' VAL . . . . . 0.578 HG12 HG13 ' A' ' 224' ' ' VAL . 0.6 OUTLIER -131.39 155.41 41.79 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 C-N-CA 120.605 -0.438 . . . . 0.0 110.829 -176.182 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 26.1 m -110.17 142.67 41.37 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-N 115.425 -0.807 . . . . 0.0 109.629 177.474 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 48.7 m -107.92 158.22 17.54 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-N 115.804 -0.634 . . . . 0.0 109.484 178.39 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.662 HD22 ' SD ' ' A' ' 220' ' ' MET . 33.9 tp -64.5 117.21 7.0 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 178.459 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 236' ' ' ASP . . . . . 0.539 ' HA ' ' CE1' ' A' ' 273' ' ' TYR . 37.4 p-10 -59.71 -28.56 67.43 Favored 'General case' 0 C--O 1.239 0.515 0 CA-C-O 120.885 0.374 . . . . 0.0 111.872 -173.144 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 72.4 mm-40 -66.22 -33.18 75.18 Favored 'General case' 0 C--N 1.311 -1.068 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.316 178.78 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -99.51 122.96 43.32 Favored 'General case' 0 CA--C 1.516 -0.337 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.408 179.795 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 90.2 mtm180 -75.57 138.73 41.67 Favored 'General case' 0 C--N 1.316 -0.861 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 174.915 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 240' ' ' HIS . . . . . 0.474 ' HB2' ' CD2' ' A' ' 242' ' ' PHE . 6.4 p80 -88.82 -37.73 15.17 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 121.026 0.441 . . . . 0.0 109.924 177.26 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 81.24 10.73 84.36 Favored Glycine 0 CA--C 1.505 -0.592 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 179.405 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 242' ' ' PHE . . . . . 0.493 ' CD1' ' N ' ' A' ' 242' ' ' PHE . 3.7 m-30 -81.22 147.14 30.11 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.305 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -131.17 167.42 19.18 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 109.095 -0.705 . . . . 0.0 109.095 172.359 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 2.9 m -59.48 129.38 41.7 Favored 'General case' 0 C--N 1.294 -1.835 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.556 -176.561 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 83.8 1.8 89.85 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 111.807 -0.517 . . . . 0.0 111.807 -179.165 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 44.4 t0 -77.69 159.62 29.01 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 117.315 0.557 . . . . 0.0 110.255 178.476 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 247' ' ' PHE . . . . . 0.429 ' HA ' ' O ' ' A' ' 265' ' ' MET . 66.0 m-85 -110.48 133.79 52.95 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 116.592 -0.276 . . . . 0.0 110.394 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.426 ' O ' ' SD ' ' A' ' 265' ' ' MET . 3.1 m -129.98 162.22 38.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.54 -179.093 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 5.0 m -126.19 151.79 46.89 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.332 -0.849 . . . . 0.0 109.016 175.782 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 250' ' ' PHE . . . . . 0.563 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 74.4 m-85 -109.6 155.9 20.85 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.409 0.623 . . . . 0.0 111.693 -176.25 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 44.8 m -152.4 151.82 31.28 Favored 'General case' 0 C--N 1.308 -1.211 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.579 175.851 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 30.7 mm-40 51.89 28.47 5.13 Favored 'General case' 0 C--N 1.317 -0.808 0 N-CA-C 113.018 0.747 . . . . 0.0 113.018 176.427 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 0.541 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 60.8 t -82.36 129.67 37.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 174.216 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 81.9 mt-30 -101.59 138.15 38.96 Favored 'General case' 0 C--O 1.243 0.745 0 C-N-CA 120.272 -0.571 . . . . 0.0 111.296 -175.275 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 81.73 -57.53 4.92 Favored Glycine 0 C--O 1.239 0.417 0 N-CA-C 109.969 -1.252 . . . . 0.0 109.969 -176.47 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 256' ' ' MET . . . . . 0.505 ' SD ' HD11 ' A' ' 259' ' ' LEU . 57.0 ttm -85.78 65.04 8.94 Favored 'General case' 0 CA--C 1.516 -0.364 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 175.383 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 257' ' ' ILE . . . . . 0.436 ' O ' ' HB2' ' A' ' 260' ' ' ASN . 49.1 pt -73.92 -19.55 17.58 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-N 114.659 -1.155 . . . . 0.0 111.875 -172.848 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 15.4 tt0 -58.16 -36.39 72.94 Favored 'General case' 0 C--N 1.321 -0.647 0 C-N-CA 119.547 -0.861 . . . . 0.0 110.055 -177.636 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 259' ' ' LEU . . . . . 0.875 HD21 ' CE2' ' A' ' 283' ' ' PHE . 90.4 mt -61.44 -40.39 94.27 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 177.814 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 260' ' ' ASN . . . . . 0.541 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 98.3 m-20 -60.24 -40.1 89.06 Favored 'General case' 0 CA--C 1.508 -0.635 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 178.376 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -102.27 22.72 36.8 Favored Glycine 0 C--N 1.315 -0.615 0 CA-C-N 115.468 -0.787 . . . . 0.0 111.919 -178.259 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 262' ' ' CYS . . . . . 0.4 ' HB3' ' HA ' ' A' ' 259' ' ' LEU . 11.1 t -111.14 146.48 36.78 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 117.308 0.554 . . . . 0.0 111.734 -176.994 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 -59.31 158.99 17.35 Favored Pre-proline 0 C--N 1.327 -0.376 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 174.005 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 264' ' ' PRO . . . . . 0.421 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 37.6 Cg_endo -62.64 148.16 93.75 Favored 'Trans proline' 0 N--CA 1.493 1.491 0 C-N-CA 121.578 1.519 . . . . 0.0 111.395 179.159 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 265' ' ' MET . . . . . 0.623 ' N ' ' SD ' ' A' ' 265' ' ' MET . 0.3 OUTLIER -124.7 150.49 46.09 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.731 -174.412 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 266' ' ' GLU . . . . . 0.522 ' OE2' ' NZ ' ' A' ' 268' ' ' LYS . 0.7 OUTLIER -71.53 140.14 49.77 Favored 'General case' 0 C--O 1.24 0.596 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 172.958 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 267' ' ' ILE . . . . . 0.687 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.5 pp -130.63 159.92 42.25 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-O 121.245 0.545 . . . . 0.0 111.958 -177.065 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 268' ' ' LYS . . . . . 0.522 ' NZ ' ' OE2' ' A' ' 266' ' ' GLU . 35.4 mttp -128.79 120.51 26.48 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.617 178.182 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.421 HG23 ' O ' ' A' ' 269' ' ' VAL . 26.8 m -82.58 100.14 6.07 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.256 0 CA-C-O 121.018 0.437 . . . . 0.0 111.85 -176.657 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 270' ' ' LEU . . . . . 0.446 HD12 ' CG2' ' A' ' 231' ' ' VAL . 97.4 mt -65.81 -41.07 92.32 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.341 0.591 . . . . 0.0 109.636 177.264 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -139.41 179.49 18.67 Favored Glycine 0 C--N 1.317 -0.525 0 N-CA-C 109.253 -1.539 . . . . 0.0 109.253 178.166 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -61.99 -30.23 82.9 Favored 'Trans proline' 0 C--N 1.306 -1.694 0 C-N-CA 121.899 1.733 . . . . 0.0 111.067 -178.27 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 273' ' ' TYR . . . . . 0.539 ' CE1' ' HA ' ' A' ' 236' ' ' ASP . 72.9 m-85 -122.56 6.8 9.49 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 112.782 0.66 . . . . 0.0 112.782 179.027 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 7.0 p -119.41 126.89 52.43 Favored 'General case' 0 C--O 1.243 0.717 0 CA-C-O 120.67 0.272 . . . . 0.0 110.461 177.658 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 275' ' ' PHE . . . . . 0.533 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -133.0 163.2 29.76 Favored 'General case' 0 CA--C 1.493 -1.243 0 C-N-CA 120.446 -0.501 . . . . 0.0 112.296 179.893 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 276' ' ' SER . . . . . 0.517 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 5.0 p -130.65 143.27 50.63 Favored 'General case' 0 N--CA 1.43 -1.432 0 C-N-CA 120.611 -0.436 . . . . 0.0 111.526 -174.781 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 277' ' ' ILE . . . . . 0.628 HG22 HG22 ' A' ' 267' ' ' ILE . 32.6 pt -141.31 165.79 18.6 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.765 0 CA-C-N 114.614 -1.176 . . . . 0.0 111.488 -172.784 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 278' ' ' CYS . . . . . 0.406 ' O ' ' HA ' ' A' ' 229' ' ' PRO . 0.9 OUTLIER -27.5 -90.99 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.687 0 N-CA-C 113.757 1.021 . . . . 0.0 113.757 -176.379 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 279' ' ' ASP . . . . . 0.424 ' HB3' ' HB2' ' A' ' 282' ' ' ASN . 50.7 t0 -148.81 113.56 5.39 Favored 'General case' 0 CA--C 1.504 -0.825 0 CA-C-N 116.615 -0.266 . . . . 0.0 110.293 -175.911 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 280' ' ' THR . . . . . 0.705 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 26.7 p -73.65 -23.52 59.87 Favored 'General case' 0 N--CA 1.426 -1.627 0 CA-C-O 121.086 0.47 . . . . 0.0 110.04 177.411 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -67.75 -20.75 65.27 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.06 -0.973 . . . . 0.0 108.783 173.243 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 282' ' ' ASN . . . . . 0.424 ' HB2' ' HB3' ' A' ' 279' ' ' ASP . 18.8 t30 -89.63 -9.08 51.0 Favored 'General case' 0 CA--C 1.51 -0.588 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.455 -179.547 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 283' ' ' PHE . . . . . 0.875 ' CE2' HD21 ' A' ' 259' ' ' LEU . 21.3 m-85 -92.14 -71.76 0.63 Allowed 'General case' 0 CA--C 1.505 -0.757 0 CA-C-O 121.66 0.743 . . . . 0.0 109.643 179.002 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER 168.95 -175.78 0.03 OUTLIER 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 114.133 -1.394 . . . . 0.0 107.967 -173.908 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 7.9 t70 -92.41 121.43 33.88 Favored 'General case' 0 C--N 1.322 -0.617 0 C-N-CA 120.246 -0.582 . . . . 0.0 111.925 -178.861 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 12.1 t80 -69.58 126.73 30.63 Favored 'General case' 0 C--O 1.237 0.423 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 177.299 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 96.4 mt -106.08 -58.26 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 CA-C-O 121.021 0.438 . . . . 0.0 110.13 174.834 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 22.3 ptt180 -166.91 -179.31 4.64 Favored 'General case' 0 C--O 1.24 0.554 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.934 -176.285 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 65.64 -156.29 49.13 Favored Glycine 0 C--N 1.331 0.305 0 N-CA-C 110.6 -1.0 . . . . 0.0 110.6 178.051 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 290' ' ' GLY . . . . . 0.403 ' CA ' HG22 ' A' ' 253' ' ' VAL . . . 105.42 122.81 5.1 Favored Glycine 0 CA--C 1.52 0.373 0 CA-C-O 121.266 0.37 . . . . 0.0 112.813 176.413 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 95.6 mt -123.0 130.76 74.25 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 N-CA-C 107.587 -1.264 . . . . 0.0 107.587 175.262 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 292' ' ' VAL . . . . . 0.474 HG22 ' CZ ' ' A' ' 242' ' ' PHE . 4.0 p -126.35 137.98 56.08 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 -177.455 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 293' ' ' SER . . . . . 0.405 ' HA ' ' HA ' ' A' ' 218' ' ' SER . 12.5 m -129.64 147.27 51.42 Favored 'General case' 0 CA--C 1.509 -0.598 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.498 -178.425 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 294' ' ' GLN . . . . . 0.459 ' HB3' ' CD1' ' A' ' 242' ' ' PHE . 0.7 OUTLIER -82.61 139.83 33.55 Favored 'General case' 0 CA--C 1.507 -0.678 0 C-N-CA 120.183 -0.607 . . . . 0.0 110.535 175.41 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 79.1 t -121.49 129.06 75.91 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.154 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 177.811 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 16.9 mmtp -85.9 97.53 10.28 Favored 'General case' 0 C--N 1.315 -0.915 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 179.466 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 297' ' ' VAL . . . . . 0.439 ' O ' HG23 ' A' ' 297' ' ' VAL . 6.0 m -90.55 119.94 69.01 Favored Pre-proline 0 N--CA 1.442 -0.872 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.541 -179.029 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -57.81 139.83 91.64 Favored 'Trans proline' 0 N--CA 1.488 1.163 0 C-N-CA 121.69 1.593 . . . . 0.0 110.156 177.625 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 2.9 mptp? -107.14 153.21 22.99 Favored 'General case' 0 C--N 1.309 -1.176 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.212 -179.101 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -57.13 132.85 54.19 Favored 'General case' 0 C--N 1.317 -0.811 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 -179.45 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 95.7 mt -71.0 115.18 10.38 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.019 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 -175.406 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -82.97 159.29 22.27 Favored 'General case' 0 C--N 1.312 -1.048 0 CA-C-N 115.496 -0.775 . . . . 0.0 111.867 -176.349 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 51.8 p90 -150.8 160.17 44.05 Favored 'General case' 0 C--N 1.307 -1.277 0 CA-C-N 115.097 -0.956 . . . . 0.0 108.762 179.029 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.06 128.11 35.18 Favored 'General case' 0 C--N 1.313 -0.983 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.454 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 12.8 p -63.61 156.26 27.23 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 179.193 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -43.76 103.34 0.32 Allowed Pre-proline 0 C--N 1.327 -0.389 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.797 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 307' ' ' PRO . . . . . 0.561 ' O ' ' N ' ' A' ' 309' ' ' SER . 57.9 Cg_endo -73.96 82.38 1.77 Allowed 'Trans proline' 0 C--N 1.305 -1.712 0 C-N-CA 121.617 1.545 . . . . 0.0 111.17 -174.941 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -66.14 60.43 0.04 OUTLIER 'General case' 0 CA--C 1.515 -0.369 0 CA-C-O 121.486 0.66 . . . . 0.0 109.272 178.262 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.561 ' N ' ' O ' ' A' ' 307' ' ' PRO . 10.3 p -81.93 162.33 22.76 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 114.853 -1.067 . . . . 0.0 111.424 -176.784 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 1.8 mm? -78.31 141.55 38.4 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 176.235 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 11.8 t -126.07 110.77 24.64 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 179.02 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 312' ' ' GLU . . . . . 0.44 ' OE1' ' N ' ' A' ' 312' ' ' GLU . 57.8 mp0 . . . . . 0 C--O 1.205 -1.239 0 CA-C-O 118.472 -0.775 . . . . 0.0 110.43 -178.654 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 201' ' ' GLU . . . . . 0.441 ' N ' ' OE2' ' A' ' 201' ' ' GLU . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 110.232 -0.284 . . . . 0.0 110.232 . . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 32.6 p90 -149.11 155.13 40.25 Favored 'General case' 0 C--O 1.238 0.496 0 CA-C-O 120.994 0.426 . . . . 0.0 111.959 -177.901 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -118.4 -5.26 12.96 Favored Glycine 0 N--CA 1.461 0.365 0 N-CA-C 110.319 -1.112 . . . . 0.0 110.319 176.737 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -53.18 -15.82 1.02 Allowed 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 112.213 0.449 . . . . 0.0 112.213 -175.189 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 69.0 mt-10 -61.54 -37.76 84.94 Favored 'General case' 0 CA--C 1.514 -0.418 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 176.599 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 97.1 mtp -107.85 73.08 0.88 Allowed 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 114.832 -1.076 . . . . 0.0 109.228 177.767 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 207' ' ' VAL . . . . . 0.637 HG22 HG23 ' A' ' 209' ' ' THR . 4.8 p -100.39 114.16 38.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.14 0.495 . . . . 0.0 110.816 -177.896 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 86.7 mt -85.46 89.01 7.58 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.476 -179.105 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 209' ' ' THR . . . . . 0.637 HG23 HG22 ' A' ' 207' ' ' VAL . 1.6 p -100.21 -1.72 35.76 Favored 'General case' 0 C--N 1.314 -0.973 0 CA-C-O 121.061 0.457 . . . . 0.0 110.553 179.071 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 210' ' ' ASP . . . . . 0.412 ' O ' ' C ' ' A' ' 211' ' ' SER . 5.4 t70 -100.83 30.93 3.77 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.672 -0.694 . . . . 0.0 110.29 178.913 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 211' ' ' SER . . . . . 0.412 ' C ' ' O ' ' A' ' 210' ' ' ASP . 0.0 OUTLIER -29.58 123.47 0.15 Allowed 'General case' 0 C--O 1.236 0.353 0 CA-C-N 115.769 -0.651 . . . . 0.0 112.189 -174.984 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 212' ' ' ASN . . . . . 0.423 ' OD1' ' N ' ' A' ' 213' ' ' GLY . 50.4 t-20 -87.53 141.29 28.73 Favored 'General case' 0 C--O 1.243 0.713 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.674 -179.413 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 213' ' ' GLY . . . . . 0.423 ' N ' ' OD1' ' A' ' 212' ' ' ASN . . . 71.31 35.16 63.71 Favored Glycine 0 C--O 1.241 0.57 0 N-CA-C 111.783 -0.527 . . . . 0.0 111.783 176.806 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 73.9 mt-10 -65.06 130.85 44.88 Favored 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 120.56 -0.456 . . . . 0.0 110.465 179.007 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 215' ' ' GLN . . . . . 0.495 ' CD ' ' HD2' ' A' ' 216' ' ' PRO . 8.0 tp60 -64.33 150.45 92.94 Favored Pre-proline 0 C--N 1.321 -0.665 0 N-CA-C 106.155 -1.795 . . . . 0.0 106.155 171.452 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 216' ' ' PRO . . . . . 0.495 ' HD2' ' CD ' ' A' ' 215' ' ' GLN . 74.7 Cg_exo -53.13 135.51 59.55 Favored 'Trans proline' 0 C--O 1.247 0.934 0 N-CA-C 108.7 -1.308 . . . . 0.0 108.7 -178.987 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 217' ' ' LEU . . . . . 0.458 ' CB ' ' HG2' ' A' ' 294' ' ' GLN . 0.3 OUTLIER -46.62 112.12 0.46 Allowed 'General case' 0 CA--C 1.505 -0.781 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.218 -168.436 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 218' ' ' SER . . . . . 0.43 ' HA ' ' O ' ' A' ' 292' ' ' VAL . 15.6 m -127.96 150.67 49.8 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 -179.041 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -138.05 152.57 48.95 Favored 'General case' 0 C--N 1.311 -1.095 0 CA-C-O 120.848 0.356 . . . . 0.0 111.112 -177.468 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 220' ' ' MET . . . . . 0.567 ' SD ' HG12 ' A' ' 291' ' ' ILE . 3.5 tpp -76.11 126.82 31.71 Favored 'General case' 0 N--CA 1.443 -0.821 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 174.647 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 72.5 t -77.14 129.48 37.33 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.122 0 N-CA-C 109.646 -0.502 . . . . 0.0 109.646 -178.419 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 3.0 m -83.43 -73.07 0.43 Allowed 'General case' 0 N--CA 1.437 -1.108 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 176.374 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 223' ' ' MET . . . . . 0.449 ' C ' ' SD ' ' A' ' 223' ' ' MET . 3.6 ppp? -138.38 152.79 48.73 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.42 -0.354 . . . . 0.0 111.658 174.566 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 224' ' ' VAL . . . . . 0.647 HG13 HG12 ' A' ' 232' ' ' VAL . 61.6 t -119.84 126.55 75.42 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.991 0 N-CA-C 108.323 -0.991 . . . . 0.0 108.323 175.08 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 225' ' ' THR . . . . . 0.489 ' O ' ' OG1' ' A' ' 280' ' ' THR . 71.0 p -84.82 126.77 33.73 Favored 'General case' 0 C--N 1.322 -0.594 0 C-N-CA 119.726 -0.79 . . . . 0.0 109.648 176.974 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 86.5 tttt -77.86 89.85 4.08 Favored 'General case' 0 C--N 1.316 -0.874 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 -178.435 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 227' ' ' ASP . . . . . . . . . . . . . 43.5 t0 -163.86 173.68 12.43 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.429 -177.363 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 228' ' ' ASN . . . . . 0.419 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 1.7 t-20 -133.14 123.54 17.94 Favored Pre-proline 0 C--N 1.323 -0.559 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.855 172.926 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 229' ' ' PRO . . . . . 0.419 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 55.3 Cg_endo -66.78 144.25 68.2 Favored 'Cis proline' 0 C--N 1.311 -1.4 0 C-N-CA 122.845 -1.731 . . . . 0.0 109.774 -2.266 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 230' ' ' GLY . . . . . 0.479 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -84.03 139.06 18.1 Favored Glycine 0 CA--C 1.502 -0.766 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 -178.985 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 231' ' ' VAL . . . . . 0.496 ' CG2' HD12 ' A' ' 270' ' ' LEU . 2.4 p -124.78 137.57 57.01 Favored 'Isoleucine or valine' 0 C--O 1.243 0.745 0 N-CA-C 109.967 -0.382 . . . . 0.0 109.967 177.162 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 232' ' ' VAL . . . . . 0.647 HG12 HG13 ' A' ' 224' ' ' VAL . 0.6 OUTLIER -132.61 155.34 41.23 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.892 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.801 -178.493 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 21.7 m -109.06 144.19 37.4 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.811 178.861 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 2.1 m -107.6 150.44 26.87 Favored 'General case' 0 C--N 1.316 -0.882 0 C-N-CA 123.023 0.529 . . . . 0.0 109.718 -179.662 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 37.4 tp -65.27 134.51 53.79 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.431 -176.638 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 236' ' ' ASP . . . . . 0.428 ' O ' ' NH1' ' A' ' 239' ' ' ARG . 13.0 t70 -49.1 -44.51 42.29 Favored 'General case' 0 N--CA 1.474 0.748 0 N-CA-C 114.0 1.111 . . . . 0.0 114.0 -171.779 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 237' ' ' GLU . . . . . 0.518 ' O ' ' NH1' ' A' ' 239' ' ' ARG . 54.6 mp0 -63.83 -33.5 75.82 Favored 'General case' 0 C--N 1.316 -0.851 0 C-N-CA 119.044 -1.062 . . . . 0.0 109.615 -177.534 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -77.36 95.2 4.35 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 112.869 0.692 . . . . 0.0 112.869 -177.952 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 239' ' ' ARG . . . . . 0.518 ' NH1' ' O ' ' A' ' 237' ' ' GLU . 0.0 OUTLIER -73.39 92.28 1.83 Allowed 'General case' 0 C--O 1.237 0.395 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 169.755 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 240' ' ' HIS . . . . . 0.604 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 9.4 p80 -53.0 -47.02 68.58 Favored 'General case' 0 C--O 1.213 -0.853 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.297 -174.382 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 76.8 20.75 75.83 Favored Glycine 0 C--N 1.311 -0.811 0 N-CA-C 110.416 -1.074 . . . . 0.0 110.416 177.752 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 242' ' ' PHE . . . . . 0.578 ' CE1' ' HB3' ' A' ' 294' ' ' GLN . 5.2 m-30 -80.17 143.63 33.68 Favored 'General case' 0 C--N 1.318 -0.778 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 179.405 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -119.41 166.26 13.29 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-O 121.153 0.502 . . . . 0.0 110.663 175.604 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 9.1 m -59.44 127.56 32.66 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 115.774 -0.648 . . . . 0.0 109.55 -179.032 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 84.54 6.7 85.48 Favored Glycine 0 N--CA 1.438 -1.175 0 N-CA-C 111.698 -0.561 . . . . 0.0 111.698 -179.815 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 246' ' ' ASP . . . . . 0.434 ' CG ' HE22 ' A' ' 294' ' ' GLN . 3.6 t0 -84.36 165.42 18.25 Favored 'General case' 0 CA--C 1.512 -0.483 0 C-N-CA 119.377 -0.929 . . . . 0.0 109.494 176.814 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 247' ' ' PHE . . . . . 0.552 ' CZ ' ' HB2' ' A' ' 266' ' ' GLU . 47.3 m-85 -112.61 138.11 49.87 Favored 'General case' 0 C--N 1.315 -0.906 0 N-CA-C 111.935 0.346 . . . . 0.0 111.935 -175.476 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.514 ' HA ' ' HA ' ' A' ' 294' ' ' GLN . 2.7 m -133.01 160.38 42.67 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.363 0 C-N-CA 120.297 -0.561 . . . . 0.0 112.189 177.213 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 2.2 m -125.13 153.89 42.3 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 114.483 -1.235 . . . . 0.0 107.694 174.329 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 250' ' ' PHE . . . . . 0.623 ' CB ' ' HB3' ' A' ' 259' ' ' LEU . 64.5 m-85 -112.83 144.64 42.03 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-O 120.865 0.364 . . . . 0.0 111.126 -179.373 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 4.0 m -140.92 161.16 38.48 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 115.503 -0.772 . . . . 0.0 109.426 176.398 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 51.3 mm-40 52.96 27.49 5.63 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 112.278 0.473 . . . . 0.0 112.278 173.507 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 0.445 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 83.4 t -88.68 133.6 30.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 177.771 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 90.9 mm-40 -100.37 145.75 27.8 Favored 'General case' 0 C--O 1.237 0.436 0 CA-C-O 120.852 0.358 . . . . 0.0 110.104 176.692 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 78.36 -68.85 2.86 Favored Glycine 0 C--N 1.315 -0.612 0 N-CA-C 110.417 -1.073 . . . . 0.0 110.417 -179.505 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 256' ' ' MET . . . . . 0.482 ' SD ' ' HD2' ' A' ' 283' ' ' PHE . 29.9 ttm -79.55 68.11 5.5 Favored 'General case' 0 C--N 1.321 -0.638 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 178.087 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 44.9 pt -75.23 -19.21 16.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.857 -175.344 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 258' ' ' GLN . . . . . 0.447 ' O ' ' N ' ' A' ' 262' ' ' CYS . 0.2 OUTLIER -53.18 -39.66 63.81 Favored 'General case' 0 C--O 1.213 -0.849 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 177.576 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 259' ' ' LEU . . . . . 0.978 HD21 ' CE2' ' A' ' 283' ' ' PHE . 94.6 mt -61.6 -41.96 98.19 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.137 179.075 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 260' ' ' ASN . . . . . 0.445 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 91.5 m-20 -59.73 -41.25 90.5 Favored 'General case' 0 CA--C 1.51 -0.567 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 179.524 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -101.14 9.48 57.89 Favored Glycine 0 CA--C 1.523 0.537 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.942 -177.884 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 262' ' ' CYS . . . . . 0.447 ' N ' ' O ' ' A' ' 258' ' ' GLN . 15.6 t -87.99 144.24 26.65 Favored 'General case' 0 C--O 1.241 0.632 0 CA-C-N 117.174 0.487 . . . . 0.0 111.415 -176.122 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -61.21 156.06 52.51 Favored Pre-proline 0 C--N 1.319 -0.721 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 173.6 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 264' ' ' PRO . . . . . 0.413 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 39.3 Cg_endo -64.77 143.32 79.95 Favored 'Trans proline' 0 C--N 1.307 -1.618 0 C-N-CA 120.757 0.971 . . . . 0.0 109.842 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 265' ' ' MET . . . . . 0.469 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 19.5 ptp -126.1 153.61 44.26 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 112.07 0.396 . . . . 0.0 112.07 -174.45 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 266' ' ' GLU . . . . . 0.552 ' HB2' ' CZ ' ' A' ' 247' ' ' PHE . 75.8 tt0 -79.82 137.34 36.93 Favored 'General case' 0 C--O 1.238 0.478 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 179.789 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 267' ' ' ILE . . . . . 0.641 HG22 HG22 ' A' ' 277' ' ' ILE . 1.9 pp -128.33 163.02 33.63 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 N-CA-C 113.752 1.019 . . . . 0.0 113.752 -169.674 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 52.9 tttp -124.95 121.3 34.06 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.148 -0.933 . . . . 0.0 109.995 175.155 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.429 HG11 ' O ' ' A' ' 242' ' ' PHE . 29.5 m -75.64 132.19 33.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 C-N-CA 121.096 -0.242 . . . . 0.0 110.723 178.432 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 270' ' ' LEU . . . . . 0.613 HD11 ' HB3' ' A' ' 276' ' ' SER . 84.5 mt -106.38 -13.82 15.26 Favored 'General case' 0 CA--C 1.515 -0.393 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.737 -179.335 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -170.6 -177.93 40.98 Favored Glycine 0 C--N 1.318 -0.436 0 N-CA-C 110.364 -1.094 . . . . 0.0 110.364 -177.801 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 272' ' ' PRO . . . . . 0.604 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 36.2 Cg_endo -61.52 -31.4 87.51 Favored 'Trans proline' 0 C--N 1.308 -1.588 0 C-N-CA 122.097 1.865 . . . . 0.0 111.118 -178.302 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 273' ' ' TYR . . . . . 0.413 ' CE1' ' HA ' ' A' ' 236' ' ' ASP . 88.7 m-85 -124.49 7.43 8.31 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.877 -0.602 . . . . 0.0 112.407 -179.569 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 11.0 p -123.07 141.14 52.29 Favored 'General case' 0 C--O 1.244 0.784 0 C-N-CA 120.146 -0.622 . . . . 0.0 111.957 -177.893 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 275' ' ' PHE . . . . . 0.564 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -143.34 165.95 26.09 Favored 'General case' 0 CA--C 1.508 -0.654 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.17 178.113 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 276' ' ' SER . . . . . 0.613 ' HB3' HD11 ' A' ' 270' ' ' LEU . 4.6 p -133.08 146.02 51.28 Favored 'General case' 0 N--CA 1.439 -1.01 0 N-CA-C 112.502 0.556 . . . . 0.0 112.502 -175.918 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 277' ' ' ILE . . . . . 0.641 HG22 HG22 ' A' ' 267' ' ' ILE . 29.1 pt -141.46 167.99 16.0 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.896 0 CA-C-N 114.224 -1.353 . . . . 0.0 111.332 -172.102 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 1.6 p -28.75 -95.19 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.759 0 N-CA-C 113.354 0.872 . . . . 0.0 113.354 -177.436 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -143.8 108.7 4.94 Favored 'General case' 0 CA--C 1.501 -0.912 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -178.626 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 280' ' ' THR . . . . . 0.773 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 17.8 p -64.58 -30.63 71.66 Favored 'General case' 0 C--N 1.29 -2.016 0 CA-C-O 121.492 0.663 . . . . 0.0 110.459 177.55 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -61.26 -31.37 71.18 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-N 114.836 -1.075 . . . . 0.0 110.297 175.953 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -87.07 -9.44 55.42 Favored 'General case' 0 CA--C 1.507 -0.686 0 C-N-CA 119.362 -0.935 . . . . 0.0 110.24 -176.609 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 283' ' ' PHE . . . . . 0.978 ' CE2' HD21 ' A' ' 259' ' ' LEU . 19.1 m-85 -77.11 -71.61 0.4 Allowed 'General case' 0 N--CA 1.437 -1.106 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 169.455 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 284' ' ' SER . . . . . 0.406 ' CB ' ' HA ' ' A' ' 256' ' ' MET . 0.0 OUTLIER 175.92 -169.5 0.05 Allowed 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 113.975 -1.466 . . . . 0.0 109.129 -175.574 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -97.47 120.66 38.24 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-O 120.377 0.132 . . . . 0.0 110.772 -177.432 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 286' ' ' TYR . . . . . 0.46 ' CZ ' ' HA ' ' A' ' 288' ' ' ARG . 64.6 t80 -63.87 126.41 27.53 Favored 'General case' 0 N--CA 1.478 0.94 0 C-N-CA 122.754 0.422 . . . . 0.0 111.254 -177.543 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 4.1 mm -100.92 -65.39 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.666 173.399 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 288' ' ' ARG . . . . . 0.46 ' HA ' ' CZ ' ' A' ' 286' ' ' TYR . 0.1 OUTLIER -173.25 -178.8 1.8 Allowed 'General case' 0 C--O 1.243 0.751 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.305 178.58 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 68.33 -156.75 52.99 Favored Glycine 0 CA--C 1.504 -0.625 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 175.432 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 290' ' ' GLY . . . . . 0.42 ' HA3' HG22 ' A' ' 253' ' ' VAL . . . 106.72 129.68 6.31 Favored Glycine 0 N--CA 1.437 -1.251 0 C-N-CA 120.884 -0.674 . . . . 0.0 112.014 177.498 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 291' ' ' ILE . . . . . 0.567 HG12 ' SD ' ' A' ' 220' ' ' MET . 96.5 mt -122.43 130.58 74.41 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.31 0 N-CA-C 107.215 -1.402 . . . . 0.0 107.215 173.172 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 292' ' ' VAL . . . . . 0.43 ' O ' ' HA ' ' A' ' 218' ' ' SER . 2.6 p -112.12 126.9 69.56 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.828 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 -178.182 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 3.3 m -115.93 121.22 41.67 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 110.041 -0.355 . . . . 0.0 110.041 -176.915 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 294' ' ' GLN . . . . . 0.578 ' HB3' ' CE1' ' A' ' 242' ' ' PHE . 0.0 OUTLIER -75.76 138.85 41.5 Favored 'General case' 0 N--CA 1.435 -1.197 0 C-N-CA 120.149 -0.621 . . . . 0.0 110.576 178.362 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 295' ' ' VAL . . . . . 0.42 ' N ' ' O ' ' A' ' 247' ' ' PHE . 3.2 t -106.52 106.11 20.0 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.196 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 179.6 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 296' ' ' LYS . . . . . 0.424 ' HD2' ' NE2' ' A' ' 294' ' ' GLN . 13.6 tptt -75.11 111.5 10.4 Favored 'General case' 0 N--CA 1.435 -1.214 0 N-CA-C 106.854 -1.536 . . . . 0.0 106.854 174.998 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 5.2 m -42.41 153.12 0.31 Allowed Pre-proline 0 C--N 1.321 -0.67 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.26 -169.691 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -61.94 -16.08 47.33 Favored 'Trans proline' 0 C--N 1.31 -1.494 0 C-N-CA 122.757 2.304 . . . . 0.0 110.884 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 27.0 mmtp -54.61 131.87 44.06 Favored 'General case' 0 C--O 1.24 0.584 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 179.035 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -96.39 118.84 33.75 Favored 'General case' 0 CA--C 1.507 -0.69 0 C-N-CA 120.44 -0.504 . . . . 0.0 110.166 175.274 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 44.3 pt -134.78 160.27 41.32 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.157 0 CA-C-N 115.453 -0.794 . . . . 0.0 109.856 -177.275 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -74.03 123.48 24.44 Favored 'General case' 0 C--N 1.311 -1.07 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 176.041 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 303' ' ' PHE . . . . . 0.402 ' CG ' ' N ' ' A' ' 304' ' ' LYS . 88.2 t80 -101.22 157.27 16.9 Favored 'General case' 0 C--N 1.312 -1.041 0 CA-C-N 116.145 -0.479 . . . . 0.0 109.855 -176.28 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 304' ' ' LYS . . . . . 0.402 ' N ' ' CG ' ' A' ' 303' ' ' PHE . 32.3 mmtp -47.74 107.33 0.12 Allowed 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.194 -0.457 . . . . 0.0 109.847 -177.554 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 70.1 m -71.68 143.08 49.82 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-N 116.333 -0.394 . . . . 0.0 109.991 178.327 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 48.1 mt -54.78 115.02 7.86 Favored Pre-proline 0 C--N 1.324 -0.52 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 177.222 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 307' ' ' PRO . . . . . 0.492 ' O ' ' N ' ' A' ' 309' ' ' SER . 53.1 Cg_exo -58.29 141.75 97.03 Favored 'Trans proline' 0 N--CA 1.495 1.596 0 C-N-CA 121.957 1.772 . . . . 0.0 111.262 -175.971 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -66.71 65.29 0.05 Allowed 'General case' 0 CA--C 1.516 -0.352 0 CA-C-O 121.309 0.576 . . . . 0.0 109.88 177.981 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.492 ' N ' ' O ' ' A' ' 307' ' ' PRO . 4.8 m -62.41 150.42 39.83 Favored 'General case' 0 C--N 1.31 -1.114 0 CA-C-N 115.496 -0.774 . . . . 0.0 109.534 -179.102 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 75.3 mt -68.68 76.66 0.29 Allowed 'General case' 0 C--N 1.323 -0.586 0 C-N-CA 120.393 -0.523 . . . . 0.0 110.206 -175.3 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 311' ' ' VAL . . . . . 0.556 ' O ' HG13 ' A' ' 311' ' ' VAL . 12.6 p -76.41 99.26 1.96 Allowed 'Isoleucine or valine' 0 C--O 1.243 0.73 0 CA-C-N 115.954 -0.567 . . . . 0.0 109.766 179.781 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 99.6 mt-10 . . . . . 0 C--O 1.21 -1.016 0 CA-C-O 118.491 -0.766 . . . . 0.0 110.11 -176.956 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 201' ' ' GLU . . . . . 0.543 ' O ' ' N ' ' A' ' 203' ' ' GLY . 14.1 mm-40 . . . . . 0 N--CA 1.48 1.041 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 202' ' ' PHE . . . . . 0.447 ' C ' ' H ' ' A' ' 204' ' ' GLU . 81.1 m-85 60.74 -57.83 0.09 Allowed 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 122.744 0.417 . . . . 0.0 110.584 -175.93 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 203' ' ' GLY . . . . . 0.543 ' N ' ' O ' ' A' ' 201' ' ' GLU . . . -73.49 42.27 1.02 Allowed Glycine 0 C--N 1.311 -0.825 0 N-CA-C 110.143 -1.183 . . . . 0.0 110.143 176.193 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 204' ' ' GLU . . . . . 0.524 ' OE2' ' N ' ' A' ' 201' ' ' GLU . 73.4 mm-40 -59.94 -33.22 71.61 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 -179.679 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 205' ' ' GLU . . . . . 0.438 ' O ' ' N ' ' A' ' 207' ' ' VAL . 99.8 mt-10 -62.01 -21.72 65.11 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 114.605 -1.18 . . . . 0.0 110.906 177.837 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 99.5 mtp -64.92 72.01 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.923 0.392 . . . . 0.0 111.397 -175.695 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 207' ' ' VAL . . . . . 0.438 ' N ' ' O ' ' A' ' 205' ' ' GLU . 8.3 m -121.3 127.96 75.86 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.095 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 170.728 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 67.8 mt -89.47 69.78 7.98 Favored 'General case' 0 C--N 1.319 -0.718 0 C-N-CA 119.637 -0.825 . . . . 0.0 109.914 -173.996 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 19.0 m -71.55 -41.56 68.96 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.103 -0.953 . . . . 0.0 110.278 176.275 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 9.8 p-10 -51.48 -27.25 9.97 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.351 -177.49 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 1.4 m -56.22 134.32 53.06 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 179.754 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 28.8 t-20 -92.05 135.54 33.88 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 112.433 0.531 . . . . 0.0 112.433 -174.418 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 73.44 20.39 79.85 Favored Glycine 0 N--CA 1.452 -0.275 0 CA-C-N 115.349 -0.841 . . . . 0.0 112.944 172.446 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -93.9 114.95 27.28 Favored 'General case' 0 C--O 1.239 0.538 0 CA-C-N 117.678 0.739 . . . . 0.0 110.172 176.287 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 11.9 mt-30 -113.2 109.06 52.14 Favored Pre-proline 0 C--N 1.319 -0.747 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.36 179.716 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -71.55 102.3 1.27 Allowed 'Trans proline' 0 C--N 1.312 -1.379 0 C-N-CA 121.139 1.226 . . . . 0.0 110.319 178.302 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 217' ' ' LEU . . . . . 0.494 HD12 ' O ' ' A' ' 239' ' ' ARG . 0.5 OUTLIER -90.29 125.7 35.6 Favored 'General case' 0 C--N 1.316 -0.88 0 CA-C-N 115.716 -0.675 . . . . 0.0 109.882 -179.487 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 34.5 m -119.19 132.57 55.97 Favored 'General case' 0 C--N 1.324 -0.532 0 O-C-N 123.661 0.601 . . . . 0.0 110.616 -179.652 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 219' ' ' ALA . . . . . 0.421 ' HB2' ' HA ' ' A' ' 240' ' ' HIS . . . -122.53 139.55 53.77 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.821 0.343 . . . . 0.0 110.259 -179.436 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 1.3 tpt -76.6 122.37 24.53 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 177.813 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 73.5 t -74.19 132.65 33.05 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 -177.642 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 222' ' ' SER . . . . . 0.408 ' HG ' HG22 ' A' ' 233' ' ' THR . 5.8 p -90.68 -54.64 3.9 Favored 'General case' 0 N--CA 1.434 -1.252 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 177.829 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -138.53 151.87 47.73 Favored 'General case' 0 C--O 1.222 -0.389 0 N-CA-C 112.649 0.611 . . . . 0.0 112.649 174.856 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 224' ' ' VAL . . . . . 0.726 HG11 ' SD ' ' A' ' 256' ' ' MET . 39.5 t -126.64 132.33 70.3 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 172.143 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -104.1 122.98 46.42 Favored 'General case' 0 C--N 1.313 -1.002 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 -177.817 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 226' ' ' LYS . . . . . 0.464 ' NZ ' ' OD1' ' A' ' 285' ' ' ASP . 0.0 OUTLIER -76.3 77.72 3.07 Favored 'General case' 0 C--O 1.234 0.265 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 179.379 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 227' ' ' ASP . . . . . 0.59 ' N ' ' OG1' ' A' ' 280' ' ' THR . 2.8 t0 -148.42 178.34 8.68 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.762 179.459 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 228' ' ' ASN . . . . . 0.489 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.1 OUTLIER -138.47 125.25 13.06 Favored Pre-proline 0 C--N 1.324 -0.507 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.21 176.43 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 229' ' ' PRO . . . . . 0.489 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 38.2 Cg_endo -65.0 144.76 62.38 Favored 'Cis proline' 0 N--CA 1.499 1.814 0 C-N-CA 123.286 -1.548 . . . . 0.0 110.564 -1.063 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 230' ' ' GLY . . . . . 0.548 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -68.66 136.96 29.95 Favored Glycine 0 N--CA 1.445 -0.732 0 N-CA-C 110.05 -1.22 . . . . 0.0 110.05 -177.915 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 231' ' ' VAL . . . . . 0.409 HG23 HD12 ' A' ' 270' ' ' LEU . 2.1 p -127.05 133.93 67.23 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 177.772 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 232' ' ' VAL . . . . . 0.436 HG22 ' CD1' ' A' ' 275' ' ' PHE . 0.6 OUTLIER -134.76 156.7 40.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 C-N-CA 120.084 -0.646 . . . . 0.0 111.451 -179.695 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 233' ' ' THR . . . . . 0.408 HG22 ' HG ' ' A' ' 222' ' ' SER . 6.7 m -111.37 140.68 45.75 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 115.148 -0.933 . . . . 0.0 109.044 178.755 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 44.5 m -107.92 155.97 19.71 Favored 'General case' 0 C--N 1.315 -0.903 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 176.621 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 40.3 tp -57.74 133.71 55.6 Favored 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 177.401 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -53.8 -46.57 71.1 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.145 0.498 . . . . 0.0 110.557 -170.599 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 59.1 mp0 -68.04 -20.33 64.98 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.93 -0.577 . . . . 0.0 112.375 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -73.93 94.84 2.38 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.629 -177.253 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 239' ' ' ARG . . . . . 0.494 ' O ' HD12 ' A' ' 217' ' ' LEU . 77.3 mtp85 -71.44 99.31 1.98 Allowed 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 176.149 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 240' ' ' HIS . . . . . 0.661 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 12.8 p80 -68.2 -42.97 79.1 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 120.791 0.329 . . . . 0.0 111.748 -176.182 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 80.32 14.42 80.31 Favored Glycine 0 C--N 1.315 -0.586 0 N-CA-C 110.791 -0.924 . . . . 0.0 110.791 -178.514 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 242' ' ' PHE . . . . . 0.513 ' CD1' ' HB3' ' A' ' 294' ' ' GLN . 5.2 m-30 -81.0 142.97 32.87 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -179.613 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 243' ' ' GLU . . . . . 0.402 ' H ' ' CB ' ' A' ' 246' ' ' ASP . 95.0 mt-10 -112.19 167.88 10.06 Favored 'General case' 0 CA--C 1.505 -0.76 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 172.882 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 244' ' ' THR . . . . . 0.523 HG23 ' HG3' ' A' ' 268' ' ' LYS . 21.1 m -62.58 126.24 26.65 Favored 'General case' 0 N--CA 1.436 -1.165 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 169.919 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 245' ' ' GLY . . . . . 0.5 ' HA2' ' CG ' ' A' ' 266' ' ' GLU . . . 82.04 7.21 88.14 Favored Glycine 0 C--N 1.309 -0.941 0 C-N-CA 120.902 -0.666 . . . . 0.0 111.717 -179.029 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 246' ' ' ASP . . . . . 0.41 ' O ' ' HA ' ' A' ' 266' ' ' GLU . 42.1 t0 -84.87 161.7 19.78 Favored 'General case' 0 C--O 1.235 0.305 0 C-N-CA 120.049 -0.66 . . . . 0.0 109.952 177.798 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 247' ' ' PHE . . . . . 0.472 ' HA ' ' O ' ' A' ' 265' ' ' MET . 30.1 m-85 -109.94 131.7 54.82 Favored 'General case' 0 C--O 1.242 0.702 0 N-CA-C 112.134 0.42 . . . . 0.0 112.134 -174.35 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.511 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.7 m -129.92 160.99 40.42 Favored 'Isoleucine or valine' 0 C--O 1.236 0.381 0 CA-C-N 115.89 -0.596 . . . . 0.0 111.884 -179.334 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 3.0 m -126.49 156.0 41.42 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 173.661 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 250' ' ' PHE . . . . . 0.627 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 91.9 m-85 -112.72 146.84 38.01 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-O 120.518 0.199 . . . . 0.0 111.072 -174.059 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 43.4 m -134.4 151.65 51.32 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.105 178.989 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 4.0 mm-40 41.91 37.12 0.74 Allowed 'General case' 0 C--O 1.245 0.832 0 N-CA-C 113.266 0.839 . . . . 0.0 113.266 174.671 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 0.464 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 79.2 t -89.56 129.98 39.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 174.641 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 34.1 mt-30 -99.3 141.32 32.23 Favored 'General case' 0 C--O 1.24 0.577 0 C-N-CA 120.523 -0.471 . . . . 0.0 111.222 -178.249 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 79.61 -57.22 4.49 Favored Glycine 0 CA--C 1.507 -0.438 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -177.081 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 256' ' ' MET . . . . . 0.726 ' SD ' HG11 ' A' ' 224' ' ' VAL . 4.2 ttm -86.74 49.59 1.84 Allowed 'General case' 0 C--N 1.314 -0.949 0 CA-C-O 121.911 0.862 . . . . 0.0 108.721 176.344 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 257' ' ' ILE . . . . . 0.481 ' O ' ' HB2' ' A' ' 260' ' ' ASN . 46.5 pt -68.22 -24.32 29.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 114.453 -1.249 . . . . 0.0 110.917 -174.969 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 258' ' ' GLN . . . . . 0.585 ' HG3' ' SG ' ' A' ' 262' ' ' CYS . 69.2 tp60 -57.68 -30.07 65.17 Favored 'General case' 0 C--N 1.318 -0.795 0 C-N-CA 119.458 -0.897 . . . . 0.0 109.608 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 259' ' ' LEU . . . . . 0.902 HD21 ' CE2' ' A' ' 283' ' ' PHE . 94.3 mt -62.07 -40.21 95.03 Favored 'General case' 0 N--CA 1.448 -0.55 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 174.038 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 260' ' ' ASN . . . . . 0.481 ' HB2' ' O ' ' A' ' 257' ' ' ILE . 96.8 m-20 -60.31 -40.89 92.18 Favored 'General case' 0 CA--C 1.514 -0.431 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 179.58 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -98.33 17.65 58.22 Favored Glycine 0 CA--C 1.525 0.706 0 CA-C-N 115.447 -0.797 . . . . 0.0 112.005 -179.392 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 262' ' ' CYS . . . . . 0.585 ' SG ' ' HG3' ' A' ' 258' ' ' GLN . 1.5 m -93.97 146.59 23.82 Favored 'General case' 0 CA--C 1.508 -0.661 0 C-N-CA 120.579 -0.448 . . . . 0.0 111.032 -179.379 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 46.6 mt-30 -59.81 161.2 12.37 Favored Pre-proline 0 C--N 1.323 -0.548 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 172.277 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 264' ' ' PRO . . . . . 0.511 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 38.0 Cg_endo -63.37 143.39 88.67 Favored 'Trans proline' 0 C--N 1.307 -1.651 0 N-CA-C 108.437 -1.409 . . . . 0.0 108.437 174.974 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 265' ' ' MET . . . . . 0.472 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 22.7 ptp -135.35 152.36 51.37 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 112.071 0.397 . . . . 0.0 112.071 -171.222 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 266' ' ' GLU . . . . . 0.5 ' CG ' ' HA2' ' A' ' 245' ' ' GLY . 39.5 tt0 -71.79 136.94 47.27 Favored 'General case' 0 C--N 1.331 -0.228 0 O-C-N 124.034 0.834 . . . . 0.0 109.516 178.757 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 267' ' ' ILE . . . . . 0.68 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.9 pp -128.3 162.39 34.85 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-O 121.142 0.496 . . . . 0.0 112.1 -179.346 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 268' ' ' LYS . . . . . 0.523 ' HG3' HG23 ' A' ' 244' ' ' THR . 60.1 tttm -118.98 131.52 56.02 Favored 'General case' 0 C--O 1.219 -0.501 0 CA-C-N 115.66 -0.7 . . . . 0.0 109.541 174.081 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 23.2 m -82.4 128.21 38.93 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.974 0 C-N-CA 120.313 -0.555 . . . . 0.0 110.276 176.822 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 270' ' ' LEU . . . . . 0.547 HD11 ' HB3' ' A' ' 276' ' ' SER . 95.6 mt -98.99 -17.89 18.07 Favored 'General case' 0 CA--C 1.502 -0.871 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 178.298 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -171.27 177.0 44.4 Favored Glycine 0 N--CA 1.443 -0.872 0 N-CA-C 108.546 -1.821 . . . . 0.0 108.546 179.092 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 272' ' ' PRO . . . . . 0.661 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 60.2 Cg_exo -54.07 -38.32 87.09 Favored 'Trans proline' 0 C--N 1.298 -2.091 0 C-N-CA 121.443 1.429 . . . . 0.0 110.559 -179.219 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 8.9 m-85 -118.69 11.57 12.8 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 112.646 0.61 . . . . 0.0 112.646 -174.455 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 22.2 p -130.13 143.59 50.87 Favored 'General case' 0 C--O 1.242 0.675 0 C-N-CA 120.669 -0.413 . . . . 0.0 111.177 177.158 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 275' ' ' PHE . . . . . 0.521 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -146.59 165.85 28.26 Favored 'General case' 0 C--O 1.246 0.869 0 N-CA-C 112.363 0.505 . . . . 0.0 112.363 178.75 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 276' ' ' SER . . . . . 0.547 ' HB3' HD11 ' A' ' 270' ' ' LEU . 4.4 p -130.88 143.01 50.42 Favored 'General case' 0 N--CA 1.431 -1.416 0 CA-C-O 121.773 0.797 . . . . 0.0 111.605 -178.695 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 277' ' ' ILE . . . . . 0.624 HG22 HG22 ' A' ' 267' ' ' ILE . 33.8 pt -135.91 165.32 29.95 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.058 0 CA-C-N 114.428 -1.26 . . . . 0.0 110.71 -173.136 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 15.2 t -30.54 -90.71 0.0 OUTLIER 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 112.859 0.689 . . . . 0.0 112.859 -174.874 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 279' ' ' ASP . . . . . 0.481 ' CG ' ' HB2' ' A' ' 228' ' ' ASN . 66.3 t0 -148.93 117.18 6.43 Favored 'General case' 0 N--CA 1.447 -0.593 0 CA-C-O 120.943 0.402 . . . . 0.0 110.827 -178.91 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 280' ' ' THR . . . . . 0.734 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 21.3 p -65.49 -27.33 68.41 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.54 176.56 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -64.35 -19.36 65.41 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.664 175.889 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -88.49 -9.88 50.91 Favored 'General case' 0 CA--C 1.508 -0.655 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.378 179.839 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 283' ' ' PHE . . . . . 0.902 ' CE2' HD21 ' A' ' 259' ' ' LEU . 4.4 m-85 -93.69 -64.96 1.03 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 174.303 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 284' ' ' SER . . . . . 0.422 ' OG ' ' HA ' ' A' ' 256' ' ' MET . 1.9 p 169.43 -94.18 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 115.205 -0.907 . . . . 0.0 111.625 177.242 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 285' ' ' ASP . . . . . 0.531 ' O ' ' N ' ' A' ' 256' ' ' MET . 45.0 t0 -156.19 166.09 34.46 Favored 'General case' 0 C--O 1.214 -0.786 0 N-CA-C 110.409 -0.219 . . . . 0.0 110.409 -177.308 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 286' ' ' TYR . . . . . 0.515 ' CZ ' ' HA ' ' A' ' 288' ' ' ARG . 68.2 t80 -99.61 119.4 38.02 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 110.226 -0.287 . . . . 0.0 110.226 177.359 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 21.1 mm -99.91 -56.44 5.2 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.586 0 N-CA-C 109.114 -0.698 . . . . 0.0 109.114 173.575 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 288' ' ' ARG . . . . . 0.515 ' HA ' ' CZ ' ' A' ' 286' ' ' TYR . 45.9 ptt85 177.87 -173.92 0.14 Allowed 'General case' 0 C--O 1.241 0.639 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.145 175.532 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 66.16 -158.93 47.67 Favored Glycine 0 CA--C 1.51 -0.281 0 N-CA-C 111.018 -0.833 . . . . 0.0 111.018 176.619 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 110.6 127.15 5.16 Favored Glycine 0 N--CA 1.447 -0.592 0 CA-C-O 121.52 0.511 . . . . 0.0 112.988 175.224 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 94.2 mt -130.32 133.07 64.5 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.807 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 174.312 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 3.8 p -124.52 134.29 67.14 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 C-N-CA 120.442 -0.503 . . . . 0.0 109.669 -177.969 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 293' ' ' SER . . . . . 0.477 ' HA ' ' O ' ' A' ' 217' ' ' LEU . 2.6 m -127.23 145.43 50.77 Favored 'General case' 0 C--N 1.324 -0.532 0 C-N-CA 120.488 -0.485 . . . . 0.0 111.042 -178.364 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 294' ' ' GLN . . . . . 0.513 ' HB3' ' CD1' ' A' ' 242' ' ' PHE . 0.3 OUTLIER -84.27 148.74 26.53 Favored 'General case' 0 CA--C 1.508 -0.659 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.185 176.661 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 59.0 t -122.3 128.29 75.43 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.926 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 177.965 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 296' ' ' LYS . . . . . 0.405 ' NZ ' ' O ' ' A' ' 297' ' ' VAL . 24.6 tptp -83.95 98.07 9.6 Favored 'General case' 0 N--CA 1.441 -0.905 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 174.56 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 297' ' ' VAL . . . . . 0.46 HG23 ' NZ ' ' A' ' 299' ' ' LYS . 26.5 m -80.89 162.12 61.01 Favored Pre-proline 0 C--N 1.312 -1.036 0 CA-C-N 115.798 -0.637 . . . . 0.0 109.928 -176.628 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -56.84 138.11 84.33 Favored 'Trans proline' 0 C--N 1.304 -1.768 0 C-N-CA 121.516 1.477 . . . . 0.0 112.1 -177.205 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 299' ' ' LYS . . . . . 0.46 ' NZ ' HG23 ' A' ' 297' ' ' VAL . 33.2 mmtm -139.25 -174.42 3.86 Favored 'General case' 0 C--N 1.314 -0.973 0 CA-C-N 114.611 -1.177 . . . . 0.0 108.371 177.115 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 300' ' ' LYS . . . . . 0.421 ' O ' ' N ' ' A' ' 302' ' ' SER . 8.1 tttm -69.74 122.73 19.76 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 168.057 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 99.1 mt -61.65 89.07 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-O 121.565 0.697 . . . . 0.0 110.032 -175.805 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 302' ' ' SER . . . . . 0.421 ' N ' ' O ' ' A' ' 300' ' ' LYS . 0.7 OUTLIER -134.03 85.14 2.17 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-N 114.894 -1.048 . . . . 0.0 109.716 -177.081 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 27.2 p90 -104.68 130.09 52.76 Favored 'General case' 0 C--O 1.242 0.667 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.71 -177.693 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 32.6 tttp -48.74 107.59 0.14 Allowed 'General case' 0 CA--C 1.51 -0.562 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.516 -174.733 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 8.5 m -130.32 148.48 52.15 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.286 179.72 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -90.05 127.36 53.9 Favored Pre-proline 0 C--N 1.322 -0.589 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 176.821 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -65.21 -25.2 57.83 Favored 'Trans proline' 0 C--N 1.306 -1.659 0 C-N-CA 121.961 1.774 . . . . 0.0 111.412 178.769 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -97.99 -178.14 3.98 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.899 -0.591 . . . . 0.0 111.621 -178.15 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 5.4 p -77.0 -161.56 0.22 Allowed 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.476 -0.784 . . . . 0.0 110.313 177.904 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 51.2 tp -62.89 133.09 54.14 Favored 'General case' 0 CA--C 1.508 -0.66 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 175.667 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 16.5 m -114.8 129.01 71.67 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-O 120.882 0.373 . . . . 0.0 111.055 -177.598 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 33.0 mp0 . . . . . 0 C--O 1.209 -1.069 0 CA-C-O 117.735 -1.126 . . . . 0.0 108.939 -179.803 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 . . . . . 0 N--CA 1.477 0.893 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 9.4 m-30 66.55 13.43 9.29 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.4 -179.404 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -57.44 -21.28 40.74 Favored Glycine 0 C--O 1.237 0.303 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 177.105 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 204' ' ' GLU . . . . . 0.49 ' CD ' ' H ' ' A' ' 204' ' ' GLU . 0.5 OUTLIER -40.37 -29.86 0.09 Allowed 'General case' 0 C--O 1.237 0.405 0 C-N-CA 123.514 0.726 . . . . 0.0 111.343 -179.316 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 205' ' ' GLU . . . . . 0.46 ' O ' ' N ' ' A' ' 207' ' ' VAL . 98.8 mt-10 -60.79 -30.67 70.19 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.581 -177.986 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 7.0 tpt -67.04 71.0 0.09 Allowed 'General case' 0 C--N 1.327 -0.383 0 C-N-CA 119.846 -0.742 . . . . 0.0 109.845 -178.543 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 207' ' ' VAL . . . . . 0.46 ' N ' ' O ' ' A' ' 205' ' ' GLU . 15.3 m -139.11 155.3 26.48 Favored 'Isoleucine or valine' 0 C--O 1.239 0.539 0 CA-C-N 115.607 -0.724 . . . . 0.0 109.86 177.179 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 208' ' ' LEU . . . . . 0.423 HD11 ' HB3' ' A' ' 298' ' ' PRO . 90.3 mt -123.58 70.28 1.05 Allowed 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.061 0.458 . . . . 0.0 110.218 176.363 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -118.96 33.26 5.73 Favored 'General case' 0 C--N 1.311 -1.098 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.433 176.796 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -61.31 -43.92 98.06 Favored 'General case' 0 CA--C 1.513 -0.449 0 CA-C-N 115.13 -0.941 . . . . 0.0 110.385 -174.86 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 2.8 m -89.59 149.29 22.91 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.001 -179.129 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 58.9 t-20 -98.55 111.94 24.14 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 174.411 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 118.91 -8.59 12.66 Favored Glycine 0 C--O 1.24 0.512 0 N-CA-C 111.905 -0.478 . . . . 0.0 111.905 179.655 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 92.7 mt-10 -84.01 112.92 20.62 Favored 'General case' 0 C--O 1.238 0.472 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 175.937 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 27.5 mt-30 -110.95 142.12 25.58 Favored Pre-proline 0 C--N 1.323 -0.58 0 N-CA-C 109.581 -0.525 . . . . 0.0 109.581 177.724 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_exo -60.25 142.58 98.53 Favored 'Trans proline' 0 C--N 1.309 -1.539 0 C-N-CA 121.407 1.405 . . . . 0.0 108.797 173.678 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 217' ' ' LEU . . . . . 0.476 HD12 ' O ' ' A' ' 240' ' ' HIS . 0.1 OUTLIER -61.55 118.7 7.38 Favored 'General case' 0 C--N 1.324 -0.501 0 C-N-CA 119.413 -0.915 . . . . 0.0 109.51 -177.686 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 4.6 m -126.3 147.95 49.62 Favored 'General case' 0 C--N 1.313 -1.011 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.335 -176.374 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 219' ' ' ALA . . . . . 0.487 ' HB1' ' HB1' ' A' ' 238' ' ' ALA . . . -152.5 153.8 34.22 Favored 'General case' 0 C--O 1.24 0.605 0 CA-C-O 121.112 0.482 . . . . 0.0 111.062 -178.709 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 71.3 mtm -80.15 129.67 34.66 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.652 -0.703 . . . . 0.0 109.662 175.9 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 57.5 t -76.29 131.24 35.25 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.694 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 177.991 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 46.8 p -88.72 -65.84 0.98 Allowed 'General case' 0 C--N 1.309 -1.169 0 C-N-CA 120.325 -0.55 . . . . 0.0 110.024 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 23.3 ptm -137.73 142.43 40.99 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.923 -0.58 . . . . 0.0 112.205 176.581 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 224' ' ' VAL . . . . . 0.885 HG22 ' HB ' ' A' ' 232' ' ' VAL . 75.0 t -119.89 133.57 66.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 177.294 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 225' ' ' THR . . . . . 0.478 ' O ' ' OG1' ' A' ' 280' ' ' THR . 62.7 p -98.5 128.6 44.91 Favored 'General case' 0 C--N 1.323 -0.569 0 C-N-CA 120.234 -0.587 . . . . 0.0 110.974 -179.517 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.86 85.76 3.44 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 177.908 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 227' ' ' ASP . . . . . 0.403 ' OD1' ' N ' ' A' ' 228' ' ' ASN . 2.6 t0 -152.04 175.82 12.15 Favored 'General case' 0 N--CA 1.469 0.521 0 CA-C-N 116.476 -0.329 . . . . 0.0 111.39 -175.495 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 228' ' ' ASN . . . . . 0.502 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 9.4 t30 -140.69 124.09 10.17 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.508 174.625 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 229' ' ' PRO . . . . . 0.502 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 40.4 Cg_endo -65.22 142.24 52.16 Favored 'Cis proline' 0 N--CA 1.493 1.488 0 C-N-CA 122.702 -1.791 . . . . 0.0 109.854 -1.12 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 230' ' ' GLY . . . . . 0.493 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -74.39 136.84 21.84 Favored Glycine 0 C--N 1.315 -0.629 0 N-CA-C 110.575 -1.01 . . . . 0.0 110.575 -176.957 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.1 p -127.69 137.74 56.75 Favored 'Isoleucine or valine' 0 C--O 1.248 0.997 0 CA-C-O 120.807 0.337 . . . . 0.0 110.697 177.574 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 232' ' ' VAL . . . . . 0.885 ' HB ' HG22 ' A' ' 224' ' ' VAL . 0.7 OUTLIER -132.28 157.17 43.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.951 179.292 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 233' ' ' THR . . . . . 0.47 ' HA ' ' O ' ' A' ' 273' ' ' TYR . 0.9 OUTLIER -114.36 146.96 39.88 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.388 -178.836 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 34.0 m -107.31 152.24 24.4 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.111 -0.495 . . . . 0.0 109.948 179.263 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 235' ' ' LEU . . . . . 0.482 ' HB3' ' HB3' ' A' ' 238' ' ' ALA . 15.7 tp -51.72 135.09 29.78 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 -178.881 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 24.7 p-10 -48.63 -47.44 40.2 Favored 'General case' 0 N--CA 1.475 0.793 0 N-CA-C 111.936 0.347 . . . . 0.0 111.936 -171.838 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -70.51 -34.65 72.55 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-O 120.944 0.402 . . . . 0.0 111.62 178.218 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 238' ' ' ALA . . . . . 0.487 ' HB1' ' HB1' ' A' ' 219' ' ' ALA . . . -83.96 89.42 7.23 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.262 -176.615 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 239' ' ' ARG . . . . . 0.52 ' NH1' ' O ' ' A' ' 239' ' ' ARG . 0.0 OUTLIER -78.83 123.16 26.94 Favored 'General case' 0 CA--C 1.513 -0.443 0 N-CA-C 108.771 -0.825 . . . . 0.0 108.771 173.698 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 240' ' ' HIS . . . . . 0.602 ' H ' ' CD2' ' A' ' 240' ' ' HIS . 7.0 p80 -57.13 -48.71 77.98 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.397 -175.818 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 80.01 19.93 68.84 Favored Glycine 0 C--N 1.314 -0.666 0 N-CA-C 110.131 -1.188 . . . . 0.0 110.131 -177.674 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 242' ' ' PHE . . . . . 0.681 ' CD2' HG11 ' A' ' 248' ' ' VAL . 8.3 m-30 -81.53 151.87 27.54 Favored 'General case' 0 C--N 1.316 -0.877 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 177.946 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -116.19 160.78 19.92 Favored 'General case' 0 C--N 1.314 -0.935 0 CA-C-O 120.893 0.378 . . . . 0.0 110.887 177.491 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 244' ' ' THR . . . . . 0.527 HG23 HG22 ' A' ' 269' ' ' VAL . 0.0 OUTLIER -58.84 125.88 25.37 Favored 'General case' 0 C--N 1.312 -1.029 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 -179.65 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 80.86 5.81 89.83 Favored Glycine 0 C--N 1.319 -0.365 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 -178.326 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 246' ' ' ASP . . . . . 0.477 ' OD2' ' NZ ' ' A' ' 299' ' ' LYS . 5.3 t70 -79.86 162.34 25.09 Favored 'General case' 0 CA--C 1.514 -0.42 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 178.416 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 247' ' ' PHE . . . . . . . . . . . . . 78.0 m-85 -109.78 129.04 55.67 Favored 'General case' 0 C--O 1.242 0.708 0 CA-C-O 120.846 0.355 . . . . 0.0 111.191 -177.488 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.681 HG11 ' CD2' ' A' ' 242' ' ' PHE . 2.4 m -129.95 162.26 38.01 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.399 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.364 178.369 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.48 145.82 46.87 Favored 'General case' 0 C--N 1.308 -1.226 0 CA-C-N 115.324 -0.853 . . . . 0.0 109.982 177.363 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 250' ' ' PHE . . . . . 0.649 ' CD2' HD22 ' A' ' 259' ' ' LEU . 67.5 m-85 -104.81 145.68 30.04 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.65 177.701 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 4.3 m -143.36 150.12 38.69 Favored 'General case' 0 C--N 1.309 -1.153 0 N-CA-C 110.084 -0.339 . . . . 0.0 110.084 176.07 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 23.7 mm-40 54.1 26.78 6.86 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 112.816 0.673 . . . . 0.0 112.816 173.07 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 0.517 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 88.0 t -76.53 130.93 35.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 173.702 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 86.5 mm-40 -100.45 139.72 35.72 Favored 'General case' 0 C--O 1.244 0.765 0 C-N-CA 119.68 -0.808 . . . . 0.0 111.651 -176.152 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 78.71 -58.16 4.21 Favored Glycine 0 C--O 1.239 0.453 0 N-CA-C 108.983 -1.647 . . . . 0.0 108.983 -173.688 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 256' ' ' MET . . . . . 0.566 ' SD ' HG11 ' A' ' 224' ' ' VAL . 31.7 mtt -80.57 61.04 4.14 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-O 121.242 0.544 . . . . 0.0 109.788 172.682 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 257' ' ' ILE . . . . . 0.401 ' O ' ' HB2' ' A' ' 260' ' ' ASN . 41.8 pt -76.23 -15.78 15.14 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.731 -178.512 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 258' ' ' GLN . . . . . 0.414 ' O ' ' N ' ' A' ' 262' ' ' CYS . 70.5 tp60 -55.38 -39.31 69.99 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 179.423 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 259' ' ' LEU . . . . . 0.91 HD21 ' CE2' ' A' ' 283' ' ' PHE . 89.0 mt -61.86 -41.71 98.17 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.747 -0.661 . . . . 0.0 109.925 176.908 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 260' ' ' ASN . . . . . 0.517 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 97.9 m-20 -61.29 -40.58 94.67 Favored 'General case' 0 CA--C 1.509 -0.612 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 179.347 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -87.66 -5.67 78.0 Favored Glycine 0 CA--C 1.523 0.538 0 CA-C-N 115.529 -0.76 . . . . 0.0 111.496 -178.936 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 262' ' ' CYS . . . . . 0.414 ' N ' ' O ' ' A' ' 258' ' ' GLN . 49.0 t -87.98 150.58 23.36 Favored 'General case' 0 CA--C 1.512 -0.493 0 CA-C-O 120.765 0.317 . . . . 0.0 111.062 -178.285 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 263' ' ' GLN . . . . . 0.642 ' CD ' ' H ' ' A' ' 263' ' ' GLN . 0.0 OUTLIER -72.45 169.39 17.09 Favored Pre-proline 0 C--N 1.319 -0.758 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 172.631 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 264' ' ' PRO . . . . . 0.454 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 27.7 Cg_exo -61.76 145.12 97.5 Favored 'Trans proline' 0 C--N 1.307 -1.608 0 C-N-CA 121.462 1.441 . . . . 0.0 109.983 179.099 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 265' ' ' MET . . . . . 0.655 ' N ' ' SD ' ' A' ' 265' ' ' MET . 0.8 OUTLIER -122.83 157.26 32.85 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 -176.466 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 266' ' ' GLU . . . . . 0.403 ' HA ' ' O ' ' A' ' 246' ' ' ASP . 64.1 tt0 -75.94 134.85 40.12 Favored 'General case' 0 C--O 1.238 0.493 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 175.513 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 267' ' ' ILE . . . . . 0.703 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.9 pp -128.66 163.3 33.63 Favored 'Isoleucine or valine' 0 C--O 1.237 0.405 0 N-CA-C 114.095 1.146 . . . . 0.0 114.095 -170.495 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 268' ' ' LYS . . . . . 0.493 ' NZ ' ' OG ' ' A' ' 276' ' ' SER . 8.0 mtpm? -119.36 123.31 43.84 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-N 115.009 -0.996 . . . . 0.0 110.065 178.737 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.527 HG22 HG23 ' A' ' 244' ' ' THR . 30.1 m -84.59 97.93 5.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-O 121.087 0.47 . . . . 0.0 111.236 177.056 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 91.9 mt -66.79 -40.4 88.14 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.528 0.68 . . . . 0.0 109.747 176.38 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -155.33 -177.85 28.99 Favored Glycine 0 N--CA 1.447 -0.624 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 -179.827 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 272' ' ' PRO . . . . . 0.5 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 35.6 Cg_endo -61.32 -30.88 88.49 Favored 'Trans proline' 0 C--N 1.306 -1.702 0 C-N-CA 122.066 1.844 . . . . 0.0 111.471 -178.519 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 273' ' ' TYR . . . . . 0.47 ' O ' ' HA ' ' A' ' 233' ' ' THR . 94.5 m-85 -122.85 7.0 9.33 Favored 'General case' 0 C--N 1.319 -0.733 0 N-CA-C 112.942 0.719 . . . . 0.0 112.942 -178.497 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 4.3 p -126.84 129.02 47.45 Favored 'General case' 0 C--O 1.244 0.816 0 CA-C-O 120.884 0.374 . . . . 0.0 110.835 178.031 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 275' ' ' PHE . . . . . 0.518 ' HD2' HD13 ' A' ' 267' ' ' ILE . 0.0 OUTLIER -139.41 160.47 39.76 Favored 'General case' 0 CA--C 1.499 -0.986 0 C-N-CA 120.446 -0.502 . . . . 0.0 112.206 177.281 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 276' ' ' SER . . . . . 0.493 ' OG ' ' NZ ' ' A' ' 268' ' ' LYS . 10.9 p -130.79 154.49 47.95 Favored 'General case' 0 N--CA 1.43 -1.427 0 CA-C-O 121.456 0.646 . . . . 0.0 111.953 -175.11 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 277' ' ' ILE . . . . . 0.672 ' C ' HD12 ' A' ' 277' ' ' ILE . 2.5 pp -138.19 -172.48 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.154 0 CA-C-N 114.313 -1.312 . . . . 0.0 108.961 -176.926 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 278' ' ' CYS . . . . . 0.524 ' N ' HD12 ' A' ' 277' ' ' ILE . 0.5 OUTLIER -48.14 -85.93 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.751 0.31 . . . . 0.0 111.708 -178.245 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 31.7 t0 -145.0 115.45 7.62 Favored 'General case' 0 CA--C 1.515 -0.397 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.534 -177.625 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 280' ' ' THR . . . . . 0.69 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 12.6 p -71.42 -22.66 61.83 Favored 'General case' 0 N--CA 1.432 -1.37 0 CA-C-O 121.108 0.48 . . . . 0.0 109.77 176.294 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -67.37 -19.85 65.48 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 174.765 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 26.8 t-20 -89.2 -9.16 51.83 Favored 'General case' 0 CA--C 1.505 -0.752 0 CA-C-N 115.662 -0.699 . . . . 0.0 109.637 178.408 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 283' ' ' PHE . . . . . 0.91 ' CE2' HD21 ' A' ' 259' ' ' LEU . 22.8 m-30 -84.28 -79.0 0.22 Allowed 'General case' 0 N--CA 1.441 -0.906 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 174.612 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 284' ' ' SER . . . . . 0.436 ' CB ' ' HA ' ' A' ' 256' ' ' MET . 0.0 OUTLIER 175.01 -165.21 0.03 OUTLIER 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 114.892 -1.049 . . . . 0.0 109.589 -175.674 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 27.7 t0 -92.81 118.64 31.32 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.643 0.259 . . . . 0.0 111.301 178.997 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 286' ' ' TYR . . . . . 0.493 ' HB2' ' SD ' ' A' ' 256' ' ' MET . 6.1 t80 -68.86 122.0 17.73 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.6 179.341 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 96.4 mt -103.0 -59.9 3.15 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 175.027 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 50.8 ptt85 179.7 -163.04 0.04 OUTLIER 'General case' 0 C--O 1.24 0.553 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.397 174.755 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 68.83 -147.93 47.3 Favored Glycine 0 C--O 1.237 0.336 0 N-CA-C 109.811 -1.316 . . . . 0.0 109.811 -179.05 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 87.13 122.11 1.53 Allowed Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.823 175.111 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 97.7 mt -118.19 128.9 75.18 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.137 0 N-CA-C 107.262 -1.385 . . . . 0.0 107.262 172.346 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 14.9 p -116.94 128.92 74.24 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 -179.658 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 3.4 m -134.52 143.52 47.49 Favored 'General case' 0 N--CA 1.439 -0.996 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.409 -176.903 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 294' ' ' GLN . . . . . 0.423 ' HB2' ' CD1' ' A' ' 242' ' ' PHE . 11.2 tt0 -67.07 151.88 46.79 Favored 'General case' 0 N--CA 1.432 -1.358 0 CA-C-N 115.378 -0.828 . . . . 0.0 108.924 173.88 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 61.6 t -106.59 126.17 62.41 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 N-CA-C 107.975 -1.121 . . . . 0.0 107.975 176.398 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 2.6 tmtm? -66.01 98.99 0.46 Allowed 'General case' 0 N--CA 1.438 -1.046 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 -178.508 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 297' ' ' VAL . . . . . 0.401 ' O ' ' HG3' ' A' ' 299' ' ' LYS . 52.9 t -103.53 129.24 25.77 Favored Pre-proline 0 C--N 1.306 -1.303 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 179.211 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 298' ' ' PRO . . . . . 0.423 ' HB3' HD11 ' A' ' 208' ' ' LEU . 37.4 Cg_endo -68.8 86.13 0.47 Allowed 'Trans proline' 0 C--N 1.302 -1.872 0 N-CA-C 108.232 -1.488 . . . . 0.0 108.232 176.229 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 299' ' ' LYS . . . . . 0.477 ' NZ ' ' OD2' ' A' ' 246' ' ' ASP . 66.8 mttm -68.23 125.51 26.62 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.477 -171.734 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 19.0 pttm -129.99 130.4 44.96 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.409 176.573 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 47.0 pt -136.05 147.13 28.32 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.231 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 176.141 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -85.65 77.44 9.81 Favored 'General case' 0 C--N 1.313 -0.999 0 N-CA-C 107.65 -1.241 . . . . 0.0 107.65 175.111 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 16.9 t80 -165.08 145.78 7.33 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 114.754 -1.112 . . . . 0.0 108.92 -177.401 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 42.6 tttm -78.77 143.84 35.73 Favored 'General case' 0 C--N 1.313 -1.012 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 174.627 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 2.0 m -48.11 138.37 9.44 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.915 0.388 . . . . 0.0 111.755 -171.649 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 306' ' ' LEU . . . . . 0.841 ' H ' HD12 ' A' ' 306' ' ' LEU . 0.4 OUTLIER -92.45 162.39 29.87 Favored Pre-proline 0 C--N 1.327 -0.406 0 CA-C-N 115.703 -0.68 . . . . 0.0 109.912 179.602 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 307' ' ' PRO . . . . . 0.411 ' HD2' ' HB3' ' A' ' 306' ' ' LEU . 74.1 Cg_endo -73.88 42.5 0.72 Allowed 'Trans proline' 0 N--CA 1.493 1.452 0 C-N-CA 122.272 1.981 . . . . 0.0 111.678 178.763 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -78.6 86.3 4.6 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 177.043 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 4.8 m -68.4 137.89 54.9 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.698 -173.786 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 310' ' ' LEU . . . . . 0.651 ' O ' HG13 ' A' ' 311' ' ' VAL . 75.6 mt -117.1 126.71 53.25 Favored 'General case' 0 C--O 1.235 0.303 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 174.964 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 311' ' ' VAL . . . . . 0.651 HG13 ' O ' ' A' ' 310' ' ' LEU . 0.3 OUTLIER -162.9 146.74 3.42 Favored 'Isoleucine or valine' 0 C--O 1.236 0.352 0 O-C-N 123.409 0.443 . . . . 0.0 111.225 177.796 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 68.0 mt-10 . . . . . 0 C--O 1.211 -0.973 0 CA-C-O 118.496 -0.764 . . . . 0.0 109.86 175.096 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 201' ' ' GLU . . . . . 0.485 ' OE1' ' N ' ' A' ' 201' ' ' GLU . 0.0 OUTLIER . . . . . 0 N--CA 1.483 1.184 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 . . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 202' ' ' PHE . . . . . 0.631 ' CE2' ' HG3' ' A' ' 206' ' ' MET . 34.8 t80 -57.32 -42.01 81.02 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.594 -0.73 . . . . 0.0 109.731 -179.853 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -53.02 -24.56 20.95 Favored Glycine 0 C--N 1.314 -0.69 0 CA-C-N 115.352 -0.84 . . . . 0.0 111.356 176.844 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 64.9 mt-10 -64.59 -46.84 80.96 Favored 'General case' 0 CA--C 1.508 -0.64 0 C-N-CA 119.373 -0.931 . . . . 0.0 109.174 177.04 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 3.9 mp0 -70.84 -38.37 73.19 Favored 'General case' 0 N--CA 1.444 -0.761 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 174.885 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 206' ' ' MET . . . . . 0.631 ' HG3' ' CE2' ' A' ' 202' ' ' PHE . 26.4 mmt -89.64 79.82 6.74 Favored 'General case' 0 C--O 1.24 0.6 0 CA-C-N 115.517 -0.765 . . . . 0.0 112.252 -178.515 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 207' ' ' VAL . . . . . 0.504 ' O ' ' N ' ' A' ' 209' ' ' THR . 3.7 m -114.45 131.45 66.46 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.098 0 N-CA-C 107.542 -1.281 . . . . 0.0 107.542 169.685 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 86.6 mt -62.61 75.86 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.478 0.656 . . . . 0.0 110.366 -172.151 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 209' ' ' THR . . . . . 0.504 ' N ' ' O ' ' A' ' 207' ' ' VAL . 1.2 p -123.36 3.95 9.11 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 114.774 -1.103 . . . . 0.0 111.573 -177.251 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -51.77 -42.49 62.44 Favored 'General case' 0 CA--C 1.509 -0.615 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 -179.824 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 211' ' ' SER . . . . . 0.511 ' CB ' ' HG3' ' A' ' 214' ' ' GLU . 1.5 m -115.04 118.35 33.16 Favored 'General case' 0 C--N 1.309 -1.176 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 174.432 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 16.0 t-20 -95.66 121.56 37.49 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 112.767 0.654 . . . . 0.0 112.767 -173.885 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 71.85 40.79 57.21 Favored Glycine 0 C--O 1.236 0.264 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.996 174.059 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 214' ' ' GLU . . . . . 0.511 ' HG3' ' CB ' ' A' ' 211' ' ' SER . 16.9 mm-40 -87.48 99.19 11.84 Favored 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 120.415 -0.514 . . . . 0.0 110.893 179.411 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 215' ' ' GLN . . . . . 0.505 ' H ' ' CD ' ' A' ' 215' ' ' GLN . 0.0 OUTLIER -76.77 129.69 78.36 Favored Pre-proline 0 C--N 1.317 -0.842 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 173.303 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -56.15 133.93 61.04 Favored 'Trans proline' 0 C--N 1.31 -1.452 0 C-N-CA 121.053 1.169 . . . . 0.0 110.524 -177.029 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 217' ' ' LEU . . . . . 0.459 HD22 ' HA ' ' A' ' 217' ' ' LEU . 0.3 OUTLIER -79.04 141.93 36.99 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.242 -178.881 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 96.4 p -155.06 164.3 39.07 Favored 'General case' 0 N--CA 1.446 -0.652 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.258 -177.967 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -154.5 163.22 40.52 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-N 115.548 -0.751 . . . . 0.0 109.682 177.246 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 8.4 ttt -78.78 127.0 31.47 Favored 'General case' 0 N--CA 1.436 -1.144 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 175.703 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 98.0 t -69.22 130.13 33.98 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.174 0 N-CA-C 107.726 -1.213 . . . . 0.0 107.726 178.017 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -84.6 -70.36 0.58 Allowed 'General case' 0 N--CA 1.432 -1.331 0 C-N-CA 120.211 -0.596 . . . . 0.0 109.922 179.649 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 8.5 ptm -138.08 146.25 42.71 Favored 'General case' 0 N--CA 1.47 0.536 0 N-CA-C 112.446 0.536 . . . . 0.0 112.446 174.827 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 224' ' ' VAL . . . . . 0.8 HG22 ' HB ' ' A' ' 232' ' ' VAL . 53.1 t -121.94 132.85 70.01 Favored 'Isoleucine or valine' 0 C--O 1.239 0.537 0 C-N-CA 122.814 0.446 . . . . 0.0 110.557 178.97 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 39.2 p -88.25 133.0 34.16 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.554 -0.293 . . . . 0.0 110.694 178.731 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 15.9 tttm -82.11 80.16 8.42 Favored 'General case' 0 C--O 1.241 0.623 0 C-N-CA 120.349 -0.54 . . . . 0.0 110.014 177.549 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 227' ' ' ASP . . . . . 0.605 ' N ' ' OG1' ' A' ' 280' ' ' THR . 2.2 t0 -154.3 -179.86 8.32 Favored 'General case' 0 C--O 1.247 0.93 0 CA-C-N 115.391 -0.822 . . . . 0.0 111.2 178.853 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 228' ' ' ASN . . . . . 0.523 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.4 OUTLIER -141.77 125.48 9.91 Favored Pre-proline 0 C--N 1.324 -0.502 0 CA-C-N 115.529 -0.759 . . . . 0.0 109.645 176.747 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 229' ' ' PRO . . . . . 0.523 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 42.6 Cg_endo -64.71 142.32 50.21 Favored 'Cis proline' 0 N--CA 1.491 1.379 0 C-N-CA 122.995 -1.669 . . . . 0.0 110.198 -0.651 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 230' ' ' GLY . . . . . 0.562 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -74.42 138.89 24.84 Favored Glycine 0 C--N 1.308 -0.981 0 N-CA-C 109.912 -1.275 . . . . 0.0 109.912 -178.531 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.2 p -125.08 130.98 73.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 176.271 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 232' ' ' VAL . . . . . 0.8 ' HB ' HG22 ' A' ' 224' ' ' VAL . 0.7 OUTLIER -133.64 156.54 41.55 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 C-N-CA 120.502 -0.479 . . . . 0.0 110.494 -177.255 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 233' ' ' THR . . . . . 0.427 ' HA ' ' O ' ' A' ' 273' ' ' TYR . 2.4 m -105.35 149.27 26.22 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 115.268 -0.878 . . . . 0.0 109.321 177.777 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 2.6 m -113.08 147.26 37.66 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 175.478 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 33.7 tp -53.7 113.92 1.36 Allowed 'General case' 0 C--N 1.312 -1.065 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 178.623 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 36.7 p-10 -63.1 -10.38 14.41 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.94 -170.87 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 76.5 mm-40 -65.47 -32.76 74.55 Favored 'General case' 0 C--N 1.312 -1.048 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.231 177.982 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -121.45 133.52 55.06 Favored 'General case' 0 C--O 1.233 0.223 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.839 -177.868 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 239' ' ' ARG . . . . . 0.552 ' NH1' ' O ' ' A' ' 242' ' ' PHE . 0.1 OUTLIER -77.87 112.57 14.89 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 173.439 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 240' ' ' HIS . . . . . 0.605 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 2.8 p80 -43.19 -34.2 1.08 Allowed 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 121.133 0.492 . . . . 0.0 109.988 -179.011 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 87.19 8.36 75.25 Favored Glycine 0 CA--C 1.503 -0.669 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 179.724 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 242' ' ' PHE . . . . . 0.552 ' O ' ' NH1' ' A' ' 239' ' ' ARG . 5.7 m-30 -81.82 146.16 30.04 Favored 'General case' 0 N--CA 1.444 -0.772 0 CA-C-O 120.85 0.357 . . . . 0.0 110.19 -179.192 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 243' ' ' GLU . . . . . 0.529 ' HG3' ' CE1' ' A' ' 303' ' ' PHE . 64.9 mm-40 -121.67 167.99 12.3 Favored 'General case' 0 C--N 1.309 -1.19 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.431 176.446 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 17.7 m -61.1 124.15 19.72 Favored 'General case' 0 C--N 1.298 -1.633 0 C-N-CA 120.152 -0.619 . . . . 0.0 109.718 -178.682 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 245' ' ' GLY . . . . . 0.41 ' HA2' ' CG ' ' A' ' 266' ' ' GLU . . . 82.64 7.39 87.49 Favored Glycine 0 CA--C 1.523 0.578 0 CA-C-N 116.192 -0.458 . . . . 0.0 112.066 179.312 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 246' ' ' ASP . . . . . 0.44 ' OD1' ' N ' ' A' ' 247' ' ' PHE . 40.3 t0 -74.41 162.15 29.13 Favored 'General case' 0 C--O 1.238 0.482 0 CA-C-N 117.44 0.62 . . . . 0.0 109.457 177.809 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 247' ' ' PHE . . . . . 0.44 ' N ' ' OD1' ' A' ' 246' ' ' ASP . 78.3 m-85 -109.31 131.05 55.43 Favored 'General case' 0 C--N 1.316 -0.849 0 N-CA-C 109.705 -0.479 . . . . 0.0 109.705 -179.27 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.433 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 3.1 m -129.04 163.29 34.48 Favored 'Isoleucine or valine' 0 C--O 1.24 0.602 0 CA-C-O 121.027 0.441 . . . . 0.0 112.058 -177.251 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 9.6 p -133.91 162.04 33.13 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 114.522 -1.217 . . . . 0.0 108.905 175.172 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 250' ' ' PHE . . . . . 0.595 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 82.1 m-85 -124.37 159.36 30.52 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.087 0.47 . . . . 0.0 111.831 -169.231 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 20.2 m -158.42 160.0 36.36 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.192 177.489 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 78.0 mm-40 52.17 20.39 1.31 Allowed 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 113.234 0.827 . . . . 0.0 113.234 175.971 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 253' ' ' VAL . . . . . 0.43 HG22 ' CA ' ' A' ' 290' ' ' GLY . 12.4 t -85.94 131.06 35.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 175.969 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 87.5 mt-30 -96.93 144.06 27.21 Favored 'General case' 0 C--O 1.24 0.56 0 C-N-CA 120.666 -0.413 . . . . 0.0 110.649 -179.689 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 77.75 -57.43 3.86 Favored Glycine 0 CA--C 1.509 -0.321 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -177.158 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 256' ' ' MET . . . . . 0.522 ' HG2' ' HB3' ' A' ' 283' ' ' PHE . 15.3 ttm -85.81 55.84 3.7 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-O 121.493 0.663 . . . . 0.0 109.446 175.684 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 44.4 pt -73.93 -18.1 17.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.036 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 3.5 tp60 -54.1 -39.04 66.02 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 108.231 -1.026 . . . . 0.0 108.231 178.157 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 259' ' ' LEU . . . . . 0.846 HD21 ' CE2' ' A' ' 283' ' ' PHE . 85.5 mt -62.16 -41.67 98.52 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.121 177.07 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 97.2 m-20 -59.98 -40.53 89.45 Favored 'General case' 0 CA--C 1.506 -0.734 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 -176.436 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -102.27 14.75 56.77 Favored Glycine 0 CA--C 1.523 0.552 0 CA-C-N 115.787 -0.642 . . . . 0.0 112.235 -179.603 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 262' ' ' CYS . . . . . 0.439 ' HB2' ' HA ' ' A' ' 259' ' ' LEU . 1.1 m -91.16 158.83 16.4 Favored 'General case' 0 CA--C 1.513 -0.456 0 CA-C-N 117.469 0.634 . . . . 0.0 111.684 -178.005 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -76.59 151.25 82.69 Favored Pre-proline 0 C--N 1.323 -0.553 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 173.927 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 264' ' ' PRO . . . . . 0.75 ' HB3' HG21 ' A' ' 295' ' ' VAL . 49.5 Cg_endo -64.01 147.11 91.82 Favored 'Trans proline' 0 C--N 1.306 -1.668 0 C-N-CA 121.76 1.64 . . . . 0.0 112.052 -176.177 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 265' ' ' MET . . . . . 0.502 ' SD ' ' HZ ' ' A' ' 283' ' ' PHE . 7.8 ptp -134.07 157.4 46.22 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 112.484 0.55 . . . . 0.0 112.484 -173.661 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 266' ' ' GLU . . . . . 0.481 ' OE2' ' NZ ' ' A' ' 268' ' ' LYS . 39.6 tt0 -73.57 141.55 46.64 Favored 'General case' 0 C--O 1.241 0.631 0 O-C-N 124.006 0.816 . . . . 0.0 109.846 177.015 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 267' ' ' ILE . . . . . 0.681 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.8 pp -130.66 163.58 36.05 Favored 'Isoleucine or valine' 0 C--O 1.237 0.445 0 N-CA-C 112.114 0.413 . . . . 0.0 112.114 -177.99 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 268' ' ' LYS . . . . . 0.481 ' NZ ' ' OE2' ' A' ' 266' ' ' GLU . 45.1 mmtm -124.88 127.35 46.97 Favored 'General case' 0 CA--C 1.541 0.628 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 174.555 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.482 HG23 ' O ' ' A' ' 269' ' ' VAL . 27.2 m -83.64 98.27 5.3 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.612 0 CA-C-O 120.887 0.375 . . . . 0.0 111.507 -179.818 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 98.6 mt -65.73 -42.46 90.99 Favored 'General case' 0 CA--C 1.513 -0.46 0 CA-C-O 121.399 0.619 . . . . 0.0 109.577 178.137 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -145.04 176.44 24.08 Favored Glycine 0 C--N 1.314 -0.693 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 178.499 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 272' ' ' PRO . . . . . 0.605 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 67.9 Cg_exo -54.03 -40.05 82.86 Favored 'Trans proline' 0 C--N 1.305 -1.72 0 C-N-CA 122.159 1.906 . . . . 0.0 111.068 -178.805 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 273' ' ' TYR . . . . . 0.427 ' O ' ' HA ' ' A' ' 233' ' ' THR . 6.9 m-85 -115.71 8.96 15.08 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.623 -176.062 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.7 p -126.74 124.97 40.97 Favored 'General case' 0 C--O 1.247 0.937 0 CA-C-O 121.047 0.451 . . . . 0.0 111.431 179.284 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 275' ' ' PHE . . . . . 0.536 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -133.09 164.72 26.39 Favored 'General case' 0 CA--C 1.494 -1.189 0 C-N-CA 120.492 -0.483 . . . . 0.0 112.224 177.95 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 276' ' ' SER . . . . . 0.5 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 13.7 p -132.12 152.4 51.26 Favored 'General case' 0 N--CA 1.432 -1.347 0 C-N-CA 120.436 -0.506 . . . . 0.0 110.944 -176.382 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 277' ' ' ILE . . . . . 0.628 HG22 HG22 ' A' ' 267' ' ' ILE . 0.2 OUTLIER -138.26 -169.19 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.195 0 CA-C-N 115.258 -0.883 . . . . 0.0 110.564 -175.185 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 12.9 m -58.32 -75.64 0.05 OUTLIER 'General case' 0 CA--C 1.536 0.438 0 N-CA-C 112.941 0.719 . . . . 0.0 112.941 -175.273 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 279' ' ' ASP . . . . . 0.425 ' HB3' ' HB2' ' A' ' 282' ' ' ASN . 66.7 t0 -154.99 114.78 3.74 Favored 'General case' 0 N--CA 1.45 -0.441 0 O-C-N 122.266 -0.271 . . . . 0.0 111.122 -175.276 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 280' ' ' THR . . . . . 0.678 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 21.5 p -66.89 -29.52 69.43 Favored 'General case' 0 C--N 1.303 -1.417 0 CA-C-O 121.101 0.477 . . . . 0.0 110.262 174.962 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 281' ' ' SER . . . . . 0.416 ' N ' ' OD1' ' A' ' 279' ' ' ASP . 0.3 OUTLIER -62.28 -19.45 63.26 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 115.29 -0.868 . . . . 0.0 109.125 174.794 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 282' ' ' ASN . . . . . 0.425 ' HB2' ' HB3' ' A' ' 279' ' ' ASP . 2.1 m-80 -88.48 -8.48 54.82 Favored 'General case' 0 CA--C 1.507 -0.703 0 N-CA-C 109.454 -0.572 . . . . 0.0 109.454 175.163 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 283' ' ' PHE . . . . . 0.846 ' CE2' HD21 ' A' ' 259' ' ' LEU . 12.2 m-30 -98.82 -83.35 0.42 Allowed 'General case' 0 N--CA 1.442 -0.843 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 174.8 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 284' ' ' SER . . . . . 0.416 ' H ' ' HB2' ' A' ' 283' ' ' PHE . 0.2 OUTLIER 172.88 -162.02 0.02 OUTLIER 'General case' 0 N--CA 1.448 -0.535 0 C-N-CA 124.908 1.283 . . . . 0.0 107.929 -178.998 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 9.4 p-10 -91.64 169.99 10.28 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.666 0.27 . . . . 0.0 110.631 175.618 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 86.2 t80 -106.85 120.98 43.48 Favored 'General case' 0 C--O 1.239 0.531 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.199 179.731 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 287' ' ' ILE . . . . . 0.485 ' O ' ' HG3' ' A' ' 288' ' ' ARG . 96.9 mt -93.32 -57.67 4.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 109.993 -0.373 . . . . 0.0 109.993 175.413 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 288' ' ' ARG . . . . . 0.485 ' HG3' ' O ' ' A' ' 287' ' ' ILE . 15.9 mtm180 -178.9 179.05 0.72 Allowed 'General case' 0 C--O 1.243 0.722 0 C-N-CA 124.525 1.13 . . . . 0.0 110.122 177.773 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 69.52 -163.14 51.75 Favored Glycine 0 C--O 1.235 0.21 0 N-CA-C 111.275 -0.73 . . . . 0.0 111.275 175.903 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 290' ' ' GLY . . . . . 0.43 ' CA ' HG22 ' A' ' 253' ' ' VAL . . . 113.68 128.23 4.72 Favored Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 121.251 -0.5 . . . . 0.0 113.076 175.686 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 98.5 mt -124.42 132.11 71.81 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.858 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 172.751 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 292' ' ' VAL . . . . . 0.415 HG22 ' CZ ' ' A' ' 242' ' ' PHE . 5.5 p -125.33 137.69 56.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -178.189 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 4.4 m -132.18 147.0 52.4 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.299 -177.299 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -75.08 152.11 38.61 Favored 'General case' 0 CA--C 1.507 -0.7 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 173.318 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 295' ' ' VAL . . . . . 0.75 HG21 ' HB3' ' A' ' 264' ' ' PRO . 21.0 t -99.0 126.6 52.19 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.095 0 C-N-CA 120.449 -0.501 . . . . 0.0 111.635 -175.07 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 55.9 tttp -82.47 98.69 9.04 Favored 'General case' 0 N--CA 1.44 -0.959 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 175.739 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 297' ' ' VAL . . . . . 0.569 ' HB ' ' HD2' ' A' ' 298' ' ' PRO . 17.6 m -98.04 -178.78 0.76 Allowed Pre-proline 0 C--N 1.31 -1.139 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 178.846 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 298' ' ' PRO . . . . . 0.569 ' HD2' ' HB ' ' A' ' 297' ' ' VAL . 76.2 Cg_exo -54.36 -38.31 89.07 Favored 'Trans proline' 0 C--N 1.308 -1.589 0 C-N-CA 121.301 1.334 . . . . 0.0 110.314 177.346 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 299' ' ' LYS . . . . . 0.46 ' O ' ' NZ ' ' A' ' 299' ' ' LYS . 0.0 OUTLIER -137.9 114.38 10.36 Favored 'General case' 0 C--O 1.247 0.951 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.9 177.03 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 300' ' ' LYS . . . . . 0.509 ' HG3' ' N ' ' A' ' 301' ' ' ILE . 22.8 pttm -71.81 -156.35 0.03 OUTLIER 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 174.619 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 301' ' ' ILE . . . . . 0.795 HD13 ' H ' ' A' ' 301' ' ' ILE . 0.1 OUTLIER -99.85 128.38 51.76 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.887 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 173.194 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 49.2 m -74.1 144.97 44.73 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 178.948 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 303' ' ' PHE . . . . . 0.529 ' CE1' ' HG3' ' A' ' 243' ' ' GLU . 20.0 m-85 -101.58 147.28 26.59 Favored 'General case' 0 C--N 1.312 -1.042 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -175.166 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -71.45 129.45 38.82 Favored 'General case' 0 C--N 1.313 -1.01 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 176.337 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 6.8 m -73.43 149.15 42.63 Favored 'General case' 0 C--N 1.309 -1.163 0 C-N-CA 120.981 -0.288 . . . . 0.0 110.834 -176.083 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 90.4 mt -55.0 153.13 12.28 Favored Pre-proline 0 C--O 1.242 0.669 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 177.58 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -63.18 142.74 87.96 Favored 'Trans proline' 0 C--N 1.302 -1.914 0 C-N-CA 121.301 1.334 . . . . 0.0 110.856 -177.504 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -132.32 133.36 43.94 Favored 'General case' 0 C--N 1.315 -0.925 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 179.554 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 2.3 m -71.49 137.92 48.55 Favored 'General case' 0 C--N 1.308 -1.225 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 -178.826 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 92.1 mt -102.08 60.23 0.85 Allowed 'General case' 0 CA--C 1.509 -0.623 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 174.754 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 15.1 m -148.54 162.64 5.58 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.237 0 CA-C-N 114.025 -1.443 . . . . 0.0 107.978 176.683 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 . . . . . 0 C--O 1.204 -1.316 0 CA-C-O 118.492 -0.766 . . . . 0.0 110.917 177.394 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 217' ' ' LEU . . . . . 0.545 HD13 ' N ' ' A' ' 218' ' ' SER . 0.2 OUTLIER . . . . . 0 CA--C 1.505 -0.77 0 N-CA-C 106.439 -1.689 . . . . 0.0 106.439 . . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 218' ' ' SER . . . . . 0.545 ' N ' HD13 ' A' ' 217' ' ' LEU . 50.3 m -113.84 146.78 39.48 Favored 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 -173.506 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 219' ' ' ALA . . . . . 0.895 ' HB1' ' HB1' ' A' ' 238' ' ' ALA . . . -138.73 148.69 44.21 Favored 'General case' 0 C--O 1.243 0.742 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.099 -174.278 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 97.4 mmm -74.63 125.15 28.04 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.599 -0.728 . . . . 0.0 109.873 176.26 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 60.1 t -87.06 129.11 39.08 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.948 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 177.136 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -83.87 -69.96 0.6 Allowed 'General case' 0 N--CA 1.433 -1.309 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 176.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -138.12 156.29 47.9 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.274 174.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 224' ' ' VAL . . . . . 0.56 ' CG1' ' SD ' ' A' ' 256' ' ' MET . 62.0 t -122.48 133.58 68.26 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.946 0 N-CA-C 108.18 -1.045 . . . . 0.0 108.18 173.488 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -102.83 121.91 43.43 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-O 120.555 0.217 . . . . 0.0 110.603 -175.842 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 226' ' ' LYS . . . . . 0.416 ' HA ' ' OG1' ' A' ' 280' ' ' THR . 0.4 OUTLIER -70.52 89.67 0.71 Allowed 'General case' 0 C--O 1.242 0.704 0 CA-C-O 120.966 0.412 . . . . 0.0 109.967 178.979 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 227' ' ' ASP . . . . . 0.431 ' OD1' ' N ' ' A' ' 228' ' ' ASN . 52.9 t0 -158.47 171.69 19.69 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.492 -0.776 . . . . 0.0 109.993 -176.789 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 228' ' ' ASN . . . . . 0.454 ' HB2' ' CG ' ' A' ' 279' ' ' ASP . 0.7 OUTLIER -136.16 123.32 14.46 Favored Pre-proline 0 C--N 1.325 -0.459 0 CA-C-N 116.576 -0.284 . . . . 0.0 110.544 175.192 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 229' ' ' PRO . . . . . 0.452 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 45.7 Cg_endo -65.89 146.5 71.49 Favored 'Cis proline' 0 N--CA 1.494 1.538 0 C-N-CA 122.783 -1.757 . . . . 0.0 109.22 -1.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . 0.536 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -68.43 144.06 41.8 Favored Glycine 0 C--O 1.219 -0.812 0 N-CA-C 109.787 -1.325 . . . . 0.0 109.787 -177.72 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 231' ' ' VAL . . . . . 0.45 HG23 HD12 ' A' ' 270' ' ' LEU . 2.5 p -128.12 134.95 64.02 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 CA-C-N 116.989 0.394 . . . . 0.0 110.079 178.168 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 232' ' ' VAL . . . . . 0.5 HG12 HG13 ' A' ' 224' ' ' VAL . 0.6 OUTLIER -133.8 156.44 41.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 C-N-CA 120.428 -0.509 . . . . 0.0 110.836 -179.817 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 24.5 m -117.49 134.3 55.01 Favored 'General case' 0 C--O 1.242 0.693 0 CA-C-N 115.998 -0.546 . . . . 0.0 109.683 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.8 m -106.4 158.58 16.79 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.961 -175.372 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.485 ' O ' ' HB3' ' A' ' 238' ' ' ALA . 22.8 tp -63.29 150.79 42.39 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.226 -0.897 . . . . 0.0 108.686 179.225 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -59.63 -39.7 85.16 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 121.089 0.471 . . . . 0.0 109.847 -177.697 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 237' ' ' GLU . . . . . 0.447 ' O ' ' N ' ' A' ' 239' ' ' ARG . 98.8 mt-10 -70.53 -21.09 62.76 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.16 174.062 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 238' ' ' ALA . . . . . 0.895 ' HB1' ' HB1' ' A' ' 219' ' ' ALA . . . -65.83 61.25 0.03 OUTLIER 'General case' 0 C--O 1.241 0.653 0 CA-C-O 121.227 0.537 . . . . 0.0 111.027 -178.472 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 239' ' ' ARG . . . . . 0.447 ' N ' ' O ' ' A' ' 237' ' ' GLU . 61.5 mtp180 -67.78 85.09 0.21 Allowed 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 174.215 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 240' ' ' HIS . . . . . 0.627 ' HB2' ' CG ' ' A' ' 242' ' ' PHE . 3.5 p80 -57.92 -46.83 84.39 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-N 115.163 -0.926 . . . . 0.0 112.398 -170.903 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 80.32 14.47 80.23 Favored Glycine 0 C--N 1.313 -0.743 0 N-CA-C 109.867 -1.293 . . . . 0.0 109.867 -174.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 242' ' ' PHE . . . . . 0.681 ' CD1' ' HB3' ' A' ' 294' ' ' GLN . 4.6 m-30 -80.02 148.69 31.01 Favored 'General case' 0 CA--C 1.509 -0.617 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 -179.301 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 243' ' ' GLU . . . . . 0.474 ' HB2' ' HB2' ' A' ' 246' ' ' ASP . 37.7 mt-10 -115.46 150.66 36.12 Favored 'General case' 0 C--N 1.308 -1.238 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 179.634 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 244' ' ' THR . . . . . 0.56 ' OG1' HG22 ' A' ' 269' ' ' VAL . 32.6 m -62.43 127.62 32.16 Favored 'General case' 0 C--N 1.305 -1.34 0 C-N-CA 119.235 -0.986 . . . . 0.0 108.652 177.316 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 86.16 4.01 84.44 Favored Glycine 0 C--N 1.311 -0.847 0 N-CA-C 110.489 -1.044 . . . . 0.0 110.489 -176.326 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 246' ' ' ASP . . . . . 0.474 ' HB2' ' HB2' ' A' ' 243' ' ' GLU . 31.6 t0 -81.58 164.06 22.16 Favored 'General case' 0 CA--C 1.515 -0.402 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 177.737 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 247' ' ' PHE . . . . . 0.46 ' HA ' ' O ' ' A' ' 265' ' ' MET . 69.3 m-85 -110.05 134.68 51.89 Favored 'General case' 0 C--N 1.311 -1.085 0 O-C-N 123.413 0.446 . . . . 0.0 110.337 -179.644 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 248' ' ' VAL . . . . . 0.545 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 3.1 m -132.04 163.81 36.46 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.572 0 CA-C-O 120.745 0.307 . . . . 0.0 111.082 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 12.0 p -130.89 162.2 30.17 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 115.126 -0.943 . . . . 0.0 108.896 176.509 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 250' ' ' PHE . . . . . 0.583 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 73.7 m-85 -121.57 157.92 29.67 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-O 121.146 0.498 . . . . 0.0 111.6 -174.763 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 3.7 m -152.25 155.89 38.63 Favored 'General case' 0 C--N 1.313 -1.017 0 CA-C-N 115.473 -0.785 . . . . 0.0 109.473 175.359 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 54.21 25.77 6.09 Favored 'General case' 0 C--N 1.314 -0.947 0 N-CA-C 112.7 0.63 . . . . 0.0 112.7 174.846 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 0.401 HG22 ' CA ' ' A' ' 290' ' ' GLY . 95.6 t -82.53 129.76 36.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 174.487 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -99.92 138.59 36.78 Favored 'General case' 0 C--O 1.24 0.601 0 C-N-CA 120.548 -0.461 . . . . 0.0 110.361 -179.74 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 80.94 -61.56 4.54 Favored Glycine 0 C--N 1.319 -0.378 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 -175.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 256' ' ' MET . . . . . 0.56 ' SD ' ' CG1' ' A' ' 224' ' ' VAL . 31.3 mtt -80.71 62.43 4.75 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.608 0.718 . . . . 0.0 110.172 174.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 257' ' ' ILE . . . . . 0.4 ' O ' ' HB2' ' A' ' 260' ' ' ASN . 47.6 pt -72.54 -19.41 19.19 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.86 -177.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 258' ' ' GLN . . . . . 0.473 ' HB2' ' HG ' ' A' ' 284' ' ' SER . 0.7 OUTLIER -56.02 -39.36 71.82 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 -179.624 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 259' ' ' LEU . . . . . 0.939 HD21 ' CE2' ' A' ' 283' ' ' PHE . 89.8 mt -62.21 -41.7 98.62 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 116.009 -0.542 . . . . 0.0 109.742 178.767 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 260' ' ' ASN . . . . . 0.4 ' HB2' ' O ' ' A' ' 257' ' ' ILE . 97.1 m-20 -60.76 -40.72 93.52 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 178.798 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -96.95 11.04 66.12 Favored Glycine 0 CA--C 1.526 0.78 0 CA-C-N 115.485 -0.78 . . . . 0.0 112.676 -177.664 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 262' ' ' CYS . . . . . 0.401 ' N ' ' O ' ' A' ' 258' ' ' GLN . 4.0 m -102.84 146.75 27.81 Favored 'General case' 0 CA--C 1.517 -0.315 0 CA-C-N 117.6 0.7 . . . . 0.0 111.475 -179.457 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 51.5 mt-30 -62.34 161.96 22.29 Favored Pre-proline 0 C--N 1.326 -0.421 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 172.865 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 264' ' ' PRO . . . . . 0.545 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 37.6 Cg_endo -62.56 146.02 95.4 Favored 'Trans proline' 0 C--N 1.305 -1.727 0 C-N-CA 121.33 1.353 . . . . 0.0 111.219 178.644 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 265' ' ' MET . . . . . 0.611 ' N ' ' SD ' ' A' ' 265' ' ' MET . 0.9 OUTLIER -128.35 162.27 27.48 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 116.782 -0.19 . . . . 0.0 111.502 -175.702 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 70.3 tt0 -71.0 139.4 50.5 Favored 'General case' 0 C--O 1.245 0.818 0 O-C-N 123.585 0.553 . . . . 0.0 109.621 176.641 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 267' ' ' ILE . . . . . 0.65 HG22 HG22 ' A' ' 277' ' ' ILE . 1.9 pp -127.41 152.43 35.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-O 121.049 0.452 . . . . 0.0 111.777 -179.766 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . 0.458 ' HA ' HG23 ' A' ' 244' ' ' THR . 63.8 mttp -129.3 114.23 15.97 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.852 178.816 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.56 HG22 ' OG1' ' A' ' 244' ' ' THR . 34.7 m -74.98 106.75 4.94 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 CA-C-O 121.145 0.497 . . . . 0.0 112.242 -176.679 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 270' ' ' LEU . . . . . 0.45 HD12 HG23 ' A' ' 231' ' ' VAL . 92.9 mt -66.11 -41.02 91.14 Favored 'General case' 0 N--CA 1.449 -0.503 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.517 175.546 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -149.04 -176.19 22.12 Favored Glycine 0 C--N 1.322 -0.224 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 178.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 272' ' ' PRO . . . . . 0.429 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 33.6 Cg_endo -60.98 -34.84 90.14 Favored 'Trans proline' 0 N--CA 1.496 1.672 0 C-N-CA 121.97 1.78 . . . . 0.0 111.992 -177.29 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 57.1 m-85 -118.76 7.75 11.69 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 112.245 0.461 . . . . 0.0 112.245 178.826 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 6.0 p -120.97 124.36 44.7 Favored 'General case' 0 C--N 1.319 -0.725 0 C-N-CA 120.888 -0.325 . . . . 0.0 110.323 178.586 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 275' ' ' PHE . . . . . 0.521 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -132.66 157.55 44.55 Favored 'General case' 0 CA--C 1.501 -0.924 0 C-N-CA 120.133 -0.627 . . . . 0.0 112.599 179.43 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . 0.536 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 7.4 p -125.79 142.36 51.55 Favored 'General case' 0 N--CA 1.431 -1.408 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.937 -173.803 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 277' ' ' ILE . . . . . 0.65 HG22 HG22 ' A' ' 267' ' ' ILE . 32.8 pt -139.77 163.56 24.73 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.917 0 CA-C-N 115.166 -0.924 . . . . 0.0 111.964 -172.783 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 278' ' ' CYS . . . . . 0.414 ' C ' ' O ' ' A' ' 277' ' ' ILE . 86.1 m -17.78 -96.25 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 124.413 1.085 . . . . 0.0 113.611 -178.86 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . 0.454 ' CG ' ' HB2' ' A' ' 228' ' ' ASN . 67.2 t0 -149.38 112.51 4.91 Favored 'General case' 0 CA--C 1.499 -1.017 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 178.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . 0.791 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 11.3 p -67.21 -23.81 65.78 Favored 'General case' 0 N--CA 1.42 -1.949 0 CA-C-O 121.084 0.468 . . . . 0.0 110.4 179.08 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -66.28 -19.12 65.73 Favored 'General case' 0 C--N 1.315 -0.897 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.613 173.478 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 282' ' ' ASN . . . . . 0.48 ' ND2' ' C ' ' A' ' 282' ' ' ASN . 0.0 OUTLIER -91.46 2.72 56.22 Favored 'General case' 0 CA--C 1.513 -0.474 0 C-N-CA 120.409 -0.516 . . . . 0.0 109.809 176.324 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 283' ' ' PHE . . . . . 0.939 ' CE2' HD21 ' A' ' 259' ' ' LEU . 16.2 m-85 -100.98 -76.52 0.56 Allowed 'General case' 0 N--CA 1.445 -0.703 0 CA-C-O 121.404 0.621 . . . . 0.0 109.417 173.616 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 284' ' ' SER . . . . . 0.473 ' HG ' ' HB2' ' A' ' 258' ' ' GLN . 0.0 OUTLIER 166.48 -175.06 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 114.41 -1.268 . . . . 0.0 109.132 -172.875 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 285' ' ' ASP . . . . . 0.415 ' C ' ' HG3' ' A' ' 256' ' ' MET . 19.8 m-20 -86.5 134.5 33.67 Favored 'General case' 0 N--CA 1.472 0.643 0 CA-C-N 117.406 0.094 . . . . 0.0 110.756 179.143 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 286' ' ' TYR . . . . . 0.455 ' HB2' ' SD ' ' A' ' 256' ' ' MET . 55.5 t80 -76.65 128.34 34.5 Favored 'General case' 0 N--CA 1.468 0.447 0 C-N-CA 123.102 0.561 . . . . 0.0 111.094 179.256 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 7.0 mm -100.75 -69.15 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 116.563 -0.29 . . . . 0.0 110.672 173.271 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 95.5 mtm-85 -160.8 -179.44 7.59 Favored 'General case' 0 C--O 1.241 0.63 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.452 -178.748 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 63.35 -143.74 48.58 Favored Glycine 0 CA--C 1.498 -1.027 0 CA-C-N 114.963 -1.017 . . . . 0.0 111.338 174.03 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 290' ' ' GLY . . . . . 0.401 ' CA ' HG22 ' A' ' 253' ' ' VAL . . . 98.76 123.15 4.82 Favored Glycine 0 N--CA 1.436 -1.324 0 C-N-CA 120.968 -0.634 . . . . 0.0 111.774 178.625 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 47.9 mm -119.05 130.18 74.2 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.488 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 175.28 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 11.3 p -122.04 135.87 60.77 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.985 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 -178.063 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . 0.497 ' HA ' ' O ' ' A' ' 217' ' ' LEU . 0.3 OUTLIER -136.19 140.03 43.26 Favored 'General case' 0 C--N 1.316 -0.878 0 C-N-CA 120.478 -0.489 . . . . 0.0 110.237 -177.416 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 294' ' ' GLN . . . . . 0.681 ' HB3' ' CD1' ' A' ' 242' ' ' PHE . 2.3 pt20 . . . . . 0 CA--C 1.502 -0.902 0 C-N-CA 120.083 -0.647 . . . . 0.0 110.847 178.322 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 217' ' ' LEU . . . . . 0.521 ' HB3' ' O ' ' A' ' 240' ' ' HIS . 0.4 OUTLIER . . . . . 0 CA--C 1.514 -0.43 0 N-CA-C 110.448 -0.205 . . . . 0.0 110.448 . . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 66.8 m -131.48 153.78 49.41 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-N 116.416 -0.357 . . . . 0.0 110.174 175.68 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -150.84 155.63 39.6 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.531 -0.304 . . . . 0.0 111.368 -178.404 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 220' ' ' MET . . . . . 0.435 ' SD ' HD22 ' A' ' 235' ' ' LEU . 92.1 mtp -76.83 135.37 38.89 Favored 'General case' 0 N--CA 1.447 -0.615 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.549 176.512 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 94.3 t -87.13 130.99 36.11 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.067 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 175.567 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 222' ' ' SER . . . . . 0.419 ' OG ' ' N ' ' A' ' 223' ' ' MET . 0.0 OUTLIER -82.44 -71.51 0.48 Allowed 'General case' 0 C--N 1.308 -1.216 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 176.836 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 223' ' ' MET . . . . . 0.419 ' N ' ' OG ' ' A' ' 222' ' ' SER . 5.5 ptm -137.66 149.09 46.29 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.711 174.843 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 224' ' ' VAL . . . . . 0.708 HG13 ' CG1' ' A' ' 232' ' ' VAL . 2.3 t -113.37 124.3 69.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 174.822 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 225' ' ' THR . . . . . 0.509 ' O ' HG21 ' A' ' 280' ' ' THR . 74.6 p -79.66 133.08 36.38 Favored 'General case' 0 C--N 1.321 -0.647 0 C-N-CA 120.474 -0.491 . . . . 0.0 110.491 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 226' ' ' LYS . . . . . 0.445 ' NZ ' ' OD1' ' A' ' 285' ' ' ASP . 0.1 OUTLIER -79.21 75.11 5.76 Favored 'General case' 0 C--O 1.243 0.727 0 CA-C-O 121.283 0.563 . . . . 0.0 109.595 179.22 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 227' ' ' ASP . . . . . 0.522 ' N ' ' OG1' ' A' ' 280' ' ' THR . 3.9 t0 -148.72 176.56 10.26 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-N 115.475 -0.784 . . . . 0.0 110.594 -179.742 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 228' ' ' ASN . . . . . 0.485 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.2 OUTLIER -142.87 123.52 8.16 Favored Pre-proline 0 C--N 1.313 -1.02 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.881 179.05 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 229' ' ' PRO . . . . . 0.485 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 47.8 Cg_endo -63.83 146.69 62.47 Favored 'Cis proline' 0 N--CA 1.496 1.62 0 C-N-CA 123.185 -1.589 . . . . 0.0 110.744 -2.12 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . 0.516 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -76.04 141.14 26.7 Favored Glycine 0 N--CA 1.443 -0.857 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 -178.173 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 231' ' ' VAL . . . . . 0.575 HG23 HD12 ' A' ' 270' ' ' LEU . 2.3 p -124.1 133.0 70.5 Favored 'Isoleucine or valine' 0 C--O 1.241 0.624 0 N-CA-C 109.059 -0.719 . . . . 0.0 109.059 174.22 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 232' ' ' VAL . . . . . 0.708 ' CG1' HG13 ' A' ' 224' ' ' VAL . 0.7 OUTLIER -132.34 156.36 42.34 Favored 'Isoleucine or valine' 0 C--O 1.246 0.895 0 C-N-CA 120.438 -0.505 . . . . 0.0 110.353 -175.024 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 233' ' ' THR . . . . . 0.5 ' HA ' ' O ' ' A' ' 273' ' ' TYR . 1.6 p -106.41 159.07 16.43 Favored 'General case' 0 N--CA 1.441 -0.907 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.665 177.556 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 39.3 m -124.36 161.95 24.86 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 123.063 0.545 . . . . 0.0 109.861 -178.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.435 HD22 ' SD ' ' A' ' 220' ' ' MET . 37.2 tp -62.87 135.7 57.46 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 107.88 -1.155 . . . . 0.0 107.88 176.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 236' ' ' ASP . . . . . 0.438 ' O ' ' CZ ' ' A' ' 273' ' ' TYR . 1.9 m-20 -59.54 -35.65 74.62 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-O 121.251 0.548 . . . . 0.0 111.117 -173.611 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 70.1 mt-10 -86.47 -5.02 59.26 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.605 -177.611 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -101.99 100.47 10.76 Favored 'General case' 0 CA--C 1.516 -0.344 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.554 179.393 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 66.4 mtp180 -86.82 107.53 18.34 Favored 'General case' 0 C--N 1.317 -0.847 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 -179.686 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 240' ' ' HIS . . . . . 0.521 ' O ' ' HB3' ' A' ' 217' ' ' LEU . 9.9 p80 -57.48 -47.38 82.05 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.655 -176.902 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 71.18 25.31 75.85 Favored Glycine 0 C--N 1.309 -0.92 0 N-CA-C 109.783 -1.327 . . . . 0.0 109.783 -179.173 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 242' ' ' PHE . . . . . 0.496 ' CD2' ' HB2' ' A' ' 240' ' ' HIS . 15.4 m-30 -79.51 141.28 36.84 Favored 'General case' 0 N--CA 1.435 -1.213 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 -179.82 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 243' ' ' GLU . . . . . 0.505 ' HB2' ' HB2' ' A' ' 246' ' ' ASP . 96.5 mt-10 -96.79 146.5 24.84 Favored 'General case' 0 C--N 1.31 -1.138 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.343 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.1 122.44 16.09 Favored 'General case' 0 C--N 1.307 -1.269 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 -178.408 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 85.0 7.33 83.92 Favored Glycine 0 N--CA 1.442 -0.912 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 -177.211 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 246' ' ' ASP . . . . . 0.505 ' HB2' ' HB2' ' A' ' 243' ' ' GLU . 13.5 t0 -83.79 168.3 16.29 Favored 'General case' 0 C--O 1.24 0.557 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 176.032 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 247' ' ' PHE . . . . . 0.46 ' HA ' ' O ' ' A' ' 265' ' ' MET . 66.3 m-85 -109.4 141.6 41.55 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 112.099 0.407 . . . . 0.0 112.099 -176.349 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 248' ' ' VAL . . . . . 0.445 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.8 m -134.21 161.16 41.18 Favored 'Isoleucine or valine' 0 C--O 1.241 0.655 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.098 178.059 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 47.7 m -128.04 159.37 35.24 Favored 'General case' 0 C--N 1.321 -0.669 0 C-N-CA 124.338 1.055 . . . . 0.0 108.53 173.626 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 250' ' ' PHE . . . . . 0.508 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 69.9 m-85 -110.54 145.8 37.15 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 121.264 0.554 . . . . 0.0 112.171 -177.789 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 19.7 m -137.73 153.3 49.77 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.227 177.048 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 71.6 mm-40 56.08 21.37 5.05 Favored 'General case' 0 C--N 1.314 -0.954 0 N-CA-C 113.354 0.872 . . . . 0.0 113.354 173.023 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 0.437 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 94.1 t -84.37 130.7 35.53 Favored 'Isoleucine or valine' 0 C--O 1.239 0.52 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 177.262 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . 0.414 ' HB2' ' O ' ' A' ' 288' ' ' ARG . 83.1 mt-30 -105.26 144.44 32.05 Favored 'General case' 0 C--O 1.243 0.728 0 CA-C-O 121.001 0.429 . . . . 0.0 109.897 176.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 84.91 -68.42 3.5 Favored Glycine 0 C--N 1.313 -0.747 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -174.049 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 256' ' ' MET . . . . . 0.536 ' HG3' ' N ' ' A' ' 286' ' ' TYR . 47.8 mtt -78.25 65.04 3.51 Favored 'General case' 0 CA--C 1.515 -0.381 0 CA-C-O 121.397 0.617 . . . . 0.0 110.318 173.072 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 46.9 pt -70.82 -23.06 23.54 Favored 'Isoleucine or valine' 0 C--O 1.244 0.797 0 CA-C-N 115.475 -0.784 . . . . 0.0 110.135 -178.271 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 258' ' ' GLN . . . . . 0.542 ' HG3' ' SG ' ' A' ' 262' ' ' CYS . 70.7 tp60 -60.8 -36.62 79.49 Favored 'General case' 0 N--CA 1.445 -0.682 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 179.459 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 259' ' ' LEU . . . . . 0.677 HD21 ' CD2' ' A' ' 283' ' ' PHE . 92.3 mt -61.88 -40.52 95.68 Favored 'General case' 0 N--CA 1.448 -0.542 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.204 179.09 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 260' ' ' ASN . . . . . 0.437 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 98.8 m-20 -60.2 -41.14 92.35 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 179.218 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -96.48 10.94 67.06 Favored Glycine 0 CA--C 1.532 1.132 0 CA-C-N 116.042 -0.527 . . . . 0.0 112.269 179.572 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 262' ' ' CYS . . . . . 0.542 ' SG ' ' HG3' ' A' ' 258' ' ' GLN . 1.2 m -82.24 142.41 32.15 Favored 'General case' 0 CA--C 1.513 -0.444 0 CA-C-N 117.382 0.591 . . . . 0.0 110.827 -178.379 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 27.9 mm100 -62.57 152.51 80.76 Favored Pre-proline 0 C--N 1.321 -0.662 0 N-CA-C 107.572 -1.27 . . . . 0.0 107.572 171.582 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 264' ' ' PRO . . . . . 0.445 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 36.8 Cg_endo -61.22 142.96 98.11 Favored 'Trans proline' 0 C--N 1.307 -1.644 0 C-N-CA 121.059 1.172 . . . . 0.0 110.447 -178.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 265' ' ' MET . . . . . 0.46 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 24.0 ptp -129.12 154.34 46.81 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 112.162 0.43 . . . . 0.0 112.162 -172.429 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -71.02 136.1 48.17 Favored 'General case' 0 C--O 1.245 0.816 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 177.611 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 267' ' ' ILE . . . . . 0.635 HG22 HG22 ' A' ' 277' ' ' ILE . 2.0 pp -126.65 158.54 36.94 Favored 'Isoleucine or valine' 0 C--O 1.243 0.735 0 N-CA-C 112.546 0.573 . . . . 0.0 112.546 -175.864 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 75.1 tttt -127.83 115.81 19.2 Favored 'General case' 0 N--CA 1.448 -0.532 0 CA-C-N 115.213 -0.903 . . . . 0.0 109.86 -179.322 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 17.8 m -70.59 134.5 29.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.244 -179.629 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 270' ' ' LEU . . . . . 0.575 HD12 HG23 ' A' ' 231' ' ' VAL . 81.6 mt -107.75 -24.16 11.81 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.023 0.44 . . . . 0.0 110.124 178.161 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -176.4 -178.27 46.05 Favored Glycine 0 C--N 1.319 -0.396 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 -178.072 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 272' ' ' PRO . . . . . 0.428 ' O ' ' CD2' ' A' ' 240' ' ' HIS . 75.5 Cg_exo -52.89 -43.6 55.21 Favored 'Trans proline' 0 C--N 1.311 -1.424 0 C-N-CA 121.958 1.772 . . . . 0.0 111.582 -177.303 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 273' ' ' TYR . . . . . 0.5 ' O ' ' HA ' ' A' ' 233' ' ' THR . 7.3 m-85 -117.76 10.75 13.4 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 115.933 -0.576 . . . . 0.0 112.084 -176.407 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 5.4 p -123.77 130.02 51.98 Favored 'General case' 0 C--N 1.321 -0.66 0 C-N-CA 120.927 -0.309 . . . . 0.0 110.992 -179.51 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 275' ' ' PHE . . . . . 0.547 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -143.81 164.08 31.52 Favored 'General case' 0 C--O 1.238 0.48 0 C-N-CA 120.926 -0.309 . . . . 0.0 111.406 175.811 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . 0.522 ' HB3' HD11 ' A' ' 270' ' ' LEU . 4.4 p -131.05 145.38 52.0 Favored 'General case' 0 C--O 1.244 0.805 0 C-N-CA 120.672 -0.411 . . . . 0.0 111.912 -175.723 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 277' ' ' ILE . . . . . 0.635 HG22 HG22 ' A' ' 267' ' ' ILE . 35.0 pt -140.18 165.05 21.86 Favored 'Isoleucine or valine' 0 C--O 1.236 0.368 0 CA-C-N 114.766 -1.107 . . . . 0.0 112.582 -173.077 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 278' ' ' CYS . . . . . 0.413 ' SG ' ' SD ' ' A' ' 265' ' ' MET . 2.6 p -27.2 -94.76 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.416 0 N-CA-C 114.478 1.288 . . . . 0.0 114.478 -176.394 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 58.2 m-20 -144.48 110.0 5.24 Favored 'General case' 0 CA--C 1.513 -0.456 0 CA-C-N 116.622 -0.263 . . . . 0.0 111.423 -171.402 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . 0.785 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 59.7 p -66.02 -27.7 68.31 Favored 'General case' 0 C--N 1.31 -1.137 0 CA-C-O 121.215 0.531 . . . . 0.0 109.712 172.066 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 1.5 p -63.68 -17.06 62.57 Favored 'General case' 0 N--CA 1.43 -1.435 0 CA-C-N 114.799 -1.092 . . . . 0.0 109.753 174.071 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 17.9 t-20 -98.27 -8.71 26.74 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.6 175.05 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 283' ' ' PHE . . . . . 0.785 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 15.6 m-30 -90.66 -83.08 0.27 Allowed 'General case' 0 C--O 1.237 0.404 0 CA-C-O 121.436 0.636 . . . . 0.0 110.952 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 169.25 -174.0 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 114.342 -1.299 . . . . 0.0 108.874 -173.71 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 285' ' ' ASP . . . . . 0.445 ' OD1' ' NZ ' ' A' ' 226' ' ' LYS . 31.1 t0 -92.99 112.36 24.3 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 120.906 -0.318 . . . . 0.0 111.678 -179.788 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 286' ' ' TYR . . . . . 0.536 ' N ' ' HG3' ' A' ' 256' ' ' MET . 12.4 t80 -63.66 128.49 36.07 Favored 'General case' 0 CA--C 1.512 -0.485 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 177.865 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 287' ' ' ILE . . . . . 0.448 HG22 ' HG2' ' A' ' 288' ' ' ARG . 96.5 mt -106.64 -64.06 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 175.894 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . 0.448 ' HG2' HG22 ' A' ' 287' ' ' ILE . 9.6 ptp180 -161.15 -178.67 6.9 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.088 178.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 70.02 -161.08 53.19 Favored Glycine 0 CA--C 1.504 -0.615 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 178.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 108.8 117.59 4.06 Favored Glycine 0 N--CA 1.442 -0.958 0 C-N-CA 120.934 -0.651 . . . . 0.0 113.291 174.686 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 97.2 mt -118.16 130.34 73.17 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.25 0 N-CA-C 107.321 -1.363 . . . . 0.0 107.321 170.562 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 4.8 p -109.19 128.89 64.77 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 -179.355 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 36.7 m -116.63 137.42 52.2 Favored 'General case' 0 N--CA 1.438 -1.039 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.932 -176.543 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 . . . . . 0 N--CA 1.431 -1.399 0 CA-C-N 115.609 -0.723 . . . . 0.0 109.752 176.884 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 217' ' ' LEU . . . . . 0.481 ' N ' ' OE1' ' A' ' 294' ' ' GLN . 3.8 mm? . . . . . 0 CA--C 1.503 -0.829 0 N-CA-C 112.35 0.5 . . . . 0.0 112.35 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 5.9 m -142.79 133.45 25.21 Favored 'General case' 0 N--CA 1.441 -0.92 0 CA-C-N 115.126 -0.943 . . . . 0.0 109.533 175.803 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -147.78 164.41 33.71 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 121.336 0.589 . . . . 0.0 112.295 -177.129 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 220' ' ' MET . . . . . 0.69 ' SD ' ' N ' ' A' ' 220' ' ' MET . 0.0 OUTLIER -74.77 132.62 41.75 Favored 'General case' 0 C--O 1.243 0.747 0 CA-C-N 115.023 -0.99 . . . . 0.0 109.876 178.264 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 52.4 t -88.91 130.21 38.67 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 175.142 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 36.9 p -88.1 -57.72 2.83 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 120.351 -0.54 . . . . 0.0 110.189 -178.661 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 1.7 ptm -137.04 149.75 47.64 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.481 175.69 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 224' ' ' VAL . . . . . 0.63 HG11 ' SD ' ' A' ' 256' ' ' MET . 21.7 t -127.21 132.32 69.76 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.963 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 174.004 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -106.42 121.55 44.48 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 -177.082 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 226' ' ' LYS . . . . . 0.548 ' HA ' ' HB ' ' A' ' 280' ' ' THR . 0.1 OUTLIER -77.38 73.39 3.95 Favored 'General case' 0 C--O 1.237 0.436 0 C-N-CA 119.721 -0.792 . . . . 0.0 111.642 -179.596 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 227' ' ' ASP . . . . . 0.419 ' N ' ' OG1' ' A' ' 280' ' ' THR . 41.5 t0 -126.23 -178.85 4.47 Favored 'General case' 0 C--O 1.238 0.499 0 CA-C-N 114.827 -1.079 . . . . 0.0 109.989 -179.587 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 228' ' ' ASN . . . . . 0.436 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.4 OUTLIER -136.89 123.19 13.54 Favored Pre-proline 0 CA--C 1.538 0.499 0 CA-C-O 120.571 0.224 . . . . 0.0 111.205 175.799 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 229' ' ' PRO . . . . . 0.436 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 50.0 Cg_endo -66.8 151.0 82.05 Favored 'Cis proline' 0 N--CA 1.495 1.61 0 C-N-CA 123.288 -1.547 . . . . 0.0 108.592 -2.397 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . 0.687 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -63.28 139.96 44.62 Favored Glycine 0 C--N 1.315 -0.586 0 C-N-CA 119.515 -1.326 . . . . 0.0 110.233 -175.249 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 3.1 p -125.07 131.3 72.68 Favored 'Isoleucine or valine' 0 C--O 1.241 0.641 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 178.408 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 232' ' ' VAL . . . . . 0.5 HG22 ' CD1' ' A' ' 275' ' ' PHE . 0.7 OUTLIER -135.26 157.14 39.95 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-N 116.546 -0.297 . . . . 0.0 110.334 -178.293 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 233' ' ' THR . . . . . 0.458 ' HA ' ' O ' ' A' ' 273' ' ' TYR . 11.9 m -114.78 147.03 40.33 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.012 177.365 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 55.7 m -106.47 153.09 22.79 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.021 -178.315 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.415 ' HB3' ' HB3' ' A' ' 238' ' ' ALA . 32.9 tp -56.81 130.03 43.93 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 -179.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 236' ' ' ASP . . . . . 0.538 ' HA ' ' CE1' ' A' ' 273' ' ' TYR . 34.6 t70 -55.23 -42.97 74.08 Favored 'General case' 0 CA--C 1.509 -0.62 0 CA-C-O 121.459 0.647 . . . . 0.0 109.865 -176.26 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -64.79 -33.54 76.23 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-N 114.851 -1.068 . . . . 0.0 110.52 -179.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 238' ' ' ALA . . . . . 0.415 ' HB3' ' HB3' ' A' ' 235' ' ' LEU . . . -114.94 92.8 4.06 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.532 -176.828 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 239' ' ' ARG . . . . . 0.454 ' HG2' ' CE1' ' A' ' 273' ' ' TYR . 58.9 mtm180 -67.29 138.14 56.62 Favored 'General case' 0 N--CA 1.448 -0.532 0 C-N-CA 119.927 -0.709 . . . . 0.0 109.821 174.334 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 240' ' ' HIS . . . . . 0.656 ' H ' ' CD2' ' A' ' 240' ' ' HIS . 6.2 p80 -58.9 -45.35 90.5 Favored 'General case' 0 C--N 1.313 -0.988 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.414 178.384 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 80.26 12.67 82.9 Favored Glycine 0 C--N 1.319 -0.39 0 N-CA-C 109.73 -1.348 . . . . 0.0 109.73 -177.871 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 242' ' ' PHE . . . . . 0.594 ' CD2' ' HB2' ' A' ' 240' ' ' HIS . 8.6 m-30 -81.61 149.58 28.53 Favored 'General case' 0 N--CA 1.442 -0.862 0 CA-C-N 115.327 -0.436 . . . . 0.0 110.329 -179.813 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -117.96 150.76 38.7 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-N 115.335 -0.848 . . . . 0.0 108.783 176.828 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 244' ' ' THR . . . . . 0.71 ' OG1' HG22 ' A' ' 269' ' ' VAL . 28.5 m -57.56 125.75 24.27 Favored 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 119.319 -0.952 . . . . 0.0 109.16 179.643 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 104.27 -10.93 51.17 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 -175.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 68.3 m-20 -67.73 147.56 52.46 Favored 'General case' 0 C--N 1.328 -0.358 0 O-C-N 122.82 -0.224 . . . . 0.0 111.0 178.18 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 247' ' ' PHE . . . . . 0.445 ' HA ' ' O ' ' A' ' 265' ' ' MET . 66.9 m-85 -109.52 125.75 52.82 Favored 'General case' 0 C--O 1.242 0.697 0 CA-C-N 116.1 -0.5 . . . . 0.0 109.909 178.037 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 248' ' ' VAL . . . . . 0.49 HG12 ' HG2' ' A' ' 294' ' ' GLN . 3.4 m -132.48 164.52 34.78 Favored 'Isoleucine or valine' 0 C--O 1.246 0.908 0 N-CA-C 112.472 0.545 . . . . 0.0 112.472 -175.794 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 13.5 p -131.98 159.25 39.29 Favored 'General case' 0 C--O 1.241 0.634 0 CA-C-N 114.66 -1.155 . . . . 0.0 108.911 174.856 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 250' ' ' PHE . . . . . 0.574 ' CD1' HD22 ' A' ' 259' ' ' LEU . 65.9 m-85 -114.85 159.21 20.92 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 121.327 0.584 . . . . 0.0 112.529 -172.725 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 7.0 m -157.5 161.73 38.85 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-N 115.208 -0.905 . . . . 0.0 109.323 174.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . 0.445 ' HG3' HD12 ' A' ' 291' ' ' ILE . 61.9 mm-40 59.17 18.47 6.53 Favored 'General case' 0 CA--C 1.544 0.732 0 N-CA-C 112.024 0.379 . . . . 0.0 112.024 177.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 0.47 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 57.3 t -86.98 132.41 32.5 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 178.734 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 90.2 mt-30 -105.83 146.05 30.4 Favored 'General case' 0 C--O 1.24 0.589 0 CA-C-O 121.244 0.545 . . . . 0.0 111.096 177.511 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . 0.424 ' HA3' HG13 ' A' ' 287' ' ' ILE . . . 79.65 -65.94 3.61 Favored Glycine 0 CA--C 1.505 -0.585 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 -177.255 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 256' ' ' MET . . . . . 0.63 ' SD ' HG11 ' A' ' 224' ' ' VAL . 26.5 ttm -81.98 54.5 2.49 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-O 121.551 0.691 . . . . 0.0 109.324 175.106 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 257' ' ' ILE . . . . . 0.404 ' O ' ' HB2' ' A' ' 260' ' ' ASN . 48.2 pt -68.81 -20.06 24.58 Favored 'Isoleucine or valine' 0 C--O 1.239 0.546 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.607 -176.061 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 258' ' ' GLN . . . . . 0.694 ' HG3' ' SG ' ' A' ' 262' ' ' CYS . 47.4 tp60 -56.42 -31.66 64.13 Favored 'General case' 0 N--CA 1.439 -1.002 0 C-N-CA 120.009 -0.676 . . . . 0.0 110.353 178.851 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 259' ' ' LEU . . . . . 1.057 HD21 ' CE2' ' A' ' 283' ' ' PHE . 78.9 mt -62.18 -41.32 98.22 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 120.911 0.386 . . . . 0.0 110.323 174.17 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 260' ' ' ASN . . . . . 0.47 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 98.3 m-20 -59.77 -40.52 88.48 Favored 'General case' 0 CA--C 1.509 -0.612 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 -179.852 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -101.27 17.32 55.91 Favored Glycine 0 C--N 1.322 -0.2 0 CA-C-N 115.543 -0.753 . . . . 0.0 112.158 -178.425 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 262' ' ' CYS . . . . . 0.694 ' SG ' ' HG3' ' A' ' 258' ' ' GLN . 0.9 OUTLIER -91.77 155.32 18.33 Favored 'General case' 0 CA--C 1.51 -0.565 0 CA-C-N 117.157 0.478 . . . . 0.0 111.687 -178.009 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 28.1 mm-40 -74.18 153.72 88.39 Favored Pre-proline 0 C--N 1.325 -0.491 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 170.612 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -65.37 148.78 88.49 Favored 'Trans proline' 0 C--N 1.305 -1.716 0 C-N-CA 121.375 1.383 . . . . 0.0 111.253 -178.538 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 265' ' ' MET . . . . . 0.483 ' SD ' HD12 ' A' ' 277' ' ' ILE . 12.9 ptp -138.38 160.21 40.1 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.831 -174.853 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 266' ' ' GLU . . . . . 0.427 ' OE2' ' NZ ' ' A' ' 268' ' ' LYS . 36.1 tt0 -71.48 144.82 49.54 Favored 'General case' 0 C--O 1.242 0.663 0 O-C-N 123.999 0.812 . . . . 0.0 109.325 177.097 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 267' ' ' ILE . . . . . 0.687 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.5 pp -126.71 155.16 37.21 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-O 120.753 0.311 . . . . 0.0 111.501 -179.704 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . 0.638 ' HA ' HG23 ' A' ' 244' ' ' THR . 65.9 mttm -127.99 123.31 34.45 Favored 'General case' 0 C--O 1.239 0.548 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 177.496 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.71 HG22 ' OG1' ' A' ' 244' ' ' THR . 34.6 m -81.42 105.11 10.93 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.689 0 CA-C-O 121.284 0.564 . . . . 0.0 112.484 -176.398 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 92.4 mt -67.13 -41.42 86.15 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.639 -0.709 . . . . 0.0 110.089 175.927 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -150.51 -177.65 24.64 Favored Glycine 0 CA--C 1.52 0.356 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 -179.202 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 272' ' ' PRO . . . . . 0.605 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 33.7 Cg_endo -62.51 -32.23 80.17 Favored 'Trans proline' 0 C--N 1.309 -1.541 0 C-N-CA 121.883 1.722 . . . . 0.0 110.726 -177.203 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 273' ' ' TYR . . . . . 0.538 ' CE1' ' HA ' ' A' ' 236' ' ' ASP . 74.2 m-85 -116.87 0.07 12.39 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.608 -0.724 . . . . 0.0 112.89 -179.015 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -120.17 127.71 52.73 Favored 'General case' 0 C--O 1.242 0.696 0 C-N-CA 120.658 -0.417 . . . . 0.0 111.659 178.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 275' ' ' PHE . . . . . 0.536 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -133.43 162.68 31.21 Favored 'General case' 0 CA--C 1.501 -0.936 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.535 177.12 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . 0.521 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 4.4 p -134.4 146.92 50.32 Favored 'General case' 0 C--N 1.313 -0.984 0 C-N-CA 119.949 -0.701 . . . . 0.0 111.629 -178.579 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 277' ' ' ILE . . . . . 0.565 HG22 HG22 ' A' ' 267' ' ' ILE . 34.9 pt -137.26 167.8 22.52 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.961 0 CA-C-N 114.694 -1.139 . . . . 0.0 111.481 -173.243 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 278' ' ' CYS . . . . . 0.404 ' C ' ' O ' ' A' ' 277' ' ' ILE . 71.7 m -22.05 -85.02 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.764 0 N-CA-C 113.771 1.026 . . . . 0.0 113.771 -175.409 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . 0.429 ' HB3' ' HB2' ' A' ' 282' ' ' ASN . 58.4 t0 -153.26 106.76 3.01 Favored 'General case' 0 CA--C 1.506 -0.743 0 CA-C-O 120.753 0.311 . . . . 0.0 110.372 179.552 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . 0.817 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 5.9 p -65.99 -27.46 68.15 Favored 'General case' 0 C--N 1.297 -1.695 0 CA-C-O 121.214 0.531 . . . . 0.0 111.057 177.07 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -64.81 -19.98 66.14 Favored 'General case' 0 C--N 1.314 -0.978 0 CA-C-N 115.464 -0.789 . . . . 0.0 109.183 174.776 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 282' ' ' ASN . . . . . 0.429 ' HB2' ' HB3' ' A' ' 279' ' ' ASP . 0.2 OUTLIER -87.76 -8.55 55.86 Favored 'General case' 0 CA--C 1.508 -0.667 0 N-CA-C 108.752 -0.832 . . . . 0.0 108.752 179.554 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 283' ' ' PHE . . . . . 1.057 ' CE2' HD21 ' A' ' 259' ' ' LEU . 13.3 m-85 -92.25 -77.01 0.44 Allowed 'General case' 0 N--CA 1.443 -0.798 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 174.159 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 169.23 -179.3 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 114.522 -1.217 . . . . 0.0 109.702 -174.401 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 35.8 t0 -85.62 132.96 34.07 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 116.496 -0.32 . . . . 0.0 111.179 178.804 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 286' ' ' TYR . . . . . 0.687 ' CZ ' ' HA ' ' A' ' 288' ' ' ARG . 91.1 t80 -68.56 130.56 43.21 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.096 -179.895 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 287' ' ' ILE . . . . . 0.424 HG13 ' HA3' ' A' ' 255' ' ' GLY . 85.8 mt -100.17 -63.11 1.76 Allowed 'Isoleucine or valine' 0 CA--C 1.514 -0.433 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 170.072 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . 0.687 ' HA ' ' CZ ' ' A' ' 286' ' ' TYR . 9.5 ptm180 -172.41 -173.2 1.02 Allowed 'General case' 0 C--O 1.243 0.726 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.987 175.307 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 68.48 -163.08 49.51 Favored Glycine 0 CA--C 1.507 -0.464 0 N-CA-C 110.629 -0.988 . . . . 0.0 110.629 175.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 113.97 124.61 4.07 Favored Glycine 0 N--CA 1.443 -0.889 0 C-N-CA 121.462 -0.399 . . . . 0.0 112.486 175.768 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . 0.445 HD12 ' HG3' ' A' ' 252' ' ' GLU . 92.2 mt -123.09 132.51 71.26 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 172.234 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . 0.469 ' HB ' ' CE2' ' A' ' 250' ' ' PHE . 4.9 p -118.1 133.45 64.86 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 C-N-CA 120.624 -0.431 . . . . 0.0 110.028 -176.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 3.9 m -128.13 146.56 50.67 Favored 'General case' 0 N--CA 1.446 -0.64 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.648 -175.142 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 294' ' ' GLN . . . . . 0.539 ' HG3' ' CE1' ' A' ' 242' ' ' PHE . 90.7 mt-30 . . . . . 0 CA--C 1.505 -0.778 0 CA-C-O 121.279 0.561 . . . . 0.0 110.224 176.481 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 217' ' ' LEU . . . . . 0.792 HD13 ' N ' ' A' ' 218' ' ' SER . 1.3 tm? . . . . . 0 CA--C 1.51 -0.592 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 218' ' ' SER . . . . . 0.792 ' N ' HD13 ' A' ' 217' ' ' LEU . 75.6 m -114.72 131.45 56.76 Favored 'General case' 0 N--CA 1.438 -1.066 0 CA-C-N 115.846 -0.615 . . . . 0.0 109.358 178.238 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 219' ' ' ALA . . . . . 0.566 ' HB1' ' HB1' ' A' ' 238' ' ' ALA . . . -127.74 150.33 49.84 Favored 'General case' 0 CA--C 1.503 -0.845 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.899 -177.097 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 220' ' ' MET . . . . . 0.71 ' SD ' HG12 ' A' ' 291' ' ' ILE . 87.6 mmm -76.56 131.21 38.81 Favored 'General case' 0 N--CA 1.44 -0.926 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 176.587 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 91.5 t -75.51 128.21 37.14 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.311 0 N-CA-C 107.586 -1.265 . . . . 0.0 107.586 175.877 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 222' ' ' SER . . . . . 0.628 ' CB ' ' HG1' ' A' ' 233' ' ' THR . 0.1 OUTLIER -84.6 -67.33 0.8 Allowed 'General case' 0 N--CA 1.437 -1.087 0 C-N-CA 119.717 -0.793 . . . . 0.0 109.375 179.703 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 3.6 ptm -137.9 151.39 47.97 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 112.552 0.575 . . . . 0.0 112.552 173.056 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 224' ' ' VAL . . . . . 0.717 HG22 ' HB ' ' A' ' 232' ' ' VAL . 68.8 t -123.78 132.59 71.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 174.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 28.2 p -92.76 131.32 37.92 Favored 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 121.031 -0.268 . . . . 0.0 110.38 179.588 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 6.0 ttmt -77.94 87.61 4.12 Favored 'General case' 0 N--CA 1.446 -0.646 0 C-N-CA 119.477 -0.889 . . . . 0.0 109.152 178.548 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 227' ' ' ASP . . . . . 0.526 ' N ' ' OG1' ' A' ' 280' ' ' THR . 47.5 t0 -158.63 175.0 14.19 Favored 'General case' 0 C--N 1.312 -1.056 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.532 -179.574 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 228' ' ' ASN . . . . . 0.475 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.9 OUTLIER -140.85 123.56 9.75 Favored Pre-proline 0 C--O 1.237 0.406 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.112 173.866 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 229' ' ' PRO . . . . . 0.475 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 44.8 Cg_endo -66.31 144.7 67.88 Favored 'Cis proline' 0 C--N 1.313 -1.294 0 C-N-CA 122.492 -1.878 . . . . 0.0 109.308 -2.029 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . 0.48 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -82.71 144.9 23.37 Favored Glycine 0 C--N 1.312 -0.8 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 -178.179 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 231' ' ' VAL . . . . . 0.416 HG23 HD12 ' A' ' 270' ' ' LEU . 2.6 p -121.22 130.53 74.56 Favored 'Isoleucine or valine' 0 C--O 1.241 0.657 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 176.299 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 232' ' ' VAL . . . . . 0.717 ' HB ' HG22 ' A' ' 224' ' ' VAL . 0.7 OUTLIER -132.66 157.14 42.95 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 CA-C-N 116.264 -0.425 . . . . 0.0 109.874 -177.413 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 233' ' ' THR . . . . . 0.652 HG22 HG22 ' A' ' 274' ' ' THR . 61.6 p -110.35 158.47 18.41 Favored 'General case' 0 N--CA 1.429 -1.486 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.229 179.711 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.8 m -113.08 148.97 34.14 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 172.656 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 40.2 tp -56.69 133.73 54.17 Favored 'General case' 0 C--N 1.308 -1.22 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 -179.69 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 236' ' ' ASP . . . . . 0.409 ' O ' ' CE1' ' A' ' 273' ' ' TYR . 7.8 t70 -52.72 -37.96 60.02 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.683 -171.523 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 10.0 mm-40 -75.31 -6.67 51.1 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.076 -178.011 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 238' ' ' ALA . . . . . 0.566 ' HB1' ' HB1' ' A' ' 219' ' ' ALA . . . -97.39 99.88 11.32 Favored 'General case' 0 C--O 1.239 0.505 0 N-CA-C 112.554 0.575 . . . . 0.0 112.554 -175.453 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 239' ' ' ARG . . . . . 0.412 ' O ' ' C ' ' A' ' 240' ' ' HIS . 0.0 OUTLIER -70.61 66.49 0.34 Allowed 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 116.519 -0.31 . . . . 0.0 110.678 175.396 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 240' ' ' HIS . . . . . 0.6 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 14.0 p80 -33.49 -49.04 0.28 Allowed 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.227 0.537 . . . . 0.0 111.291 -178.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 79.41 19.31 71.83 Favored Glycine 0 C--O 1.245 0.841 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 178.432 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 242' ' ' PHE . . . . . 0.673 ' CD1' ' HB3' ' A' ' 294' ' ' GLN . 4.3 m-30 -79.85 141.53 36.1 Favored 'General case' 0 N--CA 1.444 -0.745 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 -179.256 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 243' ' ' GLU . . . . . 0.473 ' HB2' ' HB2' ' A' ' 246' ' ' ASP . 96.5 mt-10 -109.35 158.37 17.97 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 178.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 7.9 m -65.14 123.98 20.93 Favored 'General case' 0 C--N 1.312 -1.022 0 C-N-CA 119.115 -1.034 . . . . 0.0 108.538 178.101 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 85.87 8.04 80.11 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.559 -1.016 . . . . 0.0 110.559 -176.374 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 246' ' ' ASP . . . . . 0.473 ' HB2' ' HB2' ' A' ' 243' ' ' GLU . 45.7 t0 -82.44 167.19 18.7 Favored 'General case' 0 CA--C 1.518 -0.287 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 179.616 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 247' ' ' PHE . . . . . 0.419 ' HA ' ' O ' ' A' ' 265' ' ' MET . 95.8 m-85 -111.95 137.77 49.48 Favored 'General case' 0 C--O 1.24 0.584 0 CA-C-O 120.64 0.257 . . . . 0.0 111.295 -177.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 248' ' ' VAL . . . . . 0.562 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.6 m -133.58 160.89 41.96 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.306 0 CA-C-N 116.557 -0.292 . . . . 0.0 111.159 177.5 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 2.9 p -117.84 152.01 36.21 Favored 'General case' 0 C--N 1.318 -0.786 0 C-N-CA 123.958 0.903 . . . . 0.0 109.404 175.082 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 250' ' ' PHE . . . . . 0.644 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 75.0 m-85 -110.92 146.56 36.35 Favored 'General case' 0 CA--C 1.506 -0.715 0 C-N-CA 122.695 0.398 . . . . 0.0 110.758 -178.007 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 2.0 m -154.59 154.65 33.37 Favored 'General case' 0 C--N 1.31 -1.149 0 C-N-CA 120.765 -0.374 . . . . 0.0 110.145 176.778 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 73.5 mm-40 55.13 30.18 13.94 Favored 'General case' 0 C--N 1.313 -0.979 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.787 176.17 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 0.703 HG22 ' HA2' ' A' ' 290' ' ' GLY . 2.8 t -97.93 115.24 37.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 177.269 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . 0.416 ' HG3' ' HD2' ' A' ' 288' ' ' ARG . 2.0 mm100 -79.1 137.76 37.64 Favored 'General case' 0 C--O 1.238 0.473 0 CA-C-O 121.035 0.445 . . . . 0.0 111.481 -179.769 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . 0.405 ' N ' HD12 ' A' ' 287' ' ' ILE . . . 81.99 -55.59 4.92 Favored Glycine 0 CA--C 1.506 -0.479 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 -178.579 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 256' ' ' MET . . . . . 0.552 ' SD ' HG11 ' A' ' 224' ' ' VAL . 3.1 ttm -81.24 49.93 1.35 Allowed 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.814 0.816 . . . . 0.0 109.215 176.927 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 46.7 pt -72.13 -20.73 20.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-N 114.836 -1.074 . . . . 0.0 110.974 -176.61 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 258' ' ' GLN . . . . . 0.599 ' O ' ' SG ' ' A' ' 262' ' ' CYS . 2.8 tp-100 -54.48 -41.07 69.12 Favored 'General case' 0 N--CA 1.448 -0.555 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 179.147 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 259' ' ' LEU . . . . . 0.689 HD21 ' CZ ' ' A' ' 283' ' ' PHE . 98.2 mt -63.09 -39.92 96.14 Favored 'General case' 0 N--CA 1.445 -0.695 0 CA-C-N 114.861 -1.063 . . . . 0.0 110.116 177.545 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -59.76 -40.74 89.19 Favored 'General case' 0 CA--C 1.51 -0.591 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 -178.161 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -88.59 -1.12 81.16 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 115.548 -0.751 . . . . 0.0 112.106 -179.594 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 262' ' ' CYS . . . . . 0.599 ' SG ' ' O ' ' A' ' 258' ' ' GLN . 61.5 m -83.1 153.34 24.91 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-N 117.157 0.479 . . . . 0.0 111.017 -179.259 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 5.9 mm100 -79.07 163.96 57.33 Favored Pre-proline 0 C--N 1.323 -0.567 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 169.116 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 264' ' ' PRO . . . . . 0.562 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 36.7 Cg_exo -59.54 143.32 99.71 Favored 'Trans proline' 0 C--N 1.307 -1.608 0 C-N-CA 121.013 1.142 . . . . 0.0 111.105 -176.823 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 265' ' ' MET . . . . . 0.642 ' N ' ' SD ' ' A' ' 265' ' ' MET . 0.9 OUTLIER -126.88 160.76 30.02 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 116.627 -0.26 . . . . 0.0 111.396 -175.966 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 3.2 tt0 -71.44 137.72 48.49 Favored 'General case' 0 C--O 1.241 0.632 0 O-C-N 123.653 0.596 . . . . 0.0 110.224 178.697 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 267' ' ' ILE . . . . . 0.732 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.7 pp -132.01 162.96 38.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.113 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 64.3 mttp -124.85 136.22 53.61 Favored 'General case' 0 C--O 1.216 -0.705 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 175.189 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 15.9 m -95.64 102.3 13.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 CA-C-O 121.355 0.597 . . . . 0.0 111.634 -179.403 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 270' ' ' LEU . . . . . 0.416 HD12 HG23 ' A' ' 231' ' ' VAL . 95.9 mt -66.8 -39.77 87.87 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.672 178.278 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -144.73 -170.3 13.82 Favored Glycine 0 N--CA 1.465 0.585 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 -176.516 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 272' ' ' PRO . . . . . 0.6 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 28.6 Cg_endo -59.31 -37.82 88.55 Favored 'Trans proline' 0 N--CA 1.491 1.37 0 C-N-CA 121.95 1.767 . . . . 0.0 111.88 -177.103 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 273' ' ' TYR . . . . . 0.409 ' CE1' ' O ' ' A' ' 236' ' ' ASP . 23.1 m-85 -124.03 5.53 8.61 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 111.726 0.269 . . . . 0.0 111.726 176.834 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 274' ' ' THR . . . . . 0.652 HG22 HG22 ' A' ' 233' ' ' THR . 0.7 OUTLIER -105.99 128.43 53.82 Favored 'General case' 0 C--N 1.32 -0.715 0 C-N-CA 120.586 -0.445 . . . . 0.0 110.724 -175.757 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 275' ' ' PHE . . . . . 0.562 ' CD1' HG22 ' A' ' 232' ' ' VAL . 0.0 OUTLIER -136.11 161.57 35.35 Favored 'General case' 0 CA--C 1.505 -0.77 0 C-N-CA 120.828 -0.349 . . . . 0.0 111.871 179.154 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . 0.48 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 3.7 p -131.83 139.86 48.98 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-O 121.272 0.558 . . . . 0.0 111.883 -175.413 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 277' ' ' ILE . . . . . 0.497 HG22 HG22 ' A' ' 267' ' ' ILE . 37.0 pt -136.95 164.56 30.02 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.723 0 CA-C-N 114.69 -1.141 . . . . 0.0 112.378 -172.099 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 278' ' ' CYS . . . . . 0.449 ' O ' ' HA ' ' A' ' 229' ' ' PRO . 71.2 m -29.73 -92.15 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.402 0 N-CA-C 114.113 1.153 . . . . 0.0 114.113 -176.794 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 19.8 t0 -145.78 114.38 6.79 Favored 'General case' 0 CA--C 1.503 -0.847 0 CA-C-O 120.719 0.295 . . . . 0.0 111.214 -175.673 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . 0.733 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 21.7 p -65.53 -30.59 71.36 Favored 'General case' 0 C--N 1.3 -1.586 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.576 176.18 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -65.32 -20.16 66.28 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 115.271 -0.877 . . . . 0.0 109.321 177.339 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -87.37 -8.09 57.02 Favored 'General case' 0 CA--C 1.506 -0.717 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.848 179.663 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 283' ' ' PHE . . . . . 0.733 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 5.3 m-85 -94.96 -68.38 0.8 Allowed 'General case' 0 N--CA 1.443 -0.824 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 172.808 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 284' ' ' SER . . . . . 0.406 ' OG ' ' HA ' ' A' ' 256' ' ' MET . 1.7 p 164.39 -87.93 0.0 OUTLIER 'General case' 0 C--O 1.244 0.763 0 CA-C-N 115.246 -0.888 . . . . 0.0 110.909 176.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 285' ' ' ASP . . . . . 0.492 ' O ' ' N ' ' A' ' 256' ' ' MET . 3.7 t0 -157.59 165.32 35.86 Favored 'General case' 0 C--O 1.22 -0.496 0 CA-C-N 116.614 -0.266 . . . . 0.0 111.055 179.579 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 286' ' ' TYR . . . . . 0.461 ' O ' ' CD2' ' A' ' 286' ' ' TYR . 35.7 t80 -106.8 89.22 2.95 Favored 'General case' 0 C--N 1.319 -0.728 0 C-N-CA 123.317 0.647 . . . . 0.0 110.038 179.052 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 287' ' ' ILE . . . . . 0.414 HG22 ' HG3' ' A' ' 288' ' ' ARG . 96.5 mt -70.44 -46.11 72.04 Favored 'Isoleucine or valine' 0 C--O 1.24 0.597 0 CA-C-O 121.197 0.522 . . . . 0.0 110.14 179.235 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . 0.416 ' HD2' ' HG3' ' A' ' 254' ' ' GLN . 0.0 OUTLIER 173.45 173.09 0.15 Allowed 'General case' 0 C--O 1.243 0.755 0 CA-C-N 115.588 -0.733 . . . . 0.0 111.219 -177.623 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 68.08 -140.9 36.79 Favored Glycine 0 CA--C 1.508 -0.363 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 175.39 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 290' ' ' GLY . . . . . 0.703 ' HA2' HG22 ' A' ' 253' ' ' VAL . . . 97.31 115.58 3.34 Favored Glycine 0 N--CA 1.442 -0.913 0 C-N-CA 121.487 -0.387 . . . . 0.0 112.148 176.71 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . 0.71 HG12 ' SD ' ' A' ' 220' ' ' MET . 89.8 mt -116.08 130.46 70.77 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.93 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 174.111 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 2.8 p -118.08 127.34 75.29 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 -179.231 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . 0.42 ' HA ' ' O ' ' A' ' 217' ' ' LEU . 4.7 m -121.43 122.76 40.5 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.258 -176.155 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 294' ' ' GLN . . . . . 0.673 ' HB3' ' CD1' ' A' ' 242' ' ' PHE . 12.8 pt20 . . . . . 0 CA--C 1.497 -1.093 0 CA-C-O 121.257 0.551 . . . . 0.0 111.872 -179.358 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.244 0.774 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 218' ' ' SER . . . . . 0.423 ' OG ' ' OG ' ' A' ' 293' ' ' SER . 22.4 m -131.9 152.35 51.11 Favored 'General case' 0 N--CA 1.442 -0.829 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.529 -175.787 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -145.79 156.06 43.34 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.56 179.855 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 97.7 mtp -76.46 140.39 41.23 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 174.62 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 97.9 t -80.89 129.21 37.91 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.014 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 178.263 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 29.0 m -77.98 -70.58 0.47 Allowed 'General case' 0 N--CA 1.434 -1.273 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 177.36 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 5.9 ptm -138.25 160.29 39.85 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.275 174.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 224' ' ' VAL . . . . . 0.522 HG11 ' SD ' ' A' ' 256' ' ' MET . 61.3 t -124.53 132.13 71.77 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.037 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 173.867 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -100.35 120.33 39.78 Favored 'General case' 0 C--N 1.313 -1.013 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 -177.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 226' ' ' LYS . . . . . 0.519 ' NZ ' ' OD1' ' A' ' 285' ' ' ASP . 0.0 OUTLIER -71.82 82.11 0.9 Allowed 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.003 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 227' ' ' ASP . . . . . 0.513 ' N ' ' OG1' ' A' ' 280' ' ' THR . 4.1 t70 -153.49 -175.45 5.36 Favored 'General case' 0 C--O 1.246 0.886 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.037 -179.319 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 228' ' ' ASN . . . . . 0.557 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.2 OUTLIER -142.12 124.08 8.98 Favored Pre-proline 0 C--N 1.331 -0.228 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.307 176.696 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 229' ' ' PRO . . . . . 0.557 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 33.7 Cg_exo -61.71 147.02 50.93 Favored 'Cis proline' 0 N--CA 1.489 1.213 0 C-N-CA 123.091 -1.629 . . . . 0.0 109.984 -1.73 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . 0.635 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -68.71 134.12 27.77 Favored Glycine 0 C--N 1.3 -1.461 0 N-CA-C 108.864 -1.694 . . . . 0.0 108.864 179.064 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 231' ' ' VAL . . . . . 0.457 ' HB ' ' OG ' ' A' ' 276' ' ' SER . 2.1 p -125.7 132.34 70.94 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 117.332 0.566 . . . . 0.0 110.11 179.549 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 232' ' ' VAL . . . . . 0.458 HG22 ' CD1' ' A' ' 275' ' ' PHE . 0.7 OUTLIER -135.07 156.98 40.33 Favored 'Isoleucine or valine' 0 C--O 1.248 0.979 0 C-N-CA 120.754 -0.378 . . . . 0.0 110.084 -178.697 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 233' ' ' THR . . . . . 0.514 HG22 HG23 ' A' ' 274' ' ' THR . 14.9 p -105.56 154.8 19.89 Favored 'General case' 0 N--CA 1.435 -1.209 0 CA-C-N 116.134 -0.485 . . . . 0.0 109.822 176.844 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 2.1 m -111.78 161.07 16.71 Favored 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 176.043 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 38.4 tp -60.07 121.91 13.06 Favored 'General case' 0 C--N 1.309 -1.157 0 N-CA-C 107.143 -1.428 . . . . 0.0 107.143 178.659 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 236' ' ' ASP . . . . . 0.478 ' O ' ' NH2' ' A' ' 239' ' ' ARG . 13.9 p-10 -51.67 -44.93 63.24 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.29 0.566 . . . . 0.0 111.021 -171.55 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -64.9 -35.17 80.29 Favored 'General case' 0 C--N 1.301 -1.538 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.128 -179.355 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -70.98 95.9 1.23 Allowed 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.777 -179.198 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 239' ' ' ARG . . . . . 0.578 ' NH2' ' OH ' ' A' ' 273' ' ' TYR . 0.0 OUTLIER -62.66 99.09 0.14 Allowed 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 172.124 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 240' ' ' HIS . . . . . 0.474 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 7.2 p80 -59.48 -46.47 88.71 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.891 -175.278 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 83.5 13.09 76.93 Favored Glycine 0 C--N 1.32 -0.351 0 N-CA-C 110.505 -1.038 . . . . 0.0 110.505 -178.897 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 242' ' ' PHE . . . . . 0.518 ' CD1' ' HB3' ' A' ' 294' ' ' GLN . 4.2 m-30 -82.01 138.3 34.91 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.422 -0.585 . . . . 0.0 109.422 179.511 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -110.28 161.96 15.09 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-O 121.315 0.578 . . . . 0.0 109.656 175.642 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 244' ' ' THR . . . . . 0.436 HG22 ' HD2' ' A' ' 268' ' ' LYS . 0.2 OUTLIER -63.71 111.41 2.4 Favored 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 178.589 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 104.86 0.15 42.07 Favored Glycine 0 CA--C 1.52 0.385 0 N-CA-C 111.661 -0.576 . . . . 0.0 111.661 -178.717 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 42.3 m-20 -72.95 161.65 30.44 Favored 'General case' 0 CA--C 1.514 -0.417 0 CA-C-N 116.918 0.359 . . . . 0.0 110.562 175.703 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 247' ' ' PHE . . . . . 0.458 ' HA ' ' O ' ' A' ' 265' ' ' MET . 70.3 m-85 -109.49 130.31 55.51 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.929 -0.578 . . . . 0.0 109.721 177.471 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 248' ' ' VAL . . . . . 0.477 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.3 m -132.4 161.29 41.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 C-N-CA 120.619 -0.432 . . . . 0.0 110.817 179.548 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 3.4 p -126.64 149.61 49.4 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.842 174.427 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 250' ' ' PHE . . . . . 0.607 ' CD1' HD22 ' A' ' 259' ' ' LEU . 71.6 m-85 -102.99 162.42 12.95 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.117 -176.104 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 69.1 m -157.31 155.21 30.29 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.323 174.451 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 19.3 mt-10 51.76 26.37 3.45 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 113.123 0.786 . . . . 0.0 113.123 178.733 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 0.484 HG22 ' HA2' ' A' ' 290' ' ' GLY . 16.2 t -82.18 117.47 28.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 174.22 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 87.4 mt-30 -89.28 144.36 26.15 Favored 'General case' 0 C--O 1.245 0.859 0 CA-C-O 121.218 0.533 . . . . 0.0 111.486 -176.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 77.82 -60.42 3.77 Favored Glycine 0 N--CA 1.449 -0.475 0 N-CA-C 109.702 -1.359 . . . . 0.0 109.702 -177.184 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 256' ' ' MET . . . . . 0.522 ' SD ' HG11 ' A' ' 224' ' ' VAL . 57.3 ttm -86.57 65.43 9.03 Favored 'General case' 0 C--N 1.318 -0.775 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 174.831 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 257' ' ' ILE . . . . . 0.404 ' O ' ' HB2' ' A' ' 260' ' ' ASN . 47.4 pt -75.42 -17.22 15.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 115.176 -0.92 . . . . 0.0 111.322 -174.31 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 258' ' ' GLN . . . . . 0.4 ' O ' ' N ' ' A' ' 262' ' ' CYS . 6.6 mp0 -55.3 -35.98 65.69 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 -178.742 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 259' ' ' LEU . . . . . 1.01 HD21 ' CE2' ' A' ' 283' ' ' PHE . 91.6 mt -62.18 -41.83 98.7 Favored 'General case' 0 C--N 1.315 -0.897 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.785 176.87 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 260' ' ' ASN . . . . . 0.433 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 97.5 m-20 -60.84 -40.32 92.4 Favored 'General case' 0 CA--C 1.512 -0.495 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 179.753 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -91.28 -3.79 69.21 Favored Glycine 0 CA--C 1.522 0.489 0 CA-C-N 115.466 -0.788 . . . . 0.0 111.968 -177.104 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 262' ' ' CYS . . . . . 0.4 ' N ' ' O ' ' A' ' 258' ' ' GLN . 2.9 m -87.18 141.78 28.39 Favored 'General case' 0 CA--C 1.514 -0.424 0 CA-C-N 117.249 0.524 . . . . 0.0 110.812 -177.053 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 29.3 pt20 -63.36 165.58 10.92 Favored Pre-proline 0 C--N 1.323 -0.554 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 176.054 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 264' ' ' PRO . . . . . 0.477 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 36.8 Cg_exo -60.1 141.9 97.19 Favored 'Trans proline' 0 C--N 1.316 -1.148 0 N-CA-C 109.245 -1.098 . . . . 0.0 109.245 177.42 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 265' ' ' MET . . . . . 0.458 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 23.1 ptp -134.21 155.34 50.3 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 111.969 0.359 . . . . 0.0 111.969 -173.002 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 266' ' ' GLU . . . . . 0.414 ' HB2' ' CE2' ' A' ' 247' ' ' PHE . 78.5 tt0 -71.5 137.87 48.49 Favored 'General case' 0 C--O 1.239 0.519 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.865 179.306 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 267' ' ' ILE . . . . . 0.701 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.8 pp -129.03 164.19 32.07 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.995 -177.16 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . 0.436 ' HD2' HG22 ' A' ' 244' ' ' THR . 48.4 mmtm -129.05 125.09 36.53 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 109.114 -0.698 . . . . 0.0 109.114 176.158 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 14.9 m -79.24 125.12 38.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 C-N-CA 120.743 -0.383 . . . . 0.0 110.578 179.801 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 270' ' ' LEU . . . . . 0.539 HD11 ' OG ' ' A' ' 276' ' ' SER . 78.6 mt -101.64 -12.49 18.38 Favored 'General case' 0 C--O 1.237 0.427 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.284 -179.034 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -164.4 -179.57 38.62 Favored Glycine 0 C--N 1.317 -0.491 0 N-CA-C 109.892 -1.283 . . . . 0.0 109.892 -177.048 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 272' ' ' PRO . . . . . 0.474 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 26.2 Cg_endo -59.7 -39.71 71.14 Favored 'Trans proline' 0 C--N 1.306 -1.687 0 C-N-CA 122.159 1.906 . . . . 0.0 111.148 -177.577 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 273' ' ' TYR . . . . . 0.578 ' OH ' ' NH2' ' A' ' 239' ' ' ARG . 29.2 m-85 -123.95 13.4 9.14 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-N 115.328 -0.851 . . . . 0.0 110.686 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 274' ' ' THR . . . . . 0.514 HG23 HG22 ' A' ' 233' ' ' THR . 0.2 OUTLIER -119.1 127.49 53.41 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 -174.433 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 275' ' ' PHE . . . . . 0.559 ' CE2' HG21 ' A' ' 267' ' ' ILE . 0.0 OUTLIER -140.47 161.75 36.98 Favored 'General case' 0 CA--C 1.502 -0.89 0 C-N-CA 120.645 -0.422 . . . . 0.0 112.126 -179.588 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . 0.539 ' OG ' HD11 ' A' ' 270' ' ' LEU . 1.8 m -130.07 156.07 45.12 Favored 'General case' 0 N--CA 1.433 -1.307 0 CA-C-O 121.568 0.699 . . . . 0.0 112.75 -177.172 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 277' ' ' ILE . . . . . 0.746 ' C ' HD12 ' A' ' 277' ' ' ILE . 2.3 pp -137.16 -179.28 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.273 0 CA-C-N 113.682 -1.599 . . . . 0.0 109.113 -177.518 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -40.1 -88.88 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.406 0 O-C-N 123.516 0.51 . . . . 0.0 112.185 179.753 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . 0.493 ' O ' ' ND2' ' A' ' 282' ' ' ASN . 65.5 t0 -149.22 115.55 5.81 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-O 120.602 0.239 . . . . 0.0 111.26 -178.097 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . 0.635 HG23 ' HA3' ' A' ' 230' ' ' GLY . 14.6 p -63.56 -29.65 70.88 Favored 'General case' 0 C--N 1.308 -1.233 0 CA-C-O 121.295 0.569 . . . . 0.0 110.166 175.25 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -63.82 -19.57 65.12 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-N 115.329 -0.851 . . . . 0.0 109.763 177.146 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 282' ' ' ASN . . . . . 0.493 ' ND2' ' O ' ' A' ' 279' ' ' ASP . 0.0 OUTLIER -95.05 -7.97 38.02 Favored 'General case' 0 C--N 1.344 0.334 0 C-N-CA 120.507 -0.477 . . . . 0.0 110.436 177.949 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 283' ' ' PHE . . . . . 1.01 ' CE2' HD21 ' A' ' 259' ' ' LEU . 21.4 m-30 -85.2 -80.74 0.21 Allowed 'General case' 0 CA--C 1.512 -0.498 0 CA-C-O 121.854 0.835 . . . . 0.0 109.035 175.609 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 284' ' ' SER . . . . . 0.435 ' OG ' ' HA ' ' A' ' 256' ' ' MET . 0.1 OUTLIER 175.45 -173.37 0.08 Allowed 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 114.121 -1.399 . . . . 0.0 108.196 -176.442 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 285' ' ' ASP . . . . . 0.519 ' OD1' ' NZ ' ' A' ' 226' ' ' LYS . 33.4 t0 -91.18 116.3 28.7 Favored 'General case' 0 C--N 1.316 -0.876 0 C-N-CA 121.045 -0.262 . . . . 0.0 111.668 -178.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 286' ' ' TYR . . . . . 0.405 ' OH ' ' NH2' ' A' ' 288' ' ' ARG . 1.1 t80 -64.94 135.32 55.54 Favored 'General case' 0 CA--C 1.511 -0.53 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.37 179.24 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 287' ' ' ILE . . . . . 0.518 ' C ' ' HG2' ' A' ' 288' ' ' ARG . 96.9 mt -118.71 -74.78 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.433 -1.306 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.737 174.731 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . 0.533 ' HA ' ' NE ' ' A' ' 288' ' ' ARG . 4.1 mmp_? -148.71 175.58 11.09 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.587 -177.511 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 75.35 -156.3 48.35 Favored Glycine 0 C--O 1.238 0.393 0 N-CA-C 110.689 -0.964 . . . . 0.0 110.689 178.145 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 290' ' ' GLY . . . . . 0.484 ' HA2' HG22 ' A' ' 253' ' ' VAL . . . 103.82 111.56 3.59 Favored Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 121.712 -0.28 . . . . 0.0 112.524 176.416 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 93.2 mt -121.16 131.7 72.37 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.928 0 N-CA-C 107.532 -1.284 . . . . 0.0 107.532 173.605 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 2.8 p -122.61 137.07 57.38 Favored 'Isoleucine or valine' 0 C--O 1.242 0.683 0 C-N-CA 120.702 -0.399 . . . . 0.0 111.17 -174.893 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . 0.423 ' OG ' ' OG ' ' A' ' 218' ' ' SER . 41.7 m -126.21 140.31 52.64 Favored 'General case' 0 CA--C 1.51 -0.565 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.438 179.533 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 294' ' ' GLN . . . . . 0.518 ' HB3' ' CD1' ' A' ' 242' ' ' PHE . 0.9 OUTLIER . . . . . 0 CA--C 1.504 -0.823 0 C-N-CA 120.499 -0.48 . . . . 0.0 110.023 176.764 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 217' ' ' LEU . . . . . 0.474 HD12 ' O ' ' A' ' 240' ' ' HIS . 0.5 OUTLIER . . . . . 0 N--CA 1.44 -0.964 0 N-CA-C 109.7 -0.481 . . . . 0.0 109.7 . . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 218' ' ' SER . . . . . 0.428 ' HA ' ' O ' ' A' ' 292' ' ' VAL . 4.0 m -128.71 145.04 51.28 Favored 'General case' 0 N--CA 1.435 -1.179 0 CA-C-N 115.489 -0.778 . . . . 0.0 110.433 -177.057 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 219' ' ' ALA . . . . . 0.474 ' HB2' ' HA ' ' A' ' 240' ' ' HIS . . . -130.24 154.96 47.05 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.395 179.078 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 220' ' ' MET . . . . . 0.601 ' SD ' HG12 ' A' ' 291' ' ' ILE . 87.8 mmm -82.46 129.34 34.88 Favored 'General case' 0 N--CA 1.438 -1.041 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 177.831 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 65.5 t -76.23 132.6 32.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 -179.808 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 222' ' ' SER . . . . . 0.435 ' O ' ' OH ' ' A' ' 286' ' ' TYR . 33.5 m -97.16 -68.52 0.8 Allowed 'General case' 0 N--CA 1.44 -0.964 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.044 179.083 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 223' ' ' MET . . . . . 0.595 ' C ' ' SD ' ' A' ' 223' ' ' MET . 1.8 ppp? -137.14 147.95 46.31 Favored 'General case' 0 C--N 1.323 -0.567 0 C-N-CA 120.686 -0.406 . . . . 0.0 112.0 173.533 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 224' ' ' VAL . . . . . 0.7 HG22 ' HB ' ' A' ' 232' ' ' VAL . 71.2 t -125.83 131.79 71.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 N-CA-C 109.546 -0.538 . . . . 0.0 109.546 177.233 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 23.0 p -88.09 129.82 35.19 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.78 -0.368 . . . . 0.0 110.15 177.534 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 226' ' ' LYS . . . . . 0.424 ' CE ' ' O ' ' A' ' 284' ' ' SER . 51.9 tttm -80.27 81.6 6.5 Favored 'General case' 0 N--CA 1.447 -0.601 0 CA-C-O 121.674 0.749 . . . . 0.0 109.984 179.235 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 227' ' ' ASP . . . . . 0.557 ' N ' ' OG1' ' A' ' 280' ' ' THR . 42.7 t0 -151.14 169.49 21.73 Favored 'General case' 0 C--O 1.245 0.826 0 CA-C-N 114.508 -1.224 . . . . 0.0 108.923 -177.085 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 228' ' ' ASN . . . . . 0.467 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 15.8 p-10 -140.91 121.83 8.96 Favored Pre-proline 0 C--N 1.325 -0.494 0 C-N-CA 120.516 -0.473 . . . . 0.0 111.717 176.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 229' ' ' PRO . . . . . 0.467 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 56.6 Cg_endo -65.12 142.96 55.04 Favored 'Cis proline' 0 C--N 1.311 -1.424 0 C-N-CA 122.632 -1.82 . . . . 0.0 109.437 -4.138 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . 0.474 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -93.14 154.69 22.0 Favored Glycine 0 C--N 1.311 -0.817 0 N-CA-C 110.192 -1.163 . . . . 0.0 110.192 -177.296 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 231' ' ' VAL . . . . . 0.447 HG23 HD12 ' A' ' 270' ' ' LEU . 2.4 p -123.3 137.66 55.87 Favored 'Isoleucine or valine' 0 C--O 1.239 0.529 0 CA-C-N 116.724 0.262 . . . . 0.0 110.318 179.188 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 232' ' ' VAL . . . . . 0.7 ' HB ' HG22 ' A' ' 224' ' ' VAL . 0.8 OUTLIER -130.95 155.9 42.32 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.016 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.299 -177.998 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 233' ' ' THR . . . . . 0.403 ' O ' ' HB2' ' A' ' 222' ' ' SER . 27.6 m -110.73 140.45 45.11 Favored 'General case' 0 C--N 1.312 -1.028 0 CA-C-N 115.49 -0.777 . . . . 0.0 108.918 174.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 48.2 m -107.69 162.22 14.18 Favored 'General case' 0 C--N 1.314 -0.954 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 179.315 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 50.1 tp -61.41 130.32 45.5 Favored 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 179.198 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 55.6 m-20 -58.75 -40.41 83.79 Favored 'General case' 0 N--CA 1.476 0.857 0 CA-C-O 120.902 0.382 . . . . 0.0 111.244 -174.823 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 54.6 mp0 -64.85 -29.79 70.76 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.254 178.36 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -77.5 138.97 39.52 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.796 -176.164 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 239' ' ' ARG . . . . . 0.403 HH11 ' HD2' ' A' ' 239' ' ' ARG . 49.9 mtp85 -104.36 108.92 20.56 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.795 174.413 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 240' ' ' HIS . . . . . 0.567 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 12.7 p80 -67.01 -46.65 73.84 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-O 121.248 0.546 . . . . 0.0 109.804 176.416 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 77.87 14.74 82.03 Favored Glycine 0 CA--C 1.502 -0.743 0 N-CA-C 109.837 -1.305 . . . . 0.0 109.837 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 242' ' ' PHE . . . . . 0.525 ' CD2' ' HB2' ' A' ' 240' ' ' HIS . 8.7 m-30 -80.26 143.21 33.89 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 -177.391 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 243' ' ' GLU . . . . . 0.404 ' OE1' ' N ' ' A' ' 244' ' ' THR . 1.3 mm-40 -107.66 159.95 16.07 Favored 'General case' 0 C--N 1.308 -1.239 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.712 174.716 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 244' ' ' THR . . . . . 0.404 ' N ' ' OE1' ' A' ' 243' ' ' GLU . 0.2 OUTLIER -62.35 117.66 6.42 Favored 'General case' 0 C--N 1.297 -1.679 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 177.305 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 90.53 4.42 70.48 Favored Glycine 0 C--N 1.313 -0.748 0 N-CA-C 111.393 -0.683 . . . . 0.0 111.393 -177.679 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 23.7 t0 -79.23 163.28 25.1 Favored 'General case' 0 C--O 1.237 0.422 0 N-CA-C 109.319 -0.622 . . . . 0.0 109.319 176.531 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 247' ' ' PHE . . . . . 0.484 ' CE2' ' HB2' ' A' ' 266' ' ' GLU . 89.7 m-85 -111.3 134.09 53.14 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.507 0.194 . . . . 0.0 110.572 -176.112 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 248' ' ' VAL . . . . . 0.53 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.9 m -131.17 165.94 30.12 Favored 'Isoleucine or valine' 0 C--O 1.239 0.51 0 CA-C-O 121.345 0.593 . . . . 0.0 112.441 -176.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 10.8 p -135.24 163.24 30.41 Favored 'General case' 0 C--N 1.32 -0.713 0 C-N-CA 124.92 1.288 . . . . 0.0 109.264 176.065 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 250' ' ' PHE . . . . . 0.603 ' CB ' ' HB3' ' A' ' 259' ' ' LEU . 78.7 m-85 -125.67 158.88 33.65 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.574 0.226 . . . . 0.0 111.027 -172.096 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 251' ' ' SER . . . . . 0.416 ' N ' ' O ' ' A' ' 291' ' ' ILE . 2.0 m -155.9 164.65 38.23 Favored 'General case' 0 C--N 1.322 -0.623 0 C-N-CA 122.326 0.251 . . . . 0.0 110.466 177.584 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 50.5 mm-40 48.59 27.36 1.45 Allowed 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.44 -0.346 . . . . 0.0 111.929 176.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 44.0 t -84.12 130.76 35.37 Favored 'Isoleucine or valine' 0 C--O 1.235 0.323 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 179.152 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 97.7 mm-40 -95.65 135.35 37.44 Favored 'General case' 0 C--O 1.247 0.954 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 178.86 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . 0.52 ' CA ' HD12 ' A' ' 287' ' ' ILE . . . 84.53 -68.64 3.47 Favored Glycine 0 C--N 1.312 -0.752 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 -178.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 256' ' ' MET . . . . . 0.481 ' SD ' ' C ' ' A' ' 284' ' ' SER . 1.7 tpp -81.68 67.69 7.75 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.48 0.657 . . . . 0.0 109.407 176.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 257' ' ' ILE . . . . . 0.469 ' O ' ' HB2' ' A' ' 260' ' ' ASN . 48.5 pt -73.94 -21.24 17.98 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.945 0 CA-C-N 115.231 -0.895 . . . . 0.0 110.69 -176.546 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 258' ' ' GLN . . . . . 0.669 ' HG3' ' SG ' ' A' ' 262' ' ' CYS . 52.5 tp60 -56.52 -33.49 66.09 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.167 179.633 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 259' ' ' LEU . . . . . 1.018 HD21 ' CE2' ' A' ' 283' ' ' PHE . 84.4 mt -62.16 -39.97 94.41 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.048 174.702 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 260' ' ' ASN . . . . . 0.469 ' HB2' ' O ' ' A' ' 257' ' ' ILE . 97.1 m-20 -59.9 -40.53 89.08 Favored 'General case' 0 C--O 1.238 0.45 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.713 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -102.24 16.38 55.46 Favored Glycine 0 CA--C 1.527 0.816 0 CA-C-N 115.901 -0.59 . . . . 0.0 112.386 -178.363 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 262' ' ' CYS . . . . . 0.669 ' SG ' ' HG3' ' A' ' 258' ' ' GLN . 1.1 m -88.14 156.3 19.33 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-N 117.184 0.492 . . . . 0.0 112.028 -178.086 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 38.2 mt-30 -73.0 160.11 83.7 Favored Pre-proline 0 C--O 1.241 0.61 0 N-CA-C 107.761 -1.199 . . . . 0.0 107.761 171.423 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 264' ' ' PRO . . . . . 0.53 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 59.4 Cg_endo -66.77 145.9 76.72 Favored 'Trans proline' 0 C--N 1.309 -1.537 0 C-N-CA 121.086 1.191 . . . . 0.0 110.353 178.281 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 265' ' ' MET . . . . . 0.422 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 20.8 ptp -136.47 152.53 50.66 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 112.007 0.373 . . . . 0.0 112.007 -172.473 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 266' ' ' GLU . . . . . 0.484 ' HB2' ' CE2' ' A' ' 247' ' ' PHE . 69.5 tt0 -71.48 140.71 50.09 Favored 'General case' 0 C--O 1.239 0.532 0 O-C-N 123.898 0.749 . . . . 0.0 109.487 177.388 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 267' ' ' ILE . . . . . 0.746 HD12 ' C ' ' A' ' 267' ' ' ILE . 2.1 pp -128.37 165.98 26.64 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-O 121.205 0.526 . . . . 0.0 112.069 -176.608 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . 0.426 ' HB2' ' OG ' ' A' ' 276' ' ' SER . 62.3 mttm -124.99 123.06 39.06 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 178.628 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 9.3 m -86.08 94.86 4.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 C-N-CA 119.363 -0.935 . . . . 0.0 109.966 176.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 270' ' ' LEU . . . . . 0.447 HD12 HG23 ' A' ' 231' ' ' VAL . 97.0 mt -65.49 -41.21 93.5 Favored 'General case' 0 CA--C 1.511 -0.535 0 CA-C-N 115.424 -0.807 . . . . 0.0 109.441 -178.752 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -138.07 -178.5 16.18 Favored Glycine 0 N--CA 1.448 -0.532 0 N-CA-C 108.401 -1.88 . . . . 0.0 108.401 178.591 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 272' ' ' PRO . . . . . 0.567 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 38.4 Cg_endo -64.12 -32.7 63.34 Favored 'Trans proline' 0 C--N 1.303 -1.85 0 C-N-CA 121.513 1.475 . . . . 0.0 111.307 -177.448 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -124.5 9.54 8.43 Favored 'General case' 0 C--O 1.24 0.555 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.861 -178.407 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 7.9 p -125.66 126.56 44.89 Favored 'General case' 0 C--O 1.247 0.962 0 CA-C-O 121.171 0.51 . . . . 0.0 110.844 179.582 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 275' ' ' PHE . . . . . 0.523 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -139.56 163.98 31.12 Favored 'General case' 0 CA--C 1.502 -0.897 0 N-CA-C 112.532 0.567 . . . . 0.0 112.532 -175.871 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . 0.474 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 4.1 p -130.59 152.67 49.71 Favored 'General case' 0 N--CA 1.436 -1.159 0 CA-C-O 121.241 0.543 . . . . 0.0 112.225 -174.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 277' ' ' ILE . . . . . 0.731 ' C ' HD12 ' A' ' 277' ' ' ILE . 2.0 pp -134.92 173.19 14.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 114.684 -1.144 . . . . 0.0 111.461 -174.033 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 278' ' ' CYS . . . . . 0.457 ' O ' ' HA ' ' A' ' 229' ' ' PRO . 1.5 p -48.95 -78.77 0.02 OUTLIER 'General case' 0 C--N 1.323 -0.556 0 C-N-CA 123.815 0.846 . . . . 0.0 113.05 -177.173 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . 0.528 ' HB2' ' CB ' ' A' ' 282' ' ' ASN . 9.8 m-20 -140.1 103.87 4.71 Favored 'General case' 0 N--CA 1.452 -0.354 0 O-C-N 122.315 -0.241 . . . . 0.0 110.644 -176.256 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . 0.74 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 20.7 p -65.46 -32.75 74.53 Favored 'General case' 0 C--N 1.315 -0.892 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 172.672 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -61.57 -23.1 65.75 Favored 'General case' 0 N--CA 1.43 -1.464 0 CA-C-N 114.019 -1.446 . . . . 0.0 109.522 175.307 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 282' ' ' ASN . . . . . 0.528 ' CB ' ' HB2' ' A' ' 279' ' ' ASP . 15.0 t30 -89.11 -10.16 48.38 Favored 'General case' 0 CA--C 1.51 -0.596 0 C-N-CA 120.372 -0.531 . . . . 0.0 109.825 178.866 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 283' ' ' PHE . . . . . 1.018 ' CE2' HD21 ' A' ' 259' ' ' LEU . 12.7 m-30 -83.76 -74.78 0.36 Allowed 'General case' 0 N--CA 1.441 -0.882 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 172.033 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 284' ' ' SER . . . . . 0.481 ' C ' ' SD ' ' A' ' 256' ' ' MET . 0.2 OUTLIER 171.68 -112.38 0.0 OUTLIER 'General case' 0 CA--C 1.541 0.631 0 CA-C-N 115.223 -0.899 . . . . 0.0 110.355 -178.552 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 285' ' ' ASP . . . . . 0.44 ' N ' ' SD ' ' A' ' 256' ' ' MET . 41.1 t0 -145.58 119.13 9.09 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 119.03 0.832 . . . . 0.0 110.687 177.495 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 286' ' ' TYR . . . . . 0.435 ' OH ' ' O ' ' A' ' 222' ' ' SER . 1.7 t80 -68.19 123.96 22.14 Favored 'General case' 0 C--O 1.239 0.523 0 CA-C-O 120.739 0.305 . . . . 0.0 110.789 178.53 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 287' ' ' ILE . . . . . 0.52 HD12 ' CA ' ' A' ' 255' ' ' GLY . 96.7 mt -106.03 -54.71 6.0 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.863 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.316 176.285 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 9.7 ptp180 -169.69 -179.05 3.2 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.079 177.842 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 63.6 -151.09 49.24 Favored Glycine 0 C--O 1.239 0.421 0 N-CA-C 110.605 -0.998 . . . . 0.0 110.605 177.281 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 99.24 129.42 6.55 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 121.59 -0.338 . . . . 0.0 112.525 175.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . 0.601 HG12 ' SD ' ' A' ' 220' ' ' MET . 98.1 mt -125.24 133.77 68.51 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 175.704 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . 0.428 ' O ' ' HA ' ' A' ' 218' ' ' SER . 4.5 p -122.63 134.6 65.35 Favored 'Isoleucine or valine' 0 C--O 1.241 0.615 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -177.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 23.6 m -127.44 145.29 50.88 Favored 'General case' 0 CA--C 1.513 -0.478 0 CA-C-O 120.624 0.249 . . . . 0.0 111.016 -178.418 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 294' ' ' GLN . . . . . 0.417 ' O ' ' NE2' ' A' ' 294' ' ' GLN . 1.6 pp0? . . . . . 0 C--N 1.323 -0.557 0 CA-C-N 116.517 -0.31 . . . . 0.0 110.424 178.091 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 217' ' ' LEU . . . . . 0.433 ' HB3' ' O ' ' A' ' 240' ' ' HIS . 0.1 OUTLIER . . . . . 0 CA--C 1.511 -0.536 0 N-CA-C 108.365 -0.976 . . . . 0.0 108.365 . . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 218' ' ' SER . . . . . 0.411 ' HA ' ' HA ' ' A' ' 293' ' ' SER . 0.7 OUTLIER -127.0 147.73 50.12 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-O 120.745 0.307 . . . . 0.0 110.499 -174.734 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -146.41 154.41 41.58 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.509 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 56.3 mtm -79.98 138.95 37.18 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.842 176.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 99.2 t -85.13 130.01 36.85 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.94 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 -178.901 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 65.4 m -83.35 -70.68 0.54 Allowed 'General case' 0 N--CA 1.434 -1.254 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 179.414 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -138.57 152.94 48.62 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.834 174.007 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 224' ' ' VAL . . . . . 0.58 HG22 ' HB ' ' A' ' 232' ' ' VAL . 53.6 t -120.93 132.43 70.45 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 175.329 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 75.5 p -90.85 116.56 28.77 Favored 'General case' 0 C--O 1.236 0.393 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 175.435 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 226' ' ' LYS . . . . . 0.494 ' HA ' ' OG1' ' A' ' 280' ' ' THR . 3.7 tttm -75.86 64.37 1.81 Allowed 'General case' 0 C--O 1.249 1.06 0 C-N-CA 120.616 -0.434 . . . . 0.0 111.259 -175.147 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 227' ' ' ASP . . . . . 0.416 ' N ' ' OG1' ' A' ' 280' ' ' THR . 36.0 t0 -133.04 -175.69 3.87 Favored 'General case' 0 C--O 1.243 0.752 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.621 178.358 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 228' ' ' ASN . . . . . 0.485 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.6 OUTLIER -138.52 125.29 13.04 Favored Pre-proline 0 CA--C 1.533 0.307 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.031 175.631 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 229' ' ' PRO . . . . . 0.485 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 48.6 Cg_endo -66.35 141.24 52.34 Favored 'Cis proline' 0 C--N 1.313 -1.337 0 C-N-CA 122.715 -1.785 . . . . 0.0 110.01 -1.04 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . 0.453 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -75.13 139.3 24.79 Favored Glycine 0 C--N 1.308 -1.01 0 N-CA-C 110.662 -0.975 . . . . 0.0 110.662 -177.745 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 231' ' ' VAL . . . . . 0.412 ' CG2' HD12 ' A' ' 270' ' ' LEU . 2.4 p -128.29 137.56 57.08 Favored 'Isoleucine or valine' 0 C--O 1.244 0.775 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 175.001 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 232' ' ' VAL . . . . . 0.58 ' HB ' HG22 ' A' ' 224' ' ' VAL . 0.6 OUTLIER -133.53 155.67 40.65 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.786 0 C-N-CA 120.475 -0.49 . . . . 0.0 110.985 -178.693 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 3.1 m -104.06 140.65 37.46 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 115.459 -0.791 . . . . 0.0 108.902 176.769 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.9 m -107.35 156.84 18.48 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -178.593 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.467 ' HB3' ' HB3' ' A' ' 238' ' ' ALA . 27.0 tp -58.47 130.21 45.7 Favored 'General case' 0 C--N 1.318 -0.801 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 -178.334 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -55.32 -44.03 75.45 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 120.992 0.425 . . . . 0.0 110.69 -175.025 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 237' ' ' GLU . . . . . 0.403 ' H ' ' CD ' ' A' ' 237' ' ' GLU . 1.7 mp0 -67.6 -23.18 65.35 Favored 'General case' 0 C--N 1.312 -1.065 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.604 -179.72 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 238' ' ' ALA . . . . . 0.467 ' HB3' ' HB3' ' A' ' 235' ' ' LEU . . . -94.54 90.75 6.29 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.964 0.412 . . . . 0.0 111.984 -175.002 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.74 110.12 2.69 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 108.633 -0.876 . . . . 0.0 108.633 174.799 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 240' ' ' HIS . . . . . 0.577 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 12.3 p80 -64.44 -49.81 70.0 Favored 'General case' 0 C--O 1.216 -0.674 0 CA-C-O 120.647 0.26 . . . . 0.0 111.212 -176.501 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 80.71 17.8 72.07 Favored Glycine 0 C--O 1.242 0.599 0 N-CA-C 110.961 -0.855 . . . . 0.0 110.961 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 242' ' ' PHE . . . . . 0.414 ' CD2' ' HB2' ' A' ' 240' ' ' HIS . 7.3 m-30 -81.38 139.94 35.01 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 179.391 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 76.6 mm-40 -98.79 157.13 16.49 Favored 'General case' 0 C--N 1.308 -1.201 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 172.601 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 244' ' ' THR . . . . . 0.666 HG23 ' HA ' ' A' ' 268' ' ' LYS . 25.0 m -65.57 123.4 19.58 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 172.86 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 94.72 0.09 64.64 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 110.994 -0.842 . . . . 0.0 110.994 -174.705 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 45.9 t0 -79.31 159.62 27.13 Favored 'General case' 0 C--O 1.239 0.542 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 176.736 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 247' ' ' PHE . . . . . . . . . . . . . 87.4 m-85 -110.29 129.96 55.64 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.311 -176.559 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 248' ' ' VAL . . . . . 0.496 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.4 m -128.33 161.54 36.65 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.332 0 C-N-CA 120.658 -0.417 . . . . 0.0 111.494 -179.09 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 50.1 m -129.63 153.15 48.38 Favored 'General case' 0 N--CA 1.444 -0.774 0 CA-C-N 115.108 -0.951 . . . . 0.0 108.676 172.817 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 250' ' ' PHE . . . . . 0.639 ' CD1' HD22 ' A' ' 259' ' ' LEU . 73.5 m-85 -105.26 145.25 30.92 Favored 'General case' 0 C--N 1.311 -1.066 0 C-N-CA 122.948 0.499 . . . . 0.0 109.882 -177.333 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 4.8 m -132.17 151.54 51.74 Favored 'General case' 0 C--N 1.304 -1.387 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 175.145 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 7.3 mm-40 47.34 38.22 7.03 Favored 'General case' 0 C--N 1.308 -1.233 0 N-CA-C 112.938 0.718 . . . . 0.0 112.938 174.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 0.54 HG13 ' CE1' ' A' ' 286' ' ' TYR . 24.2 t -85.2 132.38 31.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 172.499 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 98.6 mm-40 -96.76 145.12 26.11 Favored 'General case' 0 C--N 1.32 -0.698 0 C-N-CA 120.68 -0.408 . . . . 0.0 110.214 176.671 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 81.19 -67.51 3.6 Favored Glycine 0 C--N 1.32 -0.352 0 N-CA-C 110.244 -1.143 . . . . 0.0 110.244 -177.207 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 256' ' ' MET . . . . . 0.484 ' HG3' ' C ' ' A' ' 285' ' ' ASP . 47.8 mtt -78.65 65.65 3.97 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.475 0.655 . . . . 0.0 110.586 176.219 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 48.9 pt -66.27 -23.78 32.37 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.897 0 CA-C-N 115.285 -0.871 . . . . 0.0 109.577 179.511 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 258' ' ' GLN . . . . . 0.421 ' NE2' ' O ' ' A' ' 283' ' ' PHE . 1.3 mp0 -54.37 -40.99 68.67 Favored 'General case' 0 N--CA 1.442 -0.862 0 CA-C-N 115.14 -0.936 . . . . 0.0 109.044 178.485 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 259' ' ' LEU . . . . . 0.906 HD21 ' CE2' ' A' ' 283' ' ' PHE . 87.3 mt -62.92 -41.83 99.59 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.783 178.067 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 260' ' ' ASN . . . . . 0.491 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 93.3 m-20 -59.37 -41.03 88.38 Favored 'General case' 0 CA--C 1.509 -0.623 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 -177.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -102.36 10.98 56.74 Favored Glycine 0 CA--C 1.525 0.706 0 CA-C-N 116.027 -0.533 . . . . 0.0 112.265 -179.359 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 262' ' ' CYS . . . . . 0.415 ' HB2' ' O ' ' A' ' 258' ' ' GLN . 11.8 t -88.48 139.98 29.93 Favored 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 117.512 0.656 . . . . 0.0 111.458 -177.471 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 9.6 mp0 -56.4 158.53 7.7 Favored Pre-proline 0 C--N 1.322 -0.621 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 173.219 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 264' ' ' PRO . . . . . 0.496 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 36.7 Cg_endo -61.71 146.87 96.4 Favored 'Trans proline' 0 N--CA 1.495 1.568 0 C-N-CA 121.488 1.459 . . . . 0.0 111.713 -178.719 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 265' ' ' MET . . . . . 0.63 ' N ' ' SD ' ' A' ' 265' ' ' MET . 0.0 OUTLIER -119.35 152.27 37.06 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.888 -176.461 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 73.0 tt0 -76.53 137.17 39.42 Favored 'General case' 0 C--O 1.238 0.46 0 N-CA-C 107.964 -1.124 . . . . 0.0 107.964 174.803 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 267' ' ' ILE . . . . . 0.708 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.9 pp -129.51 159.09 41.92 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 N-CA-C 113.069 0.766 . . . . 0.0 113.069 -174.928 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . 0.666 ' HA ' HG23 ' A' ' 244' ' ' THR . 65.6 mttm -123.54 115.04 20.88 Favored 'General case' 0 CA--C 1.534 0.331 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.367 178.694 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.436 HG22 ' OG1' ' A' ' 244' ' ' THR . 17.7 m -78.35 100.18 3.26 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.497 0 CA-C-O 121.138 0.494 . . . . 0.0 111.613 -179.149 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 270' ' ' LEU . . . . . 0.412 HD12 ' CG2' ' A' ' 231' ' ' VAL . 97.5 mt -66.25 -40.82 90.44 Favored 'General case' 0 CA--C 1.513 -0.462 0 CA-C-N 115.723 -0.672 . . . . 0.0 110.477 179.033 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -145.17 179.5 22.23 Favored Glycine 0 C--N 1.315 -0.638 0 N-CA-C 109.724 -1.35 . . . . 0.0 109.724 -177.238 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 272' ' ' PRO . . . . . 0.577 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 33.0 Cg_endo -61.39 -31.82 88.74 Favored 'Trans proline' 0 C--N 1.303 -1.845 0 C-N-CA 121.797 1.665 . . . . 0.0 110.976 -178.448 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 88.4 m-85 -121.36 8.67 10.25 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.18 -0.464 . . . . 0.0 112.067 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -123.77 126.34 46.31 Favored 'General case' 0 C--O 1.242 0.665 0 CA-C-O 120.855 0.359 . . . . 0.0 110.998 -179.48 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 275' ' ' PHE . . . . . 0.561 ' CE2' HG21 ' A' ' 267' ' ' ILE . 0.0 OUTLIER -132.71 161.03 35.05 Favored 'General case' 0 CA--C 1.499 -1.007 0 C-N-CA 120.733 -0.387 . . . . 0.0 111.766 178.038 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . 0.453 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 7.7 p -133.36 154.39 50.78 Favored 'General case' 0 N--CA 1.432 -1.346 0 CA-C-O 121.25 0.547 . . . . 0.0 112.456 -173.636 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 277' ' ' ILE . . . . . 0.699 HG22 HG22 ' A' ' 267' ' ' ILE . 35.7 pt -140.94 -165.93 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 CA-C-N 113.991 -1.458 . . . . 0.0 109.569 -171.049 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 278' ' ' CYS . . . . . 0.484 ' O ' ' HA ' ' A' ' 229' ' ' PRO . 14.7 p -69.81 -110.64 0.0 OUTLIER 'General case' 0 N--CA 1.45 -0.474 0 O-C-N 122.996 0.185 . . . . 0.0 111.056 178.793 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . 0.442 ' CG ' ' HB2' ' A' ' 228' ' ' ASN . 50.8 t0 -117.5 119.9 36.47 Favored 'General case' 0 CA--C 1.507 -0.682 0 CA-C-O 121.048 0.452 . . . . 0.0 110.855 -179.591 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . 0.51 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 9.4 p -64.44 -29.29 70.35 Favored 'General case' 0 C--N 1.292 -1.919 0 CA-C-N 115.501 -0.772 . . . . 0.0 109.597 175.186 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -65.19 -11.66 42.99 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.008 -0.996 . . . . 0.0 109.642 174.483 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 -85.87 -8.65 57.92 Favored 'General case' 0 CA--C 1.507 -0.69 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 175.772 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 283' ' ' PHE . . . . . 0.906 ' CE2' HD21 ' A' ' 259' ' ' LEU . 3.3 m-85 -99.73 -78.41 0.51 Allowed 'General case' 0 N--CA 1.442 -0.84 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 171.117 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 284' ' ' SER . . . . . 0.474 ' OG ' ' N ' ' A' ' 285' ' ' ASP . 31.3 t 168.33 -144.33 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.291 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 -179.121 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 285' ' ' ASP . . . . . 0.484 ' C ' ' HG3' ' A' ' 256' ' ' MET . 64.8 m-20 -98.46 131.67 44.53 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 122.289 0.236 . . . . 0.0 110.567 176.734 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 286' ' ' TYR . . . . . 0.54 ' CE1' HG13 ' A' ' 253' ' ' VAL . 13.0 t80 -84.23 125.56 32.33 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 178.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 287' ' ' ILE . . . . . 0.401 ' O ' ' CG ' ' A' ' 288' ' ' ARG . 9.3 mm -94.01 -54.07 7.67 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 N-CA-C 110.471 -0.196 . . . . 0.0 110.471 179.539 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . 0.401 ' CG ' ' O ' ' A' ' 287' ' ' ILE . 0.7 OUTLIER 176.34 -178.0 0.14 Allowed 'General case' 0 C--O 1.244 0.766 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.019 -179.53 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 64.98 -140.64 42.3 Favored Glycine 0 CA--C 1.5 -0.856 0 N-CA-C 110.027 -1.229 . . . . 0.0 110.027 177.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 290' ' ' GLY . . . . . 0.45 ' HA3' HG22 ' A' ' 253' ' ' VAL . . . 87.93 126.34 2.41 Favored Glycine 0 N--CA 1.434 -1.478 0 C-N-CA 120.82 -0.705 . . . . 0.0 111.474 177.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 82.1 mt -120.62 131.21 73.37 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 N-CA-C 106.474 -1.676 . . . . 0.0 106.474 175.06 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 3.9 p -117.85 133.1 65.72 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.051 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -176.038 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . 0.411 ' HA ' ' HA ' ' A' ' 218' ' ' SER . 1.4 m -129.35 141.16 51.15 Favored 'General case' 0 CA--C 1.505 -0.781 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.71 -177.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 294' ' ' GLN . . . . . 0.492 ' HA ' ' HA ' ' A' ' 248' ' ' VAL . 0.2 OUTLIER . . . . . 0 C--N 1.318 -0.797 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 172.398 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 217' ' ' LEU . . . . . 0.424 HD13 ' HA ' ' A' ' 217' ' ' LEU . 0.1 OUTLIER . . . . . 0 C--O 1.234 0.28 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 . . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 24.1 m -133.63 152.46 51.9 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.277 -174.092 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -142.98 156.08 44.8 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 116.037 -0.528 . . . . 0.0 110.559 177.303 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 220' ' ' MET . . . . . 0.545 ' SD ' HD12 ' A' ' 291' ' ' ILE . 1.6 mpp? -75.22 134.57 41.13 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 176.659 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 99.3 t -82.06 128.29 38.85 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.886 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 178.836 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 20.2 m -86.3 -71.59 0.54 Allowed 'General case' 0 N--CA 1.439 -0.993 0 CA-C-N 116.017 -0.538 . . . . 0.0 109.876 178.037 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 8.7 ptm -137.71 149.68 46.69 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.168 174.504 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 224' ' ' VAL . . . . . 0.532 HG22 ' HB ' ' A' ' 232' ' ' VAL . 72.4 t -121.74 127.27 75.46 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.993 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 174.748 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 225' ' ' THR . . . . . 0.413 ' O ' HG21 ' A' ' 280' ' ' THR . 11.6 p -77.44 130.72 37.41 Favored 'General case' 0 CA--C 1.512 -0.485 0 C-N-CA 120.399 -0.52 . . . . 0.0 110.382 -179.117 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 226' ' ' LYS . . . . . 0.555 ' NZ ' ' OG ' ' A' ' 281' ' ' SER . 26.7 tptp -81.97 74.5 8.95 Favored 'General case' 0 N--CA 1.441 -0.916 0 N-CA-C 108.728 -0.842 . . . . 0.0 108.728 176.232 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 227' ' ' ASP . . . . . 0.465 ' CG ' ' H ' ' A' ' 228' ' ' ASN . 8.6 t70 -153.65 -173.15 4.47 Favored 'General case' 0 C--O 1.244 0.797 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.599 -176.224 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 228' ' ' ASN . . . . . 0.533 ' ND2' ' O ' ' A' ' 228' ' ' ASN . 0.1 OUTLIER -140.51 125.08 10.85 Favored Pre-proline 0 N--CA 1.452 -0.353 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.2 176.094 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 229' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -69.68 148.31 86.29 Favored 'Cis proline' 0 C--N 1.311 -1.422 0 C-N-CA 123.029 -1.655 . . . . 0.0 109.722 -1.636 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . 0.614 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -71.32 130.38 18.57 Favored Glycine 0 C--N 1.311 -0.839 0 N-CA-C 109.231 -1.548 . . . . 0.0 109.231 -179.719 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.1 p -120.93 131.35 73.18 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.8 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 177.903 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 232' ' ' VAL . . . . . 0.532 ' HB ' HG22 ' A' ' 224' ' ' VAL . 0.6 OUTLIER -130.09 153.13 38.47 Favored 'Isoleucine or valine' 0 C--O 1.249 1.061 0 C-N-CA 119.474 -0.89 . . . . 0.0 111.361 -174.78 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 3.1 m -108.11 140.37 41.4 Favored 'General case' 0 N--CA 1.432 -1.358 0 CA-C-N 114.807 -1.088 . . . . 0.0 108.857 177.832 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 34.6 m -107.28 161.0 15.18 Favored 'General case' 0 C--N 1.308 -1.227 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 178.422 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 40.1 tp -60.53 127.65 32.76 Favored 'General case' 0 C--N 1.314 -0.978 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 -178.747 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -56.79 -39.89 74.93 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-O 121.242 0.544 . . . . 0.0 110.608 -174.481 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -65.89 -29.63 70.1 Favored 'General case' 0 C--N 1.308 -1.224 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.99 179.602 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -96.96 130.92 44.2 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 112.106 0.41 . . . . 0.0 112.106 -172.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 90.6 mtm-85 -86.3 137.45 32.6 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 174.351 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 240' ' ' HIS . . . . . 0.574 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 8.9 p80 -88.62 -45.18 10.07 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 121.073 0.463 . . . . 0.0 109.832 175.699 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 83.25 12.15 79.41 Favored Glycine 0 C--O 1.239 0.436 0 N-CA-C 110.719 -0.952 . . . . 0.0 110.719 178.539 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 242' ' ' PHE . . . . . 0.506 ' CD1' ' HB3' ' A' ' 294' ' ' GLN . 4.4 m-30 -80.87 145.35 31.4 Favored 'General case' 0 C--N 1.318 -0.781 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 -179.495 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 243' ' ' GLU . . . . . 0.463 ' H ' ' CB ' ' A' ' 246' ' ' ASP . 98.2 mt-10 -122.17 168.1 12.39 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.951 -179.158 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 17.7 m -58.84 122.12 12.8 Favored 'General case' 0 C--N 1.313 -1.003 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 179.356 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 78.48 7.02 88.14 Favored Glycine 0 C--N 1.319 -0.394 0 N-CA-C 111.25 -0.74 . . . . 0.0 111.25 179.646 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 246' ' ' ASP . . . . . 0.463 ' CB ' ' H ' ' A' ' 243' ' ' GLU . 40.0 t0 -76.93 162.2 27.78 Favored 'General case' 0 CA--C 1.514 -0.43 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 178.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 247' ' ' PHE . . . . . 0.466 ' HA ' ' O ' ' A' ' 265' ' ' MET . 72.3 m-85 -109.64 137.21 47.79 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.041 0.448 . . . . 0.0 111.511 -177.534 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 248' ' ' VAL . . . . . 0.452 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.9 m -133.47 162.02 40.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.308 178.792 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 67.1 m -125.89 151.48 46.85 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 172.692 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 250' ' ' PHE . . . . . 0.586 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 88.3 m-85 -107.37 149.58 27.7 Favored 'General case' 0 C--N 1.308 -1.207 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.218 -175.552 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 7.3 p -146.92 156.8 43.36 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.231 179.424 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 87.0 mt-10 45.8 26.8 0.4 Allowed 'General case' 0 C--N 1.316 -0.849 0 N-CA-C 112.914 0.709 . . . . 0.0 112.914 177.767 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 0.505 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 52.5 t -83.32 132.78 30.59 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.415 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 174.921 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 93.8 mm-40 -98.52 137.23 37.49 Favored 'General case' 0 C--N 1.317 -0.833 0 C-N-CA 120.043 -0.663 . . . . 0.0 110.036 -179.254 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 83.38 -57.28 5.07 Favored Glycine 0 C--N 1.317 -0.514 0 N-CA-C 110.899 -0.881 . . . . 0.0 110.899 -177.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 256' ' ' MET . . . . . 0.411 ' SD ' HG11 ' A' ' 224' ' ' VAL . 4.4 ttm -78.29 63.11 3.11 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.632 0.729 . . . . 0.0 109.388 178.747 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 48.6 pt -69.76 -25.59 28.72 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 114.853 -1.067 . . . . 0.0 111.39 -174.748 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 258' ' ' GLN . . . . . 0.474 ' HG3' ' SG ' ' A' ' 262' ' ' CYS . 60.9 tp60 -58.93 -40.6 85.07 Favored 'General case' 0 CA--C 1.509 -0.608 0 C-N-CA 120.343 -0.543 . . . . 0.0 110.085 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 259' ' ' LEU . . . . . 0.628 HD21 ' CE2' ' A' ' 283' ' ' PHE . 96.0 mt -62.51 -42.28 99.4 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.981 -0.554 . . . . 0.0 109.554 179.009 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 260' ' ' ASN . . . . . 0.505 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 99.0 m-20 -60.23 -40.44 90.22 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.079 -178.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -92.19 -5.12 65.98 Favored Glycine 0 CA--C 1.523 0.557 0 C-N-CA 121.268 -0.491 . . . . 0.0 111.904 -178.238 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 262' ' ' CYS . . . . . 0.474 ' SG ' ' HG3' ' A' ' 258' ' ' GLN . 1.1 m -78.19 154.6 30.98 Favored 'General case' 0 C--N 1.326 -0.456 0 C-N-CA 120.363 -0.535 . . . . 0.0 111.614 -176.207 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . 0.561 ' CD ' ' H ' ' A' ' 263' ' ' GLN . 0.0 OUTLIER -67.9 170.72 6.67 Favored Pre-proline 0 C--N 1.322 -0.623 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 172.93 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 264' ' ' PRO . . . . . 0.452 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 45.1 Cg_endo -63.92 142.99 84.22 Favored 'Trans proline' 0 C--N 1.311 -1.436 0 N-CA-C 109.452 -1.018 . . . . 0.0 109.452 177.555 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 265' ' ' MET . . . . . 0.466 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 17.1 ptp -130.97 153.97 48.64 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 112.254 0.464 . . . . 0.0 112.254 -173.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -71.83 137.54 47.63 Favored 'General case' 0 C--O 1.236 0.383 0 O-C-N 124.133 0.896 . . . . 0.0 109.919 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 267' ' ' ILE . . . . . 0.673 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.8 pp -128.47 162.5 34.99 Favored 'Isoleucine or valine' 0 C--O 1.244 0.771 0 CA-C-O 121.085 0.469 . . . . 0.0 112.106 -179.035 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 61.4 mttm -122.6 126.5 47.82 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.522 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 13.0 m -84.92 123.69 39.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 C-N-CA 120.644 -0.422 . . . . 0.0 111.477 -179.567 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 90.0 mt -102.86 -12.01 17.86 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.588 178.334 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -171.81 -177.77 41.67 Favored Glycine 0 C--N 1.318 -0.463 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.109 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 272' ' ' PRO . . . . . 0.574 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 29.8 Cg_endo -60.37 -34.1 93.67 Favored 'Trans proline' 0 C--N 1.306 -1.677 0 C-N-CA 122.091 1.861 . . . . 0.0 111.7 -179.785 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 73.1 m-85 -125.59 10.04 7.8 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.172 -179.722 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -120.7 128.5 53.01 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 116.486 -0.324 . . . . 0.0 110.51 -173.167 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 275' ' ' PHE . . . . . 0.518 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -141.54 166.25 25.28 Favored 'General case' 0 CA--C 1.508 -0.659 0 N-CA-C 112.597 0.592 . . . . 0.0 112.597 178.748 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . 0.452 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 7.8 p -133.66 146.92 51.32 Favored 'General case' 0 N--CA 1.44 -0.952 0 CA-C-O 121.182 0.515 . . . . 0.0 111.276 -179.73 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 277' ' ' ILE . . . . . 0.412 HG22 HG22 ' A' ' 267' ' ' ILE . 28.9 pt -139.79 164.1 23.98 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.005 0 CA-C-N 114.518 -1.219 . . . . 0.0 111.511 -173.174 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -23.99 -92.76 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.574 0 N-CA-C 113.603 0.964 . . . . 0.0 113.603 -176.71 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . 0.439 ' HB3' ' HB2' ' A' ' 282' ' ' ASN . 66.8 t0 -151.34 121.75 7.35 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 -177.597 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . 0.679 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 23.7 p -65.04 -30.12 71.07 Favored 'General case' 0 C--N 1.293 -1.882 0 CA-C-O 120.982 0.42 . . . . 0.0 111.095 177.01 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 281' ' ' SER . . . . . 0.555 ' OG ' ' NZ ' ' A' ' 226' ' ' LYS . 15.7 m -70.39 -14.59 62.62 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.017 174.132 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 282' ' ' ASN . . . . . 0.439 ' HB2' ' HB3' ' A' ' 279' ' ' ASP . 60.4 t30 -89.22 -5.71 57.44 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.872 174.395 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 283' ' ' PHE . . . . . 0.679 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 12.4 m-85 -102.89 -73.86 0.65 Allowed 'General case' 0 CA--C 1.511 -0.521 0 CA-C-O 121.594 0.711 . . . . 0.0 109.79 175.057 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 172.48 -166.36 0.02 OUTLIER 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 114.02 -1.446 . . . . 0.0 107.827 -171.895 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -97.06 146.4 25.05 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 117.907 0.322 . . . . 0.0 111.115 178.068 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 10.8 t80 -86.54 123.17 31.44 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.006 -179.816 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 287' ' ' ILE . . . . . 0.567 ' O ' ' HG3' ' A' ' 288' ' ' ARG . 21.4 mm -100.51 -73.66 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -0.981 0 CA-C-N 116.501 -0.318 . . . . 0.0 110.265 176.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . 0.567 ' HG3' ' O ' ' A' ' 287' ' ' ILE . 92.1 mtt-85 -164.61 178.43 7.33 Favored 'General case' 0 C--O 1.242 0.663 0 C-N-CA 124.112 0.965 . . . . 0.0 110.409 179.265 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 68.63 -158.14 52.78 Favored Glycine 0 CA--C 1.505 -0.536 0 N-CA-C 110.319 -1.113 . . . . 0.0 110.319 177.078 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 108.31 113.57 3.69 Favored Glycine 0 N--CA 1.439 -1.158 0 C-N-CA 120.769 -0.729 . . . . 0.0 111.946 177.715 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . 0.545 HD12 ' SD ' ' A' ' 220' ' ' MET . 43.5 mm -112.96 128.71 69.55 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.477 0 N-CA-C 105.899 -1.889 . . . . 0.0 105.899 172.352 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 3.5 p -118.9 134.45 62.51 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.039 0 C-N-CA 120.253 -0.579 . . . . 0.0 109.657 -177.694 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 15.2 m -125.21 144.48 50.43 Favored 'General case' 0 CA--C 1.508 -0.65 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.91 -176.504 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 294' ' ' GLN . . . . . 0.506 ' HB3' ' CD1' ' A' ' 242' ' ' PHE . 3.4 pt20 . . . . . 0 CA--C 1.502 -0.873 0 C-N-CA 120.205 -0.598 . . . . 0.0 110.745 179.159 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 217' ' ' LEU . . . . . 0.629 HD11 ' NH2' ' A' ' 239' ' ' ARG . 0.1 OUTLIER . . . . . 0 C--O 1.239 0.543 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 . . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 218' ' ' SER . . . . . 0.431 ' OG ' ' OG ' ' A' ' 293' ' ' SER . 45.9 m -132.46 148.6 52.4 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.692 -174.574 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -143.08 157.11 44.83 Favored 'General case' 0 CA--C 1.51 -0.573 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.884 178.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 66.2 mtt -75.18 144.2 42.83 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 115.736 -0.666 . . . . 0.0 109.61 176.503 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 95.7 t -85.38 129.32 38.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.35 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 222' ' ' SER . . . . . 0.546 ' HG ' ' C ' ' A' ' 233' ' ' THR . 25.3 p -94.44 -55.14 3.26 Favored 'General case' 0 N--CA 1.439 -0.979 0 CA-C-O 120.867 0.365 . . . . 0.0 110.218 -178.164 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -137.46 149.39 46.81 Favored 'General case' 0 C--O 1.219 -0.551 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.599 177.573 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 224' ' ' VAL . . . . . 0.461 ' HB ' ' CD1' ' A' ' 286' ' ' TYR . 43.2 t -124.96 133.2 70.09 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.828 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 172.667 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -103.88 116.88 33.08 Favored 'General case' 0 C--N 1.31 -1.141 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 -178.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 226' ' ' LYS . . . . . 0.435 ' HA ' ' OG1' ' A' ' 280' ' ' THR . 88.1 tttt -78.55 90.38 4.51 Favored 'General case' 0 CA--C 1.505 -0.776 0 C-N-CA 119.296 -0.962 . . . . 0.0 110.044 -177.924 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 227' ' ' ASP . . . . . 0.617 ' H ' ' HG1' ' A' ' 280' ' ' THR . 43.9 t0 -159.5 179.85 8.55 Favored 'General case' 0 C--N 1.307 -1.241 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.03 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 228' ' ' ASN . . . . . 0.472 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 1.8 p30 -132.99 125.5 19.15 Favored Pre-proline 0 C--N 1.324 -0.523 0 CA-C-N 115.878 -0.601 . . . . 0.0 109.912 175.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 229' ' ' PRO . . . . . 0.472 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 46.4 Cg_endo -66.32 145.12 69.42 Favored 'Cis proline' 0 N--CA 1.491 1.349 0 C-N-CA 123.204 -1.582 . . . . 0.0 110.641 -0.68 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . 0.511 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -68.01 132.86 28.77 Favored Glycine 0 N--CA 1.452 -0.234 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.169 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.9 p -128.26 136.12 60.91 Favored 'Isoleucine or valine' 0 C--O 1.241 0.629 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 178.35 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 232' ' ' VAL . . . . . 0.56 HG22 ' CD1' ' A' ' 275' ' ' PHE . 0.6 OUTLIER -134.85 156.01 39.21 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.047 0 C-N-CA 120.164 -0.614 . . . . 0.0 110.493 -179.422 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 233' ' ' THR . . . . . 0.546 ' C ' ' HG ' ' A' ' 222' ' ' SER . 21.7 m -104.65 144.78 31.25 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 115.413 -0.812 . . . . 0.0 109.106 176.11 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 2.4 m -106.1 159.51 16.02 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 177.484 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.567 ' HB3' ' HB3' ' A' ' 238' ' ' ALA . 43.1 tp -57.85 127.24 31.07 Favored 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 -178.469 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 236' ' ' ASP . . . . . 0.402 ' O ' ' CZ ' ' A' ' 273' ' ' TYR . 7.5 m-20 -62.46 -37.91 87.75 Favored 'General case' 0 CA--C 1.512 -0.497 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.19 -172.279 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 57.9 mp0 -69.67 -19.5 63.59 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.659 177.734 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 238' ' ' ALA . . . . . 0.567 ' HB3' ' HB3' ' A' ' 235' ' ' LEU . . . -108.78 99.94 9.23 Favored 'General case' 0 C--O 1.238 0.479 0 N-CA-C 112.102 0.408 . . . . 0.0 112.102 -177.197 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 239' ' ' ARG . . . . . 0.629 ' NH2' HD11 ' A' ' 217' ' ' LEU . 0.0 OUTLIER -70.57 117.4 12.05 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 173.342 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 240' ' ' HIS . . . . . 0.606 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 6.6 p80 -66.54 -45.71 78.49 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.681 -179.504 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 82.31 21.43 60.55 Favored Glycine 0 C--N 1.315 -0.62 0 N-CA-C 110.775 -0.93 . . . . 0.0 110.775 -178.275 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 242' ' ' PHE . . . . . 0.772 ' HB3' HD11 ' A' ' 267' ' ' ILE . 7.5 m-30 -83.74 156.02 22.79 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 120.69 0.281 . . . . 0.0 110.339 179.629 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 -124.3 165.08 18.29 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.545 174.821 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 244' ' ' THR . . . . . 0.62 HG23 ' HA ' ' A' ' 268' ' ' LYS . 0.2 OUTLIER -69.61 126.44 29.74 Favored 'General case' 0 C--N 1.319 -0.76 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 177.374 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 90.43 2.38 73.43 Favored Glycine 0 C--N 1.317 -0.513 0 N-CA-C 110.476 -1.05 . . . . 0.0 110.476 -176.422 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 246' ' ' ASP . . . . . 0.511 ' O ' HG12 ' A' ' 267' ' ' ILE . 46.3 t0 -77.8 163.86 25.72 Favored 'General case' 0 C--O 1.237 0.445 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 176.427 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 247' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -115.84 128.85 56.13 Favored 'General case' 0 C--O 1.241 0.637 0 O-C-N 123.287 0.367 . . . . 0.0 110.661 -178.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 248' ' ' VAL . . . . . 0.541 ' CG1' HD13 ' A' ' 267' ' ' ILE . 2.4 m -132.4 164.58 34.56 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.308 0 C-N-CA 120.223 -0.591 . . . . 0.0 111.905 178.287 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 31.4 m -130.66 153.0 49.41 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.179 172.56 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 250' ' ' PHE . . . . . 0.604 ' CD1' HD22 ' A' ' 259' ' ' LEU . 61.3 m-85 -103.14 146.58 28.18 Favored 'General case' 0 C--N 1.322 -0.616 0 C-N-CA 122.729 0.411 . . . . 0.0 110.327 -178.912 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 2.5 m -143.74 153.06 42.04 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.417 176.715 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 49.42 37.51 12.09 Favored 'General case' 0 C--O 1.245 0.865 0 N-CA-C 113.044 0.757 . . . . 0.0 113.044 175.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 0.65 HG22 ' HA3' ' A' ' 290' ' ' GLY . 78.7 t -90.37 132.38 35.13 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 175.853 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 86.8 mt-30 -88.08 140.56 29.36 Favored 'General case' 0 C--O 1.242 0.709 0 C-N-CA 120.411 -0.516 . . . . 0.0 110.068 177.487 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 80.06 -63.82 4.03 Favored Glycine 0 C--N 1.314 -0.691 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 179.174 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 256' ' ' MET . . . . . 0.464 ' N ' ' O ' ' A' ' 285' ' ' ASP . 20.9 ttm -84.69 71.76 10.78 Favored 'General case' 0 CA--C 1.504 -0.804 0 C-N-CA 119.853 -0.739 . . . . 0.0 109.377 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 45.0 pt -80.35 -15.3 12.91 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 CA-C-N 115.005 -0.998 . . . . 0.0 110.144 -177.756 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 258' ' ' GLN . . . . . 0.504 ' O ' ' SG ' ' A' ' 262' ' ' CYS . 63.3 tp60 -57.53 -39.13 75.92 Favored 'General case' 0 N--CA 1.437 -1.11 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 177.643 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 259' ' ' LEU . . . . . 0.854 HD21 ' CE2' ' A' ' 283' ' ' PHE . 88.1 mt -62.78 -40.67 98.01 Favored 'General case' 0 N--CA 1.449 -0.508 0 CA-C-N 115.113 -0.949 . . . . 0.0 110.222 175.001 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -60.04 -40.63 90.06 Favored 'General case' 0 C--O 1.241 0.607 0 N-CA-C 109.306 -0.628 . . . . 0.0 109.306 -179.577 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -101.18 23.2 36.25 Favored Glycine 0 CA--C 1.526 0.736 0 N-CA-C 111.246 -0.741 . . . . 0.0 111.246 -179.178 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 262' ' ' CYS . . . . . 0.504 ' SG ' ' O ' ' A' ' 258' ' ' GLN . 1.3 m -96.68 147.34 24.01 Favored 'General case' 0 C--O 1.239 0.51 0 CA-C-N 117.362 0.581 . . . . 0.0 112.382 -177.708 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 5.3 mt-30 -61.93 154.34 68.62 Favored Pre-proline 0 C--N 1.324 -0.518 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 170.699 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 264' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -64.4 145.06 87.4 Favored 'Trans proline' 0 C--N 1.304 -1.806 0 C-N-CA 121.08 1.187 . . . . 0.0 109.868 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 265' ' ' MET . . . . . 0.554 ' N ' ' SD ' ' A' ' 265' ' ' MET . 0.2 OUTLIER -122.8 148.8 44.96 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 112.405 0.52 . . . . 0.0 112.405 -174.237 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 266' ' ' GLU . . . . . 0.419 ' HA ' ' O ' ' A' ' 246' ' ' ASP . 75.8 tt0 -77.97 134.3 37.87 Favored 'General case' 0 C--O 1.242 0.662 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 174.355 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 267' ' ' ILE . . . . . 0.772 HD11 ' HB3' ' A' ' 242' ' ' PHE . 49.5 pt -125.26 159.64 32.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 N-CA-C 114.023 1.12 . . . . 0.0 114.023 -166.342 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . 0.62 ' HA ' HG23 ' A' ' 244' ' ' THR . 66.5 mttm -120.55 106.59 11.93 Favored 'General case' 0 CA--C 1.537 0.459 0 CA-C-N 115.154 -0.93 . . . . 0.0 110.021 177.325 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.4 HG22 ' H ' ' A' ' 269' ' ' VAL . 17.3 m -80.24 102.31 6.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 120.999 0.428 . . . . 0.0 110.516 178.452 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 96.1 mt -66.3 -41.27 89.99 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.964 -179.707 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -149.16 -172.09 18.49 Favored Glycine 0 C--N 1.318 -0.458 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -177.383 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 272' ' ' PRO . . . . . 0.606 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 37.9 Cg_endo -62.98 -33.93 72.68 Favored 'Trans proline' 0 C--N 1.308 -1.57 0 C-N-CA 121.827 1.685 . . . . 0.0 111.369 -178.024 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 273' ' ' TYR . . . . . 0.409 ' O ' ' HA ' ' A' ' 233' ' ' THR . 83.3 m-85 -122.54 8.44 9.55 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 112.818 0.673 . . . . 0.0 112.818 -177.968 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 2.8 p -120.88 128.05 52.44 Favored 'General case' 0 C--O 1.243 0.747 0 CA-C-O 120.605 0.24 . . . . 0.0 110.865 178.923 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 275' ' ' PHE . . . . . 0.561 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -138.25 159.44 42.04 Favored 'General case' 0 CA--C 1.507 -0.697 0 C-N-CA 120.671 -0.411 . . . . 0.0 111.658 177.667 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 7.9 p -137.79 154.29 49.58 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.521 -173.388 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 277' ' ' ILE . . . . . 0.487 HG22 HG22 ' A' ' 267' ' ' ILE . 0.1 OUTLIER -141.72 -155.04 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.912 0 CA-C-N 115.428 -0.805 . . . . 0.0 110.106 -173.087 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 1.1 p -60.04 -89.03 0.0 OUTLIER 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 116.499 -0.318 . . . . 0.0 111.306 178.338 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . 0.596 ' HB3' HD22 ' A' ' 282' ' ' ASN . 66.0 t0 -151.7 118.98 5.94 Favored 'General case' 0 N--CA 1.447 -0.611 0 CA-C-O 120.825 0.345 . . . . 0.0 111.421 -176.736 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . 0.646 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 11.1 p -64.34 -30.34 71.39 Favored 'General case' 0 C--N 1.299 -1.626 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.101 175.095 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -61.73 -21.05 64.17 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.449 175.852 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 282' ' ' ASN . . . . . 0.596 HD22 ' HB3' ' A' ' 279' ' ' ASP . 40.1 m-80 -93.94 -3.83 50.9 Favored 'General case' 0 N--CA 1.451 -0.419 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.023 176.847 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 283' ' ' PHE . . . . . 0.854 ' CE2' HD21 ' A' ' 259' ' ' LEU . 22.8 m-85 -91.84 -80.72 0.35 Allowed 'General case' 0 CA--C 1.512 -0.508 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 171.674 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 3.9 p 179.25 -109.85 0.0 OUTLIER 'General case' 0 N--CA 1.453 -0.305 0 CA-C-N 115.193 -0.912 . . . . 0.0 109.675 173.463 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 285' ' ' ASP . . . . . 0.464 ' O ' ' N ' ' A' ' 256' ' ' MET . 2.1 p-10 -145.49 163.37 34.9 Favored 'General case' 0 C--O 1.219 -0.514 0 N-CA-C 107.667 -1.234 . . . . 0.0 107.667 174.114 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 286' ' ' TYR . . . . . 0.461 ' CD1' ' HB ' ' A' ' 224' ' ' VAL . 1.1 p90 -123.95 145.51 49.11 Favored 'General case' 0 N--CA 1.468 0.442 0 C-N-CA 119.663 -0.815 . . . . 0.0 111.495 -178.046 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 96.9 mt -100.77 -57.68 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 176.781 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 32.2 ptt-85 -176.17 -169.3 0.31 Allowed 'General case' 0 C--O 1.242 0.688 0 CA-C-N 115.447 -0.797 . . . . 0.0 109.979 177.584 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 67.32 -153.47 52.9 Favored Glycine 0 CA--C 1.502 -0.779 0 N-CA-C 110.944 -0.863 . . . . 0.0 110.944 175.837 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 290' ' ' GLY . . . . . 0.65 ' HA3' HG22 ' A' ' 253' ' ' VAL . . . 93.51 136.49 7.96 Favored Glycine 0 N--CA 1.442 -0.958 0 N-CA-C 111.778 -0.529 . . . . 0.0 111.778 176.841 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 92.2 mt -122.87 129.38 75.17 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 173.756 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 3.8 p -112.21 129.72 67.19 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 178.855 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . 0.431 ' OG ' ' OG ' ' A' ' 218' ' ' SER . 55.7 m -126.9 147.88 50.05 Favored 'General case' 0 CA--C 1.5 -0.972 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.371 -174.495 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 294' ' ' GLN . . . . . 0.431 ' HG3' ' CE1' ' A' ' 242' ' ' PHE . 85.0 mt-30 . . . . . 0 C--N 1.318 -0.772 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 171.804 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 217' ' ' LEU . . . . . 0.707 HD13 ' N ' ' A' ' 218' ' ' SER . 0.3 OUTLIER . . . . . 0 CA--C 1.513 -0.445 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 . . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 218' ' ' SER . . . . . 0.707 ' N ' HD13 ' A' ' 217' ' ' LEU . 50.8 m -114.04 131.88 56.21 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.163 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 219' ' ' ALA . . . . . 0.622 ' HB1' ' HB1' ' A' ' 238' ' ' ALA . . . -131.75 150.74 52.05 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.703 -175.362 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 97.8 mtp -81.02 129.69 34.66 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.163 178.42 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . 0.455 HG11 ' CG2' ' A' ' 224' ' ' VAL . 97.3 t -79.85 133.98 28.54 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.011 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 177.356 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 13.8 p -93.28 -62.0 1.46 Allowed 'General case' 0 N--CA 1.436 -1.151 0 C-N-CA 120.129 -0.628 . . . . 0.0 109.777 -179.358 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -138.06 139.05 39.36 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.946 173.818 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 224' ' ' VAL . . . . . 0.742 HG13 HG12 ' A' ' 232' ' ' VAL . 59.4 t -117.01 130.79 71.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 174.489 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 62.3 p -88.02 138.9 31.05 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-O 120.826 0.346 . . . . 0.0 110.944 -178.509 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 226' ' ' LYS . . . . . 0.451 ' NZ ' ' OD2' ' A' ' 285' ' ' ASP . 2.6 tptm -78.34 77.66 4.83 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 178.807 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 227' ' ' ASP . . . . . 0.41 ' H ' ' HG1' ' A' ' 280' ' ' THR . 45.8 t0 -157.0 174.04 16.12 Favored 'General case' 0 N--CA 1.468 0.454 0 N-CA-C 112.249 0.462 . . . . 0.0 112.249 -176.172 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 228' ' ' ASN . . . . . 0.482 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.4 OUTLIER -130.86 125.14 21.16 Favored Pre-proline 0 N--CA 1.451 -0.403 0 CA-C-N 115.382 -0.826 . . . . 0.0 110.244 173.083 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 229' ' ' PRO . . . . . 0.482 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 24.6 Cg_exo -64.86 147.37 70.15 Favored 'Cis proline' 0 C--N 1.31 -1.498 0 C-N-CA 123.611 -1.412 . . . . 0.0 110.059 -2.157 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . 0.664 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -72.75 100.86 1.03 Allowed Glycine 0 C--N 1.295 -1.704 0 N-CA-C 110.025 -1.23 . . . . 0.0 110.025 -179.732 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 231' ' ' VAL . . . . . 0.621 HG23 HD12 ' A' ' 270' ' ' LEU . 7.1 p -88.51 127.32 41.51 Favored 'Isoleucine or valine' 0 C--O 1.244 0.784 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 177.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 232' ' ' VAL . . . . . 0.742 HG12 HG13 ' A' ' 224' ' ' VAL . 0.6 OUTLIER -131.46 156.43 42.64 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.897 0 CA-C-O 121.124 0.488 . . . . 0.0 109.827 -177.503 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -117.69 145.45 44.41 Favored 'General case' 0 N--CA 1.429 -1.489 0 CA-C-N 114.838 -1.074 . . . . 0.0 109.032 179.336 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.8 m -107.0 160.3 15.64 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.095 -177.553 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 24.1 tp -54.82 132.62 46.61 Favored 'General case' 0 C--N 1.314 -0.966 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 178.749 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 236' ' ' ASP . . . . . 0.41 ' O ' ' CE1' ' A' ' 273' ' ' TYR . 28.4 t70 -53.89 -42.82 69.07 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-O 121.341 0.591 . . . . 0.0 111.007 -176.174 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 74.0 mt-10 -65.49 -32.15 73.61 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.32 179.126 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 238' ' ' ALA . . . . . 0.622 ' HB1' ' HB1' ' A' ' 219' ' ' ALA . . . -72.11 135.03 46.1 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.961 0.41 . . . . 0.0 111.896 -176.861 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 66.2 mtp180 -113.13 92.96 4.19 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 175.565 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 240' ' ' HIS . . . . . 0.567 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 7.3 p80 -54.7 -49.12 71.48 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 -173.337 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 79.86 17.57 74.67 Favored Glycine 0 C--N 1.309 -0.964 0 N-CA-C 110.491 -1.044 . . . . 0.0 110.491 -179.21 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 242' ' ' PHE . . . . . 0.49 ' CD2' ' HB2' ' A' ' 240' ' ' HIS . 6.5 m-30 -80.4 144.12 32.93 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 -179.11 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -106.83 164.85 11.77 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.346 0.594 . . . . 0.0 111.364 179.145 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -65.56 120.8 13.55 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 177.866 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 79.76 7.69 88.3 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 -177.358 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 43.2 t0 -79.51 166.49 21.9 Favored 'General case' 0 C--O 1.233 0.188 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 -179.694 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 247' ' ' PHE . . . . . 0.496 ' HA ' ' O ' ' A' ' 265' ' ' MET . 26.9 m-85 -110.19 133.63 53.04 Favored 'General case' 0 C--O 1.239 0.525 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -176.868 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 248' ' ' VAL . . . . . 0.499 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 3.0 m -131.89 160.37 42.47 Favored 'Isoleucine or valine' 0 C--O 1.237 0.435 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.472 178.144 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 1.2 m -121.84 161.65 22.34 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 114.907 -1.042 . . . . 0.0 109.171 173.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 250' ' ' PHE . . . . . 0.527 ' CB ' ' HB3' ' A' ' 259' ' ' LEU . 61.0 m-85 -125.88 151.77 46.45 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 110.306 -0.257 . . . . 0.0 110.306 -175.066 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 16.4 m -156.36 163.08 39.91 Favored 'General case' 0 C--O 1.215 -0.719 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 177.032 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 67.3 mm-40 54.4 30.15 12.24 Favored 'General case' 0 C--N 1.316 -0.887 0 N-CA-C 111.746 0.276 . . . . 0.0 111.746 175.419 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 0.657 HG22 ' CA ' ' A' ' 290' ' ' GLY . 2.9 t -98.96 126.74 52.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 176.758 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 83.2 mt-30 -90.94 138.41 31.62 Favored 'General case' 0 C--O 1.246 0.906 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 178.224 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 81.2 -59.0 4.82 Favored Glycine 0 C--O 1.244 0.76 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 -178.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 256' ' ' MET . . . . . 0.509 ' SD ' HG11 ' A' ' 224' ' ' VAL . 3.8 ttm -80.13 49.86 1.16 Allowed 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 121.988 0.899 . . . . 0.0 109.766 178.285 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 47.6 pt -67.43 -22.29 28.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 114.262 -1.335 . . . . 0.0 111.116 -176.768 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 258' ' ' GLN . . . . . 0.516 ' HG3' ' HG ' ' A' ' 262' ' ' CYS . 63.9 tp60 -57.1 -39.11 74.43 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 179.199 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 259' ' ' LEU . . . . . 0.682 HD21 ' CE2' ' A' ' 283' ' ' PHE . 99.2 mt -62.15 -40.8 97.17 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 115.47 -0.786 . . . . 0.0 109.721 178.037 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 -60.27 -40.98 92.28 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 -178.254 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -99.27 17.86 57.32 Favored Glycine 0 CA--C 1.521 0.464 0 N-CA-C 111.55 -0.62 . . . . 0.0 111.55 -179.633 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 262' ' ' CYS . . . . . 0.516 ' HG ' ' HG3' ' A' ' 258' ' ' GLN . 1.4 m -94.45 160.39 14.68 Favored 'General case' 0 C--O 1.239 0.512 0 CA-C-N 117.052 0.426 . . . . 0.0 110.455 -179.71 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -82.1 159.72 64.67 Favored Pre-proline 0 C--N 1.318 -0.766 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 172.306 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 264' ' ' PRO . . . . . 0.499 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 24.3 Cg_exo -62.16 143.26 94.29 Favored 'Trans proline' 0 C--N 1.309 -1.538 0 CA-C-N 119.743 0.944 . . . . 0.0 109.949 -179.248 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 265' ' ' MET . . . . . 0.496 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 8.7 ptp -133.57 167.94 19.56 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 112.892 0.701 . . . . 0.0 112.892 -175.088 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 72.2 tt0 -70.1 139.88 52.6 Favored 'General case' 0 C--O 1.243 0.735 0 O-C-N 124.164 0.915 . . . . 0.0 110.177 -179.69 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 267' ' ' ILE . . . . . 0.616 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.7 pp -129.22 154.35 39.97 Favored 'Isoleucine or valine' 0 C--O 1.243 0.755 0 CA-C-O 121.263 0.554 . . . . 0.0 111.526 178.389 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 66.2 mttm -125.72 109.61 12.79 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.744 -178.052 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 18.8 m -70.39 131.39 34.32 Favored 'Isoleucine or valine' 0 C--O 1.237 0.407 0 CA-C-O 120.681 0.277 . . . . 0.0 111.235 -177.394 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 270' ' ' LEU . . . . . 0.621 HD12 HG23 ' A' ' 231' ' ' VAL . 95.1 mt -109.48 -25.55 10.43 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.582 179.149 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -156.41 -174.79 26.61 Favored Glycine 0 CA--C 1.511 -0.188 0 N-CA-C 110.124 -1.19 . . . . 0.0 110.124 -179.218 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 272' ' ' PRO . . . . . 0.567 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 28.6 Cg_endo -60.24 -39.87 64.41 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 121.844 1.696 . . . . 0.0 111.439 -177.434 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 273' ' ' TYR . . . . . 0.41 ' CE1' ' O ' ' A' ' 236' ' ' ASP . 57.6 m-85 -118.98 9.81 12.0 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.207 178.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -116.01 129.14 56.23 Favored 'General case' 0 C--O 1.241 0.612 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.727 -172.465 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 275' ' ' PHE . . . . . 0.575 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -144.24 167.87 21.41 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 111.84 0.311 . . . . 0.0 111.84 179.729 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . 0.432 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 4.6 p -133.27 142.26 48.42 Favored 'General case' 0 C--N 1.319 -0.728 0 C-N-CA 120.764 -0.374 . . . . 0.0 111.65 -177.353 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 277' ' ' ILE . . . . . 0.502 HG22 HG22 ' A' ' 267' ' ' ILE . 38.0 pt -137.02 163.07 33.25 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-N 115.137 -0.938 . . . . 0.0 111.739 -176.779 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 278' ' ' CYS . . . . . 0.434 ' C ' ' O ' ' A' ' 277' ' ' ILE . 88.1 m -14.98 -92.73 0.0 OUTLIER 'General case' 0 CA--C 1.543 0.703 0 N-CA-C 113.979 1.103 . . . . 0.0 113.979 -177.893 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . 0.416 ' CG ' ' HB3' ' A' ' 228' ' ' ASN . 67.1 t0 -154.99 114.82 3.75 Favored 'General case' 0 CA--C 1.509 -0.601 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 -179.209 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . 0.796 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 20.8 p -65.43 -27.79 68.78 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-O 120.99 0.424 . . . . 0.0 110.755 178.488 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -63.08 -23.95 67.68 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-N 115.169 -0.923 . . . . 0.0 109.224 175.526 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 20.4 t-20 -89.14 -9.53 50.65 Favored 'General case' 0 CA--C 1.512 -0.518 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.932 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 283' ' ' PHE . . . . . 0.796 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 10.2 m-85 -87.05 -64.86 1.08 Allowed 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 172.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 284' ' ' SER . . . . . 0.475 ' OG ' ' HA ' ' A' ' 256' ' ' MET . 2.4 p 170.35 -101.27 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 114.306 -1.316 . . . . 0.0 109.415 176.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 285' ' ' ASP . . . . . 0.47 ' O ' ' N ' ' A' ' 256' ' ' MET . 5.9 t0 -148.92 164.25 35.08 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-O 120.611 0.243 . . . . 0.0 110.793 176.851 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 286' ' ' TYR . . . . . 0.441 ' N ' ' OD1' ' A' ' 285' ' ' ASP . 83.9 t80 -94.69 114.99 26.99 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 177.387 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 22.2 mm -100.12 -58.73 3.69 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.519 175.012 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 85.5 mtm180 -160.97 167.53 26.34 Favored 'General case' 0 CA--C 1.503 -0.84 0 O-C-N 123.604 0.565 . . . . 0.0 112.352 178.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 51.21 -138.97 26.34 Favored Glycine 0 CA--C 1.504 -0.649 0 CA-C-N 113.339 -1.755 . . . . 0.0 112.556 168.891 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 290' ' ' GLY . . . . . 0.657 ' CA ' HG22 ' A' ' 253' ' ' VAL . . . 100.83 117.32 4.14 Favored Glycine 0 N--CA 1.433 -1.565 0 N-CA-C 110.602 -0.999 . . . . 0.0 110.602 -177.637 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 87.3 mt -108.75 128.06 64.8 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.285 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 175.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 3.3 p -118.85 135.38 59.46 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.035 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 -178.115 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . 0.475 ' HA ' ' O ' ' A' ' 217' ' ' LEU . 4.7 m -128.9 147.65 50.85 Favored 'General case' 0 N--CA 1.442 -0.856 0 C-N-CA 120.323 -0.551 . . . . 0.0 112.466 -174.426 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 48.1 tt0 . . . . . 0 N--CA 1.443 -0.823 0 CA-C-N 114.998 -1.001 . . . . 0.0 111.295 177.932 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 217' ' ' LEU . . . . . 0.448 HD22 ' HA ' ' A' ' 217' ' ' LEU . 0.5 OUTLIER . . . . . 0 CA--C 1.506 -0.746 0 N-CA-C 110.661 -0.126 . . . . 0.0 110.661 . . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 67.1 m -124.38 149.13 47.01 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.458 179.044 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -148.31 151.08 34.78 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.181 179.046 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 71.8 mtm -78.92 136.87 37.39 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 116.039 -0.528 . . . . 0.0 109.719 176.761 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 91.5 t -86.11 130.87 35.83 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.148 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -81.82 -71.01 0.5 Allowed 'General case' 0 N--CA 1.435 -1.179 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 178.656 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 223' ' ' MET . . . . . 0.661 ' C ' ' SD ' ' A' ' 223' ' ' MET . 2.1 ppp? -138.43 147.79 43.7 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 112.393 0.516 . . . . 0.0 112.393 173.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 224' ' ' VAL . . . . . 0.785 HG13 HG12 ' A' ' 232' ' ' VAL . 55.1 t -122.55 131.76 72.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 176.345 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 225' ' ' THR . . . . . 0.441 ' O ' ' OG1' ' A' ' 280' ' ' THR . 49.8 p -87.56 134.67 33.58 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 110.503 -0.184 . . . . 0.0 110.503 179.43 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 226' ' ' LYS . . . . . 0.492 ' NZ ' ' OD1' ' A' ' 285' ' ' ASP . 0.7 OUTLIER -80.42 76.88 7.23 Favored 'General case' 0 C--O 1.239 0.541 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 176.8 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 227' ' ' ASP . . . . . 0.433 ' H ' ' HG1' ' A' ' 280' ' ' THR . 5.8 t70 -147.87 177.33 9.42 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.302 -176.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 228' ' ' ASN . . . . . 0.474 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 4.3 t-20 -139.78 124.23 11.13 Favored Pre-proline 0 C--N 1.326 -0.414 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.415 176.072 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 229' ' ' PRO . . . . . 0.474 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 48.2 Cg_endo -66.17 144.59 66.84 Favored 'Cis proline' 0 C--N 1.313 -1.319 0 C-N-CA 122.802 -1.749 . . . . 0.0 109.873 -1.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . 0.503 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -70.69 138.29 28.41 Favored Glycine 0 C--O 1.222 -0.635 0 N-CA-C 109.821 -1.312 . . . . 0.0 109.821 -177.862 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.5 p -123.05 131.1 73.88 Favored 'Isoleucine or valine' 0 C--O 1.242 0.674 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 177.048 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 232' ' ' VAL . . . . . 0.785 HG12 HG13 ' A' ' 224' ' ' VAL . 0.7 OUTLIER -133.05 156.78 42.56 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 C-N-CA 120.347 -0.541 . . . . 0.0 110.819 -176.557 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 233' ' ' THR . . . . . 0.466 HG23 ' CG2' ' A' ' 274' ' ' THR . 0.2 OUTLIER -110.2 147.91 32.85 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 115.073 -0.967 . . . . 0.0 108.577 177.844 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 2.8 m -107.36 146.83 31.1 Favored 'General case' 0 C--N 1.313 -0.987 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 177.457 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 14.0 tp -49.41 125.26 10.78 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 -177.841 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 16.1 t70 -52.39 -40.84 62.58 Favored 'General case' 0 CA--C 1.507 -0.68 0 CA-C-N 116.463 -0.335 . . . . 0.0 111.07 -171.611 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 83.6 mt-10 -65.47 -35.41 80.81 Favored 'General case' 0 C--N 1.314 -0.977 0 C-N-CA 120.33 -0.548 . . . . 0.0 110.606 -177.794 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -72.34 138.32 47.23 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 112.442 0.534 . . . . 0.0 112.442 -175.226 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 84.9 mtp180 -105.14 104.42 14.15 Favored 'General case' 0 C--O 1.239 0.509 0 CA-C-N 115.734 -0.666 . . . . 0.0 109.26 172.829 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 240' ' ' HIS . . . . . 0.457 ' HB2' ' CG ' ' A' ' 242' ' ' PHE . 8.4 p80 -67.38 -46.96 71.76 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.923 -0.581 . . . . 0.0 111.599 -176.685 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 241' ' ' GLY . . . . . 0.441 ' N ' ' ND1' ' A' ' 240' ' ' HIS . . . 83.33 12.44 78.67 Favored Glycine 0 C--N 1.31 -0.902 0 N-CA-C 110.477 -1.049 . . . . 0.0 110.477 -176.909 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 242' ' ' PHE . . . . . 0.457 ' CG ' ' HB2' ' A' ' 240' ' ' HIS . 4.3 m-30 -80.84 145.39 31.41 Favored 'General case' 0 CA--C 1.514 -0.41 0 CA-C-O 120.731 0.301 . . . . 0.0 110.261 -178.915 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 243' ' ' GLU . . . . . 0.465 ' N ' ' OD2' ' A' ' 246' ' ' ASP . 99.2 mt-10 -131.55 165.01 24.55 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 115.734 -0.666 . . . . 0.0 109.592 173.392 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 244' ' ' THR . . . . . 0.439 HG23 ' HA ' ' A' ' 268' ' ' LYS . 4.9 m -59.56 125.82 25.15 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 -178.739 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 99.6 -5.88 58.74 Favored Glycine 0 C--N 1.318 -0.441 0 N-CA-C 111.215 -0.754 . . . . 0.0 111.215 -177.425 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 246' ' ' ASP . . . . . 0.465 ' OD2' ' N ' ' A' ' 243' ' ' GLU . 0.9 OUTLIER -67.54 149.64 49.87 Favored 'General case' 0 CA--C 1.502 -0.884 0 C-N-CA 120.814 -0.355 . . . . 0.0 111.44 176.525 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 247' ' ' PHE . . . . . 0.403 ' HA ' ' O ' ' A' ' 265' ' ' MET . 61.7 m-85 -108.74 125.84 52.36 Favored 'General case' 0 C--N 1.317 -0.81 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 176.142 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 248' ' ' VAL . . . . . 0.457 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.9 m -128.09 160.86 37.41 Favored 'Isoleucine or valine' 0 C--O 1.24 0.566 0 C-N-CA 120.47 -0.492 . . . . 0.0 111.577 -175.38 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 44.1 m -124.17 160.21 28.36 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-N 114.778 -1.101 . . . . 0.0 108.679 173.495 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 250' ' ' PHE . . . . . 0.558 ' CB ' ' HB3' ' A' ' 259' ' ' LEU . 76.4 m-85 -123.99 153.89 40.62 Favored 'General case' 0 C--N 1.314 -0.935 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 -173.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 14.6 p -159.69 161.17 34.83 Favored 'General case' 0 C--N 1.309 -1.176 0 C-N-CA 120.969 -0.293 . . . . 0.0 111.266 177.162 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 27.1 mm-40 51.62 27.86 4.29 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.395 177.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 0.542 HG22 ' CA ' ' A' ' 290' ' ' GLY . 6.5 t -90.3 129.41 41.21 Favored 'Isoleucine or valine' 0 C--O 1.236 0.371 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 175.802 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 81.4 mt-30 -94.27 136.86 34.1 Favored 'General case' 0 C--O 1.244 0.785 0 C-N-CA 120.276 -0.57 . . . . 0.0 109.836 -178.16 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 82.59 -58.15 5.01 Favored Glycine 0 C--N 1.32 -0.323 0 N-CA-C 109.945 -1.262 . . . . 0.0 109.945 -176.853 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 256' ' ' MET . . . . . 0.485 ' N ' ' O ' ' A' ' 285' ' ' ASP . 4.3 ttm -81.73 53.76 2.23 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.665 0.745 . . . . 0.0 109.708 177.797 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 257' ' ' ILE . . . . . 0.427 ' O ' ' HB2' ' A' ' 260' ' ' ASN . 48.8 pt -69.37 -23.16 26.23 Favored 'Isoleucine or valine' 0 C--O 1.242 0.702 0 CA-C-N 115.042 -0.981 . . . . 0.0 110.899 -175.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 258' ' ' GLN . . . . . 0.425 ' O ' ' SG ' ' A' ' 262' ' ' CYS . 1.2 mp0 -56.5 -37.07 69.9 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 179.673 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 259' ' ' LEU . . . . . 0.873 HD21 ' CE2' ' A' ' 283' ' ' PHE . 93.0 mt -62.35 -40.2 95.61 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.755 175.375 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 260' ' ' ASN . . . . . 0.427 ' HB2' ' O ' ' A' ' 257' ' ' ILE . 98.1 m-20 -59.32 -39.79 84.2 Favored 'General case' 0 CA--C 1.516 -0.336 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 -178.322 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -98.21 8.78 62.92 Favored Glycine 0 CA--C 1.531 1.043 0 CA-C-N 116.165 -0.47 . . . . 0.0 112.224 -178.083 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 262' ' ' CYS . . . . . 0.425 ' SG ' ' O ' ' A' ' 258' ' ' GLN . 1.7 m -88.51 146.02 25.41 Favored 'General case' 0 C--O 1.236 0.39 0 O-C-N 122.262 -0.552 . . . . 0.0 112.204 -176.407 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 36.4 mt-30 -64.73 156.91 77.04 Favored Pre-proline 0 C--N 1.325 -0.476 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 171.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 264' ' ' PRO . . . . . 0.457 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 38.1 Cg_endo -63.5 144.24 89.9 Favored 'Trans proline' 0 C--N 1.318 -1.06 0 C-N-CA 121.098 1.199 . . . . 0.0 110.426 -178.794 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 265' ' ' MET . . . . . 0.403 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 11.3 ptp -133.6 154.45 50.87 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 112.174 0.435 . . . . 0.0 112.174 -175.597 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 34.8 tt0 -71.34 143.85 50.11 Favored 'General case' 0 C--O 1.236 0.378 0 O-C-N 123.837 0.711 . . . . 0.0 109.328 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 267' ' ' ILE . . . . . 0.671 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.9 pp -131.92 165.77 30.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 N-CA-C 112.639 0.607 . . . . 0.0 112.639 -175.957 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . 0.439 ' HA ' HG23 ' A' ' 244' ' ' THR . 49.9 tttp -124.83 125.46 44.03 Favored 'General case' 0 C--O 1.217 -0.612 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.343 177.79 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.414 HG23 ' O ' ' A' ' 269' ' ' VAL . 35.5 m -93.12 102.61 13.83 Favored 'Isoleucine or valine' 0 C--O 1.238 0.472 0 C-N-CA 120.452 -0.499 . . . . 0.0 111.235 179.127 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 95.9 mt -66.57 -39.44 88.48 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.148 -179.424 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -143.34 -169.74 12.73 Favored Glycine 0 C--N 1.32 -0.311 0 N-CA-C 110.441 -1.064 . . . . 0.0 110.441 -177.775 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 272' ' ' PRO . . . . . 0.401 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 39.7 Cg_endo -64.11 -33.29 61.98 Favored 'Trans proline' 0 C--N 1.306 -1.707 0 C-N-CA 122.038 1.825 . . . . 0.0 111.714 -179.287 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 90.6 m-85 -126.51 10.11 7.23 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 112.1 0.407 . . . . 0.0 112.1 -177.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 274' ' ' THR . . . . . 0.466 ' CG2' HG23 ' A' ' 233' ' ' THR . 1.1 p -121.61 131.11 53.93 Favored 'General case' 0 C--O 1.244 0.765 0 CA-C-N 116.701 -0.227 . . . . 0.0 111.072 -177.182 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 275' ' ' PHE . . . . . 0.543 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -139.31 161.68 36.84 Favored 'General case' 0 CA--C 1.511 -0.541 0 N-CA-C 112.34 0.496 . . . . 0.0 112.34 179.147 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . 0.495 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 4.2 p -130.38 144.1 51.18 Favored 'General case' 0 N--CA 1.437 -1.078 0 CA-C-O 121.246 0.546 . . . . 0.0 111.512 -175.827 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 277' ' ' ILE . . . . . 0.56 HG22 HG22 ' A' ' 267' ' ' ILE . 31.8 pt -139.0 165.84 23.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 114.725 -1.125 . . . . 0.0 111.824 -173.304 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 278' ' ' CYS . . . . . 0.435 ' O ' ' HA ' ' A' ' 229' ' ' PRO . 4.8 m -28.36 -86.4 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.57 0 N-CA-C 113.498 0.925 . . . . 0.0 113.498 -175.51 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 55.3 t0 -153.02 112.2 3.81 Favored 'General case' 0 CA--C 1.508 -0.645 0 CA-C-O 120.5 0.19 . . . . 0.0 110.498 -177.374 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . 0.774 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 21.6 p -67.68 -28.79 67.98 Favored 'General case' 0 C--N 1.303 -1.428 0 CA-C-O 121.323 0.582 . . . . 0.0 110.645 176.314 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -63.99 -21.56 66.55 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 115.067 -0.969 . . . . 0.0 108.521 175.604 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 44.3 t30 -88.42 -8.7 54.54 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.398 -179.501 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 283' ' ' PHE . . . . . 0.873 ' CE2' HD21 ' A' ' 259' ' ' LEU . 7.2 m-85 -92.45 -67.71 0.84 Allowed 'General case' 0 CA--C 1.512 -0.492 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.273 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 284' ' ' SER . . . . . 0.436 ' OG ' ' HA ' ' A' ' 256' ' ' MET . 3.8 p 173.41 -105.8 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 114.85 -1.068 . . . . 0.0 110.565 176.392 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 285' ' ' ASP . . . . . 0.492 ' OD1' ' NZ ' ' A' ' 226' ' ' LYS . 40.2 t0 -145.44 158.8 43.77 Favored 'General case' 0 C--O 1.217 -0.606 0 CA-C-O 120.408 0.147 . . . . 0.0 110.607 -179.637 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 66.7 t80 -101.1 118.89 37.89 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.744 -0.207 . . . . 0.0 110.634 179.628 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 287' ' ' ILE . . . . . 0.439 ' O ' ' HG3' ' A' ' 288' ' ' ARG . 97.1 mt -97.94 -63.86 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 175.79 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . 0.439 ' HG3' ' O ' ' A' ' 287' ' ' ILE . 67.5 mtm180 -166.96 175.86 7.35 Favored 'General case' 0 C--O 1.24 0.601 0 C-N-CA 123.973 0.909 . . . . 0.0 110.605 176.342 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 70.24 -158.8 53.53 Favored Glycine 0 C--N 1.318 -0.462 0 N-CA-C 111.053 -0.819 . . . . 0.0 111.053 175.103 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 290' ' ' GLY . . . . . 0.542 ' CA ' HG22 ' A' ' 253' ' ' VAL . . . 104.93 124.77 5.46 Favored Glycine 0 N--CA 1.442 -0.955 0 N-CA-C 111.977 -0.449 . . . . 0.0 111.977 177.258 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 95.7 mt -116.93 131.64 69.02 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.037 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 174.629 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 4.8 p -120.11 135.04 61.67 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.026 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 -179.138 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 15.6 m -132.03 144.81 51.03 Favored 'General case' 0 C--N 1.319 -0.759 0 C-N-CA 120.063 -0.655 . . . . 0.0 112.535 -174.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 48.5 tt0 . . . . . 0 CA--C 1.489 -1.381 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 168.31 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 217' ' ' LEU . . . . . 0.469 ' HB3' ' O ' ' A' ' 240' ' ' HIS . 0.2 OUTLIER . . . . . 0 C--O 1.237 0.409 0 N-CA-C 110.223 -0.288 . . . . 0.0 110.223 . . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 16.5 p -136.18 156.16 49.09 Favored 'General case' 0 CA--C 1.51 -0.595 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.509 -177.352 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 219' ' ' ALA . . . . . 0.53 ' HA ' ' HB1' ' A' ' 238' ' ' ALA . . . -150.72 151.2 32.06 Favored 'General case' 0 N--CA 1.448 -0.556 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.134 -178.751 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 220' ' ' MET . . . . . 0.505 ' SD ' HG12 ' A' ' 291' ' ' ILE . 1.5 mpp? -73.67 131.2 41.39 Favored 'General case' 0 C--O 1.244 0.772 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 177.891 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 69.1 t -74.77 131.76 34.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 178.659 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 58.0 m -92.2 -69.09 0.76 Allowed 'General case' 0 N--CA 1.435 -1.176 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.342 179.661 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 12.6 ptm -138.14 148.59 45.07 Favored 'General case' 0 N--CA 1.472 0.63 0 C-N-CA 120.999 -0.281 . . . . 0.0 111.141 172.762 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 224' ' ' VAL . . . . . 0.55 HG22 ' HB ' ' A' ' 232' ' ' VAL . 52.9 t -121.67 129.35 75.58 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 174.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 17.2 p -81.29 128.03 33.36 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 119.85 -0.74 . . . . 0.0 110.54 179.623 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 17.0 tptm -76.4 84.11 3.14 Favored 'General case' 0 N--CA 1.437 -1.097 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 177.463 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 227' ' ' ASP . . . . . 0.543 ' N ' ' OG1' ' A' ' 280' ' ' THR . 4.8 t0 -159.97 175.74 12.67 Favored 'General case' 0 C--O 1.245 0.861 0 CA-C-N 115.53 -0.759 . . . . 0.0 110.304 -176.162 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 228' ' ' ASN . . . . . 0.48 ' N ' ' OD1' ' A' ' 227' ' ' ASP . 0.1 OUTLIER -143.01 122.75 7.75 Favored Pre-proline 0 C--N 1.321 -0.656 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.838 172.65 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 229' ' ' PRO . . . . . 0.48 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 42.0 Cg_endo -65.23 148.33 73.27 Favored 'Cis proline' 0 N--CA 1.496 1.652 0 C-N-CA 122.908 -1.705 . . . . 0.0 109.875 -1.507 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . 0.484 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -88.43 140.57 16.19 Favored Glycine 0 C--N 1.315 -0.612 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 -177.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.4 p -121.01 132.79 69.59 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.579 0 CA-C-N 117.182 0.491 . . . . 0.0 109.791 177.125 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 232' ' ' VAL . . . . . 0.556 HG22 ' CD1' ' A' ' 275' ' ' PHE . 0.6 OUTLIER -129.83 153.63 39.12 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.042 0 C-N-CA 120.038 -0.665 . . . . 0.0 111.214 -176.581 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 233' ' ' THR . . . . . 0.444 ' HA ' ' O ' ' A' ' 273' ' ' TYR . 0.6 OUTLIER -106.84 140.48 39.61 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-N 115.151 -0.931 . . . . 0.0 109.445 178.065 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.8 m -107.07 160.39 15.59 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-N 116.182 -0.463 . . . . 0.0 109.823 -178.339 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.464 ' HB3' ' HB3' ' A' ' 238' ' ' ALA . 41.5 tp -63.74 131.34 47.58 Favored 'General case' 0 C--N 1.32 -0.674 0 C-N-CA 120.686 -0.406 . . . . 0.0 109.975 -177.678 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 19.0 p-10 -51.61 -44.43 62.88 Favored 'General case' 0 N--CA 1.475 0.801 0 CA-C-N 115.881 -0.6 . . . . 0.0 111.073 -176.628 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 92.6 mt-10 -65.77 -35.24 80.16 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 179.556 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 238' ' ' ALA . . . . . 0.53 ' HB1' ' HA ' ' A' ' 219' ' ' ALA . . . -91.54 92.61 8.58 Favored 'General case' 0 N--CA 1.439 -1.017 0 CA-C-N 115.481 -0.781 . . . . 0.0 111.855 -175.261 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 84.7 mtp180 -75.66 118.13 18.15 Favored 'General case' 0 C--N 1.312 -1.022 0 N-CA-C 108.478 -0.934 . . . . 0.0 108.478 174.386 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 240' ' ' HIS . . . . . 0.615 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 7.1 p80 -60.09 -46.09 90.73 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.799 -176.939 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 78.87 19.12 73.66 Favored Glycine 0 C--O 1.238 0.381 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 -178.532 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 242' ' ' PHE . . . . . 0.544 ' CD2' ' HB2' ' A' ' 240' ' ' HIS . 10.4 m-30 -81.04 146.66 30.53 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 -179.545 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 73.9 mm-40 -101.64 158.88 15.77 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 116.011 -0.54 . . . . 0.0 109.672 172.544 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 16.3 m -66.66 126.72 29.83 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 174.762 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 88.14 2.78 80.06 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -176.491 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 15.2 t0 -79.42 167.51 20.74 Favored 'General case' 0 CA--C 1.516 -0.337 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 178.285 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 247' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -112.66 134.71 54.05 Favored 'General case' 0 C--O 1.244 0.811 0 O-C-N 123.127 0.267 . . . . 0.0 110.874 -176.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 248' ' ' VAL . . . . . 0.47 HG11 ' CD2' ' A' ' 242' ' ' PHE . 2.9 m -131.59 160.92 42.03 Favored 'Isoleucine or valine' 0 C--O 1.236 0.369 0 CA-C-O 121.078 0.466 . . . . 0.0 111.899 178.37 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 249' ' ' SER . . . . . 0.444 ' OG ' ' HG3' ' A' ' 264' ' ' PRO . 1.3 m -123.26 153.48 40.13 Favored 'General case' 0 C--O 1.244 0.798 0 CA-C-N 114.893 -1.048 . . . . 0.0 109.229 176.653 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 250' ' ' PHE . . . . . 0.446 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 79.3 m-85 -109.43 153.0 24.63 Favored 'General case' 0 CA--C 1.505 -0.773 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.787 -179.357 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 251' ' ' SER . . . . . 0.475 ' O ' ' HA2' ' A' ' 290' ' ' GLY . 39.0 m -152.71 154.69 35.76 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-N 115.694 -0.684 . . . . 0.0 109.196 176.688 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 12.6 mm-40 57.47 21.17 6.71 Favored 'General case' 0 CA--C 1.542 0.655 0 N-CA-C 112.664 0.616 . . . . 0.0 112.664 177.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 0.59 HG13 ' CE1' ' A' ' 286' ' ' TYR . 61.5 t -76.0 133.89 30.23 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 C-N-CA 120.949 -0.3 . . . . 0.0 111.0 178.759 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . 0.411 ' OE1' ' HG2' ' A' ' 288' ' ' ARG . 85.2 mt-30 -96.78 136.01 37.93 Favored 'General case' 0 C--O 1.24 0.605 0 O-C-N 123.334 0.396 . . . . 0.0 110.045 179.251 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 76.35 -61.4 3.13 Favored Glycine 0 N--CA 1.463 0.453 0 N-CA-C 111.472 -0.651 . . . . 0.0 111.472 177.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 256' ' ' MET . . . . . 0.664 ' SD ' HD11 ' A' ' 259' ' ' LEU . 48.5 ttm -77.67 63.08 2.69 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 178.547 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 48.9 pt -70.22 -20.63 23.01 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 114.914 -1.039 . . . . 0.0 111.136 -173.786 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 258' ' ' GLN . . . . . 0.566 ' HG3' ' SG ' ' A' ' 262' ' ' CYS . 55.7 tp60 -54.76 -39.53 68.42 Favored 'General case' 0 N--CA 1.44 -0.955 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.035 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 259' ' ' LEU . . . . . 0.664 HD11 ' SD ' ' A' ' 256' ' ' MET . 97.8 mt -62.58 -41.71 99.11 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.17 -0.468 . . . . 0.0 109.909 178.542 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -61.52 -40.38 94.41 Favored 'General case' 0 CA--C 1.509 -0.598 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 178.377 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -94.64 13.12 67.81 Favored Glycine 0 CA--C 1.527 0.801 0 CA-C-N 115.395 -0.82 . . . . 0.0 111.775 -178.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 262' ' ' CYS . . . . . 0.566 ' SG ' ' HG3' ' A' ' 258' ' ' GLN . 1.0 OUTLIER -105.64 156.92 17.8 Favored 'General case' 0 CA--C 1.508 -0.637 0 CA-C-N 117.45 0.625 . . . . 0.0 112.322 -178.051 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 28.4 mt-30 -71.52 158.38 88.03 Favored Pre-proline 0 C--N 1.319 -0.733 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 171.431 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 264' ' ' PRO . . . . . 0.444 ' HG3' ' OG ' ' A' ' 249' ' ' SER . 26.0 Cg_exo -61.87 147.47 95.15 Favored 'Trans proline' 0 C--N 1.304 -1.809 0 C-N-CA 121.347 1.365 . . . . 0.0 110.551 177.514 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 265' ' ' MET . . . . . . . . . . . . . 4.4 ptp -125.64 164.78 19.84 Favored 'General case' 0 N--CA 1.473 0.706 0 N-CA-C 111.79 0.293 . . . . 0.0 111.79 -177.673 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -71.04 142.62 50.88 Favored 'General case' 0 CA--C 1.513 -0.443 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 176.517 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 267' ' ' ILE . . . . . 0.75 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.7 pp -131.04 160.04 42.56 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 CA-C-O 121.054 0.454 . . . . 0.0 111.611 -179.82 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 55.5 mttm -130.6 110.63 11.55 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -177.187 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.418 HG23 ' O ' ' A' ' 269' ' ' VAL . 27.7 m -77.17 102.1 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 CA-C-O 121.389 0.614 . . . . 0.0 112.255 -176.771 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 97.0 mt -69.6 -39.11 77.46 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.521 177.208 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -144.26 -175.34 17.3 Favored Glycine 0 N--CA 1.461 0.361 0 N-CA-C 109.977 -1.249 . . . . 0.0 109.977 -178.434 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 272' ' ' PRO . . . . . 0.615 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 36.9 Cg_endo -62.15 -34.27 79.61 Favored 'Trans proline' 0 C--N 1.313 -1.341 0 C-N-CA 121.888 1.725 . . . . 0.0 110.939 -177.914 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 273' ' ' TYR . . . . . 0.444 ' O ' ' HA ' ' A' ' 233' ' ' THR . 94.4 m-85 -123.12 6.57 9.19 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.575 -0.739 . . . . 0.0 112.253 -179.796 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 2.2 p -117.11 127.39 54.09 Favored 'General case' 0 C--O 1.244 0.795 0 CA-C-O 121.046 0.45 . . . . 0.0 110.901 179.455 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 275' ' ' PHE . . . . . 0.576 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -137.28 161.94 34.87 Favored 'General case' 0 CA--C 1.502 -0.872 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.092 -179.085 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . 0.484 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 4.4 p -132.22 145.84 51.6 Favored 'General case' 0 C--N 1.309 -1.163 0 C-N-CA 120.369 -0.532 . . . . 0.0 112.124 -173.864 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 277' ' ' ILE . . . . . 0.591 HG22 HG22 ' A' ' 267' ' ' ILE . 28.0 pt -139.22 164.77 24.43 Favored 'Isoleucine or valine' 0 C--O 1.243 0.726 0 CA-C-N 114.744 -1.117 . . . . 0.0 112.899 -172.368 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 2.2 m -28.63 -88.27 0.0 OUTLIER 'General case' 0 C--O 1.237 0.405 0 N-CA-C 113.928 1.084 . . . . 0.0 113.928 -176.099 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 59.8 t0 -152.4 115.65 4.7 Favored 'General case' 0 CA--C 1.507 -0.696 0 CA-C-O 120.695 0.283 . . . . 0.0 110.793 -175.764 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . 0.673 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 29.7 p -64.84 -29.53 70.49 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-O 121.023 0.44 . . . . 0.0 110.732 175.611 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -64.64 -23.74 67.36 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.324 175.751 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 18.0 t-20 -89.2 -9.31 51.3 Favored 'General case' 0 CA--C 1.509 -0.612 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.77 -179.557 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 283' ' ' PHE . . . . . 0.673 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 15.7 m-85 -92.46 -75.27 0.49 Allowed 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 121.641 0.734 . . . . 0.0 109.372 174.938 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 284' ' ' SER . . . . . 0.405 ' O ' ' CE ' ' A' ' 256' ' ' MET . 0.1 OUTLIER 165.6 -174.23 0.02 OUTLIER 'General case' 0 C--N 1.313 -1.0 0 N-CA-C 106.835 -1.543 . . . . 0.0 106.835 -174.066 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -94.98 121.56 36.72 Favored 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 119.687 -0.805 . . . . 0.0 111.899 -179.782 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 286' ' ' TYR . . . . . 0.59 ' CE1' HG13 ' A' ' 253' ' ' VAL . 3.3 t80 -72.74 108.19 5.6 Favored 'General case' 0 C--O 1.236 0.386 0 C-N-CA 123.535 0.734 . . . . 0.0 109.744 -177.359 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 287' ' ' ILE . . . . . 0.606 ' O ' ' HB3' ' A' ' 288' ' ' ARG . 89.9 mt -67.39 -44.94 86.72 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.66 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 173.077 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . 0.606 ' HB3' ' O ' ' A' ' 287' ' ' ILE . 7.4 ptm180 157.95 -161.26 0.0 OUTLIER 'General case' 0 C--O 1.237 0.409 0 C-N-CA 124.89 1.276 . . . . 0.0 109.164 177.476 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . 0.537 ' N ' ' HG3' ' A' ' 288' ' ' ARG . . . 70.99 -157.16 53.51 Favored Glycine 0 CA--C 1.5 -0.903 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 176.498 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 290' ' ' GLY . . . . . 0.475 ' HA2' ' O ' ' A' ' 251' ' ' SER . . . 88.84 145.82 12.02 Favored Glycine 0 N--CA 1.436 -1.309 0 CA-C-O 121.533 0.518 . . . . 0.0 112.714 175.52 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . 0.505 HG12 ' SD ' ' A' ' 220' ' ' MET . 92.6 mt -123.41 128.52 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.344 0 N-CA-C 106.74 -1.578 . . . . 0.0 106.74 172.658 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 14.8 p -107.68 130.6 59.74 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.823 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 -179.801 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 3.8 m -132.27 146.9 52.32 Favored 'General case' 0 CA--C 1.506 -0.73 0 C-N-CA 120.52 -0.472 . . . . 0.0 112.187 -173.817 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 49.2 tt0 . . . . . 0 CA--C 1.497 -1.085 0 CA-C-N 115.342 -0.844 . . . . 0.0 109.601 174.368 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 217' ' ' LEU . . . . . 0.429 ' HB3' ' O ' ' A' ' 240' ' ' HIS . 3.7 mm? . . . . . 0 CA--C 1.509 -0.627 0 CA-C-O 120.524 0.202 . . . . 0.0 111.524 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 3.7 m -132.22 132.1 42.77 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 175.423 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -145.38 152.95 40.67 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-O 120.744 0.307 . . . . 0.0 110.762 179.551 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -73.71 134.8 43.59 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.055 178.745 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 98.7 t -80.17 131.12 34.82 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.102 0 N-CA-C 107.406 -1.331 . . . . 0.0 107.406 172.553 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 11.8 p -95.69 -60.48 1.64 Allowed 'General case' 0 N--CA 1.439 -1.016 0 C-N-CA 120.237 -0.585 . . . . 0.0 110.645 -177.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 223' ' ' MET . . . . . 0.568 ' C ' ' SD ' ' A' ' 223' ' ' MET . 0.5 OUTLIER -138.42 141.7 39.54 Favored 'General case' 0 C--O 1.221 -0.407 0 N-CA-C 112.219 0.452 . . . . 0.0 112.219 175.78 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 224' ' ' VAL . . . . . 0.639 HG22 ' HB ' ' A' ' 232' ' ' VAL . 48.4 t -125.19 132.25 71.41 Favored 'Isoleucine or valine' 0 C--O 1.24 0.587 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 177.441 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 5.5 p -99.76 117.36 33.92 Favored 'General case' 0 C--O 1.237 0.424 0 C-N-CA 120.373 -0.531 . . . . 0.0 110.324 176.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 226' ' ' LYS . . . . . 0.512 ' HD3' ' HA ' ' A' ' 281' ' ' SER . 0.0 OUTLIER -67.55 85.51 0.19 Allowed 'General case' 0 C--O 1.242 0.687 0 N-CA-C 110.151 -0.315 . . . . 0.0 110.151 178.756 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 227' ' ' ASP . . . . . 0.594 ' N ' ' OG1' ' A' ' 280' ' ' THR . 4.2 t70 -150.73 -177.61 6.09 Favored 'General case' 0 C--O 1.242 0.686 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.518 -179.045 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 228' ' ' ASN . . . . . 0.494 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.0 OUTLIER -141.28 125.59 10.39 Favored Pre-proline 0 N--CA 1.467 0.396 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.967 174.96 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 229' ' ' PRO . . . . . 0.494 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 55.7 Cg_endo -66.17 147.77 75.18 Favored 'Cis proline' 0 N--CA 1.496 1.634 0 C-N-CA 123.347 -1.522 . . . . 0.0 110.116 -0.566 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . 0.494 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -70.71 138.45 28.61 Favored Glycine 0 N--CA 1.449 -0.473 0 N-CA-C 110.004 -1.238 . . . . 0.0 110.004 -178.154 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 231' ' ' VAL . . . . . 0.683 HG23 ' CD1' ' A' ' 270' ' ' LEU . 1.8 p -125.69 131.78 71.6 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.804 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 176.335 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 232' ' ' VAL . . . . . 0.639 ' HB ' HG22 ' A' ' 224' ' ' VAL . 0.8 OUTLIER -137.28 157.0 34.43 Favored 'Isoleucine or valine' 0 C--O 1.248 0.988 0 C-N-CA 120.103 -0.639 . . . . 0.0 111.548 -177.553 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 233' ' ' THR . . . . . 0.444 HG23 ' CG2' ' A' ' 274' ' ' THR . 6.0 m -113.07 146.9 38.35 Favored 'General case' 0 C--N 1.309 -1.162 0 CA-C-N 114.987 -1.006 . . . . 0.0 109.532 178.613 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 24.7 m -107.36 160.97 15.22 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 178.244 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.43 ' HB3' ' HB3' ' A' ' 238' ' ' ALA . 45.2 tp -59.31 128.61 37.97 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 179.431 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -51.35 -44.78 62.15 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.846 -175.164 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 76.8 mt-10 -65.85 -33.08 75.01 Favored 'General case' 0 C--N 1.311 -1.066 0 C-N-CA 120.724 -0.39 . . . . 0.0 111.147 178.834 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 238' ' ' ALA . . . . . 0.43 ' HB3' ' HB3' ' A' ' 235' ' ' LEU . . . -91.62 102.68 15.32 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.729 -175.1 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 78.5 mtm-85 -74.22 127.36 32.77 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 107.717 -1.216 . . . . 0.0 107.717 174.713 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 240' ' ' HIS . . . . . 0.536 ' H ' ' CD2' ' A' ' 240' ' ' HIS . 6.8 p80 -66.28 -45.45 80.44 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 121.137 0.494 . . . . 0.0 110.855 -179.018 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 81.45 12.12 82.33 Favored Glycine 0 C--N 1.311 -0.823 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 -178.257 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 242' ' ' PHE . . . . . 0.519 ' CE1' ' HB2' ' A' ' 294' ' ' GLN . 4.0 m-30 -81.5 151.95 27.55 Favored 'General case' 0 CA--C 1.504 -0.804 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 178.373 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -130.57 158.07 40.98 Favored 'General case' 0 C--N 1.309 -1.178 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 177.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 244' ' ' THR . . . . . 0.743 HG23 ' HG2' ' A' ' 268' ' ' LYS . 22.8 m -57.85 127.97 34.71 Favored 'General case' 0 C--N 1.306 -1.284 0 C-N-CA 120.007 -0.677 . . . . 0.0 109.973 -177.26 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 92.06 -6.41 78.91 Favored Glycine 0 N--CA 1.449 -0.497 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.609 -179.019 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 246' ' ' ASP . . . . . 0.442 ' CG ' HE21 ' A' ' 294' ' ' GLN . 1.7 t70 -79.24 162.4 25.71 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 117.223 0.511 . . . . 0.0 111.004 -179.821 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 247' ' ' PHE . . . . . 0.48 ' HA ' ' O ' ' A' ' 265' ' ' MET . 73.0 m-85 -111.94 131.39 55.41 Favored 'General case' 0 C--O 1.24 0.574 0 N-CA-C 112.241 0.46 . . . . 0.0 112.241 -176.076 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 248' ' ' VAL . . . . . 0.498 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.6 m -132.71 158.88 43.39 Favored 'Isoleucine or valine' 0 C--O 1.235 0.319 0 CA-C-O 120.873 0.368 . . . . 0.0 111.809 177.397 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 49.6 m -123.92 160.55 27.28 Favored 'General case' 0 C--N 1.319 -0.734 0 C-N-CA 124.498 1.119 . . . . 0.0 108.565 173.029 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 250' ' ' PHE . . . . . 0.641 ' CE1' HD22 ' A' ' 259' ' ' LEU . 68.4 m-85 -110.63 146.72 35.68 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 120.461 0.172 . . . . 0.0 111.081 -177.364 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 1.5 m -133.54 153.39 51.68 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 176.24 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . 0.462 ' O ' ' NE2' ' A' ' 254' ' ' GLN . 79.1 mm-40 55.37 30.34 14.71 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 112.81 0.671 . . . . 0.0 112.81 173.213 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 0.538 HG11 ' HB3' ' A' ' 256' ' ' MET . 51.3 t -89.01 134.69 27.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 N-CA-C 110.231 -0.285 . . . . 0.0 110.231 177.319 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . 0.462 ' NE2' ' O ' ' A' ' 252' ' ' GLU . 3.9 mp0 -99.81 135.19 41.61 Favored 'General case' 0 C--O 1.239 0.518 0 CA-C-O 121.031 0.443 . . . . 0.0 110.658 178.909 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 83.37 -55.08 5.02 Favored Glycine 0 C--N 1.32 -0.321 0 N-CA-C 111.098 -0.801 . . . . 0.0 111.098 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 256' ' ' MET . . . . . 0.538 ' HB3' HG11 ' A' ' 253' ' ' VAL . 4.6 ttm -83.41 69.47 10.03 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 178.481 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 45.5 pt -72.69 -22.23 20.08 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.916 0 CA-C-N 114.78 -1.1 . . . . 0.0 111.075 -174.78 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 258' ' ' GLN . . . . . 0.496 ' O ' ' SG ' ' A' ' 262' ' ' CYS . 23.4 mp0 -59.34 -41.49 89.29 Favored 'General case' 0 C--N 1.313 -0.994 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 179.359 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 259' ' ' LEU . . . . . 0.948 HD21 ' CE2' ' A' ' 283' ' ' PHE . 90.4 mt -62.8 -41.92 99.49 Favored 'General case' 0 N--CA 1.443 -0.802 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.589 178.198 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 260' ' ' ASN . . . . . 0.519 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 89.5 m-20 -60.44 -41.22 93.6 Favored 'General case' 0 CA--C 1.507 -0.678 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 -179.206 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -100.39 14.11 59.6 Favored Glycine 0 C--N 1.316 -0.583 0 N-CA-C 111.359 -0.696 . . . . 0.0 111.359 -178.495 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 262' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 258' ' ' GLN . 1.2 m -85.62 144.81 27.65 Favored 'General case' 0 C--O 1.242 0.707 0 C-N-CA 120.714 -0.394 . . . . 0.0 110.786 -179.607 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 95.7 mm-40 -68.96 162.96 60.87 Favored Pre-proline 0 C--N 1.315 -0.892 0 N-CA-C 107.4 -1.333 . . . . 0.0 107.4 170.224 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 264' ' ' PRO . . . . . 0.498 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 24.1 Cg_exo -61.46 143.89 97.71 Favored 'Trans proline' 0 C--N 1.307 -1.637 0 N-CA-C 109.562 -0.976 . . . . 0.0 109.562 -178.129 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 265' ' ' MET . . . . . 0.48 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 8.9 ptp -126.65 150.8 48.74 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 116.689 -0.232 . . . . 0.0 110.935 -175.296 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -70.92 137.49 49.29 Favored 'General case' 0 C--O 1.242 0.686 0 O-C-N 123.828 0.705 . . . . 0.0 109.14 178.846 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 267' ' ' ILE . . . . . 0.57 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.9 pp -127.24 161.24 34.89 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-O 120.867 0.365 . . . . 0.0 111.601 -175.727 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . 0.743 ' HG2' HG23 ' A' ' 244' ' ' THR . 0.0 OUTLIER -127.38 120.87 29.47 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 176.621 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.626 HG22 ' OG1' ' A' ' 244' ' ' THR . 28.3 m -69.92 133.71 31.39 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 C-N-CA 120.653 -0.419 . . . . 0.0 111.337 -177.972 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 270' ' ' LEU . . . . . 0.683 ' CD1' HG23 ' A' ' 231' ' ' VAL . 74.5 mt -97.06 -46.08 6.32 Favored 'General case' 0 CA--C 1.508 -0.67 0 CA-C-O 121.422 0.63 . . . . 0.0 109.537 177.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -149.25 -171.46 17.92 Favored Glycine 0 C--N 1.311 -0.843 0 N-CA-C 108.428 -1.869 . . . . 0.0 108.428 179.84 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 272' ' ' PRO . . . . . 0.52 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 37.8 Cg_endo -62.71 -30.66 78.63 Favored 'Trans proline' 0 C--N 1.301 -1.957 0 C-N-CA 121.332 1.355 . . . . 0.0 111.054 -179.12 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 95.3 m-85 -122.86 11.45 9.66 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 113.32 0.859 . . . . 0.0 113.32 -178.07 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 274' ' ' THR . . . . . 0.444 ' CG2' HG23 ' A' ' 233' ' ' THR . 20.4 p -130.09 146.38 51.74 Favored 'General case' 0 C--O 1.241 0.638 0 C-N-CA 120.66 -0.416 . . . . 0.0 111.259 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 275' ' ' PHE . . . . . 0.502 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -150.0 166.1 30.7 Favored 'General case' 0 C--O 1.243 0.736 0 N-CA-C 112.1 0.408 . . . . 0.0 112.1 177.161 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -129.21 141.83 51.03 Favored 'General case' 0 N--CA 1.438 -1.046 0 C-N-CA 120.535 -0.466 . . . . 0.0 111.382 179.643 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 277' ' ' ILE . . . . . 0.55 HG22 HG22 ' A' ' 267' ' ' ILE . 39.4 pt -136.17 166.38 26.95 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.79 0 CA-C-N 114.649 -1.159 . . . . 0.0 111.227 -171.653 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 278' ' ' CYS . . . . . 0.432 ' C ' ' O ' ' A' ' 277' ' ' ILE . 0.9 OUTLIER -21.3 -93.53 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 123.845 0.858 . . . . 0.0 113.137 -176.831 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . 0.444 ' OD1' ' N ' ' A' ' 281' ' ' SER . 60.9 t0 -151.98 116.41 5.04 Favored 'General case' 0 CA--C 1.508 -0.645 0 CA-C-N 116.639 -0.255 . . . . 0.0 110.53 -177.937 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . 0.732 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 11.8 p -66.38 -26.73 67.4 Favored 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 120.508 -0.477 . . . . 0.0 110.832 175.014 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 281' ' ' SER . . . . . 0.512 ' HA ' ' HD3' ' A' ' 226' ' ' LYS . 0.8 OUTLIER -66.38 -20.73 66.15 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.497 -0.774 . . . . 0.0 109.511 174.582 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -87.51 -9.7 53.79 Favored 'General case' 0 CA--C 1.504 -0.797 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 178.316 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 283' ' ' PHE . . . . . 0.948 ' CE2' HD21 ' A' ' 259' ' ' LEU . 8.0 m-85 -92.18 -82.9 0.31 Allowed 'General case' 0 N--CA 1.44 -0.943 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 170.921 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 284' ' ' SER . . . . . 0.438 ' HB2' ' O ' ' A' ' 283' ' ' PHE . 9.5 t 169.1 -149.18 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 177.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -85.74 166.44 16.1 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-O 120.59 0.234 . . . . 0.0 110.414 174.655 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 286' ' ' TYR . . . . . 0.58 ' CE2' HG21 ' A' ' 224' ' ' VAL . 12.9 t80 -119.55 102.04 8.36 Favored 'General case' 0 N--CA 1.467 0.394 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 178.486 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 287' ' ' ILE . . . . . 0.561 ' O ' ' HB3' ' A' ' 288' ' ' ARG . 93.4 mt -66.79 -45.53 87.65 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.824 0 C-N-CA 120.211 -0.596 . . . . 0.0 110.287 -179.085 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . 0.561 ' HB3' ' O ' ' A' ' 287' ' ' ILE . 14.7 ptm180 168.4 -173.51 0.02 OUTLIER 'General case' 0 C--O 1.238 0.492 0 O-C-N 123.934 0.771 . . . . 0.0 111.165 -176.45 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 64.96 -147.38 50.99 Favored Glycine 0 C--N 1.338 0.691 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.55 174.313 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 290' ' ' GLY . . . . . 0.513 ' HA3' HG22 ' A' ' 253' ' ' VAL . . . 92.16 127.5 4.16 Favored Glycine 0 N--CA 1.443 -0.87 0 CA-C-O 121.252 0.362 . . . . 0.0 113.399 174.636 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 95.0 mt -115.76 127.69 73.26 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.047 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 170.84 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 7.4 p -98.89 132.06 44.91 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 179.641 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -121.42 122.85 40.7 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-N 115.473 -0.785 . . . . 0.0 110.525 -172.331 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 294' ' ' GLN . . . . . 0.519 ' HB2' ' CE1' ' A' ' 242' ' ' PHE . 49.0 tt0 . . . . . 0 CA--C 1.497 -1.086 0 C-N-CA 119.973 -0.691 . . . . 0.0 109.218 172.647 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 217' ' ' LEU . . . . . 0.532 ' O ' ' HA ' ' A' ' 293' ' ' SER . 0.5 OUTLIER . . . . . 0 CA--C 1.493 -1.233 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 . . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 3.0 m -115.43 132.01 56.75 Favored 'General case' 0 C--N 1.313 -1.011 0 O-C-N 123.445 0.465 . . . . 0.0 110.097 -176.2 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 219' ' ' ALA . . . . . 0.436 ' HA ' ' HB1' ' A' ' 238' ' ' ALA . . . -134.4 142.66 47.23 Favored 'General case' 0 N--CA 1.449 -0.516 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.02 -178.804 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 220' ' ' MET . . . . . 0.649 ' SD ' HG12 ' A' ' 291' ' ' ILE . 99.6 mmm -72.18 131.93 43.44 Favored 'General case' 0 C--O 1.244 0.764 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.255 175.829 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 80.5 t -85.11 128.14 39.29 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.999 0 N-CA-C 108.971 -0.752 . . . . 0.0 108.971 178.798 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 222' ' ' SER . . . . . 0.491 ' OG ' ' N ' ' A' ' 223' ' ' MET . 0.1 OUTLIER -79.82 -72.66 0.39 Allowed 'General case' 0 N--CA 1.434 -1.247 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 177.924 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 223' ' ' MET . . . . . 0.491 ' N ' ' OG ' ' A' ' 222' ' ' SER . 8.6 ptm -137.69 147.15 44.59 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.703 -0.68 . . . . 0.0 111.646 175.612 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 224' ' ' VAL . . . . . 0.845 HG13 HG12 ' A' ' 232' ' ' VAL . 59.6 t -122.07 130.16 74.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 175.447 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 41.0 p -77.31 134.72 38.44 Favored 'General case' 0 C--N 1.321 -0.668 0 C-N-CA 120.604 -0.438 . . . . 0.0 110.775 179.451 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 21.8 tptm -77.63 65.66 3.18 Favored 'General case' 0 C--O 1.24 0.596 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 174.784 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 227' ' ' ASP . . . . . 0.472 ' N ' ' OG1' ' A' ' 280' ' ' THR . 2.3 t0 -147.33 177.41 9.24 Favored 'General case' 0 C--O 1.245 0.816 0 CA-C-N 115.41 -0.814 . . . . 0.0 111.251 -171.802 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 228' ' ' ASN . . . . . 0.61 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 16.0 p-10 -144.13 124.39 7.58 Favored Pre-proline 0 C--N 1.319 -0.754 0 CA-C-N 115.525 -0.762 . . . . 0.0 110.82 175.755 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 229' ' ' PRO . . . . . 0.61 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 34.1 Cg_exo -60.18 143.18 33.09 Favored 'Cis proline' 0 N--CA 1.489 1.256 0 C-N-CA 123.14 -1.608 . . . . 0.0 110.926 -1.192 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . 0.756 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -74.79 131.06 12.25 Favored Glycine 0 C--N 1.296 -1.681 0 N-CA-C 108.184 -1.966 . . . . 0.0 108.184 176.221 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.1 p -124.96 133.39 69.6 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.791 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 232' ' ' VAL . . . . . 0.845 HG12 HG13 ' A' ' 224' ' ' VAL . 0.7 OUTLIER -131.01 155.57 42.07 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.224 0 C-N-CA 120.27 -0.572 . . . . 0.0 110.863 -176.446 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 63.3 m -108.85 135.08 50.64 Favored 'General case' 0 C--N 1.307 -1.254 0 CA-C-N 115.247 -0.888 . . . . 0.0 108.636 176.553 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 44.6 m -105.64 151.11 24.8 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 -177.334 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 38.6 tp -56.24 132.11 49.77 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 -175.528 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 236' ' ' ASP . . . . . 0.541 ' O ' ' NH2' ' A' ' 239' ' ' ARG . 23.0 p-10 -52.42 -44.23 65.31 Favored 'General case' 0 N--CA 1.474 0.734 0 CA-C-O 121.072 0.463 . . . . 0.0 110.606 -174.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 237' ' ' GLU . . . . . 0.413 ' HA ' ' NH2' ' A' ' 239' ' ' ARG . 99.6 mt-10 -64.59 -34.91 79.36 Favored 'General case' 0 C--N 1.302 -1.466 0 CA-C-N 115.641 -0.708 . . . . 0.0 110.421 178.62 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 238' ' ' ALA . . . . . 0.436 ' HB1' ' HA ' ' A' ' 219' ' ' ALA . . . -79.76 73.63 6.48 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 116.004 -0.544 . . . . 0.0 112.176 -174.759 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 239' ' ' ARG . . . . . 0.541 ' NH2' ' O ' ' A' ' 236' ' ' ASP . 0.0 OUTLIER -58.2 90.19 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.024 0.44 . . . . 0.0 110.607 176.477 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 240' ' ' HIS . . . . . 0.473 ' O ' ' HB3' ' A' ' 217' ' ' LEU . 9.1 p80 -55.19 -48.57 73.63 Favored 'General case' 0 C--O 1.217 -0.629 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.249 -175.411 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 78.3 24.56 63.18 Favored Glycine 0 C--N 1.311 -0.858 0 N-CA-C 110.874 -0.891 . . . . 0.0 110.874 179.25 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 242' ' ' PHE . . . . . 0.429 ' CD1' ' HB2' ' A' ' 294' ' ' GLN . 9.3 m-30 -80.19 144.16 33.2 Favored 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 177.869 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -116.03 158.42 23.15 Favored 'General case' 0 C--N 1.312 -1.052 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.737 -177.695 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -56.58 118.03 4.45 Favored 'General case' 0 C--N 1.311 -1.069 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 178.618 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . 0.476 ' HA2' ' CG ' ' A' ' 266' ' ' GLU . . . 86.85 5.95 80.4 Favored Glycine 0 C--O 1.243 0.672 0 C-N-CA 120.847 -0.692 . . . . 0.0 111.892 -179.531 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -83.14 163.99 20.5 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-N 117.199 0.499 . . . . 0.0 109.913 177.676 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 247' ' ' PHE . . . . . 0.432 ' HA ' ' O ' ' A' ' 265' ' ' MET . 74.9 m-85 -111.18 135.79 51.19 Favored 'General case' 0 C--O 1.238 0.483 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -173.521 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 248' ' ' VAL . . . . . 0.471 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 3.1 m -131.13 161.92 40.17 Favored 'Isoleucine or valine' 0 C--O 1.237 0.421 0 CA-C-O 121.063 0.458 . . . . 0.0 111.996 178.62 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 2.5 m -125.9 165.09 19.36 Favored 'General case' 0 C--N 1.321 -0.664 0 C-N-CA 124.773 1.229 . . . . 0.0 108.115 173.506 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 250' ' ' PHE . . . . . 0.628 ' CE1' HD22 ' A' ' 259' ' ' LEU . 96.5 m-85 -124.31 156.78 36.37 Favored 'General case' 0 C--N 1.317 -0.816 0 N-CA-C 110.505 -0.183 . . . . 0.0 110.505 -176.115 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 1.2 m -156.62 161.27 39.92 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.222 -0.444 . . . . 0.0 109.823 176.368 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 16.2 mt-10 51.85 28.63 5.19 Favored 'General case' 0 C--N 1.314 -0.939 0 N-CA-C 112.305 0.483 . . . . 0.0 112.305 177.865 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 0.543 HG22 ' CA ' ' A' ' 290' ' ' GLY . 3.2 t -92.78 127.4 44.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 176.363 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 77.3 mt-30 -91.27 138.16 31.81 Favored 'General case' 0 C--O 1.241 0.609 0 CA-C-O 120.827 0.346 . . . . 0.0 110.585 -177.508 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . 0.54 ' CA ' HD12 ' A' ' 287' ' ' ILE . . . 76.23 -58.45 3.22 Favored Glycine 0 C--N 1.319 -0.376 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 -179.052 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 256' ' ' MET . . . . . 0.423 ' SD ' HD11 ' A' ' 259' ' ' LEU . 30.7 ttm -77.32 50.36 0.77 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.429 0.633 . . . . 0.0 109.603 176.619 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 46.2 pt -71.11 -18.05 20.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-N 115.233 -0.894 . . . . 0.0 111.218 -175.12 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 258' ' ' GLN . . . . . 0.571 ' HG3' ' HG ' ' A' ' 262' ' ' CYS . 68.5 tp60 -54.86 -38.37 67.39 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 177.897 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 259' ' ' LEU . . . . . 0.822 HD21 ' CE2' ' A' ' 283' ' ' PHE . 93.7 mt -62.22 -40.48 96.24 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.506 -0.77 . . . . 0.0 110.197 176.343 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -59.49 -40.24 86.37 Favored 'General case' 0 CA--C 1.51 -0.59 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 -179.186 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -101.97 21.99 39.85 Favored Glycine 0 CA--C 1.524 0.656 0 CA-C-N 115.927 -0.578 . . . . 0.0 112.049 -179.312 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 262' ' ' CYS . . . . . 0.571 ' HG ' ' HG3' ' A' ' 258' ' ' GLN . 1.3 m -95.95 149.35 21.66 Favored 'General case' 0 C--O 1.236 0.382 0 CA-C-N 117.33 0.565 . . . . 0.0 111.488 -179.429 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . 0.525 ' CD ' ' H ' ' A' ' 263' ' ' GLN . 16.6 mp0 -67.66 156.07 89.82 Favored Pre-proline 0 C--N 1.325 -0.475 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 172.572 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 264' ' ' PRO . . . . . 0.471 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 37.3 Cg_endo -62.67 143.09 91.77 Favored 'Trans proline' 0 C--N 1.308 -1.575 0 C-N-CA 120.722 0.948 . . . . 0.0 110.25 179.131 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 265' ' ' MET . . . . . 0.432 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 22.5 ptp -130.55 155.01 47.23 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.663 -173.513 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 266' ' ' GLU . . . . . 0.476 ' CG ' ' HA2' ' A' ' 245' ' ' GLY . 39.7 tt0 -71.8 144.56 49.11 Favored 'General case' 0 C--O 1.239 0.535 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 177.777 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 267' ' ' ILE . . . . . 0.646 HD12 ' C ' ' A' ' 267' ' ' ILE . 2.1 pp -128.27 162.06 35.46 Favored 'Isoleucine or valine' 0 C--O 1.249 1.043 0 N-CA-C 113.608 0.966 . . . . 0.0 113.608 -175.221 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 25.7 mtpp -118.7 109.42 16.08 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 114.762 -1.108 . . . . 0.0 109.66 -178.406 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 8.2 m -80.65 96.04 2.71 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.457 0 C-N-CA 120.275 -0.57 . . . . 0.0 111.268 178.103 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 98.4 mt -67.25 -40.59 86.26 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.406 0.622 . . . . 0.0 110.131 178.128 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -139.64 177.54 20.38 Favored Glycine 0 C--N 1.315 -0.609 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.29 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_endo -60.1 -31.54 93.47 Favored 'Trans proline' 0 C--N 1.302 -1.881 0 C-N-CA 121.772 1.648 . . . . 0.0 111.233 -178.769 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 22.9 m-85 -123.94 11.08 8.93 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.422 179.383 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -122.52 125.67 46.23 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 116.025 -0.534 . . . . 0.0 109.654 -176.276 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 275' ' ' PHE . . . . . 0.545 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -138.68 164.02 30.61 Favored 'General case' 0 CA--C 1.501 -0.931 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 -179.611 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . 0.524 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 6.4 p -137.49 159.07 42.97 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.456 -178.082 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 277' ' ' ILE . . . . . 0.694 ' C ' HD12 ' A' ' 277' ' ' ILE . 2.5 pp -138.05 -173.74 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 CA-C-N 114.977 -1.01 . . . . 0.0 109.948 -175.825 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 278' ' ' CYS . . . . . 0.46 ' O ' ' HA ' ' A' ' 229' ' ' PRO . 1.2 p -46.87 -93.83 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.304 0 O-C-N 123.324 0.39 . . . . 0.0 111.812 -179.694 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -137.55 126.75 24.55 Favored 'General case' 0 CA--C 1.514 -0.406 0 N-CA-C 109.541 -0.541 . . . . 0.0 109.541 -179.323 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . 0.756 HG23 ' HA3' ' A' ' 230' ' ' GLY . 25.0 p -69.56 -23.76 63.61 Favored 'General case' 0 C--N 1.317 -0.808 0 C-N-CA 119.436 -0.906 . . . . 0.0 108.682 171.06 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -61.85 -21.05 64.34 Favored 'General case' 0 N--CA 1.435 -1.199 0 CA-C-N 114.635 -1.166 . . . . 0.0 108.812 173.802 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 29.3 t-20 -89.22 -9.13 51.92 Favored 'General case' 0 CA--C 1.509 -0.621 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.481 175.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 283' ' ' PHE . . . . . 0.822 ' CE2' HD21 ' A' ' 259' ' ' LEU . 19.5 m-30 -95.79 -87.91 0.28 Allowed 'General case' 0 N--CA 1.444 -0.74 0 CA-C-O 121.524 0.678 . . . . 0.0 110.456 178.396 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 284' ' ' SER . . . . . 0.418 ' CB ' ' HA ' ' A' ' 256' ' ' MET . 0.0 OUTLIER 170.3 -170.22 0.02 OUTLIER 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 107.689 -1.226 . . . . 0.0 107.689 -173.44 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -94.06 131.37 39.62 Favored 'General case' 0 N--CA 1.471 0.623 0 CA-C-N 118.646 0.657 . . . . 0.0 112.766 -176.052 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 286' ' ' TYR . . . . . 0.474 ' O ' ' CD2' ' A' ' 286' ' ' TYR . 60.8 t80 -68.87 87.04 0.35 Allowed 'General case' 0 N--CA 1.472 0.639 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.177 177.399 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 287' ' ' ILE . . . . . 0.577 ' O ' ' HG3' ' A' ' 288' ' ' ARG . 87.5 mt -69.94 -48.05 65.58 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.723 0 C-N-CA 120.298 -0.561 . . . . 0.0 110.806 175.405 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . 0.577 ' HG3' ' O ' ' A' ' 287' ' ' ILE . 43.8 mtp180 -170.52 170.67 6.78 Favored 'General case' 0 N--CA 1.47 0.574 0 N-CA-C 112.986 0.735 . . . . 0.0 112.986 -179.114 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 56.48 -143.55 38.51 Favored Glycine 0 N--CA 1.466 0.681 0 CA-C-N 113.77 -1.559 . . . . 0.0 113.199 167.483 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 290' ' ' GLY . . . . . 0.543 ' CA ' HG22 ' A' ' 253' ' ' VAL . . . 100.71 130.31 6.99 Favored Glycine 0 N--CA 1.441 -1.009 0 CA-C-O 121.163 0.313 . . . . 0.0 112.506 178.93 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . 0.649 HG12 ' SD ' ' A' ' 220' ' ' MET . 95.2 mt -116.29 129.82 72.08 Favored 'Isoleucine or valine' 0 C--O 1.244 0.769 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 171.675 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 7.2 p -109.31 130.35 62.47 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.064 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 176.789 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . 0.532 ' HA ' ' O ' ' A' ' 217' ' ' LEU . 3.2 m -131.08 138.73 49.69 Favored 'General case' 0 N--CA 1.441 -0.875 0 C-N-CA 120.43 -0.508 . . . . 0.0 111.558 -175.124 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 294' ' ' GLN . . . . . 0.453 ' OE1' ' N ' ' A' ' 217' ' ' LEU . 2.7 tm0? . . . . . 0 C--N 1.316 -0.88 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 173.29 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 217' ' ' LEU . . . . . 0.406 ' HB3' ' O ' ' A' ' 240' ' ' HIS . 0.2 OUTLIER . . . . . 0 C--O 1.239 0.549 0 CA-C-O 120.89 0.376 . . . . 0.0 110.327 . . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 8.5 t -151.72 152.61 32.98 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.012 -175.683 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -143.57 160.38 40.73 Favored 'General case' 0 C--O 1.244 0.797 0 CA-C-O 120.918 0.389 . . . . 0.0 110.95 178.413 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 97.2 mtp -71.57 136.73 47.58 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.463 -0.79 . . . . 0.0 109.239 176.474 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 91.1 t -83.7 129.48 37.46 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.052 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 178.027 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 74.9 m -79.79 -73.05 0.37 Allowed 'General case' 0 N--CA 1.432 -1.34 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 177.704 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 223' ' ' MET . . . . . 0.477 ' SD ' ' HB ' ' A' ' 233' ' ' THR . 1.0 OUTLIER -139.71 161.95 36.31 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.111 172.771 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 224' ' ' VAL . . . . . 0.725 HG11 ' SD ' ' A' ' 256' ' ' MET . 69.6 t -127.37 129.8 70.69 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 175.749 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 225' ' ' THR . . . . . 0.509 ' O ' HG21 ' A' ' 280' ' ' THR . 75.4 p -78.88 131.25 36.35 Favored 'General case' 0 C--O 1.225 -0.225 0 C-N-CA 120.08 -0.648 . . . . 0.0 110.163 177.615 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 226' ' ' LYS . . . . . 0.605 ' HE3' ' HA ' ' A' ' 281' ' ' SER . 0.0 OUTLIER -77.72 52.28 1.0 Allowed 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 120.723 0.297 . . . . 0.0 110.868 -179.012 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 227' ' ' ASP . . . . . 0.419 ' CG ' ' H ' ' A' ' 228' ' ' ASN . 42.3 t0 -131.29 -179.8 5.57 Favored 'General case' 0 C--O 1.242 0.674 0 CA-C-O 120.862 0.363 . . . . 0.0 111.952 -178.562 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 228' ' ' ASN . . . . . 0.474 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 1.5 p30 -137.6 125.07 13.95 Favored Pre-proline 0 CA--C 1.539 0.536 0 CA-C-N 115.162 -0.926 . . . . 0.0 109.634 175.073 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 229' ' ' PRO . . . . . 0.474 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 44.9 Cg_endo -65.63 143.87 61.41 Favored 'Cis proline' 0 N--CA 1.49 1.314 0 C-N-CA 123.121 -1.616 . . . . 0.0 109.984 -0.46 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . 0.559 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -76.26 136.9 20.34 Favored Glycine 0 C--N 1.305 -1.157 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 -177.301 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 231' ' ' VAL . . . . . 0.482 HG23 HD12 ' A' ' 270' ' ' LEU . 1.6 p -125.74 133.84 68.1 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 175.82 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 232' ' ' VAL . . . . . 0.618 ' HB ' HG22 ' A' ' 224' ' ' VAL . 0.7 OUTLIER -132.42 156.36 42.33 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.81 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.241 -176.713 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 233' ' ' THR . . . . . 0.477 ' HB ' ' SD ' ' A' ' 223' ' ' MET . 24.4 m -109.65 143.93 38.71 Favored 'General case' 0 N--CA 1.441 -0.914 0 CA-C-N 115.848 -0.614 . . . . 0.0 109.675 176.278 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 34.2 m -107.58 157.55 17.96 Favored 'General case' 0 C--N 1.31 -1.127 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 -179.552 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 33.2 tp -57.19 123.27 14.74 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 -178.062 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 236' ' ' ASP . . . . . 0.405 ' HA ' ' CD1' ' A' ' 273' ' ' TYR . 8.4 p-10 -59.7 -32.71 70.77 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.211 0.529 . . . . 0.0 111.05 -175.717 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -66.89 -32.07 73.09 Favored 'General case' 0 C--N 1.303 -1.42 0 CA-C-N 115.751 -0.658 . . . . 0.0 112.047 177.444 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -109.08 132.99 53.58 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 120.777 0.322 . . . . 0.0 111.647 -176.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 90.2 mtm-85 -91.39 133.6 35.33 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 175.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 240' ' ' HIS . . . . . 0.623 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 3.0 p80 -66.57 -40.55 89.02 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.749 0.309 . . . . 0.0 111.208 -179.516 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 82.34 20.71 61.83 Favored Glycine 0 C--N 1.316 -0.544 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 -176.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 242' ' ' PHE . . . . . 0.502 ' CD2' ' HB2' ' A' ' 240' ' ' HIS . 7.6 m-30 -92.31 146.41 23.72 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.184 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 71.4 mm-40 -109.27 160.07 16.43 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.512 171.471 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 19.9 m -64.6 122.36 16.63 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 175.717 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 95.04 0.14 63.87 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 111.564 -0.614 . . . . 0.0 111.564 -178.668 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 48.6 t0 -76.76 163.93 26.34 Favored 'General case' 0 C--O 1.238 0.489 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 176.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 247' ' ' PHE . . . . . 0.459 ' HA ' ' O ' ' A' ' 265' ' ' MET . 83.1 m-85 -110.27 129.82 55.66 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.522 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 248' ' ' VAL . . . . . 0.494 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.3 m -129.98 159.45 41.99 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 C-N-CA 120.357 -0.537 . . . . 0.0 111.519 -178.162 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 40.7 m -122.65 159.6 27.55 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 114.308 -1.315 . . . . 0.0 108.81 172.926 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 250' ' ' PHE . . . . . 0.605 ' CB ' ' HB3' ' A' ' 259' ' ' LEU . 79.1 m-85 -118.79 157.82 26.82 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.271 -174.167 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 4.8 m -151.59 157.48 42.25 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.324 178.078 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER 50.62 27.44 2.94 Favored 'General case' 0 C--N 1.308 -1.196 0 N-CA-C 112.87 0.693 . . . . 0.0 112.87 174.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 0.478 HG22 ' CA ' ' A' ' 290' ' ' GLY . 12.6 t -88.81 129.23 40.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 175.237 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . 0.477 ' NE2' ' N ' ' A' ' 254' ' ' GLN . 1.5 mp0 -97.27 138.91 34.03 Favored 'General case' 0 C--O 1.242 0.665 0 C-N-CA 120.737 -0.385 . . . . 0.0 110.84 -178.723 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 80.55 -55.66 4.69 Favored Glycine 0 C--O 1.238 0.358 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 -176.3 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 256' ' ' MET . . . . . 0.725 ' SD ' HG11 ' A' ' 224' ' ' VAL . 3.4 ttm -84.55 48.18 1.48 Allowed 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 175.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 257' ' ' ILE . . . . . 0.416 ' O ' ' HB2' ' A' ' 260' ' ' ASN . 48.8 pt -69.37 -20.6 24.28 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.758 0 CA-C-N 114.745 -1.116 . . . . 0.0 110.542 -174.544 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 258' ' ' GLN . . . . . 0.472 ' O ' ' SG ' ' A' ' 262' ' ' CYS . 2.5 mp0 -54.14 -35.1 61.87 Favored 'General case' 0 C--N 1.318 -0.801 0 N-CA-C 108.351 -0.981 . . . . 0.0 108.351 177.297 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 259' ' ' LEU . . . . . 0.94 HD21 ' CE2' ' A' ' 283' ' ' PHE . 92.5 mt -62.04 -41.24 97.9 Favored 'General case' 0 N--CA 1.445 -0.683 0 CA-C-N 115.399 -0.819 . . . . 0.0 109.915 176.154 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 260' ' ' ASN . . . . . 0.431 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 97.5 m-20 -60.71 -40.05 90.82 Favored 'General case' 0 CA--C 1.512 -0.49 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 -179.618 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -100.13 11.74 60.35 Favored Glycine 0 CA--C 1.524 0.62 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.872 -178.45 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 262' ' ' CYS . . . . . 0.472 ' SG ' ' O ' ' A' ' 258' ' ' GLN . 1.3 m -88.37 152.71 21.73 Favored 'General case' 0 CA--C 1.51 -0.579 0 CA-C-N 116.988 0.394 . . . . 0.0 110.787 -178.185 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 47.7 mt-30 -72.24 160.84 81.67 Favored Pre-proline 0 C--N 1.32 -0.678 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 173.331 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 264' ' ' PRO . . . . . 0.494 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 20.9 Cg_exo -61.47 143.75 97.56 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 N-CA-C 109.224 -1.106 . . . . 0.0 109.224 178.628 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 265' ' ' MET . . . . . 0.459 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 24.3 ptp -133.32 158.19 43.6 Favored 'General case' 0 C--N 1.317 -0.842 0 C-N-CA 120.98 -0.288 . . . . 0.0 111.695 -174.015 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 66.4 tt0 -71.25 139.18 49.94 Favored 'General case' 0 CA--C 1.507 -0.679 0 O-C-N 123.664 0.603 . . . . 0.0 109.718 176.372 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 267' ' ' ILE . . . . . 0.746 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.9 pp -131.74 160.14 42.6 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.865 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.274 178.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 64.7 mttp -130.21 125.84 35.91 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.135 176.41 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 17.9 m -84.73 106.6 14.97 Favored 'Isoleucine or valine' 0 C--O 1.235 0.315 0 CA-C-O 121.18 0.514 . . . . 0.0 111.837 -177.436 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 270' ' ' LEU . . . . . 0.482 HD12 HG23 ' A' ' 231' ' ' VAL . 91.0 mt -66.27 -40.3 90.04 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.458 -0.792 . . . . 0.0 109.45 177.451 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -147.16 -175.46 20.06 Favored Glycine 0 C--N 1.321 -0.299 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 179.069 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 272' ' ' PRO . . . . . 0.623 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 36.4 Cg_endo -61.99 -33.93 82.1 Favored 'Trans proline' 0 C--N 1.307 -1.625 0 C-N-CA 121.778 1.652 . . . . 0.0 111.153 -177.619 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 273' ' ' TYR . . . . . 0.405 ' CD1' ' HA ' ' A' ' 236' ' ' ASP . 93.9 m-85 -119.19 6.51 11.24 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.984 -0.553 . . . . 0.0 112.18 -179.751 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 2.9 p -119.95 126.22 50.33 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 120.712 0.291 . . . . 0.0 110.506 179.323 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 275' ' ' PHE . . . . . 0.566 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -138.0 162.93 32.84 Favored 'General case' 0 CA--C 1.499 -0.992 0 C-N-CA 120.766 -0.374 . . . . 0.0 111.987 -179.744 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . 0.467 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 4.7 p -132.47 151.2 51.98 Favored 'General case' 0 N--CA 1.433 -1.277 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.921 -173.204 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 277' ' ' ILE . . . . . 0.746 HG22 HG22 ' A' ' 267' ' ' ILE . 2.2 pp -138.19 175.57 8.48 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 CA-C-N 114.824 -1.08 . . . . 0.0 110.505 -175.684 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 278' ' ' CYS . . . . . 0.444 ' N ' HD12 ' A' ' 277' ' ' ILE . 1.4 p -42.58 -88.44 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.435 0 N-CA-C 112.744 0.646 . . . . 0.0 112.744 -179.707 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . 0.455 ' O ' ' HB2' ' A' ' 282' ' ' ASN . 18.1 t0 -145.75 121.04 10.23 Favored 'General case' 0 CA--C 1.515 -0.371 0 CA-C-O 120.767 0.317 . . . . 0.0 111.109 -176.277 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . 0.657 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 35.9 p -68.22 -25.75 65.36 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-O 121.26 0.553 . . . . 0.0 110.534 176.546 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 281' ' ' SER . . . . . 0.605 ' HA ' ' HE3' ' A' ' 226' ' ' LYS . 0.7 OUTLIER -69.76 -12.86 61.96 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.459 -0.791 . . . . 0.0 109.519 176.06 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 282' ' ' ASN . . . . . 0.455 ' HB2' ' O ' ' A' ' 279' ' ' ASP . 2.0 m-80 -88.06 -6.06 58.15 Favored 'General case' 0 CA--C 1.509 -0.627 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 173.604 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 283' ' ' PHE . . . . . 0.94 ' CE2' HD21 ' A' ' 259' ' ' LEU . 6.0 m-85 -100.41 -71.8 0.69 Allowed 'General case' 0 N--CA 1.444 -0.738 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 172.29 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 1.6 p 167.02 -99.04 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.466 0 CA-C-N 115.144 -0.935 . . . . 0.0 110.213 178.81 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 285' ' ' ASP . . . . . 0.519 ' O ' ' N ' ' A' ' 256' ' ' MET . 48.4 t0 -150.74 163.33 38.85 Favored 'General case' 0 C--O 1.214 -0.815 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 177.416 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 286' ' ' TYR . . . . . 0.434 ' CE2' ' HA ' ' A' ' 288' ' ' ARG . 71.6 t80 -100.54 124.1 45.65 Favored 'General case' 0 C--N 1.318 -0.774 0 C-N-CA 121.1 -0.24 . . . . 0.0 110.841 -179.777 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 287' ' ' ILE . . . . . 0.435 ' O ' ' CG ' ' A' ' 288' ' ' ARG . 96.6 mt -100.06 -61.5 2.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 C-N-CA 120.77 -0.372 . . . . 0.0 110.455 173.696 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . 0.435 ' CG ' ' O ' ' A' ' 287' ' ' ILE . 54.6 mtp180 -166.67 176.79 6.96 Favored 'General case' 0 C--O 1.241 0.617 0 CA-C-O 121.135 0.493 . . . . 0.0 111.787 179.064 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 67.95 -156.27 52.8 Favored Glycine 0 CA--C 1.508 -0.399 0 CA-C-N 115.284 -0.871 . . . . 0.0 111.104 174.893 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 290' ' ' GLY . . . . . 0.478 ' CA ' HG22 ' A' ' 253' ' ' VAL . . . 109.91 123.81 4.68 Favored Glycine 0 N--CA 1.443 -0.893 0 N-CA-C 112.281 -0.327 . . . . 0.0 112.281 176.255 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 99.2 mt -127.52 133.72 67.19 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.09 0 N-CA-C 107.496 -1.298 . . . . 0.0 107.496 173.676 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . 0.414 HG22 ' CZ ' ' A' ' 242' ' ' PHE . 4.0 p -124.76 136.06 61.93 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.893 0 C-N-CA 120.466 -0.494 . . . . 0.0 109.824 -177.529 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 4.4 m -127.42 146.75 50.37 Favored 'General case' 0 C--O 1.237 0.441 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.768 -178.414 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 CA--C 1.51 -0.588 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 173.449 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 217' ' ' LEU . . . . . 0.455 ' HB3' ' O ' ' A' ' 240' ' ' HIS . 0.1 OUTLIER . . . . . 0 N--CA 1.444 -0.76 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 . . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 218' ' ' SER . . . . . 0.405 ' HA ' ' HA ' ' A' ' 293' ' ' SER . 5.1 m -130.89 151.87 50.84 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.867 -174.719 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -144.84 160.59 41.04 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.051 0.453 . . . . 0.0 110.803 179.05 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 220' ' ' MET . . . . . 0.662 ' SD ' HD22 ' A' ' 235' ' ' LEU . 92.7 mtp -75.57 130.74 39.31 Favored 'General case' 0 N--CA 1.443 -0.814 0 CA-C-N 115.366 -0.834 . . . . 0.0 108.916 176.474 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 99.7 t -78.92 128.69 38.35 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.92 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 176.413 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 26.9 m -85.26 -72.73 0.47 Allowed 'General case' 0 C--N 1.307 -1.245 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 178.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 223' ' ' MET . . . . . 0.535 ' C ' ' SD ' ' A' ' 223' ' ' MET . 2.7 ppp? -138.2 151.26 47.52 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 112.235 0.457 . . . . 0.0 112.235 174.168 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 224' ' ' VAL . . . . . 0.578 HG13 HG12 ' A' ' 232' ' ' VAL . 62.2 t -121.11 126.65 75.38 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 176.098 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 225' ' ' THR . . . . . 0.497 ' O ' ' OG1' ' A' ' 280' ' ' THR . 37.5 p -77.53 133.72 38.46 Favored 'General case' 0 C--N 1.327 -0.386 0 C-N-CA 120.259 -0.576 . . . . 0.0 110.407 178.49 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 20.6 tptm -78.32 77.23 4.81 Favored 'General case' 0 C--N 1.316 -0.87 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 179.813 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 227' ' ' ASP . . . . . 0.418 ' H ' ' HG1' ' A' ' 280' ' ' THR . 1.5 t0 -161.31 178.09 9.53 Favored 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 112.615 0.598 . . . . 0.0 112.615 -176.208 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 228' ' ' ASN . . . . . 0.502 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 2.0 t-20 -140.29 124.46 10.75 Favored Pre-proline 0 CA--C 1.533 0.324 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.786 175.086 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 229' ' ' PRO . . . . . 0.502 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 46.8 Cg_endo -65.61 143.57 60.0 Favored 'Cis proline' 0 N--CA 1.492 1.402 0 C-N-CA 122.759 -1.767 . . . . 0.0 109.717 -1.244 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . 0.517 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -81.9 140.02 20.48 Favored Glycine 0 CA--C 1.501 -0.795 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 -178.496 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 231' ' ' VAL . . . . . 0.446 ' CG2' HD12 ' A' ' 270' ' ' LEU . 2.4 p -122.79 133.85 67.71 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 176.922 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 232' ' ' VAL . . . . . 0.578 HG12 HG13 ' A' ' 224' ' ' VAL . 0.6 OUTLIER -131.39 155.41 41.79 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 C-N-CA 120.605 -0.438 . . . . 0.0 110.829 -176.182 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 26.1 m -110.17 142.67 41.37 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-N 115.425 -0.807 . . . . 0.0 109.629 177.474 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 48.7 m -107.92 158.22 17.54 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-N 115.804 -0.634 . . . . 0.0 109.484 178.39 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.662 HD22 ' SD ' ' A' ' 220' ' ' MET . 33.9 tp -64.5 117.21 7.0 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 178.459 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 236' ' ' ASP . . . . . 0.539 ' HA ' ' CE1' ' A' ' 273' ' ' TYR . 37.4 p-10 -59.71 -28.56 67.43 Favored 'General case' 0 C--O 1.239 0.515 0 CA-C-O 120.885 0.374 . . . . 0.0 111.872 -173.144 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 72.4 mm-40 -66.22 -33.18 75.18 Favored 'General case' 0 C--N 1.311 -1.068 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.316 178.78 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -99.51 122.96 43.32 Favored 'General case' 0 CA--C 1.516 -0.337 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.408 179.795 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 90.2 mtm180 -75.57 138.73 41.67 Favored 'General case' 0 C--N 1.316 -0.861 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 174.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 240' ' ' HIS . . . . . 0.474 ' HB2' ' CD2' ' A' ' 242' ' ' PHE . 6.4 p80 -88.82 -37.73 15.17 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 121.026 0.441 . . . . 0.0 109.924 177.26 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 81.24 10.73 84.36 Favored Glycine 0 CA--C 1.505 -0.592 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 179.405 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 242' ' ' PHE . . . . . 0.493 ' CD1' ' N ' ' A' ' 242' ' ' PHE . 3.7 m-30 -81.22 147.14 30.11 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.305 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -131.17 167.42 19.18 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 109.095 -0.705 . . . . 0.0 109.095 172.359 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 2.9 m -59.48 129.38 41.7 Favored 'General case' 0 C--N 1.294 -1.835 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.556 -176.561 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 83.8 1.8 89.85 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 111.807 -0.517 . . . . 0.0 111.807 -179.165 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 44.4 t0 -77.69 159.62 29.01 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 117.315 0.557 . . . . 0.0 110.255 178.476 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 247' ' ' PHE . . . . . 0.429 ' HA ' ' O ' ' A' ' 265' ' ' MET . 66.0 m-85 -110.48 133.79 52.95 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 116.592 -0.276 . . . . 0.0 110.394 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 248' ' ' VAL . . . . . 0.426 ' O ' ' SD ' ' A' ' 265' ' ' MET . 3.1 m -129.98 162.22 38.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.54 -179.093 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 5.0 m -126.19 151.79 46.89 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.332 -0.849 . . . . 0.0 109.016 175.782 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 250' ' ' PHE . . . . . 0.563 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 74.4 m-85 -109.6 155.9 20.85 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.409 0.623 . . . . 0.0 111.693 -176.25 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 44.8 m -152.4 151.82 31.28 Favored 'General case' 0 C--N 1.308 -1.211 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.579 175.851 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 30.7 mm-40 51.89 28.47 5.13 Favored 'General case' 0 C--N 1.317 -0.808 0 N-CA-C 113.018 0.747 . . . . 0.0 113.018 176.427 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 0.541 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 60.8 t -82.36 129.67 37.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 174.216 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 81.9 mt-30 -101.59 138.15 38.96 Favored 'General case' 0 C--O 1.243 0.745 0 C-N-CA 120.272 -0.571 . . . . 0.0 111.296 -175.275 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 81.73 -57.53 4.92 Favored Glycine 0 C--O 1.239 0.417 0 N-CA-C 109.969 -1.252 . . . . 0.0 109.969 -176.47 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 256' ' ' MET . . . . . 0.505 ' SD ' HD11 ' A' ' 259' ' ' LEU . 57.0 ttm -85.78 65.04 8.94 Favored 'General case' 0 CA--C 1.516 -0.364 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 175.383 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 257' ' ' ILE . . . . . 0.436 ' O ' ' HB2' ' A' ' 260' ' ' ASN . 49.1 pt -73.92 -19.55 17.58 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-N 114.659 -1.155 . . . . 0.0 111.875 -172.848 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 15.4 tt0 -58.16 -36.39 72.94 Favored 'General case' 0 C--N 1.321 -0.647 0 C-N-CA 119.547 -0.861 . . . . 0.0 110.055 -177.636 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 259' ' ' LEU . . . . . 0.875 HD21 ' CE2' ' A' ' 283' ' ' PHE . 90.4 mt -61.44 -40.39 94.27 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 177.814 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 260' ' ' ASN . . . . . 0.541 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 98.3 m-20 -60.24 -40.1 89.06 Favored 'General case' 0 CA--C 1.508 -0.635 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 178.376 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -102.27 22.72 36.8 Favored Glycine 0 C--N 1.315 -0.615 0 CA-C-N 115.468 -0.787 . . . . 0.0 111.919 -178.259 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 262' ' ' CYS . . . . . 0.4 ' HB3' ' HA ' ' A' ' 259' ' ' LEU . 11.1 t -111.14 146.48 36.78 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 117.308 0.554 . . . . 0.0 111.734 -176.994 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 -59.31 158.99 17.35 Favored Pre-proline 0 C--N 1.327 -0.376 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 174.005 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 264' ' ' PRO . . . . . 0.421 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 37.6 Cg_endo -62.64 148.16 93.75 Favored 'Trans proline' 0 N--CA 1.493 1.491 0 C-N-CA 121.578 1.519 . . . . 0.0 111.395 179.159 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 265' ' ' MET . . . . . 0.623 ' N ' ' SD ' ' A' ' 265' ' ' MET . 0.3 OUTLIER -124.7 150.49 46.09 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.731 -174.412 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 266' ' ' GLU . . . . . 0.522 ' OE2' ' NZ ' ' A' ' 268' ' ' LYS . 0.7 OUTLIER -71.53 140.14 49.77 Favored 'General case' 0 C--O 1.24 0.596 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 172.958 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 267' ' ' ILE . . . . . 0.687 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.5 pp -130.63 159.92 42.25 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-O 121.245 0.545 . . . . 0.0 111.958 -177.065 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . 0.522 ' NZ ' ' OE2' ' A' ' 266' ' ' GLU . 35.4 mttp -128.79 120.51 26.48 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.617 178.182 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.421 HG23 ' O ' ' A' ' 269' ' ' VAL . 26.8 m -82.58 100.14 6.07 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.256 0 CA-C-O 121.018 0.437 . . . . 0.0 111.85 -176.657 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 270' ' ' LEU . . . . . 0.446 HD12 ' CG2' ' A' ' 231' ' ' VAL . 97.4 mt -65.81 -41.07 92.32 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.341 0.591 . . . . 0.0 109.636 177.264 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -139.41 179.49 18.67 Favored Glycine 0 C--N 1.317 -0.525 0 N-CA-C 109.253 -1.539 . . . . 0.0 109.253 178.166 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -61.99 -30.23 82.9 Favored 'Trans proline' 0 C--N 1.306 -1.694 0 C-N-CA 121.899 1.733 . . . . 0.0 111.067 -178.27 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 273' ' ' TYR . . . . . 0.539 ' CE1' ' HA ' ' A' ' 236' ' ' ASP . 72.9 m-85 -122.56 6.8 9.49 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 112.782 0.66 . . . . 0.0 112.782 179.027 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 7.0 p -119.41 126.89 52.43 Favored 'General case' 0 C--O 1.243 0.717 0 CA-C-O 120.67 0.272 . . . . 0.0 110.461 177.658 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 275' ' ' PHE . . . . . 0.533 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -133.0 163.2 29.76 Favored 'General case' 0 CA--C 1.493 -1.243 0 C-N-CA 120.446 -0.501 . . . . 0.0 112.296 179.893 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . 0.517 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 5.0 p -130.65 143.27 50.63 Favored 'General case' 0 N--CA 1.43 -1.432 0 C-N-CA 120.611 -0.436 . . . . 0.0 111.526 -174.781 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 277' ' ' ILE . . . . . 0.628 HG22 HG22 ' A' ' 267' ' ' ILE . 32.6 pt -141.31 165.79 18.6 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.765 0 CA-C-N 114.614 -1.176 . . . . 0.0 111.488 -172.784 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 278' ' ' CYS . . . . . 0.406 ' O ' ' HA ' ' A' ' 229' ' ' PRO . 0.9 OUTLIER -27.5 -90.99 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.687 0 N-CA-C 113.757 1.021 . . . . 0.0 113.757 -176.379 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . 0.424 ' HB3' ' HB2' ' A' ' 282' ' ' ASN . 50.7 t0 -148.81 113.56 5.39 Favored 'General case' 0 CA--C 1.504 -0.825 0 CA-C-N 116.615 -0.266 . . . . 0.0 110.293 -175.911 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . 0.705 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 26.7 p -73.65 -23.52 59.87 Favored 'General case' 0 N--CA 1.426 -1.627 0 CA-C-O 121.086 0.47 . . . . 0.0 110.04 177.411 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -67.75 -20.75 65.27 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.06 -0.973 . . . . 0.0 108.783 173.243 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 282' ' ' ASN . . . . . 0.424 ' HB2' ' HB3' ' A' ' 279' ' ' ASP . 18.8 t30 -89.63 -9.08 51.0 Favored 'General case' 0 CA--C 1.51 -0.588 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.455 -179.547 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 283' ' ' PHE . . . . . 0.875 ' CE2' HD21 ' A' ' 259' ' ' LEU . 21.3 m-85 -92.14 -71.76 0.63 Allowed 'General case' 0 CA--C 1.505 -0.757 0 CA-C-O 121.66 0.743 . . . . 0.0 109.643 179.002 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER 168.95 -175.78 0.03 OUTLIER 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 114.133 -1.394 . . . . 0.0 107.967 -173.908 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 7.9 t70 -92.41 121.43 33.88 Favored 'General case' 0 C--N 1.322 -0.617 0 C-N-CA 120.246 -0.582 . . . . 0.0 111.925 -178.861 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 12.1 t80 -69.58 126.73 30.63 Favored 'General case' 0 C--O 1.237 0.423 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 177.299 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 96.4 mt -106.08 -58.26 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 CA-C-O 121.021 0.438 . . . . 0.0 110.13 174.834 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 22.3 ptt180 -166.91 -179.31 4.64 Favored 'General case' 0 C--O 1.24 0.554 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.934 -176.285 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 65.64 -156.29 49.13 Favored Glycine 0 C--N 1.331 0.305 0 N-CA-C 110.6 -1.0 . . . . 0.0 110.6 178.051 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 290' ' ' GLY . . . . . 0.403 ' CA ' HG22 ' A' ' 253' ' ' VAL . . . 105.42 122.81 5.1 Favored Glycine 0 CA--C 1.52 0.373 0 CA-C-O 121.266 0.37 . . . . 0.0 112.813 176.413 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 95.6 mt -123.0 130.76 74.25 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 N-CA-C 107.587 -1.264 . . . . 0.0 107.587 175.262 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . 0.474 HG22 ' CZ ' ' A' ' 242' ' ' PHE . 4.0 p -126.35 137.98 56.08 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 -177.455 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . 0.405 ' HA ' ' HA ' ' A' ' 218' ' ' SER . 12.5 m -129.64 147.27 51.42 Favored 'General case' 0 CA--C 1.509 -0.598 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.498 -178.425 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 294' ' ' GLN . . . . . 0.459 ' HB3' ' CD1' ' A' ' 242' ' ' PHE . 0.7 OUTLIER . . . . . 0 CA--C 1.507 -0.678 0 C-N-CA 120.183 -0.607 . . . . 0.0 110.535 175.41 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 217' ' ' LEU . . . . . 0.458 ' CB ' ' HG2' ' A' ' 294' ' ' GLN . 0.3 OUTLIER . . . . . 0 CA--C 1.505 -0.781 0 CA-C-O 121.089 0.471 . . . . 0.0 111.218 . . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 218' ' ' SER . . . . . 0.43 ' HA ' ' O ' ' A' ' 292' ' ' VAL . 15.6 m -127.96 150.67 49.8 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 -179.041 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -138.05 152.57 48.95 Favored 'General case' 0 C--N 1.311 -1.095 0 CA-C-O 120.848 0.356 . . . . 0.0 111.112 -177.468 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 220' ' ' MET . . . . . 0.567 ' SD ' HG12 ' A' ' 291' ' ' ILE . 3.5 tpp -76.11 126.82 31.71 Favored 'General case' 0 N--CA 1.443 -0.821 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 174.647 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 72.5 t -77.14 129.48 37.33 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.122 0 N-CA-C 109.646 -0.502 . . . . 0.0 109.646 -178.419 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 3.0 m -83.43 -73.07 0.43 Allowed 'General case' 0 N--CA 1.437 -1.108 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 176.374 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 223' ' ' MET . . . . . 0.449 ' C ' ' SD ' ' A' ' 223' ' ' MET . 3.6 ppp? -138.38 152.79 48.73 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.42 -0.354 . . . . 0.0 111.658 174.566 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 224' ' ' VAL . . . . . 0.647 HG13 HG12 ' A' ' 232' ' ' VAL . 61.6 t -119.84 126.55 75.42 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.991 0 N-CA-C 108.323 -0.991 . . . . 0.0 108.323 175.08 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 225' ' ' THR . . . . . 0.489 ' O ' ' OG1' ' A' ' 280' ' ' THR . 71.0 p -84.82 126.77 33.73 Favored 'General case' 0 C--N 1.322 -0.594 0 C-N-CA 119.726 -0.79 . . . . 0.0 109.648 176.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 86.5 tttt -77.86 89.85 4.08 Favored 'General case' 0 C--N 1.316 -0.874 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 -178.435 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 227' ' ' ASP . . . . . . . . . . . . . 43.5 t0 -163.86 173.68 12.43 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.429 -177.363 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 228' ' ' ASN . . . . . 0.419 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.8 OUTLIER -133.14 123.54 17.94 Favored Pre-proline 0 C--N 1.323 -0.559 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.855 172.926 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 229' ' ' PRO . . . . . 0.419 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 55.3 Cg_endo -66.78 144.25 68.2 Favored 'Cis proline' 0 C--N 1.311 -1.4 0 C-N-CA 122.845 -1.731 . . . . 0.0 109.774 -2.266 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . 0.479 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -84.03 139.06 18.1 Favored Glycine 0 CA--C 1.502 -0.766 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 -178.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 231' ' ' VAL . . . . . 0.496 ' CG2' HD12 ' A' ' 270' ' ' LEU . 2.4 p -124.78 137.57 57.01 Favored 'Isoleucine or valine' 0 C--O 1.243 0.745 0 N-CA-C 109.967 -0.382 . . . . 0.0 109.967 177.162 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 232' ' ' VAL . . . . . 0.647 HG12 HG13 ' A' ' 224' ' ' VAL . 0.6 OUTLIER -132.61 155.34 41.23 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.892 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.801 -178.493 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 21.7 m -109.06 144.19 37.4 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.811 178.861 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 2.1 m -107.6 150.44 26.87 Favored 'General case' 0 C--N 1.316 -0.882 0 C-N-CA 123.023 0.529 . . . . 0.0 109.718 -179.662 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 37.4 tp -65.27 134.51 53.79 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.431 -176.638 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 236' ' ' ASP . . . . . 0.428 ' O ' ' NH1' ' A' ' 239' ' ' ARG . 13.0 t70 -49.1 -44.51 42.29 Favored 'General case' 0 N--CA 1.474 0.748 0 N-CA-C 114.0 1.111 . . . . 0.0 114.0 -171.779 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 237' ' ' GLU . . . . . 0.518 ' O ' ' NH1' ' A' ' 239' ' ' ARG . 54.6 mp0 -63.83 -33.5 75.82 Favored 'General case' 0 C--N 1.316 -0.851 0 C-N-CA 119.044 -1.062 . . . . 0.0 109.615 -177.534 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -77.36 95.2 4.35 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 112.869 0.692 . . . . 0.0 112.869 -177.952 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 239' ' ' ARG . . . . . 0.518 ' NH1' ' O ' ' A' ' 237' ' ' GLU . 0.0 OUTLIER -73.39 92.28 1.83 Allowed 'General case' 0 C--O 1.237 0.395 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 169.755 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 240' ' ' HIS . . . . . 0.604 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 9.4 p80 -53.0 -47.02 68.58 Favored 'General case' 0 C--O 1.213 -0.853 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.297 -174.382 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 76.8 20.75 75.83 Favored Glycine 0 C--N 1.311 -0.811 0 N-CA-C 110.416 -1.074 . . . . 0.0 110.416 177.752 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 242' ' ' PHE . . . . . 0.578 ' CE1' ' HB3' ' A' ' 294' ' ' GLN . 5.2 m-30 -80.17 143.63 33.68 Favored 'General case' 0 C--N 1.318 -0.778 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 179.405 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -119.41 166.26 13.29 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-O 121.153 0.502 . . . . 0.0 110.663 175.604 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 9.1 m -59.44 127.56 32.66 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 115.774 -0.648 . . . . 0.0 109.55 -179.032 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 84.54 6.7 85.48 Favored Glycine 0 N--CA 1.438 -1.175 0 N-CA-C 111.698 -0.561 . . . . 0.0 111.698 -179.815 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 246' ' ' ASP . . . . . 0.434 ' CG ' HE22 ' A' ' 294' ' ' GLN . 3.6 t0 -84.36 165.42 18.25 Favored 'General case' 0 CA--C 1.512 -0.483 0 C-N-CA 119.377 -0.929 . . . . 0.0 109.494 176.814 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 247' ' ' PHE . . . . . 0.552 ' CZ ' ' HB2' ' A' ' 266' ' ' GLU . 47.3 m-85 -112.61 138.11 49.87 Favored 'General case' 0 C--N 1.315 -0.906 0 N-CA-C 111.935 0.346 . . . . 0.0 111.935 -175.476 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 248' ' ' VAL . . . . . 0.514 ' HA ' ' HA ' ' A' ' 294' ' ' GLN . 2.7 m -133.01 160.38 42.67 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.363 0 C-N-CA 120.297 -0.561 . . . . 0.0 112.189 177.213 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 2.2 m -125.13 153.89 42.3 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 114.483 -1.235 . . . . 0.0 107.694 174.329 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 250' ' ' PHE . . . . . 0.623 ' CB ' ' HB3' ' A' ' 259' ' ' LEU . 64.5 m-85 -112.83 144.64 42.03 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-O 120.865 0.364 . . . . 0.0 111.126 -179.373 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 4.0 m -140.92 161.16 38.48 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 115.503 -0.772 . . . . 0.0 109.426 176.398 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 51.3 mm-40 52.96 27.49 5.63 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 112.278 0.473 . . . . 0.0 112.278 173.507 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 0.445 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 83.4 t -88.68 133.6 30.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 177.771 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 90.9 mm-40 -100.37 145.75 27.8 Favored 'General case' 0 C--O 1.237 0.436 0 CA-C-O 120.852 0.358 . . . . 0.0 110.104 176.692 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 78.36 -68.85 2.86 Favored Glycine 0 C--N 1.315 -0.612 0 N-CA-C 110.417 -1.073 . . . . 0.0 110.417 -179.505 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 256' ' ' MET . . . . . 0.482 ' SD ' ' HD2' ' A' ' 283' ' ' PHE . 29.9 ttm -79.55 68.11 5.5 Favored 'General case' 0 C--N 1.321 -0.638 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 178.087 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 44.9 pt -75.23 -19.21 16.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.857 -175.344 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 258' ' ' GLN . . . . . 0.447 ' O ' ' N ' ' A' ' 262' ' ' CYS . 0.2 OUTLIER -53.18 -39.66 63.81 Favored 'General case' 0 C--O 1.213 -0.849 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 177.576 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 259' ' ' LEU . . . . . 0.978 HD21 ' CE2' ' A' ' 283' ' ' PHE . 94.6 mt -61.6 -41.96 98.19 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.137 179.075 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 260' ' ' ASN . . . . . 0.445 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 91.5 m-20 -59.73 -41.25 90.5 Favored 'General case' 0 CA--C 1.51 -0.567 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 179.524 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -101.14 9.48 57.89 Favored Glycine 0 CA--C 1.523 0.537 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.942 -177.884 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 262' ' ' CYS . . . . . 0.447 ' N ' ' O ' ' A' ' 258' ' ' GLN . 15.6 t -87.99 144.24 26.65 Favored 'General case' 0 C--O 1.241 0.632 0 CA-C-N 117.174 0.487 . . . . 0.0 111.415 -176.122 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -61.21 156.06 52.51 Favored Pre-proline 0 C--N 1.319 -0.721 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 173.6 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 264' ' ' PRO . . . . . 0.413 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 39.3 Cg_endo -64.77 143.32 79.95 Favored 'Trans proline' 0 C--N 1.307 -1.618 0 C-N-CA 120.757 0.971 . . . . 0.0 109.842 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 265' ' ' MET . . . . . 0.469 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 19.5 ptp -126.1 153.61 44.26 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 112.07 0.396 . . . . 0.0 112.07 -174.45 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 266' ' ' GLU . . . . . 0.552 ' HB2' ' CZ ' ' A' ' 247' ' ' PHE . 75.8 tt0 -79.82 137.34 36.93 Favored 'General case' 0 C--O 1.238 0.478 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 179.789 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 267' ' ' ILE . . . . . 0.641 HG22 HG22 ' A' ' 277' ' ' ILE . 1.9 pp -128.33 163.02 33.63 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 N-CA-C 113.752 1.019 . . . . 0.0 113.752 -169.674 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 52.9 tttp -124.95 121.3 34.06 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.148 -0.933 . . . . 0.0 109.995 175.155 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.429 HG11 ' O ' ' A' ' 242' ' ' PHE . 29.5 m -75.64 132.19 33.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 C-N-CA 121.096 -0.242 . . . . 0.0 110.723 178.432 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 270' ' ' LEU . . . . . 0.613 HD11 ' HB3' ' A' ' 276' ' ' SER . 84.5 mt -106.38 -13.82 15.26 Favored 'General case' 0 CA--C 1.515 -0.393 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.737 -179.335 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -170.6 -177.93 40.98 Favored Glycine 0 C--N 1.318 -0.436 0 N-CA-C 110.364 -1.094 . . . . 0.0 110.364 -177.801 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 272' ' ' PRO . . . . . 0.604 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 36.2 Cg_endo -61.52 -31.4 87.51 Favored 'Trans proline' 0 C--N 1.308 -1.588 0 C-N-CA 122.097 1.865 . . . . 0.0 111.118 -178.302 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 273' ' ' TYR . . . . . 0.413 ' CE1' ' HA ' ' A' ' 236' ' ' ASP . 88.7 m-85 -124.49 7.43 8.31 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.877 -0.602 . . . . 0.0 112.407 -179.569 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 11.0 p -123.07 141.14 52.29 Favored 'General case' 0 C--O 1.244 0.784 0 C-N-CA 120.146 -0.622 . . . . 0.0 111.957 -177.893 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 275' ' ' PHE . . . . . 0.564 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -143.34 165.95 26.09 Favored 'General case' 0 CA--C 1.508 -0.654 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.17 178.113 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . 0.613 ' HB3' HD11 ' A' ' 270' ' ' LEU . 4.6 p -133.08 146.02 51.28 Favored 'General case' 0 N--CA 1.439 -1.01 0 N-CA-C 112.502 0.556 . . . . 0.0 112.502 -175.918 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 277' ' ' ILE . . . . . 0.641 HG22 HG22 ' A' ' 267' ' ' ILE . 29.1 pt -141.46 167.99 16.0 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.896 0 CA-C-N 114.224 -1.353 . . . . 0.0 111.332 -172.102 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 1.6 p -28.75 -95.19 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.759 0 N-CA-C 113.354 0.872 . . . . 0.0 113.354 -177.436 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -143.8 108.7 4.94 Favored 'General case' 0 CA--C 1.501 -0.912 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -178.626 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . 0.773 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 17.8 p -64.58 -30.63 71.66 Favored 'General case' 0 C--N 1.29 -2.016 0 CA-C-O 121.492 0.663 . . . . 0.0 110.459 177.55 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -61.26 -31.37 71.18 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-N 114.836 -1.075 . . . . 0.0 110.297 175.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -87.07 -9.44 55.42 Favored 'General case' 0 CA--C 1.507 -0.686 0 C-N-CA 119.362 -0.935 . . . . 0.0 110.24 -176.609 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 283' ' ' PHE . . . . . 0.978 ' CE2' HD21 ' A' ' 259' ' ' LEU . 19.1 m-85 -77.11 -71.61 0.4 Allowed 'General case' 0 N--CA 1.437 -1.106 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 169.455 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 284' ' ' SER . . . . . 0.406 ' CB ' ' HA ' ' A' ' 256' ' ' MET . 0.0 OUTLIER 175.92 -169.5 0.05 Allowed 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 113.975 -1.466 . . . . 0.0 109.129 -175.574 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -97.47 120.66 38.24 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-O 120.377 0.132 . . . . 0.0 110.772 -177.432 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 286' ' ' TYR . . . . . 0.46 ' CZ ' ' HA ' ' A' ' 288' ' ' ARG . 64.6 t80 -63.87 126.41 27.53 Favored 'General case' 0 N--CA 1.478 0.94 0 C-N-CA 122.754 0.422 . . . . 0.0 111.254 -177.543 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 4.1 mm -100.92 -65.39 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.666 173.399 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . 0.46 ' HA ' ' CZ ' ' A' ' 286' ' ' TYR . 0.1 OUTLIER -173.25 -178.8 1.8 Allowed 'General case' 0 C--O 1.243 0.751 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.305 178.58 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 68.33 -156.75 52.99 Favored Glycine 0 CA--C 1.504 -0.625 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 175.432 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 290' ' ' GLY . . . . . 0.42 ' HA3' HG22 ' A' ' 253' ' ' VAL . . . 106.72 129.68 6.31 Favored Glycine 0 N--CA 1.437 -1.251 0 C-N-CA 120.884 -0.674 . . . . 0.0 112.014 177.498 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . 0.567 HG12 ' SD ' ' A' ' 220' ' ' MET . 96.5 mt -122.43 130.58 74.41 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.31 0 N-CA-C 107.215 -1.402 . . . . 0.0 107.215 173.172 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . 0.43 ' O ' ' HA ' ' A' ' 218' ' ' SER . 2.6 p -112.12 126.9 69.56 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.828 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 -178.182 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 3.3 m -115.93 121.22 41.67 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 110.041 -0.355 . . . . 0.0 110.041 -176.915 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 294' ' ' GLN . . . . . 0.578 ' HB3' ' CE1' ' A' ' 242' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.435 -1.197 0 C-N-CA 120.149 -0.621 . . . . 0.0 110.576 178.362 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 217' ' ' LEU . . . . . 0.494 HD12 ' O ' ' A' ' 239' ' ' ARG . 0.5 OUTLIER . . . . . 0 CA--C 1.513 -0.478 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 . . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 34.5 m -119.19 132.57 55.97 Favored 'General case' 0 C--N 1.324 -0.532 0 O-C-N 123.661 0.601 . . . . 0.0 110.616 -179.652 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 219' ' ' ALA . . . . . 0.421 ' HB2' ' HA ' ' A' ' 240' ' ' HIS . . . -122.53 139.55 53.77 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.821 0.343 . . . . 0.0 110.259 -179.436 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 1.3 tpt -76.6 122.37 24.53 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 177.813 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 73.5 t -74.19 132.65 33.05 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 -177.642 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 222' ' ' SER . . . . . 0.408 ' HG ' HG22 ' A' ' 233' ' ' THR . 5.8 p -90.68 -54.64 3.9 Favored 'General case' 0 N--CA 1.434 -1.252 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 177.829 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -138.53 151.87 47.73 Favored 'General case' 0 C--O 1.222 -0.389 0 N-CA-C 112.649 0.611 . . . . 0.0 112.649 174.856 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 224' ' ' VAL . . . . . 0.726 HG11 ' SD ' ' A' ' 256' ' ' MET . 39.5 t -126.64 132.33 70.3 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 172.143 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -104.1 122.98 46.42 Favored 'General case' 0 C--N 1.313 -1.002 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 -177.817 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 226' ' ' LYS . . . . . 0.464 ' NZ ' ' OD1' ' A' ' 285' ' ' ASP . 0.0 OUTLIER -76.3 77.72 3.07 Favored 'General case' 0 C--O 1.234 0.265 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 179.379 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 227' ' ' ASP . . . . . 0.59 ' N ' ' OG1' ' A' ' 280' ' ' THR . 2.8 t0 -148.42 178.34 8.68 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.762 179.459 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 228' ' ' ASN . . . . . 0.489 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.1 OUTLIER -138.47 125.25 13.06 Favored Pre-proline 0 C--N 1.324 -0.507 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.21 176.43 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 229' ' ' PRO . . . . . 0.489 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 38.2 Cg_endo -65.0 144.76 62.38 Favored 'Cis proline' 0 N--CA 1.499 1.814 0 C-N-CA 123.286 -1.548 . . . . 0.0 110.564 -1.063 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . 0.548 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -68.66 136.96 29.95 Favored Glycine 0 N--CA 1.445 -0.732 0 N-CA-C 110.05 -1.22 . . . . 0.0 110.05 -177.915 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 231' ' ' VAL . . . . . 0.409 HG23 HD12 ' A' ' 270' ' ' LEU . 2.1 p -127.05 133.93 67.23 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 177.772 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 232' ' ' VAL . . . . . 0.436 HG22 ' CD1' ' A' ' 275' ' ' PHE . 0.6 OUTLIER -134.76 156.7 40.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 C-N-CA 120.084 -0.646 . . . . 0.0 111.451 -179.695 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 233' ' ' THR . . . . . 0.408 HG22 ' HG ' ' A' ' 222' ' ' SER . 6.7 m -111.37 140.68 45.75 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 115.148 -0.933 . . . . 0.0 109.044 178.755 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 44.5 m -107.92 155.97 19.71 Favored 'General case' 0 C--N 1.315 -0.903 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 176.621 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 40.3 tp -57.74 133.71 55.6 Favored 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 177.401 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -53.8 -46.57 71.1 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.145 0.498 . . . . 0.0 110.557 -170.599 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 59.1 mp0 -68.04 -20.33 64.98 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.93 -0.577 . . . . 0.0 112.375 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -73.93 94.84 2.38 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.629 -177.253 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 239' ' ' ARG . . . . . 0.494 ' O ' HD12 ' A' ' 217' ' ' LEU . 77.3 mtp85 -71.44 99.31 1.98 Allowed 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 176.149 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 240' ' ' HIS . . . . . 0.661 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 12.8 p80 -68.2 -42.97 79.1 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 120.791 0.329 . . . . 0.0 111.748 -176.182 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 80.32 14.42 80.31 Favored Glycine 0 C--N 1.315 -0.586 0 N-CA-C 110.791 -0.924 . . . . 0.0 110.791 -178.514 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 242' ' ' PHE . . . . . 0.513 ' CD1' ' HB3' ' A' ' 294' ' ' GLN . 5.2 m-30 -81.0 142.97 32.87 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -179.613 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 243' ' ' GLU . . . . . 0.402 ' H ' ' CB ' ' A' ' 246' ' ' ASP . 95.0 mt-10 -112.19 167.88 10.06 Favored 'General case' 0 CA--C 1.505 -0.76 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 172.882 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 244' ' ' THR . . . . . 0.523 HG23 ' HG3' ' A' ' 268' ' ' LYS . 21.1 m -62.58 126.24 26.65 Favored 'General case' 0 N--CA 1.436 -1.165 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 169.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . 0.5 ' HA2' ' CG ' ' A' ' 266' ' ' GLU . . . 82.04 7.21 88.14 Favored Glycine 0 C--N 1.309 -0.941 0 C-N-CA 120.902 -0.666 . . . . 0.0 111.717 -179.029 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 246' ' ' ASP . . . . . 0.41 ' O ' ' HA ' ' A' ' 266' ' ' GLU . 42.1 t0 -84.87 161.7 19.78 Favored 'General case' 0 C--O 1.235 0.305 0 C-N-CA 120.049 -0.66 . . . . 0.0 109.952 177.798 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 247' ' ' PHE . . . . . 0.472 ' HA ' ' O ' ' A' ' 265' ' ' MET . 30.1 m-85 -109.94 131.7 54.82 Favored 'General case' 0 C--O 1.242 0.702 0 N-CA-C 112.134 0.42 . . . . 0.0 112.134 -174.35 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 248' ' ' VAL . . . . . 0.511 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.7 m -129.92 160.99 40.42 Favored 'Isoleucine or valine' 0 C--O 1.236 0.381 0 CA-C-N 115.89 -0.596 . . . . 0.0 111.884 -179.334 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 3.0 m -126.49 156.0 41.42 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 173.661 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 250' ' ' PHE . . . . . 0.627 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 91.9 m-85 -112.72 146.84 38.01 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-O 120.518 0.199 . . . . 0.0 111.072 -174.059 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 43.4 m -134.4 151.65 51.32 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.105 178.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 4.0 mm-40 41.91 37.12 0.74 Allowed 'General case' 0 C--O 1.245 0.832 0 N-CA-C 113.266 0.839 . . . . 0.0 113.266 174.671 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 0.464 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 79.2 t -89.56 129.98 39.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 174.641 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . 0.574 HE22 ' CZ ' ' A' ' 288' ' ' ARG . 75.3 mt-30 -99.3 141.32 32.23 Favored 'General case' 0 C--O 1.24 0.577 0 C-N-CA 120.523 -0.471 . . . . 0.0 111.222 -178.249 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 79.61 -57.22 4.49 Favored Glycine 0 CA--C 1.507 -0.438 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -177.081 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 256' ' ' MET . . . . . 0.726 ' SD ' HG11 ' A' ' 224' ' ' VAL . 4.2 ttm -86.74 49.59 1.84 Allowed 'General case' 0 C--N 1.314 -0.949 0 CA-C-O 121.911 0.862 . . . . 0.0 108.721 176.344 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 257' ' ' ILE . . . . . 0.481 ' O ' ' HB2' ' A' ' 260' ' ' ASN . 46.5 pt -68.22 -24.32 29.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 114.453 -1.249 . . . . 0.0 110.917 -174.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 258' ' ' GLN . . . . . 0.585 ' HG3' ' SG ' ' A' ' 262' ' ' CYS . 69.2 tp60 -57.68 -30.07 65.17 Favored 'General case' 0 C--N 1.318 -0.795 0 C-N-CA 119.458 -0.897 . . . . 0.0 109.608 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 259' ' ' LEU . . . . . 0.902 HD21 ' CE2' ' A' ' 283' ' ' PHE . 94.3 mt -62.07 -40.21 95.03 Favored 'General case' 0 N--CA 1.448 -0.55 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 174.038 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 260' ' ' ASN . . . . . 0.481 ' HB2' ' O ' ' A' ' 257' ' ' ILE . 96.8 m-20 -60.31 -40.89 92.18 Favored 'General case' 0 CA--C 1.514 -0.431 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 179.58 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -98.33 17.65 58.22 Favored Glycine 0 CA--C 1.525 0.706 0 CA-C-N 115.447 -0.797 . . . . 0.0 112.005 -179.392 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 262' ' ' CYS . . . . . 0.585 ' SG ' ' HG3' ' A' ' 258' ' ' GLN . 1.5 m -93.97 146.59 23.82 Favored 'General case' 0 CA--C 1.508 -0.661 0 C-N-CA 120.579 -0.448 . . . . 0.0 111.032 -179.379 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 46.6 mt-30 -59.81 161.2 12.37 Favored Pre-proline 0 C--N 1.323 -0.548 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 172.277 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 264' ' ' PRO . . . . . 0.511 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 38.0 Cg_endo -63.37 143.39 88.67 Favored 'Trans proline' 0 C--N 1.307 -1.651 0 N-CA-C 108.437 -1.409 . . . . 0.0 108.437 174.974 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 265' ' ' MET . . . . . 0.472 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 22.7 ptp -135.35 152.36 51.37 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 112.071 0.397 . . . . 0.0 112.071 -171.222 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 266' ' ' GLU . . . . . 0.5 ' CG ' ' HA2' ' A' ' 245' ' ' GLY . 39.5 tt0 -71.79 136.94 47.27 Favored 'General case' 0 C--N 1.331 -0.228 0 O-C-N 124.034 0.834 . . . . 0.0 109.516 178.757 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 267' ' ' ILE . . . . . 0.68 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.9 pp -128.3 162.39 34.85 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-O 121.142 0.496 . . . . 0.0 112.1 -179.346 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . 0.523 ' HG3' HG23 ' A' ' 244' ' ' THR . 60.1 tttm -118.98 131.52 56.02 Favored 'General case' 0 C--O 1.219 -0.501 0 CA-C-N 115.66 -0.7 . . . . 0.0 109.541 174.081 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 23.2 m -82.4 128.21 38.93 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.974 0 C-N-CA 120.313 -0.555 . . . . 0.0 110.276 176.822 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 270' ' ' LEU . . . . . 0.547 HD11 ' HB3' ' A' ' 276' ' ' SER . 95.6 mt -98.99 -17.89 18.07 Favored 'General case' 0 CA--C 1.502 -0.871 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 178.298 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -171.27 177.0 44.4 Favored Glycine 0 N--CA 1.443 -0.872 0 N-CA-C 108.546 -1.821 . . . . 0.0 108.546 179.092 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 272' ' ' PRO . . . . . 0.661 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 60.2 Cg_exo -54.07 -38.32 87.09 Favored 'Trans proline' 0 C--N 1.298 -2.091 0 C-N-CA 121.443 1.429 . . . . 0.0 110.559 -179.219 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 8.9 m-85 -118.69 11.57 12.8 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 112.646 0.61 . . . . 0.0 112.646 -174.455 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 22.2 p -130.13 143.59 50.87 Favored 'General case' 0 C--O 1.242 0.675 0 C-N-CA 120.669 -0.413 . . . . 0.0 111.177 177.158 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 275' ' ' PHE . . . . . 0.521 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -146.59 165.85 28.26 Favored 'General case' 0 C--O 1.246 0.869 0 N-CA-C 112.363 0.505 . . . . 0.0 112.363 178.75 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . 0.547 ' HB3' HD11 ' A' ' 270' ' ' LEU . 4.4 p -130.88 143.01 50.42 Favored 'General case' 0 N--CA 1.431 -1.416 0 CA-C-O 121.773 0.797 . . . . 0.0 111.605 -178.695 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 277' ' ' ILE . . . . . 0.624 HG22 HG22 ' A' ' 267' ' ' ILE . 33.8 pt -135.91 165.32 29.95 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.058 0 CA-C-N 114.428 -1.26 . . . . 0.0 110.71 -173.136 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 15.2 t -30.54 -90.71 0.0 OUTLIER 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 112.859 0.689 . . . . 0.0 112.859 -174.874 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . 0.481 ' CG ' ' HB2' ' A' ' 228' ' ' ASN . 66.3 t0 -148.93 117.18 6.43 Favored 'General case' 0 N--CA 1.447 -0.593 0 CA-C-O 120.943 0.402 . . . . 0.0 110.827 -178.91 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . 0.734 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 21.3 p -65.49 -27.33 68.41 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.54 176.56 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -64.35 -19.36 65.41 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.664 175.889 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -88.49 -9.88 50.91 Favored 'General case' 0 CA--C 1.508 -0.655 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.378 179.839 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 283' ' ' PHE . . . . . 0.902 ' CE2' HD21 ' A' ' 259' ' ' LEU . 4.4 m-85 -93.69 -64.96 1.03 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 174.303 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 284' ' ' SER . . . . . 0.422 ' OG ' ' HA ' ' A' ' 256' ' ' MET . 1.9 p 169.43 -94.18 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 115.205 -0.907 . . . . 0.0 111.625 177.242 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 285' ' ' ASP . . . . . 0.531 ' O ' ' N ' ' A' ' 256' ' ' MET . 45.0 t0 -156.19 166.09 34.46 Favored 'General case' 0 C--O 1.214 -0.786 0 N-CA-C 110.409 -0.219 . . . . 0.0 110.409 -177.308 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 286' ' ' TYR . . . . . 0.515 ' CZ ' ' HA ' ' A' ' 288' ' ' ARG . 68.2 t80 -99.61 119.4 38.02 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 110.226 -0.287 . . . . 0.0 110.226 177.359 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 21.1 mm -99.91 -56.44 5.2 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.586 0 N-CA-C 109.114 -0.698 . . . . 0.0 109.114 173.575 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . 0.574 ' CZ ' HE22 ' A' ' 254' ' ' GLN . 45.9 ptt85 177.87 -173.92 0.14 Allowed 'General case' 0 C--O 1.241 0.639 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.145 175.532 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 66.16 -158.93 47.67 Favored Glycine 0 CA--C 1.51 -0.281 0 N-CA-C 111.018 -0.833 . . . . 0.0 111.018 176.619 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 110.6 127.15 5.16 Favored Glycine 0 N--CA 1.447 -0.592 0 CA-C-O 121.52 0.511 . . . . 0.0 112.988 175.224 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 94.2 mt -130.32 133.07 64.5 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.807 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 174.312 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 3.8 p -124.52 134.29 67.14 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 C-N-CA 120.442 -0.503 . . . . 0.0 109.669 -177.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . 0.477 ' HA ' ' O ' ' A' ' 217' ' ' LEU . 2.6 m -127.23 145.43 50.77 Favored 'General case' 0 C--N 1.324 -0.532 0 C-N-CA 120.488 -0.485 . . . . 0.0 111.042 -178.364 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 294' ' ' GLN . . . . . 0.513 ' HB3' ' CD1' ' A' ' 242' ' ' PHE . 0.3 OUTLIER . . . . . 0 CA--C 1.508 -0.659 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.185 176.661 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 217' ' ' LEU . . . . . 0.476 HD12 ' O ' ' A' ' 240' ' ' HIS . 0.1 OUTLIER . . . . . 0 CA--C 1.513 -0.473 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 . . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 4.6 m -126.3 147.95 49.62 Favored 'General case' 0 C--N 1.313 -1.011 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.335 -176.374 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 219' ' ' ALA . . . . . 0.487 ' HB1' ' HB1' ' A' ' 238' ' ' ALA . . . -152.5 153.8 34.22 Favored 'General case' 0 C--O 1.24 0.605 0 CA-C-O 121.112 0.482 . . . . 0.0 111.062 -178.709 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 71.3 mtm -80.15 129.67 34.66 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.652 -0.703 . . . . 0.0 109.662 175.9 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 57.5 t -76.29 131.24 35.25 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.694 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 177.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 46.8 p -88.72 -65.84 0.98 Allowed 'General case' 0 C--N 1.309 -1.169 0 C-N-CA 120.325 -0.55 . . . . 0.0 110.024 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 23.3 ptm -137.73 142.43 40.99 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.923 -0.58 . . . . 0.0 112.205 176.581 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 224' ' ' VAL . . . . . 0.885 HG22 ' HB ' ' A' ' 232' ' ' VAL . 75.0 t -119.89 133.57 66.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 177.294 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 225' ' ' THR . . . . . 0.478 ' O ' ' OG1' ' A' ' 280' ' ' THR . 62.7 p -98.5 128.6 44.91 Favored 'General case' 0 C--N 1.323 -0.569 0 C-N-CA 120.234 -0.587 . . . . 0.0 110.974 -179.517 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.86 85.76 3.44 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 177.908 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 227' ' ' ASP . . . . . 0.403 ' OD1' ' N ' ' A' ' 228' ' ' ASN . 2.6 t0 -152.04 175.82 12.15 Favored 'General case' 0 N--CA 1.469 0.521 0 CA-C-N 116.476 -0.329 . . . . 0.0 111.39 -175.495 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 228' ' ' ASN . . . . . 0.502 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 9.4 t30 -140.69 124.09 10.17 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.508 174.625 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 229' ' ' PRO . . . . . 0.502 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 40.4 Cg_endo -65.22 142.24 52.16 Favored 'Cis proline' 0 N--CA 1.493 1.488 0 C-N-CA 122.702 -1.791 . . . . 0.0 109.854 -1.12 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . 0.493 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -74.39 136.84 21.84 Favored Glycine 0 C--N 1.315 -0.629 0 N-CA-C 110.575 -1.01 . . . . 0.0 110.575 -176.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.1 p -127.69 137.74 56.75 Favored 'Isoleucine or valine' 0 C--O 1.248 0.997 0 CA-C-O 120.807 0.337 . . . . 0.0 110.697 177.574 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 232' ' ' VAL . . . . . 0.885 ' HB ' HG22 ' A' ' 224' ' ' VAL . 0.7 OUTLIER -132.28 157.17 43.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.951 179.292 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 233' ' ' THR . . . . . 0.47 ' HA ' ' O ' ' A' ' 273' ' ' TYR . 0.9 OUTLIER -114.36 146.96 39.88 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.388 -178.836 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 34.0 m -107.31 152.24 24.4 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.111 -0.495 . . . . 0.0 109.948 179.263 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . 0.482 ' HB3' ' HB3' ' A' ' 238' ' ' ALA . 15.7 tp -51.72 135.09 29.78 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 -178.881 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 24.7 p-10 -48.63 -47.44 40.2 Favored 'General case' 0 N--CA 1.475 0.793 0 N-CA-C 111.936 0.347 . . . . 0.0 111.936 -171.838 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -70.51 -34.65 72.55 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-O 120.944 0.402 . . . . 0.0 111.62 178.218 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 238' ' ' ALA . . . . . 0.487 ' HB1' ' HB1' ' A' ' 219' ' ' ALA . . . -83.96 89.42 7.23 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.262 -176.615 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 239' ' ' ARG . . . . . 0.52 ' NH1' ' O ' ' A' ' 239' ' ' ARG . 0.0 OUTLIER -78.83 123.16 26.94 Favored 'General case' 0 CA--C 1.513 -0.443 0 N-CA-C 108.771 -0.825 . . . . 0.0 108.771 173.698 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 240' ' ' HIS . . . . . 0.602 ' H ' ' CD2' ' A' ' 240' ' ' HIS . 7.0 p80 -57.13 -48.71 77.98 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.397 -175.818 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 80.01 19.93 68.84 Favored Glycine 0 C--N 1.314 -0.666 0 N-CA-C 110.131 -1.188 . . . . 0.0 110.131 -177.674 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 242' ' ' PHE . . . . . 0.681 ' CD2' HG11 ' A' ' 248' ' ' VAL . 8.3 m-30 -81.53 151.87 27.54 Favored 'General case' 0 C--N 1.316 -0.877 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 177.946 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -116.19 160.78 19.92 Favored 'General case' 0 C--N 1.314 -0.935 0 CA-C-O 120.893 0.378 . . . . 0.0 110.887 177.491 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 244' ' ' THR . . . . . 0.527 HG23 HG22 ' A' ' 269' ' ' VAL . 0.0 OUTLIER -58.84 125.88 25.37 Favored 'General case' 0 C--N 1.312 -1.029 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 -179.65 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 80.86 5.81 89.83 Favored Glycine 0 C--N 1.319 -0.365 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 -178.326 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 246' ' ' ASP . . . . . 0.509 ' CG ' HE21 ' A' ' 294' ' ' GLN . 5.3 t70 -79.86 162.34 25.09 Favored 'General case' 0 CA--C 1.514 -0.42 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 178.416 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 247' ' ' PHE . . . . . . . . . . . . . 78.0 m-85 -109.78 129.04 55.67 Favored 'General case' 0 C--O 1.242 0.708 0 CA-C-O 120.846 0.355 . . . . 0.0 111.191 -177.488 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 248' ' ' VAL . . . . . 0.681 HG11 ' CD2' ' A' ' 242' ' ' PHE . 2.4 m -129.95 162.26 38.01 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.399 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.364 178.369 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.48 145.82 46.87 Favored 'General case' 0 C--N 1.308 -1.226 0 CA-C-N 115.324 -0.853 . . . . 0.0 109.982 177.363 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 250' ' ' PHE . . . . . 0.649 ' CD2' HD22 ' A' ' 259' ' ' LEU . 67.5 m-85 -104.81 145.68 30.04 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.65 177.701 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 4.3 m -143.36 150.12 38.69 Favored 'General case' 0 C--N 1.309 -1.153 0 N-CA-C 110.084 -0.339 . . . . 0.0 110.084 176.07 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 23.7 mm-40 54.1 26.78 6.86 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 112.816 0.673 . . . . 0.0 112.816 173.07 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 0.517 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 88.0 t -76.53 130.93 35.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 173.702 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 86.5 mm-40 -100.45 139.72 35.72 Favored 'General case' 0 C--O 1.244 0.765 0 C-N-CA 119.68 -0.808 . . . . 0.0 111.651 -176.152 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 78.71 -58.16 4.21 Favored Glycine 0 C--O 1.239 0.453 0 N-CA-C 108.983 -1.647 . . . . 0.0 108.983 -173.688 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 256' ' ' MET . . . . . 0.566 ' SD ' HG11 ' A' ' 224' ' ' VAL . 31.7 mtt -80.57 61.04 4.14 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-O 121.242 0.544 . . . . 0.0 109.788 172.682 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 257' ' ' ILE . . . . . 0.401 ' O ' ' HB2' ' A' ' 260' ' ' ASN . 41.8 pt -76.23 -15.78 15.14 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.731 -178.512 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 258' ' ' GLN . . . . . 0.414 ' O ' ' N ' ' A' ' 262' ' ' CYS . 70.5 tp60 -55.38 -39.31 69.99 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 179.423 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 259' ' ' LEU . . . . . 0.91 HD21 ' CE2' ' A' ' 283' ' ' PHE . 89.0 mt -61.86 -41.71 98.17 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.747 -0.661 . . . . 0.0 109.925 176.908 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 260' ' ' ASN . . . . . 0.517 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 97.9 m-20 -61.29 -40.58 94.67 Favored 'General case' 0 CA--C 1.509 -0.612 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 179.347 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -87.66 -5.67 78.0 Favored Glycine 0 CA--C 1.523 0.538 0 CA-C-N 115.529 -0.76 . . . . 0.0 111.496 -178.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 262' ' ' CYS . . . . . 0.414 ' N ' ' O ' ' A' ' 258' ' ' GLN . 49.0 t -87.98 150.58 23.36 Favored 'General case' 0 CA--C 1.512 -0.493 0 CA-C-O 120.765 0.317 . . . . 0.0 111.062 -178.285 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . 0.642 ' CD ' ' H ' ' A' ' 263' ' ' GLN . 0.0 OUTLIER -72.45 169.39 17.09 Favored Pre-proline 0 C--N 1.319 -0.758 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 172.631 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 264' ' ' PRO . . . . . 0.454 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 27.7 Cg_exo -61.76 145.12 97.5 Favored 'Trans proline' 0 C--N 1.307 -1.608 0 C-N-CA 121.462 1.441 . . . . 0.0 109.983 179.099 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 265' ' ' MET . . . . . 0.655 ' N ' ' SD ' ' A' ' 265' ' ' MET . 0.8 OUTLIER -122.83 157.26 32.85 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 -176.466 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 266' ' ' GLU . . . . . 0.403 ' HA ' ' O ' ' A' ' 246' ' ' ASP . 64.1 tt0 -75.94 134.85 40.12 Favored 'General case' 0 C--O 1.238 0.493 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 175.513 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 267' ' ' ILE . . . . . 0.703 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.9 pp -128.66 163.3 33.63 Favored 'Isoleucine or valine' 0 C--O 1.237 0.405 0 N-CA-C 114.095 1.146 . . . . 0.0 114.095 -170.495 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . 0.493 ' NZ ' ' OG ' ' A' ' 276' ' ' SER . 8.0 mtpm? -119.36 123.31 43.84 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-N 115.009 -0.996 . . . . 0.0 110.065 178.737 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.527 HG22 HG23 ' A' ' 244' ' ' THR . 30.1 m -84.59 97.93 5.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-O 121.087 0.47 . . . . 0.0 111.236 177.056 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 91.9 mt -66.79 -40.4 88.14 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.528 0.68 . . . . 0.0 109.747 176.38 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -155.33 -177.85 28.99 Favored Glycine 0 N--CA 1.447 -0.624 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 -179.827 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 272' ' ' PRO . . . . . 0.5 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 35.6 Cg_endo -61.32 -30.88 88.49 Favored 'Trans proline' 0 C--N 1.306 -1.702 0 C-N-CA 122.066 1.844 . . . . 0.0 111.471 -178.519 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 273' ' ' TYR . . . . . 0.47 ' O ' ' HA ' ' A' ' 233' ' ' THR . 94.5 m-85 -122.85 7.0 9.33 Favored 'General case' 0 C--N 1.319 -0.733 0 N-CA-C 112.942 0.719 . . . . 0.0 112.942 -178.497 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 4.3 p -126.84 129.02 47.45 Favored 'General case' 0 C--O 1.244 0.816 0 CA-C-O 120.884 0.374 . . . . 0.0 110.835 178.031 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 275' ' ' PHE . . . . . 0.518 ' HD2' HD13 ' A' ' 267' ' ' ILE . 0.0 OUTLIER -139.41 160.47 39.76 Favored 'General case' 0 CA--C 1.499 -0.986 0 C-N-CA 120.446 -0.502 . . . . 0.0 112.206 177.281 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . 0.493 ' OG ' ' NZ ' ' A' ' 268' ' ' LYS . 10.9 p -130.79 154.49 47.95 Favored 'General case' 0 N--CA 1.43 -1.427 0 CA-C-O 121.456 0.646 . . . . 0.0 111.953 -175.11 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 277' ' ' ILE . . . . . 0.672 ' C ' HD12 ' A' ' 277' ' ' ILE . 2.5 pp -138.19 -172.48 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.154 0 CA-C-N 114.313 -1.312 . . . . 0.0 108.961 -176.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 278' ' ' CYS . . . . . 0.524 ' N ' HD12 ' A' ' 277' ' ' ILE . 0.5 OUTLIER -48.14 -85.93 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.751 0.31 . . . . 0.0 111.708 -178.245 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 31.7 t0 -145.0 115.45 7.62 Favored 'General case' 0 CA--C 1.515 -0.397 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.534 -177.625 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . 0.69 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 12.6 p -71.42 -22.66 61.83 Favored 'General case' 0 N--CA 1.432 -1.37 0 CA-C-O 121.108 0.48 . . . . 0.0 109.77 176.294 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -67.37 -19.85 65.48 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 174.765 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 26.8 t-20 -89.2 -9.16 51.83 Favored 'General case' 0 CA--C 1.505 -0.752 0 CA-C-N 115.662 -0.699 . . . . 0.0 109.637 178.408 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 283' ' ' PHE . . . . . 0.91 ' CE2' HD21 ' A' ' 259' ' ' LEU . 22.8 m-30 -84.28 -79.0 0.22 Allowed 'General case' 0 N--CA 1.441 -0.906 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 174.612 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 284' ' ' SER . . . . . 0.436 ' CB ' ' HA ' ' A' ' 256' ' ' MET . 0.0 OUTLIER 175.01 -165.21 0.03 OUTLIER 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 114.892 -1.049 . . . . 0.0 109.589 -175.674 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 27.7 t0 -92.81 118.64 31.32 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.643 0.259 . . . . 0.0 111.301 178.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 286' ' ' TYR . . . . . 0.493 ' HB2' ' SD ' ' A' ' 256' ' ' MET . 6.1 t80 -68.86 122.0 17.73 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.6 179.341 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 96.4 mt -103.0 -59.9 3.15 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 175.027 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 50.8 ptt85 179.7 -163.04 0.04 OUTLIER 'General case' 0 C--O 1.24 0.553 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.397 174.755 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 68.83 -147.93 47.3 Favored Glycine 0 C--O 1.237 0.336 0 N-CA-C 109.811 -1.316 . . . . 0.0 109.811 -179.05 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 87.13 122.11 1.53 Allowed Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.823 175.111 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 97.7 mt -118.19 128.9 75.18 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.137 0 N-CA-C 107.262 -1.385 . . . . 0.0 107.262 172.346 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 14.9 p -116.94 128.92 74.24 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 -179.658 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 3.4 m -134.52 143.52 47.49 Favored 'General case' 0 N--CA 1.439 -0.996 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.409 -176.903 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 294' ' ' GLN . . . . . 0.509 HE21 ' CG ' ' A' ' 246' ' ' ASP . 52.6 tt0 . . . . . 0 N--CA 1.432 -1.358 0 CA-C-N 115.378 -0.828 . . . . 0.0 108.924 173.88 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 217' ' ' LEU . . . . . 0.459 HD22 ' HA ' ' A' ' 217' ' ' LEU . 0.3 OUTLIER . . . . . 0 CA--C 1.515 -0.395 0 CA-C-O 120.764 0.316 . . . . 0.0 111.242 . . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 96.4 p -155.06 164.3 39.07 Favored 'General case' 0 N--CA 1.446 -0.652 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.258 -177.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -154.5 163.22 40.52 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-N 115.548 -0.751 . . . . 0.0 109.682 177.246 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 8.4 ttt -78.78 127.0 31.47 Favored 'General case' 0 N--CA 1.436 -1.144 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 175.703 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 98.0 t -69.22 130.13 33.98 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.174 0 N-CA-C 107.726 -1.213 . . . . 0.0 107.726 178.017 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -84.6 -70.36 0.58 Allowed 'General case' 0 N--CA 1.432 -1.331 0 C-N-CA 120.211 -0.596 . . . . 0.0 109.922 179.649 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 8.5 ptm -138.08 146.25 42.71 Favored 'General case' 0 N--CA 1.47 0.536 0 N-CA-C 112.446 0.536 . . . . 0.0 112.446 174.827 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 224' ' ' VAL . . . . . 0.8 HG22 ' HB ' ' A' ' 232' ' ' VAL . 53.1 t -121.94 132.85 70.01 Favored 'Isoleucine or valine' 0 C--O 1.239 0.537 0 C-N-CA 122.814 0.446 . . . . 0.0 110.557 178.97 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 39.2 p -88.25 133.0 34.16 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.554 -0.293 . . . . 0.0 110.694 178.731 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 15.9 tttm -82.11 80.16 8.42 Favored 'General case' 0 C--O 1.241 0.623 0 C-N-CA 120.349 -0.54 . . . . 0.0 110.014 177.549 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 227' ' ' ASP . . . . . 0.605 ' N ' ' OG1' ' A' ' 280' ' ' THR . 2.2 t0 -154.3 -179.86 8.32 Favored 'General case' 0 C--O 1.247 0.93 0 CA-C-N 115.391 -0.822 . . . . 0.0 111.2 178.853 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 228' ' ' ASN . . . . . 0.523 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.4 OUTLIER -141.77 125.48 9.91 Favored Pre-proline 0 C--N 1.324 -0.502 0 CA-C-N 115.529 -0.759 . . . . 0.0 109.645 176.747 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 229' ' ' PRO . . . . . 0.523 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 42.6 Cg_endo -64.71 142.32 50.21 Favored 'Cis proline' 0 N--CA 1.491 1.379 0 C-N-CA 122.995 -1.669 . . . . 0.0 110.198 -0.651 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 230' ' ' GLY . . . . . 0.562 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -74.42 138.89 24.84 Favored Glycine 0 C--N 1.308 -0.981 0 N-CA-C 109.912 -1.275 . . . . 0.0 109.912 -178.531 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.2 p -125.08 130.98 73.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 176.271 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 232' ' ' VAL . . . . . 0.8 ' HB ' HG22 ' A' ' 224' ' ' VAL . 0.7 OUTLIER -133.64 156.54 41.55 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 C-N-CA 120.502 -0.479 . . . . 0.0 110.494 -177.255 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 233' ' ' THR . . . . . 0.427 ' HA ' ' O ' ' A' ' 273' ' ' TYR . 2.4 m -105.35 149.27 26.22 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 115.268 -0.878 . . . . 0.0 109.321 177.777 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 2.6 m -113.08 147.26 37.66 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 175.478 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 33.7 tp -53.7 113.92 1.36 Allowed 'General case' 0 C--N 1.312 -1.065 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 178.623 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 36.7 p-10 -63.1 -10.38 14.41 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.94 -170.87 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 76.5 mm-40 -65.47 -32.76 74.55 Favored 'General case' 0 C--N 1.312 -1.048 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.231 177.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -121.45 133.52 55.06 Favored 'General case' 0 C--O 1.233 0.223 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.839 -177.868 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 239' ' ' ARG . . . . . 0.552 ' NH1' ' O ' ' A' ' 242' ' ' PHE . 0.1 OUTLIER -77.87 112.57 14.89 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 173.439 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 240' ' ' HIS . . . . . 0.605 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 2.8 p80 -43.19 -34.2 1.08 Allowed 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 121.133 0.492 . . . . 0.0 109.988 -179.011 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 87.19 8.36 75.25 Favored Glycine 0 CA--C 1.503 -0.669 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 179.724 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 242' ' ' PHE . . . . . 0.552 ' O ' ' NH1' ' A' ' 239' ' ' ARG . 5.7 m-30 -81.82 146.16 30.04 Favored 'General case' 0 N--CA 1.444 -0.772 0 CA-C-O 120.85 0.357 . . . . 0.0 110.19 -179.192 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 243' ' ' GLU . . . . . 0.421 ' OE2' ' NH2' ' A' ' 239' ' ' ARG . 64.9 mm-40 -121.67 167.99 12.3 Favored 'General case' 0 C--N 1.309 -1.19 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.431 176.446 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 17.7 m -61.1 124.15 19.72 Favored 'General case' 0 C--N 1.298 -1.633 0 C-N-CA 120.152 -0.619 . . . . 0.0 109.718 -178.682 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 245' ' ' GLY . . . . . 0.41 ' HA2' ' CG ' ' A' ' 266' ' ' GLU . . . 82.64 7.39 87.49 Favored Glycine 0 CA--C 1.523 0.578 0 CA-C-N 116.192 -0.458 . . . . 0.0 112.066 179.312 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 246' ' ' ASP . . . . . 0.44 ' OD1' ' N ' ' A' ' 247' ' ' PHE . 40.3 t0 -74.41 162.15 29.13 Favored 'General case' 0 C--O 1.238 0.482 0 CA-C-N 117.44 0.62 . . . . 0.0 109.457 177.809 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 247' ' ' PHE . . . . . 0.44 ' N ' ' OD1' ' A' ' 246' ' ' ASP . 78.3 m-85 -109.31 131.05 55.43 Favored 'General case' 0 C--N 1.316 -0.849 0 N-CA-C 109.705 -0.479 . . . . 0.0 109.705 -179.27 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 248' ' ' VAL . . . . . 0.433 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 3.1 m -129.04 163.29 34.48 Favored 'Isoleucine or valine' 0 C--O 1.24 0.602 0 CA-C-O 121.027 0.441 . . . . 0.0 112.058 -177.251 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 9.6 p -133.91 162.04 33.13 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 114.522 -1.217 . . . . 0.0 108.905 175.172 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 250' ' ' PHE . . . . . 0.595 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 82.1 m-85 -124.37 159.36 30.52 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.087 0.47 . . . . 0.0 111.831 -169.231 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 20.2 m -158.42 160.0 36.36 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.192 177.489 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 78.0 mm-40 52.17 20.39 1.31 Allowed 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 113.234 0.827 . . . . 0.0 113.234 175.971 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 253' ' ' VAL . . . . . 0.43 HG22 ' CA ' ' A' ' 290' ' ' GLY . 12.4 t -85.94 131.06 35.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 175.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 87.5 mt-30 -96.93 144.06 27.21 Favored 'General case' 0 C--O 1.24 0.56 0 C-N-CA 120.666 -0.413 . . . . 0.0 110.649 -179.689 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 77.75 -57.43 3.86 Favored Glycine 0 CA--C 1.509 -0.321 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -177.158 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 256' ' ' MET . . . . . 0.522 ' HG2' ' HB3' ' A' ' 283' ' ' PHE . 15.3 ttm -85.81 55.84 3.7 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-O 121.493 0.663 . . . . 0.0 109.446 175.684 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 44.4 pt -73.93 -18.1 17.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.036 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 3.5 tp60 -54.1 -39.04 66.02 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 108.231 -1.026 . . . . 0.0 108.231 178.157 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 259' ' ' LEU . . . . . 0.846 HD21 ' CE2' ' A' ' 283' ' ' PHE . 85.5 mt -62.16 -41.67 98.52 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.121 177.07 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 97.2 m-20 -59.98 -40.53 89.45 Favored 'General case' 0 CA--C 1.506 -0.734 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 -176.436 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -102.27 14.75 56.77 Favored Glycine 0 CA--C 1.523 0.552 0 CA-C-N 115.787 -0.642 . . . . 0.0 112.235 -179.603 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 262' ' ' CYS . . . . . 0.439 ' HB2' ' HA ' ' A' ' 259' ' ' LEU . 1.1 m -91.16 158.83 16.4 Favored 'General case' 0 CA--C 1.513 -0.456 0 CA-C-N 117.469 0.634 . . . . 0.0 111.684 -178.005 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -76.59 151.25 82.69 Favored Pre-proline 0 C--N 1.323 -0.553 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 173.927 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 264' ' ' PRO . . . . . 0.433 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 49.5 Cg_endo -64.01 147.11 91.82 Favored 'Trans proline' 0 C--N 1.306 -1.668 0 C-N-CA 121.76 1.64 . . . . 0.0 112.052 -176.177 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 265' ' ' MET . . . . . 0.502 ' SD ' ' HZ ' ' A' ' 283' ' ' PHE . 7.8 ptp -134.07 157.4 46.22 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 112.484 0.55 . . . . 0.0 112.484 -173.661 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 266' ' ' GLU . . . . . 0.481 ' OE2' ' NZ ' ' A' ' 268' ' ' LYS . 39.6 tt0 -73.57 141.55 46.64 Favored 'General case' 0 C--O 1.241 0.631 0 O-C-N 124.006 0.816 . . . . 0.0 109.846 177.015 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 267' ' ' ILE . . . . . 0.681 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.8 pp -130.66 163.58 36.05 Favored 'Isoleucine or valine' 0 C--O 1.237 0.445 0 N-CA-C 112.114 0.413 . . . . 0.0 112.114 -177.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 268' ' ' LYS . . . . . 0.481 ' NZ ' ' OE2' ' A' ' 266' ' ' GLU . 45.1 mmtm -124.88 127.35 46.97 Favored 'General case' 0 CA--C 1.541 0.628 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 174.555 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.482 HG23 ' O ' ' A' ' 269' ' ' VAL . 27.2 m -83.64 98.27 5.3 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.612 0 CA-C-O 120.887 0.375 . . . . 0.0 111.507 -179.818 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 98.6 mt -65.73 -42.46 90.99 Favored 'General case' 0 CA--C 1.513 -0.46 0 CA-C-O 121.399 0.619 . . . . 0.0 109.577 178.137 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -145.04 176.44 24.08 Favored Glycine 0 C--N 1.314 -0.693 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 178.499 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 272' ' ' PRO . . . . . 0.605 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 67.9 Cg_exo -54.03 -40.05 82.86 Favored 'Trans proline' 0 C--N 1.305 -1.72 0 C-N-CA 122.159 1.906 . . . . 0.0 111.068 -178.805 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 273' ' ' TYR . . . . . 0.427 ' O ' ' HA ' ' A' ' 233' ' ' THR . 6.9 m-85 -115.71 8.96 15.08 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.623 -176.062 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.7 p -126.74 124.97 40.97 Favored 'General case' 0 C--O 1.247 0.937 0 CA-C-O 121.047 0.451 . . . . 0.0 111.431 179.284 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 275' ' ' PHE . . . . . 0.536 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -133.09 164.72 26.39 Favored 'General case' 0 CA--C 1.494 -1.189 0 C-N-CA 120.492 -0.483 . . . . 0.0 112.224 177.95 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . 0.5 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 13.7 p -132.12 152.4 51.26 Favored 'General case' 0 N--CA 1.432 -1.347 0 C-N-CA 120.436 -0.506 . . . . 0.0 110.944 -176.382 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 277' ' ' ILE . . . . . 0.628 HG22 HG22 ' A' ' 267' ' ' ILE . 0.2 OUTLIER -138.26 -169.19 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.195 0 CA-C-N 115.258 -0.883 . . . . 0.0 110.564 -175.185 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 12.9 m -58.32 -75.64 0.05 OUTLIER 'General case' 0 CA--C 1.536 0.438 0 N-CA-C 112.941 0.719 . . . . 0.0 112.941 -175.273 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 279' ' ' ASP . . . . . 0.425 ' HB3' ' HB2' ' A' ' 282' ' ' ASN . 66.7 t0 -154.99 114.78 3.74 Favored 'General case' 0 N--CA 1.45 -0.441 0 O-C-N 122.266 -0.271 . . . . 0.0 111.122 -175.276 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . 0.678 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 21.5 p -66.89 -29.52 69.43 Favored 'General case' 0 C--N 1.303 -1.417 0 CA-C-O 121.101 0.477 . . . . 0.0 110.262 174.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 281' ' ' SER . . . . . 0.416 ' N ' ' OD1' ' A' ' 279' ' ' ASP . 0.3 OUTLIER -62.28 -19.45 63.26 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 115.29 -0.868 . . . . 0.0 109.125 174.794 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 282' ' ' ASN . . . . . 0.425 ' HB2' ' HB3' ' A' ' 279' ' ' ASP . 2.1 m-80 -88.48 -8.48 54.82 Favored 'General case' 0 CA--C 1.507 -0.703 0 N-CA-C 109.454 -0.572 . . . . 0.0 109.454 175.163 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 283' ' ' PHE . . . . . 0.846 ' CE2' HD21 ' A' ' 259' ' ' LEU . 12.2 m-30 -98.82 -83.35 0.42 Allowed 'General case' 0 N--CA 1.442 -0.843 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 174.8 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 284' ' ' SER . . . . . 0.416 ' H ' ' HB2' ' A' ' 283' ' ' PHE . 0.2 OUTLIER 172.88 -162.02 0.02 OUTLIER 'General case' 0 N--CA 1.448 -0.535 0 C-N-CA 124.908 1.283 . . . . 0.0 107.929 -178.998 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 9.4 p-10 -91.64 169.99 10.28 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.666 0.27 . . . . 0.0 110.631 175.618 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 86.2 t80 -106.85 120.98 43.48 Favored 'General case' 0 C--O 1.239 0.531 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.199 179.731 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 287' ' ' ILE . . . . . 0.485 ' O ' ' HG3' ' A' ' 288' ' ' ARG . 96.9 mt -93.32 -57.67 4.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 109.993 -0.373 . . . . 0.0 109.993 175.413 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 288' ' ' ARG . . . . . 0.485 ' HG3' ' O ' ' A' ' 287' ' ' ILE . 15.9 mtm180 -178.9 179.05 0.72 Allowed 'General case' 0 C--O 1.243 0.722 0 C-N-CA 124.525 1.13 . . . . 0.0 110.122 177.773 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 69.52 -163.14 51.75 Favored Glycine 0 C--O 1.235 0.21 0 N-CA-C 111.275 -0.73 . . . . 0.0 111.275 175.903 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 290' ' ' GLY . . . . . 0.43 ' CA ' HG22 ' A' ' 253' ' ' VAL . . . 113.68 128.23 4.72 Favored Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 121.251 -0.5 . . . . 0.0 113.076 175.686 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 98.5 mt -124.42 132.11 71.81 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.858 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 172.751 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . 0.415 HG22 ' CZ ' ' A' ' 242' ' ' PHE . 5.5 p -125.33 137.69 56.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -178.189 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 4.4 m -132.18 147.0 52.4 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.299 -177.299 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 CA--C 1.507 -0.7 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 173.318 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . 0.517 ' C ' ' H ' ' A' ' 203' ' ' GLY . 1.7 mp0 . . . . . 0 N--CA 1.479 1.021 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 13.9 m-85 65.02 -33.1 0.15 Allowed 'General case' 0 N--CA 1.475 0.784 0 C-N-CA 122.824 0.45 . . . . 0.0 111.754 178.296 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . 0.517 ' H ' ' C ' ' A' ' 201' ' ' GLU . . . -60.81 -35.14 89.51 Favored Glycine 0 C--O 1.213 -1.205 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 177.3 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 204' ' ' GLU . . . . . 0.494 ' OE1' ' N ' ' A' ' 201' ' ' GLU . 1.8 mp0 -54.76 -45.21 74.19 Favored 'General case' 0 C--N 1.315 -0.897 0 N-CA-C 108.258 -1.016 . . . . 0.0 108.258 177.739 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -72.02 -44.28 63.66 Favored 'General case' 0 N--CA 1.444 -0.749 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.108 173.358 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 78.0 mtm -95.38 69.84 3.11 Favored 'General case' 0 C--O 1.24 0.574 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.583 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . 0.475 HG12 ' O ' ' A' ' 204' ' ' GLU . 9.9 p -149.21 149.95 14.37 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.054 0 CA-C-N 115.707 -0.679 . . . . 0.0 109.654 175.147 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 208' ' ' LEU . . . . . 0.499 ' C ' ' H ' ' A' ' 210' ' ' ASP . 89.4 mt -71.71 144.01 49.46 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-O 121.015 0.436 . . . . 0.0 110.557 178.534 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 7.9 p -74.58 34.39 0.1 Allowed 'General case' 0 C--N 1.306 -1.287 0 CA-C-N 115.425 -0.807 . . . . 0.0 110.021 175.397 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 210' ' ' ASP . . . . . 0.499 ' H ' ' C ' ' A' ' 208' ' ' LEU . 18.2 p-10 -50.28 -28.47 7.82 Favored 'General case' 0 CA--C 1.512 -0.504 0 CA-C-N 115.408 -0.815 . . . . 0.0 110.641 -174.805 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -60.6 94.17 0.03 OUTLIER 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 173.256 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 212' ' ' ASN . . . . . 0.518 ' C ' ' H ' ' A' ' 214' ' ' GLU . 17.7 t30 -85.33 105.09 15.73 Favored 'General case' 0 CA--C 1.507 -0.698 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.277 -173.679 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 66.82 -39.24 0.18 Allowed Glycine 0 CA--C 1.526 0.733 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -176.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 214' ' ' GLU . . . . . 0.518 ' H ' ' C ' ' A' ' 212' ' ' ASN . 74.8 mm-40 -71.18 110.1 5.63 Favored 'General case' 0 N--CA 1.446 -0.672 0 N-CA-C 110.197 -0.298 . . . . 0.0 110.197 178.911 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -95.23 150.85 38.22 Favored Pre-proline 0 C--N 1.317 -0.846 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 172.669 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -57.79 139.23 89.62 Favored 'Trans proline' 0 C--N 1.3 -1.982 0 N-CA-C 109.406 -1.036 . . . . 0.0 109.406 179.131 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 217' ' ' LEU . . . . . 0.545 HD13 ' N ' ' A' ' 218' ' ' SER . 0.2 OUTLIER -86.16 124.46 32.6 Favored 'General case' 0 CA--C 1.505 -0.77 0 N-CA-C 106.439 -1.689 . . . . 0.0 106.439 178.586 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 218' ' ' SER . . . . . 0.545 ' N ' HD13 ' A' ' 217' ' ' LEU . 50.3 m -113.84 146.78 39.48 Favored 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 -173.506 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 219' ' ' ALA . . . . . 0.895 ' HB1' ' HB1' ' A' ' 238' ' ' ALA . . . -138.73 148.69 44.21 Favored 'General case' 0 C--O 1.243 0.742 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.099 -174.278 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 97.4 mmm -74.63 125.15 28.04 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.599 -0.728 . . . . 0.0 109.873 176.26 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 60.1 t -87.06 129.11 39.08 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.948 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 177.136 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -83.87 -69.96 0.6 Allowed 'General case' 0 N--CA 1.433 -1.309 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 176.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -138.12 156.29 47.9 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.274 174.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 224' ' ' VAL . . . . . 0.56 ' CG1' ' SD ' ' A' ' 256' ' ' MET . 62.0 t -122.48 133.58 68.26 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.946 0 N-CA-C 108.18 -1.045 . . . . 0.0 108.18 173.488 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -102.83 121.91 43.43 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-O 120.555 0.217 . . . . 0.0 110.603 -175.842 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 226' ' ' LYS . . . . . 0.416 ' HA ' ' OG1' ' A' ' 280' ' ' THR . 0.4 OUTLIER -70.52 89.67 0.71 Allowed 'General case' 0 C--O 1.242 0.704 0 CA-C-O 120.966 0.412 . . . . 0.0 109.967 178.979 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 227' ' ' ASP . . . . . 0.431 ' OD1' ' N ' ' A' ' 228' ' ' ASN . 52.9 t0 -158.47 171.69 19.69 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.492 -0.776 . . . . 0.0 109.993 -176.789 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 228' ' ' ASN . . . . . 0.454 ' HB2' ' CG ' ' A' ' 279' ' ' ASP . 0.7 OUTLIER -136.16 123.32 14.46 Favored Pre-proline 0 C--N 1.325 -0.459 0 CA-C-N 116.576 -0.284 . . . . 0.0 110.544 175.192 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 229' ' ' PRO . . . . . 0.452 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 45.7 Cg_endo -65.89 146.5 71.49 Favored 'Cis proline' 0 N--CA 1.494 1.538 0 C-N-CA 122.783 -1.757 . . . . 0.0 109.22 -1.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . 0.536 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -68.43 144.06 41.8 Favored Glycine 0 C--O 1.219 -0.812 0 N-CA-C 109.787 -1.325 . . . . 0.0 109.787 -177.72 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 231' ' ' VAL . . . . . 0.45 HG23 HD12 ' A' ' 270' ' ' LEU . 2.5 p -128.12 134.95 64.02 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 CA-C-N 116.989 0.394 . . . . 0.0 110.079 178.168 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 232' ' ' VAL . . . . . 0.5 HG12 HG13 ' A' ' 224' ' ' VAL . 0.6 OUTLIER -133.8 156.44 41.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 C-N-CA 120.428 -0.509 . . . . 0.0 110.836 -179.817 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 24.5 m -117.49 134.3 55.01 Favored 'General case' 0 C--O 1.242 0.693 0 CA-C-N 115.998 -0.546 . . . . 0.0 109.683 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.8 m -106.4 158.58 16.79 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.961 -175.372 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.485 ' O ' ' HB3' ' A' ' 238' ' ' ALA . 22.8 tp -63.29 150.79 42.39 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.226 -0.897 . . . . 0.0 108.686 179.225 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -59.63 -39.7 85.16 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 121.089 0.471 . . . . 0.0 109.847 -177.697 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 237' ' ' GLU . . . . . 0.447 ' O ' ' N ' ' A' ' 239' ' ' ARG . 98.8 mt-10 -70.53 -21.09 62.76 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.16 174.062 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . 0.895 ' HB1' ' HB1' ' A' ' 219' ' ' ALA . . . -65.83 61.25 0.03 OUTLIER 'General case' 0 C--O 1.241 0.653 0 CA-C-O 121.227 0.537 . . . . 0.0 111.027 -178.472 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 239' ' ' ARG . . . . . 0.447 ' N ' ' O ' ' A' ' 237' ' ' GLU . 61.5 mtp180 -67.78 85.09 0.21 Allowed 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 174.215 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 240' ' ' HIS . . . . . 0.627 ' HB2' ' CG ' ' A' ' 242' ' ' PHE . 3.5 p80 -57.92 -46.83 84.39 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-N 115.163 -0.926 . . . . 0.0 112.398 -170.903 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 80.32 14.47 80.23 Favored Glycine 0 C--N 1.313 -0.743 0 N-CA-C 109.867 -1.293 . . . . 0.0 109.867 -174.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 242' ' ' PHE . . . . . 0.681 ' CD1' ' HB3' ' A' ' 294' ' ' GLN . 4.6 m-30 -80.02 148.69 31.01 Favored 'General case' 0 CA--C 1.509 -0.617 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 -179.301 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 243' ' ' GLU . . . . . 0.474 ' HB2' ' HB2' ' A' ' 246' ' ' ASP . 37.7 mt-10 -115.46 150.66 36.12 Favored 'General case' 0 C--N 1.308 -1.238 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 179.634 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 244' ' ' THR . . . . . 0.56 ' OG1' HG22 ' A' ' 269' ' ' VAL . 32.6 m -62.43 127.62 32.16 Favored 'General case' 0 C--N 1.305 -1.34 0 C-N-CA 119.235 -0.986 . . . . 0.0 108.652 177.316 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 86.16 4.01 84.44 Favored Glycine 0 C--N 1.311 -0.847 0 N-CA-C 110.489 -1.044 . . . . 0.0 110.489 -176.326 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 246' ' ' ASP . . . . . 0.474 ' HB2' ' HB2' ' A' ' 243' ' ' GLU . 31.6 t0 -81.58 164.06 22.16 Favored 'General case' 0 CA--C 1.515 -0.402 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 177.737 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 247' ' ' PHE . . . . . 0.46 ' HA ' ' O ' ' A' ' 265' ' ' MET . 69.3 m-85 -110.05 134.68 51.89 Favored 'General case' 0 C--N 1.311 -1.085 0 O-C-N 123.413 0.446 . . . . 0.0 110.337 -179.644 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.545 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 3.1 m -132.04 163.81 36.46 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.572 0 CA-C-O 120.745 0.307 . . . . 0.0 111.082 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 12.0 p -130.89 162.2 30.17 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 115.126 -0.943 . . . . 0.0 108.896 176.509 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 250' ' ' PHE . . . . . 0.583 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 73.7 m-85 -121.57 157.92 29.67 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-O 121.146 0.498 . . . . 0.0 111.6 -174.763 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 3.7 m -152.25 155.89 38.63 Favored 'General case' 0 C--N 1.313 -1.017 0 CA-C-N 115.473 -0.785 . . . . 0.0 109.473 175.359 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 54.21 25.77 6.09 Favored 'General case' 0 C--N 1.314 -0.947 0 N-CA-C 112.7 0.63 . . . . 0.0 112.7 174.846 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 0.401 HG22 ' CA ' ' A' ' 290' ' ' GLY . 95.6 t -82.53 129.76 36.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 174.487 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -99.92 138.59 36.78 Favored 'General case' 0 C--O 1.24 0.601 0 C-N-CA 120.548 -0.461 . . . . 0.0 110.361 -179.74 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 80.94 -61.56 4.54 Favored Glycine 0 C--N 1.319 -0.378 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 -175.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 256' ' ' MET . . . . . 0.56 ' SD ' ' CG1' ' A' ' 224' ' ' VAL . 31.3 mtt -80.71 62.43 4.75 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.608 0.718 . . . . 0.0 110.172 174.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 257' ' ' ILE . . . . . 0.4 ' O ' ' HB2' ' A' ' 260' ' ' ASN . 47.6 pt -72.54 -19.41 19.19 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.86 -177.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 258' ' ' GLN . . . . . 0.473 ' HB2' ' HG ' ' A' ' 284' ' ' SER . 0.7 OUTLIER -56.02 -39.36 71.82 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 -179.624 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 259' ' ' LEU . . . . . 0.939 HD21 ' CE2' ' A' ' 283' ' ' PHE . 89.8 mt -62.21 -41.7 98.62 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 116.009 -0.542 . . . . 0.0 109.742 178.767 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 260' ' ' ASN . . . . . 0.4 ' HB2' ' O ' ' A' ' 257' ' ' ILE . 97.1 m-20 -60.76 -40.72 93.52 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 178.798 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -96.95 11.04 66.12 Favored Glycine 0 CA--C 1.526 0.78 0 CA-C-N 115.485 -0.78 . . . . 0.0 112.676 -177.664 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 262' ' ' CYS . . . . . 0.401 ' N ' ' O ' ' A' ' 258' ' ' GLN . 4.0 m -102.84 146.75 27.81 Favored 'General case' 0 CA--C 1.517 -0.315 0 CA-C-N 117.6 0.7 . . . . 0.0 111.475 -179.457 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 51.5 mt-30 -62.34 161.96 22.29 Favored Pre-proline 0 C--N 1.326 -0.421 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 172.865 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 264' ' ' PRO . . . . . 0.545 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 37.6 Cg_endo -62.56 146.02 95.4 Favored 'Trans proline' 0 C--N 1.305 -1.727 0 C-N-CA 121.33 1.353 . . . . 0.0 111.219 178.644 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 265' ' ' MET . . . . . 0.611 ' N ' ' SD ' ' A' ' 265' ' ' MET . 0.9 OUTLIER -128.35 162.27 27.48 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 116.782 -0.19 . . . . 0.0 111.502 -175.702 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 70.3 tt0 -71.0 139.4 50.5 Favored 'General case' 0 C--O 1.245 0.818 0 O-C-N 123.585 0.553 . . . . 0.0 109.621 176.641 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 267' ' ' ILE . . . . . 0.65 HG22 HG22 ' A' ' 277' ' ' ILE . 1.9 pp -127.41 152.43 35.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-O 121.049 0.452 . . . . 0.0 111.777 -179.766 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . 0.458 ' HA ' HG23 ' A' ' 244' ' ' THR . 63.8 mttp -129.3 114.23 15.97 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.852 178.816 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.56 HG22 ' OG1' ' A' ' 244' ' ' THR . 34.7 m -74.98 106.75 4.94 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 CA-C-O 121.145 0.497 . . . . 0.0 112.242 -176.679 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 270' ' ' LEU . . . . . 0.45 HD12 HG23 ' A' ' 231' ' ' VAL . 92.9 mt -66.11 -41.02 91.14 Favored 'General case' 0 N--CA 1.449 -0.503 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.517 175.546 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -149.04 -176.19 22.12 Favored Glycine 0 C--N 1.322 -0.224 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 178.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 272' ' ' PRO . . . . . 0.429 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 33.6 Cg_endo -60.98 -34.84 90.14 Favored 'Trans proline' 0 N--CA 1.496 1.672 0 C-N-CA 121.97 1.78 . . . . 0.0 111.992 -177.29 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 57.1 m-85 -118.76 7.75 11.69 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 112.245 0.461 . . . . 0.0 112.245 178.826 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 6.0 p -120.97 124.36 44.7 Favored 'General case' 0 C--N 1.319 -0.725 0 C-N-CA 120.888 -0.325 . . . . 0.0 110.323 178.586 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 275' ' ' PHE . . . . . 0.521 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -132.66 157.55 44.55 Favored 'General case' 0 CA--C 1.501 -0.924 0 C-N-CA 120.133 -0.627 . . . . 0.0 112.599 179.43 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . 0.536 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 7.4 p -125.79 142.36 51.55 Favored 'General case' 0 N--CA 1.431 -1.408 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.937 -173.803 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . 0.65 HG22 HG22 ' A' ' 267' ' ' ILE . 32.8 pt -139.77 163.56 24.73 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.917 0 CA-C-N 115.166 -0.924 . . . . 0.0 111.964 -172.783 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 278' ' ' CYS . . . . . 0.414 ' C ' ' O ' ' A' ' 277' ' ' ILE . 86.1 m -17.78 -96.25 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 124.413 1.085 . . . . 0.0 113.611 -178.86 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . 0.454 ' CG ' ' HB2' ' A' ' 228' ' ' ASN . 67.2 t0 -149.38 112.51 4.91 Favored 'General case' 0 CA--C 1.499 -1.017 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 178.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . 0.791 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 11.3 p -67.21 -23.81 65.78 Favored 'General case' 0 N--CA 1.42 -1.949 0 CA-C-O 121.084 0.468 . . . . 0.0 110.4 179.08 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -66.28 -19.12 65.73 Favored 'General case' 0 C--N 1.315 -0.897 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.613 173.478 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 282' ' ' ASN . . . . . 0.48 ' ND2' ' C ' ' A' ' 282' ' ' ASN . 0.0 OUTLIER -91.46 2.72 56.22 Favored 'General case' 0 CA--C 1.513 -0.474 0 C-N-CA 120.409 -0.516 . . . . 0.0 109.809 176.324 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . 0.939 ' CE2' HD21 ' A' ' 259' ' ' LEU . 16.2 m-85 -100.98 -76.52 0.56 Allowed 'General case' 0 N--CA 1.445 -0.703 0 CA-C-O 121.404 0.621 . . . . 0.0 109.417 173.616 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 284' ' ' SER . . . . . 0.473 ' HG ' ' HB2' ' A' ' 258' ' ' GLN . 0.0 OUTLIER 166.48 -175.06 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 114.41 -1.268 . . . . 0.0 109.132 -172.875 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 285' ' ' ASP . . . . . 0.415 ' C ' ' HG3' ' A' ' 256' ' ' MET . 19.8 m-20 -86.5 134.5 33.67 Favored 'General case' 0 N--CA 1.472 0.643 0 CA-C-N 117.406 0.094 . . . . 0.0 110.756 179.143 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . 0.455 ' HB2' ' SD ' ' A' ' 256' ' ' MET . 55.5 t80 -76.65 128.34 34.5 Favored 'General case' 0 N--CA 1.468 0.447 0 C-N-CA 123.102 0.561 . . . . 0.0 111.094 179.256 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 7.0 mm -100.75 -69.15 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 116.563 -0.29 . . . . 0.0 110.672 173.271 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 95.5 mtm-85 -160.8 -179.44 7.59 Favored 'General case' 0 C--O 1.241 0.63 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.452 -178.748 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 63.35 -143.74 48.58 Favored Glycine 0 CA--C 1.498 -1.027 0 CA-C-N 114.963 -1.017 . . . . 0.0 111.338 174.03 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . 0.401 ' CA ' HG22 ' A' ' 253' ' ' VAL . . . 98.76 123.15 4.82 Favored Glycine 0 N--CA 1.436 -1.324 0 C-N-CA 120.968 -0.634 . . . . 0.0 111.774 178.625 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 47.9 mm -119.05 130.18 74.2 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.488 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 175.28 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 11.3 p -122.04 135.87 60.77 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.985 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 -178.063 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . 0.497 ' HA ' ' O ' ' A' ' 217' ' ' LEU . 0.3 OUTLIER -136.19 140.03 43.26 Favored 'General case' 0 C--N 1.316 -0.878 0 C-N-CA 120.478 -0.489 . . . . 0.0 110.237 -177.416 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 294' ' ' GLN . . . . . 0.681 ' HB3' ' CD1' ' A' ' 242' ' ' PHE . 2.3 pt20 -74.42 142.22 44.99 Favored 'General case' 0 CA--C 1.502 -0.902 0 C-N-CA 120.083 -0.647 . . . . 0.0 110.847 178.322 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 11.4 t -131.84 96.79 2.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 176.046 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 296' ' ' LYS . . . . . 0.439 ' HZ1' ' CD ' ' A' ' 243' ' ' GLU . 68.4 mttm -77.85 105.65 9.17 Favored 'General case' 0 N--CA 1.433 -1.291 0 N-CA-C 106.918 -1.512 . . . . 0.0 106.918 175.32 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 3.5 m -42.84 145.47 0.88 Allowed Pre-proline 0 C--N 1.325 -0.488 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.722 -171.507 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_exo -52.71 140.28 56.74 Favored 'Trans proline' 0 C--N 1.309 -1.548 0 C-N-CA 121.897 1.731 . . . . 0.0 111.853 -176.688 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 20.9 mmtm -121.98 154.15 37.59 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.659 -0.701 . . . . 0.0 109.494 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 50.6 mttp -73.48 149.82 42.05 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 107.4 -1.333 . . . . 0.0 107.4 170.67 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 41.1 pt -49.68 108.56 0.09 OUTLIER 'Isoleucine or valine' 0 C--O 1.235 0.291 0 C-N-CA 119.025 -1.07 . . . . 0.0 109.237 -178.396 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 31.3 t -155.56 166.24 34.13 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.1 -170.191 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 80.6 t80 -102.96 111.61 24.04 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 116.171 -0.468 . . . . 0.0 109.771 177.598 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . 0.5 ' HD3' ' HA ' ' A' ' 304' ' ' LYS . 20.6 mmtm -110.5 149.67 30.0 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.67 177.515 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -53.06 92.62 0.01 OUTLIER 'General case' 0 C--O 1.24 0.578 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 178.322 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 306' ' ' LEU . . . . . 0.669 ' H ' HD23 ' A' ' 306' ' ' LEU . 0.2 OUTLIER -61.46 153.22 70.55 Favored Pre-proline 0 C--N 1.321 -0.639 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.845 -176.886 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . 0.492 ' O ' ' C ' ' A' ' 308' ' ' ALA . 36.6 Cg_exo -61.67 155.65 52.5 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 C-N-CA 122.417 2.078 . . . . 0.0 109.822 174.39 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . 0.492 ' C ' ' O ' ' A' ' 307' ' ' PRO . . . -27.91 120.48 0.11 Allowed 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 120.839 0.352 . . . . 0.0 110.823 -175.365 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 4.2 m -60.76 147.74 41.4 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.461 -174.302 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 310' ' ' LEU . . . . . 0.513 HD12 ' N ' ' A' ' 310' ' ' LEU . 7.7 mp -78.15 140.12 39.0 Favored 'General case' 0 C--O 1.243 0.74 0 CA-C-N 115.847 -0.615 . . . . 0.0 109.834 -176.626 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 26.7 m -107.78 125.03 64.27 Favored 'Isoleucine or valine' 0 C--O 1.239 0.519 0 CA-C-O 120.903 0.383 . . . . 0.0 111.101 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 67.7 mt-10 . . . . . 0 C--O 1.202 -1.4 0 CA-C-O 118.463 -0.78 . . . . 0.0 110.542 -178.554 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . 0.569 ' C ' ' H ' ' A' ' 203' ' ' GLY . 96.8 mt-10 . . . . . 0 N--CA 1.476 0.853 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 22.6 m-85 63.31 -29.17 0.09 Allowed 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 123.45 0.7 . . . . 0.0 111.798 -178.22 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . 0.569 ' H ' ' C ' ' A' ' 201' ' ' GLU . . . -60.66 -34.93 88.33 Favored Glycine 0 C--N 1.319 -0.364 0 N-CA-C 109.941 -1.264 . . . . 0.0 109.941 178.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 204' ' ' GLU . . . . . 0.483 ' OE1' ' N ' ' A' ' 201' ' ' GLU . 1.6 mp0 -62.49 -40.48 96.84 Favored 'General case' 0 CA--C 1.516 -0.351 0 CA-C-O 121.307 0.575 . . . . 0.0 109.509 177.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 99.9 mt-10 -67.04 -39.3 86.94 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.813 -179.498 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 206' ' ' MET . . . . . 0.43 ' CE ' HG13 ' A' ' 295' ' ' VAL . 48.4 ttm -91.17 93.97 9.36 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.932 -176.424 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 27.2 m -132.35 158.39 43.27 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.292 178.228 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 208' ' ' LEU . . . . . 0.66 HD11 ' O ' ' A' ' 296' ' ' LYS . 5.1 mp -127.29 149.41 50.04 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 122.573 0.349 . . . . 0.0 110.247 179.618 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -102.34 -47.36 4.52 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 112.132 0.419 . . . . 0.0 112.132 177.142 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 210' ' ' ASP . . . . . 0.496 ' OD1' ' N ' ' A' ' 211' ' ' SER . 34.9 p-10 -64.18 -48.66 75.07 Favored 'General case' 0 CA--C 1.51 -0.575 0 C-N-CA 120.443 -0.503 . . . . 0.0 109.831 177.522 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 211' ' ' SER . . . . . 0.496 ' N ' ' OD1' ' A' ' 210' ' ' ASP . 4.4 m -76.01 144.22 41.0 Favored 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 114.871 -1.059 . . . . 0.0 109.58 178.659 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 212' ' ' ASN . . . . . 0.42 ' O ' ' C ' ' A' ' 213' ' ' GLY . 57.4 t-20 -84.88 91.77 8.11 Favored 'General case' 0 CA--C 1.514 -0.429 0 C-N-CA 120.643 -0.423 . . . . 0.0 110.192 -178.838 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 213' ' ' GLY . . . . . 0.469 ' O ' ' NE2' ' A' ' 215' ' ' GLN . . . 29.94 50.85 0.16 Allowed Glycine 0 C--N 1.334 0.44 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.54 178.642 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -69.83 128.44 36.4 Favored 'General case' 0 N--CA 1.442 -0.842 0 C-N-CA 120.728 -0.389 . . . . 0.0 110.398 -175.582 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 215' ' ' GLN . . . . . 0.469 ' NE2' ' O ' ' A' ' 213' ' ' GLY . 67.3 mm-40 -88.2 113.88 56.99 Favored Pre-proline 0 N--CA 1.443 -0.796 0 N-CA-C 108.636 -0.875 . . . . 0.0 108.636 175.821 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 216' ' ' PRO . . . . . 0.416 ' HD3' ' HA ' ' A' ' 215' ' ' GLN . 47.2 Cg_exo -57.6 146.27 85.27 Favored 'Trans proline' 0 N--CA 1.496 1.627 0 C-N-CA 122.437 2.092 . . . . 0.0 112.951 -172.099 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 217' ' ' LEU . . . . . 0.521 ' HB3' ' O ' ' A' ' 240' ' ' HIS . 0.4 OUTLIER -75.7 148.07 38.91 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.232 -0.895 . . . . 0.0 110.448 179.359 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 66.8 m -131.48 153.78 49.41 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-N 116.416 -0.357 . . . . 0.0 110.174 175.68 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -150.84 155.63 39.6 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.531 -0.304 . . . . 0.0 111.368 -178.404 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 220' ' ' MET . . . . . 0.435 ' SD ' HD22 ' A' ' 235' ' ' LEU . 92.1 mtp -76.83 135.37 38.89 Favored 'General case' 0 N--CA 1.447 -0.615 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.549 176.512 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 94.3 t -87.13 130.99 36.11 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.067 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 175.567 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 222' ' ' SER . . . . . 0.419 ' OG ' ' N ' ' A' ' 223' ' ' MET . 0.0 OUTLIER -82.44 -71.51 0.48 Allowed 'General case' 0 C--N 1.308 -1.216 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 176.836 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 223' ' ' MET . . . . . 0.419 ' N ' ' OG ' ' A' ' 222' ' ' SER . 5.5 ptm -137.66 149.09 46.29 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.711 174.843 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 224' ' ' VAL . . . . . 0.708 HG13 ' CG1' ' A' ' 232' ' ' VAL . 2.3 t -113.37 124.3 69.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 174.822 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . 0.509 ' O ' HG21 ' A' ' 280' ' ' THR . 74.6 p -79.66 133.08 36.38 Favored 'General case' 0 C--N 1.321 -0.647 0 C-N-CA 120.474 -0.491 . . . . 0.0 110.491 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 226' ' ' LYS . . . . . 0.445 ' NZ ' ' OD1' ' A' ' 285' ' ' ASP . 0.1 OUTLIER -79.21 75.11 5.76 Favored 'General case' 0 C--O 1.243 0.727 0 CA-C-O 121.283 0.563 . . . . 0.0 109.595 179.22 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 227' ' ' ASP . . . . . 0.522 ' N ' ' OG1' ' A' ' 280' ' ' THR . 3.9 t0 -148.72 176.56 10.26 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-N 115.475 -0.784 . . . . 0.0 110.594 -179.742 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 228' ' ' ASN . . . . . 0.485 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.2 OUTLIER -142.87 123.52 8.16 Favored Pre-proline 0 C--N 1.313 -1.02 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.881 179.05 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 229' ' ' PRO . . . . . 0.485 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 47.8 Cg_endo -63.83 146.69 62.47 Favored 'Cis proline' 0 N--CA 1.496 1.62 0 C-N-CA 123.185 -1.589 . . . . 0.0 110.744 -2.12 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . 0.516 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -76.04 141.14 26.7 Favored Glycine 0 N--CA 1.443 -0.857 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 -178.173 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 231' ' ' VAL . . . . . 0.575 HG23 HD12 ' A' ' 270' ' ' LEU . 2.3 p -124.1 133.0 70.5 Favored 'Isoleucine or valine' 0 C--O 1.241 0.624 0 N-CA-C 109.059 -0.719 . . . . 0.0 109.059 174.22 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 232' ' ' VAL . . . . . 0.708 ' CG1' HG13 ' A' ' 224' ' ' VAL . 0.7 OUTLIER -132.34 156.36 42.34 Favored 'Isoleucine or valine' 0 C--O 1.246 0.895 0 C-N-CA 120.438 -0.505 . . . . 0.0 110.353 -175.024 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 233' ' ' THR . . . . . 0.5 ' HA ' ' O ' ' A' ' 273' ' ' TYR . 1.6 p -106.41 159.07 16.43 Favored 'General case' 0 N--CA 1.441 -0.907 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.665 177.556 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 39.3 m -124.36 161.95 24.86 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 123.063 0.545 . . . . 0.0 109.861 -178.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.435 HD22 ' SD ' ' A' ' 220' ' ' MET . 37.2 tp -62.87 135.7 57.46 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 107.88 -1.155 . . . . 0.0 107.88 176.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 236' ' ' ASP . . . . . 0.438 ' O ' ' CZ ' ' A' ' 273' ' ' TYR . 1.9 m-20 -59.54 -35.65 74.62 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-O 121.251 0.548 . . . . 0.0 111.117 -173.611 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 70.1 mt-10 -86.47 -5.02 59.26 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.605 -177.611 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -101.99 100.47 10.76 Favored 'General case' 0 CA--C 1.516 -0.344 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.554 179.393 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 66.4 mtp180 -86.82 107.53 18.34 Favored 'General case' 0 C--N 1.317 -0.847 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 -179.686 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 240' ' ' HIS . . . . . 0.521 ' O ' ' HB3' ' A' ' 217' ' ' LEU . 9.9 p80 -57.48 -47.38 82.05 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.655 -176.902 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 71.18 25.31 75.85 Favored Glycine 0 C--N 1.309 -0.92 0 N-CA-C 109.783 -1.327 . . . . 0.0 109.783 -179.173 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 242' ' ' PHE . . . . . 0.496 ' CD2' ' HB2' ' A' ' 240' ' ' HIS . 15.4 m-30 -79.51 141.28 36.84 Favored 'General case' 0 N--CA 1.435 -1.213 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 -179.82 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 243' ' ' GLU . . . . . 0.505 ' HB2' ' HB2' ' A' ' 246' ' ' ASP . 96.5 mt-10 -96.79 146.5 24.84 Favored 'General case' 0 C--N 1.31 -1.138 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.343 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.1 122.44 16.09 Favored 'General case' 0 C--N 1.307 -1.269 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 -178.408 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 85.0 7.33 83.92 Favored Glycine 0 N--CA 1.442 -0.912 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 -177.211 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 246' ' ' ASP . . . . . 0.505 ' HB2' ' HB2' ' A' ' 243' ' ' GLU . 13.5 t0 -83.79 168.3 16.29 Favored 'General case' 0 C--O 1.24 0.557 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 176.032 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 247' ' ' PHE . . . . . 0.46 ' HA ' ' O ' ' A' ' 265' ' ' MET . 66.3 m-85 -109.4 141.6 41.55 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 112.099 0.407 . . . . 0.0 112.099 -176.349 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.445 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.8 m -134.21 161.16 41.18 Favored 'Isoleucine or valine' 0 C--O 1.241 0.655 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.098 178.059 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 249' ' ' SER . . . . . 0.425 ' OG ' HG21 ' A' ' 295' ' ' VAL . 47.7 m -128.04 159.37 35.24 Favored 'General case' 0 C--N 1.321 -0.669 0 C-N-CA 124.338 1.055 . . . . 0.0 108.53 173.626 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 250' ' ' PHE . . . . . 0.508 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 69.9 m-85 -110.54 145.8 37.15 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 121.264 0.554 . . . . 0.0 112.171 -177.789 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 19.7 m -137.73 153.3 49.77 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.227 177.048 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 71.6 mm-40 56.08 21.37 5.05 Favored 'General case' 0 C--N 1.314 -0.954 0 N-CA-C 113.354 0.872 . . . . 0.0 113.354 173.023 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 0.437 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 94.1 t -84.37 130.7 35.53 Favored 'Isoleucine or valine' 0 C--O 1.239 0.52 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 177.262 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . 0.414 ' HB2' ' O ' ' A' ' 288' ' ' ARG . 83.1 mt-30 -105.26 144.44 32.05 Favored 'General case' 0 C--O 1.243 0.728 0 CA-C-O 121.001 0.429 . . . . 0.0 109.897 176.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 84.91 -68.42 3.5 Favored Glycine 0 C--N 1.313 -0.747 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -174.049 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 256' ' ' MET . . . . . 0.536 ' HG3' ' N ' ' A' ' 286' ' ' TYR . 47.8 mtt -78.25 65.04 3.51 Favored 'General case' 0 CA--C 1.515 -0.381 0 CA-C-O 121.397 0.617 . . . . 0.0 110.318 173.072 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 46.9 pt -70.82 -23.06 23.54 Favored 'Isoleucine or valine' 0 C--O 1.244 0.797 0 CA-C-N 115.475 -0.784 . . . . 0.0 110.135 -178.271 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 258' ' ' GLN . . . . . 0.542 ' HG3' ' SG ' ' A' ' 262' ' ' CYS . 70.7 tp60 -60.8 -36.62 79.49 Favored 'General case' 0 N--CA 1.445 -0.682 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 179.459 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 259' ' ' LEU . . . . . 0.677 HD21 ' CD2' ' A' ' 283' ' ' PHE . 92.3 mt -61.88 -40.52 95.68 Favored 'General case' 0 N--CA 1.448 -0.542 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.204 179.09 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 260' ' ' ASN . . . . . 0.437 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 98.8 m-20 -60.2 -41.14 92.35 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 179.218 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -96.48 10.94 67.06 Favored Glycine 0 CA--C 1.532 1.132 0 CA-C-N 116.042 -0.527 . . . . 0.0 112.269 179.572 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 262' ' ' CYS . . . . . 0.542 ' SG ' ' HG3' ' A' ' 258' ' ' GLN . 1.2 m -82.24 142.41 32.15 Favored 'General case' 0 CA--C 1.513 -0.444 0 CA-C-N 117.382 0.591 . . . . 0.0 110.827 -178.379 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 27.9 mm100 -62.57 152.51 80.76 Favored Pre-proline 0 C--N 1.321 -0.662 0 N-CA-C 107.572 -1.27 . . . . 0.0 107.572 171.582 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 264' ' ' PRO . . . . . 0.579 ' HB3' HG21 ' A' ' 295' ' ' VAL . 36.8 Cg_endo -61.22 142.96 98.11 Favored 'Trans proline' 0 C--N 1.307 -1.644 0 C-N-CA 121.059 1.172 . . . . 0.0 110.447 -178.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 265' ' ' MET . . . . . 0.46 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 24.0 ptp -129.12 154.34 46.81 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 112.162 0.43 . . . . 0.0 112.162 -172.429 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -71.02 136.1 48.17 Favored 'General case' 0 C--O 1.245 0.816 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 177.611 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 267' ' ' ILE . . . . . 0.635 HG22 HG22 ' A' ' 277' ' ' ILE . 2.0 pp -126.65 158.54 36.94 Favored 'Isoleucine or valine' 0 C--O 1.243 0.735 0 N-CA-C 112.546 0.573 . . . . 0.0 112.546 -175.864 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 75.1 tttt -127.83 115.81 19.2 Favored 'General case' 0 N--CA 1.448 -0.532 0 CA-C-N 115.213 -0.903 . . . . 0.0 109.86 -179.322 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 17.8 m -70.59 134.5 29.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.244 -179.629 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 270' ' ' LEU . . . . . 0.575 HD12 HG23 ' A' ' 231' ' ' VAL . 81.6 mt -107.75 -24.16 11.81 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.023 0.44 . . . . 0.0 110.124 178.161 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -176.4 -178.27 46.05 Favored Glycine 0 C--N 1.319 -0.396 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 -178.072 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 272' ' ' PRO . . . . . 0.428 ' O ' ' CD2' ' A' ' 240' ' ' HIS . 75.5 Cg_exo -52.89 -43.6 55.21 Favored 'Trans proline' 0 C--N 1.311 -1.424 0 C-N-CA 121.958 1.772 . . . . 0.0 111.582 -177.303 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 273' ' ' TYR . . . . . 0.5 ' O ' ' HA ' ' A' ' 233' ' ' THR . 7.3 m-85 -117.76 10.75 13.4 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 115.933 -0.576 . . . . 0.0 112.084 -176.407 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 5.4 p -123.77 130.02 51.98 Favored 'General case' 0 C--N 1.321 -0.66 0 C-N-CA 120.927 -0.309 . . . . 0.0 110.992 -179.51 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 275' ' ' PHE . . . . . 0.547 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -143.81 164.08 31.52 Favored 'General case' 0 C--O 1.238 0.48 0 C-N-CA 120.926 -0.309 . . . . 0.0 111.406 175.811 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . 0.522 ' HB3' HD11 ' A' ' 270' ' ' LEU . 4.4 p -131.05 145.38 52.0 Favored 'General case' 0 C--O 1.244 0.805 0 C-N-CA 120.672 -0.411 . . . . 0.0 111.912 -175.723 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . 0.635 HG22 HG22 ' A' ' 267' ' ' ILE . 35.0 pt -140.18 165.05 21.86 Favored 'Isoleucine or valine' 0 C--O 1.236 0.368 0 CA-C-N 114.766 -1.107 . . . . 0.0 112.582 -173.077 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 278' ' ' CYS . . . . . 0.413 ' SG ' ' SD ' ' A' ' 265' ' ' MET . 2.6 p -27.2 -94.76 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.416 0 N-CA-C 114.478 1.288 . . . . 0.0 114.478 -176.394 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 58.2 m-20 -144.48 110.0 5.24 Favored 'General case' 0 CA--C 1.513 -0.456 0 CA-C-N 116.622 -0.263 . . . . 0.0 111.423 -171.402 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . 0.785 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 59.7 p -66.02 -27.7 68.31 Favored 'General case' 0 C--N 1.31 -1.137 0 CA-C-O 121.215 0.531 . . . . 0.0 109.712 172.066 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 1.5 p -63.68 -17.06 62.57 Favored 'General case' 0 N--CA 1.43 -1.435 0 CA-C-N 114.799 -1.092 . . . . 0.0 109.753 174.071 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 17.9 t-20 -98.27 -8.71 26.74 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.6 175.05 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . 0.785 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 15.6 m-30 -90.66 -83.08 0.27 Allowed 'General case' 0 C--O 1.237 0.404 0 CA-C-O 121.436 0.636 . . . . 0.0 110.952 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 169.25 -174.0 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 114.342 -1.299 . . . . 0.0 108.874 -173.71 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 285' ' ' ASP . . . . . 0.445 ' OD1' ' NZ ' ' A' ' 226' ' ' LYS . 31.1 t0 -92.99 112.36 24.3 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 120.906 -0.318 . . . . 0.0 111.678 -179.788 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . 0.536 ' N ' ' HG3' ' A' ' 256' ' ' MET . 12.4 t80 -63.66 128.49 36.07 Favored 'General case' 0 CA--C 1.512 -0.485 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 177.865 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 287' ' ' ILE . . . . . 0.448 HG22 ' HG2' ' A' ' 288' ' ' ARG . 96.5 mt -106.64 -64.06 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 175.894 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . 0.448 ' HG2' HG22 ' A' ' 287' ' ' ILE . 9.6 ptp180 -161.15 -178.67 6.9 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.088 178.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 70.02 -161.08 53.19 Favored Glycine 0 CA--C 1.504 -0.615 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 178.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 108.8 117.59 4.06 Favored Glycine 0 N--CA 1.442 -0.958 0 C-N-CA 120.934 -0.651 . . . . 0.0 113.291 174.686 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 97.2 mt -118.16 130.34 73.17 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.25 0 N-CA-C 107.321 -1.363 . . . . 0.0 107.321 170.562 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 4.8 p -109.19 128.89 64.77 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 -179.355 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 36.7 m -116.63 137.42 52.2 Favored 'General case' 0 N--CA 1.438 -1.039 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.932 -176.543 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -68.04 147.27 52.61 Favored 'General case' 0 N--CA 1.431 -1.399 0 CA-C-N 115.609 -0.723 . . . . 0.0 109.752 176.884 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . 0.579 HG21 ' HB3' ' A' ' 264' ' ' PRO . 76.2 t -126.23 97.95 4.56 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.869 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 173.774 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 296' ' ' LYS . . . . . 0.66 ' O ' HD11 ' A' ' 208' ' ' LEU . 4.8 mttp -97.11 99.25 10.76 Favored 'General case' 0 N--CA 1.435 -1.206 0 N-CA-C 109.003 -0.739 . . . . 0.0 109.003 179.555 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 5.0 m -104.58 165.38 13.4 Favored Pre-proline 0 C--N 1.318 -0.786 0 CA-C-N 115.216 -0.902 . . . . 0.0 108.951 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_exo -60.41 104.91 0.27 Allowed 'Trans proline' 0 C--N 1.302 -1.913 0 C-N-CA 120.48 0.787 . . . . 0.0 110.192 177.815 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 49.4 mttp -79.4 147.34 32.38 Favored 'General case' 0 C--N 1.321 -0.666 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 174.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 300' ' ' LYS . . . . . 0.567 ' NZ ' ' OG ' ' A' ' 302' ' ' SER . 62.3 tttm -63.43 128.03 33.98 Favored 'General case' 0 C--N 1.319 -0.736 0 C-N-CA 118.684 -1.207 . . . . 0.0 108.29 179.938 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 40.4 mm -78.3 91.19 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.048 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 302' ' ' SER . . . . . 0.567 ' OG ' ' NZ ' ' A' ' 300' ' ' LYS . 7.2 m -155.43 94.97 1.65 Allowed 'General case' 0 C--N 1.302 -1.485 0 CA-C-N 115.263 -0.881 . . . . 0.0 109.396 -177.014 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 92.0 m-85 -132.83 153.9 50.84 Favored 'General case' 0 C--N 1.308 -1.231 0 CA-C-N 115.501 -0.772 . . . . 0.0 108.959 -176.499 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 23.2 mmtm -65.69 158.12 28.27 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 176.33 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 4.1 m -56.71 138.8 52.25 Favored 'General case' 0 C--N 1.311 -1.095 0 C-N-CA 121.029 -0.268 . . . . 0.0 110.712 -172.565 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 306' ' ' LEU . . . . . 0.41 ' HB3' ' HD2' ' A' ' 307' ' ' PRO . 38.1 mt -62.21 170.29 2.29 Favored Pre-proline 0 C--O 1.243 0.724 0 N-CA-C 108.092 -1.077 . . . . 0.0 108.092 176.113 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . 0.41 ' HD2' ' HB3' ' A' ' 306' ' ' LEU . 50.1 Cg_exo -56.81 138.67 86.55 Favored 'Trans proline' 0 C--N 1.304 -1.784 0 C-N-CA 120.9 1.067 . . . . 0.0 110.275 -178.327 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . 0.424 ' O ' ' HG ' ' A' ' 310' ' ' LEU . . . -101.3 163.33 12.33 Favored 'General case' 0 CA--C 1.503 -0.839 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.465 179.429 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -72.01 83.36 0.96 Allowed 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 175.797 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 310' ' ' LEU . . . . . 0.424 ' HG ' ' O ' ' A' ' 308' ' ' ALA . 67.2 mt -77.59 117.08 18.68 Favored 'General case' 0 CA--C 1.508 -0.643 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.432 -172.678 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 6.6 m -123.25 130.39 74.33 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 175.382 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 312' ' ' GLU . . . . . 0.455 ' H ' ' CD ' ' A' ' 312' ' ' GLU . 51.1 mp0 . . . . . 0 C--O 1.214 -0.794 0 CA-C-O 118.081 -0.961 . . . . 0.0 110.616 -176.409 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . 0.562 ' O ' ' N ' ' A' ' 203' ' ' GLY . 0.0 OUTLIER . . . . . 0 N--CA 1.483 1.211 0 N-CA-C 107.699 -1.222 . . . . 0.0 107.699 . . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 202' ' ' PHE . . . . . 0.464 ' CD1' ' C ' ' A' ' 202' ' ' PHE . 0.1 OUTLIER 56.46 -47.8 0.03 OUTLIER 'General case' 0 N--CA 1.473 0.678 0 C-N-CA 123.889 0.876 . . . . 0.0 113.036 -179.505 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . 0.562 ' N ' ' O ' ' A' ' 201' ' ' GLU . . . -101.33 17.99 54.64 Favored Glycine 0 C--O 1.235 0.211 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 177.462 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 204' ' ' GLU . . . . . 0.491 ' OE1' ' N ' ' A' ' 201' ' ' GLU . 66.4 mt-10 -120.98 26.08 9.27 Favored 'General case' 0 C--N 1.323 -0.549 0 C-N-CA 122.584 0.354 . . . . 0.0 110.959 -178.381 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -62.88 -16.82 60.32 Favored 'General case' 0 C--O 1.24 0.57 0 CA-C-O 121.177 0.513 . . . . 0.0 110.305 -177.052 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 77.5 mtm -62.59 150.86 39.48 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.756 -177.838 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 27.7 m -129.5 160.92 39.95 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.867 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 173.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 73.7 mt -100.15 107.72 19.66 Favored 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 120.808 -0.357 . . . . 0.0 111.367 -173.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 9.8 m -64.37 -43.05 95.72 Favored 'General case' 0 C--N 1.316 -0.865 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 173.416 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 22.4 m-20 -60.76 -41.69 95.96 Favored 'General case' 0 CA--C 1.517 -0.315 0 CA-C-N 115.463 -0.789 . . . . 0.0 110.625 -176.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 211' ' ' SER . . . . . 0.43 ' CB ' ' HB2' ' A' ' 214' ' ' GLU . 0.8 OUTLIER -116.93 90.94 3.44 Favored 'General case' 0 C--N 1.318 -0.774 0 N-CA-C 107.514 -1.291 . . . . 0.0 107.514 172.423 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 55.3 t30 -79.19 112.89 16.85 Favored 'General case' 0 CA--C 1.51 -0.585 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.648 -171.735 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 68.86 17.65 71.66 Favored Glycine 0 CA--C 1.509 -0.29 0 N-CA-C 109.292 -1.523 . . . . 0.0 109.292 -177.776 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 214' ' ' GLU . . . . . 0.43 ' HB2' ' CB ' ' A' ' 211' ' ' SER . 99.0 mt-10 -110.75 112.43 24.3 Favored 'General case' 0 N--CA 1.438 -1.075 0 CA-C-O 121.214 0.53 . . . . 0.0 111.413 -177.385 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 215' ' ' GLN . . . . . 0.466 ' CB ' ' CD ' ' A' ' 216' ' ' PRO . 2.6 mt-30 -110.9 -172.25 0.23 Allowed Pre-proline 0 C--N 1.306 -1.305 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 171.702 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 216' ' ' PRO . . . . . 0.466 ' CD ' ' CB ' ' A' ' 215' ' ' GLN . 50.4 Cg_exo -56.43 139.21 86.6 Favored 'Trans proline' 0 C--N 1.301 -1.953 0 C-N-CA 121.034 1.156 . . . . 0.0 110.779 178.157 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 217' ' ' LEU . . . . . 0.47 ' HB3' ' O ' ' A' ' 240' ' ' HIS . 3.8 mm? -81.52 149.5 28.67 Favored 'General case' 0 CA--C 1.503 -0.829 0 N-CA-C 112.35 0.5 . . . . 0.0 112.35 -178.897 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 5.9 m -142.79 133.45 25.21 Favored 'General case' 0 N--CA 1.441 -0.92 0 CA-C-N 115.126 -0.943 . . . . 0.0 109.533 175.803 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -147.78 164.41 33.71 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 121.336 0.589 . . . . 0.0 112.295 -177.129 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 220' ' ' MET . . . . . 0.69 ' SD ' ' N ' ' A' ' 220' ' ' MET . 0.0 OUTLIER -74.77 132.62 41.75 Favored 'General case' 0 C--O 1.243 0.747 0 CA-C-N 115.023 -0.99 . . . . 0.0 109.876 178.264 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 52.4 t -88.91 130.21 38.67 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 175.142 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 36.9 p -88.1 -57.72 2.83 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 120.351 -0.54 . . . . 0.0 110.189 -178.661 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 1.7 ptm -137.04 149.75 47.64 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.481 175.69 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 224' ' ' VAL . . . . . 0.63 HG11 ' SD ' ' A' ' 256' ' ' MET . 21.7 t -127.21 132.32 69.76 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.963 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 174.004 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -106.42 121.55 44.48 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 -177.082 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 226' ' ' LYS . . . . . 0.548 ' HA ' ' HB ' ' A' ' 280' ' ' THR . 0.1 OUTLIER -77.38 73.39 3.95 Favored 'General case' 0 C--O 1.237 0.436 0 C-N-CA 119.721 -0.792 . . . . 0.0 111.642 -179.596 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 227' ' ' ASP . . . . . 0.419 ' N ' ' OG1' ' A' ' 280' ' ' THR . 41.5 t0 -126.23 -178.85 4.47 Favored 'General case' 0 C--O 1.238 0.499 0 CA-C-N 114.827 -1.079 . . . . 0.0 109.989 -179.587 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 228' ' ' ASN . . . . . 0.436 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.4 OUTLIER -136.89 123.19 13.54 Favored Pre-proline 0 CA--C 1.538 0.499 0 CA-C-O 120.571 0.224 . . . . 0.0 111.205 175.799 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 229' ' ' PRO . . . . . 0.436 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 50.0 Cg_endo -66.8 151.0 82.05 Favored 'Cis proline' 0 N--CA 1.495 1.61 0 C-N-CA 123.288 -1.547 . . . . 0.0 108.592 -2.397 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . 0.687 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -63.28 139.96 44.62 Favored Glycine 0 C--N 1.315 -0.586 0 C-N-CA 119.515 -1.326 . . . . 0.0 110.233 -175.249 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 3.1 p -125.07 131.3 72.68 Favored 'Isoleucine or valine' 0 C--O 1.241 0.641 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 178.408 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 232' ' ' VAL . . . . . 0.5 HG22 ' CD1' ' A' ' 275' ' ' PHE . 0.7 OUTLIER -135.26 157.14 39.95 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-N 116.546 -0.297 . . . . 0.0 110.334 -178.293 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 233' ' ' THR . . . . . 0.458 ' HA ' ' O ' ' A' ' 273' ' ' TYR . 11.9 m -114.78 147.03 40.33 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.012 177.365 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 55.7 m -106.47 153.09 22.79 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.021 -178.315 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.415 ' HB3' ' HB3' ' A' ' 238' ' ' ALA . 32.9 tp -56.81 130.03 43.93 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 -179.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 236' ' ' ASP . . . . . 0.538 ' HA ' ' CE1' ' A' ' 273' ' ' TYR . 34.6 t70 -55.23 -42.97 74.08 Favored 'General case' 0 CA--C 1.509 -0.62 0 CA-C-O 121.459 0.647 . . . . 0.0 109.865 -176.26 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -64.79 -33.54 76.23 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-N 114.851 -1.068 . . . . 0.0 110.52 -179.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . 0.415 ' HB3' ' HB3' ' A' ' 235' ' ' LEU . . . -114.94 92.8 4.06 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.532 -176.828 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 239' ' ' ARG . . . . . 0.454 ' HG2' ' CE1' ' A' ' 273' ' ' TYR . 58.9 mtm180 -67.29 138.14 56.62 Favored 'General case' 0 N--CA 1.448 -0.532 0 C-N-CA 119.927 -0.709 . . . . 0.0 109.821 174.334 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 240' ' ' HIS . . . . . 0.656 ' H ' ' CD2' ' A' ' 240' ' ' HIS . 6.2 p80 -58.9 -45.35 90.5 Favored 'General case' 0 C--N 1.313 -0.988 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.414 178.384 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 80.26 12.67 82.9 Favored Glycine 0 C--N 1.319 -0.39 0 N-CA-C 109.73 -1.348 . . . . 0.0 109.73 -177.871 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 242' ' ' PHE . . . . . 0.594 ' CD2' ' HB2' ' A' ' 240' ' ' HIS . 8.6 m-30 -81.61 149.58 28.53 Favored 'General case' 0 N--CA 1.442 -0.862 0 CA-C-N 115.327 -0.436 . . . . 0.0 110.329 -179.813 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 243' ' ' GLU . . . . . 0.532 ' CD ' ' HZ2' ' A' ' 300' ' ' LYS . 97.2 mt-10 -117.96 150.76 38.7 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-N 115.335 -0.848 . . . . 0.0 108.783 176.828 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 244' ' ' THR . . . . . 0.71 ' OG1' HG22 ' A' ' 269' ' ' VAL . 28.5 m -57.56 125.75 24.27 Favored 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 119.319 -0.952 . . . . 0.0 109.16 179.643 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 104.27 -10.93 51.17 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 -175.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 246' ' ' ASP . . . . . 0.45 ' OD1' ' NZ ' ' A' ' 300' ' ' LYS . 68.3 m-20 -67.73 147.56 52.46 Favored 'General case' 0 C--N 1.328 -0.358 0 O-C-N 122.82 -0.224 . . . . 0.0 111.0 178.18 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 247' ' ' PHE . . . . . 0.445 ' HA ' ' O ' ' A' ' 265' ' ' MET . 66.9 m-85 -109.52 125.75 52.82 Favored 'General case' 0 C--O 1.242 0.697 0 CA-C-N 116.1 -0.5 . . . . 0.0 109.909 178.037 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.49 HG12 ' HG2' ' A' ' 294' ' ' GLN . 3.4 m -132.48 164.52 34.78 Favored 'Isoleucine or valine' 0 C--O 1.246 0.908 0 N-CA-C 112.472 0.545 . . . . 0.0 112.472 -175.794 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 13.5 p -131.98 159.25 39.29 Favored 'General case' 0 C--O 1.241 0.634 0 CA-C-N 114.66 -1.155 . . . . 0.0 108.911 174.856 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 250' ' ' PHE . . . . . 0.574 ' CD1' HD22 ' A' ' 259' ' ' LEU . 65.9 m-85 -114.85 159.21 20.92 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 121.327 0.584 . . . . 0.0 112.529 -172.725 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 7.0 m -157.5 161.73 38.85 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-N 115.208 -0.905 . . . . 0.0 109.323 174.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . 0.445 ' HG3' HD12 ' A' ' 291' ' ' ILE . 61.9 mm-40 59.17 18.47 6.53 Favored 'General case' 0 CA--C 1.544 0.732 0 N-CA-C 112.024 0.379 . . . . 0.0 112.024 177.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 0.47 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 57.3 t -86.98 132.41 32.5 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 178.734 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 90.2 mt-30 -105.83 146.05 30.4 Favored 'General case' 0 C--O 1.24 0.589 0 CA-C-O 121.244 0.545 . . . . 0.0 111.096 177.511 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . 0.424 ' HA3' HG13 ' A' ' 287' ' ' ILE . . . 79.65 -65.94 3.61 Favored Glycine 0 CA--C 1.505 -0.585 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 -177.255 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 256' ' ' MET . . . . . 0.63 ' SD ' HG11 ' A' ' 224' ' ' VAL . 26.5 ttm -81.98 54.5 2.49 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-O 121.551 0.691 . . . . 0.0 109.324 175.106 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 257' ' ' ILE . . . . . 0.404 ' O ' ' HB2' ' A' ' 260' ' ' ASN . 48.2 pt -68.81 -20.06 24.58 Favored 'Isoleucine or valine' 0 C--O 1.239 0.546 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.607 -176.061 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 258' ' ' GLN . . . . . 0.694 ' HG3' ' SG ' ' A' ' 262' ' ' CYS . 47.4 tp60 -56.42 -31.66 64.13 Favored 'General case' 0 N--CA 1.439 -1.002 0 C-N-CA 120.009 -0.676 . . . . 0.0 110.353 178.851 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 259' ' ' LEU . . . . . 1.057 HD21 ' CE2' ' A' ' 283' ' ' PHE . 78.9 mt -62.18 -41.32 98.22 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 120.911 0.386 . . . . 0.0 110.323 174.17 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 260' ' ' ASN . . . . . 0.47 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 98.3 m-20 -59.77 -40.52 88.48 Favored 'General case' 0 CA--C 1.509 -0.612 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 -179.852 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -101.27 17.32 55.91 Favored Glycine 0 C--N 1.322 -0.2 0 CA-C-N 115.543 -0.753 . . . . 0.0 112.158 -178.425 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 262' ' ' CYS . . . . . 0.694 ' SG ' ' HG3' ' A' ' 258' ' ' GLN . 0.9 OUTLIER -91.77 155.32 18.33 Favored 'General case' 0 CA--C 1.51 -0.565 0 CA-C-N 117.157 0.478 . . . . 0.0 111.687 -178.009 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 28.1 mm-40 -74.18 153.72 88.39 Favored Pre-proline 0 C--N 1.325 -0.491 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 170.612 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 264' ' ' PRO . . . . . 0.674 ' CB ' HG21 ' A' ' 295' ' ' VAL . 56.2 Cg_endo -65.37 148.78 88.49 Favored 'Trans proline' 0 C--N 1.305 -1.716 0 C-N-CA 121.375 1.383 . . . . 0.0 111.253 -178.538 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 265' ' ' MET . . . . . 0.483 ' SD ' HD12 ' A' ' 277' ' ' ILE . 12.9 ptp -138.38 160.21 40.1 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.831 -174.853 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 266' ' ' GLU . . . . . 0.427 ' OE2' ' NZ ' ' A' ' 268' ' ' LYS . 36.1 tt0 -71.48 144.82 49.54 Favored 'General case' 0 C--O 1.242 0.663 0 O-C-N 123.999 0.812 . . . . 0.0 109.325 177.097 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 267' ' ' ILE . . . . . 0.687 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.5 pp -126.71 155.16 37.21 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-O 120.753 0.311 . . . . 0.0 111.501 -179.704 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . 0.638 ' HA ' HG23 ' A' ' 244' ' ' THR . 65.9 mttm -127.99 123.31 34.45 Favored 'General case' 0 C--O 1.239 0.548 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 177.496 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.71 HG22 ' OG1' ' A' ' 244' ' ' THR . 34.6 m -81.42 105.11 10.93 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.689 0 CA-C-O 121.284 0.564 . . . . 0.0 112.484 -176.398 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 92.4 mt -67.13 -41.42 86.15 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.639 -0.709 . . . . 0.0 110.089 175.927 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -150.51 -177.65 24.64 Favored Glycine 0 CA--C 1.52 0.356 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 -179.202 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 272' ' ' PRO . . . . . 0.605 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 33.7 Cg_endo -62.51 -32.23 80.17 Favored 'Trans proline' 0 C--N 1.309 -1.541 0 C-N-CA 121.883 1.722 . . . . 0.0 110.726 -177.203 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 273' ' ' TYR . . . . . 0.538 ' CE1' ' HA ' ' A' ' 236' ' ' ASP . 74.2 m-85 -116.87 0.07 12.39 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.608 -0.724 . . . . 0.0 112.89 -179.015 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -120.17 127.71 52.73 Favored 'General case' 0 C--O 1.242 0.696 0 C-N-CA 120.658 -0.417 . . . . 0.0 111.659 178.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 275' ' ' PHE . . . . . 0.536 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -133.43 162.68 31.21 Favored 'General case' 0 CA--C 1.501 -0.936 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.535 177.12 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . 0.521 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 4.4 p -134.4 146.92 50.32 Favored 'General case' 0 C--N 1.313 -0.984 0 C-N-CA 119.949 -0.701 . . . . 0.0 111.629 -178.579 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . 0.565 HG22 HG22 ' A' ' 267' ' ' ILE . 34.9 pt -137.26 167.8 22.52 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.961 0 CA-C-N 114.694 -1.139 . . . . 0.0 111.481 -173.243 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 278' ' ' CYS . . . . . 0.404 ' C ' ' O ' ' A' ' 277' ' ' ILE . 71.7 m -22.05 -85.02 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.764 0 N-CA-C 113.771 1.026 . . . . 0.0 113.771 -175.409 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . 0.429 ' HB3' ' HB2' ' A' ' 282' ' ' ASN . 58.4 t0 -153.26 106.76 3.01 Favored 'General case' 0 CA--C 1.506 -0.743 0 CA-C-O 120.753 0.311 . . . . 0.0 110.372 179.552 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . 0.817 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 5.9 p -65.99 -27.46 68.15 Favored 'General case' 0 C--N 1.297 -1.695 0 CA-C-O 121.214 0.531 . . . . 0.0 111.057 177.07 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -64.81 -19.98 66.14 Favored 'General case' 0 C--N 1.314 -0.978 0 CA-C-N 115.464 -0.789 . . . . 0.0 109.183 174.776 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 282' ' ' ASN . . . . . 0.429 ' HB2' ' HB3' ' A' ' 279' ' ' ASP . 0.2 OUTLIER -87.76 -8.55 55.86 Favored 'General case' 0 CA--C 1.508 -0.667 0 N-CA-C 108.752 -0.832 . . . . 0.0 108.752 179.554 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . 1.057 ' CE2' HD21 ' A' ' 259' ' ' LEU . 13.3 m-85 -92.25 -77.01 0.44 Allowed 'General case' 0 N--CA 1.443 -0.798 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 174.159 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 169.23 -179.3 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 114.522 -1.217 . . . . 0.0 109.702 -174.401 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 35.8 t0 -85.62 132.96 34.07 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 116.496 -0.32 . . . . 0.0 111.179 178.804 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . 0.687 ' CZ ' ' HA ' ' A' ' 288' ' ' ARG . 91.1 t80 -68.56 130.56 43.21 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.096 -179.895 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 287' ' ' ILE . . . . . 0.424 HG13 ' HA3' ' A' ' 255' ' ' GLY . 85.8 mt -100.17 -63.11 1.76 Allowed 'Isoleucine or valine' 0 CA--C 1.514 -0.433 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 170.072 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . 0.687 ' HA ' ' CZ ' ' A' ' 286' ' ' TYR . 9.5 ptm180 -172.41 -173.2 1.02 Allowed 'General case' 0 C--O 1.243 0.726 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.987 175.307 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 68.48 -163.08 49.51 Favored Glycine 0 CA--C 1.507 -0.464 0 N-CA-C 110.629 -0.988 . . . . 0.0 110.629 175.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 113.97 124.61 4.07 Favored Glycine 0 N--CA 1.443 -0.889 0 C-N-CA 121.462 -0.399 . . . . 0.0 112.486 175.768 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . 0.445 HD12 ' HG3' ' A' ' 252' ' ' GLU . 92.2 mt -123.09 132.51 71.26 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 172.234 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . 0.469 ' HB ' ' CE2' ' A' ' 250' ' ' PHE . 4.9 p -118.1 133.45 64.86 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 C-N-CA 120.624 -0.431 . . . . 0.0 110.028 -176.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 3.9 m -128.13 146.56 50.67 Favored 'General case' 0 N--CA 1.446 -0.64 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.648 -175.142 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 294' ' ' GLN . . . . . 0.539 ' HG3' ' CE1' ' A' ' 242' ' ' PHE . 90.7 mt-30 -78.1 163.6 25.74 Favored 'General case' 0 CA--C 1.505 -0.778 0 CA-C-O 121.279 0.561 . . . . 0.0 110.224 176.481 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . 0.674 HG21 ' CB ' ' A' ' 264' ' ' PRO . 14.5 t -111.67 159.96 11.32 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-N 115.122 -0.945 . . . . 0.0 109.552 179.377 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 30.6 mttp -69.22 97.02 0.88 Allowed 'General case' 0 N--CA 1.438 -1.057 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 297' ' ' VAL . . . . . 0.459 ' HB ' ' HD2' ' A' ' 298' ' ' PRO . 22.5 m -103.04 170.73 5.91 Favored Pre-proline 0 C--N 1.31 -1.147 0 CA-C-N 115.769 -0.651 . . . . 0.0 109.675 -179.857 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 298' ' ' PRO . . . . . 0.459 ' HD2' ' HB ' ' A' ' 297' ' ' VAL . 33.9 Cg_exo -61.02 149.52 88.66 Favored 'Trans proline' 0 C--N 1.307 -1.637 0 C-N-CA 121.84 1.693 . . . . 0.0 109.404 174.043 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . 0.453 ' HG2' ' O ' ' A' ' 300' ' ' LYS . 50.4 tttm -42.67 140.54 1.27 Allowed 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.04 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 300' ' ' LYS . . . . . 0.532 ' HZ2' ' CD ' ' A' ' 243' ' ' GLU . 34.1 mttm -63.31 137.09 58.06 Favored 'General case' 0 C--O 1.244 0.777 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 175.672 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 301' ' ' ILE . . . . . 0.461 ' O ' HG13 ' A' ' 301' ' ' ILE . 45.9 pt -66.44 118.95 10.71 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.77 0 CA-C-N 115.765 -0.652 . . . . 0.0 112.291 -170.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 11.6 m -84.78 154.43 22.38 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.345 -0.843 . . . . 0.0 108.865 173.603 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 25.9 m-85 -100.48 141.42 33.36 Favored 'General case' 0 C--N 1.312 -1.031 0 N-CA-C 107.467 -1.309 . . . . 0.0 107.467 172.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 65.2 mttp -50.06 106.87 0.13 Allowed 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 119.684 -0.806 . . . . 0.0 110.098 -173.357 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -129.39 151.16 50.33 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 115.213 -0.903 . . . . 0.0 109.686 -176.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 20.8 mt -59.29 146.05 79.75 Favored Pre-proline 0 C--N 1.316 -0.849 0 C-N-CA 120.248 -0.581 . . . . 0.0 109.689 178.485 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . 0.414 ' O ' ' C ' ' A' ' 308' ' ' ALA . 58.4 Cg_endo -71.12 47.7 0.81 Allowed 'Trans proline' 0 N--CA 1.489 1.248 0 C-N-CA 122.291 1.994 . . . . 0.0 110.508 -179.577 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . 0.414 ' C ' ' O ' ' A' ' 307' ' ' PRO . . . -28.65 96.72 0.01 OUTLIER 'General case' 0 C--O 1.239 0.504 0 CA-C-N 115.05 -0.977 . . . . 0.0 112.015 -175.368 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 4.2 m -89.76 90.72 8.33 Favored 'General case' 0 C--O 1.238 0.483 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 173.72 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -65.3 106.17 1.29 Allowed 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.953 -171.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 70.3 t -116.35 127.76 73.86 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.059 0 N-CA-C 106.704 -1.591 . . . . 0.0 106.704 174.602 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 46.3 tp10 . . . . . 0 C--O 1.213 -0.868 0 CA-C-O 118.175 -0.917 . . . . 0.0 109.956 -174.281 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 . . . . . 0 N--CA 1.474 0.744 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 202' ' ' PHE . . . . . 0.411 ' C ' ' N ' ' A' ' 204' ' ' GLU . 0.4 OUTLIER -126.67 37.2 4.34 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.727 179.903 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -48.46 -19.73 1.33 Allowed Glycine 0 CA--C 1.521 0.45 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 178.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 204' ' ' GLU . . . . . 0.411 ' N ' ' C ' ' A' ' 202' ' ' PHE . 65.1 mm-40 -54.09 -19.49 5.01 Favored 'General case' 0 C--O 1.236 0.393 0 C-N-CA 122.761 0.424 . . . . 0.0 110.209 178.429 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 99.4 mt-10 -62.42 -39.74 94.29 Favored 'General case' 0 CA--C 1.512 -0.485 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 176.851 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 77.6 mtm -107.25 104.1 13.64 Favored 'General case' 0 N--CA 1.447 -0.612 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.634 177.301 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 12.1 m -115.02 128.85 72.02 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 176.47 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 52.3 tp -85.89 98.97 11.08 Favored 'General case' 0 N--CA 1.442 -0.855 0 C-N-CA 120.385 -0.526 . . . . 0.0 110.262 -177.245 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -107.35 -72.04 0.73 Allowed 'General case' 0 C--N 1.309 -1.157 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 175.209 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 210' ' ' ASP . . . . . 0.423 ' OD1' ' N ' ' A' ' 211' ' ' SER . 1.8 p30 -101.16 -48.33 4.44 Favored 'General case' 0 C--O 1.244 0.782 0 CA-C-N 115.785 -0.643 . . . . 0.0 109.698 170.902 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 211' ' ' SER . . . . . 0.433 ' OG ' ' HB2' ' A' ' 296' ' ' LYS . 2.2 m -122.44 157.08 32.7 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.66 -179.185 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 30.0 t-20 -91.59 110.51 21.83 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.78 0.324 . . . . 0.0 110.8 177.579 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 74.11 -39.9 1.02 Allowed Glycine 0 C--N 1.317 -0.509 0 CA-C-N 116.134 -0.485 . . . . 0.0 112.14 179.329 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 214' ' ' GLU . . . . . 0.458 ' CD ' HH12 ' A' ' 239' ' ' ARG . 76.2 mm-40 -67.41 123.36 20.17 Favored 'General case' 0 C--N 1.324 -0.506 0 C-N-CA 120.321 -0.552 . . . . 0.0 111.356 -179.611 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 215' ' ' GLN . . . . . 0.552 ' O ' ' N ' ' A' ' 217' ' ' LEU . 0.0 OUTLIER -111.82 178.36 1.0 Allowed Pre-proline 0 C--N 1.316 -0.857 0 N-CA-C 108.231 -1.025 . . . . 0.0 108.231 177.378 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 216' ' ' PRO . . . . . 0.517 ' HD2' ' HB2' ' A' ' 215' ' ' GLN . 34.2 Cg_exo -59.89 74.36 0.06 OUTLIER 'Trans proline' 0 N--CA 1.492 1.418 0 C-N-CA 121.242 1.295 . . . . 0.0 110.033 176.471 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 217' ' ' LEU . . . . . 0.792 HD13 ' N ' ' A' ' 218' ' ' SER . 1.3 tm? -76.3 129.07 36.11 Favored 'General case' 0 CA--C 1.51 -0.592 0 CA-C-N 115.281 -0.872 . . . . 0.0 109.418 -175.279 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 218' ' ' SER . . . . . 0.792 ' N ' HD13 ' A' ' 217' ' ' LEU . 75.6 m -114.72 131.45 56.76 Favored 'General case' 0 N--CA 1.438 -1.066 0 CA-C-N 115.846 -0.615 . . . . 0.0 109.358 178.238 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 219' ' ' ALA . . . . . 0.566 ' HB1' ' HB1' ' A' ' 238' ' ' ALA . . . -127.74 150.33 49.84 Favored 'General case' 0 CA--C 1.503 -0.845 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.899 -177.097 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 220' ' ' MET . . . . . 0.71 ' SD ' HG12 ' A' ' 291' ' ' ILE . 87.6 mmm -76.56 131.21 38.81 Favored 'General case' 0 N--CA 1.44 -0.926 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 176.587 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 91.5 t -75.51 128.21 37.14 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.311 0 N-CA-C 107.586 -1.265 . . . . 0.0 107.586 175.877 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 222' ' ' SER . . . . . 0.628 ' CB ' ' HG1' ' A' ' 233' ' ' THR . 0.1 OUTLIER -84.6 -67.33 0.8 Allowed 'General case' 0 N--CA 1.437 -1.087 0 C-N-CA 119.717 -0.793 . . . . 0.0 109.375 179.703 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 3.6 ptm -137.9 151.39 47.97 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 112.552 0.575 . . . . 0.0 112.552 173.056 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 224' ' ' VAL . . . . . 0.717 HG22 ' HB ' ' A' ' 232' ' ' VAL . 68.8 t -123.78 132.59 71.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 174.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 28.2 p -92.76 131.32 37.92 Favored 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 121.031 -0.268 . . . . 0.0 110.38 179.588 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 6.0 ttmt -77.94 87.61 4.12 Favored 'General case' 0 N--CA 1.446 -0.646 0 C-N-CA 119.477 -0.889 . . . . 0.0 109.152 178.548 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 227' ' ' ASP . . . . . 0.526 ' N ' ' OG1' ' A' ' 280' ' ' THR . 47.5 t0 -158.63 175.0 14.19 Favored 'General case' 0 C--N 1.312 -1.056 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.532 -179.574 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 228' ' ' ASN . . . . . 0.475 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.9 OUTLIER -140.85 123.56 9.75 Favored Pre-proline 0 C--O 1.237 0.406 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.112 173.866 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 229' ' ' PRO . . . . . 0.475 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 44.8 Cg_endo -66.31 144.7 67.88 Favored 'Cis proline' 0 C--N 1.313 -1.294 0 C-N-CA 122.492 -1.878 . . . . 0.0 109.308 -2.029 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . 0.48 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -82.71 144.9 23.37 Favored Glycine 0 C--N 1.312 -0.8 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 -178.179 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 231' ' ' VAL . . . . . 0.416 HG23 HD12 ' A' ' 270' ' ' LEU . 2.6 p -121.22 130.53 74.56 Favored 'Isoleucine or valine' 0 C--O 1.241 0.657 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 176.299 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 232' ' ' VAL . . . . . 0.717 ' HB ' HG22 ' A' ' 224' ' ' VAL . 0.7 OUTLIER -132.66 157.14 42.95 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 CA-C-N 116.264 -0.425 . . . . 0.0 109.874 -177.413 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 233' ' ' THR . . . . . 0.652 HG22 HG22 ' A' ' 274' ' ' THR . 61.6 p -110.35 158.47 18.41 Favored 'General case' 0 N--CA 1.429 -1.486 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.229 179.711 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.8 m -113.08 148.97 34.14 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 172.656 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 40.2 tp -56.69 133.73 54.17 Favored 'General case' 0 C--N 1.308 -1.22 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 -179.69 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 236' ' ' ASP . . . . . 0.409 ' O ' ' CE1' ' A' ' 273' ' ' TYR . 7.8 t70 -52.72 -37.96 60.02 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.683 -171.523 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 10.0 mm-40 -75.31 -6.67 51.1 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.076 -178.011 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . 0.566 ' HB1' ' HB1' ' A' ' 219' ' ' ALA . . . -97.39 99.88 11.32 Favored 'General case' 0 C--O 1.239 0.505 0 N-CA-C 112.554 0.575 . . . . 0.0 112.554 -175.453 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 239' ' ' ARG . . . . . 0.458 HH12 ' CD ' ' A' ' 214' ' ' GLU . 0.0 OUTLIER -70.61 66.49 0.34 Allowed 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 116.519 -0.31 . . . . 0.0 110.678 175.396 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 240' ' ' HIS . . . . . 0.6 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 14.0 p80 -33.49 -49.04 0.28 Allowed 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.227 0.537 . . . . 0.0 111.291 -178.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 79.41 19.31 71.83 Favored Glycine 0 C--O 1.245 0.841 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 178.432 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 242' ' ' PHE . . . . . 0.673 ' CD1' ' HB3' ' A' ' 294' ' ' GLN . 4.3 m-30 -79.85 141.53 36.1 Favored 'General case' 0 N--CA 1.444 -0.745 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 -179.256 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 243' ' ' GLU . . . . . 0.473 ' HB2' ' HB2' ' A' ' 246' ' ' ASP . 96.5 mt-10 -109.35 158.37 17.97 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 178.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 244' ' ' THR . . . . . 0.603 HG21 HD22 ' A' ' 306' ' ' LEU . 7.9 m -65.14 123.98 20.93 Favored 'General case' 0 C--N 1.312 -1.022 0 C-N-CA 119.115 -1.034 . . . . 0.0 108.538 178.101 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 85.87 8.04 80.11 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.559 -1.016 . . . . 0.0 110.559 -176.374 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 246' ' ' ASP . . . . . 0.473 ' HB2' ' HB2' ' A' ' 243' ' ' GLU . 45.7 t0 -82.44 167.19 18.7 Favored 'General case' 0 CA--C 1.518 -0.287 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 179.616 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 247' ' ' PHE . . . . . 0.419 ' HA ' ' O ' ' A' ' 265' ' ' MET . 95.8 m-85 -111.95 137.77 49.48 Favored 'General case' 0 C--O 1.24 0.584 0 CA-C-O 120.64 0.257 . . . . 0.0 111.295 -177.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.562 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.6 m -133.58 160.89 41.96 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.306 0 CA-C-N 116.557 -0.292 . . . . 0.0 111.159 177.5 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 2.9 p -117.84 152.01 36.21 Favored 'General case' 0 C--N 1.318 -0.786 0 C-N-CA 123.958 0.903 . . . . 0.0 109.404 175.082 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 250' ' ' PHE . . . . . 0.644 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 75.0 m-85 -110.92 146.56 36.35 Favored 'General case' 0 CA--C 1.506 -0.715 0 C-N-CA 122.695 0.398 . . . . 0.0 110.758 -178.007 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 2.0 m -154.59 154.65 33.37 Favored 'General case' 0 C--N 1.31 -1.149 0 C-N-CA 120.765 -0.374 . . . . 0.0 110.145 176.778 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 73.5 mm-40 55.13 30.18 13.94 Favored 'General case' 0 C--N 1.313 -0.979 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.787 176.17 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 0.703 HG22 ' HA2' ' A' ' 290' ' ' GLY . 2.8 t -97.93 115.24 37.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 177.269 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . 0.416 ' HG3' ' HD2' ' A' ' 288' ' ' ARG . 2.0 mm100 -79.1 137.76 37.64 Favored 'General case' 0 C--O 1.238 0.473 0 CA-C-O 121.035 0.445 . . . . 0.0 111.481 -179.769 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . 0.405 ' N ' HD12 ' A' ' 287' ' ' ILE . . . 81.99 -55.59 4.92 Favored Glycine 0 CA--C 1.506 -0.479 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 -178.579 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 256' ' ' MET . . . . . 0.552 ' SD ' HG11 ' A' ' 224' ' ' VAL . 3.1 ttm -81.24 49.93 1.35 Allowed 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.814 0.816 . . . . 0.0 109.215 176.927 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 46.7 pt -72.13 -20.73 20.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-N 114.836 -1.074 . . . . 0.0 110.974 -176.61 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 258' ' ' GLN . . . . . 0.599 ' O ' ' SG ' ' A' ' 262' ' ' CYS . 2.8 tp-100 -54.48 -41.07 69.12 Favored 'General case' 0 N--CA 1.448 -0.555 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 179.147 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 259' ' ' LEU . . . . . 0.689 HD21 ' CZ ' ' A' ' 283' ' ' PHE . 98.2 mt -63.09 -39.92 96.14 Favored 'General case' 0 N--CA 1.445 -0.695 0 CA-C-N 114.861 -1.063 . . . . 0.0 110.116 177.545 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -59.76 -40.74 89.19 Favored 'General case' 0 CA--C 1.51 -0.591 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 -178.161 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -88.59 -1.12 81.16 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 115.548 -0.751 . . . . 0.0 112.106 -179.594 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 262' ' ' CYS . . . . . 0.599 ' SG ' ' O ' ' A' ' 258' ' ' GLN . 61.5 m -83.1 153.34 24.91 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-N 117.157 0.479 . . . . 0.0 111.017 -179.259 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 5.9 mm100 -79.07 163.96 57.33 Favored Pre-proline 0 C--N 1.323 -0.567 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 169.116 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 264' ' ' PRO . . . . . 0.562 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 36.7 Cg_exo -59.54 143.32 99.71 Favored 'Trans proline' 0 C--N 1.307 -1.608 0 C-N-CA 121.013 1.142 . . . . 0.0 111.105 -176.823 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 265' ' ' MET . . . . . 0.642 ' N ' ' SD ' ' A' ' 265' ' ' MET . 0.9 OUTLIER -126.88 160.76 30.02 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 116.627 -0.26 . . . . 0.0 111.396 -175.966 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 3.2 tt0 -71.44 137.72 48.49 Favored 'General case' 0 C--O 1.241 0.632 0 O-C-N 123.653 0.596 . . . . 0.0 110.224 178.697 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 267' ' ' ILE . . . . . 0.732 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.7 pp -132.01 162.96 38.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.113 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 64.3 mttp -124.85 136.22 53.61 Favored 'General case' 0 C--O 1.216 -0.705 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 175.189 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 15.9 m -95.64 102.3 13.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 CA-C-O 121.355 0.597 . . . . 0.0 111.634 -179.403 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 270' ' ' LEU . . . . . 0.416 HD12 HG23 ' A' ' 231' ' ' VAL . 95.9 mt -66.8 -39.77 87.87 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.672 178.278 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -144.73 -170.3 13.82 Favored Glycine 0 N--CA 1.465 0.585 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 -176.516 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 272' ' ' PRO . . . . . 0.6 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 28.6 Cg_endo -59.31 -37.82 88.55 Favored 'Trans proline' 0 N--CA 1.491 1.37 0 C-N-CA 121.95 1.767 . . . . 0.0 111.88 -177.103 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 273' ' ' TYR . . . . . 0.409 ' CE1' ' O ' ' A' ' 236' ' ' ASP . 23.1 m-85 -124.03 5.53 8.61 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 111.726 0.269 . . . . 0.0 111.726 176.834 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 274' ' ' THR . . . . . 0.652 HG22 HG22 ' A' ' 233' ' ' THR . 0.7 OUTLIER -105.99 128.43 53.82 Favored 'General case' 0 C--N 1.32 -0.715 0 C-N-CA 120.586 -0.445 . . . . 0.0 110.724 -175.757 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 275' ' ' PHE . . . . . 0.562 ' CD1' HG22 ' A' ' 232' ' ' VAL . 0.0 OUTLIER -136.11 161.57 35.35 Favored 'General case' 0 CA--C 1.505 -0.77 0 C-N-CA 120.828 -0.349 . . . . 0.0 111.871 179.154 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . 0.48 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 3.7 p -131.83 139.86 48.98 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-O 121.272 0.558 . . . . 0.0 111.883 -175.413 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . 0.497 HG22 HG22 ' A' ' 267' ' ' ILE . 37.0 pt -136.95 164.56 30.02 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.723 0 CA-C-N 114.69 -1.141 . . . . 0.0 112.378 -172.099 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 278' ' ' CYS . . . . . 0.449 ' O ' ' HA ' ' A' ' 229' ' ' PRO . 71.2 m -29.73 -92.15 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.402 0 N-CA-C 114.113 1.153 . . . . 0.0 114.113 -176.794 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 19.8 t0 -145.78 114.38 6.79 Favored 'General case' 0 CA--C 1.503 -0.847 0 CA-C-O 120.719 0.295 . . . . 0.0 111.214 -175.673 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . 0.733 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 21.7 p -65.53 -30.59 71.36 Favored 'General case' 0 C--N 1.3 -1.586 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.576 176.18 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -65.32 -20.16 66.28 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 115.271 -0.877 . . . . 0.0 109.321 177.339 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -87.37 -8.09 57.02 Favored 'General case' 0 CA--C 1.506 -0.717 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.848 179.663 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . 0.733 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 5.3 m-85 -94.96 -68.38 0.8 Allowed 'General case' 0 N--CA 1.443 -0.824 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 172.808 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 284' ' ' SER . . . . . 0.406 ' OG ' ' HA ' ' A' ' 256' ' ' MET . 1.7 p 164.39 -87.93 0.0 OUTLIER 'General case' 0 C--O 1.244 0.763 0 CA-C-N 115.246 -0.888 . . . . 0.0 110.909 176.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 285' ' ' ASP . . . . . 0.492 ' O ' ' N ' ' A' ' 256' ' ' MET . 3.7 t0 -157.59 165.32 35.86 Favored 'General case' 0 C--O 1.22 -0.496 0 CA-C-N 116.614 -0.266 . . . . 0.0 111.055 179.579 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . 0.461 ' O ' ' CD2' ' A' ' 286' ' ' TYR . 35.7 t80 -106.8 89.22 2.95 Favored 'General case' 0 C--N 1.319 -0.728 0 C-N-CA 123.317 0.647 . . . . 0.0 110.038 179.052 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 287' ' ' ILE . . . . . 0.414 HG22 ' HG3' ' A' ' 288' ' ' ARG . 96.5 mt -70.44 -46.11 72.04 Favored 'Isoleucine or valine' 0 C--O 1.24 0.597 0 CA-C-O 121.197 0.522 . . . . 0.0 110.14 179.235 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . 0.416 ' HD2' ' HG3' ' A' ' 254' ' ' GLN . 0.0 OUTLIER 173.45 173.09 0.15 Allowed 'General case' 0 C--O 1.243 0.755 0 CA-C-N 115.588 -0.733 . . . . 0.0 111.219 -177.623 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 68.08 -140.9 36.79 Favored Glycine 0 CA--C 1.508 -0.363 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 175.39 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . 0.703 ' HA2' HG22 ' A' ' 253' ' ' VAL . . . 97.31 115.58 3.34 Favored Glycine 0 N--CA 1.442 -0.913 0 C-N-CA 121.487 -0.387 . . . . 0.0 112.148 176.71 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . 0.71 HG12 ' SD ' ' A' ' 220' ' ' MET . 89.8 mt -116.08 130.46 70.77 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.93 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 174.111 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 2.8 p -118.08 127.34 75.29 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 -179.231 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . 0.42 ' HA ' ' O ' ' A' ' 217' ' ' LEU . 4.7 m -121.43 122.76 40.5 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.258 -176.155 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 294' ' ' GLN . . . . . 0.673 ' HB3' ' CD1' ' A' ' 242' ' ' PHE . 12.8 pt20 -66.57 159.66 26.94 Favored 'General case' 0 CA--C 1.497 -1.093 0 CA-C-O 121.257 0.551 . . . . 0.0 111.872 -179.358 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 2.5 t -144.15 96.26 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.563 0 CA-C-N 114.184 -1.371 . . . . 0.0 108.153 172.2 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 296' ' ' LYS . . . . . 0.433 ' HB2' ' OG ' ' A' ' 211' ' ' SER . 51.4 mttp -83.77 101.72 11.79 Favored 'General case' 0 N--CA 1.438 -1.073 0 N-CA-C 109.009 -0.738 . . . . 0.0 109.009 176.34 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 18.6 m -63.05 135.97 96.47 Favored Pre-proline 0 N--CA 1.442 -0.841 0 CA-C-N 115.475 -0.784 . . . . 0.0 110.991 -173.794 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -64.38 -20.48 66.39 Favored 'Trans proline' 0 N--CA 1.492 1.432 0 C-N-CA 122.365 2.043 . . . . 0.0 110.174 177.011 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 21.2 mmtp -96.05 92.92 6.68 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 173.06 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 47.4 mttp -84.55 140.81 31.16 Favored 'General case' 0 C--N 1.31 -1.141 0 N-CA-C 109.67 -0.492 . . . . 0.0 109.67 -179.009 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 301' ' ' ILE . . . . . 0.644 HD12 ' H ' ' A' ' 301' ' ' ILE . 0.3 OUTLIER -80.44 164.06 3.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 116.64 -0.255 . . . . 0.0 110.618 178.302 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 4.3 m -78.88 79.16 5.3 Favored 'General case' 0 C--N 1.323 -0.562 0 C-N-CA 120.115 -0.634 . . . . 0.0 110.525 -177.674 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 303' ' ' PHE . . . . . 0.561 ' HD1' HD13 ' A' ' 301' ' ' ILE . 81.1 m-85 -133.45 140.56 47.36 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-N 115.251 -0.886 . . . . 0.0 108.67 173.282 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 19.4 mttt -80.49 148.55 30.4 Favored 'General case' 0 C--N 1.315 -0.91 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 176.703 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 2.6 m -57.76 141.39 48.91 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 107.726 -1.213 . . . . 0.0 107.726 177.166 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 306' ' ' LEU . . . . . 0.603 HD22 HG21 ' A' ' 244' ' ' THR . 0.9 OUTLIER -66.5 176.85 0.93 Allowed Pre-proline 0 C--N 1.312 -1.033 0 C-N-CA 120.559 -0.456 . . . . 0.0 109.852 -178.104 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . 0.477 ' O ' ' N ' ' A' ' 309' ' ' SER . 38.1 Cg_exo -58.89 -18.46 42.31 Favored 'Trans proline' 0 N--CA 1.494 1.52 0 C-N-CA 122.336 2.024 . . . . 0.0 111.446 179.41 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -59.45 74.73 0.01 OUTLIER 'General case' 0 C--O 1.237 0.428 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.241 -179.338 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.477 ' N ' ' O ' ' A' ' 307' ' ' PRO . 4.8 m -130.52 158.87 38.78 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.539 -176.636 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 96.6 mt -66.96 144.86 55.97 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.087 178.477 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 29.0 m -134.09 162.37 39.31 Favored 'Isoleucine or valine' 0 C--O 1.24 0.598 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.549 -179.728 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 99.4 mt-10 . . . . . 0 C--O 1.205 -1.266 0 CA-C-O 118.085 -0.959 . . . . 0.0 110.128 179.14 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . 0.623 ' O ' ' N ' ' A' ' 203' ' ' GLY . 76.5 mm-40 . . . . . 0 N--CA 1.48 1.057 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 202' ' ' PHE . . . . . 0.499 ' CG ' ' N ' ' A' ' 203' ' ' GLY . 0.1 OUTLIER 47.91 -58.04 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.767 0 C-N-CA 124.901 1.28 . . . . 0.0 114.028 -176.682 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . 0.623 ' N ' ' O ' ' A' ' 201' ' ' GLU . . . -68.91 -41.92 80.35 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 110.942 -0.863 . . . . 0.0 110.942 177.861 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -63.1 -40.13 96.72 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.358 0.599 . . . . 0.0 110.545 -175.911 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 205' ' ' GLU . . . . . 0.48 ' OE2' ' N ' ' A' ' 201' ' ' GLU . 52.0 mp0 -62.68 -17.43 60.54 Favored 'General case' 0 C--N 1.306 -1.321 0 CA-C-N 115.256 -0.884 . . . . 0.0 111.351 -178.561 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 12.5 tpt -71.08 124.76 25.15 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.825 0.345 . . . . 0.0 110.767 -177.519 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . 0.619 ' O ' ' N ' ' A' ' 209' ' ' THR . 28.6 m -128.8 167.73 23.48 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.766 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 177.881 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 10.9 mp -59.64 70.32 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.546 0 CA-C-O 121.82 0.819 . . . . 0.0 109.926 -177.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 209' ' ' THR . . . . . 0.619 ' N ' ' O ' ' A' ' 207' ' ' VAL . 5.8 m -73.45 -42.98 61.28 Favored 'General case' 0 C--N 1.307 -1.254 0 CA-C-N 114.507 -1.224 . . . . 0.0 110.616 -177.269 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 10.6 p-10 -57.48 -46.93 83.15 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.016 -0.993 . . . . 0.0 112.805 -172.618 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 4.7 m -115.09 109.96 18.84 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 112.712 0.634 . . . . 0.0 112.712 -174.395 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 99.4 m-20 -102.25 130.5 48.95 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 170.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 60.1 66.21 2.87 Favored Glycine 0 C--O 1.239 0.418 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 -176.271 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 70.6 mt-10 -56.94 145.58 29.61 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.03 0.443 . . . . 0.0 112.006 -175.384 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -40.84 146.55 0.46 Allowed Pre-proline 0 C--N 1.324 -0.536 0 CA-C-N 115.072 -0.967 . . . . 0.0 112.55 -175.671 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_exo -62.81 154.88 63.13 Favored 'Trans proline' 0 N--CA 1.495 1.616 0 C-N-CA 123.05 2.5 . . . . 0.0 109.994 170.794 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 217' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -45.95 118.34 1.83 Allowed 'General case' 0 C--O 1.244 0.774 0 C-N-CA 120.343 -0.543 . . . . 0.0 109.868 -177.256 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 218' ' ' SER . . . . . 0.423 ' OG ' ' OG ' ' A' ' 293' ' ' SER . 22.4 m -131.9 152.35 51.11 Favored 'General case' 0 N--CA 1.442 -0.829 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.529 -175.787 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -145.79 156.06 43.34 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.56 179.855 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 97.7 mtp -76.46 140.39 41.23 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 174.62 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 97.9 t -80.89 129.21 37.91 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.014 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 178.263 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 29.0 m -77.98 -70.58 0.47 Allowed 'General case' 0 N--CA 1.434 -1.273 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 177.36 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 5.9 ptm -138.25 160.29 39.85 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.275 174.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 224' ' ' VAL . . . . . 0.522 HG11 ' SD ' ' A' ' 256' ' ' MET . 61.3 t -124.53 132.13 71.77 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.037 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 173.867 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -100.35 120.33 39.78 Favored 'General case' 0 C--N 1.313 -1.013 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 -177.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 226' ' ' LYS . . . . . 0.519 ' NZ ' ' OD1' ' A' ' 285' ' ' ASP . 0.0 OUTLIER -71.82 82.11 0.9 Allowed 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.003 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 227' ' ' ASP . . . . . 0.513 ' N ' ' OG1' ' A' ' 280' ' ' THR . 4.1 t70 -153.49 -175.45 5.36 Favored 'General case' 0 C--O 1.246 0.886 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.037 -179.319 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 228' ' ' ASN . . . . . 0.557 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.2 OUTLIER -142.12 124.08 8.98 Favored Pre-proline 0 C--N 1.331 -0.228 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.307 176.696 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 229' ' ' PRO . . . . . 0.557 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 33.7 Cg_exo -61.71 147.02 50.93 Favored 'Cis proline' 0 N--CA 1.489 1.213 0 C-N-CA 123.091 -1.629 . . . . 0.0 109.984 -1.73 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . 0.635 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -68.71 134.12 27.77 Favored Glycine 0 C--N 1.3 -1.461 0 N-CA-C 108.864 -1.694 . . . . 0.0 108.864 179.064 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 231' ' ' VAL . . . . . 0.457 ' HB ' ' OG ' ' A' ' 276' ' ' SER . 2.1 p -125.7 132.34 70.94 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 117.332 0.566 . . . . 0.0 110.11 179.549 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 232' ' ' VAL . . . . . 0.458 HG22 ' CD1' ' A' ' 275' ' ' PHE . 0.7 OUTLIER -135.07 156.98 40.33 Favored 'Isoleucine or valine' 0 C--O 1.248 0.979 0 C-N-CA 120.754 -0.378 . . . . 0.0 110.084 -178.697 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 233' ' ' THR . . . . . 0.514 HG22 HG23 ' A' ' 274' ' ' THR . 14.9 p -105.56 154.8 19.89 Favored 'General case' 0 N--CA 1.435 -1.209 0 CA-C-N 116.134 -0.485 . . . . 0.0 109.822 176.844 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 2.1 m -111.78 161.07 16.71 Favored 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 176.043 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 38.4 tp -60.07 121.91 13.06 Favored 'General case' 0 C--N 1.309 -1.157 0 N-CA-C 107.143 -1.428 . . . . 0.0 107.143 178.659 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 236' ' ' ASP . . . . . 0.478 ' O ' ' NH2' ' A' ' 239' ' ' ARG . 13.9 p-10 -51.67 -44.93 63.24 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.29 0.566 . . . . 0.0 111.021 -171.55 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -64.9 -35.17 80.29 Favored 'General case' 0 C--N 1.301 -1.538 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.128 -179.355 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -70.98 95.9 1.23 Allowed 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.777 -179.198 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 239' ' ' ARG . . . . . 0.578 ' NH2' ' OH ' ' A' ' 273' ' ' TYR . 0.0 OUTLIER -62.66 99.09 0.14 Allowed 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 172.124 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 240' ' ' HIS . . . . . 0.474 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 7.2 p80 -59.48 -46.47 88.71 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.891 -175.278 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 83.5 13.09 76.93 Favored Glycine 0 C--N 1.32 -0.351 0 N-CA-C 110.505 -1.038 . . . . 0.0 110.505 -178.897 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 242' ' ' PHE . . . . . 0.518 ' CD1' ' HB3' ' A' ' 294' ' ' GLN . 4.2 m-30 -82.01 138.3 34.91 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.422 -0.585 . . . . 0.0 109.422 179.511 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -110.28 161.96 15.09 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-O 121.315 0.578 . . . . 0.0 109.656 175.642 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 244' ' ' THR . . . . . 0.436 HG22 ' HD2' ' A' ' 268' ' ' LYS . 0.2 OUTLIER -63.71 111.41 2.4 Favored 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 178.589 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 104.86 0.15 42.07 Favored Glycine 0 CA--C 1.52 0.385 0 N-CA-C 111.661 -0.576 . . . . 0.0 111.661 -178.717 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 42.3 m-20 -72.95 161.65 30.44 Favored 'General case' 0 CA--C 1.514 -0.417 0 CA-C-N 116.918 0.359 . . . . 0.0 110.562 175.703 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 247' ' ' PHE . . . . . 0.458 ' HA ' ' O ' ' A' ' 265' ' ' MET . 70.3 m-85 -109.49 130.31 55.51 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.929 -0.578 . . . . 0.0 109.721 177.471 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.477 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.3 m -132.4 161.29 41.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 C-N-CA 120.619 -0.432 . . . . 0.0 110.817 179.548 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 3.4 p -126.64 149.61 49.4 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.842 174.427 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 250' ' ' PHE . . . . . 0.607 ' CD1' HD22 ' A' ' 259' ' ' LEU . 71.6 m-85 -102.99 162.42 12.95 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.117 -176.104 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 69.1 m -157.31 155.21 30.29 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.323 174.451 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 19.3 mt-10 51.76 26.37 3.45 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 113.123 0.786 . . . . 0.0 113.123 178.733 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 0.484 HG22 ' HA2' ' A' ' 290' ' ' GLY . 16.2 t -82.18 117.47 28.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 174.22 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 87.4 mt-30 -89.28 144.36 26.15 Favored 'General case' 0 C--O 1.245 0.859 0 CA-C-O 121.218 0.533 . . . . 0.0 111.486 -176.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 77.82 -60.42 3.77 Favored Glycine 0 N--CA 1.449 -0.475 0 N-CA-C 109.702 -1.359 . . . . 0.0 109.702 -177.184 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 256' ' ' MET . . . . . 0.522 ' SD ' HG11 ' A' ' 224' ' ' VAL . 57.3 ttm -86.57 65.43 9.03 Favored 'General case' 0 C--N 1.318 -0.775 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 174.831 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 257' ' ' ILE . . . . . 0.404 ' O ' ' HB2' ' A' ' 260' ' ' ASN . 47.4 pt -75.42 -17.22 15.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 115.176 -0.92 . . . . 0.0 111.322 -174.31 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 258' ' ' GLN . . . . . 0.4 ' O ' ' N ' ' A' ' 262' ' ' CYS . 6.6 mp0 -55.3 -35.98 65.69 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 -178.742 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 259' ' ' LEU . . . . . 1.01 HD21 ' CE2' ' A' ' 283' ' ' PHE . 91.6 mt -62.18 -41.83 98.7 Favored 'General case' 0 C--N 1.315 -0.897 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.785 176.87 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 260' ' ' ASN . . . . . 0.433 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 97.5 m-20 -60.84 -40.32 92.4 Favored 'General case' 0 CA--C 1.512 -0.495 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 179.753 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -91.28 -3.79 69.21 Favored Glycine 0 CA--C 1.522 0.489 0 CA-C-N 115.466 -0.788 . . . . 0.0 111.968 -177.104 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 262' ' ' CYS . . . . . 0.4 ' N ' ' O ' ' A' ' 258' ' ' GLN . 2.9 m -87.18 141.78 28.39 Favored 'General case' 0 CA--C 1.514 -0.424 0 CA-C-N 117.249 0.524 . . . . 0.0 110.812 -177.053 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 29.3 pt20 -63.36 165.58 10.92 Favored Pre-proline 0 C--N 1.323 -0.554 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 176.054 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 264' ' ' PRO . . . . . 0.477 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 36.8 Cg_exo -60.1 141.9 97.19 Favored 'Trans proline' 0 C--N 1.316 -1.148 0 N-CA-C 109.245 -1.098 . . . . 0.0 109.245 177.42 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 265' ' ' MET . . . . . 0.458 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 23.1 ptp -134.21 155.34 50.3 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 111.969 0.359 . . . . 0.0 111.969 -173.002 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 266' ' ' GLU . . . . . 0.414 ' HB2' ' CE2' ' A' ' 247' ' ' PHE . 78.5 tt0 -71.5 137.87 48.49 Favored 'General case' 0 C--O 1.239 0.519 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.865 179.306 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 267' ' ' ILE . . . . . 0.701 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.8 pp -129.03 164.19 32.07 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.995 -177.16 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . 0.436 ' HD2' HG22 ' A' ' 244' ' ' THR . 48.4 mmtm -129.05 125.09 36.53 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 109.114 -0.698 . . . . 0.0 109.114 176.158 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 14.9 m -79.24 125.12 38.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 C-N-CA 120.743 -0.383 . . . . 0.0 110.578 179.801 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 270' ' ' LEU . . . . . 0.539 HD11 ' OG ' ' A' ' 276' ' ' SER . 78.6 mt -101.64 -12.49 18.38 Favored 'General case' 0 C--O 1.237 0.427 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.284 -179.034 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -164.4 -179.57 38.62 Favored Glycine 0 C--N 1.317 -0.491 0 N-CA-C 109.892 -1.283 . . . . 0.0 109.892 -177.048 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 272' ' ' PRO . . . . . 0.474 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 26.2 Cg_endo -59.7 -39.71 71.14 Favored 'Trans proline' 0 C--N 1.306 -1.687 0 C-N-CA 122.159 1.906 . . . . 0.0 111.148 -177.577 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 273' ' ' TYR . . . . . 0.578 ' OH ' ' NH2' ' A' ' 239' ' ' ARG . 29.2 m-85 -123.95 13.4 9.14 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-N 115.328 -0.851 . . . . 0.0 110.686 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 274' ' ' THR . . . . . 0.514 HG23 HG22 ' A' ' 233' ' ' THR . 0.2 OUTLIER -119.1 127.49 53.41 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 -174.433 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 275' ' ' PHE . . . . . 0.559 ' CE2' HG21 ' A' ' 267' ' ' ILE . 0.0 OUTLIER -140.47 161.75 36.98 Favored 'General case' 0 CA--C 1.502 -0.89 0 C-N-CA 120.645 -0.422 . . . . 0.0 112.126 -179.588 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . 0.539 ' OG ' HD11 ' A' ' 270' ' ' LEU . 1.8 m -130.07 156.07 45.12 Favored 'General case' 0 N--CA 1.433 -1.307 0 CA-C-O 121.568 0.699 . . . . 0.0 112.75 -177.172 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . 0.746 ' C ' HD12 ' A' ' 277' ' ' ILE . 2.3 pp -137.16 -179.28 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.273 0 CA-C-N 113.682 -1.599 . . . . 0.0 109.113 -177.518 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -40.1 -88.88 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.406 0 O-C-N 123.516 0.51 . . . . 0.0 112.185 179.753 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . 0.493 ' O ' ' ND2' ' A' ' 282' ' ' ASN . 65.5 t0 -149.22 115.55 5.81 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-O 120.602 0.239 . . . . 0.0 111.26 -178.097 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . 0.635 HG23 ' HA3' ' A' ' 230' ' ' GLY . 14.6 p -63.56 -29.65 70.88 Favored 'General case' 0 C--N 1.308 -1.233 0 CA-C-O 121.295 0.569 . . . . 0.0 110.166 175.25 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -63.82 -19.57 65.12 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-N 115.329 -0.851 . . . . 0.0 109.763 177.146 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 282' ' ' ASN . . . . . 0.493 ' ND2' ' O ' ' A' ' 279' ' ' ASP . 0.0 OUTLIER -95.05 -7.97 38.02 Favored 'General case' 0 C--N 1.344 0.334 0 C-N-CA 120.507 -0.477 . . . . 0.0 110.436 177.949 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . 1.01 ' CE2' HD21 ' A' ' 259' ' ' LEU . 21.4 m-30 -85.2 -80.74 0.21 Allowed 'General case' 0 CA--C 1.512 -0.498 0 CA-C-O 121.854 0.835 . . . . 0.0 109.035 175.609 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 284' ' ' SER . . . . . 0.435 ' OG ' ' HA ' ' A' ' 256' ' ' MET . 0.1 OUTLIER 175.45 -173.37 0.08 Allowed 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 114.121 -1.399 . . . . 0.0 108.196 -176.442 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 285' ' ' ASP . . . . . 0.519 ' OD1' ' NZ ' ' A' ' 226' ' ' LYS . 33.4 t0 -91.18 116.3 28.7 Favored 'General case' 0 C--N 1.316 -0.876 0 C-N-CA 121.045 -0.262 . . . . 0.0 111.668 -178.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . 0.405 ' OH ' ' NH2' ' A' ' 288' ' ' ARG . 1.1 t80 -64.94 135.32 55.54 Favored 'General case' 0 CA--C 1.511 -0.53 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.37 179.24 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 287' ' ' ILE . . . . . 0.518 ' C ' ' HG2' ' A' ' 288' ' ' ARG . 96.9 mt -118.71 -74.78 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.433 -1.306 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.737 174.731 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . 0.533 ' HA ' ' NE ' ' A' ' 288' ' ' ARG . 4.1 mmp_? -148.71 175.58 11.09 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.587 -177.511 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 75.35 -156.3 48.35 Favored Glycine 0 C--O 1.238 0.393 0 N-CA-C 110.689 -0.964 . . . . 0.0 110.689 178.145 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . 0.484 ' HA2' HG22 ' A' ' 253' ' ' VAL . . . 103.82 111.56 3.59 Favored Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 121.712 -0.28 . . . . 0.0 112.524 176.416 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 93.2 mt -121.16 131.7 72.37 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.928 0 N-CA-C 107.532 -1.284 . . . . 0.0 107.532 173.605 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 2.8 p -122.61 137.07 57.38 Favored 'Isoleucine or valine' 0 C--O 1.242 0.683 0 C-N-CA 120.702 -0.399 . . . . 0.0 111.17 -174.893 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . 0.423 ' OG ' ' OG ' ' A' ' 218' ' ' SER . 41.7 m -126.21 140.31 52.64 Favored 'General case' 0 CA--C 1.51 -0.565 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.438 179.533 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 294' ' ' GLN . . . . . 0.518 ' HB3' ' CD1' ' A' ' 242' ' ' PHE . 0.9 OUTLIER -82.11 141.49 33.07 Favored 'General case' 0 CA--C 1.504 -0.823 0 C-N-CA 120.499 -0.48 . . . . 0.0 110.023 176.764 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 39.0 t -131.05 127.02 60.44 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.176 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 178.798 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 64.0 mttp -87.14 98.16 11.15 Favored 'General case' 0 N--CA 1.432 -1.328 0 N-CA-C 107.399 -1.334 . . . . 0.0 107.399 170.732 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 297' ' ' VAL . . . . . 0.615 ' HB ' ' CD ' ' A' ' 298' ' ' PRO . 12.4 m -82.31 -174.4 0.52 Allowed Pre-proline 0 C--N 1.313 -1.018 0 N-CA-C 108.96 -0.756 . . . . 0.0 108.96 -177.36 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 298' ' ' PRO . . . . . 0.615 ' CD ' ' HB ' ' A' ' 297' ' ' VAL . 71.8 Cg_exo -53.28 -32.78 62.49 Favored 'Trans proline' 0 N--CA 1.495 1.584 0 C-N-CA 121.39 1.394 . . . . 0.0 109.232 179.208 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . 0.577 ' H ' HG23 ' A' ' 297' ' ' VAL . 64.4 mttp -87.55 94.47 9.72 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 171.478 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 300' ' ' LYS . . . . . 0.401 ' H ' ' HG3' ' A' ' 300' ' ' LYS . 0.0 OUTLIER -125.1 135.74 52.97 Favored 'General case' 0 C--N 1.311 -1.077 0 C-N-CA 120.994 -0.282 . . . . 0.0 110.463 -177.565 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 43.9 mm -104.31 115.27 45.92 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.937 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 174.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 4.3 m -100.99 126.05 47.63 Favored 'General case' 0 C--N 1.317 -0.847 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 178.799 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 55.8 p90 -138.27 152.44 48.55 Favored 'General case' 0 C--N 1.316 -0.873 0 C-N-CA 120.973 -0.291 . . . . 0.0 110.8 -175.042 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 63.2 mttp -74.36 107.0 6.25 Favored 'General case' 0 CA--C 1.508 -0.643 0 N-CA-C 109.187 -0.671 . . . . 0.0 109.187 179.373 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 3.4 m -82.31 126.39 32.08 Favored 'General case' 0 C--N 1.311 -1.079 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 175.728 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 9.6 mp -43.83 129.58 4.14 Favored Pre-proline 0 C--N 1.327 -0.378 0 CA-C-N 116.621 -0.263 . . . . 0.0 110.292 -175.409 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -59.09 -32.76 97.92 Favored 'Trans proline' 0 N--CA 1.492 1.397 0 C-N-CA 121.824 1.683 . . . . 0.0 110.753 -179.567 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -110.16 60.01 0.6 Allowed 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 108.085 -1.08 . . . . 0.0 108.085 170.263 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -77.0 140.7 40.47 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.648 -0.706 . . . . 0.0 111.683 -174.696 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 97.3 mt -109.65 127.43 54.55 Favored 'General case' 0 C--N 1.316 -0.878 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 174.628 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 2.1 p -93.89 113.2 28.13 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.003 0 N-CA-C 107.702 -1.221 . . . . 0.0 107.702 173.551 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 . . . . . 0 C--N 1.311 -1.086 0 CA-C-O 118.021 -0.99 . . . . 0.0 110.716 -171.557 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . 0.496 ' OE1' ' N ' ' A' ' 201' ' ' GLU . 1.8 mp0 . . . . . 0 N--CA 1.472 0.629 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 202' ' ' PHE . . . . . 0.494 ' CE1' ' HG3' ' A' ' 205' ' ' GLU . 28.2 p90 -144.99 161.48 39.28 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.03 -0.532 . . . . 0.0 112.198 -179.436 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -56.16 -41.72 86.59 Favored Glycine 0 C--O 1.225 -0.415 0 CA-C-N 115.635 -0.711 . . . . 0.0 112.529 -170.829 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 204' ' ' GLU . . . . . 0.428 ' H ' ' CD ' ' A' ' 204' ' ' GLU . 1.9 mp0 -53.99 -26.48 26.27 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-O 121.12 0.486 . . . . 0.0 110.836 -176.718 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 205' ' ' GLU . . . . . 0.494 ' HG3' ' CE1' ' A' ' 202' ' ' PHE . 61.6 mt-10 -67.04 -37.54 84.29 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.525 -0.761 . . . . 0.0 111.47 179.06 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 78.8 mtm -79.45 133.27 36.53 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 112.183 0.438 . . . . 0.0 112.183 -175.307 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . 0.533 HG12 ' HG2' ' A' ' 215' ' ' GLN . 29.0 m -131.13 161.4 41.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 176.374 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 208' ' ' LEU . . . . . 0.434 HD12 ' N ' ' A' ' 208' ' ' LEU . 7.6 mp -112.9 123.79 51.12 Favored 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 120.424 -0.51 . . . . 0.0 110.956 -179.837 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 20.6 p -66.73 -30.48 70.72 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.889 0.376 . . . . 0.0 110.232 174.863 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 3.0 t70 -58.46 -48.7 79.89 Favored 'General case' 0 N--CA 1.471 0.604 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.045 176.349 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 211' ' ' SER . . . . . 0.446 ' CB ' ' HB2' ' A' ' 214' ' ' GLU . 5.9 m -75.08 161.87 29.04 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-N 114.981 -1.008 . . . . 0.0 109.578 179.385 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 212' ' ' ASN . . . . . 0.405 ' O ' ' HG3' ' A' ' 214' ' ' GLU . 24.2 t30 -84.53 84.4 7.67 Favored 'General case' 0 C--O 1.239 0.517 0 C-N-CA 119.804 -0.758 . . . . 0.0 110.169 -177.117 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 59.55 39.93 95.65 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 110.662 -0.975 . . . . 0.0 110.662 -179.257 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 214' ' ' GLU . . . . . 0.446 ' HB2' ' CB ' ' A' ' 211' ' ' SER . 28.1 mt-10 -119.71 161.89 19.95 Favored 'General case' 0 C--O 1.24 0.587 0 CA-C-O 121.217 0.532 . . . . 0.0 111.28 -175.181 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 215' ' ' GLN . . . . . 0.533 ' HG2' HG12 ' A' ' 207' ' ' VAL . 57.1 mt-30 -104.59 173.87 3.07 Favored Pre-proline 0 C--N 1.313 -1.005 0 N-CA-C 105.581 -2.007 . . . . 0.0 105.581 164.295 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 216' ' ' PRO . . . . . 0.429 ' HD3' ' CD1' ' A' ' 208' ' ' LEU . 49.5 Cg_exo -60.92 138.94 82.19 Favored 'Trans proline' 0 C--N 1.305 -1.731 0 N-CA-C 108.32 -1.454 . . . . 0.0 108.32 173.253 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 217' ' ' LEU . . . . . 0.474 HD12 ' O ' ' A' ' 240' ' ' HIS . 0.5 OUTLIER -77.97 102.27 7.28 Favored 'General case' 0 N--CA 1.44 -0.964 0 C-N-CA 119.365 -0.934 . . . . 0.0 109.7 -179.747 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 218' ' ' SER . . . . . 0.428 ' HA ' ' O ' ' A' ' 292' ' ' VAL . 4.0 m -128.71 145.04 51.28 Favored 'General case' 0 N--CA 1.435 -1.179 0 CA-C-N 115.489 -0.778 . . . . 0.0 110.433 -177.057 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 219' ' ' ALA . . . . . 0.474 ' HB2' ' HA ' ' A' ' 240' ' ' HIS . . . -130.24 154.96 47.05 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.395 179.078 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 220' ' ' MET . . . . . 0.601 ' SD ' HG12 ' A' ' 291' ' ' ILE . 87.8 mmm -82.46 129.34 34.88 Favored 'General case' 0 N--CA 1.438 -1.041 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 177.831 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 65.5 t -76.23 132.6 32.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 -179.808 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 222' ' ' SER . . . . . 0.435 ' O ' ' OH ' ' A' ' 286' ' ' TYR . 33.5 m -97.16 -68.52 0.8 Allowed 'General case' 0 N--CA 1.44 -0.964 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.044 179.083 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 223' ' ' MET . . . . . 0.595 ' C ' ' SD ' ' A' ' 223' ' ' MET . 1.8 ppp? -137.14 147.95 46.31 Favored 'General case' 0 C--N 1.323 -0.567 0 C-N-CA 120.686 -0.406 . . . . 0.0 112.0 173.533 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 224' ' ' VAL . . . . . 0.7 HG22 ' HB ' ' A' ' 232' ' ' VAL . 71.2 t -125.83 131.79 71.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 N-CA-C 109.546 -0.538 . . . . 0.0 109.546 177.233 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 23.0 p -88.09 129.82 35.19 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.78 -0.368 . . . . 0.0 110.15 177.534 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 226' ' ' LYS . . . . . 0.424 ' CE ' ' O ' ' A' ' 284' ' ' SER . 51.9 tttm -80.27 81.6 6.5 Favored 'General case' 0 N--CA 1.447 -0.601 0 CA-C-O 121.674 0.749 . . . . 0.0 109.984 179.235 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 227' ' ' ASP . . . . . 0.557 ' N ' ' OG1' ' A' ' 280' ' ' THR . 42.7 t0 -151.14 169.49 21.73 Favored 'General case' 0 C--O 1.245 0.826 0 CA-C-N 114.508 -1.224 . . . . 0.0 108.923 -177.085 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 228' ' ' ASN . . . . . 0.467 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 15.8 p-10 -140.91 121.83 8.96 Favored Pre-proline 0 C--N 1.325 -0.494 0 C-N-CA 120.516 -0.473 . . . . 0.0 111.717 176.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 229' ' ' PRO . . . . . 0.467 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 56.6 Cg_endo -65.12 142.96 55.04 Favored 'Cis proline' 0 C--N 1.311 -1.424 0 C-N-CA 122.632 -1.82 . . . . 0.0 109.437 -4.138 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . 0.474 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -93.14 154.69 22.0 Favored Glycine 0 C--N 1.311 -0.817 0 N-CA-C 110.192 -1.163 . . . . 0.0 110.192 -177.296 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 231' ' ' VAL . . . . . 0.447 HG23 HD12 ' A' ' 270' ' ' LEU . 2.4 p -123.3 137.66 55.87 Favored 'Isoleucine or valine' 0 C--O 1.239 0.529 0 CA-C-N 116.724 0.262 . . . . 0.0 110.318 179.188 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 232' ' ' VAL . . . . . 0.7 ' HB ' HG22 ' A' ' 224' ' ' VAL . 0.8 OUTLIER -130.95 155.9 42.32 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.016 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.299 -177.998 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 233' ' ' THR . . . . . 0.403 ' O ' ' HB2' ' A' ' 222' ' ' SER . 27.6 m -110.73 140.45 45.11 Favored 'General case' 0 C--N 1.312 -1.028 0 CA-C-N 115.49 -0.777 . . . . 0.0 108.918 174.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 48.2 m -107.69 162.22 14.18 Favored 'General case' 0 C--N 1.314 -0.954 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 179.315 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 50.1 tp -61.41 130.32 45.5 Favored 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 179.198 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 55.6 m-20 -58.75 -40.41 83.79 Favored 'General case' 0 N--CA 1.476 0.857 0 CA-C-O 120.902 0.382 . . . . 0.0 111.244 -174.823 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 54.6 mp0 -64.85 -29.79 70.76 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.254 178.36 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -77.5 138.97 39.52 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.796 -176.164 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 239' ' ' ARG . . . . . 0.403 HH11 ' HD2' ' A' ' 239' ' ' ARG . 49.9 mtp85 -104.36 108.92 20.56 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.795 174.413 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 240' ' ' HIS . . . . . 0.567 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 12.7 p80 -67.01 -46.65 73.84 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-O 121.248 0.546 . . . . 0.0 109.804 176.416 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 77.87 14.74 82.03 Favored Glycine 0 CA--C 1.502 -0.743 0 N-CA-C 109.837 -1.305 . . . . 0.0 109.837 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 242' ' ' PHE . . . . . 0.525 ' CD2' ' HB2' ' A' ' 240' ' ' HIS . 8.7 m-30 -80.26 143.21 33.89 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 -177.391 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 243' ' ' GLU . . . . . 0.404 ' OE1' ' N ' ' A' ' 244' ' ' THR . 1.3 mm-40 -107.66 159.95 16.07 Favored 'General case' 0 C--N 1.308 -1.239 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.712 174.716 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 244' ' ' THR . . . . . 0.404 ' N ' ' OE1' ' A' ' 243' ' ' GLU . 0.2 OUTLIER -62.35 117.66 6.42 Favored 'General case' 0 C--N 1.297 -1.679 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 177.305 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 90.53 4.42 70.48 Favored Glycine 0 C--N 1.313 -0.748 0 N-CA-C 111.393 -0.683 . . . . 0.0 111.393 -177.679 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 23.7 t0 -79.23 163.28 25.1 Favored 'General case' 0 C--O 1.237 0.422 0 N-CA-C 109.319 -0.622 . . . . 0.0 109.319 176.531 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 247' ' ' PHE . . . . . 0.484 ' CE2' ' HB2' ' A' ' 266' ' ' GLU . 89.7 m-85 -111.3 134.09 53.14 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.507 0.194 . . . . 0.0 110.572 -176.112 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.53 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.9 m -131.17 165.94 30.12 Favored 'Isoleucine or valine' 0 C--O 1.239 0.51 0 CA-C-O 121.345 0.593 . . . . 0.0 112.441 -176.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 10.8 p -135.24 163.24 30.41 Favored 'General case' 0 C--N 1.32 -0.713 0 C-N-CA 124.92 1.288 . . . . 0.0 109.264 176.065 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 250' ' ' PHE . . . . . 0.603 ' CB ' ' HB3' ' A' ' 259' ' ' LEU . 78.7 m-85 -125.67 158.88 33.65 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.574 0.226 . . . . 0.0 111.027 -172.096 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 251' ' ' SER . . . . . 0.416 ' N ' ' O ' ' A' ' 291' ' ' ILE . 2.0 m -155.9 164.65 38.23 Favored 'General case' 0 C--N 1.322 -0.623 0 C-N-CA 122.326 0.251 . . . . 0.0 110.466 177.584 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 50.5 mm-40 48.59 27.36 1.45 Allowed 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.44 -0.346 . . . . 0.0 111.929 176.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . . . . . . . . . 44.0 t -84.12 130.76 35.37 Favored 'Isoleucine or valine' 0 C--O 1.235 0.323 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 179.152 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 97.7 mm-40 -95.65 135.35 37.44 Favored 'General case' 0 C--O 1.247 0.954 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 178.86 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . 0.52 ' CA ' HD12 ' A' ' 287' ' ' ILE . . . 84.53 -68.64 3.47 Favored Glycine 0 C--N 1.312 -0.752 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 -178.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 256' ' ' MET . . . . . 0.481 ' SD ' ' C ' ' A' ' 284' ' ' SER . 1.7 tpp -81.68 67.69 7.75 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.48 0.657 . . . . 0.0 109.407 176.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 257' ' ' ILE . . . . . 0.469 ' O ' ' HB2' ' A' ' 260' ' ' ASN . 48.5 pt -73.94 -21.24 17.98 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.945 0 CA-C-N 115.231 -0.895 . . . . 0.0 110.69 -176.546 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 258' ' ' GLN . . . . . 0.669 ' HG3' ' SG ' ' A' ' 262' ' ' CYS . 52.5 tp60 -56.52 -33.49 66.09 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.167 179.633 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 259' ' ' LEU . . . . . 1.018 HD21 ' CE2' ' A' ' 283' ' ' PHE . 84.4 mt -62.16 -39.97 94.41 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.048 174.702 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 260' ' ' ASN . . . . . 0.469 ' HB2' ' O ' ' A' ' 257' ' ' ILE . 97.1 m-20 -59.9 -40.53 89.08 Favored 'General case' 0 C--O 1.238 0.45 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.713 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -102.24 16.38 55.46 Favored Glycine 0 CA--C 1.527 0.816 0 CA-C-N 115.901 -0.59 . . . . 0.0 112.386 -178.363 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 262' ' ' CYS . . . . . 0.669 ' SG ' ' HG3' ' A' ' 258' ' ' GLN . 1.1 m -88.14 156.3 19.33 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-N 117.184 0.492 . . . . 0.0 112.028 -178.086 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 38.2 mt-30 -73.0 160.11 83.7 Favored Pre-proline 0 C--O 1.241 0.61 0 N-CA-C 107.761 -1.199 . . . . 0.0 107.761 171.423 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 264' ' ' PRO . . . . . 0.53 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 59.4 Cg_endo -66.77 145.9 76.72 Favored 'Trans proline' 0 C--N 1.309 -1.537 0 C-N-CA 121.086 1.191 . . . . 0.0 110.353 178.281 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 265' ' ' MET . . . . . 0.422 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 20.8 ptp -136.47 152.53 50.66 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 112.007 0.373 . . . . 0.0 112.007 -172.473 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 266' ' ' GLU . . . . . 0.484 ' HB2' ' CE2' ' A' ' 247' ' ' PHE . 69.5 tt0 -71.48 140.71 50.09 Favored 'General case' 0 C--O 1.239 0.532 0 O-C-N 123.898 0.749 . . . . 0.0 109.487 177.388 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 267' ' ' ILE . . . . . 0.746 HD12 ' C ' ' A' ' 267' ' ' ILE . 2.1 pp -128.37 165.98 26.64 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-O 121.205 0.526 . . . . 0.0 112.069 -176.608 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . 0.426 ' HB2' ' OG ' ' A' ' 276' ' ' SER . 62.3 mttm -124.99 123.06 39.06 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 178.628 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 9.3 m -86.08 94.86 4.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 C-N-CA 119.363 -0.935 . . . . 0.0 109.966 176.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 270' ' ' LEU . . . . . 0.447 HD12 HG23 ' A' ' 231' ' ' VAL . 97.0 mt -65.49 -41.21 93.5 Favored 'General case' 0 CA--C 1.511 -0.535 0 CA-C-N 115.424 -0.807 . . . . 0.0 109.441 -178.752 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -138.07 -178.5 16.18 Favored Glycine 0 N--CA 1.448 -0.532 0 N-CA-C 108.401 -1.88 . . . . 0.0 108.401 178.591 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 272' ' ' PRO . . . . . 0.567 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 38.4 Cg_endo -64.12 -32.7 63.34 Favored 'Trans proline' 0 C--N 1.303 -1.85 0 C-N-CA 121.513 1.475 . . . . 0.0 111.307 -177.448 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -124.5 9.54 8.43 Favored 'General case' 0 C--O 1.24 0.555 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.861 -178.407 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 7.9 p -125.66 126.56 44.89 Favored 'General case' 0 C--O 1.247 0.962 0 CA-C-O 121.171 0.51 . . . . 0.0 110.844 179.582 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 275' ' ' PHE . . . . . 0.523 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -139.56 163.98 31.12 Favored 'General case' 0 CA--C 1.502 -0.897 0 N-CA-C 112.532 0.567 . . . . 0.0 112.532 -175.871 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . 0.474 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 4.1 p -130.59 152.67 49.71 Favored 'General case' 0 N--CA 1.436 -1.159 0 CA-C-O 121.241 0.543 . . . . 0.0 112.225 -174.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . 0.731 ' C ' HD12 ' A' ' 277' ' ' ILE . 2.0 pp -134.92 173.19 14.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 114.684 -1.144 . . . . 0.0 111.461 -174.033 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 278' ' ' CYS . . . . . 0.457 ' O ' ' HA ' ' A' ' 229' ' ' PRO . 1.5 p -48.95 -78.77 0.02 OUTLIER 'General case' 0 C--N 1.323 -0.556 0 C-N-CA 123.815 0.846 . . . . 0.0 113.05 -177.173 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . 0.528 ' HB2' ' CB ' ' A' ' 282' ' ' ASN . 9.8 m-20 -140.1 103.87 4.71 Favored 'General case' 0 N--CA 1.452 -0.354 0 O-C-N 122.315 -0.241 . . . . 0.0 110.644 -176.256 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . 0.74 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 20.7 p -65.46 -32.75 74.53 Favored 'General case' 0 C--N 1.315 -0.892 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 172.672 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -61.57 -23.1 65.75 Favored 'General case' 0 N--CA 1.43 -1.464 0 CA-C-N 114.019 -1.446 . . . . 0.0 109.522 175.307 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 282' ' ' ASN . . . . . 0.528 ' CB ' ' HB2' ' A' ' 279' ' ' ASP . 15.0 t30 -89.11 -10.16 48.38 Favored 'General case' 0 CA--C 1.51 -0.596 0 C-N-CA 120.372 -0.531 . . . . 0.0 109.825 178.866 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . 1.018 ' CE2' HD21 ' A' ' 259' ' ' LEU . 12.7 m-30 -83.76 -74.78 0.36 Allowed 'General case' 0 N--CA 1.441 -0.882 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 172.033 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 284' ' ' SER . . . . . 0.481 ' C ' ' SD ' ' A' ' 256' ' ' MET . 0.2 OUTLIER 171.68 -112.38 0.0 OUTLIER 'General case' 0 CA--C 1.541 0.631 0 CA-C-N 115.223 -0.899 . . . . 0.0 110.355 -178.552 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 285' ' ' ASP . . . . . 0.44 ' N ' ' SD ' ' A' ' 256' ' ' MET . 41.1 t0 -145.58 119.13 9.09 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 119.03 0.832 . . . . 0.0 110.687 177.495 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . 0.435 ' OH ' ' O ' ' A' ' 222' ' ' SER . 1.7 t80 -68.19 123.96 22.14 Favored 'General case' 0 C--O 1.239 0.523 0 CA-C-O 120.739 0.305 . . . . 0.0 110.789 178.53 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 287' ' ' ILE . . . . . 0.52 HD12 ' CA ' ' A' ' 255' ' ' GLY . 96.7 mt -106.03 -54.71 6.0 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.863 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.316 176.285 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 9.7 ptp180 -169.69 -179.05 3.2 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.079 177.842 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 63.6 -151.09 49.24 Favored Glycine 0 C--O 1.239 0.421 0 N-CA-C 110.605 -0.998 . . . . 0.0 110.605 177.281 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 99.24 129.42 6.55 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 121.59 -0.338 . . . . 0.0 112.525 175.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . 0.601 HG12 ' SD ' ' A' ' 220' ' ' MET . 98.1 mt -125.24 133.77 68.51 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 175.704 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . 0.428 ' O ' ' HA ' ' A' ' 218' ' ' SER . 4.5 p -122.63 134.6 65.35 Favored 'Isoleucine or valine' 0 C--O 1.241 0.615 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 -177.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 23.6 m -127.44 145.29 50.88 Favored 'General case' 0 CA--C 1.513 -0.478 0 CA-C-O 120.624 0.249 . . . . 0.0 111.016 -178.418 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 294' ' ' GLN . . . . . 0.417 ' O ' ' NE2' ' A' ' 294' ' ' GLN . 1.6 pp0? -75.38 148.26 39.36 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.517 -0.31 . . . . 0.0 110.424 178.091 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 72.4 t -126.52 130.79 71.77 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 177.601 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 1.4 mmpp? -98.83 99.44 10.52 Favored 'General case' 0 C--O 1.244 0.8 0 CA-C-O 121.49 0.662 . . . . 0.0 111.243 -179.897 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 297' ' ' VAL . . . . . 0.594 ' HB ' ' HD2' ' A' ' 298' ' ' PRO . 24.1 m -74.3 -176.9 0.56 Allowed Pre-proline 0 CA--C 1.542 0.655 0 CA-C-N 114.745 -1.116 . . . . 0.0 108.856 178.819 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 298' ' ' PRO . . . . . 0.594 ' HD2' ' HB ' ' A' ' 297' ' ' VAL . 77.4 Cg_exo -54.85 -35.55 89.06 Favored 'Trans proline' 0 N--CA 1.491 1.38 0 C-N-CA 121.711 1.607 . . . . 0.0 111.32 177.725 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . 0.441 ' NZ ' ' O ' ' A' ' 300' ' ' LYS . 62.3 tttm -69.46 137.5 52.68 Favored 'General case' 0 C--O 1.239 0.521 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.402 -179.372 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 300' ' ' LYS . . . . . 0.441 ' O ' ' NZ ' ' A' ' 299' ' ' LYS . 67.4 mttm -97.6 157.22 16.15 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.594 170.737 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 47.2 pt -99.17 130.01 48.76 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.955 0 CA-C-O 120.77 0.319 . . . . 0.0 111.374 -179.554 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 8.0 m -131.53 157.18 44.25 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 115.931 -0.577 . . . . 0.0 109.779 -177.333 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 85.2 t80 -111.5 132.43 54.5 Favored 'General case' 0 C--N 1.315 -0.895 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 -178.843 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 64.4 mttp -66.38 136.49 55.83 Favored 'General case' 0 CA--C 1.515 -0.376 0 C-N-CA 120.734 -0.386 . . . . 0.0 110.245 -175.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 6.2 m -70.5 141.18 51.98 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.003 177.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 6.1 mp -76.49 156.18 83.36 Favored Pre-proline 0 C--N 1.327 -0.396 0 C-N-CA 120.729 -0.388 . . . . 0.0 110.588 -177.334 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -61.95 -28.28 80.66 Favored 'Trans proline' 0 N--CA 1.496 1.636 0 C-N-CA 122.189 1.926 . . . . 0.0 110.559 179.492 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -141.29 143.22 33.95 Favored 'General case' 0 N--CA 1.445 -0.697 0 CA-C-N 115.728 -0.669 . . . . 0.0 109.509 176.61 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.49 ' O ' HG22 ' A' ' 311' ' ' VAL . 6.4 m -72.89 158.48 35.42 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.988 -0.551 . . . . 0.0 111.013 -178.816 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 310' ' ' LEU . . . . . 0.469 HD13 ' HA ' ' A' ' 310' ' ' LEU . 4.3 mm? -70.49 79.31 0.57 Allowed 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 178.166 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 311' ' ' VAL . . . . . 0.49 HG22 ' O ' ' A' ' 309' ' ' SER . 26.9 m -126.86 161.55 33.34 Favored 'Isoleucine or valine' 0 C--O 1.241 0.647 0 CA-C-N 115.35 -0.841 . . . . 0.0 109.949 -176.827 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 86.8 mt-10 . . . . . 0 C--O 1.202 -1.428 0 CA-C-O 118.899 -0.572 . . . . 0.0 110.232 -179.121 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . 0.567 ' O ' ' N ' ' A' ' 203' ' ' GLY . 0.7 OUTLIER . . . . . 0 N--CA 1.479 0.981 0 N-CA-C 110.021 -0.363 . . . . 0.0 110.021 . . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 33.4 m-85 21.45 -70.54 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.368 0 C-N-CA 125.539 1.536 . . . . 0.0 114.223 -178.09 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 201' ' ' GLU . . . -63.18 -34.0 88.78 Favored Glycine 0 N--CA 1.454 -0.143 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 -177.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 204' ' ' GLU . . . . . 0.45 ' OE1' ' N ' ' A' ' 201' ' ' GLU . 99.6 mt-10 -65.62 -44.25 87.06 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.838 0.351 . . . . 0.0 110.388 -179.63 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 205' ' ' GLU . . . . . 0.497 ' OE1' ' N ' ' A' ' 201' ' ' GLU . 2.2 mp0 -62.77 -37.18 85.63 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.568 -177.641 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 64.2 ttp -89.45 120.98 31.24 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.471 -179.381 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 61.6 t -122.04 130.53 74.49 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.803 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 173.476 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 208' ' ' LEU . . . . . 0.525 ' C ' ' H ' ' A' ' 210' ' ' ASP . 10.9 mp -76.29 74.42 3.09 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.036 0.446 . . . . 0.0 111.422 -175.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 209' ' ' THR . . . . . 0.45 HG21 ' NE2' ' A' ' 215' ' ' GLN . 0.2 OUTLIER -71.21 34.55 0.05 OUTLIER 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.98 172.273 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 210' ' ' ASP . . . . . 0.525 ' H ' ' C ' ' A' ' 208' ' ' LEU . 32.9 t70 -58.1 -38.95 77.42 Favored 'General case' 0 CA--C 1.512 -0.507 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.776 -175.235 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 1.1 m -57.79 91.6 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 175.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 23.3 t-20 -61.35 122.16 14.43 Favored 'General case' 0 CA--C 1.507 -0.7 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.276 -173.008 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 104.5 -22.39 34.4 Favored Glycine 0 C--O 1.24 0.517 0 N-CA-C 111.286 -0.726 . . . . 0.0 111.286 178.628 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 80.6 mm-40 -84.82 97.34 9.67 Favored 'General case' 0 N--CA 1.447 -0.6 0 C-N-CA 119.791 -0.763 . . . . 0.0 109.568 176.846 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 215' ' ' GLN . . . . . 0.45 ' NE2' HG21 ' A' ' 209' ' ' THR . 45.9 mm-40 -112.69 102.44 54.46 Favored Pre-proline 0 C--N 1.32 -0.707 0 CA-C-N 115.751 -0.659 . . . . 0.0 109.379 177.711 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -74.1 102.71 1.56 Allowed 'Trans proline' 0 C--N 1.305 -1.744 0 C-N-CA 121.318 1.345 . . . . 0.0 109.454 177.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 217' ' ' LEU . . . . . 0.433 ' HB3' ' O ' ' A' ' 240' ' ' HIS . 0.1 OUTLIER -54.04 128.04 28.95 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 108.365 -0.976 . . . . 0.0 108.365 -177.428 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 218' ' ' SER . . . . . 0.411 ' HA ' ' HA ' ' A' ' 293' ' ' SER . 0.7 OUTLIER -127.0 147.73 50.12 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-O 120.745 0.307 . . . . 0.0 110.499 -174.734 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -146.41 154.41 41.58 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.509 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 56.3 mtm -79.98 138.95 37.18 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.842 176.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 99.2 t -85.13 130.01 36.85 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.94 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 -178.901 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 65.4 m -83.35 -70.68 0.54 Allowed 'General case' 0 N--CA 1.434 -1.254 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 179.414 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -138.57 152.94 48.62 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.834 174.007 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 224' ' ' VAL . . . . . 0.58 HG22 ' HB ' ' A' ' 232' ' ' VAL . 53.6 t -120.93 132.43 70.45 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 175.329 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 75.5 p -90.85 116.56 28.77 Favored 'General case' 0 C--O 1.236 0.393 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 175.435 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 226' ' ' LYS . . . . . 0.494 ' HA ' ' OG1' ' A' ' 280' ' ' THR . 3.7 tttm -75.86 64.37 1.81 Allowed 'General case' 0 C--O 1.249 1.06 0 C-N-CA 120.616 -0.434 . . . . 0.0 111.259 -175.147 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 227' ' ' ASP . . . . . 0.416 ' N ' ' OG1' ' A' ' 280' ' ' THR . 36.0 t0 -133.04 -175.69 3.87 Favored 'General case' 0 C--O 1.243 0.752 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.621 178.358 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 228' ' ' ASN . . . . . 0.485 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.6 OUTLIER -138.52 125.29 13.04 Favored Pre-proline 0 CA--C 1.533 0.307 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.031 175.631 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 229' ' ' PRO . . . . . 0.485 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 48.6 Cg_endo -66.35 141.24 52.34 Favored 'Cis proline' 0 C--N 1.313 -1.337 0 C-N-CA 122.715 -1.785 . . . . 0.0 110.01 -1.04 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . 0.453 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -75.13 139.3 24.79 Favored Glycine 0 C--N 1.308 -1.01 0 N-CA-C 110.662 -0.975 . . . . 0.0 110.662 -177.745 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 231' ' ' VAL . . . . . 0.412 ' CG2' HD12 ' A' ' 270' ' ' LEU . 2.4 p -128.29 137.56 57.08 Favored 'Isoleucine or valine' 0 C--O 1.244 0.775 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 175.001 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 232' ' ' VAL . . . . . 0.58 ' HB ' HG22 ' A' ' 224' ' ' VAL . 0.6 OUTLIER -133.53 155.67 40.65 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.786 0 C-N-CA 120.475 -0.49 . . . . 0.0 110.985 -178.693 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 3.1 m -104.06 140.65 37.46 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 115.459 -0.791 . . . . 0.0 108.902 176.769 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.9 m -107.35 156.84 18.48 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -178.593 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.467 ' HB3' ' HB3' ' A' ' 238' ' ' ALA . 27.0 tp -58.47 130.21 45.7 Favored 'General case' 0 C--N 1.318 -0.801 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 -178.334 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -55.32 -44.03 75.45 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 120.992 0.425 . . . . 0.0 110.69 -175.025 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 237' ' ' GLU . . . . . 0.403 ' H ' ' CD ' ' A' ' 237' ' ' GLU . 1.7 mp0 -67.6 -23.18 65.35 Favored 'General case' 0 C--N 1.312 -1.065 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.604 -179.72 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . 0.467 ' HB3' ' HB3' ' A' ' 235' ' ' LEU . . . -94.54 90.75 6.29 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.964 0.412 . . . . 0.0 111.984 -175.002 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.74 110.12 2.69 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 108.633 -0.876 . . . . 0.0 108.633 174.799 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 240' ' ' HIS . . . . . 0.577 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 12.3 p80 -64.44 -49.81 70.0 Favored 'General case' 0 C--O 1.216 -0.674 0 CA-C-O 120.647 0.26 . . . . 0.0 111.212 -176.501 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 80.71 17.8 72.07 Favored Glycine 0 C--O 1.242 0.599 0 N-CA-C 110.961 -0.855 . . . . 0.0 110.961 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 242' ' ' PHE . . . . . 0.414 ' CD2' ' HB2' ' A' ' 240' ' ' HIS . 7.3 m-30 -81.38 139.94 35.01 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 179.391 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 76.6 mm-40 -98.79 157.13 16.49 Favored 'General case' 0 C--N 1.308 -1.201 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 172.601 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 244' ' ' THR . . . . . 0.666 HG23 ' HA ' ' A' ' 268' ' ' LYS . 25.0 m -65.57 123.4 19.58 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 172.86 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 94.72 0.09 64.64 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 110.994 -0.842 . . . . 0.0 110.994 -174.705 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 45.9 t0 -79.31 159.62 27.13 Favored 'General case' 0 C--O 1.239 0.542 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 176.736 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 247' ' ' PHE . . . . . 0.406 ' CE1' ' HG3' ' A' ' 299' ' ' LYS . 87.4 m-85 -110.29 129.96 55.64 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.311 -176.559 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.496 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.4 m -128.33 161.54 36.65 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.332 0 C-N-CA 120.658 -0.417 . . . . 0.0 111.494 -179.09 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 50.1 m -129.63 153.15 48.38 Favored 'General case' 0 N--CA 1.444 -0.774 0 CA-C-N 115.108 -0.951 . . . . 0.0 108.676 172.817 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 250' ' ' PHE . . . . . 0.639 ' CD1' HD22 ' A' ' 259' ' ' LEU . 73.5 m-85 -105.26 145.25 30.92 Favored 'General case' 0 C--N 1.311 -1.066 0 C-N-CA 122.948 0.499 . . . . 0.0 109.882 -177.333 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 4.8 m -132.17 151.54 51.74 Favored 'General case' 0 C--N 1.304 -1.387 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 175.145 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 7.3 mm-40 47.34 38.22 7.03 Favored 'General case' 0 C--N 1.308 -1.233 0 N-CA-C 112.938 0.718 . . . . 0.0 112.938 174.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 0.54 HG13 ' CE1' ' A' ' 286' ' ' TYR . 24.2 t -85.2 132.38 31.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 172.499 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 98.6 mm-40 -96.76 145.12 26.11 Favored 'General case' 0 C--N 1.32 -0.698 0 C-N-CA 120.68 -0.408 . . . . 0.0 110.214 176.671 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 81.19 -67.51 3.6 Favored Glycine 0 C--N 1.32 -0.352 0 N-CA-C 110.244 -1.143 . . . . 0.0 110.244 -177.207 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 256' ' ' MET . . . . . 0.484 ' HG3' ' C ' ' A' ' 285' ' ' ASP . 47.8 mtt -78.65 65.65 3.97 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.475 0.655 . . . . 0.0 110.586 176.219 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 48.9 pt -66.27 -23.78 32.37 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.897 0 CA-C-N 115.285 -0.871 . . . . 0.0 109.577 179.511 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 258' ' ' GLN . . . . . 0.421 ' NE2' ' O ' ' A' ' 283' ' ' PHE . 1.3 mp0 -54.37 -40.99 68.67 Favored 'General case' 0 N--CA 1.442 -0.862 0 CA-C-N 115.14 -0.936 . . . . 0.0 109.044 178.485 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 259' ' ' LEU . . . . . 0.906 HD21 ' CE2' ' A' ' 283' ' ' PHE . 87.3 mt -62.92 -41.83 99.59 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.783 178.067 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 260' ' ' ASN . . . . . 0.491 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 93.3 m-20 -59.37 -41.03 88.38 Favored 'General case' 0 CA--C 1.509 -0.623 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 -177.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -102.36 10.98 56.74 Favored Glycine 0 CA--C 1.525 0.706 0 CA-C-N 116.027 -0.533 . . . . 0.0 112.265 -179.359 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 262' ' ' CYS . . . . . 0.415 ' HB2' ' O ' ' A' ' 258' ' ' GLN . 11.8 t -88.48 139.98 29.93 Favored 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 117.512 0.656 . . . . 0.0 111.458 -177.471 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 9.6 mp0 -56.4 158.53 7.7 Favored Pre-proline 0 C--N 1.322 -0.621 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 173.219 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 264' ' ' PRO . . . . . 0.496 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 36.7 Cg_endo -61.71 146.87 96.4 Favored 'Trans proline' 0 N--CA 1.495 1.568 0 C-N-CA 121.488 1.459 . . . . 0.0 111.713 -178.719 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 265' ' ' MET . . . . . 0.63 ' N ' ' SD ' ' A' ' 265' ' ' MET . 0.0 OUTLIER -119.35 152.27 37.06 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.888 -176.461 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 73.0 tt0 -76.53 137.17 39.42 Favored 'General case' 0 C--O 1.238 0.46 0 N-CA-C 107.964 -1.124 . . . . 0.0 107.964 174.803 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 267' ' ' ILE . . . . . 0.708 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.9 pp -129.51 159.09 41.92 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 N-CA-C 113.069 0.766 . . . . 0.0 113.069 -174.928 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . 0.666 ' HA ' HG23 ' A' ' 244' ' ' THR . 65.6 mttm -123.54 115.04 20.88 Favored 'General case' 0 CA--C 1.534 0.331 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.367 178.694 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.436 HG22 ' OG1' ' A' ' 244' ' ' THR . 17.7 m -78.35 100.18 3.26 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.497 0 CA-C-O 121.138 0.494 . . . . 0.0 111.613 -179.149 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 270' ' ' LEU . . . . . 0.412 HD12 ' CG2' ' A' ' 231' ' ' VAL . 97.5 mt -66.25 -40.82 90.44 Favored 'General case' 0 CA--C 1.513 -0.462 0 CA-C-N 115.723 -0.672 . . . . 0.0 110.477 179.033 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -145.17 179.5 22.23 Favored Glycine 0 C--N 1.315 -0.638 0 N-CA-C 109.724 -1.35 . . . . 0.0 109.724 -177.238 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 272' ' ' PRO . . . . . 0.577 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 33.0 Cg_endo -61.39 -31.82 88.74 Favored 'Trans proline' 0 C--N 1.303 -1.845 0 C-N-CA 121.797 1.665 . . . . 0.0 110.976 -178.448 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 88.4 m-85 -121.36 8.67 10.25 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.18 -0.464 . . . . 0.0 112.067 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -123.77 126.34 46.31 Favored 'General case' 0 C--O 1.242 0.665 0 CA-C-O 120.855 0.359 . . . . 0.0 110.998 -179.48 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 275' ' ' PHE . . . . . 0.561 ' CE2' HG21 ' A' ' 267' ' ' ILE . 0.0 OUTLIER -132.71 161.03 35.05 Favored 'General case' 0 CA--C 1.499 -1.007 0 C-N-CA 120.733 -0.387 . . . . 0.0 111.766 178.038 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . 0.453 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 7.7 p -133.36 154.39 50.78 Favored 'General case' 0 N--CA 1.432 -1.346 0 CA-C-O 121.25 0.547 . . . . 0.0 112.456 -173.636 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . 0.699 HG22 HG22 ' A' ' 267' ' ' ILE . 35.7 pt -140.94 -165.93 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 CA-C-N 113.991 -1.458 . . . . 0.0 109.569 -171.049 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 278' ' ' CYS . . . . . 0.484 ' O ' ' HA ' ' A' ' 229' ' ' PRO . 14.7 p -69.81 -110.64 0.0 OUTLIER 'General case' 0 N--CA 1.45 -0.474 0 O-C-N 122.996 0.185 . . . . 0.0 111.056 178.793 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . 0.442 ' CG ' ' HB2' ' A' ' 228' ' ' ASN . 50.8 t0 -117.5 119.9 36.47 Favored 'General case' 0 CA--C 1.507 -0.682 0 CA-C-O 121.048 0.452 . . . . 0.0 110.855 -179.591 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . 0.51 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 9.4 p -64.44 -29.29 70.35 Favored 'General case' 0 C--N 1.292 -1.919 0 CA-C-N 115.501 -0.772 . . . . 0.0 109.597 175.186 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -65.19 -11.66 42.99 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.008 -0.996 . . . . 0.0 109.642 174.483 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 5.1 t-20 -85.87 -8.65 57.92 Favored 'General case' 0 CA--C 1.507 -0.69 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 175.772 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . 0.906 ' CE2' HD21 ' A' ' 259' ' ' LEU . 3.3 m-85 -99.73 -78.41 0.51 Allowed 'General case' 0 N--CA 1.442 -0.84 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 171.117 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 284' ' ' SER . . . . . 0.474 ' OG ' ' N ' ' A' ' 285' ' ' ASP . 31.3 t 168.33 -144.33 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.291 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 -179.121 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 285' ' ' ASP . . . . . 0.484 ' C ' ' HG3' ' A' ' 256' ' ' MET . 64.8 m-20 -98.46 131.67 44.53 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 122.289 0.236 . . . . 0.0 110.567 176.734 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . 0.54 ' CE1' HG13 ' A' ' 253' ' ' VAL . 13.0 t80 -84.23 125.56 32.33 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 178.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 287' ' ' ILE . . . . . 0.401 ' O ' ' CG ' ' A' ' 288' ' ' ARG . 9.3 mm -94.01 -54.07 7.67 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 N-CA-C 110.471 -0.196 . . . . 0.0 110.471 179.539 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . 0.401 ' CG ' ' O ' ' A' ' 287' ' ' ILE . 0.7 OUTLIER 176.34 -178.0 0.14 Allowed 'General case' 0 C--O 1.244 0.766 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.019 -179.53 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 64.98 -140.64 42.3 Favored Glycine 0 CA--C 1.5 -0.856 0 N-CA-C 110.027 -1.229 . . . . 0.0 110.027 177.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . 0.45 ' HA3' HG22 ' A' ' 253' ' ' VAL . . . 87.93 126.34 2.41 Favored Glycine 0 N--CA 1.434 -1.478 0 C-N-CA 120.82 -0.705 . . . . 0.0 111.474 177.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 82.1 mt -120.62 131.21 73.37 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 N-CA-C 106.474 -1.676 . . . . 0.0 106.474 175.06 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 3.9 p -117.85 133.1 65.72 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.051 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -176.038 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . 0.411 ' HA ' ' HA ' ' A' ' 218' ' ' SER . 1.4 m -129.35 141.16 51.15 Favored 'General case' 0 CA--C 1.505 -0.781 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.71 -177.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 294' ' ' GLN . . . . . 0.492 ' HA ' ' HA ' ' A' ' 248' ' ' VAL . 0.2 OUTLIER -74.03 146.43 43.74 Favored 'General case' 0 C--N 1.318 -0.797 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 172.398 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 59.2 t -110.71 128.0 67.37 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.171 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 -179.501 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 7.9 mmmm -80.81 98.49 7.83 Favored 'General case' 0 C--N 1.321 -0.644 0 C-N-CA 120.631 -0.427 . . . . 0.0 110.31 -179.19 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 297' ' ' VAL . . . . . 0.428 ' HB ' ' HD2' ' A' ' 298' ' ' PRO . 0.2 OUTLIER -103.98 165.29 13.7 Favored Pre-proline 0 C--N 1.316 -0.878 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.241 177.621 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 298' ' ' PRO . . . . . 0.447 ' O ' ' HG3' ' A' ' 300' ' ' LYS . 38.4 Cg_endo -64.81 -6.9 13.47 Favored 'Trans proline' 0 C--N 1.308 -1.587 0 C-N-CA 122.738 2.292 . . . . 0.0 112.48 178.041 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . 0.406 ' HG3' ' CE1' ' A' ' 247' ' ' PHE . 75.2 mmtt -45.43 109.12 0.15 Allowed 'General case' 0 C--O 1.239 0.505 0 CA-C-N 116.501 -0.318 . . . . 0.0 110.231 -179.242 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 300' ' ' LYS . . . . . 0.447 ' HG3' ' O ' ' A' ' 298' ' ' PRO . 49.6 mttp -124.26 155.71 38.14 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 116.473 -0.33 . . . . 0.0 110.391 177.73 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 41.7 mm -67.12 131.32 32.82 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 176.499 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 73.2 m -155.37 162.17 40.87 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-O 120.778 0.323 . . . . 0.0 111.123 -175.345 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 303' ' ' PHE . . . . . 0.407 ' HB2' HD11 ' A' ' 310' ' ' LEU . 94.6 m-85 -132.29 152.14 51.51 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 -179.753 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -68.15 141.72 55.96 Favored 'General case' 0 C--N 1.321 -0.646 0 C-N-CA 120.995 -0.282 . . . . 0.0 110.294 -177.249 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -69.86 95.45 0.92 Allowed 'General case' 0 N--CA 1.445 -0.705 0 CA-C-O 120.978 0.418 . . . . 0.0 110.028 179.25 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 306' ' ' LEU . . . . . 0.404 ' O ' ' OG ' ' A' ' 309' ' ' SER . 6.7 mp -96.87 166.35 14.11 Favored Pre-proline 0 C--N 1.323 -0.58 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 179.799 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_exo -52.39 -40.8 70.15 Favored 'Trans proline' 0 N--CA 1.495 1.596 0 C-N-CA 121.903 1.735 . . . . 0.0 110.328 178.702 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -94.55 65.05 3.12 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 171.868 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.404 ' OG ' ' O ' ' A' ' 306' ' ' LEU . 0.8 OUTLIER -63.36 167.77 5.05 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.37 -176.62 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 310' ' ' LEU . . . . . 0.407 HD11 ' HB2' ' A' ' 303' ' ' PHE . 77.4 mt -66.44 135.32 54.11 Favored 'General case' 0 C--O 1.239 0.516 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 179.759 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 79.2 t -128.04 134.89 64.2 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.239 -178.766 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 90.4 mt-10 . . . . . 0 C--O 1.208 -1.129 0 CA-C-O 118.228 -0.891 . . . . 0.0 110.84 179.224 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . 0.513 ' OE1' ' N ' ' A' ' 201' ' ' GLU . 1.8 mp0 . . . . . 0 N--CA 1.473 0.705 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 80.3 m-85 -92.43 81.36 4.88 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 178.562 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -78.6 -1.34 82.64 Favored Glycine 0 C--N 1.319 -0.416 0 N-CA-C 110.821 -0.912 . . . . 0.0 110.821 -179.226 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -54.56 -24.19 19.93 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.365 0.603 . . . . 0.0 109.605 179.569 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -64.36 -36.69 84.97 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-N 115.272 -0.877 . . . . 0.0 110.523 179.444 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 99.4 mtp -81.26 89.61 6.06 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.035 0.445 . . . . 0.0 111.862 -175.418 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 2.8 t -123.16 90.33 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.875 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 171.772 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 3.6 mp -97.32 72.45 2.41 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.762 -173.409 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 1.2 m -97.72 8.64 44.33 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 174.269 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 210' ' ' ASP . . . . . 0.474 ' CG ' ' N ' ' A' ' 211' ' ' SER . 13.0 p-10 -58.66 -48.59 80.54 Favored 'General case' 0 CA--C 1.508 -0.653 0 CA-C-N 115.199 -0.909 . . . . 0.0 109.682 179.233 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 211' ' ' SER . . . . . 0.474 ' N ' ' CG ' ' A' ' 210' ' ' ASP . 0.9 OUTLIER -74.22 123.21 24.09 Favored 'General case' 0 N--CA 1.439 -1.023 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.212 -178.765 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 212' ' ' ASN . . . . . 0.412 ' O ' ' HB2' ' A' ' 296' ' ' LYS . 65.6 t30 -95.97 107.63 19.92 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.714 -175.83 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 71.73 -39.26 0.63 Allowed Glycine 0 CA--C 1.525 0.661 0 CA-C-N 116.411 -0.358 . . . . 0.0 112.636 178.257 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 214' ' ' GLU . . . . . 0.424 ' OE1' ' NZ ' ' A' ' 296' ' ' LYS . 68.0 mt-10 -132.04 162.37 30.94 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 117.168 0.484 . . . . 0.0 111.977 -179.455 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 2.9 mt-30 -54.15 153.78 8.85 Favored Pre-proline 0 C--N 1.327 -0.379 0 CA-C-N 115.332 -0.849 . . . . 0.0 111.707 -176.789 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 61.8 Cg_endo -75.73 53.6 3.7 Favored 'Trans proline' 0 C--N 1.309 -1.532 0 C-N-CA 122.57 2.18 . . . . 0.0 110.698 175.634 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 217' ' ' LEU . . . . . 0.424 HD13 ' HA ' ' A' ' 217' ' ' LEU . 0.1 OUTLIER -47.24 115.7 1.18 Allowed 'General case' 0 C--O 1.234 0.28 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 -178.052 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 24.1 m -133.63 152.46 51.9 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.277 -174.092 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -142.98 156.08 44.8 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 116.037 -0.528 . . . . 0.0 110.559 177.303 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 220' ' ' MET . . . . . 0.545 ' SD ' HD12 ' A' ' 291' ' ' ILE . 1.6 mpp? -75.22 134.57 41.13 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 176.659 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 99.3 t -82.06 128.29 38.85 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.886 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 178.836 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 20.2 m -86.3 -71.59 0.54 Allowed 'General case' 0 N--CA 1.439 -0.993 0 CA-C-N 116.017 -0.538 . . . . 0.0 109.876 178.037 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 8.7 ptm -137.71 149.68 46.69 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.168 174.504 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 224' ' ' VAL . . . . . 0.532 HG22 ' HB ' ' A' ' 232' ' ' VAL . 72.4 t -121.74 127.27 75.46 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.993 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 174.748 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . 0.413 ' O ' HG21 ' A' ' 280' ' ' THR . 11.6 p -77.44 130.72 37.41 Favored 'General case' 0 CA--C 1.512 -0.485 0 C-N-CA 120.399 -0.52 . . . . 0.0 110.382 -179.117 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 226' ' ' LYS . . . . . 0.555 ' NZ ' ' OG ' ' A' ' 281' ' ' SER . 26.7 tptp -81.97 74.5 8.95 Favored 'General case' 0 N--CA 1.441 -0.916 0 N-CA-C 108.728 -0.842 . . . . 0.0 108.728 176.232 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 227' ' ' ASP . . . . . 0.465 ' CG ' ' H ' ' A' ' 228' ' ' ASN . 8.6 t70 -153.65 -173.15 4.47 Favored 'General case' 0 C--O 1.244 0.797 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.599 -176.224 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 228' ' ' ASN . . . . . 0.533 ' ND2' ' O ' ' A' ' 228' ' ' ASN . 0.1 OUTLIER -140.51 125.08 10.85 Favored Pre-proline 0 N--CA 1.452 -0.353 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.2 176.094 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 229' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -69.68 148.31 86.29 Favored 'Cis proline' 0 C--N 1.311 -1.422 0 C-N-CA 123.029 -1.655 . . . . 0.0 109.722 -1.636 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . 0.614 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -71.32 130.38 18.57 Favored Glycine 0 C--N 1.311 -0.839 0 N-CA-C 109.231 -1.548 . . . . 0.0 109.231 -179.719 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.1 p -120.93 131.35 73.18 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.8 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 177.903 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 232' ' ' VAL . . . . . 0.532 ' HB ' HG22 ' A' ' 224' ' ' VAL . 0.6 OUTLIER -130.09 153.13 38.47 Favored 'Isoleucine or valine' 0 C--O 1.249 1.061 0 C-N-CA 119.474 -0.89 . . . . 0.0 111.361 -174.78 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 3.1 m -108.11 140.37 41.4 Favored 'General case' 0 N--CA 1.432 -1.358 0 CA-C-N 114.807 -1.088 . . . . 0.0 108.857 177.832 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 34.6 m -107.28 161.0 15.18 Favored 'General case' 0 C--N 1.308 -1.227 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 178.422 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 40.1 tp -60.53 127.65 32.76 Favored 'General case' 0 C--N 1.314 -0.978 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 -178.747 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -56.79 -39.89 74.93 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-O 121.242 0.544 . . . . 0.0 110.608 -174.481 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -65.89 -29.63 70.1 Favored 'General case' 0 C--N 1.308 -1.224 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.99 179.602 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -96.96 130.92 44.2 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 112.106 0.41 . . . . 0.0 112.106 -172.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 90.6 mtm-85 -86.3 137.45 32.6 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 174.351 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 240' ' ' HIS . . . . . 0.574 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 8.9 p80 -88.62 -45.18 10.07 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 121.073 0.463 . . . . 0.0 109.832 175.699 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 83.25 12.15 79.41 Favored Glycine 0 C--O 1.239 0.436 0 N-CA-C 110.719 -0.952 . . . . 0.0 110.719 178.539 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 242' ' ' PHE . . . . . 0.506 ' CD1' ' HB3' ' A' ' 294' ' ' GLN . 4.4 m-30 -80.87 145.35 31.4 Favored 'General case' 0 C--N 1.318 -0.781 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 -179.495 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 243' ' ' GLU . . . . . 0.463 ' H ' ' CB ' ' A' ' 246' ' ' ASP . 98.2 mt-10 -122.17 168.1 12.39 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.951 -179.158 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 17.7 m -58.84 122.12 12.8 Favored 'General case' 0 C--N 1.313 -1.003 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 179.356 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 78.48 7.02 88.14 Favored Glycine 0 C--N 1.319 -0.394 0 N-CA-C 111.25 -0.74 . . . . 0.0 111.25 179.646 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 246' ' ' ASP . . . . . 0.463 ' CB ' ' H ' ' A' ' 243' ' ' GLU . 40.0 t0 -76.93 162.2 27.78 Favored 'General case' 0 CA--C 1.514 -0.43 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 178.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 247' ' ' PHE . . . . . 0.466 ' HA ' ' O ' ' A' ' 265' ' ' MET . 72.3 m-85 -109.64 137.21 47.79 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.041 0.448 . . . . 0.0 111.511 -177.534 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.452 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.9 m -133.47 162.02 40.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.308 178.792 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 249' ' ' SER . . . . . 0.44 ' OG ' HG21 ' A' ' 295' ' ' VAL . 67.1 m -125.89 151.48 46.85 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 172.692 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 250' ' ' PHE . . . . . 0.586 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 88.3 m-85 -107.37 149.58 27.7 Favored 'General case' 0 C--N 1.308 -1.207 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.218 -175.552 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 7.3 p -146.92 156.8 43.36 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.231 179.424 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 87.0 mt-10 45.8 26.8 0.4 Allowed 'General case' 0 C--N 1.316 -0.849 0 N-CA-C 112.914 0.709 . . . . 0.0 112.914 177.767 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 0.505 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 52.5 t -83.32 132.78 30.59 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.415 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 174.921 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 93.8 mm-40 -98.52 137.23 37.49 Favored 'General case' 0 C--N 1.317 -0.833 0 C-N-CA 120.043 -0.663 . . . . 0.0 110.036 -179.254 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 83.38 -57.28 5.07 Favored Glycine 0 C--N 1.317 -0.514 0 N-CA-C 110.899 -0.881 . . . . 0.0 110.899 -177.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 256' ' ' MET . . . . . 0.411 ' SD ' HG11 ' A' ' 224' ' ' VAL . 4.4 ttm -78.29 63.11 3.11 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.632 0.729 . . . . 0.0 109.388 178.747 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 48.6 pt -69.76 -25.59 28.72 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 114.853 -1.067 . . . . 0.0 111.39 -174.748 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 258' ' ' GLN . . . . . 0.474 ' HG3' ' SG ' ' A' ' 262' ' ' CYS . 60.9 tp60 -58.93 -40.6 85.07 Favored 'General case' 0 CA--C 1.509 -0.608 0 C-N-CA 120.343 -0.543 . . . . 0.0 110.085 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 259' ' ' LEU . . . . . 0.628 HD21 ' CE2' ' A' ' 283' ' ' PHE . 96.0 mt -62.51 -42.28 99.4 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.981 -0.554 . . . . 0.0 109.554 179.009 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 260' ' ' ASN . . . . . 0.505 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 99.0 m-20 -60.23 -40.44 90.22 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.079 -178.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -92.19 -5.12 65.98 Favored Glycine 0 CA--C 1.523 0.557 0 C-N-CA 121.268 -0.491 . . . . 0.0 111.904 -178.238 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 262' ' ' CYS . . . . . 0.474 ' SG ' ' HG3' ' A' ' 258' ' ' GLN . 1.1 m -78.19 154.6 30.98 Favored 'General case' 0 C--N 1.326 -0.456 0 C-N-CA 120.363 -0.535 . . . . 0.0 111.614 -176.207 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . 0.561 ' CD ' ' H ' ' A' ' 263' ' ' GLN . 0.0 OUTLIER -67.9 170.72 6.67 Favored Pre-proline 0 C--N 1.322 -0.623 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 172.93 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 264' ' ' PRO . . . . . 0.452 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 45.1 Cg_endo -63.92 142.99 84.22 Favored 'Trans proline' 0 C--N 1.311 -1.436 0 N-CA-C 109.452 -1.018 . . . . 0.0 109.452 177.555 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 265' ' ' MET . . . . . 0.466 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 17.1 ptp -130.97 153.97 48.64 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 112.254 0.464 . . . . 0.0 112.254 -173.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -71.83 137.54 47.63 Favored 'General case' 0 C--O 1.236 0.383 0 O-C-N 124.133 0.896 . . . . 0.0 109.919 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 267' ' ' ILE . . . . . 0.673 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.8 pp -128.47 162.5 34.99 Favored 'Isoleucine or valine' 0 C--O 1.244 0.771 0 CA-C-O 121.085 0.469 . . . . 0.0 112.106 -179.035 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 61.4 mttm -122.6 126.5 47.82 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.522 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 13.0 m -84.92 123.69 39.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 C-N-CA 120.644 -0.422 . . . . 0.0 111.477 -179.567 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 90.0 mt -102.86 -12.01 17.86 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.588 178.334 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -171.81 -177.77 41.67 Favored Glycine 0 C--N 1.318 -0.463 0 N-CA-C 110.279 -1.128 . . . . 0.0 110.279 -179.109 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 272' ' ' PRO . . . . . 0.574 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 29.8 Cg_endo -60.37 -34.1 93.67 Favored 'Trans proline' 0 C--N 1.306 -1.677 0 C-N-CA 122.091 1.861 . . . . 0.0 111.7 -179.785 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 73.1 m-85 -125.59 10.04 7.8 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.172 -179.722 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -120.7 128.5 53.01 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 116.486 -0.324 . . . . 0.0 110.51 -173.167 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 275' ' ' PHE . . . . . 0.518 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -141.54 166.25 25.28 Favored 'General case' 0 CA--C 1.508 -0.659 0 N-CA-C 112.597 0.592 . . . . 0.0 112.597 178.748 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . 0.452 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 7.8 p -133.66 146.92 51.32 Favored 'General case' 0 N--CA 1.44 -0.952 0 CA-C-O 121.182 0.515 . . . . 0.0 111.276 -179.73 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . 0.412 HG22 HG22 ' A' ' 267' ' ' ILE . 28.9 pt -139.79 164.1 23.98 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.005 0 CA-C-N 114.518 -1.219 . . . . 0.0 111.511 -173.174 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -23.99 -92.76 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.574 0 N-CA-C 113.603 0.964 . . . . 0.0 113.603 -176.71 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . 0.439 ' HB3' ' HB2' ' A' ' 282' ' ' ASN . 66.8 t0 -151.34 121.75 7.35 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 -177.597 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . 0.679 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 23.7 p -65.04 -30.12 71.07 Favored 'General case' 0 C--N 1.293 -1.882 0 CA-C-O 120.982 0.42 . . . . 0.0 111.095 177.01 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 281' ' ' SER . . . . . 0.555 ' OG ' ' NZ ' ' A' ' 226' ' ' LYS . 15.7 m -70.39 -14.59 62.62 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.017 174.132 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 282' ' ' ASN . . . . . 0.439 ' HB2' ' HB3' ' A' ' 279' ' ' ASP . 60.4 t30 -89.22 -5.71 57.44 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.872 174.395 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . 0.679 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 12.4 m-85 -102.89 -73.86 0.65 Allowed 'General case' 0 CA--C 1.511 -0.521 0 CA-C-O 121.594 0.711 . . . . 0.0 109.79 175.057 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 172.48 -166.36 0.02 OUTLIER 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 114.02 -1.446 . . . . 0.0 107.827 -171.895 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -97.06 146.4 25.05 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 117.907 0.322 . . . . 0.0 111.115 178.068 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 10.8 t80 -86.54 123.17 31.44 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.006 -179.816 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 287' ' ' ILE . . . . . 0.567 ' O ' ' HG3' ' A' ' 288' ' ' ARG . 21.4 mm -100.51 -73.66 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -0.981 0 CA-C-N 116.501 -0.318 . . . . 0.0 110.265 176.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . 0.567 ' HG3' ' O ' ' A' ' 287' ' ' ILE . 92.1 mtt-85 -164.61 178.43 7.33 Favored 'General case' 0 C--O 1.242 0.663 0 C-N-CA 124.112 0.965 . . . . 0.0 110.409 179.265 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 68.63 -158.14 52.78 Favored Glycine 0 CA--C 1.505 -0.536 0 N-CA-C 110.319 -1.113 . . . . 0.0 110.319 177.078 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 108.31 113.57 3.69 Favored Glycine 0 N--CA 1.439 -1.158 0 C-N-CA 120.769 -0.729 . . . . 0.0 111.946 177.715 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . 0.545 HD12 ' SD ' ' A' ' 220' ' ' MET . 43.5 mm -112.96 128.71 69.55 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.477 0 N-CA-C 105.899 -1.889 . . . . 0.0 105.899 172.352 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 3.5 p -118.9 134.45 62.51 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.039 0 C-N-CA 120.253 -0.579 . . . . 0.0 109.657 -177.694 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 15.2 m -125.21 144.48 50.43 Favored 'General case' 0 CA--C 1.508 -0.65 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.91 -176.504 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 294' ' ' GLN . . . . . 0.506 ' HB3' ' CD1' ' A' ' 242' ' ' PHE . 3.4 pt20 -77.76 151.48 34.05 Favored 'General case' 0 CA--C 1.502 -0.873 0 C-N-CA 120.205 -0.598 . . . . 0.0 110.745 179.159 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . 0.444 HG11 ' HG3' ' A' ' 264' ' ' PRO . 76.8 t -130.66 130.7 64.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.563 0 N-CA-C 108.315 -0.994 . . . . 0.0 108.315 175.841 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 296' ' ' LYS . . . . . 0.452 ' NZ ' ' OE1' ' A' ' 294' ' ' GLN . 27.0 mmtp -103.86 105.87 16.2 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 120.071 -0.652 . . . . 0.0 109.429 177.015 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 297' ' ' VAL . . . . . 0.702 ' HB ' ' HD2' ' A' ' 298' ' ' PRO . 34.5 m -55.21 -175.65 0.04 OUTLIER Pre-proline 0 CA--C 1.54 0.591 0 CA-C-N 115.082 -0.963 . . . . 0.0 108.68 177.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 298' ' ' PRO . . . . . 0.702 ' HD2' ' HB ' ' A' ' 297' ' ' VAL . 87.0 Cg_exo -48.2 84.83 0.02 OUTLIER 'Trans proline' 0 N--CA 1.493 1.444 0 C-N-CA 121.201 1.267 . . . . 0.0 111.095 -178.09 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . 0.573 ' N ' ' O ' ' A' ' 297' ' ' VAL . 43.9 tttp -109.94 137.76 47.26 Favored 'General case' 0 CA--C 1.502 -0.868 0 CA-C-N 115.474 -0.785 . . . . 0.0 111.786 -175.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 300' ' ' LYS . . . . . 0.403 ' O ' ' HG2' ' A' ' 299' ' ' LYS . 24.3 mmtp -83.74 135.23 34.63 Favored 'General case' 0 N--CA 1.433 -1.287 0 N-CA-C 106.94 -1.504 . . . . 0.0 106.94 171.34 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 47.6 pt -74.89 -177.13 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.908 0 C-N-CA 120.357 -0.537 . . . . 0.0 109.867 -177.264 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 17.6 m -74.62 151.75 39.31 Favored 'General case' 0 C--N 1.316 -0.863 0 C-N-CA 120.318 -0.553 . . . . 0.0 109.862 178.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -125.77 154.46 42.52 Favored 'General case' 0 C--N 1.315 -0.897 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 179.477 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -65.14 140.03 58.74 Favored 'General case' 0 C--N 1.313 -0.997 0 N-CA-C 108.752 -0.832 . . . . 0.0 108.752 179.715 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 2.6 m -62.0 142.88 57.24 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.927 -173.646 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 306' ' ' LEU . . . . . 0.55 ' HB2' ' HD2' ' A' ' 307' ' ' PRO . 0.9 OUTLIER -59.1 178.31 0.23 Allowed Pre-proline 0 C--O 1.239 0.546 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.499 177.793 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . 0.55 ' HD2' ' HB2' ' A' ' 306' ' ' LEU . 24.1 Cg_exo -61.27 41.94 0.07 OUTLIER 'Trans proline' 0 N--CA 1.499 1.831 0 C-N-CA 122.391 2.061 . . . . 0.0 112.509 177.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . 0.52 ' N ' ' O ' ' A' ' 306' ' ' LEU . . . -82.08 -174.5 5.12 Favored 'General case' 0 C--O 1.24 0.59 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 175.122 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 3.8 m -56.22 131.44 47.91 Favored 'General case' 0 C--N 1.319 -0.719 0 C-N-CA 120.228 -0.589 . . . . 0.0 109.605 179.155 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 94.2 mt -75.66 148.98 38.27 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 109.276 -0.639 . . . . 0.0 109.276 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 2.7 m -114.84 128.91 71.77 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 CA-C-O 120.624 0.249 . . . . 0.0 111.333 -178.458 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 67.0 mt-10 . . . . . 0 C--O 1.204 -1.303 0 CA-C-O 118.462 -0.78 . . . . 0.0 111.747 179.296 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . 0.485 ' O ' ' HG3' ' A' ' 205' ' ' GLU . 65.2 mm-40 . . . . . 0 N--CA 1.476 0.854 0 N-CA-C 108.525 -0.916 . . . . 0.0 108.525 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 202' ' ' PHE . . . . . 0.479 ' CG ' ' N ' ' A' ' 203' ' ' GLY . 28.1 p90 -53.87 -46.71 71.38 Favored 'General case' 0 CA--C 1.513 -0.459 0 CA-C-N 115.955 -0.566 . . . . 0.0 112.084 -172.215 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . 0.479 ' N ' ' CG ' ' A' ' 202' ' ' PHE . . . -57.1 -47.76 85.02 Favored Glycine 0 C--N 1.318 -0.439 0 C-N-CA 119.837 -1.173 . . . . 0.0 110.357 -177.733 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 204' ' ' GLU . . . . . 0.426 ' OE1' ' N ' ' A' ' 204' ' ' GLU . 55.2 mp0 -66.39 -43.22 86.45 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 121.126 0.488 . . . . 0.0 110.208 177.35 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 205' ' ' GLU . . . . . 0.485 ' HG3' ' O ' ' A' ' 201' ' ' GLU . 83.1 mt-10 -66.43 -38.07 86.6 Favored 'General case' 0 C--O 1.241 0.633 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.708 -178.644 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 206' ' ' MET . . . . . 0.431 ' N ' ' O ' ' A' ' 202' ' ' PHE . 21.5 mmt -65.37 72.56 0.05 OUTLIER 'General case' 0 C--O 1.238 0.449 0 CA-C-O 121.383 0.611 . . . . 0.0 111.518 -178.261 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . 0.439 ' N ' ' O ' ' A' ' 205' ' ' GLU . 16.4 m -137.78 161.33 33.28 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.009 0 CA-C-N 114.902 -1.045 . . . . 0.0 109.051 173.723 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 69.8 mt -92.4 125.17 36.93 Favored 'General case' 0 C--N 1.316 -0.881 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 178.301 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 209' ' ' THR . . . . . 0.468 HG23 ' N ' ' A' ' 210' ' ' ASP . 15.3 t -88.38 -57.44 2.92 Favored 'General case' 0 C--O 1.24 0.604 0 C-N-CA 120.332 -0.547 . . . . 0.0 111.379 -175.861 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 210' ' ' ASP . . . . . 0.468 ' N ' HG23 ' A' ' 209' ' ' THR . 3.7 p-10 -74.85 -41.85 59.07 Favored 'General case' 0 CA--C 1.515 -0.402 0 C-N-CA 120.229 -0.589 . . . . 0.0 110.38 178.908 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -68.71 92.4 0.48 Allowed 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.817 -178.598 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 40.3 t-20 -97.53 128.91 44.65 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.309 -0.86 . . . . 0.0 109.717 179.82 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 70.72 33.1 66.73 Favored Glycine 0 N--CA 1.452 -0.264 0 N-CA-C 110.658 -0.977 . . . . 0.0 110.658 -176.721 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 2.7 mm-40 -110.23 152.87 25.57 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 121.014 0.435 . . . . 0.0 110.779 179.376 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 215' ' ' GLN . . . . . 0.422 ' CD ' ' H ' ' A' ' 215' ' ' GLN . 2.7 mp0 -74.38 150.24 87.09 Favored Pre-proline 0 C--N 1.313 -1.005 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.265 -178.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -60.24 147.49 93.41 Favored 'Trans proline' 0 C--N 1.307 -1.655 0 C-N-CA 122.264 1.976 . . . . 0.0 109.912 173.62 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 217' ' ' LEU . . . . . 0.629 HD11 ' NH2' ' A' ' 239' ' ' ARG . 0.1 OUTLIER -47.01 123.38 5.22 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 -178.607 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 218' ' ' SER . . . . . 0.431 ' OG ' ' OG ' ' A' ' 293' ' ' SER . 45.9 m -132.46 148.6 52.4 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.692 -174.574 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -143.08 157.11 44.83 Favored 'General case' 0 CA--C 1.51 -0.573 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.884 178.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 66.2 mtt -75.18 144.2 42.83 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 115.736 -0.666 . . . . 0.0 109.61 176.503 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 95.7 t -85.38 129.32 38.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.35 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 222' ' ' SER . . . . . 0.546 ' HG ' ' C ' ' A' ' 233' ' ' THR . 25.3 p -94.44 -55.14 3.26 Favored 'General case' 0 N--CA 1.439 -0.979 0 CA-C-O 120.867 0.365 . . . . 0.0 110.218 -178.164 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -137.46 149.39 46.81 Favored 'General case' 0 C--O 1.219 -0.551 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.599 177.573 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 224' ' ' VAL . . . . . 0.461 ' HB ' ' CD1' ' A' ' 286' ' ' TYR . 43.2 t -124.96 133.2 70.09 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.828 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 172.667 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -103.88 116.88 33.08 Favored 'General case' 0 C--N 1.31 -1.141 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 -178.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 226' ' ' LYS . . . . . 0.435 ' HA ' ' OG1' ' A' ' 280' ' ' THR . 88.1 tttt -78.55 90.38 4.51 Favored 'General case' 0 CA--C 1.505 -0.776 0 C-N-CA 119.296 -0.962 . . . . 0.0 110.044 -177.924 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 227' ' ' ASP . . . . . 0.617 ' H ' ' HG1' ' A' ' 280' ' ' THR . 43.9 t0 -159.5 179.85 8.55 Favored 'General case' 0 C--N 1.307 -1.241 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.03 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 228' ' ' ASN . . . . . 0.472 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 1.8 p30 -132.99 125.5 19.15 Favored Pre-proline 0 C--N 1.324 -0.523 0 CA-C-N 115.878 -0.601 . . . . 0.0 109.912 175.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 229' ' ' PRO . . . . . 0.472 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 46.4 Cg_endo -66.32 145.12 69.42 Favored 'Cis proline' 0 N--CA 1.491 1.349 0 C-N-CA 123.204 -1.582 . . . . 0.0 110.641 -0.68 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . 0.511 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -68.01 132.86 28.77 Favored Glycine 0 N--CA 1.452 -0.234 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.169 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.9 p -128.26 136.12 60.91 Favored 'Isoleucine or valine' 0 C--O 1.241 0.629 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 178.35 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 232' ' ' VAL . . . . . 0.56 HG22 ' CD1' ' A' ' 275' ' ' PHE . 0.6 OUTLIER -134.85 156.01 39.21 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.047 0 C-N-CA 120.164 -0.614 . . . . 0.0 110.493 -179.422 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 233' ' ' THR . . . . . 0.546 ' C ' ' HG ' ' A' ' 222' ' ' SER . 21.7 m -104.65 144.78 31.25 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 115.413 -0.812 . . . . 0.0 109.106 176.11 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 2.4 m -106.1 159.51 16.02 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 177.484 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.567 ' HB3' ' HB3' ' A' ' 238' ' ' ALA . 43.1 tp -57.85 127.24 31.07 Favored 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 -178.469 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 236' ' ' ASP . . . . . 0.402 ' O ' ' CZ ' ' A' ' 273' ' ' TYR . 7.5 m-20 -62.46 -37.91 87.75 Favored 'General case' 0 CA--C 1.512 -0.497 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.19 -172.279 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 57.9 mp0 -69.67 -19.5 63.59 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.659 177.734 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . 0.567 ' HB3' ' HB3' ' A' ' 235' ' ' LEU . . . -108.78 99.94 9.23 Favored 'General case' 0 C--O 1.238 0.479 0 N-CA-C 112.102 0.408 . . . . 0.0 112.102 -177.197 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 239' ' ' ARG . . . . . 0.629 ' NH2' HD11 ' A' ' 217' ' ' LEU . 0.0 OUTLIER -70.57 117.4 12.05 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 173.342 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 240' ' ' HIS . . . . . 0.606 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 6.6 p80 -66.54 -45.71 78.49 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.681 -179.504 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 82.31 21.43 60.55 Favored Glycine 0 C--N 1.315 -0.62 0 N-CA-C 110.775 -0.93 . . . . 0.0 110.775 -178.275 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 242' ' ' PHE . . . . . 0.772 ' HB3' HD11 ' A' ' 267' ' ' ILE . 7.5 m-30 -83.74 156.02 22.79 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 120.69 0.281 . . . . 0.0 110.339 179.629 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 -124.3 165.08 18.29 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.545 174.821 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 244' ' ' THR . . . . . 0.62 HG23 ' HA ' ' A' ' 268' ' ' LYS . 0.2 OUTLIER -69.61 126.44 29.74 Favored 'General case' 0 C--N 1.319 -0.76 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 177.374 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 90.43 2.38 73.43 Favored Glycine 0 C--N 1.317 -0.513 0 N-CA-C 110.476 -1.05 . . . . 0.0 110.476 -176.422 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 246' ' ' ASP . . . . . 0.511 ' O ' HG12 ' A' ' 267' ' ' ILE . 46.3 t0 -77.8 163.86 25.72 Favored 'General case' 0 C--O 1.237 0.445 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 176.427 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 247' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -115.84 128.85 56.13 Favored 'General case' 0 C--O 1.241 0.637 0 O-C-N 123.287 0.367 . . . . 0.0 110.661 -178.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.541 ' CG1' HD13 ' A' ' 267' ' ' ILE . 2.4 m -132.4 164.58 34.56 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.308 0 C-N-CA 120.223 -0.591 . . . . 0.0 111.905 178.287 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 31.4 m -130.66 153.0 49.41 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.179 172.56 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 250' ' ' PHE . . . . . 0.604 ' CD1' HD22 ' A' ' 259' ' ' LEU . 61.3 m-85 -103.14 146.58 28.18 Favored 'General case' 0 C--N 1.322 -0.616 0 C-N-CA 122.729 0.411 . . . . 0.0 110.327 -178.912 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 2.5 m -143.74 153.06 42.04 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.417 176.715 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 49.42 37.51 12.09 Favored 'General case' 0 C--O 1.245 0.865 0 N-CA-C 113.044 0.757 . . . . 0.0 113.044 175.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 0.65 HG22 ' HA3' ' A' ' 290' ' ' GLY . 78.7 t -90.37 132.38 35.13 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 175.853 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 86.8 mt-30 -88.08 140.56 29.36 Favored 'General case' 0 C--O 1.242 0.709 0 C-N-CA 120.411 -0.516 . . . . 0.0 110.068 177.487 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 80.06 -63.82 4.03 Favored Glycine 0 C--N 1.314 -0.691 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 179.174 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 256' ' ' MET . . . . . 0.464 ' N ' ' O ' ' A' ' 285' ' ' ASP . 20.9 ttm -84.69 71.76 10.78 Favored 'General case' 0 CA--C 1.504 -0.804 0 C-N-CA 119.853 -0.739 . . . . 0.0 109.377 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 45.0 pt -80.35 -15.3 12.91 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 CA-C-N 115.005 -0.998 . . . . 0.0 110.144 -177.756 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 258' ' ' GLN . . . . . 0.504 ' O ' ' SG ' ' A' ' 262' ' ' CYS . 63.3 tp60 -57.53 -39.13 75.92 Favored 'General case' 0 N--CA 1.437 -1.11 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 177.643 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 259' ' ' LEU . . . . . 0.854 HD21 ' CE2' ' A' ' 283' ' ' PHE . 88.1 mt -62.78 -40.67 98.01 Favored 'General case' 0 N--CA 1.449 -0.508 0 CA-C-N 115.113 -0.949 . . . . 0.0 110.222 175.001 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -60.04 -40.63 90.06 Favored 'General case' 0 C--O 1.241 0.607 0 N-CA-C 109.306 -0.628 . . . . 0.0 109.306 -179.577 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -101.18 23.2 36.25 Favored Glycine 0 CA--C 1.526 0.736 0 N-CA-C 111.246 -0.741 . . . . 0.0 111.246 -179.178 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 262' ' ' CYS . . . . . 0.504 ' SG ' ' O ' ' A' ' 258' ' ' GLN . 1.3 m -96.68 147.34 24.01 Favored 'General case' 0 C--O 1.239 0.51 0 CA-C-N 117.362 0.581 . . . . 0.0 112.382 -177.708 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 5.3 mt-30 -61.93 154.34 68.62 Favored Pre-proline 0 C--N 1.324 -0.518 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 170.699 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 264' ' ' PRO . . . . . 0.798 ' HB3' HG21 ' A' ' 295' ' ' VAL . 50.9 Cg_endo -64.4 145.06 87.4 Favored 'Trans proline' 0 C--N 1.304 -1.806 0 C-N-CA 121.08 1.187 . . . . 0.0 109.868 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 265' ' ' MET . . . . . 0.554 ' N ' ' SD ' ' A' ' 265' ' ' MET . 0.2 OUTLIER -122.8 148.8 44.96 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 112.405 0.52 . . . . 0.0 112.405 -174.237 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 266' ' ' GLU . . . . . 0.419 ' HA ' ' O ' ' A' ' 246' ' ' ASP . 75.8 tt0 -77.97 134.3 37.87 Favored 'General case' 0 C--O 1.242 0.662 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 174.355 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 267' ' ' ILE . . . . . 0.772 HD11 ' HB3' ' A' ' 242' ' ' PHE . 49.5 pt -125.26 159.64 32.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 N-CA-C 114.023 1.12 . . . . 0.0 114.023 -166.342 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . 0.62 ' HA ' HG23 ' A' ' 244' ' ' THR . 66.5 mttm -120.55 106.59 11.93 Favored 'General case' 0 CA--C 1.537 0.459 0 CA-C-N 115.154 -0.93 . . . . 0.0 110.021 177.325 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.4 HG22 ' H ' ' A' ' 269' ' ' VAL . 17.3 m -80.24 102.31 6.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 120.999 0.428 . . . . 0.0 110.516 178.452 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 96.1 mt -66.3 -41.27 89.99 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.964 -179.707 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -149.16 -172.09 18.49 Favored Glycine 0 C--N 1.318 -0.458 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -177.383 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 272' ' ' PRO . . . . . 0.606 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 37.9 Cg_endo -62.98 -33.93 72.68 Favored 'Trans proline' 0 C--N 1.308 -1.57 0 C-N-CA 121.827 1.685 . . . . 0.0 111.369 -178.024 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 273' ' ' TYR . . . . . 0.409 ' O ' ' HA ' ' A' ' 233' ' ' THR . 83.3 m-85 -122.54 8.44 9.55 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 112.818 0.673 . . . . 0.0 112.818 -177.968 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 2.8 p -120.88 128.05 52.44 Favored 'General case' 0 C--O 1.243 0.747 0 CA-C-O 120.605 0.24 . . . . 0.0 110.865 178.923 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 275' ' ' PHE . . . . . 0.561 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -138.25 159.44 42.04 Favored 'General case' 0 CA--C 1.507 -0.697 0 C-N-CA 120.671 -0.411 . . . . 0.0 111.658 177.667 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 7.9 p -137.79 154.29 49.58 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.521 -173.388 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . 0.487 HG22 HG22 ' A' ' 267' ' ' ILE . 0.1 OUTLIER -141.72 -155.04 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.912 0 CA-C-N 115.428 -0.805 . . . . 0.0 110.106 -173.087 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 1.1 p -60.04 -89.03 0.0 OUTLIER 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 116.499 -0.318 . . . . 0.0 111.306 178.338 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . 0.596 ' HB3' HD22 ' A' ' 282' ' ' ASN . 66.0 t0 -151.7 118.98 5.94 Favored 'General case' 0 N--CA 1.447 -0.611 0 CA-C-O 120.825 0.345 . . . . 0.0 111.421 -176.736 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . 0.646 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 11.1 p -64.34 -30.34 71.39 Favored 'General case' 0 C--N 1.299 -1.626 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.101 175.095 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -61.73 -21.05 64.17 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.449 175.852 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 282' ' ' ASN . . . . . 0.596 HD22 ' HB3' ' A' ' 279' ' ' ASP . 40.1 m-80 -93.94 -3.83 50.9 Favored 'General case' 0 N--CA 1.451 -0.419 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.023 176.847 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . 0.854 ' CE2' HD21 ' A' ' 259' ' ' LEU . 22.8 m-85 -91.84 -80.72 0.35 Allowed 'General case' 0 CA--C 1.512 -0.508 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 171.674 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 3.9 p 179.25 -109.85 0.0 OUTLIER 'General case' 0 N--CA 1.453 -0.305 0 CA-C-N 115.193 -0.912 . . . . 0.0 109.675 173.463 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 285' ' ' ASP . . . . . 0.464 ' O ' ' N ' ' A' ' 256' ' ' MET . 2.1 p-10 -145.49 163.37 34.9 Favored 'General case' 0 C--O 1.219 -0.514 0 N-CA-C 107.667 -1.234 . . . . 0.0 107.667 174.114 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . 0.461 ' CD1' ' HB ' ' A' ' 224' ' ' VAL . 1.1 p90 -123.95 145.51 49.11 Favored 'General case' 0 N--CA 1.468 0.442 0 C-N-CA 119.663 -0.815 . . . . 0.0 111.495 -178.046 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 96.9 mt -100.77 -57.68 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 176.781 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 32.2 ptt-85 -176.17 -169.3 0.31 Allowed 'General case' 0 C--O 1.242 0.688 0 CA-C-N 115.447 -0.797 . . . . 0.0 109.979 177.584 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 67.32 -153.47 52.9 Favored Glycine 0 CA--C 1.502 -0.779 0 N-CA-C 110.944 -0.863 . . . . 0.0 110.944 175.837 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . 0.65 ' HA3' HG22 ' A' ' 253' ' ' VAL . . . 93.51 136.49 7.96 Favored Glycine 0 N--CA 1.442 -0.958 0 N-CA-C 111.778 -0.529 . . . . 0.0 111.778 176.841 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 92.2 mt -122.87 129.38 75.17 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 173.756 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 3.8 p -112.21 129.72 67.19 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 178.855 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . 0.431 ' OG ' ' OG ' ' A' ' 218' ' ' SER . 55.7 m -126.9 147.88 50.05 Favored 'General case' 0 CA--C 1.5 -0.972 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.371 -174.495 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 294' ' ' GLN . . . . . 0.431 ' HG3' ' CE1' ' A' ' 242' ' ' PHE . 85.0 mt-30 -63.85 164.03 10.86 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 171.804 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . 0.798 HG21 ' HB3' ' A' ' 264' ' ' PRO . 60.7 t -127.24 111.68 26.12 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 176.763 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 8.0 tmtm? -75.69 97.88 3.93 Favored 'General case' 0 N--CA 1.443 -0.811 0 C-N-CA 118.803 -1.159 . . . . 0.0 108.859 177.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 35.7 m -56.54 134.97 77.29 Favored Pre-proline 0 C--O 1.245 0.849 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 178.918 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_exo -54.4 -43.34 59.62 Favored 'Trans proline' 0 N--CA 1.489 1.225 0 C-N-CA 121.226 1.284 . . . . 0.0 108.969 177.665 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 19.5 tptm -137.86 133.61 34.1 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 114.714 -1.13 . . . . 0.0 109.15 171.807 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 300' ' ' LYS . . . . . 0.595 ' NZ ' ' OG ' ' A' ' 302' ' ' SER . 1.1 ttpm? -89.25 111.39 22.18 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 177.808 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 301' ' ' ILE . . . . . 0.401 HD13 HG21 ' A' ' 301' ' ' ILE . 37.8 pt -70.43 137.55 23.72 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.961 0 C-N-CA 120.636 -0.425 . . . . 0.0 110.544 179.879 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 302' ' ' SER . . . . . 0.595 ' OG ' ' NZ ' ' A' ' 300' ' ' LYS . 1.5 m -122.85 149.94 43.52 Favored 'General case' 0 C--O 1.242 0.675 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.8 -178.179 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 21.2 t80 -149.08 149.41 31.04 Favored 'General case' 0 C--N 1.32 -0.685 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 177.429 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 67.5 mttm -107.44 152.85 23.64 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.345 178.838 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . 0.459 ' O ' ' C ' ' A' ' 306' ' ' LEU . 8.9 m -63.94 143.27 57.99 Favored 'General case' 0 C--N 1.315 -0.894 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 176.798 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 306' ' ' LEU . . . . . 0.459 ' C ' ' O ' ' A' ' 305' ' ' SER . 1.3 mp -30.77 106.94 0.24 Allowed Pre-proline 0 C--O 1.234 0.27 0 O-C-N 123.373 0.421 . . . . 0.0 111.171 -175.883 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_exo -59.0 143.18 99.92 Favored 'Trans proline' 0 C--N 1.311 -1.422 0 C-N-CA 122.114 1.876 . . . . 0.0 110.416 -178.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -70.25 149.43 47.46 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.861 -178.743 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 1.3 m -68.61 95.39 0.64 Allowed 'General case' 0 C--O 1.24 0.585 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 176.046 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 3.1 pp -112.64 145.51 40.29 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 112.935 0.717 . . . . 0.0 112.935 -171.303 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 6.3 m -131.81 132.02 61.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 115.098 -0.955 . . . . 0.0 109.12 175.341 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 36.2 mt-10 . . . . . 0 C--O 1.204 -1.336 0 CA-C-O 118.52 -0.752 . . . . 0.0 110.196 -176.189 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . 0.413 ' N ' ' OE1' ' A' ' 201' ' ' GLU . 1.9 mp0 . . . . . 0 N--CA 1.487 1.423 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 93.8 m-85 -70.92 137.71 49.48 Favored 'General case' 0 C--O 1.239 0.549 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 -179.147 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -115.81 44.61 1.44 Allowed Glycine 0 C--N 1.32 -0.345 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 -179.53 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 75.1 mm-40 -71.82 -44.11 64.46 Favored 'General case' 0 C--N 1.319 -0.734 0 C-N-CA 120.232 -0.587 . . . . 0.0 111.538 -178.572 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -72.9 -42.82 63.16 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.496 -0.482 . . . . 0.0 110.871 175.683 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 95.3 mtp -115.79 125.72 53.1 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 108.998 -0.742 . . . . 0.0 108.998 178.835 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 22.8 m -110.61 132.26 59.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-O 121.093 0.473 . . . . 0.0 111.1 178.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 85.1 mt -88.36 85.02 6.81 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.887 -176.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 44.9 p -132.87 -73.03 0.51 Allowed 'General case' 0 C--N 1.316 -0.871 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 176.74 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -121.26 -24.18 5.54 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-N 114.644 -1.162 . . . . 0.0 109.209 174.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -56.72 127.85 33.58 Favored 'General case' 0 N--CA 1.442 -0.86 0 CA-C-N 115.128 -0.942 . . . . 0.0 111.801 -176.254 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 212' ' ' ASN . . . . . 0.434 ' H ' ' CD ' ' A' ' 214' ' ' GLU . 0.5 OUTLIER -114.35 84.46 2.05 Favored 'General case' 0 C--O 1.24 0.558 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.694 173.531 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 47.94 34.95 12.22 Favored Glycine 0 CA--C 1.525 0.659 0 CA-C-N 116.358 -0.383 . . . . 0.0 112.698 174.448 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 214' ' ' GLU . . . . . 0.434 ' CD ' ' H ' ' A' ' 212' ' ' ASN . 58.7 mp0 -59.17 132.94 55.53 Favored 'General case' 0 C--O 1.242 0.685 0 CA-C-N 117.37 0.585 . . . . 0.0 112.149 -178.186 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 5.2 mt-30 -112.47 156.7 41.87 Favored Pre-proline 0 C--N 1.32 -0.7 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 168.355 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -55.73 132.79 54.19 Favored 'Trans proline' 0 C--N 1.303 -1.842 0 C-N-CA 121.299 1.333 . . . . 0.0 111.163 -178.043 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 217' ' ' LEU . . . . . 0.707 HD13 ' N ' ' A' ' 218' ' ' SER . 0.3 OUTLIER -113.85 126.81 55.6 Favored 'General case' 0 C--N 1.317 -0.816 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 179.405 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 218' ' ' SER . . . . . 0.707 ' N ' HD13 ' A' ' 217' ' ' LEU . 50.8 m -114.04 131.88 56.21 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.163 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 219' ' ' ALA . . . . . 0.622 ' HB1' ' HB1' ' A' ' 238' ' ' ALA . . . -131.75 150.74 52.05 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.703 -175.362 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 97.8 mtp -81.02 129.69 34.66 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.163 178.42 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . 0.455 HG11 ' CG2' ' A' ' 224' ' ' VAL . 97.3 t -79.85 133.98 28.54 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.011 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 177.356 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 13.8 p -93.28 -62.0 1.46 Allowed 'General case' 0 N--CA 1.436 -1.151 0 C-N-CA 120.129 -0.628 . . . . 0.0 109.777 -179.358 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -138.06 139.05 39.36 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.946 173.818 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 224' ' ' VAL . . . . . 0.742 HG13 HG12 ' A' ' 232' ' ' VAL . 59.4 t -117.01 130.79 71.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 174.489 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 62.3 p -88.02 138.9 31.05 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-O 120.826 0.346 . . . . 0.0 110.944 -178.509 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 226' ' ' LYS . . . . . 0.451 ' NZ ' ' OD2' ' A' ' 285' ' ' ASP . 2.6 tptm -78.34 77.66 4.83 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 178.807 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 227' ' ' ASP . . . . . 0.41 ' H ' ' HG1' ' A' ' 280' ' ' THR . 45.8 t0 -157.0 174.04 16.12 Favored 'General case' 0 N--CA 1.468 0.454 0 N-CA-C 112.249 0.462 . . . . 0.0 112.249 -176.172 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 228' ' ' ASN . . . . . 0.482 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.4 OUTLIER -130.86 125.14 21.16 Favored Pre-proline 0 N--CA 1.451 -0.403 0 CA-C-N 115.382 -0.826 . . . . 0.0 110.244 173.083 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 229' ' ' PRO . . . . . 0.482 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 24.6 Cg_exo -64.86 147.37 70.15 Favored 'Cis proline' 0 C--N 1.31 -1.498 0 C-N-CA 123.611 -1.412 . . . . 0.0 110.059 -2.157 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . 0.664 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -72.75 100.86 1.03 Allowed Glycine 0 C--N 1.295 -1.704 0 N-CA-C 110.025 -1.23 . . . . 0.0 110.025 -179.732 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 231' ' ' VAL . . . . . 0.621 HG23 HD12 ' A' ' 270' ' ' LEU . 7.1 p -88.51 127.32 41.51 Favored 'Isoleucine or valine' 0 C--O 1.244 0.784 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 177.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 232' ' ' VAL . . . . . 0.742 HG12 HG13 ' A' ' 224' ' ' VAL . 0.6 OUTLIER -131.46 156.43 42.64 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.897 0 CA-C-O 121.124 0.488 . . . . 0.0 109.827 -177.503 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -117.69 145.45 44.41 Favored 'General case' 0 N--CA 1.429 -1.489 0 CA-C-N 114.838 -1.074 . . . . 0.0 109.032 179.336 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.8 m -107.0 160.3 15.64 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.095 -177.553 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 24.1 tp -54.82 132.62 46.61 Favored 'General case' 0 C--N 1.314 -0.966 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 178.749 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 236' ' ' ASP . . . . . 0.41 ' O ' ' CE1' ' A' ' 273' ' ' TYR . 28.4 t70 -53.89 -42.82 69.07 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-O 121.341 0.591 . . . . 0.0 111.007 -176.174 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 74.0 mt-10 -65.49 -32.15 73.61 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.32 179.126 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . 0.622 ' HB1' ' HB1' ' A' ' 219' ' ' ALA . . . -72.11 135.03 46.1 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.961 0.41 . . . . 0.0 111.896 -176.861 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 66.2 mtp180 -113.13 92.96 4.19 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 175.565 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 240' ' ' HIS . . . . . 0.567 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 7.3 p80 -54.7 -49.12 71.48 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 -173.337 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 79.86 17.57 74.67 Favored Glycine 0 C--N 1.309 -0.964 0 N-CA-C 110.491 -1.044 . . . . 0.0 110.491 -179.21 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 242' ' ' PHE . . . . . 0.49 ' CD2' ' HB2' ' A' ' 240' ' ' HIS . 6.5 m-30 -80.4 144.12 32.93 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 -179.11 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -106.83 164.85 11.77 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.346 0.594 . . . . 0.0 111.364 179.145 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -65.56 120.8 13.55 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 177.866 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 79.76 7.69 88.3 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 -177.358 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 43.2 t0 -79.51 166.49 21.9 Favored 'General case' 0 C--O 1.233 0.188 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 -179.694 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 247' ' ' PHE . . . . . 0.496 ' HA ' ' O ' ' A' ' 265' ' ' MET . 26.9 m-85 -110.19 133.63 53.04 Favored 'General case' 0 C--O 1.239 0.525 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -176.868 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.499 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 3.0 m -131.89 160.37 42.47 Favored 'Isoleucine or valine' 0 C--O 1.237 0.435 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.472 178.144 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 1.2 m -121.84 161.65 22.34 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 114.907 -1.042 . . . . 0.0 109.171 173.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 250' ' ' PHE . . . . . 0.527 ' CB ' ' HB3' ' A' ' 259' ' ' LEU . 61.0 m-85 -125.88 151.77 46.45 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 110.306 -0.257 . . . . 0.0 110.306 -175.066 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 16.4 m -156.36 163.08 39.91 Favored 'General case' 0 C--O 1.215 -0.719 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 177.032 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 67.3 mm-40 54.4 30.15 12.24 Favored 'General case' 0 C--N 1.316 -0.887 0 N-CA-C 111.746 0.276 . . . . 0.0 111.746 175.419 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 0.657 HG22 ' CA ' ' A' ' 290' ' ' GLY . 2.9 t -98.96 126.74 52.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 176.758 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 83.2 mt-30 -90.94 138.41 31.62 Favored 'General case' 0 C--O 1.246 0.906 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 178.224 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 81.2 -59.0 4.82 Favored Glycine 0 C--O 1.244 0.76 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 -178.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 256' ' ' MET . . . . . 0.509 ' SD ' HG11 ' A' ' 224' ' ' VAL . 3.8 ttm -80.13 49.86 1.16 Allowed 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 121.988 0.899 . . . . 0.0 109.766 178.285 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 47.6 pt -67.43 -22.29 28.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 114.262 -1.335 . . . . 0.0 111.116 -176.768 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 258' ' ' GLN . . . . . 0.516 ' HG3' ' HG ' ' A' ' 262' ' ' CYS . 63.9 tp60 -57.1 -39.11 74.43 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 179.199 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 259' ' ' LEU . . . . . 0.682 HD21 ' CE2' ' A' ' 283' ' ' PHE . 99.2 mt -62.15 -40.8 97.17 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 115.47 -0.786 . . . . 0.0 109.721 178.037 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 -60.27 -40.98 92.28 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 -178.254 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -99.27 17.86 57.32 Favored Glycine 0 CA--C 1.521 0.464 0 N-CA-C 111.55 -0.62 . . . . 0.0 111.55 -179.633 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 262' ' ' CYS . . . . . 0.516 ' HG ' ' HG3' ' A' ' 258' ' ' GLN . 1.4 m -94.45 160.39 14.68 Favored 'General case' 0 C--O 1.239 0.512 0 CA-C-N 117.052 0.426 . . . . 0.0 110.455 -179.71 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -82.1 159.72 64.67 Favored Pre-proline 0 C--N 1.318 -0.766 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 172.306 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 264' ' ' PRO . . . . . 0.499 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 24.3 Cg_exo -62.16 143.26 94.29 Favored 'Trans proline' 0 C--N 1.309 -1.538 0 CA-C-N 119.743 0.944 . . . . 0.0 109.949 -179.248 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 265' ' ' MET . . . . . 0.496 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 8.7 ptp -133.57 167.94 19.56 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 112.892 0.701 . . . . 0.0 112.892 -175.088 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 72.2 tt0 -70.1 139.88 52.6 Favored 'General case' 0 C--O 1.243 0.735 0 O-C-N 124.164 0.915 . . . . 0.0 110.177 -179.69 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 267' ' ' ILE . . . . . 0.616 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.7 pp -129.22 154.35 39.97 Favored 'Isoleucine or valine' 0 C--O 1.243 0.755 0 CA-C-O 121.263 0.554 . . . . 0.0 111.526 178.389 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 66.2 mttm -125.72 109.61 12.79 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.744 -178.052 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 18.8 m -70.39 131.39 34.32 Favored 'Isoleucine or valine' 0 C--O 1.237 0.407 0 CA-C-O 120.681 0.277 . . . . 0.0 111.235 -177.394 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 270' ' ' LEU . . . . . 0.621 HD12 HG23 ' A' ' 231' ' ' VAL . 95.1 mt -109.48 -25.55 10.43 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.582 179.149 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -156.41 -174.79 26.61 Favored Glycine 0 CA--C 1.511 -0.188 0 N-CA-C 110.124 -1.19 . . . . 0.0 110.124 -179.218 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 272' ' ' PRO . . . . . 0.567 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 28.6 Cg_endo -60.24 -39.87 64.41 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 121.844 1.696 . . . . 0.0 111.439 -177.434 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 273' ' ' TYR . . . . . 0.41 ' CE1' ' O ' ' A' ' 236' ' ' ASP . 57.6 m-85 -118.98 9.81 12.0 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.207 178.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -116.01 129.14 56.23 Favored 'General case' 0 C--O 1.241 0.612 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.727 -172.465 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 275' ' ' PHE . . . . . 0.575 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -144.24 167.87 21.41 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 111.84 0.311 . . . . 0.0 111.84 179.729 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . 0.432 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 4.6 p -133.27 142.26 48.42 Favored 'General case' 0 C--N 1.319 -0.728 0 C-N-CA 120.764 -0.374 . . . . 0.0 111.65 -177.353 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . 0.502 HG22 HG22 ' A' ' 267' ' ' ILE . 38.0 pt -137.02 163.07 33.25 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-N 115.137 -0.938 . . . . 0.0 111.739 -176.779 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 278' ' ' CYS . . . . . 0.434 ' C ' ' O ' ' A' ' 277' ' ' ILE . 88.1 m -14.98 -92.73 0.0 OUTLIER 'General case' 0 CA--C 1.543 0.703 0 N-CA-C 113.979 1.103 . . . . 0.0 113.979 -177.893 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . 0.416 ' CG ' ' HB3' ' A' ' 228' ' ' ASN . 67.1 t0 -154.99 114.82 3.75 Favored 'General case' 0 CA--C 1.509 -0.601 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 -179.209 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . 0.796 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 20.8 p -65.43 -27.79 68.78 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-O 120.99 0.424 . . . . 0.0 110.755 178.488 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -63.08 -23.95 67.68 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-N 115.169 -0.923 . . . . 0.0 109.224 175.526 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 20.4 t-20 -89.14 -9.53 50.65 Favored 'General case' 0 CA--C 1.512 -0.518 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.932 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . 0.796 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 10.2 m-85 -87.05 -64.86 1.08 Allowed 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 172.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 284' ' ' SER . . . . . 0.475 ' OG ' ' HA ' ' A' ' 256' ' ' MET . 2.4 p 170.35 -101.27 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 114.306 -1.316 . . . . 0.0 109.415 176.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 285' ' ' ASP . . . . . 0.47 ' O ' ' N ' ' A' ' 256' ' ' MET . 5.9 t0 -148.92 164.25 35.08 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-O 120.611 0.243 . . . . 0.0 110.793 176.851 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . 0.441 ' N ' ' OD1' ' A' ' 285' ' ' ASP . 83.9 t80 -94.69 114.99 26.99 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 177.387 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 22.2 mm -100.12 -58.73 3.69 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.519 175.012 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 85.5 mtm180 -160.97 167.53 26.34 Favored 'General case' 0 CA--C 1.503 -0.84 0 O-C-N 123.604 0.565 . . . . 0.0 112.352 178.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 51.21 -138.97 26.34 Favored Glycine 0 CA--C 1.504 -0.649 0 CA-C-N 113.339 -1.755 . . . . 0.0 112.556 168.891 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . 0.657 ' CA ' HG22 ' A' ' 253' ' ' VAL . . . 100.83 117.32 4.14 Favored Glycine 0 N--CA 1.433 -1.565 0 N-CA-C 110.602 -0.999 . . . . 0.0 110.602 -177.637 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 87.3 mt -108.75 128.06 64.8 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.285 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 175.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 3.3 p -118.85 135.38 59.46 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.035 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 -178.115 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . 0.475 ' HA ' ' O ' ' A' ' 217' ' ' LEU . 4.7 m -128.9 147.65 50.85 Favored 'General case' 0 N--CA 1.442 -0.856 0 C-N-CA 120.323 -0.551 . . . . 0.0 112.466 -174.426 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 48.1 tt0 -75.74 138.42 41.25 Favored 'General case' 0 N--CA 1.443 -0.823 0 CA-C-N 114.998 -1.001 . . . . 0.0 111.295 177.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 22.8 t -121.63 98.18 5.67 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 N-CA-C 106.99 -1.485 . . . . 0.0 106.99 170.624 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 296' ' ' LYS . . . . . 0.501 ' C ' ' HD3' ' A' ' 296' ' ' LYS . 0.6 OUTLIER -73.05 98.36 2.53 Favored 'General case' 0 N--CA 1.438 -1.057 0 C-N-CA 118.966 -1.094 . . . . 0.0 108.93 -175.932 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 297' ' ' VAL . . . . . 0.494 ' O ' ' NZ ' ' A' ' 296' ' ' LYS . 33.1 m -72.8 118.35 67.42 Favored Pre-proline 0 N--CA 1.438 -1.074 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.515 -178.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -59.58 -28.93 88.64 Favored 'Trans proline' 0 N--CA 1.498 1.776 0 C-N-CA 122.125 1.883 . . . . 0.0 109.623 174.04 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 66.5 mttm -54.45 148.97 11.03 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 114.679 -1.146 . . . . 0.0 108.379 179.536 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 63.0 mttp -67.73 132.49 47.55 Favored 'General case' 0 CA--C 1.511 -0.554 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 174.548 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 301' ' ' ILE . . . . . 0.701 HD13 ' H ' ' A' ' 301' ' ' ILE . 0.0 OUTLIER -84.18 127.07 40.15 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 C-N-CA 120.354 -0.538 . . . . 0.0 110.965 -177.647 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -79.46 93.44 5.39 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.564 177.658 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 31.2 p90 -144.84 163.99 32.43 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 178.762 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 44.3 mttm -72.83 119.71 17.45 Favored 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 -176.856 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 6.9 m -65.46 141.86 58.36 Favored 'General case' 0 C--N 1.316 -0.87 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 179.182 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 1.9 mp -63.1 136.65 96.78 Favored Pre-proline 0 C--N 1.318 -0.766 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 -177.302 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_exo -56.85 -35.3 98.2 Favored 'Trans proline' 0 N--CA 1.497 1.677 0 C-N-CA 122.179 1.919 . . . . 0.0 110.004 178.533 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -68.18 174.36 3.97 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.08 -0.964 . . . . 0.0 110.195 179.079 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 4.5 m -67.04 138.99 57.59 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 177.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 88.8 mt -78.9 146.83 33.33 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 116.566 -0.288 . . . . 0.0 110.739 -178.019 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 22.6 m -77.96 134.44 28.31 Favored 'Isoleucine or valine' 0 C--O 1.238 0.477 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 172.031 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 91.5 mt-10 . . . . . 0 C--O 1.203 -1.387 0 CA-C-O 118.182 -0.913 . . . . 0.0 111.331 -173.338 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . 0.468 ' N ' ' OE1' ' A' ' 204' ' ' GLU . 0.0 OUTLIER . . . . . 0 N--CA 1.475 0.777 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 . . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 -63.38 -42.72 98.84 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.581 -178.463 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -61.07 -40.65 98.82 Favored Glycine 0 C--N 1.317 -0.518 0 N-CA-C 111.374 -0.691 . . . . 0.0 111.374 -176.643 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 204' ' ' GLU . . . . . 0.468 ' OE1' ' N ' ' A' ' 201' ' ' GLU . 2.4 mp0 -66.73 2.5 1.34 Allowed 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 112.154 0.427 . . . . 0.0 112.154 -178.268 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 2.8 pp20? -53.83 -18.51 3.35 Favored 'General case' 0 C--O 1.242 0.677 0 CA-C-O 121.215 0.531 . . . . 0.0 109.812 179.102 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 77.2 mtm -59.85 148.37 34.98 Favored 'General case' 0 N--CA 1.444 -0.735 0 CA-C-N 115.172 -0.922 . . . . 0.0 109.824 -179.736 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . 0.416 ' O ' ' N ' ' A' ' 209' ' ' THR . 27.1 m -86.5 175.55 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.147 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 169.809 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 208' ' ' LEU . . . . . 0.422 HD23 ' HA ' ' A' ' 208' ' ' LEU . 96.7 mt -72.36 72.47 0.95 Allowed 'General case' 0 C--N 1.308 -1.196 0 C-N-CA 118.948 -1.101 . . . . 0.0 110.043 -179.797 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 209' ' ' THR . . . . . 0.416 ' N ' ' O ' ' A' ' 207' ' ' VAL . 0.8 OUTLIER -71.2 -3.1 18.38 Favored 'General case' 0 N--CA 1.447 -0.616 0 CA-C-N 114.928 -1.033 . . . . 0.0 109.293 173.864 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 16.1 t70 -57.73 -43.44 85.31 Favored 'General case' 0 N--CA 1.442 -0.83 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 172.625 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 211' ' ' SER . . . . . 0.446 ' O ' ' C ' ' A' ' 212' ' ' ASN . 0.1 OUTLIER -65.0 91.75 0.1 Allowed 'General case' 0 N--CA 1.441 -0.915 0 N-CA-C 106.249 -1.76 . . . . 0.0 106.249 166.212 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 212' ' ' ASN . . . . . 0.446 ' C ' ' O ' ' A' ' 211' ' ' SER . 24.0 t-20 -29.14 94.81 0.01 OUTLIER 'General case' 0 CA--C 1.516 -0.339 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.844 -168.501 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 213' ' ' GLY . . . . . 0.432 ' C ' ' O ' ' A' ' 212' ' ' ASN . . . 29.76 66.48 0.12 Allowed Glycine 0 C--N 1.337 0.626 0 N-CA-C 111.082 -0.807 . . . . 0.0 111.082 -179.7 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 214' ' ' GLU . . . . . 0.446 ' OE2' ' NZ ' ' A' ' 296' ' ' LYS . 1.7 pt-20 -41.34 96.42 0.01 OUTLIER 'General case' 0 C--O 1.246 0.883 0 N-CA-C 112.579 0.585 . . . . 0.0 112.579 -172.27 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 215' ' ' GLN . . . . . 0.617 ' HB3' ' CD ' ' A' ' 216' ' ' PRO . 34.2 mm-40 -89.96 179.64 1.47 Allowed Pre-proline 0 C--N 1.321 -0.659 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 171.519 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 216' ' ' PRO . . . . . 0.617 ' CD ' ' HB3' ' A' ' 215' ' ' GLN . 50.4 Cg_exo -56.27 141.42 88.54 Favored 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 121.34 1.36 . . . . 0.0 111.077 -176.085 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 217' ' ' LEU . . . . . 0.448 HD22 ' HA ' ' A' ' 217' ' ' LEU . 0.5 OUTLIER -80.18 134.98 36.19 Favored 'General case' 0 CA--C 1.506 -0.746 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.661 -176.237 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 67.1 m -124.38 149.13 47.01 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.458 179.044 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -148.31 151.08 34.78 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.181 179.046 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 71.8 mtm -78.92 136.87 37.39 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 116.039 -0.528 . . . . 0.0 109.719 176.761 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 91.5 t -86.11 130.87 35.83 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.148 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -81.82 -71.01 0.5 Allowed 'General case' 0 N--CA 1.435 -1.179 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 178.656 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 223' ' ' MET . . . . . 0.661 ' C ' ' SD ' ' A' ' 223' ' ' MET . 2.1 ppp? -138.43 147.79 43.7 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 112.393 0.516 . . . . 0.0 112.393 173.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 224' ' ' VAL . . . . . 0.785 HG13 HG12 ' A' ' 232' ' ' VAL . 55.1 t -122.55 131.76 72.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 176.345 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . 0.441 ' O ' ' OG1' ' A' ' 280' ' ' THR . 49.8 p -87.56 134.67 33.58 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 110.503 -0.184 . . . . 0.0 110.503 179.43 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 226' ' ' LYS . . . . . 0.492 ' NZ ' ' OD1' ' A' ' 285' ' ' ASP . 0.7 OUTLIER -80.42 76.88 7.23 Favored 'General case' 0 C--O 1.239 0.541 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 176.8 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 227' ' ' ASP . . . . . 0.433 ' H ' ' HG1' ' A' ' 280' ' ' THR . 5.8 t70 -147.87 177.33 9.42 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.302 -176.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 228' ' ' ASN . . . . . 0.474 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 4.3 t-20 -139.78 124.23 11.13 Favored Pre-proline 0 C--N 1.326 -0.414 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.415 176.072 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 229' ' ' PRO . . . . . 0.474 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 48.2 Cg_endo -66.17 144.59 66.84 Favored 'Cis proline' 0 C--N 1.313 -1.319 0 C-N-CA 122.802 -1.749 . . . . 0.0 109.873 -1.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . 0.503 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -70.69 138.29 28.41 Favored Glycine 0 C--O 1.222 -0.635 0 N-CA-C 109.821 -1.312 . . . . 0.0 109.821 -177.862 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.5 p -123.05 131.1 73.88 Favored 'Isoleucine or valine' 0 C--O 1.242 0.674 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 177.048 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 232' ' ' VAL . . . . . 0.785 HG12 HG13 ' A' ' 224' ' ' VAL . 0.7 OUTLIER -133.05 156.78 42.56 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 C-N-CA 120.347 -0.541 . . . . 0.0 110.819 -176.557 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 233' ' ' THR . . . . . 0.466 HG23 ' CG2' ' A' ' 274' ' ' THR . 0.2 OUTLIER -110.2 147.91 32.85 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 115.073 -0.967 . . . . 0.0 108.577 177.844 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 2.8 m -107.36 146.83 31.1 Favored 'General case' 0 C--N 1.313 -0.987 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 177.457 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 14.0 tp -49.41 125.26 10.78 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 -177.841 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 16.1 t70 -52.39 -40.84 62.58 Favored 'General case' 0 CA--C 1.507 -0.68 0 CA-C-N 116.463 -0.335 . . . . 0.0 111.07 -171.611 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 83.6 mt-10 -65.47 -35.41 80.81 Favored 'General case' 0 C--N 1.314 -0.977 0 C-N-CA 120.33 -0.548 . . . . 0.0 110.606 -177.794 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -72.34 138.32 47.23 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 112.442 0.534 . . . . 0.0 112.442 -175.226 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 84.9 mtp180 -105.14 104.42 14.15 Favored 'General case' 0 C--O 1.239 0.509 0 CA-C-N 115.734 -0.666 . . . . 0.0 109.26 172.829 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 240' ' ' HIS . . . . . 0.457 ' HB2' ' CG ' ' A' ' 242' ' ' PHE . 8.4 p80 -67.38 -46.96 71.76 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.923 -0.581 . . . . 0.0 111.599 -176.685 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 241' ' ' GLY . . . . . 0.441 ' N ' ' ND1' ' A' ' 240' ' ' HIS . . . 83.33 12.44 78.67 Favored Glycine 0 C--N 1.31 -0.902 0 N-CA-C 110.477 -1.049 . . . . 0.0 110.477 -176.909 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 242' ' ' PHE . . . . . 0.457 ' CG ' ' HB2' ' A' ' 240' ' ' HIS . 4.3 m-30 -80.84 145.39 31.41 Favored 'General case' 0 CA--C 1.514 -0.41 0 CA-C-O 120.731 0.301 . . . . 0.0 110.261 -178.915 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 243' ' ' GLU . . . . . 0.465 ' N ' ' OD2' ' A' ' 246' ' ' ASP . 99.2 mt-10 -131.55 165.01 24.55 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 115.734 -0.666 . . . . 0.0 109.592 173.392 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 244' ' ' THR . . . . . 0.439 HG23 ' HA ' ' A' ' 268' ' ' LYS . 4.9 m -59.56 125.82 25.15 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 -178.739 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 99.6 -5.88 58.74 Favored Glycine 0 C--N 1.318 -0.441 0 N-CA-C 111.215 -0.754 . . . . 0.0 111.215 -177.425 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 246' ' ' ASP . . . . . 0.465 ' OD2' ' N ' ' A' ' 243' ' ' GLU . 0.9 OUTLIER -67.54 149.64 49.87 Favored 'General case' 0 CA--C 1.502 -0.884 0 C-N-CA 120.814 -0.355 . . . . 0.0 111.44 176.525 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 247' ' ' PHE . . . . . 0.403 ' HA ' ' O ' ' A' ' 265' ' ' MET . 61.7 m-85 -108.74 125.84 52.36 Favored 'General case' 0 C--N 1.317 -0.81 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 176.142 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.457 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.9 m -128.09 160.86 37.41 Favored 'Isoleucine or valine' 0 C--O 1.24 0.566 0 C-N-CA 120.47 -0.492 . . . . 0.0 111.577 -175.38 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 44.1 m -124.17 160.21 28.36 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-N 114.778 -1.101 . . . . 0.0 108.679 173.495 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 250' ' ' PHE . . . . . 0.558 ' CB ' ' HB3' ' A' ' 259' ' ' LEU . 76.4 m-85 -123.99 153.89 40.62 Favored 'General case' 0 C--N 1.314 -0.935 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 -173.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 14.6 p -159.69 161.17 34.83 Favored 'General case' 0 C--N 1.309 -1.176 0 C-N-CA 120.969 -0.293 . . . . 0.0 111.266 177.162 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 27.1 mm-40 51.62 27.86 4.29 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.395 177.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 0.542 HG22 ' CA ' ' A' ' 290' ' ' GLY . 6.5 t -90.3 129.41 41.21 Favored 'Isoleucine or valine' 0 C--O 1.236 0.371 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 175.802 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 81.4 mt-30 -94.27 136.86 34.1 Favored 'General case' 0 C--O 1.244 0.785 0 C-N-CA 120.276 -0.57 . . . . 0.0 109.836 -178.16 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 82.59 -58.15 5.01 Favored Glycine 0 C--N 1.32 -0.323 0 N-CA-C 109.945 -1.262 . . . . 0.0 109.945 -176.853 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 256' ' ' MET . . . . . 0.485 ' N ' ' O ' ' A' ' 285' ' ' ASP . 4.3 ttm -81.73 53.76 2.23 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.665 0.745 . . . . 0.0 109.708 177.797 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 257' ' ' ILE . . . . . 0.427 ' O ' ' HB2' ' A' ' 260' ' ' ASN . 48.8 pt -69.37 -23.16 26.23 Favored 'Isoleucine or valine' 0 C--O 1.242 0.702 0 CA-C-N 115.042 -0.981 . . . . 0.0 110.899 -175.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 258' ' ' GLN . . . . . 0.425 ' O ' ' SG ' ' A' ' 262' ' ' CYS . 1.2 mp0 -56.5 -37.07 69.9 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 179.673 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 259' ' ' LEU . . . . . 0.873 HD21 ' CE2' ' A' ' 283' ' ' PHE . 93.0 mt -62.35 -40.2 95.61 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.755 175.375 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 260' ' ' ASN . . . . . 0.427 ' HB2' ' O ' ' A' ' 257' ' ' ILE . 98.1 m-20 -59.32 -39.79 84.2 Favored 'General case' 0 CA--C 1.516 -0.336 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 -178.322 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -98.21 8.78 62.92 Favored Glycine 0 CA--C 1.531 1.043 0 CA-C-N 116.165 -0.47 . . . . 0.0 112.224 -178.083 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 262' ' ' CYS . . . . . 0.425 ' SG ' ' O ' ' A' ' 258' ' ' GLN . 1.7 m -88.51 146.02 25.41 Favored 'General case' 0 C--O 1.236 0.39 0 O-C-N 122.262 -0.552 . . . . 0.0 112.204 -176.407 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 36.4 mt-30 -64.73 156.91 77.04 Favored Pre-proline 0 C--N 1.325 -0.476 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 171.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 264' ' ' PRO . . . . . 0.457 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 38.1 Cg_endo -63.5 144.24 89.9 Favored 'Trans proline' 0 C--N 1.318 -1.06 0 C-N-CA 121.098 1.199 . . . . 0.0 110.426 -178.794 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 265' ' ' MET . . . . . 0.403 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 11.3 ptp -133.6 154.45 50.87 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 112.174 0.435 . . . . 0.0 112.174 -175.597 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 34.8 tt0 -71.34 143.85 50.11 Favored 'General case' 0 C--O 1.236 0.378 0 O-C-N 123.837 0.711 . . . . 0.0 109.328 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 267' ' ' ILE . . . . . 0.671 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.9 pp -131.92 165.77 30.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 N-CA-C 112.639 0.607 . . . . 0.0 112.639 -175.957 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . 0.439 ' HA ' HG23 ' A' ' 244' ' ' THR . 49.9 tttp -124.83 125.46 44.03 Favored 'General case' 0 C--O 1.217 -0.612 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.343 177.79 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.414 HG23 ' O ' ' A' ' 269' ' ' VAL . 35.5 m -93.12 102.61 13.83 Favored 'Isoleucine or valine' 0 C--O 1.238 0.472 0 C-N-CA 120.452 -0.499 . . . . 0.0 111.235 179.127 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 95.9 mt -66.57 -39.44 88.48 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.148 -179.424 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -143.34 -169.74 12.73 Favored Glycine 0 C--N 1.32 -0.311 0 N-CA-C 110.441 -1.064 . . . . 0.0 110.441 -177.775 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 272' ' ' PRO . . . . . 0.401 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 39.7 Cg_endo -64.11 -33.29 61.98 Favored 'Trans proline' 0 C--N 1.306 -1.707 0 C-N-CA 122.038 1.825 . . . . 0.0 111.714 -179.287 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 90.6 m-85 -126.51 10.11 7.23 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 112.1 0.407 . . . . 0.0 112.1 -177.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 274' ' ' THR . . . . . 0.466 ' CG2' HG23 ' A' ' 233' ' ' THR . 1.1 p -121.61 131.11 53.93 Favored 'General case' 0 C--O 1.244 0.765 0 CA-C-N 116.701 -0.227 . . . . 0.0 111.072 -177.182 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 275' ' ' PHE . . . . . 0.543 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -139.31 161.68 36.84 Favored 'General case' 0 CA--C 1.511 -0.541 0 N-CA-C 112.34 0.496 . . . . 0.0 112.34 179.147 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . 0.495 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 4.2 p -130.38 144.1 51.18 Favored 'General case' 0 N--CA 1.437 -1.078 0 CA-C-O 121.246 0.546 . . . . 0.0 111.512 -175.827 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . 0.56 HG22 HG22 ' A' ' 267' ' ' ILE . 31.8 pt -139.0 165.84 23.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 114.725 -1.125 . . . . 0.0 111.824 -173.304 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 278' ' ' CYS . . . . . 0.435 ' O ' ' HA ' ' A' ' 229' ' ' PRO . 4.8 m -28.36 -86.4 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.57 0 N-CA-C 113.498 0.925 . . . . 0.0 113.498 -175.51 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 55.3 t0 -153.02 112.2 3.81 Favored 'General case' 0 CA--C 1.508 -0.645 0 CA-C-O 120.5 0.19 . . . . 0.0 110.498 -177.374 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . 0.774 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 21.6 p -67.68 -28.79 67.98 Favored 'General case' 0 C--N 1.303 -1.428 0 CA-C-O 121.323 0.582 . . . . 0.0 110.645 176.314 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -63.99 -21.56 66.55 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 115.067 -0.969 . . . . 0.0 108.521 175.604 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 44.3 t30 -88.42 -8.7 54.54 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.398 -179.501 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . 0.873 ' CE2' HD21 ' A' ' 259' ' ' LEU . 7.2 m-85 -92.45 -67.71 0.84 Allowed 'General case' 0 CA--C 1.512 -0.492 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.273 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 284' ' ' SER . . . . . 0.436 ' OG ' ' HA ' ' A' ' 256' ' ' MET . 3.8 p 173.41 -105.8 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 114.85 -1.068 . . . . 0.0 110.565 176.392 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 285' ' ' ASP . . . . . 0.492 ' OD1' ' NZ ' ' A' ' 226' ' ' LYS . 40.2 t0 -145.44 158.8 43.77 Favored 'General case' 0 C--O 1.217 -0.606 0 CA-C-O 120.408 0.147 . . . . 0.0 110.607 -179.637 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 66.7 t80 -101.1 118.89 37.89 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.744 -0.207 . . . . 0.0 110.634 179.628 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 287' ' ' ILE . . . . . 0.439 ' O ' ' HG3' ' A' ' 288' ' ' ARG . 97.1 mt -97.94 -63.86 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 175.79 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . 0.439 ' HG3' ' O ' ' A' ' 287' ' ' ILE . 67.5 mtm180 -166.96 175.86 7.35 Favored 'General case' 0 C--O 1.24 0.601 0 C-N-CA 123.973 0.909 . . . . 0.0 110.605 176.342 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 70.24 -158.8 53.53 Favored Glycine 0 C--N 1.318 -0.462 0 N-CA-C 111.053 -0.819 . . . . 0.0 111.053 175.103 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . 0.542 ' CA ' HG22 ' A' ' 253' ' ' VAL . . . 104.93 124.77 5.46 Favored Glycine 0 N--CA 1.442 -0.955 0 N-CA-C 111.977 -0.449 . . . . 0.0 111.977 177.258 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 95.7 mt -116.93 131.64 69.02 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.037 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 174.629 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 4.8 p -120.11 135.04 61.67 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.026 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 -179.138 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 15.6 m -132.03 144.81 51.03 Favored 'General case' 0 C--N 1.319 -0.759 0 C-N-CA 120.063 -0.655 . . . . 0.0 112.535 -174.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 294' ' ' GLN . . . . . 0.554 ' O ' ' HB3' ' A' ' 216' ' ' PRO . 48.5 tt0 -72.52 148.02 45.43 Favored 'General case' 0 CA--C 1.489 -1.381 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 168.31 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . 0.553 HG12 HG13 ' A' ' 297' ' ' VAL . 73.8 t -121.91 131.39 73.24 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.765 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 -178.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 296' ' ' LYS . . . . . 0.446 ' NZ ' ' OE2' ' A' ' 214' ' ' GLU . 20.5 mttp -72.52 96.62 1.97 Allowed 'General case' 0 C--O 1.238 0.448 0 N-CA-C 106.469 -1.678 . . . . 0.0 106.469 173.725 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 297' ' ' VAL . . . . . 0.553 HG13 HG12 ' A' ' 295' ' ' VAL . 4.9 m -105.65 118.52 55.25 Favored Pre-proline 0 C--N 1.314 -0.947 0 CA-C-N 116.178 -0.465 . . . . 0.0 112.225 -174.426 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_exo -60.84 139.78 87.0 Favored 'Trans proline' 0 C--N 1.309 -1.507 0 N-CA-C 106.064 -2.322 . . . . 0.0 106.064 165.717 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -67.71 134.2 50.66 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 118.468 -1.293 . . . . 0.0 111.239 -174.221 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 66.7 mttm -69.23 160.88 30.35 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.346 -0.843 . . . . 0.0 108.91 179.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 94.9 mt -70.15 119.84 16.93 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.867 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 176.877 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 2.1 m -76.26 101.28 5.38 Favored 'General case' 0 C--N 1.305 -1.336 0 CA-C-N 115.527 -0.761 . . . . 0.0 111.875 -170.897 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 73.5 m-85 -109.88 115.06 29.13 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 174.016 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 63.1 mttm -70.52 133.86 47.17 Favored 'General case' 0 C--N 1.317 -0.835 0 C-N-CA 119.565 -0.854 . . . . 0.0 109.212 -178.203 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 5.2 m -71.82 152.51 42.61 Favored 'General case' 0 C--N 1.312 -1.055 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 179.01 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 306' ' ' LEU . . . . . 0.404 ' HA ' HD23 ' A' ' 306' ' ' LEU . 52.5 mt -46.82 131.06 8.64 Favored Pre-proline 0 C--O 1.238 0.456 0 N-CA-C 109.268 -0.641 . . . . 0.0 109.268 -179.865 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_exo -53.9 -42.54 65.74 Favored 'Trans proline' 0 N--CA 1.493 1.488 0 C-N-CA 121.952 1.768 . . . . 0.0 111.041 -176.1 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -109.13 105.75 15.35 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.223 178.244 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 2.8 m -71.37 83.81 0.79 Allowed 'General case' 0 N--CA 1.445 -0.708 0 C-N-CA 120.225 -0.59 . . . . 0.0 109.578 177.13 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 92.1 mt -99.23 134.51 41.98 Favored 'General case' 0 CA--C 1.507 -0.708 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.424 -178.648 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 17.3 m -113.37 130.96 66.42 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.113 -178.565 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 45.1 tp10 . . . . . 0 C--O 1.204 -1.315 0 CA-C-O 118.389 -0.815 . . . . 0.0 109.777 -175.565 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . 0.476 ' N ' ' OE2' ' A' ' 204' ' ' GLU . 97.2 mt-10 . . . . . 0 N--CA 1.481 1.098 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -69.79 -34.83 74.27 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 112.563 0.579 . . . . 0.0 112.563 179.519 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -53.62 -45.47 67.91 Favored Glycine 0 CA--C 1.526 0.745 0 C-N-CA 121.342 -0.456 . . . . 0.0 112.041 -171.672 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 204' ' ' GLU . . . . . 0.607 ' CD ' ' H ' ' A' ' 204' ' ' GLU . 2.4 pm0 -68.02 -37.06 80.94 Favored 'General case' 0 CA--C 1.513 -0.45 0 C-N-CA 120.507 -0.477 . . . . 0.0 110.145 177.13 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 -61.95 -38.49 88.7 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 179.701 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 66.0 mtt -66.82 147.82 52.74 Favored 'General case' 0 N--CA 1.446 -0.667 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 175.532 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 21.4 m -119.67 158.54 21.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 CA-C-O 120.939 0.399 . . . . 0.0 110.78 -175.441 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 87.5 mt -78.96 155.73 28.81 Favored 'General case' 0 C--N 1.313 -1.017 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.116 179.012 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 7.5 m -58.56 -42.14 87.24 Favored 'General case' 0 C--N 1.31 -1.132 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 179.293 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 6.9 p-10 -73.97 -5.62 42.42 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.856 -0.611 . . . . 0.0 112.295 -179.022 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 55.7 m -40.35 112.04 0.25 Allowed 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.85 0.357 . . . . 0.0 111.752 -177.099 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 53.7 t-20 -91.39 117.46 29.7 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 177.189 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 131.12 53.93 0.09 OUTLIER Glycine 0 C--N 1.317 -0.483 0 N-CA-C 109.783 -1.327 . . . . 0.0 109.783 -175.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 214' ' ' GLU . . . . . 0.505 ' H ' ' CD ' ' A' ' 214' ' ' GLU . 1.8 mp0 -56.31 152.09 11.75 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 115.088 -0.556 . . . . 0.0 110.692 -178.797 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 14.7 pt20 -48.62 138.01 12.16 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.134 -179.873 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 216' ' ' PRO . . . . . 0.453 ' HB2' ' O ' ' A' ' 294' ' ' GLN . 31.5 Cg_exo -60.42 147.42 94.16 Favored 'Trans proline' 0 C--N 1.311 -1.446 0 C-N-CA 122.099 1.866 . . . . 0.0 110.263 -179.8 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 217' ' ' LEU . . . . . 0.469 ' HB3' ' O ' ' A' ' 240' ' ' HIS . 0.2 OUTLIER -51.75 131.08 30.07 Favored 'General case' 0 C--O 1.237 0.409 0 N-CA-C 110.223 -0.288 . . . . 0.0 110.223 -177.801 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 16.5 p -136.18 156.16 49.09 Favored 'General case' 0 CA--C 1.51 -0.595 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.509 -177.352 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 219' ' ' ALA . . . . . 0.53 ' HA ' ' HB1' ' A' ' 238' ' ' ALA . . . -150.72 151.2 32.06 Favored 'General case' 0 N--CA 1.448 -0.556 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.134 -178.751 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 220' ' ' MET . . . . . 0.505 ' SD ' HG12 ' A' ' 291' ' ' ILE . 1.5 mpp? -73.67 131.2 41.39 Favored 'General case' 0 C--O 1.244 0.772 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 177.891 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 69.1 t -74.77 131.76 34.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 178.659 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 58.0 m -92.2 -69.09 0.76 Allowed 'General case' 0 N--CA 1.435 -1.176 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.342 179.661 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 12.6 ptm -138.14 148.59 45.07 Favored 'General case' 0 N--CA 1.472 0.63 0 C-N-CA 120.999 -0.281 . . . . 0.0 111.141 172.762 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 224' ' ' VAL . . . . . 0.55 HG22 ' HB ' ' A' ' 232' ' ' VAL . 52.9 t -121.67 129.35 75.58 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 174.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 17.2 p -81.29 128.03 33.36 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 119.85 -0.74 . . . . 0.0 110.54 179.623 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 17.0 tptm -76.4 84.11 3.14 Favored 'General case' 0 N--CA 1.437 -1.097 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 177.463 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 227' ' ' ASP . . . . . 0.543 ' N ' ' OG1' ' A' ' 280' ' ' THR . 4.8 t0 -159.97 175.74 12.67 Favored 'General case' 0 C--O 1.245 0.861 0 CA-C-N 115.53 -0.759 . . . . 0.0 110.304 -176.162 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 228' ' ' ASN . . . . . 0.48 ' N ' ' OD1' ' A' ' 227' ' ' ASP . 0.1 OUTLIER -143.01 122.75 7.75 Favored Pre-proline 0 C--N 1.321 -0.656 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.838 172.65 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 229' ' ' PRO . . . . . 0.48 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 42.0 Cg_endo -65.23 148.33 73.27 Favored 'Cis proline' 0 N--CA 1.496 1.652 0 C-N-CA 122.908 -1.705 . . . . 0.0 109.875 -1.507 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . 0.484 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -88.43 140.57 16.19 Favored Glycine 0 C--N 1.315 -0.612 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 -177.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.4 p -121.01 132.79 69.59 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.579 0 CA-C-N 117.182 0.491 . . . . 0.0 109.791 177.125 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 232' ' ' VAL . . . . . 0.556 HG22 ' CD1' ' A' ' 275' ' ' PHE . 0.6 OUTLIER -129.83 153.63 39.12 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.042 0 C-N-CA 120.038 -0.665 . . . . 0.0 111.214 -176.581 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 233' ' ' THR . . . . . 0.444 ' HA ' ' O ' ' A' ' 273' ' ' TYR . 0.6 OUTLIER -106.84 140.48 39.61 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-N 115.151 -0.931 . . . . 0.0 109.445 178.065 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 1.8 m -107.07 160.39 15.59 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-N 116.182 -0.463 . . . . 0.0 109.823 -178.339 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.464 ' HB3' ' HB3' ' A' ' 238' ' ' ALA . 41.5 tp -63.74 131.34 47.58 Favored 'General case' 0 C--N 1.32 -0.674 0 C-N-CA 120.686 -0.406 . . . . 0.0 109.975 -177.678 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 19.0 p-10 -51.61 -44.43 62.88 Favored 'General case' 0 N--CA 1.475 0.801 0 CA-C-N 115.881 -0.6 . . . . 0.0 111.073 -176.628 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 92.6 mt-10 -65.77 -35.24 80.16 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 179.556 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . 0.53 ' HB1' ' HA ' ' A' ' 219' ' ' ALA . . . -91.54 92.61 8.58 Favored 'General case' 0 N--CA 1.439 -1.017 0 CA-C-N 115.481 -0.781 . . . . 0.0 111.855 -175.261 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 84.7 mtp180 -75.66 118.13 18.15 Favored 'General case' 0 C--N 1.312 -1.022 0 N-CA-C 108.478 -0.934 . . . . 0.0 108.478 174.386 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 240' ' ' HIS . . . . . 0.615 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 7.1 p80 -60.09 -46.09 90.73 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.799 -176.939 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 78.87 19.12 73.66 Favored Glycine 0 C--O 1.238 0.381 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 -178.532 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 242' ' ' PHE . . . . . 0.544 ' CD2' ' HB2' ' A' ' 240' ' ' HIS . 10.4 m-30 -81.04 146.66 30.53 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 -179.545 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 73.9 mm-40 -101.64 158.88 15.77 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 116.011 -0.54 . . . . 0.0 109.672 172.544 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 16.3 m -66.66 126.72 29.83 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 174.762 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 88.14 2.78 80.06 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -176.491 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 15.2 t0 -79.42 167.51 20.74 Favored 'General case' 0 CA--C 1.516 -0.337 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 178.285 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 247' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -112.66 134.71 54.05 Favored 'General case' 0 C--O 1.244 0.811 0 O-C-N 123.127 0.267 . . . . 0.0 110.874 -176.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.47 HG11 ' CD2' ' A' ' 242' ' ' PHE . 2.9 m -131.59 160.92 42.03 Favored 'Isoleucine or valine' 0 C--O 1.236 0.369 0 CA-C-O 121.078 0.466 . . . . 0.0 111.899 178.37 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 249' ' ' SER . . . . . 0.444 ' OG ' ' HG3' ' A' ' 264' ' ' PRO . 1.3 m -123.26 153.48 40.13 Favored 'General case' 0 C--O 1.244 0.798 0 CA-C-N 114.893 -1.048 . . . . 0.0 109.229 176.653 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 250' ' ' PHE . . . . . 0.446 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 79.3 m-85 -109.43 153.0 24.63 Favored 'General case' 0 CA--C 1.505 -0.773 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.787 -179.357 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 251' ' ' SER . . . . . 0.475 ' O ' ' HA2' ' A' ' 290' ' ' GLY . 39.0 m -152.71 154.69 35.76 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-N 115.694 -0.684 . . . . 0.0 109.196 176.688 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 12.6 mm-40 57.47 21.17 6.71 Favored 'General case' 0 CA--C 1.542 0.655 0 N-CA-C 112.664 0.616 . . . . 0.0 112.664 177.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 0.59 HG13 ' CE1' ' A' ' 286' ' ' TYR . 61.5 t -76.0 133.89 30.23 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 C-N-CA 120.949 -0.3 . . . . 0.0 111.0 178.759 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . 0.411 ' OE1' ' HG2' ' A' ' 288' ' ' ARG . 85.2 mt-30 -96.78 136.01 37.93 Favored 'General case' 0 C--O 1.24 0.605 0 O-C-N 123.334 0.396 . . . . 0.0 110.045 179.251 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 76.35 -61.4 3.13 Favored Glycine 0 N--CA 1.463 0.453 0 N-CA-C 111.472 -0.651 . . . . 0.0 111.472 177.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 256' ' ' MET . . . . . 0.664 ' SD ' HD11 ' A' ' 259' ' ' LEU . 48.5 ttm -77.67 63.08 2.69 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 178.547 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 48.9 pt -70.22 -20.63 23.01 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 114.914 -1.039 . . . . 0.0 111.136 -173.786 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 258' ' ' GLN . . . . . 0.566 ' HG3' ' SG ' ' A' ' 262' ' ' CYS . 55.7 tp60 -54.76 -39.53 68.42 Favored 'General case' 0 N--CA 1.44 -0.955 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.035 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 259' ' ' LEU . . . . . 0.664 HD11 ' SD ' ' A' ' 256' ' ' MET . 97.8 mt -62.58 -41.71 99.11 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.17 -0.468 . . . . 0.0 109.909 178.542 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -61.52 -40.38 94.41 Favored 'General case' 0 CA--C 1.509 -0.598 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 178.377 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -94.64 13.12 67.81 Favored Glycine 0 CA--C 1.527 0.801 0 CA-C-N 115.395 -0.82 . . . . 0.0 111.775 -178.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 262' ' ' CYS . . . . . 0.566 ' SG ' ' HG3' ' A' ' 258' ' ' GLN . 1.0 OUTLIER -105.64 156.92 17.8 Favored 'General case' 0 CA--C 1.508 -0.637 0 CA-C-N 117.45 0.625 . . . . 0.0 112.322 -178.051 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 28.4 mt-30 -71.52 158.38 88.03 Favored Pre-proline 0 C--N 1.319 -0.733 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 171.431 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 264' ' ' PRO . . . . . 0.62 ' CB ' HG21 ' A' ' 295' ' ' VAL . 26.0 Cg_exo -61.87 147.47 95.15 Favored 'Trans proline' 0 C--N 1.304 -1.809 0 C-N-CA 121.347 1.365 . . . . 0.0 110.551 177.514 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 265' ' ' MET . . . . . . . . . . . . . 4.4 ptp -125.64 164.78 19.84 Favored 'General case' 0 N--CA 1.473 0.706 0 N-CA-C 111.79 0.293 . . . . 0.0 111.79 -177.673 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -71.04 142.62 50.88 Favored 'General case' 0 CA--C 1.513 -0.443 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 176.517 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 267' ' ' ILE . . . . . 0.75 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.7 pp -131.04 160.04 42.56 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 CA-C-O 121.054 0.454 . . . . 0.0 111.611 -179.82 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 55.5 mttm -130.6 110.63 11.55 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 -177.187 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.418 HG23 ' O ' ' A' ' 269' ' ' VAL . 27.7 m -77.17 102.1 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 CA-C-O 121.389 0.614 . . . . 0.0 112.255 -176.771 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 97.0 mt -69.6 -39.11 77.46 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.521 177.208 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -144.26 -175.34 17.3 Favored Glycine 0 N--CA 1.461 0.361 0 N-CA-C 109.977 -1.249 . . . . 0.0 109.977 -178.434 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 272' ' ' PRO . . . . . 0.615 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 36.9 Cg_endo -62.15 -34.27 79.61 Favored 'Trans proline' 0 C--N 1.313 -1.341 0 C-N-CA 121.888 1.725 . . . . 0.0 110.939 -177.914 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 273' ' ' TYR . . . . . 0.444 ' O ' ' HA ' ' A' ' 233' ' ' THR . 94.4 m-85 -123.12 6.57 9.19 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.575 -0.739 . . . . 0.0 112.253 -179.796 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 2.2 p -117.11 127.39 54.09 Favored 'General case' 0 C--O 1.244 0.795 0 CA-C-O 121.046 0.45 . . . . 0.0 110.901 179.455 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 275' ' ' PHE . . . . . 0.576 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -137.28 161.94 34.87 Favored 'General case' 0 CA--C 1.502 -0.872 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.092 -179.085 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . 0.484 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 4.4 p -132.22 145.84 51.6 Favored 'General case' 0 C--N 1.309 -1.163 0 C-N-CA 120.369 -0.532 . . . . 0.0 112.124 -173.864 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . 0.591 HG22 HG22 ' A' ' 267' ' ' ILE . 28.0 pt -139.22 164.77 24.43 Favored 'Isoleucine or valine' 0 C--O 1.243 0.726 0 CA-C-N 114.744 -1.117 . . . . 0.0 112.899 -172.368 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 2.2 m -28.63 -88.27 0.0 OUTLIER 'General case' 0 C--O 1.237 0.405 0 N-CA-C 113.928 1.084 . . . . 0.0 113.928 -176.099 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 59.8 t0 -152.4 115.65 4.7 Favored 'General case' 0 CA--C 1.507 -0.696 0 CA-C-O 120.695 0.283 . . . . 0.0 110.793 -175.764 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . 0.673 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 29.7 p -64.84 -29.53 70.49 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-O 121.023 0.44 . . . . 0.0 110.732 175.611 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -64.64 -23.74 67.36 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.324 175.751 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 18.0 t-20 -89.2 -9.31 51.3 Favored 'General case' 0 CA--C 1.509 -0.612 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.77 -179.557 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . 0.673 ' CD2' ' HA ' ' A' ' 280' ' ' THR . 15.7 m-85 -92.46 -75.27 0.49 Allowed 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 121.641 0.734 . . . . 0.0 109.372 174.938 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 284' ' ' SER . . . . . 0.405 ' O ' ' CE ' ' A' ' 256' ' ' MET . 0.1 OUTLIER 165.6 -174.23 0.02 OUTLIER 'General case' 0 C--N 1.313 -1.0 0 N-CA-C 106.835 -1.543 . . . . 0.0 106.835 -174.066 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -94.98 121.56 36.72 Favored 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 119.687 -0.805 . . . . 0.0 111.899 -179.782 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . 0.59 ' CE1' HG13 ' A' ' 253' ' ' VAL . 3.3 t80 -72.74 108.19 5.6 Favored 'General case' 0 C--O 1.236 0.386 0 C-N-CA 123.535 0.734 . . . . 0.0 109.744 -177.359 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 287' ' ' ILE . . . . . 0.606 ' O ' ' HB3' ' A' ' 288' ' ' ARG . 89.9 mt -67.39 -44.94 86.72 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.66 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 173.077 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . 0.606 ' HB3' ' O ' ' A' ' 287' ' ' ILE . 7.4 ptm180 157.95 -161.26 0.0 OUTLIER 'General case' 0 C--O 1.237 0.409 0 C-N-CA 124.89 1.276 . . . . 0.0 109.164 177.476 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . 0.537 ' N ' ' HG3' ' A' ' 288' ' ' ARG . . . 70.99 -157.16 53.51 Favored Glycine 0 CA--C 1.5 -0.903 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 176.498 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . 0.475 ' HA2' ' O ' ' A' ' 251' ' ' SER . . . 88.84 145.82 12.02 Favored Glycine 0 N--CA 1.436 -1.309 0 CA-C-O 121.533 0.518 . . . . 0.0 112.714 175.52 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . 0.505 HG12 ' SD ' ' A' ' 220' ' ' MET . 92.6 mt -123.41 128.52 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.344 0 N-CA-C 106.74 -1.578 . . . . 0.0 106.74 172.658 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 14.8 p -107.68 130.6 59.74 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.823 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 -179.801 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 3.8 m -132.27 146.9 52.32 Favored 'General case' 0 CA--C 1.506 -0.73 0 C-N-CA 120.52 -0.472 . . . . 0.0 112.187 -173.817 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 294' ' ' GLN . . . . . 0.453 ' O ' ' HB2' ' A' ' 216' ' ' PRO . 49.2 tt0 -70.51 154.19 42.14 Favored 'General case' 0 CA--C 1.497 -1.085 0 CA-C-N 115.342 -0.844 . . . . 0.0 109.601 174.368 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . 0.62 HG21 ' CB ' ' A' ' 264' ' ' PRO . 2.5 t -114.73 127.19 72.35 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.599 0 N-CA-C 108.177 -1.045 . . . . 0.0 108.177 172.002 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 296' ' ' LYS . . . . . 0.47 ' O ' ' HG3' ' A' ' 296' ' ' LYS . 23.3 pttp -112.84 98.06 6.95 Favored 'General case' 0 N--CA 1.434 -1.234 0 C-N-CA 119.756 -0.778 . . . . 0.0 110.83 179.77 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 297' ' ' VAL . . . . . 0.454 ' HB ' ' HD2' ' A' ' 298' ' ' PRO . 31.5 m -68.87 171.85 5.73 Favored Pre-proline 0 C--N 1.314 -0.955 0 N-CA-C 107.225 -1.398 . . . . 0.0 107.225 173.747 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 298' ' ' PRO . . . . . 0.454 ' HD2' ' HB ' ' A' ' 297' ' ' VAL . 50.2 Cg_exo -55.84 140.49 85.24 Favored 'Trans proline' 0 C--N 1.303 -1.839 0 N-CA-C 108.173 -1.51 . . . . 0.0 108.173 177.975 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 60.0 mttp -65.25 141.59 58.58 Favored 'General case' 0 C--N 1.313 -0.988 0 C-N-CA 119.687 -0.805 . . . . 0.0 110.32 -175.012 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 69.1 mttm -66.75 140.95 57.88 Favored 'General case' 0 N--CA 1.44 -0.935 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 -177.519 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 18.4 tt -46.27 114.1 0.18 Allowed 'Isoleucine or valine' 0 C--O 1.241 0.629 0 CA-C-O 121.428 0.632 . . . . 0.0 111.245 -173.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 3.3 m -74.38 144.66 44.29 Favored 'General case' 0 N--CA 1.441 -0.917 0 CA-C-N 115.256 -0.883 . . . . 0.0 109.964 -177.849 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 93.6 t80 -132.84 157.4 45.13 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 177.198 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 32.6 mmtp -60.07 107.7 0.67 Allowed 'General case' 0 C--N 1.32 -0.677 0 C-N-CA 119.987 -0.685 . . . . 0.0 110.819 -176.559 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -80.0 171.88 14.51 Favored 'General case' 0 C--N 1.311 -1.096 0 CA-C-N 115.344 -0.844 . . . . 0.0 109.898 176.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 306' ' ' LEU . . . . . 0.535 HD13 HD12 ' A' ' 310' ' ' LEU . 94.8 mt -48.84 155.81 0.99 Allowed Pre-proline 0 C--N 1.328 -0.357 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 176.001 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_exo -52.48 -39.0 75.41 Favored 'Trans proline' 0 N--CA 1.501 1.953 0 C-N-CA 121.939 1.759 . . . . 0.0 110.42 -177.499 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . 0.463 ' O ' ' N ' ' A' ' 310' ' ' LEU . . . -149.94 171.11 17.33 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 175.52 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 1.3 m -62.47 83.47 0.02 OUTLIER 'General case' 0 C--N 1.317 -0.847 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 175.391 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 310' ' ' LEU . . . . . 0.535 HD12 HD13 ' A' ' 306' ' ' LEU . 96.5 mt -61.06 111.07 1.55 Allowed 'General case' 0 C--O 1.237 0.422 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.335 -171.74 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 29.0 m -137.06 161.62 35.26 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 CA-C-N 115.154 -0.93 . . . . 0.0 108.565 174.272 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 43.3 mt-10 . . . . . 0 C--O 1.204 -1.34 0 CA-C-O 118.625 -0.702 . . . . 0.0 109.989 179.488 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . 0.514 ' CD ' ' H ' ' A' ' 202' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.476 0.853 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 . . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 202' ' ' PHE . . . . . 0.514 ' H ' ' CD ' ' A' ' 201' ' ' GLU . 87.3 m-85 -125.75 -2.43 7.25 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.143 175.595 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -100.86 14.88 58.64 Favored Glycine 0 N--CA 1.459 0.199 0 N-CA-C 111.721 -0.551 . . . . 0.0 111.721 -175.165 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 204' ' ' GLU . . . . . 0.456 ' OE2' ' N ' ' A' ' 201' ' ' GLU . 55.3 mp0 -52.3 -14.48 0.46 Allowed 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 111.927 0.343 . . . . 0.0 111.927 -179.442 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 205' ' ' GLU . . . . . 0.475 ' N ' ' CD ' ' A' ' 205' ' ' GLU . 2.6 mm-40 -54.72 -37.64 66.11 Favored 'General case' 0 C--O 1.236 0.38 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 175.689 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 99.7 mmm -106.0 96.92 6.82 Favored 'General case' 0 N--CA 1.444 -0.744 0 CA-C-N 114.713 -1.131 . . . . 0.0 108.476 172.039 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 2.7 p -128.1 143.2 41.64 Favored 'Isoleucine or valine' 0 C--O 1.243 0.711 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 -178.714 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 96.0 mt -65.75 136.09 55.78 Favored 'General case' 0 C--O 1.238 0.492 0 CA-C-N 116.186 -0.461 . . . . 0.0 109.997 -176.391 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 4.7 p -79.12 25.39 0.29 Allowed 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.892 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 210' ' ' ASP . . . . . 0.439 ' O ' ' C ' ' A' ' 211' ' ' SER . 28.0 t70 -64.09 -34.73 78.71 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.138 -0.483 . . . . 0.0 112.084 -176.813 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 211' ' ' SER . . . . . 0.439 ' C ' ' O ' ' A' ' 210' ' ' ASP . 0.9 OUTLIER -29.85 108.61 0.04 OUTLIER 'General case' 0 CA--C 1.539 0.521 0 O-C-N 123.61 0.569 . . . . 0.0 111.421 -177.656 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 26.8 t-20 -72.1 148.97 45.22 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.497 -0.774 . . . . 0.0 111.435 -175.126 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 80.87 6.36 89.48 Favored Glycine 0 C--O 1.235 0.206 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.465 177.81 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -118.46 126.35 51.85 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.552 0.215 . . . . 0.0 110.621 179.179 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 6.7 mt-30 -109.49 140.21 21.88 Favored Pre-proline 0 C--N 1.318 -0.765 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 178.743 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 216' ' ' PRO . . . . . 0.44 ' O ' HD22 ' A' ' 217' ' ' LEU . 72.1 Cg_endo -73.18 142.98 34.91 Favored 'Trans proline' 0 C--N 1.305 -1.72 0 C-N-CA 122.214 1.943 . . . . 0.0 110.047 176.196 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 217' ' ' LEU . . . . . 0.44 HD22 ' O ' ' A' ' 216' ' ' PRO . 3.7 mm? -114.01 136.74 52.57 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 116.644 -0.253 . . . . 0.0 111.524 178.326 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 3.7 m -132.22 132.1 42.77 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 175.423 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -145.38 152.95 40.67 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-O 120.744 0.307 . . . . 0.0 110.762 179.551 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -73.71 134.8 43.59 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.055 178.745 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 98.7 t -80.17 131.12 34.82 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.102 0 N-CA-C 107.406 -1.331 . . . . 0.0 107.406 172.553 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 11.8 p -95.69 -60.48 1.64 Allowed 'General case' 0 N--CA 1.439 -1.016 0 C-N-CA 120.237 -0.585 . . . . 0.0 110.645 -177.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 223' ' ' MET . . . . . 0.568 ' C ' ' SD ' ' A' ' 223' ' ' MET . 0.5 OUTLIER -138.42 141.7 39.54 Favored 'General case' 0 C--O 1.221 -0.407 0 N-CA-C 112.219 0.452 . . . . 0.0 112.219 175.78 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 224' ' ' VAL . . . . . 0.639 HG22 ' HB ' ' A' ' 232' ' ' VAL . 48.4 t -125.19 132.25 71.41 Favored 'Isoleucine or valine' 0 C--O 1.24 0.587 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 177.441 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 5.5 p -99.76 117.36 33.92 Favored 'General case' 0 C--O 1.237 0.424 0 C-N-CA 120.373 -0.531 . . . . 0.0 110.324 176.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 226' ' ' LYS . . . . . 0.512 ' HD3' ' HA ' ' A' ' 281' ' ' SER . 0.0 OUTLIER -67.55 85.51 0.19 Allowed 'General case' 0 C--O 1.242 0.687 0 N-CA-C 110.151 -0.315 . . . . 0.0 110.151 178.756 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 227' ' ' ASP . . . . . 0.594 ' N ' ' OG1' ' A' ' 280' ' ' THR . 4.2 t70 -150.73 -177.61 6.09 Favored 'General case' 0 C--O 1.242 0.686 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.518 -179.045 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 228' ' ' ASN . . . . . 0.494 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.0 OUTLIER -141.28 125.59 10.39 Favored Pre-proline 0 N--CA 1.467 0.396 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.967 174.96 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 229' ' ' PRO . . . . . 0.494 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 55.7 Cg_endo -66.17 147.77 75.18 Favored 'Cis proline' 0 N--CA 1.496 1.634 0 C-N-CA 123.347 -1.522 . . . . 0.0 110.116 -0.566 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . 0.494 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -70.71 138.45 28.61 Favored Glycine 0 N--CA 1.449 -0.473 0 N-CA-C 110.004 -1.238 . . . . 0.0 110.004 -178.154 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 231' ' ' VAL . . . . . 0.683 HG23 ' CD1' ' A' ' 270' ' ' LEU . 1.8 p -125.69 131.78 71.6 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.804 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 176.335 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 232' ' ' VAL . . . . . 0.639 ' HB ' HG22 ' A' ' 224' ' ' VAL . 0.8 OUTLIER -137.28 157.0 34.43 Favored 'Isoleucine or valine' 0 C--O 1.248 0.988 0 C-N-CA 120.103 -0.639 . . . . 0.0 111.548 -177.553 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 233' ' ' THR . . . . . 0.444 HG23 ' CG2' ' A' ' 274' ' ' THR . 6.0 m -113.07 146.9 38.35 Favored 'General case' 0 C--N 1.309 -1.162 0 CA-C-N 114.987 -1.006 . . . . 0.0 109.532 178.613 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 24.7 m -107.36 160.97 15.22 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 178.244 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.43 ' HB3' ' HB3' ' A' ' 238' ' ' ALA . 45.2 tp -59.31 128.61 37.97 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 179.431 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -51.35 -44.78 62.15 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.846 -175.164 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 76.8 mt-10 -65.85 -33.08 75.01 Favored 'General case' 0 C--N 1.311 -1.066 0 C-N-CA 120.724 -0.39 . . . . 0.0 111.147 178.834 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . 0.43 ' HB3' ' HB3' ' A' ' 235' ' ' LEU . . . -91.62 102.68 15.32 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.729 -175.1 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 78.5 mtm-85 -74.22 127.36 32.77 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 107.717 -1.216 . . . . 0.0 107.717 174.713 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 240' ' ' HIS . . . . . 0.536 ' H ' ' CD2' ' A' ' 240' ' ' HIS . 6.8 p80 -66.28 -45.45 80.44 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 121.137 0.494 . . . . 0.0 110.855 -179.018 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 81.45 12.12 82.33 Favored Glycine 0 C--N 1.311 -0.823 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 -178.257 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 242' ' ' PHE . . . . . 0.519 ' CE1' ' HB2' ' A' ' 294' ' ' GLN . 4.0 m-30 -81.5 151.95 27.55 Favored 'General case' 0 CA--C 1.504 -0.804 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 178.373 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -130.57 158.07 40.98 Favored 'General case' 0 C--N 1.309 -1.178 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 177.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 244' ' ' THR . . . . . 0.743 HG23 ' HG2' ' A' ' 268' ' ' LYS . 22.8 m -57.85 127.97 34.71 Favored 'General case' 0 C--N 1.306 -1.284 0 C-N-CA 120.007 -0.677 . . . . 0.0 109.973 -177.26 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 92.06 -6.41 78.91 Favored Glycine 0 N--CA 1.449 -0.497 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.609 -179.019 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 246' ' ' ASP . . . . . 0.442 ' CG ' HE21 ' A' ' 294' ' ' GLN . 1.7 t70 -79.24 162.4 25.71 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 117.223 0.511 . . . . 0.0 111.004 -179.821 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 247' ' ' PHE . . . . . 0.48 ' HA ' ' O ' ' A' ' 265' ' ' MET . 73.0 m-85 -111.94 131.39 55.41 Favored 'General case' 0 C--O 1.24 0.574 0 N-CA-C 112.241 0.46 . . . . 0.0 112.241 -176.076 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.498 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.6 m -132.71 158.88 43.39 Favored 'Isoleucine or valine' 0 C--O 1.235 0.319 0 CA-C-O 120.873 0.368 . . . . 0.0 111.809 177.397 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 49.6 m -123.92 160.55 27.28 Favored 'General case' 0 C--N 1.319 -0.734 0 C-N-CA 124.498 1.119 . . . . 0.0 108.565 173.029 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 250' ' ' PHE . . . . . 0.641 ' CE1' HD22 ' A' ' 259' ' ' LEU . 68.4 m-85 -110.63 146.72 35.68 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 120.461 0.172 . . . . 0.0 111.081 -177.364 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 1.5 m -133.54 153.39 51.68 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 176.24 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . 0.462 ' O ' ' NE2' ' A' ' 254' ' ' GLN . 79.1 mm-40 55.37 30.34 14.71 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 112.81 0.671 . . . . 0.0 112.81 173.213 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 0.538 HG11 ' HB3' ' A' ' 256' ' ' MET . 51.3 t -89.01 134.69 27.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 N-CA-C 110.231 -0.285 . . . . 0.0 110.231 177.319 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . 0.462 ' NE2' ' O ' ' A' ' 252' ' ' GLU . 3.9 mp0 -99.81 135.19 41.61 Favored 'General case' 0 C--O 1.239 0.518 0 CA-C-O 121.031 0.443 . . . . 0.0 110.658 178.909 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 83.37 -55.08 5.02 Favored Glycine 0 C--N 1.32 -0.321 0 N-CA-C 111.098 -0.801 . . . . 0.0 111.098 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 256' ' ' MET . . . . . 0.538 ' HB3' HG11 ' A' ' 253' ' ' VAL . 4.6 ttm -83.41 69.47 10.03 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 178.481 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 45.5 pt -72.69 -22.23 20.08 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.916 0 CA-C-N 114.78 -1.1 . . . . 0.0 111.075 -174.78 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 258' ' ' GLN . . . . . 0.496 ' O ' ' SG ' ' A' ' 262' ' ' CYS . 23.4 mp0 -59.34 -41.49 89.29 Favored 'General case' 0 C--N 1.313 -0.994 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 179.359 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 259' ' ' LEU . . . . . 0.948 HD21 ' CE2' ' A' ' 283' ' ' PHE . 90.4 mt -62.8 -41.92 99.49 Favored 'General case' 0 N--CA 1.443 -0.802 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.589 178.198 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 260' ' ' ASN . . . . . 0.519 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 89.5 m-20 -60.44 -41.22 93.6 Favored 'General case' 0 CA--C 1.507 -0.678 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 -179.206 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -100.39 14.11 59.6 Favored Glycine 0 C--N 1.316 -0.583 0 N-CA-C 111.359 -0.696 . . . . 0.0 111.359 -178.495 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 262' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 258' ' ' GLN . 1.2 m -85.62 144.81 27.65 Favored 'General case' 0 C--O 1.242 0.707 0 C-N-CA 120.714 -0.394 . . . . 0.0 110.786 -179.607 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 95.7 mm-40 -68.96 162.96 60.87 Favored Pre-proline 0 C--N 1.315 -0.892 0 N-CA-C 107.4 -1.333 . . . . 0.0 107.4 170.224 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 264' ' ' PRO . . . . . 0.498 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 24.1 Cg_exo -61.46 143.89 97.71 Favored 'Trans proline' 0 C--N 1.307 -1.637 0 N-CA-C 109.562 -0.976 . . . . 0.0 109.562 -178.129 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 265' ' ' MET . . . . . 0.48 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 8.9 ptp -126.65 150.8 48.74 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 116.689 -0.232 . . . . 0.0 110.935 -175.296 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -70.92 137.49 49.29 Favored 'General case' 0 C--O 1.242 0.686 0 O-C-N 123.828 0.705 . . . . 0.0 109.14 178.846 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 267' ' ' ILE . . . . . 0.57 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.9 pp -127.24 161.24 34.89 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-O 120.867 0.365 . . . . 0.0 111.601 -175.727 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . 0.743 ' HG2' HG23 ' A' ' 244' ' ' THR . 0.0 OUTLIER -127.38 120.87 29.47 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 176.621 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.626 HG22 ' OG1' ' A' ' 244' ' ' THR . 28.3 m -69.92 133.71 31.39 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 C-N-CA 120.653 -0.419 . . . . 0.0 111.337 -177.972 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 270' ' ' LEU . . . . . 0.683 ' CD1' HG23 ' A' ' 231' ' ' VAL . 74.5 mt -97.06 -46.08 6.32 Favored 'General case' 0 CA--C 1.508 -0.67 0 CA-C-O 121.422 0.63 . . . . 0.0 109.537 177.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -149.25 -171.46 17.92 Favored Glycine 0 C--N 1.311 -0.843 0 N-CA-C 108.428 -1.869 . . . . 0.0 108.428 179.84 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 272' ' ' PRO . . . . . 0.52 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 37.8 Cg_endo -62.71 -30.66 78.63 Favored 'Trans proline' 0 C--N 1.301 -1.957 0 C-N-CA 121.332 1.355 . . . . 0.0 111.054 -179.12 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 95.3 m-85 -122.86 11.45 9.66 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 113.32 0.859 . . . . 0.0 113.32 -178.07 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 274' ' ' THR . . . . . 0.444 ' CG2' HG23 ' A' ' 233' ' ' THR . 20.4 p -130.09 146.38 51.74 Favored 'General case' 0 C--O 1.241 0.638 0 C-N-CA 120.66 -0.416 . . . . 0.0 111.259 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 275' ' ' PHE . . . . . 0.502 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -150.0 166.1 30.7 Favored 'General case' 0 C--O 1.243 0.736 0 N-CA-C 112.1 0.408 . . . . 0.0 112.1 177.161 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -129.21 141.83 51.03 Favored 'General case' 0 N--CA 1.438 -1.046 0 C-N-CA 120.535 -0.466 . . . . 0.0 111.382 179.643 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . 0.55 HG22 HG22 ' A' ' 267' ' ' ILE . 39.4 pt -136.17 166.38 26.95 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.79 0 CA-C-N 114.649 -1.159 . . . . 0.0 111.227 -171.653 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 278' ' ' CYS . . . . . 0.432 ' C ' ' O ' ' A' ' 277' ' ' ILE . 0.9 OUTLIER -21.3 -93.53 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 123.845 0.858 . . . . 0.0 113.137 -176.831 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . 0.444 ' OD1' ' N ' ' A' ' 281' ' ' SER . 60.9 t0 -151.98 116.41 5.04 Favored 'General case' 0 CA--C 1.508 -0.645 0 CA-C-N 116.639 -0.255 . . . . 0.0 110.53 -177.937 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . 0.732 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 11.8 p -66.38 -26.73 67.4 Favored 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 120.508 -0.477 . . . . 0.0 110.832 175.014 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 281' ' ' SER . . . . . 0.512 ' HA ' ' HD3' ' A' ' 226' ' ' LYS . 0.8 OUTLIER -66.38 -20.73 66.15 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.497 -0.774 . . . . 0.0 109.511 174.582 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -87.51 -9.7 53.79 Favored 'General case' 0 CA--C 1.504 -0.797 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 178.316 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . 0.948 ' CE2' HD21 ' A' ' 259' ' ' LEU . 8.0 m-85 -92.18 -82.9 0.31 Allowed 'General case' 0 N--CA 1.44 -0.943 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 170.921 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 284' ' ' SER . . . . . 0.438 ' HB2' ' O ' ' A' ' 283' ' ' PHE . 9.5 t 169.1 -149.18 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 177.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -85.74 166.44 16.1 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-O 120.59 0.234 . . . . 0.0 110.414 174.655 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . 0.58 ' CE2' HG21 ' A' ' 224' ' ' VAL . 12.9 t80 -119.55 102.04 8.36 Favored 'General case' 0 N--CA 1.467 0.394 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 178.486 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 287' ' ' ILE . . . . . 0.561 ' O ' ' HB3' ' A' ' 288' ' ' ARG . 93.4 mt -66.79 -45.53 87.65 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.824 0 C-N-CA 120.211 -0.596 . . . . 0.0 110.287 -179.085 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . 0.561 ' HB3' ' O ' ' A' ' 287' ' ' ILE . 14.7 ptm180 168.4 -173.51 0.02 OUTLIER 'General case' 0 C--O 1.238 0.492 0 O-C-N 123.934 0.771 . . . . 0.0 111.165 -176.45 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 64.96 -147.38 50.99 Favored Glycine 0 C--N 1.338 0.691 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.55 174.313 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . 0.513 ' HA3' HG22 ' A' ' 253' ' ' VAL . . . 92.16 127.5 4.16 Favored Glycine 0 N--CA 1.443 -0.87 0 CA-C-O 121.252 0.362 . . . . 0.0 113.399 174.636 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 95.0 mt -115.76 127.69 73.26 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.047 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 170.84 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 7.4 p -98.89 132.06 44.91 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 179.641 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -121.42 122.85 40.7 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-N 115.473 -0.785 . . . . 0.0 110.525 -172.331 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 294' ' ' GLN . . . . . 0.595 ' OE1' ' NZ ' ' A' ' 296' ' ' LYS . 49.0 tt0 -71.93 139.86 48.92 Favored 'General case' 0 CA--C 1.497 -1.086 0 C-N-CA 119.973 -0.691 . . . . 0.0 109.218 172.647 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . 0.419 HG21 ' HG3' ' A' ' 264' ' ' PRO . 24.0 t -119.25 109.21 25.85 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 N-CA-C 107.726 -1.213 . . . . 0.0 107.726 172.841 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 296' ' ' LYS . . . . . 0.595 ' NZ ' ' OE1' ' A' ' 294' ' ' GLN . 6.7 mmtm -72.63 98.29 2.32 Favored 'General case' 0 N--CA 1.436 -1.166 0 C-N-CA 119.385 -0.926 . . . . 0.0 109.77 -176.822 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 84.2 t -88.37 149.39 44.57 Favored Pre-proline 0 C--N 1.316 -0.879 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 177.075 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_exo -53.03 132.63 48.52 Favored 'Trans proline' 0 C--N 1.318 -1.076 0 CA-C-N 119.989 1.032 . . . . 0.0 109.651 177.146 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 35.0 mmtp -89.46 -162.92 0.92 Allowed 'General case' 0 C--N 1.315 -0.924 0 CA-C-N 115.626 -0.715 . . . . 0.0 110.49 -174.268 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 21.0 mmtp -51.42 152.45 2.59 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 -177.739 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 98.5 mt -77.21 127.17 38.19 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.84 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 179.764 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 1.1 m -77.58 88.64 3.89 Favored 'General case' 0 C--N 1.311 -1.074 0 CA-C-N 116.207 -0.451 . . . . 0.0 109.946 -178.86 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 87.9 t80 -102.19 130.29 48.81 Favored 'General case' 0 CA--C 1.505 -0.758 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 -179.894 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 64.7 mttm -83.09 106.12 14.63 Favored 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 179.657 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 6.4 m -75.94 156.55 34.1 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.388 -179.271 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 306' ' ' LEU . . . . . 0.964 HD22 ' H ' ' A' ' 306' ' ' LEU . 0.3 OUTLIER -39.46 143.55 0.53 Allowed Pre-proline 0 C--N 1.327 -0.406 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.465 -179.241 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . 0.496 ' O ' ' N ' ' A' ' 309' ' ' SER . 76.2 Cg_exo -53.98 -39.55 84.64 Favored 'Trans proline' 0 N--CA 1.497 1.689 0 C-N-CA 122.534 2.156 . . . . 0.0 110.622 -179.155 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -59.91 79.81 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.408 0 CA-C-N 115.302 -0.863 . . . . 0.0 109.915 177.907 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.496 ' N ' ' O ' ' A' ' 307' ' ' PRO . 4.6 m -70.08 145.02 51.94 Favored 'General case' 0 C--N 1.306 -1.301 0 CA-C-N 115.335 -0.848 . . . . 0.0 109.042 -179.125 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 89.3 mt -77.65 130.51 36.93 Favored 'General case' 0 C--N 1.322 -0.63 0 C-N-CA 119.803 -0.759 . . . . 0.0 109.281 179.816 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 59.7 t -121.89 128.42 75.66 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.848 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 177.817 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 78.7 mm-40 . . . . . 0 C--O 1.202 -1.414 0 CA-C-O 118.326 -0.845 . . . . 0.0 110.717 -179.175 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . 0.455 ' N ' ' OE1' ' A' ' 204' ' ' GLU . 0.0 OUTLIER . . . . . 0 N--CA 1.476 0.845 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 . . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 86.5 t80 -59.25 -47.12 86.53 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.188 -176.132 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -64.62 -41.14 97.93 Favored Glycine 0 C--N 1.314 -0.642 0 N-CA-C 111.243 -0.743 . . . . 0.0 111.243 178.86 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 204' ' ' GLU . . . . . 0.455 ' OE1' ' N ' ' A' ' 201' ' ' GLU . 2.8 mp0 -59.53 -31.75 69.69 Favored 'General case' 0 C--O 1.237 0.446 0 CA-C-N 116.728 0.264 . . . . 0.0 111.404 -176.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 58.3 mt-10 -62.02 -35.81 79.68 Favored 'General case' 0 C--N 1.317 -0.841 0 N-CA-C 109.675 -0.491 . . . . 0.0 109.675 178.103 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 206' ' ' MET . . . . . 0.478 ' HG3' ' N ' ' A' ' 207' ' ' VAL . 62.9 tpp -92.11 161.14 14.88 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.733 177.376 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . 0.607 HG12 HG23 ' A' ' 209' ' ' THR . 17.8 t -88.82 128.23 41.11 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.947 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 176.407 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 208' ' ' LEU . . . . . 0.449 ' HB3' ' H ' ' A' ' 213' ' ' GLY . 90.4 mt -70.78 75.38 0.61 Allowed 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 -179.593 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 209' ' ' THR . . . . . 0.607 HG23 HG12 ' A' ' 207' ' ' VAL . 2.2 p -118.41 -54.73 2.27 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.505 -0.77 . . . . 0.0 111.077 -177.349 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 210' ' ' ASP . . . . . 0.402 ' CG ' ' N ' ' A' ' 211' ' ' SER . 19.8 p-10 -63.59 -39.65 94.92 Favored 'General case' 0 CA--C 1.507 -0.705 0 N-CA-C 107.356 -1.35 . . . . 0.0 107.356 171.772 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 211' ' ' SER . . . . . 0.614 ' OG ' ' NZ ' ' A' ' 300' ' ' LYS . 9.1 m -114.98 94.31 4.69 Favored 'General case' 0 N--CA 1.43 -1.463 0 CA-C-N 113.732 -1.577 . . . . 0.0 108.258 177.149 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 59.5 t-20 -83.0 107.76 15.82 Favored 'General case' 0 C--N 1.322 -0.605 0 C-N-CA 120.613 -0.435 . . . . 0.0 111.258 -173.702 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 213' ' ' GLY . . . . . 0.449 ' H ' ' HB3' ' A' ' 208' ' ' LEU . . . 47.57 45.78 23.47 Favored Glycine 0 C--O 1.236 0.26 0 N-CA-C 111.449 -0.661 . . . . 0.0 111.449 177.204 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -83.82 97.89 9.42 Favored 'General case' 0 N--CA 1.445 -0.715 0 C-N-CA 119.851 -0.739 . . . . 0.0 111.032 -177.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -113.07 144.04 30.35 Favored Pre-proline 0 C--N 1.316 -0.889 0 N-CA-C 107.28 -1.378 . . . . 0.0 107.28 170.22 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -55.69 131.12 44.2 Favored 'Trans proline' 0 C--N 1.3 -1.997 0 N-CA-C 109.672 -0.934 . . . . 0.0 109.672 -179.026 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 217' ' ' LEU . . . . . 0.532 ' O ' ' HA ' ' A' ' 293' ' ' SER . 0.5 OUTLIER -87.64 125.98 34.69 Favored 'General case' 0 CA--C 1.493 -1.233 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 177.572 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 3.0 m -115.43 132.01 56.75 Favored 'General case' 0 C--N 1.313 -1.011 0 O-C-N 123.445 0.465 . . . . 0.0 110.097 -176.2 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 219' ' ' ALA . . . . . 0.436 ' HA ' ' HB1' ' A' ' 238' ' ' ALA . . . -134.4 142.66 47.23 Favored 'General case' 0 N--CA 1.449 -0.516 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.02 -178.804 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 220' ' ' MET . . . . . 0.649 ' SD ' HG12 ' A' ' 291' ' ' ILE . 99.6 mmm -72.18 131.93 43.44 Favored 'General case' 0 C--O 1.244 0.764 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.255 175.829 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 80.5 t -85.11 128.14 39.29 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.999 0 N-CA-C 108.971 -0.752 . . . . 0.0 108.971 178.798 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 222' ' ' SER . . . . . 0.491 ' OG ' ' N ' ' A' ' 223' ' ' MET . 0.1 OUTLIER -79.82 -72.66 0.39 Allowed 'General case' 0 N--CA 1.434 -1.247 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 177.924 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 223' ' ' MET . . . . . 0.491 ' N ' ' OG ' ' A' ' 222' ' ' SER . 8.6 ptm -137.69 147.15 44.59 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.703 -0.68 . . . . 0.0 111.646 175.612 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 224' ' ' VAL . . . . . 0.845 HG13 HG12 ' A' ' 232' ' ' VAL . 59.6 t -122.07 130.16 74.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 175.447 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 41.0 p -77.31 134.72 38.44 Favored 'General case' 0 C--N 1.321 -0.668 0 C-N-CA 120.604 -0.438 . . . . 0.0 110.775 179.451 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 21.8 tptm -77.63 65.66 3.18 Favored 'General case' 0 C--O 1.24 0.596 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 174.784 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 227' ' ' ASP . . . . . 0.472 ' N ' ' OG1' ' A' ' 280' ' ' THR . 2.3 t0 -147.33 177.41 9.24 Favored 'General case' 0 C--O 1.245 0.816 0 CA-C-N 115.41 -0.814 . . . . 0.0 111.251 -171.802 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 228' ' ' ASN . . . . . 0.61 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 16.0 p-10 -144.13 124.39 7.58 Favored Pre-proline 0 C--N 1.319 -0.754 0 CA-C-N 115.525 -0.762 . . . . 0.0 110.82 175.755 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 229' ' ' PRO . . . . . 0.61 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 34.1 Cg_exo -60.18 143.18 33.09 Favored 'Cis proline' 0 N--CA 1.489 1.256 0 C-N-CA 123.14 -1.608 . . . . 0.0 110.926 -1.192 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . 0.756 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -74.79 131.06 12.25 Favored Glycine 0 C--N 1.296 -1.681 0 N-CA-C 108.184 -1.966 . . . . 0.0 108.184 176.221 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.1 p -124.96 133.39 69.6 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.791 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 232' ' ' VAL . . . . . 0.845 HG12 HG13 ' A' ' 224' ' ' VAL . 0.7 OUTLIER -131.01 155.57 42.07 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.224 0 C-N-CA 120.27 -0.572 . . . . 0.0 110.863 -176.446 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 63.3 m -108.85 135.08 50.64 Favored 'General case' 0 C--N 1.307 -1.254 0 CA-C-N 115.247 -0.888 . . . . 0.0 108.636 176.553 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 44.6 m -105.64 151.11 24.8 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 -177.334 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 38.6 tp -56.24 132.11 49.77 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 -175.528 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 236' ' ' ASP . . . . . 0.541 ' O ' ' NH2' ' A' ' 239' ' ' ARG . 23.0 p-10 -52.42 -44.23 65.31 Favored 'General case' 0 N--CA 1.474 0.734 0 CA-C-O 121.072 0.463 . . . . 0.0 110.606 -174.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 237' ' ' GLU . . . . . 0.413 ' HA ' ' NH2' ' A' ' 239' ' ' ARG . 99.6 mt-10 -64.59 -34.91 79.36 Favored 'General case' 0 C--N 1.302 -1.466 0 CA-C-N 115.641 -0.708 . . . . 0.0 110.421 178.62 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . 0.436 ' HB1' ' HA ' ' A' ' 219' ' ' ALA . . . -79.76 73.63 6.48 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 116.004 -0.544 . . . . 0.0 112.176 -174.759 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 239' ' ' ARG . . . . . 0.541 ' NH2' ' O ' ' A' ' 236' ' ' ASP . 0.0 OUTLIER -58.2 90.19 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.024 0.44 . . . . 0.0 110.607 176.477 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 240' ' ' HIS . . . . . 0.473 ' O ' ' HB3' ' A' ' 217' ' ' LEU . 9.1 p80 -55.19 -48.57 73.63 Favored 'General case' 0 C--O 1.217 -0.629 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.249 -175.411 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 78.3 24.56 63.18 Favored Glycine 0 C--N 1.311 -0.858 0 N-CA-C 110.874 -0.891 . . . . 0.0 110.874 179.25 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 242' ' ' PHE . . . . . 0.429 ' CD1' ' HB2' ' A' ' 294' ' ' GLN . 9.3 m-30 -80.19 144.16 33.2 Favored 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 177.869 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -116.03 158.42 23.15 Favored 'General case' 0 C--N 1.312 -1.052 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.737 -177.695 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -56.58 118.03 4.45 Favored 'General case' 0 C--N 1.311 -1.069 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 178.618 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . 0.476 ' HA2' ' CG ' ' A' ' 266' ' ' GLU . . . 86.85 5.95 80.4 Favored Glycine 0 C--O 1.243 0.672 0 C-N-CA 120.847 -0.692 . . . . 0.0 111.892 -179.531 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -83.14 163.99 20.5 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-N 117.199 0.499 . . . . 0.0 109.913 177.676 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 247' ' ' PHE . . . . . 0.432 ' HA ' ' O ' ' A' ' 265' ' ' MET . 74.9 m-85 -111.18 135.79 51.19 Favored 'General case' 0 C--O 1.238 0.483 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -173.521 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.471 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 3.1 m -131.13 161.92 40.17 Favored 'Isoleucine or valine' 0 C--O 1.237 0.421 0 CA-C-O 121.063 0.458 . . . . 0.0 111.996 178.62 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 2.5 m -125.9 165.09 19.36 Favored 'General case' 0 C--N 1.321 -0.664 0 C-N-CA 124.773 1.229 . . . . 0.0 108.115 173.506 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 250' ' ' PHE . . . . . 0.628 ' CE1' HD22 ' A' ' 259' ' ' LEU . 96.5 m-85 -124.31 156.78 36.37 Favored 'General case' 0 C--N 1.317 -0.816 0 N-CA-C 110.505 -0.183 . . . . 0.0 110.505 -176.115 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 1.2 m -156.62 161.27 39.92 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.222 -0.444 . . . . 0.0 109.823 176.368 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 16.2 mt-10 51.85 28.63 5.19 Favored 'General case' 0 C--N 1.314 -0.939 0 N-CA-C 112.305 0.483 . . . . 0.0 112.305 177.865 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 0.543 HG22 ' CA ' ' A' ' 290' ' ' GLY . 3.2 t -92.78 127.4 44.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 176.363 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 77.3 mt-30 -91.27 138.16 31.81 Favored 'General case' 0 C--O 1.241 0.609 0 CA-C-O 120.827 0.346 . . . . 0.0 110.585 -177.508 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . 0.54 ' CA ' HD12 ' A' ' 287' ' ' ILE . . . 76.23 -58.45 3.22 Favored Glycine 0 C--N 1.319 -0.376 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 -179.052 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 256' ' ' MET . . . . . 0.423 ' SD ' HD11 ' A' ' 259' ' ' LEU . 30.7 ttm -77.32 50.36 0.77 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.429 0.633 . . . . 0.0 109.603 176.619 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 46.2 pt -71.11 -18.05 20.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-N 115.233 -0.894 . . . . 0.0 111.218 -175.12 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 258' ' ' GLN . . . . . 0.571 ' HG3' ' HG ' ' A' ' 262' ' ' CYS . 68.5 tp60 -54.86 -38.37 67.39 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 177.897 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 259' ' ' LEU . . . . . 0.822 HD21 ' CE2' ' A' ' 283' ' ' PHE . 93.7 mt -62.22 -40.48 96.24 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.506 -0.77 . . . . 0.0 110.197 176.343 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -59.49 -40.24 86.37 Favored 'General case' 0 CA--C 1.51 -0.59 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 -179.186 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -101.97 21.99 39.85 Favored Glycine 0 CA--C 1.524 0.656 0 CA-C-N 115.927 -0.578 . . . . 0.0 112.049 -179.312 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 262' ' ' CYS . . . . . 0.571 ' HG ' ' HG3' ' A' ' 258' ' ' GLN . 1.3 m -95.95 149.35 21.66 Favored 'General case' 0 C--O 1.236 0.382 0 CA-C-N 117.33 0.565 . . . . 0.0 111.488 -179.429 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . 0.525 ' CD ' ' H ' ' A' ' 263' ' ' GLN . 16.6 mp0 -67.66 156.07 89.82 Favored Pre-proline 0 C--N 1.325 -0.475 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 172.572 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 264' ' ' PRO . . . . . 0.471 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 37.3 Cg_endo -62.67 143.09 91.77 Favored 'Trans proline' 0 C--N 1.308 -1.575 0 C-N-CA 120.722 0.948 . . . . 0.0 110.25 179.131 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 265' ' ' MET . . . . . 0.432 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 22.5 ptp -130.55 155.01 47.23 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 116.477 -0.329 . . . . 0.0 111.663 -173.513 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 266' ' ' GLU . . . . . 0.476 ' CG ' ' HA2' ' A' ' 245' ' ' GLY . 39.7 tt0 -71.8 144.56 49.11 Favored 'General case' 0 C--O 1.239 0.535 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 177.777 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 267' ' ' ILE . . . . . 0.646 HD12 ' C ' ' A' ' 267' ' ' ILE . 2.1 pp -128.27 162.06 35.46 Favored 'Isoleucine or valine' 0 C--O 1.249 1.043 0 N-CA-C 113.608 0.966 . . . . 0.0 113.608 -175.221 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 25.7 mtpp -118.7 109.42 16.08 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 114.762 -1.108 . . . . 0.0 109.66 -178.406 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 8.2 m -80.65 96.04 2.71 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.457 0 C-N-CA 120.275 -0.57 . . . . 0.0 111.268 178.103 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 98.4 mt -67.25 -40.59 86.26 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.406 0.622 . . . . 0.0 110.131 178.128 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -139.64 177.54 20.38 Favored Glycine 0 C--N 1.315 -0.609 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.29 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_endo -60.1 -31.54 93.47 Favored 'Trans proline' 0 C--N 1.302 -1.881 0 C-N-CA 121.772 1.648 . . . . 0.0 111.233 -178.769 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 22.9 m-85 -123.94 11.08 8.93 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.422 179.383 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -122.52 125.67 46.23 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 116.025 -0.534 . . . . 0.0 109.654 -176.276 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 275' ' ' PHE . . . . . 0.545 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -138.68 164.02 30.61 Favored 'General case' 0 CA--C 1.501 -0.931 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 -179.611 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . 0.524 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 6.4 p -137.49 159.07 42.97 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.456 -178.082 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . 0.694 ' C ' HD12 ' A' ' 277' ' ' ILE . 2.5 pp -138.05 -173.74 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 CA-C-N 114.977 -1.01 . . . . 0.0 109.948 -175.825 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 278' ' ' CYS . . . . . 0.46 ' O ' ' HA ' ' A' ' 229' ' ' PRO . 1.2 p -46.87 -93.83 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.304 0 O-C-N 123.324 0.39 . . . . 0.0 111.812 -179.694 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -137.55 126.75 24.55 Favored 'General case' 0 CA--C 1.514 -0.406 0 N-CA-C 109.541 -0.541 . . . . 0.0 109.541 -179.323 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . 0.756 HG23 ' HA3' ' A' ' 230' ' ' GLY . 25.0 p -69.56 -23.76 63.61 Favored 'General case' 0 C--N 1.317 -0.808 0 C-N-CA 119.436 -0.906 . . . . 0.0 108.682 171.06 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -61.85 -21.05 64.34 Favored 'General case' 0 N--CA 1.435 -1.199 0 CA-C-N 114.635 -1.166 . . . . 0.0 108.812 173.802 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 29.3 t-20 -89.22 -9.13 51.92 Favored 'General case' 0 CA--C 1.509 -0.621 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.481 175.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . 0.822 ' CE2' HD21 ' A' ' 259' ' ' LEU . 19.5 m-30 -95.79 -87.91 0.28 Allowed 'General case' 0 N--CA 1.444 -0.74 0 CA-C-O 121.524 0.678 . . . . 0.0 110.456 178.396 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 284' ' ' SER . . . . . 0.418 ' CB ' ' HA ' ' A' ' 256' ' ' MET . 0.0 OUTLIER 170.3 -170.22 0.02 OUTLIER 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 107.689 -1.226 . . . . 0.0 107.689 -173.44 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -94.06 131.37 39.62 Favored 'General case' 0 N--CA 1.471 0.623 0 CA-C-N 118.646 0.657 . . . . 0.0 112.766 -176.052 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . 0.474 ' O ' ' CD2' ' A' ' 286' ' ' TYR . 60.8 t80 -68.87 87.04 0.35 Allowed 'General case' 0 N--CA 1.472 0.639 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.177 177.399 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 287' ' ' ILE . . . . . 0.577 ' O ' ' HG3' ' A' ' 288' ' ' ARG . 87.5 mt -69.94 -48.05 65.58 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.723 0 C-N-CA 120.298 -0.561 . . . . 0.0 110.806 175.405 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . 0.577 ' HG3' ' O ' ' A' ' 287' ' ' ILE . 43.8 mtp180 -170.52 170.67 6.78 Favored 'General case' 0 N--CA 1.47 0.574 0 N-CA-C 112.986 0.735 . . . . 0.0 112.986 -179.114 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 56.48 -143.55 38.51 Favored Glycine 0 N--CA 1.466 0.681 0 CA-C-N 113.77 -1.559 . . . . 0.0 113.199 167.483 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . 0.543 ' CA ' HG22 ' A' ' 253' ' ' VAL . . . 100.71 130.31 6.99 Favored Glycine 0 N--CA 1.441 -1.009 0 CA-C-O 121.163 0.313 . . . . 0.0 112.506 178.93 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . 0.649 HG12 ' SD ' ' A' ' 220' ' ' MET . 95.2 mt -116.29 129.82 72.08 Favored 'Isoleucine or valine' 0 C--O 1.244 0.769 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 171.675 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 7.2 p -109.31 130.35 62.47 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.064 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 176.789 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . 0.532 ' HA ' ' O ' ' A' ' 217' ' ' LEU . 3.2 m -131.08 138.73 49.69 Favored 'General case' 0 N--CA 1.441 -0.875 0 C-N-CA 120.43 -0.508 . . . . 0.0 111.558 -175.124 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 294' ' ' GLN . . . . . 0.429 ' HB2' ' CD1' ' A' ' 242' ' ' PHE . 2.7 tm0? -76.89 148.99 36.12 Favored 'General case' 0 C--N 1.316 -0.88 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 173.29 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 54.2 t -109.62 130.0 63.47 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.031 0 C-N-CA 120.506 -0.477 . . . . 0.0 109.99 -178.302 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 296' ' ' LYS . . . . . 0.515 ' O ' ' HG2' ' A' ' 296' ' ' LYS . 0.0 OUTLIER -62.53 103.54 0.42 Allowed 'General case' 0 N--CA 1.44 -0.941 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 177.797 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 297' ' ' VAL . . . . . 0.556 HG22 ' H ' ' A' ' 299' ' ' LYS . 2.7 p -59.6 127.92 85.53 Favored Pre-proline 0 C--N 1.315 -0.909 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.299 -174.46 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -66.02 -22.79 54.68 Favored 'Trans proline' 0 N--CA 1.497 1.735 0 C-N-CA 122.3 2.0 . . . . 0.0 111.067 179.879 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . 0.556 ' H ' HG22 ' A' ' 297' ' ' VAL . 46.9 mmtm -97.25 143.26 28.21 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.74 -178.799 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 300' ' ' LYS . . . . . 0.614 ' NZ ' ' OG ' ' A' ' 211' ' ' SER . 11.7 mmtp -119.74 150.09 40.95 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.071 177.161 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 43.8 pt -64.83 130.65 30.22 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.898 -178.048 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 29.3 m -125.92 153.18 44.61 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.209 -176.85 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 89.3 m-85 -125.8 149.21 48.78 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 116.136 -0.484 . . . . 0.0 109.847 -177.738 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 49.2 mmtm -78.01 141.15 39.09 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 116.579 -0.282 . . . . 0.0 110.686 -178.293 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -128.64 162.81 26.47 Favored 'General case' 0 C--O 1.244 0.806 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.321 179.541 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 306' ' ' LEU . . . . . 0.717 ' H ' HD12 ' A' ' 306' ' ' LEU . 0.0 OUTLIER -88.21 160.48 45.66 Favored Pre-proline 0 C--N 1.323 -0.561 0 N-CA-C 109.295 -0.632 . . . . 0.0 109.295 176.126 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 78.4 Cg_exo -54.65 -39.89 86.8 Favored 'Trans proline' 0 N--CA 1.497 1.711 0 C-N-CA 122.161 1.908 . . . . 0.0 111.112 -179.824 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -150.62 152.56 34.22 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.272 176.518 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 13.2 p -78.93 168.37 19.8 Favored 'General case' 0 C--N 1.314 -0.946 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 175.517 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 85.1 mt -101.19 131.18 47.29 Favored 'General case' 0 C--N 1.324 -0.536 0 C-N-CA 120.541 -0.464 . . . . 0.0 110.239 177.888 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 2.3 t -123.35 132.68 70.97 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.004 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 -178.568 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.205 -1.268 0 CA-C-O 118.26 -0.876 . . . . 0.0 110.586 -179.633 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . 0.556 ' O ' ' N ' ' A' ' 203' ' ' GLY . 2.2 pm0 . . . . . 0 N--CA 1.483 1.178 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 202' ' ' PHE . . . . . 0.415 ' O ' ' N ' ' A' ' 204' ' ' GLU . 91.5 m-85 59.57 -62.31 0.05 OUTLIER 'General case' 0 N--CA 1.467 0.407 0 C-N-CA 122.697 0.399 . . . . 0.0 110.748 -178.022 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . 0.556 ' N ' ' O ' ' A' ' 201' ' ' GLU . . . -67.75 47.5 0.32 Allowed Glycine 0 N--CA 1.466 0.666 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 176.603 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 204' ' ' GLU . . . . . 0.415 ' N ' ' O ' ' A' ' 202' ' ' PHE . 48.8 mt-10 -70.89 -49.95 40.38 Favored 'General case' 0 C--N 1.319 -0.746 0 O-C-N 122.177 -0.602 . . . . 0.0 111.26 -177.186 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -71.71 -52.29 18.55 Favored 'General case' 0 C--O 1.235 0.314 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 178.894 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 99.6 mmm -103.3 129.6 50.35 Favored 'General case' 0 CA--C 1.503 -0.833 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 173.683 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 5.2 t -86.65 111.18 21.12 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.905 0 C-N-CA 120.304 -0.558 . . . . 0.0 110.354 -175.869 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 84.7 mt -81.73 81.27 7.83 Favored 'General case' 0 N--CA 1.442 -0.84 0 CA-C-N 115.564 -0.744 . . . . 0.0 109.304 -179.831 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 5.8 m -102.2 32.82 3.34 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 115.556 -0.747 . . . . 0.0 109.973 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -61.11 -36.66 80.29 Favored 'General case' 0 CA--C 1.507 -0.68 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.383 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 211' ' ' SER . . . . . 0.435 ' HB3' ' CD ' ' A' ' 214' ' ' GLU . 10.9 m -91.5 90.06 7.48 Favored 'General case' 0 N--CA 1.435 -1.206 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 175.824 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 59.7 t30 -113.49 98.94 7.39 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.712 -0.677 . . . . 0.0 109.74 -179.45 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 48.03 60.94 5.22 Favored Glycine 0 C--O 1.237 0.287 0 N-CA-C 109.365 -1.494 . . . . 0.0 109.365 -176.108 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 214' ' ' GLU . . . . . 0.435 ' CD ' ' HB3' ' A' ' 211' ' ' SER . 65.4 mt-10 -60.65 137.5 58.17 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-O 120.758 0.314 . . . . 0.0 111.194 -173.656 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 90.1 mt-30 -59.99 159.57 19.97 Favored Pre-proline 0 C--O 1.24 0.583 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 174.547 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -56.8 144.84 86.2 Favored 'Trans proline' 0 C--N 1.304 -1.804 0 C-N-CA 121.743 1.629 . . . . 0.0 110.669 -178.824 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 217' ' ' LEU . . . . . 0.406 ' HB3' ' O ' ' A' ' 240' ' ' HIS . 0.2 OUTLIER -58.64 138.25 57.05 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.327 -177.056 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 8.5 t -151.72 152.61 32.98 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.012 -175.683 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -143.57 160.38 40.73 Favored 'General case' 0 C--O 1.244 0.797 0 CA-C-O 120.918 0.389 . . . . 0.0 110.95 178.413 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 97.2 mtp -71.57 136.73 47.58 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.463 -0.79 . . . . 0.0 109.239 176.474 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 91.1 t -83.7 129.48 37.46 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.052 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 178.027 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 74.9 m -79.79 -73.05 0.37 Allowed 'General case' 0 N--CA 1.432 -1.34 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 177.704 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 223' ' ' MET . . . . . 0.477 ' SD ' ' HB ' ' A' ' 233' ' ' THR . 1.0 OUTLIER -139.71 161.95 36.31 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.111 172.771 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 224' ' ' VAL . . . . . 0.725 HG11 ' SD ' ' A' ' 256' ' ' MET . 69.6 t -127.37 129.8 70.69 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 175.749 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . 0.509 ' O ' HG21 ' A' ' 280' ' ' THR . 75.4 p -78.88 131.25 36.35 Favored 'General case' 0 C--O 1.225 -0.225 0 C-N-CA 120.08 -0.648 . . . . 0.0 110.163 177.615 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 226' ' ' LYS . . . . . 0.605 ' HE3' ' HA ' ' A' ' 281' ' ' SER . 0.0 OUTLIER -77.72 52.28 1.0 Allowed 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 120.723 0.297 . . . . 0.0 110.868 -179.012 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 227' ' ' ASP . . . . . 0.419 ' CG ' ' H ' ' A' ' 228' ' ' ASN . 42.3 t0 -131.29 -179.8 5.57 Favored 'General case' 0 C--O 1.242 0.674 0 CA-C-O 120.862 0.363 . . . . 0.0 111.952 -178.562 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 228' ' ' ASN . . . . . 0.474 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 1.5 p30 -137.6 125.07 13.95 Favored Pre-proline 0 CA--C 1.539 0.536 0 CA-C-N 115.162 -0.926 . . . . 0.0 109.634 175.073 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 229' ' ' PRO . . . . . 0.474 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 44.9 Cg_endo -65.63 143.87 61.41 Favored 'Cis proline' 0 N--CA 1.49 1.314 0 C-N-CA 123.121 -1.616 . . . . 0.0 109.984 -0.46 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . 0.559 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -76.26 136.9 20.34 Favored Glycine 0 C--N 1.305 -1.157 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 -177.301 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 231' ' ' VAL . . . . . 0.482 HG23 HD12 ' A' ' 270' ' ' LEU . 1.6 p -125.74 133.84 68.1 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 175.82 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 232' ' ' VAL . . . . . 0.618 ' HB ' HG22 ' A' ' 224' ' ' VAL . 0.7 OUTLIER -132.42 156.36 42.33 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.81 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.241 -176.713 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 233' ' ' THR . . . . . 0.477 ' HB ' ' SD ' ' A' ' 223' ' ' MET . 24.4 m -109.65 143.93 38.71 Favored 'General case' 0 N--CA 1.441 -0.914 0 CA-C-N 115.848 -0.614 . . . . 0.0 109.675 176.278 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 34.2 m -107.58 157.55 17.96 Favored 'General case' 0 C--N 1.31 -1.127 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 -179.552 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 33.2 tp -57.19 123.27 14.74 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 -178.062 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 236' ' ' ASP . . . . . 0.405 ' HA ' ' CD1' ' A' ' 273' ' ' TYR . 8.4 p-10 -59.7 -32.71 70.77 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.211 0.529 . . . . 0.0 111.05 -175.717 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -66.89 -32.07 73.09 Favored 'General case' 0 C--N 1.303 -1.42 0 CA-C-N 115.751 -0.658 . . . . 0.0 112.047 177.444 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -109.08 132.99 53.58 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 120.777 0.322 . . . . 0.0 111.647 -176.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 90.2 mtm-85 -91.39 133.6 35.33 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 175.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 240' ' ' HIS . . . . . 0.623 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 3.0 p80 -66.57 -40.55 89.02 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.749 0.309 . . . . 0.0 111.208 -179.516 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 82.34 20.71 61.83 Favored Glycine 0 C--N 1.316 -0.544 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 -176.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 242' ' ' PHE . . . . . 0.502 ' CD2' ' HB2' ' A' ' 240' ' ' HIS . 7.6 m-30 -92.31 146.41 23.72 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 -179.184 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 71.4 mm-40 -109.27 160.07 16.43 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.512 171.471 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 19.9 m -64.6 122.36 16.63 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 175.717 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 95.04 0.14 63.87 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 111.564 -0.614 . . . . 0.0 111.564 -178.668 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 48.6 t0 -76.76 163.93 26.34 Favored 'General case' 0 C--O 1.238 0.489 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 176.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 247' ' ' PHE . . . . . 0.459 ' HA ' ' O ' ' A' ' 265' ' ' MET . 83.1 m-85 -110.27 129.82 55.66 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 -179.522 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.494 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.3 m -129.98 159.45 41.99 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 C-N-CA 120.357 -0.537 . . . . 0.0 111.519 -178.162 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 249' ' ' SER . . . . . 0.651 ' OG ' HG21 ' A' ' 295' ' ' VAL . 40.7 m -122.65 159.6 27.55 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 114.308 -1.315 . . . . 0.0 108.81 172.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 250' ' ' PHE . . . . . 0.605 ' CB ' ' HB3' ' A' ' 259' ' ' LEU . 79.1 m-85 -118.79 157.82 26.82 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.271 -174.167 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 4.8 m -151.59 157.48 42.25 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.324 178.078 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER 50.62 27.44 2.94 Favored 'General case' 0 C--N 1.308 -1.196 0 N-CA-C 112.87 0.693 . . . . 0.0 112.87 174.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 0.478 HG22 ' CA ' ' A' ' 290' ' ' GLY . 12.6 t -88.81 129.23 40.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 175.237 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . 0.477 ' NE2' ' N ' ' A' ' 254' ' ' GLN . 1.5 mp0 -97.27 138.91 34.03 Favored 'General case' 0 C--O 1.242 0.665 0 C-N-CA 120.737 -0.385 . . . . 0.0 110.84 -178.723 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 80.55 -55.66 4.69 Favored Glycine 0 C--O 1.238 0.358 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 -176.3 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 256' ' ' MET . . . . . 0.725 ' SD ' HG11 ' A' ' 224' ' ' VAL . 3.4 ttm -84.55 48.18 1.48 Allowed 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 175.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 257' ' ' ILE . . . . . 0.416 ' O ' ' HB2' ' A' ' 260' ' ' ASN . 48.8 pt -69.37 -20.6 24.28 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.758 0 CA-C-N 114.745 -1.116 . . . . 0.0 110.542 -174.544 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 258' ' ' GLN . . . . . 0.472 ' O ' ' SG ' ' A' ' 262' ' ' CYS . 2.5 mp0 -54.14 -35.1 61.87 Favored 'General case' 0 C--N 1.318 -0.801 0 N-CA-C 108.351 -0.981 . . . . 0.0 108.351 177.297 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 259' ' ' LEU . . . . . 0.94 HD21 ' CE2' ' A' ' 283' ' ' PHE . 92.5 mt -62.04 -41.24 97.9 Favored 'General case' 0 N--CA 1.445 -0.683 0 CA-C-N 115.399 -0.819 . . . . 0.0 109.915 176.154 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 260' ' ' ASN . . . . . 0.431 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 97.5 m-20 -60.71 -40.05 90.82 Favored 'General case' 0 CA--C 1.512 -0.49 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 -179.618 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -100.13 11.74 60.35 Favored Glycine 0 CA--C 1.524 0.62 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.872 -178.45 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 262' ' ' CYS . . . . . 0.472 ' SG ' ' O ' ' A' ' 258' ' ' GLN . 1.3 m -88.37 152.71 21.73 Favored 'General case' 0 CA--C 1.51 -0.579 0 CA-C-N 116.988 0.394 . . . . 0.0 110.787 -178.185 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 47.7 mt-30 -72.24 160.84 81.67 Favored Pre-proline 0 C--N 1.32 -0.678 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 173.331 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 264' ' ' PRO . . . . . 0.494 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 20.9 Cg_exo -61.47 143.75 97.56 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 N-CA-C 109.224 -1.106 . . . . 0.0 109.224 178.628 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 265' ' ' MET . . . . . 0.459 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 24.3 ptp -133.32 158.19 43.6 Favored 'General case' 0 C--N 1.317 -0.842 0 C-N-CA 120.98 -0.288 . . . . 0.0 111.695 -174.015 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 266' ' ' GLU . . . . . . . . . . . . . 66.4 tt0 -71.25 139.18 49.94 Favored 'General case' 0 CA--C 1.507 -0.679 0 O-C-N 123.664 0.603 . . . . 0.0 109.718 176.372 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 267' ' ' ILE . . . . . 0.746 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.9 pp -131.74 160.14 42.6 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.865 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.274 178.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 64.7 mttp -130.21 125.84 35.91 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.135 176.41 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 17.9 m -84.73 106.6 14.97 Favored 'Isoleucine or valine' 0 C--O 1.235 0.315 0 CA-C-O 121.18 0.514 . . . . 0.0 111.837 -177.436 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 270' ' ' LEU . . . . . 0.482 HD12 HG23 ' A' ' 231' ' ' VAL . 91.0 mt -66.27 -40.3 90.04 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.458 -0.792 . . . . 0.0 109.45 177.451 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -147.16 -175.46 20.06 Favored Glycine 0 C--N 1.321 -0.299 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 179.069 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 272' ' ' PRO . . . . . 0.623 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 36.4 Cg_endo -61.99 -33.93 82.1 Favored 'Trans proline' 0 C--N 1.307 -1.625 0 C-N-CA 121.778 1.652 . . . . 0.0 111.153 -177.619 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 273' ' ' TYR . . . . . 0.405 ' CD1' ' HA ' ' A' ' 236' ' ' ASP . 93.9 m-85 -119.19 6.51 11.24 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.984 -0.553 . . . . 0.0 112.18 -179.751 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 2.9 p -119.95 126.22 50.33 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 120.712 0.291 . . . . 0.0 110.506 179.323 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 275' ' ' PHE . . . . . 0.566 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -138.0 162.93 32.84 Favored 'General case' 0 CA--C 1.499 -0.992 0 C-N-CA 120.766 -0.374 . . . . 0.0 111.987 -179.744 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . 0.467 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 4.7 p -132.47 151.2 51.98 Favored 'General case' 0 N--CA 1.433 -1.277 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.921 -173.204 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . 0.746 HG22 HG22 ' A' ' 267' ' ' ILE . 2.2 pp -138.19 175.57 8.48 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 CA-C-N 114.824 -1.08 . . . . 0.0 110.505 -175.684 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 278' ' ' CYS . . . . . 0.444 ' N ' HD12 ' A' ' 277' ' ' ILE . 1.4 p -42.58 -88.44 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.435 0 N-CA-C 112.744 0.646 . . . . 0.0 112.744 -179.707 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . 0.455 ' O ' ' HB2' ' A' ' 282' ' ' ASN . 18.1 t0 -145.75 121.04 10.23 Favored 'General case' 0 CA--C 1.515 -0.371 0 CA-C-O 120.767 0.317 . . . . 0.0 111.109 -176.277 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . 0.657 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 35.9 p -68.22 -25.75 65.36 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-O 121.26 0.553 . . . . 0.0 110.534 176.546 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 281' ' ' SER . . . . . 0.605 ' HA ' ' HE3' ' A' ' 226' ' ' LYS . 0.7 OUTLIER -69.76 -12.86 61.96 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.459 -0.791 . . . . 0.0 109.519 176.06 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 282' ' ' ASN . . . . . 0.455 ' HB2' ' O ' ' A' ' 279' ' ' ASP . 2.0 m-80 -88.06 -6.06 58.15 Favored 'General case' 0 CA--C 1.509 -0.627 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 173.604 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . 0.94 ' CE2' HD21 ' A' ' 259' ' ' LEU . 6.0 m-85 -100.41 -71.8 0.69 Allowed 'General case' 0 N--CA 1.444 -0.738 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 172.29 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 1.6 p 167.02 -99.04 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.466 0 CA-C-N 115.144 -0.935 . . . . 0.0 110.213 178.81 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 285' ' ' ASP . . . . . 0.519 ' O ' ' N ' ' A' ' 256' ' ' MET . 48.4 t0 -150.74 163.33 38.85 Favored 'General case' 0 C--O 1.214 -0.815 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 177.416 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . 0.434 ' CE2' ' HA ' ' A' ' 288' ' ' ARG . 71.6 t80 -100.54 124.1 45.65 Favored 'General case' 0 C--N 1.318 -0.774 0 C-N-CA 121.1 -0.24 . . . . 0.0 110.841 -179.777 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 287' ' ' ILE . . . . . 0.435 ' O ' ' CG ' ' A' ' 288' ' ' ARG . 96.6 mt -100.06 -61.5 2.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 C-N-CA 120.77 -0.372 . . . . 0.0 110.455 173.696 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . 0.435 ' CG ' ' O ' ' A' ' 287' ' ' ILE . 54.6 mtp180 -166.67 176.79 6.96 Favored 'General case' 0 C--O 1.241 0.617 0 CA-C-O 121.135 0.493 . . . . 0.0 111.787 179.064 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 67.95 -156.27 52.8 Favored Glycine 0 CA--C 1.508 -0.399 0 CA-C-N 115.284 -0.871 . . . . 0.0 111.104 174.893 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . 0.478 ' CA ' HG22 ' A' ' 253' ' ' VAL . . . 109.91 123.81 4.68 Favored Glycine 0 N--CA 1.443 -0.893 0 N-CA-C 112.281 -0.327 . . . . 0.0 112.281 176.255 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 99.2 mt -127.52 133.72 67.19 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.09 0 N-CA-C 107.496 -1.298 . . . . 0.0 107.496 173.676 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . 0.414 HG22 ' CZ ' ' A' ' 242' ' ' PHE . 4.0 p -124.76 136.06 61.93 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.893 0 C-N-CA 120.466 -0.494 . . . . 0.0 109.824 -177.529 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 4.4 m -127.42 146.75 50.37 Favored 'General case' 0 C--O 1.237 0.441 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.768 -178.414 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -73.21 141.06 47.33 Favored 'General case' 0 CA--C 1.51 -0.588 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 173.449 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . 0.651 HG21 ' OG ' ' A' ' 249' ' ' SER . 69.9 t -125.51 135.71 63.12 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.067 0 C-N-CA 120.667 -0.413 . . . . 0.0 110.73 -176.25 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 51.5 mttp -86.11 99.23 11.36 Favored 'General case' 0 N--CA 1.442 -0.845 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 175.365 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 297' ' ' VAL . . . . . 0.54 ' O ' ' N ' ' A' ' 299' ' ' LYS . 14.5 m -56.47 171.98 0.37 Allowed Pre-proline 0 C--N 1.321 -0.655 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.236 -178.12 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 298' ' ' PRO . . . . . 0.445 ' HD2' ' HB ' ' A' ' 297' ' ' VAL . 34.1 Cg_exo -59.79 75.86 0.06 OUTLIER 'Trans proline' 0 N--CA 1.491 1.34 0 C-N-CA 121.652 1.568 . . . . 0.0 109.519 176.663 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . 0.54 ' N ' ' O ' ' A' ' 297' ' ' VAL . 27.0 tttm -137.96 157.97 45.3 Favored 'General case' 0 C--N 1.308 -1.229 0 CA-C-N 114.945 -1.025 . . . . 0.0 110.77 -170.199 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 300' ' ' LYS . . . . . 0.52 ' O ' ' NZ ' ' A' ' 299' ' ' LYS . 48.0 mmtm -64.76 150.3 47.65 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 172.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 44.2 pt -68.28 132.81 32.52 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.803 0 C-N-CA 120.906 -0.318 . . . . 0.0 110.383 -176.006 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 4.4 m -139.38 134.35 32.33 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.399 178.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 93.3 m-85 -129.2 147.45 51.04 Favored 'General case' 0 C--N 1.317 -0.812 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 176.679 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 62.2 mttm -99.8 110.19 22.57 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.263 177.16 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . 0.456 ' O ' ' C ' ' A' ' 306' ' ' LEU . 1.4 m -72.91 93.44 1.72 Allowed 'General case' 0 C--N 1.311 -1.103 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 175.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 306' ' ' LEU . . . . . 0.456 ' C ' ' O ' ' A' ' 305' ' ' SER . 54.9 mt -33.29 125.49 0.43 Allowed Pre-proline 0 C--O 1.236 0.38 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 -173.836 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -64.09 146.82 91.36 Favored 'Trans proline' 0 C--N 1.304 -1.805 0 C-N-CA 121.781 1.654 . . . . 0.0 111.118 -174.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . 0.466 ' O ' ' C ' ' A' ' 309' ' ' SER . . . -56.23 148.5 18.22 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 179.372 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.466 ' C ' ' O ' ' A' ' 308' ' ' ALA . 1.2 m -28.52 106.32 0.03 OUTLIER 'General case' 0 C--N 1.319 -0.75 0 O-C-N 123.455 0.472 . . . . 0.0 111.634 -174.404 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 67.1 mt -71.67 101.76 2.62 Favored 'General case' 0 CA--C 1.51 -0.585 0 CA-C-N 116.383 -0.372 . . . . 0.0 110.34 -178.731 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 17.8 m -128.93 132.41 67.43 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.124 176.584 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 90.0 mt-10 . . . . . 0 C--O 1.205 -1.289 0 CA-C-O 118.558 -0.734 . . . . 0.0 111.19 179.66 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . 0.502 ' OE1' ' N ' ' A' ' 201' ' ' GLU . 45.2 mp0 . . . . . 0 N--CA 1.478 0.967 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 71.1 m-85 -139.26 145.79 39.63 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -179.609 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -113.44 29.23 8.05 Favored Glycine 0 C--O 1.225 -0.463 0 C-N-CA 121.055 -0.593 . . . . 0.0 112.137 -178.601 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 99.8 mt-10 -64.27 -42.35 96.5 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 117.073 0.437 . . . . 0.0 110.255 179.696 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 51.4 tp10 -67.29 -40.25 86.08 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.181 -176.329 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 99.7 mtp -79.5 99.3 7.19 Favored 'General case' 0 C--O 1.238 0.471 0 N-CA-C 110.11 -0.33 . . . . 0.0 110.11 179.501 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . 0.463 ' C ' HD22 ' A' ' 208' ' ' LEU . 27.0 m -100.13 72.58 0.47 Allowed 'Isoleucine or valine' 0 C--O 1.245 0.861 0 CA-C-O 121.361 0.601 . . . . 0.0 112.238 -177.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 208' ' ' LEU . . . . . 0.671 HD22 ' N ' ' A' ' 208' ' ' LEU . 1.5 mm? -123.09 112.68 18.04 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 174.182 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -65.63 -44.22 87.12 Favored 'General case' 0 C--O 1.236 0.353 0 C-N-CA 119.753 -0.779 . . . . 0.0 109.805 176.118 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -127.78 -70.29 0.7 Allowed 'General case' 0 CA--C 1.507 -0.689 0 CA-C-N 115.099 -0.955 . . . . 0.0 108.852 173.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -121.01 -162.49 0.96 Allowed 'General case' 0 C--N 1.314 -0.965 0 CA-C-N 114.166 -1.379 . . . . 0.0 108.861 177.863 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 212' ' ' ASN . . . . . 0.61 ' HA ' HD12 ' A' ' 208' ' ' LEU . 0.0 OUTLIER -67.45 174.88 3.08 Favored 'General case' 0 C--N 1.322 -0.629 0 C-N-CA 120.844 -0.342 . . . . 0.0 110.158 176.126 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 213' ' ' GLY . . . . . 0.5 ' N ' ' ND2' ' A' ' 212' ' ' ASN . . . 131.99 37.94 0.27 Allowed Glycine 0 C--N 1.318 -0.452 0 N-CA-C 109.315 -1.514 . . . . 0.0 109.315 -176.611 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 214' ' ' GLU . . . . . 0.416 ' H ' ' CD ' ' A' ' 214' ' ' GLU . 53.8 mp0 -63.62 159.78 18.2 Favored 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 123.665 0.786 . . . . 0.0 109.26 -179.564 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 27.9 mt-30 -45.74 154.38 0.56 Allowed Pre-proline 0 C--N 1.326 -0.448 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 178.417 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -65.16 143.92 79.59 Favored 'Trans proline' 0 C--N 1.305 -1.731 0 C-N-CA 121.492 1.461 . . . . 0.0 109.479 176.549 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 217' ' ' LEU . . . . . 0.455 ' HB3' ' O ' ' A' ' 240' ' ' HIS . 0.1 OUTLIER -67.46 125.14 25.2 Favored 'General case' 0 C--N 1.313 -0.98 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 -178.889 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 218' ' ' SER . . . . . 0.405 ' HA ' ' HA ' ' A' ' 293' ' ' SER . 5.1 m -130.89 151.87 50.84 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.867 -174.719 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -144.84 160.59 41.04 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.051 0.453 . . . . 0.0 110.803 179.05 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 220' ' ' MET . . . . . 0.662 ' SD ' HD22 ' A' ' 235' ' ' LEU . 92.7 mtp -75.57 130.74 39.31 Favored 'General case' 0 N--CA 1.443 -0.814 0 CA-C-N 115.366 -0.834 . . . . 0.0 108.916 176.474 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 99.7 t -78.92 128.69 38.35 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.92 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 176.413 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 26.9 m -85.26 -72.73 0.47 Allowed 'General case' 0 C--N 1.307 -1.245 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 178.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 223' ' ' MET . . . . . 0.535 ' C ' ' SD ' ' A' ' 223' ' ' MET . 2.7 ppp? -138.2 151.26 47.52 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 112.235 0.457 . . . . 0.0 112.235 174.168 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 224' ' ' VAL . . . . . 0.578 HG13 HG12 ' A' ' 232' ' ' VAL . 62.2 t -121.11 126.65 75.38 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 176.098 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . 0.497 ' O ' ' OG1' ' A' ' 280' ' ' THR . 37.5 p -77.53 133.72 38.46 Favored 'General case' 0 C--N 1.327 -0.386 0 C-N-CA 120.259 -0.576 . . . . 0.0 110.407 178.49 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 20.6 tptm -78.32 77.23 4.81 Favored 'General case' 0 C--N 1.316 -0.87 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 179.813 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 227' ' ' ASP . . . . . 0.418 ' H ' ' HG1' ' A' ' 280' ' ' THR . 1.5 t0 -161.31 178.09 9.53 Favored 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 112.615 0.598 . . . . 0.0 112.615 -176.208 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 228' ' ' ASN . . . . . 0.502 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 2.0 t-20 -140.29 124.46 10.75 Favored Pre-proline 0 CA--C 1.533 0.324 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.786 175.086 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 229' ' ' PRO . . . . . 0.502 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 46.8 Cg_endo -65.61 143.57 60.0 Favored 'Cis proline' 0 N--CA 1.492 1.402 0 C-N-CA 122.759 -1.767 . . . . 0.0 109.717 -1.244 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . 0.517 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -81.9 140.02 20.48 Favored Glycine 0 CA--C 1.501 -0.795 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 -178.496 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 231' ' ' VAL . . . . . 0.446 ' CG2' HD12 ' A' ' 270' ' ' LEU . 2.4 p -122.79 133.85 67.71 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 176.922 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 232' ' ' VAL . . . . . 0.578 HG12 HG13 ' A' ' 224' ' ' VAL . 0.6 OUTLIER -131.39 155.41 41.79 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 C-N-CA 120.605 -0.438 . . . . 0.0 110.829 -176.182 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 26.1 m -110.17 142.67 41.37 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-N 115.425 -0.807 . . . . 0.0 109.629 177.474 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 48.7 m -107.92 158.22 17.54 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-N 115.804 -0.634 . . . . 0.0 109.484 178.39 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.662 HD22 ' SD ' ' A' ' 220' ' ' MET . 33.9 tp -64.5 117.21 7.0 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 178.459 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 236' ' ' ASP . . . . . 0.539 ' HA ' ' CE1' ' A' ' 273' ' ' TYR . 37.4 p-10 -59.71 -28.56 67.43 Favored 'General case' 0 C--O 1.239 0.515 0 CA-C-O 120.885 0.374 . . . . 0.0 111.872 -173.144 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 72.4 mm-40 -66.22 -33.18 75.18 Favored 'General case' 0 C--N 1.311 -1.068 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.316 178.78 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -99.51 122.96 43.32 Favored 'General case' 0 CA--C 1.516 -0.337 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.408 179.795 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 239' ' ' ARG . . . . . . . . . . . . . 90.2 mtm180 -75.57 138.73 41.67 Favored 'General case' 0 C--N 1.316 -0.861 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 174.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 240' ' ' HIS . . . . . 0.474 ' HB2' ' CD2' ' A' ' 242' ' ' PHE . 6.4 p80 -88.82 -37.73 15.17 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 121.026 0.441 . . . . 0.0 109.924 177.26 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 81.24 10.73 84.36 Favored Glycine 0 CA--C 1.505 -0.592 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 179.405 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 242' ' ' PHE . . . . . 0.493 ' CD1' ' N ' ' A' ' 242' ' ' PHE . 3.7 m-30 -81.22 147.14 30.11 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -179.305 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -131.17 167.42 19.18 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 109.095 -0.705 . . . . 0.0 109.095 172.359 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 2.9 m -59.48 129.38 41.7 Favored 'General case' 0 C--N 1.294 -1.835 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.556 -176.561 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 83.8 1.8 89.85 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 111.807 -0.517 . . . . 0.0 111.807 -179.165 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 246' ' ' ASP . . . . . . . . . . . . . 44.4 t0 -77.69 159.62 29.01 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 117.315 0.557 . . . . 0.0 110.255 178.476 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 247' ' ' PHE . . . . . 0.429 ' HA ' ' O ' ' A' ' 265' ' ' MET . 66.0 m-85 -110.48 133.79 52.95 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 116.592 -0.276 . . . . 0.0 110.394 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.426 ' O ' ' SD ' ' A' ' 265' ' ' MET . 3.1 m -129.98 162.22 38.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.54 -179.093 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 5.0 m -126.19 151.79 46.89 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.332 -0.849 . . . . 0.0 109.016 175.782 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 250' ' ' PHE . . . . . 0.563 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 74.4 m-85 -109.6 155.9 20.85 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.409 0.623 . . . . 0.0 111.693 -176.25 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 44.8 m -152.4 151.82 31.28 Favored 'General case' 0 C--N 1.308 -1.211 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.579 175.851 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 30.7 mm-40 51.89 28.47 5.13 Favored 'General case' 0 C--N 1.317 -0.808 0 N-CA-C 113.018 0.747 . . . . 0.0 113.018 176.427 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 0.541 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 60.8 t -82.36 129.67 37.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 174.216 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 81.9 mt-30 -101.59 138.15 38.96 Favored 'General case' 0 C--O 1.243 0.745 0 C-N-CA 120.272 -0.571 . . . . 0.0 111.296 -175.275 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 81.73 -57.53 4.92 Favored Glycine 0 C--O 1.239 0.417 0 N-CA-C 109.969 -1.252 . . . . 0.0 109.969 -176.47 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 256' ' ' MET . . . . . 0.505 ' SD ' HD11 ' A' ' 259' ' ' LEU . 57.0 ttm -85.78 65.04 8.94 Favored 'General case' 0 CA--C 1.516 -0.364 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 175.383 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 257' ' ' ILE . . . . . 0.436 ' O ' ' HB2' ' A' ' 260' ' ' ASN . 49.1 pt -73.92 -19.55 17.58 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-N 114.659 -1.155 . . . . 0.0 111.875 -172.848 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 15.4 tt0 -58.16 -36.39 72.94 Favored 'General case' 0 C--N 1.321 -0.647 0 C-N-CA 119.547 -0.861 . . . . 0.0 110.055 -177.636 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 259' ' ' LEU . . . . . 0.875 HD21 ' CE2' ' A' ' 283' ' ' PHE . 90.4 mt -61.44 -40.39 94.27 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 177.814 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 260' ' ' ASN . . . . . 0.541 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 98.3 m-20 -60.24 -40.1 89.06 Favored 'General case' 0 CA--C 1.508 -0.635 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 178.376 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -102.27 22.72 36.8 Favored Glycine 0 C--N 1.315 -0.615 0 CA-C-N 115.468 -0.787 . . . . 0.0 111.919 -178.259 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 262' ' ' CYS . . . . . 0.4 ' HB3' ' HA ' ' A' ' 259' ' ' LEU . 11.1 t -111.14 146.48 36.78 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 117.308 0.554 . . . . 0.0 111.734 -176.994 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 -59.31 158.99 17.35 Favored Pre-proline 0 C--N 1.327 -0.376 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 174.005 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 264' ' ' PRO . . . . . 0.421 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 37.6 Cg_endo -62.64 148.16 93.75 Favored 'Trans proline' 0 N--CA 1.493 1.491 0 C-N-CA 121.578 1.519 . . . . 0.0 111.395 179.159 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 265' ' ' MET . . . . . 0.623 ' N ' ' SD ' ' A' ' 265' ' ' MET . 0.3 OUTLIER -124.7 150.49 46.09 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.731 -174.412 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 266' ' ' GLU . . . . . 0.522 ' OE2' ' NZ ' ' A' ' 268' ' ' LYS . 0.7 OUTLIER -71.53 140.14 49.77 Favored 'General case' 0 C--O 1.24 0.596 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 172.958 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 267' ' ' ILE . . . . . 0.687 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.5 pp -130.63 159.92 42.25 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-O 121.245 0.545 . . . . 0.0 111.958 -177.065 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . 0.522 ' NZ ' ' OE2' ' A' ' 266' ' ' GLU . 35.4 mttp -128.79 120.51 26.48 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.617 178.182 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.421 HG23 ' O ' ' A' ' 269' ' ' VAL . 26.8 m -82.58 100.14 6.07 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.256 0 CA-C-O 121.018 0.437 . . . . 0.0 111.85 -176.657 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 270' ' ' LEU . . . . . 0.446 HD12 ' CG2' ' A' ' 231' ' ' VAL . 97.4 mt -65.81 -41.07 92.32 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.341 0.591 . . . . 0.0 109.636 177.264 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -139.41 179.49 18.67 Favored Glycine 0 C--N 1.317 -0.525 0 N-CA-C 109.253 -1.539 . . . . 0.0 109.253 178.166 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 272' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -61.99 -30.23 82.9 Favored 'Trans proline' 0 C--N 1.306 -1.694 0 C-N-CA 121.899 1.733 . . . . 0.0 111.067 -178.27 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 273' ' ' TYR . . . . . 0.539 ' CE1' ' HA ' ' A' ' 236' ' ' ASP . 72.9 m-85 -122.56 6.8 9.49 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 112.782 0.66 . . . . 0.0 112.782 179.027 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 7.0 p -119.41 126.89 52.43 Favored 'General case' 0 C--O 1.243 0.717 0 CA-C-O 120.67 0.272 . . . . 0.0 110.461 177.658 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 275' ' ' PHE . . . . . 0.533 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -133.0 163.2 29.76 Favored 'General case' 0 CA--C 1.493 -1.243 0 C-N-CA 120.446 -0.501 . . . . 0.0 112.296 179.893 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . 0.517 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 5.0 p -130.65 143.27 50.63 Favored 'General case' 0 N--CA 1.43 -1.432 0 C-N-CA 120.611 -0.436 . . . . 0.0 111.526 -174.781 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . 0.628 HG22 HG22 ' A' ' 267' ' ' ILE . 32.6 pt -141.31 165.79 18.6 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.765 0 CA-C-N 114.614 -1.176 . . . . 0.0 111.488 -172.784 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 278' ' ' CYS . . . . . 0.406 ' O ' ' HA ' ' A' ' 229' ' ' PRO . 0.9 OUTLIER -27.5 -90.99 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.687 0 N-CA-C 113.757 1.021 . . . . 0.0 113.757 -176.379 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . 0.424 ' HB3' ' HB2' ' A' ' 282' ' ' ASN . 50.7 t0 -148.81 113.56 5.39 Favored 'General case' 0 CA--C 1.504 -0.825 0 CA-C-N 116.615 -0.266 . . . . 0.0 110.293 -175.911 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . 0.705 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 26.7 p -73.65 -23.52 59.87 Favored 'General case' 0 N--CA 1.426 -1.627 0 CA-C-O 121.086 0.47 . . . . 0.0 110.04 177.411 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -67.75 -20.75 65.27 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.06 -0.973 . . . . 0.0 108.783 173.243 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 282' ' ' ASN . . . . . 0.424 ' HB2' ' HB3' ' A' ' 279' ' ' ASP . 18.8 t30 -89.63 -9.08 51.0 Favored 'General case' 0 CA--C 1.51 -0.588 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.455 -179.547 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . 0.875 ' CE2' HD21 ' A' ' 259' ' ' LEU . 21.3 m-85 -92.14 -71.76 0.63 Allowed 'General case' 0 CA--C 1.505 -0.757 0 CA-C-O 121.66 0.743 . . . . 0.0 109.643 179.002 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 284' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER 168.95 -175.78 0.03 OUTLIER 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 114.133 -1.394 . . . . 0.0 107.967 -173.908 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 7.9 t70 -92.41 121.43 33.88 Favored 'General case' 0 C--N 1.322 -0.617 0 C-N-CA 120.246 -0.582 . . . . 0.0 111.925 -178.861 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 12.1 t80 -69.58 126.73 30.63 Favored 'General case' 0 C--O 1.237 0.423 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 177.299 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 96.4 mt -106.08 -58.26 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 CA-C-O 121.021 0.438 . . . . 0.0 110.13 174.834 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 22.3 ptt180 -166.91 -179.31 4.64 Favored 'General case' 0 C--O 1.24 0.554 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.934 -176.285 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 65.64 -156.29 49.13 Favored Glycine 0 C--N 1.331 0.305 0 N-CA-C 110.6 -1.0 . . . . 0.0 110.6 178.051 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . 0.403 ' CA ' HG22 ' A' ' 253' ' ' VAL . . . 105.42 122.81 5.1 Favored Glycine 0 CA--C 1.52 0.373 0 CA-C-O 121.266 0.37 . . . . 0.0 112.813 176.413 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 95.6 mt -123.0 130.76 74.25 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 N-CA-C 107.587 -1.264 . . . . 0.0 107.587 175.262 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . 0.474 HG22 ' CZ ' ' A' ' 242' ' ' PHE . 4.0 p -126.35 137.98 56.08 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 -177.455 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . 0.405 ' HA ' ' HA ' ' A' ' 218' ' ' SER . 12.5 m -129.64 147.27 51.42 Favored 'General case' 0 CA--C 1.509 -0.598 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.498 -178.425 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 294' ' ' GLN . . . . . 0.459 ' HB3' ' CD1' ' A' ' 242' ' ' PHE . 0.7 OUTLIER -82.61 139.83 33.55 Favored 'General case' 0 CA--C 1.507 -0.678 0 C-N-CA 120.183 -0.607 . . . . 0.0 110.535 175.41 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 79.1 t -121.49 129.06 75.91 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.154 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 177.811 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 16.9 mmtp -85.9 97.53 10.28 Favored 'General case' 0 C--N 1.315 -0.915 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 179.466 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 297' ' ' VAL . . . . . 0.439 ' O ' HG23 ' A' ' 297' ' ' VAL . 6.0 m -90.55 119.94 69.01 Favored Pre-proline 0 N--CA 1.442 -0.872 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.541 -179.029 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -57.81 139.83 91.64 Favored 'Trans proline' 0 N--CA 1.488 1.163 0 C-N-CA 121.69 1.593 . . . . 0.0 110.156 177.625 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 2.9 mptp? -107.14 153.21 22.99 Favored 'General case' 0 C--N 1.309 -1.176 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.212 -179.101 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -57.13 132.85 54.19 Favored 'General case' 0 C--N 1.317 -0.811 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 -179.45 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 95.7 mt -71.0 115.18 10.38 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.019 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 -175.406 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -82.97 159.29 22.27 Favored 'General case' 0 C--N 1.312 -1.048 0 CA-C-N 115.496 -0.775 . . . . 0.0 111.867 -176.349 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 51.8 p90 -150.8 160.17 44.05 Favored 'General case' 0 C--N 1.307 -1.277 0 CA-C-N 115.097 -0.956 . . . . 0.0 108.762 179.029 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.06 128.11 35.18 Favored 'General case' 0 C--N 1.313 -0.983 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.454 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 12.8 p -63.61 156.26 27.23 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 179.193 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -43.76 103.34 0.32 Allowed Pre-proline 0 C--N 1.327 -0.389 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.797 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . 0.561 ' O ' ' N ' ' A' ' 309' ' ' SER . 57.9 Cg_endo -73.96 82.38 1.77 Allowed 'Trans proline' 0 C--N 1.305 -1.712 0 C-N-CA 121.617 1.545 . . . . 0.0 111.17 -174.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -66.14 60.43 0.04 OUTLIER 'General case' 0 CA--C 1.515 -0.369 0 CA-C-O 121.486 0.66 . . . . 0.0 109.272 178.262 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.561 ' N ' ' O ' ' A' ' 307' ' ' PRO . 10.3 p -81.93 162.33 22.76 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 114.853 -1.067 . . . . 0.0 111.424 -176.784 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 1.8 mm? -78.31 141.55 38.4 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 176.235 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 11.8 t -126.07 110.77 24.64 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 179.02 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 312' ' ' GLU . . . . . 0.44 ' OE1' ' N ' ' A' ' 312' ' ' GLU . 57.8 mp0 . . . . . 0 C--O 1.205 -1.239 0 CA-C-O 118.472 -0.775 . . . . 0.0 110.43 -178.654 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . 0.441 ' N ' ' OE2' ' A' ' 201' ' ' GLU . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 110.232 -0.284 . . . . 0.0 110.232 . . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 32.6 p90 -149.11 155.13 40.25 Favored 'General case' 0 C--O 1.238 0.496 0 CA-C-O 120.994 0.426 . . . . 0.0 111.959 -177.901 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -118.4 -5.26 12.96 Favored Glycine 0 N--CA 1.461 0.365 0 N-CA-C 110.319 -1.112 . . . . 0.0 110.319 176.737 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -53.18 -15.82 1.02 Allowed 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 112.213 0.449 . . . . 0.0 112.213 -175.189 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 69.0 mt-10 -61.54 -37.76 84.94 Favored 'General case' 0 CA--C 1.514 -0.418 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 176.599 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 97.1 mtp -107.85 73.08 0.88 Allowed 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 114.832 -1.076 . . . . 0.0 109.228 177.767 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . 0.637 HG22 HG23 ' A' ' 209' ' ' THR . 4.8 p -100.39 114.16 38.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.14 0.495 . . . . 0.0 110.816 -177.896 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 86.7 mt -85.46 89.01 7.58 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.476 -179.105 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 209' ' ' THR . . . . . 0.637 HG23 HG22 ' A' ' 207' ' ' VAL . 1.6 p -100.21 -1.72 35.76 Favored 'General case' 0 C--N 1.314 -0.973 0 CA-C-O 121.061 0.457 . . . . 0.0 110.553 179.071 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 210' ' ' ASP . . . . . 0.412 ' O ' ' C ' ' A' ' 211' ' ' SER . 5.4 t70 -100.83 30.93 3.77 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.672 -0.694 . . . . 0.0 110.29 178.913 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 211' ' ' SER . . . . . 0.412 ' C ' ' O ' ' A' ' 210' ' ' ASP . 0.0 OUTLIER -29.58 123.47 0.15 Allowed 'General case' 0 C--O 1.236 0.353 0 CA-C-N 115.769 -0.651 . . . . 0.0 112.189 -174.984 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 212' ' ' ASN . . . . . 0.423 ' OD1' ' N ' ' A' ' 213' ' ' GLY . 50.4 t-20 -87.53 141.29 28.73 Favored 'General case' 0 C--O 1.243 0.713 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.674 -179.413 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 213' ' ' GLY . . . . . 0.423 ' N ' ' OD1' ' A' ' 212' ' ' ASN . . . 71.31 35.16 63.71 Favored Glycine 0 C--O 1.241 0.57 0 N-CA-C 111.783 -0.527 . . . . 0.0 111.783 176.806 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 73.9 mt-10 -65.06 130.85 44.88 Favored 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 120.56 -0.456 . . . . 0.0 110.465 179.007 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 215' ' ' GLN . . . . . 0.495 ' CD ' ' HD2' ' A' ' 216' ' ' PRO . 8.0 tp60 -64.33 150.45 92.94 Favored Pre-proline 0 C--N 1.321 -0.665 0 N-CA-C 106.155 -1.795 . . . . 0.0 106.155 171.452 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 216' ' ' PRO . . . . . 0.495 ' HD2' ' CD ' ' A' ' 215' ' ' GLN . 74.7 Cg_exo -53.13 135.51 59.55 Favored 'Trans proline' 0 C--O 1.247 0.934 0 N-CA-C 108.7 -1.308 . . . . 0.0 108.7 -178.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 217' ' ' LEU . . . . . 0.458 ' CB ' ' HG2' ' A' ' 294' ' ' GLN . 0.3 OUTLIER -46.62 112.12 0.46 Allowed 'General case' 0 CA--C 1.505 -0.781 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.218 -168.436 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 218' ' ' SER . . . . . 0.43 ' HA ' ' O ' ' A' ' 292' ' ' VAL . 15.6 m -127.96 150.67 49.8 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 -179.041 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -138.05 152.57 48.95 Favored 'General case' 0 C--N 1.311 -1.095 0 CA-C-O 120.848 0.356 . . . . 0.0 111.112 -177.468 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 220' ' ' MET . . . . . 0.567 ' SD ' HG12 ' A' ' 291' ' ' ILE . 3.5 tpp -76.11 126.82 31.71 Favored 'General case' 0 N--CA 1.443 -0.821 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 174.647 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 72.5 t -77.14 129.48 37.33 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.122 0 N-CA-C 109.646 -0.502 . . . . 0.0 109.646 -178.419 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 3.0 m -83.43 -73.07 0.43 Allowed 'General case' 0 N--CA 1.437 -1.108 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 176.374 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 223' ' ' MET . . . . . 0.449 ' C ' ' SD ' ' A' ' 223' ' ' MET . 3.6 ppp? -138.38 152.79 48.73 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.42 -0.354 . . . . 0.0 111.658 174.566 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 224' ' ' VAL . . . . . 0.647 HG13 HG12 ' A' ' 232' ' ' VAL . 61.6 t -119.84 126.55 75.42 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.991 0 N-CA-C 108.323 -0.991 . . . . 0.0 108.323 175.08 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . 0.489 ' O ' ' OG1' ' A' ' 280' ' ' THR . 71.0 p -84.82 126.77 33.73 Favored 'General case' 0 C--N 1.322 -0.594 0 C-N-CA 119.726 -0.79 . . . . 0.0 109.648 176.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 86.5 tttt -77.86 89.85 4.08 Favored 'General case' 0 C--N 1.316 -0.874 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 -178.435 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 227' ' ' ASP . . . . . . . . . . . . . 43.5 t0 -163.86 173.68 12.43 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.429 -177.363 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 228' ' ' ASN . . . . . 0.419 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.8 OUTLIER -133.14 123.54 17.94 Favored Pre-proline 0 C--N 1.323 -0.559 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.855 172.926 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 229' ' ' PRO . . . . . 0.419 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 55.3 Cg_endo -66.78 144.25 68.2 Favored 'Cis proline' 0 C--N 1.311 -1.4 0 C-N-CA 122.845 -1.731 . . . . 0.0 109.774 -2.266 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . 0.479 ' O ' ' HA ' ' A' ' 276' ' ' SER . . . -84.03 139.06 18.1 Favored Glycine 0 CA--C 1.502 -0.766 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 -178.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 231' ' ' VAL . . . . . 0.496 ' CG2' HD12 ' A' ' 270' ' ' LEU . 2.4 p -124.78 137.57 57.01 Favored 'Isoleucine or valine' 0 C--O 1.243 0.745 0 N-CA-C 109.967 -0.382 . . . . 0.0 109.967 177.162 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 232' ' ' VAL . . . . . 0.647 HG12 HG13 ' A' ' 224' ' ' VAL . 0.6 OUTLIER -132.61 155.34 41.23 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.892 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.801 -178.493 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 233' ' ' THR . . . . . . . . . . . . . 21.7 m -109.06 144.19 37.4 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.811 178.861 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 2.1 m -107.6 150.44 26.87 Favored 'General case' 0 C--N 1.316 -0.882 0 C-N-CA 123.023 0.529 . . . . 0.0 109.718 -179.662 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 37.4 tp -65.27 134.51 53.79 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.431 -176.638 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 236' ' ' ASP . . . . . 0.428 ' O ' ' NH1' ' A' ' 239' ' ' ARG . 13.0 t70 -49.1 -44.51 42.29 Favored 'General case' 0 N--CA 1.474 0.748 0 N-CA-C 114.0 1.111 . . . . 0.0 114.0 -171.779 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 237' ' ' GLU . . . . . 0.518 ' O ' ' NH1' ' A' ' 239' ' ' ARG . 54.6 mp0 -63.83 -33.5 75.82 Favored 'General case' 0 C--N 1.316 -0.851 0 C-N-CA 119.044 -1.062 . . . . 0.0 109.615 -177.534 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -77.36 95.2 4.35 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 112.869 0.692 . . . . 0.0 112.869 -177.952 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 239' ' ' ARG . . . . . 0.518 ' NH1' ' O ' ' A' ' 237' ' ' GLU . 0.0 OUTLIER -73.39 92.28 1.83 Allowed 'General case' 0 C--O 1.237 0.395 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 169.755 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 240' ' ' HIS . . . . . 0.604 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 9.4 p80 -53.0 -47.02 68.58 Favored 'General case' 0 C--O 1.213 -0.853 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.297 -174.382 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 76.8 20.75 75.83 Favored Glycine 0 C--N 1.311 -0.811 0 N-CA-C 110.416 -1.074 . . . . 0.0 110.416 177.752 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 242' ' ' PHE . . . . . 0.578 ' CE1' ' HB3' ' A' ' 294' ' ' GLN . 5.2 m-30 -80.17 143.63 33.68 Favored 'General case' 0 C--N 1.318 -0.778 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 179.405 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -119.41 166.26 13.29 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-O 121.153 0.502 . . . . 0.0 110.663 175.604 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 9.1 m -59.44 127.56 32.66 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 115.774 -0.648 . . . . 0.0 109.55 -179.032 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 84.54 6.7 85.48 Favored Glycine 0 N--CA 1.438 -1.175 0 N-CA-C 111.698 -0.561 . . . . 0.0 111.698 -179.815 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 246' ' ' ASP . . . . . 0.434 ' CG ' HE22 ' A' ' 294' ' ' GLN . 3.6 t0 -84.36 165.42 18.25 Favored 'General case' 0 CA--C 1.512 -0.483 0 C-N-CA 119.377 -0.929 . . . . 0.0 109.494 176.814 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 247' ' ' PHE . . . . . 0.552 ' CZ ' ' HB2' ' A' ' 266' ' ' GLU . 47.3 m-85 -112.61 138.11 49.87 Favored 'General case' 0 C--N 1.315 -0.906 0 N-CA-C 111.935 0.346 . . . . 0.0 111.935 -175.476 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.514 ' HA ' ' HA ' ' A' ' 294' ' ' GLN . 2.7 m -133.01 160.38 42.67 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.363 0 C-N-CA 120.297 -0.561 . . . . 0.0 112.189 177.213 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 2.2 m -125.13 153.89 42.3 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 114.483 -1.235 . . . . 0.0 107.694 174.329 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 250' ' ' PHE . . . . . 0.623 ' CB ' ' HB3' ' A' ' 259' ' ' LEU . 64.5 m-85 -112.83 144.64 42.03 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-O 120.865 0.364 . . . . 0.0 111.126 -179.373 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 4.0 m -140.92 161.16 38.48 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 115.503 -0.772 . . . . 0.0 109.426 176.398 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 51.3 mm-40 52.96 27.49 5.63 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 112.278 0.473 . . . . 0.0 112.278 173.507 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 0.445 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 83.4 t -88.68 133.6 30.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 177.771 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 90.9 mm-40 -100.37 145.75 27.8 Favored 'General case' 0 C--O 1.237 0.436 0 CA-C-O 120.852 0.358 . . . . 0.0 110.104 176.692 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 78.36 -68.85 2.86 Favored Glycine 0 C--N 1.315 -0.612 0 N-CA-C 110.417 -1.073 . . . . 0.0 110.417 -179.505 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 256' ' ' MET . . . . . 0.482 ' SD ' ' HD2' ' A' ' 283' ' ' PHE . 29.9 ttm -79.55 68.11 5.5 Favored 'General case' 0 C--N 1.321 -0.638 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 178.087 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 44.9 pt -75.23 -19.21 16.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.857 -175.344 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 258' ' ' GLN . . . . . 0.447 ' O ' ' N ' ' A' ' 262' ' ' CYS . 0.2 OUTLIER -53.18 -39.66 63.81 Favored 'General case' 0 C--O 1.213 -0.849 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 177.576 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 259' ' ' LEU . . . . . 0.978 HD21 ' CE2' ' A' ' 283' ' ' PHE . 94.6 mt -61.6 -41.96 98.19 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.137 179.075 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 260' ' ' ASN . . . . . 0.445 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 91.5 m-20 -59.73 -41.25 90.5 Favored 'General case' 0 CA--C 1.51 -0.567 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 179.524 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -101.14 9.48 57.89 Favored Glycine 0 CA--C 1.523 0.537 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.942 -177.884 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 262' ' ' CYS . . . . . 0.447 ' N ' ' O ' ' A' ' 258' ' ' GLN . 15.6 t -87.99 144.24 26.65 Favored 'General case' 0 C--O 1.241 0.632 0 CA-C-N 117.174 0.487 . . . . 0.0 111.415 -176.122 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -61.21 156.06 52.51 Favored Pre-proline 0 C--N 1.319 -0.721 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 173.6 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 264' ' ' PRO . . . . . 0.413 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 39.3 Cg_endo -64.77 143.32 79.95 Favored 'Trans proline' 0 C--N 1.307 -1.618 0 C-N-CA 120.757 0.971 . . . . 0.0 109.842 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 265' ' ' MET . . . . . 0.469 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 19.5 ptp -126.1 153.61 44.26 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 112.07 0.396 . . . . 0.0 112.07 -174.45 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 266' ' ' GLU . . . . . 0.552 ' HB2' ' CZ ' ' A' ' 247' ' ' PHE . 75.8 tt0 -79.82 137.34 36.93 Favored 'General case' 0 C--O 1.238 0.478 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 179.789 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 267' ' ' ILE . . . . . 0.641 HG22 HG22 ' A' ' 277' ' ' ILE . 1.9 pp -128.33 163.02 33.63 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 N-CA-C 113.752 1.019 . . . . 0.0 113.752 -169.674 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . . . . . . . . . 52.9 tttp -124.95 121.3 34.06 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.148 -0.933 . . . . 0.0 109.995 175.155 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.429 HG11 ' O ' ' A' ' 242' ' ' PHE . 29.5 m -75.64 132.19 33.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 C-N-CA 121.096 -0.242 . . . . 0.0 110.723 178.432 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 270' ' ' LEU . . . . . 0.613 HD11 ' HB3' ' A' ' 276' ' ' SER . 84.5 mt -106.38 -13.82 15.26 Favored 'General case' 0 CA--C 1.515 -0.393 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.737 -179.335 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -170.6 -177.93 40.98 Favored Glycine 0 C--N 1.318 -0.436 0 N-CA-C 110.364 -1.094 . . . . 0.0 110.364 -177.801 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 272' ' ' PRO . . . . . 0.604 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 36.2 Cg_endo -61.52 -31.4 87.51 Favored 'Trans proline' 0 C--N 1.308 -1.588 0 C-N-CA 122.097 1.865 . . . . 0.0 111.118 -178.302 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 273' ' ' TYR . . . . . 0.413 ' CE1' ' HA ' ' A' ' 236' ' ' ASP . 88.7 m-85 -124.49 7.43 8.31 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.877 -0.602 . . . . 0.0 112.407 -179.569 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 11.0 p -123.07 141.14 52.29 Favored 'General case' 0 C--O 1.244 0.784 0 C-N-CA 120.146 -0.622 . . . . 0.0 111.957 -177.893 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 275' ' ' PHE . . . . . 0.564 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -143.34 165.95 26.09 Favored 'General case' 0 CA--C 1.508 -0.654 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.17 178.113 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . 0.613 ' HB3' HD11 ' A' ' 270' ' ' LEU . 4.6 p -133.08 146.02 51.28 Favored 'General case' 0 N--CA 1.439 -1.01 0 N-CA-C 112.502 0.556 . . . . 0.0 112.502 -175.918 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . 0.641 HG22 HG22 ' A' ' 267' ' ' ILE . 29.1 pt -141.46 167.99 16.0 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.896 0 CA-C-N 114.224 -1.353 . . . . 0.0 111.332 -172.102 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 1.6 p -28.75 -95.19 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.759 0 N-CA-C 113.354 0.872 . . . . 0.0 113.354 -177.436 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -143.8 108.7 4.94 Favored 'General case' 0 CA--C 1.501 -0.912 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 -178.626 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . 0.773 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 17.8 p -64.58 -30.63 71.66 Favored 'General case' 0 C--N 1.29 -2.016 0 CA-C-O 121.492 0.663 . . . . 0.0 110.459 177.55 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -61.26 -31.37 71.18 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-N 114.836 -1.075 . . . . 0.0 110.297 175.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -87.07 -9.44 55.42 Favored 'General case' 0 CA--C 1.507 -0.686 0 C-N-CA 119.362 -0.935 . . . . 0.0 110.24 -176.609 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . 0.978 ' CE2' HD21 ' A' ' 259' ' ' LEU . 19.1 m-85 -77.11 -71.61 0.4 Allowed 'General case' 0 N--CA 1.437 -1.106 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 169.455 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 284' ' ' SER . . . . . 0.406 ' CB ' ' HA ' ' A' ' 256' ' ' MET . 0.0 OUTLIER 175.92 -169.5 0.05 Allowed 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 113.975 -1.466 . . . . 0.0 109.129 -175.574 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -97.47 120.66 38.24 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-O 120.377 0.132 . . . . 0.0 110.772 -177.432 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . 0.46 ' CZ ' ' HA ' ' A' ' 288' ' ' ARG . 64.6 t80 -63.87 126.41 27.53 Favored 'General case' 0 N--CA 1.478 0.94 0 C-N-CA 122.754 0.422 . . . . 0.0 111.254 -177.543 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 4.1 mm -100.92 -65.39 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.666 173.399 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . 0.46 ' HA ' ' CZ ' ' A' ' 286' ' ' TYR . 0.1 OUTLIER -173.25 -178.8 1.8 Allowed 'General case' 0 C--O 1.243 0.751 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.305 178.58 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 68.33 -156.75 52.99 Favored Glycine 0 CA--C 1.504 -0.625 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 175.432 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . 0.42 ' HA3' HG22 ' A' ' 253' ' ' VAL . . . 106.72 129.68 6.31 Favored Glycine 0 N--CA 1.437 -1.251 0 C-N-CA 120.884 -0.674 . . . . 0.0 112.014 177.498 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . 0.567 HG12 ' SD ' ' A' ' 220' ' ' MET . 96.5 mt -122.43 130.58 74.41 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.31 0 N-CA-C 107.215 -1.402 . . . . 0.0 107.215 173.172 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . 0.43 ' O ' ' HA ' ' A' ' 218' ' ' SER . 2.6 p -112.12 126.9 69.56 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.828 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 -178.182 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 3.3 m -115.93 121.22 41.67 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 110.041 -0.355 . . . . 0.0 110.041 -176.915 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 294' ' ' GLN . . . . . 0.578 ' HB3' ' CE1' ' A' ' 242' ' ' PHE . 0.0 OUTLIER -75.76 138.85 41.5 Favored 'General case' 0 N--CA 1.435 -1.197 0 C-N-CA 120.149 -0.621 . . . . 0.0 110.576 178.362 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . 0.42 ' N ' ' O ' ' A' ' 247' ' ' PHE . 3.2 t -106.52 106.11 20.0 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.196 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 179.6 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 296' ' ' LYS . . . . . 0.424 ' HD2' ' NE2' ' A' ' 294' ' ' GLN . 13.6 tptt -75.11 111.5 10.4 Favored 'General case' 0 N--CA 1.435 -1.214 0 N-CA-C 106.854 -1.536 . . . . 0.0 106.854 174.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 297' ' ' VAL . . . . . . . . . . . . . 5.2 m -42.41 153.12 0.31 Allowed Pre-proline 0 C--N 1.321 -0.67 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.26 -169.691 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -61.94 -16.08 47.33 Favored 'Trans proline' 0 C--N 1.31 -1.494 0 C-N-CA 122.757 2.304 . . . . 0.0 110.884 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . . . . . . . . . 27.0 mmtp -54.61 131.87 44.06 Favored 'General case' 0 C--O 1.24 0.584 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 179.035 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -96.39 118.84 33.75 Favored 'General case' 0 CA--C 1.507 -0.69 0 C-N-CA 120.44 -0.504 . . . . 0.0 110.166 175.274 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 44.3 pt -134.78 160.27 41.32 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.157 0 CA-C-N 115.453 -0.794 . . . . 0.0 109.856 -177.275 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -74.03 123.48 24.44 Favored 'General case' 0 C--N 1.311 -1.07 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 176.041 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 303' ' ' PHE . . . . . 0.402 ' CG ' ' N ' ' A' ' 304' ' ' LYS . 88.2 t80 -101.22 157.27 16.9 Favored 'General case' 0 C--N 1.312 -1.041 0 CA-C-N 116.145 -0.479 . . . . 0.0 109.855 -176.28 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . 0.402 ' N ' ' CG ' ' A' ' 303' ' ' PHE . 32.3 mmtp -47.74 107.33 0.12 Allowed 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.194 -0.457 . . . . 0.0 109.847 -177.554 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 70.1 m -71.68 143.08 49.82 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-N 116.333 -0.394 . . . . 0.0 109.991 178.327 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 48.1 mt -54.78 115.02 7.86 Favored Pre-proline 0 C--N 1.324 -0.52 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 177.222 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . 0.492 ' O ' ' N ' ' A' ' 309' ' ' SER . 53.1 Cg_exo -58.29 141.75 97.03 Favored 'Trans proline' 0 N--CA 1.495 1.596 0 C-N-CA 121.957 1.772 . . . . 0.0 111.262 -175.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -66.71 65.29 0.05 Allowed 'General case' 0 CA--C 1.516 -0.352 0 CA-C-O 121.309 0.576 . . . . 0.0 109.88 177.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.492 ' N ' ' O ' ' A' ' 307' ' ' PRO . 4.8 m -62.41 150.42 39.83 Favored 'General case' 0 C--N 1.31 -1.114 0 CA-C-N 115.496 -0.774 . . . . 0.0 109.534 -179.102 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 75.3 mt -68.68 76.66 0.29 Allowed 'General case' 0 C--N 1.323 -0.586 0 C-N-CA 120.393 -0.523 . . . . 0.0 110.206 -175.3 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 311' ' ' VAL . . . . . 0.556 ' O ' HG13 ' A' ' 311' ' ' VAL . 12.6 p -76.41 99.26 1.96 Allowed 'Isoleucine or valine' 0 C--O 1.243 0.73 0 CA-C-N 115.954 -0.567 . . . . 0.0 109.766 179.781 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 99.6 mt-10 . . . . . 0 C--O 1.21 -1.016 0 CA-C-O 118.491 -0.766 . . . . 0.0 110.11 -176.956 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . 0.543 ' O ' ' N ' ' A' ' 203' ' ' GLY . 14.1 mm-40 . . . . . 0 N--CA 1.48 1.041 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 202' ' ' PHE . . . . . 0.447 ' C ' ' H ' ' A' ' 204' ' ' GLU . 81.1 m-85 60.74 -57.83 0.09 Allowed 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 122.744 0.417 . . . . 0.0 110.584 -175.93 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . 0.543 ' N ' ' O ' ' A' ' 201' ' ' GLU . . . -73.49 42.27 1.02 Allowed Glycine 0 C--N 1.311 -0.825 0 N-CA-C 110.143 -1.183 . . . . 0.0 110.143 176.193 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 204' ' ' GLU . . . . . 0.524 ' OE2' ' N ' ' A' ' 201' ' ' GLU . 73.4 mm-40 -59.94 -33.22 71.61 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 -179.679 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 205' ' ' GLU . . . . . 0.438 ' O ' ' N ' ' A' ' 207' ' ' VAL . 99.8 mt-10 -62.01 -21.72 65.11 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 114.605 -1.18 . . . . 0.0 110.906 177.837 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 99.5 mtp -64.92 72.01 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.923 0.392 . . . . 0.0 111.397 -175.695 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . 0.438 ' N ' ' O ' ' A' ' 205' ' ' GLU . 8.3 m -121.3 127.96 75.86 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.095 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 170.728 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 67.8 mt -89.47 69.78 7.98 Favored 'General case' 0 C--N 1.319 -0.718 0 C-N-CA 119.637 -0.825 . . . . 0.0 109.914 -173.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 19.0 m -71.55 -41.56 68.96 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.103 -0.953 . . . . 0.0 110.278 176.275 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 9.8 p-10 -51.48 -27.25 9.97 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.351 -177.49 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 1.4 m -56.22 134.32 53.06 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 179.754 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 28.8 t-20 -92.05 135.54 33.88 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 112.433 0.531 . . . . 0.0 112.433 -174.418 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 73.44 20.39 79.85 Favored Glycine 0 N--CA 1.452 -0.275 0 CA-C-N 115.349 -0.841 . . . . 0.0 112.944 172.446 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -93.9 114.95 27.28 Favored 'General case' 0 C--O 1.239 0.538 0 CA-C-N 117.678 0.739 . . . . 0.0 110.172 176.287 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 11.9 mt-30 -113.2 109.06 52.14 Favored Pre-proline 0 C--N 1.319 -0.747 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.36 179.716 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -71.55 102.3 1.27 Allowed 'Trans proline' 0 C--N 1.312 -1.379 0 C-N-CA 121.139 1.226 . . . . 0.0 110.319 178.302 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 217' ' ' LEU . . . . . 0.494 HD12 ' O ' ' A' ' 239' ' ' ARG . 0.5 OUTLIER -90.29 125.7 35.6 Favored 'General case' 0 C--N 1.316 -0.88 0 CA-C-N 115.716 -0.675 . . . . 0.0 109.882 -179.487 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 34.5 m -119.19 132.57 55.97 Favored 'General case' 0 C--N 1.324 -0.532 0 O-C-N 123.661 0.601 . . . . 0.0 110.616 -179.652 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 219' ' ' ALA . . . . . 0.421 ' HB2' ' HA ' ' A' ' 240' ' ' HIS . . . -122.53 139.55 53.77 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.821 0.343 . . . . 0.0 110.259 -179.436 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 1.3 tpt -76.6 122.37 24.53 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 177.813 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 73.5 t -74.19 132.65 33.05 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 -177.642 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 222' ' ' SER . . . . . 0.408 ' HG ' HG22 ' A' ' 233' ' ' THR . 5.8 p -90.68 -54.64 3.9 Favored 'General case' 0 N--CA 1.434 -1.252 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 177.829 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -138.53 151.87 47.73 Favored 'General case' 0 C--O 1.222 -0.389 0 N-CA-C 112.649 0.611 . . . . 0.0 112.649 174.856 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 224' ' ' VAL . . . . . 0.726 HG11 ' SD ' ' A' ' 256' ' ' MET . 39.5 t -126.64 132.33 70.3 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 172.143 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -104.1 122.98 46.42 Favored 'General case' 0 C--N 1.313 -1.002 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 -177.817 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 226' ' ' LYS . . . . . 0.464 ' NZ ' ' OD1' ' A' ' 285' ' ' ASP . 0.0 OUTLIER -76.3 77.72 3.07 Favored 'General case' 0 C--O 1.234 0.265 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 179.379 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 227' ' ' ASP . . . . . 0.59 ' N ' ' OG1' ' A' ' 280' ' ' THR . 2.8 t0 -148.42 178.34 8.68 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.762 179.459 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 228' ' ' ASN . . . . . 0.489 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.1 OUTLIER -138.47 125.25 13.06 Favored Pre-proline 0 C--N 1.324 -0.507 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.21 176.43 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 229' ' ' PRO . . . . . 0.489 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 38.2 Cg_endo -65.0 144.76 62.38 Favored 'Cis proline' 0 N--CA 1.499 1.814 0 C-N-CA 123.286 -1.548 . . . . 0.0 110.564 -1.063 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . 0.548 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -68.66 136.96 29.95 Favored Glycine 0 N--CA 1.445 -0.732 0 N-CA-C 110.05 -1.22 . . . . 0.0 110.05 -177.915 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 231' ' ' VAL . . . . . 0.409 HG23 HD12 ' A' ' 270' ' ' LEU . 2.1 p -127.05 133.93 67.23 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 177.772 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 232' ' ' VAL . . . . . 0.436 HG22 ' CD1' ' A' ' 275' ' ' PHE . 0.6 OUTLIER -134.76 156.7 40.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 C-N-CA 120.084 -0.646 . . . . 0.0 111.451 -179.695 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 233' ' ' THR . . . . . 0.408 HG22 ' HG ' ' A' ' 222' ' ' SER . 6.7 m -111.37 140.68 45.75 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 115.148 -0.933 . . . . 0.0 109.044 178.755 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 44.5 m -107.92 155.97 19.71 Favored 'General case' 0 C--N 1.315 -0.903 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 176.621 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 40.3 tp -57.74 133.71 55.6 Favored 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 177.401 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -53.8 -46.57 71.1 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.145 0.498 . . . . 0.0 110.557 -170.599 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 59.1 mp0 -68.04 -20.33 64.98 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.93 -0.577 . . . . 0.0 112.375 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -73.93 94.84 2.38 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.629 -177.253 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 239' ' ' ARG . . . . . 0.494 ' O ' HD12 ' A' ' 217' ' ' LEU . 77.3 mtp85 -71.44 99.31 1.98 Allowed 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 176.149 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 240' ' ' HIS . . . . . 0.661 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 12.8 p80 -68.2 -42.97 79.1 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 120.791 0.329 . . . . 0.0 111.748 -176.182 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 80.32 14.42 80.31 Favored Glycine 0 C--N 1.315 -0.586 0 N-CA-C 110.791 -0.924 . . . . 0.0 110.791 -178.514 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 242' ' ' PHE . . . . . 0.513 ' CD1' ' HB3' ' A' ' 294' ' ' GLN . 5.2 m-30 -81.0 142.97 32.87 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -179.613 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 243' ' ' GLU . . . . . 0.402 ' H ' ' CB ' ' A' ' 246' ' ' ASP . 95.0 mt-10 -112.19 167.88 10.06 Favored 'General case' 0 CA--C 1.505 -0.76 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 172.882 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 244' ' ' THR . . . . . 0.523 HG23 ' HG3' ' A' ' 268' ' ' LYS . 21.1 m -62.58 126.24 26.65 Favored 'General case' 0 N--CA 1.436 -1.165 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 169.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . 0.5 ' HA2' ' CG ' ' A' ' 266' ' ' GLU . . . 82.04 7.21 88.14 Favored Glycine 0 C--N 1.309 -0.941 0 C-N-CA 120.902 -0.666 . . . . 0.0 111.717 -179.029 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 246' ' ' ASP . . . . . 0.41 ' O ' ' HA ' ' A' ' 266' ' ' GLU . 42.1 t0 -84.87 161.7 19.78 Favored 'General case' 0 C--O 1.235 0.305 0 C-N-CA 120.049 -0.66 . . . . 0.0 109.952 177.798 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 247' ' ' PHE . . . . . 0.472 ' HA ' ' O ' ' A' ' 265' ' ' MET . 30.1 m-85 -109.94 131.7 54.82 Favored 'General case' 0 C--O 1.242 0.702 0 N-CA-C 112.134 0.42 . . . . 0.0 112.134 -174.35 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.511 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 2.7 m -129.92 160.99 40.42 Favored 'Isoleucine or valine' 0 C--O 1.236 0.381 0 CA-C-N 115.89 -0.596 . . . . 0.0 111.884 -179.334 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 3.0 m -126.49 156.0 41.42 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 173.661 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 250' ' ' PHE . . . . . 0.627 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 91.9 m-85 -112.72 146.84 38.01 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-O 120.518 0.199 . . . . 0.0 111.072 -174.059 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 43.4 m -134.4 151.65 51.32 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.105 178.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 4.0 mm-40 41.91 37.12 0.74 Allowed 'General case' 0 C--O 1.245 0.832 0 N-CA-C 113.266 0.839 . . . . 0.0 113.266 174.671 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 0.464 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 79.2 t -89.56 129.98 39.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 174.641 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . 0.574 HE22 ' CZ ' ' A' ' 288' ' ' ARG . 75.3 mt-30 -99.3 141.32 32.23 Favored 'General case' 0 C--O 1.24 0.577 0 C-N-CA 120.523 -0.471 . . . . 0.0 111.222 -178.249 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 79.61 -57.22 4.49 Favored Glycine 0 CA--C 1.507 -0.438 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -177.081 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 256' ' ' MET . . . . . 0.726 ' SD ' HG11 ' A' ' 224' ' ' VAL . 4.2 ttm -86.74 49.59 1.84 Allowed 'General case' 0 C--N 1.314 -0.949 0 CA-C-O 121.911 0.862 . . . . 0.0 108.721 176.344 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 257' ' ' ILE . . . . . 0.481 ' O ' ' HB2' ' A' ' 260' ' ' ASN . 46.5 pt -68.22 -24.32 29.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 114.453 -1.249 . . . . 0.0 110.917 -174.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 258' ' ' GLN . . . . . 0.585 ' HG3' ' SG ' ' A' ' 262' ' ' CYS . 69.2 tp60 -57.68 -30.07 65.17 Favored 'General case' 0 C--N 1.318 -0.795 0 C-N-CA 119.458 -0.897 . . . . 0.0 109.608 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 259' ' ' LEU . . . . . 0.902 HD21 ' CE2' ' A' ' 283' ' ' PHE . 94.3 mt -62.07 -40.21 95.03 Favored 'General case' 0 N--CA 1.448 -0.55 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 174.038 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 260' ' ' ASN . . . . . 0.481 ' HB2' ' O ' ' A' ' 257' ' ' ILE . 96.8 m-20 -60.31 -40.89 92.18 Favored 'General case' 0 CA--C 1.514 -0.431 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 179.58 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -98.33 17.65 58.22 Favored Glycine 0 CA--C 1.525 0.706 0 CA-C-N 115.447 -0.797 . . . . 0.0 112.005 -179.392 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 262' ' ' CYS . . . . . 0.585 ' SG ' ' HG3' ' A' ' 258' ' ' GLN . 1.5 m -93.97 146.59 23.82 Favored 'General case' 0 CA--C 1.508 -0.661 0 C-N-CA 120.579 -0.448 . . . . 0.0 111.032 -179.379 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 46.6 mt-30 -59.81 161.2 12.37 Favored Pre-proline 0 C--N 1.323 -0.548 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 172.277 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 264' ' ' PRO . . . . . 0.511 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 38.0 Cg_endo -63.37 143.39 88.67 Favored 'Trans proline' 0 C--N 1.307 -1.651 0 N-CA-C 108.437 -1.409 . . . . 0.0 108.437 174.974 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 265' ' ' MET . . . . . 0.472 ' O ' ' HA ' ' A' ' 247' ' ' PHE . 22.7 ptp -135.35 152.36 51.37 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 112.071 0.397 . . . . 0.0 112.071 -171.222 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 266' ' ' GLU . . . . . 0.5 ' CG ' ' HA2' ' A' ' 245' ' ' GLY . 39.5 tt0 -71.79 136.94 47.27 Favored 'General case' 0 C--N 1.331 -0.228 0 O-C-N 124.034 0.834 . . . . 0.0 109.516 178.757 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 267' ' ' ILE . . . . . 0.68 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.9 pp -128.3 162.39 34.85 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-O 121.142 0.496 . . . . 0.0 112.1 -179.346 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . 0.523 ' HG3' HG23 ' A' ' 244' ' ' THR . 60.1 tttm -118.98 131.52 56.02 Favored 'General case' 0 C--O 1.219 -0.501 0 CA-C-N 115.66 -0.7 . . . . 0.0 109.541 174.081 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . . . . . . . . . 23.2 m -82.4 128.21 38.93 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.974 0 C-N-CA 120.313 -0.555 . . . . 0.0 110.276 176.822 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 270' ' ' LEU . . . . . 0.547 HD11 ' HB3' ' A' ' 276' ' ' SER . 95.6 mt -98.99 -17.89 18.07 Favored 'General case' 0 CA--C 1.502 -0.871 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 178.298 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -171.27 177.0 44.4 Favored Glycine 0 N--CA 1.443 -0.872 0 N-CA-C 108.546 -1.821 . . . . 0.0 108.546 179.092 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 272' ' ' PRO . . . . . 0.661 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 60.2 Cg_exo -54.07 -38.32 87.09 Favored 'Trans proline' 0 C--N 1.298 -2.091 0 C-N-CA 121.443 1.429 . . . . 0.0 110.559 -179.219 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 273' ' ' TYR . . . . . . . . . . . . . 8.9 m-85 -118.69 11.57 12.8 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 112.646 0.61 . . . . 0.0 112.646 -174.455 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 22.2 p -130.13 143.59 50.87 Favored 'General case' 0 C--O 1.242 0.675 0 C-N-CA 120.669 -0.413 . . . . 0.0 111.177 177.158 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 275' ' ' PHE . . . . . 0.521 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -146.59 165.85 28.26 Favored 'General case' 0 C--O 1.246 0.869 0 N-CA-C 112.363 0.505 . . . . 0.0 112.363 178.75 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . 0.547 ' HB3' HD11 ' A' ' 270' ' ' LEU . 4.4 p -130.88 143.01 50.42 Favored 'General case' 0 N--CA 1.431 -1.416 0 CA-C-O 121.773 0.797 . . . . 0.0 111.605 -178.695 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . 0.624 HG22 HG22 ' A' ' 267' ' ' ILE . 33.8 pt -135.91 165.32 29.95 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.058 0 CA-C-N 114.428 -1.26 . . . . 0.0 110.71 -173.136 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 15.2 t -30.54 -90.71 0.0 OUTLIER 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 112.859 0.689 . . . . 0.0 112.859 -174.874 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . 0.481 ' CG ' ' HB2' ' A' ' 228' ' ' ASN . 66.3 t0 -148.93 117.18 6.43 Favored 'General case' 0 N--CA 1.447 -0.593 0 CA-C-O 120.943 0.402 . . . . 0.0 110.827 -178.91 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . 0.734 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 21.3 p -65.49 -27.33 68.41 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.54 176.56 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -64.35 -19.36 65.41 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.664 175.889 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -88.49 -9.88 50.91 Favored 'General case' 0 CA--C 1.508 -0.655 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.378 179.839 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . 0.902 ' CE2' HD21 ' A' ' 259' ' ' LEU . 4.4 m-85 -93.69 -64.96 1.03 Allowed 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 174.303 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 284' ' ' SER . . . . . 0.422 ' OG ' ' HA ' ' A' ' 256' ' ' MET . 1.9 p 169.43 -94.18 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 115.205 -0.907 . . . . 0.0 111.625 177.242 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 285' ' ' ASP . . . . . 0.531 ' O ' ' N ' ' A' ' 256' ' ' MET . 45.0 t0 -156.19 166.09 34.46 Favored 'General case' 0 C--O 1.214 -0.786 0 N-CA-C 110.409 -0.219 . . . . 0.0 110.409 -177.308 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . 0.515 ' CZ ' ' HA ' ' A' ' 288' ' ' ARG . 68.2 t80 -99.61 119.4 38.02 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 110.226 -0.287 . . . . 0.0 110.226 177.359 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 21.1 mm -99.91 -56.44 5.2 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.586 0 N-CA-C 109.114 -0.698 . . . . 0.0 109.114 173.575 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . 0.574 ' CZ ' HE22 ' A' ' 254' ' ' GLN . 45.9 ptt85 177.87 -173.92 0.14 Allowed 'General case' 0 C--O 1.241 0.639 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.145 175.532 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 66.16 -158.93 47.67 Favored Glycine 0 CA--C 1.51 -0.281 0 N-CA-C 111.018 -0.833 . . . . 0.0 111.018 176.619 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 110.6 127.15 5.16 Favored Glycine 0 N--CA 1.447 -0.592 0 CA-C-O 121.52 0.511 . . . . 0.0 112.988 175.224 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 94.2 mt -130.32 133.07 64.5 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.807 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 174.312 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 3.8 p -124.52 134.29 67.14 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 C-N-CA 120.442 -0.503 . . . . 0.0 109.669 -177.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . 0.477 ' HA ' ' O ' ' A' ' 217' ' ' LEU . 2.6 m -127.23 145.43 50.77 Favored 'General case' 0 C--N 1.324 -0.532 0 C-N-CA 120.488 -0.485 . . . . 0.0 111.042 -178.364 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 294' ' ' GLN . . . . . 0.513 ' HB3' ' CD1' ' A' ' 242' ' ' PHE . 0.3 OUTLIER -84.27 148.74 26.53 Favored 'General case' 0 CA--C 1.508 -0.659 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.185 176.661 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 59.0 t -122.3 128.29 75.43 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.926 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 177.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 296' ' ' LYS . . . . . 0.405 ' NZ ' ' O ' ' A' ' 297' ' ' VAL . 24.6 tptp -83.95 98.07 9.6 Favored 'General case' 0 N--CA 1.441 -0.905 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 174.56 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 297' ' ' VAL . . . . . 0.46 HG23 ' NZ ' ' A' ' 299' ' ' LYS . 26.5 m -80.89 162.12 61.01 Favored Pre-proline 0 C--N 1.312 -1.036 0 CA-C-N 115.798 -0.637 . . . . 0.0 109.928 -176.628 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 298' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -56.84 138.11 84.33 Favored 'Trans proline' 0 C--N 1.304 -1.768 0 C-N-CA 121.516 1.477 . . . . 0.0 112.1 -177.205 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . 0.46 ' NZ ' HG23 ' A' ' 297' ' ' VAL . 33.2 mmtm -139.25 -174.42 3.86 Favored 'General case' 0 C--N 1.314 -0.973 0 CA-C-N 114.611 -1.177 . . . . 0.0 108.371 177.115 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 300' ' ' LYS . . . . . 0.421 ' O ' ' N ' ' A' ' 302' ' ' SER . 8.1 tttm -69.74 122.73 19.76 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 168.057 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 99.1 mt -61.65 89.07 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-O 121.565 0.697 . . . . 0.0 110.032 -175.805 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 302' ' ' SER . . . . . 0.421 ' N ' ' O ' ' A' ' 300' ' ' LYS . 0.7 OUTLIER -134.03 85.14 2.17 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-N 114.894 -1.048 . . . . 0.0 109.716 -177.081 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 27.2 p90 -104.68 130.09 52.76 Favored 'General case' 0 C--O 1.242 0.667 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.71 -177.693 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 32.6 tttp -48.74 107.59 0.14 Allowed 'General case' 0 CA--C 1.51 -0.562 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.516 -174.733 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 8.5 m -130.32 148.48 52.15 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.286 179.72 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -90.05 127.36 53.9 Favored Pre-proline 0 C--N 1.322 -0.589 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 176.821 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -65.21 -25.2 57.83 Favored 'Trans proline' 0 C--N 1.306 -1.659 0 C-N-CA 121.961 1.774 . . . . 0.0 111.412 178.769 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -97.99 -178.14 3.98 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.899 -0.591 . . . . 0.0 111.621 -178.15 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 5.4 p -77.0 -161.56 0.22 Allowed 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.476 -0.784 . . . . 0.0 110.313 177.904 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 51.2 tp -62.89 133.09 54.14 Favored 'General case' 0 CA--C 1.508 -0.66 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 175.667 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 16.5 m -114.8 129.01 71.67 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-O 120.882 0.373 . . . . 0.0 111.055 -177.598 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 33.0 mp0 . . . . . 0 C--O 1.209 -1.069 0 CA-C-O 117.735 -1.126 . . . . 0.0 108.939 -179.803 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 . . . . . 0 N--CA 1.477 0.893 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 202' ' ' PHE . . . . . . . . . . . . . 9.4 m-30 66.55 13.43 9.29 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.4 -179.404 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -57.44 -21.28 40.74 Favored Glycine 0 C--O 1.237 0.303 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 177.105 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 204' ' ' GLU . . . . . 0.49 ' CD ' ' H ' ' A' ' 204' ' ' GLU . 0.5 OUTLIER -40.37 -29.86 0.09 Allowed 'General case' 0 C--O 1.237 0.405 0 C-N-CA 123.514 0.726 . . . . 0.0 111.343 -179.316 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 205' ' ' GLU . . . . . 0.46 ' O ' ' N ' ' A' ' 207' ' ' VAL . 98.8 mt-10 -60.79 -30.67 70.19 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.581 -177.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 206' ' ' MET . . . . . . . . . . . . . 7.0 tpt -67.04 71.0 0.09 Allowed 'General case' 0 C--N 1.327 -0.383 0 C-N-CA 119.846 -0.742 . . . . 0.0 109.845 -178.543 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . 0.46 ' N ' ' O ' ' A' ' 205' ' ' GLU . 15.3 m -139.11 155.3 26.48 Favored 'Isoleucine or valine' 0 C--O 1.239 0.539 0 CA-C-N 115.607 -0.724 . . . . 0.0 109.86 177.179 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 208' ' ' LEU . . . . . 0.423 HD11 ' HB3' ' A' ' 298' ' ' PRO . 90.3 mt -123.58 70.28 1.05 Allowed 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.061 0.458 . . . . 0.0 110.218 176.363 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 209' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -118.96 33.26 5.73 Favored 'General case' 0 C--N 1.311 -1.098 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.433 176.796 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -61.31 -43.92 98.06 Favored 'General case' 0 CA--C 1.513 -0.449 0 CA-C-N 115.13 -0.941 . . . . 0.0 110.385 -174.86 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 211' ' ' SER . . . . . . . . . . . . . 2.8 m -89.59 149.29 22.91 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.001 -179.129 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 58.9 t-20 -98.55 111.94 24.14 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 174.411 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 118.91 -8.59 12.66 Favored Glycine 0 C--O 1.24 0.512 0 N-CA-C 111.905 -0.478 . . . . 0.0 111.905 179.655 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 214' ' ' GLU . . . . . . . . . . . . . 92.7 mt-10 -84.01 112.92 20.62 Favored 'General case' 0 C--O 1.238 0.472 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 175.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 215' ' ' GLN . . . . . . . . . . . . . 27.5 mt-30 -110.95 142.12 25.58 Favored Pre-proline 0 C--N 1.323 -0.58 0 N-CA-C 109.581 -0.525 . . . . 0.0 109.581 177.724 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_exo -60.25 142.58 98.53 Favored 'Trans proline' 0 C--N 1.309 -1.539 0 C-N-CA 121.407 1.405 . . . . 0.0 108.797 173.678 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 217' ' ' LEU . . . . . 0.476 HD12 ' O ' ' A' ' 240' ' ' HIS . 0.1 OUTLIER -61.55 118.7 7.38 Favored 'General case' 0 C--N 1.324 -0.501 0 C-N-CA 119.413 -0.915 . . . . 0.0 109.51 -177.686 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 4.6 m -126.3 147.95 49.62 Favored 'General case' 0 C--N 1.313 -1.011 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.335 -176.374 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 219' ' ' ALA . . . . . 0.487 ' HB1' ' HB1' ' A' ' 238' ' ' ALA . . . -152.5 153.8 34.22 Favored 'General case' 0 C--O 1.24 0.605 0 CA-C-O 121.112 0.482 . . . . 0.0 111.062 -178.709 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 71.3 mtm -80.15 129.67 34.66 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.652 -0.703 . . . . 0.0 109.662 175.9 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 57.5 t -76.29 131.24 35.25 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.694 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 177.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 46.8 p -88.72 -65.84 0.98 Allowed 'General case' 0 C--N 1.309 -1.169 0 C-N-CA 120.325 -0.55 . . . . 0.0 110.024 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 23.3 ptm -137.73 142.43 40.99 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.923 -0.58 . . . . 0.0 112.205 176.581 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 224' ' ' VAL . . . . . 0.885 HG22 ' HB ' ' A' ' 232' ' ' VAL . 75.0 t -119.89 133.57 66.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 177.294 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . 0.478 ' O ' ' OG1' ' A' ' 280' ' ' THR . 62.7 p -98.5 128.6 44.91 Favored 'General case' 0 C--N 1.323 -0.569 0 C-N-CA 120.234 -0.587 . . . . 0.0 110.974 -179.517 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.86 85.76 3.44 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 177.908 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 227' ' ' ASP . . . . . 0.403 ' OD1' ' N ' ' A' ' 228' ' ' ASN . 2.6 t0 -152.04 175.82 12.15 Favored 'General case' 0 N--CA 1.469 0.521 0 CA-C-N 116.476 -0.329 . . . . 0.0 111.39 -175.495 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 228' ' ' ASN . . . . . 0.502 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 9.4 t30 -140.69 124.09 10.17 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.508 174.625 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 229' ' ' PRO . . . . . 0.502 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 40.4 Cg_endo -65.22 142.24 52.16 Favored 'Cis proline' 0 N--CA 1.493 1.488 0 C-N-CA 122.702 -1.791 . . . . 0.0 109.854 -1.12 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . 0.493 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -74.39 136.84 21.84 Favored Glycine 0 C--N 1.315 -0.629 0 N-CA-C 110.575 -1.01 . . . . 0.0 110.575 -176.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.1 p -127.69 137.74 56.75 Favored 'Isoleucine or valine' 0 C--O 1.248 0.997 0 CA-C-O 120.807 0.337 . . . . 0.0 110.697 177.574 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 232' ' ' VAL . . . . . 0.885 ' HB ' HG22 ' A' ' 224' ' ' VAL . 0.7 OUTLIER -132.28 157.17 43.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.951 179.292 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 233' ' ' THR . . . . . 0.47 ' HA ' ' O ' ' A' ' 273' ' ' TYR . 0.9 OUTLIER -114.36 146.96 39.88 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.388 -178.836 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 34.0 m -107.31 152.24 24.4 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.111 -0.495 . . . . 0.0 109.948 179.263 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . 0.482 ' HB3' ' HB3' ' A' ' 238' ' ' ALA . 15.7 tp -51.72 135.09 29.78 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 -178.881 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 24.7 p-10 -48.63 -47.44 40.2 Favored 'General case' 0 N--CA 1.475 0.793 0 N-CA-C 111.936 0.347 . . . . 0.0 111.936 -171.838 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -70.51 -34.65 72.55 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-O 120.944 0.402 . . . . 0.0 111.62 178.218 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . 0.487 ' HB1' ' HB1' ' A' ' 219' ' ' ALA . . . -83.96 89.42 7.23 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.262 -176.615 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 239' ' ' ARG . . . . . 0.52 ' NH1' ' O ' ' A' ' 239' ' ' ARG . 0.0 OUTLIER -78.83 123.16 26.94 Favored 'General case' 0 CA--C 1.513 -0.443 0 N-CA-C 108.771 -0.825 . . . . 0.0 108.771 173.698 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 240' ' ' HIS . . . . . 0.602 ' H ' ' CD2' ' A' ' 240' ' ' HIS . 7.0 p80 -57.13 -48.71 77.98 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.397 -175.818 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 80.01 19.93 68.84 Favored Glycine 0 C--N 1.314 -0.666 0 N-CA-C 110.131 -1.188 . . . . 0.0 110.131 -177.674 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 242' ' ' PHE . . . . . 0.681 ' CD2' HG11 ' A' ' 248' ' ' VAL . 8.3 m-30 -81.53 151.87 27.54 Favored 'General case' 0 C--N 1.316 -0.877 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 177.946 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 243' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -116.19 160.78 19.92 Favored 'General case' 0 C--N 1.314 -0.935 0 CA-C-O 120.893 0.378 . . . . 0.0 110.887 177.491 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 244' ' ' THR . . . . . 0.527 HG23 HG22 ' A' ' 269' ' ' VAL . 0.0 OUTLIER -58.84 125.88 25.37 Favored 'General case' 0 C--N 1.312 -1.029 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 -179.65 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 80.86 5.81 89.83 Favored Glycine 0 C--N 1.319 -0.365 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 -178.326 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 246' ' ' ASP . . . . . 0.509 ' CG ' HE21 ' A' ' 294' ' ' GLN . 5.3 t70 -79.86 162.34 25.09 Favored 'General case' 0 CA--C 1.514 -0.42 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 178.416 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 247' ' ' PHE . . . . . . . . . . . . . 78.0 m-85 -109.78 129.04 55.67 Favored 'General case' 0 C--O 1.242 0.708 0 CA-C-O 120.846 0.355 . . . . 0.0 111.191 -177.488 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.681 HG11 ' CD2' ' A' ' 242' ' ' PHE . 2.4 m -129.95 162.26 38.01 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.399 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.364 178.369 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.48 145.82 46.87 Favored 'General case' 0 C--N 1.308 -1.226 0 CA-C-N 115.324 -0.853 . . . . 0.0 109.982 177.363 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 250' ' ' PHE . . . . . 0.649 ' CD2' HD22 ' A' ' 259' ' ' LEU . 67.5 m-85 -104.81 145.68 30.04 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.65 177.701 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 4.3 m -143.36 150.12 38.69 Favored 'General case' 0 C--N 1.309 -1.153 0 N-CA-C 110.084 -0.339 . . . . 0.0 110.084 176.07 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 23.7 mm-40 54.1 26.78 6.86 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 112.816 0.673 . . . . 0.0 112.816 173.07 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 0.517 ' O ' ' ND2' ' A' ' 260' ' ' ASN . 88.0 t -76.53 130.93 35.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 173.702 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 86.5 mm-40 -100.45 139.72 35.72 Favored 'General case' 0 C--O 1.244 0.765 0 C-N-CA 119.68 -0.808 . . . . 0.0 111.651 -176.152 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 78.71 -58.16 4.21 Favored Glycine 0 C--O 1.239 0.453 0 N-CA-C 108.983 -1.647 . . . . 0.0 108.983 -173.688 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 256' ' ' MET . . . . . 0.566 ' SD ' HG11 ' A' ' 224' ' ' VAL . 31.7 mtt -80.57 61.04 4.14 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-O 121.242 0.544 . . . . 0.0 109.788 172.682 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 257' ' ' ILE . . . . . 0.401 ' O ' ' HB2' ' A' ' 260' ' ' ASN . 41.8 pt -76.23 -15.78 15.14 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.731 -178.512 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 258' ' ' GLN . . . . . 0.414 ' O ' ' N ' ' A' ' 262' ' ' CYS . 70.5 tp60 -55.38 -39.31 69.99 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 179.423 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 259' ' ' LEU . . . . . 0.91 HD21 ' CE2' ' A' ' 283' ' ' PHE . 89.0 mt -61.86 -41.71 98.17 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.747 -0.661 . . . . 0.0 109.925 176.908 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 260' ' ' ASN . . . . . 0.517 ' ND2' ' O ' ' A' ' 253' ' ' VAL . 97.9 m-20 -61.29 -40.58 94.67 Favored 'General case' 0 CA--C 1.509 -0.612 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 179.347 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -87.66 -5.67 78.0 Favored Glycine 0 CA--C 1.523 0.538 0 CA-C-N 115.529 -0.76 . . . . 0.0 111.496 -178.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 262' ' ' CYS . . . . . 0.414 ' N ' ' O ' ' A' ' 258' ' ' GLN . 49.0 t -87.98 150.58 23.36 Favored 'General case' 0 CA--C 1.512 -0.493 0 CA-C-O 120.765 0.317 . . . . 0.0 111.062 -178.285 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . 0.642 ' CD ' ' H ' ' A' ' 263' ' ' GLN . 0.0 OUTLIER -72.45 169.39 17.09 Favored Pre-proline 0 C--N 1.319 -0.758 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 172.631 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 264' ' ' PRO . . . . . 0.454 ' HA ' ' O ' ' A' ' 248' ' ' VAL . 27.7 Cg_exo -61.76 145.12 97.5 Favored 'Trans proline' 0 C--N 1.307 -1.608 0 C-N-CA 121.462 1.441 . . . . 0.0 109.983 179.099 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 265' ' ' MET . . . . . 0.655 ' N ' ' SD ' ' A' ' 265' ' ' MET . 0.8 OUTLIER -122.83 157.26 32.85 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 -176.466 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 266' ' ' GLU . . . . . 0.403 ' HA ' ' O ' ' A' ' 246' ' ' ASP . 64.1 tt0 -75.94 134.85 40.12 Favored 'General case' 0 C--O 1.238 0.493 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 175.513 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 267' ' ' ILE . . . . . 0.703 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.9 pp -128.66 163.3 33.63 Favored 'Isoleucine or valine' 0 C--O 1.237 0.405 0 N-CA-C 114.095 1.146 . . . . 0.0 114.095 -170.495 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . 0.493 ' NZ ' ' OG ' ' A' ' 276' ' ' SER . 8.0 mtpm? -119.36 123.31 43.84 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-N 115.009 -0.996 . . . . 0.0 110.065 178.737 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.527 HG22 HG23 ' A' ' 244' ' ' THR . 30.1 m -84.59 97.93 5.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-O 121.087 0.47 . . . . 0.0 111.236 177.056 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 91.9 mt -66.79 -40.4 88.14 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.528 0.68 . . . . 0.0 109.747 176.38 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -155.33 -177.85 28.99 Favored Glycine 0 N--CA 1.447 -0.624 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 -179.827 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 272' ' ' PRO . . . . . 0.5 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 35.6 Cg_endo -61.32 -30.88 88.49 Favored 'Trans proline' 0 C--N 1.306 -1.702 0 C-N-CA 122.066 1.844 . . . . 0.0 111.471 -178.519 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 273' ' ' TYR . . . . . 0.47 ' O ' ' HA ' ' A' ' 233' ' ' THR . 94.5 m-85 -122.85 7.0 9.33 Favored 'General case' 0 C--N 1.319 -0.733 0 N-CA-C 112.942 0.719 . . . . 0.0 112.942 -178.497 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 4.3 p -126.84 129.02 47.45 Favored 'General case' 0 C--O 1.244 0.816 0 CA-C-O 120.884 0.374 . . . . 0.0 110.835 178.031 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 275' ' ' PHE . . . . . 0.518 ' HD2' HD13 ' A' ' 267' ' ' ILE . 0.0 OUTLIER -139.41 160.47 39.76 Favored 'General case' 0 CA--C 1.499 -0.986 0 C-N-CA 120.446 -0.502 . . . . 0.0 112.206 177.281 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . 0.493 ' OG ' ' NZ ' ' A' ' 268' ' ' LYS . 10.9 p -130.79 154.49 47.95 Favored 'General case' 0 N--CA 1.43 -1.427 0 CA-C-O 121.456 0.646 . . . . 0.0 111.953 -175.11 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . 0.672 ' C ' HD12 ' A' ' 277' ' ' ILE . 2.5 pp -138.19 -172.48 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.154 0 CA-C-N 114.313 -1.312 . . . . 0.0 108.961 -176.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 278' ' ' CYS . . . . . 0.524 ' N ' HD12 ' A' ' 277' ' ' ILE . 0.5 OUTLIER -48.14 -85.93 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.751 0.31 . . . . 0.0 111.708 -178.245 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . . . . . . . . . 31.7 t0 -145.0 115.45 7.62 Favored 'General case' 0 CA--C 1.515 -0.397 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.534 -177.625 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . 0.69 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 12.6 p -71.42 -22.66 61.83 Favored 'General case' 0 N--CA 1.432 -1.37 0 CA-C-O 121.108 0.48 . . . . 0.0 109.77 176.294 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 281' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -67.37 -19.85 65.48 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 174.765 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 282' ' ' ASN . . . . . . . . . . . . . 26.8 t-20 -89.2 -9.16 51.83 Favored 'General case' 0 CA--C 1.505 -0.752 0 CA-C-N 115.662 -0.699 . . . . 0.0 109.637 178.408 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . 0.91 ' CE2' HD21 ' A' ' 259' ' ' LEU . 22.8 m-30 -84.28 -79.0 0.22 Allowed 'General case' 0 N--CA 1.441 -0.906 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 174.612 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 284' ' ' SER . . . . . 0.436 ' CB ' ' HA ' ' A' ' 256' ' ' MET . 0.0 OUTLIER 175.01 -165.21 0.03 OUTLIER 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 114.892 -1.049 . . . . 0.0 109.589 -175.674 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 27.7 t0 -92.81 118.64 31.32 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.643 0.259 . . . . 0.0 111.301 178.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . 0.493 ' HB2' ' SD ' ' A' ' 256' ' ' MET . 6.1 t80 -68.86 122.0 17.73 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.6 179.341 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 287' ' ' ILE . . . . . . . . . . . . . 96.4 mt -103.0 -59.9 3.15 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 175.027 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . . . . . . . . . 50.8 ptt85 179.7 -163.04 0.04 OUTLIER 'General case' 0 C--O 1.24 0.553 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.397 174.755 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 68.83 -147.93 47.3 Favored Glycine 0 C--O 1.237 0.336 0 N-CA-C 109.811 -1.316 . . . . 0.0 109.811 -179.05 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 87.13 122.11 1.53 Allowed Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.823 175.111 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 97.7 mt -118.19 128.9 75.18 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.137 0 N-CA-C 107.262 -1.385 . . . . 0.0 107.262 172.346 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 14.9 p -116.94 128.92 74.24 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 -179.658 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 3.4 m -134.52 143.52 47.49 Favored 'General case' 0 N--CA 1.439 -0.996 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.409 -176.903 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 294' ' ' GLN . . . . . 0.509 HE21 ' CG ' ' A' ' 246' ' ' ASP . 52.6 tt0 -67.07 151.88 46.79 Favored 'General case' 0 N--CA 1.432 -1.358 0 CA-C-N 115.378 -0.828 . . . . 0.0 108.924 173.88 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 61.6 t -106.59 126.17 62.41 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 N-CA-C 107.975 -1.121 . . . . 0.0 107.975 176.398 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 2.6 tmtm? -66.01 98.99 0.46 Allowed 'General case' 0 N--CA 1.438 -1.046 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 -178.508 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 297' ' ' VAL . . . . . 0.401 ' O ' ' HG3' ' A' ' 299' ' ' LYS . 52.9 t -103.53 129.24 25.77 Favored Pre-proline 0 C--N 1.306 -1.303 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 179.211 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 298' ' ' PRO . . . . . 0.423 ' HB3' HD11 ' A' ' 208' ' ' LEU . 37.4 Cg_endo -68.8 86.13 0.47 Allowed 'Trans proline' 0 C--N 1.302 -1.872 0 N-CA-C 108.232 -1.488 . . . . 0.0 108.232 176.229 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . 0.477 ' NZ ' ' OD2' ' A' ' 246' ' ' ASP . 66.8 mttm -68.23 125.51 26.62 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.477 -171.734 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 300' ' ' LYS . . . . . . . . . . . . . 19.0 pttm -129.99 130.4 44.96 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.409 176.573 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 301' ' ' ILE . . . . . . . . . . . . . 47.0 pt -136.05 147.13 28.32 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.231 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 176.141 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -85.65 77.44 9.81 Favored 'General case' 0 C--N 1.313 -0.999 0 N-CA-C 107.65 -1.241 . . . . 0.0 107.65 175.111 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 303' ' ' PHE . . . . . . . . . . . . . 16.9 t80 -165.08 145.78 7.33 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 114.754 -1.112 . . . . 0.0 108.92 -177.401 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 42.6 tttm -78.77 143.84 35.73 Favored 'General case' 0 C--N 1.313 -1.012 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 174.627 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 2.0 m -48.11 138.37 9.44 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.915 0.388 . . . . 0.0 111.755 -171.649 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 306' ' ' LEU . . . . . 0.841 ' H ' HD12 ' A' ' 306' ' ' LEU . 0.4 OUTLIER -92.45 162.39 29.87 Favored Pre-proline 0 C--N 1.327 -0.406 0 CA-C-N 115.703 -0.68 . . . . 0.0 109.912 179.602 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . 0.411 ' HD2' ' HB3' ' A' ' 306' ' ' LEU . 74.1 Cg_endo -73.88 42.5 0.72 Allowed 'Trans proline' 0 N--CA 1.493 1.452 0 C-N-CA 122.272 1.981 . . . . 0.0 111.678 178.763 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -78.6 86.3 4.6 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 177.043 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 4.8 m -68.4 137.89 54.9 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.698 -173.786 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 310' ' ' LEU . . . . . 0.651 ' O ' HG13 ' A' ' 311' ' ' VAL . 75.6 mt -117.1 126.71 53.25 Favored 'General case' 0 C--O 1.235 0.303 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 174.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 311' ' ' VAL . . . . . 0.651 HG13 ' O ' ' A' ' 310' ' ' LEU . 0.3 OUTLIER -162.9 146.74 3.42 Favored 'Isoleucine or valine' 0 C--O 1.236 0.352 0 O-C-N 123.409 0.443 . . . . 0.0 111.225 177.796 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 68.0 mt-10 . . . . . 0 C--O 1.211 -0.973 0 CA-C-O 118.496 -0.764 . . . . 0.0 109.86 175.096 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . 0.485 ' OE1' ' N ' ' A' ' 201' ' ' GLU . 0.0 OUTLIER . . . . . 0 N--CA 1.483 1.184 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 . . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 202' ' ' PHE . . . . . 0.631 ' CE2' ' HG3' ' A' ' 206' ' ' MET . 34.8 t80 -57.32 -42.01 81.02 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.594 -0.73 . . . . 0.0 109.731 -179.853 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 203' ' ' GLY . . . . . . . . . . . . . . . -53.02 -24.56 20.95 Favored Glycine 0 C--N 1.314 -0.69 0 CA-C-N 115.352 -0.84 . . . . 0.0 111.356 176.844 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 204' ' ' GLU . . . . . . . . . . . . . 64.9 mt-10 -64.59 -46.84 80.96 Favored 'General case' 0 CA--C 1.508 -0.64 0 C-N-CA 119.373 -0.931 . . . . 0.0 109.174 177.04 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 205' ' ' GLU . . . . . . . . . . . . . 3.9 mp0 -70.84 -38.37 73.19 Favored 'General case' 0 N--CA 1.444 -0.761 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 174.885 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 206' ' ' MET . . . . . 0.631 ' HG3' ' CE2' ' A' ' 202' ' ' PHE . 26.4 mmt -89.64 79.82 6.74 Favored 'General case' 0 C--O 1.24 0.6 0 CA-C-N 115.517 -0.765 . . . . 0.0 112.252 -178.515 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . 0.504 ' O ' ' N ' ' A' ' 209' ' ' THR . 3.7 m -114.45 131.45 66.46 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.098 0 N-CA-C 107.542 -1.281 . . . . 0.0 107.542 169.685 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 208' ' ' LEU . . . . . . . . . . . . . 86.6 mt -62.61 75.86 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.478 0.656 . . . . 0.0 110.366 -172.151 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 209' ' ' THR . . . . . 0.504 ' N ' ' O ' ' A' ' 207' ' ' VAL . 1.2 p -123.36 3.95 9.11 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 114.774 -1.103 . . . . 0.0 111.573 -177.251 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 210' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -51.77 -42.49 62.44 Favored 'General case' 0 CA--C 1.509 -0.615 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 -179.824 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 211' ' ' SER . . . . . 0.511 ' CB ' ' HG3' ' A' ' 214' ' ' GLU . 1.5 m -115.04 118.35 33.16 Favored 'General case' 0 C--N 1.309 -1.176 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 174.432 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 212' ' ' ASN . . . . . . . . . . . . . 16.0 t-20 -95.66 121.56 37.49 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 112.767 0.654 . . . . 0.0 112.767 -173.885 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 213' ' ' GLY . . . . . . . . . . . . . . . 71.85 40.79 57.21 Favored Glycine 0 C--O 1.236 0.264 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.996 174.059 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 214' ' ' GLU . . . . . 0.511 ' HG3' ' CB ' ' A' ' 211' ' ' SER . 16.9 mm-40 -87.48 99.19 11.84 Favored 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 120.415 -0.514 . . . . 0.0 110.893 179.411 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 215' ' ' GLN . . . . . 0.505 ' H ' ' CD ' ' A' ' 215' ' ' GLN . 0.0 OUTLIER -76.77 129.69 78.36 Favored Pre-proline 0 C--N 1.317 -0.842 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 173.303 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 216' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -56.15 133.93 61.04 Favored 'Trans proline' 0 C--N 1.31 -1.452 0 C-N-CA 121.053 1.169 . . . . 0.0 110.524 -177.029 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 217' ' ' LEU . . . . . 0.459 HD22 ' HA ' ' A' ' 217' ' ' LEU . 0.3 OUTLIER -79.04 141.93 36.99 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.242 -178.881 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 218' ' ' SER . . . . . . . . . . . . . 96.4 p -155.06 164.3 39.07 Favored 'General case' 0 N--CA 1.446 -0.652 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.258 -177.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 219' ' ' ALA . . . . . . . . . . . . . . . -154.5 163.22 40.52 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-N 115.548 -0.751 . . . . 0.0 109.682 177.246 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 220' ' ' MET . . . . . . . . . . . . . 8.4 ttt -78.78 127.0 31.47 Favored 'General case' 0 N--CA 1.436 -1.144 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 175.703 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 221' ' ' VAL . . . . . . . . . . . . . 98.0 t -69.22 130.13 33.98 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.174 0 N-CA-C 107.726 -1.213 . . . . 0.0 107.726 178.017 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 222' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -84.6 -70.36 0.58 Allowed 'General case' 0 N--CA 1.432 -1.331 0 C-N-CA 120.211 -0.596 . . . . 0.0 109.922 179.649 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 223' ' ' MET . . . . . . . . . . . . . 8.5 ptm -138.08 146.25 42.71 Favored 'General case' 0 N--CA 1.47 0.536 0 N-CA-C 112.446 0.536 . . . . 0.0 112.446 174.827 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 224' ' ' VAL . . . . . 0.8 HG22 ' HB ' ' A' ' 232' ' ' VAL . 53.1 t -121.94 132.85 70.01 Favored 'Isoleucine or valine' 0 C--O 1.239 0.537 0 C-N-CA 122.814 0.446 . . . . 0.0 110.557 178.97 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 39.2 p -88.25 133.0 34.16 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.554 -0.293 . . . . 0.0 110.694 178.731 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 226' ' ' LYS . . . . . . . . . . . . . 15.9 tttm -82.11 80.16 8.42 Favored 'General case' 0 C--O 1.241 0.623 0 C-N-CA 120.349 -0.54 . . . . 0.0 110.014 177.549 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 227' ' ' ASP . . . . . 0.605 ' N ' ' OG1' ' A' ' 280' ' ' THR . 2.2 t0 -154.3 -179.86 8.32 Favored 'General case' 0 C--O 1.247 0.93 0 CA-C-N 115.391 -0.822 . . . . 0.0 111.2 178.853 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 228' ' ' ASN . . . . . 0.523 ' HA ' ' C ' ' A' ' 229' ' ' PRO . 0.4 OUTLIER -141.77 125.48 9.91 Favored Pre-proline 0 C--N 1.324 -0.502 0 CA-C-N 115.529 -0.759 . . . . 0.0 109.645 176.747 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 229' ' ' PRO . . . . . 0.523 ' C ' ' HA ' ' A' ' 228' ' ' ASN . 42.6 Cg_endo -64.71 142.32 50.21 Favored 'Cis proline' 0 N--CA 1.491 1.379 0 C-N-CA 122.995 -1.669 . . . . 0.0 110.198 -0.651 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 230' ' ' GLY . . . . . 0.562 ' HA3' HG23 ' A' ' 280' ' ' THR . . . -74.42 138.89 24.84 Favored Glycine 0 C--N 1.308 -0.981 0 N-CA-C 109.912 -1.275 . . . . 0.0 109.912 -178.531 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 231' ' ' VAL . . . . . . . . . . . . . 2.2 p -125.08 130.98 73.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 176.271 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 232' ' ' VAL . . . . . 0.8 ' HB ' HG22 ' A' ' 224' ' ' VAL . 0.7 OUTLIER -133.64 156.54 41.55 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 C-N-CA 120.502 -0.479 . . . . 0.0 110.494 -177.255 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 233' ' ' THR . . . . . 0.427 ' HA ' ' O ' ' A' ' 273' ' ' TYR . 2.4 m -105.35 149.27 26.22 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 115.268 -0.878 . . . . 0.0 109.321 177.777 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 234' ' ' CYS . . . . . . . . . . . . . 2.6 m -113.08 147.26 37.66 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 175.478 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 235' ' ' LEU . . . . . . . . . . . . . 33.7 tp -53.7 113.92 1.36 Allowed 'General case' 0 C--N 1.312 -1.065 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 178.623 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 236' ' ' ASP . . . . . . . . . . . . . 36.7 p-10 -63.1 -10.38 14.41 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.94 -170.87 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 237' ' ' GLU . . . . . . . . . . . . . 76.5 mm-40 -65.47 -32.76 74.55 Favored 'General case' 0 C--N 1.312 -1.048 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.231 177.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 238' ' ' ALA . . . . . . . . . . . . . . . -121.45 133.52 55.06 Favored 'General case' 0 C--O 1.233 0.223 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.839 -177.868 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 239' ' ' ARG . . . . . 0.552 ' NH1' ' O ' ' A' ' 242' ' ' PHE . 0.1 OUTLIER -77.87 112.57 14.89 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 173.439 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 240' ' ' HIS . . . . . 0.605 ' NE2' ' O ' ' A' ' 272' ' ' PRO . 2.8 p80 -43.19 -34.2 1.08 Allowed 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 121.133 0.492 . . . . 0.0 109.988 -179.011 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 241' ' ' GLY . . . . . . . . . . . . . . . 87.19 8.36 75.25 Favored Glycine 0 CA--C 1.503 -0.669 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 179.724 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 242' ' ' PHE . . . . . 0.552 ' O ' ' NH1' ' A' ' 239' ' ' ARG . 5.7 m-30 -81.82 146.16 30.04 Favored 'General case' 0 N--CA 1.444 -0.772 0 CA-C-O 120.85 0.357 . . . . 0.0 110.19 -179.192 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 243' ' ' GLU . . . . . 0.529 ' HG3' ' CE1' ' A' ' 303' ' ' PHE . 64.9 mm-40 -121.67 167.99 12.3 Favored 'General case' 0 C--N 1.309 -1.19 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.431 176.446 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 244' ' ' THR . . . . . . . . . . . . . 17.7 m -61.1 124.15 19.72 Favored 'General case' 0 C--N 1.298 -1.633 0 C-N-CA 120.152 -0.619 . . . . 0.0 109.718 -178.682 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . 0.41 ' HA2' ' CG ' ' A' ' 266' ' ' GLU . . . 82.64 7.39 87.49 Favored Glycine 0 CA--C 1.523 0.578 0 CA-C-N 116.192 -0.458 . . . . 0.0 112.066 179.312 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 246' ' ' ASP . . . . . 0.44 ' OD1' ' N ' ' A' ' 247' ' ' PHE . 40.3 t0 -74.41 162.15 29.13 Favored 'General case' 0 C--O 1.238 0.482 0 CA-C-N 117.44 0.62 . . . . 0.0 109.457 177.809 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 247' ' ' PHE . . . . . 0.44 ' N ' ' OD1' ' A' ' 246' ' ' ASP . 78.3 m-85 -109.31 131.05 55.43 Favored 'General case' 0 C--N 1.316 -0.849 0 N-CA-C 109.705 -0.479 . . . . 0.0 109.705 -179.27 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.433 ' O ' ' HA ' ' A' ' 264' ' ' PRO . 3.1 m -129.04 163.29 34.48 Favored 'Isoleucine or valine' 0 C--O 1.24 0.602 0 CA-C-O 121.027 0.441 . . . . 0.0 112.058 -177.251 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 249' ' ' SER . . . . . . . . . . . . . 9.6 p -133.91 162.04 33.13 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 114.522 -1.217 . . . . 0.0 108.905 175.172 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 250' ' ' PHE . . . . . 0.595 ' CG ' ' HB3' ' A' ' 259' ' ' LEU . 82.1 m-85 -124.37 159.36 30.52 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.087 0.47 . . . . 0.0 111.831 -169.231 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 251' ' ' SER . . . . . . . . . . . . . 20.2 m -158.42 160.0 36.36 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.192 177.489 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 252' ' ' GLU . . . . . . . . . . . . . 78.0 mm-40 52.17 20.39 1.31 Allowed 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 113.234 0.827 . . . . 0.0 113.234 175.971 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 253' ' ' VAL . . . . . 0.43 HG22 ' CA ' ' A' ' 290' ' ' GLY . 12.4 t -85.94 131.06 35.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 175.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 254' ' ' GLN . . . . . . . . . . . . . 87.5 mt-30 -96.93 144.06 27.21 Favored 'General case' 0 C--O 1.24 0.56 0 C-N-CA 120.666 -0.413 . . . . 0.0 110.649 -179.689 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 255' ' ' GLY . . . . . . . . . . . . . . . 77.75 -57.43 3.86 Favored Glycine 0 CA--C 1.509 -0.321 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -177.158 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 256' ' ' MET . . . . . 0.522 ' HG2' ' HB3' ' A' ' 283' ' ' PHE . 15.3 ttm -85.81 55.84 3.7 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-O 121.493 0.663 . . . . 0.0 109.446 175.684 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 257' ' ' ILE . . . . . . . . . . . . . 44.4 pt -73.93 -18.1 17.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.036 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 258' ' ' GLN . . . . . . . . . . . . . 3.5 tp60 -54.1 -39.04 66.02 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 108.231 -1.026 . . . . 0.0 108.231 178.157 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 259' ' ' LEU . . . . . 0.846 HD21 ' CE2' ' A' ' 283' ' ' PHE . 85.5 mt -62.16 -41.67 98.52 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.121 177.07 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 260' ' ' ASN . . . . . . . . . . . . . 97.2 m-20 -59.98 -40.53 89.45 Favored 'General case' 0 CA--C 1.506 -0.734 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 -176.436 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . -102.27 14.75 56.77 Favored Glycine 0 CA--C 1.523 0.552 0 CA-C-N 115.787 -0.642 . . . . 0.0 112.235 -179.603 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 262' ' ' CYS . . . . . 0.439 ' HB2' ' HA ' ' A' ' 259' ' ' LEU . 1.1 m -91.16 158.83 16.4 Favored 'General case' 0 CA--C 1.513 -0.456 0 CA-C-N 117.469 0.634 . . . . 0.0 111.684 -178.005 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -76.59 151.25 82.69 Favored Pre-proline 0 C--N 1.323 -0.553 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 173.927 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 264' ' ' PRO . . . . . 0.75 ' HB3' HG21 ' A' ' 295' ' ' VAL . 49.5 Cg_endo -64.01 147.11 91.82 Favored 'Trans proline' 0 C--N 1.306 -1.668 0 C-N-CA 121.76 1.64 . . . . 0.0 112.052 -176.177 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 265' ' ' MET . . . . . 0.502 ' SD ' ' HZ ' ' A' ' 283' ' ' PHE . 7.8 ptp -134.07 157.4 46.22 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 112.484 0.55 . . . . 0.0 112.484 -173.661 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 266' ' ' GLU . . . . . 0.481 ' OE2' ' NZ ' ' A' ' 268' ' ' LYS . 39.6 tt0 -73.57 141.55 46.64 Favored 'General case' 0 C--O 1.241 0.631 0 O-C-N 124.006 0.816 . . . . 0.0 109.846 177.015 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 267' ' ' ILE . . . . . 0.681 HD12 ' C ' ' A' ' 267' ' ' ILE . 1.8 pp -130.66 163.58 36.05 Favored 'Isoleucine or valine' 0 C--O 1.237 0.445 0 N-CA-C 112.114 0.413 . . . . 0.0 112.114 -177.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 268' ' ' LYS . . . . . 0.481 ' NZ ' ' OE2' ' A' ' 266' ' ' GLU . 45.1 mmtm -124.88 127.35 46.97 Favored 'General case' 0 CA--C 1.541 0.628 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 174.555 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.482 HG23 ' O ' ' A' ' 269' ' ' VAL . 27.2 m -83.64 98.27 5.3 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.612 0 CA-C-O 120.887 0.375 . . . . 0.0 111.507 -179.818 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 270' ' ' LEU . . . . . . . . . . . . . 98.6 mt -65.73 -42.46 90.99 Favored 'General case' 0 CA--C 1.513 -0.46 0 CA-C-O 121.399 0.619 . . . . 0.0 109.577 178.137 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 271' ' ' GLY . . . . . . . . . . . . . . . -145.04 176.44 24.08 Favored Glycine 0 C--N 1.314 -0.693 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 178.499 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 272' ' ' PRO . . . . . 0.605 ' O ' ' NE2' ' A' ' 240' ' ' HIS . 67.9 Cg_exo -54.03 -40.05 82.86 Favored 'Trans proline' 0 C--N 1.305 -1.72 0 C-N-CA 122.159 1.906 . . . . 0.0 111.068 -178.805 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 273' ' ' TYR . . . . . 0.427 ' O ' ' HA ' ' A' ' 233' ' ' THR . 6.9 m-85 -115.71 8.96 15.08 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.623 -176.062 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 274' ' ' THR . . . . . . . . . . . . . 1.7 p -126.74 124.97 40.97 Favored 'General case' 0 C--O 1.247 0.937 0 CA-C-O 121.047 0.451 . . . . 0.0 111.431 179.284 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 275' ' ' PHE . . . . . 0.536 ' CD1' ' C ' ' A' ' 275' ' ' PHE . 0.0 OUTLIER -133.09 164.72 26.39 Favored 'General case' 0 CA--C 1.494 -1.189 0 C-N-CA 120.492 -0.483 . . . . 0.0 112.224 177.95 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . 0.5 ' HA ' ' O ' ' A' ' 230' ' ' GLY . 13.7 p -132.12 152.4 51.26 Favored 'General case' 0 N--CA 1.432 -1.347 0 C-N-CA 120.436 -0.506 . . . . 0.0 110.944 -176.382 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . 0.628 HG22 HG22 ' A' ' 267' ' ' ILE . 0.2 OUTLIER -138.26 -169.19 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.195 0 CA-C-N 115.258 -0.883 . . . . 0.0 110.564 -175.185 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 278' ' ' CYS . . . . . . . . . . . . . 12.9 m -58.32 -75.64 0.05 OUTLIER 'General case' 0 CA--C 1.536 0.438 0 N-CA-C 112.941 0.719 . . . . 0.0 112.941 -175.273 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 279' ' ' ASP . . . . . 0.425 ' HB3' ' HB2' ' A' ' 282' ' ' ASN . 66.7 t0 -154.99 114.78 3.74 Favored 'General case' 0 N--CA 1.45 -0.441 0 O-C-N 122.266 -0.271 . . . . 0.0 111.122 -175.276 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . 0.678 ' HA ' ' CD2' ' A' ' 283' ' ' PHE . 21.5 p -66.89 -29.52 69.43 Favored 'General case' 0 C--N 1.303 -1.417 0 CA-C-O 121.101 0.477 . . . . 0.0 110.262 174.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 281' ' ' SER . . . . . 0.416 ' N ' ' OD1' ' A' ' 279' ' ' ASP . 0.3 OUTLIER -62.28 -19.45 63.26 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 115.29 -0.868 . . . . 0.0 109.125 174.794 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 282' ' ' ASN . . . . . 0.425 ' HB2' ' HB3' ' A' ' 279' ' ' ASP . 2.1 m-80 -88.48 -8.48 54.82 Favored 'General case' 0 CA--C 1.507 -0.703 0 N-CA-C 109.454 -0.572 . . . . 0.0 109.454 175.163 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 283' ' ' PHE . . . . . 0.846 ' CE2' HD21 ' A' ' 259' ' ' LEU . 12.2 m-30 -98.82 -83.35 0.42 Allowed 'General case' 0 N--CA 1.442 -0.843 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 174.8 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 284' ' ' SER . . . . . 0.416 ' H ' ' HB2' ' A' ' 283' ' ' PHE . 0.2 OUTLIER 172.88 -162.02 0.02 OUTLIER 'General case' 0 N--CA 1.448 -0.535 0 C-N-CA 124.908 1.283 . . . . 0.0 107.929 -178.998 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 285' ' ' ASP . . . . . . . . . . . . . 9.4 p-10 -91.64 169.99 10.28 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.666 0.27 . . . . 0.0 110.631 175.618 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 86.2 t80 -106.85 120.98 43.48 Favored 'General case' 0 C--O 1.239 0.531 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.199 179.731 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 287' ' ' ILE . . . . . 0.485 ' O ' ' HG3' ' A' ' 288' ' ' ARG . 96.9 mt -93.32 -57.67 4.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 109.993 -0.373 . . . . 0.0 109.993 175.413 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 288' ' ' ARG . . . . . 0.485 ' HG3' ' O ' ' A' ' 287' ' ' ILE . 15.9 mtm180 -178.9 179.05 0.72 Allowed 'General case' 0 C--O 1.243 0.722 0 C-N-CA 124.525 1.13 . . . . 0.0 110.122 177.773 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 289' ' ' GLY . . . . . . . . . . . . . . . 69.52 -163.14 51.75 Favored Glycine 0 C--O 1.235 0.21 0 N-CA-C 111.275 -0.73 . . . . 0.0 111.275 175.903 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . 0.43 ' CA ' HG22 ' A' ' 253' ' ' VAL . . . 113.68 128.23 4.72 Favored Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 121.251 -0.5 . . . . 0.0 113.076 175.686 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 291' ' ' ILE . . . . . . . . . . . . . 98.5 mt -124.42 132.11 71.81 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.858 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 172.751 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . 0.415 HG22 ' CZ ' ' A' ' 242' ' ' PHE . 5.5 p -125.33 137.69 56.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -178.189 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 4.4 m -132.18 147.0 52.4 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.299 -177.299 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 294' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -75.08 152.11 38.61 Favored 'General case' 0 CA--C 1.507 -0.7 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 173.318 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . 0.75 HG21 ' HB3' ' A' ' 264' ' ' PRO . 21.0 t -99.0 126.6 52.19 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.095 0 C-N-CA 120.449 -0.501 . . . . 0.0 111.635 -175.07 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 296' ' ' LYS . . . . . . . . . . . . . 55.9 tttp -82.47 98.69 9.04 Favored 'General case' 0 N--CA 1.44 -0.959 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 175.739 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 297' ' ' VAL . . . . . 0.569 ' HB ' ' HD2' ' A' ' 298' ' ' PRO . 17.6 m -98.04 -178.78 0.76 Allowed Pre-proline 0 C--N 1.31 -1.139 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 178.846 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 298' ' ' PRO . . . . . 0.569 ' HD2' ' HB ' ' A' ' 297' ' ' VAL . 76.2 Cg_exo -54.36 -38.31 89.07 Favored 'Trans proline' 0 C--N 1.308 -1.589 0 C-N-CA 121.301 1.334 . . . . 0.0 110.314 177.346 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 299' ' ' LYS . . . . . 0.46 ' O ' ' NZ ' ' A' ' 299' ' ' LYS . 0.0 OUTLIER -137.9 114.38 10.36 Favored 'General case' 0 C--O 1.247 0.951 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.9 177.03 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 300' ' ' LYS . . . . . 0.509 ' HG3' ' N ' ' A' ' 301' ' ' ILE . 22.8 pttm -71.81 -156.35 0.03 OUTLIER 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 174.619 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 301' ' ' ILE . . . . . 0.795 HD13 ' H ' ' A' ' 301' ' ' ILE . 0.1 OUTLIER -99.85 128.38 51.76 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.887 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 173.194 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 302' ' ' SER . . . . . . . . . . . . . 49.2 m -74.1 144.97 44.73 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 178.948 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 303' ' ' PHE . . . . . 0.529 ' CE1' ' HG3' ' A' ' 243' ' ' GLU . 20.0 m-85 -101.58 147.28 26.59 Favored 'General case' 0 C--N 1.312 -1.042 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -175.166 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 304' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -71.45 129.45 38.82 Favored 'General case' 0 C--N 1.313 -1.01 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 176.337 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 6.8 m -73.43 149.15 42.63 Favored 'General case' 0 C--N 1.309 -1.163 0 C-N-CA 120.981 -0.288 . . . . 0.0 110.834 -176.083 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 306' ' ' LEU . . . . . . . . . . . . . 90.4 mt -55.0 153.13 12.28 Favored Pre-proline 0 C--O 1.242 0.669 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 177.58 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -63.18 142.74 87.96 Favored 'Trans proline' 0 C--N 1.302 -1.914 0 C-N-CA 121.301 1.334 . . . . 0.0 110.856 -177.504 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . . . . . . . . . . . -132.32 133.36 43.94 Favored 'General case' 0 C--N 1.315 -0.925 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 179.554 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . . . . . . . . . 2.3 m -71.49 137.92 48.55 Favored 'General case' 0 C--N 1.308 -1.225 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 -178.826 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 310' ' ' LEU . . . . . . . . . . . . . 92.1 mt -102.08 60.23 0.85 Allowed 'General case' 0 CA--C 1.509 -0.623 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 174.754 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 311' ' ' VAL . . . . . . . . . . . . . 15.1 m -148.54 162.64 5.58 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.237 0 CA-C-N 114.025 -1.443 . . . . 0.0 107.978 176.683 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 312' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 . . . . . 0 C--O 1.204 -1.316 0 CA-C-O 118.492 -0.766 . . . . 0.0 110.917 177.394 . . . . . . . . 0 0 . 1 stop_ save_